PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Li, XF; Briehl, RW; Bookchin, RM; Josephs, R; Wei, BY; Manning, JM; Ferrone, FA				Li, XF; Briehl, RW; Bookchin, RM; Josephs, R; Wei, BY; Manning, JM; Ferrone, FA			Sickle hemoglobin polymer stability probed by triple and quadruple mutant hybrids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MOUSE MODEL; DEOXYHEMOGLOBIN-S; CRYSTAL-STRUCTURE; INTERMOLECULAR CONTACTS; NUCLEATION; RESOLUTION; VOLUME; FIBERS; SITES; ALA	As part of an effort to understand the interactions in HbS polymerization, we have produced and studied a recombinant triple mutant, D6A(alpha)/D75Y(alpha)/E121R(beta), and a quadruple mutant comprising the preceding mutation plus the natural genetic mutation of sickle hemoglobin, E6V(beta). These recombinant hemoglobins expressed in yeast were extensively characterized, and their structure and oxygen binding cooperativity were found to be normal. Their tetramer-dimer dissociation constants were within a factor of 2 of HbA and HbS. Polymerization of these mutants mixed with HbS was investigated by a micromethod based on volume exclusion by dextran. The elevated solubility of mixtures of HbS with HbA and HbF in dextran could be accurately predicted without any variable parameters. Relative to HbS, the copolymerization probability of the quadruple mutant(HbS hybrid was found to be 6.2, and the copolymerization probability for the triple mutant/HbS hybrid was 0.52. The pure quadruple mutant had a solubility slightly above that of its hybrid with HbS. One way to explain these results is to require significant cis-trans differences in the polymer and that HbA assemble above 42.5 g/dl. A second way to explain these data is by the modification of motional freedom, thereby changing vibrational entropy in the polymer.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60035 USA; Drexel Univ, Dept Phys, Philadelphia, PA 19104 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Northeastern Univ, Dept Biochem, Boston, MA 02115 USA	University of Chicago; Drexel University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Northeastern University	Ferrone, FA (corresponding author), Univ Penn, Dept Phys, 3201 Chestnut St, Philadelphia, PA 19104 USA.							ADACHI K, 1982, BLOOD CELLS, V8, P213; ADACHI K, 1982, BLOOD CELLS, V8, P224; BENESCH RE, 1977, NATURE, V269, P772, DOI 10.1038/269772a0; BENESCH RE, 1979, J BIOL CHEM, V254, P8169; Bookchin RM, 1999, J BIOL CHEM, V274, P6689, DOI 10.1074/jbc.274.10.6689; BOOKCHIN RM, 1967, J BIOL CHEM, V242, P248; Cao ZQ, 1997, BIOPHYS J, V72, P343, DOI 10.1016/S0006-3495(97)78673-9; Cao ZQ, 1997, J MOL BIOL, V265, P580, DOI 10.1006/jmbi.1996.0749; DELLANO JJM, 1993, P NATL ACAD SCI USA, V90, P918, DOI 10.1073/pnas.90.3.918; DELLANO JJM, 1994, PROTEIN SCI, V3, P1206, DOI 10.1002/pro.5560030806; Dumoulin A, 1997, J BIOL CHEM, V272, P31326, DOI 10.1074/jbc.272.50.31326; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; FERMI G, 1981, ATLAS MOL STRUCTURES, V2, P75; FERRONE FA, 1985, J MOL BIOL, V183, P611, DOI 10.1016/0022-2836(85)90175-5; Harrington DJ, 1997, J MOL BIOL, V272, P398, DOI 10.1006/jmbi.1997.1253; HIMANEN JP, 1995, J BIOL CHEM, V270, P13885, DOI 10.1074/jbc.270.23.13885; Himanen JP, 1996, J BIOL CHEM, V271, P25152, DOI 10.1074/jbc.271.41.25152; Ivanova M, 2001, J MOL BIOL, V314, P851, DOI 10.1006/jmbi.2001.5163; Li XF, 1997, BLOOD, V90, P4620, DOI 10.1182/blood.V90.11.4620.4620_4620_4627; Manning LR, 1996, PROTEIN SCI, V5, P775; MILNER PF, 1970, NEW ENGL J MED, V283, P1417, DOI 10.1056/NEJM197012242832601; MINTON AP, 1981, BIOPOLYMERS, V20, P2093, DOI 10.1002/bip.1981.360201006; MINTON AP, 1977, J MOL BIOL, V100, P519; MONPLAISIR N, 1986, P NATL ACAD SCI USA, V83, P9363, DOI 10.1073/pnas.83.24.9363; NAGEL RL, 1980, NATURE, V283, P832, DOI 10.1038/283832a0; PADLAN EA, 1985, J BIOL CHEM, V260, P8272; Roufberg A, 2000, PROTEIN SCI, V9, P1031, DOI 10.1110/ps.9.5.1031; TRUDEL M, 1991, EMBO J, V10, P3157, DOI 10.1002/j.1460-2075.1991.tb04877.x; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WATOWICH SJ, 1989, J MOL BIOL, V209, P821, DOI 10.1016/0022-2836(89)90610-4; WATOWICH SJ, 1993, J STRUCT BIOL, V111, P161, DOI 10.1006/jsbi.1993.1047; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2	32	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13479	13487		10.1074/jbc.M108149200	http://dx.doi.org/10.1074/jbc.M108149200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11782463	hybrid			2022-12-27	WOS:000175096000020
J	Kulkarni, S; Das, S; Funk, CD; Murray, D; Cho, W				Kulkarni, S; Das, S; Funk, CD; Murray, D; Cho, W			Molecular basis of the specific subcellular localization of the C2-like domain of 5-lipoxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); KINASE-C-ALPHA; MEMBRANE-BINDING; PROTEIN INTERACTIONS; TERMINAL DOMAIN; CALCIUM; TRANSLOCATION; DOCKING; DETERMINANTS; RESONANCE	The activation of 5-lipoxygenase (5-LO) involves its calcium-dependent translocation to the nuclear envelope, where it catalyzes the two-step transformation of arachidonic acid into leukotriene A(4), leading to the synthesis of various leukotrienes. To understand the mechanism by which 5-LO is specifically targeted to the nuclear envelope, we studied the membrane binding properties of the amino-terminal domain of 5-LO, which has been proposed to have a C2 domain-like structure. The model building, electrostatic potential calculation, and in vitro membrane binding studies of the isolated C2-like domain of 5-LO and selected mutants show that this Ca2+-dependent domain selectively binds zwitterionic phosphatidylcholine, which is conferred by tryptophan residues (Trp(13), Trp(75), and Trp(102)) located in the putative Ca2+-binding loops. The spatiotemporal dynamics of the enhanced green fluorescence protein-tagged C2-like domain of 5-LO and mutants in living cells also show that the phosphatidylcholine selectivity of the C2-like domain accounts for the specific targeting of 5-LO to the nuclear envelope. Together, these results show that the C2-like domain of 5-LO is a genuine Ca2+. dependent membrane-targeting domain and that the subcellular localization of the domain is governed in large part by its membrane binding properties.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cornell University; University of Pennsylvania; University of Pennsylvania	Cho, W (corresponding author), Univ Illinois, Dept Chem, M-C 111,845 W Taylor St, Chicago, IL 60607 USA.		Kulkarni, Shilpa/F-2159-2010; Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NHLBI NIH HHS [HL 58464] Funding Source: Medline; NIGMS NIH HHS [GM 52598, GM 53987] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598, R01GM053987] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ananthanarayanan B, 2002, J BIOL CHEM, V277, P3568, DOI 10.1074/jbc.M109705200; Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; BRETSCHER MS, 1972, NATURE-NEW BIOL, V236, P11, DOI 10.1038/newbio236011a0; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Hammarberg T, 1999, BIOCHEMISTRY-US, V38, P4441, DOI 10.1021/bi9824700; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; Murray D, 2002, MOL CELL, V9, P145, DOI 10.1016/S1097-2765(01)00426-9; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P3089, DOI 10.1021/bi001968a; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; Naylor CE, 1999, J MOL BIOL, V294, P757, DOI 10.1006/jmbi.1999.3279; Naylor CE, 1998, NAT STRUCT BIOL, V5, P738, DOI 10.1038/1447; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOGUCHI M, 1994, BBA-LIPID LIPID MET, V1215, P300, DOI 10.1016/0005-2760(94)90057-4; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Peters-Golden M, 1998, AM J RESP CRIT CARE, V157, pS227, DOI 10.1164/ajrccm.157.6.mar4; Peters-Golden M, 2001, FEBS LETT, V487, P323, DOI 10.1016/S0014-5793(00)02374-7; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Stahelin RV, 2001, BIOCHEM J, V359, P679, DOI 10.1042/0264-6021:3590679; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; Williams SD, 2000, J LIPID RES, V41, P1585	42	142	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13167	13174		10.1074/jbc.M112393200	http://dx.doi.org/10.1074/jbc.M112393200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11796736	hybrid			2022-12-27	WOS:000175036300086
J	Geib, S; Sandoz, G; Cornet, V; Mabrouk, K; Fund-Saunier, O; Bichet, D; Villaz, M; Hoshi, T; Sabatier, JM; De Waard, M				Geib, S; Sandoz, G; Cornet, V; Mabrouk, K; Fund-Saunier, O; Bichet, D; Villaz, M; Hoshi, T; Sabatier, JM; De Waard, M			The interaction between the I-II loop and the III-IV loop of Ca(V)2.1 contributes to voltage-dependent inactivation in a beta-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL REGION; CHANNEL ALPHA(1) SUBUNIT; G-PROTEIN MODULATION; CALCIUM-CHANNEL; MOLECULAR DETERMINANTS; N-TYPE; CA2+; BLOCK; LINKER; IDENTIFICATION	We have investigated the molecular mechanisms whereby the I-II loop controls voltage-dependent inactivation in P/Q calcium channels. We demonstrate that the I-II loop is localized in a central position to control calcium channel activity through the interaction with several cytoplasmic sequences; including the III-IV loop. Several experiments reveal the crucial role of the interaction between the I-II loop and the III-IV loop in channel inactivation. First, point mutations of two amino acid residues of the I-II loop of Ca(v)2.1 (Arg-387 or Glu-388) facilitate voltage-dependent inactivation. Second, overexpression of the III-IV loop, or injection of a peptide derived from this loop, produces a similar inactivation behavior than the mutated channels. Third, the III-IV peptide has no effect on channels mutated in the I-II loop. Thus, both point mutations and overexpression of the III-IV loop appear to act similarly on inactivation, by competing off the native interaction between the I-II and the III-IV loops of Ca(v)2.1. As they are known to affect inactivation, we also analyzed the effects of beta subunits on these interactions. In experiments in which the beta(4) subunit is co-expressed, the III-IV peptide is no longer able to regulate channel inactivation. We conclude that (i) the contribution of the I-II loop to inactivation is partly mediated by an interaction with the III-IV loop and (ii) the beta subunits partially control inactivation by modifying this interaction. These data provide novel insights into the mechanisms whereby the beta subunit, the I-II loop, and the III-IV loop altogether can contribute to regulate inactivation in high voltage-activated calcium channels.	CEA, Equipe Miate INSERM 99 31, Lab Canaux Ion & Signalisat, Dept Biol Mol & Struct, F-38054 Grenoble 9, France; INSERM Unite 464, Lab Neurobiol Canaux Ion, Fac Med N, F-13916 Marseille 20, France; CNRS UMR 6560, Biochim Lab, Fac Med N, F-13916 Marseille 20, France; Univ Iowa, Dept Phys & Biophys, Iowa City, IA 52242 USA	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Iowa	De Waard, M (corresponding author), CEA, Equipe Miate INSERM 99 31, Lab Canaux Ion & Signalisat, Dept Biol Mol & Struct, 17 Rue Martyrs, F-38054 Grenoble 9, France.	mdewaard@cea.fr	sandoz, guillaume/AAI-9236-2020; De Waard, Michel/G-7406-2014	sandoz, guillaume/0000-0003-1251-0852; De Waard, Michel/0000-0002-2782-9615; Bichet, Delphine/0000-0002-9601-089X; SABATIER, Jean-Marc/0000-0002-9040-5647				Berrou L, 2001, BIOPHYS J, V80, P215, DOI 10.1016/S0006-3495(01)76008-0; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Canti C, 1999, J NEUROSCI, V19, P6855, DOI 10.1523/JNEUROSCI.19-16-06855.1999; Cens T, 1999, J BIOL CHEM, V274, P5483, DOI 10.1074/jbc.274.9.5483; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DEWAARD M, 1995, J PHYSIOL-LONDON, V485, P619, DOI 10.1113/jphysiol.1995.sp020757; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; EAHOLTZ G, 1994, NEURON, V12, P1041, DOI 10.1016/0896-6273(94)90312-3; EPPIG JJ, 1976, IN VITRO CELL DEV B, V12, P418; Forsythe ID, 1998, NEURON, V20, P797, DOI 10.1016/S0896-6273(00)81017-X; Hering S, 1997, P NATL ACAD SCI USA, V94, P13323, DOI 10.1073/pnas.94.24.13323; Hering S, 1998, TRENDS PHARMACOL SCI, V19, P439, DOI 10.1016/S0165-6147(98)01258-9; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; Hille B., 1992, IONIC CHANNELS EXCIT; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; KUO CC, 1993, NATURE, V365, P258, DOI 10.1038/365258a0; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Patil PG, 1998, NEURON, V20, P1027, DOI 10.1016/S0896-6273(00)80483-3; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Qin N, 1996, AM J PHYSIOL-CELL PH, V271, pC1539, DOI 10.1152/ajpcell.1996.271.5.C1539; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Restituito S, 2000, J NEUROSCI, V20, P9046; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; Spaetgens RL, 1999, J BIOL CHEM, V274, P22428, DOI 10.1074/jbc.274.32.22428; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; Stephens GJ, 2000, J PHYSIOL-LONDON, V525, P377, DOI 10.1111/j.1469-7793.2000.t01-1-00377.x; Stotz SC, 2001, TRENDS NEUROSCI, V24, P176, DOI 10.1016/S0166-2236(00)01738-0; Stotz SC, 2000, J BIOL CHEM, V275, P24575, DOI 10.1074/jbc.M000399200; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Walker D, 1999, J BIOL CHEM, V274, P12383, DOI 10.1074/jbc.274.18.12383; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; Wei S, 2000, CIRC RES, V86, P175, DOI 10.1161/01.RES.86.2.175; Yamaguchi H, 1998, J BIOL CHEM, V273, P19348, DOI 10.1074/jbc.273.30.19348; Zamponi GW, 1996, J NEUROSCI, V16, P2430; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0	43	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10003	10013		10.1074/jbc.M106231200	http://dx.doi.org/10.1074/jbc.M106231200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11790766	hybrid, Green Published			2022-12-27	WOS:000174549200054
J	Gho, YS; Yoon, WH; Chae, CB				Gho, YS; Yoon, WH; Chae, CB			Antiplasmin activity of a peptide that binds to the receptor-binding site of angiogenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTERY ENDOTHELIAL-CELLS; PLASMINOGEN-ACTIVATOR; PHOSPHOLIPASE-C; CARCINOMA-CELLS; ACTIN; RIBONUCLEASE; PROTEIN; ACID; COMPLEMENTARY; SEQUENCE	It has been suggested that angiogenin binds to an actin-like molecule present on the surface of endothelial cells. Actin inhibits plasmin activity, but the angiogenin-actin complex is not active. In this report, we found that plasmin inhibits the interaction between angiogenin and actin suggesting a possibility that both angiogenin and plasmin may bind to a similar site on actin. Here we report that chANG, an antiangiogenin peptide that binds to the actin-binding site of angiogenin, inhibits the proteolytic activity of plasmin without any apparent effect on the activities of plasminogen activators and matrix metalloproteases. Its antiplasmin activity is comparable with that of actin. chANG inhibits plasmin activity via its binding to plasmin kringle domains while scrambled chANG does not bind to plasmin. chANG also inhibits the invasion of angiogenin-secreting human fibrosarcoma and colorectal carcinoma cells without effecting migration. Furthermore, chANG blocks angiogenesis induced by fibrosarcoma cells and metastasis of colorectal carcinoma cells to the liver. Therefore, the 11-amino acid peptide chANG has both antiangiogenin and antiplasmin activity, and could be useful in the development of anticancer agents.	Pohang Univ Sci & Technol, Dept Life Sci, Div Mol & Life Sci, Pohang 790784, South Korea; Kyung Hee Univ, Grad Sch E W Med Sci, Yongin 449701, South Korea; Chungnam Natl Univ, Coll Med, Dept Surg, Dae Jun, South Korea	Pohang University of Science & Technology (POSTECH); Kyung Hee University; Chungnam National University	Chae, CB (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Div Mol & Life Sci, Pohang 790784, South Korea.							ALBINI A, 1987, CANCER RES, V47, P3239; BADET J, 1989, P NATL ACAD SCI USA, V86, P8427, DOI 10.1073/pnas.86.21.8427; BEINTEMA JJ, 1984, ANAL BIOCHEM, V136, P48, DOI 10.1016/0003-2697(84)90306-3; BICKNELL R, 1989, P NATL ACAD SCI USA, V86, P1573, DOI 10.1073/pnas.86.5.1573; BICKNELL R, 1988, P NATL ACAD SCI USA, V85, P5961, DOI 10.1073/pnas.85.16.5961; BRESALIER RS, 1991, J CLIN INVEST, V87, P1037, DOI 10.1172/JCI115063; DANE K, 1985, ADV CANCER RES, V44, P139; Farina AR, 1996, BIOTECHNIQUES, V21, P904; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; Gho YS, 1997, J BIOL CHEM, V272, P24294, DOI 10.1074/jbc.272.39.24294; GRANZOW R, 1992, BIO-TECHNOL, V10, P390, DOI 10.1038/nbt0492-390; HALLAHAN TW, 1991, P NATL ACAD SCI USA, V88, P2222, DOI 10.1073/pnas.88.6.2222; HARPER JW, 1989, BIOCHEMISTRY-US, V28, P1875, DOI 10.1021/bi00430a067; HU GF, 1993, BIOCHEM BIOPH RES CO, V197, P682, DOI 10.1006/bbrc.1993.2533; HU GF, 1994, P NATL ACAD SCI USA, V91, P12096, DOI 10.1073/pnas.91.25.12096; HU GF, 1993, P NATL ACAD SCI USA, V90, P1217, DOI 10.1073/pnas.90.4.1217; HU GF, 1991, P NATL ACAD SCI USA, V88, P2227, DOI 10.1073/pnas.88.6.2227; IMAMURA H, 1994, CANCER RES, V54, P3620; JIMI S, 1995, BIOCHEM BIOPH RES CO, V211, P476, DOI 10.1006/bbrc.1995.1838; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; LIND SE, 1991, J BIOL CHEM, V266, P5273; LIND SE, 1991, J BIOL CHEM, V266, P17673; LONGSTAFF C, 1994, BLOOD COAGUL FIBRIN, V5, P537; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; MOORE F, 1990, BIOCHEMISTRY-US, V29, P228, DOI 10.1021/bi00453a031; MOROIANU J, 1993, P NATL ACAD SCI USA, V90, P3815, DOI 10.1073/pnas.90.9.3815; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; MOSCATELLI D, 1981, J CELL BIOL, V91, P201; Okumura Y, 1997, FEBS LETT, V402, P181, DOI 10.1016/S0014-5793(96)01523-2; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; RAINES RT, 1995, J BIOL CHEM, V270, P17180, DOI 10.1074/jbc.270.29.17180; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; WIMAN B, 1979, BIOCHIM BIOPHYS ACTA, V579, P142, DOI 10.1016/0005-2795(79)90094-1	34	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9690	9694		10.1074/jbc.M105526200	http://dx.doi.org/10.1074/jbc.M105526200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11782452	hybrid			2022-12-27	WOS:000174549200013
J	Lapouge, K; Smith, SJM; Groemping, Y; Rittinger, K				Lapouge, K; Smith, SJM; Groemping, Y; Rittinger, K			Architecture of the p40-p47-p67phox complex in the resting state of the NADPH oxidase - A central role for p67(phox)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CELL-FREE SYSTEM; DOMAIN-MEDIATED INTERACTIONS; SRC HOMOLOGY-3 DOMAINS; SH3 DOMAIN; FLAVOCYTOCHROME B(558); SUPEROXIDE PRODUCTION; CYTOSOLIC COMPONENTS; HUMAN NEUTROPHILS; ACTIVATION	The phagocyte NADPH oxidase is a multiprotein enzyme whose subunits are partitioned between the cytosol and plasma membrane in resting cells. Upon exposure to appropriate stimuli multiple phosphorylation events in the cytosolic components take place, which induce rearrangements in a number of protein-protein interactions, ultimately leading to translocation of the cytoplasmic complex to the membrane. To understand the molecular mechanisms that underlie the assembly and activation process we have carried out a detailed study of the protein-protein interactions that occur in the p40-p47-p67(phox) Complex of the resting oxidase. Here we show that this complex contains one copy of each protein, which assembles to form a heterotrimeric complex. The apparent high molecular weight of this complex, as observed by gel filtration studies, is due to an extended, non-globular shape rather than to the presence of multiple copies of any of the proteins. Isothermal titration calorimetry measurements of the interactions between the individual components of this complex demonstrate that p67(phox) is the primary binding partner of p47(phox) in the resting state. These findings, in combination with earlier reports, allow us to propose a model for the architecture of the resting complex in which p67(phox) acts as the bridging molecule that connects p40(phox) and p47(phox).	Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England	MRC National Institute for Medical Research	Rittinger, K (corresponding author), Natl Inst Med Res, Div Prot Struct, Mill Hill, London NW7 1AA, England.		Rittinger, Katrin/D-2586-2014; Rittinger, Katrin/N-3344-2019	Rittinger, Katrin/0000-0002-7698-4435; Rittinger, Katrin/0000-0002-7698-4435; Lapouge, Karine/0000-0003-0620-9553	MRC [MC_U117565398] Funding Source: UKRI; Medical Research Council [MC_U117565398] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Clark RA, 1999, J INFECT DIS, V179, pS309, DOI 10.1086/513849; Cross AR, 2000, BIOCHEM J, V349, P113, DOI 10.1042/0264-6021:3490113; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; Dusi S, 1996, BIOCHEM J, V314, P409, DOI 10.1042/bj3140409; ElBenna J, 1996, J BIOL CHEM, V271, P6374; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; FINAN P, 1994, J BIOL CHEM, V269, P13752; Fuchs A, 1996, BBA-MOL CELL RES, V1312, P39, DOI 10.1016/0167-4889(96)00020-1; Grizot S, 2001, BIOCHEMISTRY-US, V40, P3127, DOI 10.1021/bi0028439; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; Hata K, 1998, J BIOL CHEM, V273, P4232, DOI 10.1074/jbc.273.7.4232; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; Ito T, 1996, FEBS LETT, V385, P229, DOI 10.1016/0014-5793(96)00387-0; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; Johnson JL, 1998, J BIOL CHEM, V273, P35147, DOI 10.1074/jbc.273.52.35147; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; Leusen JHW, 1996, J LAB CLIN MED, V128, P461, DOI 10.1016/S0022-2143(96)90043-8; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; Nakamura R, 1998, EUR J BIOCHEM, V251, P583, DOI 10.1046/j.1432-1327.1998.2510583.x; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; Park JW, 1997, BIOCHEMISTRY-US, V36, P7474, DOI 10.1021/bi9700936; PARK JW, 1994, BIOCHEMISTRY-US, V33, P2907, DOI 10.1021/bi00176a021; PARK JW, 1992, J BIOL CHEM, V267, P17327; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Sathyamoorthy M, 1997, J BIOL CHEM, V272, P9141; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; SOMEYA A, 1993, FEBS LETT, V330, P215, DOI 10.1016/0014-5793(93)80276-Z; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Swain SD, 1997, J BIOL CHEM, V272, P29502, DOI 10.1074/jbc.272.47.29502; Tsunawaki S, 1996, J EXP MED, V184, P893, DOI 10.1084/jem.184.3.893; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; Wientjes FB, 1996, BIOCHEM J, V317, P919, DOI 10.1042/bj3170919; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; Wilson L, 1997, INFLAMM RES, V46, P265, DOI 10.1007/s000110050185; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051	51	123	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10121	10128		10.1074/jbc.M112065200	http://dx.doi.org/10.1074/jbc.M112065200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11796733	hybrid			2022-12-27	WOS:000174549200069
J	Matsuura, B; Dong, MQ; Miller, LJ				Matsuura, B; Dong, MQ; Miller, LJ			Differential determinants for peptide and non-peptidyl ligand binding to the motilin receptor - Critical role of second extracellular loop for peptide binding and action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE SECRETAGOGUE	The predicted second extracellular loop domain of the motilin receptor is of particular interest because it is a region that is quite distinct from the analogous regions in other family members that are most closely related and because the initial report of the photoaffinity labeling of a domain of this receptor included this region (Coulie, B. J., Matsuura, B., Dong, M., Hadac, E. M., Pinon, D. I., Feighner, S. D., Howard, A. D., and Miller, L. J. (2001) J. Biol. Chem. 276, 35518-35522). In the current work, motilin receptor constructs were prepared that included sequential deletions ranging from single residues to twelve amino acid segments throughout this 67 amino acid domain. Each construct was expressed in COS cells and characterized for motilin radioligand binding and motilin-stimulated intracellular calcium responses. The only segments that had negative impact on motilin binding and biological activity included deletion constructs DeltaCys(235), Delta179-182, and Delta241-246. Cys(235) is likely involved in the highly conserved and functionally important disulfide bond linking the first and second loops of G protein-coupled receptors. Alanine replacements for each of the amino acid residues in the other two segments revealed that the perimembranous residues at both ends of this loop, Val(179) and Leu(245) and Arg(246), were responsible for the negative impact on motilin binding and biological activity. Of note, these mutants responded normally to the non-peptidyl agonist, erythromycin. These data support important functional roles for both amino-terminal and carboxyl-terminal perimembranous regions of the second loop for responses to the natural agonist peptide, while supporting independent determinants for action of a non-peptidyl agonist ligand.	Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Biochem Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Miller, LJ (corresponding author), Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Internal Med, 200 1st St SW,Guggenheim 17, Rochester, MN 55905 USA.							Asmann YW, 2000, MOL PHARMACOL, V58, P911, DOI 10.1124/mol.58.5.911; Coulie B, 2001, J BIOL CHEM, V276, P35518, DOI 10.1074/jbc.M104489200; Feighner SD, 1999, SCIENCE, V284, P2184, DOI 10.1126/science.284.5423.2184; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; Hosoda H, 2000, J BIOL CHEM, V275, P21995, DOI 10.1074/jbc.M002784200; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; McKee KK, 1997, GENOMICS, V46, P426, DOI 10.1006/geno.1997.5069; MONSON PJ, 1980, ANAL BIOCHEM, V107, P220; POITRAS P, 1992, BIOCHEM BIOPH RES CO, V183, P36, DOI 10.1016/0006-291X(92)91605-P; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463	15	32	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9834	9839		10.1074/jbc.M111051200	http://dx.doi.org/10.1074/jbc.M111051200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11781320	hybrid			2022-12-27	WOS:000174549200033
J	Welzenbach, K; Hommel, U; Weitz-Schmidt, G				Welzenbach, K; Hommel, U; Weitz-Schmidt, G			Small molecule inhibitors induce conformational changes in the I domain and the I-like domain of lymphocyte function-associated antigen-1 - Molecular insights into integrin inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROPELLER DOMAIN; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; COUNTER-RECEPTOR; STRUCTURAL BASIS; BINDING-SITE; A-DOMAIN; SUBUNIT; LFA-1; ANTAGONISTS	The beta(2) integrin lymphocyte function-associated antigen-1 (LFA-1) is a conformationally flexible alpha/beta heterodimeric receptor, which is expressed on the surface of all leukocytes. LFA-1 mediates cell adhesion crucial for normal immune and inflammatory responses. Intracellular signals or cations are required to convert LFA-1 from a nonligand binding to a ligand binding state. Here we investigated the effect of small molecule inhibitors on LFA-1 by monitoring the binding of monoclonal antibodies mapped to different receptor domains. The inhibitors were found to not only induce epitope changes in the I domain of the alpha(L) chain but also in the I-like domain of the 132 chain depending on the individual chemical structure of the inhibitor and its binding site. For the first time, we provide strong evidence that the I-like domain represents a target for allosteric LFA-1 inhibition similar to the well established regulatory L-site on the I domain of LFA-1. Moreover, the antibody binding patterns observed in the presence of the various inhibitors establish a conformational interaction between the LFA-1 I domain and the I-like domain in the native receptor that is formed upon activation. Differentially targeting the binding sites of the inhibitors, the L-site and the I-like domain, may open new avenues for highly specific therapeutic intervention in diseases where integrins play a pathophysiological role.	Novartis Pharma AG, Preclin Res, CH-4002 Basel, Switzerland	Novartis	Weitz-Schmidt, G (corresponding author), Novartis Pharma AG, Preclin Res, CH-4002 Basel, Switzerland.	gabriele.weitz@pharma.novartis.com						Birner U, 2000, INT IMMUNOL, V12, P141, DOI 10.1093/intimm/12.2.141; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Gottlieb A, 2000, J AM ACAD DERMATOL, V42, P428, DOI 10.1016/S0190-9622(00)90214-7; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hogg N, 2001, J LEUKOCYTE BIOL, V69, P893; Hu DD, 1999, J BIOL CHEM, V274, P4633, DOI 10.1074/jbc.274.8.4633; HUANG C, 1995, LEUCOCYTE TYPING, V5, P1595; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3162, DOI 10.1073/pnas.94.7.3162; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; Kelly TA, 1999, J IMMUNOL, V163, P5173; LA ROCHE, 2000, Patent No. 0021920; Last-Barney K, 2001, J AM CHEM SOC, V123, P5643, DOI 10.1021/ja0104249; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Liu G, 2001, J MED CHEM, V44, P1202, DOI 10.1021/jm000503f; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Lupher ML, 2001, J IMMUNOL, V167, P1431, DOI 10.4049/jimmunol.167.3.1431; Martin X, 2000, TRANSPLANT P, V32, P481, DOI 10.1016/S0041-1345(00)00849-6; Nakakura EK, 1996, TRANSPLANTATION, V62, P547, DOI 10.1097/00007890-199609150-00001; RANDI AM, 1994, J BIOL CHEM, V269, P12395; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong YM, 2001, J BIOL CHEM, V276, P19340, DOI 10.1074/jbc.M008903200; Zang Q, 2000, J BIOL CHEM, V275, P22202, DOI 10.1074/jbc.M002883200	32	70	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10590	10598		10.1074/jbc.M110521200	http://dx.doi.org/10.1074/jbc.M110521200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11781316	hybrid			2022-12-27	WOS:000174549200129
J	Nakanishi, A; Imajoh-Ohmi, S; Hanaoka, F				Nakanishi, A; Imajoh-Ohmi, S; Hanaoka, F			Characterization of the interaction between DNA gyrase inhibitor and DNA gyrase of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBIOTIC MICROCIN B17; PLASMID CCDB PROTEIN; N-TERMINAL FRAGMENT; B-PROTEIN; POSTTRANSLATIONAL MODIFICATIONS; COUMARIN DRUGS; LETD CCDB; PURIFICATION; CLEAVAGE; COMPLEXES	Escherichia coli DNA gyrase is comprised of two subunits, GyrA and GyrB. Previous studies have shown that GyrI, a regulatory factor of DNA gyrase activity, inhibits the supercoiling activity of DNA gyrase and that both overexpression and antisense expression of the gyrI gene suppress cell proliferation. Here we have analyzed the interaction of GyrI with DNA gyrase using two approaches. First, immunoprecipitation experiments revealed that GyrI interacts preferentially with the holoenzyme in an ATP-independent manner, although a weak interaction was also detected between GyrI and the individual GyrA and GyrB subunits. Second, surface plasmon resonance experiments indicated that GyrI binds to the gyrase holoenzyme with higher affinity than to either the GyrA or GyrB subunit alone. Unlike quinolone antibiotics, GyrI was not effective in stabilizing the cleavable complex consisting of gyrase and DNA. Further, we identified an 8-residue synthetic peptide, corresponding to amino acids (89)ITGGQYAV(96) of GyrI, which inhibits gyrase activity in an in vitro supercoiling assay. Surface plasmon resonance analysis of the ITGGQYAV-containing peptide-gyrase interaction indicated a high association constant for this interaction. These results suggest that amino acids 89-96 of GyrI are essential for its interaction with, and inhibition of, DNA gyrase.	Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan; RIKEN, Inst Phys & Chem Res, Cellular Physiol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 108, Japan	Osaka University; Japan Science & Technology Agency (JST); RIKEN; University of Tokyo	Hanaoka, F (corresponding author), Osaka Univ, Inst Mol & Cellular Biol, 1-3 Yamadaoka, Suita, Osaka 5650871, Japan.	fhanaoka@imcb.osaka-u.ac.jp						ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; AOYAMA H, 1988, ANTIMICROB AGENTS CH, V32, P104, DOI 10.1128/AAC.32.1.104; Bahassi EM, 1999, J BIOL CHEM, V274, P10936, DOI 10.1074/jbc.274.16.10936; BAQUERO MR, 1995, MOL MICROBIOL, V18, P301, DOI 10.1111/j.1365-2958.1995.mmi_18020301.x; BAYER A, 1995, EUR J BIOCHEM, V234, P414, DOI 10.1111/j.1432-1033.1995.414_b.x; BERNARD P, 1992, J MOL BIOL, V226, P735, DOI 10.1016/0022-2836(92)90629-X; BERNARD P, 1993, J MOL BIOL, V234, P534, DOI 10.1006/jmbi.1993.1609; Brino L, 2000, J BIOL CHEM, V275, P9468, DOI 10.1074/jbc.275.13.9468; Couturier M, 1998, TRENDS MICROBIOL, V6, P269, DOI 10.1016/S0966-842X(98)01311-0; GELLERT M, 1979, P NATL ACAD SCI USA, V76, P6289, DOI 10.1073/pnas.76.12.6289; Gorgani NN, 1997, BIOCHEMISTRY-US, V36, P6653, DOI 10.1021/bi962573n; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; Kampranis SC, 1999, BIOCHEMISTRY-US, V38, P1967, DOI 10.1021/bi982320p; Kampranis SC, 1999, P NATL ACAD SCI USA, V96, P8414, DOI 10.1073/pnas.96.15.8414; Krebs B, 1998, J BIOL CHEM, V273, P2858, DOI 10.1074/jbc.273.5.2858; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis RJ, 1996, EMBO J, V15, P1412, DOI 10.1002/j.1460-2075.1996.tb00483.x; LIU J, 1994, P NATL ACAD SCI USA, V91, P4618, DOI 10.1073/pnas.91.11.4618; Madison LL, 1997, MOL MICROBIOL, V23, P161, DOI 10.1046/j.1365-2958.1997.2041565.x; Maki S, 1996, J MOL BIOL, V256, P473, DOI 10.1006/jmbi.1996.0102; MAKI S, 1992, J BIOL CHEM, V267, P12244; Mattson DL, 1996, ANAL BIOCHEM, V240, P306, DOI 10.1006/abio.1996.0364; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; MAXWELL A, 1993, MOL MICROBIOL, V9, P681, DOI 10.1111/j.1365-2958.1993.tb01728.x; MENZEL R, 1994, ADV PHARM A, V29, P201; Milne JC, 1999, BIOCHEMISTRY-US, V38, P4768, DOI 10.1021/bi982975q; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; NAKANISHI A, 1992, J BIOL CHEM, V267, P19072; Nakanishi A, 1998, J BIOL CHEM, V273, P1933, DOI 10.1074/jbc.273.4.1933; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; SATO K, 1986, ANTIMICROB AGENTS CH, V30, P777, DOI 10.1128/AAC.30.5.777; Scheirer KE, 1997, J BIOL CHEM, V272, P27202, DOI 10.1074/jbc.272.43.27202; Ueda T, 1998, J BIOCHEM-TOKYO, V124, P712, DOI 10.1093/oxfordjournals.jbchem.a022171; VIZAN JL, 1991, EMBO J, V10, P467, DOI 10.1002/j.1460-2075.1991.tb07969.x; Wentzell LM, 2000, J MOL BIOL, V304, P779, DOI 10.1006/jmbi.2000.4266; Wigley D.B., 1995, NUCL ACIDS MOL BIOL, P165; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WILLMOTT CJR, 1994, J MOL BIOL, V242, P351, DOI 10.1006/jmbi.1994.1586; YORGEY P, 1994, P NATL ACAD SCI USA, V91, P4519, DOI 10.1073/pnas.91.10.4519	40	12	14	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8949	8954		10.1074/jbc.M111278200	http://dx.doi.org/10.1074/jbc.M111278200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11777918	hybrid			2022-12-27	WOS:000174400600030
J	Selbach, M; Moese, S; Hauck, CR; Meyer, TF; Backert, S				Selbach, M; Moese, S; Hauck, CR; Meyer, TF; Backert, S			Src is the kinase of the Helicobacter pylori CagA protein in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC EPITHELIAL-CELLS; IV SECRETION; C-SRC; TRANSLOCATION; PHOSPHORYLATION; VIRULENCE; DISEASE; ANTIGEN	The gastric pathogen Helicobacter pylori uses a type IV secretion system to inject the bacterial CagA protein into gastric epithelial cells. Within the host cell, CagA becomes phosphorylated on tyrosine residues and initiates cytoskeletal rearrangements. We demonstrate here that Src-like protein-tyrosine kinases mediate CagA phosphorylation in vitro and in vivo. First, the Src-specific tyrosine kinase inhibitor PP2 specifically blocks CagA phosphorylation and cytoskeletal rearrangements thereby inhibiting the CagA-induced hummingbird phenotype of gastric epithelial cells. Second, CagA is in vivo phosphorylated by transiently expressed c-Src. Third, recombinant c-Src and lysates derived from c-Src-expressing fibroblasts but not lysates derived from Src-, Yes-, and Fyn-deficient cells phosphorylated CagA in vitro. Fourth, a transfected CagA-GFP fusion protein is phosphorylated in vivo in Src-positive fibroblasts but not in Src-, Yes-, and Fyn-deficient cells. Because a CagA-GFP fusion protein mutated in an EPIYA motif is not efficiently phosphorylated. in any of these fibroblast cells, the CagA EPIYA motif appears to constitute the major c-Src phosphorylation site conserved among CagA-positive Helicobacter strains.	Max Planck Inst Infekt Biol, Abt Mol BIol, D-10117 Berlin, Germany; Univ Wurzburg, Zentrum Infekt Forsch, D-97070 Wurzburg, Germany	Max Planck Society; University of Wurzburg	Meyer, TF (corresponding author), Max Planck Inst Infekt Biol, Abt Mol BIol, Schumannstr 20-21, D-10117 Berlin, Germany.		Selbach, Matthias/C-5988-2008; Meyer, Thomas F. F/J-2485-2013	Meyer, Thomas F. F/0000-0002-6120-8679				Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Backert S, 2001, MOL MICROBIOL, V42, P631, DOI 10.1046/j.1365-2958.2001.02649.x; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; Cover TL, 1999, GASTROENTEROLOGY, V117, P257, DOI 10.1016/S0016-5085(99)70575-5; Crabtree JE, 1999, J CLIN PATHOL, V52, P653, DOI 10.1136/jcp.52.9.653; Fischer W, 2001, MOL MICROBIOL, V42, P1337, DOI 10.1046/j.1365-2958.2001.02714.x; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HIGASHI H, 2001, SCIENCE; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; KARN J, 1989, ONCOGENE, V4, P773; Kenny B, 1999, MOL MICROBIOL, V31, P1229, DOI 10.1046/j.1365-2958.1999.01265.x; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LEVITZKI A, 1991, TRENDS PHARMACOL SCI, V12, P171, DOI 10.1016/0165-6147(91)90538-4; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Montecucco C, 2001, NAT REV MOL CELL BIO, V2, P457, DOI 10.1038/35073084; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Selbach M, 2002, INFECT IMMUN, V70, P665, DOI 10.1128/IAI.70.2.665-671.2002; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Tian MX, 1997, MOL BIOL CELL, V8, P1183, DOI 10.1091/mbc.8.7.1183	27	331	347	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					6775	6778		10.1074/jbc.C100754200	http://dx.doi.org/10.1074/jbc.C100754200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11788577	hybrid, Green Published			2022-12-27	WOS:000174104300005
J	Huang, DS; Cheung, AT; Parsons, JT; Bryer-Ash, M				Huang, DS; Cheung, AT; Parsons, JT; Bryer-Ash, M			Focal adhesion kinase (FAK) regulates insulin-stimulated glycogen synthesis in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; SYNTHASE KINASE-3; RECEPTOR SUBSTRATE-1; DIFFERENTIAL REGULATION; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; POTENTIAL ROLE; CELL-ADHESION	Experimental data support a role for FAK, an important component of the integrin signaling pathway, in insulin action. To test the hypothesis that FAK plays a regulatory role in hepatic insulin action, we overexpressed wild type (WT), a kinase inactive (KR), or a COOH-terminal focal adhesion targeting (FAT) sequence-truncated mutant of FAK in HepG2 hepatoma cells. In control untransfected (NON) and vector (CMV2)- and WT-transfected cells, insulin stimulated an expected 54 +/- 13, 37 +/- 4, and 47 +/- 12 increase in [U-C-14]glucose incorporation into glycogen, respectively. This was entirely abolished in the presence of either KR (-1 +/- 7%) or FAT mutants (0 +/- 8%, n = 5, p < 0.05 for KR or FAT versus other groups), and this was associated with a significant attenuation of incremental insulin-stimulated glycogen synthase (GS) activity. Insulin-stimulated serine phosphorylation of Akt/protein kinase B was significantly impaired in mutant-transfected cells. Moreover, the ability of insulin to inactivate GS kinase-3 beta (GSK-3 beta), the regulatory enzyme immediately upstream of GS, by serine phosphorylation (308 +/- 16, 321 +/- 41, and 458 +/- 34 optical densitometric units (odu) in NON, CMV2, and WT, respectively, p < 0.02 for WT versus CMV2) was attenuated in the presence of either FAT (205 +/- 14, p < 0.01) or KR (189 +/- 4, p < 0.005) mutants. FAK co-immunoprecipitated with GSK-3beta, but only in cells overexpressing the KR (374 +/- 254 odu) and FAT (555 +/- 308) mutants was this association stimulated by insulin compared with NON (-209 +/- 92), CMV2 (-47 +/- 70), and WT (-39 +/- 31 odu). This suggests that FAK and GSK-3beta form both a constitutive association and a transient complex upon insulin stimulation, the dissociation of which requires normal function and localization of FAK. We conclude that FAK regulates the activity of Akt/protein kinase B and GSK-3beta and the association of GSK-3beta with FAK to influence insulin-stimulated glycogen synthesis in hepatocytes. Insulin action may be subject to regulation by the integrin signaling pathway, ensuring that these growth and differentiation-promoting pathways act in a coordinated and/or complementary manner.	Univ Calif Los Angeles, Sch Med, Div Endocrinol Diabet & Hypertens, Gonda Goldschmied Diabet Ctr, Los Angeles, CA 90095 USA; W Los Angeles Vet Adm Med Ctr, Res Serv, Los Angeles, CA 90095 USA; Univ Tennessee, Hlth Sci Ctr, Memphis, TN 38103 USA; Vet Adm Med Ctr, Res Serv, Memphis, TN 38103 USA; Univ Virginia, Charlottesville, VA 22908 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Virginia	Bryer-Ash, M (corresponding author), Univ Calif Los Angeles, Sch Med, Div Endocrinol Diabet & Hypertens, Gonda Goldschmied Diabet Ctr, 900 Vet Ave,Warren Hall 24-130, Los Angeles, CA 90095 USA.	mbryerash@mednet.ucla.edu			NCRR NIH HHS [RR00211] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGIUS L, 1990, BIOCHEM J, V266, P91, DOI 10.1042/bj2660091; AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BACKER JM, 1992, J BIOL CHEM, V267, P1367; Baron V, 1998, J BIOL CHEM, V273, P7162, DOI 10.1074/jbc.273.12.7162; Bogdanovic E, 2001, DIABETES, V50, pA267; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Cheung AT, 2000, DIABETES, V49, P810, DOI 10.2337/diabetes.49.5.810; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Disatnik MH, 1999, J BIOL CHEM, V274, P32486, DOI 10.1074/jbc.274.45.32486; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GOODE N, 1992, J BIOL CHEM, V267, P16878; Guilherme A, 1998, J BIOL CHEM, V273, P22899, DOI 10.1074/jbc.273.36.22899; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Halse R, 1999, J BIOL CHEM, V274, P776, DOI 10.1074/jbc.274.2.776; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1997, J CELL SCI, V110, P401; ILLC D, 1995, NATURE, V377, P539; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kurowski TG, 1999, DIABETES, V48, P658, DOI 10.2337/diabetes.48.3.658; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavoie L, 1999, J BIOL CHEM, V274, P28279, DOI 10.1074/jbc.274.40.28279; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; Lebrun P, 1998, J BIOL CHEM, V273, P32244, DOI 10.1074/jbc.273.48.32244; Lebrun P, 2000, J BIOL CHEM, V275, P38371, DOI 10.1074/jbc.M006162200; Lee HS, 2000, J BONE MINER RES, V15, P1501, DOI 10.1359/jbmr.2000.15.8.1501; Lin YS, 2001, AM J PHYSIOL-ENDOC M, V281, pE8, DOI 10.1152/ajpendo.2001.281.1.E8; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; Markuns JF, 1999, J BIOL CHEM, V274, P24896, DOI 10.1074/jbc.274.35.24896; Matsumoto M, 2001, J BIOL CHEM, V276, P14400, DOI 10.1074/jbc.M011093200; Noe V, 1999, BIOCHEM SOC SYMP, V65, P43; OKADA T, 1994, J BIOL CHEM, V269, P3568; Proud CG, 1997, BIOCHEM J, V328, P329; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Ridyard MS, 2001, CELL BIOL INT, V25, P215, DOI 10.1006/cbir.2000.0634; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SMITH RL, 1985, J BIOL CHEM, V260, P273; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; Sung CK, 1998, J RECEPT SIGNAL TR R, V18, P243, DOI 10.3109/10799899809047746; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; VanderZon GCM, 1996, BIOCHEMISTRY-US, V35, P10377, DOI 10.1021/bi960350r; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wang QH, 1998, MOL BIOL CELL, V9, P3057, DOI 10.1091/mbc.9.11.3057; WOODGETT JR, 1994, SEMIN CANCER BIOL, V5, P269; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217	69	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18151	18160		10.1074/jbc.M104252200	http://dx.doi.org/10.1074/jbc.M104252200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11809746	hybrid			2022-12-27	WOS:000175685100097
J	Uesono, Y; Toh-e, A				Uesono, Y; Toh-e, A			Transient inhibition of translation initiation by osmotic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE CASCADE; GENE-EXPRESSION; MESSENGER-RNA; RIBOSOME BIOGENESIS; POP2 GENE; BINDING; GLYCEROL; RAPAMYCIN	Cells respond and adapt to changes in the environment. In this study, we examined the effect of environmental stresses on protein synthesis in the yeast Sac. charomyces cerevisiae. We found that osmotic stress causes irreversible inhibition of methionine uptake, transient inhibition of uracil uptake, transient stimulation of glucose uptake, transient repression of ribosomal protein (RP) genes such as CYH2 and RPS27, and the transient inhibition of translation initiation. Rapid inhibition of translation initiation by osmotic stress requires a novel pathway, different from the amino acid-sensing pathway, the glucose-sensing pathway, and the TOR pathway. The Hog1 MAP kinase pathway is not involved in the inhibition of either methionine uptake or translation initiation but is required for the adaptation of translation initiation after inhibition and the repression of RP genes by osmotic stress. These results suggest that the transient inhibition of translation initiation occurs as a result of a combination of both acute inhibition of translation and the long-term activation of translation by the Hog1 pathway.	Univ Tokyo, Grad Sch Sci, Dept Sci Biol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Uesono, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Sci Biol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	uesono@biol.s.u-tokyo.ac.jp						ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Ashe MP, 2000, MOL BIOL CELL, V11, P833, DOI 10.1091/mbc.11.3.833; BAIM SB, 1985, MOL CELL BIOL, V5, P1839, DOI 10.1128/MCB.5.8.1839; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Berset C, 1998, P NATL ACAD SCI USA, V95, P4264, DOI 10.1073/pnas.95.8.4264; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; CHOWDHURY S, 1992, J CELL BIOL, V118, P561, DOI 10.1083/jcb.118.3.561; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; HARTWELL LH, 1969, P NATL ACAD SCI USA, V62, P468, DOI 10.1073/pnas.62.2.468; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kleijn M, 1998, EUR J BIOCHEM, V253, P531, DOI 10.1046/j.1432-1327.1998.2530531.x; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LUYTEN K, 1995, EMBO J, V14, P1360, DOI 10.1002/j.1460-2075.1995.tb07122.x; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MAGER WH, 1993, MOL MICROBIOL, V10, P253, DOI 10.1111/j.1365-2958.1993.tb01951.x; McCarthy JEG, 1998, MICROBIOL MOL BIOL R, V62, P1492, DOI 10.1128/MMBR.62.4.1492-1553.1998; Moriya H, 2001, GENE DEV, V15, P1217, DOI 10.1101/gad.884001; NIKAWA J, 1987, GENE DEV, V1, P931, DOI 10.1101/gad.1.9.931; Norbeck J, 1997, J BIOL CHEM, V272, P5544, DOI 10.1074/jbc.272.9.5544; O'Rourke SM, 1998, GENE DEV, V12, P2874, DOI 10.1101/gad.12.18.2874; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Ptushkina M, 1998, EMBO J, V17, P4798, DOI 10.1093/emboj/17.16.4798; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SAKAI A, 1992, NUCLEIC ACIDS RES, V20, P6227, DOI 10.1093/nar/20.23.6227; Sasaki T, 2000, MOL CELL BIOL, V20, P7971, DOI 10.1128/MCB.20.21.7971-7979.2000; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Shimizu-Yoshida Y, 1999, YEAST, V15, P1357, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1357::AID-YEA465>3.0.CO;2-Y; SHORTLE D, 1982, SCIENCE, V217, P371, DOI 10.1126/science.7046050; Slaninova I, 2000, ARCH MICROBIOL, V173, P245, DOI 10.1007/s002030000136; Smith A, 1998, EMBO J, V17, P3556, DOI 10.1093/emboj/17.13.3556; Tamas MJ, 1999, MOL MICROBIOL, V31, P1087, DOI 10.1046/j.1365-2958.1999.01248.x; Tarun SZ, 1997, MOL CELL BIOL, V17, P6876, DOI 10.1128/MCB.17.12.6876; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Uesono Y, 1997, J BIOL CHEM, V272, P16103, DOI 10.1074/jbc.272.26.16103; Valasek L, 1998, J BIOL CHEM, V273, P21253, DOI 10.1074/jbc.273.33.21253; VARELA JCS, 1992, MOL MICROBIOL, V6, P2183, DOI 10.1111/j.1365-2958.1992.tb01392.x; Welch EM, 1999, EMBO J, V18, P6134, DOI 10.1093/emboj/18.21.6134; Zhu SH, 1998, J BIOL CHEM, V273, P1808, DOI 10.1074/jbc.273.3.1808	51	100	104	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13848	13855		10.1074/jbc.M108848200	http://dx.doi.org/10.1074/jbc.M108848200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11796711	hybrid			2022-12-27	WOS:000175096000067
J	Gotoh, T; Oyadomari, S; Mori, K; Mori, M				Gotoh, T; Oyadomari, S; Mori, K; Mori, M			Nitric oxide-induced apoptosis in RAW 264.7 macrophages is mediated by endoplasmic reticulum stress pathway involving ATF6 and CHOP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-Y CBF; PROTEIN; ELEMENT; EXPRESSION; BINDING; GENE; IDENTIFICATION; PROTEOLYSIS; INDUCTION; ACTIVATOR	Excess nitric oxide (NO) induces apoptosis in some cell types including macrophages; however, the cascade of NO-mediated apoptosis is not fully understood. We investigated the initial steps of NO-mediated apoptosis in mouse macrophage-like RAW 264.7 cells. When cells were treated with bacterial lipopolysaccharide (LPS) plus interferon-gamma (IFN-gamma), NO-mediated apoptosis occurred. Under these conditions, p53 accumulation was not observed, indicating that DNA damage is not the main trigger of NO-mediated apoptosis. On the other hand, mRNA and protein for CHOP, a transcription factor known to be induced by endoplasmic reticulum (ER) stress, were induced. The CHOP induction by LPS/IFN-gamma treatment preceded cytochrome c release from mitochondria. In addition, p90ATF6, an ER membrane-bound transcription factor involved in ER stress response, was cleaved to its active soluble form p50ATF6, which was transported to nucleus and bound to the ER stress response element of the CHOP gene. In the luciferase reporter assay, both the CHOP-bindiug element of the Rous sarcoma virus long terminal repeat and ER stress response element of the CHOP gene were activated by LPS/IFN-gamma treatment. When RAW 264.7 cells or COS-7 cells were transfected with expression plasmids for CHOP, p90ATF6, or p50ATF6, cell death was observed. In addition, apoptosis induced by p50ATF6 was prevented by a CHOP dominant negative form as well as by an ATF6 dominant negative form, and LPS/IFN-gamma-induced apoptosis was prevented by the CHOP dominant negative form. Peritoneal macrophages from CHOP knockout mice showed resistance to NO-induced apoptosis. These results indicate that the ER stress pathway involving ATF6 and CHOP plays a key role in NO-mediated apoptosis in macrophages.	Kumamoto Univ, Sch Med, Dept Mol Genet, Kumamoto 8600811, Japan; Kyoto Univ, Grad Sch Biostudies, Kyoto 6068304, Japan	Kumamoto University; Kyoto University	Mori, K (corresponding author), Kumamoto Univ, Sch Med, Dept Mol Genet, Honjo 2-2-1, Kumamoto 8600811, Japan.	tomomi@gpo.kumamoto-u.ac.jp	Oyadomari, Seiichi/GZA-7157-2022; Oyadomari, Seiichi/GZA-7072-2022; Mori, Kazutoshi/K-6106-2015					Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Dimmeler S, 1997, NITRIC OXIDE-BIOL CH, V1, P275, DOI 10.1006/niox.1997.0133; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Gotoh T, 2001, CELL DEATH DIFFER, V8, P357, DOI 10.1038/sj.cdd.4400829; GOTOH T, 1994, J BIOCHEM-TOKYO, V115, P778, DOI 10.1093/oxfordjournals.jbchem.a124409; Gotoh T, 1999, J CELL BIOL, V144, P427, DOI 10.1083/jcb.144.3.427; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Haze K, 2001, BIOCHEM J, V355, P19, DOI 10.1042/0264-6021:3550019; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawahara K, 2001, FEBS LETT, V506, P135, DOI 10.1016/S0014-5793(01)02898-8; Kroncke KD, 1997, NITRIC OXIDE-BIOL CH, V1, P107, DOI 10.1006/niox.1997.0118; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; MIYAZAKI J, 1989, GENE, V79, P269; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Salimuddin, 1999, AM J PHYSIOL-ENDOC M, V277, pE110, DOI 10.1152/ajpendo.1999.277.1.E110; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Urano F, 2000, J CELL SCI, V113, P3697; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	35	209	228	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12343	12350	PII 10.1074/jbc.M107988200	10.1074/jbc.M107988200	http://dx.doi.org/10.1074/jbc.M107988200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805088	hybrid			2022-12-27	WOS:000174846400097
J	Hirohata, S; Wang, LW; Miyagi, M; Yan, L; Seldin, MF; Keene, DR; Crabb, JW; Apte, SS				Hirohata, S; Wang, LW; Miyagi, M; Yan, L; Seldin, MF; Keene, DR; Crabb, JW; Apte, SS			Punctin, a novel ADAMTS-like molecule, ADAMTSL-1, in extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; HUMAN GELATINASE-A; CELL-ADHESION; TNF-ALPHA; TS FAMILY; PROTEIN; DOMAIN; FIBRONECTIN; BINDING; IDENTIFICATION	Punctin (ADAMTSL-1) is a secreted molecule resembling members of the ADAMTS family of proteases. Punctin lacks the pro-metalloprotease and the disintegrin-like domain typical of this family but contains other ADAMTS domains in precise order including four thrombospondin type I repeats. Punctin is the product of a distinct gene on human chromosome 9p21-22 and mouse chromosome 4 that is expressed in adult skeletal muscle. His-tagged punctin expressed in stably transfected High-Five(TM) insect cells was purified to apparent homogeneity by Ni-chromatography of conditioned medium. The NH2 terminus is not blocked and has the sequence EEDRD and so forth as determined by Edman degradation, demonstrating signal peptidase processing. Recombinant epitope-tagged punctin has a calculated mass of 59,991 Da but exhibits major molecular species of 61970 +/- 6 Da and 62131 +/- 5 Da as measured by liquid chromatography electrospray mass spectrometry. Punctin is a glycoprotein based on carbohydrate staining and liquid chromatography electrospray mass spectrometry glycopeptide analysis. Glycosylation occurs at a single N-linked site as demonstrated by altered electrophoretic migration of punctin expressed in the presence of tunicamycin A. Punctin contains disulfide bonds based on antibody accessibility and electrophoretic migration under reducing versus nonreducing conditions. Rotary shadowing demonstrates that punctin is hatchet-shaped having a globular region attached to a short stem. In transfected COS-1 cells, punctin is deposited in the cell substratum in a punctate fashion and is excluded from focal contacts. Punctin is the first member of a novel family of ADAMTS-like proteins that may have important functions in the extracellular matrix.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Orthopaed Surg, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Cole Eye Inst, Dept Ophthalm Res, Cleveland, OH 44195 USA; Univ Calif Davis, Rowe Program Genet, Dept Biol Chem, Davis, CA 95616 USA; Univ Calif Davis, Rowe Program Genet, Dept Med, Davis, CA 95616 USA; Shriners Hosp Children, Portland, OR 97201 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of California System; University of California Davis; University of California System; University of California Davis	Apte, SS (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, 9500 Euclid Ave ND20, Cleveland, OH 44195 USA.			Apte, Suneel/0000-0001-8441-1226	NEI NIH HHS [EY06603] Funding Source: Medline; NHGRI NIH HHS [HGO0734] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000734] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bein K, 2000, J BIOL CHEM, V275, P32167, DOI 10.1074/jbc.M003834200; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Bornstein P, 2000, MATRIX BIOL, V19, P557, DOI 10.1016/S0945-053X(00)00104-9; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Crabb JW, 1998, J BIOL CHEM, V273, P20712, DOI 10.1074/jbc.273.33.20712; CRABB JW, 1997, CURRENT PROTOCOLS PR; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Georgiadis KE, 1999, GENOMICS, V62, P312, DOI 10.1006/geno.1999.6014; HAYMAN EG, 1982, J CELL BIOL, V94, P28, DOI 10.1083/jcb.94.1.28; HAYMAN EG, 1985, EXP CELL RES, V160, P245, DOI 10.1016/0014-4827(85)90173-9; Holden P, 2001, J BIOL CHEM, V276, P6046, DOI 10.1074/jbc.M009507200; Hulmes DJS, 1997, MATRIX BIOL, V16, P41, DOI 10.1016/S0945-053X(97)90115-3; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; Isogai Z, 1996, CANCER RES, V56, P3902; Kapron JT, 1997, PROTEIN SCI, V6, P2120; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kramerova IA, 2000, DEVELOPMENT, V127, P5475; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; MADDOX BK, 1989, J BIOL CHEM, V264, P21381; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Nardi JB, 1999, INSECT BIOCHEM MOLEC, V29, P883, DOI 10.1016/S0965-1748(99)00064-8; OHJI M, 1994, INVEST OPHTH VIS SCI, V35, P479; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SINGER II, 1987, EXP CELL RES, V173, P558, DOI 10.1016/0014-4827(87)90295-3; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; Solomon KA, 1999, J IMMUNOL, V163, P4105; STASKUS PW, 1991, J BIOL CHEM, V266, P449; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WATSON ML, 1994, METH MOL G, V5, P369; YAMAGATA M, 1993, J CELL SCI, V106, P55; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345; Zolkiewska A, 1999, EXP CELL RES, V252, P423, DOI 10.1006/excr.1999.4632	43	67	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12182	12189		10.1074/jbc.M109665200	http://dx.doi.org/10.1074/jbc.M109665200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805097	hybrid			2022-12-27	WOS:000174846400076
J	Lang, R; Gomes, AV; Zhao, JJ; Housmans, PR; Miller, T; Potter, JD				Lang, R; Gomes, AV; Zhao, JJ; Housmans, PR; Miller, T; Potter, JD			Functional analysis of a troponin I (R145G) mutation associated with familial hypertrophic cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC-MUSCLE CONTRACTION; PROTEIN-C GENE; INHIBITORY REGION; T MUTATIONS; INTRACELLULAR CA2+; ALTERED REGULATION; CALCIUM-BINDING; MYOSIN; TROPOMYOSIN; PHOSPHORYLATION	Familial hypertrophic cardiomyopathy has been associated with several mutations in the gene encoding human cardiac troponin I (HCTnI). A missense mutation in the inhibitory region of TnI replaces an arginine residue at position 145 with a glycine and cosegregates with the disease. Results from several assays indicate that the inhibitory function of HCTnI(R145G) is significantly reduced. When HCTnI(R145G) was incorporated into whole troponin, Tn(R145G) (HCTnT.HCTnIR(145G).HCTnC), only partial inhibition of the actin-tropomyosin-myosin ATPase activity was observed in the absence of Ca2+ compared with wild type Tn (HCTnT.HCTnI-HCTnC). Maximal activation of actin-tropomyosin-myosin ATPase in the presence of Ca2+ was also decreased in Tn(R145G) when compared with Tn. Using skinned cardiac muscle fibers, we determined that in comparison with the wild type complex 1) the complex containing HCTnI(R145G) only inhibited 84% of Ca2+-unregulated force, 2) the recovery of Ca2+-activated force was decreased, and 3) there was a significant increase in the Ca2+ sensitivity of force development. Computer modeling of troponin C and I variables predicts that the primary defect in TnI caused by these mutations would lead to diastolic dysfunction. These results suggest that severe diastolic dysfunction and somewhat decreased contractility would be prominent clinical features and that hypertrophy could arise as a compensatory mechanism.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33101 USA; Mayo Clin & Mayo Fdn, Dept Anesthesiol, Rochester, MN 55905 USA	University of Miami; Mayo Clinic	Potter, JD (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, POB 016189 R-189, Miami, FL 33101 USA.	jdpotter@miami.edu	Gomes, Aldrin V/I-6529-2018	Gomes, Aldrin V/0000-0002-9819-3036	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042325, R01HL042325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036365] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42325] Funding Source: Medline; NIGMS NIH HHS [GM36365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMOUR KL, 1993, GENE, V131, P287, DOI 10.1016/0378-1119(93)90308-P; Bhavsar PK, 1996, GENOMICS, V35, P11, DOI 10.1006/geno.1996.0317; BLINKS JR, 1986, CIRCULATION, V73, P85; BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; Deng Y, 2001, BIOCHEMISTRY-US, V40, P14593, DOI 10.1021/bi0115232; Elliott K, 2000, J BIOL CHEM, V275, P22069, DOI 10.1074/jbc.M002502200; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; Fiske CH, 1925, J BIOL CHEM, V66, P375; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GREASER ML, 1971, J BIOL CHEM, V246, P4226; HATAKENAKA M, 1992, EUR J BIOCHEM, V205, P985, DOI 10.1111/j.1432-1033.1992.tb16865.x; Hernandez OM, 2001, J APPL PHYSIOL, V90, P1125, DOI 10.1152/jappl.2001.90.3.1125; Hoffmann B, 2001, Hum Mutat, V17, P524, DOI 10.1002/humu.1143; HOFMANN PA, 1987, AM J PHYSIOL, V253, pC541, DOI 10.1152/ajpcell.1987.253.4.C541; Housmans PR, 2000, ANESTHESIOLOGY, V93, P189, DOI 10.1097/00000542-200007000-00030; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; James J, 2000, CIRC RES, V87, P805, DOI 10.1161/01.RES.87.9.805; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; Knollmann BC, 2001, TRENDS CARDIOVAS MED, V11, P206, DOI 10.1016/S1050-1738(01)00115-3; Kokado H, 2000, CIRCULATION, V102, P663, DOI 10.1161/01.CIR.102.6.663; LANDESBERG A, 1994, AM J PHYSIOL, V266, pH1260, DOI 10.1152/ajpheart.1994.266.3.H1260; Marian AJ, 1998, J CARDIOVASC ELECTR, V9, P88, DOI 10.1111/j.1540-8167.1998.tb00871.x; Mikane T, 1997, AM J PHYSIOL-HEART C, V273, pH2891, DOI 10.1152/ajpheart.1997.273.6.H2891; Miller T, 2001, J BIOL CHEM, V276, P3743, DOI 10.1074/jbc.M006746200; Mogensen J, 1999, J CLIN INVEST, V103, pR39, DOI 10.1172/JCI6460; Morner S, 2000, J MOL CELL CARDIOL, V32, P521, DOI 10.1006/jmcc.1999.1099; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; Satoh M, 1999, BIOCHEM BIOPH RES CO, V262, P411, DOI 10.1006/bbrc.1999.1221; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; Szczesna D, 1999, J BIOL CHEM, V274, P29536, DOI 10.1074/jbc.274.41.29536; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; Takahashi-Yanaga F, 2000, J BIOCHEM-TOKYO, V127, P355, DOI 10.1093/oxfordjournals.jbchem.a022615; TALBOT JA, 1981, J BIOL CHEM, V256, P2374; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; VALLINS WJ, 1990, FEBS LETT, V270, P57, DOI 10.1016/0014-5793(90)81234-F; Van Eyk Jennifer E., 1993, Methods (Orlando), V5, P264, DOI 10.1006/meth.1993.1033; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; YUE DT, 1986, J GEN PHYSIOL, V87, P223, DOI 10.1085/jgp.87.2.223; ZHANG R, 1995, CIRC RES, V76, P1028, DOI 10.1161/01.RES.76.6.1028; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; ZOT AS, 1989, BIOCHEMISTRY-US, V28, P6751, DOI 10.1021/bi00442a031	46	66	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11670	11678		10.1074/jbc.M108912200	http://dx.doi.org/10.1074/jbc.M108912200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11801593	hybrid			2022-12-27	WOS:000174846400009
J	Meier, A; Livingstone-Zatchej, M; Thoma, F				Meier, A; Livingstone-Zatchej, M; Thoma, F			Repair of active and silenced rDNA in yeast - The contributions of photolyase and transcription-coupled nucleotide excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CYCLOBUTANE PYRIMIDINE DIMER; MODULATES DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; NONTRANSCRIBED STRAND; CHROMATIN TRANSITIONS; RIBOSOMAL GENES; THYMINE DIMER; IN-VIVO; DAMAGE	DNA repair by photolyase (photoreactivation) and nucleotide excision repair (NER) are the major pathways to remove UV-induced cyclobutane-pyrimidine dimers (CPDs). The nucleolus is a nuclear subcompartment containing the ribosomal RNA genes (rDNA) of which a fraction is transcribed by RNA polymerase I (RNAP-I), and the rest is silenced. Here yeast was used to investigate how photoreactivation and NER contribute to repair of active and inactive rDNA. Cells were irradiated with UV light and exposed to different repair conditions. Nuclei were isolated, and the active genes were separated from the inactive genes by restriction endonuclease digestion. CPDs were measured in total rDNA, in both fractions, and in the GAL10 gene. Repair in rDNA was as efficient as in GAL10 indicating that both pathways have unrestricted access to the nucleolus. Photoreactivation was much faster than NER and therefore was the predominant repair pathway. Active genes were faster repaired by photolyase than were silenced genes providing evidence for an open chromatin structure during repair. The transcribed strands of active genes, but not of inactive genes, were slightly faster repaired by NER providing evidence for transcription-coupled repair by RNAP-I. There was no pronounced inhibition of photoreactivation by RNAP-I in the transcribed strand, which is in contrast to genes transcribed by RNAP-II and suggests different stabilities of RNAP-I and RNAP-II stalled at CPDs.	ETH Honggerberg, Inst Zellbiol, Dept Biol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Thoma, F (corresponding author), ETH Honggerberg, Inst Zellbiol, Dept Biol, CH-8093 Zurich, Switzerland.							Aboussekhra A, 1998, GENE DEV, V12, P411, DOI 10.1101/gad.12.3.411; Aboussekhra A, 1999, EMBO J, V18, P433, DOI 10.1093/emboj/18.2.433; Balajee AS, 1999, NUCLEIC ACIDS RES, V27, P2511, DOI 10.1093/nar/27.12.2511; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; Cavalli G, 1996, EMBO J, V15, P590, DOI 10.1002/j.1460-2075.1996.tb00391.x; CHRISTIANS FC, 1994, MUTAT RES, V323, P179, DOI 10.1016/0165-7992(94)90031-0; CHRISTIANS FC, 1993, BIOCHEMISTRY-US, V32, P10512, DOI 10.1021/bi00090a030; CONCONI A, 1989, CELL, V57, P753, DOI 10.1016/0092-8674(89)90790-3; DAMMANN R, 1995, MOL CELL BIOL, V15, P5294; DAMMANN R, 1993, NUCLEIC ACIDS RES, V21, P2331, DOI 10.1093/nar/21.10.2331; Dammann R, 1997, MOL CELL BIOL, V17, P219, DOI 10.1128/MCB.17.1.219; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Fritz LK, 1996, J BIOL CHEM, V271, P12972, DOI 10.1074/jbc.271.22.12972; FRITZ LK, 1995, BIOCHEMISTRY-US, V34, P13117, DOI 10.1021/bi00040a024; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; Hara R, 1999, J BIOL CHEM, V274, P24779, DOI 10.1074/jbc.274.35.24779; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Leger-Silvestre I, 1999, CHROMOSOMA, V108, P103, DOI 10.1007/s004120050357; LivingstoneZatchej M, 1997, NUCLEIC ACIDS RES, V25, P3795, DOI 10.1093/nar/25.19.3795; Lucchini R, 1998, TRANSCRIPTION RIBOSO, P255; Meijer M, 1999, BIOESSAYS, V21, P596, DOI 10.1002/(SICI)1521-1878(199907)21:7<596::AID-BIES8>3.0.CO;2-5; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Moggs JG, 1999, BIOCHIMIE, V81, P45, DOI 10.1016/S0300-9084(99)80037-6; Muller M, 2000, MOL CELL, V5, P767, DOI 10.1016/S1097-2765(00)80317-2; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Petit C, 1999, BIOCHIMIE, V81, P15, DOI 10.1016/S0300-9084(99)80034-0; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; Sancar A, 1996, SCIENCE, V272, P48, DOI 10.1126/science.272.5258.48; Sancar GB, 2000, MUTAT RES-FUND MOL M, V451, P25, DOI 10.1016/S0027-5107(00)00038-5; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; Sherman F, 1986, LAB COURSE MANUAL ME; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; Smerdon MJ, 1999, PROG NUCLEIC ACID RE, V62, P227; SOGO JM, 1984, J MOL BIOL, V178, P897, DOI 10.1016/0022-2836(84)90318-8; STEVNSNER T, 1993, CARCINOGENESIS, V14, P1591, DOI 10.1093/carcin/14.8.1591; Suter B, 2000, NUCLEIC ACIDS RES, V28, P4083, DOI 10.1093/nar/28.21.4083; Suter B, 2000, NUCLEIC ACIDS RES, V28, P2060, DOI 10.1093/nar/28.10.2060; Suter B, 1997, EMBO J, V16, P2150, DOI 10.1093/emboj/16.8.2150; Suter B, 1999, METHOD ENZYMOL, V304, P447; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; Tijsterman M, 1999, MOL CELL BIOL, V19, P934; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; Tornaletti S, 1999, J BIOL CHEM, V274, P24124, DOI 10.1074/jbc.274.34.24124; Tu YQ, 1996, EMBO J, V15, P675, DOI 10.1002/j.1460-2075.1996.tb00400.x; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; Verhage RA, 1996, NUCLEIC ACIDS RES, V24, P1020, DOI 10.1093/nar/24.6.1020; VOS JMH, 1991, MOL CELL BIOL, V11, P2245, DOI 10.1128/MCB.11.4.2245; Wellinger RE, 1997, EMBO J, V16, P5046, DOI 10.1093/emboj/16.16.5046; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x	52	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11845	11852		10.1074/jbc.M110941200	http://dx.doi.org/10.1074/jbc.M110941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805105	hybrid			2022-12-27	WOS:000174846400032
J	Schwartz, Z; Sylvia, VL; Larsson, D; Nemere, I; Casasola, D; Dean, DD; Boyan, BD				Schwartz, Z; Sylvia, VL; Larsson, D; Nemere, I; Casasola, D; Dean, DD; Boyan, BD			1 alpha 25(OH)(2)D-3 regulates chondrocyte matrix vesicle protein kinase C (PKQ) directly via G-protein-dependent mechanisms and indirectly via incorporation of PKC during matrix vesicle biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D METABOLITES; GROWTH-PLATE CHONDROCYTES; CARTILAGE CELLS-INVITRO; RESTING ZONE; MEMBRANE-RECEPTOR; ARACHIDONIC-ACID; PHOSPHOLIPASE-D; ALKALINE-PHOSPHATASE; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; NONGENOMIC REGULATION	Matrix vesicles are extracellular organelles involved in mineral formation that are regulated by 1alpha,25 (OH)(2)D-3. Prior studies have shown that protein kinase C (PKC) activity is involved in mediating the effects of 1alpha,25(OH),D, in both matrix vesicles and plasma membranes. Here, we examined the regulation of matrix vesicle PKC by 1alpha,25(OH)(2)D-3 during biogenesis and after deposition in the matrix. When growth zone costochondral chondrocytes were treated for 9 min with 1alpha,25 (OH)(2)D-3, PCKzeta in matrix vesicles was inhibited, while PKCalpha in plasma membranes was increased. In contrast, after treatment for 12 or 24 h, PKCzeta in matrix vesicles was increased, while PKCa in plasma membranes was unchanged. The effect of 1alpha,25(OH)(2)D-3 was stereospecific and metabolite-specific. Monensin blocked the increase in matrix vesicle PKC after 24 h, suggesting the secosteroid-regulated packaging of PKC. In addition, the 1alpha,25(OH)(2)D-3 membrane vitamin D receptor (1,25-mVDR) was involved, since a specific antibody blocked the 1alpha,25(OH)(2)D-3-dependent changes in PKC after both long and short treatment times. In contrast, antibodies to annexin II had no effect, and there was no evidence for the presence of the nuclear VDR on Western blots. To investigate the signaling pathways involved in regulating matrix vesicle PKC activity after biosynthesis, matrix vesicles were isolated and then treated for 9 min with 1alpha,25(OH)(2)D-3 in the presence and absence of specific inhibitors. Inhibition of phosphatidylinositol-phospholipase C, phospholipase D, or G(i)/G(s). had no effect. However, inhibition of G(q) blocked the effect of 1alpha,25(OH)(2)D-3. The rapid effect of 1alpha,25(OH)(2)D-3 also involved the 1,25-mVDR. Moreover, arachidonic acid was found to stimulate PKC when added directly to isolated matrix vesicles. These results indicate that matrix vesicle PKC is regulated by 1alpha,25(OH)(2)D-3 at three levels: 1) during matrix vesicle biogenesis; 2) through direct action on the membrane; and 3) through production of other factors such as arachidonic acid.	Univ Texas, Hlth Sci Ctr, Dept Orthopaed, San Antonio, TX 78229 USA; Hebrew Univ Jerusalem, IL-91120 Jerusalem, Israel; Utah State Univ, Logan, UT 84322 USA	University of Texas System; University of Texas Health San Antonio; Hebrew University of Jerusalem; Utah System of Higher Education; Utah State University	Boyan, BD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Orthopaed, MSC 7774,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.		Nemere, Ilka/A-7077-2008	Dean, David/0000-0002-4512-9065	NIDCR NIH HHS [DE-05937, DE-08603] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE005937, R01DE008603] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Baran DT, 2000, J CELL BIOCHEM, V78, P34, DOI 10.1002/(SICI)1097-4644(20000701)78:1<34::AID-JCB4>3.3.CO;2-Q; Boyan B. D., 1997, Vitamin D., P395; BOYAN BD, 1988, ENDOCRINOLOGY, V122, P2851, DOI 10.1210/endo-122-6-2851; BOYAN BD, 1988, BONE, V9, P185, DOI 10.1016/8756-3282(88)90008-7; Boyan BD, 1999, STEROIDS, V64, P129, DOI 10.1016/S0039-128X(98)00099-3; BOYAN BD, 1994, J BIOL CHEM, V269, P28374; Boyan BD, 1998, J CELL PHYSIOL, V176, P516, DOI 10.1002/(SICI)1097-4652(199809)176:3<516::AID-JCP8>3.3.CO;2-I; BOYAN BD, 1984, CALCIFIED TISSUE INT, V36, P332, DOI 10.1007/BF02405339; BOYAN BD, 2002, IN PRESS DISORDERS B; BOYAN BD, IN PRESS CRIT REV OR; BOYAN BD, 2002, IN PRESS STEROIDS; CARRASCOMARIN E, 1994, EUR J IMMUNOL, V24, P2031, DOI 10.1002/eji.1830240915; de Boland AR, 1998, J CELL BIOCHEM, V69, P470, DOI 10.1002/(SICI)1097-4644(19980615)69:4<470::AID-JCB8>3.0.CO;2-K; Dean DD, 1996, CALCIFIED TISSUE INT, V59, P109, DOI 10.1007/s002239900096; DEAN DD, 1992, CALCIFIED TISSUE INT, V50, P342, DOI 10.1007/BF00301632; DEBOLAND AR, 1994, CELL SIGNAL, V6, P717, DOI 10.1016/0898-6568(94)00042-5; DUGGAN J, 2001, J DENT RES, V80, P44; EINHORN TA, 1989, J ORTHOPAED RES, V7, P792, DOI 10.1002/jor.1100070604; Facchinetti MM, 1999, CELL SIGNAL, V11, P39, DOI 10.1016/S0898-6568(98)00029-1; Facchinetti MM, 1998, J LIPID RES, V39, P197; Kirsch T, 2000, J BIOL CHEM, V275, P35577, DOI 10.1074/jbc.M005648200; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; LEACH RJ, 1995, J BONE MINER RES, V10, P1614; LOPEZRUIZ MP, 1992, ENDOCRINOLOGY, V130, P1122, DOI 10.1210/en.130.3.1122; Maeda S, 2001, J BONE MINER RES, V16, P1281, DOI 10.1359/jbmr.2001.16.7.1281; MOLLINEDO F, 1994, J IMMUNOL, V153, P2457; MORELLI S, 1993, BIOCHEM J, V289, P675, DOI 10.1042/bj2890675; Nemere I, 1998, J BONE MINER RES, V13, P1353, DOI 10.1359/jbmr.1998.13.9.1353; NEMERE I, 1994, J BIOL CHEM, V269, P23750; Nemere I, 2000, AM J PHYSIOL-ENDOC M, V278, pE1104, DOI 10.1152/ajpendo.2000.278.6.E1104; NEMERE I, 1996, J BONE MINER RES, V11, pS312; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NORMAN AW, 1992, BIOCHEM BIOPH RES CO, V189, P1450, DOI 10.1016/0006-291X(92)90237-F; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Pedrozo HA, 1999, J BONE MINER RES, V14, P856, DOI 10.1359/jbmr.1999.14.6.856; Pedrozo HA, 1999, CALCIFIED TISSUE INT, V64, P50, DOI 10.1007/s002239900578; PERESS NS, 1974, CALC TISS RES, V14, P275, DOI 10.1007/BF02060301; Racz A, 1999, J BIOL CHEM, V274, P19352, DOI 10.1074/jbc.274.27.19352; Schmitz JP, 1996, J CELL PHYSIOL, V168, P570, DOI 10.1002/(SICI)1097-4652(199609)168:3<570::AID-JCP9>3.3.CO;2-S; SCHWARTZ Z, 1988, ENDOCRINOLOGY, V123, P2878, DOI 10.1210/endo-123-6-2878; Schwartz Z, 1998, ENDOCRINOLOGY, V139, P1825, DOI 10.1210/en.139.4.1825; SCHWARTZ Z, 1990, BIOCHIM BIOPHYS ACTA, V1027, P278, DOI 10.1016/0005-2736(90)90319-J; SCHWARTZ Z, 1988, ENDOCRINOLOGY, V122, P2191, DOI 10.1210/endo-122-5-2191; SCHWARTZ Z, 1992, ENDOCRINOLOGY, V130, P2495, DOI 10.1210/en.130.5.2495; Schwartz Z, 2001, J BIOMED MATER RES, V56, P417, DOI 10.1002/1097-4636(20010905)56:3<417::AID-JBM1111>3.0.CO;2-K; Schwartz Z, 2001, STEROIDS, V66, P683, DOI 10.1016/S0039-128X(01)00100-3; SCHWARTZ Z, 1988, J BIOL CHEM, V263, P6023; SHAH BH, 1995, P NATL ACAD SCI USA, V92, P1886, DOI 10.1073/pnas.92.6.1886; SIMBOLICAMPBELL M, 1994, J BIOL CHEM, V269, P3257; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SWAIN LD, 1992, BONE MINER, V17, P192, DOI 10.1016/0169-6009(92)90735-V; SWAIN LD, 1993, BONE, V14, P609, DOI 10.1016/8756-3282(93)90082-L; Sylvia VL, 1998, J BONE MINER RES, V13, P559, DOI 10.1359/jbmr.1998.13.4.559; SYLVIA VL, 1993, J CELL PHYSIOL, V157, P271, DOI 10.1002/jcp.1041570209; Sylvia VL, 1996, J CELL PHYSIOL, V167, P380, DOI 10.1002/(SICI)1097-4652(199606)167:3<380::AID-JCP2>3.0.CO;2-L; Sylvia VL, 2001, J STEROID BIOCHEM, V78, P261, DOI 10.1016/S0960-0760(01)00099-1; TARTAKOFF AM, 1977, J EXP MED, V146, P1332, DOI 10.1084/jem.146.5.1332; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	59	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11828	11837		10.1074/jbc.M110398200	http://dx.doi.org/10.1074/jbc.M110398200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805100	hybrid			2022-12-27	WOS:000174846400030
J	Craig, TA; Benson, LM; Venyaminov, SY; Klimtchuk, ES; Bajzer, Z; Prendergast, FG; Naylor, S; Kumar, R				Craig, TA; Benson, LM; Venyaminov, SY; Klimtchuk, ES; Bajzer, Z; Prendergast, FG; Naylor, S; Kumar, R			The metal-binding properties of DREAM - Evidence for calcium-mediated changes in DREAM structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM SPECTRA; AMYLOID PRECURSOR PROTEIN; INDUCED CONFORMATIONAL-CHANGES; ALZHEIMERS-DISEASE; BETA-PROTEIN; DNA-BINDING; PRESENILINS; MUTATION	DREAM, an EF-hand protein, associates with and modulates the activity of presenilins and Kv4 potassium channels in neural and cardiac tissues and represses prodynorphin and c-fos gene expression by binding to DNA response elements in these genes. Information concerning the metal-binding properties of DREAM and the consequences of metal binding on protein structure are important in understanding how this protein functions in cells. We now show that DREAM binds 1 mol of calcium/mol of protein with relatively high affinity and another 3 mol of calcium with lower affinity. DREAM binds 1 mol of magnesium/mol of protein. DREAM, pre-loaded with 1 mol of calcium, binds 1 mol of magnesium, thus demonstrating that the magnesium-binding site is distinct from the high affinity calcium-binding site. Analysis of metal binding to mutant DREAM protein constructs localizes the high affinity calcium-binding site and the magnesium-binding site to EF-hands 3 or 4. Binding of calcium but not magnesium changes the con. formation, stability, and a-helical content of DREAM. Calcium, but not magnesium, reduces the affinity of apo-DREAM for specific DNA response elements in the pro. dynorphin and c-fos genes. We conclude that DREAM binds calcium and magnesium and that calcium, but not magnesium, modulates DREAM structure and function.	Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Biomed Mass Spectrometry & Funct Proteom Facil, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Kumar, R (corresponding author), Mayo Clin & Mayo Fdn, Dept Med, 200 1st St SW, Rochester, MN 55905 USA.	rkumar@mayo.edu		Kumar, Rajiv/0000-0003-3497-3057	NIDDK NIH HHS [R01 DK025409, R01 DK058546, DK58546, DK25409] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025409, R01DK058546] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V3; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; Bootman MD, 2000, CELL MOL LIFE SCI, V57, P371, DOI 10.1007/PL00000699; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Coughlan CM, 2000, PHARMACOL THERAPEUT, V86, P111, DOI 10.1016/S0163-7258(00)00036-X; Craig TA, 1997, BIOCHEMISTRY-US, V36, P10482, DOI 10.1021/bi970561b; Craig TA, 1996, BIOCHEM BIOPH RES CO, V218, P902, DOI 10.1006/bbrc.1996.0160; Czech C, 2000, PROG NEUROBIOL, V60, P363, DOI 10.1016/S0301-0082(99)00033-7; Fisher JR, 2000, PROTEIN EXPRES PURIF, V20, P66, DOI 10.1006/prep.2000.1298; GROSS MD, 1987, J BIOL CHEM, V262, P6539; HARDING GE, 2001, NAT NEUROSCI, V4, P2651; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JAENICKE L, 1974, ANAL BIOCHEM, V61, P623, DOI 10.1016/0003-2697(74)90429-1; Johnson KL, 1997, RAPID COMMUN MASS SP, V11, P939, DOI 10.1002/(SICI)1097-0231(199705)11:8<939::AID-RCM936>3.0.CO;2-3; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; KNOTT G, 1996, MATH MODELING LAB ML, P48; Kulic L, 2000, P NATL ACAD SCI USA, V97, P5913, DOI 10.1073/pnas.100049897; Ledo F, 2000, MOL CELL BIOL, V20, P9120, DOI 10.1128/MCB.20.24.9120-9126.2000; Ledo F, 2000, BBA-MOL CELL RES, V1498, P162, DOI 10.1016/S0167-4889(00)00092-6; Leissring MA, 2000, P NATL ACAD SCI USA, V97, P8590, DOI 10.1073/pnas.97.15.8590; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Lewis PA, 2000, BIOCHEM BIOPH RES CO, V277, P261, DOI 10.1006/bbrc.2000.3646; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Mandel G, 1999, NATURE, V398, P29, DOI 10.1038/17933; MATTEUCCI MD, 1981, J AM CHEM SOC, V103, P3185, DOI 10.1021/ja00401a041; Mellstrom B, 2001, CURR OPIN NEUROBIOL, V11, P312, DOI 10.1016/S0959-4388(00)00213-0; NAKAYAMA S, 1994, ANNU REV BIOPH BIOM, V23, P473, DOI 10.1146/annurev.bb.23.060194.002353; Nishimura M, 1999, CLIN GENET, V55, P219, DOI 10.1034/j.1399-0004.1999.550401.x; Osawa M, 2001, J BIOL CHEM, V276, P41005, DOI 10.1074/jbc.M105842200; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Russo C, 2000, NATURE, V405, P531, DOI 10.1038/35014735; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sreerama N, 2000, ANAL BIOCHEM, V287, P243, DOI 10.1006/abio.2000.4879; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Sreerama N, 1999, PROTEIN SCI, V8, P370; Sreerama N, 2001, ANAL BIOCHEM, V299, P271, DOI 10.1006/abio.2001.5420; VANSTOKKUM IHM, 1991, ANAL BIOCHEM, V291, P110; Veenstra TD, 1997, BIOCHEMISTRY-US, V36, P3535, DOI 10.1021/bi9628329; Veenstra TD, 1998, NAT BIOTECHNOL, V16, P262, DOI 10.1038/nbt0398-262; Veenstra TD, 1998, RAPID COMMUN MASS SP, V12, P613, DOI 10.1002/(SICI)1097-0231(19980529)12:10<613::AID-RCM202>3.0.CO;2-5; Veenstra TD, 1997, EUR MASS SPECTROM, V3, P453, DOI 10.1255/ejms.179; Veenstra TD, 1998, J AM SOC MASS SPECTR, V9, P8, DOI 10.1016/S1044-0305(97)00229-8; VENYAMINOV SY, 1994, ANAL BIOCHEM, V222, P176, DOI 10.1006/abio.1994.1470; Verdile G, 2000, J BIOL CHEM, V275, P20794, DOI 10.1074/jbc.C000208200; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Yang Q, 1999, ANAL CHEM, V71, p183A, DOI 10.1021/ac990246q; Zhang DM, 2000, NEUROREPORT, V11, P3227, DOI 10.1097/00001756-200009280-00035	57	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10955	10966		10.1074/jbc.M109660200	http://dx.doi.org/10.1074/jbc.M109660200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11788589	hybrid			2022-12-27	WOS:000174613100027
J	He, T; Stepulak, A; Holmstrom, TH; Omary, MB; Eriksson, JE				He, T; Stepulak, A; Holmstrom, TH; Omary, MB; Eriksson, JE			The intermediate filament protein keratin 8 is a novel cytoplasmic substrate for c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; HUMAN EPITHELIAL-CELLS; INDUCED APOPTOSIS; IN-VITRO; MAP KINASES; PHOSPHORYLATION; JNK; ACTIVATION; STRESS; REORGANIZATION	Keratins 8 (KS) and IS are the primary intermediate filaments of simple epithelia. Phosphorylation of keratins at specific sites affects their organization, assembly dynamics, and their interaction with signaling molecules. A number of keratin in vitro and in vivo phosphorylation sites have been identified. One example is KS Ser-73, which has been implicated as an important phosphorylation site during mitosis, cell stress, and apoptosis. We show that K8 is strongly phosphorylated on Ser-73 upon stimulation of the pro-apoptotic cytokine receptor Fas/CD95/Apo-1 in HT-29 cells. Kinase assays showed that c-Jun N-terminal kinase (JNK) was also activated with activation kinetics corresponding to that of K8 phosphorylation. Furthermore, KS was also phosphorylated on Ser-73 by JNK in vitro, yielding similar phosphopeptide maps as the in vivo phosphorylated material. In addition, co-immunoprecipitation studies revealed that part of JNK is associated with K8 in vivo, correlating with decreased ability of JNK to phosphorylate the endogenous c-Jun. Taken together, K8 is a new cytoplasmic target for JNK in Fas receptor-mediated signaling. The functional significance of this phosphorylation could relate to regulation of JNK signaling and/or regulation of keratin dynamics.	Turku Univ, Physiol Anim Lab, Dept Biol, FIN-20014 Turku, Finland; Turku Univ, Turku Ctr Biotechnol, FIN-20521 Turku, Finland; Abo Akad Univ, Turku Ctr Biotechnol, FIN-20521 Turku, Finland; Abo Akad Univ, Dept Biochem & Pharm, FIN-20521 Turku, Finland; Tech Univ Lublin, Sch Med, Dept Biochem & Mol Biol, PL-20123 Lublin, Poland; Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany; Palo Alto Vet Affairs Med Ctr, Dept Med, Palo Alto, CA 94304 USA; Stanford Univ, Dept Med, Palo Alto, CA 94304 USA	University of Turku; University of Turku; Abo Akademi University; Abo Akademi University; Lublin University of Technology; Medical University of Lublin; Max Planck Society; Stanford University	Eriksson, JE (corresponding author), Turku Univ, Physiol Anim Lab, Dept Biol, Sci Bldg 1, FIN-20014 Turku, Finland.			Stepulak, Andrzej/0000-0002-1872-394X; Omary, Bishr/0000-0002-8624-2347	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052951] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52951] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu-Martin MT, 1999, AM J PHYSIOL-GASTR L, V276, pG599, DOI 10.1152/ajpgi.1999.276.3.G599; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARIBAULT H, 1989, J CELL BIOL, V109, P1665, DOI 10.1083/jcb.109.4.1665; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; Cahill MA, 1996, ONCOGENE, V13, P2087; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Caulin C, 2000, J CELL BIOL, V149, P17, DOI 10.1083/jcb.149.1.17; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; Eriksson JE, 1998, METHOD ENZYMOL, V298, P542, DOI 10.1016/S0076-6879(98)98044-2; Feng L, 1999, J CELL SCI, V112, P2081; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Giasson BI, 1996, J BIOL CHEM, V271, P30404, DOI 10.1074/jbc.271.48.30404; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Ku NO, 2000, J CELL BIOL, V149, P547, DOI 10.1083/jcb.149.3.547; Ku NO, 1996, J CLIN INVEST, V98, P1034, DOI 10.1172/JCI118864; Ku NO, 1997, J BIOL CHEM, V272, P33197, DOI 10.1074/jbc.272.52.33197; KU NO, 1994, J CELL BIOL, V127, P161, DOI 10.1083/jcb.127.1.161; Ku NO, 2002, J BIOL CHEM, V277, P10775, DOI 10.1074/jbc.M107623200; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; LIAO J, 1995, EXP CELL RES, V219, P348, DOI 10.1006/excr.1995.1238; LIAO J, 1995, J BIOL CHEM, V270, P915, DOI 10.1074/jbc.270.2.915; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Liao J, 1997, J BIOL CHEM, V272, P17565, DOI 10.1074/jbc.272.28.17565; Mikhailov A, 2001, TOXICON, V39, P1453, DOI 10.1016/S0041-0101(01)00104-0; Omary M B, 1998, Subcell Biochem, V31, P105; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Reynolds CH, 1997, J NEUROCHEM, V68, P1736; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Toivola DM, 1997, J CELL SCI, V110, P23; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9	53	89	97	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10767	10774		10.1074/jbc.M111436200	http://dx.doi.org/10.1074/jbc.M111436200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11781324	hybrid			2022-12-27	WOS:000174613100005
J	Laybutt, DR; Sharma, A; Sgroi, DC; Gaudet, J; Bonner-Weir, S; Weir, GC				Laybutt, DR; Sharma, A; Sgroi, DC; Gaudet, J; Bonner-Weir, S; Weir, GC			Genetic regulation of metabolic pathways in beta-cells disrupted by hyperglycemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; PROLIFERATOR-ACTIVATED RECEPTORS; RAT PANCREATIC-ISLETS; FREE FATTY-ACIDS; UNCOUPLING PROTEIN-2; GLUCOSE-TOLERANCE; OBESE RATS; EXPRESSION; OVEREXPRESSION; PLASMA	In models of type 2 diabetes the expression of beta-cell genes is altered, but these changes have not fully explained the impairment in beta-cell function. We hypothesized that changes in beta-cell phenotype and global alterations in both carbohydrate and lipid pathways are likely to contribute to secretory abnormalities. Therefore, expression of genes involved in carbohydrate and lipid metabolism were analyzed in islets 4 weeks after 85-95% partial pancreatectomy (Px) when beta-cells have impaired glucose-induced insulin secretion and ATP synthesis. Px rats after 1 week developed mild to severe hyperglycemia that was stable for the next 3 weeks, whereas neither plasma triglyceride, non-esterified fatty acid, or islet triglyceride levels were altered. Expression of peroxisome proliferator-activated receptors (PPARs), with several target genes, were reciprocally regulated; PPARalpha was markedly reduced even at low level hyperglycemia, whereas PPARgamma was progressively increased with increasing hyperglycemia. Uncoupling protein 2 (UCP-2) was increased as were other genes barely expressed in sham islets including lactate dehydrogenase-A (LDH-A), lactate (monocarboxylate) transporters, glucose-6-phosphatase, fructose-1,6-bisphosphatase, 12-lipoxygenase, and cyclooxygenase 2. On the other hand, the expression of beta-cell-associated genes, insulin, and GLUT2 were decreased. Treating Px rats with phlorizin normalized hyperglycemia without effecting plasma fatty acids and reversed the changes in gene expression implicating the importance of hyperglycemia per se in the loss of beta-cell phenotype. In addition, parallel changes were observed in beta-cell-enriched tissue dissected by laser capture microdissection from the central core of islets. In conclusion, chronic hyperglycemia leads to a critical loss of beta-cell differentiation with altered expression of genes involved in multiple metabolic pathways diversionary to normal beta-cell glucose metabolism. This global maladaptation in gene expression at the time of increased secretory demand may contribute to the beta-cell dysfunction found in diabetes.	Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, Boston, MA 02215 USA; Massachusetts Gen Hosp, Mol Pathol Unit, Boston, MA 02129 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Massachusetts General Hospital	Weir, GC (corresponding author), Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, 1 Joslin Pl, Boston, MA 02215 USA.	Gordon.Weir@joslin.harvard.edu	Sgroi, Dennis/AAV-2487-2021	Bonner-Weir, Susan/0000-0003-4682-0656	NIDDK NIH HHS [DK-36836, DK-35449] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK035449] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ainscow EK, 2000, DIABETES, V49, P1149, DOI 10.2337/diabetes.49.7.1149; Bollheimer LC, 1998, J CLIN INVEST, V101, P1094, DOI 10.1172/JCI420; BONNERWEIR S, 1983, J CLIN INVEST, V71, P1544, DOI 10.1172/JCI110910; BRUN T, 1993, J BIOL CHEM, V268, P18905; BRUNZELL JD, 1976, J CLIN ENDOCR METAB, V42, P222, DOI 10.1210/jcem-42-2-222; Chan CB, 2001, DIABETES, V50, P1302, DOI 10.2337/diabetes.50.6.1302; Chan CB, 1999, DIABETES, V48, P1482, DOI 10.2337/diabetes.48.7.1482; Cnop M, 2001, DIABETES, V50, P1771, DOI 10.2337/diabetes.50.8.1771; Dubois M, 2000, DIABETOLOGIA, V43, P1165, DOI 10.1007/s001250051508; Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Gremlich S, 1997, J BIOL CHEM, V272, P30261, DOI 10.1074/jbc.272.48.30261; Higa M, 1999, P NATL ACAD SCI USA, V96, P11513, DOI 10.1073/pnas.96.20.11513; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; HOSOKAWA H, 1995, DIABETES, V44, P1328, DOI 10.2337/diabetes.44.11.1328; Ishihara H, 1999, J CLIN INVEST, V104, P1621, DOI 10.1172/JCI7515; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Kassis N, 2000, Int J Exp Diabetes Res, V1, P185, DOI 10.1155/EDR.2000.185; KHAN A, 1990, DIABETES, V39, P456, DOI 10.2337/diabetes.39.4.456; Kim H, 2000, DIABETES, V49, P1517, DOI 10.2337/diabetes.49.9.1517; KOSAKA K, 1980, DIABETOLOGIA, V18, P23, DOI 10.1007/BF01228297; Lameloise N, 2001, DIABETES, V50, P803, DOI 10.2337/diabetes.50.4.803; Laybutt DR, 2002, DIABETES, V51, P413, DOI 10.2337/diabetes.51.2.413; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; Lee Y, 1997, DIABETES, V46, P408, DOI 10.2337/diabetes.46.3.408; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; Li LX, 2001, BIOCHEM BIOPH RES CO, V282, P273, DOI 10.1006/bbrc.2001.4577; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; Ma ZM, 1996, J BIOL CHEM, V271, P1029, DOI 10.1074/jbc.271.2.1029; Maedler K, 2001, DIABETES, V50, P69, DOI 10.2337/diabetes.50.1.69; NEWGARD CB, 2000, HDB PHYSL 7, V2, P125; Patane G, 2001, DIABETES, V50, pA363; PERLEY M, 1966, DIABETES, V15, P867, DOI 10.2337/diab.15.12.867; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; Roduit R, 2001, DIABETES, V50, P1970, DOI 10.2337/diabetes.50.9.1970; Roduit R, 2000, J BIOL CHEM, V275, P35799, DOI 10.1074/jbc.M006001200; ROSEN ED, 2001, DIABETES, V50; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Sgroi DC, 1999, CANCER RES, V59, P5656; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shimabukuro M, 1997, BIOCHEM BIOPH RES CO, V237, P359, DOI 10.1006/bbrc.1997.7140; Steil GM, 2001, AM J PHYSIOL-ENDOC M, V280, pE788, DOI 10.1152/ajpendo.2001.280.5.E788; TOKUYAMA Y, 1995, DIABETES, V44, P1447, DOI 10.2337/diabetes.44.12.1447; Tran POT, 1999, J BIOL CHEM, V274, P31245, DOI 10.1074/jbc.274.44.31245; Wang MY, 1999, DIABETES, V48, P1020, DOI 10.2337/diabetes.48.5.1020; Wang MY, 1998, P NATL ACAD SCI USA, V95, P11921, DOI 10.1073/pnas.95.20.11921; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; WEIR GC, 2000, DIABETES MELLITUS, P595; Weitgasser R, 1999, DIABETOLOGIA, V42, P256; Winzell MS, 2001, DIABETES, V50, P2225, DOI 10.2337/diabetes.50.10.2225; Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270; Yoshikawa H, 2001, METABOLISM, V50, P613, DOI 10.1053/meta.2001.22565; ZAMBON A, 1993, J LIPID RES, V34, P1021; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6; Zhao C, 2001, DIABETES, V50, P361, DOI 10.2337/diabetes.50.2.361; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042; Zhou YT, 1998, P NATL ACAD SCI USA, V95, P8898, DOI 10.1073/pnas.95.15.8898	57	156	162	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10912	10921		10.1074/jbc.M111751200	http://dx.doi.org/10.1074/jbc.M111751200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11782487	hybrid			2022-12-27	WOS:000174613100022
J	Nguyen, KT; Zong, CS; Uttamsingh, S; Sachdev, P; Bhanot, M; Le, MT; Chan, JLK; Wang, LH				Nguyen, KT; Zong, CS; Uttamsingh, S; Sachdev, P; Bhanot, M; Le, MT; Chan, JLK; Wang, LH			The role of phosphatidylinositol 3-kinase, Rho family GTPases, and STAT3 in Ros-induced cell transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; PROTOONCOGENE C-ROS; SARCOMA VIRUS UR2; CYCLE PROGRESSION; MAP KINASE; PROTEIN; GROWTH; ACTIVATION; SURVIVAL; INSULIN	Using loss-of-function mutants of Ros and inducible epidermal growth factor receptor-Ros chimeras we investigated the role of various signaling pathways in Rosinduced cell transformation. Inhibition of the mitogen-activated protein kinase (MAPK) pathway with the MEK (MAP/extracellular signal-regulated kinase kinase) inhibitor PD98059 had little effect on the Ros-induced monolayer and anchorage-independent growth of chicken embryo fibroblasts and NIH3T3 cells even though more than 70% of the MAPK was inhibited. In contrast, inhibiting the phosphatidylinositol 3-kinase (PI3K) pathway with the drug LY294002, a dominant negative mutant of PI3K, Ap85, or the phosphatidylinositol phosphatase PTEN (phosphatase and tensin homologue deleted in chromosome ten) resulted in a dramatic reduction of v-Ros- and epidermal growth factor receptor-Ros-promoted anchorage-independent growth of chicken embryo fibroblasts and NIH3T3 cells, respectively. Parallel and downstream components of PI3K signaling such as the Rho family GTPases (Rac, Rho, Cdc42) and the survival factor Akt were all shown to contribute to Ros-induced anchorage-independent growth, although Rac appeared to be less important for Ros-induced colony formation in NIH3T3 cells. Furthermore, the transformation-attenuated v-Ros mutants F419 and DI could be complemented by constitutively active mutants of PI3K and Akt. Finally, we found that overexpressing a constitutively active mutant of STAT3 (STAT3C) conferred a resistance to the inhibition of Ros-induced anchorage-independent growth by LY294002, suggesting a possible overlap of functions between PI3K and STAT3 signaling in mediating Ros-induced anchorage-independent growth.	CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Wang, LH (corresponding author), CUNY Mt Sinai Sch Med, Dept Microbiol, Box 1124, New York, NY 10029 USA.	lu-hai.wang@mssm.edu	Wang, Lu-Hai/E-3986-2010		NATIONAL CANCER INSTITUTE [R01CA029339] Funding Source: NIH RePORTER; NCI NIH HHS [CA29339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Ariyoshi K, 2000, J BIOL CHEM, V275, P24407, DOI 10.1074/jbc.M909771199; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Boerner JL, 2001, J BIOL CHEM, V276, P3691, DOI 10.1074/jbc.M003801200; Bottomley MJ, 1998, BBA-MOL CELL BIOL L, V1436, P165, DOI 10.1016/S0005-2760(98)00141-6; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; CHEN JM, 1994, ONCOGENE, V9, P773; CHEN JM, 1991, ONCOGENE, V6, P257; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; del Peso L, 1997, ONCOGENE, V15, P3047; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOWNWARD J, 1998, MOL B INT U, V3, P171; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; JONG SMJ, 1987, ONCOGENE RES, V1, P7; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Maruta H, 1999, ANN NY ACAD SCI, V886, P48, DOI 10.1111/j.1749-6632.1999.tb09399.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; NECKAMEYER WS, 1984, J VIROL, V50, P914, DOI 10.1128/JVI.50.3.914-921.1984; Nguyen KT, 2000, ONCOGENE, V19, P5385, DOI 10.1038/sj.onc.1203911; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nur-E-Kamal MSA, 1999, ONCOGENE, V18, P7787; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; Sachdev P, 2001, J BIOL CHEM, V276, P26461, DOI 10.1074/jbc.M010995200; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; WANG LH, 1982, J VIROL, V41, P833, DOI 10.1128/JVI.41.3.833-841.1982; Xiong QH, 1996, MOL CELL BIOL, V16, P1509; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; ZONG CS, 1993, J VIROL, V67, P6453, DOI 10.1128/JVI.67.11.6453-6462.1993; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065; Zong CS, 1997, J BIOL CHEM, V272, P1500, DOI 10.1074/jbc.272.3.1500	53	45	49	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11107	11115		10.1074/jbc.M108166200	http://dx.doi.org/10.1074/jbc.M108166200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11799110	hybrid			2022-12-27	WOS:000174613100047
J	Ogunshola, OO; Antic, A; Donoghue, MJ; Fan, SY; Kim, H; Stewart, WB; Madri, JA; Ment, LR				Ogunshola, OO; Antic, A; Donoghue, MJ; Fan, SY; Kim, H; Stewart, WB; Madri, JA; Ment, LR			Paracrine and autocrine functions of neuronal vascular endothelial growth factor (VEGF) in the central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; RAT-BRAIN; MOUSE-BRAIN; CELLS; EXPRESSION; ISCHEMIA; ANGIOGENESIS; INDUCTION; PROTEIN; DAMAGE	Recent data have demonstrated that vascular endothelial growth factor (VEGF) is expressed by subsets of neurons, coincident with angiogenesis within the developing cerebral cortex. Here we investigate the characteristics of VEGF expression by neurons and test the hypothesis that VEGF may serve both paracrine and autocrine functions in the developing central nervous system. To begin to address these questions, we assayed expression of VEGF and one of its potential receptors, Flk-1 (VEGFR-2), in the embryonic mouse forebrain and embryonic cortical neurons grown in vitro. Both VEGF and Flk-1 are present in subsets of post-mitotic neurons in vivo and in vitro. Moreover, VEGF levels are up-regulated in neuronal cultures subjected to hypoxia, consistent with our previous results in vivo. While the abundance of Flk-1 is unaffected by hypoxia, the receptor exhibits a higher level of tyrosine phosphorylation, as do downstream signaling kinases, including extracellular signal-regulated protein kinase, p90RSK and STAT3a, demonstrating activation of the VEGF pathway. These same signaling components also exhibited higher tyrosine phosphorylation levels in response to exogenous addition of rVEGFA(165). This activation was diminished in the presence of specific inhibitors of Flk-1 function and agents that sequester VEGF, resulting in a dose-dependent increase in apoptosis in these neuronal cultures. Further, inhibition of MEK resulted in increased apoptosis, while inhibition of phosphatidylinositol 3-kinase had no appreciable affect. In addition to the novel function for VEGF that we describe in neuronal survival, neuronal VEGF also affected the organization and differentiation of brain endothelial cells in a three-dimensional culture paradigm, consistent wit its more traditional role as a vascular agent. Thus, our in vitro data support a role for neuronal VEGF in both paracrine and autocrine signaling in the maintenance of neurons and endothelia in the central nervous system.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University; Yale University	Madri, JA (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St POB 208023, New Haven, CT 06520 USA.	joseph.madri@yale.edu		Ogunshola, Omolara/0000-0002-1197-4914	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038979] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS035476] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01-DK38979] Funding Source: Medline; NINDS NIH HHS [P01-NS 35476] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arbiser JL, 2000, AM J PATHOL, V156, P1469, DOI 10.1016/S0002-9440(10)65015-8; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hayashi T, 1997, STROKE, V28, P2039, DOI 10.1161/01.STR.28.10.2039; Hayashi T, 1998, J CEREBR BLOOD F MET, V18, P887, DOI 10.1097/00004647-199808000-00009; Hennequin LF, 1999, J MED CHEM, V42, P5369, DOI 10.1021/jm990345w; Hobson MI, 2000, J ANAT, V197, P591, DOI 10.1046/j.1469-7580.2000.19740591.x; Ilan N, 1999, J CELL SCI, V112, P3005; Issa R, 1999, LAB INVEST, V79, P417; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; Jin KL, 2000, NEUROSCIENCE, V99, P577, DOI 10.1016/S0306-4522(00)00207-4; Jin KL, 2000, J MOL NEUROSCI, V14, P197, DOI 10.1385/JMN:14:3:197; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kuo NT, 1999, J APPL PHYSIOL, V86, P260, DOI 10.1152/jappl.1999.86.1.260; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Ogunshola OO, 2000, DEV BRAIN RES, V119, P139, DOI 10.1016/S0165-3806(99)00125-X; ROUX F, 1994, J CELL PHYSIOL, V159, P101, DOI 10.1002/jcp.1041590114; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; Sondell M, 1999, BRAIN RES, V846, P219, DOI 10.1016/S0006-8993(99)02056-9; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Strawn LM, 1996, CANCER RES, V56, P3540; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Yourey PA, 2000, J NEUROSCI, V20, P6781, DOI 10.1523/JNEUROSCI.20-18-06781.2000	32	208	225	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11410	11415		10.1074/jbc.M111085200	http://dx.doi.org/10.1074/jbc.M111085200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11777931	hybrid			2022-12-27	WOS:000174613100084
J	Yang, FJ; Li, XY; Sharma, M; Sasaki, CY; Longo, DL; Lim, B; Sun, ZJ				Yang, FJ; Li, XY; Sharma, M; Sasaki, CY; Longo, DL; Lim, B; Sun, ZJ			Linking beta-catenin to androgen-signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-RECEPTOR FUNCTION; E-CADHERIN; PROSTATE-CANCER; TRANSCRIPTIONAL COACTIVATOR; COLORECTAL-CANCER; ESTROGEN-RECEPTOR; GASTRIC-CANCER; REPEAT REGION; ALPHA-CATENIN; EXPRESSION	The androgen-signaling pathway is important for the growth and progression of prostate cancer cells. The growth-promoting effects of androgen on prostate cells are mediated mostly through the androgen receptor (AR). There is increasing evidence that transcription activation by AR is mediated through interaction with other cofactors. beta-Catenin plays a critical role in embryonic development and tumorigenesis through its effects on E-cadherin-mediated cell adhesion and Wnt-dependent signal transduction. Here, we demonstrate that a specific protein-protein interaction occurs between beta-catenin and AR. Unlike the steroid hormone receptor coactivator 1 (SRC1), beta-catenin showed a strong interaction with AR but not with other steroid hormone receptors such as estrogen receptor alpha, progesterone receptor beta, and glucocorticoid receptor. The ligand binding domain of AR and the NH2 terminus combined with the first six armadillo repeats of beta-catenin were shown to be necessary for the interaction. Through this specific interaction, beta-catenin augments the ligand-dependent activity of AR in prostate cancer cells. Moreover, expression of E-cadherin in E-cadherin-negative prostate cancer cells results in redistribution of the cytoplasmic beta-catenin to the cell membrane and reduction of AR-mediated transcription. These data suggest that loss of E-cadherin can elevate the cellular levels of beta-catenin in prostate cancer cells, which may directly contribute to invasiveness and a more malignant tumor phenotype by augmenting AR activity during prostate cancer progression.	Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA; NIA, NIH, Immunol Lab, Baltimore, MD 21224 USA	Stanford University; Stanford University; Harvard University; Beth Israel Deaconess Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Sun, ZJ (corresponding author), Stanford Univ, Sch Med, Dept Surg, R135,Edwards Bldg, Stanford, CA 94305 USA.	zsun@stanford.edu	Longo, Dan L./F-6022-2011		NCI NIH HHS [R01 CA087767-02, R01 CA070297-12, R01 CA087767-05, R01 CA070297-11A2, R29 CA070297-05, R29 CA070297-04S1, R29 CA070297-04, R01 CA070297, CA70297, R01 CA070297-08, R29 CA070297, R01 CA070297-09, R01 CA087767-03, R01 CA070297-10, R01 CA070297-06A1, R29 CA070297-05S1, R01 CA087767-01A2, R01 CA087767, R01 CA087767-04, R29 CA070297-03, R01 CA070297-07] Funding Source: Medline; NIDDK NIH HHS [R56 DK061002, R01 DK061002-01A1, R01 DK061002-03, R01 DK061002-05, R01 DK061002, DK54417, DK47636, R56 DK061002-06A1, R01 DK061002-02, R01 DK061002-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA070297, R01CA087767, R01CA070297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047636, R01DK054417, R56DK061002, R01DK061002] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Barker N, 2000, BIOESSAYS, V22, P961; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BIRCHMEIER W, 1995, CANCER SURV, V24, P129; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Gayther SA, 1998, CANCER RES, V58, P4086; GRAFF JR, 1995, CANCER RES, V55, P5195; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HOECK W, 1992, J STEROID BIOCHEM, V41, P283, DOI 10.1016/0960-0760(92)90353-K; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; Hulsken J, 2000, J CELL SCI, V113, P3545; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; James P, 1996, GENETICS, V144, P1425; Jenster G, 1999, SEMIN ONCOL, V26, P407; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; MINK S, 1990, NUCLEIC ACIDS RES, V18, P2017, DOI 10.1093/nar/18.8.2017; Mitchell S, 2000, BJU INT, V85, P932, DOI 10.1046/j.1464-410x.2000.00606.x; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; ONATE SA, 1995, SCIENCE, V270, P1354; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Pai LM, 1996, J BIOL CHEM, V271, P32411, DOI 10.1074/jbc.271.50.32411; Pang S, 1997, CANCER RES, V57, P495; Paul R, 1997, BRIT J UROL, V79, P37, DOI 10.1111/j.1464-410X.1997.tb00799.x; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Richmond PJM, 1997, CANCER RES, V57, P3189; ROVERA G, 1974, EXP CELL RES, V89, P295, DOI 10.1016/0014-4827(74)90793-9; Sasaki CY, 2000, CANCER RES, V60, P7057; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Truica CI, 2000, CANCER RES, V60, P4709; UMBAS R, 1992, CANCER RES, V52, P5104; van de Wetering M, 2001, CANCER RES, V61, P278; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Voeller HJ, 1998, CANCER RES, V58, P2520; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	54	290	296	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11336	11344		10.1074/jbc.M111962200	http://dx.doi.org/10.1074/jbc.M111962200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11792709	hybrid			2022-12-27	WOS:000174613100075
J	Brann, AB; Tcherpakov, M; Williams, IM; Futerman, AH; Fainzilber, M				Brann, AB; Tcherpakov, M; Williams, IM; Futerman, AH; Fainzilber, M			Nerve growth factor-induced p75-mediated death of cultured hippocampal neurons is age-dependent and transduced through ceramide generated by neutral sphingomyelinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P75 NEUROTROPHIN RECEPTOR; BOVINE BRAIN; APOPTOSIS; SURVIVAL; P75(NTR); INHIBITOR; INTERACTS; OUTGROWTH; PROTEIN; BINDING	Binding of nerve growth factor (NGF) to the p75 neurotrophin receptor (p75) in cultured hippocampal neurons has been reported to cause seemingly contrasting effects, namely ceramide-dependent axonal outgrowth of freshly plated neurons, versus Jun kinase (Jnk)-dependent cell death in older neurons. We now show that the apoptotic effects of NGF in hippocampal neurons are observed only from the 2nd day of culture onward. This switch in the effect of NGF is correlated with an increase in p75 expression levels and increasing levels of ceramide generation as the cultures mature. NGF application to neuronal cultures from p75(exonIII-/-) mice had no effect on ceramide levels and did not affect neuronal viability. The neutral sphingomyelinase inhibitor, scyphostatin, inhibited NGF-induced ceramide generation and neuronal death, whereas hippocampal neurons cultured from acid sphingomyelinase(-/-) mice were as susceptible to NGF-induced death as wild type neurons. The acid ceramidase inhibitor, (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol, enhanced cell death, supporting a role for ceramide itself and not a downstream lipid metabolite. Finally, scyphostatin inhibited NGF-induced Jnk phosphorylation in hippocampal neurons. These data indicate an initiating role of ceramide generated by neutral sphingomyelinase in the diverse neuronal responses induced by binding of neurotrophins to p75.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Fainzilber, M (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.			Futerman, Anthony/0000-0003-0013-0115; Fainzilber, Mike/0000-0001-8173-8557				AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Barker PA, 1998, CELL DEATH DIFFER, V5, P346, DOI 10.1038/sj.cdd.4400375; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; Bentley CA, 2000, J NEUROSCI, V20, P7706; Bernardo K, 2000, J BIOL CHEM, V275, P7641, DOI 10.1074/jbc.275.11.7641; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Bilderback TR, 2001, J NEUROCHEM, V76, P1540, DOI 10.1046/j.1471-4159.2001.00171.x; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Brann AB, 1999, J NEUROSCI, V19, P8199; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CHEN CS, 1995, J BIOL CHEM, V270, P13291, DOI 10.1074/jbc.270.22.13291; Coffey ET, 2000, J NEUROSCI, V20, P7602; de Chaves EP, 2001, J BIOL CHEM, V276, P36207, DOI 10.1074/jbc.M104282200; Della-Bianca V, 2001, J BIOL CHEM, V276, P38929, DOI 10.1074/jbc.M107454200; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; Dobrowsky RT, 2000, CELL SIGNAL, V12, P81, DOI 10.1016/S0898-6568(99)00072-8; Edsall LC, 1997, J NEUROSCI, V17, P6952; Fainzilber M, 1996, SCIENCE, V274, P1540, DOI 10.1126/science.274.5292.1540; Frade JM, 1999, DEVELOPMENT, V126, P683; Friedman WJ, 2000, J NEUROSCI, V20, P6340, DOI 10.1523/JNEUROSCI.20-17-06340.2000; Furuya S, 1998, J NEUROCHEM, V71, P366; Goslin K., 1998, CULTURING NERVE CELL, P339; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Holopainen JM, 2000, BIOPHYS J, V78, P830, DOI 10.1016/S0006-3495(00)76640-9; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; HUBER LJ, 1995, DEV BIOL, V167, P227, DOI 10.1006/dbio.1995.1019; Ibanez CF, 1998, TRENDS NEUROSCI, V21, P438, DOI 10.1016/S0166-2236(98)01266-1; Jaaro H, 2001, TRENDS NEUROSCI, V24, P79, DOI 10.1016/S0166-2236(00)01690-8; Jung SY, 2000, J NEUROCHEM, V75, P1004, DOI 10.1046/j.1471-4159.2000.0751004.x; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Khursigara G, 2001, J NEUROSCI, V21, P5854, DOI 10.1523/JNEUROSCI.21-16-05854.2001; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kong HY, 2001, J NEUROSCI, V21, P176, DOI 10.1523/JNEUROSCI.21-01-00176.2001; Lee FS, 2001, CURR OPIN NEUROBIOL, V11, P281, DOI 10.1016/S0959-4388(00)00209-9; LEE KF, 1994, SCIENCE, V263, P1447, DOI 10.1126/science.8128229; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Liu B, 2000, METHOD ENZYMOL, V311, P156; Mitoma J, 1998, J NEUROSCI RES, V51, P712, DOI 10.1002/(SICI)1097-4547(19980315)51:6<712::AID-JNR5>3.3.CO;2-Q; Moore AN, 1999, NEUROSCIENCE, V94, P405, DOI 10.1016/S0306-4522(99)00288-2; Nara F, 1999, J ANTIBIOT, V52, P531, DOI 10.7164/antibiotics.52.531; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Pelled D, 2000, J INHERIT METAB DIS, V23, P175, DOI 10.1023/A:1005622001239; Roux PP, 2001, J BIOL CHEM, V276, P23097, DOI 10.1074/jbc.M011520200; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; Ryden M, 1997, J BIOL CHEM, V272, P16322, DOI 10.1074/jbc.272.26.16322; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Schutze S, 1999, J BIOL CHEM, V274, P10203, DOI 10.1074/jbc.274.15.10203; Schwarz A, 1997, J NEUROSCI, V17, P2929; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Stucky CL, 1997, J NEUROSCI, V17, P4398; Tanaka M, 1997, J AM CHEM SOC, V119, P7871, DOI 10.1021/ja9713385; Tuffereau C, 1998, EMBO J, V17, P7250, DOI 10.1093/emboj/17.24.7250; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; von Schack D, 2001, NAT NEUROSCI, V4, P977, DOI 10.1038/nn730; Wang SY, 2000, AM J PATHOL, V157, P1247, DOI 10.1016/S0002-9440(10)64640-8; Willaime S, 2001, EUR J NEUROSCI, V13, P2037, DOI 10.1046/j.0953-816x.2001.01581.x; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; Yu ZF, 2000, J MOL NEUROSCI, V15, P85, DOI 10.1385/JMN:15:2:85; Zha XH, 1998, J CELL BIOL, V140, P39, DOI 10.1083/jcb.140.1.39	70	104	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9812	9818		10.1074/jbc.M109862200	http://dx.doi.org/10.1074/jbc.M109862200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11777929	hybrid			2022-12-27	WOS:000174549200030
J	Fujita, N; Sato, S; Ishida, A; Tsuruo, T				Fujita, N; Sato, S; Ishida, A; Tsuruo, T			Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; AKT KINASE; BCR-ABL; APOPTOSIS; DESTABILIZATION; GELDANAMYCIN; INHIBITION; DISRUPTION; ACTIVATION; RADICICOL	Serine/threonine kinase Akt is thought to mediate many biological actions toward anti-apoptotic responses. Screening of drugs that could interfere with the Akt signaling pathway revealed that Hsp90 inhibitors (e.g. geldanamycin, radicicol, and its analogues) induced Akt dephosphorylation, which resulted in Akt inactivation and apoptosis of the cells. Hsp90 inhibitors did not directly affect Akt kinase activity in vitro. Thus, we examined the effects of Hsp90 inhibitors on upstream Akt kinases, phosphatidylinositide-3-OH kinase (PI3K) and 3-phosphoinositide-dependent protein kinase-1 (PDK1). Hsp90 inhibitors had no effect on PI3K protein expression. In contrast, treatment of the cells with Hsp90 inhibitors decreased the amount of PDK1 without directly inhibiting PDK1 kinase activity. We found that the kinase domain of PDK1 was essential for complex formation with Hsp90 and that Hsp90 inhibitors suppressed PDK1 binding to Hsp90. PDK1 degradation mechanisms revealed that inhibition of PDK1 binding to Hsp90 caused proteasome-dependent degradation of PDK1. Treatment of proteasome inhibitors increased the amount of detergent-insoluble PDK1 in Hsp90 inhibitor-treated cells. Therefore, the association of PDK1 with Hsp90 regulates its stability, solubility, and signaling. Because Akt binding to Hsp90 is also involved in the maintenance of Akt kinase activity, Hsp90 plays an important role in PDK1-Akt survival signaling pathway.	Univ Tokyo, Inst Mol & Cellular Biosci, Dept Cell Growth & Regulat, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Dept Cell Growth & Regulat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	ttsuruo@iam.u-tokyo.ac.jp	Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Ballif BA, 2001, J BIOL CHEM, V276, P12466, DOI 10.1074/jbc.M009939200; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; FERRARINI M, 1992, INT J CANCER, V51, P613, DOI 10.1002/ijc.2910510418; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Hostein I, 2001, CANCER RES, V61, P4003; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Miyata Y, 2001, J BIOL CHEM, V276, P21841, DOI 10.1074/jbc.M010944200; Nakashio A, 2000, CANCER RES, V60, P5303; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; Neckers L, 1999, DRUG RESIST UPDATE, V2, P165, DOI 10.1054/drup.1999.0082; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nimmanapalli R, 2001, CANCER RES, V61, P1799; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; Sellers WR, 1999, J CLIN INVEST, V104, P1655, DOI 10.1172/JCI9053; Shiotsu Y, 2000, BLOOD, V96, P2284, DOI 10.1182/blood.V96.6.2284; Soga S, 1999, CANCER RES, V59, P2931; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	40	174	182	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10346	10353		10.1074/jbc.M106736200	http://dx.doi.org/10.1074/jbc.M106736200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11779851	hybrid			2022-12-27	WOS:000174549200098
J	Hong, J; Zhang, G; Dong, F; Rechler, MM				Hong, J; Zhang, G; Dong, F; Rechler, MM			Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN-3 AUTOCRINE LOOP; LUNG EPITHELIAL-CELLS; BREAST-CANCER; RETINOIC ACID; FACTOR-BETA; PROTEOLYTIC FRAGMENT; LINE PC-3; TARGETED DISRUPTION; NUCLEAR TRANSPORT; HEPARIN-BINDING	Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) can stimulate apoptosis and inhibit cell proliferation directly and independently of binding IGFs or indirectly by forming complexes with IGF-I and IGF-II that prevent them from activating the IGF-I receptor to stimulate cell survival and proliferation. To date, IGF-independent actions only have been demonstrated in a limited number of cells that do not synthesize or respond to IGFs. To assess the general importance of IGF-independent mechanisms, we have generated human IGFBP-3 mutants that cannot bind IGF-I or IGF-II by substituting alanine for six residues in the proposed IGF binding site, Ile(56)/Tyr(57)/Arg(75)/Leu(77)/Leu(80)/Leu(81), and expressing the 6m-hIGFBP-3 mutant construct in Chinese hamster ovary cells. Binding of both IGF-I and IGF-II to 6m-hIGFBP-3 was reduced > 80-fold. The nonbinding 6m-hIGFBP-3 mutant still was able to inhibit DNA synthesis in a mink lung epithelial cell line in which inhibition by wild-type hIGFBP-3 previously had been shown to be exclusively IGF-independent. 6m-hIGFBP-3 only can act by IGF-independent mechanisms since it is unable to form complexes with the IGFs that inhibit their action. We next compared the ability of wild-type and 6m-hIGFBP-3 to stimulate apoptosis in serum-deprived PC-3 human prostate cancer cells. PC-3 cells are known to synthesize and respond to IGF-II, so that IGFBP-3 could potentially act by either IGF-dependent or IGF-independent mechanisms. In fact, 6m-hIGFBP-3 stimulated PC-3 cell death and stimulated apoptosis-induced DNA fragmentation to the same extent and with the same concentration dependence as wild-type hIGFBP-3. These results indicate that IGF-independent mechanisms are major contributors to IGFBP-3-induced apoptosis in PC-3 cells and may play a wider role in the antiproliferative and antitumorigenic actions of IGFBP-3.	NIDDK, Natl Inst Hlth, Clin Endocrinol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Rechler, MM (corresponding author), NIDDK, Natl Inst Hlth, Clin Endocrinol Branch, Bldg 10 Rm 8D12, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK055006] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMO ML, 1992, ENDOCRINOLOGY, V131, P1858, DOI 10.1210/en.131.4.1858; ANDREATTAVANLEYEN S, 1994, J CELL PHYSIOL, V160, P265, DOI 10.1002/jcp.1041600208; Angelloz-Nicoud P, 1998, GROWTH HORM IGF RES, V8, P71, DOI 10.1016/S1096-6374(98)80324-9; ANGELLOZNICOUD P, 1995, ENDOCRINOLOGY, V136, P5485, DOI 10.1210/en.136.12.5485; Arai T, 1996, J BIOL CHEM, V271, P6099, DOI 10.1074/jbc.271.11.6099; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BAYNE ML, 1990, J BIOL CHEM, V265, P15648; Boyle BJ, 2001, J UROLOGY, V165, P1319, DOI 10.1016/S0022-5347(01)69892-6; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Butt AJ, 2000, J BIOL CHEM, V275, P39174, DOI 10.1074/jbc.M908888199; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Clemmons David R., 1997, Cytokine and Growth Factor Reviews, V8, P45, DOI 10.1016/S1359-6101(96)00053-6; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; Fanayan S, 2000, J BIOL CHEM, V275, P39146, DOI 10.1074/jbc.M006964200; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; Gaddipati JP, 2000, ANTICANCER RES, V20, P2547; Galanis M, 2001, J ENDOCRINOL, V169, P123, DOI 10.1677/joe.0.1690123; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; Gucev ZS, 1996, CANCER RES, V56, P1545; Han GR, 1997, J BIOL CHEM, V272, P13711, DOI 10.1074/jbc.272.21.13711; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hashimoto R, 1997, J BIOL CHEM, V272, P27936, DOI 10.1074/jbc.272.44.27936; Hochscheid R, 2000, J ENDOCRINOL, V166, P553, DOI 10.1677/joe.0.1660553; Hollowood AD, 2000, INT J CANCER, V88, P336, DOI 10.1002/1097-0215(20001101)88:3<336::AID-IJC3>3.3.CO;2-1; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; Huynh H, 1998, INT J ONCOL, V13, P137; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; Hwa V, 1997, ENDOCRINE, V6, P235, DOI 10.1007/BF02820498; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; Kimura G, 1996, Int J Urol, V3, P39; Lalou C, 1996, ENDOCRINOLOGY, V137, P3206, DOI 10.1210/en.137.8.3206; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Leal SM, 1999, J BIOL CHEM, V274, P6711, DOI 10.1074/jbc.274.10.6711; Li WL, 1997, ENDOCRINOLOGY, V138, P1763, DOI 10.1210/en.138.4.1763; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; LIU L, 1992, J CELL PHYSIOL, V153, P15, DOI 10.1002/jcp.1041530104; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; MacDonald RG, 1999, J GASTROEN HEPATOL, V14, P72, DOI 10.1046/j.1440-1746.1999.01803.x; MARTIN JL, 1995, ENDOCRINOLOGY, V136, P1219, DOI 10.1210/en.136.3.1219; MARTIN JL, 1991, ENDOCRINOLOGY, V128, P1425, DOI 10.1210/endo-128-3-1425; Modric T, 2001, ENDOCRINOLOGY, V142, P1958, DOI 10.1210/en.142.5.1958; Murphy LJ, 1998, J MOL ENDOCRINOL, V21, P97, DOI 10.1677/jme.0.0210097; Nickerson T, 1997, BIOCHEM BIOPH RES CO, V237, P690, DOI 10.1006/bbrc.1997.7089; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH YM, 1993, J BIOL CHEM, V268, P14964; Perks CM, 2000, J CELL BIOCHEM, V80, P248; Petridou E, 1999, INT J CANCER, V80, P494, DOI 10.1002/(SICI)1097-0215(19990209)80:4<494::AID-IJC2>3.3.CO;2-B; PIETRZKOWSKI Z, 1993, CANCER RES, V53, P1102; Qin XZ, 1998, J BIOL CHEM, V273, P23509, DOI 10.1074/jbc.273.36.23509; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Rechler MM, 1998, TRENDS ENDOCRIN MET, V9, P176, DOI 10.1016/S1043-2760(98)00047-2; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; Ricort JM, 2001, ENDOCRINOLOGY, V142, P108, DOI 10.1210/en.142.1.108; Rozen F, 1998, INT J ONCOL, V13, P865; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Song H, 2000, J MOL ENDOCRINOL, V24, P43, DOI 10.1677/jme.0.0240043; Spagnoli A, 2001, J BIOL CHEM, V276, P5533, DOI 10.1074/jbc.M005088200; Spencer E. Martin, 1995, Progress in Growth Factor Research, V6, P209; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; VelezYanguas MC, 1996, J CLIN ENDOCR METAB, V81, P93, DOI 10.1210/jc.81.1.93; Vorwerk P, 1997, J CLIN ENDOCR METAB, V82, P2368, DOI 10.1210/jc.82.7.2368; Williams AC, 2000, CANCER RES, V60, P22; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1176, DOI 10.1210/mend-2-12-1176; Wraight CJ, 1998, J INVEST DERMATOL, V111, P239, DOI 10.1046/j.1523-1747.1998.00258.x; Wu HB, 2000, J CELL BIOCHEM, V77, P288, DOI 10.1002/(SICI)1097-4644(20000501)77:2<288::AID-JCB11>3.0.CO;2-J; YANG YWH, 1993, HDB ENDOCRINE RES TE, P181; Yu H, 1999, JNCI-J NATL CANCER I, V91, P151, DOI 10.1093/jnci/91.2.151; Zadeh SM, 1997, ENDOCRINOLOGY, V138, P3069, DOI 10.1210/en.138.7.3069; Zeslawski W, 2001, EMBO J, V20, P3638, DOI 10.1093/emboj/20.14.3638	74	132	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10489	10497		10.1074/jbc.M109604200	http://dx.doi.org/10.1074/jbc.M109604200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11784719	hybrid			2022-12-27	WOS:000174549200117
J	Kellner, DG; Hung, SC; Weiss, KE; Sligar, SG				Kellner, DG; Hung, SC; Weiss, KE; Sligar, SG			Kinetic characterization of Compound I formation in the thermostable cytochrome P450 CYP119	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; HORSERADISH-PEROXIDASE; SPECTRA; PEROXY; CHLOROPEROXIDASE; INTERMEDIATE; INACTIVATION; DERIVATIVES; STABILITY; P450CAM	The kinetics of formation and breakdown of the putative active oxygenating intermediate in cytochrome P450, a ferryl-oxo-(pi) porphyrin cation radical (Compound 1), have been analyzed in the reaction of a thermostable P450, CYP119, with meta-chloroperoxybenzoic acid (m-CPBA). Upon rapid mixing of m-CPBA with the ferric form of CYP119, an intermediate with spectral features characteristic of a ferryl-oxo-(pi) porphyrin cation radical was clearly observed and identified by the absorption maxima at 370, 610, and 690 nm. The rate constant for the formation of Compound I was 3.20 (+/-0.3) x :10(5) m(-1) s(-1) at pH 7.0, 4 degreesC, and this rate decreased with increasing pH. Compound I of CYP119 decomposed back to the ferric form with a first order rate constant of 29.4 +/- 3.4 s(-1), which increased with increasing pH. These findings form the first kinetic analysis of Compound I formation and decay in the reaction of m-CPBA with ferric P450.	Univ Illinois, Sch Mol & Cellular Biol, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Coll Med, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Sligar, SG (corresponding author), Univ Illinois, Sch Mol & Cellular Biol, Dept Biochem, 505 S Goodwin Ave, Urbana, IL 61801 USA.	s-sligar@uiuc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031756, R01GM033775, R37GM031756] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31756, GM33775] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIKENS J, 1994, J AM CHEM SOC, V116, P1143, DOI 10.1021/ja00082a051; ARAISO T, 1981, CAN J BIOCHEM CELL B, V59, P233, DOI 10.1139/o81-031; Bakovic M, 1996, BIOCHEM CELL BIOL, V74, P117, DOI 10.1139/o96-013; BANGCHAROENPAURPONG O, 1986, J BIOL CHEM, V261, P8089; BENECKY MJ, 1993, BIOCHEMISTRY-US, V32, P11929, DOI 10.1021/bi00095a024; BLAKE RC, 1989, J BIOL CHEM, V264, P3694; DAVIES DM, 1976, BIOCHEM J, V157, P247, DOI 10.1042/bj1570247; Davydov R, 1999, J AM CHEM SOC, V121, P10654, DOI 10.1021/ja9918829; Davydov R, 2001, J AM CHEM SOC, V123, P1403, DOI 10.1021/ja003583l; Denisov IG, 2001, J BIOL CHEM, V276, P11648, DOI 10.1074/jbc.M010219200; Denisov IG, 2001, J INORG BIOCHEM, V87, P215, DOI 10.1016/S0162-0134(01)00328-2; Egawa T, 2001, J BIOL INORG CHEM, V6, P46, DOI 10.1007/s007750000181; EGAWA T, 1992, FEBS LETT, V305, P206, DOI 10.1016/0014-5793(92)80668-7; EGAWA T, 1994, BIOCHEM BIOPH RES CO, V201, P1464, DOI 10.1006/bbrc.1994.1868; Fabian M, 2001, BIOCHEMISTRY-US, V40, P1867, DOI 10.1021/bi002373i; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; Guengerich FP, 1997, MOL PHARMACOL, V51, P147, DOI 10.1124/mol.51.1.147; HAGER LP, 1972, J AM CHEM SOC, V94, P4364, DOI 10.1021/ja00767a068; Harris D, 2001, J INORG BIOCHEM, V83, P309, DOI 10.1016/S0162-0134(00)00177-X; HOSTEN CM, 1994, J BIOL CHEM, V269, P13966; JONES P, 1972, BIOCHEM J, V130, P411, DOI 10.1042/bj1300411; Kincaid JR, 1996, J BIOL CHEM, V271, P28805, DOI 10.1074/jbc.271.46.28805; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; MARKLUND S, 1974, BIOCHIM BIOPHYS ACTA, V350, P304, DOI 10.1016/0005-2744(74)90504-X; Maves SA, 2001, PROTEIN SCI, V10, P161, DOI 10.1110/ps.17601; McLean MA, 1998, BIOCHEM BIOPH RES CO, V252, P166, DOI 10.1006/bbrc.1998.9584; Michels PC, 1997, APPL ENVIRON MICROB, V63, P3985, DOI 10.1128/AEM.63.10.3985-3991.1997; PALANIAPPAN V, 1989, J BIOL CHEM, V264, P16046; Pfister TD, 2001, BIOCHEMISTRY-US, V40, P14942, DOI 10.1021/bi011400h; RAMETTE RW, 1965, J AM CHEM SOC, V87, P5001, DOI 10.1021/ja00950a005; Raner GM, 2000, J INORG BIOCHEM, V81, P153, DOI 10.1016/S0162-0134(00)00098-2; RodriguezLopez JN, 1997, J BIOL CHEM, V272, P5469, DOI 10.1074/jbc.272.9.5469; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Schunemann V, 2000, FEBS LETT, V479, P149, DOI 10.1016/S0014-5793(00)01886-X; SLIGAR SG, 1976, MICROSOMES DRUG OXID, P204; Tschirret-Guth RA, 2001, J AM CHEM SOC, V123, P3412, DOI 10.1021/ja003947+; VAZ ADN, 1994, BIOCHEMISTRY-US, V33, P13651, DOI 10.1021/bi00250a015; WAGNER GC, 1983, FEBS LETT, V156, P244, DOI 10.1016/0014-5793(83)80505-5; YU CA, 1974, J BIOL CHEM, V249, P94	39	186	185	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9641	9644		10.1074/jbc.C100745200	http://dx.doi.org/10.1074/jbc.C100745200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11799104	hybrid			2022-12-27	WOS:000174549200006
J	Koike, C; Fung, JJ; Geller, DA; Kannagi, R; Libert, T; Luppi, P; Nakashima, I; Profozich, J; Rudert, W; Sharma, SB; Starzl, TE; Trucco, M				Koike, C; Fung, JJ; Geller, DA; Kannagi, R; Libert, T; Luppi, P; Nakashima, I; Profozich, J; Rudert, W; Sharma, SB; Starzl, TE; Trucco, M			Molecular basis of evolutionary loss of the alpha 1,3-galactosyltransferase gene in higher primates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE ALPHA-1,3-GALACTOSYLTRANSFERASE; ALPHA-1,3 GALACTOSYLTRANSFERASE; GENOMIC ORGANIZATION; CDNA; EXPRESSION; SEQUENCE; ALPHA-1->3-GALACTOSYLTRANSFERASE; ISOFORMS; EPITOPE; MONKEYS	Galactose-alpha1,3-galactose (alphaGal) epitopes, the synthesis of which requires the enzyme product of alpha1,3-galactosyltransferase (alpha1,3GT), are sugar chains on the cell surface of most mammalian species. Notable exceptions are higher primates including Old World monkeys, apes, and humans. The alphaGal-negative species as well as mice with deletion of the alpha1,3GT gene produce abundant anti-alphaGal antibodies. The evolutionary loss of aGal epitopes has been attributed to point mutations in the coding region of the gene. Because no transcripts could be found in the higher primate species with Northern blot analysis, a potential alternative explanation has been loss of upstream regulation of the gene. Here, we have demonstrated that the rhesus promoter is functional. More importantly, a variety of full-length transcripts were detected with sensitive PCR-based methods in the tissues of rhesus monkeys, orangutans, and humans. Five crucial mutations were delineated in the coding region of the human and rhesus and three in the orangutan, any one of which could be responsible for inactivation of the alpha1,3GT gene. Two of the mutations were shared by all three higher primates. These findings, which elucidate the molecular basis for the evolutionary loss of aGal expression, may have implications in medical research.	Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Falk Clin, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Div Immunogenet, Dept Pediat, Pittsburgh, PA 15213 USA; Aichi Canc Ctr, Dept Pathol, Chikusa, Nagoya, Japan; Nagoya Univ, Sch Med, Dept Immunol, Showa, Nagoya 466, Japan	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Aichi Cancer Center; Nagoya University	Koike, C (corresponding author), Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Falk Clin, 3601 Fifth Ave,4th Fl, Pittsburgh, PA 15213 USA.	koikec@msx.upmc.edu	FUNG, John Julian/A-2679-2012; Kannagi, Reiji/Q-6459-2018; Luppi, Pierre-Hervé/C-4333-2014	FUNG, John Julian/0000-0002-3038-0441; Kannagi, Reiji/0000-0003-4202-2921; Luppi, Pierre-Hervé/0000-0002-0503-423X	NIAID NIH HHS [AI40329, R01 AI/DK38899] Funding Source: Medline; NIDDK NIH HHS [R01 DK049615, R01 DK029961-19, DK29961, R01 DK054232, R01 DK54232, DK49615] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040329, R01AI038899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029961, R01DK029961, R01DK054232, R01DK049615] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		COOPER DKC, 1993, LANCET, V342, P682, DOI 10.1016/0140-6736(93)91791-J; ETIENNEDECERF J, 1991, AUTOIMMUNITY, V10, P81; GALILI U, 1988, J BIOL CHEM, V263, P17755; GALILI U, 1991, P NATL ACAD SCI USA, V88, P7401, DOI 10.1073/pnas.88.16.7401; GALILI U, 1987, P NATL ACAD SCI USA, V84, P1369, DOI 10.1073/pnas.84.5.1369; HENION TR, 1994, GLYCOBIOLOGY, V4, P193, DOI 10.1093/glycob/4.2.193; Joziasse DH, 1999, BBA-MOL BASIS DIS, V1455, P403, DOI 10.1016/S0925-4439(99)00056-3; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1991, J BIOL CHEM, V266, P6991; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; Katayama A, 1998, GLYCOCONJUGATE J, V15, P583, DOI 10.1023/A:1006963809894; Koike C, 2000, TRANSPLANTATION, V70, P1275, DOI 10.1097/00007890-200011150-00004; Koike C, 2001, TRANSPL P, V33, P710, DOI 10.1016/S0041-1345(00)02216-8; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; Mang R, 1999, J VIROL, V73, P7021, DOI 10.1128/JVI.73.8.7021-7026.1999; OLIOL R, 1986, VAX SANG, V51, P161; PETRYNIAK J, 1991, CANCER LETT, V60, P59, DOI 10.1016/0304-3835(91)90049-N; Sandrin Mauro S., 1994, Xenotransplantation, V1, P81, DOI 10.1111/j.1399-3089.1994.tb00053.x; STRAHAN KM, 1995, IMMUNOGENETICS, V41, P101, DOI 10.1007/BF00182319; Vanhove B, 1997, BBA-MOL CELL RES, V1356, P1, DOI 10.1016/S0167-4889(96)00151-6; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0	22	64	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10114	10120		10.1074/jbc.M110527200	http://dx.doi.org/10.1074/jbc.M110527200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11773054	hybrid, Green Accepted			2022-12-27	WOS:000174549200068
J	Mariconti, L; Pellegrini, B; Cantoni, R; Stevens, R; Bergounioux, C; Cella, R; Albani, D				Mariconti, L; Pellegrini, B; Cantoni, R; Stevens, R; Bergounioux, C; Cella, R; Albani, D			The E2F family of transcription factors from Arabidopsis thaliana - Novel and conserved components of the retinoblastoma/E2F pathway in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; NUCLEAR-LOCALIZATION; PROTEIN; EXPRESSION; APOPTOSIS; GENES; DP; PROLIFERATION; PROTOPLASTS; RECRUITMENT	The E2F transcription factors are key components of the cyclin D/retinoblastoma/E2F pathway. Here we demonstrate that Arabidopsis thaliana contains six functional AtE2F genes that are all expressed in cell suspension culture but show different patterns of expression during cell cycle progression. According to their structural and functional features, the six AtE2Fs can be divided into two distinct groups; although the three members of the first group, AtE2Fa, AtE2Fb and AtE2Fc, possess all the conserved domains found in other plant and animal E2Fs, the remaining AtE2Fs are novel proteins, which reveal a duplication of the DNA binding domain but lack any other conserved region. Furthermore, the AtE2Fs of the first group are functional transcription factors that in association with AtDP proteins can recognize specifically an E2F cis-element and can transactivate an E2F-responsive reporter gene in plant cells. In contrast, the AtE2Fs of the second group can bind specifically the E2F site without interacting with DP partners but cannot activate gene expression and, instead, are able to inhibit E2F-dependent activation of gene expression in Arabidopsis cells. These findings suggest distinctive roles for the plant E2F proteins and point to a complex concerted regulation of E2F-dependent gene expression in plant cells.	Univ Sassari, Dept Bot & Plant Ecol, I-07100 Sassari, Italy; Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy; Univ Paris 11, Inst Plant Biotechnol, F-91400 Orsay, France	University of Sassari; University of Pavia; UDICE-French Research Universities; Universite Paris Saclay	Albani, D (corresponding author), Univ Sassari, Dept Bot & Plant Ecol, Via Muroni 25, I-07100 Sassari, Italy.	albani@ssmain.uniss.it	Stevens, Rebecca G/A-4408-2013	Stevens, Rebecca G/0000-0003-4401-7923; Albani, Diego/0000-0002-1793-9212				Albani D, 1997, PLANT CELL, V9, P171, DOI 10.1105/tpc.9.2.171; Albani D, 2000, J BIOL CHEM, V275, P19258, DOI 10.1074/jbc.M909390199; AXELOS M, 1992, PLANT PHYSIOL BIOCH, V30, P123; Bandara LR, 1997, NAT BIOTECHNOL, V15, P896, DOI 10.1038/nbt0997-896; BARTELS D, 1983, NUCLEIC ACIDS RES, V11, P2961, DOI 10.1093/nar/11.10.2961; Black AR, 1999, GENE, V237, P281, DOI 10.1016/S0378-1119(99)00305-4; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; Chaboute ME, 2000, PLANT CELL, V12, P1987, DOI 10.1105/tpc.12.10.1987; Cress WD, 1996, MOL CELL BIOL, V16, P2119; de Jager SM, 2001, PLANT MOL BIOL, V47, P555, DOI 10.1023/A:1011848528377; delaLuna S, 1996, J CELL SCI, V109, P2443; Doutriaux MP, 1998, MOL GEN GENET, V257, P283, DOI 10.1007/s004380050649; Egelkrout EM, 2001, PLANT CELL, V13, P1437, DOI 10.1105/tpc.13.6.1437; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; GALLIE DR, 1989, PLANT CELL, V1, P301, DOI 10.1105/tpc.1.3.301; Gutierrez C, 2000, PLANT MOL BIOL, V43, P763, DOI 10.1023/A:1006462028363; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magae J, 1996, J CELL SCI, V109, P1717; Magyar Z, 2000, FEBS LETT, V486, P79, DOI 10.1016/S0014-5793(00)02238-9; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Ramirez-Parra E, 1999, NUCLEIC ACIDS RES, V27, P3527, DOI 10.1093/nar/27.17.3527; Ramirez-Parra E, 2000, FEBS LETT, V486, P73, DOI 10.1016/S0014-5793(00)02239-0; Sekine M, 1999, FEBS LETT, V460, P117, DOI 10.1016/S0014-5793(99)01296-X; Stals H, 2001, TRENDS PLANT SCI, V6, P359, DOI 10.1016/S1360-1385(01)02016-7; TIMMERMANS MCP, 1990, J BIOTECHNOL, V14, P333, DOI 10.1016/0168-1656(90)90117-T; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	36	138	180	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9911	9919		10.1074/jbc.M110616200	http://dx.doi.org/10.1074/jbc.M110616200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11786543	Green Published, hybrid			2022-12-27	WOS:000174549200042
J	Sangan, P; Rajendran, VM; Geibel, JP; Binder, HJ				Sangan, P; Rajendran, VM; Geibel, JP; Binder, HJ			Cloning and expression of a chloride-dependent Na+-H+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; IDENTIFICATION; SECRETION; ISOFORMS; DOMAINS; FAMILY; CRYPTS; NHE-3; COLON; FLUID	Electroneutral Na+-H+ exchange is present in virtually all cells, mediating the exchange of extracellular Na+ for intracellular H+ and, thus, plays an important role in the regulation of intracellular pH, cell volume, and transepithelial Na+ absorption. Recent transport studies demonstrated the presence of a novel chloride-dependent Na+-H+ exchange in the apical membrane of crypt cells of rat distal colon. We describe the cloning of a 2.5-kb full-length cDNA from rat distal colon that encodes 438 amino acids and has six putative transmembrane spanning domains. Of the 438 amino acids 375 amino acids at the N-terminal region are identical to Na+-H+ exchange (NHE)-1 isoform with the remaining 63 amino acids comprising a completely novel C terminus. In situ hybridization revealed that this transcript is expressed in colonic crypt cells, whereas Northern blot analysis established the presence of its 2.5-kb mRNA in multiple tissues. Despite its much smaller size compared with all other known Na+-H+ exchange isoforms, NHE-deficient PS120 fibroblasts stably transfected with this cDNA exhibited Na+-dependent intracellular pH recovery to an acid load that was chloride-dependent and inhibited both by 5-ethylisopropylamiloride, an amiloride analogue, and by 5'-nitro-2-(3-phenylproplyamino)benzoic acid, a Cl- channel blocker, but only minimally affected by 25 mum 3-methylsulfonyl-4piperidonbenzoyl-guanidine, an NHE-1 and NHE-2 isoform inhibitor. In contrast to other Na+-H+ exchange isoforms in colonic epithelial cells, chloride-dependent Na+-H+ exchange mRNA abundance was increased by dietary sodium depletion. Based on these results we predict that chloride-dependent Na+-H+ exchange represents a new class of Na+-H+ exchangers that may regulate ion transport in several organs.	Yale Univ, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Yale Univ, Dept Surg, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Binder, HJ (corresponding author), Yale Univ, Dept Internal Med, 333 Cedar St,POB 208019, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK014669] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 14669] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aharonovitz O, 2001, AM J PHYSIOL-CELL PH, V281, pC133, DOI 10.1152/ajpcell.2001.281.1.C133; Bell SM, 1999, AM J PHYSIOL-CELL PH, V276, pC788, DOI 10.1152/ajpcell.1999.276.4.C788; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; Cabado AG, 1996, J BIOL CHEM, V271, P3590; Chambrey R, 1997, AM J PHYSIOL-CELL PH, V273, pC1064, DOI 10.1152/ajpcell.1997.273.3.C1064; Choi JY, 2000, J CLIN INVEST, V105, P1141, DOI 10.1172/JCI9260; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; Geibel JP, 2001, GASTROENTEROLOGY, V120, P144, DOI 10.1053/gast.2001.20890; HALEVY J, 1986, GASTROENTEROLOGY, V91, P1277; HOGAN B, 1986, MANIPULATING MOUSE E, P228; Ikeda T, 1997, J BIOCHEM-TOKYO, V121, P295; Ikuma M, 1999, AM J PHYSIOL-GASTR L, V276, pG539, DOI 10.1152/ajpgi.1999.276.2.G539; JENNINGS ML, 1986, AM J PHYSIOL, V251, pC32, DOI 10.1152/ajpcell.1986.251.1.C32; Lee MG, 2000, J CLIN INVEST, V105, P1651, DOI 10.1172/JCI9207; Miyata Y, 2000, AM J PHYSIOL-CELL PH, V278, pC1218, DOI 10.1152/ajpcell.2000.278.6.C1218; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; PARKER JC, 1983, AM J PHYSIOL, V244, pC324, DOI 10.1152/ajpcell.1983.244.5.C324; Rajendran VM, 1998, AM J PHYSIOL-GASTR L, V274, pG424, DOI 10.1152/ajpgi.1998.274.2.G424; Rajendran VM, 1999, AM J PHYSIOL-GASTR L, V276, pG73, DOI 10.1152/ajpgi.1999.276.1.G73; RAJENDRAN VM, 1995, J BIOL CHEM, V270, P11051, DOI 10.1074/jbc.270.19.11051; Rajendran VM, 1999, AM J PHYSIOL-GASTR L, V276, pG132, DOI 10.1152/ajpgi.1999.276.1.G132; Rajendran VM, 2001, AM J PHYSIOL-GASTR L, V280, pG400, DOI 10.1152/ajpgi.2001.280.3.G400; Sangan PC, 1997, AM J PHYSIOL-CELL PH, V272, pC685, DOI 10.1152/ajpcell.1997.272.2.C685; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; SINGH SK, 1995, J CLIN INVEST, V96, P2373, DOI 10.1172/JCI118294; TSE M, 1993, J MEMBRANE BIOL, V135, P93; Wagner CA, 1998, P NATL ACAD SCI USA, V95, P9665, DOI 10.1073/pnas.95.16.9665; WELSH MJ, 1982, SCIENCE, V218, P1219, DOI 10.1126/science.6293054; YUN CHC, 1993, J BIOL CHEM, V268, P206	32	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9668	9675		10.1074/jbc.M110852200	http://dx.doi.org/10.1074/jbc.M110852200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11773056	hybrid			2022-12-27	WOS:000174549200010
J	Woods, SL; Whitelaw, ML				Woods, SL; Whitelaw, ML			Differential activities of murine single minded 1 (SIM1) and SIM2 on a hypoxic response element - Cross-talk between basic helix-loop-helix/Per-Arnt-Sim homology transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; INDUCIBLE FACTOR 1-ALPHA; BHLH-PAS PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; CLOSE SEQUENCE SIMILARITY; NUCLEAR TRANSLOCATOR ARNT; TRACHEAL CELL FATES; DIOXIN RECEPTOR; CNS MIDLINE; DOWN-SYNDROME	The basic helix-loop-helix/Per-Arnt-Sim homology (bHLH-PAS,S) protein family comprises a group of transcriptional regulators that often respond to a variety of developmental and environmental stimuli. Two murine members of this family, Single Minded 1 (SIM1) and Single Minded 2 (SIM2), are essential for postnatal survival but differ from other prototypical family members such as the dioxin receptor (DR) and hypoxia-inducible factors, in that they behave as transcriptional repressors in mammalian one-hybrid experiments and have yet to be ascribed a regulating signal. In cell lines engineered to stably express SIM1 and SIM2, we show that both are nuclear proteins that constitutively complex with the general bHLH/PAS partner factor, ARNT. We report that the murine SIM factors, in combination with ARNT, attenuate transcription from the hypoxia-inducible erythropoietin (EPO) enhancer during hypoxia. Such cross-talk between coexpressed bHLH/PAS factors can occur through competition for ARNT, which we find evident in SIM repression of DR-induced transcription from a xenobiotic response element reporter gene. However, SIM1/ARNT, but not SIM2/ARNT, can activate transcription from the EPO enhancer at normoxia, implying that the SIM proteins have the ability to bind hypoxia response elements and affect either activation or repression of transcription. This notion is supported by co-immunoprecipitation of EPO enhancer sequences with the SIM2 protein. SIM protein levels decrease with hypoxia treatment in our stable cell lines, although levels of the transcripts encoding SIM1 and SIM2 and the approximately 2-h half-lives of each protein are unchanged during hypoxia. Inhibition of protein synthesis, known to occur in cells during hypoxic stress in order to decrease ATP utilization, appears to account for the fall in SIM levels. Our data suggest the existence of a hypoxic switch mechanism in cells that coexpress hypoxia-inducible factor and SIM proteins, where upregulation and activation of hypoxia-inducible factor-1alpha is concomitant with attenuation of SIM activities.	Univ Adelaide, Dept Mol Biosci Biochem, Adelaide, SA 5005, Australia; Univ Adelaide, Ctr Mol Genet Dev, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide	Whitelaw, ML (corresponding author), Univ Adelaide, Dept Mol Biosci Biochem, Adelaide, SA 5005, Australia.			Woods, Susan/0000-0002-8955-2017				BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Chrast R, 2000, HUM MOL GENET, V9, P1853, DOI 10.1093/hmg/9.12.1853; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Ema M, 1999, HUM MOL GENET, V8, P1409, DOI 10.1093/hmg/8.8.1409; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ema M, 1996, BIOCHEM BIOPH RES CO, V218, P588, DOI 10.1006/bbrc.1996.0104; Ema M, 1996, MOL CELL BIOL, V16, P5865; Epstein DJ, 2000, DEVELOPMENT, V127, P4701; Fan CM, 1996, MOL CELL NEUROSCI, V7, P1, DOI 10.1006/mcne.1996.0001; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Gorlach A, 2000, BBA-GENE STRUCT EXPR, V1493, P125, DOI 10.1016/S0167-4781(00)00172-X; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Heid SE, 2000, MOL PHARMACOL, V57, P82; Hirose K, 1996, MOL CELL BIOL, V16, P1706; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Holder JL, 2000, HUM MOL GENET, V9, P101; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Isaac DD, 1996, GENE DEV, V10, P103, DOI 10.1101/gad.10.1.103; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; KRAGGERUD SM, 1995, ANTICANCER RES, V15, P683; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; Lees MJ, 1999, MOL CELL BIOL, V19, P5811; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Ma Y, 2000, J NEUROSCI, V20, P4596, DOI 10.1523/JNEUROSCI.20-12-04596.2000; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; McGuire J, 2001, J BIOL CHEM, V276, P41841, DOI 10.1074/jbc.M105607200; Michaud JL, 2000, MECH DEVELOP, V90, P253, DOI 10.1016/S0925-4773(99)00328-7; Michaud JL, 1998, GENE DEV, V12, P3264, DOI 10.1101/gad.12.20.3264; Michaud JL, 2001, HUM MOL GENET, V10, P1465, DOI 10.1093/hmg/10.14.1465; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Moffett P, 1996, GENOMICS, V35, P144, DOI 10.1006/geno.1996.0333; Moffett P, 1997, MOL CELL BIOL, V17, P4933, DOI 10.1128/MCB.17.9.4933; Moffett P, 2000, FEBS LETT, V466, P80, DOI 10.1016/S0014-5793(99)01750-0; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; Ohshiro T, 1997, DEVELOPMENT, V124, P3975; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; PALLISGAARD N, 1994, GENE, V138, P115, DOI 10.1016/0378-1119(94)90791-9; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; Probst MR, 1997, J BIOL CHEM, V272, P4451, DOI 10.1074/jbc.272.7.4451; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Scully KM, 2000, SCIENCE, V290, P1127, DOI 10.1126/science.290.5494.1127; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; Tinton SA, 1999, FEBS LETT, V446, P55, DOI 10.1016/S0014-5793(99)00185-4; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Ward MP, 1998, DEVELOPMENT, V125, P1599; WHARTON KA, 1993, MECH DEVELOP, V40, P141, DOI 10.1016/0925-4773(93)90072-6; WHARTON KA, 1994, DEVELOPMENT, V120, P3563; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; Wood SA, 1997, MECH DEVELOP, V63, P29, DOI 10.1016/S0925-4773(97)00672-2; Yamaki A, 1996, GENOMICS, V35, P136, DOI 10.1006/geno.1996.0332; Yamaki A, 2001, GENE, V270, P265, DOI 10.1016/S0378-1119(01)00450-4; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079; Zelzer E, 2000, MECH DEVELOP, V91, P163, DOI 10.1016/S0925-4773(99)00295-6	69	62	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10236	10243		10.1074/jbc.M110752200	http://dx.doi.org/10.1074/jbc.M110752200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11782478	hybrid			2022-12-27	WOS:000174549200084
J	Maile, LA; Clemmons, DR				Maile, LA; Clemmons, DR			Regulation of insulin-like growth factor I receptor dephosphorylation by SHPS-1 and the tyrosine phosphatase SHP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; ACTIVATED PROTEIN-KINASE; SRC HOMOLOGY-2 DOMAINS; SMOOTH-MUSCLE CELLS; IGF-I; SIGNAL-TRANSDUCTION; SYP PHOSPHATASE; SH2 DOMAINS; PHOSPHORYLATION; SH-PTP2	Activation of insulin-like growth factor I receptor (IGF-IR) kinase is an important site of control of IGF-I-linked intracellular signaling pathways. One potentially important regulatory variable is IGF-IR dephosphorylation. It has been shown that SHP-2, a tyrosine phosphatase, can bind to the activated IGF-IR in vitro; however, its role in IGF-IR dephosphorylation in whole cells is unknown. These studies were undertaken to determine whether SHP-2 was a candidate for mediating IGF-IR dephosphorylation. The IGF-IR in smooth muscle cells was dephosphorylated rapidly beginning 10 min after ligand addition, and this was temporally associated with SHP-2 binding to the receptor. IGF-I stimulated SHPS-1 phosphorylation and the subsequent recruitment of SHP-2. In cells expressing a SHPS-1 mutant that did not bind SHP-2 there was no recruitment of SHP-2 to the IGF-IR. Cells expressing a catalytically inactive form of SHP-2 showed SHP-2 recruitment to SHPS-1, but this did not result in SHPS-1 dephosphorylation, and there was a prolonged IGF-IR phosphorylation response after IGF-I stimulation. These studies indicate that IGF-IR stimulates phosphorylation of SHPS-1 which is critical for SHP-2 recruitment to the plasma membrane and for its recruitment to the IGF-IR. Recruitment of SHP-2 to the receptor then results in receptor dephosphorylation. The regulation of this process may be an important determinant of IGF-IR-mediated signaling.	Univ N Carolina, Div Endocrinol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Clemmons, DR (corresponding author), Univ N Carolina, Div Endocrinol, CB7170,6111 Thurston Bowles, Chapel Hill, NC 27599 USA.				NIA NIH HHS [AG-02331] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG002331, R01AG002331] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BASERGA R, 1995, CANCER RES, V55, P249; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Blakesley Vicky A., 1996, Cytokine and Growth Factor Reviews, V7, P153, DOI 10.1016/1359-6101(96)00015-9; CAPARO A, 1995, J BIOL CHEM, V270, P15639; DeMali KA, 1999, J BIOL CHEM, V274, P19551, DOI 10.1074/jbc.274.28.19551; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GOCKERMAN A, 1995, ENDOCRINOLOGY, V136, P4168, DOI 10.1210/en.136.10.4168; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Imai Y, 1997, J CLIN INVEST, V100, P2596, DOI 10.1172/JCI119803; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KATO H, 1993, J BIOL CHEM, V268, P2655; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; QUING ZQ, 2000, MOL CELL BIOL, V20, P1526; Rocchi S, 1996, ENDOCRINOLOGY, V137, P4944, DOI 10.1210/en.137.11.4944; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SEELY BL, 1995, J BIOL CHEM, V270, P19151, DOI 10.1074/jbc.270.32.19151; Stofega MR, 2000, J BIOL CHEM, V275, P28222; Stofega MR, 1998, J BIOL CHEM, V273, P7112, DOI 10.1074/jbc.273.12.7112; Stofega MR, 2000, MOL ENDOCRINOL, V14, P1338, DOI 10.1210/me.14.9.1338; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; XIAO S, 1994, J BIOL CHEM, V269, P21244; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217	39	74	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8955	8960		10.1074/jbc.M109258200	http://dx.doi.org/10.1074/jbc.M109258200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11779860	hybrid, Green Published			2022-12-27	WOS:000174400600031
J	Morris, JR; Keep, NH; Solomon, E				Morris, JR; Keep, NH; Solomon, E			Identification of residues required for the interaction of BARD1 with BRCA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER-PREDISPOSING MUTATIONS; PROTEIN-PROTEIN INTERACTIONS; RING DOMAIN; BREAST; BRCA1-BARD1	The breast and ovarian cancer predisposition gene product BRCA1, binds to BARD1 at its N terminus. In cells BRCA1 is found as a heterodimer with BARD1 and may represent the functionally active form of BRCA1. Using yeast two-hybrid and split-hybrid screens we have identified 16 independent missense mutations which prevent the ability of the BARD1 N terminus to heterodimerize with BRCA1. With reference to the recent structure of the BARD1-BRCA1 RING complex (Brzovic, P. S., Rajagopal, P., Hoyt, D. W., King, M-C., and Klevit, R. E. (2001) Nat. Struct. Biol. 8, 833-837) we note two classes of mutation; those that map to the hydrophobic core forming the BARD1:BRCA1 interface and are substitutions of leucine, and those that map to residues forming intramolecular contacts either in helical packing, or in the conserved zinc chelating cysteine residues of the RING itself. The directed mutation of charged residues predicted to play a role in the interaction could not alone prevent heterodimer formation suggesting that, while polar interactions may participate in the specificity of the interaction, they are not crucial. Together these data provide functional evidence for the requirement of a hydrophobic interface and illustrate that disruption of the tertiary structure by mutations away from the interface itself are able to prevent formation of the heterodimer.	Guys Kings & St Thomas Sch Med, Dept Med & Mol Genet, Canc Genet Lab, London SE1 9RT, England; Univ London Birkbeck Coll, BBSRC Bloomsbury Ctr Struct Biol, London WC1E 7HX, England; Univ London Birkbeck Coll, Sch Crystallog, London WC1E 7HX, England	University of London; King's College London; University of London; Birkbeck University London; University of London; Birkbeck University London	Solomon, E (corresponding author), Guys Kings & St Thomas Sch Med, Dept Med & Mol Genet, Canc Genet Lab, London SE1 9RT, England.	ellen.solomon@kcl.ac.uk	Morris, Joanna/AAK-3388-2021; Keep, N/C-2759-2008; Keep, Nicholas/R-3493-2019	Keep, N/0000-0002-5042-1837; Keep, Nicholas/0000-0002-5042-1837; Morris, Joanna/0000-0001-9762-8133	MRC [G9600577] Funding Source: UKRI; Medical Research Council [G9600577] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Brzovic PS, 2001, J BIOL CHEM, V276, P41399, DOI 10.1074/jbc.M106551200; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; HAOTHAI TH, 1998, HUM MOL GENET, V7, P195; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; KEOHAVONG P, 1989, P NATL ACAD SCI USA, V86, P9253, DOI 10.1073/pnas.86.23.9253; Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; PRINTEN JA, 1994, GENETICS, V138, P609; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shih HM, 1996, P NATL ACAD SCI USA, V93, P13896, DOI 10.1073/pnas.93.24.13896; Venkitaraman AR, 2001, J CELL SCI, V114, P3591; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yoshikawa K, 2000, INT J CANCER, V88, P28, DOI 10.1002/1097-0215(20001001)88:1<28::AID-IJC5>3.0.CO;2-4	24	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9382	9386		10.1074/jbc.M109249200	http://dx.doi.org/10.1074/jbc.M109249200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11773071	hybrid			2022-12-27	WOS:000174400600087
J	Pannaccione, A; Castaldo, P; Ficker, E; Annunziato, L; Taglialatela, M				Pannaccione, A; Castaldo, P; Ficker, E; Annunziato, L; Taglialatela, M			Histidines 578 and 587 in the S-5-S-6 linker of the human Ether-a-gogo related gene-1 K+ channels confer sensitivity to reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG VENTRICULAR MYOCYTES; HERG POTASSIUM CHANNEL; NITRIC-OXIDE; LIPID-PEROXIDATION; CARDIAC-ARRHYTHMIA; OXIDATIVE STRESS; MOLECULAR-BASIS; NERVOUS-SYSTEM; NEURONAL DEATH; MECHANISM	The K+ channels encoded by the human Ether-a-gogo Related Gene-1 (hERG1) are crucially involved in controlling heart and brain excitability and are selectively influenced by reactive oxygen species (ROS). To localize the molecular regions involved in ROS-induced modulation of hERG1, segmental exchanges between the ROS-sensitive hERG1 and the ROS-insensitive bovine ether-a-gogo gene (bEAG) K+ channels were generated, and the sensitivity of these chimeric channels to ROS was studied with the two-microelectrode voltage-clamp technique upon their expression in Xenopus oocytes. Substitution of the S-5-S-6 linker of hERG1 with the corresponding bEAG region removed channel sensitivity to ROS, whereas the reverse chimeric exchange introduced ROS sensitivity into bEAG. Mutation of each of the two hERG1 histidines at positions 578 and 587 within the S-5-S-6 linker generated K+ channels insensitive to modulation by ROS. In addition, the two iron chelators desferrioxamine (1 mm) and o-phenanthroline (0.2 mm) significantly inhibited hERG1 outward K+ currents and prevented hERG1 inhibition induced by the ROS-scavenging enzyme catalase (1000 units/ml). Finally, the hERG1-inhibitory effect exerted by the iron chelators was prevented by the hERG1 H578D/H587Y double mutation. Collectively, the results obtained suggest that histidines at positions 578 and 587 in the S-5-S-6 linker region of hERG1 K+ channels are crucial players in ROS-induced modulation of hERG1 K+ channels.	Univ Naples Federico II, Pharmacol Sect, Dept Neurosci, Sch Med,Unit Pharmacol, I-80131 Naples, Italy	University of Naples Federico II	Taglialatela, M (corresponding author), Univ Naples Federico II, Pharmacol Sect, Dept Neurosci, Sch Med,Unit Pharmacol, Via S Pansini 5, I-80131 Naples, Italy.		Pannaccione, Anna/Q-7629-2019; Taglialatela, Maurizio/ABH-4262-2020; Taglialatela, Maurizio/K-1840-2013; Taglialatela, Maurizio/AAB-8621-2022; Taglialatela, Maurizio/A-2062-2019	Taglialatela, Maurizio/0000-0002-8202-0560; Taglialatela, Maurizio/0000-0002-8202-0560; ANNUNZIATO, LUCIO/0000-0002-8534-8270; PANNACCIONE, Anna/0000-0003-1500-1690				Arcangeli A, 1995, J PHYSIOL-LONDON, V489, P455, DOI 10.1113/jphysiol.1995.sp021065; Berube J, 1999, PFLUG ARCH EUR J PHY, V438, P419, DOI 10.1007/s004240050930; Berube J, 2001, J PHARMACOL EXP THER, V297, P96; Boumans H, 1997, J BIOL CHEM, V272, P16753, DOI 10.1074/jbc.272.27.16753; Carmeliet E, 1999, PHYSIOL REV, V79, P917, DOI 10.1152/physrev.1999.79.3.917; CERBAI E, 1991, CIRCULATION, V84, P1773, DOI 10.1161/01.CIR.84.4.1773; CHEVION M, 1988, FREE RADICAL BIO MED, V5, P27, DOI 10.1016/0891-5849(88)90059-7; CHEVION M, 1993, P NATL ACAD SCI USA, V90, P1102, DOI 10.1073/pnas.90.3.1102; Chiesa N, 1997, J PHYSIOL-LONDON, V501, P313, DOI 10.1111/j.1469-7793.1997.313bn.x; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DARLEYUSMAR V, 1995, FEBS LETT, V369, P131, DOI 10.1016/0014-5793(95)00764-Z; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dun W, 1999, PFLUG ARCH EUR J PHY, V439, P141, DOI 10.1007/s004240051138; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; Faravelli L, 1996, J PHYSIOL-LONDON, V496, P13, DOI 10.1113/jphysiol.1996.sp021661; Ficker E, 1998, CIRC RES, V82, P386, DOI 10.1161/01.RES.82.3.386; Frings S, 1998, J GEN PHYSIOL, V111, P583, DOI 10.1085/jgp.111.4.583; Goss SPA, 1999, METHOD ENZYMOL, V301, P444; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HALLIWELL B, 1989, FREE RADICAL BIO MED, V2, P1; Ho WK, 1999, BIOPHYS J, V76, P1959, DOI 10.1016/S0006-3495(99)77355-8; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Inglefield JR, 1997, HIPPOCAMPUS, V7, P511, DOI 10.1002/(SICI)1098-1063(1997)7:5<511::AID-HIPO7>3.3.CO;2-V; JABR RI, 1993, CIRC RES, V72, P1229, DOI 10.1161/01.RES.72.6.1229; Jiang M, 1999, AM J PHYSIOL-HEART C, V277, pH1283, DOI 10.1152/ajpheart.1999.277.4.H1283; Jo SH, 1999, PFLUG ARCH EUR J PHY, V438, P23, DOI 10.1007/s004240050875; KANEKO M, 1994, MOL CELL BIOCHEM, V139, P91, DOI 10.1007/BF00944207; KANNER J, 1991, ARCH BIOCHEM BIOPHYS, V289, P130, DOI 10.1016/0003-9861(91)90452-O; KORSMEYER SJ, 1995, BBA-MOL BASIS DIS, V1271, P63, DOI 10.1016/0925-4439(95)00011-R; Kourie JI, 1998, AM J PHYSIOL-CELL PH, V275, pC1, DOI 10.1152/ajpcell.1998.275.1.C1; LLOYD JB, 1991, BIOCHEM PHARMACOL, V41, P1361, DOI 10.1016/0006-2952(91)90109-I; MARTIN RL, 1994, TRENDS NEUROSCI, V17, P251, DOI 10.1016/0166-2236(94)90008-6; NAKAYA H, 1987, AM J PHYSIOL, V253, pH1089, DOI 10.1152/ajpheart.1987.253.5.H1089; OUBIDAR M, 1994, FREE RADICAL BIO MED, V16, P861, DOI 10.1016/0891-5849(94)90205-4; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Saganich MJ, 2001, J NEUROSCI, V21, P4609, DOI 10.1523/JNEUROSCI.21-13-04609.2001; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Shi WM, 1997, J NEUROSCI, V17, P9423; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; Taglialatela M, 1999, MOL PHARMACOL, V56, P1298, DOI 10.1124/mol.56.6.1298; Taglialatela M, 1997, P NATL ACAD SCI USA, V94, P11698, DOI 10.1073/pnas.94.21.11698; TSUSHIMA RG, 1990, J CARDIOVASC PHARM, V16, P50, DOI 10.1097/00005344-199007000-00008; UCHIDA K, 1993, FEBS LETT, V332, P208, DOI 10.1016/0014-5793(93)80632-5; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; WHALLEY DW, 1994, CARDIAC ARRHYTHMIAS, P109; Ying WH, 1999, J NEUROCHEM, V73, P1549, DOI 10.1046/j.1471-4159.1999.0731549.x; YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139; Zhao F, 1997, J BIOL CHEM, V272, P9019	52	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8912	8919		10.1074/jbc.M111353200	http://dx.doi.org/10.1074/jbc.M111353200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11756457	hybrid, Green Published			2022-12-27	WOS:000174400600025
J	Coppi, A; Merali, S; Eichinger, D				Coppi, A; Merali, S; Eichinger, D			The enteric parasite Entamoeba uses an autocrine catecholamine system during differentiation into the infectious cyst stage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICTYOSTELIUM-DISCOIDEUM; TRYPANOSOMA-CRUZI; ADHERENCE LECTIN; GENE-EXPRESSION; ENCYSTATION; HISTOLYTICA; INVADENS; GALACTOSE; CELLS; MECHANISMS	Enteric amoebae of the genus Entamoeba travel from host to host in an encysted form. We previously showed that in vitro cyst development of Entamoeba invadens requires the addition of defined amounts of multivalent galactose-terminated molecules, such as mucin, to the cultures. The amoeba surface lectin that binds mucin is presumed to convey transmembrane signals when clustered by the ligand, but the signaling molecules that function downstream of the lectin are not known. We report here that Entamoeba encystation was induced in the absence of galactose ligand when catecholamines were added to the encystation medium. Micromolar amounts of both epinephrine and norepinephrine induced encystation. Of a variety of synthetic catecholamine agonists tested, only beta(1)-adrenergic receptor agonists supported encystation, whereas alpha- and beta(2)-adrenergic receptor agonists did not. Only beta(1)-adrenergic receptor antagonists inhibited encystation, and did so even when exogenous catecholamines were not added, indicating that catecholamine binding is required for encystation and suggesting an endogenous source of the ligand. High performance liquid chromatography analysis of Entamoeba extracts showed that the amoebae themselves contain catecholamines and at least one of these is released when the cells are stimulated to encyst with galactose-terminated ligands. The presence of catecholamine binding sites on the surface of amoeba trophozoites was confirmed using radiolabeled catecholamine antagonist. Amoeba encystment was inhibited by addition of beta(1)-adrenergic receptor antagonist to cells that were stimulated to differentiate with either galactose ligand or catecholamines, but not with dibutyryl cAMP. This suggests that the amoeba catecholamine receptor functions downstream of the galactose lectin and upstream of adenylyl cyclase. This enteric protozoan parasite, therefore, contains the components of an autocrine catecholamine ligand-receptor system that may act in conjunction with a galactose lectin to regulate differentiation into the infectious cyst stage.	NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA	New York University	Coppi, A (corresponding author), NYU, Sch Med, Dept Med & Mol Parasitol, 341 E 25th St, New York, NY 10010 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI041947, R01AI044893, R01AI041947] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44893, AI41947, AI07180] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVRON B, 1986, J PROTOZOOL, V33, P522, DOI 10.1111/j.1550-7408.1986.tb05655.x; CHADEE K, 1987, J CLIN INVEST, V80, P1245, DOI 10.1172/JCI113199; Chakraborti S, 2000, CELL SIGNAL, V12, P499, DOI 10.1016/S0898-6568(00)00087-5; Cho J, 1998, J PARASITOL, V84, P705, DOI 10.2307/3284574; CLARKE M, 1988, DEV GENET, V9, P315, DOI 10.1002/dvg.1020090413; CONNELLY MC, 1988, J PARASITOL, V74, P379, DOI 10.2307/3282042; COOPER JR, 1996, BIOCH BASIS NEUROPHA, P226; Coppi A, 1999, MOL BIOCHEM PARASIT, V102, P67, DOI 10.1016/S0166-6851(99)00085-7; Day WA, 2001, INFECT IMMUN, V69, P15, DOI 10.1128/IAI.69.1.15-23.2001; DEBLASI A, 1989, AM J HYPERTENS, V2; DECASTRO SL, 1987, COMP BIOCHEM PHYS C, V87, P5, DOI 10.1016/0742-8413(87)90170-8; Diamond L.S., 1987, P1; Docherty JR, 1998, EUR J PHARMACOL, V361, P1, DOI 10.1016/S0014-2999(98)00682-7; Eichinger D, 1997, BIOESSAYS, V19, P633, DOI 10.1002/bies.950190714; Fields BS, 1996, TRENDS MICROBIOL, V4, P286, DOI 10.1016/0966-842X(96)10041-X; GROSS JD, 1994, MICROBIOL REV, V58, P330, DOI 10.1128/MMBR.58.3.330-351.1994; Gruenheid S, 2000, TRENDS MICROBIOL, V8, P442, DOI 10.1016/S0966-842X(00)01818-7; HEITHIER H, 1994, BIOCHEMISTRY-US, V33, P9126, DOI 10.1021/bi00197a015; JAIN R, 1992, GENE DEV, V6, P390, DOI 10.1101/gad.6.3.390; Johnson M, 1998, AM J RESP CRIT CARE, V158, pS146, DOI 10.1164/ajrccm.158.supplement_2.13tac110; Kugler S, 2000, P NATL ACAD SCI USA, V97, P8794, DOI 10.1073/pnas.97.16.8794; Malven P. V., 1993, MAMMALIAN NEUROENDOC; MCCONNACHIE EW, 1969, PARASITOLOGY, V59, P41, DOI 10.1017/S003118200006981X; MCCONNACHIE EW, 1955, PARASITOLOGY, V45, P452, DOI 10.1017/S0031182000027803; MEEROVITCH E, 1961, J PARASITOL, V47, P791, DOI 10.2307/3275473; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; Merali S, 1996, J CHROMATOGR B, V675, P321, DOI 10.1016/0378-4347(95)00363-0; PALACIOS JM, 1989, LIFE SCI, V44, P2057, DOI 10.1016/0024-3205(89)90352-4; PETRI WA, 1989, J BIOL CHEM, V264, P3007; PETRI WA, 1987, J CLIN INVEST, V80, P1238, DOI 10.1172/JCI113198; RAIZADA MK, 1972, J CELL BIOL, V52, P743, DOI 10.1083/jcb.52.3.743; RAVDIN JI, 1981, J CLIN INVEST, V68, P1305, DOI 10.1172/JCI110377; RENGPIEN S, 1975, J PARASITOL, V61, P24, DOI 10.2307/3279100; SANCHEZ L, 1994, MOL BIOCHEM PARASIT, V67, P125, DOI 10.1016/0166-6851(94)90102-3; VAZQUEZDELARACISNEROS LG, 1984, J PARASITOL, V70, P629, DOI 10.2307/3281741; VERMA AK, 1974, BIOCHEM PHARMACOL, V23, P57, DOI 10.1016/0006-2952(74)90313-X; VERMA AK, 1976, INDIAN J BIOCHEM BIO, V13, P71; Vines RR, 1998, MOL BIOL CELL, V9, P2069, DOI 10.1091/mbc.9.8.2069	38	59	60	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8083	8090		10.1074/jbc.M111895200	http://dx.doi.org/10.1074/jbc.M111895200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11779874	hybrid			2022-12-27	WOS:000174268000059
J	Koipally, J; Heller, EJ; Seavitt, JR; Georgopoulos, K				Koipally, J; Heller, EJ; Seavitt, JR; Georgopoulos, K			Unconventional potentiation of gene expression by Ikaros	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; DNA-BINDING; CENTROMERIC HETEROCHROMATIN; LYMPHOCYTE DEVELOPMENT; COMPLEXES; FAMILY; DIFFERENTIATION; ACTIVATION; REPRESSION; MECHANISM	Ikaros is essential for the normal development and regulated proliferation of lymphoid cells. In lymphocytes, Ikaros exists as an integral component of chromatin-remodeling complexes, including the Mi-2beta/nucleosome remodeling and deacetylation complex (NuRD) complex. It is expected that Ikaros, together with these associated activities effects repression, but here we show that they may also potentiate gene expression in cycling cells. Ikaros cannot activate transcription by itself, instead, it enhances the activity of both weak and strong activators. For this role in potentiation, Ikaros requires its DNA binding and dimerization domains. The DNA binding and dimerization properties of Ikaros are also responsible for its targeting to pericentromeric heterochromatin (PC-HQ. Significantly, Ikaros mutants with altered specificity for DNA binding that are unable to localize to PC-HC are incapable of stimulating transcription from reporters bearing their cognate sites. Thus, potentiation of gene expression by Ikaros correlates strongly with its ability to localize to PC-HC in combination with the chromatin remodeler Mi-2beta.	Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Georgopoulos, K (corresponding author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, E Bldg 149,13th St, Charlestown, MA 02129 USA.				NIAID NIH HHS [R01 AI 380342-08] Funding Source: Medline; NIGMS NIH HHS [F32-GM-20724] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM020724] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad K, 2001, CELL, V104, P839, DOI 10.1016/S0092-8674(01)00281-1; Avitahl N, 1999, IMMUNITY, V10, P333, DOI 10.1016/S1074-7613(00)80033-3; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; CORTES M, 1999, CURR OPIN IMMUNOL; DiFronzo NL, 2002, J VIROL, V76, P78, DOI 10.1128/JVI.76.1.78-87.2002; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; GEORGOPOULOS K, 1997, CURR OPIN IMMUNOL, V9, P228; GREISMAN HA, 1997, SCIENCE, V275, P857; Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; Honma Y, 1999, FEBS LETT, V447, P76, DOI 10.1016/S0014-5793(99)00265-3; Kelley CM, 1998, CURR BIOL, V8, P508, DOI 10.1016/S0960-9822(98)70202-7; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; KOIPALLY J, 2000, COLD SPRING HARB SYM, V64, P1; Lundgren M, 2000, CELL, V103, P733, DOI 10.1016/S0092-8674(00)00177-X; MOLNAR A, 1994, MOL CELL BIOL, V14, P785; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; Nadeau G, 2000, EMBO REP, V1, P260, DOI 10.1093/embo-reports/kvd059; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; Okano H, 1999, ONCOGENE, V18, P6677, DOI 10.1038/sj.onc.1203100; Perdomo J, 2000, J BIOL CHEM, V275, P38347, DOI 10.1074/jbc.M005457200; Sabbattini P, 2001, EMBO J, V20, P2812, DOI 10.1093/emboj/20.11.2812; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Trinh LA, 2001, GENE DEV, V15, P1817, DOI 10.1101/gad.905601; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Winandy S, 1999, J EXP MED, V190, P1039, DOI 10.1084/jem.190.8.1039; Wolfe SA, 1999, J MOL BIOL, V285, P1917, DOI 10.1006/jmbi.1998.2421	33	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13007	13015		10.1074/jbc.M111371200	http://dx.doi.org/10.1074/jbc.M111371200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11799125	hybrid			2022-12-27	WOS:000175036300067
J	Bao, YP; Cook, LJ; O'Donovan, D; Uyama, E; Rubinsztein, DC				Bao, YP; Cook, LJ; O'Donovan, D; Uyama, E; Rubinsztein, DC			Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL HUNTINGTIN; HEAT-SHOCK; INTRANUCLEAR INCLUSIONS; PROTEIN AGGREGATION; SUPPRESSION; BINDING; PABP2; EXPANSIONS; EXPRESSION; HOXD13	Autosomal dominant oculopharyngeal muscular dystrophy (OPMD) is characterized pathologically by intranuclear inclusions in skeletal muscles and is caused by the expansion of a 10-alanine stretch to 12-17 alanines in the intranuclear poly(A)-binding protein 2 (PABP2). Whereas PABP2 is a major component of the inclusions in OPMD, the pathogenic mechanisms causing disease are unknown. Here we show that polyalanine expansions in PABP2 cause increased numbers of inclusions and enhance death in COS-7 cells. We observed similar increases of protein aggregation and cell death with nuclear-targeted green fluorescent protein linked to longer versus shorter polyalanine stretches. Intranuclear aggregates in our OPMD cell model were associated with heat shock protein (HSP) 40 (HDJ-1) and HSP70. Human HDJ-1, yeast hsp104, a bacterially derived GroEL minichaperone, and the chemical chaperone Me2SO reduced both aggregation and cell death in our OPMD model without affecting the levels of PABP2, and similar trends were seen with green fluorescent protein with long polyalanine stretches. Thus, polyalanine expansion mutations in different protein contexts cause proteins to misfold/aggregate and kill cells. The situation in OPMD appears to have many parallels with polyglutamine diseases, raising the possibility that misfolded, aggregate-prone proteins may perturb similar pathways, irrespective of the nature of the mutation or protein context.	Addenbrookes Hosp, Cambridge Inst Med Res, Dept Med Genet, Cambridge CB2 2XY, England; Addenbrookes Hosp, Dept Histopathol, Cambridge CB2 2QH, England; Kumamoto Univ, Sch Med, Dept Neurol, Kumamoto 8600811, Japan	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Kumamoto University	Rubinsztein, DC (corresponding author), Addenbrookes Hosp, Cambridge Inst Med Res, Dept Med Genet, Wellcome MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	dcr1000@cus.cam.ac.uk	Rubinsztein, David C/C-3472-2011					Becher MW, 2000, ANN NEUROL, V48, P812, DOI 10.1002/1531-8249(200011)48:5<812::AID-ANA20>3.3.CO;2-U; Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; Benoit B, 1999, NUCLEIC ACIDS RES, V27, P3771, DOI 10.1093/nar/27.19.3771; Blondelle SE, 1997, BIOCHEMISTRY-US, V36, P8393, DOI 10.1021/bi963015b; Brais B, 1998, NAT GENET, V18, P164, DOI 10.1038/ng0298-164; Calado A, 2000, HUM MOL GENET, V9, P2321, DOI 10.1093/oxfordjournals.hmg.a018924; Calado A, 2000, J CELL SCI, V113, P2309; Carmichael J, 2000, P NATL ACAD SCI USA, V97, P9701, DOI 10.1073/pnas.170280697; Chai YH, 1999, J NEUROSCI, V19, P10338; Chan HYE, 2000, HUM MOL GENET, V9, P2811, DOI 10.1093/hmg/9.19.2811; Chatellier J, 2000, J MOL BIOL, V304, P883, DOI 10.1006/jmbi.2000.4277; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Fan XP, 2001, HUM MOL GENET, V10, P2341, DOI 10.1093/hmg/10.21.2341; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Goodman FR, 1997, P NATL ACAD SCI USA, V94, P7458, DOI 10.1073/pnas.94.14.7458; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Johnson KR, 1998, HUM MOL GENET, V7, P1033, DOI 10.1093/hmg/7.6.1033; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nagao Y, 2000, BBA-MOL BASIS DIS, V1502, P247, DOI 10.1016/S0925-4439(00)00047-8; NEMETH A, 1995, NUCLEIC ACIDS RES, V23, P4034, DOI 10.1093/nar/23.20.4034; Peters MF, 1999, MOL CELL NEUROSCI, V14, P121, DOI 10.1006/mcne.1999.0773; Rankin J, 2000, BIOCHEM J, V348, P15, DOI 10.1042/0264-6021:3480015; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Shanmugam V, 2000, ANN NEUROL, V48, P798; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Sittler A, 2001, HUM MOL GENET, V10, P1307, DOI 10.1093/hmg/10.12.1307; Tome FMS, 1997, NEUROMUSCULAR DISORD, V7, pS63, DOI 10.1016/S0960-8966(97)00085-0; Uyama E, 2000, MUSCLE NERVE, V23, P1549, DOI 10.1002/1097-4598(200010)23:10<1549::AID-MUS11>3.0.CO;2-0; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898; Zhou H, 2001, J BIOL CHEM, V276, P48417, DOI 10.1074/jbc.M104140200	32	91	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12263	12269		10.1074/jbc.M109633200	http://dx.doi.org/10.1074/jbc.M109633200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11796717	hybrid			2022-12-27	WOS:000174846400086
J	Li, BJ; Ishii, T; Tan, CP; Soh, JW; Goff, SP				Li, BJ; Ishii, T; Tan, CP; Soh, JW; Goff, SP			Pathways of induction of peroxiredoxin I expression in osteoblasts - Roles of p38 mitogen-activated protein kinase and protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TYROSINE KINASE; PAG GENE-PRODUCT; OXIDATIVE STRESS; FREE-RADICALS; PHYSIOLOGICAL INHIBITOR; SIGNAL-TRANSDUCTION; BONE-RESORPTION; CELLS; SUPEROXIDE; CLONING	Peroxiredoxin I (Prx I) is an oxidative stress-inducible antioxidant protein with thioredoxin peroxidase activity. Here we report that the levels of Prx I mRNA and protein are dramatically increased in a murine osteoblast cell line, MC3T3-E1, by treatment with sodium arsenate. We further studied the signaling pathways that control the induction of Prx I expression. The treatment of osteoblasts with arsenate activated ERK1/2, JNK, and p38 MAPK. Pre-treating cells with inhibitors of p38 MAPK abolished the induction of Prx I protein but had minimal effect on the induction of Prx I mRNA, suggesting that p38 MAPK activity was required for post-transcriptional regulation. The inhibition of ERK1 and ERK2 had no effect on the induction of Prx I expression. Furthermore, rottlerin, an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III, abrogated the up-regulation at both protein and mRNA levels. Staurosporine and Go6983, inhibitors for PKC, also inhibited the induction of Prx I, suggesting that protein kinase Cdelta is required for the induction by arsenate. PKCdelta was activated by arsenate treatment by in vitro kinase assays. The inhibition of PKCdelta by rottlerin did not affect the activation of p38 MAPK by arsenate. These results suggest that there are two separate signaling pathways involved in the up-regulation of Prx I protein in response to arsenate, PKCdelta required for transcriptional activation and p38 MAPK required for post-transcriptional regulation.	Columbia Univ, Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY USA; Columbia Univ, Coll Phys & Surg, Howard Hughes Med Inst, New York, NY USA; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore; Univ Tsukuba, Inst Basic Med Sci, Dept Biochem, Tsukuba, Ibaraki 3058575, Japan	Columbia University; Columbia University; Howard Hughes Medical Institute; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; University of Tsukuba	Li, BJ (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Biochem & Mol Biophys, HHSC1128,701 W 168th St, New York, NY 10032 USA.		Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547				Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Carpenter L, 2001, J BIOL CHEM, V276, P5368, DOI 10.1074/jbc.M010036200; GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hensley K, 2000, FREE RADICAL BIO MED, V28, P1456, DOI 10.1016/S0891-5849(00)00252-5; IMMENSCHUH S, 1995, BIOCHEMISTRY-US, V34, P13407, DOI 10.1021/bi00041a018; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; ISHII T, 1993, J BIOL CHEM, V268, P18633; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; KAWAI S, 1994, J BIOCHEM-TOKYO, V115, P641, DOI 10.1093/oxfordjournals.jbchem.a124388; KEY LL, 1994, BONE, V15, P431, DOI 10.1016/8756-3282(94)90821-4; Kontny E, 2000, J LEUKOCYTE BIOL, V67, P249, DOI 10.1002/jlb.67.2.249; Lee Y, 1999, J BIOL CHEM, V274, P19792, DOI 10.1074/jbc.274.28.19792; McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5; Otieno MA, 2000, CANCER RES, V60, P4391; Pietersma A, 1997, BIOCHEM BIOPH RES CO, V230, P44, DOI 10.1006/bbrc.1996.5886; Porter AC, 1999, ONCOGENE, V18, P7794, DOI 10.1038/sj.onc.1203214; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; Prosperi MT, 1998, FEBS LETT, V423, P39, DOI 10.1016/S0014-5793(98)00057-X; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; STEINBECK MJ, 1994, J CELL BIOL, V126, P765, DOI 10.1083/jcb.126.3.765; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; YIM MB, 1994, J BIOL CHEM, V269, P1621	28	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12418	12422		10.1074/jbc.M111443200	http://dx.doi.org/10.1074/jbc.M111443200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11796722	hybrid			2022-12-27	WOS:000174846400107
J	Blacque, OE; Worrall, DM				Blacque, OE; Worrall, DM			Evidence for a direct interaction between the tumor suppressor serpin, maspin, and types I and III collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIUM-DERIVED FACTOR; PLASMINOGEN-ACTIVATOR; NEUROTROPHIC ACTIVITY; INTRACELLULAR SERPIN; BINDING-PROTEIN; PROCOLLAGEN-I; INHIBITOR; CELL; FAMILY; PURIFICATION	Maspin (mammary uterine protease inhibitor) was originally identified as a tumor suppressor protein in human breast epithelial cells and is a member of the serine proteases inhibitor (serpin) superfamily. It inhibits tumor cell motility and angiogenesis, and although predominantly cytoplasmic, it is also localized to the cell surface. In this study we have investigated the use of the yeast two-hybrid interaction trap to identify novel maspin targets. A target human fibroblast cDNA library was screened, and the alpha-2 chain of type I collagen was identified as a potential interactant. Binding studies with isolated proteins showed interaction between recombinant maspin and types I and III collagen but not other collagen subtypes, a profile strikingly similar to mouse pigment epithelium-derived factor (caspin), which is similarly down-regulated in murine adenocarcinoma tumors and is a potent inhibitor of angiogenesis. Kinetic analysis using an IAsys resonant mirror biosensor determined the dissociation constant of maspin for collagen type I to be 0.63 mum. Further two-hybrid interactions with maspin truncation constructs suggest that collagen binding is localized to amino acids 84-112 of maspin, which aligns with the collagen-binding region of colligin. A direct interaction between exogenous or cell surface maspin and extracellular matrix collagen may contribute to a cell adhesion role in the prevention of tumor cell migration and angiogenesis.	Univ Coll Dublin, Dept Biochem, Dublin 4, Ireland; Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland	University College Dublin; University College Dublin	Worrall, DM (corresponding author), Univ Coll Dublin, Dept Biochem, Dublin 4, Ireland.	mworrall@ucd.ie	Blacque, Oliver/AAL-8860-2021	Blacque, Oliver/0000-0003-1598-2695				Alberdi E, 1998, BIOCHEMISTRY-US, V37, P10643, DOI 10.1021/bi9802317; Ball EH, 1997, ADV EXP MED BIOL, V425, P239; BECERRA SP, 1995, J BIOL CHEM, V270, P25992, DOI 10.1074/jbc.270.43.25992; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CLARKE EP, 1993, J CELL BIOL, V121, P193, DOI 10.1083/jcb.121.1.193; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; DONOVAN FM, 1994, J BIOL CHEM, V269, P17199; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; JAIN N, 1994, BIOCHEM J, V304, P61, DOI 10.1042/bj3040061; Jensen PH, 1996, J BIOL CHEM, V271, P26892, DOI 10.1074/jbc.271.43.26892; KorpulaMastalerz R, 1996, ACTA BIOCHIM POL, V43, P419; Kozaki K, 1998, J BIOL CHEM, V273, P15125, DOI 10.1074/jbc.273.24.15125; Kuo HJ, 1997, J BIOL CHEM, V272, P26522, DOI 10.1074/jbc.272.42.26522; McCarthy BJ, 1997, J MOL BIOL, V267, P561, DOI 10.1006/jmbi.1996.0909; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; Ngamkitidechakul C, 2001, INVEST OPHTH VIS SCI, V42, P3135; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; Sager R, 1997, ADV EXP MED BIOL, V425, P77; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHNEIDER SS, 1995, P NATL ACAD SCI USA, V92, P3147, DOI 10.1073/pnas.92.8.3147; Seftor REB, 1998, CANCER RES, V58, P5681; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; SUN JR, 1995, BBA-PROTEIN STRUCT M, V1252, P28, DOI 10.1016/0167-4838(95)00108-7; Wapnir IL, 1996, INVAS METAST, V16, P308; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhang M, 1999, DEV BIOL, V215, P278, DOI 10.1006/dbio.1999.9442; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	36	86	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10783	10788		10.1074/jbc.M110992200	http://dx.doi.org/10.1074/jbc.M110992200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11788595	hybrid			2022-12-27	WOS:000174613100007
J	Herbert, TP; Tee, AR; Proud, CG				Herbert, TP; Tee, AR; Proud, CG			The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CAP-DEPENDENT TRANSLATION; PHAS-I; MAMMALIAN TARGET; 4E-BINDING PROTEIN-1; (S/T)P SITES; INSULIN; INITIATION; RAPAMYCIN; INHIBITOR	The phorbol ester, 12-O-tetradecanoylphorbol 13-acetate (TPA), a potent stimulator of Erk, leads to the phosphorylation of 4E-BP1 and its dissociation from eIF4E. In contrast to agonists such as insulin, this occurs independently of PKB activation. In this report, we investigate the mechanism by which TPA regulates 4E-BP1 phosphorylation. Treatment of HEK293 cells with TPA was found to result in the phosphorylation of 4E-BP1 at Ser(64), Thr(69), and Thr(36/45). The TPA-stimulated phosphorylation of all these sites is sensitive to inhibitors of MEK and to the inhibitor of mTOR, rapamycin, indicating that inputs from both mTOR and MEK are required for the regulation of 4E-BP1 phosphorylation by TPA. Indeed, evidence is presented that mTOR may initially be required for the phosphorylation of Thr(45) in a priming step, which is necessary for the subsequent phosphorylation of Ser(64) and Thr(69) through an Erk-dependent pathway. Overexpression of constitutively active MEK in HEK293 cells resulted both in the phosphorylation of 4E-BP1 at Ser(64) and Thr(36/45) and its release from eIF4E. In this case, the phosphorylation of these sites was also blocked by inhibitors of MEK or by rapamycin. In conclusion, the Erk pathway, via mechanisms also requiring mTOR, regulates the phosphorylation of multiple sites in 4E-BP1 in vivo and this is sufficient for the release of 4E-BP1 from eIF4E.	Univ Dundee, Sch Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland	University of Dundee	Herbert, TP (corresponding author), Univ Leicester, Dept Biochem, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	tph4@le.ac.uk		Proud, Christopher/0000-0003-0704-6442; Tee, Andrew/0000-0002-5577-4631; Herbert, Terence/0000-0001-5402-0814				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Bhandari BK, 2001, KIDNEY INT, V59, P866; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Diggle TA, 1996, BIOCHEM J, V316, P447, DOI 10.1042/bj3160447; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fadden P, 1997, J BIOL CHEM, V272, P10240; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Heesom KJ, 1998, BIOCHEM J, V336, P39, DOI 10.1042/bj3360039; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; Karim MM, 2001, J BIOL CHEM, V276, P20750, DOI 10.1074/jbc.M011068200; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kumar V, 2000, EMBO J, V19, P1087, DOI 10.1093/emboj/19.5.1087; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; Ptushkina M, 1999, EMBO J, V18, P4068, DOI 10.1093/emboj/18.14.4068; Rao GN, 1999, J BIOL CHEM, V274, P12925, DOI 10.1074/jbc.274.18.12925; RASMUSSEN H, 1995, ENDOCR REV, V16, P649, DOI 10.1210/er.16.5.649; Robinson MJ, 1996, J BIOL CHEM, V271, P29734, DOI 10.1074/jbc.271.47.29734; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SMITH M R, 1990, New Biologist, V2, P648; Takata M, 1999, J BIOL CHEM, V274, P20611, DOI 10.1074/jbc.274.29.20611; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Yang DQ, 1999, FEBS LETT, V453, P387, DOI 10.1016/S0014-5793(99)00762-0	41	157	162	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11591	11596		10.1074/jbc.M110367200	http://dx.doi.org/10.1074/jbc.M110367200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11799119	Green Accepted, hybrid			2022-12-27	WOS:000174613100107
J	Ku, NO; Azhar, S; Omary, MB				Ku, NO; Azhar, S; Omary, MB			Keratin 8 phosphorylation by p38 kinase regulates cellular keratin filament reorganization - Modulation by a keratin 1-like disease-causing mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; ACTIVATED PROTEIN-KINASE; GENETIC SKIN DISEASES; INTERMEDIATE FILAMENTS; IN-VIVO; EPITHELIAL-CELLS; SOLUBILITY; APOPTOSIS; STRESS; MICE	Keratin 8 (K8) serine 73 occurs within a relatively conserved type II keratin motif ((68)NQSLLSPL) and becomes phosphorylated in cultured cells and organs during mitosis, cell stress, and apoptosis. Here we show that Ser-73 is exclusively phosphorylated in vitro by p38 mitogen-activated protein kinase. In cells, Ser-73 phosphorylation occurs in association with p38 kinase activation and is inhibited by SB203580 but not by PD98059. Trans. fection of K8 Ser-73 --> Ala or K8 Ser-73 --> Asp with K18 generates normal-appearing filaments. In contrast, exposure to okadaic acid results in keratin filament destabilization in cells expressing wild-type or Ser-73 --> Asp K8, whereas Ser-73 --> Ala K8-expressing cells maintain relatively stable filaments. p38 kinase associates with K8/18 immunoprecipitates and binds selectively with K8 using an in vitro overlay assay. Given that K1 Leu-160 --> Pro ((157)NQSLLQPL --> (157)NQSPLQPL) leads to epidermolytic hyperkeratosis, we tested and showed that the analogous K8 Leu-71 --> Pro leads to K8 hyperphosphorylation by p38 kinase in vitro and in transfected cells, likely due to Ser-70 neo-phosphorylation, in association with significant keratin filament collapse upon cell exposure to okadaic acid. Hence, K8 Ser-73 is a physiologic phosphorylation site for p38 kinase, and its phosphorylation plays an important role in keratin filament reorganization. The Ser-73 --> Ala-associated filament reorganization defect is rescued by a Ser-73 --> Asp mutation. Also, disease-causing keratin mutations can modulate keratin phosphorylation and organization, which may affect disease pathogenesis.	Vet Affairs Palo Alto Hlth Care Syst, Dept Med, Palo Alto, CA 94304 USA; Vet Affairs Palo Alto Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Ctr Digest Dis, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Omary, MB (corresponding author), Vet Affairs Palo Alto Hlth Care Syst, Dept Med, Palo Alto, CA 94304 USA.			Omary, Bishr/0000-0002-8624-2347	NIDDK NIH HHS [DK52951, DK56339] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056339, R01DK052951] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CALNEK D, 1993, DIFFERENTIATION, V53, P95, DOI 10.1111/j.1432-0436.1993.tb00649.x; Cano E, 1996, ONCOGENE, V12, P805; CHIPEV CC, 1992, CELL, V70, P821, DOI 10.1016/0092-8674(92)90315-4; CHOU CF, 1993, J CELL SCI, V105, P433; Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5; Craxton A, 1999, ADV IMMUNOL, V73, P79, DOI 10.1016/S0065-2776(08)60786-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deschesnes RG, 2001, MOL BIOL CELL, V12, P1569, DOI 10.1091/mbc.12.6.1569; Ding WX, 2000, HEPATOLOGY, V32, P547, DOI 10.1053/jhep.2000.16183; ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K; FUCHS E, 1992, CELL, V69, P899, DOI 10.1016/0092-8674(92)90607-E; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; He T, 2002, J BIOL CHEM, V277, P10767, DOI 10.1074/jbc.M111436200; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; Hooser SB, 2000, TOXICOL PATHOL, V28, P726, DOI 10.1177/019262330002800513; Hu MCT, 1999, J BIOL CHEM, V274, P7095, DOI 10.1074/jbc.274.11.7095; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; Irvine AD, 1999, BRIT J DERMATOL, V140, P815, DOI 10.1046/j.1365-2133.1999.02810.x; Jochimsen EM, 1998, NEW ENGL J MED, V338, P873, DOI 10.1056/NEJM199803263381304; Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Ku NO, 1997, J BIOL CHEM, V272, P7556, DOI 10.1074/jbc.272.11.7556; Ku NO, 1999, AM J PHYSIOL-GASTR L, V277, pG1108, DOI 10.1152/ajpgi.1999.277.6.G1108; Ku NO, 1998, J CELL BIOL, V143, P2023, DOI 10.1083/jcb.143.7.2023; Ku NO, 2001, J BIOL CHEM, V276, P26792, DOI 10.1074/jbc.M103315200; Ku NO, 2001, NEW ENGL J MED, V344, P1580, DOI 10.1056/NEJM200105243442103; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO J, 1995, J BIOL CHEM, V270, P915, DOI 10.1074/jbc.270.2.915; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Liao J, 1997, J BIOL CHEM, V272, P17565, DOI 10.1074/jbc.272.28.17565; LIAO J, 1995, J CELL BIOL, V131, P1291, DOI 10.1083/jcb.131.5.1291; Magin TM, 2000, PROTOPLASMA, V211, P140, DOI 10.1007/BF01304482; Marceau N, 2001, BIOCHEM CELL BIOL, V79, P543, DOI 10.1139/bcb-79-5-543; MOLL R, 1990, J CELL BIOL, V111, P567, DOI 10.1083/jcb.111.2.567; Muller FB, 1998, J INVEST DERMATOL, V111, P900, DOI 10.1046/j.1523-1747.1998.00374.x; Omary M B, 1998, Subcell Biochem, V31, P105; Omary MB, 1997, HEPATOLOGY, V25, P1043, DOI 10.1002/hep.510250537; Omary MB, 2002, HEPATOLOGY, V35, P251, DOI 10.1053/jhep.2002.31165; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; RUNNEGAR MT, 1993, AM J PHYSIOL, V265, pG224, DOI 10.1152/ajpgi.1993.265.2.G224; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STEINERT PM, 1993, TRENDS GENET, V9, P280, DOI 10.1016/0168-9525(93)90014-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; YANO T, 1991, EUR J BIOCHEM, V197, P281, DOI 10.1111/j.1432-1033.1991.tb15909.x; Zhou XJ, 1999, J BIOL CHEM, V274, P12861, DOI 10.1074/jbc.274.18.12861	51	102	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10775	10782		10.1074/jbc.M107623200	http://dx.doi.org/10.1074/jbc.M107623200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11788583	hybrid			2022-12-27	WOS:000174613100006
J	Fan, WH; Karnovsky, MJ				Fan, WH; Karnovsky, MJ			Increased MMP-2 expression in connective tissue growth factor over-expression vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; NEOINTIMA FORMATION; GENE-EXPRESSION; CAROTID-ARTERY; INHIBITORS; BIGLYCAN; AP-2; PROTEOGLYCANS; PATHOGENESIS; DISEASES	Connective tissue growth factor (CTGF) is abundantly expressed in the vascular smooth muscle cells (VSMC) of atherosclerotic lesions but not in normal vessels. CTGF is able to promote VSMC proliferation and migration and influences the composition of extracellular matrix. The mechanisms for controlling these events remain unclear. We studied the effects of CTGF on matrix metalloproteinases (MMPs) by introducing a CTGF overexpression construct into VSMC. We found that the over-expression of CTGF significantly increased the activity of MMP-2 in VSMC conditioned medium. MMP-2 activity was similarly increased by exogenous CTGF treatment, and this effect could be blocked by an anti-CTGF antibody. We also showed that the increased MMP-2 activity was due to an increase in MMP-2 mRNA levels in VSMC. We further studied the mechanisms involved in the regulation of MMP-2 mRNA levels and found that the AP-2 transcription factor is responsible for most of the CTGF-induced MMP-2 transcription. Because MMP-2 is an important factor directly involved in controlling cell movement and the turnover of extracellular matrix, our study may provide a mechanism for CTGF-promoted VSMC migration.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Fan, WH (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.				NHLBI NIH HHS [HL17747] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL017747, R01HL017747] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bassiouny HS, 1998, CIRCULATION, V98, P157, DOI 10.1161/01.CIR.98.2.157; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; Brown PD, 1998, BREAST CANCER RES TR, V52, P125, DOI 10.1023/A:1006119319695; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; Fabunmi RP, 1996, BIOCHEM J, V315, P335, DOI 10.1042/bj3150335; Fan WH, 2000, EUR J CELL BIOL, V79, P915, DOI 10.1078/0171-9335-00122; George SJ, 1997, ARTERIOSCL THROM VAS, V17, P2500, DOI 10.1161/01.ATV.17.11.2500; Godin D, 2000, CIRCULATION, V102, P2861; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Knox JB, 1997, CIRCULATION, V95, P205, DOI 10.1161/01.CIR.95.1.205; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Lamparter S, 2000, Z KARDIOL, V89, P949, DOI 10.1007/s003920070169; Li YY, 2000, CARDIOVASC RES, V46, P214, DOI 10.1016/S0008-6363(00)00003-1; Li ZH, 1996, AM J PATHOL, V148, P121; Lijnen HR, 2001, THROMB HAEMOSTASIS, V86, P324; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MATRISIAN LM, 1994, ANN NY ACAD SCI, V732, P42, DOI 10.1111/j.1749-6632.1994.tb24723.x; Miralles F, 1998, J CELL BIOL, V143, P827, DOI 10.1083/jcb.143.3.827; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; NEWBY AC, 1994, BASIC RES CARDIOL, V89, P59; NIKOL S, 1992, J CLIN INVEST, V90, P1582, DOI 10.1172/JCI116027; Oemar BS, 1997, ARTERIOSCL THROM VAS, V17, P1483, DOI 10.1161/01.ATV.17.8.1483; Parsons SL, 1997, BRIT J SURG, V84, P160, DOI 10.1002/bjs.1800840206; PUKAC LA, 1991, AM J PATHOL, V139, P1501; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Sang Q X, 1998, Cell Res, V8, P171; Ungefroren H, 1996, J BIOL CHEM, V271, P15787, DOI 10.1074/jbc.271.26.15787; WEGROWSKI Y, 1995, GENOMICS, V30, P8, DOI 10.1006/geno.1995.0002; Yamakawa T, 2000, ATHEROSCLEROSIS, V152, P287, DOI 10.1016/S0021-9150(99)00475-X; ZEMPO N, 1994, J VASC SURG, V20, P209, DOI 10.1016/0741-5214(94)90008-6	35	68	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9800	9805		10.1074/jbc.M111213200	http://dx.doi.org/10.1074/jbc.M111213200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11773059	hybrid			2022-12-27	WOS:000174549200028
J	Hill, JA; Rothermel, B; Yoo, KD; Cabuay, B; Demetroulis, E; Weiss, RM; Kutschke, W; Bassel-Duby, R; Williams, RS				Hill, JA; Rothermel, B; Yoo, KD; Cabuay, B; Demetroulis, E; Weiss, RM; Kutschke, W; Bassel-Duby, R; Williams, RS			Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy - Preservation of systolic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; EXPRESSION	Calcineurin is a Ca2+/calmodulin-activated protein phosphatase that transduces hypertrophic stimuli to regulate transcriptional control of myocyte transformation. It is not known whether overexpression of MCIP1, a recently described endogenous inhibitor of calcineurin, impacts the hypertrophic response to pathophysiologically relevant pressure overload. Further, the functional consequences of calcineurin inhibition by MCIP1 under conditions of hemodynamic stress are unknown. Transgenic mice expressing a human cDNA encoding hMCIP1 in the myocardium were subjected to thoracic aortic banding. Transgenic mice and wild type littermates tolerated pressure overload equally well. Wild type mice developed left ventricular hypertrophy, but the hypertrophic response in transgenics was significantly blunted. An isoform of MCIP1 transcript was up-regulated by pressure stress, whereas MCIP2 transcript was not. Expression patterns of fetal genes were differentially regulated in banded MCIP1 hearts compared with wild type. Echocardiography performed at 3 weeks and 3 months revealed preservation of both left ventricular size and systolic function in banded MCIP1 mice despite the attenuated hypertrophic response. These data demonstrate attenuation of hypertrophic transformation when calcineurin is inhibited by MCIP1. Further, these data suggest that activation of hypertrophic marker genes may not be directly dependent on calcineurin activity. Finally, they demonstrate that ventricular performance is preserved despite attenuation of compensatory hypertrophy.	Univ Iowa, Coll Med, Div Cardiovasc, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Interdisciplinary Grad Program Mol Biol, Iowa City, IA 52242 USA; Dept Vet Affairs, Iowa City, IA 52242 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Duke Univ, Sch Med, Off Dean, Durham, NC 27710 USA	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Duke University	Hill, JA (corresponding author), Univ Iowa, Coll Med, Div Cardiovasc, Dept Internal Med, Iowa City, IA 52242 USA.			Demetroulis, Elaine/0000-0002-4824-5942	NHLBI NIH HHS [HL03908] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown DW, 2000, AM HEART J, V140, P848, DOI 10.1067/mhj.2000.111112; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; De Windt LJ, 2001, P NATL ACAD SCI USA, V98, P3322, DOI 10.1073/pnas.031371998; Dorn GW, 2001, CIRCULATION, V104, P9, DOI 10.1161/01.CIR.104.1.9; Esposito G, 2002, CIRCULATION, V105, P85, DOI 10.1161/hc0102.101365; Esposito G, 2001, CIRCULATION, V103, P1453, DOI 10.1161/01.CIR.103.10.1453; Fatkin D, 2000, J CLIN INVEST, V106, P1351, DOI 10.1172/JCI11093; Fuentes JJ, 1997, GENOMICS, V44, P358, DOI 10.1006/geno.1997.4866; Hill JA, 2000, CIRCULATION, V101, P2863, DOI 10.1161/01.CIR.101.24.2863; Kingsbury TJ, 2000, GENE DEV, V14, P1595; Leinwand LA, 2001, P NATL ACAD SCI USA, V98, P2947, DOI 10.1073/pnas.051033698; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Shimoyama M, 1999, CIRCULATION, V100, P2449, DOI 10.1161/01.CIR.100.24.2449; Uozumi H, 2001, J BIOL CHEM, V276, P23115, DOI 10.1074/jbc.M100814200; Wang ZY, 2001, J BIOL CHEM, V276, P17706, DOI 10.1074/jbc.M100544200; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; Zou YZ, 2001, CIRCULATION, V104, P97, DOI 10.1161/01.CIR.104.1.97	21	98	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10251	10255		10.1074/jbc.M110722200	http://dx.doi.org/10.1074/jbc.M110722200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11786544	hybrid			2022-12-27	WOS:000174549200086
J	Hori, R; Kashiba, M; Toma, T; Yachie, A; Goda, N; Makino, N; Soejima, A; Nagasawa, T; Nakabayashi, K; Suematsu, M				Hori, R; Kashiba, M; Toma, T; Yachie, A; Goda, N; Makino, N; Soejima, A; Nagasawa, T; Nakabayashi, K; Suematsu, M			Gene Transfection of H25A mutant heme oxygenase-1 protects cells against hydroperoxide-induced cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; CARBON-MONOXIDE; RAT-LIVER; EXPRESSION; INDUCTION; FIBROBLASTS; APOPTOSIS; BILIRUBIN; IRON	Heme oxygenase (HO)-1 is a stress-inducible enzyme protecting cells against oxidative stress, and mechanisms have been considered to depend exclusively on its enzyme activity. This study aimed to examine if the protein lacking catalytic activities could also display such resistance against oxidative stress. Stable transfectants of rat wild type HO-1 cDNA (HO-1-U937) and those of its H25A mutant gene (mHO-1-U937) were established using human monoblastic lymphoma cell U937. HO-1-U937 and mHO-1-U937 used in the study exhibited similar levels of the protein expression, while only the former increased enzyme activities. HO-1- and mHO-1 U937 cells became more and less sensitive to H2O2 than mock transfectants, respectively; such distinct susceptibility between the cells was ascribable to differences in the capacity to scavenge H2O2 through catalase and to execute iron-mediated oxidant propagation. On the other hand, both cell lines exhibited greater resistance to tertbutyl hydroperoxide than mock transfectants. The resistance of HO-1-U937 to hydroperoxides appeared to result from antioxidant properties of bilirubin, an HO-derived product, while that of mHO-1-U937 was ascribable to increased contents of catalase and glutathione. These results provided evidence that gene transfection of the activity-lacking mutant HO-1 protects cells against oxidative stress through multiple mechanisms involving up-regulation of catalase and glutathione contents.	Keio Univ, Sch Med, Dept Biochem & Integrat Med Biol, Shinjuku Ku, Tokyo 1608582, Japan; Kyorin Univ, Sch Med, Dept Internal Med, Tokyo 1818611, Japan; Kanazawa Univ, Sch Hlth Sci, Dept Lab Sci, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Sch Med, Dept Pediat, Kanazawa, Ishikawa 9200934, Japan	Keio University; Kyorin University; Kanazawa University; Kanazawa University	Suematsu, M (corresponding author), Keio Univ, Sch Med, Dept Biochem & Integrat Med Biol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.		Yachie, Akihiro/C-4660-2015; Suematsu, Makoto/O-5762-2018; Goda, Nobuhito/W-2468-2019; Suematsu, Makoto/I-8135-2013	Suematsu, Makoto/0000-0002-7165-6336; Suematsu, Makoto/0000-0002-7165-6336; Goda, Nobuhito/0000-0003-0295-4257				ABRAHAM NG, 1988, INT J BIOCHEM, V20, P543, DOI 10.1016/0020-711X(88)90093-6; APPLEGATE LA, 1991, CANCER RES, V51, P974; Bornman L, 1999, J CELL PHYSIOL, V178, P1; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Clark JE, 2000, BIOCHEM J, V348, P615, DOI 10.1042/0264-6021:3480615; Flohe L., 1982, FREE RADICAL BIO MED, V5, P223; Goda N, 1998, J CLIN INVEST, V101, P604, DOI 10.1172/JCI1324; Gonzalez-Flecha B, 2000, ANN NY ACAD SCI, V899, P69; GRISHAM M B, 1985, Journal of Free Radicals in Biology and Medicine, V1, P227, DOI 10.1016/0748-5514(85)90122-9; ITOMAKI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P253, DOI 10.1006/abbi.1995.1160; Kvam E, 2000, FREE RADICAL BIO MED, V28, P1191, DOI 10.1016/S0891-5849(00)00205-7; Kyokane T, 2001, GASTROENTEROLOGY, V120, P1227, DOI 10.1053/gast.2001.23249; Makino N, 2001, HEPATOLOGY, V33, P32, DOI 10.1053/jhep.2001.21161; MEERHOF LJ, 1980, J RETICULOENDOTH SOC, V28, P419; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; Petrache I, 2000, AM J PHYSIOL-LUNG C, V278, pL312, DOI 10.1152/ajplung.2000.278.2.L312; PROHASKA JR, 1976, J NEUROCHEM, V27, P1379, DOI 10.1111/j.1471-4159.1976.tb02619.x; Shinoda Y, 1998, HEPATOLOGY, V28, P286, DOI 10.1002/hep.510280202; STOCKER R, 1990, FREE RADICAL RES COM, V9, P101, DOI 10.3109/10715769009148577; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P5918, DOI 10.1073/pnas.84.16.5918; Suttner DM, 1999, FASEB J, V13, P1800, DOI 10.1096/fasebj.13.13.1800; THORLEYLAWSON DA, 1985, J EXP MED, V162, P45, DOI 10.1084/jem.162.1.45; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; WILKS A, 1993, J BIOL CHEM, V268, P22357; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; YOSHIDA T, 1978, J BIOL CHEM, V253, P8479	27	97	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10712	10718		10.1074/jbc.M107749200	http://dx.doi.org/10.1074/jbc.M107749200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11786534	hybrid			2022-12-27	WOS:000174549200146
J	Yan, ZF; Kim, GY; Deng, XB; Friedman, E				Yan, ZF; Kim, GY; Deng, XB; Friedman, E			Transforming growth factor beta 1 induces proliferation in colon carcinoma cells by Ras-dependent, smad-independent down-regulation of p21cip1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSORS SMAD2; TGF-BETA; CANCER-CELLS; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; PROTEIN-KINASE; HEXAMETHYLENE BISACETAMIDE; MEDIATED TRANSCRIPTION; RECEPTOR COMPLEX; IN-VIVO	Transforming growth factor beta1 (TGFbeta1) can act as a tumor suppressor or a tumor promoter depending on the characteristics of the malignant cell. We recently demonstrated that colon carcinoma cells transfected with oncogenic cellular K-rasV12, but not oncogenic cellular H-rasV12, switched from TGFbeta1-insensitive to TGF/beta1-growth-stimulated and also became more invasive (Yan, Z., Deng, X., and Friedman, E. (2001) J. Biol. Chem 276, 1555-1563). We now demonstrate that TGFbeta1 growth stimulation of colon carcinoma cells is Ras-dependent and smad-independent. In U9 colon carcinoma cells, which are responsive to TGFbeta1 by growth stimulation, a truncating mutation at Gln-311 was found in the smad4 gene. Very little smad4 protein was detected in these cells. Loss of smad4 protein was confirmed by functional studies. In U9 cells co-transfected wild-type smad4, but not mutant smad4, mediated response of the 3TP-lux and pSBE promoter reporter constructs to TGFbeta1. Proliferation initiated by TGFbeta1 in U9 cells required Ras-mediated down-regulation of p21cip1 protein. Less p21cip1 was associated with cdk2-cyclin complexes in TGFbeta1-treated U9 cells, and the cdk2 complexes had increased kinase activity. Elevation of p21cip1 levels diminished proliferative response to TGFbeta1. U9 cells expressing DN-N17ras neither proliferated in response to TGFbeta1 nor down-regulated the cdk inhibitor p21cip1, and TGFbeta1 activation of 3TP-lux in U9 cells was inhibited by DN-N17ras in a dose-dependent manner. TGFbeta1 also decreased p21cip1 levels and stimulated proliferation in SW480 cells, which express mutant K-Ras but no smad4 protein. TGFbeta1 did not activate or inhibit the p21cip1 promoter construct in U9 cells even in the presence of co-transfected smad4, or alter p21cip1 mRNA levels. Thus the decrease in p21cip1 levels was mediated by a TGFbeta-initiated Ras-dependent, but smad-independent post-transcriptional mechanism.	SUNY Syracuse, Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Friedman, E (corresponding author), SUNY Syracuse, Upstate Med Univ, Dept Pathol, 2303 Weiskotten Hall,750 E Adams St, Syracuse, NY 13210 USA.				NCI NIH HHS [R01 CA75708] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075708] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFTI A, 1997, J BIOL CHEM, V272, P1429; Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; Bellis SL, 1999, J CELL PHYSIOL, V181, P33, DOI 10.1002/(SICI)1097-4652(199910)181:1<33::AID-JCP4>3.0.CO;2-#; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; COPPA A, 1995, CELL GROWTH DIFFER, V6, P281; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; Dai JL, 1998, CANCER RES, V58, P4592; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Deng XB, 1999, CELL GROWTH DIFFER, V10, P11; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Fan D, 1989, Cancer Commun, V1, P117; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FILMUS J, 1994, ONCOGENE, V9, P3627; FRIEDMAN E, 1995, CANCER EPIDEM BIOMAR, V4, P549; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; HOHL RJ, 1995, J BIOL CHEM, V270, P17508, DOI 10.1074/jbc.270.29.17508; HSU S, 1994, CELL GROWTH DIFFER, V5, P267; HSU S, 1995, J CELL PHYSIOL, V165, P239, DOI 10.1002/jcp.1041650204; HUANG F, 1994, ONCOGENE, V9, P3701; HUANG F, 1995, CELL GROWTH DIFFER, V6, P1635; Hunt KK, 1998, CANCER RES, V58, P5656; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Jones JB, 2000, NUCLEIC ACIDS RES, V28, P2363, DOI 10.1093/nar/28.12.2363; Kansra S, 2000, INT J CANCER, V87, P373, DOI 10.1002/1097-0215(20000801)87:3<373::AID-IJC10>3.0.CO;2-X; LEE H, 1993, J BIOL CHEM, V268, P8181; LEE HS, 1993, J BIOL CHEM, V268, P5255; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Matsuzaki K, 2000, CANCER RES, V60, P1394; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Nishimori S, 2001, J BIOL CHEM, V276, P10700, DOI 10.1074/jbc.M007499200; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Park BJ, 2000, CANCER RES, V60, P3031; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Picon A, 1998, CANCER EPIDEM BIOMAR, V7, P497; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Riggins GJ, 1997, CANCER RES, V57, P2578; ROBERTS A, 1990, PEPTIDE GROWTH FACTO, V1, pCH8; Rodeck U, 1999, CANCER RES, V59, P547; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; SCHROY P, 1990, CANCER RES, V50, P261; SCHROY PC, 1988, CANCER RES, V48, P5487; Schutte M, 1996, CANCER RES, V56, P2527; Sebti SM, 2000, ONCOGENE, V19, P6584, DOI 10.1038/sj.onc.1204146; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Vogt A, 1996, ONCOGENE, V13, P1991; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yan ZF, 1997, J BIOL CHEM, V272, P27902, DOI 10.1074/jbc.272.44.27902; YAN ZF, 1994, J BIOL CHEM, V269, P13231; Yan ZF, 2001, J BIOL CHEM, V276, P1555, DOI 10.1074/jbc.M004553200; YAN ZF, 1992, ONCOGENE, V7, P801; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	69	34	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9870	9879		10.1074/jbc.M107646200	http://dx.doi.org/10.1074/jbc.M107646200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11784716	hybrid			2022-12-27	WOS:000174549200037
J	Lay, AJ; Jiang, XM; Daly, E; Sun, L; Hogg, PJ				Lay, AJ; Jiang, XM; Daly, E; Sun, L; Hogg, PJ			Plasmin reduction by phosphoglycerate kinase is a thiol-independent process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; SITE-DIRECTED MUTAGENESIS; LEWIS-LUNG-CARCINOMA; 3-PHOSPHOGLYCERATE KINASE; ANGIOGENESIS INHIBITOR; GLYCOLYTIC ENZYME; ANGIOSTATIN; BINDING; COMPLEX; MATRIX	Phosphoglycerate kinase (PGK) is secreted by tumor cells and facilitates reduction of disulfide bond(s) in plasmin (Lay, A. J., Jiang, X.-M., Kisker, O., Flynn, E.. Underwood, A., Condron, R., and Hogg, P. J. (2000) Nature 408,869-873). The angiogenesis inhibitor, angiostatin, is cleaved from the reduced plasmin by a combination of serine- and metalloproteinases. The chemistry of protein reductants is typically mediated by a pair of closely spaced Cys residues. There are seven Cys in human PGK, and mutation of all seven to Ala did not appreciably affect plasmin reductase activity, although some of the mutations perturbed the tertiary structure of the protein. Cys-379 and Cys-380 are close to the hinge that links the N- and C-terminal domains of PGK. Alkylation/oxidation of Cys-379 and -380 by four different thiol-reactive compounds reduced plasmin reductase activity to 7-35% of control. Binding of 3-phosphoglycerate and/or MgATP to the N- and C-terminal domains of PGK, respectively, triggers a hinge bending conformational change in the enzyme. Incubation of PGK with 3-phosphoglycerate and/or MgATP ablated plasmin reductase activity, with half-maximal inhibitory effects at similar to1 mm concentration. In summary, reduction of plasmin by PGK is a thiol-independent process, although either alkylation/oxidation of the fast-reacting Cys near the hinge or hinge bending conformational change in PGK perturbs plasmin reduction by PGK, perhaps by obstructing the interaction of plasmin with PGK or perturbing conformational changes in PGK required for plasmin reduction.	Univ New S Wales, Sch Med Sci, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia; Prince Wales Hosp, Dept Haematol, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Hogg, PJ (corresponding author), Univ New S Wales, Sch Med Sci, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia.			Hogg, Philip/0000-0001-6486-2863				Alloush HM, 1997, MICROBIOL-SGM, V143, P321, DOI 10.1099/00221287-143-2-321; BANKS RD, 1979, NATURE, V279, P773, DOI 10.1038/279773a0; BLAKE CCF, 1974, J MOL BIOL, V84, P585, DOI 10.1016/0022-2836(74)90118-1; Cao RH, 1999, P NATL ACAD SCI USA, V96, P5728, DOI 10.1073/pnas.96.10.5728; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; Chang Y, 1998, BIOCHEMISTRY-US, V37, P3258, DOI 10.1021/bi972284e; Cornelius LA, 1998, J IMMUNOL, V161, P6845; CSERPAN I, 1983, EUR J BIOCHEM, V131, P157, DOI 10.1111/j.1432-1033.1983.tb07243.x; DAVIES GJ, 1994, ACTA CRYSTALLOGR D, V50, P202, DOI 10.1107/S0907444993011138; DEKANY K, 1984, EUR J BIOCHEM, V139, P125, DOI 10.1111/j.1432-1033.1984.tb07985.x; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARLOS K, 1992, PROTEINS, V12, P133, DOI 10.1002/prot.340120207; HICKEY MJ, 1995, BIOCH SOC T S, V23, P607; Jiang XM, 1999, J BIOL CHEM, V274, P2416, DOI 10.1074/jbc.274.4.2416; JOAO HC, 1992, EUR J BIOCHEM, V205, P1077, DOI 10.1111/j.1432-1033.1992.tb16876.x; Kassam G, 2001, J BIOL CHEM, V276, P8924, DOI 10.1074/jbc.M009071200; KATZ BA, 1986, J BIOL CHEM, V261, P5480; Lawrence DA, 1996, J LEUKOCYTE BIOL, V60, P611, DOI 10.1002/jlb.60.5.611; Lay AJ, 2000, NATURE, V408, P869, DOI 10.1038/35048596; May A, 1996, PROTEINS, V24, P292; McHarg J, 1999, EUR J BIOCHEM, V259, P939, DOI 10.1046/j.1432-1327.1999.00133.x; MINARD P, 1989, EUR J BIOCHEM, V185, P419, DOI 10.1111/j.1432-1033.1989.tb15131.x; Mulligan-Kehoe MJ, 2001, J BIOL CHEM, V276, P8588, DOI 10.1074/jbc.M006434200; O'Reilly MS, 1999, J BIOL CHEM, V274, P29568, DOI 10.1074/jbc.274.41.29568; Ogino T, 1999, J BIOL CHEM, V274, P35999, DOI 10.1074/jbc.274.50.35999; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Popanda O, 1998, BBA-GENE STRUCT EXPR, V1397, P102, DOI 10.1016/S0167-4781(97)00229-7; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SINEV MA, 1989, EUR J BIOCHEM, V180, P61, DOI 10.1111/j.1432-1033.1989.tb14615.x; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; Stathakis P, 1999, J BIOL CHEM, V274, P8910, DOI 10.1074/jbc.274.13.8910; Szilagyi AN, 2001, J MOL BIOL, V306, P499, DOI 10.1006/jmbi.2000.4294; Tager M, 1997, EXP HEMATOL, V25, P601; TOMPA P, 1986, EUR J BIOCHEM, V154, P643, DOI 10.1111/j.1432-1033.1986.tb09446.x; VAS M, 1987, EUR J BIOCHEM, V163, P365, DOI 10.1111/j.1432-1033.1987.tb10808.x; VISHWANATHA JK, 1992, J CELL SCI, V101, P25; WATSON HC, 1982, EMBO J, V1, P1635, DOI 10.1002/j.1460-2075.1982.tb01366.x; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WU HL, 1987, P NATL ACAD SCI USA, V84, P8292, DOI 10.1073/pnas.84.23.8292; WU HL, 1987, P NATL ACAD SCI USA, V84, P8793, DOI 10.1073/pnas.84.24.8793; Xie LJ, 2001, J EXP MED, V193, P1341, DOI 10.1084/jem.193.12.1341	45	34	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9062	9068		10.1074/jbc.M111531200	http://dx.doi.org/10.1074/jbc.M111531200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11782484	hybrid			2022-12-27	WOS:000174400600045
J	Rozanov, DV; Ghebrehiwet, B; Postnova, TI; Eichinger, A; Deryugina, EI; Strongin, AY				Rozanov, DV; Ghebrehiwet, B; Postnova, TI; Eichinger, A; Deryugina, EI; Strongin, AY			The hemopexin-like C-terminal domain of membrane type 1 matrix metalloproteinase regulates proteolysis of a multifunctional protein, gC1qR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; EPSTEIN-BARR-VIRUS; GLOBULAR HEADS; MITOCHONDRIAL MATRIX; TISSUE INHIBITOR; IV COLLAGENASE; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; CELLULAR PROTEIN; PROGELATINASE-A	Matrix metalloproteinases (MMPs) including membrane type 1 MMP (MT1-MMP) can degrade extracellular matrix and cell surface receptor molecules and have an essential function in malignancy. Recently, we established a functional link between MT1-MMP and the receptor of complement component 1q (gC1qR). The gC1qR is known as a compartment-specific regulator of diverse cellular and viral proteins. Once released by proliferating cells, soluble gC1qR may inhibit complement component 1q hemolytic activity and play important roles in vivo in assisting tumor cells to evade destruction by complement. Here, we report that gC1qR is susceptible to MT1-MMP proteolysis in vitro and in cc cultures. The major MT1-MMP cleavage site (Gly(79) down arrow Gln(80)) is localized within the structurally disordered loop connecting the 133 and the 134 strands of gC1qR. The recombinant MT1-MMP construct that included the catalytic domain but lacked the hemopexin-like domain lost the proteolytic capacity; however, it retained the ability to bind gC1qR. Inhibition of MT1-MMP activity by a hydroxamate inhibitor converted the protease into a cell surface receptor of gC1qR and promoted co-precipitation MT1-MMP with the soluble gC1qR protein. It is tempting to hypothesize that these novel mechanisms may play important roles in vivo and have to be taken into account in designing hydroxamate-based cancer therapy.	Burnham Inst, La Jolla, CA 92037 USA; SUNY Stony Brook, Dept Pathol & Med, Stony Brook, NY 11794 USA	Sanford Burnham Prebys Medical Discovery Institute; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Postnova, TI (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016	NATIONAL CANCER INSTITUTE [R01CA083017, R01CA077470] Funding Source: NIH RePORTER; NCI NIH HHS [CA77470, CA83017] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Braun L, 2000, EMBO J, V19, P1458, DOI 10.1093/emboj/19.7.1458; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; Carroll M C, 2000, Adv Immunol, V74, P61; Chen WT, 1999, ANN NY ACAD SCI, V878, P361, DOI 10.1111/j.1749-6632.1999.tb07695.x; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GALARDY RE, 1994, CANCER RES, V54, P4715; Ghebrehiwet B, 1996, HYBRIDOMA, V15, P333, DOI 10.1089/hyb.1996.15.333; Ghebrehiwet B, 1998, IMMUNOBIOLOGY, V199, P225, DOI 10.1016/S0171-2985(98)80029-6; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; Ha HY, 2001, CANCER RES, V61, P984; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Ito S, 2000, VIROLOGY, V266, P110, DOI 10.1006/viro.1999.0054; Jiang JZ, 1999, P NATL ACAD SCI USA, V96, P3572, DOI 10.1073/pnas.96.7.3572; Joseph K, 1999, CLIN IMMUNOL, V92, P246, DOI 10.1006/clim.1999.4753; Joseph K, 1999, IMMUNOPHARMACOLOGY, V43, P203, DOI 10.1016/S0162-3109(99)00136-8; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kataoka H, 1999, AM J PATHOL, V154, P457, DOI 10.1016/S0002-9440(10)65292-3; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kittlesen DJ, 2000, J CLIN INVEST, V106, P1239, DOI 10.1172/JCI10323; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; Lang R, 2001, J MOL BIOL, V312, P731, DOI 10.1006/jmbi.2001.4954; Lim BL, 1998, GENE, V209, P229, DOI 10.1016/S0378-1119(98)00055-9; Lu PD, 1999, CLIN IMMUNOL, V90, P360, DOI 10.1006/clim.1998.4660; Maquoi E, 2000, EXP CELL RES, V261, P348, DOI 10.1006/excr.2000.5063; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Muta T, 1997, J BIOL CHEM, V272, P24363, DOI 10.1074/jbc.272.39.24363; Nabeshima K, 2000, CANCER RES, V60, P3364; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nagase H, 1998, Cell Res, V8, P179; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nguyen T, 2000, INFECT IMMUN, V68, P2061, DOI 10.1128/IAI.68.4.2061-2068.2000; Ohkubo S, 1999, BIOCHEM BIOPH RES CO, V266, P308, DOI 10.1006/bbrc.1999.1816; Peerschke EIB, 1998, BLOOD COAGUL FIBRIN, V9, P29, DOI 10.1097/00001721-199801000-00004; Peterson KL, 1997, CLIN IMMUNOL IMMUNOP, V84, P17, DOI 10.1006/clin.1997.4374; Ratnikov B, 2000, ANAL BIOCHEM, V286, P149, DOI 10.1006/abio.2000.4798; Ratnikov BI, 2002, J BIOL CHEM, V277, P7377, DOI 10.1074/jbc.M109580200; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schaerer MT, 2001, J BIOL CHEM, V276, P26597, DOI 10.1074/jbc.M102534200; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Seytter T, 1998, YEAST, V14, P303, DOI 10.1002/(SICI)1097-0061(19980315)14:4<303::AID-YEA217>3.0.CO;2-N; Shalinsky DR, 1999, CLIN CANCER RES, V5, P1905; Shofuda K, 1998, J BIOCHEM-TOKYO, V124, P462, DOI 10.1093/oxfordjournals.jbchem.a022136; Sim RB, 2000, BIOCHEM SOC T, V28, P545, DOI 10.1042/bst0280545; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200; STRONGIN AY, 1993, KIDNEY INT, V43, P158, DOI 10.1038/ki.1993.26; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Tange TO, 1996, J BIOL CHEM, V271, P10066, DOI 10.1074/jbc.271.17.10066; VAKSER IA, 1994, PROTEINS, V20, P320, DOI 10.1002/prot.340200405; VAKSER IA, 1995, PROTEIN ENG, V8, P371, DOI 10.1093/protein/8.4.371; Wang YL, 1997, VIROLOGY, V236, P18, DOI 10.1006/viro.1997.8739; Xu ZJ, 1999, J BIOL CHEM, V274, P21149, DOI 10.1074/jbc.274.30.21149	62	43	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9318	9325		10.1074/jbc.M110711200	http://dx.doi.org/10.1074/jbc.M110711200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11773076	hybrid			2022-12-27	WOS:000174400600079
J	Bhat, MB; Ma, J				Bhat, MB; Ma, J			The transmembrane segment of ryanodine receptor contains an intracellular membrane retention signal for Ca2+ release channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; ENDOPLASMIC-RETICULUM; FUNCTIONAL EXPRESSION; DOMAIN; OLIGOMERIZATION; LOCALIZATION; GLYCOPROTEIN; RETRIEVAL; SUBUNIT; REGION	The ryanodine receptor (RyR) is a large homotetrameric protein with a hydrophobic domain at the C-terminal end that resides in the endoplasmic reticulum (ER) or sarcoplasmic reticulum membrane and forms the conduction pore of a Ca2+ release channel. Our previous studies showed that RyR expressed in heterologous cells localized to the ER membrane. Confocal microscopic imaging indicated that the ER retention signal is likely present within the C-terminal portion of RyR, a region that contains four putative transmembrane segments. To identify the amino acid sequence responsible for ER retention of RyR, we expressed fusion proteins containing intercellular adhesion molecule (ICAM), various fragments of RyR, and green fluorescent protein (GFP) in Chinese hamster ovary and COS-7 cells. ICAM is a plasma membrane-resident glycoprotein and serves as a reporter for protein trafficking to the cell surface membrane. Imaging analyses indicated that ICAM-GFP fusion proteins with RyR sequence preceding the four transmembrane segments, ICAM-RyR-(3661-3993)-GFP, and with RyR sequence corresponding to transmembrane segments 1, 2, and 3, ICAM-RyR-(4558-4671)-GFP and ICAM-RyR-(4830-4919)-GFP, were localized to the plasma membrane; fusion proteins containing the fourth transmembrane segment of RyR, ICAM-RyR-(4913-4943)-GFP, were retained in the ER. Biochemical assay showed that ICAM-RyR-GFP fusion proteins that target to the plasma membrane are fully glycosylated, and those retained in the intracellular membrane are core-glycosylated. Together our data indicate that amino acids 4918-4943 of RyR contain the signal sequence for ER retention of the Ca2+ release channel.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Cleveland Clin Fdn, Ctr Anesthesiol Res FF40, Cleveland, OH 44195 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Cleveland Clinic Foundation	Ma, J (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.	maj2@umdnj.edu			NATIONAL CANCER INSTITUTE [R01CA095739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015556] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA95739] Funding Source: Medline; NIA NIH HHS [R01-AG15556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; Bella J, 1999, J STRUCT BIOL, V128, P69, DOI 10.1006/jsbi.1999.4143; BEZPROZVANNY I, 1995, J MEMBRANE BIOL, V145, P205; Bhat MB, 1999, BIOPHYS J, V77, P808, DOI 10.1016/S0006-3495(99)76933-X; Bhat MB, 1997, BIOPHYS J, V73, P1320, DOI 10.1016/S0006-3495(97)78165-7; Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; Galvan DL, 1999, J BIOL CHEM, V274, P29483, DOI 10.1074/jbc.274.41.29483; Hayek SM, 2000, BIOCHEM J, V351, P57, DOI 10.1042/0264-6021:3510057; Hobman TC, 1997, J VIROL, V71, P7670, DOI 10.1128/JVI.71.10.7670-7680.1997; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Lorenzon NM, 2001, ARCH BIOCHEM BIOPHYS, V388, P13, DOI 10.1006/abbi.2000.2263; Manjunatha B, 1997, J GEN PHYSIOL, V110, P749, DOI 10.1085/jgp.110.6.749; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; Ramos-Franco J, 1999, J GEN PHYSIOL, V114, P243, DOI 10.1085/jgp.114.2.243; Sayers LG, 1997, BIOCHEM J, V323, P273, DOI 10.1042/bj3230273; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; TAKESHIMA H, 1994, FEBS LETT, V337, P81, DOI 10.1016/0014-5793(94)80634-9; TAKESHIMA H, 1993, FEBS LETT, V322, P105, DOI 10.1016/0014-5793(93)81547-D; XIE JX, 1995, J BIOL CHEM, V270, P28084; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970	26	16	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8597	8601		10.1074/jbc.M107609200	http://dx.doi.org/10.1074/jbc.M107609200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11779857	hybrid			2022-12-27	WOS:000174268000124
J	Dhawan, P; Richmond, A				Dhawan, P; Richmond, A			A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; GROWTH-STIMULATORY ACTIVITY; DEPENDENT GENE-EXPRESSION; ERK PATHWAY; IKK COMPLEX; ALPHA GENE; TRANSCRIPTION; PHOSPHORYLATION; BETA	Constitutive activation of NF-kappaB is an emerging hallmark of various types of tumors including breast, colon, pancreatic, ovarian, and melanoma. In melanoma cells, the basal expression of the CXC chemokine, CXCL1, is constitutively up-regulated. This up-regulation can be attributed in part to constitutive activation of NF-kappaB. Previous studies have shown an elevated basal IkappaB kinase (IKK) activity in Hs294T melanoma cells, which leads to an increased rate of IkappaB phosphorylation and degradation. This increase in IkappaB-alpha phosphorylation and degradation leads to an similar to19-fold higher nuclear localization of NF-kappaB. However, the upstream IKK kinase activity is up-regulated by only about 2-fold and cannot account for the observed increase in NF-kappaB activity. We now demonstrate that NF-kappaB-inducing kinase (NIK) is highly expressed in melanoma cells, and IKK-associated NIK activity is enhanced in these cells compared with the normal cells. Kinase-dead NIK blocked constitutive NF-kappaB or CXCL1 promoter activity in Hs294T melanoma cells, but not in control normal human epidermal melanocytes. Transient overexpression of wild type NIK results in increased phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2), which is inhibited in a concentration-dependent manner by PD98059, an inhibitor of p42/44 MAPK. Moreover, the NF-kappaB promoter activity decreased with overexpression of dominant negative ERK expression constructs, and EMSA analyses further support the hypothesis that ERK acts upstream of NF-kappaB and regulates the NF-kappaB DNA binding activity. Taken together, our data implicate involvement of IkappaB kinase and MAPK signaling cascades in NIK-induced constitutive activation of NF-kappaB.	Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Dept Vet Affairs, Nashville, TN 37212 USA	Vanderbilt University	Richmond, A (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, MCN T-2212, Nashville, TN 37232 USA.		Richmond, Ann/A-3048-2014	RICHMOND, ANN/0000-0002-9580-900X	NCI NIH HHS [CA 68485, P30 CA068485, R01 CA034590, CA34590, R01 CA056704-07, CA56704, R01 CA056704-09, R01 CA056704-08] Funding Source: Medline; NIAMS NIH HHS [P30 AR 41943, P30 AR041943] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034590, P30CA068485, R01CA056704, R23CA034590] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041943] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Birkenkamp KU, 2000, BRIT J PHARMACOL, V131, P99, DOI 10.1038/sj.bjp.0703534; Briant L, 1998, J IMMUNOL, V160, P1875; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Carter KB, 2000, J BIOL CHEM, V275, P27858; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DERYNCK R, 1990, BIOCHEMISTRY-US, V29, P10225, DOI 10.1021/bi00496a011; DeSilva DR, 1996, J EXP MED, V183, P2017, DOI 10.1084/jem.183.5.2017; Devalaraja MN, 1999, CANCER RES, V59, P1372; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fischer C, 1999, J BIOL CHEM, V274, P24625, DOI 10.1074/jbc.274.35.24625; Foehr ED, 2000, J BIOL CHEM, V275, P34021, DOI 10.1074/jbc.C000507200; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kouba DJ, 2001, J BIOL CHEM, V276, P6214, DOI 10.1074/jbc.M004511200; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; SHATTUCK RL, 1994, MOL CELL BIOL, V14, P791, DOI 10.1128/MCB.14.1.791; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Sonoda Y, 1997, J BIOL CHEM, V272, P15366, DOI 10.1074/jbc.272.24.15366; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Takaori-Kondo A, 2000, BIOCHEM BIOPH RES CO, V272, P856, DOI 10.1006/bbrc.2000.2860; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; Wang DZ, 2001, J BIOL CHEM, V276, P3650, DOI 10.1074/jbc.M006115200; Wood LD, 1995, J BIOL CHEM, V270, P30619, DOI 10.1074/jbc.270.51.30619; WOOD LD, 1995, NUCLEIC ACIDS RES, V23, P4210, DOI 10.1093/nar/23.20.4210; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Yang JM, 2001, CANCER RES, V61, P4901; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	48	231	240	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7920	7928		10.1074/jbc.M112210200	http://dx.doi.org/10.1074/jbc.M112210200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11773061	Green Accepted, hybrid			2022-12-27	WOS:000174268000039
J	Ding, QX; Lewis, JJ; Strum, KM; Dimayuga, E; Bruce-Keller, AJ; Dunn, JC; Keller, JN				Ding, QX; Lewis, JJ; Strum, KM; Dimayuga, E; Bruce-Keller, AJ; Dunn, JC; Keller, JN			Polyglutamine expansion, protein aggregation, proteasome activity, and neural survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKED PROTEIN; HUNTINGTONS-DISEASE; OXIDATIVE STRESS; INTRANUCLEAR INCLUSIONS; NEUROLOGICAL PHENOTYPE; MUTANT HUNTINGTIN; HEAT-SHOCK; CELLS; INHIBITION; EXPRESSION	Huntington's disease (HD) is one of eight established triplet repeat neurodegenerative disorders, which are collectively caused by the genetic expansion of polyglutamine repeats. While the mechanism(s) by which polyglutamine expansion causes neurodegeneration in each of these disorders is being intensely investigated, the underlying cause of polyglutamine toxicity has not been fully elucidated. A number of studies have focused on the potential role of protein aggregation and disruption of the proteasome proteolytic pathway in polyglutamine-mediated neurodegeneration. However, at present it is not clear whether polyglutamine-mediated protein aggregation is sufficient to induce cell death, nor has it been clearly determined whether proteasome inhibition precedes, coincides, or occurs as the result of the formation of polyglutamine-associated protein aggregation. To address these important components of polyglutamine toxicity, in the present study we utilized neural SH-SY5Y cells stably transfected with polyglutamine-green fluorescent protein constructs to examine the effects of polyglutamine expansion on protein aggregation, proteasome activity, and neural cell survival. Data from the present study demonstrate that polyglutamine expansion does not dramatically impair proteasome activity or elevate protein aggregate formation under basal conditions, but does significantly impair the ability of the proteasome to respond to stress, and increases stress-induced protein aggregation following stress, all in the absence of neural cell death.	Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Kentucky, Dept Sci Biol, Lexington, KY 40536 USA; Univ Kentucky, Dept Gerontol, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky	Keller, JN (corresponding author), Univ Kentucky, Dept Anat & Neurobiol, 101 Sanders Brown Bldg, Lexington, KY 40536 USA.	Jnkell0@pop.uky.edu	Bruce-Keller, Annadora/N-1954-2017; Keller, Jeffrey N/N-1975-2017	keller, jeffrey/0000-0002-9892-7423				Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Carter RJ, 1999, J NEUROSCI, V19, P3248; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; de Cristofaro T, 1999, BIOCHEM BIOPH RES CO, V260, P150, DOI 10.1006/bbrc.1999.0851; Ding QX, 2001, J NEUROCHEM, V77, P1010, DOI 10.1046/j.1471-4159.2001.00302.x; Ding QX, 2001, FREE RADICAL BIO MED, V31, P574, DOI 10.1016/S0891-5849(01)00635-9; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; Goldberg AL, 1997, BIOL CHEM, V378, P131; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Kaytor MD, 1999, J BIOL CHEM, V274, P37507, DOI 10.1074/jbc.274.53.37507; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Keller JN, 2000, J CEREBR BLOOD F MET, V20, P1467, DOI 10.1097/00004647-200010000-00008; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Keller JN, 1998, J NEUROSCI, V18, P687; Keller JN, 2000, J NEUROSCI RES, V61, P436, DOI 10.1002/1097-4547(20000815)61:4<436::AID-JNR10>3.0.CO;2-Z; Kim M, 1999, J NEUROSCI, V19, P964; Kuemmerle S, 1999, ANN NEUROL, V46, P842; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Li SH, 1999, J NEUROSCI, V19, P5159; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; McLean PJ, 2001, NEUROSCIENCE, V104, P901, DOI 10.1016/S0306-4522(01)00113-0; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; Moulder KL, 1999, J NEUROSCI, V19, P705; Ordway JM, 1997, CELL, V91, P753, DOI 10.1016/S0092-8674(00)80464-X; Orr HT, 2001, GENE DEV, V15, P925, DOI 10.1101/gad.888401; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Pasquini LA, 2000, J NEUROSCI RES, V59, P601, DOI 10.1002/(SICI)1097-4547(20000301)59:5<601::AID-JNR3>3.0.CO;2-1; Paulson HL, 2000, BRAIN PATHOL, V10, P293, DOI 10.1111/j.1750-3639.2000.tb00263.x; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; Reinheckel T, 2000, ARCH BIOCHEM BIOPHYS, V377, P65, DOI 10.1006/abbi.2000.1717; Ross CA, 1999, PHILOS T ROY SOC B, V354, P1005, DOI 10.1098/rstb.1999.0452; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Salon ML, 2000, J NEUROSCI RES, V62, P302, DOI 10.1002/1097-4547(20001015)62:2<302::AID-JNR15>3.0.CO;2-L; Satyal SH, 2000, P NATL ACAD SCI USA, V97, P5750, DOI 10.1073/pnas.100107297; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Sieradzan KA, 2001, NEUROPATH APPL NEURO, V27, P1, DOI 10.1046/j.0305-1846.2001.00299.x; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Wanker EE, 2000, BIOL CHEM, V381, P937, DOI 10.1515/BC.2000.114; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898; Zeron MM, 2001, MOL CELL NEUROSCI, V17, P41, DOI 10.1006/mcne.2000.0909; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217; Zoghbi HY, 1999, CURR OPIN NEUROBIOL, V9, P566, DOI 10.1016/S0959-4388(99)00013-6	47	93	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13935	13942		10.1074/jbc.M107706200	http://dx.doi.org/10.1074/jbc.M107706200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11782460	hybrid			2022-12-27	WOS:000175096000077
J	Dobritzsch, D; Ricagno, S; Schneider, G; Schnackerz, KD; Lindqvist, Y				Dobritzsch, D; Ricagno, S; Schneider, G; Schnackerz, KD; Lindqvist, Y			Crystal structure of the productive ternary complex of dihydropyrimidine dehydrogenase with NADPH and 5-iodouracil - Implications for mechanism of inhibition and electron transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL PYRIMIDINEMIA; CDNA CLONING; 5-FLUOROURACIL; PHARMACOKINETICS; FLUOROURACIL; DEFICIENCY; TOXICITY; LIVER; DPD	Dihydroprymidine dehydrogenase catalyzes the first and rate-limiting step in pyrimidine degradation by converting pyrimidines to the corresponding 5,6-dihydro compounds. The three-dimensional structures of a binary complex with the inhibitor 5-iodouracil and two ternary complexes with NADPH and the inhibitors 5-iodouracil and uracil-4-acetic acid were determined by x-ray crystallography. In the ternary complexes, NADPH is bound in a catalytically competent fashion, with the nicotinamide ring in a position suitable for hydride transfer to FAD. The structures provide a complete picture of the electron transfer chain from NADPH to the substrate, 5-iodouracil, spanning a distance of 56 Angstrom and involving FAD, four [Fe-S] clusters, and FMN as cofactors. The crystallographic analysis further reveals that pyrimidine binding triggers a conformational change of a flexible active-site loop in the alpha/beta-barrel domain, resulting in placement of a catalytically crucial cysteine close to the bound substrate. Loop closure requires physiological pH, which is also necessary for correct binding of NADPH. Binding of the voluminous competitive inhibitor uracil-4-acetic acid prevents loop closure due to steric hindrance. The three-dimensional structure of the ternary complex enzyme-NADPH-5-iodouracil supports the proposal that this compound acts as a mechanism-based inhibitor, covalently modifying the active-site residue Cys-671, resulting in S-(hexahydro-2,4-dioxo-5-pyrimidinyl)cysteine.	Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Struct Biol, S-17177 Stockholm, Sweden; Theodor Boveri Inst Biowissensch, D-97074 Wurzburg, Germany	Karolinska Institutet	Lindqvist, Y (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Struct Biol, S-17177 Stockholm, Sweden.	ylva@alfa.mbb.ki.se	Ricagno, Stefano/AAH-9763-2020; Dobritzsch, Doreen/H-7334-2018; Lindqvist, Ylva/F-9009-2010; Ricagno, Stefano/G-1456-2015	Ricagno, Stefano/0000-0001-6678-5873; Ricagno, Stefano/0000-0001-6678-5873; Schneider, Gunter/0000-0003-0622-5713; Lindqvist, Ylva/0000-0003-3162-8661				Albin N, 1996, DNA SEQUENCE, V6, P243, DOI 10.3109/10425179609008450; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; de Bono JS, 2001, INVEST NEW DRUG, V19, P41, DOI 10.1023/A:1006404701008; DIASIO RB, 1988, J CLIN INVEST, V81, P47, DOI 10.1172/JCI113308; Dobritzsch D, 2001, EMBO J, V20, P650, DOI 10.1093/emboj/20.4.650; Dobritzsch D, 2001, ACTA CRYSTALLOGR D, V57, P153, DOI 10.1107/S0907444900015250; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; HEGGIE GD, 1987, CANCER RES, V47, P2203; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu GA, 1996, PROTEIN DATA BANK Q, V78, P10; LU ZH, 1993, CANCER RES, V53, P5433; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MILANO G, 1994, ANTICANCER RES, V14, P2295; NAGUIB FNM, 1989, BIOCHEM PHARMACOL, V38, P1471, DOI 10.1016/0006-2952(89)90187-1; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Papamichael D, 2000, STEM CELLS, V18, P166, DOI 10.1634/stemcells.18-3-166; PODSCHUN B, 1990, J BIOL CHEM, V265, P12966; PORTER DJT, 1991, J BIOL CHEM, V266, P19988; Rosenbaum K, 1997, PROTEIN EXPRES PURIF, V10, P185, DOI 10.1006/prep.1997.0735; Rosenbaum K, 1998, BIOCHEMISTRY-US, V37, P17598, DOI 10.1021/bi9815997; Rowland P, 1998, PROTEIN SCI, V7, P1269, DOI 10.1002/pro.5560070601; Shehata N, 1999, CANCER INVEST, V17, P201, DOI 10.3109/07357909909021422; Traut TW, 1996, PROG NUCLEIC ACID RE, V53, P1, DOI 10.1016/S0079-6603(08)60142-7; TUCHMAN M, 1985, NEW ENGL J MED, V313, P245, DOI 10.1056/NEJM198507253130407; van Kuilenburg ABP, 2000, CLIN CANCER RES, V6, P4705; WASTERNACK C, 1980, PHARMACOL THERAPEUT, V8, P629, DOI 10.1016/0163-7258(80)90079-0; WOODCOCK TM, 1980, CANCER-AM CANCER SOC, V45, P1135, DOI 10.1002/1097-0142(19800315)45:5+<1135::AID-CNCR2820451318>3.0.CO;2-Q; YOKOTA H, 1994, J BIOL CHEM, V269, P23192; Ziegler GA, 2000, BIOCHEMISTRY-US, V39, P10986, DOI 10.1021/bi000079k	35	45	47	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13155	13166		10.1074/jbc.M111877200	http://dx.doi.org/10.1074/jbc.M111877200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11796730	hybrid			2022-12-27	WOS:000175036300085
J	Marchand, C; Zhang, XC; Pais, GCG; Cowansage, K; Neamati, N; Burke, TR; Pommier, Y				Marchand, C; Zhang, XC; Pais, GCG; Cowansage, K; Neamati, N; Burke, TR; Pommier, Y			Structural determinants for HIV-1 integrase inhibition by beta-diketo acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND TRANSFER; DNA; COMPLEXES; BINDING; TARGET	Among all the HIV-1 integrase inhibitors, the beta-diketo acids (DKAs) represent a major lead in anti-HIV-1 integrase drug design. These derivatives inhibit the integration reaction in vitro with a strong specificity for the 3'-end joining step. They are also antiviral and inhibit integration in vivo. The aim of the present study has been to investigate the molecular interactions between DKAs and HIV-1 integrase. We have compared 5CITEP with one of the most potent DKAs reported by the Merck group (L-708,906) and found that 5CITEP inhibits 3'-processing at concentrations where L-708,906 is only active on strand transfer. We also report a novel bifunctional DKA derivative that inhibits 3'-processing even more effectively than 5CITEP. The interactions of these inhibitors with the viral DNA donor ends have been studied by performing experiments with oligonucleotides containing defined modifications. We propose that the bifunctional DKA derivative binds to both the acceptor and donor sites of HIV-1 integrase, whereas the monofunctional L-708,906 derivative binds selectively to the acceptor site.	NCI, NIH, Ctr Canc Res, Mol Pharmacol Lab, Bethesda, MD 20892 USA; NCI, Ctr Canc Res, Med Chem Lab, Frederick, MD 21702 USA; Univ So Calif, Coll Pharm, Los Angeles, CA 90089 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Southern California	Pommier, Y (corresponding author), NCI, NIH, Ctr Canc Res, Mol Pharmacol Lab, Bldg 37,Rm 5065, Bethesda, MD 20892 USA.		Burke, Terrence R/N-2601-2014; Marchand, Christophe/D-8559-2016	Burke, Terrence/0000-0001-9925-8586				BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BROWN PO, 1998, RETROVIRUSES, P161; d'Angelo J, 2001, PATHOL BIOL, V49, P237, DOI 10.1016/S0369-8114(01)00135-3; De Clercq E, 2000, MED RES REV, V20, P323, DOI 10.1002/1098-1128(200009)20:5<323::AID-MED1>3.0.CO;2-A; Espeseth AS, 2000, P NATL ACAD SCI USA, V97, P11244, DOI 10.1073/pnas.200139397; FARNET CM, 1991, J VIROL, V65, P1910, DOI 10.1128/JVI.65.4.1910-1915.1991; Goldgur Y, 1999, P NATL ACAD SCI USA, V96, P13040, DOI 10.1073/pnas.96.23.13040; HAZUDA DJ, 1994, J BIOL CHEM, V269, P3999; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Marchand C, 2001, METHOD ENZYMOL, V340, P624; Mazumder A, 1996, J BIOL CHEM, V271, P27330, DOI 10.1074/jbc.271.44.27330; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; Neamati N, 2000, Adv Pharmacol, V49, P147; Pommier Y, 2000, ANTIVIR RES, V47, P139, DOI 10.1016/S0166-3542(00)00112-1; Pommier Y, 1997, ANTIVIR CHEM CHEMOTH, V8, P463, DOI 10.1177/095632029700800601; Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673; SKALKA AM, 1999, RETROVIRAL INTEGRATI, P52	17	116	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12596	12603		10.1074/jbc.M110758200	http://dx.doi.org/10.1074/jbc.M110758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11805103	hybrid			2022-12-27	WOS:000175036300016
J	Perozzo, R; Kuo, M; Sidhu, ABS; Valiyaveettil, JT; Bittman, R; Jacobs, WR; Fidock, DA; Sacchettini, JC				Perozzo, R; Kuo, M; Sidhu, ABS; Valiyaveettil, JT; Bittman, R; Jacobs, WR; Fidock, DA; Sacchettini, JC			Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; PARASITE PLASMODIUM-FALCIPARUM; RAPE BRASSICA-NAPUS; MYCOBACTERIUM-TUBERCULOSIS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ACP REDUCTASE; APICOMPLEXAN PARASITES; STAPHYLOCOCCUS-AUREUS; GLUTATHIONE-REDUCTASE	The human malaria parasite Plasmodium falciparum synthesizes fatty acids using a type II pathway that is absent in humans. The final step in fatty acid elongation is catalyzed by enoyl acyl carrier protein reductase, a validated antimicrobial drug target. Here, we report the cloning and expression of the P. falciparum enoyl acyl carrier protein reductase gene, which encodes a 50-kDa protein (PfENR) predicted to target to the unique parasite apicoplast. Purified PfENR was crystallized, and its structure resolved as a binary complex with NADH, a ternary complex with triclosan and NAD(+), and as ternary complexes bound to the triclosan analogs 1 and 2 with NADH. Novel structural features were identified in the PfENR binding loop region that most closely resembled bacterial homologs; elsewhere the protein was similar to ENR from the plant Brassica napus (root mean square for Calphas, 0.30 Angstrom). Triclosan and its analogs 1 and 2 killed multidrug-resistant strains of intra-erythrocytic P. falciparum parasites at sub to low micromolar concentrations in vitro. These data define the structural basis of triclosan binding to PfENR and will facilitate structure-based optimization of PfENR inhibitors.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA; CUNY Queens Coll, Dept Chem & Biochem, Flushing, NY 11367 USA	Texas A&M University System; Texas A&M University College Station; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; City University of New York (CUNY) System; Queens College NY (CUNY)	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.			Fidock, David/0000-0001-6753-8938; Jacobs, William/0000-0003-3321-3080	NIAID NIH HHS [AI 43268] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI043268, R01AI043268] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldock C, 1998, J MOL BIOL, V284, P1529, DOI 10.1006/jmbi.1998.2271; Baldock C, 1996, SCIENCE, V274, P2107, DOI 10.1126/science.274.5295.2107; BARTZOKAS CA, 1984, NEW ENGL J MED, V311, P1422, DOI 10.1056/NEJM198411293112207; BERGLER H, 1994, J BIOL CHEM, V269, P5493; Bernstein NK, 1999, NAT STRUCT BIOL, V6, P32, DOI 10.1038/4905; Bhargava HN, 1996, AM J INFECT CONTROL, V24, P209, DOI 10.1016/S0196-6553(96)90017-6; Claros MG, 1997, CURR OPIN STRUC BIOL, V7, P394, DOI 10.1016/S0959-440X(97)80057-7; Coppel Ross L., 1998, P185; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; Driver MS, 1996, J AM CHEM SOC, V118, P7217, DOI 10.1021/ja960937t; Farber PM, 1996, EUR J BIOCHEM, V239, P655, DOI 10.1111/j.1432-1033.1996.0655u.x; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; Fidock DA, 1998, MOL PHARMACOL, V54, P1140, DOI 10.1124/mol.54.6.1140; Fisher M, 2000, STRUCTURE, V8, P339, DOI 10.1016/S0969-2126(00)00115-5; FULCO AJ, 1983, PROG LIPID RES, V22, P133, DOI 10.1016/0163-7827(83)90005-X; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Gilberger TW, 2000, MOL BIOCHEM PARASIT, V107, P169, DOI 10.1016/S0166-6851(00)00188-2; He CY, 2001, EMBO J, V20, P330, DOI 10.1093/emboj/20.3.330; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; Heath RJ, 2000, J BIOL CHEM, V275, P4654, DOI 10.1074/jbc.275.7.4654; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAPPES B, 1995, MOL BIOCHEM PARASIT, V72, P163, DOI 10.1016/0166-6851(95)00075-C; KATER MM, 1994, PLANT MOL BIOL, V25, P771, DOI 10.1007/BF00028873; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; Marcoux JF, 1997, J AM CHEM SOC, V119, P10539, DOI 10.1021/ja971901j; McFadden GI, 1999, TRENDS MICROBIOL, V7, P328, DOI 10.1016/S0966-842X(99)01547-4; McFadden GI, 1997, BIOESSAYS, V19, P1033, DOI 10.1002/bies.950191114; MCFADDEN GI, 1996, NATURE, V381, P480; McLeod R, 2001, INT J PARASITOL, V31, P109, DOI 10.1016/S0020-7519(01)00111-4; McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970; McMurry LM, 1999, ANTIMICROB AGENTS CH, V43, P711, DOI 10.1128/AAC.43.3.711; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palmer JD, 1996, P NATL ACAD SCI USA, V93, P7432, DOI 10.1073/pnas.93.15.7432; Parikh S, 1999, BIOCHEMISTRY-US, V38, P13623, DOI 10.1021/bi990529c; Qiu XY, 1999, PROTEIN SCI, V8, P2529, DOI 10.1110/ps.8.11.2529; RAFFERTY JB, 1995, STRUCTURE, V3, P927, DOI 10.1016/S0969-2126(01)00227-1; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Roos DS, 1999, CURR OPIN MICROBIOL, V2, P426, DOI 10.1016/S1369-5274(99)80075-7; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Roujeinikova A, 1999, J MOL BIOL, V294, P527, DOI 10.1006/jmbi.1999.3240; Roujeinikova A, 1999, J BIOL CHEM, V274, P30811, DOI 10.1074/jbc.274.43.30811; Rozwarski DA, 1999, J BIOL CHEM, V274, P15582, DOI 10.1074/jbc.274.22.15582; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; SHIMAKATA T, 1982, ARCH BIOCHEM BIOPHYS, V218, P77, DOI 10.1016/0003-9861(82)90323-X; SLABAS AR, 1986, BIOCHIM BIOPHYS ACTA, V877, P271, DOI 10.1016/0005-2760(86)90304-8; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Stewart MJ, 1999, J MOL BIOL, V290, P859, DOI 10.1006/jmbi.1999.2907; Sullivan M, 2000, MOL BIOCHEM PARASIT, V109, P17, DOI 10.1016/S0166-6851(00)00226-7; Surolia N, 2001, NAT MED, V7, P167, DOI 10.1038/84612; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Ward WHJ, 1999, BIOCHEMISTRY-US, V38, P12514, DOI 10.1021/bi9907779; WEBSTER J, 1992, J HOSP INFECT, V21, P137, DOI 10.1016/0195-6701(92)90033-I; WHO, 1999, WORLD HLTH REP 1999, P49; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449	62	182	191	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13106	13114		10.1074/jbc.M112000200	http://dx.doi.org/10.1074/jbc.M112000200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11792710	hybrid			2022-12-27	WOS:000175036300079
J	Zito, F; Vinh, J; Popot, JL; Finazzi, G				Zito, F; Vinh, J; Popot, JL; Finazzi, G			Chimeric fusions of subunit IV and PetL in the b6f complex of Chlamydomonas reinhardtii - Structural implications and consequences on state transitions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME B(6)F COMPLEX; OPEN READING FRAME; PROTEIN-PHOSPHORYLATION; MEMBRANE-PROTEIN; ELECTRON-TRANSFER; CHLOROPLAST PROTEIN; ENERGY-DISTRIBUTION; BC(1) COMPLEX; LHCII KINASE; GREEN-ALGAE	The cytochrome b(6)f complex of Chlamydomonas reinhardtii contains four large subunits and at least three small ones, PetG, PetL, and PetM, whose role and location are unknown. Chimeric proteins have been constructed, in which the C terminus of subunit IV is fused to either one or the other of the two putative N termini of PetL. Biochemical and functional analysis of the chimeras together with mass spectrometry analysis of the wild-type (WT) complex led to the following conclusions: W neither a free subunit IV C terminus nor a free PetL N terminus is required for assembly of the b6f complex; (ii) the first AUG codon in the sequence of the gene petL is used for initiation; (iii) the N terminus of WT PetL lies in the lumen; (iv) in the WT complex, the N terminus of PetL and the C terminus of subunit IV are within reach of each other; (v) the purified b(6)f complex from C. reinhardtii contains an eighth, hitherto unrecognized subunit, PetN; and (vi) the ability to perform state transitions is lost in the chimeric mutants, although (vii) the Q-cycle is unaffected. A structural hypothesis is presented to account for this peculiar phenotype.	Inst Biol Physicochim, CNRS, UMR 7099, F-75005 Paris, France; Univ Paris 07, CNRS, UMR 7099, F-75005 Paris, France; Ecole Super Phys & Chim Ind Ville Paris, UMR 7637, F-75005 Paris, France; Univ Milan, CNR, Ctr Biol Cellulare & Mol Piante, I-20133 Milan, Italy; Inst Biol Physicochim, UPR 1261 CNRS, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Consiglio Nazionale delle Ricerche (CNR); University of Milan	Zito, F (corresponding author), Inst Biol Physicochim, CNRS, UMR 7099, 13 Rue Pierre & Marie Curie, F-75005 Paris, France.	francesca.zito@ibpc.fr	Vinh, Joelle/K-1347-2015	Vinh, Joelle/0000-0001-7184-2668; Zito, Francesca/0000-0003-1783-5090				ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; Asamizu E, 1999, DNA Res, V6, P369, DOI 10.1093/dnares/6.6.369; Baymann F, 1999, J BIOL CHEM, V274, P22957, DOI 10.1074/jbc.274.33.22957; BENNETT J, 1991, ANNU REV PLANT PHYS, V42, P281, DOI 10.1146/annurev.pp.42.060191.001433; BENNOUN P, 1970, BIOCHIM BIOPHYS ACTA, V216, P357, DOI 10.1016/0005-2728(70)90227-6; BENNOUN P, 1982, P NATL ACAD SCI-BIOL, V79, P4352, DOI 10.1073/pnas.79.14.4352; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; BERTHOLD D, 1995, PHOTOSYNTH RES, V2, P571; BIBI E, 1991, P NATL ACAD SCI USA, V88, P7271, DOI 10.1073/pnas.88.16.7271; BONAVENTURA C, 1969, BIOCHIM BIOPHYS ACTA, V189, P366, DOI 10.1016/0005-2728(69)90168-6; Boronowsky U, 2001, BBA-BIOENERGETICS, V1506, P55, DOI 10.1016/S0005-2728(01)00184-0; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5; Breyton C, 1997, J BIOL CHEM, V272, P21892, DOI 10.1074/jbc.272.35.21892; Breyton C, 2000, BBA-BIOENERGETICS, V1459, P467, DOI 10.1016/S0005-2728(00)00185-7; Breyton C, 2000, J BIOL CHEM, V275, P13195, DOI 10.1074/jbc.275.18.13195; BULTE L, 1990, BIOCHIM BIOPHYS ACTA, V1020, P72, DOI 10.1016/0005-2728(90)90095-L; BUTLER WL, 1978, ANNU REV PLANT PHYS, V29, P345, DOI 10.1146/annurev.pp.29.060178.002021; Choquet Y, 1998, P NATL ACAD SCI USA, V95, P4380, DOI 10.1073/pnas.95.8.4380; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; CROFTS A, 1987, CYTOCHROME SYSTEMS M, P617; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; deVitry C, 1996, J BIOL CHEM, V271, P10667, DOI 10.1074/jbc.271.18.10667; Elich TD, 1997, FEBS LETT, V411, P236, DOI 10.1016/S0014-5793(97)00698-4; Finazzi G, 1998, BIOCHEMISTRY-US, V37, P9999, DOI 10.1021/bi980320j; Finazzi G, 1997, BIOCHEMISTRY-US, V36, P2867, DOI 10.1021/bi962717y; Finazzi G, 2001, J BIOL CHEM, V276, P9770, DOI 10.1074/jbc.M010092200; Fulgosi H, 1998, EMBO J, V17, P1577, DOI 10.1093/emboj/17.6.1577; GAL A, 1990, J BIOL CHEM, V265, P19742; Hager M, 1999, EMBO J, V18, P5834, DOI 10.1093/emboj/18.21.5834; HALEY J, 1989, P NATL ACAD SCI USA, V86, P1534, DOI 10.1073/pnas.86.5.1534; Hamel P, 2000, J BIOL CHEM, V275, P17072, DOI 10.1074/jbc.M001468200; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; HORTON P, 1981, BIOCHIM BIOPHYS ACTA, V635, P53, DOI 10.1016/0005-2728(81)90006-2; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JOLIOT P, 1994, P NATL ACAD SCI USA, V91, P1034, DOI 10.1073/pnas.91.3.1034; JOLIOT P, 1974, BIOCHIM BIOPHYS ACTA, V357, P267, DOI 10.1016/0005-2728(74)90066-8; JOLIOT P, 1980, J CHIM PHYS PCB, V77, P209, DOI 10.1051/jcp/1980770209; JOLIOT P, 1998, MOL BIOL CHLOROPLAST, P433; JUNGE W, 1968, Z NATURFORSCH PT B, VB 23, P244, DOI 10.1515/znb-1968-0222; Kaneko T, 1996, DNA Res, V3, P109; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; MCGOVERN K, 1991, EMBO J, V10, P2773, DOI 10.1002/j.1460-2075.1991.tb07826.x; McNamara VP, 1997, P NATL ACAD SCI USA, V94, P14173, DOI 10.1073/pnas.94.25.14173; MITCHELL P, 1975, FEBS LETT, V59, P137, DOI 10.1016/0014-5793(75)80359-0; PICCIONI RG, 1981, EUR J BIOCHEM, V117, P93; Pierre Y, 1997, J BIOL CHEM, V272, P21901, DOI 10.1074/jbc.272.35.21901; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; PIERRE Y, 1993, CR ACAD SCI III-VIE, V316, P1404; POPOT JL, 1995, CURR OPIN BIOTECH, V6, P394, DOI 10.1016/0958-1669(95)80068-9; Popot JL, 2000, ANNU REV BIOCHEM, V69, P881, DOI 10.1146/annurev.biochem.69.1.881; POPOT JL, 1993, CURR OPIN STRUC BIOL, V3, P532, DOI 10.1016/0959-440X(93)90079-Z; POPOT JL, 1994, METH PHYS S, P41; ROCHAIX JD, 1978, J MOL BIOL, V126, P597, DOI 10.1016/0022-2836(78)90011-6; Rohl T, 2001, J BIOL CHEM, V276, P35465, DOI 10.1074/jbc.M103005200; SCHMIDT CL, 1993, PHOTOSYNTH RES, V38, P73, DOI 10.1007/BF00015063; Schoepp B, 1999, FEBS LETT, V450, P245, DOI 10.1016/S0014-5793(99)00511-6; Snyders S, 2001, J BIOL CHEM, V276, P32169, DOI 10.1074/jbc.M102539200; Snyders S, 1999, J BIOL CHEM, V274, P9137, DOI 10.1074/jbc.274.14.9137; SUEOKA N, 1960, P NATL ACAD SCI USA, V46, P83, DOI 10.1073/pnas.46.1.83; Takahashi Y, 1996, EMBO J, V15, P3498, DOI 10.1002/j.1460-2075.1996.tb00718.x; Vener AV, 1997, P NATL ACAD SCI USA, V94, P1585, DOI 10.1073/pnas.94.4.1585; VENER AV, 1995, J BIOL CHEM, V270, P25225, DOI 10.1074/jbc.270.42.25225; Wollman F.-A., 1988, PHOTOCATALYTIC PRODU, P210; Wollman FA, 2001, EMBO J, V20, P3623, DOI 10.1093/emboj/20.14.3623; WOLLMAN FA, 1984, J CELL BIOL, V98, P1, DOI 10.1083/jcb.98.1.1; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zhou JH, 1996, J BIOL CHEM, V271, P6225, DOI 10.1074/jbc.271.11.6225; Zito F, 1999, EMBO J, V18, P2961, DOI 10.1093/emboj/18.11.2961	71	33	34	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12446	12455		10.1074/jbc.M110914200	http://dx.doi.org/10.1074/jbc.M110914200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11796719	hybrid			2022-12-27	WOS:000174846400111
J	Leary, SC; Hill, BC; Lyons, CN; Carlson, CG; Michaud, D; Kraft, CS; Ko, K; Glerum, DM; Moyes, CD				Leary, SC; Hill, BC; Lyons, CN; Carlson, CG; Michaud, D; Kraft, CS; Ko, K; Glerum, DM; Moyes, CD			Chronic treatment with azide in situ leads to an irreversible loss of cytochrome c oxidase activity via holoenzyme dissociation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE-NATIVE-ELECTROPHORESIS; OXIDATIVE-PHOSPHORYLATION ENZYMES; NITRIC-OXIDE; SACCHAROMYCES-CEREVISIAE; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; INHIBITION; COPPER; GENE; DEFICIENCY	Chronic treatment of cultured cells with very low levels of azide (I-50 < 10 mu(M)) leads to slow (t(1/2) = 6 h), irreversible loss of cytochrome c oxidase (COX) activity. Azide-mediated COX losses were not accompanied by inhibition of other mitochondrial enzymes and were not dependent upon electron flux through oxidative phosphorylation. Although azide treatment also reduced activity (but not content) of both CuZn superoxide dismutase and catalase, a spectrum of pro-oxidants (and anti-oxidants) failed to mimic (or prevent) azide effects, arguing that losses in COX activity were not due to resultant compromises in free radical scavenging. Loss of COX activity was not attributable to reduced rates of mitochondrial protein synthesis or declines in either COX subunit mRNA or protein levels (COX I, II, IV). Co-incubation experiments using copper (CuCl2 Cu-His) and copper chelators (neocuproine, bathocuproine) indicated that azide effects were not mediated by interactions with either Cu-A or Cu-B. In contrast, difference spectroscopy and high performance liquid chromatography analyses demonstrated azide-induced losses in cytochrome aa(3) content although not to the same extent as catalytic activity. Differential azide effects on COX content relative to COX activity were confirmed using a refined inhibition time course in combination with blue native electrophoresis, and established that holoenzyme dissociation occurs subsequent to losses in catalytic activity. Collectively, these data suggest that COX deficiency can arise through enhanced holoenzyme dissociation, possibly through interactions with the structure or coordination of its heme moieties.	Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Univ Alberta, Dept Med Genet, Edmonton, AB T6G 2S2, Canada	Queens University - Canada; Queens University - Canada; University of Alberta	Moyes, CD (corresponding author), Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada.	moyesc@biology.queensu.ca	Leary, Scot/B-3036-2012; Glerum, Moira/AHD-3271-2022					Aebi H., 1974, METHODS ENZYMATIC AN, Vsecond, P673, DOI [DOI 10.1016/B978-0-12-091302-2.50032-3, 10.1016/B978-0-12-091302-2.50032-3]; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; Barros MH, 2001, FEBS LETT, V492, P133, DOI 10.1016/S0014-5793(01)02249-9; Bennett M C, 1992, J Geriatr Psychiatry Neurol, V5, P93; Bennett MC, 1996, J NEUROCHEM, V66, P2606; Berndt JD, 2001, J TOXICOL ENV HEAL A, V63, P67, DOI 10.1080/152873901750128380; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BINDOFF LA, 1991, J NEUROL SCI, V104, P203, DOI 10.1016/0022-510X(91)90311-T; Budinger GRS, 1998, J BIOL CHEM, V273, P3320, DOI 10.1074/jbc.273.6.3320; Cabiscol E, 2000, J BIOL CHEM, V275, P27393; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chen YR, 1999, J BIOL CHEM, V274, P24611, DOI 10.1074/jbc.274.35.24611; Chen YR, 2000, BIOCHEMISTRY-US, V39, P4415, DOI 10.1021/bi992652+; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8; CHRZANOWSKALIGHTOWLERS ZMA, 1994, J BIOL CHEM, V269, P27322; Crapo J D, 1978, Methods Enzymol, V53, P382; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; Ghadermarzi M, 1999, BBA-PROTEIN STRUCT M, V1431, P30, DOI 10.1016/S0167-4838(99)00021-7; Giuffre A, 1996, J BIOL CHEM, V271, P33404, DOI 10.1074/jbc.271.52.33404; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Hanson BJ, 2001, J BIOL CHEM, V276, P16296, DOI 10.1074/jbc.M011162200; HARRIS DA, 1989, BIOCHIM BIOPHYS ACTA, V974, P156, DOI 10.1016/S0005-2728(89)80368-8; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795; KLEMENT P, 1995, ANAL BIOCHEM, V231, P218, DOI 10.1006/abio.1995.1523; KOBAYASHI H, 1977, J BIOCHEM-TOKYO, V81, P1071, DOI 10.1093/oxfordjournals.jbchem.a131530; KRALL J, 1988, J BIOL CHEM, V263, P1910; Kuznetsov AV, 1996, J BIOL CHEM, V271, P283, DOI 10.1074/jbc.271.1.283; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lardinois OM, 1996, BBA-PROTEIN STRUCT M, V1298, P180, DOI 10.1016/S0167-4838(96)00130-6; Leary SC, 1998, BBA-BIOENERGETICS, V1365, P522, DOI 10.1016/S0005-2728(98)00105-4; Leist P, 1996, FREE RADICAL BIO MED, V21, P297, DOI 10.1016/0891-5849(96)00045-7; LI WB, 1993, BIOCHEMISTRY-US, V32, P1833, DOI 10.1021/bi00058a018; Lucas DT, 1998, P NATL ACAD SCI USA, V95, P510, DOI 10.1073/pnas.95.2.510; MARGOLIASH E, 1960, BIOCHEM J, V74, P339, DOI 10.1042/bj0740339; MISRA HP, 1978, ARCH BIOCHEM BIOPHYS, V189, P317, DOI 10.1016/0003-9861(78)90218-7; Moyes CD, 1997, AM J PHYSIOL-CELL PH, V272, pC1345, DOI 10.1152/ajpcell.1997.272.4.C1345; Narayan P, 2001, J MOL CELL CARDIOL, V33, P121, DOI 10.1006/jmcc.2000.1282; PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090; PARTRIDGE RS, 1994, ARCH BIOCHEM BIOPHYS, V310, P210, DOI 10.1006/abbi.1994.1159; Rep M, 1996, SCIENCE, V274, P103, DOI 10.1126/science.274.5284.103; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; SCHAGGER H, 1995, ELECTROPHORESIS, V16, P763, DOI 10.1002/elps.11501601125; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Sharpe MA, 1998, J BIOL CHEM, V273, P30961, DOI 10.1074/jbc.273.47.30961; Torres J, 1998, J BIOL CHEM, V273, P8756, DOI 10.1074/jbc.273.15.8756; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P174, DOI 10.1021/bi00052a023; Valnot I, 2000, AM J HUM GENET, V67, P1104; Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245; van Dyck L, 1998, GENE DEV, V12, P1515, DOI 10.1101/gad.12.10.1515; VANBUUREN KJ, 1972, BIOCHIM BIOPHYS ACTA, V256, P258, DOI 10.1016/0005-2728(72)90057-6; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WEINTRAUB ST, 1982, J BIOL CHEM, V257, P4940; WEINTRAUB ST, 1981, J BIOL CHEM, V256, P1669; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P9757; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804	64	64	66	0	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11321	11328		10.1074/jbc.M112303200	http://dx.doi.org/10.1074/jbc.M112303200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11796734	hybrid, Green Submitted			2022-12-27	WOS:000174613100073
J	Berry, FB; Saleem, RA; Walter, MA				Berry, FB; Saleem, RA; Walter, MA			FOXC1 transcriptional regulation is mediated by N- and C-terminal activation domains and contains a phosphorylated transcriptional inhibitory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD/WINGED-HELIX GENE; FORK-HEAD; PROTEIN; MUTATION; FKHL7; MF1; GLAUCOMA; COMPLEX; FREAC-2; FAMILY	Mutations in the FOXC1 gene result in Axenfeld-Rieger malformations of the anterior segment of the eye and lead to an increased susceptibility of glaucoma. To understand how the FOXC1 protein may function in contributing to these malformations, we identified functional regions in FOXC1 required for nuclear localization and transcriptional regulation. Two regions in the FOXC1 forkhead domain, one rich in basic amino acid residues, and a second, highly conserved among all FOX proteins, were necessary for nuclear localization of the FOXC1 protein. However, only the basic region was sufficient for nuclear localization. Two transcriptional activation domains were identified in the extreme N- and C-terminal regions of FOXC1. A transcription inhibitory domain was located at the central region of the protein. This region was able to reduce the trans-activation potential of the C-terminal activation domain, as well as the GAL4 activation domain. Lastly, we demonstrate that FOXC1 is a phosphoprotein, and a number of residues predicted to be phosphorylated were localized to the FOXC1 inhibitory domain. Removal of residues 215366 resulted in a transcriptionally hyperactive FOXC1 protein, which displayed a reduced level of phosphorylation. These results indicate that FOXC1 is under complex regulatory control with multiple functional domains modulating FOXC1 transcriptional regulation.	Univ Alberta, Dept Ophthalmol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Med Genet, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta	Berry, FB (corresponding author), Univ Alberta, Dept Ophthalmol, Edmonton, AB T6G 2H7, Canada.							Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Clifton-Bligh RJ, 1998, NAT GENET, V19, P399, DOI 10.1038/1294; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Crisponi L, 2001, NAT GENET, V27, P159, DOI 10.1038/84781; Fang JM, 2000, AM J HUM GENET, V67, P1382, DOI 10.1086/316915; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Hellqvist M, 1996, J BIOL CHEM, V271, P4482; Hellqvist M, 1998, J BIOL CHEM, V273, P23335, DOI 10.1074/jbc.273.36.23335; Kaestner KH, 2000, GENE DEV, V14, P142; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kidson SH, 1999, DEV BIOL, V211, P306, DOI 10.1006/dbio.1999.9314; Klenova EM, 2001, MOL CELL BIOL, V21, P2221, DOI 10.1128/MCB.21.6.2221-2234.2001; Kume T, 2001, GENE DEV, V15, P2470, DOI 10.1101/gad.907301; Kume T, 1998, CELL, V93, P985, DOI 10.1016/S0092-8674(00)81204-0; Lai CSL, 2001, NATURE, V413, P519, DOI 10.1038/35097076; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Lehmann OJ, 2000, AM J HUM GENET, V67, P1129; MADDEN SL, 1993, ONCOGENE, V8, P1713; Mears AJ, 1998, AM J HUM GENET, V63, P1316, DOI 10.1086/302109; Mirzayans F, 2000, EUR J HUM GENET, V8, P71, DOI 10.1038/sj.ejhg.5200354; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; Nishimura DY, 2001, AM J HUM GENET, V68, P364, DOI 10.1086/318183; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Saleem RA, 2001, AM J HUM GENET, V68, P627, DOI 10.1086/318792; Shim YS, 2000, MOL CELL BIOL, V20, P8958, DOI 10.1128/MCB.20.23.8958-8968.2000; Swiderski RE, 1999, DEV DYNAM, V216, P16, DOI 10.1002/(SICI)1097-0177(199909)216:1<16::AID-DVDY4>3.0.CO;2-1; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Topczewska JM, 2001, MECH DEVELOP, V100, P343, DOI 10.1016/S0925-4773(00)00534-7; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; Winnier GE, 1997, GENE DEV, V11, P926, DOI 10.1101/gad.11.7.926	37	81	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10292	10297		10.1074/jbc.M110266200	http://dx.doi.org/10.1074/jbc.M110266200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11782474	hybrid			2022-12-27	WOS:000174549200091
J	Diakonova, M; Gunter, DR; Herrington, J; Carter-Su, C				Diakonova, M; Gunter, DR; Herrington, J; Carter-Su, C			SH2-B beta is a Rac-binding protein that regulates cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE; ACTIN POLYMERIZATION; CDC42; RECEPTOR; KINASE; MIGRATION; GTPASES; DOMAIN; RHO; IDENTIFICATION	The Src homology 2 (SH2) domain-containing protein SH2-Bbeta binds to and is a substrate of the growth hormone (GH) and cytokine receptor-associated tyrosine kinase JAK2. SH2-Bbeta also binds, via its SH2 domain, to multiple activated growth factor receptor tyrosine kinases. We have previously implicated SH2-Bbeta in GH and platelet-derived growth factor regulation of the actin cytoskeleton. We extend these findings by establishing a potentiating effect of SH2-Bbeta on GH-dependent cell motility and defining regions of SH2-Bbeta required for this potentiation. Time-lapse video microscopy, phagokinetic, and/or wounding assays demonstrate reduced movement of cells overexpressing SH2-Bbeta lacking an intact SH2 domain because of a point mutation or a C-terminal truncation. An N-terminal proline-rich domain (amino acids 85-106) of SH2-Bbeta is required for inhibition of cellular motility by SH2 domain-deficient mutants. Co-immunoprecipitation experiments indicate that Rac binds to this domain. GH is shown to activate endogenous Rac, and dominant negative mutants of SH2-Bbeta are shown to inhibit membrane ruffling induced by constitutively active Rac. These findings suggest that SH2-Bbeta is an adapter protein that facilitates actin rearrangement and cellular motility by recruiting Rac and potentially Rac-regulating, Rac effector, or other actin-regulating proteins to activated cytokine (e.g. GH) and growth factor receptors.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Carter-Su, C (corresponding author), Univ Michigan, Sch Med, Dept Physiol, 6804 Med Sci 2,1301 E Catherine St, Ann Arbor, MI 48109 USA.			Diakonova, Maria/0000-0002-4554-2730	NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [T32RR007008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054222, P60DK020572] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA46592] Funding Source: Medline; NCRR NIH HHS [T32-RR07008-21] Funding Source: Medline; NIAMS NIH HHS [P60-AR20557] Funding Source: Medline; NIDDK NIH HHS [R01-DK54222, R01 DK054222, P60 DK020572, 5P60-DK20572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BERSHADSKY AD, 1991, CELL MOTIL CYTOSKEL, V19, P152, DOI 10.1002/cm.970190303; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; Carter-Su C, 1998, RECENT PROG HORM RES, V53, P61; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; EMTNER M, 1990, MOL ENDOCRINOL, V4, P2014, DOI 10.1210/mend-4-12-2014; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Herrington J, 2000, J BIOL CHEM, V275, P13126, DOI 10.1074/jbc.275.17.13126; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MOHR C, 1990, FEBS LETT, V275, P168, DOI 10.1016/0014-5793(90)81464-Y; NIXON T, 1983, J CELL PHYSIOL, V115, P291, DOI 10.1002/jcp.1041150312; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Qian XZ, 2001, MOL CELL BIOL, V21, P1613, DOI 10.1128/MCB.21.5.1613-1620.2001; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Riedel H, 2000, ONCOGENE, V19, P39, DOI 10.1038/sj.onc.1203253; Rui LY, 2000, MOL CELL BIOL, V20, P3168, DOI 10.1128/MCB.20.9.3168-3177.2000; Rui LY, 1999, J BIOL CHEM, V274, P10590, DOI 10.1074/jbc.274.15.10590; Rui LY, 1998, J BIOL CHEM, V273, P21239, DOI 10.1074/jbc.273.33.21239; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; Small J V, 1988, Electron Microsc Rev, V1, P155; Swanson JA, 1999, J CELL SCI, V112, P307; VARANI J, 1978, AM J PATHOL, V90, P159; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; WIEDERMANN CJ, 1993, BLOOD, V82, P954; Yin HL, 1999, J BIOL CHEM, V274, P32529, DOI 10.1074/jbc.274.46.32529	44	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10669	10677		10.1074/jbc.M111138200	http://dx.doi.org/10.1074/jbc.M111138200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11786545	hybrid			2022-12-27	WOS:000174549200140
J	Ryttersgaard, C; Griffith, SC; Sawaya, MR; MacLaren, DC; Clarke, S; Yeates, TO				Ryttersgaard, C; Griffith, SC; Sawaya, MR; MacLaren, DC; Clarke, S; Yeates, TO			Crystal structure of human L-isoaspartyl methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CARBOXYL METHYLTRANSFERASE; O-METHYLTRANSFERASE; DAMAGED PROTEINS; BOVINE BRAIN; REPAIR; PURIFICATION; EXPRESSION; PROGRAM; RDEL	The enzyme L-isoaspartyl methyltransferase initiates the repair of damaged proteins by recognizing and methylating isomerized and racemized aspartyl residues in aging proteins. The crystal structure of the human enzyme containing a bound S-adenosyl-L-homocysteine cofactor is reported here at a resolution of 2.1 Angstrom. A comparison of the human enzyme to homologs from two other species reveals several significant differences among otherwise similar structures. In all three structures, we find that three conserved charged residues are buried in the protein interior near the active site. Electrostatics calculations suggest that these buried charges might make significant contributions to the energetics of binding the charged S-adenosyl-L-Methionine cofactor and to catalysis. We suggest a possible structural explanation for the observed differences in reactivity toward the structurally similar L-isoaspartyl and D-aspartyl residues in the human, archael, and eubacterial enzymes. Finally, the human structure reveals that the known genetic polymorphism at residue 119 (Val/Ile) maps to an exposed region away from the active site.	Univ Calif Los Angeles, Dept Chem & Biochem, DOE, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, DOE, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA	United States Department of Energy (DOE); University of California System; University of California Los Angeles; United States Department of Energy (DOE); University of California System; University of California Los Angeles	Yeates, TO (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, DOE, Lab Struct Biol & Mol Med, Box 951569, Los Angeles, CA 90095 USA.			Yeates, Todd/0000-0001-5709-9839	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018000] Funding Source: NIH RePORTER; NIA NIH HHS [AG18000] Funding Source: Medline; NIGMS NIH HHS [GM26020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chavous DA, 2001, P NATL ACAD SCI USA, V98, P14814, DOI 10.1073/pnas.251446498; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; DeVry CG, 1999, J HUM GENET, V44, P275, DOI 10.1007/s100380050161; FAUMAN EB, 1999, S ADENOSYLMETHIONINE, P1, DOI DOI 10.1142/9789812813077_0001; GRIFFITH S, 2002, THESIS U CALIFORNIA; Griffith SC, 2001, J MOL BIOL, V313, P1103, DOI 10.1006/jmbi.2001.5095; HENZEL WJ, 1989, J BIOL CHEM, V264, P15905; Ichikawa JK, 1998, ARCH BIOCHEM BIOPHYS, V358, P222, DOI 10.1006/abbi.1998.0830; Ingrosso D, 2000, EUR J BIOCHEM, V267, P4397, DOI 10.1046/j.1432-1327.2000.01485.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kagan RM, 1997, COMP BIOCHEM PHYS B, V117, P379, DOI 10.1016/S0305-0491(96)00333-1; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; MACLAREN DC, 1992, BIOCHEM BIOPH RES CO, V185, P277, DOI 10.1016/S0006-291X(05)80987-8; MACLAREN DC, 1995, PROTEIN EXPRES PURIF, V6, P99, DOI 10.1006/prep.1995.1013; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POTTER SM, 1992, BIOCHEMISTRY-US, V31, P6339, DOI 10.1021/bi00142a025; Press W., 1986, NUMERICAL RECIPES; REDINHO M, 1995, THESIS U CALIFORNIA; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; Skinner MM, 2000, STRUCTURE, V8, P1189, DOI 10.1016/S0969-2126(00)00522-0; Smith CD, 1997, PROTEINS, V28, P457; Thapar N, 2000, PROTEIN EXPRES PURIF, V20, P237, DOI 10.1006/prep.2000.1311; Thapar N, 2002, J BIOL CHEM, V277, P1058, DOI 10.1074/jbc.M108261200; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; YEATES TO, 1987, P NATL ACAD SCI USA, V84, P6438, DOI 10.1073/pnas.84.18.6438; Young AL, 2001, J BIOL CHEM, V276, P37161, DOI 10.1074/jbc.M106682200	31	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10642	10646		10.1074/jbc.M200229200	http://dx.doi.org/10.1074/jbc.M200229200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11792715	hybrid			2022-12-27	WOS:000174549200136
J	Stenner-Liewen, F; Liewen, H; Zapata, JM; Pawlowski, K; Godzik, A; Reed, JC				Stenner-Liewen, F; Liewen, H; Zapata, JM; Pawlowski, K; Godzik, A; Reed, JC			CADD, a Chlamydia protein that interacts with death receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACHOMATIS INFECTION; APOPTOSIS; CELLS; PSITTACI; SEQUENCE	We report here the identification of a bacterial protein capable of interacting with mammalian death receptors in vitro and in vivo. The protein is encoded in the genome of Chlamydia trachomatis and has homologues in other Chlamydia species. This protein, which we refer to as "Chlamydia protein associating with death domains" (CADD), induces apoptosis in a variety of mammalian cell lines when expressed by transient gene transfection. Apoptosis induction can be blocked by Caspase inhibitors, indicating that CADD triggers cell death by engaging the host apoptotic machinery. CADD interacts with death domains of tumor necrosis factor (TNF) family receptors TNFR1, Fas, DR4, and DR5 but not with the respective downstream adaptors. In infected epithelial cells, CADD is expressed late in the infectious cycle of C. trachomatis and co-localizes with Fas in the proximity of the inclusion body. The results suggest a role for CADD modulating the apoptosis pathways of cells infected, revealing a new mechanism of host-pathogen interaction.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham.org	Godzik, Adam/A-7279-2009; Zapata, Juan M/J-6304-2014; Godzik, Adam/AAW-1467-2020; Pawlowski, Krzysztof/E-3262-2012; Pawłowski, Krzysztof/C-2949-2013	Godzik, Adam/0000-0002-2425-852X; Zapata, Juan M/0000-0002-0110-0009; Godzik, Adam/0000-0002-2425-852X; Pawłowski, Krzysztof/0000-0002-5367-0935; Stenner, Frank/0000-0003-4541-8817; Liewen, Heike/0000-0002-6161-4749	NCI NIH HHS [CA68390] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anttila T, 2001, JAMA-J AM MED ASSOC, V285, P47, DOI 10.1001/jama.285.1.47; CAMPBELL S, 1989, J GEN MICROBIOL, V135, P1153; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Fan T, 1998, J EXP MED, V187, P487, DOI 10.1084/jem.187.4.487; Fischer SF, 2001, INFECT IMMUN, V69, P7121, DOI 10.1128/IAI.69.11.7121-7129.2001; Gerard HC, 1997, MOL GEN GENET, V255, P637, DOI 10.1007/s004380050538; Gibellini D, 1998, ZBL BAKT-INT J MED M, V288, P35, DOI 10.1016/S0934-8840(98)80095-9; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; MEULENBERG JJM, 1990, FEMS MICROBIOL LETT, V71, P337, DOI 10.1016/0378-1097(90)90244-K; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Ojcius DM, 1998, J BIOL CHEM, V273, P7052, DOI 10.1074/jbc.273.12.7052; Ojcius DM, 1998, J IMMUNOL, V161, P4220; Perfettini JL, 2000, INFECT IMMUN, V68, P2237, DOI 10.1128/IAI.68.4.2237-2244.2000; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Rychlewski L, 2000, PROTEIN SCI, V9, P232, DOI 10.1110/ps.9.2.232; SCHACHTER J, 1982, JAMA-J AM MED ASSOC, V248, P2134, DOI 10.1001/jama.248.17.2134; Schoier J, 2001, MICROB PATHOGENESIS, V31, P173, DOI 10.1006/mpat.2001.0460; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	18	69	73	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9633	9636		10.1074/jbc.C100693200	http://dx.doi.org/10.1074/jbc.C100693200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11805081	hybrid			2022-12-27	WOS:000174549200004
J	Gao, GQ; Li, Y; Gee, S; Dudley, A; Fant, J; Crosson, C; Ma, JX				Gao, GQ; Li, Y; Gee, S; Dudley, A; Fant, J; Crosson, C; Ma, JX			Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor - A possible mechanism for the anti-angiogenic activity of plasminogen kringle 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PROLIFERATIVE DIABETIC-RETINOPATHY; FACTOR EXPRESSION; CELL-GROWTH; INHIBITOR; NEOVASCULARIZATION; ANGIOSTATIN; HYPOXIA; TRANSCRIPTION; FIBROBLASTS	We have previously shown that intravitreal injection of plasminogen kringle 5 (K5), a potent angiogenic inhibitor, inhibits ischemia-induced retinal neovascularization in a rat model. Here we report that K5 downregulates an endogenous angiogenic stimulator, vascular endothelial growth factor (VEGF) and up-regulates an angiogenic inhibitor, pigment epithelium-derived factor (PEDF) in a dose-dependent manner in vascular cells and in the retina. The regulation of VEGF and PEDF by K5 in the retina correlates with its anti-angiogenic effect in a rat model of ischemia-induced retinopathy. Retinal RNA levels of VEGF and PEDF are also changed by K5. K5 inhibits the p42/p44 MAP kinase activation and nuclear translocation of hypoxia-inducible factor-la, which may be responsible for the down-regulation of VEGF. Down-regulation of endogenous; angiogenic stimulators and up-regulation of endogenous angiogenic inhibitors, thus leading toward restoration of the balance in angiogenic control, may represent a mechanism for the anti-angiogenic activity of K5.	Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29403 USA	Medical University of South Carolina	Ma, JX (corresponding author), Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29403 USA.	majx@musc.edu			NATIONAL EYE INSTITUTE [R01EY012600, R01EY009741, R01EY012231] Funding Source: NIH RePORTER; NEI NIH HHS [EY12600, EY09741, EY12231] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; Aiello LP, 1996, ARCH OPHTHALMOL-CHIC, V114, P1252, DOI 10.1001/archopht.1996.01100140452016; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Blom M L, 1994, Del Med J, V66, P379; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Castellino FJ, 1997, CIBA F SYMP, V212, P46; Coljee VW, 2000, J CELL BIOCHEM, V79, P442, DOI 10.1002/1097-4644(20001201)79:3<442::AID-JCB90>3.0.CO;2-Z; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X; GLASER BM, 1985, ARCH OPHTHALMOL-CHIC, V103, P1870; GRANT MB, 1991, INVEST OPHTH VIS SCI, V32, P53; Hata Y, 1999, DIABETES, V48, P1145, DOI 10.2337/diabetes.48.5.1145; JACOBSON B, 1984, ARCH OPHTHALMOL-CHIC, V102, P1543; Ji WR, 1998, BIOCHEM BIOPH RES CO, V247, P414, DOI 10.1006/bbrc.1998.8825; Jimenez B, 2001, J MOL MED-JMM, V78, P663, DOI 10.1007/s001090000178; KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1217, DOI 10.1001/archopht.1994.01090210105023; Lu H, 1999, BIOCHEM BIOPH RES CO, V258, P668, DOI 10.1006/bbrc.1999.0612; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pages G, 2000, ANN NY ACAD SCI, V902, P187; PEER J, 1995, LAB INVEST, V72, P638; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Punglia RS, 1997, DIABETES, V46, P1619, DOI 10.2337/diabetes.46.10.1619; RAYMOND L, 1982, EXP EYE RES, V34, P267, DOI 10.1016/0014-4835(82)90060-4; Redlitz A, 1999, J VASC RES, V36, P28, DOI 10.1159/000025623; Seko Y, 1998, J CELL PHYSIOL, V175, P239, DOI 10.1002/(SICI)1097-4652(199806)175:3<239::AID-JCP1>3.0.CO;2-P; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Sodhi A, 2000, CANCER RES, V60, P4873; Steinkuller PG, 1999, J AAPOS, V3, P26, DOI 10.1016/S1091-8531(99)70091-1; Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200; Terada Y, 1999, NEPHROL DIAL TRANSPL, V14, P45, DOI 10.1093/ndt/14.suppl_1.45; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wood SM, 1997, INT J BIOCHEM CELL B, V29, P1419, DOI 10.1016/S1357-2725(97)00129-5; Yamamoto H, 2001, INVEST OPHTH VIS SCI, V42, pS244; Zhang D, 2001, DIABETOLOGIA, V44, P757, DOI 10.1007/s001250051685	44	109	133	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9492	9497		10.1074/jbc.M108004200	http://dx.doi.org/10.1074/jbc.M108004200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11782462	hybrid			2022-12-27	WOS:000174400600101
J	Liang, GS; Yang, J; Horton, JD; Hammer, RE; Goldstein, JL; Brown, MS				Liang, GS; Yang, J; Horton, JD; Hammer, RE; Goldstein, JL; Brown, MS			Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; TRANSGENIC MICE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; IN-VIVO; CHOLESTEROL-SYNTHESIS; CULTURED-CELLS; INSULIN; ACTIVATION; SREBP-1C	Two treatments, fasting/refeeding and administration of liver X receptor (LXR) agonists, elevate the mRNA for sterol regulatory element-binding protein-1c (SREBP-1c) and enhance lipid synthesis in liver. These treatments do not affect the mRNA for SREBP-la, an alternative transcript from the same gene. Through homologous recombination, we eliminated the exon encoding SREBP-1c from the mouse genome, leaving the SREBP-la transcript intact. On a normal diet, livers of SREBP-1c(-/-) mice manifested reductions in multiple mRNAs encoding enzymes of fatty acid and triglyceride synthesis, including acetylCoA carboxylase (ACC) and fatty acid synthase WAS). In contrast, SREBP-1c(-/-) livers showed a compensatory increase in hepatic SREBP-2 mRNA, accompanied by increased mRNA levels for cholesterol biosynthetic enzymes. In fasted/refed animals, ACC and FAS mRNAs rose, but not to the same extent as in wild-type livers. The refeeding-induced increase in SREBP-1c(-/-) mice was greater than in mice lacking SREBP cleavage-activating protein (SCAP), in which all nuclear SREBPs are absent. Thus, SREBP-2 and/or SREBP-la can substitute partially for SREBP-1c in permitting an insulin-mediated increase in ACC and FAS mRNAs. In contrast, mRNAs for several other lipogenic enzymes (glucose-6-phosphate dehydrogenase, malic enzyme, glycerol-3-phosphate acyltransferase, and stearoyl-CoA desaturase-1) showed a complete failure of the normal inductive response to refeeding, indicating specific reliance on SREBP-1c. Moreover, these mRNAs, as well as multiple other lipogenic mRNAs, showed a markedly blunted response to the LXR agonist T090137, indicating an essential role of SREBP-1c in the LXR response.	SW Texas State Univ, Med Ctr, Howard Hughes Med Inst, Dept Mol Genet, Dallas, TX 75390 USA; SW Texas State Univ, Med Ctr, Howard Hughes Med Inst, Dept Internal Med, Dallas, TX 75390 USA; SW Texas State Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Dallas, TX 75390 USA	Howard Hughes Medical Institute; Texas State University System; Texas State University San Marcos; Howard Hughes Medical Institute; Texas State University System; Texas State University San Marcos; Howard Hughes Medical Institute; Texas State University System; Texas State University San Marcos	Goldstein, JL (corresponding author), SW Texas State Univ, Med Ctr, Howard Hughes Med Inst, Dept Mol Genet, Dallas, TX 75390 USA.	joe.goldstein@utsouthwestern.edu; mike.brown@utsouthwestern.edu		Hammer, Robert E./0000-0001-5487-7551	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*APPL BIOS, 2001, US B APPL BIOS, V23; Becard D, 2001, DIABETES, V50, P2425, DOI 10.2337/diabetes.50.11.2425; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Bunting M, 1999, GENE DEV, V13, P1524, DOI 10.1101/gad.13.12.1524; Casado M, 1999, J BIOL CHEM, V274, P2009, DOI 10.1074/jbc.274.4.2009; Chakravarty K, 2001, J BIOL CHEM, V276, P34816, DOI 10.1074/jbc.M103310200; Edwards PA, 2000, BBA-MOL CELL BIOL L, V1529, P103, DOI 10.1016/S1388-1981(00)00140-2; Fere P, 2001, BIOCHEM SOC T, V29, P547; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Latasa MJ, 2000, P NATL ACAD SCI USA, V97, P10619, DOI 10.1073/pnas.180306597; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301; Moon YS, 2000, J BIOL CHEM, V275, P10121, DOI 10.1074/jbc.275.14.10121; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; SATO R, 1994, J BIOL CHEM, V269, P17267; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Sul HS, 1998, ANNU REV NUTR, V18, P331, DOI 10.1146/annurev.nutr.18.1.331; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; Yang J, 2001, P NATL ACAD SCI USA, V98, P13607, DOI 10.1073/pnas.201524598; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	41	501	520	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9520	9528		10.1074/jbc.M111421200	http://dx.doi.org/10.1074/jbc.M111421200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11782483	hybrid			2022-12-27	WOS:000174400600105
J	Potter, RM; Key, TA; Gurevich, VV; Sklar, LA; Prossnitz, ER				Potter, RM; Key, TA; Gurevich, VV; Sklar, LA; Prossnitz, ER			Arrestin variants display differential binding characteristics for the phosphorylated N-formyl peptide receptor carboxyl terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; VISUAL ARRESTIN; SYNTHETIC PHOSPHOPEPTIDE; CLATHRIN ADAPTER; HUMAN NEUTROPHIL; RHODOPSIN; DESENSITIZATION; ENDOCYTOSIS; ACTIVATION	The phosphorylation-dependent binding of arrestins to cytoplasmic domains of G protein-coupled receptors (GPCRs) is thought to be a crucial step in receptor desensitization. In some GPCR systems, arrestins have also been demonstrated to be involved in receptor internalization, resensitization, and the activation of signaling cascades. The objective of the current study was to examine binding interactions of members of the arrestin family with the formyl peptide receptor (FPR), a member of the GPCR family of receptors. Peptides representing the unphosphorylated and phosphorylated carboxyl terminus of the FPR were synthesized and bound to polystyrene beads via a biotin/streptavidin interaction. Using fluorescein-conjugated arrestins, binding interactions between arrestins and the bead-bound FPR carboxyl terminus were analyzed by flow cytometry. Arrestin-2 and arrestin-3 bound to the FPRcarboxyl-terminal peptide in aphosphorylation-dependent manner, with K-d values in the micromolar range. Binding of visual arrestin, which binds rhodopsin with high selectivity, was not observed. Arrestin-2-(1-382) and arrestin-3-(1-393), truncated mutant forms of arrestin that display phosphorylation-independent binding to intact receptors, were also observed to bind the bead-bound FPR terminus in a phosphorylation-dependent manner, but with much greater affinity than the full-length arrestins, yielding Kd values in the 5-50 nm range. Two additional arrestin mutants, which are full-length but display phosphorylation-independent binding to intact GPCRs, were evaluated for their binding affinity to the FPR carboxyl terminus. Whereas the single point mutant, arrestin-2 R169E, displayed an affinity similar to that of the full-length arrestins, the triple point mutant, arrestin-2 I386A/V387A/F388A, displayed an affinity more similar to that of the truncated forms of arrestin. The results suggest that the carboxyl terminus of arrestin is a critical determinant in regulating the binding affinity of arrestin for the phosphorylated domains of GPCRs.	Univ New Mexico, Dept Cell Biol & Physiol, Hlth Sci Ctr, Albuquerque, NM 87131 USA; Univ New Mexico, Canc Res & Treatment Ctr, Hlth Sci Ctr, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Pathol, Hlth Sci Ctr, Albuquerque, NM 87131 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Los Alamos Natl Lab, Natl Flow Cytometry Resource, Biosci Div, Los Alamos, NM 87545 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; Vanderbilt University; United States Department of Energy (DOE); Los Alamos National Laboratory	Prossnitz, ER (corresponding author), Univ New Mexico, Dept Cell Biol & Physiol, Hlth Sci Ctr, Albuquerque, NM 87131 USA.	eprossnitz@salud.unm.edu	Gurevich, Vsevolod/A-3236-2008; Prossnitz, Eric/I-4599-2019; Prossnitz, Eric R./B-4543-2008	Gurevich, Vsevolod/0000-0002-3950-5351; Prossnitz, Eric/0000-0001-9190-8302; 	NCRR NIH HHS [RR01315] Funding Source: Medline; NEI NIH HHS [EY11500] Funding Source: Medline; NIAID NIH HHS [AI43932, AI36357] Funding Source: Medline; NIGMS NIH HHS [GM60799, GM63097] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001315] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036357, R01AI036357, R01AI043932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R24GM060799, R01GM063097] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; Bennett TA, 2001, J BIOL CHEM, V276, P49195, DOI 10.1074/jbc.M106414200; Bennett TA, 2001, J BIOL CHEM, V276, P22453, DOI 10.1074/jbc.M009679200; Buranda T, 2001, ANAL BIOCHEM, V298, P151, DOI 10.1006/abio.2001.5363; Celver JP, 2001, J BIOL CHEM, V276, P4894, DOI 10.1074/jbc.M007437200; Cen B, 2001, J NEUROCHEM, V76, P1887, DOI 10.1046/j.1471-4159.2001.00204.x; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Gelber EI, 1999, J NEUROCHEM, V72, P2206, DOI 10.1046/j.1471-4159.1999.0722206.x; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gurevich VV, 2000, METHOD ENZYMOL, V315, P422; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; Gurrath M, 2001, CURR MED CHEM, V8, P1605, DOI 10.2174/0929867013371798; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Key TA, 2001, J BIOL CHEM, V276, P49204, DOI 10.1074/jbc.M109475200; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Maestes DC, 1999, J BIOL CHEM, V274, P29791, DOI 10.1074/jbc.274.42.29791; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDowell JH, 1999, BIOCHEMISTRY-US, V38, P6119, DOI 10.1021/bi990175p; McDowell JH, 2001, INVEST OPHTH VIS SCI, V42, P1439; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Prossnitz ER, 1997, J BIOL CHEM, V272, P15213, DOI 10.1074/jbc.272.24.15213; PUIG J, 1995, FEBS LETT, V362, P185, DOI 10.1016/0014-5793(95)00225-X; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SKLAR LA, 1984, J BIOL CHEM, V259, P5661; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836	43	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8970	8978		10.1074/jbc.M111086200	http://dx.doi.org/10.1074/jbc.M111086200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11777932	hybrid			2022-12-27	WOS:000174400600033
J	Wang, SP; Krits, I; Bai, ST; Lee, BS				Wang, SP; Krits, I; Bai, ST; Lee, BS			Regulation of enhanced vacuolar H+-ATPase expression in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; CYTOPLASMIC PH REGULATION; RENAL TUBULAR-ACIDOSIS; PROTON PUMP; INTERCALATED CELLS; MAMMALIAN-CELLS; B1 SUBUNIT; B2 SUBUNIT; V-ATPASE; GENE	The proton-translocating vacuolar ATPase (V-ATPase) acidifies the endocytic network of eukaryotic cells. Although all eukaryotic cell types require low to moderate levels of V-ATPase, some proton-secreting cells express amplified levels for use in specialized membrane domains. To characterize genetic elements required for this heightened expression, we studied transcription and stability of mRNA encoding the V-ATPase c subunit in a low expressing fibroblast cell line (NIH 3T3) and a high expressing macrophage cell line (RAW 264.7). Isolation of the promoter and mapping of the transcriptional start site indicated that the c subunit promoter is TATA-less and initiates transcription at a single site. Promoter activity was regulated through the same transcription factor binding sites in both cell types, which showed no discernible difference in rates of c subunit transcription. In contrast, c subunit transcripts showed markedly greater stability in RAW cells than in 3T3 cells, as did other constitutively expressed V-ATPase subunit transcripts. Only the B and 'a' subunits, which are expressed in multiple isoforms, were not regulated solely by mRNA stability. These results suggest that overall expression levels of the V-ATPase are set primarily by regulation of mRNA stability and that transcriptional mechanisms determine subunit composition in varying cell types.	Ohio State Univ, Dept Physiol & Cell Biol, Coll Med & Publ Hlth, Columbus, OH 43210 USA; Washington Univ, Sch Med, Div Renal, St Louis, MO 63110 USA	Ohio State University; Washington University (WUSTL)	Lee, BS (corresponding author), Ohio State Univ, Dept Physiol & Cell Biol, Coll Med & Publ Hlth, 302 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.		Lee, Beth S/E-9578-2010	Lee, Beth S/0000-0002-1468-6387				BASTANI B, 1991, J CLIN INVEST, V88, P126, DOI 10.1172/JCI115268; BERNASCONI P, 1990, J BIOL CHEM, V265, P17428; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; GABIG TG, 1981, ANNU REV MED, V32, P313, DOI 10.1146/annurev.me.32.020181.001525; GILLESPIE GAJ, 1991, P NATL ACAD SCI USA, V88, P4289, DOI 10.1073/pnas.88.10.4289; GREENBERG ME, 1997, CURRENT PROTOCOLS MO; HASEBE M, 1992, BIOCHEM BIOPH RES CO, V183, P856, DOI 10.1016/0006-291X(92)90562-Y; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200; Jansen RP, 1999, FASEB J, V13, P455, DOI 10.1096/fasebj.13.3.455; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KHALILI K, 1984, J MOL BIOL, V180, P1007, DOI 10.1016/0022-2836(84)90268-7; Korner K, 1997, NUCLEIC ACIDS RES, V25, P4933, DOI 10.1093/nar/25.24.4933; KROWCZYNSKA A, 1985, J MOL BIOL, V181, P231, DOI 10.1016/0022-2836(85)90087-7; LaitalaLeinonen T, 1996, MOL BIOL CELL, V7, P129, DOI 10.1091/mbc.7.1.129; Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164; LEE BS, 1995, J BIOL CHEM, V270, P7320, DOI 10.1074/jbc.270.13.7320; Lee BS, 1996, AM J PHYSIOL-CELL PH, V270, pC382, DOI 10.1152/ajpcell.1996.270.1.C382; Lee BS, 1997, J BIOL CHEM, V272, P174; Lee BS, 1999, J BONE MINER RES, V14, P2127, DOI 10.1359/jbmr.1999.14.12.2127; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SAKAI D, 1995, BONE, V17, P111, DOI 10.1016/S8756-3282(95)00152-2; Sambrook J., 2002, MOL CLONING LAB MANU; Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756-3282(99)00278-1; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; SWALLOW CJ, 1990, SURGERY, V108, P363; SWALLOW CJ, 1991, CLIN INVEST MED, V14, P367; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; WEISS IM, 1995, MOL CELL BIOL, V15, P2457	42	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8827	8834		10.1074/jbc.M111959200	http://dx.doi.org/10.1074/jbc.M111959200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11786555	hybrid			2022-12-27	WOS:000174400600013
J	Balasubramanian, R; Pray-Grant, MG; Selleck, W; Grant, PA; Tan, S				Balasubramanian, R; Pray-Grant, MG; Selleck, W; Grant, PA; Tan, S			Role of the Ada2 and Ada3 transcriptional coactivators in histone acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDIC ACTIVATION DOMAINS; IN-VIVO; ACETYLTRANSFERASE ACTIVITY; NUCLEOSOMAL ARRAYS; CRYSTAL-STRUCTURE; YEAST GCN5P; COMPLEX; ADAPTER; PROTEIN; RESOLUTION	Previous studies have shown that the transcriptional coactivator protein Gcn5 functions as a catalytic histone acetyltransferase (HAT). In this work, we examine the roles of the Ada2 and Ada3 coactivator proteins that are functionally linked to Gcn5. We show that yeast Ada2, Ada3, and Gcn5 form a catalytic core of the ADA and Spt-Ada-Gcn5-acetyltransferase HAT complexes, which is necessary and sufficient in vitro for nucleosomal HAT activity and lysine specificity of the intact HAT complexes. We also demonstrate that Ada3 is necessary for Gcn5-dependent nucleosomal HAT activity in yeast extracts. Our results suggest that Ada2 potentiates the Gcn5 catalytic activity and that Ada3 facilitates nucleosomal acetylation and an expanded lysine specificity.	Penn State Univ, Dept Biochem & Mol Biol, Ctr Gene Regulat, University Pk, PA 16802 USA; Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Virginia	Tan, S (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Ctr Gene Regulat, 108 Althouse Lab, University Pk, PA 16802 USA.		Balasubramanian, Ramakrishnan/C-7620-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060489] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-58646-01] Funding Source: Medline; NIGMS NIH HHS [GM-60489] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Candau R, 1996, J BIOL CHEM, V271, P5237; Cote J, 1995, METH MOL G, P108, DOI [10.1016/S1067-2389(06)80009-9, DOI 10.1016/S1067-2389(06)80009-9]; Gaiser F, 2000, J MOL BIOL, V302, P1119, DOI 10.1006/jmbi.2000.4110; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; Sendra R, 2000, J BIOL CHEM, V275, P24928, DOI 10.1074/jbc.M003783200; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; Syntichaki P, 1998, J BIOL CHEM, V273, P24414, DOI 10.1074/jbc.273.38.24414; Tan S, 2001, PROTEIN EXPRES PURIF, V21, P224, DOI 10.1006/prep.2000.1363; Tan S, 2000, J MOL BIOL, V297, P947, DOI 10.1006/jmbi.2000.3606; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Tse C, 1998, J BIOL CHEM, V273, P32388, DOI 10.1074/jbc.273.49.32388; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; van Holde KE., 1989, SPRINGER SERIES MOL; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Winkler GS, 2001, J BIOL CHEM, V276, P32743, DOI 10.1074/jbc.M105303200; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	38	162	165	4	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7989	7995		10.1074/jbc.M110849200	http://dx.doi.org/10.1074/jbc.M110849200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11773077	hybrid			2022-12-27	WOS:000174268000047
J	Kalthoff, C; Alves, J; Urbanke, C; Knorr, R; Ungewickell, EJ				Kalthoff, C; Alves, J; Urbanke, C; Knorr, R; Ungewickell, EJ			Unusual structural organization of the endocytic proteins AP180 and epsin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN ASSEMBLY PROTEIN; APPENDAGE DOMAIN; TERMINAL DOMAIN; COATED VESICLES; ALPHA-ADAPTIN; BINDING-SITE; EH-DOMAIN; SIZE; CHROMATOGRAPHY; INTERACT	Epsin and AP180/CALM are important endocytic accessory proteins that are believed to be involved in the formation of clathrin coats. Both proteins associate with phosphorylated membrane inositol lipids through their epsin N-terminal homology domains and with other components of the endocytic machinery through short peptide motifs in their carboxyl-terminal segments. Using hydrodynamic and spectroscopic methods, we demonstrate that the parts of epsin 1 and AP180 that are involved in protein-protein interactions behave as poorly structured flexible polypeptide chains with little or no conventional secondary structure. The predominant cytosolic forms of both proteins are monomers. Furthermore, we show that recombinant epsin 1, like AP180, drives in vitro assembly of clathrin cages. We conclude that the epsin N-terminal homology domain-containing proteins AP180/CALM and epsin 1 have a very similar molecular architecture that is designed for the rapid and efficient recruitment of the principal coat components clathrin and AP-2 at the sites of coated pit assembly.	Hannover Med Sch, Ctr Anat, Dept Cell Biol, D-30125 Hannover, Germany; Hannover Med Sch, Ctr Biochem, Dept Biophys Chem, D-30125 Hannover, Germany	Hannover Medical School; Hannover Medical School	Ungewickell, EJ (corresponding author), Hannover Med Sch, Ctr Anat, Dept Cell Biol, Carl Neuberg Str 1, D-30125 Hannover, Germany.							AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Drake MT, 2001, J BIOL CHEM, V276, P28700, DOI 10.1074/jbc.M104226200; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Hao WH, 1999, J BIOL CHEM, V274, P22785, DOI 10.1074/jbc.274.32.22785; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; KOHTZ DS, 1988, J BIOL CHEM, V263, P7418; Laue TM, 1992, COMPUTER AIDED INTER, P90; LAURENT TC, 1964, J CHROMATOGR, V14, P331; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; LINDNER R, 1992, J BIOL CHEM, V267, P16567; Mao YX, 2001, CELL, V104, P433, DOI 10.1016/S0092-8674(01)00230-6; McMahon HT, 1999, CURR BIOL, V9, pR332, DOI 10.1016/S0960-9822(99)80206-1; Mishra SK, 2001, J BIOL CHEM, V276, P46230, DOI 10.1074/jbc.M108177200; Morgan JR, 2000, J NEUROSCI, V20, P8667; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; MURPHY JE, 1992, J BIOL CHEM, V267, P10850; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; POTSCHKA M, 1987, ANAL BIOCHEM, V162, P47, DOI 10.1016/0003-2697(87)90009-1; PRASAD K, 1988, BIOCHEMISTRY-US, V27, P6098, DOI 10.1021/bi00416a040; Rosenthal JA, 1999, J BIOL CHEM, V274, P33959, DOI 10.1074/jbc.274.48.33959; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Scheele U, 2001, J BIOL CHEM, V276, P36131, DOI 10.1074/jbc.M106511200; SOBER HA, 1970, CRC HDB BIOCH SELECT, pC10; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; TADEI K, 2001, TRENDS CELL BIOL, V11, P385; Tebar F, 1999, MOL BIOL CELL, V10, P2687, DOI 10.1091/mbc.10.8.2687; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; YE W, 1995, J NEUROSCI RES, V41, P15, DOI 10.1002/jnr.490410104; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9	37	116	120	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8209	8216		10.1074/jbc.M111587200	http://dx.doi.org/10.1074/jbc.M111587200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11756460	hybrid			2022-12-27	WOS:000174268000075
J	Sonoyama, J; Matsumura, I; Ezoe, S; Satoh, Y; Zhang, X; Kataoka, Y; Takai, E; Mizuki, M; Machii, T; Wakao, H; Kanakura, Y				Sonoyama, J; Matsumura, I; Ezoe, S; Satoh, Y; Zhang, X; Kataoka, Y; Takai, E; Mizuki, M; Machii, T; Wakao, H; Kanakura, Y			Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; BCR-ABL; HEMATOPOIETIC-CELLS; TRANSGENIC MICE; MEGAKARYOCYTIC DIFFERENTIATION; TRANSCRIPTIONAL REGULATION; SIGNAL TRANSDUCER; V-ABL	BCR/ABL tyrosine kinase generated from the chromosomal translocation t(9;22) causes chronic myelogenous leukemia and acute lymphoblastic leukemia. To examine the roles of BCR/ABL-activated individual signaling molecules and their cooperation in leukemogenesis, we inducibly expressed a dominant negative (DN) form of Ras, phosphatidylinositol 3-kinase, and STAT5 alone or in combination in p210 BCR/ABL-positive K562 cells. The inducibly expressed DN Ras (N17), STAT5 (694F), and DN phosphatidylinositol 3-kinase (Deltap85) inhibited the growth by 90, 55, and 40%:, respectively. During the growth inhibition, the expression of cyclin D2 and cyclin D3 was suppressed by N17, 694F, or Deltap85; that of cyclin E by N17; and that of cyclin A by Deltap85. In addition, N17 induced apoptosis in a small proportion of K562, whereas 694F and DeltapS5 were hardly effective. In contrast, coexpression of two DN mutants in any combinations induced severe apoptosis. During these cultures, the expression of Bcl-2 was suppressed by N17, 694F, or Deltap85, and that of Bcl-XL by N17. Furthermore, although K562 was resistant to interferon-alpha- and dexamethasone-induced apoptosis, disruption of one pathway by N17, 694F, or Deltap85 sensitized K562 to these reagents. These results suggested that cooperation among these molecules is required for full leukemogenic activities of BCR/ABL.	Osaka Univ, Grad Sch Med, Dept Hematol Oncol, Suita, Osaka 5650871, Japan; Helix Res Inst, Chiba 2920812, Japan	Osaka University	Kanakura, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Hematol Oncol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		WAKAO, Hiroshi/A-4242-2012					Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Chida D, 1998, MOL ENDOCRINOL, V12, P1792, DOI 10.1210/me.12.11.1792; Cortez D, 1996, ONCOGENE, V13, P2589; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Damiano JS, 2001, LEUKEMIA, V15, P1232, DOI 10.1038/sj.leu.2402179; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; de Groot Rolf P., 2000, Molecular Cell Biology Research Communications, V3, P299, DOI 10.1006/mcbr.2000.0231; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hariharan I K, 1988, Oncogene Res, V3, P387; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KINOSHITA T, 1995, ONCOGENE, V10, P2207; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Laroche-Clary A, 2000, BIOCHEM PHARMACOL, V60, P1823, DOI 10.1016/S0006-2952(00)00497-4; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; Lu Y, 2001, ONCOGENE, V20, P4777, DOI 10.1038/sj.onc.1204607; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; Maru Y, 2001, INT J HEMATOL, V73, P308, DOI 10.1007/BF02981955; Matsumura I, 2000, BLOOD, V96, P2440; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; Sattler M, 2001, INT J HEMATOL, V73, P278, DOI 10.1007/BF02981952; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; van der Kuip H, 2001, BLOOD, V98, P1532, DOI 10.1182/blood.V98.5.1532; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	54	87	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8076	8082		10.1074/jbc.M111501200	http://dx.doi.org/10.1074/jbc.M111501200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11779872	hybrid			2022-12-27	WOS:000174268000058
J	Torres, B; Zambon, AC; Insel, PA				Torres, B; Zambon, AC; Insel, PA			P2Y(11) receptors activate adenylyl cyclase and contribute to nucleotide-promoted cAMP formation in MDCK-D-1 cells - A mechanism for nucleotide-mediated autocrine-paracrine regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; ATP; EXPRESSION; STIMULATION; FORSKOLIN; AGONISTS; PATHWAYS; CLONING	Extracellular nucleotides activate P2Y receptors, thereby increasing cAMP formation in Madin-Darby canine kidney (MDCK-D-1) cells, which express P2Y(1), P2Y(2), and P2Y(11) receptors (Post, S. R., Rump, L. C., Zambon, A., Hughes, R. J., Buda, M. D., Jacobson, J. P., Kao, C. C., and Insel, P. A. (1998) J. Biol. Chem. 273, 23093-23097). The cyclooxygenase inhibitor indomethacin (indo) eliminates UTP-promoted cAMP formation (i.e. via P2Y(2) receptors) but only partially blocks ATP-promoted cAMP formation. The latter response is completely blocked by the nonselective P2Y receptor antagonist suramin. We have sought to identify the mechanism for this P2Y receptor-mediated, indo-resistant cAMP formation. The agonist rank order potencies for cAMP formation were: ADPbetaS greater than or equal to MT-ADP > 2-MT-ATP > ADP, ATP, ATPgammaS > UTP, AMP, adenosine. We found a similar rank order in MDCK-D-1 cells overexpressing cloned green fluorescent protein-tagged P2Y(11) receptors, but the potency of the agonists was enhanced, consistent with a P2Y(11) receptor-mediated effect. cAMP generation by the P2Y(1) and P2Y(11) receptor agonist ADPbetaS was not inhibited by several P2Y(1)-selective antagonists (PPADS, A2P5P, and MRS 2179). Forskolin synergistically enhanced cAMP generation in response to ADPbetaS or PGE(2), implying that, like PGE(2), ADPbetaS activates adenylyl cyclase via G(8), a conclusion supported by results showing ADPbetaS and MT-ADP promoted activation of adenylyl cyclase activity in MDCK-D-1 membranes. We conclude that nucleotide-promoted, indo-resistant cAMP formation in MDCK-D-1 cells occurs via G(8)-linked P2Y(11) receptors. These data describing adenylyl cyclase activity via endogenous P2Y(11) receptors define a mechanism by which released nucleotides can increase cAMP in MDCK-D-1 and other P2Y(11)-containing cells.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	inseloffice@ucsd.edu						Balboa MA, 1998, MOL PHARMACOL, V53, P221, DOI 10.1124/mol.53.2.221; Chen BC, 1997, BIOCHEM BIOPH RES CO, V233, P442, DOI 10.1006/bbrc.1997.6478; Communi D, 1999, BRIT J PHARMACOL, V128, P1199, DOI 10.1038/sj.bjp.0702909; Communi D, 2001, J BIOL CHEM, V276, P41479, DOI 10.1074/jbc.M105912200; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; Communi D, 1999, BRIT J PHARMACOL, V127, P562, DOI 10.1038/sj.bjp.0702560; DARFLER FJ, 1982, J BIOL CHEM, V257, P1901; Firestein BL, 1996, AM J PHYSIOL-RENAL, V271, pF610, DOI 10.1152/ajprenal.1996.271.3.F610; Foster CJ, 2001, J CLIN INVEST, V107, P1591, DOI 10.1172/JCI12242; Insel PA, 2001, CLIN EXP PHARMACOL P, V28, P351, DOI 10.1046/j.1440-1681.2001.03452.x; Insel PA, 1996, J AUTON PHARMACOL, V16, P311, DOI 10.1111/j.1474-8673.1996.tb00042.x; JASPER JR, 1988, FASEB J, V2, P2891, DOI 10.1096/fasebj.2.13.2901994; Jin JG, 1998, J BIOL CHEM, V273, P2030, DOI 10.1074/jbc.273.4.2030; Kenakin T, 1996, PHARMACOL REV, V48, P413; LANG F, 1995, KIDNEY INT, V48, P1200, DOI 10.1038/ki.1995.403; McAlroy HL, 2000, BRIT J PHARMACOL, V131, P1651, DOI 10.1038/sj.bjp.0703743; Nandanan E, 2000, J MED CHEM, V43, P829, DOI 10.1021/jm990249v; Nicholas RA, 2001, MOL PHARMACOL, V60, P416; Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735; Ostrom RS, 2001, AM J PHYSIOL-CELL PH, V281, pC524, DOI 10.1152/ajpcell.2001.281.2.C524; Post SR, 1998, J BIOL CHEM, V273, P23093, DOI 10.1074/jbc.273.36.23093; Post SR, 1996, J BIOL CHEM, V271, P2029, DOI 10.1074/jbc.271.4.2029; Qi AD, 2001, MOL PHARMACOL, V60, P1375, DOI 10.1124/mol.60.6.1375; Qi AD, 2001, BRIT J PHARMACOL, V132, P318, DOI 10.1038/sj.bjp.0703788; Ralevic V, 1998, PHARMACOL REV, V50, P413; RODBELL M, 1971, J BIOL CHEM, V246, P1877; Schachter JB, 1996, BRIT J PHARMACOL, V118, P167, DOI 10.1111/j.1476-5381.1996.tb15381.x; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; Van der Weyden L, 2000, IMMUNOL CELL BIOL, V78, P467, DOI 10.1111/j.1440-1711.2000.t01-4-.x; von Kugelgen I, 2000, N-S ARCH PHARMACOL, V362, P310, DOI 10.1007/s002100000310; Windh RT, 2002, METHOD ENZYMOL, V344, P3; Xing MZ, 1997, J CLIN INVEST, V99, P805, DOI 10.1172/JCI119227; Zambon AC, 2001, MOL PHARMACOL, V60, P26, DOI 10.1124/mol.60.1.26; Zambon AC, 2000, AM J PHYSIOL-RENAL, V279, pF1045, DOI 10.1152/ajprenal.2000.279.6.F1045; ZEGARRAMORAN O, 1995, BRIT J PHARMACOL, V114, P1052, DOI 10.1111/j.1476-5381.1995.tb13312.x; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	36	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7761	7765		10.1074/jbc.M110352200	http://dx.doi.org/10.1074/jbc.M110352200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11788591	hybrid			2022-12-27	WOS:000174268000019
J	Nicholls, CD; McLure, KG; Shields, MA; Lee, PWK				Nicholls, CD; McLure, KG; Shields, MA; Lee, PWK			Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers - Implications on the dominant negative effect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-SUPPRESSOR P53; RING-FINGER DOMAIN; GAIN-OF-FUNCTION; MUTANT P53; TETRAMERIZATION DOMAIN; DNA-BINDING; CELL-LINES; BREAST-CANCER; OLIGOMERIZATION DOMAIN	Precisely how mutant p53 exerts a dominant negative effect over wild type p53 has been an enigma. To understand how wild type and mutant p53 form hetero-oligomers, we studied p53 biogenesis in vitro. We show here that p53 dimers are formed cotranslationally (on the polysome), whereas tetramers are formed posttranslationally (by the dimerization of dimers in solution). Coexpression of wild type and mutant p53 therefore results in 50% of the p53 generated being heterotetramers comprised of a single species: wild type dimer/mutant dimer. Using hot spot mutants of p53 and a variety of natural target sites, we show that all wild type/mutant heterotetramers manifest impaired DNA binding activity. This impairment is not due to the mutant dimeric subunit inhibiting association of the complex with DNA but rather due to the lack of significant contribution (positive cooperativity) from the mutant partner. For all heterotetramers, bias in binding is particularly pronounced against those sequences in genes responsible for apoptosis rather than cell growth arrest. These results explain the molecular basis of p53 dominant negative effect and suggest a functional role in the regulation of p53 tetramerization.	Univ Calgary, Hlth Sci Ctr, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Hlth Sci Ctr, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Lee, PWK (corresponding author), Univ Calgary, Hlth Sci Ctr, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada.							Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; Chene P, 1999, J MOL BIOL, V286, P1269, DOI 10.1006/jmbi.1999.2563; Chene P, 1997, J MOL BIOL, V273, P873, DOI 10.1006/jmbi.1997.1360; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DAVIDOFF AM, 1991, CANCER RES, V51, P2605; Deb D, 1999, INT J ONCOL, V15, P413; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1994, CANCER RES, V54, P878; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gilmore R, 1996, EMBO J, V15, P2651, DOI 10.1002/j.1460-2075.1996.tb00625.x; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; HACHIYA M, 1994, ANTICANCER RES, V14, P1853; Hara T, 2000, EXP CELL RES, V258, P152, DOI 10.1006/excr.2000.4926; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Liu YG, 2001, CARCINOGENESIS, V22, P851, DOI 10.1093/carcin/22.6.851; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1993, CANCER GENET CYTOGEN, V66, P83, DOI 10.1016/0165-4608(93)90233-C; Mateu MG, 1999, NAT STRUCT BIOL, V6, P191; MAZARS R, 1992, CANCER RES, V52, P3918; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PARK DJ, 1994, ONCOGENE, V9, P1899; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; ROLLEY N, 1995, ONCOGENE, V11, P763; Sakaguchi K, 1997, J PROTEIN CHEM, V16, P553, DOI 10.1023/A:1026334116189; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Varley JM, 1997, ONCOGENE, V14, P865, DOI 10.1038/sj.onc.1201041; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Waterman MJF, 1996, CANCER RES, V56, P158; Williams KJ, 1996, BRIT J CANCER, V74, P698, DOI 10.1038/bjc.1996.424; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	61	102	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12937	12945		10.1074/jbc.M108815200	http://dx.doi.org/10.1074/jbc.M108815200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11805092	hybrid			2022-12-27	WOS:000175036300059
J	Ishido, K; Takagaki, K; Iwafune, M; Yoshihara, S; Sasaki, M; Endo, M				Ishido, K; Takagaki, K; Iwafune, M; Yoshihara, S; Sasaki, M; Endo, M			Enzymatic attachment of glycosaminoglycan chain to peptide using the sugar chain transfer reaction with endo-beta-xylosidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGLYCOSYLATION ACTIVITY; CHEMOENZYMATIC SYNTHESIS; N-ACETYLGLUCOSAMINIDASE; DERMATAN SULFATE; OLIGOSACCHARIDES; RECONSTRUCTION; HYALURONIDASE; 2-AMINOPYRIDINE; HEXASACCHARIDE; GALACTOSIDASE	Endo-beta-xylosidase from the mid-gut gland of the molluscus Patinopecten is an endo-type glycosidase that hydrolyzes the xylosyl serine linkage between a core protein and a glycosaminoglycan (GAG) chain, releasing the intact GAG chain from proteoglycan. In this study, we investigated GAG chain transfer activity of this enzyme, in order to develop a method for attaching GAG chains to peptide. Peptidochondroitin sulfate (molecular mass of sugar chain, 30 kDa) from bovine tracheal cartilage as a donor and butyloxycarbonyl-leucyl-seryl-threonyl-arginine-(4-methylcoumaryl-7-amide) as an acceptor were incubated with endo-beta-xylosidase. As a result, a reaction product with the same fluorescence as the acceptor peptide was observed. High pressure liquid chromatography analysis, cellulose acetate membrane electrophoresis, and enzymatic digestion showed that this reaction product had the chondroitin sulfate (ChS) from the donor. Furthermore, the acceptor peptide was released from this reaction product after hydrolysis by endo-beta-xylosidase. Therefore, it was confirmed that the ChS chain released from the donor was transferred to the acceptor peptide by the GAG chain transfer reaction of endo-beta-xylosidase. The optimal pH for hydrolysis by this enzyme was found to be about 4.0, whereas that for this reaction was about 3.0. Not only the ChS but also the dermatan sulfate and the heparan sulfate were transferred to the acceptor peptide by this reaction. By using this reaction, the GAG chain could be attached to the peptide in one step. The GAG chain transfer reaction of endo-beta-xylosidase should be a significant glycotechnological tool for the artificial synthesis of proteoglycan.	Hirosaki Univ, Sch Med, Dept Biochem, Hirosaki, Aomori 0368562, Japan; Hirosaki Univ, Sch Med, Dept Surg 2, Hirosaki, Aomori 0368562, Japan	Hirosaki University; Hirosaki University	Endo, M (corresponding author), Hirosaki Univ, Sch Med, Dept Biochem, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.	endo-m@cc.hirosaki-u.ac.jp						Ajisaka K, 2001, BIOSCI BIOTECH BIOCH, V65, P1240, DOI 10.1271/bbb.65.1240; Ashida H, 2000, ARCH BIOCHEM BIOPHYS, V373, P394, DOI 10.1006/abbi.1999.1565; BARDALES RM, 1989, J BIOL CHEM, V264, P19893; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; DISTLER JJ, 1973, J BIOL CHEM, V248, P6772; Haneda K, 1998, BIOORG MED CHEM LETT, V8, P1303, DOI 10.1016/S0960-894X(98)00209-1; Hascall V.C., 1981, CELL BIOL EXTRACELLU, P39; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; HIROSE S, 1982, J BIOL CHEM, V257, P6316; HOVINGH P, 1974, CARBOHYD RES, V37, P181, DOI 10.1016/S0008-6215(00)87073-1; Kanayama N, 1997, BIOCHEM BIOPH RES CO, V238, P560, DOI 10.1006/bbrc.1997.7344; KANTOR TG, 1957, J AM CHEM SOC, V79, P152, DOI 10.1021/ja01558a040; KON A, 1991, J BIOCHEM-TOKYO, V110, P132, DOI 10.1093/oxfordjournals.jbchem.a123531; LI YT, 1991, J BIOL CHEM, V266, P10723; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MATHEWS MB, 1968, BIOCHIM BIOPHYS ACTA, V156, P419, DOI 10.1016/0304-4165(68)90277-8; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; NAKAMURA T, 1990, J BIOL CHEM, V265, P5390; OHNO Y, 1981, J BIOCHEM, V90, P1387, DOI 10.1093/oxfordjournals.jbchem.a133604; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; SAITOH H, 1995, J BIOL CHEM, V270, P3741, DOI 10.1074/jbc.270.8.3741; Silbert JE, 1995, BBA-REV BIOMEMBRANES, V1241, P371, DOI 10.1016/0304-4157(95)00011-9; Simonovic SP, 2000, WATER INT, V25, P1, DOI 10.1080/02508060008686792; Takagaki K, 1999, BIOCHEM BIOPH RES CO, V258, P741, DOI 10.1006/bbrc.1999.0697; TAKAGAKI K, 1992, GLYCOCONJUGATE J, V9, P174, DOI 10.1007/BF00731162; Takagaki K, 2000, BIOCHEM BIOPH RES CO, V270, P588, DOI 10.1006/bbrc.2000.2452; TAKAGAKI K, 1992, J BIOL CHEM, V267, P18558; TAKAGAKI K, 1990, J BIOL CHEM, V265, P854; TAKAGAKI K, 1988, J BIOL CHEM, V263, P7000; Takagaki K, 2000, TRENDS GLYCOSCI GLYC, V12, P295, DOI 10.4052/tigg.12.295; TAKAGAKI K, 1990, J BIOCHEM BIOPH METH, V21, P209, DOI 10.1016/0165-022X(90)90014-4; Takagaki K, 2000, J BIOCHEM, V127, P695, DOI 10.1093/oxfordjournals.jbchem.a022659; TAKEGAWA K, 1995, J BIOL CHEM, V270, P3094, DOI 10.1074/jbc.270.7.3094; TRIMBLE RB, 1986, J BIOL CHEM, V261, P2000; WEISSMANN B, 1954, J AM CHEM SOC, V76, P1753, DOI 10.1021/ja01636a010; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; Yamamoto K, 1997, CARBOHYD RES, V305, P415, DOI 10.1016/S0008-6215(97)10018-0; Yamamoto K, 1997, TRENDS GLYCOSCI GLYC, V9, P339, DOI 10.4052/tigg.9.339	40	8	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11889	11895		10.1074/jbc.M112183200	http://dx.doi.org/10.1074/jbc.M112183200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805117	hybrid			2022-12-27	WOS:000174846400038
J	Jo, M; Thomas, KS; Somlyo, AV; Somlyo, AP; Gonias, SL				Jo, M; Thomas, KS; Somlyo, AV; Somlyo, AP; Gonias, SL			Cooperativity between the Ras-ERK and Rho-Rho kinase pathways in urokinase-type plasminogen activator-stimulated cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; FOCAL ADHESION KINASE; RECEPTOR; MOTILITY; CYTOSKELETON; GTPASES; PHOSPHORYLATION; PROLIFERATION; DISSEMINATION; DOWNSTREAM	Binding of the urokinase-type plasminogen activator (uPA) to its receptor activates diverse cell signaling pathways. How these signals are integrated so that cell physiology is altered remains unclear. In this study, we demonstrated that migration of MCF-7 breast cancer cells and HT-1080 fibrosarcoma cells on serum-coated surfaces is stimulated by agents that activate ERK, including uPA, epidermal growth factor, and constitutively active MEK1. The promigratory activity of these agents was entirely blocked not only by the MEK-specific antagonist PD098059, but also by antagonists of the Rho-Rho kinase pathway, including Y-27632 and dominant-negative RhoA (RhoA-N19). uPA did not significantly increase the level of GTP-bound RhoA, suggesting that the constitutive activity of the Rho-Rho kinase pathway may be sufficient to support ERK-stimulated cell migration. Paradoxically, Y-27632 and RhoA-N19 increased ERK phosphorylation in MCF-7 cells, providing further evidence that ERK activation alone does not promote cell migration when Rho kinase is antagonized. When MCF-7 cell migration was stimulated by ERK-independent processes such as expression of the beta(3) integrin subunit or changing the substratum to type I collagen, Y-27632 and RhoA-N19 failed to inhibit the response. This study supports a model in which the Ras-ERK and Rho-Rho kinase pathways cooperate to promote cell migration. Neutralizing either pathway is sufficient to block the response to agents that stimulate cell migration by activating ERK.	Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Gonias, SL (corresponding author), Univ Virginia, Sch Med, Dept Pathol, POB 800214, Charlottesville, VA 22908 USA.	slg2t@virginia.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060551, P01HL019242, P01HL048807] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL-19242, R01 HL-60551, P0 HL-48807] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Chapman HA, 1999, THROMB HAEMOSTASIS, V82, P291; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; Dumler I, 1999, CURR BIOL, V9, P1468, DOI 10.1016/S0960-9822(00)80116-5; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; Filardo EJ, 1996, J CELL SCI, V109, P1615; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kanse SM, 1997, ARTERIOSCL THROM VAS, V17, P2848, DOI 10.1161/01.ATV.17.11.2848; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Konakova M, 1998, EUR J BIOCHEM, V253, P421, DOI 10.1046/j.1432-1327.1998.2530421.x; Kusch A, 2000, J BIOL CHEM, V275, P39466, DOI 10.1074/jbc.M003626200; Leng J, 1999, J BIOL CHEM, V274, P37855, DOI 10.1074/jbc.274.53.37855; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; Ma Z, 2001, J CELL SCI, V114, P3387; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; PLOUG M, 1991, J BIOL CHEM, V266, P1926; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; TAKAISHI K, 1994, ONCOGENE, V9, P273; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; Webb DJ, 2001, J CELL BIOL, V152, P741, DOI 10.1083/jcb.152.4.741; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146	47	88	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12479	12485		10.1074/jbc.M111147200	http://dx.doi.org/10.1074/jbc.M111147200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805108	hybrid			2022-12-27	WOS:000174846400115
J	Arthos, J; Cicala, C; Steenbeke, TD; Chun, TW; Cruz, CD; Hanback, DB; Khazanie, P; Nam, D; Schuck, P; Selig, SM; Van Ryk, D; Chaikin, MA; Fauci, AS				Arthos, J; Cicala, C; Steenbeke, TD; Chun, TW; Cruz, CD; Hanback, DB; Khazanie, P; Nam, D; Schuck, P; Selig, SM; Van Ryk, D; Chaikin, MA; Fauci, AS			Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein - Implications for therapeutic and vaccine strategies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RECOMBINANT SOLUBLE CD4; T-CELL LINE; CONFORMATIONAL-CHANGES; PEPTIDE INHIBITOR; HIV; BINDING; GP120; INFECTION; NEUTRALIZATION	Drug toxicities associated with HAART lend urgency to the development of new anti-HIV therapies. Inhibition of viral replication at the entry stage of the viral life cycle is an attractive strategy because it prevents de novo infection. Soluble CD4 (sCD4), the first drug in this class, failed to suppress viral replication in vivo. At least three factors contributed to this failure: sCD4 demonstrated poor neutralizing activity against most primary isolates of HIV in vitro; it demonstrated an intrinsic capacity to enhance viral replication at low concentrations; and it exhibited a relatively short half-life in vivo. Many anti-gp120 monoclonal antibodies, including neutralizing monoclonal antibodies also enhance viral replication at suboptimal concentrations. Advances in our understanding of the events leading up to viral entry suggest strategies by which this activity can be diminished. We hypothesized that by constructing a sCD4-based molecule that is large, binds multiple gp120s simultaneously, and is highly avid toward gp120, we could remove its capacity to enhance viral entry. Here we describe the construction of a polymeric CD4-IgG1 fusion protein. The hydrodynamic radius of this molecule is similar to12 nM. It can bind at least 10 gp120 subunits with binding kinetics that suggest a highly avid interaction toward virion-associated envelope. This protein does not enhance viral replication at suboptimal concentrations. These observations may aid in the design of new therapeutics and vaccines.	NIAID, Lab Immunoregulat, Bethesda, MD 20892 USA; Mol Interact Resource Div Bioengn & Phys Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA	Arthos, J (corresponding author), 10 Ctr Dr MSC 1876 Bldg 10 Rm 6A08, Bethesda, MD 20892 USA.		Chun, Tae-Wook/AAC-3101-2020; Schuck, Peter/AAA-6888-2020; Chun, Tae-Wook/W-9187-2019	Schuck, Peter/0000-0002-8859-6966; Chun, Tae-Wook/0000-0001-5153-7340; Khazanie, Prateeti/0000-0001-8959-1609	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000883, ZIAAI000883] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [Z01OD010485] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ALLAN JS, 1990, SCIENCE, V247, P1084, DOI 10.1126/science.2309120; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P7056, DOI 10.1073/pnas.88.16.7056; Berrey MM, 2001, J INFECT DIS, V183, P1466, DOI 10.1086/320189; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHAIKIN M, 1997, AM AC ALL ASTHM IMM; Chun TW, 1997, J VIROL, V71, P4436, DOI 10.1128/JVI.71.6.4436-4444.1997; CLAPHAM PR, 1992, J VIROL, V66, P3531, DOI 10.1128/JVI.66.6.3531-3537.1992; D'Souza MP, 2000, JAMA-J AM MED ASSOC, V284, P215, DOI 10.1001/jama.284.2.215; DAVIS CB, 1992, DRUG METAB DISPOS, V20, P695; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; Doranz BJ, 1999, J VIROL, V73, P10346, DOI 10.1128/JVI.73.12.10346-10358.1999; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FOLKS T, 1986, SCIENCE, V231, P600, DOI 10.1126/science.3003906; Forster MJ, 2000, J MOL BIOL, V298, P841, DOI 10.1006/jmbi.2000.3715; Gao F, 1996, J VIROL, V70, P1651, DOI 10.1128/JVI.70.3.1651-1667.1996; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; Jacobson JM, 2000, J INFECT DIS, V182, P326, DOI 10.1086/315698; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Laue T.M., 1992, COMPUTER AIDED INTER; LAYNE SP, 1990, NATURE, V346, P277, DOI 10.1038/346277a0; LIVESEY AK, 1986, J CHEM PHYS, V84, P5102, DOI 10.1063/1.450663; MOORE J, 1995, MICROW OPT TECHN LET, V9, P17, DOI 10.1002/mop.4650090108; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; ORLOFF SL, 1993, J VIROL, V67, P1461, DOI 10.1128/JVI.67.3.1461-1471.1993; OZEL M, 1988, ARCH VIROL, V100, P255, DOI 10.1007/BF01487688; Poignard P, 2001, ANNU REV IMMUNOL, V19, P253, DOI 10.1146/annurev.immunol.19.1.253; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOOLEY RT, 1990, ANN INTERN MED, V112, P247, DOI 10.7326/0003-4819-112-4-247; Schuck P, 1999, BIOPHYS J, V76, P2288, DOI 10.1016/S0006-3495(99)77384-4; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SCHUTTEN M, 1995, SCAND J IMMUNOL, V41, P18, DOI 10.1111/j.1365-3083.1995.tb03528.x; Sorensen V, 1999, J IMMUNOL, V162, P3448; Sullivan N, 1998, J VIROL, V72, P4694, DOI 10.1128/JVI.72.6.4694-4703.1998; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; Svedberg T, 1940, THE ULTRACENTRIFUGE; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; WERNER A, 1990, J VIROL, V64, P6252, DOI 10.1128/JVI.64.12.6252-6256.1990; Wiersma EJ, 1997, J IMMUNOL, V158, P1719; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILLEY RL, 1994, J VIROL, V68, P1029, DOI 10.1128/JVI.68.2.1029-1039.1994; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Zhang WT, 1999, BIOCHEMISTRY-US, V38, P9405, DOI 10.1021/bi990654o; Zhu P, 2001, J VIROL, V75, P6682, DOI 10.1128/JVI.75.14.6682-6686.2001	51	68	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11456	11464		10.1074/jbc.M111191200	http://dx.doi.org/10.1074/jbc.M111191200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11805109	hybrid			2022-12-27	WOS:000174613100090
J	Condorelli, G; Trencia, A; Vigliotta, G; Perfetti, A; Goglia, U; Cassese, A; Musti, AM; Miele, C; Santopietro, S; Formisano, P; Beguinot, F				Condorelli, G; Trencia, A; Vigliotta, G; Perfetti, A; Goglia, U; Cassese, A; Musti, AM; Miele, C; Santopietro, S; Formisano, P; Beguinot, F			Multiple members of the mitogen-activated protein kinase family are necessary for PED/PEA-15 anti-apoptotic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; C-JUN; SIGNAL-TRANSDUCTION; PEA-15; DEATH; JNK; CELLS; ERK; PHOSPHORYLATION; CDC42	293 kidney embryonic cells feature very low levels of the anti-apoptotic protein PED. In these cells, expression of PED to levels comparable with those occurring in normal adult cells inhibits apoptosis induced by growth factor deprivation and by exposure to H2O2 or anisomycin. In PED-expressing 293 cells (293(PED)), inhibition of apoptosis upon growth factor deprivation was paralleled by decreased phosphorylation of JNK1/2. In 293PED cells, decreased apoptosis induced by anisomycin and H2O2 was also accompanied by block of JNK1/2 and p38 phosphorylations, respectively. Impaired activity of these stress kinases by PED correlated with inhibition of stress-induced Cdc-42, MKK4, and MKK6 activation. At variance with JNK1/2 and p38, PED expression increased basal and growth factor-stimulated Ras-Raf-1 co-precipitation and MAPK phosphorylation and activity. Treatment of 293PED cells with the MEK inhibitor PD98059 blocked ERK1/2 phosphorylations with no effect on inhibition of JNK1/2 and p38 activities. Complete rescue of JNK and p38 functions in 293PED cells by overexpressing JNK1 or p38, respectively, enabled only partial recovery of apoptotic response to growth factor deprivation and anisomycin. However, simultaneous rescue of JNK and p38 activities accompanied by block of ERK1/2 fully restored these responses. Thus, PED controls activity of the ERK, JNK, and p38 subfamilies of MAPKs. PED anti-apoptotic function in the 293 cells requires PED simultaneous activation of ERK1/2 and inhibition of the JNK/p38 signaling systems by PED.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples Federico II, Consiglio Nazl Ric, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Calabria, Dipartimento Farmacobiol, I-87040 Arcavacata Di Rende, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Calabria	Beguinot, F (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.	beguino@unina.it	Musti, Anna Maria/M-2520-2019; Vigliotta, Giovanni/GPF-7237-2022; Formisano, Pietro/J-4237-2018; Condorelli, Gerolama/AAC-3472-2022; vigliotta, giovanni/AAW-6401-2020	Condorelli, Gerolama/0000-0003-0177-8829; vigliotta, giovanni/0000-0001-5132-0037; Formisano, Pietro/0000-0001-7020-6870; MUSTI, Anna Maria/0000-0003-1443-2739	Telethon [E.0896] Funding Source: Medline	Telethon(Fondazione Telethon)		ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Donath MY, 1999, DIABETES, V48, P738, DOI 10.2337/diabetes.48.4.738; Formisano P, 2000, MOL CELL BIOL, V20, P6323, DOI 10.1128/MCB.20.17.6323-6333.2000; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Huang Y, 2000, J BIOL CHEM, V275, P18234, DOI 10.1074/jbc.M909431199; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ishikawa Y, 1999, BIOCHEM BIOPH RES CO, V264, P696, DOI 10.1006/bbrc.1999.1542; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kitsberg D, 1999, J NEUROSCI, V19, P8244; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LALLEMAIN G, 1992, MOL CELL BIOL, V12, P2222, DOI 10.1128/MCB.12.5.2222; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lerm M, 1999, INFECT IMMUN, V67, P496, DOI 10.1128/IAI.67.2.496-503.1999; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Ramos JW, 2000, MOL BIOL CELL, V11, P2863, DOI 10.1091/mbc.11.9.2863; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Shan RJ, 1999, BLOOD, V94, P4067, DOI 10.1182/blood.V94.12.4067.424k12_4067_4076; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	28	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11013	11018		10.1074/jbc.M110934200	http://dx.doi.org/10.1074/jbc.M110934200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11790785	hybrid			2022-12-27	WOS:000174613100034
J	Gu, YS; Parker, A; Wilson, TM; Bai, HB; Chang, DY; Lu, AL				Gu, YS; Parker, A; Wilson, TM; Bai, HB; Chang, DY; Lu, AL			Human MutY homolog, a DNA glycosylase involved in base excision repair, physically and functionally interacts with mismatch repair proteins human MutS homolog 2/human MutS homolog 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; SUBCELLULAR-LOCALIZATION; ATPASE ACTIVITY; COUPLED REPAIR; HMYH; EXPRESSION; ENZYME; PCNA; RECOGNITION; CLONING	Adenines mismatched with guanines or 7,8-dihydro-8oxo-deoxyguanines that arise through DNA replication errors can be repaired by either base excision repair or mismatch repair. The human MutY homolog (hMYH), a DNA glycosylase, removes adenines from these mis matches. Human MutS homologs, hMSH2/hMSH6 (bMutSalpha), bind to the mismatches and initiate the repair on the daughter DNA strands. Human MYH is physically associated with hMSH2/bMSH6 via the hMSH6 subunit. The interaction of bMutSa and hMYH is not observed in several mismatch repair-defective cell lines. The hMutSalpha binding site is mapped to amino acid residues 232-254 of hMYH, a region conserved in the MutY family. Moreover, the binding and glycosylase activities of hMYH with an A/7,8-dihydro-S-oxo-deoxyguanine mismatch are enhanced by hMutSa. These results suggest that protein-protein interactions may be a means by which hMYH repair and mismatch repair cooperate in reducing replicative errors caused by oxidized bases.	Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Dept Radiat Oncol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Lu, AL (corresponding author), Univ Maryland, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	aluchang@umaryland.edu	Gu, Jason/AAG-8178-2021; Gu, Yesong/U-9802-2019	Gu, Jason/0000-0001-8278-6227; 	NCI NIH HHS [CA/ES78391] Funding Source: Medline; NIGMS NIH HHS [GM35132] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA078391, R01CA078391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035132] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames B.N., 1993, DNA FREE RADICALS, P1; AU KG, 1992, J BIOL CHEM, V267, P12142; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Boldogh I, 2001, NUCLEIC ACIDS RES, V29, P2802, DOI 10.1093/nar/29.13.2802; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; BOYER JC, 1995, CANCER RES, V55, P6063; Chang DK, 2000, J BIOL CHEM, V275, P18424, DOI 10.1074/jbc.M001140200; CHENG KC, 1992, J BIOL CHEM, V267, P166; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; DeWeese TL, 1998, P NATL ACAD SCI USA, V95, P11915, DOI 10.1073/pnas.95.20.11915; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Gu YS, 2001, NUCLEIC ACIDS RES, V29, P2666, DOI 10.1093/nar/29.12.2666; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Hampson R, 1997, J BIOL CHEM, V272, P28596, DOI 10.1074/jbc.272.45.28596; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Kolodner Richard D., 1994, Current Opinion in Biotechnology, V5, P585, DOI 10.1016/0958-1669(94)90079-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leadon SA, 1997, CANCER RES, V57, P3784; Lu AL, 1998, J BIOL CHEM, V273, P25098, DOI 10.1074/jbc.273.39.25098; Lu AL, 2000, METH MOL B, V152, P3; LU AL, 1998, DNA REPAIR HIGHER EU; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; McLennan AG, 1999, INT J MOL MED, V4, P79; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; Ni TT, 1999, MOL CELL, V4, P439, DOI 10.1016/S1097-2765(00)80346-9; Ohtsubo T, 2000, NUCLEIC ACIDS RES, V28, P1355, DOI 10.1093/nar/28.6.1355; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Parker A, 2000, NUCLEIC ACIDS RES, V28, P3206, DOI 10.1093/nar/28.17.3206; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Shinmura K, 1997, MUTAT RES-DNA REPAIR, V385, P75, DOI 10.1016/S0921-8777(97)00041-4; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; Slupska MM, 1999, J BACTERIOL, V181, P6210, DOI 10.1128/JB.181.19.6210-6213.1999; Takao M, 1999, NUCLEIC ACIDS RES, V27, P3638, DOI 10.1093/nar/27.18.3638; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; Tomita-Mitchell A, 2000, MUTAT RES-FUND MOL M, V450, P125, DOI 10.1016/S0027-5107(00)00020-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Wang Y, 2000, GENE DEV, V14, P927; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Wilson T, 1999, J BIOL CHEM, V274, P21659, DOI 10.1074/jbc.274.31.21659; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P743, DOI 10.1093/nar/29.3.743; YEH YC, 1991, J BIOL CHEM, V266, P6480	67	164	172	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11135	11142		10.1074/jbc.M108618200	http://dx.doi.org/10.1074/jbc.M108618200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801590	hybrid			2022-12-27	WOS:000174613100050
J	Mei, FC; Qiao, JB; Tsygankova, OM; Meinkoth, JL; Quilliam, LA; Cheng, XD				Mei, FC; Qiao, JB; Tsygankova, OM; Meinkoth, JL; Quilliam, LA; Cheng, XD			Differential signaling of cyclic AMP - Opposing effects of exchange protein directly activated by cyclic AMP and cAMP-dependent protein kinase on protein kinase B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT; LYMPHOID-CELLS; PHOSPHORYLATION; PATHWAY; BINDING; RAP1; INHIBITION; 3-KINASE; CASCADE; FAMILY	The recent discovery of Epac, a novel cAMP receptor protein, opens up a new dimension in studying cAMP-mediated cell signaling. It is conceivable that many of the cAMP functions previously attributed to cAMP-dependent protein kinase (PKA) are in fact also Epac-dependent. The finding of an additional intracellular cAMP receptor provides an opportunity to further dissect the divergent roles that cAMP exerts in different cell types. In this study, we probed cross-talk between cAMP signaling and the phosphatidylinositol 3-kinase/PKB pathways. Specifically, we examined the modulatory effects of cAMP on PKB activity by monitoring the specific roles that Epac and PKA play individually in regulating PKB activity. Our study suggests a complex regulatory scheme in which Epac and PKA mediate the opposing effects of cAMP on PKB regulation. Activation of Epac leads to a phosphatidylinositol 3-kinase-dependent PKB activation, while stimulation of PKA inhibits PKB activity. Furthermore, activation of PKB by Epac requires the proper subcellular targeting of Epac. The opposing effects of Epac and PKA on PKB activation provide a potential mechanism for the cell type-specific differential effects of cAMP. It is proposed that the net outcome of cAMP signaling is dependent upon the dynamic abundance and distribution of intracellular Epac and PKA.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sch Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Sch Med, Galveston, TX 77555 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Pennsylvania; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis	Cheng, XD (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sch Med, 301 Univ Blvd, Galveston, TX 77555 USA.	xcheng@utmb.edu	Cheng, Xiaodong/O-8176-2019; Quilliam, Lawrence/B-6447-2015; Meinkoth, Judy L/G-2900-2010; Quilliam, Lawrence/Q-4987-2019	Cheng, Xiaodong/0000-0002-3479-1694; 	NIEHS NIH HHS [ES06676] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; BUBIS J, 1988, J BIOL CHEM, V263, P9668; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; David M, 1996, J BIOL CHEM, V271, P4585; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DeBernardi MA, 1996, P NATL ACAD SCI USA, V93, P4577, DOI 10.1073/pnas.93.10.4577; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Filippa N, 1999, MOL CELL BIOL, V19, P4989; FRODIN M, 1994, J BIOL CHEM, V269, P6207; Gao XL, 2001, J BIOL CHEM, V276, P42219, DOI 10.1074/jbc.M105760200; GRAVE LM, 1990, TRENDS ENDOCRIN MET, V7, P43; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kraemer A, 2001, J MOL BIOL, V306, P1167, DOI 10.1006/jmbi.2001.4444; Medina DL, 2000, EUR J ENDOCRINOL, V143, P161, DOI 10.1530/eje.0.1430161; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; Naderi S, 2000, EUR J IMMUNOL, V30, P1757, DOI 10.1002/1521-4141(200006)30:6<1757::AID-IMMU1757>3.0.CO;2-N; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Posternak T, 1974, Methods Enzymol, V38, P399; PRIZON V, 1998, ONCOGENE, V3, P201; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rogue PJ, 1998, P NATL ACAD SCI USA, V95, P9178, DOI 10.1073/pnas.95.16.9178; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; SHABB JB, 1992, J BIOL CHEM, V267, P5723; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Webster CRL, 1999, AM J PHYSIOL-GASTR L, V277, pG1165, DOI 10.1152/ajpgi.1999.277.6.G1165; WITHERS DJ, 1995, J BIOL CHEM, V270, P21411, DOI 10.1074/jbc.270.36.21411; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171	51	239	243	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11497	11504		10.1074/jbc.M110856200	http://dx.doi.org/10.1074/jbc.M110856200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801596	hybrid			2022-12-27	WOS:000174613100095
J	D'Souza, SJA; Vespa, A; Murkherjee, S; Maher, A; Pajak, A; Dagnino, L				D'Souza, SJA; Vespa, A; Murkherjee, S; Maher, A; Pajak, A; Dagnino, L			E2F-1 is essential for normal epidermal wound repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; EXPRESSION PATTERNS; NATRIURETIC PEPTIDE; INTEGRIN EXPRESSION; DNA-REPLICATION; GROWTH-FACTOR; MICE; CELLS; KERATINOCYTES; PATHWAY	E2F factors are involved in proliferation and apoptosis. To understand the role of E2F-1 in the epidermis, we screened wild type and E2F-1(-/-) keratinocyte mRNA for genes differentially expressed in the two cell populations. We demonstrate the reduced expression of integrins alpha(5), alpha(6), beta(1), and beta(4) in E2F-1(-/-) keratinocytes associated with reduced activation of Jun terminal kinase and Erk upon integrin stimulation. As a consequence of altered integrin expression and function, E2F-1(-/-) keratinocytes also show impaired migration, adhesion to extracellular matrix proteins, and a blunted chemotactic response to transforming growth factor-gamma1. E2F-1(-/-)keratinocytes, but not dermal fibroblasts, exhibit altered patterns of proliferation, including significant delays in transit through both G(1) and S phases of the cell cycle. Recognizing that proliferation and migration are key for proper wound healing in vivo, we postulated that E2F-1(-/-) mice may exhibit abnormal epidermal repair upon injury. Consistent with our hypothesis, E2F-1(-/-) mice exhibited impaired cutaneous wound healing. This defect is associated with substantially reduced local inflammatory responses and rates of reepithelialization. Thus, we demonstrate that E2F-1 is indispensable for a hitherto unidentified cell type-specific and unique role in keratinocyte proliferation, adhesion, and migration as well as in proper wound repair and epidermal regeneration in vivo.	Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 5C1, Canada; Univ Western Ontario, Child Hlth Res Inst, London, ON N6A 5C1, Canada; Univ Western Ontario, Lawson Hlth Res Inst, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Dagnino, L (corresponding author), Univ Western Ontario, Dept Pharmacol & Toxicol, Med Sci Bldg, London, ON N6A 5C1, Canada.	ldagnino@uwo.ca		Dagnino, Lina/0000-0003-1483-5159				ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; Ashcroft GS, 2000, NAT MED, V6, P1147, DOI 10.1038/80489; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Cayirlioglu P, 2001, CURR BIOL, V11, pR178, DOI 10.1016/S0960-9822(01)00088-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; D'Souza SJA, 2001, J BIOL CHEM, V276, P23531, DOI 10.1074/jbc.M100780200; Dagnino L, 1997, MECH DEVELOP, V66, P13, DOI 10.1016/S0925-4773(97)00083-X; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; DAGNINO L, 1991, MOL ENDOCRINOL, V5, P1292, DOI 10.1210/mend-5-9-1292; DAGNINO L, 1992, HYPERTENSION, V20, P690, DOI 10.1161/01.HYP.20.5.690; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Duncan MK, 2000, J CELL SCI, V113, P3173; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fuchs E, 1994, Princess Takamatsu Symp, V24, P290; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Haase I, 2001, J CLIN INVEST, V108, P527, DOI 10.1172/JCI200112153; HERTLE MD, 1991, DEVELOPMENT, V112, P193; HERTLE MD, 1995, J INVEST DERMATOL, V104, P260, DOI 10.1111/1523-1747.ep12612801; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; Koivisto L, 1999, CELL ADHES COMMUN, V7, P245, DOI 10.3109/15419069909010806; Laurikainen L, 1996, ARCH DERMATOL RES, V288, P270; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Myster DL, 2000, DEVELOPMENT, V127, P3249; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Onishi T, 2001, BBA-MOL CELL RES, V1538, P218, DOI 10.1016/S0167-4889(01)00068-4; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Suzuki A, 2000, MOL CELL, V5, P217, DOI 10.1016/S1097-2765(00)80418-9; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728	44	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10626	10632		10.1074/jbc.M111956200	http://dx.doi.org/10.1074/jbc.M111956200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11790795	hybrid			2022-12-27	WOS:000174549200133
J	Mohrmann, K; Leijendekker, R; Gerez, L; van der Sluijs, P				Mohrmann, K; Leijendekker, R; Gerez, L; van der Sluijs, P			rab4 regulates transport to the apical plasma membrane in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED TRANSCYTOSIS; POLARIZED EPITHELIAL-CELLS; MDCK CELLS; RECYCLING ENDOSOMES; BREFELDIN-A; TRANSFERRIN RECEPTOR; GAMMA-ADAPTIN; DISTINCT; PROTEIN; PATHWAY	The small GTPase rab4 is associated with early endosomes and regulates membrane recycling in fibroblasts. rab4 is present in epithelial cells; however, neither its localization nor function has been established in this cell type. We transfected Madin-Darby canine kidney cells with rab4, the GTPase-deficient mutant rab4Q67L, and the dominant negative mutant rab4S22N that poorly binds guanine nucleotides. Confocal immunofluorescence microscopy showed that rab4 was concentrated on internal structures at the lateral side of the cell around the nucleus. Quantitative immunoelectron microscopy revealed that the majority of rab4 was localized in the upper third of the cytoplasm. In cell surface binding experiments with I-125-transferrin, we found a redistribution of transferrin receptor from the basolateral to the apical plasma membrane in cells expressing rab4 and rab4Q67L. After accumulation of transferrin at 16 degreesC in basolateral early endosomes, rab4 and rab4Q67L increased the amount of apically targeted transferrin receptor. A qualitatively similar effect was obtained in control cells treated with brefeldin A. The effects of brefeldin A and rab4 on apical targeting of transferrin receptor were not additive, suggesting that brefeldin A and rab4 may act in the same transport pathway from common endosomes.	Univ Utrecht, Sch Med, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Sch Med, Inst Biomembranes, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University	van der Sluijs, P (corresponding author), Univ Utrecht, Sch Med, Dept Cell Biol, AZU Rm G02 525 Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	pvander@knoware.nl						Apodaca G, 2001, TRAFFIC, V2, P149, DOI 10.1034/j.1600-0854.2001.020301.x; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; Bottger G, 1996, J BIOL CHEM, V271, P29191, DOI 10.1074/jbc.271.46.29191; Brown PS, 2000, TRAFFIC, V1, P124, DOI 10.1034/j.1600-0854.2000.010205.x; BUCCI C, 1994, P NATL ACAD SCI USA, V91, P5061, DOI 10.1073/pnas.91.11.5061; Casanova JE, 1999, MOL BIOL CELL, V10, P47, DOI 10.1091/mbc.10.1.47; Chavrier P, 1997, CYTOMETRY, V29, P41, DOI 10.1002/(SICI)1097-0320(19970901)29:1<41::AID-CYTO4>3.0.CO;2-G; Clift-O'Grady L, 1998, METHODS, V16, P150, DOI 10.1006/meth.1998.0662; DAMKE H, 1991, J BIOL CHEM, V266, P24829; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; de Wit H, 1999, MOL BIOL CELL, V10, P4163, DOI 10.1091/mbc.10.12.4163; de Wit H, 2001, MOL BIOL CELL, V12, P3703, DOI 10.1091/mbc.12.11.3703; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; Gagescu R, 2000, MOL BIOL CELL, V11, P2775, DOI 10.1091/mbc.11.8.2775; Gerez L, 2000, MOL BIOL CELL, V11, P2201, DOI 10.1091/mbc.11.7.2201; Gibson A, 1998, J CELL BIOL, V143, P81, DOI 10.1083/jcb.143.1.81; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Hunziker W, 1998, J BIOL CHEM, V273, P15734, DOI 10.1074/jbc.273.25.15734; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; MARTYS JL, 1995, J BIOL CHEM, V270, P25976, DOI 10.1074/jbc.270.43.25976; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Nagelkerken B, 2000, BIOCHEM J, V346, P593, DOI 10.1042/0264-6021:3460593; Nagelkerken B, 1997, ELECTROPHORESIS, V18, P2694, DOI 10.1002/elps.1150181427; Odorizzi G, 1996, J CELL BIOL, V135, P139, DOI 10.1083/jcb.135.1.139; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960-9822(01)00442-0; SCHONHORN JE, 1994, MOL CELL BIOCHEM, V135, P159, DOI 10.1007/BF00926519; Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Sprong H, 1998, J BIOL CHEM, V273, P25880, DOI 10.1074/jbc.273.40.25880; STAUBLI W, 1969, J CELL BIOL, V42, P92, DOI 10.1083/jcb.42.1.92; Tuma PL, 2001, J CELL BIOL, V154, P1197, DOI 10.1083/jcb.200105138; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1992, EMBO J, V11, P4379, DOI 10.1002/j.1460-2075.1992.tb05538.x; Verges M, 1999, P NATL ACAD SCI USA, V96, P10146, DOI 10.1073/pnas.96.18.10146; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; Wang EI, 2000, TRAFFIC, V1, P480, DOI 10.1034/j.1600-0854.2000.010606.x; Wang EX, 2001, J CELL SCI, V114, P3309; Wang XY, 2000, J BIOL CHEM, V275, P29138, DOI 10.1074/jbc.M004410200; WEIBEL ER, 1969, J CELL BIOL, V42, P68, DOI 10.1083/jcb.42.1.68; Wilson JM, 2000, MOL BIOL CELL, V11, P2657, DOI 10.1091/mbc.11.8.2657; Zacchi P, 1998, J CELL BIOL, V140, P1039, DOI 10.1083/jcb.140.5.1039	50	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10474	10481		10.1074/jbc.M111237200	http://dx.doi.org/10.1074/jbc.M111237200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11790789	hybrid			2022-12-27	WOS:000174549200115
J	Werner, ER; Bahrami, S; Heller, R; Werner-Felmayer, G				Werner, ER; Bahrami, S; Heller, R; Werner-Felmayer, G			Bacterial lipopolysaccharide down-regulates expression of GTP cyclohydrolase I feedback regulatory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAHYDROBIOPTERIN BIOSYNTHETIC ACTIVITIES; NITRIC-OXIDE SYNTHESIS; PHENYLALANINE; FIBROBLASTS; COMPLEXES; SYNTHASE; CELLS; THP-1; RNA	GTP cyclohydrolase I feedback regulatory protein (GFRP) is a 9.7-kDa protein regulating GTP cyclohydrolase I activity in dependence of tetrahydrobiopterin and phenylalanine concentrations, thus enabling stimulation of tetrahydrobiopterin biosynthesis by phenylalanine to ensure its efficient metabolism by phenylalanine hydroxylase. Here, we were interested in regulation of GFRP expression by proinflammatory cytokines and stimuli, which are known to induce GTP cyclohydrolase I expression. Recombinant human GFRP stimulated recombinant human GTP cyclohydrolase I in the presence of phenylalanine and mediated feedback inhibition by tetrahydrobiopterin. Levels of GFRP mRNA in human myelomonocytoma (THP-1) cells remained unaltered by treatment of cells with interferon-gamma or interleukin-1beta, but were significantly down-regulated by bacterial lipopolysaccharide (LPS, 1 mug/ml), without or with co-treatment by interferon-gamma, which strongly up-regulated GTP cyclohydrolase I expression and activity. GFRP expression was also suppressed in human umbilical vein endothelial cells treated with 1 mug/ml LPS, as well as in rat tissues 7 h post intraperitoneal injection of 10 mg/kg LPS. THP-1 cells stimulated with interferon-gamma alone showed increased pteridine synthesis by addition of phenylalanine to the culture medium. Cells stimulated with interferon-gamma plus LPS, in contrast, showed phenylalanine-independent pteridine synthesis. These results demonstrate that LPS down-regulates expression of GFRP, thus rendering pteridine synthesis independent of metabolic control by phenylalanine.	Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria; Ludwig Boltzmann Inst Expt & Clin Traumatol, A-1200 Vienna, Austria; Univ Jena, Ctr Vasc Biol & Med, D-99089 Erfurt, Germany	University of Innsbruck; Ludwig Boltzmann Institute; Friedrich Schiller University of Jena	Werner, ER (corresponding author), Univ Innsbruck, Inst Med Chem & Biochem, Fritz Pregl Str 3-6, A-6020 Innsbruck, Austria.	ernst.r.werner@uibk.ac.at	Heller, Regine/AAC-9353-2019	Werner-Felmayer, Gabriele/0000-0002-2340-8063; Werner, Ernst R./0000-0003-1948-3391; Bahrami, Soheyl/0000-0002-4563-6251				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Golderer G, 2001, BIOCHEM J, V355, P499, DOI 10.1042/0264-6021:3550499; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; Heller R, 2001, J BIOL CHEM, V276, P40, DOI 10.1074/jbc.M004392200; Kapatos G, 1999, J NEUROCHEM, V72, P669, DOI 10.1046/j.1471-4159.1999.0720669.x; Milstien S, 1996, J BIOL CHEM, V271, P19743, DOI 10.1074/jbc.271.33.19743; Pastor CM, 1996, J BIOL CHEM, V271, P24534, DOI 10.1074/jbc.271.40.24534; Pluss C, 1997, BRIT J PHARMACOL, V122, P534, DOI 10.1038/sj.bjp.0701395; Thony B, 2000, BIOCHEM J, V347, P1, DOI 10.1042/0264-6021:3470001; Werner ER, 1998, P SOC EXP BIOL MED, V219, P171; WERNER ER, 1990, J BIOL CHEM, V265, P3189; Werner ER, 1997, METHOD ENZYMOL, V281, P53; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; Yoneyama T, 2001, PROTEIN SCI, V10, P871, DOI 10.1110/ps.38501; Yoneyama T, 1998, J BIOL CHEM, V273, P20102, DOI 10.1074/jbc.273.32.20102	15	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10129	10133		10.1074/jbc.M107326200	http://dx.doi.org/10.1074/jbc.M107326200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11799107	hybrid			2022-12-27	WOS:000174549200070
J	McGwire, BS; O'Connell, WA; Chang, KP; Engman, DM				McGwire, BS; O'Connell, WA; Chang, KP; Engman, DM			Extracellular release of the glycosylphosphatidylinositol (GPI)-linked Leishmania surface metalloprotease, gp63, is independent of GPI phospholipolysis - Implications for parasite virulence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI; MEMBRANE GLYCOPROTEIN; PROTEINASE GP63; TUMOR INVASION; MACROPHAGES; EXPRESSION; PROMASTIGOTES; AMAZONENSIS; MEXICANA; GLYCOSYLATION	The major zinc metalloprotease of Leishmania (gp63), an important determinant of parasite virulence, is attached to the parasite surface via a glycosylphosphatidylinositol anchor. Here we report the spontaneous release of proteolytically active gp63 from a number of Leishmania isolates, causing cutaneous and visceral disease. To investigate the mechanism(s) of gp63 release, we transfected a gp63-deficient variant of Leishmania amazonensis with constructs expressing gp63 and various mutants thereof. Surprisingly, approximately half of wild type gp63 was found in the culture supernatant 12 h post-synthesis. Biochemical analysis of the extracellular gp63 revealed two forms of the protein, one that is released from the cell surface, and another, that apparently is directly secreted. Release of cell surface gp63 was significantly reduced when the proteolytic activity of the protein was inactivated by site-specific mutagenesis or inhibited by zinc chelation, suggesting that release involves autoproteolysis. The extracellular gp63 does not contain a glycosylphosphatidylinositol moiety or ethanolamine, indicating that phospholipolysis is not involved in the release process. Release of gp63 is also independent of glycosylation. The finding of proteolytically active, extracellular gp63 produced by multiple Leishmania isolates suggests a potential role of the extracellular enzyme in substrate degradation relevant to their survival in both the mammalian host and the insect vector.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Univ Illinois, Coll Med, Infect Dis Sect, Chicago, IL 60612 USA; Finch Univ Hlth Sci Chicago Med Sch, Dept Microbiol & Immunol, N Chicago, IL 60064 USA	Northwestern University; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Chicago Medical School	McGwire, BS (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, Ward 6-140,303 E Chicago Ave, Chicago, IL 60611 USA.		Engman, David/T-6747-2018	Engman, David/0000-0001-5869-9844				ALLEN S, 1995, J BIOL CHEM, V270, P4797, DOI 10.1074/jbc.270.9.4797; Bangs JD, 1997, EMBO J, V16, P4285, DOI 10.1093/emboj/16.14.4285; BOUVIER J, 1990, BIOCHEMISTRY-US, V29, P10113, DOI 10.1021/bi00495a015; BOUVIER J, 1995, METHOD ENZYMOL, V248, P614; Brittingham A, 1999, INFECT IMMUN, V67, P4477, DOI 10.1128/IAI.67.9.4477-4484.1999; BRITTINGHAM A, 1995, J IMMUNOL, V155, P3102; BUTTON LL, 1993, GENE, V134, P75, DOI 10.1016/0378-1119(93)90176-4; CHANG CS, 1986, P NATL ACAD SCI USA, V83, P100, DOI 10.1073/pnas.83.1.100; CHANG CS, 1986, MOL BIOCHEM PARASIT, V18, P197, DOI 10.1016/0166-6851(86)90038-1; CHANG KP, 1976, SCIENCE, V193, P678, DOI 10.1126/science.948742; CHAUDHURI G, 1988, MOL BIOCHEM PARASIT, V27, P43, DOI 10.1016/0166-6851(88)90023-0; CHAUDHURI G, 1989, J BIOL CHEM, V264, P7483; Chen DQ, 2000, INFECT IMMUN, V68, P80, DOI 10.1128/IAI.68.1.80-86.2000; ElSayed NMA, 1997, J BIOL CHEM, V272, P26742, DOI 10.1074/jbc.272.42.26742; FERGUSON MAJ, 1994, PARASITOLOGY, V108, P45; FIELD MC, 1991, J BIOL CHEM, V266, P8392; Garg N, 1997, J BIOL CHEM, V272, P12482, DOI 10.1074/jbc.272.19.12482; Grandgenett PM, 2000, MOL BIOCHEM PARASIT, V110, P409, DOI 10.1016/S0166-6851(00)00275-9; INVERSO JA, 1993, MOL BIOCHEM PARASIT, V57, P47, DOI 10.1016/0166-6851(93)90242-P; IP HS, 1990, MOL BIOCHEM PARASIT, V40, P163, DOI 10.1016/0166-6851(90)90038-N; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495; Joshi PB, 1998, MOL MICROBIOL, V27, P519, DOI 10.1046/j.1365-2958.1998.00689.x; LIU X, 1992, P NATL ACAD SCI USA, V89, P4991, DOI 10.1073/pnas.89.11.4991; LIU X, 1994, MOL BIOCHEM PARASIT, V66, P201, DOI 10.1016/0166-6851(94)90147-3; MACDONALD MH, 1995, BBA-PROTEIN STRUCT M, V1253, P199, DOI 10.1016/0167-4838(95)00155-5; MCGWIRE B, 1994, MOL BIOCHEM PARASIT, V66, P345, DOI 10.1016/0166-6851(94)90160-0; McGwire BS, 1996, J BIOL CHEM, V271, P7903, DOI 10.1074/jbc.271.14.7903; MCKERROW JH, 1993, ANNU REV MICROBIOL, V47, P821, DOI 10.1146/annurev.mi.47.100193.004133; MENSAWILMOT K, 1994, J CELL BIOL, V124, P935, DOI 10.1083/jcb.124.6.935; MENSAWILMOT K, 1994, BRAZ J MED BIOL RES, V27, P177; MENSAWILMOT K, 1990, MOL CELL BIOL, V10, P720, DOI 10.1128/MCB.10.2.720; Morrison CJ, 2000, BIOTECHNOL BIOENG, V68, P407, DOI 10.1002/(SICI)1097-0290(20000520)68:4<407::AID-BIT6>3.0.CO;2-S; Nunes AC, 1996, BRAZ J MED BIOL RES, V29, P1633; Redpath MB, 1998, MOL BIOCHEM PARASIT, V94, P113, DOI 10.1016/S0166-6851(98)00056-5; RIZVI FS, 1988, EUR J IMMUNOL, V18, P473, DOI 10.1002/eji.1830180323; Rolin S, 1996, J BIOL CHEM, V271, P10844, DOI 10.1074/jbc.271.18.10844; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; SOTERIADOU KP, 1992, J BIOL CHEM, V267, P13980; WEBB H, 1994, BRAZ J MED BIOL RES, V27, P349; Weise F, 2000, J CELL SCI, V113, P4587; Yu Q, 2000, GENE DEV, V14, P163; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x; Zheng XL, 1999, J BIOL CHEM, V274, P1596, DOI 10.1074/jbc.274.3.1596; ZIEGELBAUER K, 1993, BIOCHEMISTRY-US, V32, P3737, DOI 10.1021/bi00065a028	45	90	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8802	8809		10.1074/jbc.M109072200	http://dx.doi.org/10.1074/jbc.M109072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11777912	hybrid			2022-12-27	WOS:000174400600009
J	Vanhoose, AM; Emery, M; Jimenez, L; Winder, DG				Vanhoose, AM; Emery, M; Jimenez, L; Winder, DG			ERK activation by G-protein-coupled receptors in mouse brain is receptor identity-specific	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; SIGNAL-REGULATED KINASES; MAP KINASE; FREQUENCY STIMULATION; SEROTONIN RECEPTORS; HIPPOCAMPAL-NEURONS; B-RAF; INHIBITION; CASCADE; CAMP	In transfected cells and non-neuronal tissues many G-protein-coupled receptors activate p44/42 MAP kinase (ERK), a kinase involved in both hippocampal synaptic plasticity and learning and memory. However, it is not clear to what degree these receptors couple to ERK in brain. G.-coupled P-adrenergic receptor activation of ERK in neurons is critical in the regulation of synaptic plasticity in area CA1 of the hippocampus. In addition, alpha(1)- and alpha(2)-adrenergic receptors, present in CA1, could potentially activate ERK. We find that, like the beta-adrenergic receptor, the G(q)-coupled alpha(1)AR activates ERK in adult mouse CA1. However, activation of the G(i/o)-coupled alpha(2)AR does not activate ERK, nor does activation of a homologous G(i/o)-coupled receptor enriched in adult mouse CA1, the 5HT(1A) receptor. In contrast, the nonhomologous G(i/o)-coupled gamma-aminobutyric acid type B receptor does activate ERK in adult mouse CA1. Surprisingly, activation of alpha2ARs in CA1 from immature animals where basal phospho-ERK is low induces ERK phosphorylation. These data suggest that although most G-protein-coupled receptor subtypes activate ERK in non-neuronal cells, the coupling of G(i/o) to ERK is tightly regulated in brain.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Winder, DG (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.	danny.winder@mcmail.vanderbilt.edu	Winder, Danny G./H-4857-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013699] Funding Source: NIH RePORTER; NIDA NIH HHS [DA13699] Funding Source: Medline; NIGMS NIH HHS [T32 GM08554] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JP, 2000, J NEUROCHEM, V75, P2277, DOI 10.1046/j.1471-4159.2000.0752277.x; Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; ANDRADE R, 1987, N-S ARCH PHARMACOL, V336, P5; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Blum S, 1999, J NEUROSCI, V19, P3535; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Boehm S, 1999, J PHYSIOL-LONDON, V519, P439, DOI 10.1111/j.1469-7793.1999.0439m.x; BOULOUMIE A, 1994, J BIOL CHEM, V269, P30254; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CUSSAC D, 2001, AM J PHYSL RENAL PHY; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; FULFORD AJ, 1994, PSYCHOPHARMACOLOGY, V116, P183, DOI 10.1007/BF02245061; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Grewal SS, 2000, J BIOL CHEM, V275, P3722, DOI 10.1074/jbc.275.5.3722; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Katsuki H, 1997, J NEUROPHYSIOL, V77, P3013, DOI 10.1152/jn.1997.77.6.3013; Kribben A, 1997, N-S ARCH PHARMACOL, V356, P225, DOI 10.1007/PL00005045; KURINO M, 1995, J NEUROCHEM, V65, P1282; Li YW, 1998, NEUROSCIENCE, V82, P753; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; MATTHIES H, 1993, NEUROREPORT, V4, P712, DOI 10.1097/00001756-199306000-00028; Milner TA, 1998, J COMP NEUROL, V395, P310; MUELLER AL, 1981, BRAIN RES, V214, P113, DOI 10.1016/0006-8993(81)90442-X; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Nehring RB, 2000, J BIOL CHEM, V275, P35185, DOI 10.1074/jbc.M002727200; NEWBERRY NR, 1984, NATURE, V308, P450, DOI 10.1038/308450a0; Pedarzani P, 1996, EUR J NEUROSCI, V8, P2098, DOI 10.1111/j.1460-9568.1996.tb00731.x; Peng M, 1998, INVEST OPHTH VIS SCI, V39, P1721; Raymond JR, 1999, BRIT J PHARMACOL, V127, P1751, DOI 10.1038/sj.bjp.0702723; Riad N, 2000, J COMP NEUROL, V417, P181, DOI 10.1002/(SICI)1096-9861(20000207)417:2<181::AID-CNE4>3.0.CO;2-A; Roberson ED, 1999, J NEUROSCI, V19, P4337; SAKAI N, 1993, BRAIN RES, V613, P326, DOI 10.1016/0006-8993(93)90921-9; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Selcher JC, 1999, LEARN MEMORY, V6, P478, DOI 10.1101/lm.6.5.478; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Thomas MJ, 1996, NEURON, V17, P475, DOI 10.1016/S0896-6273(00)80179-8; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wang R, 1996, NEUROSCIENCE, V74, P199, DOI 10.1016/0306-4522(96)00116-9; Watabe AM, 2000, J NEUROSCI, V20, P5924, DOI 10.1523/JNEUROSCI.20-16-05924.2000; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; White JH, 2000, P NATL ACAD SCI USA, V97, P13967, DOI 10.1073/pnas.240452197; Williams NG, 1998, J BIOL CHEM, V273, P24624, DOI 10.1074/jbc.273.38.24624; Winder DG, 1999, NEURON, V24, P715, DOI 10.1016/S0896-6273(00)81124-1; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; Zhong HY, 1999, EUR J PHARMACOL, V375, P261, DOI 10.1016/S0014-2999(99)00222-8	52	54	55	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9049	9053		10.1074/jbc.M108309200	http://dx.doi.org/10.1074/jbc.M108309200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11782465	hybrid			2022-12-27	WOS:000174400600043
J	Xiong, LM; Lee, HJ; Ishitani, M; Zhu, JK				Xiong, LM; Lee, HJ; Ishitani, M; Zhu, JK			Regulation of osmotic stress-responsive gene expression by the LOS6/ABA1 locus in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID BIOSYNTHESIS; ZEAXANTHIN EPOXIDASE GENE; SIGNAL-TRANSDUCTION; 9-CIS-EPOXYCAROTENOID DIOXYGENASE; WATER-STRESS; MOLECULAR RESPONSES; DEFICIENT MUTANTS; TOLERANCE; THALIANA; PROTEIN	Drought and high salinity induce the expression of many plant genes. To understand the signal transduction mechanisms underlying the activation of these genes, we carried out a genetic screen to isolate Arabidopsis mutants defective in osmotic stress-regulated gene induction. Here we report the isolation, characterization, and cloning of a mutation, los6, which diminished osmotic stress activation of a reporter gene. RNA blot analysis indicates that under osmotic stress the transcript levels for stress-responsive genes such as RD29A, COR15A, KIN1, COR47, RD19, and ADH are lower in los6 plants than in wild type plants. los6 plants were found to have reduced phytohormone abscisic acid (ABA) accumulation and to be allelic to the ABA-deficient mutant, aba1. LOS6/ABA1 encodes a zeaxanthin epoxidase that functions in ABA biosynthesis. Its expression is enhanced by osmotic stress. Furthermore, we found that there exists a positive feedback regulation by ABA on the expression of LOS6/ABA1, which may underscore a quick adaptation strategy for plants under osmotic stress. Similar positive regulation by ABA also exists for other ABA biosynthesis genes AAO3 and LOS5/ABA3 and in certain genetic backgrounds, NCED3. This feedback regulation by ABA is impaired in the ABA-insensitive mutant abi1 but not in abi2. Moreover, the up-regulation of LOS6/ABA1, LOS5/ABA3, AAO3, and NCED3 by osmotic stress is reduced substantially in ABA-deficient mutants. Transgenic plants overexpressing LOS6/ABA1 showed an increased RD29A-LUC expression under osmotic stress. These results suggest that the level of gene induction by osmotic stress is dependent on the dosage of the zeaxanthin epoxidase enzyme.	Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA	University of Arizona	Zhu, JK (corresponding author), Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA.	jkzhu@ag.arizona.edu	Zhu, Jian-Kang/F-7658-2011	Zhu, Jian-Kang/0000-0001-5134-731X; Xiong, Liming/0000-0001-8099-0806				Agrawal GK, 2001, PLANT PHYSIOL, V125, P1248, DOI 10.1104/pp.125.3.1248; Audran C, 1998, PLANT PHYSIOL, V118, P1021, DOI 10.1104/pp.118.3.1021; BRAY EA, 1993, PLANT PHYSIOL, V103, P1035, DOI 10.1104/pp.103.4.1035; Cutler S, 1996, SCIENCE, V273, P1239, DOI 10.1126/science.273.5279.1239; DUCKHAM SC, 1991, PLANT CELL ENVIRON, V14, P601, DOI 10.1111/j.1365-3040.1991.tb01531.x; Frey A, 1999, PLANT MOL BIOL, V39, P1267, DOI 10.1023/A:1006145025631; GUERRERO F, 1986, PLANT PHYSIOL, V80, P588, DOI 10.1104/pp.80.2.588; Hasegawa PM, 2000, ANNU REV PLANT PHYS, V51, P463, DOI 10.1146/annurev.arplant.51.1.463; Hilleren P, 1999, ANNU REV GENET, V33, P229, DOI 10.1146/annurev.genet.33.1.229; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; Ishitani M, 1997, PLANT CELL, V9, P1935, DOI 10.1105/tpc.9.11.1935; Iuchi S, 2000, PLANT PHYSIOL, V123, P553, DOI 10.1104/pp.123.2.553; Iuchi S, 2001, PLANT J, V27, P325, DOI 10.1046/j.1365-313x.2001.01096.x; KOORNNEEF M, 1982, THEOR APPL GENET, V61, P385, DOI 10.1007/BF00272861; Lee HJ, 2001, GENE DEV, V15, P912, DOI 10.1101/gad.866801; LeonKloosterziel KM, 1996, PLANT J, V10, P655, DOI 10.1046/j.1365-313X.1996.10040655.x; Marin E, 1996, EMBO J, V15, P2331, DOI 10.1002/j.1460-2075.1996.tb00589.x; Muller P, 2001, PLANT PHYSIOL, V125, P1558, DOI 10.1104/pp.125.4.1558; Murata Y, 2001, PLANT CELL, V13, P2513, DOI 10.1105/tpc.13.11.2513; PARRY AD, 1990, PLANTA, V182, P118, DOI 10.1007/BF00239993; Pei ZM, 1998, SCIENCE, V282, P287, DOI 10.1126/science.282.5387.287; Pogson BJ, 2000, PHILOS T ROY SOC B, V355, P1395, DOI 10.1098/rstb.2000.0701; Qin XQ, 1999, P NATL ACAD SCI USA, V96, P15354, DOI 10.1073/pnas.96.26.15354; ROCK CD, 1991, P NATL ACAD SCI USA, V88, P7496, DOI 10.1073/pnas.88.17.7496; Seo M, 2000, P NATL ACAD SCI USA, V97, P12908, DOI 10.1073/pnas.220426197; Shinozaki K, 1997, PLANT PHYSIOL, V115, P327, DOI 10.1104/pp.115.2.327; SINDHU RK, 1988, PLANT PHYSIOL, V88, P178, DOI 10.1104/pp.88.1.178; Taylor IB, 2000, J EXP BOT, V51, P1563, DOI 10.1093/jexbot/51.350.1563; Thomashow MF, 1999, ANNU REV PLANT PHYS, V50, P571, DOI 10.1146/annurev.arplant.50.1.571; Thompson AJ, 2000, PLANT MOL BIOL, V42, P833, DOI 10.1023/A:1006448428401; Thompson AJ, 2000, PLANT J, V23, P363, DOI 10.1046/j.1365-313x.2000.00789.x; WILLIAMS J, 1994, PHYSIOL PLANTARUM, V91, P177, DOI 10.1111/j.1399-3054.1994.tb00416.x; Xiong LM, 2001, PLANT CELL, V13, P2063, DOI 10.1105/tpc.13.9.2063; Zhao ZG, 2001, AUST J PLANT PHYSIOL, V28, P1055, DOI 10.1071/PP00143; Zhu JK, 1997, CRIT REV PLANT SCI, V16, P253, DOI 10.1080/713608147	35	301	327	0	62	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8588	8596		10.1074/jbc.M109275200	http://dx.doi.org/10.1074/jbc.M109275200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11779861	hybrid			2022-12-27	WOS:000174268000123
J	Chikumi, H; Fukuhara, S; Gutkind, JS				Chikumi, H; Fukuhara, S; Gutkind, JS			Regulation of G protein-linked guanine nucleotide exchange factors for Rho, PDZ-RhoGEF, and LARG by tyrosine phosphorylation - Evidence of a role for focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; VAV PROTOONCOGENE PRODUCT; GTPASE-ACTIVATING PROTEIN; JUN NH2-TERMINAL KINASE; SERUM RESPONSE ELEMENT; DBL ONCOGENE PRODUCT; COUPLED RECEPTORS; CELLULAR-TRANSFORMATION; LYSOPHOSPHATIDIC ACID; DEPENDENT ACTIVATION	A recently identified family of guanine nucleotide exchange factors for Rho that includes PDZ-RhoGEF, LARG, and p115RhoGEF exhibits a unique structural feature consisting in the presence of area of similarity to regulators of G protein signaling (RGS). This RGS-like (RGL) domain provides a structural motif by which heterotrimeric G protein alpha subunits of the Galpha(12) family can bind and regulate the activity of RhoGEFs. Hence, these newly discovered RGL domain-containing RhoGEFs provide a direct link from Galpha12 and Galpha(13) to Rho. Recently available data suggest, however, that tyrosine kinases can regulate the ability of G protein-coupled receptors (GPCRs) to stimulate Rho, although the underlying molecular mechanisms are still unknown. Here, we found that the activation of thrombin receptors endogenously expressed in HEK-293T cells leads to a remarkable increase in the levels of GTP-bound Rho within 1 min (11-fold) and a more limited but sustained activation (4-fold) thereafter, which lasts even for several hours. Interestingly, tyrosine kinase inhibitors did not affect the early phase of Rho activation, immediately after thrombin addition, but diminished the levels of GTP-bound Rho during the delayed phase. As thrombin receptors stimulate focal adhesion kinase (FAK) potently, we explored whether this non-receptor tyrosine kinase participates in the activation of Rho by GPCRs. We obtained evidence that FAR can be activated by thrombin, Galpha(12), Galpha(13), and Galpha(q) through both Rho-dependent and Rho-independent mechanisms and that PDZ-RhoGEF and LARG can in turn be tyrosine-phosphorylated through FAK in response to thrombin, thereby enhancing the activation of Rho in vivo. These data indicate that FAK may act as a component of a positive feedback loop that results in the sustained activation of Rho by GPCRs, thus providing evidence of the existence of a novel biochemical route by which tyrosine kinases may regulate the activity of Rho through the tyrosine phosphorylation of RGL-containing RhoGEFs.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551, Z01DE000558] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Burbelo PD, 1995, J BIOL CHEM, V270, P30919, DOI 10.1074/jbc.270.52.30919; Chen Z, 2001, NAT STRUCT BIOL, V8, P805, DOI 10.1038/nsb0901-805; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 2000, J BIOL CHEM, V275, P21730, DOI 10.1074/jbc.M002410200; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GUTKIND JS, 1992, BIOCHEM BIOPH RES CO, V188, P155; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Igishi T, 1999, J BIOL CHEM, V274, P30738, DOI 10.1074/jbc.274.43.30738; Kato J, 2000, BIOCHEM BIOPH RES CO, V268, P141, DOI 10.1006/bbrc.2000.2106; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Longenecker KL, 2001, STRUCTURE, V9, P559, DOI 10.1016/S0969-2126(01)00620-7; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; NOBES CD, 1995, J CELL SCI, V108, P225; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 2000, J CELL SCI, V113, P3673; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Teramoto H, 1997, J BIOL CHEM, V272, P10751; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; VAN AL, 1997, GENE DEV, V11, P2295; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6	58	134	134	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12463	12473		10.1074/jbc.M108504200	http://dx.doi.org/10.1074/jbc.M108504200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11799111	hybrid			2022-12-27	WOS:000174846400113
J	Rao, H; Sastry, A				Rao, H; Sastry, A			Recognition of specific ubiquitin conjugates is important for the proteolytic functions of the ubiquitin-associated domain proteins Dsk2 and Rad23	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIUBIQUITIN-CHAIN-BINDING; SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; PATHWAY; DEGRADATION; MCB1	Ubiquitin (Ub) regulates important cellular processes through covalent attachment to its substrates. The fate of a substrate depends on the number of ubiquitin moieties conjugated, as well as the lysine linkage of Ub-Ub conjugation. The major function of LTh is to regulate the in vivo half-life of its substrates. Once a multi-Ub chain is attached to a substrate, it must be shielded from deubiquitylating enzymes for the 26 S proteasome to recognize it. Molecular mechanisms of the postubiquitylation processes are poorly understood. Here, we have characterized a family of proteins that preferentially binds ubiquitylated substrates and multi-Ub chains through a motif termed the ubiquitin-associated domain (UBA). Our in vivo genetic analysis demonstrates that such interactions require specific lysine residues of LTh that are important for Ub chain formation. We show that Saccharomyces cerevisiae cells lacking two of these UBA proteins, Dsk2 and Rad23, are deficient in protein degradation mediated by the UFD pathway and that the intact UBA motif of Dsk2 is essential for its function in proteolysis. Dsk2 and Rad23 can form a complex(es), suggesting that they cooperate to recognize a subset of multi-Ub chains and deliver the Ub-tagged substrates to the proteasome. Our results suggest a molecular mechanism for differentiation of substrate fates, depending on the precise nature of the mono-Ub or multi-Ub lysine linkage, and provide a foundation to further investigate postubiquitylation events.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Rao, H (corresponding author), CALTECH, Div Biol, 147-75,1200 E Calif Blvd, Pasadena, CA 91125 USA.		Wang, Hongcheng/C-5991-2013	RAO, HAI/0000-0002-4235-2210	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031530] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31530] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; Clarke DJ, 2001, MOL CELL BIOL, V21, P1997, DOI 10.1128/MCB.21.6.1997-2007.2001; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lambertson D, 1999, GENETICS, V153, P69; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939	20	152	155	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11691	11695		10.1074/jbc.M200245200	http://dx.doi.org/10.1074/jbc.M200245200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805121	Green Accepted, hybrid			2022-12-27	WOS:000174846400012
J	Mariot, P; Vanoverberghe, K; Lalevee, N; Rossier, MF; Prevarskaya, N				Mariot, P; Vanoverberghe, K; Lalevee, N; Rossier, MF; Prevarskaya, N			Overexpression of an alpha(1H) (Ca(v)3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL GLOMERULOSA CELLS; DEPENDENT PROTEIN-KINASE; CA2+ CHANNELS; IONIC CURRENTS; GROWTH-FACTOR; TUMOR-CELLS; IN-VITRO; CARCINOMA; EXPRESSION; MIBEFRADIL	Neuroendocrine differentiation of prostate epithelial cells is usually associated with an increased aggressivity and invasiveness of prostate tumors and a poor prognosis. However, the molecular mechanisms involved in this process remain poorly understood. We have investigated the possible expression of voltage-gated calcium channels in human prostate cancer epithelial LNCaP cells and their modulation during neuroendocrine differentiation. A small proportion of undifferentiated LNCaP cells displayed a voltage-dependent calcium current. This proportion and the calcium current density were significantly increased during neuroendocrine differentiation induced by long-term treatments with cyclic AMP permeant analogs or with a steroid-reduced culture medium. Biophysical and pharmacological properties of this calcium current suggest that it is carried by low-voltage activated T-type calcium channels. Reverse transcriptase-PCR experiments demonstrated that only a single type of LVA calcium channel mRNX an a,, calcium channel mRNA, is expressed in LNCaP cells. Quantitative real-time reverse transcriptase-PCR revealed that alpha(1H) mRNA was overexpressed during neuroendocrine differentiation. Finally, we show that this calcium channel promotes basal calcium entry at resting membrane potential and may facilitate neurite lengthening. This voltage-dependent calcium channel could be involved in the stimulation of mitogenic factor secretion and could therefore be a target for future therapeutic strategies.	Univ Sci & Technol Lille, INSERM EPI9938, Lab Physiol Cellulaire, F-59655 Villeneuve Dascq, France; Univ Hosp, Dept Pathol, Clin Chem Lab, CH-1211 Geneva 14, Switzerland; Univ Hosp, Dept Internal Med, Div Endocrinol & Diabetol, CH-1211 Geneva 14, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; University of Geneva; University of Geneva	Mariot, P (corresponding author), Univ Sci & Technol Lille, INSERM EPI9938, Lab Physiol Cellulaire, Batiment SN3, F-59655 Villeneuve Dascq, France.	Pascal.Mariot@univ-lille1.fr	Rossier, Michel/AAW-2895-2021; LALEVEE, Nathalie/M-4636-2016	LALEVEE, Nathalie/0000-0003-1924-1667; Prevarskaya, natacha/0000-0003-0316-197X; Mariot, Pascal/0000-0001-7226-9162				Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bijlenga P, 2000, P NATL ACAD SCI USA, V97, P7627, DOI 10.1073/pnas.97.13.7627; Bonkhoff H, 1998, PROSTATE, P18; Burchardt T, 1999, J UROLOGY, V162, P1800, DOI 10.1016/S0022-5347(05)68241-9; Chemin J, 2000, FEBS LETT, V478, P166, DOI 10.1016/S0014-5793(00)01832-9; COHEN RJ, 1990, BRIT J UROL, V66, P405, DOI 10.1111/j.1464-410X.1990.tb14963.x; Cox ME, 1999, CANCER RES, V59, P3821; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; Day ML, 1998, PFLUG ARCH EUR J PHY, V436, P834, DOI 10.1007/s004240050712; DISANTAGNESE PA, 1992, CANCER-AM CANCER SOC, V70, P254, DOI 10.1002/1097-0142(19920701)70:1+<254::AID-CNCR2820701312>3.0.CO;2-E; DZHURA I, 1994, NEUROREPORT, V5, P1960, DOI 10.1097/00001756-199410000-00030; GARBER SS, 1989, J NEUROSCI, V9, P3976; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Kuga T, 1996, CIRC RES, V79, P14, DOI 10.1161/01.RES.79.1.14; Lee JH, 1999, BIOPHYS J, V77, P3034, DOI 10.1016/S0006-3495(99)77134-1; Lee JH, 1999, J NEUROSCI, V19, P1912; Lesouhaitier O, 2001, ENDOCRINOLOGY, V142, P4320, DOI 10.1210/en.142.10.4320; Lukyanetz EA, 1999, EUR J NEUROSCI, V11, P2865, DOI 10.1046/j.1460-9568.1999.00707.x; Mansvelder HD, 2000, J PHYSIOL-LONDON, V526, P327, DOI 10.1111/j.1469-7793.2000.t01-1-00327.x; Martin RL, 2000, J PHARMACOL EXP THER, V295, P302; MATTESON DR, 1986, J GEN PHYSIOL, V87, P161, DOI 10.1085/jgp.87.1.161; McDonough SI, 1998, MOL PHARMACOL, V54, P1080, DOI 10.1124/mol.54.6.1080; Monteil A, 2000, J BIOL CHEM, V275, P6090, DOI 10.1074/jbc.275.9.6090; Mori S, 1999, BIOCHEM BIOPH RES CO, V257, P609, DOI 10.1006/bbrc.1999.0515; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Randall AD, 1998, J MEMBRANE BIOL, V161, P207, DOI 10.1007/s002329900327; Rossier MF, 1998, J PHARMACOL EXP THER, V287, P824; ROSSIER MF, 1995, J BIOL CHEM, V270, P15137, DOI 10.1074/jbc.270.25.15137; Sculptoreanu A, 2000, MOL CELL BIOCHEM, V203, P23, DOI 10.1023/A:1007010020228; Sherwood NT, 1997, P NATL ACAD SCI USA, V94, P5917, DOI 10.1073/pnas.94.11.5917; Shitaka Y, 1996, J NEUROSCI, V16, P6476; Skryma R, 2000, J PHYSIOL-LONDON, V527, P71, DOI 10.1111/j.1469-7793.2000.00071.x; SOLEM M, 1995, J NEUROSCI, V15, P5966; Spitzer NC, 2000, BIOESSAYS, V22, P811; Wang L, 1999, ENDOCRINOLOGY, V140, P1200, DOI 10.1210/en.140.3.1200; WANG Z, 1993, AM J PHYSIOL, V265, pC1239, DOI 10.1152/ajpcell.1993.265.5.C1239; XU XP, 1990, P NATL ACAD SCI USA, V87, P4655, DOI 10.1073/pnas.87.12.4655; Zelivianski S, 2001, BBA-MOL CELL RES, V1539, P28, DOI 10.1016/S0167-4889(01)00087-8; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	44	137	146	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10824	10833		10.1074/jbc.M108754200	http://dx.doi.org/10.1074/jbc.M108754200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11799114	hybrid			2022-12-27	WOS:000174613100012
J	Mayo, MW; Madrid, LV; Westerheide, SD; Jones, DR; Yuan, XJ; Baldwin, AS; Whang, YE				Mayo, MW; Madrid, LV; Westerheide, SD; Jones, DR; Yuan, XJ; Baldwin, AS; Whang, YE			PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-SURVIVAL; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATASE-ACTIVITY; ACTIVATION; KINASE; AKT; SUPPRESSOR; PHOSPHORYLATION; APOPTOSIS	PTEN is a lipid phosphatase responsible for downregulating the phosphoinositide 3-kinase product phosphatidylinositol 3,4,5-triphosphate. Phosphatidylinositol 3,4,5-triphosphate is involved in the activation of the anti-apoptotic effector target, Akt. Although the Akt pathway has been implicated in regulating NF-kappaB activity, it is controversial as to whether Akt activates NF-kappaB predominantly through mechanisms that regulate nuclear translocation or transactivation potential. In this report, we utilized PTEN as a natural biological inhibitor of Akt activity to study the effects on tumor necrosis factor (TNF)-induced activation of NF-kappaB. We found that the reintroduction of PTEN into prostate cells inhibited TNF-stimulated NF-kappaB transcriptional activity. PTEN failed to block TNF-induced = activation, IkappaBalpha degradation, p105 processing, p65 (RelA) nuclear translocation, and DNA binding of NF-kappaB. However, PTEN inhibited NF-kappaB-dependent transcription by blocking the ability of TNF to stimulate the transactivation domain of the p65 subunit. PTEN also inhibited the transactivation potential of the cyclic AMP-response element-binding protein, but this was not observed for c-Jun. The transactivation potential of p65 following TNF stimulation could be rescued from PTEN-dependent repression by re-introducing expression constructs encoding activated forms of phosphoinositide 3-kinase, Akt, or Akt and =. The ability of PTEN to inhibit the TNF-induced transactivation function of p65 is important, because expression of PTEN blocked TNF-stimulated NF-kappaB dependent gene expression, thus sensitizing cells to TNF-induced apoptosis. Maintenance of the PTEN tumor suppressor protein is therefore required to modulate Akt activity and to concomitantly control the transcriptional activity of the anti-apoptotic transcription factor NF-kappaB.	Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Dept Surg, Charlottesville, VA 22908 USA; Univ N Carolina, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	University of Virginia; University of Virginia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Mayo, MW (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, Box 800733, Charlottesville, VA 22908 USA.		Whang, Young/AAK-7435-2021	Jones, David/0000-0002-3318-0146; Whang, Young/0000-0002-1621-6661	NATIONAL CANCER INSTITUTE [R01CA072771, K01CA078595, K08CA085772, R01CA075080, K08CA083920] Funding Source: NIH RePORTER; NCI NIH HHS [CA75080, CA85772, CA72771, CA78595, CA83920] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Brasier AR, 2001, J BIOL CHEM, V276, P32080, DOI 10.1074/jbc.M102949200; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delhase M, 2000, NATURE, V406, P367, DOI 10.1038/35019154; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Furnari FB, 1998, CANCER RES, V58, P5002; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Huang H, 2001, J BIOL CHEM, V276, P38830, DOI 10.1074/jbc.M103632200; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Ozes ON, 1999, NATURE, V401, P82; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Pan ZK, 1999, J BIOL CHEM, V274, P9918, DOI 10.1074/jbc.274.15.9918; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Salmeron A, 2001, J BIOL CHEM, V276, P22215, DOI 10.1074/jbc.M101754200; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; VAN AD, 1996, SCIENCE, V274, P787; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yang CH, 2001, J BIOL CHEM, V276, P13756, DOI 10.1074/jbc.M011006200; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; YOUZ, 2001, J BIOL CHEM, V276, P26398; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	64	106	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11116	11125		10.1074/jbc.M108670200	http://dx.doi.org/10.1074/jbc.M108670200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11799112	Green Published, hybrid			2022-12-27	WOS:000174613100048
J	Cabrero, A; Alegret, M; Sanchez, RM; Adzet, T; Laguna, JC; Carrera, MV				Cabrero, A; Alegret, M; Sanchez, RM; Adzet, T; Laguna, JC; Carrera, MV			Increased reactive oxygen species production down-regulates peroxisome proliferator-activated alpha pathway in C2C12 skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; NF-KAPPA-B; RECEPTOR-ALPHA; TRANSCRIPTION FACTORS; INSULIN-RESISTANCE; INHIBITION; PALMITOYLTRANSFERASE; EXPRESSION; TRIGLYCERIDE; SENSITIVITY	Generation of reactive oxygen species may contribute to the pathogenesis of diseases involving intracellular lipid accumulation. To explore the mechanisms leading to these pathologies we tested the effects of etomoxir, an inhibitor of carnitine palmitoyltransferase I which contains a fatty acid-derived structure, in C2C12 skeletal muscle cells. Etomoxir treatment for 24 h resulted in a down-regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) mRNA expression, achieving an 87% reduction at 80 muM etomoxir. The mRNA levels of most of the PPARalpha target genes studied were reduced at 100 muM etomoxir. By using several inhibitors of de novo ceramide synthesis and C-2-ceramide we showed that they were not involved in the effects of etomoxir. Interestingly, the addition of triacsin C, a potent inhibitor of acyl-CoA synthetase, to etomoxir-treated C2C12 skeletal muscle cells did not prevent the down-regulation in PPARalpha mRNA levels, suggesting that the active form of the drug, etomoxir-CoA, was not involved. Given that saturated fatty acids may generate reactive oxygen species (ROS), we determined whether the addition of etomoxir resulted in ROS generation. Etomoxir increased ROS production and the activity of the well known redox transcription factor NF-kappaB. In the presence of the pyrrolidine dithiocarbamate, a potent antioxidant and inhibitor of NF-kappaB activity, etomoxir did not down-regulate PPARalpha mRNA in C2C12 skeletal muscle cells. These results indicate that ROS generation and NTF-kappaB activation are responsible for the down-regulation of PPARalpha and may provide a new mechanism by which intracellular lipid accumulation occurs in skeletal muscle cells.	Univ Barcelona, Fac Farm, Unit Farmacol, Dept Farmacol & Quim Terapeut, E-08028 Barcelona, Spain	University of Barcelona	Carrera, MV (corresponding author), Univ Barcelona, Fac Farm, Unit Farmacol, Dept Farmacol & Quim Terapeut, Diagonal 643, E-08028 Barcelona, Spain.	mvaz@farmacia.far.ub.es	Alegret, Marta/C-5086-2017; Laguna, JCLaguna - Juan C./C-5481-2017; Vázquez-Carrera, Manuel/H-2612-2015	Alegret, Marta/0000-0002-5652-8651; Laguna, JCLaguna - Juan C./0000-0002-7082-0704; Vázquez-Carrera, Manuel/0000-0001-7138-8207				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Barger PM, 2000, J CLIN INVEST, V105, P1723, DOI 10.1172/JCI9056; BARTLETT K, 1984, BIOCHEM SOC T, V12, P688, DOI 10.1042/bst0120688; Beier K, 1997, FEBS LETT, V412, P385, DOI 10.1016/S0014-5793(97)00805-3; Bellas RE, 1997, AM J PATHOL, V151, P891; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Cabrero A, 2001, BBA-MOL CELL BIOL L, V1532, P195, DOI 10.1016/S1388-1981(01)00131-7; DAYNES RA, 1993, J IMMUNOL, V150, P5219; DEFRONZO RA, 1985, J CLIN INVEST, V76, P149, DOI 10.1172/JCI111938; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Freeman WM, 1999, BIOTECHNIQUES, V26, P112, DOI 10.2144/99261rv01; GauthierRouviere C, 1996, MOL BIOL CELL, V7, P719, DOI 10.1091/mbc.7.5.719; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939; Jacob S, 1999, DIABETES, V48, P1113, DOI 10.2337/diabetes.48.5.1113; Jucker BM, 1999, DIABETES, V48, P134, DOI 10.2337/diabetes.48.1.134; Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123; Listenberger LL, 2001, J BIOL CHEM, V276, P14890, DOI 10.1074/jbc.M010286200; Maziere C, 1999, BIOCHEM BIOPH RES CO, V265, P116, DOI 10.1006/bbrc.1999.1644; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MCMAHON DK, 1994, AM J PHYSIOL, V266, pC1795, DOI 10.1152/ajpcell.1994.266.6.C1795; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; Oakes ND, 1997, DIABETES, V46, P1768, DOI 10.2337/diabetes.46.11.1768; Parmentier JH, 1997, BIOCHEM PHARMACOL, V54, P889, DOI 10.1016/S0006-2952(97)00256-6; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; Perseghin G, 1999, DIABETES, V48, P1600, DOI 10.2337/diabetes.48.8.1600; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Sack MN, 1997, P NATL ACAD SCI USA, V94, P6438, DOI 10.1073/pnas.94.12.6438; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; WANG E, 1991, J BIOL CHEM, V266, P14486; WOLF HPO, 1992, HORM METAB RES, V26, P62; Ye JM, 2001, DIABETES, V50, P411, DOI 10.2337/diabetes.50.2.411; Yotsumoto T, 2000, EUR J PHARMACOL, V398, P297, DOI 10.1016/S0014-2999(00)00288-0	38	55	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10100	10107		10.1074/jbc.M110321200	http://dx.doi.org/10.1074/jbc.M110321200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11792699	hybrid			2022-12-27	WOS:000174549200066
J	Mohler, PJ; Gramolini, AO; Bennett, V				Mohler, PJ; Gramolini, AO; Bennett, V			The ankyrin-B C-terminal domain determines activity of ankyrin-B/G chimeras in rescue of abnormal inositol 1,4,5-trisphosphate and ryanodine receptor distribution in ankyrin-B (-/-) neonatal cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE ANKYRIN; BRAIN ANKYRIN; BINDING-SITES; ANION-EXCHANGER; RAT-BRAIN; MEMBRANE; SPECTRIN; KIDNEY; ASSOCIATION; DIVERSITY	Ankyrins are a closely related family of membrane adaptor proteins that are believed to participate in targeting diverse membrane proteins to specialized domains in the plasma membrane and endoplasmic reticulum. This study addresses the question of how individual ankyrin isoforms achieve functional specificity when co-expressed in the same cell. Cardiomyocytes from ankyrin-B (-/-) mice display mis-localization of inositol 1,4,5-trisphosphate receptors and ryanodine receptors along with reduced contraction rates that can be rescued by expression of green fluorescent protein (GFP)-ankyrin-B but not GFP-ankyrin-G. We developed chimeric GFP expression constructs containing all combinations of the three major domains of ankyrin-B and ankyrin-G to determine which domain(s) of ankyrin-B are required for ankyrin-B-specific functions. The death/C-terminal domain of ankyrin-B determined activity of ankyrin-B/G chimeras in localization in a striated pattern in cardiomyocytes and in restoration of a normal striated distribution of both ryanodine and inositol 1,4,5-trisphosphate receptors as well as normal beat frequency of contracting cardiomyocytes. Further deletions within the death/C-terminal domain demonstrated that the C-terminal domain determines ankyrin-B activity, whereas deletion of the death domain had no effect. C-terminal domains are the most divergent between ankyrin isoforms and are candidates to encode the signal(s) that enable ankyrins to selectively target proteins to diverse cellular sites.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University	Mohler, PJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3892,355 CARL Bldg, Durham, NC 27710 USA.							Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; DAVIS J, 1989, J BIOL CHEM, V264, P6417; DAVIS JQ, 1986, J BIOL CHEM, V261, P6198; DAVIS JQ, 1984, J BIOL CHEM, V259, P1874; DAVIS LH, 1992, J BIOL CHEM, V267, P18966; Devarajan P, 1997, P NATL ACAD SCI USA, V94, P10711, DOI 10.1073/pnas.94.20.10711; El Far O, 2001, J BIOL CHEM, V276, P30662, DOI 10.1074/jbc.M102573200; HALL TG, 1987, J BIOL CHEM, V262, P10537; Hayashi T, 2001, P NATL ACAD SCI USA, V98, P491, DOI 10.1073/pnas.021413698; Jenkins SM, 2001, J CELL BIOL, V155, P739, DOI 10.1083/jcb.200109026; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; Kordeli E, 1998, J CELL SCI, V111, P2197; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; LAMBERT S, 1993, J NEUROSCI, V13, P3725; Larsen TH, 1999, HISTOCHEM CELL BIOL, V112, P307, DOI 10.1007/s004180050452; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; Scotland P, 1998, J CELL BIOL, V143, P1305, DOI 10.1083/jcb.143.5.1305; Tuvia S, 1999, J CELL BIOL, V147, P995, DOI 10.1083/jcb.147.5.995; Wood SJ, 1998, J CELL BIOL, V140, P675, DOI 10.1083/jcb.140.3.675; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	24	88	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10599	10607		10.1074/jbc.M110958200	http://dx.doi.org/10.1074/jbc.M110958200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11781319	hybrid			2022-12-27	WOS:000174549200130
J	Ohshima, N; Ishii, S; Izumi, T; Shimizu, T				Ohshima, N; Ishii, S; Izumi, T; Shimizu, T			Receptor-dependent metabolism of platelet-activating factor in murine macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED INTERNALIZATION; FACTOR PAF-ACETHER; FACTOR-ACETYLHYDROLASE; BETA(2)-ADRENERGIC RECEPTOR; FUNCTIONAL REQUIREMENTS; INDUCED SEQUESTRATION; RAT HEPATOCYTES; DOWN-REGULATION; LUNG INJURY; GUINEA-PIG	Degradation of platelet-activating factor (PAF) was examined by incubating PAF with macrophages from PAF receptor-deficient mice. The degradation rate was halved as compared with wild-type mice. The reduction of the rate was comparable with the presence of a PAF antagonist WEB 2086 in wild-type cells. PAF was internalized rapidly (t(1/2) approximate to 1 min) into wild-type macrophages. The PAF internalization was inhibited by the treatment of 0.45 m sucrose but was not affected by phorbol 12-myristate 13-acetate, suggesting that PAF internalizes into macrophages with its receptor in a clathrin-dependent manner. Internalized PAF was degraded into lyso-PAF with a half-life of 20 min. Treatment of concanavalin A inhibited the conversion of PAF into lyso-PAF, suggesting that uptake of PAF enhances PAF degradation. Lyso-PAF was subsequently metabolized into 1-alkyl-2-acyl-phosphatidylcholine. In addition, release of PAF acetylhydrolase from macrophages was enhanced when wild-type macrophages were stimulated with PAF but not from macrophages of PAF receptor-deficient mice. Thus, the PAF stimulation of macrophages leads to its degradation through both intracellular and extracellular mechanisms.	Gunma Univ, Fac Med, Dept Biochem, Maebashi, Gumma 3718511, Japan; Japan Sci Technol Corp, CREST, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Tokyo 1130033, Japan	Gunma University; Japan Science & Technology Agency (JST); University of Tokyo	Shimizu, T (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Hongo 7-3-1, Tokyo 1130033, Japan.	tshimizu@m.u-tokyo.ac.jp						Beaumont V, 1998, J BIOL CHEM, V273, P33174, DOI 10.1074/jbc.273.50.33174; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHANG SW, 1987, J CLIN INVEST, V79, P1498, DOI 10.1172/JCI112980; CONCHON S, 1994, FEBS LETT, V349, P365, DOI 10.1016/0014-5793(94)00703-9; ELSTAD MR, 1989, J BIOL CHEM, V264, P8467; GARLAND AM, 1994, BIOCHEM J, V303, P177, DOI 10.1042/bj3030177; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HERTEL C, 1985, J BIOL CHEM, V260, P2547; Hiramoto M, 1997, STROKE, V28, P2417, DOI 10.1161/01.STR.28.12.2417; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; Ishii I, 1998, J BIOL CHEM, V273, P9878, DOI 10.1074/jbc.273.16.9878; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Ishii S, 1996, BIOCHEM J, V314, P671, DOI 10.1042/bj3140671; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; Jimenez E, 1999, BIOCHEM PHARMACOL, V57, P1125, DOI 10.1016/S0006-2952(99)00013-1; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Karasawa K, 1996, J BIOCHEM-TOKYO, V120, P838; Koenig JA, 1998, BIOCHEM J, V336, P291, DOI 10.1042/bj3360291; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LACHACHI H, 1985, BIOCHEM BIOPH RES CO, V132, P460, DOI 10.1016/0006-291X(85)91156-8; LAMANT V, 1987, BIOCHEM PHARMACOL, V36, P2749, DOI 10.1016/0006-2952(87)90259-0; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LeGouill C, 1997, J BIOL CHEM, V272, P21289, DOI 10.1074/jbc.272.34.21289; MAHAN LC, 1985, P NATL ACAD SCI USA, V82, P129, DOI 10.1073/pnas.82.1.129; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; Nagase T, 1999, J CLIN INVEST, V104, P1071, DOI 10.1172/JCI7727; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; PRPIC V, 1988, J CELL BIOL, V107, P363, DOI 10.1083/jcb.107.1.363; SATOH K, 1991, J CLIN INVEST, V87, P476, DOI 10.1172/JCI115020; Seachrist JL, 2000, J BIOL CHEM, V275, P27221; STAFFORINI DM, 1990, METHOD ENZYMOL, V187, P344; Svetlov SI, 1996, ARCH BIOCHEM BIOPHYS, V327, P113, DOI 10.1006/abbi.1996.0099; Tjoelker LW, 2000, BBA-MOL CELL BIOL L, V1488, P102, DOI 10.1016/S1388-1981(00)00114-1; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6; YU SS, 1993, J BIOL CHEM, V268, P337	45	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9722	9727		10.1074/jbc.M112406200	http://dx.doi.org/10.1074/jbc.M112406200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11786559	hybrid			2022-12-27	WOS:000174549200018
J	Valbuzzi, A; Gollnick, P; Babitzke, P; Yanofsky, C				Valbuzzi, A; Gollnick, P; Babitzke, P; Yanofsky, C			The anti-trp RNA-binding attenuation protein (anti-TRAP), AT, recognizes the tryptophan-activated RNA binding domain of the TRAP regulatory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; LEADER RNA; UNKNOWN FUNCTION; OPERON; TRANSCRIPTS; EXPRESSION; FEATURES; REPEATS; APPEARS	In Bacillus subtilis, the trp RNA-binding attenuation protein (TRAP) regulates expression of genes involved in tryptophan metabolism in response to the accumulation Of L-tryptophan. Tryptophan-activated TRAP negatively regulates expression by binding to specific mRNA sequences and either promoting transcription termination or blocking translation initiation. Conversely, the accumulation of uncharged tRNA(Trp) induces synthesis of an anti-TRAP protein (AT), which forms a complex with TRAP and inhibits its activity. In this report, we investigate the structural features of TRAP required for AT recognition. A collection of TRAP mutant proteins was examined that were known to be partially or completely defective in tryptophan binding and/or RNA binding. Analyses of AT interactions with these proteins were performed using in vitro transcription termination assays and cross-linking experiments. We observed that TRAP mutant proteins that had lost the ability to bind RNA were no longer recognized by AT. Our findings suggest that AT acts by competing with messenger RNA for the RNA binding domain of TRAP. B. subtilis AT was also shown to interact with TRAP proteins from Bacillus halodurans and Bacillus stearothermophilus, implying that the structural elements required for AT recognition are conserved in the TRAP proteins of these species. Analyses of AT interaction with B. stearothermophilus TRAP at 60 degreesC demonstrated that AT is active at this elevated temperature.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; SUNY Buffalo, Dept Sci Biol, Buffalo, NY 14260 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Stanford University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Yanofsky, C (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.		Babitzke, Paul/AAL-3048-2020	Babitzke, Paul/0000-0003-2481-1062	NIGMS NIH HHS [GM52840, R01 GM052840, GM62750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062750, R01GM052840] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antson AA, 1999, NATURE, V401, P235, DOI 10.1038/45730; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BABITZKE P, 1995, J BIOL CHEM, V270, P12452, DOI 10.1074/jbc.270.21.12452; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; Babitzke P, 2001, J BACTERIOL, V183, P5795, DOI 10.1128/JB.183.20.5795-5802.2001; Baumann C, 1996, J BIOL CHEM, V271, P12269, DOI 10.1074/jbc.271.21.12269; Chen XP, 1999, J MOL BIOL, V289, P1003, DOI 10.1006/jmbi.1999.2834; CRAIG WS, 1988, METHOD ENZYMOL, V156, P333; Du HS, 1997, J BACTERIOL, V179, P2582, DOI 10.1128/jb.179.8.2582-2586.1997; Du HS, 1998, J BIOL CHEM, V273, P20494, DOI 10.1074/jbc.273.32.20494; Elliott MB, 2001, RNA, V7, P85, DOI 10.1017/S135583820100173X; GOLLNICK P, 2001, PACILLUS SUBTILIS IT, P233; HENKIN TM, 1994, MOL MICROBIOL, V13, P381, DOI 10.1111/j.1365-2958.1994.tb00432.x; MERINO E, 1995, J BACTERIOL, V177, P6362, DOI 10.1128/jb.177.22.6362-6370.1995; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; Sarsero JP, 2000, J BACTERIOL, V182, P2329, DOI 10.1128/JB.182.8.2329-2331.2000; Sarsero JP, 2000, P NATL ACAD SCI USA, V97, P2656, DOI 10.1073/pnas.050578997; SHIMOTSU H, 1986, J BACTERIOL, V166, P461, DOI 10.1128/jb.166.2.461-471.1986; STEINBERG W, 1974, J BACTERIOL, V117, P1023, DOI 10.1128/JB.117.3.1023-1034.1974; Valbuzzi A, 2001, SCIENCE, V293, P2057, DOI 10.1126/science.1062187; Yakhnin AV, 2000, J BIOL CHEM, V275, P4519, DOI 10.1074/jbc.275.6.4519; Yakhnin H, 2001, J BACTERIOL, V183, P5918, DOI 10.1128/JB.183.20.5918-5926.2001; Yang M, 1997, J MOL BIOL, V270, P696, DOI 10.1006/jmbi.1997.1149; YANOFSKY C, 1999, ENCY MOL BIOL, V4, P2676	26	43	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10608	10613		10.1074/jbc.M111813200	http://dx.doi.org/10.1074/jbc.M111813200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11786553	hybrid			2022-12-27	WOS:000174549200131
J	Watters, JJ; Sommer, JA; Pfeiffer, ZA; Prabhu, U; Guerra, AN; Bertics, PJ				Watters, JJ; Sommer, JA; Pfeiffer, ZA; Prabhu, U; Guerra, AN; Bertics, PJ			A differential role for the mitogen-activated protein kinases in lipopolysaccharide signaling - The MEK/ERK pathway is not essential for nitric oxide and interleukin 10 production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; PURINERGIC RECEPTOR MODULATION; FACTOR-ALPHA GENE; INTERFERON-GAMMA; REGULATED KINASE; CELL-LINE; SYNTHASE GENE; CUTTING EDGE; EXPRESSION	Endotoxin (lipopolysaccharide, LPS) is a component of the outer membrane of Gram-negative bacteria and promotes the activation of macrophages and microglia. Although these cells are highly LPS-responsive, they serve unique tissue-specific functions and exhibit different LPS sensitivities. Accordingly, it was of interest to evaluate whether these biological differences reside in variations within LPS signaling pathways between these two cell types. Because the mitogen-activated protein kinases ERK-1 and ERK-2 have been implicated in the control of many immune responses, we tested the concept that they are a key indicator for differences in cellular LPS sensitivity. We observed that murine RAW 264.7 macrophages and murine BV-2 microglial cells both respond to LPS by exhibiting increased IkappaBalpha degradation, enhanced NF-kappaB DNA binding activity, and elevated nitric oxide and interleukin-1beta production. Although LPS potently stimulates ERK activation in RAW 264.7 macrophages, it does not activate ERK-1/-2 in BV-2 microglia. Moreover, antagonism of the MEK/ERK pathway potentiates LPS-stimulated nitric oxide production, suggesting that LPS-stimulated ERK activation can exert inhibitory effects in macrophage-like cells. These data support the idea that ERK activation is not a required function of LPS-mediated signaling events and illustrate that alternative/additional pathways for LPS action exist in these cell types.	Univ Wisconsin, Dept Biomol Chem, Sch Med, Madison, WI 53706 USA; Univ Wisconsin, Program Mol & Cellular Pharmacol, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Bertics, PJ (corresponding author), Univ Wisconsin, Dept Biomol Chem, Sch Med, 1300 Univ Ave, Madison, WI 53706 USA.	pbertics@facstaff.wisc.edu			NCI NIH HHS [F32 CA81733, CA47881] Funding Source: Medline; NHLBI NIH HHS [HL56396] Funding Source: Medline; NIAID NIH HHS [AI34891] Funding Source: Medline; NIGMS NIH HHS [T32-GM08349, GM53271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047881, F32CA081733] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034891, U19AI034891] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053271, T32GM008349] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ajizian SJ, 1999, J INFECT DIS, V179, P939, DOI 10.1086/314659; Akashi S, 2000, BIOCHEM BIOPH RES CO, V268, P172, DOI 10.1006/bbrc.2000.2089; Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471; Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARBER SA, 1995, J IMMUNOL, V155, P1404; Beutler B, 2000, CURR OPIN MICROBIOL, V3, P23, DOI 10.1016/S1369-5274(99)00046-6; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Bhat NR, 1998, J NEUROSCI, V18, P1633; Bitting L, 1996, J BIOL CHEM, V271, P16084, DOI 10.1074/jbc.271.27.16084; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508, DOI 10.1002/jlb.67.4.508; Calingasan NY, 1998, AM J PATHOL, V153, P599, DOI 10.1016/S0002-9440(10)65602-7; Carter AB, 1999, AM J RESP CELL MOL, V20, P751, DOI 10.1165/ajrcmb.20.4.3420; Chen BC, 1999, IMMUNOLOGY, V97, P124, DOI 10.1046/j.1365-2567.1999.00747.x; Chen CC, 1999, MOL PHARMACOL, V55, P481; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Chow Jesse C., 2000, Journal of Endotoxin Research, V6, P141; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; DEMLINGER LC, 1996, NOVEL THERAPEUTIC ST, P227; Denlinger LC, 1998, INFECT IMMUN, V66, P1638, DOI 10.1128/IAI.66.4.1638-1647.1998; Durando MM, 1998, J LEUKOCYTE BIOL, V64, P259, DOI 10.1002/jlb.64.2.259; Dziarski R, 1996, J INFECT DIS, V174, P777, DOI 10.1093/infdis/174.4.777; Fenton MJ, 1998, J LEUKOCYTE BIOL, V64, P25, DOI 10.1002/jlb.64.1.25; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gordon S, 1998, RES IMMUNOL, V149, P685, DOI 10.1016/S0923-2494(99)80039-X; GRAY JG, 1993, MOL CELL BIOL, V13, P6678, DOI 10.1128/MCB.13.11.6678; Hauser C J, 1996, New Horiz, V4, P235; Heine H, 1999, J IMMUNOL, V162, P6971; HERZYK DJ, 1992, J IMMUNOL, V149, P3052; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; Hu Y, 1998, J BIOL CHEM, V273, P27170, DOI 10.1074/jbc.273.42.27170; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Kopec KK, 1998, J NEUROCHEM, V71, P2123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Licinio J, 1997, J CLIN INVEST, V100, P2941, DOI 10.1172/JCI119846; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; Means TK, 1999, J IMMUNOL, V163, P6748; Mirzoeva S, 1999, BRAIN RES, V844, P126, DOI 10.1016/S0006-8993(99)01911-3; MITCHELL JA, 1992, MOL PHARMACOL, V41, P1163; MONNING U, 1994, FEBS LETT, V342, P267, DOI 10.1016/0014-5793(94)80514-8; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; MYERS MJ, 1995, IMMUNOLOGY, V85, P318; PENNANEN N, 1995, PHARMACEUT RES, V12, P916, DOI 10.1023/A:1016281608773; PENNANEN N, 1995, INT J IMMUNOPHARMACO, V17, P475, DOI 10.1016/0192-0561(95)00030-6; Petrova TV, 1999, J BIOL CHEM, V274, P28823, DOI 10.1074/jbc.274.40.28823; PROCTOR RA, 1994, P NATL ACAD SCI USA, V91, P6017, DOI 10.1073/pnas.91.13.6017; Pyo H, 1998, NEUROREPORT, V9, P871, DOI 10.1097/00001756-199803300-00020; Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175; Sanghera JS, 1996, J IMMUNOL, V156, P4457; Schumann RR, 1998, GLIA, V22, P295, DOI 10.1002/(SICI)1098-1136(199803)22:3<295::AID-GLIA8>3.0.CO;2-4; Schumann RR, 1996, BLOOD, V87, P2805, DOI 10.1182/blood.V87.7.2805.bloodjournal8772805; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; Sommer JA, 1999, J ENDOTOXIN RES, V5, P70, DOI 10.1177/09680519990050010501; SPARACIO SM, 1992, J NEUROIMMUNOL, V39, P231, DOI 10.1016/0165-5728(92)90257-L; Sternberg EM, 1997, J CLIN INVEST, V100, P2641, DOI 10.1172/JCI119807; SURESH A, 1991, IMMUNOL LETT, V30, P93, DOI 10.1016/0165-2478(91)90095-R; TEBO JM, 1994, J IMMUNOL, V153, P4713; Vogel SN, 2000, J ENDOTOXIN RES, V6, P295, DOI 10.1177/09680519000060040301; Wang PL, 1998, ARCH ORAL BIOL, V43, P687, DOI 10.1016/S0003-9969(98)00056-9; WEST MA, 1995, J TRAUMA, V39, P404; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200; Zielasek J, 1996, ADV NEUROIMMUNOL, V6, P191, DOI 10.1016/0960-5428(96)00017-4	73	112	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9077	9087		10.1074/jbc.M104385200	http://dx.doi.org/10.1074/jbc.M104385200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11786532	hybrid			2022-12-27	WOS:000174400600047
J	Megidish, T; Xu, JH; Xu, CW				Megidish, T; Xu, JH; Xu, CW			Activation of p53 by protein inhibitor of activated Stat1 (PIAS1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER; GENE ACTIVATION; C-JUN; SUMO-1; HOMOLOG; ENCODES; MDM2; P63; P73	The tumor suppressor protein p53 functions as a transcriptional factor that activates genes controlling cell cycle arrest and apoptosis. Here, we report that protein inhibitor of activated Stat1 (PIAS1) interacts with the tetramerization and C-terminal regulatory domains of p53 in yeast two-hybrid analyses. Endogenous PIAS1 is also associated with endogenous p53 in mammalian cells. Ectopic expression of PIAS1 activates p53-mediated expression in mouse embryonic fibroblast cells (p53(-/-)) as well as a variety of other cell lines. Furthermore, ectopic expression of PIAS1 induces p53-mediated expression of cyclin-dependent kinase inhibitor p21 and G, arrest of the cell cycle in H1299 cells. In addition, a PIAS1 mutant without the RING-finger domain required for sumoylation could still activate p53-mediated gene expression, indicating that activation of p53 by PIAS1 does not require the RING-finger domain. Taken together, our results suggest that PIAS1 is a novel activator of p53.	Sloan Kettering Inst, Mol Pharmacol Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Sloan Kettering Div, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Xu, CW (corresponding author), Sloan Kettering Inst, Mol Pharmacol Program, Box 362,1275 York Ave, New York, NY 10021 USA.	w-xu@ski.mskcc.org						Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Betz A, 2001, P NATL ACAD SCI USA, V98, P9563, DOI 10.1073/pnas.171302098; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Gallagher WM, 1999, ONCOGENE, V18, P3608, DOI 10.1038/sj.onc.1202937; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hari KL, 2001, GENE DEV, V15, P1334, DOI 10.1101/gad.877901; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; Liao JY, 2000, P NATL ACAD SCI USA, V97, P5267, DOI 10.1073/pnas.97.10.5267; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, J BIOL CHEM, V276, P36624, DOI 10.1074/jbc.M101085200; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Valdez BC, 1997, BIOCHEM BIOPH RES CO, V234, P335, DOI 10.1006/bbrc.1997.6642; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Xu CW, 1997, P NATL ACAD SCI USA, V94, P12473, DOI 10.1073/pnas.94.23.12473; Xu CW, 1996, MOL CELL BIOL, V16, P564; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	37	72	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8255	8259		10.1074/jbc.C200001200	http://dx.doi.org/10.1074/jbc.C200001200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11788578	hybrid			2022-12-27	WOS:000174268000081
J	Verma, A; Deb, DK; Sassano, A; Uddin, S; Varga, J; Wickrema, A; Platanias, LC				Verma, A; Deb, DK; Sassano, A; Uddin, S; Varga, J; Wickrema, A; Platanias, LC			Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I Interferons and transforming growth factor-beta on normal hematopoiesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; TGF-BETA; MAP KINASE; TRANSCRIPTIONAL ACTIVATION; SIGNALING PATHWAYS; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; SUBSTRATE-SPECIFICITY; STRUCTURAL BASIS; IFN-GAMMA	Type I interferons (IFNs) are potent regulators of normal hematopoiesis in vitro and in vivo, but the mechanisms by which they suppress hematopoietic progenitor cell growth and differentiation are not known. In the present study we provide evidence that IFNalpha and IFNbeta induce phosphorylation of the p38 mitogen-activated protein (Map) kinase in CD34+-derived primitive human hematopoietic progenitors. Such type I IFN-inducible phosphorylation of p38 results in activation of the catalytic domain of the kinase and sequential activation of the MAPK-activated protein kinase-2 (MapKapK-2 kinase), indicating the existence of a signaling cascade, activated downstream of p38 in hematopoietic progenitors. Our data indicate that activation of this signaling cascade by the type I IFN receptor is essential for the generation of the suppressive effects of type I IFNs on normal hematopoiesis. This is shown by studies demonstrating that pharmacological inhibitors of p38 reverse the growth inhibitory effects of IFNalpha and IFNbeta on myeloid (colony-forming granulocytic-macrophage) and eythroid (burst-forming unit-erythroid) progenitor colony formation. In a similar manner, transforming growth factor beta, which also exhibits inhibitory effects on normal hematopoiesis, activates p38 and MapKapK-2 in human hematopoietic progenitors, whereas pharmacological inhibitors of p38 reverse its suppressive activities on both myeloid and erythroid colony formation. In further studies, we demonstrate that the primary mechanism by which the p38 Map kinase pathway mediates hematopoietic suppression is regulation of cell cycle progression and is unrelated to induction of apoptosis. Altogether, these findings establish that the p38 Map kinase pathway is a common effector for type I IFN and transforming growth factor beta signaling in human hematopoietic progenitors and plays a critical role in the induction of the suppressive effects of these cytokines on normal hematopoiesis.	Univ Illinois, Hematol Oncol Sect, MBRB, Chicago, IL 60607 USA; Univ Illinois, Dept Med, Rheumatol Sect, Chicago, IL 60607 USA; W Side Vet Affairs Med Ctr, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Platanias, LC (corresponding author), Univ Illinois, Hematol Oncol Sect, MBRB, MC-734,Rm 3150,900 S Ashland Ave, Chicago, IL 60607 USA.	Lplatani@uic.edu	Varga, John/AAK-6472-2021	Uddin, Shahab/0000-0003-1886-6710	NCI NIH HHS [CA73381, CA77816] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077816, R29CA073381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Alsayed Y, 2000, J IMMUNOL, V164, P1800, DOI 10.4049/jimmunol.164.4.1800; BROXMEYER HE, 1983, J IMMUNOL, V131, P1300; BROXMEYER HE, 1985, J IMMUNOL, V135, P2502; Bruno E, 1998, BLOOD, V91, P1917, DOI 10.1182/blood.V91.6.1917.1917_1917_1923; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAS D, 2000, FEBS LETT, V21, P47250; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DELFORGE A, 1990, EUR J HAEMATOL, V44, P307; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GANSER A, 1987, BLOOD, V70, P1173; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; GUGLIOTTA L, 1989, BRIT J HAEMATOL, V71, P177, DOI 10.1111/j.1365-2141.1989.tb04251.x; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; JACOBSEN SEW, 1991, BLOOD, V78, P2239, DOI 10.1182/blood.V78.9.2239.bloodjournal7892239; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KELLER JR, 1989, J CELL BIOCHEM, V39, P175, DOI 10.1002/jcb.240390209; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; KLIMPEL GR, 1982, J IMMUNOL, V129, P76; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Massague J, 2000, GENE DEV, V14, P627; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mayer IA, 2001, J BIOL CHEM, V276, P28570, DOI 10.1074/jbc.M011685200; MEANS RT, 1993, J CLIN INVEST, V91, P416, DOI 10.1172/JCI116216; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Park WH, 2000, CANCER RES, V60, P3065; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; Platanias LC, 1999, EXP HEMATOL, V27, P1315, DOI 10.1016/S0301-472X(99)00060-0; RAEFSKY EL, 1985, J IMMUNOL, V135, P2507; Sangfelt O, 2000, FRONT BIOSCI-LANDMRK, V5, pD479, DOI 10.2741/Sangfelt; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; SARGIACOMO M, 1991, ANN NY ACAD SCI, V628, P84, DOI 10.1111/j.1749-6632.1991.tb17226.x; Sitnicka E, 1996, BLOOD, V88, P82; Stadler M, 1995, ONCOGENE, V11, P2565; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Terada Y, 1999, KIDNEY INT, V56, P1378, DOI 10.1046/j.1523-1755.1999.00665.x; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; UDDIN S, 1999, HAEMA, V2, P192; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; Weekx SFA, 1998, EXP HEMATOL, V26, P1034; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yen A, 1998, CANCER RES, V58, P3163	68	141	145	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7726	7735		10.1074/jbc.M106640200	http://dx.doi.org/10.1074/jbc.M106640200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11773065	hybrid			2022-12-27	WOS:000174268000016
J	Sotomaru, Y; Katsuzawa, Y; Hatada, I; Obata, Y; Sasaki, H; Kono, T				Sotomaru, Y; Katsuzawa, Y; Hatada, I; Obata, Y; Sasaki, H; Kono, T			Unregulated expression of the imprinted genes H19 and Igf2r in mouse uniparental fetuses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRADER-WILLI-SYNDROME; METHYLATION; OOCYTES; LOCUS; CDNA; MECHANISMS; CANDIDATE; CHROMATIN; DELETION; PROTEIN	The present study shows that the H19 and Igf2r genes, which are imprinted and expressed solely from maternal alleles, are expressed in an unregulatable manner in mouse uniparental, androgenetic, and parthenogenetic fetuses at day 9.5 of gestation. In the androgenetic fetuses, the H19 and Igf2r genes were respectively expressed at 12 and 40% of the levels in biparental fetuses. In addition, the expression of both genes was excessive (1259 and 482%, respectively) in the parthenotes. These expressions of the imprinted genes were not regulated by methylation in the regulatory regions. Moreover, the expression of the antisense Igf2r RNA (Air) was also excessive and was not correlated with Igf2r gene expression in the uniparental fetuses. Taken together, these results indicate that the parental specific expression of imprinted genes is not maintained in particular genes in uniparental embryos, which in turn suggests that both parental genomes are required to establish maternal specific expression of the H19 and Igf2r genes by transacting mechanisms.	Tokyo Univ Agr, Dept Biosci, Setagaya Ku, Tokyo 1568502, Japan; Tokyo Univ Agr, Dept Anim Sci, Kanagawa 2430034, Japan; Gunma Univ, Ctr Gene Res, Gunma 3718511, Japan; Natl Inst Genet, Dept Integrated Genet, Div Human Genet, Shizuoka 4118540, Japan	Tokyo University of Agriculture; Tokyo University of Agriculture; Gunma University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Kono, T (corresponding author), Tokyo Univ Agr, Dept Biosci, Setagaya Ku, 1-1-1 Sakuragaoka, Tokyo 1568502, Japan.	tomohiro@nodai.ac.jp						BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291; BOSMIKICH A, 1995, MOL REPROD DEV, V41, P84, DOI 10.1002/mrd.1080410113; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; Brenton JD, 1999, P NATL ACAD SCI USA, V96, P9242, DOI 10.1073/pnas.96.16.9242; CATTANACH BM, 1992, NAT GENET, V2, P270, DOI 10.1038/ng1292-270; Feil R, 1997, AM J HUM GENET, V61, P1213, DOI 10.1086/301655; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Hatada I, 2001, J BIOCHEM, V130, P187, DOI 10.1093/oxfordjournals.jbchem.a002971; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; KANEKOISHINO T, 1995, NAT GENET, V11, P52, DOI 10.1038/ng0995-52; KONO T, 1993, MOL REPROD DEV, V34, P43, DOI 10.1002/mrd.1080340107; Kuroiwa Y, 1996, NAT GENET, V12, P186, DOI 10.1038/ng0296-186; LEFF SE, 1992, NAT GENET, V2, P259, DOI 10.1038/ng1292-259; Lyle R, 2000, NAT GENET, V25, P19, DOI 10.1038/75546; Miyoshi N, 1998, P NATL ACAD SCI USA, V95, P1102, DOI 10.1073/pnas.95.3.1102; QUINN P, 1982, J REPROD FERTIL, V66, P161; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; Ripoche MA, 1997, GENE DEV, V11, P1596, DOI 10.1101/gad.11.12.1596; SADO T, 1993, DEV GROWTH DIFFER, V35, P551; Sasaki H, 1995, DEVELOPMENT, V121, P4195; Sasaki H., 1993, Experientia Supplementum (Basel), V64, P469; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; Shemer R, 1996, P NATL ACAD SCI USA, V93, P6371, DOI 10.1073/pnas.93.13.6371; Sleutels F, 2000, CURR OPIN GENET DEV, V10, P229, DOI 10.1016/S0959-437X(00)00062-9; Sotomaru Y, 2001, J BIOL CHEM, V276, P26694, DOI 10.1074/jbc.M101367200; Sotomaru Yusuke, 2001, Journal of Reproduction and Development, V47, P139, DOI 10.1262/jrd.47.139; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; Tremblay KD, 1997, MOL CELL BIOL, V17, P4322, DOI 10.1128/MCB.17.8.4322; WALSH C, 1994, MECH DEVELOP, V46, P55, DOI 10.1016/0925-4773(94)90037-X; Whittingham D G, 1971, J Reprod Fertil Suppl, V14, P7; Wittwer CT, 1997, BIOTECHNIQUES, V22, P176, DOI 10.2144/97221pf02; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631; Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25	39	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12474	12478		10.1074/jbc.M109212200	http://dx.doi.org/10.1074/jbc.M109212200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805093	hybrid			2022-12-27	WOS:000174846400114
J	Wang, S; Hankinson, O				Wang, S; Hankinson, O			Functional involvement of the Brahma/SW12-related gene 1 protein in cytochrome P4501A1 transcription mediated by the aryl hydrocarbon receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-REMODELING COMPLEX; DNA-BINDING FORM; AH RECEPTOR; HISTONE ACETYLTRANSFERASE; GLUCOCORTICOID RECEPTOR; SWI/SNF COMPLEX; SWI-SNF; ORDERED RECRUITMENT; CELL-CYCLE; IN-VIVO	Chromatin remodeling is a key step in overcoming the nucleosomal repression of active transcription in eukaryotes. The mammalian SWI/SNF ATP-dependent chromatin-remodeling complexes contain multiple subunits. The ATPase activities in these complexes are attributable to either BRG-1 or the related Brahma protein. The aryl hydrocarbon receptor (AHR), after binding xenobiotic ligands such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), associates with the AHR nuclear translocator (ARNT), and the dimer so formed activates transcription of several genes, including the cytochrome P4501A1 (CYP1A1) gene. We show that BRG-1 potentiates AHR/ARNT-mediated reporter gene activity in a TCDD-dependent fashion in Hepa1c1c7 cells. Introduction of BRG-1 into the BRG-1- and hBrm-deficient SW13 and C33A human cell lines also enhances expression from a transiently transfected AHR/ARNT-dependent reporter gene. Replenishment of BRG-1 to SW13 cells also restores endogenous cytochrome P4501A1 (CYP1A1) gene expression, whereas an ATPase-deficient mutant of BRG-1 is unable to do so. Chromatin immuno-precipitation analysis demonstrated that BRG-1 associates with the enhancer region of the mouse CYP1A1 gene in vivo in a TCDD- and ARNT-dependent fashion, suggesting the specific recruitment of BRG-1 by AHR/ ARNT. Finally, we demonstrate that the glutamine-rich subdomain of the transcriptional activation domain of AHR can interact with BRG-1. Together these studies reveal a functional involvement of BRG-1 in activating CYP1A1 gene transcription and implicate the importance of ATP-dependent chromatin remodeling activity on inducible gene expression mediated by AHR/ARNT.	Univ Calif Los Angeles, Dept Pathol & Lab Med, Hlth Sci Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Hankinson, O (corresponding author), Univ Calif Los Angeles, Dept Pathol & Lab Med, Hlth Sci Ctr, Los Angeles, CA 90095 USA.				NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER; NCI NIH HHS [CA28868, R01 CA028868] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Andreola F, 1997, CANCER RES, V57, P2835; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Carver LA, 1997, J BIOL CHEM, V272, P11452; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P31845; Gao L, 2001, ARCH BIOCHEM BIOPHYS, V392, P270, DOI 10.1006/abbi.2001.2440; Gregory PD, 1999, EMBO J, V18, P6407, DOI 10.1093/emboj/18.22.6407; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HANKINSON O, 1985, J BIOL CHEM, V260, P1790; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Ko HSP, 1996, MOL CELL BIOL, V16, P430; Kobayashi A, 1997, J BIOCHEM, V122, P703; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Kumar MB, 1999, GENE EXPRESSION, V8, P273; Kumar MB, 1999, J BIOL CHEM, V274, P22155, DOI 10.1074/jbc.274.32.22155; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Ma Q, 1997, J BIOL CHEM, V272, P8878; MASON GGF, 1994, J BIOL CHEM, V269, P4438; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OKINO ST, 1995, MOL CELL BIOL, V15, P3714; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Rowlands JC, 1996, MOL PHARMACOL, V50, P538; Santiago-Josefat B, 2001, MOL CELL BIOL, V21, P1700, DOI 10.1128/MCB.21.5.1700-1709.2001; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	52	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11821	11827		10.1074/jbc.M110122200	http://dx.doi.org/10.1074/jbc.M110122200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805098	hybrid			2022-12-27	WOS:000174846400029
J	Heegaard, NHH; Roepstorff, P; Melberg, SG; Nissen, MH				Heegaard, NHH; Roepstorff, P; Melberg, SG; Nissen, MH			Cleaved beta(2)-microglobulin partially attains a conformation that has amyloidogenic features	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; DIALYSIS-RELATED AMYLOIDOSIS; MODIFIED BETA-2-MICROGLOBULIN; CAPILLARY-ELECTROPHORESIS; CHRONIC-HEMODIALYSIS; P COMPONENT; CONGO RED; IN-VITRO; PROTEIN; GLYCOSAMINOGLYCAN	beta(2)-Microglobulin, a small protein localized in serum and on cell surfaces, can adopt specific aggregating conformations that generate amyloid in tissues and joints as a complication to long-term hemodialysis. We characterize a proteolytic variant of beta(2)-microglobulin (cleaved after Lys(58)) that as a trimmed form (Lys(58) is removed) can be demonstrated in the circulation in patients with chronic disease. An unexpected electrophoretic heterogeneity of these two cleaved variants was demonstrated by capillary electrophoresis under physiological conditions. Each separated into a fast and a slow component while appearing homogeneous, except for a fraction of oxidized species detected by other techniques. The two components had different binding affinities for heparin and for the amyloid-specific dye Congo red, and the equilibrium between the two forms was dependent on solvent conditions. Together with analysis of the differences in circular dichroism, the results suggest that beta(2)-microglobulin cleaved after Lys(58) readily adopts two equilibrium conformations under native conditions. In the cleaved and trimmed beta(2)-microglobulin that appears in vivo, the less populated conformation is characterized by an increased affinity for Congo red. These observations may help elucidate why beta(2)-microglobulin polymerizes as amyloid in chronic hemodialysis and facilitate the search for means to inhibit this process.	Statens Serum Inst, Dept Autoimmunol, DK-2300 Copenhagen S, Denmark; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark; Univ Copenhagen, Inst Med Anat, DK-2200 Copenhagen N, Denmark	Statens Serum Institut; University of Southern Denmark; Novo Nordisk; University of Copenhagen	Heegaard, NHH (corresponding author), Statens Serum Inst, Dept Autoimmunol, Artillerivej 5,Bldg 81,Rm 536, DK-2300 Copenhagen S, Denmark.	nhe@ssi.dk	Nissen, Mogens/B-4825-2008	Nissen, Mogens/0000-0001-7729-8667				BECKER JW, 1985, P NATL ACAD SCI USA, V82, P4225, DOI 10.1073/pnas.82.12.4225; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; Campistol JM, 1996, KIDNEY INT, V50, P1262, DOI 10.1038/ki.1996.436; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Chiti F, 2001, J MOL BIOL, V307, P379, DOI 10.1006/jmbi.2000.4478; CUNNINGHAM BA, 1973, BIOCHEMISTRY-US, V12, P4811, DOI 10.1021/bi00748a001; Drueke TB, 1998, NEPHROL DIAL TRANSPL, V13, P58, DOI 10.1093/ndt/13.suppl_1.58; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; GEJYO F, 1986, NEW ENGL J MED, V314, P585; GOREVIC PD, 1986, P NATL ACAD SCI USA, V83, P7908, DOI 10.1073/pnas.83.20.7908; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; Heegaard NHH, 2001, J BIOL CHEM, V276, P32657, DOI 10.1074/jbc.M104452200; Heegaard NHH, 2000, J CHROMATOGR A, V894, P319, DOI 10.1016/S0021-9673(00)00579-3; HEEGAARD NHH, 2001, PROTEIN LIGAND INTER; Jadoul M, 1997, KIDNEY INT, V51, P1928, DOI 10.1038/ki.1997.262; Kelly SM, 1997, BBA-PROTEIN STRUCT M, V1338, P161, DOI 10.1016/S0167-4838(96)00190-2; KISILEVSKY R, 1988, MED HYPOTHESES, V26, P231, DOI 10.1016/0306-9877(88)90125-9; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kussmann M, 1997, J MASS SPECTROM, V32, P593; LEVEUGLE B, 1994, NEUROREPORT, V5, P1389, DOI 10.1097/00001756-199406000-00025; LINKE RP, 1989, KIDNEY INT, V36, P675, DOI 10.1038/ki.1989.245; LINKE RP, 1986, BIOCHEM BIOPH RES CO, V136, P665, DOI 10.1016/0006-291X(86)90492-4; LYON AW, 1993, J RHEUMATOL, V20, P1108; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; Miyata T, 1996, P NATL ACAD SCI USA, V93, P2353, DOI 10.1073/pnas.93.6.2353; MOMOI T, 1995, CLIN CHIM ACTA, V236, P135, DOI 10.1016/0009-8981(95)06039-G; NISSEN MH, 1987, EUR J BIOCHEM, V163, P21, DOI 10.1111/j.1432-1033.1987.tb10731.x; NISSEN MH, 1990, EUR J BIOCHEM, V189, P423, DOI 10.1111/j.1432-1033.1990.tb15505.x; Nissen MH, 1997, J IMMUNOL METHODS, V205, P29; ODANI H, 1990, BIOCHEM BIOPH RES CO, V168, P1223, DOI 10.1016/0006-291X(90)91159-P; Ohashi K, 1997, VIRCHOWS ARCH, V430, P479, DOI 10.1007/s004280050058; OKON M, 1992, BIOCHEMISTRY-US, V31, P8906, DOI 10.1021/bi00152a030; ONO K, 1994, NEPHRON, V66, P404, DOI 10.1159/000187854; OZASA H, 1989, NEPHRON, V53, P87, DOI 10.1159/000185712; PLESNER T, 1979, SCAND J IMMUNOL, V9, P247, DOI 10.1111/j.1365-3083.1979.tb02728.x; SHIMURA K, 1995, ANAL BIOCHEM, V227, P186, DOI 10.1006/abio.1995.1269; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; SKINNER M, 1988, METHOD ENZYMOL, V163, P523; SNOW AD, 1987, LAB INVEST, V57, P687; Watson DJ, 1997, J BIOL CHEM, V272, P31617, DOI 10.1074/jbc.272.50.31617; Westermark P, 1999, AMYLOID, V6, P151, DOI 10.3109/13506129909007319	42	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11184	11189		10.1074/jbc.M108837200	http://dx.doi.org/10.1074/jbc.M108837200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801591	hybrid			2022-12-27	WOS:000174613100056
J	Joseph, SB; Laffitte, BA; Patel, PH; Watson, MA; Matsukuma, KE; Walczak, R; Collins, JL; Osborne, TF; Tontonoz, P				Joseph, SB; Laffitte, BA; Patel, PH; Watson, MA; Matsukuma, KE; Walczak, R; Collins, JL; Osborne, TF; Tontonoz, P			Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEINS; STEROL REGULATION; TRANSGENIC MICE; LXR-ALPHA; TRANSCRIPTION FACTOR; OXYSTEROL RECEPTORS; HORMONAL-REGULATION; CHOLESTEROL EFFLUX; PROMOTER; METABOLISM	The nuclear receptors LXRalpha and LXRbeta have been implicated in the control of lipogenesis and cholesterol homeostasis. Ligand activation of these receptors in vivo induces expression of the LXR target gene SREBP-1c and increases plasma triglyceride levels. Expression of fatty acid synthase (FAS), a central enzyme in de novo lipogenesis and an established target of the SREBP-1 pathway, is also induced by LXR ligands. The effects of LXR ligands on FAS expression have been proposed to be entirely secondary to the induction of SREBP-1c. We demonstrate here that LXRs regulate FAS expression through direct interaction with the FAS promoter as well as through activation of SREBP-1c expression. Induction of FAS expression in HepG2 cells by LXR ligands is reduced, but not abolished, under conditions where SREBP processing is suppressed. Moreover, LXR ligands induce FAS expression in CHO-7 cells without altering expression of SREBP-1. We demonstrate that in addition to tandem SREBP sites, the FAS promoter contains a high affinity binding site for the LXR/RXR heterodimer that is conserved in diverse animal species including birds, rodents, and humans. The LXR and SREBP binding sites independently confer LXR responsiveness on the FAS promoter, and maximal induction requires both transcription factors. Transient elevation of plasma triglyceride levels in mice treated with a synthetic LXR agonist correlates with transient induction of hepatic FAS expression. These results indicate that the LXR signaling pathway modulates FAS expression through distinct but complementary mechanisms and suggest that the FAS gene may be a critical target in the control of lipogenesis by LXRs.	Univ Calif Los Angeles, Howard Hughes Med Inst, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; GlaxoSmithKline, Nucl Receptor Discovery Res, Res Triangle Pk, NC 27709 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Irvine; GlaxoSmithKline	Tontonoz, P (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Sch Med, Box 951662, Los Angeles, CA 90095 USA.		Patel, Parthive H./ABC-8505-2021	Joseph, Sean/0000-0002-2602-8517; Patel, Parthive/0000-0002-9288-8056				Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Costet P, 2000, J BIOL CHEM, V275, P28240; DeBose-Boyd RA, 2001, P NATL ACAD SCI USA, V98, P1477, DOI 10.1073/pnas.98.4.1477; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Laffitte BA, 2001, MOL CELL BIOL, V21, P7558, DOI 10.1128/MCB.21.22.7558-7568.2001; LAFFITTE BA, 2001, P NATL ACAD SCI US; Latasa MJ, 2000, P NATL ACAD SCI USA, V97, P10619, DOI 10.1073/pnas.180306597; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; Peet DJ, 1998, CURR OPIN GENET DEV, V8, P571, DOI 10.1016/S0959-437X(98)80013-0; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Sul HS, 1998, ANNU REV NUTR, V18, P331, DOI 10.1146/annurev.nutr.18.1.331; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001	33	600	630	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11019	11025		10.1074/jbc.M111041200	http://dx.doi.org/10.1074/jbc.M111041200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11790787	hybrid			2022-12-27	WOS:000174613100035
J	Barros, MH; Nobrega, FG; Tzagoloff, A				Barros, MH; Nobrega, FG; Tzagoloff, A			Mitochondrial ferredoxin is required for heme A synthesis in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; BACILLUS-SUBTILIS-CTAA; COLI SHUTTLE VECTORS; ESCHERICHIA-COLI; HUMAN ADRENODOXIN; RESTRICTION SITES; A BIOSYNTHESIS; ESSENTIAL GENE; YEAST; CODES	Heme A is a prosthetic group of all eukaryotic and some prokaryotic cytochrome oxidases. This heme differs from heme B (protoheme) at two carbon positions of the porphyrin ring. The synthesis of heme A begins with farnesylation of the vinyl group at carbon C-2 of heme B. The heme 0 product of this reaction is then converted to heme A by a further oxidation of a methyl to a formyl group on C-8. In a previous study (Barros, M. H., Carlson, C. G., Glerum, D. M., and Tzagoloff, A. (2001) FEBS Lett. 492, 133-138) we proposed that the formyl group is formed by an initial hydroxylation of the C-8 methyl by a three-component monooxygenase consisting of Cox15p, ferredoxin, and ferredoxin reductase. In the present study three lines of evidence confirm a requirement of ferredoxin in heme A synthesis. 1) Temperature-conditional yah1 mutants grown under restrictive conditions display a decrease in heme A relative to heme B. 2) The incorporation of radioactive delta-aminolevulinic acid into heme A is reduced in yah1 ts but not in the wild type after the shift to the restrictive temperature; and 3) the overexpression of Cox15p in cytochrome oxidase mutants that accumulate heme 0 leads to an increased mitochondrial concentration of heme A. The increase in heme A is greater in mutants that overexpress Cox15p and ferredoxin. These results are consistent with a requirement of ferredoxin and indirectly of ferredoxin reductase in hydroxylation of heme O.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; UNIVAP, Inst Pisquisa & Desenvolvimento, BR-12244000 Sao Jose Dos Campos, SP, Brazil	Columbia University; Universidade do Vale do Paraiba	Tzagoloff, A (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	spud@cubpet2.bio.columbia.edu	Barros, Mario H/B-8118-2012; Barros, Mario/Q-6358-2019	Barros, Mario/0000-0003-2977-9815	NIGMS NIH HHS [GM50187, R01 GM050187] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barros MH, 2001, FEBS LETT, V492, P133, DOI 10.1016/S0014-5793(01)02249-9; Barros MH, 1999, GENE, V233, P197, DOI 10.1016/S0378-1119(99)00137-7; BRENTANO ST, 1992, P NATL ACAD SCI USA, V89, P4099, DOI 10.1073/pnas.89.9.4099; CAUGHEY WS, 1975, J BIOL CHEM, V250, P7602; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Jan PS, 2000, MOL GEN GENET, V263, P483, DOI 10.1007/s004380051192; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Li J, 2001, J BIOL CHEM, V276, P1503, DOI 10.1074/jbc.M007198200; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Maniatis T., 1982, MOL CLONING; Manzella L, 1998, YEAST, V14, P839, DOI 10.1002/(SICI)1097-0061(19980630)14:9<839::AID-YEA283>3.0.CO;2-A; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; PICADOLEONARD J, 1988, J BIOL CHEM, V263, P3240; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAIKI K, 1993, J BIOL CHEM, V268, P26041; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULZE M, 1988, MOL GEN GENET, V211, P492, DOI 10.1007/BF00425706; SHEMIN D, 1953, J AM CHEM SOC, V75, P4873, DOI 10.1021/ja01115a546; SIMPSON ER, 1966, BIOCHEM BIOPH RES CO, V24, P10, DOI 10.1016/0006-291X(66)90402-5; Souza RL, 2000, J BIOL CHEM, V275, P14898, DOI 10.1074/jbc.275.20.14898; SVENSSON B, 1993, MOL MICROBIOL, V10, P193, DOI 10.1111/j.1365-2958.1993.tb00915.x; SVENSSON B, 1994, J BACTERIOL, V176, P6663, DOI 10.1128/JB.176.21.6663-6671.1994; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990	32	80	82	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9997	10002		10.1074/jbc.M112025200	http://dx.doi.org/10.1074/jbc.M112025200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11788607	hybrid			2022-12-27	WOS:000174549200053
J	Liu, Y; Buhring, HJ; Zen, K; Burst, SL; Schnell, FJ; Williams, IR; Parkos, CA				Liu, Y; Buhring, HJ; Zen, K; Burst, SL; Schnell, FJ; Williams, IR; Parkos, CA			Signal regulatory protein (SIRP alpha), a cellular ligand for CD47, regulates neutrophil transmigration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; TYROSINE-PHOSPHATASE SHP-1; MYELOID CELLS; IV COLLAGEN; RECEPTOR; MEMBRANE; IDENTIFICATION; THROMBOSPONDIN; ACTIVATION; MIGRATION	Recent studies have demonstrated that CD47 plays an important role in regulating human neutrophil (PMN) chemotaxis. Two ligands for CD47, thrombospondin and SIRPalpha, have been described. However, it is not known if SIRP-CD47 interactions play a role in regulating PMN migration. In this study, we show that SIRPalpha1 directly binds to the immunoglobulin variable domain loop of purified human CD47 and that such SIRP-CD47 interactions regulate PMN transmigration. Specifically, PAIN migration across both human epithelial monolayers and collagen-coated filters was partially inhibited by anti-SIRP monoclonal antibodies. Similar kinetics of inhibition were observed for PMN transmigration in the presence of soluble, recombinant CD47 consisting of the SIRP-binding loop. In contrast, anti-CD47 monoclonal antibodies inhibited PMN transmigration by markedly different kinetics. Results of signal transduction experiments suggested differential regulation of PMN migration by SIRP versus CD47 by phosphatidylinositol 3-kinase and tyrosine kinases, respectively. Immunoprecipitation followed by Western blotting after SDS-PAGE under nonreducing conditions suggested that several SIRP protein species may be present in PMN. Stimulation of PAIN with fMLP resulted in increased surface expression of these SIRP proteins, consistent with the existence of intracellular pools. Taken together, these results demonstrate that PAIN migration is regulated by CD47 through SIRPalpha-dependent and SIRPalpha-independent mechanisms.	Emory Univ, Dept Pathol & Lab Med, Div Gastrointestinal Pathol, Atlanta, GA 30322 USA; Univ Tubingen, Dept Internal Med 2, Div Hematol Immunol & Oncol, D-72076 Tubingen, Germany	Emory University; Eberhard Karls University of Tubingen	Liu, Y (corresponding author), Emory Univ, Dept Pathol & Lab Med, Div Gastrointestinal Pathol, Whitehead Biomed Bldg,Rm 115,615 Michael St, Atlanta, GA 30322 USA.		Williams, Ifor R/D-3648-2011; Parkos, Charles a/B-3896-2009	Williams, Ifor R/0000-0002-8810-2911; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054229, R01HL060540, R01HL054229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK010013] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60540, HL54229] Funding Source: Medline; NIAMS NIH HHS [AR44268] Funding Source: Medline; NIDDK NIH HHS [DK10013] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams S, 1998, J IMMUNOL, V161, P1853; Babic I, 2000, J IMMUNOL, V164, P3652, DOI 10.4049/jimmunol.164.7.3652; Balsam LB, 1998, J IMMUNOL, V160, P5058; Brittain JE, 2001, J CLIN INVEST, V107, P1555, DOI 10.1172/JCI10817; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Brumell JH, 1997, J BIOL CHEM, V272, P875, DOI 10.1074/jbc.272.2.875; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; Chung J, 1999, BLOOD, V94, P642, DOI 10.1182/blood.V94.2.642.414k35_642_648; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; Dietrich J, 2000, J IMMUNOL, V164, P9, DOI 10.4049/jimmunol.164.1.9; Furusawa T, 1998, J BIOCHEM-TOKYO, V123, P101; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Han X, 2000, J BIOL CHEM, V275, P37984, DOI 10.1074/jbc.M002334200; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; Liu Y, 2000, J CELL SCI, V113, P2363; Liu Y, 2001, J BIOL CHEM, V276, P40156, DOI 10.1074/jbc.M104138200; Mateo V, 1999, NAT MED, V5, P1277, DOI 10.1038/15233; Mi ZP, 2000, J COMP NEUROL, V416, P335; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; PARKOS CA, 1991, J CLIN INVEST, V88, P1605, DOI 10.1172/JCI115473; Pettersen RD, 1999, J IMMUNOL, V162, P7031; Rebres RA, 2001, J BIOL CHEM, V276, P34607, DOI 10.1074/jbc.M106107200; Reinhold MI, 1997, J EXP MED, V185, P1, DOI 10.1084/jem.185.1.1; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Seiffert M, 2001, BLOOD, V97, P2741, DOI 10.1182/blood.V97.9.2741; Shahan TA, 1999, CANCER RES, V59, P4584; Stofega MR, 2000, J BIOL CHEM, V275, P28222; Stofega MR, 1998, J BIOL CHEM, V273, P7112, DOI 10.1074/jbc.273.12.7112; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; Tomasello E, 2000, SEMIN IMMUNOL, V12, P139, DOI 10.1006/smim.2000.0216; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; Waclavicek M, 1997, J IMMUNOL, V159, P5345; Wang XQ, 1999, J CELL BIOL, V147, P389, DOI 10.1083/jcb.147.2.389; Wang XQ, 1998, MOL BIOL CELL, V9, P865, DOI 10.1091/mbc.9.4.865; Ziaie Z, 1999, BIOCHEM BIOPH RES CO, V261, P247, DOI 10.1006/bbrc.1999.1029	42	167	192	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10028	10036		10.1074/jbc.M109720200	http://dx.doi.org/10.1074/jbc.M109720200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11792697	hybrid			2022-12-27	WOS:000174549200057
J	Liu, ZX; Yu, CF; Nickel, C; Thomas, S; Cantley, LG				Liu, ZX; Yu, CF; Nickel, C; Thomas, S; Cantley, LG			Hepatocyte growth factor induces ERK-dependent paxillin phosphorylation and regulates paxillin-focal adhesion kinase association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; TYROSINE PHOSPHORYLATION; EXPRESSION; BINDING; IDENTIFICATION; LOCALIZATION; FIBRONECTIN; ACTIVATION; MECHANISM; VINCULIN	Hepatocyte growth factor (HGF) modulates cell adhesion, migration, and branching morphogenesis in cultured epithelial cells, events that require regulation of cell-matrix interactions. Using mIMCD-3 epithelial cells, we studied the effect of HGF on the focal adhesion proteins, focal adhesion kinase (FAK) and paxillin and their association. HGF was found to increase the tyrosine phosphorylation of paxillin and to a lesser degree FAK. In addition, HGF induced association of paxillin and activated ERK, correlating with a gel retardation of paxillin that was prevented with the ERK inhibitor U0126. The ability of activated ERK to phosphorylate and induce gel retardation of paxillin was confirmed in vitro in both full-length and amino-terminal paxillin. Several potential ERK phosphorylation sites in paxillin flank the paxillin-FAK association domains, so the ability of HGF to regulate paxillin-FAK association was examined. HGF induced an increase in paxillin-FAK association that was inhibited by pretreatment with U0126 and reproduced by in vitro phosphorylation of paxillin with ERK. The prevention of the FAR-paxillin association with U0126 correlated with an inhibition of the HGF-mediated FAK tyrosine phosphorylation and inhibition of HGF-dependent cell spreading and adhesion. An examination of cellular localization of FAK and paxillin demonstrated that HGF caused a condensation of focal adhesion complexes at the leading edges of cell processes and FAK-paxillin co-localization in these large complexes. Thus, these data suggest that HGF can induce serine/threonine phosphorylation of paxillin most probably mediated directly by ERK, resulting in the recruitment and activation of FAK and subsequent enhancement of cell spreading and adhesion.	Yale Univ, Sch Med, Nephrol Sect, New Haven, CT 06520 USA; Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA	Yale University; Harvard University; Beth Israel Deaconess Medical Center	Cantley, LG (corresponding author), Yale Univ, Sch Med, Nephrol Sect, 333 Cedar St,LMP 2093, New Haven, CT 06520 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653				Bellis SL, 1997, BIOCHEM J, V325, P375, DOI 10.1042/bj3250375; Beviglia L, 1999, INT J CANCER, V83, P640, DOI 10.1002/(SICI)1097-0215(19991126)83:5<640::AID-IJC13>3.0.CO;2-D; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; CANTLEY LG, 1994, AM J PHYSIOL, V267, P271; Chen HC, 1998, J BIOL CHEM, V273, P25777, DOI 10.1074/jbc.273.40.25777; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Karihaloo A, 2001, J BIOL CHEM, V276, P9166, DOI 10.1074/jbc.M009963200; Ku H, 2000, J BIOL CHEM, V275, P11333, DOI 10.1074/jbc.275.15.11333; Lai JF, 2000, J BIOL CHEM, V275, P7474, DOI 10.1074/jbc.275.11.7474; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Liu ZX, 2001, AM J PHYSIOL-RENAL, V281, pF62, DOI 10.1152/ajprenal.2001.281.1.F62; MELAMED I, 1995, J EXP MED, V181, P1071, DOI 10.1084/jem.181.3.1071; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nebe B, 1998, EXP CELL RES, V243, P263, DOI 10.1006/excr.1998.4143; OLIVER MH, 1989, J CELL SCI, V92, P513; RANKIN S, 1994, J BIOL CHEM, V269, P704; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Roshan B, 1999, J BIOL CHEM, V274, P36362, DOI 10.1074/jbc.274.51.36362; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Trusolino L, 2000, FASEB J, V14, P1629, DOI 10.1096/fj.14.11.1629; TURNER CE, 1995, J CELL SCI, V108, P333; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yu CF, 2001, J BIOL CHEM, V276, P32552, DOI 10.1074/jbc.M104493200; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	31	127	130	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10452	10458		10.1074/jbc.M107551200	http://dx.doi.org/10.1074/jbc.M107551200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11784715	hybrid			2022-12-27	WOS:000174549200112
J	Ma, Q; Shimaoka, M; Lu, C; Jing, H; Carman, CV; Springer, TA				Ma, Q; Shimaoka, M; Lu, C; Jing, H; Carman, CV; Springer, TA			Activation-induced conformational changes in the I domain region of lymphocyte function-associated antigen 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE-1 ICAM-1; BETA-PROPELLER DOMAIN; LIGAND-BINDING; A-DOMAIN; CR3-DEPENDENT ADHESION; CRYSTAL-STRUCTURE; DIVALENT-CATION; INTEGRIN; AFFINITY; LFA-1	Conformational changes in integrins are important for efficient ligand binding during activation. We proposed that the I domain of the integrin lymphocyte function-associated antigen 1 (LFA-1) could exist in both open and closed conformations and generated constitutively activated LFA-1 by locking the I domain in the open conformation. Here we provide structural and biochemical evidence to validate conformational change in the I domain of LFA-1 upon activation. Two monoclonal antibodies to alpha(L), HI111 and CBR LFA-1/1, bind wild-type LFA-1 well, but their binding is significantly reduced when LFA-1 is locked in the open conformation. Furthermore, this reduction in monoclonal antibody binding also occurs when LFA-1 is activated by divalent cations. HI111 maps to the top region of the I domain that is close to the putative ligand-binding site surrounding the MIDAS (metal ion-dependent adhesion site). The epitope of CBR LFA-1/1 is at the C-terminal segment of the I domain that links to the beta-propeller, and undergoes a large movement between the open and closed conformations. Our data demonstrate that these two regions undergo significant conformational changes during LFA-1 activation and that the I domain of activated LFA-1 adopts a similar tertiary structure as the predicted locked open form.	Ctr Blood Res, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School	Springer, TA (corresponding author), Ctr Blood Res, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.		Carman, Christopher/L-8108-2016; Carman, Christopher V./AAX-8995-2020	Carman, Christopher/0000-0001-7358-2548; Carman, Christopher V./0000-0001-7358-2548	NCI NIH HHS [CA317988] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; BINNERTS ME, 1994, EUR J IMMUNOL, V24, P2155, DOI 10.1002/eji.1830240933; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Gahmberg CG, 1997, EUR J BIOCHEM, V245, P215, DOI 10.1111/j.1432-1033.1997.00215.x; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; KNAPP W, 1989, LEUCOCYTE TYPING, V4; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; Last-Barney K, 2001, J AM CHEM SOC, V123, P5643, DOI 10.1021/ja0104249; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Legge GB, 2000, J MOL BIOL, V295, P1251, DOI 10.1006/jmbi.1999.3409; Liu G, 2001, J MED CHEM, V44, P1202, DOI 10.1021/jm000503f; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 1997, J IMMUNOL, V159, P268; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Lupher ML, 2001, J IMMUNOL, V167, P1431, DOI 10.4049/jimmunol.167.3.1431; McDowall A, 1998, J BIOL CHEM, V273, P27396, DOI 10.1074/jbc.273.42.27396; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; PETRUZZELLI L, 1995, J IMMUNOL, V155, P854; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Shimaoka M, 2000, NAT STRUCT BIOL, V7, P674, DOI 10.1038/77978; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Stephens P, 1995, CELL ADHES COMMUN, V3, P375, DOI 10.3109/15419069509081292; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2000, J BIOL CHEM, V275, P38762, DOI 10.1074/jbc.C000563200; Zang Q, 2000, J BIOL CHEM, V275, P22202, DOI 10.1074/jbc.M002883200	41	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10638	10641		10.1074/jbc.M112417200	http://dx.doi.org/10.1074/jbc.M112417200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11792712	hybrid			2022-12-27	WOS:000174549200135
J	Sugawara, A; Uruno, A; Kudo, M; Ikeda, Y; Sato, K; Taniyama, Y; Ito, S; Takeuchi, K				Sugawara, A; Uruno, A; Kudo, M; Ikeda, Y; Sato, K; Taniyama, Y; Ito, S; Takeuchi, K			Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor-gamma via an interaction with Sp1 in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; DIFFERENTIAL EXPRESSION; 5'-FLANKING REGION; MOLECULAR-CLONING; SYNTHASE GENE; RETINOIC ACID; KAPPA-B; TROGLITAZONE; REGULATOR; PROMOTER	Thromboxane (TX) A(2) exerts contraction and proliferation of vascular smooth muscle cells (VSMCs) via its specific membrane TX receptor (TXR), possibly leading to the progression of atherosclerosis. A nuclear hormone receptor, peroxisome proliferator-activated receptor (PPAR)-gamma, has recently been reported to be expressed in VSMCs. Here we examined a role of PPAR-gamma in TXR gene expression in VSMCs. PPAR-gamma ligands 15-deoxy-Delta(12,14)-prostaglandin J(2) and troglitazone reduced TXR mRNA expression levels as well as cell growth as assessed by [H-3]thymidine incorporation. Transcriptional activity of the TXR gene promoter was suppressed with PPAR-gamma ligands, and the suppression was augmented further by PPAR-gamma overexpression. By deletion and mutation analyses, the transcription suppression was shown to be the result of a -22/-7 GC box-related sequence (upstream of transcription start site). Electrophoretic mobility shift assays also showed that the sequence was bound by Sp1 but not by PPAR-gamma, and the formation of a Sp1.DNA complex was inhibited either by coincubation with PPAR-gamma or PPAR-gamma ligand treatment of VSMCs. Moreover, glutathione S-transferase pull-down assays demonstrated a direct interaction between PPAR-gamma and Sp1. In conclusion, PPAR-gamma suppresses TXR gene transcription via an interaction with Sp1. PPAR-gamma may possibly have an antiatherosclerotic action by inhibiting TXR gene expression in VSMCs.	Tohoku Univ, Grad Sch Med, Dept Med, Div Nephrol Endocrinol & Vasc Med,Aoba Ku, Sendai, Miyagi 9808574, Japan	Tohoku University	Sugawara, A (corresponding author), Tohoku Univ, Grad Sch Med, Dept Med, Div Nephrol Endocrinol & Vasc Med,Aoba Ku, 1-1 Seiryo Cho, Sendai, Miyagi 9808574, Japan.	akiras2i@mail.cc.tohoku.ac.jp	Ito, Sadayoshi/A-3933-2015; Uruno, Akira/ABF-3988-2020; Uruno, Akira/U-1812-2019	Sugawara, Akira/0000-0003-4511-8101; Ito, Sadayoshi/0000-0002-5092-3626				ABE T, 1995, J CLIN INVEST, V96, P657, DOI 10.1172/JCI118108; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Carr ME, 2001, J DIABETES COMPLICAT, V15, P44, DOI 10.1016/S1056-8727(00)00132-X; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Chung SW, 2000, J BIOL CHEM, V275, P32681, DOI 10.1074/jbc.M002577200; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DORN GW, 1992, J BIOL CHEM, V267, P24897; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Ghazzi MN, 1997, DIABETES, V46, P433, DOI 10.2337/diabetes.46.3.433; Hattori Y, 1999, RES COMMUN MOL PATH, V104, P73; Hishinuma T, 1999, PROSTAG OTH LIPID M, V58, P263, DOI 10.1016/S0090-6980(99)00029-5; Hishinuma T, 2000, PROSTAG OTH LIPID M, V62, P135, DOI 10.1016/S0090-6980(00)00059-9; Ikeda Y, 2000, J BIOL CHEM, V275, P33142, DOI 10.1074/jbc.M002319200; Imano E, 1998, DIABETES CARE, V21, P2135, DOI 10.2337/diacare.21.12.2135; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kato K, 1999, BIOCHEM BIOPH RES CO, V258, P431, DOI 10.1006/bbrc.1999.0648; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kobayashi A, 1996, J BIOL CHEM, V271, P12310, DOI 10.1074/jbc.271.21.12310; Lasserre B, 2000, PROSTAG LEUKOTR ESS, V62, P285, DOI 10.1054/plef.2000.0156; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Marx N, 1998, CIRC RES, V83, P1097, DOI 10.1161/01.RES.83.11.1097; MEHTA JL, 1988, P NATL ACAD SCI USA, V85, P4511, DOI 10.1073/pnas.85.12.4511; Minamikawa J, 1998, J CLIN ENDOCR METAB, V83, P1818, DOI 10.1210/jc.83.5.1818; OGIHARA T, 1995, AM J HYPERTENS, V8, P316, DOI 10.1016/0895-7061(95)96214-5; Okumura M, 1999, LIFE SCI, V66, P371; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pakala R, 1997, CIRCULATION, V96, P2280; REMUZZI G, 1985, J CLIN INVEST, V75, P94, DOI 10.1172/JCI111703; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Sugawara A, 1999, HYPERTENSION, V34, P363; SUGAWARA A, 1995, ENDOCRINOLOGY, V136, P1766, DOI 10.1210/en.136.4.1766; Sugawara A, 1998, ENDOCRINOLOGY, V139, P3030, DOI 10.1210/en.139.6.3030; Suzuki Y, 1999, BLOOD, V93, P4264, DOI 10.1182/blood.V93.12.4264.412k27_4264_4276; Takahashi N, 1998, BIOCHEM BIOPH RES CO, V244, P489, DOI 10.1006/bbrc.1998.8283; TAKAHASHI N, 1995, ENDOCRINOLOGY, V136, P4143, DOI 10.1210/en.136.9.4143; Takahashi N, 1996, ENDOCRINOLOGY, V137, P5170, DOI 10.1210/en.137.11.5170; TAKEUCHI K, 1993, CIRC RES, V73, P612, DOI 10.1161/01.RES.73.4.612; Takeuchi K, 1996, CYTOGENET CELL GENET, V73, P79, DOI 10.1159/000134312; Tolon RM, 1998, J BIOL CHEM, V273, P26652, DOI 10.1074/jbc.273.41.26652; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; Welch WJ, 1997, AM J PHYSIOL-RENAL, V273, pF976, DOI 10.1152/ajprenal.1997.273.6.F976; YOKOYAMA C, 1991, BIOCHEM BIOPH RES CO, V178, P1479, DOI 10.1016/0006-291X(91)91060-P	52	76	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9676	9683		10.1074/jbc.M104560200	http://dx.doi.org/10.1074/jbc.M104560200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11777901	hybrid			2022-12-27	WOS:000174549200011
J	Kuroda, TS; Fukuda, M; Ariga, H; Mikoshiba, K				Kuroda, TS; Fukuda, M; Ariga, H; Mikoshiba, K			The Slp homology domain of synaptotagmin-like proteins 1-4 and Slac2 functions as a novel Rab27A binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHOLIPID-BINDING; DOUBLE C2 PROTEIN; MOLECULAR-CLONING; FAMILY; MELANOSOME; DOC2; TRANSMEMBRANE; RABPHILIN-3A; EXOCYTOSIS; MUTATIONS	rab27A, which encodes a small GTP-binding protein, was recently identified as a gene in which mutations caused human hemophagocytic syndrome (Griscelli syndrome) and ashen mice, which exhibit defects in melanosome transport as well as in regulated granule exocytosis in cytotoxic T lymphocytes. However, little is known about the molecular mechanism of Rab27A-dependent membrane trafficking or the specific effector molecules of Rab27A. In this study, we discovered that the Slp (synaptotagmin-like protein) homology domain (SHD) of Slp1-3 and Slac2-a/b specifically and directly binds the GTP-bound form of Rab27A both in vitro and in intact cells but not of the other Rabs tested (Rab1, Rab2, Rab3A, Rab4, Rab5A, Rab6A, Rab7, Rab8, Rab9, Rab10, Rab11A, Rab17, Rab18, Rab20, Rab22, Rab23, Rab25, Rab28, and Rab37). Immunocytochemical analysis revealed that Slp2 (or Slp1) colocalized with Rab27A in the melanosomes of melanoma cells. Slp2 and Rab27A were distributed to the periphery of the cells (especially at the dendritic tips) in the wild-type melanoma cells, whereas they accumulated in the perinuclear region in the melanosome transport-defective cells (S91/Cloudman). These results strongly indicated that the SHD of Slp1-3 and Slac2 functions as an in vivo Rab27A binding domain.	RIKEN, Brain Sci Inst, Lab Dev Neurobiol, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol Minato Ku, Tokyo 1088639, Japan	RIKEN; Hokkaido University; University of Tokyo	Fukuda, M (corresponding author), RIKEN, Brain Sci Inst, Lab Dev Neurobiol, Inst Phys & Chem Res, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Mikoshiba, Katsuhiko/N-7943-2015; Ariga, Hiroyoshi/B-5895-2013; Fukuda, MItsunori/I-1511-2015	Ariga, Hiroyoshi/0000-0001-7384-2143; Fukuda, MItsunori/0000-0002-8620-5853; Kuroda, Taruho/0000-0001-6693-4496				Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; Berkowitz JKM, 2001, J BIOL CHEM, V276, P18855, DOI 10.1074/jbc.M011167200; Chen D, 1997, BIOCHEM MOL MED, V60, P27, DOI 10.1006/bmme.1996.2559; FIDLER IJ, 1975, CANCER RES, V35, P218; Fukuda M, 2001, J BIOL CHEM, V276, P40319, DOI 10.1074/jbc.M105356200; Fukuda M, 2000, BIOCHEM BIOPH RES CO, V276, P626, DOI 10.1006/bbrc.2000.3520; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, J BIOL CHEM, V276, P24441, DOI 10.1074/jbc.C100119200; Fukuda M, 2001, FEBS LETT, V503, P217, DOI 10.1016/S0014-5793(01)02738-7; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Ibata K, 2000, J NEUROCHEM, V74, P518, DOI 10.1046/j.1471-4159.2000.740518.x; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Kojima T, 1996, J BIOCHEM-TOKYO, V120, P671; Kotake K, 1997, J BIOL CHEM, V272, P29407, DOI 10.1074/jbc.272.47.29407; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOORE KJ, 1988, P NATL ACAD SCI USA, V85, P8131, DOI 10.1073/pnas.85.21.8131; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P439, DOI 10.1006/bbrc.1995.1062; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Ponting CP, 1996, PROTEIN SCI, V5, P162; Sakaguchi G, 1995, BIOCHEM BIOPH RES CO, V217, P1053, DOI 10.1006/bbrc.1995.2876; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugimori M, 1998, NEUROSCIENCE, V86, P39, DOI 10.1016/S0306-4522(97)00689-1; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XF, 2001, J CELL SCI, V114, P1091; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; YASUMURA Y, 1966, SCIENCE, V154, P1186, DOI 10.1126/science.154.3753.1186; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	46	173	184	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9212	9218		10.1074/jbc.M112414200	http://dx.doi.org/10.1074/jbc.M112414200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11773082	hybrid			2022-12-27	WOS:000174400600065
J	Li, JY; Lescure, PA; Misek, DE; Lai, YM; Chai, BX; Kuick, R; Thompson, RC; Demo, RM; Kurnit, DM; Michailidis, G; Hanash, SM; Gantz, I				Li, JY; Lescure, PA; Misek, DE; Lai, YM; Chai, BX; Kuick, R; Thompson, RC; Demo, RM; Kurnit, DM; Michailidis, G; Hanash, SM; Gantz, I			Food deprivation-induced expression of minoxidil sulfotransferase in the hypothalamus uncovered by microarray analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM	We used oligonucleotide microarrays to analyze comprehensively hypothalamic gene expression changes that correlate with energy homeostasis. We compared the hypothalamic gene expression profiles of freely fed and 48-h fasted rats using 26,379 oligonucleotide probe sets. Expression of 96 genes was up-regulated and expression of 73 genes was down-regulated in a statistically significant manner with fasting. The gene encoding the enzyme minoxidil sulfotransferase, an enzyme that catalyzes the transfer of sulfonate groups to biogenic amines and other substrates, was foremost among a set of genes whose mRNAs were uniformly detectable and displaying the greatest transcriptional changes with fasting. Northern blot analysis indicated that minoxidil sulfotransferase mRNA is up-regulated in the fasted rat and mouse, ob/ob mouse, and fa/fa rat. Results of reverse transcription quantitative PCR indicated that minoxidil sulfotransferase mRNA is also up-regulated in the microdissected arcuate and paraventricular nuclei of the fasted rat. Several index genes known to be either up-regulated (neuropeptide Y) or down-regulated (amphetamine-regulated transcript and proopiomelanocortin) with fasting were also found to be present among our set of ''differentially expressed'' genes. This study identifies a novel gene induced by fasting and demonstrates the feasibility of using oligonucleotide microarrays for the study of complex neuronal processes.	Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Stat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Communicable Dis, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Gantz, I (corresponding author), Univ Michigan, Dept Surg, 6504 MSRB I,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933, R01DK054032] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30DK34933, 1R01 DK54032-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beattie JH, 1998, P NATL ACAD SCI USA, V95, P358, DOI 10.1073/pnas.95.1.358; Dooley T P, 1999, Exp Dermatol, V8, P328; Falany CN, 1997, FASEB J, V11, P1; Good P., 1993, PERMUTATION TESTS; Kerr MK, 2000, J COMPUT BIOL, V7, P819, DOI 10.1089/10665270050514954; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; PALKOVITS M, 1973, BRAIN RES, V59, P449, DOI 10.1016/0006-8993(73)90290-4; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; SAMBROOK J, 1989, MOL CLONING LABORATO, V7, P43; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Smith GP, 2000, NUTRITION, V16, P814, DOI 10.1016/S0899-9007(00)00457-3; TYCE GM, 1986, FASEB J, V45, P2247; Uwabe K, 1997, NEUROSCIENCE, V80, P501, DOI 10.1016/S0306-4522(97)00112-7; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160	15	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9069	9076		10.1074/jbc.M110467200	http://dx.doi.org/10.1074/jbc.M110467200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11782476	hybrid			2022-12-27	WOS:000174400600046
J	Suaud, L; Li, JQ; Jiang, QS; Rubenstein, RC; Kleyman, TR				Suaud, L; Li, JQ; Jiang, QS; Rubenstein, RC; Kleyman, TR			Genistein restores functional interactions between Delta F508-CFTR and ENaC in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL SODIUM-CHANNEL; RECTIFYING CHLORIDE CHANNELS; CYSTIC-FIBROSIS MUTATION; CFTR CL CHANNEL; NA+ CHANNEL; CELL-SURFACE; A6 CELLS; IN-VIVO; TRANSPORT	The cystic fibrosis transmembrane conductance regulator (CFTR), in addition to its Cl- channel properties, has regulatory interactions with other epithelial ion channels including the epithelial Na+ channel (ENaC). Both the open probability and surface expression of wild type CFTR Cl- channels are increased significantly when CFTR is co-expressed in Xenopus oocytes with alphabetagamma-ENaC, and conversely, the activity of ENaC is inhibited following wild type CFTR activation. Using the Xenopus oocyte expression system, a lack of functional regulatory interactions between DeltaF508-CFTR and ENaC was observed following activation of DeltaF508-CFTR by forskolin and isobutylmethylxanthine (IBMX). Whole cell currents in oocytes expressing ENaC alone decreased in response to genistein but increased in response to a combination of forskolin and IBMX followed by genistein. In contrast, ENaC currents in oocytes co-expressing ENaC and DeltaF508-CFTR remained stable following stimulation with forskolin/IBMX/genistein. Furthermore, co-expression of DeltaF508-CFTR with ENaC enhanced the forskolin/IBMX/genistein-mediated activation of DeltaF508-CFTR. Our data suggest that genistein restores regulatory interactions between DeltaF508-CFTR and ENaC and that combinations of protein repair agents, such as 4-phenylbutyrate and genistein, may be necessary to restore DeltaF508-CFTR function in vivo.	Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Childrens Hosp Philadelphia, Div Pulm Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania	Kleyman, TR (corresponding author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, A919 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.			Rubenstein, Ronald/0000-0002-3138-4006	NIDDK NIH HHS [DK58046, DK56305] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058046, R01DK056305] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Briel M, 1998, J PHYSIOL-LONDON, V508, P825, DOI 10.1111/j.1469-7793.1998.825bp.x; Brown CR, 1997, J BIOENERG BIOMEMBR, V29, P491, DOI 10.1023/A:1022491124939; BURCH LH, 1995, AM J PHYSIOL-CELL PH, V269, pC511, DOI 10.1152/ajpcell.1995.269.2.C511; Chabot H, 1999, J MEMBRANE BIOL, V169, P175, DOI 10.1007/s002329900529; Choi JY, 2001, NATURE, V410, P94, DOI 10.1038/35065099; Choo-Kang LR, 2001, AM J PHYSIOL-LUNG C, V281, pL58, DOI 10.1152/ajplung.2001.281.1.L58; Chraibi A, 2001, J MEMBRANE BIOL, V183, P15, DOI 10.1007/s00232-001-0049-6; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; French PJ, 1996, J CLIN INVEST, V98, P1304, DOI 10.1172/JCI118917; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; Gao L, 1999, AM J PHYSIOL-LUNG C, V277, pL113, DOI 10.1152/ajplung.1999.277.1.L113; Hwang TC, 1997, AM J PHYSIOL-CELL PH, V273, pC988, DOI 10.1152/ajpcell.1997.273.3.C988; Illek B, 1997, AM J PHYSIOL-LUNG C, V272, pL752, DOI 10.1152/ajplung.1997.272.4.L752; Ismailov II, 1997, AM J PHYSIOL-CELL PH, V272, pC1077, DOI 10.1152/ajpcell.1997.272.4.C1077; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Ji HL, 2000, J BIOL CHEM, V275, P27947; Jiang QS, 2000, J BIOL CHEM, V275, P13266, DOI 10.1074/jbc.275.18.13266; Jiang QS, 1998, J CELL BIOL, V143, P645, DOI 10.1083/jcb.143.3.645; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KLEYMAN TR, 1994, AM J PHYSIOL, V266, pF506, DOI 10.1152/ajprenal.1994.266.3.F506; KNOWLES MR, 1995, HUM GENE THER, V6, P445, DOI 10.1089/hum.1995.6.4-445; Konig J, 2001, EMBO REP, V2, P1047, DOI 10.1093/embo-reports/kve232; Kopito Ron R., 1999, Physiological Reviews, V79, pS167; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; Ling BN, 1997, J BIOL CHEM, V272, P594; Linsdell P, 1998, AM J PHYSIOL-CELL PH, V275, pC323, DOI 10.1152/ajpcell.1998.275.1.C323; Mall M, 1996, FEBS LETT, V381, P47, DOI 10.1016/0014-5793(96)00079-8; MATSUMOTO PS, 1993, AM J PHYSIOL, V264, pC246, DOI 10.1152/ajpcell.1993.264.1.C246; Nagel G, 2001, EMBO REP, V2, P249, DOI 10.1093/embo-reports/kve045; Pasyk EA, 1997, J BIOL CHEM, V272, P7746, DOI 10.1074/jbc.272.12.7746; POULSEN JH, 1994, P NATL ACAD SCI USA, V91, P5340, DOI 10.1073/pnas.91.12.5340; Record RD, 1996, AM J PHYSIOL-CELL PH, V271, pC1079, DOI 10.1152/ajpcell.1996.271.4.C1079; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rubenstein RC, 2000, AM J PHYSIOL-CELL PH, V278, pC259, DOI 10.1152/ajpcell.2000.278.2.C259; Rubenstein RC, 1998, AM J RESP CRIT CARE, V157, P484, DOI 10.1164/ajrccm.157.2.9706088; Rubenstein RC, 1997, J CLIN INVEST, V100, P2457, DOI 10.1172/JCI119788; Rubenstein Ronald C., 1998, Current Opinion in Pediatrics, V10, P250, DOI 10.1097/00008480-199806000-00005; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Schreiber R, 1999, P NATL ACAD SCI USA, V96, P5310, DOI 10.1073/pnas.96.9.5310; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037; Sugita M, 1998, EMBO J, V17, P898, DOI 10.1093/emboj/17.4.898; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6	50	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8928	8933		10.1074/jbc.M111482200	http://dx.doi.org/10.1074/jbc.M111482200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11773060	hybrid			2022-12-27	WOS:000174400600027
J	Hirohashi, N; Vacquier, VD				Hirohashi, N; Vacquier, VD			Egg sialoglycans increase intracellular pH and potentiate the acrosome reaction of sea urchin sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUCOSE SULFATE GLYCOCONJUGATE; JELLY COAT; SIALIC-ACID; CA2+; CHANNELS; IDENTIFICATION; GLYCOPROTEIN; POLYMER; PROTEIN	Sea urchin egg jelly (EJ) triggers sperm acrosome reaction (AR), an exocytotic event required for membrane fusion of the gametes. Purified fucose sulfate polymer (FSP) in EJ is one inducer of the AR. Binding of FSP to its receptor regulates opening of two distinct calcium channels and also elevates intracellular pH (pH(i)). EJ also contains sialic acid-rich glycans (sialoglycans (SG)) that were isolated by beta-elimination followed by DEAE chromatography. In the presence of limiting amounts of FSP, the SG fraction markedly potentiates the AR; however, by itself SG has no activity. The SG fraction increases the pH(i) of sperm without increasing intracellular Ca2+. The SG-induced increase in pH(i) is not blocked by nifedipine or high K+, whereas the FSP-induced pH(i) increase is sensitive to both these agents. Treatment of the SG fraction with neuraminidase or mild metaperiodate that specifically cleaves the glycerol side chain of sialic acid abolishes the AR potentiation and ability of SG to elevate pH(i). These data are the first to show that there are at least two pathways to induce sperm pH(i) increase and that egg surface sialic acid plays a role in triggering the sperm AR.	Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Hirohashi, N (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA.	nhirohashi@ucsd.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012986, R37HD012986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK057325] Funding Source: NIH RePORTER; NICHD NIH HHS [HD12986] Funding Source: Medline; NIDDK NIH HHS [1P50DK57325] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alves AP, 1997, J BIOL CHEM, V272, P6965, DOI 10.1074/jbc.272.11.6965; Alves AP, 1998, GLYCOBIOLOGY, V8, P939, DOI 10.1093/glycob/8.9.939; AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; Darszon A, 1999, PHYSIOL REV, V79, P481, DOI 10.1152/physrev.1999.79.2.481; DISCHE Z, 1951, J BIOL CHEM, V192, P579; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; GARBERS DL, 1989, ANNU REV BIOCHEM, V58, P719, DOI 10.1146/annurev.bi.58.070189.003443; Gonzalez-Martinez MT, 2001, DEV BIOL, V236, P220, DOI 10.1006/dbio.2001.0323; GONZALEZMARTINEZ MT, 1992, DEV BIOL, V150, P193, DOI 10.1016/0012-1606(92)90018-C; GUERRERO A, 1989, J BIOL CHEM, V264, P19593; Guerrero A, 1998, BBA-MOL CELL RES, V1401, P329, DOI 10.1016/S0167-4889(97)00127-4; Hirohashi N, 2002, J BIOL CHEM, V277, P1182, DOI 10.1074/jbc.M108046200; HOTTA K, 1973, J BIOL CHEM, V248, P629; HOTTA K, 1970, J BIOL CHEM, V245, P6307; Inoue S, 2001, BIOCHEM BIOPH RES CO, V280, P104, DOI 10.1006/bbrc.2000.4084; ISHIHARA K, 1970, DEV GROWTH DIFFER, V12, P179; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; KELLER SH, 1994, DEV GROWTH DIFFER, V36, P551; KELLER SH, 1994, DEV BIOL, V162, P304, DOI 10.1006/dbio.1994.1087; KITAZUME S, 1994, J BIOL CHEM, V269, P22712; LEE HC, 1985, J BIOL CHEM, V260, P794; Lenten LV, 1971, J BIOL CHEM, V246, P1889; Mengerink KJ, 2002, J BIOL CHEM, V277, P943, DOI 10.1074/jbc.M109673200; Mengerink KJ, 2000, ZYGOTE, V8, pS28; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; SCHACKMANN RW, 1978, DEV BIOL, V65, P483, DOI 10.1016/0012-1606(78)90043-X; SCHACKMANN RW, 1981, DEV BIOL, V81, P145, DOI 10.1016/0012-1606(81)90357-2; SEGALL GK, 1979, DEV BIOL, V71, P33, DOI 10.1016/0012-1606(79)90080-0; SHIMIZU T, 1990, DEV GROWTH DIFFER, V32, P473; SUZUKI N, 1995, ZOOL SCI, V12, P13, DOI 10.2108/zsj.12.13; TERHO TT, 1971, ANAL BIOCHEM, V41, P471, DOI 10.1016/0003-2697(71)90167-9; TRIMMER JS, 1985, CELL, V40, P697, DOI 10.1016/0092-8674(85)90218-1; Vacquier VD, 1997, DEV BIOL, V192, P125, DOI 10.1006/dbio.1997.8729; Vilela-Silva ACES, 1999, GLYCOBIOLOGY, V9, P927, DOI 10.1093/glycob/9.9.927	34	44	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8041	8047		10.1074/jbc.M110661200	http://dx.doi.org/10.1074/jbc.M110661200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11777914	hybrid			2022-12-27	WOS:000174268000053
J	Iovine, N; Eastvold, J; Elsbach, P; Weiss, JP; Gioannini, TL				Iovine, N; Eastvold, J; Elsbach, P; Weiss, JP; Gioannini, TL			The carboxyl-terminal domain of closely related endotoxin-binding proteins determines the target of protein-lipopolysaccharide complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY-INCREASING PROTEIN; PERITONEAL INFLAMMATORY EXUDATE; GRAM-NEGATIVE BACTERIA; TOLL-LIKE RECEPTOR-4; (LPS)-BINDING PROTEIN; SOLUBLE CD14; EXTRACELLULAR COMPONENTS; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; INNATE IMMUNITY	The bactericidal/permeability increasing (BPI) and lipopolysaccharide (LPS)-binding (LBP) proteins are closely related two-domain proteins in which LPS binding is mediated by the NH2-terminal domain. To further define the role of the COOH-terminal domain of these proteins in delivery of LPS to specific host acceptors, we have compared interactions of LBP, BPI, LBPN-BPIC (NH2-terminal domain of LBP, COOH-terminal domain of BPI), and BPIN-LBPC with purified H-3-LPS and, subsequently, with purified leukocytes and soluble (s)CD14. The COOH-terminal domain of LBP promotes delivery of LPS to CD14 on both polymorphonuclear leukocytes and monocytes resulting in cell activation. In the presence of Ca2+ and Mg2+, LBP and BPI each promote aggregation of LPS to protein-LPS aggregates of increased size (apparent M-r > 20 X 10(6) Da), but only LPS associated with LBP and BPIN-LBPC is disaggregated in the presence of CD14. BPI and LBPN-BPIC promote apparently CD14-independent LPS association to monocytes without cell activation. These findings demonstrate that the carboxyl-terminal domain of these closely related endotoxin-binding proteins dictates the route and host responses to complexes they form with endotoxin.	Univ Iowa, Dept Internal Med, Div Infect Dis, Inflammat Program, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Div Infect Dis, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Div Infect Dis, Dept Microbiol, Iowa City, IA 52242 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; New York University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Gioannini, TL (corresponding author), Univ Iowa, Dept Internal Med, Div Infect Dis, Inflammat Program, GH 34W, Iowa City, IA 52242 USA.			Weiss, Jerrold/0000-0003-1476-4485	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK005472, R01DK005472] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK05472] Funding Source: Medline; PHS HHS [P0144642] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abrahamson SL, 1997, J BIOL CHEM, V272, P2149; Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471; BAYER ME, 1977, J BACTERIOL, V130, P1364, DOI 10.1128/JB.130.3.1364-1381.1977; Beamer LJ, 1998, PROTEIN SCI, V7, P906; Beamer LJ, 1997, SCIENCE, V276, P1861, DOI 10.1126/science.276.5320.1861; Beutler B, 2000, CURR OPIN MICROBIOL, V3, P23, DOI 10.1016/S1369-5274(99)00046-6; Beutler B, 2001, DRUG METAB DISPOS, V29, P474; Burnett RJ, 1996, ARCH SURG-CHICAGO, V131, P200; Capodici C, 1996, J IMMUNOL, V156, P4789; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Desrumaux C, 2001, J BIOL CHEM, V276, P5908, DOI 10.1074/jbc.M008420200; Dziarski R, 2000, INFECT IMMUN, V68, P5254, DOI 10.1128/IAI.68.9.5254-5260.2000; Dziarski R, 2000, CHEM IMMUNOL, V74, P83; Elsbach P, 1998, CURR OPIN IMMUNOL, V10, P45, DOI 10.1016/S0952-7915(98)80030-7; ESPEVIK T, 1993, EUR J IMMUNOL, V23, P255, DOI 10.1002/eji.1830230140; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GALANOS C, 1975, Z IMMUNITATSFORSCH, V149, P214; GAZZANOSANTORO H, 1992, INFECT IMMUN, V60, P4754, DOI 10.1128/IAI.60.11.4754-4761.1992; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; Giardina PC, 2001, J BIOL CHEM, V276, P5883, DOI 10.1074/jbc.M009273200; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAN JH, 1994, J BIOL CHEM, V269, P8172; Hubacek JA, 1997, BIOCHEM BIOPH RES CO, V236, P427, DOI 10.1006/bbrc.1997.6970; Iovine NM, 1997, P NATL ACAD SCI USA, V94, P10973, DOI 10.1073/pnas.94.20.10973; JACK RS, 1995, EUR J IMMUNOL, V25, P1436, DOI 10.1002/eji.1830250545; JUAN TSC, 1995, J BIOL CHEM, V270, P5219, DOI 10.1074/jbc.270.10.5219; Katz SS, 1999, J BIOL CHEM, V274, P36579, DOI 10.1074/jbc.274.51.36579; Lamping N, 1996, J IMMUNOL, V157, P4648; MANNION BA, 1989, J IMMUNOL, V142, P2807; MATHISON J, 1993, J CLIN INVEST, V92, P2053, DOI 10.1172/JCI116801; MUNFORD RS, 1992, J IMMUNOL METHODS, V148, P115, DOI 10.1016/0022-1759(92)90164-O; NEWMAN SL, 1995, J IMMUNOL, V154, P753; OOI CE, 1987, J BIOL CHEM, V262, P14891; OOI CE, 1991, AGENTS ACTIONS, V34, P274, DOI 10.1007/BF01993301; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RIETSCHEL ET, 1993, IMMUNOBIOLOGY, V187, P169, DOI 10.1016/S0171-2985(11)80338-4; Savedra R, 1996, J IMMUNOL, V157, P2549; Schumann RR, 1997, J IMMUNOL, V159, P5599; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SHANDS JW, 1980, J BIOL CHEM, V255, P1221; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Tanikawa K, 1998, PROG CLIN BIOL RES, V397, P191; THEOFAN G, 1994, J IMMUNOL, V152, P3623; Tobias PS, 1997, J BIOL CHEM, V272, P18682, DOI 10.1074/jbc.272.30.18682; Tobias PS, 1999, CLIN INFECT DIS, V28, P476, DOI 10.1086/515163; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1988, J BIOL CHEM, V263, P13479; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; Tobias PS, 1997, J PERIODONTAL RES, V32, P99, DOI 10.1111/j.1600-0765.1997.tb01388.x; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361; Wang QL, 2001, INFECT IMMUN, V69, P2270, DOI 10.1128/IAI.69.4.2270-2276.2001; Weidemann B, 1997, INFECT IMMUN, V65, P858, DOI 10.1128/IAI.65.3.858-864.1997; Weinrauch Y, 1999, INFECT IMMUN, V67, P3376, DOI 10.1128/IAI.67.7.3376-3382.1999; WEINRAUCH Y, 1995, J CLIN INVEST, V95, P1916, DOI 10.1172/JCI117873; WEISS J, 1992, J CLIN INVEST, V90, P1122, DOI 10.1172/JCI115930; Wiese A, 1997, BIOCHEMISTRY-US, V36, P10301, DOI 10.1021/bi970176m; WILDE CG, 1994, J BIOL CHEM, V269, P17411; Wright SD, 1999, J EXP MED, V189, P605, DOI 10.1084/jem.189.4.605; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yu B, 1996, J BIOL CHEM, V271, P4100	67	76	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7970	7978		10.1074/jbc.M109622200	http://dx.doi.org/10.1074/jbc.M109622200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11773072	hybrid			2022-12-27	WOS:000174268000045
J	Liu, WF; Wang, GP; Yakovlev, AG				Liu, WF; Wang, GP; Yakovlev, AG			Identification and functional analysis of the rat caspase-3 gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; EMBRYONIC CORTICAL-NEURONS; CEREBELLAR GRANULE CELLS; TRAUMATIC BRAIN INJURY; CEREBRAL-ISCHEMIA; INDUCED APOPTOSIS; ACTIVATION; EXPRESSION; INHIBITION; TRANSCRIPTION	Caspase-3 is the major effector in apoptosis triggered by various stimuli. Previous studies demonstrated a significant increase in transcriptional activity of the caspase-3 gene during neuronal apoptosis. Recent findings suggest that differential expression of the caspase-3 gene may underlie the regulation of apoptotic susceptibility during brain development and after acute injury to the mature brain. We identified and cloned the rat caspase-3 gene promoter, determined its structure, and examined its regulation during a course of apoptosis in PC 12 cells. Results demonstrate that this promoter lacks a TATA-box and contains a cluster of Sp1 elements and multiple transcription start sites. The first identified transcription start site is located 87-bp upstream from the first splicing site. A role of Sp1 elements in the regulation of caspase-3 promoter activity is demonstrated by the inhibition of Sp1 binding using mithramycin A. Results of deletion analysis show that an Ets-1-like element located between nucleotides -1646 and -1632 relative to the most extended transcription start site is necessary to achieve sustained transcriptional activity. Homology analysis revealed that the 5'-flanking region of the human caspase-3 gene exhibits significant similarity to a regulatory region of the rat gene.	Georgetown Univ, Dept Neurosci, Washington, DC 20007 USA	Georgetown University	Yakovlev, AG (corresponding author), Georgetown Univ, Dept Neurosci, Res Bldg,WP14,3970 Reservoir Rd NW, Washington, DC 20007 USA.	yakovlev@giccs.georgetown.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038941] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38941] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen JW, 1999, FASEB J, V13, P1875, DOI 10.1096/fasebj.13.13.1875; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Chatterjee S, 2001, ANN NEUROL, V49, P345, DOI 10.1002/ana.71.abs; Chen J, 1998, J NEUROSCI, V18, P4914; Chiang LW, 2001, P NATL ACAD SCI USA, V98, P2814, DOI 10.1073/pnas.051630598; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; de Nigris F, 2001, CANCER RES, V61, P2267; Earle E, 2000, HUM MOL GENET, V9, P187, DOI 10.1093/hmg/9.2.187; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Esch F, 1998, J NEUROSCI, V18, P4083; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; Gillardon F, 1997, MOL BRAIN RES, V50, P16, DOI 10.1016/S0169-328X(97)00162-9; Ginham R, 2001, NEUROSCI LETT, V302, P113, DOI 10.1016/S0304-3940(01)01687-1; Gottron FJ, 1997, MOL CELL NEUROSCI, V9, P159, DOI 10.1006/mcne.1997.0618; Harrison DC, 2000, MOL BRAIN RES, V75, P143, DOI 10.1016/S0169-328X(99)00305-8; Haviv R, 1997, J NEUROSCI RES, V50, P69, DOI 10.1002/(SICI)1097-4547(19971001)50:1<69::AID-JNR8>3.0.CO;2-J; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1294, DOI 10.1097/00004647-200009000-00003; JOHNSON EM, 1993, ANNU REV NEUROSCI, V16, P31, DOI 10.1146/annurev.ne.16.030193.000335; Kermer P, 1998, J NEUROSCI, V18, P4656; Kobayashi D, 2000, INT J HYPERTHER, V16, P471, DOI 10.1080/02656730050199322; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Moran J, 1999, J NEUROCHEM, V73, P568, DOI 10.1046/j.1471-4159.1999.0730568.x; Namura S, 1998, J NEUROSCI, V18, P3659; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; OWENS GP, 1992, CANCER METAST REV, V11, P149, DOI 10.1007/BF00048061; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; RATAN RR, 1994, J NEUROCHEM, V62, P376; RATAN RR, 1994, J NEUROSCI, V14, P4385; Sanij E, 2001, BIOCHEM BIOPH RES CO, V287, P1003, DOI 10.1006/bbrc.2001.5680; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Teruyama K, 2001, J CELL PHYSIOL, V188, P243, DOI 10.1002/jcp.1112; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; YAKOVLEV AG, 1995, J BIOL CHEM, V270, P6421, DOI 10.1074/jbc.270.12.6421; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yamada T, 2001, BLOOD, V97, P2300, DOI 10.1182/blood.V97.8.2300	45	72	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8273	8278		10.1074/jbc.M110768200	http://dx.doi.org/10.1074/jbc.M110768200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11773055	hybrid			2022-12-27	WOS:000174268000084
J	Chang, DY; Lu, AL				Chang, DY; Lu, AL			Functional interaction of MutY homolog with proliferating cell nuclear antigen in fission yeast, Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MUTY; C-TERMINAL DOMAIN; ADENINE-DNA GLYCOSYLASE; BASE EXCISION-REPAIR; MISMATCH REPAIR; 8-HYDROXYGUANINE 7,8-DIHYDRO-8-OXOGUANINE; SUBSTRATE-SPECIFICITY; MUTAGENIC SUBSTRATE; CATALYTIC DOMAIN; SYNTHESIS PAST	The MutY homolog (MYH) is responsible for removing adenines misincorporated on a template DNA strand containing G or 7,8-dihydro-8-oxoguanine (8-oxoG) and thus preventing G:C to T:A mutations. Human MYH has been shown to interact physically with human proliferating cell nuclear antigen (hPCNA). Here, we report that a similar interaction between SpMYH and SpPCNA occurs in the fission yeast Schizosaccharomyces pombe. Binding of SpMYH to SpPCNA was not observed when phenylalanine 444 in the PCNA binding motif of SpMYH was replaced with alanine. The F444A mutant of SpMYH expressed in yeast cells had normal adenine glycosylase and DNA binding activities. However, expression of this mutant form of SpMYH in a SpMYHDelta cell could not reduce the mutation frequency of the cell to the normal level. Moreover, SpMYH interacted with hPCNA and SpPCNA interacted with hMYH but not with F518A/ F519A mutant hMYH containing mutations in its PCNA binding motif. Although the SpMYHDelta cells expressing hMYH had partially reduced mutation frequency, the F518A/F519A mutant hMYH could not reduce the mutation frequency of SpMYHDelta cells. Thus, the interaction between SpMYH and SpPCNA is important for SpMYH biological function in mutation avoidance.	Univ Maryland, Dept Biochem & Mol Biol, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Lu, AL (corresponding author), Univ Maryland, Dept Biochem & Mol Biol, Sch Med, 108 N Greene St, Baltimore, MD 21201 USA.				NATIONAL CANCER INSTITUTE [R56CA078391, R01CA078391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035132] Funding Source: NIH RePORTER; NCI NIH HHS [CA/ES78391] Funding Source: Medline; NIGMS NIH HHS [GM35132] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Boldogh I, 2001, NUCLEIC ACIDS RES, V29, P2802, DOI 10.1093/nar/29.13.2802; Chang DY, 2001, MOL GENET GENOMICS, V266, P336, DOI 10.1007/s004380100567; CHENG KC, 1992, J BIOL CHEM, V267, P166; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gogos A, 1996, BIOCHEMISTRY-US, V35, P16665, DOI 10.1021/bi960843w; Gu YS, 2001, NUCLEIC ACIDS RES, V29, P2666, DOI 10.1093/nar/29.12.2666; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; Li XH, 2000, J BIOL CHEM, V275, P8448, DOI 10.1074/jbc.275.12.8448; Li XH, 2000, NUCLEIC ACIDS RES, V28, P4593, DOI 10.1093/nar/28.23.4593; Lu AL, 1998, J BIOL CHEM, V273, P25098, DOI 10.1074/jbc.273.39.25098; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; LU AL, 1988, GENETICS, V118, P593; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Manuel RC, 1996, J BIOL CHEM, V271, P16218, DOI 10.1074/jbc.271.27.16218; Manuel RC, 1997, BIOCHEMISTRY-US, V36, P11140, DOI 10.1021/bi9709708; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Noll DM, 1999, BIOCHEMISTRY-US, V38, P6374, DOI 10.1021/bi990335x; Ohtsubo T, 2000, NUCLEIC ACIDS RES, V28, P1355, DOI 10.1093/nar/28.6.1355; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Shinmura K, 1997, MUTAT RES-DNA REPAIR, V385, P75, DOI 10.1016/S0921-8777(97)00041-4; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P743, DOI 10.1093/nar/29.3.743; YEH YC, 1991, J BIOL CHEM, V266, P6480; Zhang P, 1999, J BIOL CHEM, V274, P26647, DOI 10.1074/jbc.274.38.26647	48	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11853	11858		10.1074/jbc.M111739200	http://dx.doi.org/10.1074/jbc.M111739200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805113	hybrid			2022-12-27	WOS:000174846400033
J	Daiber, A; Frein, D; Namgaladze, D; Ullrich, V				Daiber, A; Frein, D; Namgaladze, D; Ullrich, V			Oxidation and nitrosation in the nitrogen monoxide/superoxide system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; TYROSINE NITRATION; REDOX REGULATION; SIMULTANEOUS GENERATION; PEROXYNITRITE OXIDATION; ALCOHOL-DEHYDROGENASE; SUPEROXIDE; ZINC; (NO)-N-CENTER-DOT; NITROSYLATION	Based on the previous report of McCord and co-workers (Crow, J. P., Beckman, J. S., and McCord, J. M. (1995) Biochemistry 34, 3544-3552), the zinc dithiolate active site of alcohol dehydrogenase (ADH) has been studied as a target for cellular oxidants. In the nitrogen monoxide ((NO)-N-.)/superoxide (O-2(.-)) system, an equimolar generation of both radicals under peroxynitrite (PN) formation led to rapid inactivation of ADH activity, whereas hydrogen peroxide and (NO)-N-. alone reacted too slowly to be of physiological significance. 3-Morpholino sydnonimine inactivated the enzyme with an IC50 value of 250 nm; the corresponding values for PN, hydrogen peroxide, and (NO)-N-. were 500 nm, 50 muM, and 200 muM. When superoxide was generated at low fluxes by xanthine oxidase, it was quite effective in ADH inactivation (IC50 (XO) approximate to 1 milli-unit/ml). All inactivations were accompanied by zinc release and disulfide formation, although no strict correlation was observed. From the two zinc thiolate centers, only the zinc CYS(2)His center released the metal by oxidants. The zinc CYS4 center was also oxidized, but no second zinc atom could be found with 4-(2-pyridylazo)resorcinol (PAR) as a chelating agent except under denaturing conditions. Surprisingly, the oxidative actions of PN were abolished by a 2-3-fold excess of (NO)-N-. under generation of a nitrosating species, probably dinitrogen trioxide. We conclude that in cellular systems, low fluxes of (NO)-N-. and O-2(.-) generate peroxynitrite at levels 2 effective for zinc thiolate oxidations, facilitated by the nucleophilic nature of the complexed thiolate group. With an excess of (NO)-N-., the PN actions are blocked, which may explain the antioxidant properties of (NO)-N-. and the mechanism of cellular S-nitrosations.	Univ Konstanz, Fachbereich Biol, Math Naturwissenschaft Sekt, D-78457 Constance, Germany	University of Konstanz	Ullrich, V (corresponding author), Univ Konstanz, Fachbereich Biol, Math Naturwissenschaft Sekt, LS Ullrich Fach X-910 Sonnenbuhl, D-78457 Constance, Germany.	volker.ullrich@uni-konstanz.de						Balon TW, 2001, MED SCI SPORT EXER, V33, P382, DOI 10.1097/00005768-200103000-00008; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Caulfield JL, 1998, J BIOL CHEM, V273, P12689, DOI 10.1074/jbc.273.21.12689; Crow JP, 2000, FREE RADICAL BIO MED, V28, P1487, DOI 10.1016/S0891-5849(00)00249-5; CROW JP, 1995, BIOCHEMISTRY-US, V34, P3544, DOI 10.1021/bi00011a008; Daiber A, 2000, EUR J BIOCHEM, V267, P6729, DOI 10.1046/j.1432-1033.2000.01768.x; Daiber A, 2000, J INORG BIOCHEM, V81, P213, DOI 10.1016/S0162-0134(00)00110-0; Daiber A, 1998, NITRIC OXIDE-BIOL CH, V2, P259, DOI 10.1006/niox.1998.0186; DARLEYUSMAR VM, 1992, FREE RADICAL RES COM, V17, P9, DOI 10.3109/10715769209061085; Das DK, 2001, ANTIOXID REDOX SIGN, V3, P23, DOI 10.1089/152308601750100461; FLISS H, 1991, ARCH BIOCHEM BIOPHYS, V287, P175, DOI 10.1016/0003-9861(91)90403-6; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; Gergel D, 1996, BIOCHEMISTRY-US, V35, P16186, DOI 10.1021/bi962043r; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; Goldstein S, 1999, CHEM RES TOXICOL, V12, P132, DOI 10.1021/tx9802522; Jacob C, 1999, P NATL ACAD SCI USA, V96, P1910, DOI 10.1073/pnas.96.5.1910; Jakob U, 2000, J BIOL CHEM, V275, P38302, DOI 10.1074/jbc.M005957200; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P246; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; Kelm M, 1997, J BIOL CHEM, V272, P9922; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; Knapp LT, 2000, J BIOL CHEM, V275, P24136, DOI 10.1074/jbc.M002043200; Kuhn DM, 1999, J NEUROSCI, V19, P10289; Lee JB, 1998, J AM CHEM SOC, V120, P6053, DOI 10.1021/ja9801036; Levine RL, 2001, EXP GERONTOL, V36, P1495, DOI 10.1016/S0531-5565(01)00135-8; Maret W, 2000, J NUTR, V130, p1455S, DOI 10.1093/jn/130.5.1455S; Nakamura K, 1997, FEBS LETT, V417, P375, DOI 10.1016/S0014-5793(97)01326-4; Naskalski JW, 2001, ADV CLIN CHEM, V35, P161, DOI 10.1016/S0065-2423(01)35017-5; Pfeiffer S, 2000, J BIOL CHEM, V275, P6346, DOI 10.1074/jbc.275.9.6346; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; Pietruszko R, 1975, Adv Exp Med Biol, V56, P1; Pilichowski JF, 1995, CAN J CHEM, V73, P2143, DOI 10.1139/v95-265; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; RADI R, 1992, BIOCHIM BIOPHYS ACTA, V1122, P178, DOI 10.1016/0167-4838(92)90321-4; RADI R, 1991, J BIOL CHEM, V266, P4244; Reiter CD, 2000, J BIOL CHEM, V275, P32460, DOI 10.1074/jbc.M910433199; Sawa T, 2000, J BIOL CHEM, V275, P32467, DOI 10.1074/jbc.M910169199; Sen CK, 2001, MED SCI SPORT EXER, V33, P368, DOI 10.1097/00005768-200103000-00005; SHAW CF, 1990, INORG CHEM, V29, P403, DOI 10.1021/ic00328a012; Sies H, 1998, CHEM-BIOL INTERACT, V112, P177, DOI 10.1016/S0009-2797(97)00160-9; SQUADRITO GL, 1995, CHEM-BIOL INTERACT, V96, P203, DOI 10.1016/0009-2797(94)03591-U; Tanaka T, 2000, FREE RADICAL RES, V33, P851, DOI 10.1080/10715760000301361; VANWART HE, 1986, P NATL ACAD SCI USA, V83, P3064; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; Zou MH, 1999, BRIT J PHARMACOL, V126, P1283, DOI 10.1038/sj.bjp.0702434; Zou MH, 1999, AM J PATHOL, V154, P1359, DOI 10.1016/S0002-9440(10)65390-4; Zou MH, 1996, FEBS LETT, V382, P101, DOI 10.1016/0014-5793(96)00160-3	47	55	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11882	11888		10.1074/jbc.M111988200	http://dx.doi.org/10.1074/jbc.M111988200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805115	hybrid			2022-12-27	WOS:000174846400037
J	Kazlauskas, A; Poellinger, L; Pongratz, I				Kazlauskas, A; Poellinger, L; Pongratz, I			Two distinct regions of the immunophilin-like protein XAP2 regulate dioxin receptor function and interaction with hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ARYL-HYDROCARBON RECEPTOR; DNA-BINDING ACTIVITY; HELIX-LOOP-HELIX; AH RECEPTOR; CORE COMPLEX; IN-VIVO; LIGAND; EXPRESSION; ROLES	The dioxin (aryl hydrocarbon) receptor is a ligand inducible transcription factor, which mediates cellular responses to a variety of xenobiotic compounds such as dioxins. In the absence of ligand the receptor is associated with the molecular chaperone hsp90 and the tetratricopeptide repeat (TPR-) containing immunophilin-like protein XAP2. XAP2 has been implicated in regulation of the intracellular localization of the dioxin receptor and protection of the receptor against degradation. In this study a series of XAP2 mutants has been generated in order to identify the structural motif(s) mediating interaction with the dioxin receptor-hsp90 complex and modulation of receptor function. Immunoprecipitation experiments demonstrated that the C-terminal part of XAP2, including the TPR motifs and the region outside the TPR motifs, was required to directly contact hsp90. The N-terminal part of XAP2 was required for the stability of the ternary dioxin receptor-hsp90-XAP2 complex. In addition, the integrity of the N-terminal region of XAP2 was essential for XAP2 to regulate the intracellular localization of the dioxin receptor. In conclusion, these data demonstrate that two distinct regions of XAP2 modulate dioxin receptor function and interaction with hps90, illustrating the complexity in regulation of dioxin receptor signaling by the hsp90 molecular chaperone machinery.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Poellinger, L (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden.							ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; Bell DR, 2000, J BIOL CHEM, V275, P36407, DOI 10.1074/jbc.M004236200; CARVER LA, 1994, J BIOL CHEM, V269, P30109; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; DENIS M, 1988, ANAL BIOCHEM, V173, P405, DOI 10.1016/0003-2697(88)90207-2; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Heid SE, 2000, MOL PHARMACOL, V57, P82; Huang X, 1991, ADV APPL MATH, V12, P373; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Kazlauskas A, 2000, J BIOL CHEM, V275, P41317, DOI 10.1074/jbc.M007765200; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; Ma Q, 1997, J BIOL CHEM, V272, P8878; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; Meyer BK, 2000, CELL STRESS CHAPERON, V5, P243, DOI 10.1379/1466-1268(2000)005<0243:AHARLA>2.0.CO;2; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	29	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11795	11801		10.1074/jbc.M200053200	http://dx.doi.org/10.1074/jbc.M200053200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805120	hybrid			2022-12-27	WOS:000174846400026
J	Li, PTX; Scott, DJ; Gollnick, P				Li, PTX; Scott, DJ; Gollnick, P			Creating hetero-11-mers composed of wild-type and mutant subunits to study RNA binding to TRAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATTENUATION PROTEIN TRAP; TRP LEADER RNA; BACILLUS-SUBTILIS BINDS; OPERON; NUCLEOTIDES; TRANSLATION; FEATURES; REPEATS; GAG	TRAP ((t) under bar rp (R) under bar NA-binding (a) under bar ttenuation (p) under bar rotein) is an RNA-binding protein that regulates expression of the tryptophan biosynthetic genes in Bacillus subtilis by binding to RNA targets that contain multiple GAG and UAG repeats. TRAP is composed of 11 identical subunits arranged symmetrically in a ring. The secondary structure of the protein consists entirely of antiparallel,beta-sheets, beta-turns, and loops. We show here that the TRAP 11-mer can be reversibly denatured into unfolded monomers by guanidine hydrochloride. Removing the denaturant allows the protein to spontaneously renature into fully functional 11-mers. Based on this finding, we developed a subunit mixing method to hybridize wild-type and mutant subunits into heteromeric 11-mers by denaturation followed by subunit mixing renaturation. This method allows the study of subunit cooperativity in protein-ligand interaction such as RNA binding. Our data further support and extend the previously proposed two-step model for RNA binding to TRAP by showing that the initiation of binding requires at least one fully active subunit in the protein combined with one fully functional repeat in the RNA. The initiation complex tethers the RNA on the protein, thus allowing cooperative interaction with the remainder of the repeats.	SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA; Univ York, Dept Chem, York Struct Biol Lab, York YO10 5DD, N Yorkshire, England	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of York - UK	Gollnick, P (corresponding author), SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA.			Scott, David/0000-0002-6726-2078	NIGMS NIH HHS [GM62750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adler A J, 1973, Methods Enzymol, V27, P675; Antson AA, 1999, NATURE, V401, P235, DOI 10.1038/45730; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; ARAKAWA T, 1984, BIOCHEMISTRY-US, V23, P5924, DOI 10.1021/bi00320a005; Babitzke P, 1996, J BACTERIOL, V178, P5159, DOI 10.1128/jb.178.17.5159-5163.1996; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BABITZKE P, 1995, J BIOL CHEM, V270, P12452, DOI 10.1074/jbc.270.21.12452; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; Babitzke P, 1997, MOL MICROBIOL, V26, P1, DOI 10.1046/j.1365-2958.1997.5541915.x; Babitzke P, 2001, J BACTERIOL, V183, P5795, DOI 10.1128/JB.183.20.5795-5802.2001; Baumann C, 1996, J BIOL CHEM, V271, P12269, DOI 10.1074/jbc.271.21.12269; Baumann C, 1997, J BIOL CHEM, V272, P19863, DOI 10.1074/jbc.272.32.19863; Chen XP, 1999, J MOL BIOL, V289, P1003, DOI 10.1006/jmbi.1999.2834; Colfen H, 1997, EUR BIOPHYS J BIOPHY, V25, P333, DOI 10.1007/s002490050047; Creighton TE, 1994, MECH PROTEIN FOLDING, P1; Du HS, 1997, J BACTERIOL, V179, P2582, DOI 10.1128/jb.179.8.2582-2586.1997; Du HS, 1998, J BIOL CHEM, V273, P20494, DOI 10.1074/jbc.273.32.20494; Elliott MB, 2001, RNA, V7, P85, DOI 10.1017/S135583820100173X; Elliott MB, 1999, RNA, V5, P1277, DOI 10.1017/S1355838299991057; GOLLNICK P, 1994, MOL MICROBIOL, V11, P991, DOI 10.1111/j.1365-2958.1994.tb00377.x; KURODA MI, 1986, J BACTERIOL, V167, P792, DOI 10.1128/jb.167.3.792-798.1986; Laue T. M., 1991, ANAL ULTRACENTRIFUGA, P90; MERINO E, 1995, J BACTERIOL, V177, P6362, DOI 10.1128/jb.177.22.6362-6370.1995; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; Sarsero JP, 2000, J BACTERIOL, V182, P2329, DOI 10.1128/JB.182.8.2329-2331.2000; Tilsta L., 1996, CIRCULAR DICHROISM C, P261; YANG M, 1995, J BACTERIOL, V177, P4272, DOI 10.1128/jb.177.15.4272-4278.1995; Yang M, 1997, J MOL BIOL, V270, P696, DOI 10.1006/jmbi.1997.1149	28	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11838	11844		10.1074/jbc.M110860200	http://dx.doi.org/10.1074/jbc.M110860200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805104	hybrid			2022-12-27	WOS:000174846400031
J	Ason, B; Reznikoff, WS				Ason, B; Reznikoff, WS			Mutational analysis of the base flipping event found in Tn5 transposition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC COMPLEX; HELIX; DNA	This work identifies novel structure-function relationships between Tn5 transposase (Tnp) and its DNA recognition sequence. The Tn5 Tnp-DNA co-crystal structure revealed the protein-DNA contacts of the post-cleavage complex (Davies, D. R., Goryshin, I. Y., Reznikoff, W. S., and Rayment, I (2000) Science 289, 77-85). One of the most striking features of this complex is the rotation of thymine 2 (T2) away from the DNA helix and into a pocket within the Trip. This interaction appears similar to the "base flipping" phenomenon found in many DNA repair enzymes such as T4 endonuclease V and uracil DNA glycosylase (Roberts, R. J., and Cheng, X (1998) Annu. Rev. Biochem 67, 181-198). To study the biochemical significance of this phenomenon, we mutated the Tnp residues proposed to be involved in stabilizing this interaction and removed the T2 nucleotide to examine which steps in the transposition reaction require T2-Tnp interactions. From this work, we have determined that stacking interactions between T2 and Tnp are critical for efficient transposition in vitro. In addition, our results suggested that T2-Tnp interactions facilitate hairpin formation and hairpin resolution primarily through base stacking and that T2 plays a role in the alignment of the transposon DNA for strand transfer.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Reznikoff, WS (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.				NIGMS NIH HHS [GM50692] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allingham JS, 2001, EMBO J, V20, P2931, DOI 10.1093/emboj/20.11.2931; BERG DE, 1989, MOBILE DNA, P185; Bhasin A, 1999, J BIOL CHEM, V274, P37021, DOI 10.1074/jbc.274.52.37021; Bhasin A, 2000, J MOL BIOL, V302, P49, DOI 10.1006/jmbi.2000.4048; Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77; HANIFORD D, 1994, EMBO J, V13, P3401, DOI 10.1002/j.1460-2075.1994.tb06643.x; Jilk RA, 1996, J BACTERIOL, V178, P1671, DOI 10.1128/jb.178.6.1671-1679.1996; JOHNSON RC, 1983, NATURE, V204, P280; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; Naumann TA, 2000, P NATL ACAD SCI USA, V97, P8944, DOI 10.1073/pnas.160107997; Reznikoff WS, 1999, BIOCHEM BIOPH RES CO, V266, P729, DOI 10.1006/bbrc.1999.1891; REZNIKOFF WS, 1993, ANNU REV MICROBIOL, V47, P945, DOI 10.1146/annurev.mi.47.100193.004501; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Sakai J, 1997, CELL, V89, P205, DOI 10.1016/S0092-8674(00)80200-7; Steiniger-White M, 2000, J BIOL CHEM, V275, P23127, DOI 10.1074/jbc.M003411200; VARANI G, 1995, ANNU REV BIOPH BIOM, V24, P379, DOI 10.1146/annurev.biophys.24.1.379	16	32	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11284	11291		10.1074/jbc.M111119200	http://dx.doi.org/10.1074/jbc.M111119200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11805107	hybrid			2022-12-27	WOS:000174613100068
J	Emelyanov, AV; Kovac, CR; Sepulveda, MA; Birshtein, BK				Emelyanov, AV; Kovac, CR; Sepulveda, MA; Birshtein, BK			The interaction of Pax5 (BSAP) with Daxx can result in transcriptional activation in B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE RAG-2 PROMOTER; CREB-BINDING-PROTEIN; NUCLEAR-BODY; TERNARY COMPLEXES; 3'ALPHA ENHANCER; TARGET GENES; NF-HB; PML; APOPTOSIS; DIFFERENTIATION	Pax5 (BSAP) is essential for B cell development and acts both as a transcriptional activator and a repressor. Using a yeast two-hybrid assay to identify potential co-regulators of Pax5, we identified Daxx, a protein that is highly conserved, ubiquitously expressed, and essential for embryonic mouse development. The interaction between Pax5 and Daxx involves the partial homeodomain of Pax5 and the C-terminal fragment of Daxx. A component of promyelocytic leukemia protein nuclear bodies, Daxx has been implicated in apoptosis and characterized as a transcriptional corepressor. Upon transient transfection assay of Daxx in B cells expressing endogenous Daxx and Pax5, we observed not only transcriptional corepression but also, unexpectedly, coactivation in M12.4.1 and A20 mouse B cell lines. Pax5 domains required for coactivation were identified using 293T cells. Coactivation apparently involves recruitment of the CREB binding protein (CBP), because we precipitated complexes containing Pax5, Daxx, and CBP in B cell lines. These data suggest that Daxx can affect Pax5's roles as an activator or repressor in B cells and describe a role for Daxx as a transcriptional coactivator.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Birshtein, BK (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041572, R37AI013509, R01AI013509] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA13330] Funding Source: Medline; NIAID NIH HHS [AI41572, AI13509] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Eberhard D, 1999, CANCER RES, V59, p1716S; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, MOL CELL BIOL, V16, P3454; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Gongora R, 2001, IMMUNITY, V14, P727, DOI 10.1016/S1074-7613(01)00152-2; Hagman J, 2000, CURR TOP MICROBIOL, V245, P169; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Horcher M, 2001, IMMUNITY, V14, P779, DOI 10.1016/S1074-7613(01)00153-4; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kiriakidou M, 1997, DNA CELL BIOL, V16, P1289, DOI 10.1089/dna.1997.16.1289; Kishi H, 2000, BLOOD, V95, P3845; Kovac CR, 2000, J BIOL CHEM, V275, P16752, DOI 10.1074/jbc.M001551200; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Lauring J, 1999, MOL CELL BIOL, V19, P2601; Lechner MS, 2000, NUCLEIC ACIDS RES, V28, P2741, DOI 10.1093/nar/28.14.2741; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Li H, 2000, CURR OPIN CELL BIOL, V12, P641, DOI 10.1016/S0955-0674(00)00144-7; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Libermann TA, 1999, J BIOL CHEM, V274, P24671, DOI 10.1074/jbc.274.35.24671; Mahmoud MS, 1996, BLOOD, V87, P4311, DOI 10.1182/blood.V87.10.4311.bloodjournal87104311; Maitra S, 2000, MOL CELL BIOL, V20, P1911, DOI 10.1128/MCB.20.6.1911-1922.2000; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; Michaelson JS, 1996, J IMMUNOL, V156, P2828; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Miller J.H., 1972, EXPT MOL GENETICS; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NEURATH MF, 1994, J IMMUNOL, V153, P730; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Nutt SL, 1997, IMMUNOBIOLOGY, V198, P227, DOI 10.1016/S0171-2985(97)80043-5; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Pestell RG, 1996, MOL ENDOCRINOL, V10, P1084, DOI 10.1210/me.10.9.1084; Pluta AF, 1998, J CELL SCI, V111, P2029; Riva A, 1997, J IMMUNOL, V159, P1284; Rolink AG, 1999, NATURE, V401, P603, DOI 10.1038/44164; Ryu SW, 2000, BIOCHEM BIOPH RES CO, V279, P6, DOI 10.1006/bbrc.2000.3882; Singh M, 1996, P NATL ACAD SCI USA, V93, P4392, DOI 10.1073/pnas.93.9.4392; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; Tierney R, 2000, J VIROL, V74, P10458, DOI 10.1128/JVI.74.22.10458-10467.2000; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Wheat W, 1999, MOL CELL BIOL, V19, P2231; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; ZWOLLO P, 1994, J BIOL CHEM, V269, P15310	61	93	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11156	11164		10.1074/jbc.M111763200	http://dx.doi.org/10.1074/jbc.M111763200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11799127	hybrid			2022-12-27	WOS:000174613100053
J	Huang, JH; Kontos, CD				Huang, JH; Kontos, CD			PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PROTEIN-TYROSINE-PHOSPHATASE; TUMOR-SUPPRESSOR PTEN; PHOSPHATIDYLINOSITOL 3-KINASE; CELL-SURVIVAL; LIPID PRODUCTS; GLIOMA-CELLS; KINASE AKT; EXPRESSION; ACTIVATION	Phosphatidylinositol 3-kinase is activated by vascular endothelial growth factor (VEGF), and many of the angiogenic cellular responses of VEGF are regulated by the lipid products of phosphatidylinositol 3-kinase. The tumor suppressor PTEN has been shown to down-regulate phosphatidylinositol 3-kinase signaling, yet the effects of PTEN on VEGF-mediated signaling and angiogenesis are unknown. Inhibition of endogenous PTEN in cultured endothelial cells by adenovirus-mediated overexpression of a dominant negative PTEN mutant (PTEN-C/S) enhanced VEGF-mediated Akt phosphorylation, and this effect correlated with decreases in caspase-3 cleavage, caspase-3 activity, and DNA degradation after induction of apoptosis with tumor necrosis factor-alpha. Overexpression of PTEN-C/S also enhanced VEGF-mediated endothelial cell proliferation and migration. In contrast, overexpression of wild-type PTEN inhibited the anti-apoptotic, proliferative, and chemotactic effects of VEGF. Moreover, PTEN-C/S increased the length of vascular sprouts in the rat aortic ring assay and modulated VEGF-mediated tube formation in an in vitro angiogenesis assay, whereas PTEN-wild type inhibited these effects. Taken together, these findings demonstrate that PTEN potently modulates VEGF-mediated signaling and function and that PTEN is a viable target in therapeutic approaches to promote or inhibit angiogenesis.	Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University; Duke University	Kontos, CD (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Cardiol, Box 3629, Durham, NC 27710 USA.			Kontos, Christopher/0000-0002-8056-3115				Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Cantrell DA, 2001, J CELL SCI, V114, P1439; Channon KM, 1996, CARDIOVASC RES, V32, P962; Davies MA, 1998, CANCER RES, V58, P5285; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; DUBOIS NA, 1991, EXP CELL RES, V196, P302, DOI 10.1016/0014-4827(91)90265-V; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONTIJN R, 1995, EXP CELL RES, V216, P199, DOI 10.1006/excr.1995.1025; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Giri D, 1999, HUM PATHOL, V30, P419, DOI 10.1016/S0046-8177(99)90117-X; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hermann C, 2000, ARTERIOSCL THROM VAS, V20, P402, DOI 10.1161/01.ATV.20.2.402; Huang H, 1999, DEVELOPMENT, V126, P5365; Huang LW, 1999, J BIOL CHEM, V274, P38183, DOI 10.1074/jbc.274.53.38183; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Kurose K, 2001, AM J PATHOL, V158, P2097, DOI 10.1016/S0002-9440(10)64681-0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Luo ZY, 2000, CIRCULATION, V102, P44; MADRI JA, 1986, J HISTOCHEM CYTOCHEM, V34, P85, DOI 10.1177/34.1.2416801; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Nicosia RF, 1997, AM J PATHOL, V151, P1379; Ono H, 2001, MOL ENDOCRINOL, V15, P1411, DOI 10.1210/me.15.8.1411; Pollman MJ, 1999, J CELL PHYSIOL, V178, P359, DOI 10.1002/(SICI)1097-4652(199903)178:3<359::AID-JCP10>3.3.CO;2-F; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Schwartzbauer G, 2001, J BIOL CHEM, V276, P35786, DOI 10.1074/jbc.M102479200; Shah AS, 2001, CIRCULATION, V103, P1311; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Weng LP, 1999, CANCER RES, V59, P5808; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Xin XH, 2001, AM J PATHOL, V158, P1111, DOI 10.1016/S0002-9440(10)64058-8; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zundel W, 2000, GENE DEV, V14, P391	49	154	196	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10760	10766		10.1074/jbc.M110219200	http://dx.doi.org/10.1074/jbc.M110219200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11784722	hybrid			2022-12-27	WOS:000174613100004
J	Love, JD; Gooch, JT; Benko, S; Li, C; Nagy, L; Chatterjee, VKK; Evans, RM; Schwabe, JWR				Love, JD; Gooch, JT; Benko, S; Li, C; Nagy, L; Chatterjee, VKK; Evans, RM; Schwabe, JWR			The structural basis for the specificity of retinoid-X receptor-selective agonists: New insights into the role of helix H12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; CRYSTAL-STRUCTURE; THYROID-HORMONE; NUCLEAR RECEPTORS; RXR HETERODIMERS; MOLECULAR-BASIS; ACID; BETA; COREPRESSORS; ANTAGONISM	Ligands that specifically target retinoid-X receptors (RXRs) are emerging as potentially powerful therapies for cancer, diabetes, and the lowering of circulatory cholesterol. To date, RXR has only been crystallized in the absence of ligand or with the promiscuous ligand 9-cis retinoic acid, which also activates retinoic acid receptors. Here we present the structure of hRXRbeta in complex with the RXR-specific agonist LG100268 (LG268). The structure clearly reveals why LG268 is specific for the RXR ligand binding pocket and will not activate retinoic acid receptors. Intriguingly, in the crystals, the C-terminal "activation" helix (AF-2/helix H12) is trapped in a novel position not seen in other nuclear receptor structures such that it does not cap the ligand binding cavity. Mammalian two-hybrid assays indicate that LG268 is unable to release co-repressors from RXR unless co-activators are also present. Together these findings suggest that RXR ligands may be inefficient at repositioning helix H12.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Debrecen Univ, Med & Hlth Sci Ctr, Dept Biochem & Mol Biol, H-4012 Debrecen, Hungary; Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Howard Hughes Med Inst, La Jolla, CA 92037 USA	MRC Laboratory Molecular Biology; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Debrecen; Salk Institute; Howard Hughes Medical Institute	Schwabe, JWR (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	John.Schwabe@mrc-lmb.cam.ac.uk	Evans, Ronald/AAF-4001-2019; Schwabe, John WR/A-9132-2008; Nagy, Laszlo/A-3814-2008	Evans, Ronald/0000-0002-9986-5965; Schwabe, John WR/0000-0003-2865-4383; Nagy, Laszlo/0000-0001-6653-2155; Chatterjee, Vengalil Krishna/0000-0002-2654-8854				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BOURGUET W, 1995, PROTEIN EXPRES PURIF, V6, P604, DOI 10.1006/prep.1995.1079; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Busch K, 2000, MOL ENDOCRINOL, V14, P201, DOI 10.1210/me.14.2.201; Chen ZP, 1998, J MOL BIOL, V275, P55, DOI 10.1006/jmbi.1997.1413; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Gampe RT, 2000, GENE DEV, V14, P2229, DOI 10.1101/gad.802300; Gottardis MM, 1996, CANCER RES, V56, P5566; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kastner P, 1996, GENE DEV, V10, P80, DOI 10.1101/gad.10.1.80; Kersten S, 1996, BIOCHEMISTRY-US, V35, P3816, DOI 10.1021/bi952737k; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; Koch SSC, 1999, J MED CHEM, V42, P742, DOI 10.1021/jm980621r; Krezel W, 1998, SCIENCE, V279, P863, DOI 10.1126/science.279.5352.863; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LESLIE AGW, 1992, CCP4 ESF EACMB; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Li C, 1997, P NATL ACAD SCI USA, V94, P2278, DOI 10.1073/pnas.94.6.2278; Lin BC, 1997, MOL CELL BIOL, V17, P6131, DOI 10.1128/MCB.17.10.6131; Love JD, 2000, BIOCHEM SOC T, V28, P390, DOI 10.1042/0300-5127:0280390; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Miller VA, 1997, J CLIN ONCOL, V15, P790, DOI 10.1200/JCO.1997.15.2.790; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Peet DJ, 1998, CHEM BIOL, V5, P13, DOI 10.1016/S1074-5521(98)90083-7; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Renaud JP, 2000, CELL MOL LIFE SCI, V57, P1748, DOI 10.1007/PL00000656; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Solomin L, 1998, NATURE, V395, P398, DOI 10.1038/26515; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; Zhang JS, 1999, MOL CELL BIOL, V19, P6448; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	47	66	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11385	11391		10.1074/jbc.M110869200	http://dx.doi.org/10.1074/jbc.M110869200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11782480	hybrid			2022-12-27	WOS:000174613100081
J	Patel, S; Lochhead, PA; Rena, G; Fumagalli, S; Pende, M; Kozma, SC; Thomas, G; Sutherland, C				Patel, S; Lochhead, PA; Rena, G; Fumagalli, S; Pende, M; Kozma, SC; Thomas, G; Sutherland, C			Insulin regulation of insulin-like growth factor-binding protein-1 gene expression is dependent on the mammalian target of rapamycin, but independent of ribosomal S6 kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; GLYCOGEN-SYNTHASE KINASE-3; PHOSPHOENOLPYRUVATE CARBOXYKINASE; SIGNALING PATHWAY; RESPONSE SEQUENCE; TOR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; CELL-GROWTH; FACTOR FKHR; PEPCK GENE	Insulin inhibits the expression of the hepatic insulin-like growth factor-binding protein-1 (IGFBP-1) and glucose-6-phosphatase (G6Pase) genes. The signaling pathway that mediates these events requires the activation of phosphatidylinositol 3-kinase, whereas transfection studies have suggested an involvement of Akt (protein kinase 13) and FKHR, a transcription factor regulated by Akt. We now demonstrate that insulin repression of endogenous IGFBP-1 gene transcription was blocked by rapamycin or by amino acid starvation. Rapamycin inhibited the mammalian target of rapamycin (mTOR) and the subsequent activation of p70/p85 S6 protein kinase-1 (S6K1) by insulin, whereas amino acid depletion prevented insulin induction of these signaling molecules. Importantly, we demonstrate that insulin regulation of the thymine-rich insulin response element of the IGFBP-1 promoter was also inhibited by rapamycin. However, sustained activation of S6K1 did not repress this promoter. In addition, rapamycin did not affect insulin regulation of G6Pase expression or Akt activation. WeproposethattheseobservationsindicatethatanmTOR-dependent, but S6K-independent mechanism regulates the suppression of IGFBP-1 (but not G6Pase) gene expression by insulin. Therefore, although the insulin-responsive sequence of the G6Pase gene promoter is related to that of the IGFBP-1 promoter, the signaling pathways that mediate suppression of these genes are distinct.	Univ Dundee, Wellcome Trust Bioctr, Sch Life Sci, Div Cellular Signalling, Dundee DD1 5EH, Scotland; Friedrich Miescher Inst, CH-4058 Basel, Switzerland	University of Dundee; Friedrich Miescher Institute for Biomedical Research	Sutherland, C (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Sch Life Sci, Div Cellular Signalling, Med Sci Inst Complex,Dow St, Dundee DD1 5EH, Scotland.		Thomas, George/K-9235-2014; FUMAGALLI, Stefano/C-2914-2019; Rena, Graham/AAV-7985-2021; Pende, Mario/AFR-1348-2022	Thomas, George/0000-0003-3518-8149; Pende, Mario/0000-0002-7864-8937; Rena, Graham/0000-0002-9121-1350; Fumagalli, Stefano/0000-0001-5832-8680; Sutherland, Calum/0000-0003-4398-7434				Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Ayala JE, 1999, DIABETES, V48, P1885, DOI 10.2337/diabetes.48.9.1885; Band CJ, 1997, J BIOL CHEM, V272, P138; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CAREY M, 2000, TRANSCRIPTIONAL REGU, P87; Chan TF, 2000, P NATL ACAD SCI USA, V97, P13227, DOI 10.1073/pnas.240444197; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Denton R.M., 1997, INT TXB DIABETES MEL, P469; Dickens M, 1998, J BIOL CHEM, V273, P20144, DOI 10.1074/jbc.273.32.20144; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Dowler S, 2000, BIOCHEM J, V349, P605, DOI 10.1042/0264-6021:3490605; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; GREENBERG ME, 1998, CURRENT PROTOCOLS MO, V1; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Kaestner KH, 2000, GENE DEV, V14, P142; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; LEMAIGRE FP, 1994, BIOCHEM J, V303, P1; Lochhead PA, 2000, DIABETES, V49, P896, DOI 10.2337/diabetes.49.6.896; Lochhead PA, 2001, DIABETES, V50, P937, DOI 10.2337/diabetes.50.5.937; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nordlie RC, 1999, ANNU REV NUTR, V19, P379, DOI 10.1146/annurev.nutr.19.1.379; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; Osawa H, 1996, J BIOL CHEM, V271, P16690, DOI 10.1074/jbc.271.28.16690; Patel S, 2001, BIOCHEM J, V359, P611, DOI 10.1042/0264-6021:3590611; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Roques M, 1999, J BIOL CHEM, V274, P34005, DOI 10.1074/jbc.274.48.34005; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; Streeper RS, 1998, P NATL ACAD SCI USA, V95, P9208, DOI 10.1073/pnas.95.16.9208; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Sutherland C, 1998, J BIOL CHEM, V273, P3198, DOI 10.1074/jbc.273.6.3198; SUWANICHKUL A, 1994, J BIOL CHEM, V269, P30835; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Xie ZJ, 2000, AM J PHYSIOL-ENDOC M, V278, pE648, DOI 10.1152/ajpendo.2000.278.4.E648; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Zhang JD, 2001, P NATL ACAD SCI USA, V98, P3756, DOI 10.1073/pnas.071054598	63	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9889	9895		10.1074/jbc.M109870200	http://dx.doi.org/10.1074/jbc.M109870200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11784721	hybrid			2022-12-27	WOS:000174549200039
J	Authier, F; Metioui, M; Fabrega, S; Kouach, M; Briand, G				Authier, F; Metioui, M; Fabrega, S; Kouach, M; Briand, G			Endosomal proteolysis of internalized insulin at the C-terminal region of the B chain by cathepsin D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ISOLATED LIVER ENDOSOMES; MONOCLONAL-ANTIBODIES; DEGRADATION-PRODUCTS; LYSOSOMAL-ENZYMES; RAT HEPATOCYTES; BETA; CLEAVAGE; INHIBITION; GLUCAGON	The endosomal compartment of hepatic parenchymal cells contains an acidic endopeptidase, endosomal acidic insulinase, which hydrolyzes internalized insulin and generates the major primary end product A(1-21)-B1-24 insulin resulting from a major cleavage at residues Phe(B24)-Phe(B25). This study addresses the nature of the relevant endopeptidase activity in rat liver that is responsible for most receptor-mediated insulin degradation in vivo. The endosomal activity was shown to be aspartic acid protease cathepsin D (CD), based on biochemical similarities to purified CD in 1) the rate and site of substrate cleavage, 2) pH optimum, 3) sensitivity to pepstatin A, and 4) binding to pepstatin A-agarose. The identity of the protease was immunologically confirmed by removal of greater than 90% of the insulin-degrading activity associated with an endosomal lysate using polyclonal antibodies to CD. Moreover, the elution profile of the endosomal acidic insulinase activity on a gel-filtration TSK-GEL G3000 SWXL high performance liquid chromatography column corresponded exactly with the elution profile of the immunoreactive 45-kDa mature form of endosomal CD. Using nondenaturating immunoprecipitation and immunoblotting procedures, other endosomal aspartic acid proteases such as cathepsin E and beta-site amyloid precursor protein-cleaving enzyme (BACE) were ruled out as candidate enzymes for the endosomal degradation of internalized insulin. Immunofluorescence studies showed a largely vesicular staining pattern for internalized insulin in rat hepatocytes that colocalized partially with CD. In vivo pepstatin A treatment was without any observable effect on the insulin receptor content of endosomes but augmented the phosphotyrosine content of the endosomal insulin receptor after insulin injection. These results suggest that CD is the endosomal acidic insulinase activity which catalyzes the rate-limiting step of the in vivo cleavage at the Phe(B24)-Phe(B25) bond, generating the inactive A(1-21)-B1-24 insulin intermediate.	Fac Pharm Paris 11, INSERM, U510, F-92296 Chatenay Malabry, France; Fac Med Lille, Lab Spectrometrie Masse, F-59000 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Universite de Lille - ISITE; Universite de Lille	Authier, F (corresponding author), Fac Pharm Paris 11, INSERM, U510, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.	francois.authier@cep.u-psud.fr						ARAKI N, 1995, EXP CELL RES, V217, P469, DOI 10.1006/excr.1995.1111; AUTHIER F, 1994, J BIOL CHEM, V269, P3010; Authier F, 1998, BIOCHEM J, V332, P421, DOI 10.1042/bj3320421; AUTHIER F, 1995, J BIOL CHEM, V270, P15798, DOI 10.1074/jbc.270.26.15798; Authier F, 1996, FEBS LETT, V389, P55, DOI 10.1016/0014-5793(96)00368-7; AUTHIER F, 1995, P NATL ACAD SCI USA, V92, P3859, DOI 10.1073/pnas.92.9.3859; AUTHIER F, 1990, BIOCHEM J, V272, P703, DOI 10.1042/bj2720703; AUTHIER F, 1991, BIOCHEM J, V280, P211, DOI 10.1042/bj2800211; Authier F, 2001, ENDOCRINOLOGY, V142, P276, DOI 10.1210/en.142.1.276; AUTHIER F, 1992, ENDOCRINOLOGY, V131, P447, DOI 10.1210/en.131.1.447; Authier F, 1999, J BIOL CHEM, V274, P33723, DOI 10.1074/jbc.274.47.33723; AUTHIER F, 1994, CELLULAR PROTEOLYTIC, V15, P89; BALAVOINE S, 1990, EUR J BIOCHEM, V189, P617, DOI 10.1111/j.1432-1033.1990.tb15530.x; Benzi L, 1997, METABOLISM, V46, P1259, DOI 10.1016/S0026-0495(97)90227-4; BLUM JS, 1991, J BIOL CHEM, V266, P22091; BROSTOFF SW, 1974, J BIOL CHEM, V249, P559; CASCIERI MA, 1989, J BIOL CHEM, V264, P2199; Chapman HA, 1998, CURR OPIN IMMUNOL, V10, P93, DOI 10.1016/S0952-7915(98)80038-1; CLOT JP, 1990, MOL CELL ENDOCRINOL, V72, P175, DOI 10.1016/0303-7207(90)90142-U; DEAN RT, 1979, BIOCHEM J, V180, P339, DOI 10.1042/bj1800339; DESBUQUOIS B, 1990, EUR J BIOCHEM, V193, P501, DOI 10.1111/j.1432-1033.1990.tb19365.x; DIMENT S, 1989, J BIOL CHEM, V264, P13403; DIMENT S, 1988, J BIOL CHEM, V263, P6901; Fallon K, 1997, INFECT IMMUN, V65, P551, DOI 10.1128/IAI.65.2.551-556.1997; GLICKMAN JN, 1993, J CELL BIOL, V123, P99, DOI 10.1083/jcb.123.1.99; GRANT DAW, 1982, BIOCHEM PHARMACOL, V31, P2302, DOI 10.1016/0006-2952(82)90120-4; Gruninger-Leitch F, 2000, NAT BIOTECHNOL, V18, P66, DOI 10.1038/71944; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HAMEL FG, 1991, DIABETES, V40, P436, DOI 10.2337/diabetes.40.4.436; HAMEL FG, 1988, J BIOL CHEM, V263, P6703; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; Higaki J, 1996, J BIOL CHEM, V271, P31885, DOI 10.1074/jbc.271.50.31885; HUGHES CE, 1992, J BIOL CHEM, V267, P16011; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Jaskiewicz E, 1996, J BIOL CHEM, V271, P26395, DOI 10.1074/jbc.271.42.26395; Kagedal K, 2001, FASEB J, V15, P1592, DOI 10.1096/fj.00-0708fje; Kageyama T, 1996, BIOCHEM BIOPH RES CO, V223, P549, DOI 10.1006/bbrc.1996.0932; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; Meresse S, 1997, ELECTROPHORESIS, V18, P2682, DOI 10.1002/elps.1150181425; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; MORT JS, 1981, J HISTOCHEM CYTOCHEM, V29, P649, DOI 10.1177/29.5.6788835; Navab R, 2001, J BIOL CHEM, V276, P13644, DOI 10.1074/jbc.M100019200; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Pimenta DC, 2001, BBA-PROTEIN STRUCT M, V1544, P113, DOI 10.1016/S0167-4838(00)00209-0; Press B, 1998, J CELL BIOL, V140, P1075, DOI 10.1083/jcb.140.5.1075; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; Rochefort H, 2000, CLIN CHIM ACTA, V291, P157, DOI 10.1016/S0009-8981(99)00226-0; RODMAN JS, 1990, J LEUKOCYTE BIOL, V48, P116, DOI 10.1002/jlb.48.2.116; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; RUNQUIST EA, 1991, J BIOL CHEM, V266, P22557; RYAN MP, 1984, ENDOCRINOLOGY, V115, P591, DOI 10.1210/endo-115-2-591; Seabright PJ, 1996, BIOCHEM J, V320, P947, DOI 10.1042/bj3200947; SEGLEN PO, 1980, BIOCHIM BIOPHYS ACTA, V630, P103, DOI 10.1016/0304-4165(80)90141-5; SHII K, 1986, P NATL ACAD SCI USA, V83, P4147, DOI 10.1073/pnas.83.12.4147; TONG P, 1995, LANCET, V345, P357, DOI 10.1016/S0140-6736(95)90343-7; TOUSTER O, 1970, J CELL BIOL, V47, P604, DOI 10.1083/jcb.47.3.604; Trouet A, 1974, Methods Enzymol, V31, P323; VANNOORT JM, 1989, J BIOL CHEM, V264, P14159; Villadangos JA, 1999, IMMUNOL REV, V172, P109, DOI 10.1111/j.1600-065X.1999.tb01360.x; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; Yamamoto K, 1999, MCBU, P59	63	57	59	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9437	9446		10.1074/jbc.M110188200	http://dx.doi.org/10.1074/jbc.M110188200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11779865	hybrid			2022-12-27	WOS:000174400600094
J	Bies, J; Markus, J; Wolff, L				Bies, J; Markus, J; Wolff, L			Covalent attachment of the SUMO-1 protein to the negative regulatory domain of the c-Myb transcription factor modifies its stability and transactivation capacity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; NUCLEAR-PORE COMPLEX; GTPASE-ACTIVATING PROTEIN; DNA-BINDING; PHOSPHORYLATION SITE; V-MYB; ONCOGENIC ACTIVATION; NF-M; TRANSFORMATION; RANGAP1	The transcription factor c-Myb is subject to several types of post-translational modifications, including phosphorylation, acetylation, and ubiquitination. These modifications regulate the transcription and transforming activity as well as the proteolytic stability of c-Myb. Here we report the covalent modification of c-Myb with the small ubiquitin-related protein SUMO-1. Mutational analysis identified two major sumolation sites (Lys(499) and Lys(523)) in the negative regulatory domain. Interestingly, the single mutation K523R completely abolished modification of c-Myb with SUMO-1, suggesting that sumolation of Lys(523) is required for modification of other lysines in c-Myb. In accordance with this observation, we found that the SUMO-1-conjugating enzyme Ubc9 interacted only with a region surrounding Lys(523) (also called the PEST/EVES motif). Experiments aimed at determining the proteolytic stability of sumolated and unmodified forms of c-Myb, revealed that at least two covalently attached SUMO-1 molecules dramatically increased the stability of c-Myb. However, mutations of the SUMO-1 modification sites did not alter its stability, suggesting that a mechanism(s) other than competition of ubiquitin and SUMO-1 for the same lysine is involved in the stabilization of sumolated c-Myb protein. Finally, the K523R mutant of c-Myb, entirely deficient in sumolation, was shown to have an increased transactivation capacity on a Myb-responsive promoter, suggesting that SUMO-1 negatively regulates the transactivation function of c-Myb. Thus, modification of c-Myb with SUMO-1 represents a novel mechanism through which the negative regulatory domain can exert its suppressing activity on c-Myb transactivation capacity.	NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA; Slovak Acad Sci, Canc Res Inst, Dept Mol Virol, Bratislava 83391, Slovakia	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Slovak Academy of Sciences	Bies, J (corresponding author), NCI, Cellular Oncol Lab, NIH, 37 Convent Dr,MSC-4255, Bethesda, MD 20892 USA.		/ABB-3317-2021	/0000-0003-3998-9357				AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bies J, 2000, ONCOGENE, V19, P2846, DOI 10.1038/sj.onc.1203613; Bies J, 1996, ONCOGENE, V12, P355; Bies J, 1999, J VIROL, V73, P2038, DOI 10.1128/JVI.73.3.2038-2044.1999; Bies J, 2001, BLOOD CELL MOL DIS, V27, P422, DOI 10.1006/bcmd.2001.0400; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; Boddy MN, 1996, ONCOGENE, V13, P971; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Feikova S, 2000, NEOPLASMA, V47, P212; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; KALKBRENNER F, 1990, ONCOGENE, V5, P657; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Koller R, 1996, VIROLOGY, V224, P224, DOI 10.1006/viro.1996.0524; Ladendorff NE, 2001, ONCOGENE, V20, P125, DOI 10.1038/sj.onc.1204048; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Okura T, 1996, J IMMUNOL, V157, P4277; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; RAMSAY RG, 1991, ONCOGENE, V6, P1875; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Sano Y, 2001, J BIOL CHEM, V276, P3674, DOI 10.1074/jbc.M006896200; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Wolff L, 1996, CRIT REV ONCOGENESIS, V7, P245, DOI 10.1615/CritRevOncog.v7.i3-4.60	59	150	154	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8999	9009		10.1074/jbc.M110453200	http://dx.doi.org/10.1074/jbc.M110453200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11779867	hybrid			2022-12-27	WOS:000174400600036
J	Kumatori, A; Yang, D; Suzuki, S; Nakamura, M				Kumatori, A; Yang, D; Suzuki, S; Nakamura, M			Cooperation of STAT-1 and IRF-1 in interferon-gamma-induced transcription of the gp91(phox) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; CCAAT DISPLACEMENT PROTEIN; SEQUENCE-BINDING-PROTEIN; CLASS-II TRANSACTIVATOR; REGULATORY FACTOR-I; IFN-GAMMA; CYTOCHROME B(558); GP91-PHOX PROMOTER; CIS-ELEMENTS; EXPRESSION	Interferon (IFN)-gamma induces the expression of the gp91(phox), gene both during myeloid differentiation and also in mature phagocytes through several cis-elements and their binding proteins. To find new cis-elements for this induction, transient expression assays were performed using a reporter gene driven by serially truncated gp91(phox) promoters in U937 cells. The results suggest that a critical cis-element for induction exists in the region from bp -115 to -96 of the promoter. Site-directed mutagenesis showed that a gamma-activated sequence (GA.S) element at bp -100 (-100GA.S) of the gp91(phox) promoter plays a pivotal role for the IFN-gamma-dependent activity of the bp -115 to +12 region of the gp91(phox) promoter. Electrophoretic mobility shift assays using several GAS competitors and specific antibodies indicated that phosphorylated STAT-1alpha specifically binds to the -100GAS. Site-directed mutagenesis showed that an interferon-stimulated response element (ISRE) at bp -88 (-88ISRE) mediates the induction of the gene by IFN-gamma in cooperation with -100GAS. Electrophoretic mobility shift assay showed that IRF-1 dominantly binds to -88ISRE in an IFN-gamma-dependent fashion. These results demonstrate a new mechanism for IFN-gamma-induced transcription of the gp91(phox) gene by the cooperation of STAT-la and IRF-1 binding to -100GA.S and -881SRE, respectively.	Nagasaki Univ, Inst Trop Med, Dept Host Def Biochem, Nagasaki 8528523, Japan	Nagasaki University	Kumatori, A (corresponding author), Nagasaki Univ, Inst Trop Med, Dept Host Def Biochem, Sakamoto 1-12-4, Nagasaki 8528523, Japan.							Aittomaki S, 2000, J IMMUNOL, V164, P5689, DOI 10.4049/jimmunol.164.11.5689; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; CASSATELLA MA, 1989, J CLIN INVEST, V83, P1570, DOI 10.1172/JCI114054; Catt D, 1999, BLOOD, V94, P3151, DOI 10.1182/blood.V94.9.3151.421k38_3151_3160; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Dong YS, 1999, J IMMUNOL, V162, P4731; Eason DD, 2001, J IMMUNOL, V166, P1041, DOI 10.4049/jimmunol.166.2.1041; EILERS A, 1994, MOL CELL BIOL, V14, P1364, DOI 10.1128/MCB.14.2.1364; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Eklund EA, 1996, J IMMUNOL, V157, P2418; EKLUND EA, 1995, J BIOL CHEM, V270, P8267, DOI 10.1074/jbc.270.14.8267; Faizunnessa NN, 1997, HUM GENET, V99, P469, DOI 10.1007/PL00008702; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; Jacobsen BM, 1999, J BIOL CHEM, V274, P29984, DOI 10.1074/jbc.274.42.29984; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; Kumatori A, 1998, GENOMICS, V53, P123, DOI 10.1006/geno.1998.5510; KURIBAYASHI F, 1995, BIOCHEM BIOPH RES CO, V209, P146, DOI 10.1006/bbrc.1995.1482; Lee YJ, 1996, J IMMUNOL, V157, P1559; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lien LL, 1997, MOL CELL BIOL, V17, P2279, DOI 10.1128/MCB.17.4.2279; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; Marziali G, 1999, BLOOD, V93, P519, DOI 10.1182/blood.V93.2.519.402a01_519_526; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; NEWBURGER PE, 1988, P NATL ACAD SCI USA, V85, P5215, DOI 10.1073/pnas.85.14.5215; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Sadat MA, 1998, FEBS LETT, V436, P390; Sharf R, 1997, J BIOL CHEM, V272, P9785; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SKALNIK DG, 1991, P NATL ACAD SCI USA, V88, P8505, DOI 10.1073/pnas.88.19.8505; Suzuki S, 1998, P NATL ACAD SCI USA, V95, P6085, DOI 10.1073/pnas.95.11.6085; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TAUBER AI, 1983, MEDICINE, V62, P286, DOI 10.1097/00005792-198309000-00003; Voo KS, 1999, BLOOD, V93, P3512, DOI 10.1182/blood.V93.10.3512.410k19_3512_3520; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Yang D, 2000, J BIOL CHEM, V275, P9425, DOI 10.1074/jbc.275.13.9425; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	48	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9103	9111		10.1074/jbc.M109803200	http://dx.doi.org/10.1074/jbc.M109803200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11781315	hybrid			2022-12-27	WOS:000174400600050
J	Nakamura, F; Osborn, E; Janmey, PA; Stossel, TP				Nakamura, F; Osborn, E; Janmey, PA; Stossel, TP			Comparison of filamin A-induced cross-linking and Arp2/3 complex-mediated branching on the mechanics of actin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; F-ACTIN; 3-DIMENSIONAL STRUCTURE; ALPHA-ACTININ; LEADING-EDGE; BARBED ENDS; N-WASP; NETWORKS; CELLS; POLYMERIZATION	We compared the effects of human filamin A (FLNa) and the activated human Arp2/3 complex on mechanical properties of actin filaments. As little as 1 FLNa to 800 polymerizing actin monomers induces a sharp concentration-dependent increase in the apparent viscosity of 24 gm actin, a parameter classically defined as a gel point. The activated Arp2/3 complex, at concentrations up to 1:25 actins had no detectable actin gelation activity, even in the presence of phalloidin, to stabilize actin filaments against debranching. Increasing the activated Arp2/3 complex to actin ratio raises the FLNa concentration required to induce actin gelation, an effect ascribable to Arp2/3-mediated actin nucleation resulting in actin filament length diminution. Time lapse video microscopy of microparticles attached to actin filaments or photoactivation of fluorescence revealed actin filament immobilization by FLNa in contrast to diffusion of Arp2/3-branched actin filaments. The experimental results support theories predicting that polymer branching absent cross-linking does not lead to polymer gelation and are consistent with the observation that cells deficient in actin filament cross-linking activity have unstable surfaces. They suggest complementary roles for actin branching and cross-linking in cellular actin mechanics in vivo.	Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp Hematol Div, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Stossel, TP (corresponding author), Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp Hematol Div, 221 Longwood Ave, Boston, MA 02115 USA.	Tstossel@rics.bwh.harvard.edu	Nakamura, Fumihiko/N-5476-2016	Nakamura, Fumihiko/0000-0002-6872-4246	NHLBI NIH HHS [HL54145, HL19429] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019429, R01HL054145, R37HL019429] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham VC, 1999, BIOPHYS J, V77, P1721, DOI 10.1016/S0006-3495(99)77018-9; Almdal K., 1993, POLYM GELS NETW, V1, P5, DOI [10.1016/0966-7822(93)90020-I, DOI 10.1016/0966-7822(93)90020-I]; Amann KJ, 2001, NAT CELL BIOL, V3, P306, DOI 10.1038/35060104; [Anonymous], 1980, VISCOELASTIC PROPERT; Bailly M, 2001, CURR BIOL, V11, P620, DOI 10.1016/S0960-9822(01)00152-X; Bailly M, 1999, J CELL BIOL, V145, P331, DOI 10.1083/jcb.145.2.331; BENNETT JP, 1984, BIOCHEMISTRY-US, V23, P5081, DOI 10.1021/bi00316a039; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Blanchoin L, 1998, J BIOL CHEM, V273, P25106, DOI 10.1074/jbc.273.39.25106; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; BROTSCHI EA, 1978, J BIOL CHEM, V253, P8988; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Dembo M, 1999, BIOPHYS J, V76, P2307, DOI 10.1016/S0006-3495(99)77386-8; Eddy RJ, 1997, J CELL BIOL, V139, P1243, DOI 10.1083/jcb.139.5.1243; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; EVANS E, 1993, J CELL BIOL, V122, P1295, DOI 10.1083/jcb.122.6.1295; Flanagan LA, 2001, J CELL BIOL, V155, P511, DOI 10.1083/jcb.200105148; FLORY PJ, 1947, J AM CHEM SOC, V69, P2893, DOI 10.1021/ja01203a075; FLORY PJ, 1953, PRINCIPLES POYLM CHE; GOLDMANN WH, 1993, FEBS LETT, V336, P408, DOI 10.1016/0014-5793(93)80847-N; HARTWIG JH, 1980, J CELL BIOL, V87, P841, DOI 10.1083/jcb.87.3.841; HARTWIG JH, 1986, J CELL BIOL, V103, P1007, DOI 10.1083/jcb.103.3.1007; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HARTWIG JH, 1979, J MOL BIOL, V134, P539, DOI 10.1016/0022-2836(79)90366-8; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Hoffmeister KM, 2001, J BIOL CHEM, V276, P24751, DOI 10.1074/jbc.M011642200; Isambert H, 1996, MACROMOLECULES, V29, P1036, DOI 10.1021/ma946418x; JANMEY PA, 1990, NATURE, V345, P89, DOI 10.1038/345089a0; JANMEY PA, 1988, BIOCHEMISTRY-US, V27, P8218, DOI 10.1021/bi00421a035; LIM K, 1994, PROTEIN SCI, V3, P2233, DOI 10.1002/pro.5560031209; Mackintosh FC, 1997, CURR OPIN SOLID ST M, V2, P350, DOI 10.1016/S1359-0286(97)80127-1; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Matsudaira Paul, 1994, Seminars in Cell Biology, V5, P165, DOI 10.1006/scel.1994.1021; McGrath JL, 2000, BIOPHYS J, V79, P3258, DOI 10.1016/S0006-3495(00)76558-1; McGrath JL, 1998, BIOPHYS J, V75, P2070, DOI 10.1016/S0006-3495(98)77649-0; McGrath JL, 2000, P NATL ACAD SCI USA, V97, P6532, DOI 10.1073/pnas.100023397; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; Morse DC, 1998, MACROMOLECULES, V31, P7044, DOI 10.1021/ma980304u; Morse DC, 1998, MACROMOLECULES, V31, P7030, DOI 10.1021/ma9803032; Mullins RD, 2000, METHOD ENZYMOL, V325, P214; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Mullins RD, 1998, MOL BIOL CELL, V9, P841, DOI 10.1091/mbc.9.4.841; NIEDERMAN R, 1983, J CELL BIOL, V96, P1400, DOI 10.1083/jcb.96.5.1400; NUNNALLY MH, 1981, J BIOL CHEM, V256, P2083; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Pantaloni D, 2000, NAT CELL BIOL, V2, P385, DOI 10.1038/35017011; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Tang JX, 1997, BIOCHEMISTRY-US, V36, P12600, DOI 10.1021/bi9711386; Tang JX, 1999, BIOPHYS J, V76, P2208, DOI 10.1016/S0006-3495(99)77376-5; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; Tobita H, 1998, J POLYM SCI POL PHYS, V36, P2015, DOI 10.1002/(SICI)1099-0488(199808)36:11<2015::AID-POLB23>3.0.CO;2-8; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; Volkmann N, 2001, SCIENCE, V293, P2456, DOI 10.1126/science.1063025; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Xu JY, 1998, BIOPHYS J, V74, P2731, DOI 10.1016/S0006-3495(98)77979-2; YASUTAKA O, 1995, BIOCHEMISTRY-US, V34, P6745, DOI 10.1021/bi00020a020; YIN HL, 1980, J BIOL CHEM, V255, P9494	62	66	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9148	9154		10.1074/jbc.M111297200	http://dx.doi.org/10.1074/jbc.M111297200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11786548	hybrid			2022-12-27	WOS:000174400600056
J	Poupon, V; Polo, S; Vecchi, M; Martin, G; Dautry-Varsat, A; Cerf-Bensussan, N; Di Fiore, PP; Benmerah, A				Poupon, V; Polo, S; Vecchi, M; Martin, G; Dautry-Varsat, A; Cerf-Bensussan, N; Di Fiore, PP; Benmerah, A			Differential nucleocytoplasmic trafficking between the related endocytic proteins Eps15 and Eps15R	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; NUCLEAR EXPORT SIGNAL; CLATHRIN-MEDIATED ENDOCYTOSIS; BETA-CATENIN; COATED PITS; EH-DOMAIN; TERMINAL DOMAIN; LOCALIZATION; TRANSPORT; RECEPTOR	Eps15 and Eps15R are constitutive components of clathrin-coated pits that are required for clathrin-dependent endocytosis. The most striking difference between these two related proteins is that Eps15R is also found in the nucleus, whereas Eps15 is excluded from this compartment at steady state. To better understand the individual functions of these two proteins, the mechanisms responsible for their different localization were investigated. Interestingly, some mutants of Eps15 were found in the nucleus. This nuclear localization was correlated with the loss of the last approximate to100 amino acids of Eps15, suggesting the presence of a nuclear export signal (NES) within this region. As expected, the last 25 amino acids contain a leucine-rich sequence matching with classical NESs, show a leptomycin B-sensitive nuclear export activity, and bind to the exportin CRM1 in a leucine residue-dependent manner. In contrast, no NES could be found in Eps15R, a result in keeping with its constitutive nuclear localization that appears to be regulated by alternative splicing. Altogether, these results are the first characterization of nucleocytoplasmic shuttling signals for endocytic proteins. They also provide an explanation for the different nuclear localization of Eps15 and Eps15R and further evidence for a possible nuclear function for Eps15 protein family members.	Fac Necker Enfants Malad, INSERM E9925, F-75730 Paris 15, France; Inst Pasteur, URA 1960, CNRS, Unite Biol Interact Cellulaires, F-75724 Paris, France; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Milan, Sch Med, I-20122 Milan, Italy; Inst Mol Oncol, FIRC, I-20134 Milan, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; IRCCS European Institute of Oncology (IEO); University of Milan; IFOM - FIRC Institute of Molecular Oncology	Benmerah, A (corresponding author), Fac Necker Enfants Malad, INSERM E9925, 156 Rue Vaugirard, F-75730 Paris 15, France.		Vecchi, Manuela/L-3502-2017; Cerf-Bensussan, nadine/H-9505-2017; Polo, Simona/P-3509-2014; benmerah, alexandre/H-3742-2017; Di Fiore, Pier Paolo/K-2130-2012	Vecchi, Manuela/0000-0002-2750-9160; Cerf-Bensussan, nadine/0000-0003-0665-1245; benmerah, alexandre/0000-0003-0188-8016; Di Fiore, Pier Paolo/0000-0002-2252-0950; Polo, Simona/0000-0001-5536-9399	Telethon [D.090] Funding Source: Medline	Telethon(Fondazione Telethon)		Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Ansaldi M, 1996, ANAL BIOCHEM, V234, P110, DOI 10.1006/abio.1996.0060; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Benmerah A, 2000, J BIOL CHEM, V275, P3288, DOI 10.1074/jbc.275.5.3288; BERNARD OA, 1994, ONCOGENE, V9, P1039; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; Carbone R, 1997, CANCER RES, V57, P5498; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Coda L, 1998, J BIOL CHEM, V273, P3003, DOI 10.1074/jbc.273.5.3003; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Cupers P, 1998, J BIOL CHEM, V273, P1847, DOI 10.1074/jbc.273.4.1847; Cupers P, 1997, J BIOL CHEM, V272, P33430, DOI 10.1074/jbc.272.52.33430; Doria M, 1999, J CELL BIOL, V147, P1379, DOI 10.1083/jcb.147.7.1379; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Horton Paul, 1997, INTELLIGENT SYSTEMS, V5, P147; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Iannolo G, 1997, CANCER RES, V57, P240; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Latimer M, 1998, MOL CELL BIOL, V18, P2640, DOI 10.1128/MCB.18.5.2640; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Rosenthal JA, 1999, J BIOL CHEM, V274, P33959, DOI 10.1074/jbc.274.48.33959; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Salcini AE, 2001, NAT CELL BIOL, V3, P755, DOI 10.1038/35087075; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Spradling KD, 2001, J BIOL CHEM, V276, P29257, DOI 10.1074/jbc.M101663200; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; WONG WT, 1994, ONCOGENE, V9, P1591; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119	54	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8941	8948		10.1074/jbc.M108385200	http://dx.doi.org/10.1074/jbc.M108385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11777906	hybrid			2022-12-27	WOS:000174400600029
J	Prokova, V; Mosialos, G; Kardassis, D				Prokova, V; Mosialos, G; Kardassis, D			Inhibition of transforming growth factor beta signaling and smad-dependent activation of transcription by the latent membrane protein 1 of Epstein-Barr virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RECEPTOR-ASSOCIATED FACTORS; TGF-BETA; INFECTION MEMBRANE-PROTEIN-1; LYMPHOCYTE TRANSFORMATION; MEDIATED TRANSCRIPTION; FAMILY MEMBERS; JUNB PROMOTER; ENCODED LMP1; C-TERMINUS	Inhibition of transforming growth factor beta(TGFbeta) signaling by the Epstein-Barr virus Latent Membrane Protein 1 (LMP1) may account, at least in part, for the oncogenic activity of LMP1. We found that LMP1 is a potent inhibitor of TGFbeta signaling and Smad-dependent activation of transcription in 293 epithelial cells and COS-7 fibroblasts. LMP1 strongly inhibited the uninduced and the Smad-inducible activity of the promoters of the human p21/WAF1/Cip1 gene and the mouse Smad7 gene. Inhibition of TGFbeta signaling and Smad-dependent activation of transcription by LMP1 was greatly reduced by deletion of both C-terminal activating regions 1 and 2 of LMP1 as well as by overexpression of a non-degradable form of licB. In contrast, specific inhibitors of p38 kinase or MEK kinase did not reverse the inhibitory activity of LMP1. TGFbeta signaling was enhanced by overexpression of dominant negative forms of the LMP1 effectors TRAF2, NIK, and IKKbeta and was abolished by overexpression of p65/RelA or a p50/p65 fusion protein. Deletion of the transactivation domain of p65 abolished its inhibitory activity. Immunoblotting and immunofluorescence microscopy indicated that suppression of TGFbeta signaling and Smad transcriptional activity by LMP1 was not due to Smad degradation or cytoplasmic retention suggesting that LMP1 affects the nuclear function of Smad proteins. Our data are consistent with an essential role of NF-kappaB activation by LMP1 in the inhibition of TGFbeta signaling and Smad-mediated transcriptional responses.	Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Iraklion, Greece; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Greece; Biomed Sci Res Ctr Al Fleming, Inst Immunol, GR-16672 Vari, Greece	University of Crete; Foundation for Research & Technology - Hellas (FORTH); Alexander Fleming Biomedical Sciences Research Center	Kardassis, D (corresponding author), Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Iraklion, Greece.	karda-sis@imbb.forth.gr						Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; ARVANITAKIS L, 1995, J IMMUNOL, V155, P1047; BAICHWAL VR, 1989, ONCOGENE, V4, P67; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Devergne O, 1996, MOL CELL BIOL, V16, P7098; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 1997, ONCOGENE, V14, P2899, DOI 10.1038/sj.onc.1201258; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Floettmann JL, 1998, ONCOGENE, V17, P2383, DOI 10.1038/sj.onc.1202144; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hatzivassiliou E, 1998, J IMMUNOL, V160, P1116; He ZM, 2000, CANCER RES, V60, P1845; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Inman GJ, 2000, J GEN VIROL, V81, P1567, DOI 10.1099/0022-1317-81-6-1567; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Izumi KM, 1999, J VIROL, V73, P9908, DOI 10.1128/JVI.73.12.9908-9916.1999; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kon A, 1999, ONCOGENE, V18, P1837, DOI 10.1038/sj.onc.1202495; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lee IS, 2001, BLOOD, V97, P3596, DOI 10.1182/blood.V97.11.3596; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 2000, BIOCHEM J, V348, P591, DOI 10.1042/0264-6021:3480591; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Takanashi M, 1999, ARCH VIROL, V144, P241, DOI 10.1007/s007050050501; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0	61	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9342	9350		10.1074/jbc.M109099200	http://dx.doi.org/10.1074/jbc.M109099200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11781310	hybrid			2022-12-27	WOS:000174400600082
J	Gerken, TA; Gilmore, M; Zhang, JX				Gerken, TA; Gilmore, M; Zhang, JX			Determination of the site-specific oligosaccharide distribution of the O-glycans attached to the porcine submaxillary mucin tandem repeat - Further evidence for the modulation of O-glycan side chain structures by peptide sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; GDP-L-FUCOSE; D-GALACTOSIDE 2-ALPHA-L-FUCOSYL-TRANSFERASE; CELL-ADHESION MOLECULE; UDP-GALNAC; LINKED GLYCOSYLATION; CORE-2 BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE; IMMUNOGLOBULIN-G; CANCER-CELLS; GLYCOPEPTIDE	Little is known of the degree that polypeptide sequence and the local environment modulate the structures of O-linked glycans. Toward this understanding, the site-specific mono- (GalNAc-O-), di- (beta-Gal-1,3-alpha-GalNAc-O-), and trisaccharide (alpha-Fuc-1,2-O-Gal-1,3-alpha-GalNAc-O-) distributions have been determined for 29 of the 31 O-glycosylated Ser/Thr residues in the tandem repeat domains of blood group A-negative porcine submaxillary gland mucin. The glycosylation patterns obtained from three individual animals are in agreement with earlier incomplete determinations on a pooled mucin (Gerken, T. A., Owens, C. L., and Pasumarthy, M. (1997) J. Biol. Chem. 272,9709-9719; Gerken, T. A., Owens, C. L., and Pasumarthy, M. (1998) J. Biol. Chem. 273, 2658026588), confirming that the addition of the peptide-linked GalNAc and its substitution by beta-1,3-Gal are sensitive to local peptide sequence in a highly reproducible manner in vivo. The present data further support earlier suggestions of an inverse correlation of the density of hydroxyamino acid residues (and by inference the density of peptide GalNAc) with the extent of substitution of the peptide-linked GalNAc by beta-1,3-Gal. This effect is highly correlated for Ser-linked glycans but not for Thr-linked glycans. A similar correlation is observed with respect to the in vivo peptide GalNAc glycosylation pattern. In contrast, the addition of alpha-1,2-Fuc to beta-Gal shows no apparent correlation with hydroxyamino acid density, although a marked elevation in the fucosylation of Ser-linked glycans compared with Thr-linked glycans is observed. The above effects may represent both steric and conformational factors acting to alter the relative accessibility and activity of the glycosyltransferases toward substrate. These results demonstrate that the porcine submaxillary gland core beta3-galactosyltransferase and alpha2-fucosyltransferase exhibit unique peptide/glycopeptide sensitivities that may provide mechanisms for the modulation of O-linked side chain structures.	Case Western Reserve Univ, Sch Med, Dept Pediat, BRB, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, W A Bernbaum Ctr Cyst Fibrosis Res, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Gerken, TA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pediat, BRB, 2109 Adelbert Rd, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [P30CA043703, R01CA078834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-78834, R01 CA078834, P30-CA43703] Funding Source: Medline; NIAID NIH HHS [P30-AI36219] Funding Source: Medline; NIAMS NIH HHS [P30-AR39750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMINOFF D, 1979, J BIOL CHEM, V254, P1788; Axelsson MAB, 2001, GLYCOBIOLOGY, V11, P633, DOI 10.1093/glycob/11.8.633; Barreaud JP, 2000, GLYCOBIOLOGY, V10, P611, DOI 10.1093/glycob/10.6.611; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Bennett EP, 1999, FEBS LETT, V460, P226, DOI 10.1016/S0014-5793(99)01268-5; Berger EG, 1999, BBA-MOL BASIS DIS, V1455, P255, DOI 10.1016/S0925-4439(99)00069-1; Beum PV, 1999, J BIOL CHEM, V274, P24641, DOI 10.1074/jbc.274.35.24641; BEYER TA, 1980, J BIOL CHEM, V255, P5373; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; Brockhausen I, 1996, GLYCOCONJUGATE J, V13, P849, DOI 10.1007/BF00702349; BROCKHAUSEN I, 1990, BIOCHEMISTRY-US, V29, P10206, DOI 10.1021/bi00496a008; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Bureau V, 2001, EUR J BIOCHEM, V268, P1006, DOI 10.1046/j.1432-1327.2001.01962.x; BUTENHOF KJ, 1993, BIOCHEMISTRY-US, V32, P2650, DOI 10.1021/bi00061a025; CARLSON DM, 1968, J BIOL CHEM, V243, P616; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; Close BE, 2000, J BIOL CHEM, V275, P4484, DOI 10.1074/jbc.275.6.4484; Dalziel M, 2001, J BIOL CHEM, V276, P11007, DOI 10.1074/jbc.M006523200; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; DO KY, 1994, J BIOL CHEM, V269, P23456; DOWNS F, 1977, INT J PEPT PROT RES, V10, P315; Eckhardt AE, 1997, J BIOL CHEM, V272, P33204, DOI 10.1074/jbc.272.52.33204; Elhammer AP, 1999, GLYCOCONJUGATE J, V16, P171, DOI 10.1023/A:1026465232149; Fukuda M, 1999, BBA-MOL BASIS DIS, V1455, P205, DOI 10.1016/S0925-4439(99)00067-8; Gerken TA, 1998, J BIOL CHEM, V273, P26580, DOI 10.1074/jbc.273.41.26580; GERKEN TA, 1992, BIOCHEMISTRY-US, V31, P639, DOI 10.1021/bi00118a002; GERKEN TA, 1987, BIOCHEMISTRY-US, V26, P4689, DOI 10.1021/bi00389a015; GERKEN TA, 1986, ARCH BIOCHEM BIOPHYS, V247, P239, DOI 10.1016/0003-9861(86)90581-3; Gerken TA, 1997, J BIOL CHEM, V272, P9709; Gervais V, 1997, EUR J BIOCHEM, V247, P386, DOI 10.1111/j.1432-1033.1997.00386.x; GRANOVSKY M, 1994, EUR J BIOCHEM, V221, P1039, DOI 10.1111/j.1432-1033.1994.tb18822.x; Hanisch FG, 1999, J BIOL CHEM, V274, P9946, DOI 10.1074/jbc.274.15.9946; Hanisch FG, 2001, GLYCOBIOLOGY, V11, P731, DOI 10.1093/glycob/11.9.731; Hassan H, 2000, J BIOL CHEM, V275, P38197, DOI 10.1074/jbc.M005783200; Hitoshi S, 1996, J BIOL CHEM, V271, P16975, DOI 10.1074/jbc.271.28.16975; Iida S, 1999, FEBS LETT, V449, P230, DOI 10.1016/S0014-5793(99)00445-7; Ikehara Y, 1999, GLYCOBIOLOGY, V9, P1213, DOI 10.1093/glycob/9.11.1213; Kato K, 2001, GLYCOBIOLOGY, V11, P821, DOI 10.1093/glycob/11.10.821; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; Kirnarsky L, 1998, BIOCHEMISTRY-US, V37, P12811, DOI 10.1021/bi981034a; Kono M, 2000, BIOCHEM BIOPH RES CO, V272, P94, DOI 10.1006/bbrc.2000.2745; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; Meijerink E, 1997, MAMM GENOME, V8, P736, DOI 10.1007/s003359900556; MENGELING BJ, 1995, P NATL ACAD SCI USA, V92, P502, DOI 10.1073/pnas.92.2.502; Muller S, 1999, J BIOL CHEM, V274, P18165, DOI 10.1074/jbc.274.26.18165; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; PAULSEN H, 1991, CARBOHYD RES, V214, P199, DOI 10.1016/0008-6215(91)80029-M; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Rottger S, 1998, J CELL SCI, V111, P45; Rudd PM, 1999, J MOL BIOL, V293, P351, DOI 10.1006/jmbi.1999.3104; Schuster O, 1999, J BIOMOL NMR, V14, P33, DOI 10.1023/A:1008397304851; Skrincosky D, 1997, J BIOL CHEM, V272, P22695, DOI 10.1074/jbc.272.36.22695; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; Ten Hagen KG, 1999, J BIOL CHEM, V274, P27867; Ten Hagen KG, 2001, J BIOL CHEM, V276, P17395, DOI 10.1074/jbc.M009638200; THURIN J, 1995, J BIOL CHEM, V270, P26577, DOI 10.1074/jbc.270.44.26577; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; Toba S, 2000, BBA-GENE STRUCT EXPR, V1493, P264, DOI 10.1016/S0167-4781(00)00180-9; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; VANHALBEEK H, 1981, EUR J BIOCHEM, V118, P487; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; White KE, 2000, GENE, V246, P347, DOI 10.1016/S0378-1119(00)00050-0; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Wormald MR, 1997, BIOCHEMISTRY-US, V36, P1370, DOI 10.1021/bi9621472; Yeh JC, 1997, GLYCOBIOLOGY, V7, P241, DOI 10.1093/glycob/7.2.241; Youings A, 1996, BIOCHEM J, V314, P621, DOI 10.1042/bj3140621	71	37	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7736	7751		10.1074/jbc.M111690200	http://dx.doi.org/10.1074/jbc.M111690200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11777921	hybrid			2022-12-27	WOS:000174268000017
J	Hettwer, S; Sterner, R				Hettwer, S; Sterner, R			A novel tryptophan synthase beta-subunit from the hyperthermophile Thermotoga maritima - Quaternary structure, steady-state kinetics, and putative physiological role	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORIBOSYL ANTHRANILATE ISOMERASE; INDOLEGLYCEROL-PHOSPHATE SYNTHASE; ALPHA(2)BETA(2) COMPLEX REVEALS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; REACTION-MECHANISM; ALPHA-SUBUNIT; ACTIVE-SITES; L-SERINE; STABILITY	Tryptophan synthase catalyzes the last two steps in the biosynthesis of the amino acid tryptophan. The enzyme is an alphabetabetaalpha complex in mesophilic microorganisms. The alpha-subunit (TrpA) catalyzes the cleavage of indoleglycerol phosphate to glyceraldehyde 3-phosphate and indole, which is channeled to the active site of the associated beta-subunit (TrpB1), where it reacts with serine to yield tryptophan. The TrpA and TrpB1 proteins are encoded by the adjacent trpA and trpB1 genes in the trp operon. The genomes of many hyperthermophilic microorganisms, however, contain an additional trpB2 gene located outside of the trp operon. To reveal the properties and potential physiological role of TrpB2, the trpA, trpB1, and trpB2 genes of Thermotoga maritima were expressed heterologously in Escherichia coli, and the resulting proteins were purified and characterized. TrpA and TrpB1 form the familiar alphabetabetaalpha complex, in which the two different subunits strongly activate each other. In contrast, TrpB2 forms a beta(2)-homodimer that has a high catalytic efficiency k(cat)/K-m(indole) because of a very low K-m(indole) but does not bind to TrpA. These results suggest that TrpB2 acts as an indole rescue protein, which prevents the escape of this costly hydrophobic metabolite from the cell at the high growth temperatures of hyperthermophiles.	Univ Cologne, Inst Biochem, D-50674 Cologne, Germany	University of Cologne	Sterner, R (corresponding author), Univ Cologne, Inst Biochem, Otto Fischer Str 12-14, D-50674 Cologne, Germany.	Reinhard.Sterner@Uni-Koeln.de	Sterner, Reinhard/ABI-6781-2020	Sterner, Reinhard/0000-0001-8177-8460				ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; Beismann-Driemeyer S, 2001, J BIOL CHEM, V276, P20387, DOI 10.1074/jbc.M102012200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; DAHM A, 1997, THESIS U BASEL SWITZ; Daniel RM, 2000, CELL MOL LIFE SCI, V57, P250, DOI 10.1007/PL00000688; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; FAEDER EJ, 1970, BIOCHEMISTRY-US, V9, P4043, DOI 10.1021/bi00823a003; Fan YX, 2000, BIOCHEMISTRY-US, V39, P4692, DOI 10.1021/bi9921586; Frey M, 2000, P NATL ACAD SCI USA, V97, P14801, DOI 10.1073/pnas.260499897; Hennig M, 1997, BIOCHEMISTRY-US, V36, P6009, DOI 10.1021/bi962718q; Hocker B, 2001, CURR OPIN BIOTECH, V12, P376, DOI 10.1016/S0958-1669(00)00230-5; HOMMEL U, 1995, BIOCHEMISTRY-US, V34, P5429, DOI 10.1021/bi00016a014; Huang XY, 2001, ANNU REV BIOCHEM, V70, P149, DOI 10.1146/annurev.biochem.70.1.149; HYDE CC, 1988, J BIOL CHEM, V263, P17857; Jaenicke R, 2000, P NATL ACAD SCI USA, V97, P2962, DOI 10.1073/pnas.97.7.2962; JAENICKE R, 1991, EUR J BIOCHEM, V202, P715, DOI 10.1111/j.1432-1033.1991.tb16426.x; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; Knochel T, 2002, J BIOL CHEM, V277, P8626, DOI 10.1074/jbc.M109517200; KOPETZKI E, 1989, MOL GEN GENET, V216, P149, DOI 10.1007/BF00332244; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1991, BIOCHEMISTRY-US, V30, P479, DOI 10.1021/bi00216a025; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LEJA CA, 1995, BIOCHEMISTRY-US, V34, P6552, DOI 10.1021/bi00019a037; Merz A, 1999, J MOL BIOL, V288, P753, DOI 10.1006/jmbi.1999.2709; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; Miles EW, 1999, J BIOL CHEM, V274, P12193, DOI 10.1074/jbc.274.18.12193; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pan P, 1997, TRENDS BIOCHEM SCI, V22, P22, DOI 10.1016/S0968-0004(96)10066-9; Pappenberger G, 1997, J MOL BIOL, V274, P676, DOI 10.1006/jmbi.1997.1421; Rhee S, 1998, J BIOL CHEM, V273, P8553, DOI 10.1074/jbc.273.15.8553; Rhee S, 1998, BIOCHEMISTRY-US, V37, P10653, DOI 10.1021/bi980779d; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; SOMERO GN, 1995, ANNU REV PHYSIOL, V57, P43, DOI 10.1146/annurev.ph.57.030195.000355; Sterner R, 1996, PROTEIN SCI, V5, P2000, DOI 10.1002/pro.5560051006; STERNER R, 1995, EMBO J, V14, P4395, DOI 10.1002/j.1460-2075.1995.tb00118.x; Sterner R, 2001, METHOD ENZYMOL, V331, P270; Sterner R, 2001, CRIT REV BIOCHEM MOL, V36, P39, DOI 10.1080/20014091074174; Stetter KO, 1999, FEBS LETT, V452, P22, DOI 10.1016/S0014-5793(99)00663-8; Stetter KO, 1996, FEMS MICROBIOL REV, V18, P149, DOI 10.1111/j.1574-6976.1996.tb00233.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tang XF, 2000, EUR J BIOCHEM, V267, P6369, DOI 10.1046/j.1432-1327.2000.01721.x; Thoma R, 2000, STRUCTURE, V8, P265, DOI 10.1016/S0969-2126(00)00106-4; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; Wang DD, 2001, J BACTERIOL, V183, P4210, DOI 10.1128/JB.183.14.4210-4216.2001; WEISCHET WO, 1976, EUR J BIOCHEM, V65, P375, DOI 10.1111/j.1432-1033.1976.tb10351.x; Weyand M, 1999, BIOCHEMISTRY-US, V38, P16469, DOI 10.1021/bi9920533; Wierenga RK, 2001, FEBS LETT, V492, P193, DOI 10.1016/S0014-5793(01)02236-0; Yamagata Y, 2001, J BIOL CHEM, V276, P11062, DOI 10.1074/jbc.M009987200; YANOFSKY C, 1981, NUCLEIC ACIDS RES, V9, P6647, DOI 10.1093/nar/9.24.6647; Yanofsky C, 2001, ANNU REV BIOCHEM, V70, P1, DOI 10.1146/annurev.biochem.70.1.1; YANOFSKY C, 1999, ENCY MOL BIOL, V4, P2276	57	29	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8194	8201		10.1074/jbc.M111541200	http://dx.doi.org/10.1074/jbc.M111541200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11756459	hybrid			2022-12-27	WOS:000174268000073
J	Levenstein, ME; Kadonaga, JT				Levenstein, ME; Kadonaga, JT			Biochemical analysis of chromatin containing recombinant Drosophila core histones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKING NUMBER CHANGE; NUCLEOSOMAL ARRAYS; LAC REPRESSOR; ACETYLATION; TRANSCRIPTION; PARTICLE; COMPLEX; RESOLUTION; ACTIVATION; INVITRO	To investigate the effects of histone modifications upon chromatin structure and function, we studied the assembly and properties of chromatin that contains unmodified recombinant core histones. To this end, we synthesized the Drosophila core histones in Escherichia coli. The purified histones were lacking covalent modifications as well as their N-terminal initiating methionine residues. The recombinant histones were efficiently assembled into periodic nucleosome arrays in a completely purified recombinant system with Drosophila ATP-utilizing chromatin assembly and remodeling factor (ACIP), Drosophila nueleosome assembly protein-1, plasmid DNA, and ATP. With the Gal4-VP16 activator and a crude transcription extract, we found that the transcriptional properties of ACF-assembled chromatin containing unmodified histones were similar to those of chromatin containing native histones. We then examined ACF-catalyzed chromatin remodeling with completely purified factors and chromatin consisting of unmodified histones. In these experiments, we observed promoter-specific disruption of the regularity of nucleosome arrays upon binding of Gal4-VP16 as well as nucleosome positioning by R3 Lac repressor and subsequent nucleosome remobilization upon isopropyl-beta-D-thiogalactopyranoside-induced dissociation of R3 from the template. Thus, chromatin assembly and remodeling by ACF can occur in the absence of histone modifications.	Univ Calif San Diego, Sect Mol Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Kadonaga, JT (corresponding author), Univ Calif San Diego, Sect Mol Biol, 0347 Pacific Hall,Rm 2212B,9500 Gilman Dr, La Jolla, CA 92093 USA.	jkadonaga@ucsd.edu			NIGMS NIH HHS [GM 46995] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Bulger M., 1994, METH MOL G, V5, P241; Chang L, 1997, BIOCHEMISTRY-US, V36, P469, DOI 10.1021/bi962069i; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHEN J, 1994, J BIOL CHEM, V269, P12482; Clapier CR, 2001, MOL CELL BIOL, V21, P875, DOI 10.1128/MCB.21.3.875-883.2001; COTTEN M, 1985, NUCLEIC ACIDS RES, V13, P401, DOI 10.1093/nar/13.2.401; Flaus A, 2001, CURR OPIN GENET DEV, V11, P148, DOI 10.1016/S0959-437X(00)00172-6; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Gelbart ME, 2001, MOL CELL BIOL, V21, P2098, DOI 10.1128/MCB.21.6.2098-2106.2001; GOLDBERG ML, 1979, THESIS STANFORD U; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1996, MOL CELL BIOL, V16, P3112; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Jiang W, 2000, J BIOL CHEM, V275, P39819, DOI 10.1074/jbc.C000713200; KAMAKAKA RT, 1994, METHOD CELL BIOL, V44, P225, DOI 10.1016/S0091-679X(08)60916-4; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; LIFTON RP, 1977, COLD SPRING HARB SYM, V42, P1047, DOI 10.1101/SQB.1978.042.01.105; Loyola A, 2001, GENE DEV, V15, P2837; Luger K, 1997, J MOL BIOL, V272, P301, DOI 10.1006/jmbi.1997.1235; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; NORTON VG, 1990, J BIOL CHEM, V265, P19848; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Pazin MJ, 1998, CHROMATIN PRACTICAL, P173; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; SHIMAMURA A, 1989, J BIOL CHEM, V264, P14524; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207; Wolffe A., 1998, CHROMATIN STRUCTURE; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	41	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8749	8754		10.1074/jbc.M111212200	http://dx.doi.org/10.1074/jbc.M111212200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11773058	hybrid			2022-12-27	WOS:000174268000142
J	Cebo, C; Durier, V; Lagant, P; Maes, E; Florea, D; Lefebvre, T; Strecker, G; Vergoten, G; Zanetta, JP				Cebo, C; Durier, V; Lagant, P; Maes, E; Florea, D; Lefebvre, T; Strecker, G; Vergoten, G; Zanetta, JP			Function and molecular modeling of the interaction between human interleukin 6 and its HNK-1 oligosaccharide ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; REDUCTIVE BETA-ELIMINATION; CELL LUNG-CANCER; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; CARBOHYDRATE EPITOPE; SIGNAL-TRANSDUCTION; ADHESION MOLECULE; OVIDUCAL MUCINS	Interleukin 6 (IL-6) is endowed with a lectin activity for oligosaccharide ligands possessing the HNK-1 epitope (3-sulfated glucuronic acid) found on some mammalian glycoprotein N-glyeans (Cebo, C., Dambrouck, T., Maes, E., Laden, C., Strecker, G., Michalski, J. C., and Zanetta, J. P. (2001) J. Biol. Chem. 276, 56855691). Using high affinity oligosaccharide ligands, it is demonstrated that this lectin activity is responsible for the early dephosphorylation of tyrosine residues found on specific proteins induced by interleukin 6 in human resting lymphocytes. The gp130 glycoprotein, the signal-transducing molecule of the IL-6 pathway, is itself a molecule possessing the HNK-1 epitope. This indicates that IL-6 is a bi-functional molecule able to extracellularly associate its alpha-receptor with the gp130 surface complex. Computational modeling indicates that the lower energy conformers of the high affinity ligands of IL-6 have a common structure. Docking experiments of these conformers suggest that the carbohydrate recognition domain of IL-6 is localized in the domain previously identified as site 3 of IL-6 (Somers, W., Stahl, M., and Seehra, J. S. (1997) EMBO J. 16, 989-997), already known to be involved in interactions with gp130.	Univ Sci & Technol Lille, Lab Glycobiol Struct & Fonct, CNRS UMR 8576, F-59655 Villeneuve Dascq, France; Univ Sci & Technol Lille, Ctr Rech Etud Simulat & Modelisat, F-59655 Villeneuve Dascq, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille	Zanetta, JP (corresponding author), USTL, CNRS UMR 8576, Chim Biol Lab, F-59655 Villeneuve Dascq, France.	Jean-Pierre.Zanetta@univ-lille1.fr	Lefebvre, Tony/AAZ-1724-2021; Lefebvre, Tony/AAW-9169-2021	Lefebvre, Tony/0000-0001-9883-2240; 				ABO T, 1982, J IMMUNOL, V129, P1758; ABO T, 1981, J IMMUNOL, V127, P1024; AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; AMIGUET P, 1992, J NEUROCHEM, V58, P1676, DOI 10.1111/j.1471-4159.1992.tb10040.x; Anhuf D, 2000, J IMMUNOL, V165, P2535, DOI 10.4049/jimmunol.165.5.2535; BABA H, 1986, J NEUROIMMUNOL, V13, P89, DOI 10.1016/0165-5728(86)90052-4; Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; Boelen A, 1996, ENDOCRINOLOGY, V137, P5250, DOI 10.1210/en.137.12.5250; BOLLENSEN E, 1987, NEUROSCI LETT, V82, P77, DOI 10.1016/0304-3940(87)90174-1; BON S, 1987, J NEUROCHEM, V49, P1720, DOI 10.1111/j.1471-4159.1987.tb02429.x; BOYD B, 1993, J EXP MED, V177, P1745, DOI 10.1084/jem.177.6.1745; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; BUNN PA, 1985, BLOOD, V65, P764; BURGER D, 1993, J NEUROCHEM, V61, P1822, DOI 10.1111/j.1471-4159.1993.tb09822.x; Cebo C, 2001, J BIOL CHEM, V276, P5685, DOI 10.1074/jbc.M008662200; Ciapponi L, 1995, J BIOL CHEM, V270, P31249, DOI 10.1074/jbc.270.52.31249; Coppin A, 1999, EUR J BIOCHEM, V266, P370, DOI 10.1046/j.1432-1327.1999.00862.x; Damm W, 1997, J COMPUT CHEM, V18, P1955, DOI 10.1002/(SICI)1096-987X(199712)18:16<1955::AID-JCC1>3.0.CO;2-L; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; FIELD MC, 1992, J NEUROCHEM, V58, P993, DOI 10.1111/j.1471-4159.1992.tb09353.x; Florea D, 1997, CARBOHYD RES, V302, P179, DOI 10.1016/S0008-6215(97)00129-8; FONTAINE V, 1993, EUR J BIOCHEM, V211, P749, DOI 10.1111/j.1432-1033.1993.tb17605.x; FONTAINE V, 1994, EUR J IMMUNOL, V24, P1041, DOI 10.1002/eji.1830240505; FREDMAN P, 1993, J NEUROL, V240, P381, DOI 10.1007/BF00839972; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Fukada T, 1999, GROWTH FACTORS, V17, P81, DOI 10.3109/08977199909103518; Fukushima K, 2001, J BIOL CHEM, V276, P7351, DOI 10.1074/jbc.M008781200; GLASS WF, 1981, ANAL BIOCHEM, V115, P219, DOI 10.1016/0003-2697(81)90549-2; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; HAKOMORI S, 1985, CANCER RES, V45, P2405; HARPER JR, 1990, J NEUROCHEM, V54, P395, DOI 10.1111/j.1471-4159.1990.tb01886.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; Hirano T, 1998, Int Rev Immunol, V16, P249; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; INUZUKA T, 1984, NEUROSCI LETT, V51, P105, DOI 10.1016/0304-3940(84)90270-2; JUNGALWALA FB, 1994, NEUROCHEM RES, V19, P945, DOI 10.1007/BF00968704; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; KITAMURA K, 1976, BIOCHIM BIOPHYS ACTA, V455, P806, DOI 10.1016/0005-2736(76)90050-X; KITAMURA K, 1991, ABSTR JPN NEUR SOC, V1, P189; KRUSE J, 1985, NATURE, V316, P146, DOI 10.1038/316146a0; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; KUCHLER S, 1991, NEUROSCIENCE, V41, P551, DOI 10.1016/0306-4522(91)90348-R; Kurth I, 2000, J IMMUNOL, V164, P273, DOI 10.4049/jimmunol.164.1.273; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LEEBEEK FWG, 1992, J BIOL CHEM, V267, P14832; LI XM, 1993, J BIOL CHEM, V268, P22377; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; Luton F, 1997, J IMMUNOL, V158, P3140; Maes E, 1999, EUR J BIOCHEM, V264, P301, DOI 10.1046/j.1432-1327.1999.00544.x; MCGARRY RC, 1983, NATURE, V306, P376, DOI 10.1038/306376a0; MIKOL DD, 1990, J CELL BIOL, V110, P471, DOI 10.1083/jcb.110.2.471; NISHIMURA C, 1992, FEBS LETT, V311, P271, DOI 10.1016/0014-5793(92)81118-6; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; Okuda Y, 1999, J NEUROIMMUNOL, V101, P188, DOI 10.1016/S0165-5728(99)00139-3; Okuda Y, 2000, J NEUROIMMUNOL, V105, P120, DOI 10.1016/S0165-5728(00)00192-2; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; Qu CK, 2000, CELL RES, V10, P279, DOI 10.1038/sj.cr.7290055; QUARLES RH, 1977, BIOCHEM J, V163, P635, DOI 10.1042/bj1630635; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; SAVINO R, 1993, P NATL ACAD SCI USA, V90, P4067, DOI 10.1073/pnas.90.9.4067; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; SCHWABE M, 1994, J CLIN INVEST, V94, P2317, DOI 10.1172/JCI117596; Servidei T, 1998, NEUROSCIENCE, V82, P529; Somers W, 1997, EMBO J, V16, P989, DOI 10.1093/emboj/16.5.989; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; WARD LD, 1994, J BIOL CHEM, V269, P23286; Ward LD, 1996, J BIOL CHEM, V271, P20138, DOI 10.1074/jbc.271.33.20138; WILLISON HJ, 1986, J NEUROIMMUNOL, V10, P353, DOI 10.1016/S0165-5728(86)90018-4; Xu GY, 1997, J MOL BIOL, V268, P468, DOI 10.1006/jmbi.1997.0933; YASUEDA H, 1992, BIOCHEM BIOPH RES CO, V187, P18, DOI 10.1016/S0006-291X(05)81452-4; ZAFRIRI D, 1993, P NATL ACAD SCI USA, V90, P477, DOI 10.1073/pnas.90.2.477; Zanetta JP, 1998, GLYCOBIOLOGY, V8, pVI, DOI 10.1093/oxfordjournals.glycob.a018837; Zanetta JP, 1998, GLYCOBIOLOGY, V8, P221, DOI 10.1093/glycob/8.3.221; Zanetta JP, 1996, BIOCHEM J, V318, P49, DOI 10.1042/bj3180049	79	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12246	12252		10.1074/jbc.M106816200	http://dx.doi.org/10.1074/jbc.M106816200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11788581	hybrid			2022-12-27	WOS:000174846400084
J	Beaudoin, F; Gable, K; Sayanova, O; Dunn, T; Napier, JA				Beaudoin, F; Gable, K; Sayanova, O; Dunn, T; Napier, JA			A Saccharomyces cerevisiae gene required for heterologous fatty acid elongase activity encodes a microsomal beta-keto-reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-ANALYSIS; YEAST; DESATURASE; EXPRESSION; ENZYME; BIOSYNTHESIS; ARABIDOPSIS; RECOGNITION; SEQUENCE; MUTANTS	A number of Saccharomyces cerevisiae membrane-bound oxidoreductases were examined for potential roles in microsomal fatty acid elongation, by assaying heterologous elongating activities in individual deletion mutants. One yeast gene, YBR159w, was identified as being required for activity of both the Caenorhabditis elegans elongase PEA1 (F56H11.4) and the Arabidopsis thaliana elongase FAE1. Ybr159p shows some limited homology to human steroid dehydrogenases and is a member of the short-chain alcohol dehydrogenase superfamily. Disruption of YBR159w is not lethal, in contrast to previous reports, although the mutants are slow growing and display high temperature sensitivity. Both Ybr159p and an Arabidopsis homologue were shown to restore heterologous elongase activities when expressed in ybr159Delta mutants. Biochemical characterization of microsomal preparations from ybr159Delta cells revealed a primary perturbation in beta-ketoacyl reduction, confirming the assignment of YBR159w as encoding a component of the microsomal elongase.	Inst Arable Crops Res, Long Ashton Res Stn, Bristol BS41 9AF, Avon, England; Uniformed Serv Univ Hlth Sci, Dept Biochem, Bethesda, MD 20814 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Rothamsted Research; Uniformed Services University of the Health Sciences - USA	Napier, JA (corresponding author), Inst Arable Crops Res, Long Ashton Res Stn, Bristol BS41 9AF, Avon, England.	jon.napier@bbsrc.ac.uk		Napier, Johnathan/0000-0003-3580-3607				Athenstaedt K, 2000, J BIOL CHEM, V275, P235, DOI 10.1074/jbc.275.1.235; Beaudoin F, 2000, P NATL ACAD SCI USA, V97, P6421, DOI 10.1073/pnas.110140197; Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688; Broun P, 1999, ANNU REV NUTR, V19, P197, DOI 10.1146/annurev.nutr.19.1.197; CHANG SI, 1989, P NATL ACAD SCI USA, V86, P8373, DOI 10.1073/pnas.86.21.8373; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; Dittrich F, 1998, EUR J BIOCHEM, V252, P477, DOI 10.1046/j.1432-1327.1998.2520477.x; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Entian KD, 1999, MOL GEN GENET, V262, P683, DOI 10.1007/PL00013817; Gable K, 2000, J BIOL CHEM, V275, P7597, DOI 10.1074/jbc.275.11.7597; Gill I, 1997, TRENDS BIOTECHNOL, V15, P401, DOI 10.1016/S0167-7799(97)01076-7; KASSIR Y, 1991, METHOD ENZYMOL, V194, P94; Kohlwein SD, 2001, MOL CELL BIOL, V21, P109, DOI 10.1128/MCB.21.1.109-125.2001; Michaelson LV, 1998, J BIOL CHEM, V273, P19055, DOI 10.1074/jbc.273.30.19055; Millar AA, 1997, PLANT J, V12, P121, DOI 10.1046/j.1365-313X.1997.12010121.x; Millar AA, 1999, PHYTOCHEMISTRY, V52, P1029, DOI 10.1016/S0031-9422(99)00403-3; Napier JA, 1999, TRENDS PLANT SCI, V4, P2, DOI 10.1016/S1360-1385(98)01357-0; Napier JA, 1999, CURR OPIN PLANT BIOL, V2, P123, DOI 10.1016/S1369-5266(99)80025-9; Napier JA, 2001, LIPIDS, V36, P761, DOI 10.1007/s11745-001-0782-9; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; OH CS, 1997, J BIOL CHEM, V272, P17373; Puranen T, 1997, MOL ENDOCRINOL, V11, P77, DOI 10.1210/me.11.1.77; Rizner TL, 2001, STEROIDS, V66, P49, DOI 10.1016/S0039-128X(00)00138-0; ROSE M, 1995, YEAST, V11, P865, DOI 10.1002/yea.320110908; Sayanova O, 1997, P NATL ACAD SCI USA, V94, P4211, DOI 10.1073/pnas.94.8.4211; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Spychalla JP, 1997, P NATL ACAD SCI USA, V94, P1142, DOI 10.1073/pnas.94.4.1142; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; Xu XJ, 1997, PLANT PHYSIOL, V115, P501, DOI 10.1104/pp.115.2.501; Zhang CT, 2000, NUCLEIC ACIDS RES, V28, P2804, DOI 10.1093/nar/28.14.2804	31	72	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11481	11488		10.1074/jbc.M111441200	http://dx.doi.org/10.1074/jbc.M111441200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11792704	Green Submitted, hybrid			2022-12-27	WOS:000174613100093
J	Bieganowski, P; Garrison, PN; Hodawadekar, SC; Faye, G; Barnes, LD; Brenner, C				Bieganowski, P; Garrison, PN; Hodawadekar, SC; Faye, G; Barnes, LD; Brenner, C			Adenosine monophosphoramidase activity of Hint and Hnt1 supports function of Kin28, Ccl1, and Tfb3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-ACTIVATING KINASE; CYCLIN-DEPENDENT KINASE; RNA-POLYMERASE-II; HIT PROTEIN FAMILY; NUCLEOTIDE-BINDING PROTEINS; TRANSCRIPTION FACTOR TFIIH; HISTIDINE TRIAD PROTEINS; RING FINGER PROTEIN; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST	The histidine triad superfamily of nucleotide hydrolases and nucleotide transferases consists of a branch of proteins related to Hint and Aprataxin, a branch of Fhit-related hydrolases, and a branch of galactose-1-phosphate uridylyltransferase (GalT)-related transferases. Although substrates of Fhit and GalT are known and consequences of mutations in Aprataxin, Fhit, and GalT are known, good substrates had not been reported for any member of the Hint branch, and mutational consequences were unknown for Hint orthologs, which are the most ancient and widespread proteins in the Hint branch and in the histidine triad superfamily. Here we show that rabbit and yeast Hint hydrolyze the natural product adenosine-5'-monophosphoramidate (AMPNH(2)) in an active-site-dependent manner at second order rates exceeding 1,000,000 M-1 S-1. Yeast strains constructed with specific loss of the Hntl active site fail to grow on galactose at elevated temperatures. Loss of Hntl enzyme activity also leads to hypersensitivity to mutations in Cell, Tfb3, and Kin28, which constitute the TFIIK kinase subcomplex of general transcription factor TFIIH and to mutations in Cak1, which phosphorylates Kin28. The target of Hnt1 regulation in this pathway was shown to be downstream of Cak1 and not to affect stability of Kin28 monomers. Functional complementation of all Hnt1 phenotypes was provided by rabbit Hint, which is only 22% identical to yeast Hntl but has very similar adenosine monophosphoramidase activity.	Kimmel Canc Ctr, Struct Biol & Bioinformat Program, Philadelphia, PA 19107 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Inst Curie, UMR 2027, CNRS, F-91405 Orsay, France	Jefferson University; University of Texas System; University of Texas Health San Antonio; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Brenner, C (corresponding author), Kimmel Canc Ctr, Struct Biol & Bioinformat Program, 233 S 10th St,Rm 826, Philadelphia, PA 19107 USA.		Bieganowski, Pawel/ABC-8554-2021; Brenner, Charles/D-6339-2014	Bieganowski, Pawel/0000-0002-1169-4517; Brenner, Charles/0000-0002-4955-3226	NCI NIH HHS [R01 CA075954-05, CA75954, R01 CA075954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abend A, 1999, BIOCHEMISTRY-US, V38, P3668, DOI 10.1021/bi981895j; AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Balzarini J, 1996, P NATL ACAD SCI USA, V93, P7295, DOI 10.1073/pnas.93.14.7295; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Brachmann CB, 1998, YEAST, V14, P115; Brenner C, 1999, J CELL PHYSIOL, V181, P179, DOI 10.1002/(SICI)1097-4652(199911)181:2<179::AID-JCP1>3.0.CO;2-8; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; Bruser T, 2000, J BIOL CHEM, V275, P1691, DOI 10.1074/jbc.275.3.1691; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Cross FR, 1998, MOL CELL BIOL, V18, P2923, DOI 10.1128/MCB.18.5.2923; Date H, 2001, NAT GENET, V29, P184, DOI 10.1038/ng1001-184; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Draganescu A, 2000, J BIOL CHEM, V275, P4555, DOI 10.1074/jbc.275.7.4555; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Dumon KR, 2001, CANCER RES, V61, P4827; Enke DA, 1999, J BIOL CHEM, V274, P1949, DOI 10.1074/jbc.274.4.1949; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; Espinoza FH, 2000, MOL CELL BIOL, V20, P1898, DOI 10.1128/MCB.20.5.1898-1898.2000; Espinoza FH, 1998, MOL CELL BIOL, V18, P6365, DOI 10.1128/MCB.18.11.6365; FANKHAUSER H, 1981, BIOCHEM BIOPH RES CO, V101, P524, DOI 10.1016/0006-291X(81)91291-2; FANKHAUSER H, 1981, BIOCHEM J, V195, P545, DOI 10.1042/bj1950545; Faye G, 1997, MOL GEN GENET, V255, P460, DOI 10.1007/s004380050518; Feaver WJ, 1997, J BIOL CHEM, V272, P19319, DOI 10.1074/jbc.272.31.19319; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Ghosh S, 1996, GENE, V176, P249, DOI 10.1016/0378-1119(96)00260-0; Gilmour J, 1997, BIOCHEM J, V326, P471, DOI 10.1042/bj3260471; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; GUMPORT RI, 1971, P NATL ACAD SCI USA, V68, P2559, DOI 10.1073/pnas.68.10.2559; HERREN B, 1993, J RECEPTOR RES, V13, P725, DOI 10.3109/10799899309073689; Huang Y, 1995, BIOCHEM J, V312, P925, DOI 10.1042/bj3120925; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Ji L, 1999, CANCER RES, V59, P3333; KAISER C, 1994, METHODS YEAST GENETI, P133; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; Kimmelman J, 1999, MOL CELL BIOL, V19, P4774; Korsisaari N, 2000, J BIOL CHEM, V275, P34837, DOI 10.1074/jbc.C000505200; KUBA M, 1994, INT J BIOCHEM, V26, P235; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE H, 1971, BIOCHIM BIOPHYS ACTA, V242, P519, DOI 10.1016/0005-2744(71)90144-6; Lima CD, 1997, STRUCTURE, V5, P763, DOI 10.1016/S0969-2126(97)00231-1; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; Moreira MC, 2001, NAT GENET, V29, P189, DOI 10.1038/ng1001-189; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484; Pace HC, 2000, CURR BIOL, V10, P907, DOI 10.1016/S0960-9822(00)00621-7; Pekarsky Y, 1998, P NATL ACAD SCI USA, V95, P8744, DOI 10.1073/pnas.95.15.8744; RAZZELL WE, 1963, METHOD ENZYMOL, V6, P236, DOI 10.1016/0076-6879(63)06169-3; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROSSOMANDO EF, 1986, INT J BIOCHEM, V18, P481, DOI 10.1016/0020-711X(86)90193-X; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; TOMKINSON AE, 1991, P NATL ACAD SCI USA, V88, P400, DOI 10.1073/pnas.88.2.400; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; Valay JG, 1996, CR ACAD SCI III-VIE, V319, P183; Wedekind JE, 1996, BIOCHEMISTRY-US, V35, P11560, DOI 10.1021/bi9612677	66	97	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10852	10860		10.1074/jbc.M111480200	http://dx.doi.org/10.1074/jbc.M111480200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11805111	Green Accepted, hybrid			2022-12-27	WOS:000174613100015
J	Delmas, P; Nomura, H; Li, XG; Lakkis, M; Luo, Y; Segal, Y; Fernandez-Fernandez, JM; Harris, P; Frischauf, AM; Brown, DA; Zhou, J				Delmas, P; Nomura, H; Li, XG; Lakkis, M; Luo, Y; Segal, Y; Fernandez-Fernandez, JM; Harris, P; Frischauf, AM; Brown, DA; Zhou, J			Constitutive activation of G-proteins by polycystin-1 is antagonized by polycystin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SYMPATHETIC NEURONS; BETA-GAMMA-SUBUNITS; KIDNEY-DISEASE; CATION CHANNEL; CALCIUM-CHANNELS; CA2+ CHANNELS; IN-VITRO; PKD1; GENE; INHIBITION	Polycystin-1 (PC1), a 4,303-amino acid integral membrane protein of unknown function, interacts with polycystin-2 (PC2), a 968-amino acid alpha-type channel subunit. Mutations in their respective genes cause autosomal dominant polycystic kidney disease. Using a novel heterologous expression system and Ca2(+) and K+ channels as functional biosensors, we found that full-length PC1 functioned as a constitutive activator of G(i/o)-type but not G(q)-type G-proteins and modulated the activity of Ca2+ and K+ channels via the release of Gbetagamma subunits. PC1. lacking the N-terminal 1811 residues replicated the effects of full-length PC1. These effects were independent of regulators of G-protein signaling proteins and were lost in PC1 mutants lacking a putative G-protein binding site. Co-expression with full-length PC2, but not a C-terminal truncation mutant, abrogated the effects of PC1. Our data provide the first experimental evidence that full-length PC1 acts as an untraditional G-protein-coupled receptor, activity of which is physically regulated by PC2. Thus, our study strongly suggests that mutations in PC1 or PC2 that distort the polycystin complex would initiate abnormal G-protein signaling in autosomal dominant polycystic kidney disease.	CNRS, ITIS, FRE2362, F-13402 Marseille 20, France; UCL, Wellcome Lab Mol Pharmacol, Dept Pharmacol, London WC1E 6BT, England; Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Salzburg Univ, Inst Genet & Allgemeine Biol, A-5020 Salzburg, Austria; Harvard Univ, Sch Med, Boston, MA 02115 USA	Centre National de la Recherche Scientifique (CNRS); University of London; University College London; Harvard University; Brigham & Women's Hospital; Mayo Clinic; Salzburg University; Harvard University; Harvard Medical School	Delmas, P (corresponding author), CNRS, ITIS, FRE2362, 31 Ch J Aiguier,Batiment LNB, F-13402 Marseille 20, France.	delmas@irlnb.cnrs-mrs.fr	Fernández-Fernández, José Manuel M/M-8157-2015; Brown, David A/J-9019-2012	Fernández-Fernández, José Manuel M/0000-0003-2330-8449; 				Barr MM, 1999, NATURE, V401, P386, DOI 10.1038/43916; BROWN DA, 1980, NATURE, V283, P673, DOI 10.1038/283673a0; Bycroft M, 1999, EMBO J, V18, P297, DOI 10.1093/emboj/18.2.297; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; Chen XZ, 2001, BIOCHEM BIOPH RES CO, V282, P1251, DOI 10.1006/bbrc.2001.4720; Delmas P, 1999, J PHYSIOL-LONDON, V518, P23, DOI 10.1111/j.1469-7793.1999.0023r.x; Delmas P, 2000, NAT NEUROSCI, V3, P670, DOI 10.1038/76621; Delmas P, 1998, J PHYSIOL-LONDON, V506, P319, DOI 10.1111/j.1469-7793.1998.319bw.x; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; Fernandez-Fernandez JM, 1999, J PHYSIOL-LONDON, V515, P631, DOI 10.1111/j.1469-7793.1999.631ab.x; Filippov AK, 2000, J NEUROSCI, V20, P2867; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Geng L, 1996, J CLIN INVEST, V98, P2674, DOI 10.1172/JCI119090; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Grantham JJ, 2001, P NATL ACAD SCI USA, V98, P790, DOI 10.1073/pnas.98.3.790; Griffin MD, 1996, P ASSOC AM PHYSICIAN, V108, P185; Haley JE, 1998, J NEUROSCI, V18, P4521; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Hughes J, 1999, HUM MOL GENET, V8, P543, DOI 10.1093/hmg/8.3.543; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Kim K, 2000, P NATL ACAD SCI USA, V97, P1731, DOI 10.1073/pnas.040550097; Koptides M, 1999, HUM MOL GENET, V8, P509, DOI 10.1093/hmg/8.3.509; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Ong ACM, 1999, KIDNEY INT, V56, P1324, DOI 10.1046/j.1523-1755.1999.00659.x; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; Pritchard L, 2000, HUM MOL GENET, V9, P2617, DOI 10.1093/hmg/9.18.2617; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Schneider T, 1997, TRENDS PHARMACOL SCI, V18, P8, DOI 10.1016/S0165-6147(96)01001-2; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Vandorpe DH, 2001, J BIOL CHEM, V276, P4093, DOI 10.1074/jbc.M006252200; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; Watnick T, 2000, NAT GENET, V25, P143, DOI 10.1038/75981; Weston BS, 2001, BBA-MOL BASIS DIS, V1536, P161, DOI 10.1016/S0925-4439(01)00046-1; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6; Wu GQ, 2000, MOL GENET METAB, V69, P1, DOI 10.1006/mgme.1999.2943; Yamada M, 1998, PHARMACOL REV, V50, P723	44	147	152	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11276	11283		10.1074/jbc.M110483200	http://dx.doi.org/10.1074/jbc.M110483200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11786542	hybrid			2022-12-27	WOS:000174613100067
J	Hughes, TR; Tengku-Muhammad, TS; Irvine, SA; Ramji, DP				Hughes, TR; Tengku-Muhammad, TS; Irvine, SA; Ramji, DP			A novel role of Sp1 and Sp3 in the interferon-gamma-mediated suppression of macrophage lipoprotein lipase gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PROTEIN-KINASE CK2; FOAM CELL-FORMATION; NECROSIS-FACTOR-ALPHA; STEROL REGULATORY ELEMENT; EPIDERMAL-GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; NF-KAPPA-B; BINDING-PROTEIN; DIFFERENTIAL REGULATION	The regulation of macrophage lipoprotein lipase by cytokines is of potentially crucial importance in the pathogenesis of atherosclerosis. We have shown previously that macrophage lipoprotein lipase expression is suppressed by interferon-gamma (IFN-gamma) at the transcriptional level. We investigated the regulatory sequence elements and the transcription factors that are involved in this response. We demonstrated that the -31/+187 sequence contains the minimal IFN-gamma-responsive elements. Electrophoretic mobility shift assays showed that the binding of proteins to two regions in the -31/ + 187 sequence was reduced dramatically when the cells were exposed to IFN-gamma. Both competition electrophoretic mobility shift assays and antibody supershift assays showed that the interacting proteins were composed of Sp1 and Sp3. Mutations of the Sp1/Sp3-binding sites in the minimal IFN-gamma-responsive elements abolished the IFN-gamma-mediated suppression of promoter activity, whereas multimers of the sequence were able to impart the response to a heterologous promoter. Western blot analysis showed that IFN-gamma reduced the steady state levels of Sp3 protein. In contrast, the cytokine decreased the DNA binding activity of Sp1 without affecting the protein levels. These studies therefore reveal a novel mechanism for IFN-gamma-mediated regulation of macrophage gene transcription.	Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales	Cardiff University	Ramji, DP (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Museum Ave,POB 911, Cardiff CF10 3US, S Glam, Wales.	Ramji@cardiff.ac.uk	irvine, scott/B-1090-2019; irvine, scott/A-2392-2019; Muhammad, Tengku Sifzizul Tengku/AAW-7767-2021; Ramji, Dipak/A-7092-2010	irvine, scott/0000-0002-8926-1543; Tengku Muhammad, Tengku Sifzizul/0000-0002-9275-7988; Ramji, Dipak/0000-0002-6419-5578				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; AUWERX JH, 1989, BIOCHEMISTRY-US, V28, P4563, DOI 10.1021/bi00437a009; AUWERX JH, 1988, BIOCHEMISTRY-US, V27, P2651, DOI 10.1021/bi00408a003; Babaev VR, 1999, J CLIN INVEST, V103, P1697, DOI 10.1172/JCI6117; Babaev VR, 2000, J BIOL CHEM, V275, P26293, DOI 10.1074/jbc.M002423200; Berrier A, 1998, J IMMUNOL, V161, P2267; Brightbill HD, 2000, J IMMUNOL, V164, P1940, DOI 10.4049/jimmunol.164.4.1940; Buechler C, 2000, J LEUKOCYTE BIOL, V67, P97, DOI 10.1002/jlb.67.1.97; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Chen CJ, 1996, J BIOL CHEM, V271, P28181, DOI 10.1074/jbc.271.45.28181; CHEN HM, 1993, J BIOL CHEM, V268, P8230; Chupreta S, 2000, AM J PHYSIOL-CELL PH, V278, pC697, DOI 10.1152/ajpcell.2000.278.4.C697; Clee SM, 2000, J LIPID RES, V41, P521; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; DATTISTRUTTA R, 2000, J BIOL CHEM, V275, P29618; Davies GE, 2000, BIOCHEM BIOPH RES CO, V271, P346, DOI 10.1006/bbrc.2000.2630; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; Denson LA, 2001, J CLIN INVEST, V107, P1451, DOI 10.1172/JCI10994; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; Eichbaum Q, 1997, BLOOD, V90, P4135, DOI 10.1182/blood.V90.10.4135; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Foka P, 2001, BIOCHEM BIOPH RES CO, V285, P430, DOI 10.1006/bbrc.2001.5203; FONG LG, 1994, J LIPID RES, V35, P893; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; GACESA P, 1994, VECTORS ESSENTIAL DA; GENG YJ, 1992, J CLIN INVEST, V89, P1322, DOI 10.1172/JCI115718; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; GIMBLE JM, 1995, AM J PHYSIOL-ENDOC M, V268, pE213, DOI 10.1152/ajpendo.1995.268.2.E213; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Goldberg IJ, 2001, FRONT BIOSCI-LANDMRK, V6, pD388, DOI 10.2741/Goldberg; Granger RL, 2000, BBA-MOL BASIS DIS, V1501, P171, DOI 10.1016/S0925-4439(00)00016-8; Granger RL, 2000, BBA-GENE STRUCT EXPR, V1492, P100, DOI 10.1016/S0167-4781(00)00089-0; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; HANSSON GK, 1989, J EXP MED, V170, P1595, DOI 10.1084/jem.170.5.1595; Hauses M, 1998, J BIOL CHEM, V273, P31844, DOI 10.1074/jbc.273.48.31844; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; HILL MR, 1995, INFECT IMMUN, V63, P858, DOI 10.1128/IAI.63.3.858-864.1995; INABA T, 1995, ARTERIOSCL THROM VAS, V15, P522, DOI 10.1161/01.ATV.15.4.522; Jiang MS, 2000, P NATL ACAD SCI USA, V97, P12519, DOI 10.1073/pnas.220426097; JONASSON L, 1990, BIOCHIM BIOPHYS ACTA, V1053, P43, DOI 10.1016/0167-4889(90)90024-8; JONASSON L, 1985, J CLIN INVEST, V76, P125, DOI 10.1172/JCI111934; JONES P, 1998, VECTORS CLONING APPL, P122; KARDASSIS D, 1990, MOL CELL BIOL, V10, P2653, DOI 10.1128/MCB.10.6.2653; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Khanna-Gupta A, 2000, BLOOD, V95, P3734; Kockar FT, 2001, NUCLEIC ACIDS RES, V29, P362, DOI 10.1093/nar/29.2.362; Kosaka S, 2001, CIRCULATION, V103, P1142, DOI 10.1161/01.CIR.103.8.1142; Kumar AP, 1998, BIOCHEM BIOPH RES CO, V252, P517, DOI 10.1006/bbrc.1998.9676; LAMARRE J, 1993, J CLIN INVEST, V91, P1219, DOI 10.1172/JCI116283; Langmann T, 1997, BIOCHEM BIOPH RES CO, V230, P215, DOI 10.1006/bbrc.1996.5912; Langmann T, 1999, J LIPID RES, V40, P870; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LI H, 1993, ARTERIOSCLER THROMB, V13, P197, DOI 10.1161/01.ATV.13.2.197; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Mead JR, 1999, FEBS LETT, V462, P1, DOI 10.1016/S0014-5793(99)01495-7; Michaud SE, 2001, DIABETES, V50, P660, DOI 10.2337/diabetes.50.3.660; MORI N, 1991, ARTERIOSCLER THROMB, V11, P1315, DOI 10.1161/01.ATV.11.5.1315; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; Nicholson WJ, 1996, AM J RESP CELL MOL, V15, P88, DOI 10.1165/ajrcmb.15.1.8679226; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; Oeth P, 1997, ARTERIOSCL THROM VAS, V17, P365, DOI 10.1161/01.ATV.17.2.365; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; PARK IK, 2000, BIOCHIM BIOPHYS ACTA, V1490, P310; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; QUERFELD U, 1990, J LIPID RES, V31, P1379; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; Ray BK, 1997, J BIOL CHEM, V272, P28948, DOI 10.1074/jbc.272.46.28948; RENIER G, 1993, ARTERIOSCLER THROMB, V13, P190, DOI 10.1161/01.ATV.13.2.190; Ries S, 1998, J LIPID RES, V39, P2125; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; Sabatakos G, 1998, BIOCHEM J, V334, P205, DOI 10.1042/bj3340205; SANCEAU J, 1995, J BIOL CHEM, V270, P27920, DOI 10.1074/jbc.270.46.27920; Sartippour MR, 2000, ARTERIOSCL THROM VAS, V20, P104, DOI 10.1161/01.ATV.20.1.104; Schafer D, 1997, FEBS LETT, V417, P325, DOI 10.1016/S0014-5793(97)01314-8; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schoonjans K, 2000, J MOL BIOL, V304, P323, DOI 10.1006/jmbi.2000.4218; Shen J, 2001, J IMMUNOL, V167, P4919, DOI 10.4049/jimmunol.167.9.4919; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Tengku-Muhammad TS, 1998, CYTOKINE, V10, P38, DOI 10.1006/cyto.1997.0254; Tengku-Muhammad TS, 2000, CYTOKINE, V12, P1430, DOI 10.1006/cyto.2000.0711; Tengku-Muhammad TS, 2000, CYTOKINE, V12, P720, DOI 10.1006/cyto.1999.0620; Tengku-Muhammad TS, 1999, CYTOKINE, V11, P408, DOI 10.1006/cyto.1998.0447; TengkuMuhammad TS, 1996, CYTOKINE, V8, P525, DOI 10.1006/cyto.1996.0071; TENGKUMUHAMMAD TS, 1998, BIOCHEM SOC T, V26, P12; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; TURAKOCKAR F, 2001, NUCLEIC ACIDS RES, V29, P362; Van Eck M, 2000, ARTERIOSCL THROM VAS, V20, pE53, DOI 10.1161/01.ATV.20.9.e53; Wang QD, 2000, BIOCHEM BIOPH RES CO, V276, P466, DOI 10.1006/bbrc.2000.3512; WARNER SJC, 1989, J CLIN INVEST, V83, P1174, DOI 10.1172/JCI113998; Yang HM, 1997, EXP LUNG RES, V23, P269, DOI 10.3109/01902149709087372; Yang WS, 1998, J LIPID RES, V39, P2054; Yang WS, 1996, J LIPID RES, V37, P2627; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P10143, DOI 10.1073/pnas.88.22.10143; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; Zhang SY, 1997, ARCH BIOCHEM BIOPHYS, V338, P227, DOI 10.1006/abbi.1996.9809; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200; Zhou ZHL, 1998, J IMMUNOL, V160, P3908	111	45	47	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11097	11106		10.1074/jbc.M106774200	http://dx.doi.org/10.1074/jbc.M106774200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11796707	hybrid			2022-12-27	WOS:000174613100046
J	Kim, SH; Azam, T; Novick, D; Yoon, DY; Reznikov, LL; Bufler, P; Rubinstein, M; Dinarello, CA				Kim, SH; Azam, T; Novick, D; Yoon, DY; Reznikov, LL; Bufler, P; Rubinstein, M; Dinarello, CA			Identification of amino acid residues critical for biological activity in human interleukin-18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERFERON-GAMMA PRODUCTION; BLOOD MONONUCLEAR-CELLS; IL-18 BINDING-PROTEIN; HELPER TYPE-1 CELLS; RECEPTOR-BINDING; T-CELLS; CRYSTAL-STRUCTURE; GENE-EXPRESSION; ANTAGONIST	Interleukin-18 (IL-18) is a pro-inflammatory cytokine, and IL-18-binding protein (IL-18BP) is a naturally occurring protein that binds IL-18 and neutralizes its biological activities. Computer modeling of human IL-18 identified two charged residues, Glu-42 and Lys-89, which interact with oppositely charged amino acid residues buried in a large hydrophobic pocket of IL-18BP. The cell surface IL-18 receptor a chain competes with IL-18BP for IL-18 binding, although the IL-18 receptor a chain does not share significant homology to IL-18BP. In the present study, Glu-42 was mutated to Lys and Lys-89 to Glu; Glu-42 and Lys-89 were also deleted separately. The deletion mutants (E42X and K89X) were devoid of biological activity, and the K89E mutant lost 95% of its activity. In contrast, compared with wild-type (WT) IL-18, the E42K mutant exhibited a 2-fold increase in biological activity and required a 4-fold greater concentration of IL-18BP for neutralization. The binding of WT IL-18 and its various mutants to human natural killer cells was evaluated by competition assays. The mutant E42K was more effective than WT IL-18 in inhibiting the binding of I-125-IL-18 to natural killer cells, whereas the three inactive mutants E42X, K89E, and K89X were unable to compete with I-125-IL-18 for binding. Similarly, WT IL-18 and the E42K mutant induced degradation of Ikappa-Balpha, whereas the three biologically inactive mutants did not induce degradation. The present study reveals that Glu-42 and Lys-89 are critical amino acid residues for the integrity of IL-18 structure and are important for binding to cell surface receptors, for signal transduction, and for neutralization by IL-18BP.	Univ Colorado, Hlth Sci Ctr, Div Infect Dis, Denver, CO 80262 USA; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Korea Res Inst Biosci & Biotechnol, Yuseong Taejon 305600, South Korea	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Weizmann Institute of Science; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Kim, SH (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Infect Dis, B168,4200 E 9th Ave, Denver, CO 80262 USA.	soohyun.kim@UCHSC.edu	Dinarello, Charles/C-8524-2013	Bufler, Philip/0000-0002-5742-8273; Rubinstein, Menachem/0000-0002-3472-6614	NIAID NIH HHS [AI-15614] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015614, R37AI015614, R56AI015614] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bazan JF, 1996, NATURE, V379, P591, DOI 10.1038/379591a0; Born TL, 1998, J BIOL CHEM, V273, P29445, DOI 10.1074/jbc.273.45.29445; EHLERS M, 1995, J BIOL CHEM, V270, P8158, DOI 10.1074/jbc.270.14.8158; EVANS RJ, 1995, J BIOL CHEM, V270, P11477, DOI 10.1074/jbc.270.19.11477; GEHRKE L, 1990, J BIOL CHEM, V265, P5922; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Hoshino T, 1999, J IMMUNOL, V162, P5070; Hoshino T, 2000, EUR J IMMUNOL, V30, P1998, DOI 10.1002/1521-4141(200007)30:7<1998::AID-IMMU1998>3.0.CO;2-U; Joosten LAB, 2000, J IMMUNOL, V165, P6553, DOI 10.4049/jimmunol.165.11.6553; Kalina U, 2000, J IMMUNOL, V165, P1307, DOI 10.4049/jimmunol.165.3.1307; Kim SH, 2000, P NATL ACAD SCI USA, V97, P1190, DOI 10.1073/pnas.97.3.1190; Kim SH, 2001, J IMMUNOL, V166, P148; Kim SHM, 2001, P NATL ACAD SCI USA, V98, P3304, DOI 10.1073/pnas.051634098; Kojima H, 1999, J IMMUNOL, V162, P5063; Kojima H, 1998, BIOCHEM BIOPH RES CO, V244, P183, DOI 10.1006/bbrc.1998.8236; Kumar S, 2000, J BIOL CHEM, V275, P10308, DOI 10.1074/jbc.275.14.10308; Liu BL, 2000, CYTOKINE, V12, P1519, DOI 10.1006/cyto.2000.0749; Matsumoto S, 1997, BIOCHEM BIOPH RES CO, V234, P454, DOI 10.1006/bbrc.1997.6665; Muhl H, 2000, BIOCHEM BIOPH RES CO, V267, P960, DOI 10.1006/bbrc.1999.2064; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; Novick D, 2001, CYTOKINE, V14, P334, DOI 10.1006/cyto.2001.0914; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Pan GH, 2001, CYTOKINE, V13, P1, DOI 10.1006/cyto.2000.0799; Parnet P, 1996, J BIOL CHEM, V271, P3967; Pomerantz BJ, 2001, P NATL ACAD SCI USA, V98, P2871, DOI 10.1073/pnas.041611398; Puren AJ, 1998, J CLIN INVEST, V101, P711, DOI 10.1172/JCI1379; Puren AJ, 1999, P NATL ACAD SCI USA, V96, P2256, DOI 10.1073/pnas.96.5.2256; Puren AJ, 1998, J INFECT DIS, V178, P1830, DOI 10.1086/314481; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; Schreuder H, 1997, NATURE, V386, P194, DOI 10.1038/386194a0; Smith DE, 2000, J BIOL CHEM, V275, P1169, DOI 10.1074/jbc.275.2.1169; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; Torigoe K, 1997, J BIOL CHEM, V272, P25737, DOI 10.1074/jbc.272.41.25737; Tsuji-Takayama K, 1999, CELL IMMUNOL, V196, P41, DOI 10.1006/cimm.1999.1542; TsujiTakayama K, 1997, BIOCHEM BIOPH RES CO, V237, P126, DOI 10.1006/bbrc.1997.7099; Ushio S, 1996, J IMMUNOL, V156, P4274; Vigers GPA, 1997, NATURE, V386, P190, DOI 10.1038/386190a0; Xiang Y, 1999, VIROLOGY, V257, P297, DOI 10.1006/viro.1999.9676; Yoshimoto T, 1998, J IMMUNOL, V161, P3400	40	50	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10998	11003		10.1074/jbc.M108311200	http://dx.doi.org/10.1074/jbc.M108311200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11790772	hybrid			2022-12-27	WOS:000174613100032
J	Manji, GA; Wang, L; Geddes, BJ; Brown, M; Merriam, S; Al-Garawi, A; Mak, S; Lora, JM; Briskin, M; Jurman, M; Cao, J; DiStefano, PS; Bertin, J				Manji, GA; Wang, L; Geddes, BJ; Brown, M; Merriam, S; Al-Garawi, A; Mak, S; Lora, JM; Briskin, M; Jurman, M; Cao, J; DiStefano, PS; Bertin, J			PYPAF1, a PYRIN-containing Apaf1-like protein that assembles with ASC and regulates activation of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY-MEMBER; CASPASE ACTIVATION; APOPTOSIS; DOMAIN; GENE; INTERACTS; MUTATION; FEVER; BCL10; CED-4	The PYRIN domain is a recently identified protein-protein interaction domain that is found at the N terminus of several proteins thought to function in apoptotic and inflammatory signaling pathways. We report here that PYPAF1 (PYRIN-containing Apaf1-like protein 1) is a novel PYRIN-containing signaling protein that belongs to the nucleotide-binding site/leucine-rich repeat (NBS/LRR) family of signaling proteins. The expression of PYPAF1 is highly restricted to immune cells, and its gene maps to chromosome 1q44, a locus that is associated with the rare inflammatory diseases Muckle-Wells syndrome and familial cold urticaria. To identify downstream signaling partners of PYPAF1, we performed a mammalian two-hybrid screen and identified ASC as a PYRIN-containing protein that interacts selectively with the PYRIN domain of PYPAF1. When expressed in cells, ASC recruits PYPAF1 to distinct cytoplasmic loci and induces the activation of NTF-kappaB. Furthermore, coexpression of PYPAF1 with ASC results in a potent synergistic activation of NF-kappaB. These findings suggest that PYPAF1 and ASC function as upstream activators of NF-kappaB signaling.	Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Bertin, J (corresponding author), Millennium Pharmaceut Inc, 75 Sidney St, Cambridge, MA 02139 USA.	bertin@mpi.com						Aksentijevich I, 1997, CELL, V90, P797; Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Bertin J, 2000, J BIOL CHEM, V275, P41082, DOI 10.1074/jbc.C000726200; Bertin J, 2000, CELL DEATH DIFFER, V7, P1273, DOI 10.1038/sj.cdd.4400774; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Centola M, 2000, BLOOD, V95, P3223, DOI 10.1182/blood.V95.10.3223; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Cuisset L, 1999, AM J HUM GENET, V65, P1054, DOI 10.1086/302589; Damiano JS, 2001, GENOMICS, V75, P77, DOI 10.1006/geno.2001.6579; Dixon MS, 2000, P NATL ACAD SCI USA, V97, P8807, DOI 10.1073/pnas.97.16.8807; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Geddes BJ, 2001, BIOCHEM BIOPH RES CO, V284, P77, DOI 10.1006/bbrc.2001.4928; Hlaing T, 2001, J BIOL CHEM, V276, P9230, DOI 10.1074/jbc.M009853200; Hoffman HM, 2000, AM J HUM GENET, V66, P1693, DOI 10.1086/302874; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2000, CELL DEATH DIFFER, V7, P509, DOI 10.1038/sj.cdd.4400679; Jawaheer D, 2001, AM J HUM GENET, V68, P927, DOI 10.1086/319518; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; Koonin EV, 2000, TRENDS BIOCHEM SCI, V25, P223, DOI 10.1016/S0968-0004(00)01577-2; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; McDermott MF, 2000, ARTHRITIS RHEUM-US, V43, P2034, DOI 10.1002/1529-0131(200009)43:9<2034::AID-ANR14>3.0.CO;2-J; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; POYET JL, 2001, BIOCHEM BIOPH RES CO, V276, P28309; Richards N, 2001, J BIOL CHEM, V276, P39320, DOI 10.1074/jbc.M104730200; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Staub E, 2001, TRENDS BIOCHEM SCI, V26, P83, DOI 10.1016/S0968-0004(00)01717-5; Wang L, 2001, J BIOL CHEM, V276, P21405, DOI 10.1074/jbc.M102488200; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	34	207	225	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11570	11575		10.1074/jbc.M112208200	http://dx.doi.org/10.1074/jbc.M112208200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11786556	hybrid			2022-12-27	WOS:000174613100104
J	Shapiro, DA; Kristiansen, K; Weiner, DM; Kroeze, WK; Roth, BL				Shapiro, DA; Kristiansen, K; Weiner, DM; Kroeze, WK; Roth, BL			Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVELY ACTIVE MUTANTS; SITE-DIRECTED MUTAGENESIS; PROTEIN-COUPLED RECEPTORS; ALPHA(1B)-ADRENERGIC RECEPTOR; CONFORMATIONAL-CHANGES; MUSCARINIC RECEPTOR; INTRACELLULAR LOOP; AMINO-ACIDS; MUTATIONS; BINDING	5-Hydroxytryptamine 2A (5-HT2A) receptors are essential for the actions of serotonin (5-hydroxytryptamine (5-HT)) on physiological processes as diverse as vascular smooth muscle contraction, platelet aggregation, perception, and emotion. In this study, we investigated the molecular mechanism(s) by which 5-HT activates 5-HT2A receptors using a combination of approaches including site-directed mutagenesis, molecular modeling, and pharmacological analysis using the sensitive, cell-based functional assay R-SAT. Alanine-scanning mutagenesis of residues close to the intracellular end of H6 of the 5-HT2A receptor implicated glutamate Glu-318(6.30) in receptor activation, as also predicted by a newly constructed molecular model of the 5-HT2A receptor, which was based on the x-ray structure of bovine rhodopsin. Close examination of the molecular model suggested that Glu-318(6.30) could form a strong ionic interaction with Arg-173(3.50) of the highly conserved "(D/E)RY motif" located at the interface between the third transmembrane segment and the second intracellular loop (i2). A direct prediction of this hypothesis, that disrupting this ionic interaction by an E318(6.30)R mutation would lead to a highly constitutively active receptor with enhanced affinity for agonist, was confirmed using R-SAT. Taken together, these results predict that the disruption of a strong ionic interaction between transmembrane helices 3 and 6 of 5-HT2A receptors is essential for agonist-induced receptor activation and, as recently predicted by ourselves (B. L. Roth and D. A. Shapiro (2001) Expert Opin. Ther. Targets 5, 685-695) and others, that this may represent a general mechanism of activation for many, but not all, G-protein-coupled receptors.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; ACADIA Pharmaceut Inc, San Diego, CA 92121 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA USA; Univ Calif San Diego, Dept Psychiat, La Jolla, CA USA; Univ Tromso, Inst Pharm, Dept Pharmacol, N-9037 Tromso, Norway	Case Western Reserve University; University of California System; University of California San Diego; University of California System; University of California San Diego; UiT The Arctic University of Tromso	Roth, BL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.		Roth, Bryan L/F-3928-2010; Roth, Bryan/ABE-7032-2020	Roth, Bryan/0000-0002-0561-6520	NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH001366, R01MH057635] Funding Source: NIH RePORTER; NIMH NIH HHS [R01MH57635, KO2MH01366] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052; Almaula N, 1996, J BIOL CHEM, V271, P14672, DOI 10.1074/jbc.271.25.14672; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; Burstein ES, 1998, J BIOL CHEM, V273, P24322, DOI 10.1074/jbc.273.38.24322; CHOUDHARY MS, 1993, MOL PHARMACOL, V43, P755; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Egan CT, 1998, J PHARMACOL EXP THER, V286, P85; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HerrickDavis K, 1997, J NEUROCHEM, V69, P1138; Kobilka B K, 1998, Adv Pharmacol, V42, P470; Kristiansen K, 2000, J PHARMACOL EXP THER, V293, P735; Lattion AL, 1999, FEBS LETT, V457, P302, DOI 10.1016/S0014-5793(99)01064-9; MIN KC, 1993, J BIOL CHEM, V268, P9400; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parnot C, 2000, P NATL ACAD SCI USA, V97, P7615, DOI 10.1073/pnas.110142297; Pauwels PJ, 1999, BIOCHEM J, V343, P435, DOI 10.1042/0264-6021:3430435; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; Porter JE, 1999, J BIOL CHEM, V274, P34535, DOI 10.1074/jbc.274.49.34535; Price RD, 2001, J BIOL CHEM, V276, P44663, DOI 10.1074/jbc.M106745200; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; Roth BL, 2000, NEUROSCIENTIST, V6, P252, DOI 10.1177/107385840000600408; Roth BL, 1997, MOL PHARMACOL, V52, P259, DOI 10.1124/mol.52.2.259; Roth BL, 1999, NEURON, V23, P629, DOI 10.1016/S0896-6273(02)23443-1; Roth BL, 1998, PHARMACOL THERAPEUT, V79, P231, DOI 10.1016/S0163-7258(98)00019-9; Roth Bryan L, 2001, Expert Opin Ther Targets, V5, P685; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; Shapiro DA, 2000, MOL PHARMACOL, V58, P877, DOI 10.1124/mol.58.5.877; Spalding TA, 1997, BIOCHEMISTRY-US, V36, P10109, DOI 10.1021/bi970565g; Spalding TA, 1998, J BIOL CHEM, V273, P21563, DOI 10.1074/jbc.273.34.21563; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WANG CD, 1993, MOL PHARMACOL, V43, P931; Weiner DM, 2001, J PHARMACOL EXP THER, V299, P268; Wurch T, 1999, BRIT J PHARMACOL, V126, P939, DOI 10.1038/sj.bjp.0702379; ZHOU W, 1994, MOL PHARMACOL, V45, P165	41	147	148	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11441	11449		10.1074/jbc.M111675200	http://dx.doi.org/10.1074/jbc.M111675200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801601	hybrid, Green Published			2022-12-27	WOS:000174613100088
J	Denis, L; Grossemy, M; Douce, R; Alban, C				Denis, L; Grossemy, M; Douce, R; Alban, C			Molecular characterization of a second copy of holocarboxylase synthetase gene (hcs2) in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEA PISUM-SATIVUM; ESCHERICHIA-COLI; CARBOXYLASE GENES; HIGHER-PLANTS; BIOTIN; CDNA; PROTEIN; ORGANIZATION; EXPRESSION; DOMAINS	Holocarboxylase synthetase (HCS), catalyzing the covalent attachment of biotin, is ubiquitously represented in living organisms. Indeed, the biotinylation is a post-translational modification that allows the transformation of inactive biotin-dependent carboxylases, which are committed in fundamental metabolisms such as fatty acid synthesis, into their active holo form. Among other living organisms, plants present a peculiarly complex situation. In pea, HCS activity has been detected in three subcellular compartments and the systematic sequencing of the Arabidopsis genome revealed the occurrence of two hcs genes (hcs1 and hcs2). Hcs1 gene product had been previously characterized at molecular and biochemical levels. Here, by PCR amplification, we cloned an hcs2 cDNA from Arabidopsis thaliana (Ws ecotype) mRNA. We observed the occurrence of multiple cDNA forms which resulted from the alternative splicing of hcs2 mRNA. Furthermore, we evidenced a nucleotide polymorphism at the hcs2 gene within the Ws ecotype, which affected splicing of hcs2 mRNA. This contrasted sharply with the situation at hcs1 locus. However, this polymorphism had no apparent effect on total HCS activity in planta. Finally, hcs2 mRNAs were found 4-fold less abundant than hcs1 mRNA and the most abundant hcs2 mRNA spliced variant should code for a truncated protein. We discuss the possible role of such a multiplicity of putative HCS proteins in plants and discuss the involvement of each of hcs genes in the correct realization of biotinylation.	Aventis Cropsci, Aventis UMR 1932, INRA, Lab Mixte CNRS, F-69263 Lyon 9, France	Centre National de la Recherche Scientifique (CNRS); INRAE; Sanofi-Aventis; Sanofi France	Alban, C (corresponding author), Aventis Cropsci, Aventis UMR 1932, INRA, Lab Mixte CNRS, 14-20 Rue Pierre Baizet, F-69263 Lyon 9, France.	claude.alban@aventis.com	Alban, Claude/ABG-2296-2021	Alban, Claude/0000-0003-3587-6339				Alban C, 2000, ANNU REV PLANT PHYS, V51, P17, DOI 10.1146/annurev.arplant.51.1.17; Bergelson J, 1998, GENETICS, V148, P1311; Bergelson J, 2001, SCIENCE, V292, P2281, DOI 10.1126/science.1061337; Botto JM, 1997, BIOCHEM J, V324, P389, DOI 10.1042/bj3240389; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caicedo AL, 1999, P NATL ACAD SCI USA, V96, P302, DOI 10.1073/pnas.96.1.302; Campeau E, 2001, J BIOL CHEM, V276, P12310, DOI 10.1074/jbc.M009717200; CHANG HI, 1983, ARCH BIOCHEM BIOPHYS, V225, P237, DOI 10.1016/0003-9861(83)90026-7; CHOI JK, 1995, PLANT PHYSIOL, V109, P619, DOI 10.1104/pp.109.2.619; CRONAN JE, 1995, FEMS MICROBIOL LETT, V130, P221, DOI 10.1016/0378-1097(95)00210-V; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DUVAL M, 1994, PLANT MOL BIOL, V26, P265, DOI 10.1007/BF00039537; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; HANFSTINGL U, 1994, GENETICS, V138, P811; Henikoff S, 1998, GENETICS, V149, P307; Hiratsuka M, 1998, BBA-PROTEIN STRUCT M, V1385, P165, DOI 10.1016/S0167-4838(98)00032-6; Job C, 2001, SEED SCI RES, V11, P149; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; LEONDELRIO A, 1995, P NATL ACAD SCI USA, V92, P4626, DOI 10.1073/pnas.92.10.4626; Mukhopadhyay B, 2001, J BACTERIOL, V183, P3804, DOI 10.1128/JB.183.12.3804-3810.2001; Noel L, 1999, PLANT CELL, V11, P2099, DOI 10.1105/tpc.11.11.2099; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; Simpson GG, 1996, PLANT MOL BIOL, V32, P1, DOI 10.1007/BF00039375; SUZUKI Y, 1994, NAT GENET, V8, P122, DOI 10.1038/ng1094-122; Tissot G, 1996, BIOCHEM J, V314, P391, DOI 10.1042/bj3140391; Tissot G, 1998, EUR J BIOCHEM, V258, P586, DOI 10.1046/j.1432-1327.1998.2580586.x; Tissot G, 1997, BIOCHEM J, V323, P179, DOI 10.1042/bj3230179; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; YANAI Y, 1995, PLANT CELL PHYSIOL, V36, P779, DOI 10.1093/oxfordjournals.pcp.a078822	31	8	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10435	10444		10.1074/jbc.M111110200	http://dx.doi.org/10.1074/jbc.M111110200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11784724	Green Published, hybrid			2022-12-27	WOS:000174549200110
J	Fujita, M; Ishimi, Y; Nakamura, H; Kiyono, T; Tsurumi, T				Fujita, M; Ishimi, Y; Nakamura, H; Kiyono, T; Tsurumi, T			Nuclear organization of DNA replication initiation proteins in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; S-PHASE; CDC6 PROTEIN; CHROMATIN; ASSOCIATION; XENOPUS; HOMOLOG; MATRIX; CYCLE; SITES	Origin recognition complex (ORC), CDC6, and MCM proteins assemble sequentially to form prereplication chromatin. However, their organization remains largely unclear in mammalian cells. Here we show that ORC1 proteins are associated with non-chromatin nuclear structures and assemble in nuclear foci in mammalian cells using an in vivo chemical cross-linking method. CDC6 proteins were also found to assemble in nuclear foci on non-chromatin nuclear structures, although their physical association with ORC I has been undetectable. In contrast to the situation in yeast cells, CDC6 was found to remain associated with non-chromatin nuclear structures even after cells entered into S phase. Instead, ORC1 proteins were found to be degraded by a proteasome-dependent pathway during S phase. We also found that some ORC2 proteins are associated with non-chromatin nuclear structures like ORC1, although the remainder binds to nuclease-sensitive chromatin. Further analyses indicate that ORC2 physically interacts with ORC1 on non-chromatin nuclear structures. On the other hand, our results suggest that although a small proportion of MCM complexes are loaded onto chromatin regions near ORC foci, most of them are more widely distributed. Possible relations between such organization of prereplication chromatin and complicated origin specification in higher eukaryotic cells are discussed.	Aichi Canc Ctr, Res Inst, Div Virol, Lab Viral Oncol,Chikusa Ku, Nagoya, Aichi 4648681, Japan; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan	Aichi Cancer Center	Fujita, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Virol, Lab Viral Oncol,Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	mfujita@aichi-cc.jp	Kiyono, Tohru/H-5834-2011	Fujita, Masatoshi/0000-0001-6617-2452				AMATI B, 1990, MOL CELL BIOL, V10, P5442, DOI 10.1128/MCB.10.10.5442; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BAUMERT HG, 1989, METHOD ENZYMOL, V172, P584; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; Berezney R, 1995, INT REV CYTOL, V162A, P1; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CAPCO DG, 1982, CELL, V29, P847, DOI 10.1016/0092-8674(82)90446-9; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; COOK PR, 1988, J CELL SCI, V90, P1; DePamphilis ML, 1999, BIOESSAYS, V21, P5, DOI 10.1002/(SICI)1521-1878(199901)21:1<5::AID-BIES2>3.0.CO;2-6; Dhar SK, 2000, J BIOL CHEM, V275, P34983, DOI 10.1074/jbc.M006069200; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Dijkwel PA, 1995, INT REV CYTOL, V162A, P455; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P5398, DOI 10.1128/MCB.8.12.5398; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; Fujita M, 1996, J BIOL CHEM, V271, P4349; Fujita M, 1997, J BIOL CHEM, V272, P10928; FUJITA M, 1999, FRONT BIOSCI, V4, P816; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; HAMLIN JL, 1994, BBA-REV CANCER, V1198, P85, DOI 10.1016/0304-419X(94)90008-6; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; HYRIEN O, 1995, SCIENCE, V270, P994, DOI 10.1126/science.270.5238.994; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; JACKSON DA, 1986, EMBO J, V5, P1403, DOI 10.1002/j.1460-2075.1986.tb04374.x; Kalejta RF, 1998, MOL CELL, V2, P797, DOI 10.1016/S1097-2765(00)80294-4; Kreitz S, 2001, J BIOL CHEM, V276, P6337, DOI 10.1074/jbc.M009473200; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Ma H, 1998, J CELL BIOL, V143, P1415, DOI 10.1083/jcb.143.6.1415; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; Mizushima T, 2000, GENE DEV, V14, P1631; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Pelizon C, 2000, GENE DEV, V14, P2526, DOI 10.1101/gad.176300; Pemov A, 1998, P NATL ACAD SCI USA, V95, P14757, DOI 10.1073/pnas.95.25.14757; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Quintana DG, 1998, J BIOL CHEM, V273, P27137, DOI 10.1074/jbc.273.42.27137; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Rowles A, 1999, J CELL SCI, V112, P2011; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tatsumi Y, 2000, J BIOL CHEM, V275, P5904, DOI 10.1074/jbc.275.8.5904; Thome KC, 2000, J BIOL CHEM, V275, P35233, DOI 10.1074/jbc.M005765200; Vassetzky Y, 2000, GENE DEV, V14, P1541; Williams GH, 1998, P NATL ACAD SCI USA, V95, P14932, DOI 10.1073/pnas.95.25.14932	58	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10354	10361		10.1074/jbc.M111398200	http://dx.doi.org/10.1074/jbc.M111398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11779870	hybrid			2022-12-27	WOS:000174549200099
J	Halleck, MS; Schlegel, RA; Williamson, PL				Halleck, MS; Schlegel, RA; Williamson, PL			Reanalysis of ATP11B, a type IV P-type ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; CALCIUM-PUMP; GENE; EXPRESSION; SUBFAMILY	P-type ATPases are a venerable family of ATP-dependent ion transporters. Recently, evidence was presented that a rabbit gene in the type IV subfamily of P-type ATPases was missing a transmembrane helix (transmembrane domain 4) thought to be critical for ion transport, a deletion that would place the two major catalytic loops of the enzyme on opposite sides of the membrane. It was proposed that the resulting protein was a RING finger-binding protein that targets transcription factors to specific domains within the nucleus. From analysis of human genomic sequence data, it is shown here that the region containing transmembrane domain 4, corresponding to exon 12, is present in the human homolog of the gene, ATP11B. PCR analysis indicates that the predominant Atp11b transcripts in a rabbit cDNA library and in a mouse cDNA library also contain exon 12. The results suggest that the transcript proposed to encode the RING finger-binding protein is a minor rabbit-specific splice variant. The ATP11B gene thus may not encode a protein with a function radically different from that of other P-type ATPase transporters.	Penn State Univ, Dept Biochem & Mol Biol, S Frear Lab 410, University Pk, PA 16802 USA; Amherst Coll, Dept Biol, Amherst, MA 01002 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Amherst College	Halleck, MS (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, S Frear Lab 410, University Pk, PA 16802 USA.	msh4@psu.edu			NIGMS NIH HHS [R01 GM55862] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055862] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Bull LN, 1998, NAT GENET, V18, P219, DOI 10.1038/ng0398-219; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Dhar M, 2000, PHYSIOL GENOMICS, V4, P93, DOI 10.1152/physiolgenomics.2000.4.1.93; Ding JT, 2000, J BIOL CHEM, V275, P23378, DOI 10.1074/jbc.M910319199; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Halleck MS, 1998, GENOME RES, V8, P354, DOI 10.1101/gr.8.4.354; Halleck MS, 1999, PHYSIOL GENOMICS, V1, P139, DOI 10.1152/physiolgenomics.1999.1.3.139; HILFIKER H, 1993, J BIOL CHEM, V268, P19717; Kumar S., 1993, MEGA MOL EVOLUTIONAR; MAEDA M, 1990, J BIOL CHEM, V265, P9027; Mansharamani M, 2001, MOL CELL ENDOCRINOL, V183, P123, DOI 10.1016/S0303-7207(01)00596-2; Mansharamani M, 2001, J BIOL CHEM, V276, P3641, DOI 10.1074/jbc.M004231200; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; TURNER Z, 1995, GENOMICS, V26, P437	17	11	13	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9736	9740		10.1074/jbc.M200240200	http://dx.doi.org/10.1074/jbc.M200240200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11790799	hybrid			2022-12-27	WOS:000174549200020
J	Sah, JF; Eckert, RL; Chandraratna, RAS; Rorke, EA				Sah, JF; Eckert, RL; Chandraratna, RAS; Rorke, EA			Retinoids suppress epidermal growth factor-associated cell proliferation by inhibiting epidermal growth factor receptor-dependent ERK1/2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RECEPTOR; EPITHELIAL-CELLS; EGF RECEPTOR; ACID; EXPRESSION; GENE; DIFFERENTIATION; INTERFERON; CARCINOMA; BINDING	Human papillomavirus (HPV) is an important etiological agent in the genesis of cervical cancer. HPV-positive cervical tumors and human papillomavirus-positive cell lines display increased epidermal growth factor receptor (EGFR) expression, which is associated with increased cell proliferation. ECE16-1 cells are an HPV-immortalized human ectocervical epithelial cell line that is a model of HPV-associated cervical neoplasia and displays elevated EGFR levels. In the present study, we evaluated the effects of receptor-selective retinoid ligands on EGFR-associated signal transduction. We show that retinoic acid receptor (RAR)-selective ligands reduce EGFR level and the magnitude and duration of EGFR activation in EGF-stimulated cells. These effects are reversed by cotreatment with an RAR antagonist. To identify the mechanism, we examined the effects of retinoid treatments on EGF-dependent signaling. Stimulation with EGF causes a biphasic activation of the ERK1/2 MAPK. The first peak of activation is present at 20 min, and the second is present at 36 h. This activation subsequently leads to an increase in the cyclin D1 level and increased cell proliferation. Simultaneous treatment with EGF and a RAR-selective retinoid inhibits both phases of ERK1/2 activation, completely eliminates the cyclin D1 induction, and suppresses EGF-dependent cell proliferation. This effect is specific as retinoid treatment does not alter the level or activity of other EGFR-regulated kinases, including AKT and the MAPKs p38 and JNK. Retinoid X receptor-selective ligands, m contrast, did not regulate these responses. These results suggest that RAR ligand-associated down-regulation of EGFR activity reduces cell proliferation by reducing the magnitude and duration of EGF-dependent ERK1/2 activation.	Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Environm Hlth Sci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Allergan Pharmaceut Inc, Retinoid Res, Irvine, CA 92612 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; AbbVie; Allergan	Rorke, EA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA.	ear4@po.cwru.edu		Sah, Jerome/0000-0001-9478-7155	NCI NIH HHS [P30 CA134274] Funding Source: Medline; NIEHS NIH HHS [R0-1 ES09126] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA134274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009126] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agarwal C, 1996, J BIOL CHEM, V271, P12209, DOI 10.1074/jbc.271.21.12209; AGARWAL C, 1994, CANCER RES, V54, P2108; Agarwal C, 1996, CELL GROWTH DIFFER, V7, P521; ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen ZP, 1998, J MOL BIOL, V275, P55, DOI 10.1006/jmbi.1997.1413; COKER AL, 1993, CANCER EPIDEM BIOMAR, V2, P207; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARWICHE N, 1994, ENDOCRINOLOGY, V134, P2018, DOI 10.1210/en.134.5.2018; DE LUCA LM, 1991, FASEB J, V5, P2924; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; ECKERT RL, 1995, ADV EXP MED BIOL, V375, P31; GORODESKI GI, 1989, DIFFERENTIATION, V42, P75, DOI 10.1111/j.1432-0436.1989.tb00609.x; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; GULLICK WJ, 1986, CANCER RES, V46, P285; Haque M, 1998, NUTR REV, V56, P84, DOI 10.1111/j.1753-4887.1998.tb01699.x; Hembree JR, 1996, CANCER RES, V56, P1794; Howell SR, 1998, DRUG METAB DISPOS, V26, P234; Kersten S, 1997, J BIOL CHEM, V272, P12771, DOI 10.1074/jbc.272.19.12771; Klein ES, 1996, J BIOL CHEM, V271, P22692, DOI 10.1074/jbc.271.37.22692; Laudet V, 1997, J MOL ENDOCRINOL, V19, P207, DOI 10.1677/jme.0.0190207; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIPPMAN SM, 1993, EUR J CANCER, V29A, pS9, DOI 10.1016/0959-8049(93)90618-P; MANGELSDORF DJ, 1993, RECENT PROG HORM RES, V48, P99; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; MUNGER K, 1992, CANCER SURV, V12, P197; Nagpal S, 2000, CURR PHARM DESIGN, V6, P919, DOI 10.2174/1381612003400146; Peus D, 2000, PHOTOCHEM PHOTOBIOL, V72, P135, DOI 10.1562/0031-8655(2000)072<0135:UIEGFR>2.0.CO;2; PIRISI L, 1992, CANCER RES, V52, P187; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Rorke EA, 1997, JNCI-J NATL CANCER I, V89, P1243, DOI 10.1093/jnci/89.17.1243; RUSCH V, 1995, CANCER RES, V55, P1365; SIZEMORE N, 1993, CANCER RES, V53, P4511; SIZEMORE N, 1993, DIFFERENTIATION, V54, P219, DOI 10.1111/j.1432-0436.1993.tb01603.x; Voldborg BR, 1997, ANN ONCOL, V8, P1197, DOI 10.1023/A:1008209720526; Wadler S, 1997, CANCER, V79, P1574, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1574::AID-CNCR20>3.0.CO;2-U; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; Wolbach SB, 1933, J EXP MED, V57, P511, DOI 10.1084/jem.57.3.511; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yarden Y, 2001, EUR J CANCER, V37, pS3; ZUR HH, 1988, MOL CARCINOG, V1, P147	48	66	67	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9728	9735		10.1074/jbc.M110897200	http://dx.doi.org/10.1074/jbc.M110897200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11788593	hybrid			2022-12-27	WOS:000174549200019
J	Shibata, T; Kondo, M; Osawa, T; Shibata, N; Kobayashi, M; Uchida, K				Shibata, T; Kondo, M; Osawa, T; Shibata, N; Kobayashi, M; Uchida, K			15-deoxy-Delta(12,14)-prostaglandin J(2) - A prostaglandin D-2 metabolite generated during inflammatory processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; CYCLOPENTENONE PROSTAGLANDINS; GENE-EXPRESSION; PPAR-GAMMA; MECHANISMS; MACROPHAGE; APOPTOSIS; 9-DEOXY-DELTA-9,DELTA-12-13,14-DIHYDROPROSTAGLANDIN-D2; CYCLOOXYGENASE; MONOCYTES	Prostaglandin D-2 (PGD(2)), a major cyclooxygenase product in a variety of tissues, readily undergoes dehydration to yield the cyclopentenone-type PGs of the J(2) series, such as 15-deoxy-Delta(12,14)-PGJ(2) (15d-PGJ(2)), which have been suggested to exert anti-inflammatory effects in vivo. Meanwhile, the mechanism of these effects is not well understood and the natural site and the extent of its production in vivo remain unclear. In the present study, we raised a monoclonal antibody specific to 15d-PGJ(2) and determined its production in inflammation-related events. The monoclonal antibody (mAb11G2) was raised against the 15d-PGJ(2)-keyhole limpet hemocyanin conjugate and was found to recognize free 15d-PGJ(2) specifically. The presence of 15d-PGJ(2) in vivo was immunohistochemically verified in the cytoplasm of most of the foamy macrophages in human atherosclerotic plaques. In addition, the immunostaining of lipopolysaccharide-stimulated RAW264.7 macrophages with mAb11G2 demonstrated an enhanced intracellular accumulation of 15d-PGJ(2), suggesting that the PGD(2) metabolic pathway, generating the anti-inflammatory PGs, is indeed utilized in the cells during inflammation. The activation of macrophages also resulted in the extracellular production of PGD(2), which was associated with a significant increase in the extracellular 15d-PGJ(2) levels, and the extracellular 15d-PGJ(2) production was reproduced by incubating PGD(2) in a cell-free medium and in phosphate-buffered saline. Moreover, using a chiral high performance liquid chromatography method for separation of PGD(2) metabolites, we established a novel metabolic pathway, in which PGD(2) is converted to 15d-PGJ(2) via an albumin-independent mechanism.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan; Tokyo Womens Med Univ, Dept Pathol, Tokyo 1628666, Japan	Nagoya University; Tokyo Women's Medical University	Uchida, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan.		Shibata, Takahiro/I-6872-2014	Shibata, Takahiro/0000-0003-3194-607X; Uchida, Koji/0000-0003-3894-5299				Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Bogdan C, 2000, CURR OPIN IMMUNOL, V12, P64, DOI 10.1016/S0952-7915(99)00052-7; Bui T, 1998, BBA-GENE STRUCT EXPR, V1397, P31, DOI 10.1016/S0167-4781(97)00214-5; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fournier T, 1997, J BIOL CHEM, V272, P31065, DOI 10.1074/jbc.272.49.31065; FU JY, 1990, J BIOL CHEM, V265, P16737; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; FUKUSHIMA M, 1992, PROSTAG LEUKOTR ESS, V47, P1, DOI 10.1016/0952-3278(92)90178-L; GILES H, 1988, PROSTAGLANDINS, V35, P277, DOI 10.1016/0090-6980(88)90093-7; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; HIRATA Y, 1988, J BIOL CHEM, V263, P16619; Hortelano S, 2000, J IMMUNOL, V165, P6525, DOI 10.4049/jimmunol.165.11.6525; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kawamoto Y, 2000, J BIOL CHEM, V275, P11291, DOI 10.1074/jbc.275.15.11291; KHAN SH, 1990, P NATL ACAD SCI USA, V87, P9401, DOI 10.1073/pnas.87.23.9401; KIKAWA Y, 1984, P NATL ACAD SCI-BIOL, V81, P1317, DOI 10.1073/pnas.81.5.1317; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kondo M, 2001, J BIOL CHEM, V276, P12076, DOI 10.1074/jbc.M009630200; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Marx N, 1998, CIRC RES, V83, P1097, DOI 10.1161/01.RES.83.11.1097; MOLLOY A, 1994, J EXP MED, V180, P1499, DOI 10.1084/jem.180.4.1499; NARUMIYA S, 1987, J PHARMACOL EXP THER, V242, P306; OFFENBACHER S, 1986, J PERIODONTAL RES, V21, P101, DOI 10.1111/j.1600-0765.1986.tb01443.x; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rossi A, 1996, J BIOL CHEM, V271, P32192, DOI 10.1074/jbc.271.50.32192; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SMITH WL, 1992, AM J PHYSIOL, V263, P181; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464	33	344	349	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10459	10466		10.1074/jbc.M110314200	http://dx.doi.org/10.1074/jbc.M110314200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11786541	Green Submitted, hybrid			2022-12-27	WOS:000174549200113
J	Lamey, M; Thompson, M; Varghese, G; Chi, H; Sawzdargo, M; George, SR; O'Dowd, BF				Lamey, M; Thompson, M; Varghese, G; Chi, H; Sawzdargo, M; George, SR; O'Dowd, BF			Distinct residues in the carboxyl tail mediate agonist-induced desensitization and internalization of the human dopamine D-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; MUSCARINIC ACETYLCHOLINE-RECEPTOR; KINASE PHOSPHORYLATION SITES; PROTEIN-COUPLED RECEPTORS; ACIDIC AMINO-ACIDS; MU-OPIOID RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; DOWN-REGULATION; BETA-2-ADRENERGIC RECEPTOR; RHODOPSIN PHOSPHORYLATION	We have shown in a previous study that desensitization and internalization of the human dopamine D-1 receptor following short-term agonist exposure are mediated by temporally and biochemically distinct mechanisms. In the present study, we have used site-directed mutagenesis to remove potential phosphorylation sites in the third intracellular loop and carboxyl tail of the dopamine D-1 receptor to study these processes. Mutant D-1 receptors were stably transfected into Chinese hamster ovary cells, and kinetic parameters were measured. Mutations of Ser/Thr residues to alanine in the carboxyl tail demonstrated that the single substitution of Thr-360 abolished agonist-induced phosphorylation and desensitization of the receptor. Isolated mutation of the adjacent glutamic acid Glu-359 also abolished agonist-induced phosphorylation and desensitization of the receptor. These data suggest that Thr-360 in conjunction with Glu-359 may comprise a motif necessary for GRK2-mediated phosphorylation and desensitization. Agonist-induced internalization was not affected with mutation of either the Thr-360 or the Glu-359 residues. However, receptors with Ser/Thr residues mutated in the distal carboxyl tail (Thr-446, Thr-439, and Ser-431) failed to internalize in response to agonist activation, but were able to desensitize normally. These results indicate that agonist-induced desensitization and internalization are regulated by separate and distinct serine and threonine residues within the carboxyl tail of the human dopamine D-1 receptor.	Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Ctr Addict & Mental Hlth, Toronto, ON M5T 1R8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	O'Dowd, BF (corresponding author), Univ Toronto, Dept Pharmacol, Med Sci Bldg,Rm 4353, Toronto, ON M5S 1A8, Canada.		George, Susan R/P-9669-2018; George, Susan/W-7494-2019					BARAK LS, 1994, J BIOL CHEM, V269, P2790; BATES MD, 1993, J BIOL CHEM, V268, P14757; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Gardner B, 2001, MOL PHARMACOL, V59, P310, DOI 10.1124/mol.59.2.310; Guo J, 2000, MOL PHARMACOL, V58, P1050, DOI 10.1124/mol.58.5.1050; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; Hasbi A, 2000, J PHARMACOL EXP THER, V293, P237; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; INGLESE J, 1993, J BIOL CHEM, V268, P23735; Jiang D, 1999, MOL PHARMACOL, V56, P675; Jin WZ, 1999, J NEUROSCI, V19, P3773; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lewis MM, 1998, J PHARMACOL EXP THER, V286, P345; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; Maestes DC, 1999, J BIOL CHEM, V274, P29791, DOI 10.1074/jbc.274.42.29791; Matharu AL, 2001, J BIOL CHEM, V276, P30199, DOI 10.1074/jbc.M010650200; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; NG GYK, 1995, P NATL ACAD SCI USA, V92, P10157, DOI 10.1073/pnas.92.22.10157; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; Pak Y, 1999, J BIOL CHEM, V274, P27610, DOI 10.1074/jbc.274.39.27610; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; Palmer TM, 2000, MOL PHARMACOL, V57, P539, DOI 10.1124/mol.57.3.539; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pizard A, 1999, J BIOL CHEM, V274, P12738, DOI 10.1074/jbc.274.18.12738; Roth A, 1997, J BIOL CHEM, V272, P23769, DOI 10.1074/jbc.272.38.23769; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Seibold A, 2000, MOL PHARMACOL, V58, P1162, DOI 10.1124/mol.58.5.1162; Seibold A, 1998, J BIOL CHEM, V273, P7637, DOI 10.1074/jbc.273.13.7637; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; Tiberi M, 1996, J BIOL CHEM, V271, P3771; Tsuga H, 1998, J BIOL CHEM, V273, P5323, DOI 10.1074/jbc.273.9.5323; Wang JF, 2000, MOL PHARMACOL, V57, P687, DOI 10.1124/mol.57.4.687; ZHAO XY, 1995, BIOPHYS CHEM, V56, P183, DOI 10.1016/0301-4622(95)00031-R	48	54	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9415	9421		10.1074/jbc.M111811200	http://dx.doi.org/10.1074/jbc.M111811200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11773080	hybrid			2022-12-27	WOS:000174400600091
J	Lee, FS; Rajagopal, R; Kim, AH; Chang, PC; Chao, MV				Lee, FS; Rajagopal, R; Kim, AH; Chang, PC; Chao, MV			Activation of Trk neurotrophin receptor signaling by pituitary adenylate cyclase-activating polypeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; VASOACTIVE-INTESTINAL-PEPTIDE; CEREBELLAR GRANULE NEURONS; PROTEIN-COUPLED RECEPTORS; RAT-BRAIN; FUNCTIONAL EXPRESSION; HIPPOCAMPAL-NEURONS; PC12 CELLS; TYROSINE PHOSPHORYLATION; NEURITE OUTGROWTH	Pituitary adenylate cyclase-activating polypeptide (PACAP), a neuropeptide that acts through G protein-coupled receptors, exerts neuroprotective effects upon many neuronal populations. However, the intracellular signaling mechanisms that account for PACAP's trophic effects are not well characterized. Here we have tested the possibility that PACAP uses neurotrophin signaling pathways. We have found that PACAP treatment resulted in an increase in TrkA tyrosine kinase activity in PC12 cells and Trk13 activity in hippocampal neurons. The activation of TrkA receptors by PACAP required at least 1 h of treatment and did not involve binding to nerve growth factor. Moreover, PACAP induced an increase in activated Akt through a Trk-dependent mechanism that resulted in increased cell survival after trophic factor withdrawal. The increases in Trk and Akt were blocked by K252a, an inhibitor of Trk receptor activity. In addition, transactivation of TrkA receptors by PACAP could be inhibited with PP1, an inhibitor of Src family kinases or BAPTA/AM, (1,2-bis(2-aminophenoxy)ethane-N,N V,N-tetraacetic acid acetoxymethyl ester), an intracellular calcium chelator. Therefore, PACAP can exert trophic effects through a mechanism involving Trk receptors and utilization of tyrosine kinase signaling. This ability may explain several neuroprotective actions of PACAP upon neuronal populations after injury, nerve lesion, or neurotrophin deprivation.	NYU, Sch Med, Skirball Inst Biomol Med, Mol Neurobiol Program,Dept Physiol & Neurosci, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Med, Mol Neurobiol Program,Dept Cell Biol, New York, NY 10016 USA; Cornell Univ, Weill Med Coll, Dept Psychiat, New York, NY 10021 USA	New York University; New York University; Cornell University	Chao, MV (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, Mol Neurobiol Program,Dept Physiol & Neurosci, 540 1st Ave, New York, NY 10016 USA.	fslee@med.cornell.edu; chao@saturn.med.nyu.edu	Kim, Albert H./HGF-0057-2022	Chao, Moses/0000-0002-6969-3744	NICHD NIH HHS [HD23315] Funding Source: Medline; NINDS NIH HHS [NS21072] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD023315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS021072, R01NS021072] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aibel L, 1998, J NEUROSCI RES, V54, P424, DOI 10.1002/(SICI)1097-4547(19981101)54:3<424::AID-JNR13>3.0.CO;2-6; ARIMURA A, 1994, ANN NY ACAD SCI, V739, P228, DOI 10.1111/j.1749-6632.1994.tb19825.x; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Barrie AP, 1997, J BIOL CHEM, V272, P19666, DOI 10.1074/jbc.272.32.19666; BERG MM, 1992, J BIOL CHEM, V267, P13; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Cavallaro S, 1996, MOL PHARMACOL, V50, P60; Chang JY, 1996, NEUROSCI LETT, V206, P181, DOI 10.1016/S0304-3940(96)12468-X; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAgata V, 1996, EUR J NEUROSCI, V8, P310, DOI 10.1111/j.1460-9568.1996.tb01215.x; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DICICCOBLOOM E, 1992, REGUL PEPTIDES, V37, P319, DOI 10.1016/0167-0115(92)90634-7; GHATEI MA, 1993, J ENDOCRINOL, V134, P33; Gonzalez BJ, 1997, NEUROSCIENCE, V78, P419, DOI 10.1016/S0306-4522(96)00617-3; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hashimoto H, 1996, J COMP NEUROL, V371, P567; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; Kim AH, 2000, BRAIN RES, V886, P99, DOI 10.1016/S0006-8993(00)02944-9; Lee FS, 2001, P NATL ACAD SCI USA, V98, P3555, DOI 10.1073/pnas.061020198; Lioudyno M, 1998, J NEUROSCI RES, V51, P243, DOI 10.1002/(SICI)1097-4547(19980115)51:2<243::AID-JNR13>3.0.CO;2-9; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; MASUO Y, 1993, BRAIN RES, V602, P57, DOI 10.1016/0006-8993(93)90241-E; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Minichiello L, 1999, NEURON, V24, P401, DOI 10.1016/S0896-6273(00)80853-3; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; Morio H, 1996, BRAIN RES, V741, P82, DOI 10.1016/S0006-8993(96)00920-1; Otto C, 1999, MOL BRAIN RES, V66, P163, DOI 10.1016/S0169-328X(99)00010-8; Otto C, 2001, J NEUROSCI, V21, P5520, DOI 10.1523/JNEUROSCI.21-15-05520.2001; PALKOVITS M, 1995, BRAIN RES, V699, P116, DOI 10.1016/0006-8993(95)00869-R; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Przywara DA, 1998, J NEUROCHEM, V71, P1889; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; QUINN WG, 1979, NATURE, V277, P212, DOI 10.1038/277212a0; Reglodi D, 2000, STROKE, V31, P1411, DOI 10.1161/01.STR.31.6.1411; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Shioda S, 1998, ANN NY ACAD SCI, V865, P111, DOI 10.1111/j.1749-6632.1998.tb11169.x; SHRIVERS B, 1991, ENDOCRINOLOGY, V128, P3055; Skoglosa Y, 1999, MOL BRAIN RES, V65, P1, DOI 10.1016/S0169-328X(98)00294-0; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Tabuchi A, 2001, NEUROSCI RES, V39, P85, DOI 10.1016/S0168-0102(00)00200-5; Takei N, 1998, J NEUROSCI RES, V54, P698, DOI 10.1002/(SICI)1097-4547(19981201)54:5<698::AID-JNR15>3.0.CO;2-5; Takei N, 2000, EUR J NEUROSCI, V12, P2273, DOI 10.1046/j.1460-9568.2000.00118.x; TATSUNO I, 1992, ENDOCRINOLOGY, V131, P73, DOI 10.1210/en.131.1.73; TATSUNO I, 1990, BIOCHEM BIOPH RES CO, V168, P1027, DOI 10.1016/0006-291X(90)91132-C; TATSUNO I, 1994, PEPTIDES, V15, P55, DOI 10.1016/0196-9781(94)90170-8; TATSUNO I, 1991, ENDOCRINOLOGY, V128, P728, DOI 10.1210/endo-128-2-728; Uchida D, 1996, BRAIN RES, V736, P280, DOI 10.1016/0006-8993(96)00716-0; Vaudry D, 1999, P NATL ACAD SCI USA, V96, P9415, DOI 10.1073/pnas.96.16.9415; Villalba M, 1997, J NEUROSCI, V17, P83, DOI 10.1523/JNEUROSCI.17-01-00083.1997; Waddell S, 2000, CELL, V103, P805, DOI 10.1016/S0092-8674(00)00183-5; Yano H, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-03-j0003.2001; Zhou XR, 1999, J NEUROSCI RES, V57, P953, DOI 10.1002/(SICI)1097-4547(19990915)57:6<953::AID-JNR21>3.0.CO;2-R; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	63	168	173	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9096	9102		10.1074/jbc.M107421200	http://dx.doi.org/10.1074/jbc.M107421200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11784714	hybrid			2022-12-27	WOS:000174400600049
J	Nakatani, T; Tsuboyama-Kasaoka, N; Takahashi, M; Miura, S; Ezaki, O				Nakatani, T; Tsuboyama-Kasaoka, N; Takahashi, M; Miura, S; Ezaki, O			Mechanism for peroxisome proliferator-activated receptor-alpha activator-induced up-regulation of UCP2 mRNA in rodent hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; UNCOUPLING PROTEIN-2 EXPRESSION; KUPFFER CELLS; MESSENGER-RNA; FATTY-ACIDS; RAT-LIVER; GENE-TRANSCRIPTION; COACTIVATOR PGC-1; TNF-ALPHA; MICE	Peroxisome proliferator-activated receptor-alpha (PPARalpha) activators, fish oil feeding, or fibrate administration up-regulated mitochondrial uncoupling protein (UCP2) mRNA expression in mouse liver by 5-9-fold, whereas tumor necrosis factor-alpha (TNFalpha) also up-regulated UCP2 in liver. In this study, the mechanisms for PPARa activators-induced up-regulation of UCP2 mRNA, related to TNFalpha and reactive oxygen species (ROS), were investigated. PPARa activators-induced UCP2 up-regulation in mouse/rat liver tissues was due to their increases in hepatocytes but not in non-parenchymal cells. Addition of PPARalpha activators, WY14,643 or fenofibrate, to cultured hepatocytes up-regulated UCP2 mRNA by 5-10-fold. PPARa activators-induced up-regulation of UCP2 mRNA was not due to increased mRNA stability and required cycloheximide-sensitive short term turnover protein(s). However, expression of PPARalpha/retinoid X receptor-alpha and PGC-1 was not rate-limiting for WY14,643-induced UCP2 up-regulation. In primary hepatocytes, an exogenous oxidant, tert-butyl-hydroperoxide (TBHP), which increased ROS production, up-regulated UCP2 mRNA, whereas WY14,643 treatment did not produce. detectable ROS under the condition that fibrate markedly up-regulated UCP2. In in vivo studies, PPARalpha activators moderately up-regulated TNFalpha mRNA expression in mouse liver. An anti-oxidant pyrrolidine dithiocarbamate ammonium salt injection completely prevented their TNFalpha mRNA increases but did not prevent most of their UCP2 mRNA increases. These data indicate that PPARalpha activators upregulate UCP2 expression in hepatocytes through unknown proteins by increased transcription, and neither ROS nor TNFa production are the major causes for PPARalpha activators-induced UCP2 up-regulation.	Natl Inst Hlth Nutr, Div Clin Nutr, Shinjuku Ku, Tokyo 1628636, Japan	National Institute of Health & Nutrition - Japan	Ezaki, O (corresponding author), Natl Inst Hlth Nutr, Div Clin Nutr, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628636, Japan.		Miura, Shinji/K-6516-2013	Miura, Shinji/0000-0001-8806-9763				Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Aubert J, 1997, BIOCHEM BIOPH RES CO, V238, P606, DOI 10.1006/bbrc.1997.7348; Barton CC, 2001, HEPATOLOGY, V33, P66, DOI 10.1053/jhep.2001.20643; BASS DA, 1983, J IMMUNOL, V130, P1910; Bojes HK, 1997, CARCINOGENESIS, V18, P669, DOI 10.1093/carcin/18.4.669; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; Cortez-Pinto H, 1999, GASTROENTEROLOGY, V116, P1184, DOI 10.1016/S0016-5085(99)70022-3; Cortez-Pinto H, 1998, BIOCHEM BIOPH RES CO, V251, P313, DOI 10.1006/bbrc.1998.9473; DECKER K, 1990, EUR J BIOCHEM, V192, P245, DOI 10.1111/j.1432-1033.1990.tb19222.x; Dulloo AG, 2001, BRIT J NUTR, V86, P123, DOI 10.1079/BJN2001412; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; GOEL SK, 1986, CANCER RES, V46, P1324; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; KESTON AS, 1965, ANAL BIOCHEM, V11, P1, DOI 10.1016/0003-2697(65)90034-5; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Larrouy D, 1997, BIOCHEM BIOPH RES CO, V235, P760, DOI 10.1006/bbrc.1997.6852; Latruffe N, 1997, BIOCHIMIE, V79, P81, DOI 10.1016/S0300-9084(97)81496-4; Lauzurica P, 1999, EUR J IMMUNOL, V29, P1890, DOI 10.1002/(SICI)1521-4141(199906)29:06<1890::AID-IMMU1890>3.0.CO;2-F; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Nemeth ZH, 1998, SHOCK, V10, P49, DOI 10.1097/00024382-199807000-00009; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rose ML, 1997, CARCINOGENESIS, V18, P1453, DOI 10.1093/carcin/18.8.1453; Rusyn I, 1998, CARCINOGENESIS, V19, P1217, DOI 10.1093/carcin/19.7.1217; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHIMAOKA S, 1987, EXP CELL RES, V172, P228, DOI 10.1016/0014-4827(87)90109-1; Shimokawa T, 1998, BIOCHEM BIOPH RES CO, V251, P374, DOI 10.1006/bbrc.1998.9479; Tsuboyama-Kasaoka N, 1999, BIOCHEM BIOPH RES CO, V257, P879, DOI 10.1006/bbrc.1999.0555; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Viguerie-Bascands N, 1999, BIOCHEM BIOPH RES CO, V256, P138, DOI 10.1006/bbrc.1999.0303; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yang SQ, 2000, ARCH BIOCHEM BIOPHYS, V378, P259, DOI 10.1006/abbi.2000.1829; Yeldandi AV, 2000, MUTAT RES-FUND MOL M, V448, P159, DOI 10.1016/S0027-5107(99)00234-1; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Young ME, 2001, FASEB J, V15, P833, DOI 10.1096/fj.00-0351com	43	127	131	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9562	9569		10.1074/jbc.M110132200	http://dx.doi.org/10.1074/jbc.M110132200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11782473	hybrid			2022-12-27	WOS:000174400600109
J	Suzaki, Y; Yoshizumi, M; Kagami, S; Koyama, AH; Taketani, Y; Houchi, H; Tsuchiya, K; Takeda, E; Tamaki, T				Suzaki, Y; Yoshizumi, M; Kagami, S; Koyama, AH; Taketani, Y; Houchi, H; Tsuchiya, K; Takeda, E; Tamaki, T			Hydrogen peroxide stimulates c-Src-mediated big mitogen-activated protein kinase 1 (BMK1) and the MEF2C signaling pathway in PC12 cells - Potential role in cell survival following oxidative insults	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; SMOOTH-MUSCLE CELLS; PROTEIN-KINASE-1 BMK1; TRANSDUCTION PATHWAY; NEURONAL DIFFERENTIATION; CEREBRAL-ISCHEMIA; TYROSINE KINASES; OXYGEN RADICALS; GENE-EXPRESSION; JUN PROMOTER	Reactive oxygen species, generated by reduction-oxidation (redox) reactions, have been recognized as one of the major mediators of ischemia and reperfusion injury in the brain. Reactive oxygen species-induced cerebral events are attributable, in part, to the change in intracellular signaling molecules including mitogen-activated protein (MAP) kinases. Big MAP kinase 1 (BMK1), also known as ERK5, is a newly identified member of the MAP kinase family and has been reported to be sensitive to oxidative stress. In the present study, we examined the effect of H2O2 on BMK1 activity in PC12 cells, and we investigated the pathophysiological implication of BMK1. Findings showed that BMK1 was rapidly and significantly activated by H2O2 in a concentration-dependent manner in PC12 cells. BMK1 activation by H2O2 was inhibited by both PD98059 and U0126, which were reported to inhibit MEK5 as well as MEK1/2. c-Src was suggested to be involved in BMK1 activation from the experiments with herbimycin A and PP2, specific inhibitors of Src family kinases. Transfection of kinase-inactive Src also inhibited H2O2-induced BMK1 activation. In addition, H2O2 treatment of cells induced an enhancement of DNA binding activity of MEF2C, a downstream transcription factor of BMK1 in PC 12 cells. Finally, pretreatment of cells with PD98059 and U0126 resulted in an increase in cell death including apoptosis by H2O2 in ERKI/2 down-regulated cells as well as in intact PC12 cells. These findings suggest that c-Src mediated BMK1 activation by H2O2 may counteract ischemic cellular damage probably through the activation of MEF2C transcription factor.	Univ Tokushima, Sch Med, Dept Pharmacol, Tokushima 7708503, Japan; Univ Tokushima, Sch Med, Dept Pediat, Tokushima 7708503, Japan; Univ Tokushima, Sch Med, Dept Virol, Tokushima 7708503, Japan; Univ Tokushima, Sch Med, Dept Clin Nutr, Tokushima 7708503, Japan	Tokushima University; Tokushima University; Tokushima University; Tokushima University	Yoshizumi, M (corresponding author), Univ Tokushima, Sch Med, Dept Pharmacol, 3-18-15, Tokushima 7708503, Japan.							Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Berk BC, 1999, THROMB HAEMOSTASIS, V82, P810; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cavanaugh JE, 2001, J NEUROSCI, V21, P434, DOI 10.1523/JNEUROSCI.21-02-00434.2001; CHAN PH, 1994, BRAIN PATHOL, V4, P59; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; HYSLOP PA, 1995, BRAIN RES, V671, P181, DOI 10.1016/0006-8993(94)01291-O; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; KATO H, 1994, BRAIN RES, V634, P235, DOI 10.1016/0006-8993(94)91926-7; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; Koyama AH, 1998, ARCH VIROL, V143, P2435, DOI 10.1007/s007050050473; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LEIFER D, 1994, NEUROSCIENCE, V63, P1067, DOI 10.1016/0306-4522(94)90573-8; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Lin X, 1996, MOL BRAIN RES, V42, P307, DOI 10.1016/S0169-328X(96)00135-0; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Ozawa H, 1999, NEUROSCI LETT, V262, P57, DOI 10.1016/S0304-3940(99)00034-8; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; Takeishi Y, 1999, CIRC RES, V85, P1164; THOMAS KL, 1993, NEUROSCIENCE, V56, P741, DOI 10.1016/0306-4522(93)90371-L; Wakatsuki S, 1999, J BIOCHEM-TOKYO, V126, P1151, DOI 10.1093/oxfordjournals.jbchem.a022561; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yoshizumi M, 1998, BRIT J PHARMACOL, V125, P1019, DOI 10.1038/sj.bjp.0702141; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Zhang Y, 1998, P NATL ACAD SCI USA, V95, P2586, DOI 10.1073/pnas.95.5.2586; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	49	145	154	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9614	9621		10.1074/jbc.M111790200	http://dx.doi.org/10.1074/jbc.M111790200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11782488	hybrid			2022-12-27	WOS:000174400600115
J	Yi, JS; Kloeker, S; Jensen, CC; Bockholt, S; Honda, H; Hirai, H; Beckerle, MC				Yi, JS; Kloeker, S; Jensen, CC; Bockholt, S; Honda, H; Hirai, H; Beckerle, MC			Members of the zyxin family of LIM proteins interact with members of the p130(Cas) family of signal transducers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; MEDIATED CELL-ADHESION; HOMOLOGY 3 DOMAIN; TYROSINE-PHOSPHATASE; EXTRACELLULAR-MATRIX; BINDING-SITE; MAP KINASE; V-SRC; INTEGRIN; IDENTIFICATION	Integrin binding to extracellular matrix proteins induces formation of signaling complexes at focal adhesions. Zyxin co-localizes with integrins at sites of cell-substratum adhesion and is postulated to serve as a docking site for the assembly of multimeric protein complexes involved in regulating cell motility. Recently, we identified a new member of the zyxin family called TRIP6. TRIP6 is localized at focal adhesions and overexpression of TRIP6 slows cell migration. In an effort to define the molecular mechanism by which TRIP6 affects cell migration, the yeast two-hybrid assay was employed to identify proteins that directly bind to TRIP6. This assay revealed that both TRIP6 and zyxin interact with CasL/HEF1, a member of the Cas family. This association is mediated by the LIM region of the zyxin family members and the SH2 domain-binding region of CasL/ HEF1. Furthermore, the association between p130Cas and the two zyxin family members was demonstrated to occur in vivo by co-immunoprecipitation. Zyxin and Cas family members may cooperate to regulate cell motility.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Tokyo, Bunkyo Ku, Tokyo 1138655, Japan	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Tokyo	Beckerle, MC (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	mary.beckerle@hci.utah.edu			NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050877] Funding Source: NIH RePORTER; NCI NIH HHS [CA42014] Funding Source: Medline; NIGMS NIH HHS [R01 GM050877, GM50877] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Aplin AE, 1998, PHARMACOL REV, V50, P197; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; Astier A, 1997, LEUKEMIA LYMPHOMA, V28, P65, DOI 10.3109/10428199709058332; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; BECKERLE MC, 1986, J CELL BIOL, V103, P1679, DOI 10.1083/jcb.103.5.1679; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; Burnham MR, 1996, ONCOGENE, V12, P2467; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; Defilippi P, 1997, J BIOL CHEM, V272, P21726, DOI 10.1074/jbc.272.35.21726; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Drees B, 2000, J BIOL CHEM, V275, P22503, DOI 10.1074/jbc.M001698200; Drees BE, 1999, J CELL BIOL, V147, P1549, DOI 10.1083/jcb.147.7.1549; Fradelizi J, 2001, NAT CELL BIOL, V3, P699, DOI 10.1038/35087009; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Golsteyn RM, 1997, J CELL SCI, V110, P1893; GREBER UF, 1990, EMBO J, V9, P1495, DOI 10.1002/j.1460-2075.1990.tb08267.x; HARLOW A, 1988, ANTIBODIES LAB MANUA, P313; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Ishino M, 1995, ONCOGENE, V11, P2331; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Keegan K, 1996, ONCOGENE, V12, P1537; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Law SF, 1996, MOL CELL BIOL, V16, P3327; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Macalma T, 1996, J BIOL CHEM, V271, P31470, DOI 10.1074/jbc.271.49.31470; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Nix DA, 2001, J BIOL CHEM, V276, P34759, DOI 10.1074/jbc.M102820200; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; PATCH LA, 1995, J CELL SCI, V108, P1371; Petit MMR, 2000, MOL BIOL CELL, V11, P117, DOI 10.1091/mbc.11.1.117; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; Reinhard M, 1999, J BIOL CHEM, V274, P13410, DOI 10.1074/jbc.274.19.13410; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Seki N, 1997, DNA Res, V4, P345, DOI 10.1093/dnares/4.5.345; Shimada K, 1997, J CELL SCI, V110, P3031; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; VUORI K, 1993, J BIOL CHEM, V268, P21459; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang Y, 1999, GENE, V234, P403, DOI 10.1016/S0378-1119(99)00168-7; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YAMAWAKIKATAOKA Y, 1987, J BIOL CHEM, V262, P10791; Yi JS, 1998, GENOMICS, V49, P314, DOI 10.1006/geno.1998.5248; Zhao MK, 1999, GENE EXPRESSION, V8, P207; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	88	87	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9580	9589		10.1074/jbc.M106922200	http://dx.doi.org/10.1074/jbc.M106922200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11782456	hybrid			2022-12-27	WOS:000174400600111
J	Ito, J; Nagayasu, Y; Kato, K; Sato, R; Yokoyama, S				Ito, J; Nagayasu, Y; Kato, K; Sato, R; Yokoyama, S			Apolipoprotein A-I induces translocation of cholesterol, phospholipid, and caveolin-1 to cytosol in rat astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; BINDING CASSETTE TRANSPORTER-1; CELLULAR CHOLESTEROL; TANGIER-DISEASE; PLASMA-MEMBRANE; GENE-TRANSCRIPTION; CHAPERONE COMPLEX; MESSENGER-RNA; EFFLUX; CELLS	Intercellular cholesterol transport in the brain is carried by high density lipoprotein (HDL) generated in situ by cellular interaction with the apolipoprotein apoE, which is mainly synthesized by astrocytes, and with apoA-I secreted by cells such as endothelial cells. Rat astrocytes in fact generate HDL with extracellular apoA-I in addition to releasing HDL with endogenously synthesized apoE, seemingly by the same mechanism as the HDL assembly for systemic circulation. Relating to this reaction, apoA-I induced translocation of newly synthesized cholesterol and phospholipid to the cytosol prior to extracellular assembly of HDL, accompanied by an increase of caveolin-1 in the cytosol, activation of sterol regulatory element-binding protein, and enhancement of cholesterol synthesis. The lipid translocated into the cytosol was recovered in the fraction with a density of 1.09-1.16 g/ml as well as caveolin-1 and cyclophilin A. Cyclosporin A inhibited these apoA-I-mediated reactions and suppressed apoA-I-mediated cholesterol release. The findings suggest that such translocation of cholesterol and phospholipid into the cytosol is related to the apo A-I-mediated HDL assembly in astrocytes through functional association with caveolin-1 and a cyclosporin A-sensitive cyclophilin protein(s).	Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Inst Nat Sci, Dept Life Sci, Nagoya, Aichi 4678501, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan	Nagoya City University; Nagoya City University; University of Tokyo	Yokoyama, S (corresponding author), Nagoya City Univ, Sch Med, Mizuho Ku, Kawasumi 1,Mizuho Cho, Nagoya, Aichi 4678601, Japan.							Arakawa R, 2000, J LIPID RES, V41, P1952; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; HARA H, 1991, J BIOL CHEM, V266, P3080; Ito J, 1999, J NEUROCHEM, V72, P2362, DOI 10.1046/j.1471-4159.1999.0722362.x; Ito J, 2000, J LIPID RES, V41, P894; KATO T, 1984, BRAIN RES, V301, P83, DOI 10.1016/0006-8993(84)90405-0; Li QQ, 1997, BIOCHEMISTRY-US, V36, P12045, DOI 10.1021/bi970079t; LI QQ, 1995, J BIOL CHEM, V270, P26216, DOI 10.1074/jbc.270.44.26216; Li WP, 2001, J CELL SCI, V114, P1397; LIM R, 1973, EXP CELL RES, V79, P243, DOI 10.1016/0014-4827(73)90512-0; Liu PS, 1999, NAT CELL BIOL, V1, P369, DOI 10.1038/14067; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Nakai M, 1996, NEUROSCI LETT, V211, P41, DOI 10.1016/0304-3940(96)12716-6; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2001, J LIPID RES, V42, P1173; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; ROHEIM PS, 1979, P NATL ACAD SCI USA, V76, P4646, DOI 10.1073/pnas.76.9.4646; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; Tsujita M, 2000, BBA-MOL CELL BIOL L, V1485, P199, DOI 10.1016/S1388-1981(00)00061-5; Uittenbogaard A, 2000, J BIOL CHEM, V275, P25595, DOI 10.1074/jbc.M003401200; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; WEILERGUTTLER H, 1990, J NEUROCHEM, V54, P444, DOI 10.1111/j.1471-4159.1990.tb01892.x; YOKOYAMA S, 1982, J BIOCHEM, V91, P1267, DOI 10.1093/oxfordjournals.jbchem.a133811; Yokoyama S, 1998, BBA-LIPID LIPID MET, V1392, P1, DOI 10.1016/S0005-2760(98)00032-0	37	64	67	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7929	7935		10.1074/jbc.M103878200	http://dx.doi.org/10.1074/jbc.M103878200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11773045	hybrid			2022-12-27	WOS:000174268000040
J	Richard, SB; Ferrer, JL; Bowman, ME; Lillo, AM; Tetzlaff, CN; Cane, DE; Noel, JP				Richard, SB; Ferrer, JL; Bowman, ME; Lillo, AM; Tetzlaff, CN; Cane, DE; Noel, JP			Structure and mechanism of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase - An enzyme in the mevalonate-independent isoprenoid biosynthetic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONMEVALONATE PATHWAY; ESCHERICHIA-COLI; 4-PHOSPHATE PATHWAY; GENE; IDENTIFICATION; 5-PHOSPHATE; PRECURSOR; PROTEIN; LYTB; GCPE	The enzyme 2-C-methyl-D-erythritol 2,4-cyclodiphosphate (MECDP) synthase catalyzes the conversion of 4-diphosphocytidyl-2-C-methyl-D-erythritol 2-phosphate (CDP-ME2P) to MECDP, a highly unusual cyclodiphosphate-containing intermediate on the mevalonate-independent pathway to isopentenyl diphosphate and dimethylallyl diphosphate. We now report two x-ray crystal structures of MECDP synthase refined to 2.8-A resolution. The first structure contains a bound Mn2+ cation, and the second structure contains CMP, MECDP, and Mn2+. The protein adopts a homotrimeric quaternary structure built around a central hydrophobic cavity and three externally facing active sites. Each of these active sites is located between two adjacent monomers. A tetrahedrally arranged transition metal binding site, potentially occupied by Mn2+ sits at the base of the active site cleft. A phosphate oxygen of MECDP and the side chains of Asp8, His(10), and His(41) occupy the metal ion coordination sphere. These structures reveal for the first time the structural determinants underlying substrate, product, and Mn2+ recognition and the likely catalytic mechanism accompanying the biosynthesis of the cyclodiphosphate-containing isoprenoid precursor, MECDP.	Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA; Inst Biol Struct, F-38027 Grenoble 1, France; Brown Univ, Dept Chem, Providence, RI 02912 USA	Salk Institute; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Brown University	Noel, JP (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	noel@sbl.salk.edu	Noel, Joseph P/A-9459-2009		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030301, R01GM030301] Funding Source: NIH RePORTER; NIAID NIH HHS [AI51438] Funding Source: Medline; NIGMS NIH HHS [GM30301] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altincicek B, 2001, FEBS LETT, V499, P37, DOI 10.1016/S0014-5793(01)02516-9; Altincicek B, 2001, J BACTERIOL, V183, P2411, DOI 10.1128/JB.183.8.2411-2416.2001; Arigoni D, 1999, P NATL ACAD SCI USA, V96, P1309, DOI 10.1073/pnas.96.4.1309; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boucher Y, 2000, MOL MICROBIOL, V37, P703, DOI 10.1046/j.1365-2958.2000.02004.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campos N, 2001, FEBS LETT, V488, P170, DOI 10.1016/S0014-5793(00)02420-0; Cunningham FX, 2000, J BACTERIOL, V182, P5841, DOI 10.1128/JB.182.20.5841-5848.2000; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Eisenreich W, 2001, TRENDS PLANT SCI, V6, P78, DOI 10.1016/S1360-1385(00)01812-4; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Estevez JM, 2001, J BIOL CHEM, V276, P22901, DOI 10.1074/jbc.M100854200; Ferrer JL, 2001, ACTA CRYSTALLOGR D, V57, P1752, DOI 10.1107/S0907444901013385; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; Hecht S, 2001, P NATL ACAD SCI USA, V98, P14837, DOI 10.1073/pnas.201399298; Herz S, 2000, P NATL ACAD SCI USA, V97, P2486, DOI 10.1073/pnas.040554697; Hintz M, 2001, FEBS LETT, V509, P317, DOI 10.1016/S0014-5793(01)03191-X; Jez JM, 2000, BIOCHEMISTRY-US, V39, P890, DOI 10.1021/bi991489f; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuzuyama T, 2000, TETRAHEDRON LETT, V41, P2925, DOI 10.1016/S0040-4039(00)00295-1; Kuzuyama T, 2000, TETRAHEDRON LETT, V41, P703, DOI 10.1016/S0040-4039(99)02143-7; Ladner JE, 2000, ACTA CRYSTALLOGR D, V56, P673, DOI 10.1107/S0907444900004625; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lois LM, 1998, P NATL ACAD SCI USA, V95, P2105, DOI 10.1073/pnas.95.5.2105; Luttgen H, 2000, P NATL ACAD SCI USA, V97, P1062, DOI 10.1073/pnas.97.3.1062; McAteer S, 2001, J BACTERIOL, V183, P7403, DOI 10.1128/JB.183.24.7403-7407.2001; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parris KD, 2000, STRUCT FOLD DES, V8, P883, DOI 10.1016/S0969-2126(00)00178-7; Richard SB, 2001, NAT STRUCT BIOL, V8, P641, DOI 10.1038/89691; Rodriguez-Concepcion M, 2000, FEBS LETT, V473, P328, DOI 10.1016/S0014-5793(00)01552-0; Rohdich F, 2001, EUR J BIOCHEM, V268, P3190, DOI 10.1046/j.1432-1327.2001.02204.x; Rohdich F, 1999, P NATL ACAD SCI USA, V96, P11758, DOI 10.1073/pnas.96.21.11758; Rohmer M, 1999, NAT PROD REP, V16, P565, DOI 10.1039/a709175c; Sinha S, 1999, P NATL ACAD SCI USA, V96, P13074, DOI 10.1073/pnas.96.23.13074; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; Takagi M, 2000, TETRAHEDRON LETT, V41, P3395, DOI 10.1016/S0040-4039(00)00375-0; Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879; Volz K, 1999, PROTEIN SCI, V8, P2428; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; [No title captured]	43	64	75	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8667	8672		10.1074/jbc.C100739200	http://dx.doi.org/10.1074/jbc.C100739200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11786530	hybrid			2022-12-27	WOS:000174268000132
J	Suzuki, M; Kobayashi, H; Fujie, M; Nishida, T; Takigawa, M; Kanayama, N; Terao, T				Suzuki, M; Kobayashi, H; Fujie, M; Nishida, T; Takigawa, M; Kanayama, N; Terao, T			Kunitz-type protease inhibitor bikunin disrupts phorbol ester-induced oligomerization of CD44 variant Isoforms containing epitope v9 and subsequently suppresses expression of urokinase-type plasminogen activator in human chondrosarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY TRYPSIN-INHIBITOR; OVARIAN-CANCER CELLS; BINDING-PROTEIN; EXTRACELLULAR-MATRIX; TRANSMEMBRANE DOMAIN; HYALURONAN-BINDING; ENDOTHELIAL-CELLS; TERMINAL FRAGMENT; GENE-EXPRESSION; LINK PROTEIN	We previously found that bikunin (bik), a Kunitz-type protease inhibitor, suppresses phorbol ester (PMA)-stimulated expression of urokinase-type plasminogen activator (uPA). In the present study, we tried to answer this mechanism using human chondrosarcoma HCS-2/8 cells. Our results showed the following novel findings: (a) the standard form of CD44 (CD44s; 85 kDa) is expressed in both unstimulated and PMA-stimulated cells, while CD44v isoforms containing epitope v9 (110 kDa) are strongly up-regulated in response to treatment with PMA, (b) CD44v isoforms containing epitope v9 present on the same cell exclusively form aggregates in stimulated cells; (c) induction of uPA mRNA expression could be achieved by using a second cross-linker antibody to cross-link Fab monomers of anti-CD44; (d) co-treatment of stimulated cells with anti-CD44 mAb alone or anti-CD44v9 mAb alone suppresses PMA-induced clustering of CD44, which results in inhibition of uPA overexpression; (e) bikunin efficiently disrupts PMA-induced clustering of CD44, but does not prevent PMA-induced up-regulation of CD44v isoforms containing epitope v9; and (f) after exposure to bik, similar to150-kDa band is mainly detected with immunoprecipitation and this band is shown to be a heterodimer composed of the 110-kDa v9-containing CD44v isoforms and a 45-kDa bik receptor (bik-R). In conclusion, we provide, for the first time, evidence that the bik-R can physically interact with the CD44v isoforms containing epitope v9 and function as a repressor to down-regulate PMA-stimulated uPA expression, at least in part, by preventing clustering of CD44v isoforms containing epitope v9.	Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Equipment Ctr, Shizuoka 4313192, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Biochem & Mol Dent, Okayama 7008525, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Okayama University	Suzuki, M (corresponding author), Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Handacho 3600, Shizuoka 4313192, Japan.							ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BINETTE F, 1994, J BIOL CHEM, V269, P19116; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER WG, 1988, J BIOL CHEM, V263, P4193; DENNING SM, 1990, J IMMUNOL, V144, P7; Fujisaki T, 1999, CANCER RES, V59, P4427; GUO YJ, 1994, CANCER RES, V54, P422; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; Hirashima Y, 2001, J BIOL CHEM, V276, P13650, DOI 10.1074/jbc.M009906200; HUET S, 1989, J IMMUNOL, V143, P798; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; KNUDSON W, 1984, J CELL BIOCHEM, V25, P183, DOI 10.1002/jcb.240250402; Kobayashi H, 2000, BBA-PROTEIN STRUCT M, V1481, P310, DOI 10.1016/S0167-4838(00)00173-4; Kobayashi H, 1996, EUR J CELL BIOL, V71, P380; KOBAYASHI H, 1995, CANCER RES, V55, P1847; KOBAYASHI H, 1994, J BIOL CHEM, V269, P20642; KOBAYASHI H, 1995, J BIOL CHEM, V270, P8361, DOI 10.1074/jbc.270.14.8361; KOBAYASHI H, 1994, CLIN EXP METASTAS, V12, P117, DOI 10.1007/BF01753978; Kobayashi H, 1996, J BIOL CHEM, V271, P11362, DOI 10.1074/jbc.271.19.11362; KOBAYASHI H, 1995, BRIT J CANCER, V72, P1131, DOI 10.1038/bjc.1995.476; KOBAYASHI H, 1995, INT J CANCER, V63, P455, DOI 10.1002/ijc.2910630326; Kobayashi H, 1998, EUR J BIOCHEM, V253, P817, DOI 10.1046/j.1432-1327.1998.2530817.x; KOBAYASHI H, 1994, CANCER RES, V54, P844; KOBAYASHI H, 1994, INT J CANCER, V57, P378, DOI 10.1002/ijc.2910570315; Kobayashi H, 1998, BBA-PROTEIN STRUCT M, V1383, P253, DOI 10.1016/S0167-4838(97)00215-X; Kobayashi H, 2001, J BIOL CHEM, V276, P2015, DOI 10.1074/jbc.M007650200; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; Kobayashi H, 2000, J BIOL CHEM, V275, P21185, DOI 10.1074/jbc.M907862199; Kobayashi H, 2000, MOL HUM REPROD, V6, P735, DOI 10.1093/molehr/6.8.735; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; Koyama Y, 1996, J IMMUNOL, V157, P5097; LESLEY J, 1993, EUR J IMMUNOL, V23, P1902, DOI 10.1002/eji.1830230826; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; Liu D, 1996, J EXP MED, V183, P1987, DOI 10.1084/jem.183.5.1987; Liu DC, 1997, J IMMUNOL, V159, P2702; MEDCALF RL, 1988, J CELL BIOL, V106, P971, DOI 10.1083/jcb.106.3.971; NIIYA K, 1994, THROMB HAEMOSTASIS, V72, P92; OTA H, 1992, HISTOCHEM J, V24, P86, DOI 10.1007/BF01082444; PAULI BU, 1988, HUM PATHOL, V19, P628, DOI 10.1016/S0046-8177(88)80168-0; PERSCHL A, 1995, EUR J IMMUNOL, V25, P495, DOI 10.1002/eji.1830250228; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; Sleeman J, 1996, J CELL BIOL, V135, P1139, DOI 10.1083/jcb.135.4.1139; Sugino D, 1998, BIOTECHNOL APPL BIOC, V27, P145; Taher TEI, 1996, J BIOL CHEM, V271, P2863, DOI 10.1074/jbc.271.5.2863; Takigawa M, 1997, ENDOCRINOLOGY, V138, P4390, DOI 10.1210/en.138.10.4390; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086	47	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8022	8032		10.1074/jbc.M108545200	http://dx.doi.org/10.1074/jbc.M108545200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11777908	hybrid			2022-12-27	WOS:000174268000051
J	DeAngelis, PL; White, CL				DeAngelis, PL; White, CL			Identification and molecular cloning of a heparosan synthase from Pasteurella multocida type D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONAN SYNTHASE; CAPSULAR POLYSACCHARIDE; SEROGROUP-F; GLYCOSYLTRANSFERASE; BIOSYNTHESIS; BACTERIA; ANTIGEN; ENZYME	Pasteurella multocida Type D, a causative agent of atrophic rhinitis in swine and pasteurellosis in other domestic animals, produces an extracellular polysaccharide capsule that is a putative virulence factor. It was reported previously that the capsule was removed by treating microbes with heparin lyase III. We molecularly cloned a 617-residue enzyme, pmHS, which is a heparosan (nonsulfated, unepimerized heparin) synthase. Recombinant Escherichia coli-derived pmHS catalyzes the polymerization of the monosaccharides from UDP-GIcNAc and UDP-GIcUA. Other structurally related sugar nucleotides did not substitute. Synthase activity was stimulated about 7-25-fold by the addition of an exogenous polymer acceptor. Molecules composed of similar to500-3,000 sugar residues were produced in vitro. The polysaccharide was sensitive to the action of heparin lyase III but resistant to hyaluronan lyase. The sequence of the pmHS enzyme is not very similar to the vertebrate heparin/heparan sulfate glycosyltransferases, EXT1 and 2, or to other Pasteurella glycosaminoglycan synthases that produce hyaluronan or chondroitin. The pmHS enzyme is the first microbial dual-action glycosyltransferase to be described that forms a polysaccharide composed of beta4GIcUA-alpha4GIcNAc disaccharide repeats. In contrast, heparosan biosynthesis in E. coli K5 requires at least two separate polypeptides, KfiA and KfiC, to catalyze the same polymerization reaction.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	DeAngelis, PL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 56497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DeAngelis PL, 2000, J BIOL CHEM, V275, P24124, DOI 10.1074/jbc.M003385200; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DeAngelis PL, 1999, J BIOL CHEM, V274, P26557, DOI 10.1074/jbc.274.37.26557; Duncan G, 2001, J CLIN INVEST, V108, P511, DOI 10.1172/JCI200113737; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Griffiths G, 1998, J BIOL CHEM, V273, P11752, DOI 10.1074/jbc.273.19.11752; Hodson N, 2000, J BIOL CHEM, V275, P27311; Jing W, 2000, GLYCOBIOLOGY, V10, P883, DOI 10.1093/glycob/10.9.883; Lidholt K, 1997, BIOCHEM SOC T, V25, P866, DOI 10.1042/bst0250866; May BJ, 2001, P NATL ACAD SCI USA, V98, P3460, DOI 10.1073/pnas.051634598; RIMLER RB, 1994, VET REC, V134, P191, DOI 10.1136/vr.134.8.191; Rimler RB, 1995, VET MICROBIOL, V47, P287, DOI 10.1016/0378-1135(95)00127-1; RIMLER RB, 1987, J CLIN MICROBIOL, V25, P615, DOI 10.1128/JCM.25.4.615-618.1987; Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; RODRIGUEZ ML, 1988, EUR J BIOCHEM, V177, P117, DOI 10.1111/j.1432-1033.1988.tb14351.x; ROSNER H, 1992, CARBOHYD RES, V223, P329, DOI 10.1016/0008-6215(92)80032-V; Townsend KM, 2001, J CLIN MICROBIOL, V39, P924, DOI 10.1128/JCM.39.3.924-929.2001; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x	21	64	80	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					7209	7213		10.1074/jbc.M112130200	http://dx.doi.org/10.1074/jbc.M112130200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11756462	hybrid			2022-12-27	WOS:000174104300060
J	Collinet, B; Yuzawa, H; Chen, T; Herrera, C; Missiakas, D				Collinet, B; Yuzawa, H; Chen, T; Herrera, C; Missiakas, D			RseB binding to the periplasmic domain of RseA modulates the RseA :sigma(E) interaction in the cytoplasm and the availability of sigma(E)center dot RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-SIGMA FACTOR; HEAT-SHOCK RESPONSE; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; EXTRACYTOPLASMIC STRESS; NEGATIVE REGULATORS; INCLUSION-BODIES; PROTEIN; RPOE; CONVERSION	The Escherichia coli sigma (E) regulon has evolved to sense the presence of misfolded proteins in the bacterial envelope. Expression of periplasmic chaperones and folding catalysts is under the control of sigma (E) RNA polymerase. The N-terminal domain of RseA sequesters sigma (E) in the cytoplasmic membrane, preventing its association with core RNA polymerase, The C-terminal domain of RseA interacts with RseB, a periplasmic protein. The relative concentration of sigma (E):RseA:RseB is 2:5:1 and this ratio remains unaltered upon heat shock induction of the sigma (E) regulon. Purification from crude cellular extracts yields cytoplasmic, soluble sigma (E) RNA polymerase as web as membrane sequestered sigma (E) RseA and sigma (E).RseA.RseB. RseB binding to the C-terminal domain of RseA increases the affinity of RseA for sigma (E) by 2- to 3-fold (K-d, 50-100 nM). RseB binds also to the misfolded aggregates of MalE31, a variant of maltose binding protein that forms inclusion bodies in the periplasm. We discuss a model whereby the RseB-RseA interaction represents a measure for misfolded polypeptides in the bacterial envelope, modulating the assembly of sigma (E) RNA polymerase and the cellular heat shock response.	Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Missiakas, D (corresponding author), Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, 609 Charles Young Dr, Los Angeles, CA 90095 USA.	missiaka@microbio.ucla.edu			NIGMS NIH HHS [GM58266] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058266] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ades SE, 1999, GENE DEV, V13, P2449, DOI 10.1101/gad.13.18.2449; Beck BJ, 1997, J BACTERIOL, V179, P6504, DOI 10.1128/jb.179.21.6862-6864.1997; Betton JM, 1996, J BIOL CHEM, V271, P8046, DOI 10.1074/jbc.271.14.8046; Betton JM, 1996, J MOL BIOL, V262, P140, DOI 10.1006/jmbi.1996.0504; BUKAU B, 1993, MOL MICROBIOL, V9, P671, DOI 10.1111/j.1365-2958.1993.tb01727.x; DeLasPenas A, 1997, MOL MICROBIOL, V24, P373, DOI 10.1046/j.1365-2958.1997.3611718.x; DEVRIES CA, 1994, J BACTERIOL, V176, P6677, DOI 10.1128/JB.176.21.6677-6687.1994; Horsburgh MJ, 1999, MOL MICROBIOL, V32, P41, DOI 10.1046/j.1365-2958.1999.01323.x; Hughes KT, 1998, ANNU REV MICROBIOL, V52, P231, DOI 10.1146/annurev.micro.52.1.231; Kang JG, 1999, EMBO J, V18, P4292, DOI 10.1093/emboj/18.15.4292; LONETTO MA, 1994, P NATL ACAD SCI USA, V91, P7573, DOI 10.1073/pnas.91.16.7573; Maeda H, 2000, J BACTERIOL, V182, P1181, DOI 10.1128/JB.182.4.1181-1184.2000; MECSAS J, 1993, GENE DEV, V7, P2618, DOI 10.1101/gad.7.12b.2618; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Missiakas D, 1997, MOL MICROBIOL, V24, P355, DOI 10.1046/j.1365-2958.1997.3601713.x; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; Missiakas D, 1996, MOL MICROBIOL, V21, P871, DOI 10.1046/j.1365-2958.1996.561412.x; Missiakas D, 1998, MOL MICROBIOL, V28, P1059, DOI 10.1046/j.1365-2958.1998.00865.x; NAGAI H, 1994, P NATL ACAD SCI USA, V91, P10280, DOI 10.1073/pnas.91.22.10280; RAINA S, 1995, EMBO J, V14, P1043, DOI 10.1002/j.1460-2075.1995.tb07085.x; Raivio TL, 1999, CURR OPIN MICROBIOL, V2, P159, DOI 10.1016/S1369-5274(99)80028-9; ROUVIERE PE, 1995, EMBO J, V14, P1032, DOI 10.1002/j.1460-2075.1995.tb07084.x; Rowen DW, 2000, MOL MICROBIOL, V36, P314, DOI 10.1046/j.1365-2958.2000.01830.x; Schurr MJ, 1996, J BACTERIOL, V178, P4997, DOI 10.1128/jb.178.16.4997-5004.1996; Waller PRH, 1996, J BACTERIOL, V178, P1146, DOI 10.1128/jb.178.4.1146-1153.1996; Xie ZD, 1996, J BACTERIOL, V178, P4990, DOI 10.1128/jb.178.16.4990-4996.1996	27	57	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33898	33904		10.1074/jbc.M006214200	http://dx.doi.org/10.1074/jbc.M006214200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	11777003	hybrid			2022-12-27	WOS:000090104600099
J	Banci, L; Cavallaro, G; Kheifets, V; Mochly-Rosen, D				Banci, L; Cavallaro, G; Kheifets, V; Mochly-Rosen, D			Molecular dynamics characterization of the C2 domain of protein kinase C beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-ENERGY CALCULATIONS; INTRACELLULAR RECEPTOR; SUPEROXIDE-DISMUTASE; FUNCTIONAL-ROLE; BINDING DOMAIN; CALCIUM; REGION; LIGANDS; MOTIF; IDENTIFICATION	Protein kinase C (PKC) isozymes comprise a family of related enzymes that play a central role in many intracellular eukaryotic signaling events. Isozyme specificity is mediated by association of each PKC isozyme with specific anchoring proteins, termed RACKs. The C2 domain of betaPKC contains at least part of the RACK-binding sites. Because the C2 domain contains also a RACK-like sequence (termed pseudo-RACK), it was proposed that this pseudo-RACK site mediates intramolecular interaction with one of the RACK-binding sites in the C2 domain itself, stabilizing the inactive conformation of betaPKC. betaPKC depends on calcium for its activation, and the C2 domain contains the calcium-binding sites. The x-ray structure of the C2 domain of betaPKC shows that three Ca2+ ions can be coordinated by two opposing loops at one end of the domain. Starting from this x-ray structure, we have performed molecular dynamics (MD) calculations on the C2 domain of betaPKC bound to three Ca2+ ions, to two Ca2+ ions, and in the Ca2+-free state, in order to analyze the effect of calcium on the RACK-binding sites and the pseudo-RACK sites, as well as on the loops that constitute the binding site for the Ca2+ ions. The results show that calcium stabilizes the,G-sandwich structure of the C2 domain and thus affects two of the three RACK-binding sites within the C2 domain. Also, the interactions between the third RACK-binding site and the pseudo-RACK site are not notably modified by the removal of Ca2+ ions. On that basis, we predict that the pseudo-RACK site within the C2 domain masks a RACK-binding site in another domain of betaPKC, possibly the V5 domain. Finally, the MD modeling shows that two Ca2+ ions are able to interact with two molecules of O-phospho-L-serine. These data suggest that Ca2+ ions may be directly involved in PKC binding to phosphatidylserine, an acidic lipid located exclusively on the cytoplasmic face of membranes, that is required for PKC activation.	Univ Florence, Ctr Risonanze Magnet, I-50019 Florence, Italy; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	University of Florence; Stanford University	Banci, L (corresponding author), Univ Florence, Ctr Risonanze Magnet, Via Luigi Sacconi 6, I-50019 Florence, Italy.	banci@cerm.unifi.it	Cavallaro, Gabriele/GRE-9439-2022; Cavallaro, Gabriele/C-6991-2008	BANCI, LUCIA/0000-0003-0562-5774; Mochly-Rosen, Daria/0000-0002-6691-8733	NHLBI NIH HHS [HL 52141] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSEN HC, 1983, J COMPUT PHYS, V52, P24, DOI 10.1016/0021-9991(83)90014-1; Banci L, 1996, J BIOL INORG CHEM, V1, P264, DOI 10.1007/s007750050052; BANCI L, 1994, BIOCHEMISTRY-US, V33, P12356, DOI 10.1021/bi00207a002; BANCI L, 1992, J AM CHEM SOC, V114, P6994, DOI 10.1021/ja00044a007; BANCI L, 1994, PROTEINS, V18, P216, DOI 10.1002/prot.340180303; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; BROOKS CL, 1988, PROTEINS PERSPECTIVE; Chong LT, 1999, P NATL ACAD SCI USA, V96, P14330, DOI 10.1073/pnas.96.25.14330; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; Edwards AS, 1997, BIOCHEMISTRY-US, V36, P15615, DOI 10.1021/bi9718752; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Gordon AS, 1997, MOL PHARMACOL, V52, P554, DOI 10.1124/mol.52.4.554; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; KOLLMAN PA, 1990, ACCOUNTS CHEM RES, V23, P246, DOI 10.1021/ar00176a002; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; McCammon JA., 1987, DYNAMICS PROTEINS NU; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P3089, DOI 10.1021/bi001968a; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Newton AC, 1996, CURR BIOL, V6, P806, DOI 10.1016/S0960-9822(02)00600-0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; Pearlman DA, 1997, AMBER 5 0; Pepio AM, 1998, BIOCHEMISTRY-US, V37, P1256, DOI 10.1021/bi971841u; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; STORCH EM, 1995, BIOCHEMISTRY-US, V34, P9682, DOI 10.1021/bi00030a005; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; van Gunsteren WF, 1998, J CHEM PHYS, V108, P6109, DOI 10.1063/1.476021; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; VANGUNSTEREN WF, 1990, ANGEW CHEM INT EDIT, V29, P992, DOI 10.1002/anie.199009921; VANGUNSTEREN WF, 1993, CURR OPIN STRUC BIOL, V3, P277, DOI 10.1016/S0959-440X(05)80164-2; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Wang W, 2001, J AM CHEM SOC, V123, P3986, DOI 10.1021/ja003164o; Wong KB, 1998, BIOCHEMISTRY-US, V37, P11182, DOI 10.1021/bi980552i	59	37	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12988	12997		10.1074/jbc.M106875200	http://dx.doi.org/10.1074/jbc.M106875200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11782454	hybrid			2022-12-27	WOS:000175036300065
J	Chalfant, CE; Rathman, K; Pinkerman, RL; Wood, RE; Obeid, LM; Ogretmen, B; Hannun, YA				Chalfant, CE; Rathman, K; Pinkerman, RL; Wood, RE; Obeid, LM; Ogretmen, B; Hannun, YA			De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells - Dependence on protein phosphatase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOTHERAPY-INDUCED APOPTOSIS; INSULIN-INDUCIBLE CHANGES; RECEPTOR MESSENGER-RNA; KINASE C-BETA; SR PROTEINS; SPHINGOLIPID BIOSYNTHESIS; NEUTRAL SPHINGOMYELINASE; SIGNAL-TRANSDUCTION; CELLULAR SENESCENCE; PHOSPHATIDIC-ACID	Previous studies have demonstrated that several splice variants are derived from both the caspase 9 and Bcl-x genes in which the Bcl-x splice variant, Bcl-x(L) and the caspase 9 splice variant, caspase 9b, inhibit apoptosis in contrast to the pro-apoptotic splice variants, Bel-x(s) and caspase 9. In a recent study, we showed that ceramide induces the dephosphorylation of SR proteins, a family of protein factors that regulate alternative splicing. In this study, the regulation of the alternative processing of pre-mRNA of both caspase 9 and Bel-x(L) was examined in response to ceramide. Treatment of A549 lung adenocarcinoma cells with cellpermeable ceramide, D-e-C, ceramide, down-regulated the levels of Bcl-x(L) and caspase 9b mRNA and immunoreactive protein with a concomitant increase in the mRNA and immunoreactive protein levels of Bcl-x(s) and caspase 9 in a dose- and time-dependent manner. Pretreatment with calyculin A (5 nm), an inhibitor of protein phosphatase-1 (PP1) and protein phosphatase 2A (PP2A) blocked ceramide-induced alternative splicing in contrast to okadaic acid (10 nm), a specific inhibitor of PP2A at this concentrations in cells, demonstrating a PP1-mediated mechanism. A role for endogenous ceramide in regulating the alternative splicing of caspase 9 and Bcl-x was demonstrated using the chemotherapeutic agent, gemcitabine. Treatment of A549 cells with gemcitabine (1 muM) increased ceramide levels 3-fold via the de novo sphingolipid pathway as determined by pulse labeling experiments and inhibition studies with myriocin (50 nm), a specific inhibitor of serine palmitoyltransferase (the first step in de novo synthesis of ceramide). Treatment of A549 cells with gemcitabine downregulated the levels of Bcl-x(L) and caspase 9b mRNA with a concomitant increase in the mRNA levels of Bcl-x(s) and caspase 9. Again, inhibitors of ceramide synthesis blocked this effect. We also demonstrate that the change in the alternative splicing of caspase 9 and Bcl-x occurred prior to apoptosis following treatment with gemcitabine. Furthermore, doses of D-e-C-6 ceramide that induce the alternative splicing of both caspase 9 and Bel-x-sensitized A549 cells to daunorubicin. These data demonstrate a role for protein phosphatases 1 (PP1) and endogenous ceramide generated via the de novo pathway in regulating this mechanism. This is the first report on the dynamic regulation of RNA splicing of members of the Bcl-2 and caspase families in response to regulators of apoptosis.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509,Rm 501,Basic Sci Bldg, Charleston, SC 29425 USA.			obeid, lina/0000-0002-0734-0847	NCI NIH HHS [CA 87584] Funding Source: Medline; NIGMS NIH HHS [GM 19953-02, GM 43825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, F32GM019953, R37GM043825] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APTE SS, 1995, GENOMICS, V26, P592, DOI 10.1016/0888-7543(95)80180-T; Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHALFANT C, 1997, MECH PHYSL SIGNIFICA; CHALFANT CE, 1995, J BIOL CHEM, V270, P13326, DOI 10.1074/jbc.270.22.13326; Chalfant CE, 2001, J BIOL CHEM, V276, P44848, DOI 10.1074/jbc.M106291200; Chalfant CE, 1998, J BIOL CHEM, V273, P910, DOI 10.1074/jbc.273.2.910; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Chang TC, 1997, FEBS LETT, V415, P11, DOI 10.1016/S0014-5793(97)01083-1; Clarke PGH, 1996, ANAT EMBRYOL, V193, P81; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Du C, 1998, MOL CELL, V2, P741, DOI 10.1016/S1097-2765(00)80289-0; Du KY, 1997, MOL CELL BIOL, V17, P4096, DOI 10.1128/MCB.17.7.4096; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; GORCZYCA W, 1993, LEUKEMIA, V7, P659; Hannun YA, 1997, BIOCHEM SOC T, V25, P1171, DOI 10.1042/bst0251171; Hassan Z, 1999, EXP HEMATOL, V27, P1322, DOI 10.1016/S0301-472X(99)00066-1; HAVRILESKY LJ, 1995, OBSTET GYNECOL, V85, P1007, DOI 10.1016/0029-7844(95)00058-Y; Henkels KM, 1999, CANCER RES, V59, P3077; Hirano K, 1996, FEBS LETT, V389, P191, DOI 10.1016/0014-5793(96)00577-7; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; KERR JFR, 1992, INT REV CYTOL, V68, P251; KIM MY, 1991, J BIOL CHEM, V266, P484; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; KISIC A, 1995, J LIPID RES, V36, P787; KOSAKI A, 1993, J BIOL CHEM, V268, P21990; Kren BT, 1996, CELL GROWTH DIFFER, V7, P1633; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIN CH, 1995, RNA, V1, P234; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Lopato S, 1996, P NATL ACAD SCI USA, V93, P3074, DOI 10.1073/pnas.93.7.3074; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MEYN RE, 1994, CANCER CHEMOTH PHARM, V33, P410, DOI 10.1007/BF00686270; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; MIYASHITA T, 1992, CANCER RES, V52, P5407; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Obeid LM, 1997, J AM GERIATR SOC, V45, P361, DOI 10.1111/j.1532-5415.1997.tb00954.x; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; Patel NA, 2001, J BIOL CHEM, V276, P22648, DOI 10.1074/jbc.M101260200; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Priault M, 1999, FEBS LETT, V443, P225, DOI 10.1016/S0014-5793(98)01661-5; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schmitt E, 2000, BIOCHEM BIOPH RES CO, V270, P868, DOI 10.1006/bbrc.2000.2537; SELL SM, 1994, J BIOL CHEM, V269, P30769; Sell SM, 1999, MOL GENET METAB, V66, P189, DOI 10.1006/mgme.1998.2792; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Shi B, 1999, BIOCHEM BIOPH RES CO, V254, P779, DOI 10.1006/bbrc.1998.0130; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Srinivasula SM, 1999, CANCER RES, V59, P999; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thomas AL, 1999, CELL DEATH DIFFER, V6, P97, DOI 10.1038/sj.cdd.4400474; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WANG E, 1991, J BIOL CHEM, V266, P14486; Wilson GM, 1999, MOL CELL BIOL, V19, P4056; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; Zahler AM, 1999, METH MOL B, V118, P419; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhang P, 1997, J BIOL CHEM, V272, P9609; Zhou M, 1998, J BIOL CHEM, V273, P11930, DOI 10.1074/jbc.273.19.11930	81	269	288	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12587	12595		10.1074/jbc.M112010200	http://dx.doi.org/10.1074/jbc.M112010200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11801602	hybrid			2022-12-27	WOS:000175036300015
J	Wolff, T; Unterstab, G; Heins, G; Richt, JA; Kann, M				Wolff, T; Unterstab, G; Heins, G; Richt, JA; Kann, M			Characterization of an unusual importin a binding motif in the Borna disease virus p10 protein that directs nuclear import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCALIZATION SIGNAL; KARYOPHERIN-ALPHA; INFECTED-CELLS; CRYSTALLOGRAPHIC ANALYSIS; TARGETING SEQUENCES; MAMMALIAN-CELLS; PORE COMPLEX; RNA VIRUS; P-PROTEIN; TRANSPORT	Nuclear import of many cellular and viral proteins is mediated by short nuclear localization signals (NLS) that are recognized by intracellular receptor proteins belonging to the importin/karyopherin alpha and beta families. The primary structure of NLS is not well defined, but most contain at least three basic amino acids and harbor the relative consensus sequence K(K/R)X(K/R). We have studied the nuclear import of the Borna disease virus p10 protein that lacks a canonical oligobasic NLS. It is shown that the p10 protein exhibits all characteristics of an actively transported molecule in digitonin-permeabilized cells. Import activity was found to reside in the 20 N-terminal p10 amino acids that are devoid of an XLS consensus motif. Unexpectedly, p10-dependent import was blocked by a peptide inhibitor of importin alpha-dependent nuclear translocation, and the transport activity of the p10 N-terminal domain was shown to correlate with the ability to bind to importin alpha. These findings suggest that nuclear import of the Borna disease virus p10 protein occurs through a nonconventional karyophilic signal and highlight that the cellular importin alpha NLS receptor proteins can recognize nuclear targeting signals that substantially deviate from the consensus sequence.	Robert Koch Inst, D-13353 Berlin, Germany; Univ Giessen, Inst Vet Virol, D-35392 Giessen, Germany; Univ Giessen, Inst Med Virol, D-35392 Giessen, Germany	Robert Koch Institute; Justus Liebig University Giessen; Justus Liebig University Giessen	Wolff, T (corresponding author), Robert Koch Inst, Nordufer 20, D-13353 Berlin, Germany.		Richt, Juergen/AAL-3632-2020					ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; Adam SA, 1999, CURR OPIN CELL BIOL, V11, P402, DOI 10.1016/S0955-0674(99)80056-8; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; Bogerd HP, 1999, J BIOL CHEM, V274, P9771, DOI 10.1074/jbc.274.14.9771; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; BRIESE T, 1992, P NATL ACAD SCI USA, V89, P11486, DOI 10.1073/pnas.89.23.11486; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; COLLEDGE WH, 1986, MOL CELL BIOL, V6, P4136, DOI 10.1128/MCB.6.11.4136; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; CUBITT B, 1994, J VIROL, V68, P1371, DOI 10.1128/JVI.68.3.1371-1381.1994; DANG CV, 1989, J BIOL CHEM, V264, P18019; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; Giesen K, 2000, J GEN VIROL, V81, P2231, DOI 10.1099/0022-1317-81-9-2231; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; HORSCROFT N, 1999, P 9 INT C VIR SIDN A, P271; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kann M, 1999, J CELL BIOL, V145, P45, DOI 10.1083/jcb.145.1.45; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; Malik TH, 1999, VIROLOGY, V258, P65, DOI 10.1006/viro.1999.9715; Malik TH, 2000, J VIROL, V74, P3413, DOI 10.1128/JVI.74.7.3413-3417.2000; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MICHAEL WM, 1995, CELL, V83, P415; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Nowotny N, 2000, J VIROL, V74, P5655, DOI 10.1128/JVI.74.12.5655-5658.2000; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Schwemmle M, 1998, J BIOL CHEM, V273, P9007, DOI 10.1074/jbc.273.15.9007; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Shoya Y, 1998, J VIROL, V72, P9755, DOI 10.1128/JVI.72.12.9755-9762.1998; SMITH MR, 1992, VIROLOGY, V187, P316, DOI 10.1016/0042-6822(92)90320-O; STANDIFORD DM, 1992, J CELL BIOL, V118, P991, DOI 10.1083/jcb.118.5.991; Truant R, 1999, MOL CELL BIOL, V19, P1210; Wang P, 1997, J VIROL, V71, P1850, DOI 10.1128/JVI.71.3.1850-1856.1997; Wehner T, 1997, J GEN VIROL, V78, P2459, DOI 10.1099/0022-1317-78-10-2459; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; Wolff T, 2000, J GEN VIROL, V81, P939, DOI 10.1099/0022-1317-81-4-939; Wolff T, 1998, J VIROL, V72, P7170, DOI 10.1128/JVI.72.9.7170-7180.1998	57	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12151	12157		10.1074/jbc.M109103200	http://dx.doi.org/10.1074/jbc.M109103200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11796712	hybrid			2022-12-27	WOS:000174846400072
J	Plata, C; Meade, P; Vazquez, N; Hebert, SC; Gamba, G				Plata, C; Meade, P; Vazquez, N; Hebert, SC; Gamba, G			Functional properties of the apical Na+-K+-2Cl(-) cotransporter isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; THICK ASCENDING LIMB; NA-K-2CL COTRANSPORTER; CHLORIDE TRANSPORT; SODIUM-CHLORIDE; BUMETANIDE BINDING; BARTTERS-SYNDROME; XENOPUS-LAEVIS; ION-TRANSPORT; CO-TRANSPORT	The bumetanide-sensitive Na+:K+:2Cl(-) cotransporter (BSC1) is the major pathway for salt reabsorption in the apical membrane of the mammalian thick ascending limb of Henle. Three isoforms of the cotransporter, known as A, B, and F, exhibit axial expression along the thick ascending limb. We report here a functional comparison of the three isoforms from mouse kidney. When expressed in Xenopus oocytes the mBSC1-A isoform showed higher capacity of transport, with no difference in the amount of surface expression. Kinetic characterization revealed divergent affinities for the three cotransported ions. The observed EC50 values for Na+, K+, and Cl- were 5.0 +/- 3.9, 0.96 +/- 0.16, and 22.2 +/- 4.8 mm for mBSC1-A, 3.0 +/- 0.6, 0.76 +/- 0.07, and 11.6 +/- 0.7 mm for mBSC1-B; and 20.6 +/- 7.2, 1.54 +/- 0.16, and 29.2 +/- 2.1 mM for mBSC1-F, respectively. Bumetanide sensitivity was higher in mBSC1-B compared with the mBSC1-A and mBSC1-F isoforms. All three transporters were partially inhibited by hypotonicity but to different extents. The cell swelling-induced inhibition profile was mBSC1-F > mBSC1-B > mBSC1-A. The function of the Na+:K+:2Cl(-) cotransporter was not affected by extracellular pH or by the addition of metolazone, 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS), or R(+)-[(2n-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1- H-indenyl-5-yl) -oxyl acetic acid (DIOA) to the extracellular medium. In contrast, exposure of oocytes to HgCl2 before the uptake period reduced the activity of the cotransporter. The effect of HgCl2 was dose-dependent, and mBSC1-A and mBSC1-B exhibited higher affinity than mBSC1-F. Overall, the functional comparison of the murine apical renal-specific Na+:K+:2Cl(-) cotransporter isoforms A, B, and F reveals important functional, pharmacological, and kinetic differences, with both physiological and structural implications.	Univ Nacl Autonoma Mexico, Mol Physiol Unit, Inst Invest Biomed, Mexico City 14000, DF, Mexico; Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City 14000, DF, Mexico; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Universidad Nacional Autonoma de Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Yale University	Gamba, G (corresponding author), Univ Nacl Autonoma Mexico, Mol Physiol Unit, Inst Invest Biomed, Vasco Quiroga 15, Mexico City 14000, DF, Mexico.	gamba@conacyt.mx	Meade, Patricia/H-8825-2015; Plata, Consuelo/M-4482-2015; Plata, Consuelo/M-6461-2019; Gamba, Gerardo/P-4873-2016	Meade, Patricia/0000-0002-3587-6622; Plata, Consuelo/0000-0001-9340-8950; Gamba, Gerardo/0000-0002-4378-9043	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036803] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36803] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURG MB, 1982, KIDNEY INT, V22, P454, DOI 10.1038/ki.1982.198; BURNHAM C, 1985, BIOCHIM BIOPHYS ACTA, V821, P461, DOI 10.1016/0005-2736(85)90051-3; BURNHAM CE, 1990, AM J PHYSIOL, V259, pF383, DOI 10.1152/ajprenal.1990.259.2.F383; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Eknoyan G., 1997, DIURETIC AGENTS CLIN, P3; EVELOFF J, 1981, PFLUG ARCH EUR J PHY, V389, P263, DOI 10.1007/BF00584788; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; Gamba G, 2001, AM J PHYSIOL-RENAL, V281, pF781, DOI 10.1152/ajprenal.2001.281.5.F781; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Gamba G, 2000, CURR OPIN NEPHROL HY, V9, P535, DOI 10.1097/00041552-200009000-00013; Gamba G, 1999, KIDNEY INT, V56, P1606, DOI 10.1046/j.1523-1755.1999.00712.x; GARAY RP, 1988, MOL PHARMACOL, V33, P696; GREGER R, 1981, SCAND AUDIOL, P1; HAAS M, 1983, AM J PHYSIOL, V245, pC235, DOI 10.1152/ajpcell.1983.245.3.C235; HEBERT SC, 1992, HDB PHYSL 8, V1, P875; HUMPHREYS BD, 1995, AM J PHYSIOL-CELL PH, V268, pC201, DOI 10.1152/ajpcell.1995.268.1.C201; HUSCITHAREL A, 1986, PFLUG ARCH EUR J PHY, V407, P421, DOI 10.1007/BF00652628; IGARASHI P, 1995, AM J PHYSIOL-RENAL, V269, pF406; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Isenring P, 1998, P NATL ACAD SCI USA, V95, P7179, DOI 10.1073/pnas.95.12.7179; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; Jacoby SC, 1999, AM J PHYSIOL-CELL PH, V277, pC684, DOI 10.1152/ajpcell.1999.277.4.C684; KOENIG B, 1983, PFLUG ARCH EUR J PHY, V399, P173, DOI 10.1007/BF00656711; Mercado A, 2001, AM J PHYSIOL-CELL PH, V281, pC670, DOI 10.1152/ajpcell.2001.281.2.C670; Mercado A, 2000, J BIOL CHEM, V275, P30326, DOI 10.1074/jbc.M003112200; Monroy A, 2000, AM J PHYSIOL-RENAL, V279, pF161, DOI 10.1152/ajprenal.2000.279.1.F161; Mount DB, 1999, AM J PHYSIOL-RENAL, V276, pF347, DOI 10.1152/ajprenal.1999.276.3.F347; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Plata C, 1999, AM J PHYSIOL-RENAL, V276, pF359, DOI 10.1152/ajprenal.1999.276.3.F359; Plata C, 2001, AM J PHYSIOL-RENAL, V280, pF574, DOI 10.1152/ajprenal.2001.280.4.F574; Plata C, 2000, ARCH MED RES, V31, P21, DOI 10.1016/S0188-4409(99)00070-3; REEVES WB, 1988, AM J PHYSIOL, V255, pF1145, DOI 10.1152/ajprenal.1988.255.6.F1145; ROCHA AS, 1973, J CLIN INVEST, V52, P612, DOI 10.1172/JCI107223; SHETLAR RE, 1990, BIOCHIM BIOPHYS ACTA, V1023, P184, DOI 10.1016/0005-2736(90)90412-H; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Takahashi N, 2000, P NATL ACAD SCI USA, V97, P5434, DOI 10.1073/pnas.090091297; VAZQUEZ N, IN PRESS AM J PHYSL, V282; Yang TX, 1996, AM J PHYSIOL-RENAL, V271, pF931, DOI 10.1152/ajprenal.1996.271.4.F931; ZEIDEL M, 1997, DIURETIC AGENTS CLIN, P113	40	89	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11004	11012		10.1074/jbc.M110442200	http://dx.doi.org/10.1074/jbc.M110442200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11790783	hybrid			2022-12-27	WOS:000174613100033
J	Aoki, H; Kang, PM; Hampe, J; Yoshimura, K; Noma, T; Matsuzaki, M; Izumo, S				Aoki, H; Kang, PM; Hampe, J; Yoshimura, K; Noma, T; Matsuzaki, M; Izumo, S			Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED APOPTOSIS; FAS LIGAND EXPRESSION; CYTOCHROME-C; MOLECULAR CHARACTERIZATION; CARDIOMYOCYTE APOPTOSIS; PATHWAY; RELEASE; CELLS; BCL-2; PHOSPHORYLATION	Although oxidative stress causes activation of c-Jun N-terminal kinase (JNK) and apoptosis in many cell types, how the JNK pathway is connected to the apoptosis pathway is unclear. The molecular mechanism of JNK-mediated apoptosis was investigated in adult rat cardiac myocytes in culture as a model system that is sensitive to oxidative stress. Oxidative stress caused JNK activation, cytochrome c release, and apoptosis without new protein synthesis. Oxidative stress-induced apoptosis was abrogated by dominant negative stress-activated protein kinase/extracellular signal-regulated kinase kinase-1 (SEK1)-mediated inhibition of the JNK pathway, whereas activation of the JNK pathway by constitutively active SEK1 was sufficient to cause apoptosis. Inhibition of caspase-9, an apical caspase in the mitochondrial apoptosis pathway, suppressed oxidative stress-induced apoptosis, whereas inhibition of caspase-8 had no effect, indicating that both the JNK pathway and the mitochondrial apoptosis machinery are central to oxidative stress-induced apoptosis. Both JNK and SEK1 localized on mitochondria where JNK was activated by oxidative stress. Furthermore, active JNK caused the release of apoptogenic factors such as cytochrome c from isolated mitochondria in a cell-free assay. These findings indicate that the JNK pathway is a direct activator of mitochondrial death machinery without other cellular components and provide a molecular linkage from oxidative stress to the mitochondrial apoptosis machinery.	Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Yamaguchi Univ, Sch Med, Dept Mol Cardiovasc Biol, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Grad Sch Med, Dept Biosignal Anal, Ube, Yamaguchi 7558505, Japan	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Yamaguchi University; Yamaguchi University	Izumo, S (corresponding author), Beth Israel Deaconess Med Ctr, Div Cardiovasc, 330 Brookline Ave, Boston, MA 02215 USA.							Andreka P, 2001, CIRC RES, V88, P305, DOI 10.1161/01.RES.88.3.305; Aoki H, 2000, BIOCHEM J, V347, P275, DOI 10.1042/0264-6021:3470275; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bialik S, 1997, J CLIN INVEST, V100, P1363, DOI 10.1172/JCI119656; Das DK, 2001, ANTIOXID REDOX SIGN, V3, P23, DOI 10.1089/152308601750100461; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Feldenberg LR, 1999, AM J PHYSIOL-RENAL, V276, pF837, DOI 10.1152/ajprenal.1999.276.6.F837; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Kang PM, 2000, CIRC RES, V87, P118, DOI 10.1161/01.RES.87.2.118; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kohler C, 1999, FEBS LETT, V447, P10, DOI 10.1016/S0014-5793(99)00251-3; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Minamino T, 1999, P NATL ACAD SCI USA, V96, P15127, DOI 10.1073/pnas.96.26.15127; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Nelson DP, 2000, J CLIN INVEST, V105, P1199, DOI 10.1172/JCI8212; Ofir R, 1999, CELL DEATH DIFFER, V6, P1216, DOI 10.1038/sj.cdd.4400612; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Xiao YJ, 2000, J PHARMACOL EXP THER, V292, P8; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	33	284	300	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10244	10250		10.1074/jbc.M112355200	http://dx.doi.org/10.1074/jbc.M112355200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11786558	hybrid			2022-12-27	WOS:000174549200085
J	Holstein, SA; Wohlford-Lenane, CL; Hohl, RJ				Holstein, SA; Wohlford-Lenane, CL; Hohl, RJ			Consequences of mevalonate depletion - Differential transcriptional, translational, and post-translational up-reguiation of Ras, Rap1a, RhoA, and RhoB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; POSTTRANSLATIONAL MODIFICATIONS; TERMINAL REGION; PROTEIN; PRENYLATION; TRANSFORMATION; CYTOSKELETON; DEGRADATION; INHIBITORS; LOVASTATIN	Ras-related proteins are small GTPases that are post-translationally modified with mevalonate-derived isoprenoids. Although the effects of inhibition of isoprenylation on protein function have been examined, the consequences of depletion of isoprenoid pools on regulation of expression of isoprenylated proteins have yet to be investigated. In these studies we have shown that depletion of mevalonate results in increased total levels of Ras, Rap1a, RhoA, and RhoB in K562 cells. Cycloheximide and [S-35]methionine pulse/pulse-chase experiments reveal that mevalonate depletion increases the de novo synthesis of Ras and RhoA and decreases the degradation of existing Ras and RhoA protein. Pretreatment with actinomycin D completely prevents the induced up-regulation of RhoB and only partially prevents the up-regulation of Ras, Rapla, and RhoA. Although depletion of mevalonate does not alter steady state levels of Ras mRNA, there is an increase in RhoB mRNA Our results are the first to demonstrate that mevalonate depletion induces up-regulation of Ras and Ras-related proteins by discrete mechanisms that include modulation of transcriptional, translational, and post-translational processes.	Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Hohl, RJ (corresponding author), Univ Iowa, Dept Internal Med, C32 GH, Iowa City, IA 52242 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; Backlund PS, 1997, J BIOL CHEM, V272, P33175, DOI 10.1074/jbc.272.52.33175; Bellosta S, 2000, ANN MED, V32, P164, DOI 10.3109/07853890008998823; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Edwards PA, 2000, BBA-MOL CELL BIOL L, V1529, P103, DOI 10.1016/S1388-1981(00)00140-2; Frenette PS, 2001, NEW ENGL J MED, V345, P1419, DOI 10.1056/NEJM200111083451911; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; Fritz G, 2001, NUCLEIC ACIDS RES, V29, P792, DOI 10.1093/nar/29.3.792; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRUNDY SM, 1988, NEW ENGL J MED, V319, P24; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOHL RJ, 1995, J BIOL CHEM, V270, P17508, DOI 10.1074/jbc.270.29.17508; HORI Y, 1991, ONCOGENE, V6, P515; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; KANAI T, 1987, JPN J CANCER RES, V78, P1314; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; LEONARD S, 1990, J BIOL CHEM, V265, P5157; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OBRIG TG, 1971, J BIOL CHEM, V246, P174; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; STRAKA MS, 1995, ARCH BIOCHEM BIOPHYS, V317, P235, DOI 10.1006/abbi.1995.1158; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647; VAN AL, 1997, GENE DEV, V11, P2295; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058	37	76	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10678	10682		10.1074/jbc.M111369200	http://dx.doi.org/10.1074/jbc.M111369200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11788600	hybrid			2022-12-27	WOS:000174549200141
J	Lin, Q; Lo, CG; Cerione, RA; Yang, W				Lin, Q; Lo, CG; Cerione, RA; Yang, W			The Cdc42 target ACK2 interacts with sorting nexin 9 (SH3PX1) to regulate epidermal growth factor receptor degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; DOMAIN	Activated Cdc42-associated kinase-2 (ACK2) is a nonreceptor tyrosine kinase that serves as a specific effector for Cdc42, a Rho family small G-protein. Recently, we have found that ACK2 directly interacts with clathrin heavy chain through a clathrin-binding motif that is conserved in all endocytic adaptor proteins and regulates clathrin assembly, suggesting that ACK2 plays a role in clathrin-coated vesicle endocytosis (Yang, W., Lo, C. G., Dispenza, T., and Cerione, R. A. (2001) J. Biol. Chem. 276,17468-17473). Here we report the identification of another binding partner for ACK2 that has previously been implicated in endocytosis, namely the sorting nexin protein SH3PX1 (sorting nexin 9). The interaction occurs between a proline-rich domain of ACK2 and the Src homology 3 domain (SH3) of SH3PX1. Co-immunoprecipitation studies indicate that ACK2, clathrin, and SH3PX1 form a complex in cells. Epidermal growth factor (EGF) stimulated the tyrosine phosphorylation of SH3PX1, whereas co-transfection of ACK2 with SH3PX1 resulted in the constitutive phosphorylation of SH3PX1. However, co-transfection of the kinase-dead mutant ACK2(K158R) with SH3PX1 blocked EGF-induced tyrosine phosphorylation of SH3PX1, indicating that the EGF-stimulated phosphorylation of SH3PX1 is mediated by ACK2. EGF receptor levels were significantly decreased following EGF stimulation of cells co-expressing ACK2 and SH3PX1, thus highlighting a novel role for ACK2, working together with SH3PX1 to promote the degradation of the EGF receptor.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University; Cornell University	Yang, W (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.				NIGMS NIH HHS [GM40654, GM47458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654, R01GM047458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Barr VA, 2000, TRAFFIC, V1, P904, DOI 10.1034/j.1600-0854.2000.011109.x; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Haft CR, 2000, MOL BIOL CELL, V11, P4105, DOI 10.1091/mbc.11.12.4105; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Kurten RC, 2001, J CELL SCI, V114, P1743; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; Teo M, 2001, J BIOL CHEM, V276, P18392, DOI 10.1074/jbc.M008795200; WORBY CA, 2002, IN PRESS J BIOL CHEM; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Yang WN, 1999, J BIOL CHEM, V274, P8524, DOI 10.1074/jbc.274.13.8524; Yang WN, 2001, J BIOL CHEM, V276, P17468, DOI 10.1074/jbc.M010893200	15	70	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10134	10138		10.1074/jbc.M110329200	http://dx.doi.org/10.1074/jbc.M110329200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11799118	hybrid			2022-12-27	WOS:000174549200071
J	Sun, JF; Barbeau, B; Sato, S; Boivin, G; Goyette, N; Tremblay, MJ				Sun, JF; Barbeau, B; Sato, S; Boivin, G; Goyette, N; Tremblay, MJ			Syncytium formation and HIV-1 replication are both accentuated by purified influenza and virus-associated neuraminidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-SURFACE; ENVELOPE GLYCOPROTEINS; CD4 EXPRESSION; SIALIC ACIDS; IN-VITRO; TYPE-1; INFECTION; VACCINATION; ANTIBODY	The degree of sialylation has been shown previously to modulate the process of human immunodeficiency virus type-1 (HIV-1) infection by affecting the interaction between the virus and CD4-expressing target cells. In the present study, we investigated whether HIV-1 replication cycle was affected by neuraminidase (NA) derived from the human influenza (flu) virus. We first demonstrate that the level of HIV-1-mediated syncytium formation was greatly enhanced in the presence of purified flu NA. Pretreatment of established monocytic and lymphocytic cell lines as well as primary mononuclear cells with purified flu NA augmented also the process of virus infection. A comparable up-regulating effect was observed when using several strains of UV-inactivated whole flu virus, thereby suggesting that virus-anchored NA enzymes positively modulate the HIV-1 life cycle. Furthermore, flu NA-mediated positive effect on HIV-1 biology was abrogated with zanamivir, a specific flu NA inhibitor. Our results provide a new model allowing the investigation of the potential benefit of using NA inhibitors in the treatment of HIV-1-infected patients suffering from coinfection with NA-bearing pathogens.	CHUQ, CHUL Hop, Lab Immunoretrovirol Humaine, Ctr Rech Infectiol, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Med Biol, Ste Foy, PQ G1V 4G2, Canada	Laval University; Laval University	Tremblay, MJ (corresponding author), CHUQ, CHUL Hop, Lab Immunoretrovirol Humaine, Ctr Rech Infectiol, RC709,2705 Boul Laurier, Ste Foy, PQ G1V 4G2, Canada.	michel.j.tremblay@crchul.ulaval.ca	Barbeau, Benoit/A-1174-2010	Barbeau, Benoit/0000-0002-4108-8155; Boivin, Guy/0000-0003-3027-4662				ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; AGUILARCORDOVA E, 1994, AIDS RES HUM RETROV, V10, P295, DOI 10.1089/aid.1994.10.295; AIR GM, 1989, PROTEINS, V6, P341, DOI 10.1002/prot.340060402; ARORA DJS, 1973, CAN J MICROBIOL, V19, P633, DOI 10.1139/m73-104; Barbeau B, 1998, J VIROL, V72, P7125, DOI 10.1128/JVI.72.9.7125-7136.1998; Binley J, 1997, NATURE, V387, P346, DOI 10.1038/387346a0; Bounou S, 2002, J VIROL, V76, P1004, DOI 10.1128/JVI.76.3.1004-1014.2002; Cantin R, 1996, VIROLOGY, V218, P372, DOI 10.1006/viro.1996.0206; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; CORFIELD T, 1992, GLYCOBIOLOGY, V2, P509, DOI 10.1093/glycob/2.6.509; Dick AD, 1997, AIDS, V11, P1699, DOI 10.1097/00002030-199714000-00006; DOHERTY PC, 1995, J IMMUNOL, V155, P1023; ELS MC, 1989, VIROLOGY, V170, P346, DOI 10.1016/0042-6822(89)90394-2; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; FAILLARD H, 1989, TRENDS BIOCHEM SCI, V14, P237, DOI 10.1016/0968-0004(89)90034-0; FENOUILLET E, 1990, J VIROL, V64, P2841, DOI 10.1128/JVI.64.6.2841-2848.1990; Fortin JF, 1997, J VIROL, V71, P3588, DOI 10.1128/JVI.71.5.3588-3596.1997; Fouts TR, 1997, J VIROL, V71, P2779, DOI 10.1128/JVI.71.4.2779-2785.1997; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Frankel SS, 1997, AM J PATHOL, V151, P89; Fuller JD, 1999, CLIN INFECT DIS, V28, P541, DOI 10.1086/515170; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; GELDERBLOM HR, 1985, LANCET, V2, P1016; Genois N, 2000, J LEUKOCYTE BIOL, V68, P854; Glesby MJ, 1996, J INFECT DIS, V174, P1332, DOI 10.1093/infdis/174.6.1332; Golden MP, 2001, CLIN INFECT DIS, V32, P1366, DOI 10.1086/319989; Graziosi C, 1998, AIDS RES HUM RETROV, V14, pS135; HAYDEN FG, 1980, ANTIMICROB AGENTS CH, V17, P865, DOI 10.1128/AAC.17.5.865; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; HO DD, 1992, LANCET, V339, P1549, DOI 10.1016/0140-6736(92)91321-X; Horuk R, 1999, IMMUNOL TODAY, V20, P89, DOI 10.1016/S0167-5699(98)01396-6; Hu HL, 1996, J VIROL, V70, P7462, DOI 10.1128/JVI.70.11.7462-7470.1996; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; Kiefel MJ, 1999, PROGR MED CHEM, V36, P1, DOI 10.1016/S0079-6468(08)70044-4; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; MESTECKY J, 1987, ANN ALLERGY, V59, P54; MOCK DJ, 1987, J CLIN INVEST, V79, P620, DOI 10.1172/JCI112856; MOORE JP, 1995, AIDS, V9, P117; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PAHL HL, 1995, J VIROL, V69, P1480, DOI 10.1128/JVI.69.3.1480-1484.1995; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PEREZ VL, 1991, J IMMUNOL, V147, P3145; POLI G, 1993, CLIN INFECT DIS, V17, P224; POWELL LD, 1987, J IMMUNOL, V139, P262; Ray P K, 1977, Adv Appl Microbiol, V21, P227, DOI 10.1016/S0065-2164(08)70043-1; ROGGENTIN P, 1988, CLIN CHIM ACTA, V173, P251, DOI 10.1016/0009-8981(88)90012-5; Rosok B, 1996, CLIN EXP IMMUNOL, V104, P203, DOI 10.1046/j.1365-2249.1996.25732.x; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; Sattentau QJ, 1996, CURR OPIN IMMUNOL, V8, P540, DOI 10.1016/S0952-7915(96)80044-6; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; SONZA S, 1995, AIDS RES HUM RETROV, V11, P769, DOI 10.1089/aid.1995.11.769; Stamatos NM, 1997, VIROLOGY, V228, P123, DOI 10.1006/viro.1996.8373; STAPRANS SI, 1995, J EXP MED, V182, P1727, DOI 10.1084/jem.182.6.1727; Sun JF, 2001, VIROLOGY, V284, P26, DOI 10.1006/viro.2001.0889; Taylor G, 1996, CURR OPIN STRUC BIOL, V6, P830, DOI 10.1016/S0959-440X(96)80014-5; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Vimr Eric R., 1994, Trends in Microbiology, V2, P271, DOI 10.1016/0966-842X(94)90003-5; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Xin X, 1998, ARCH VIROL, V143, P85, DOI 10.1007/s007050050270; Zambon MC, 1999, J ANTIMICROB CHEMOTH, V44, P3, DOI 10.1093/jac/44.suppl_2.3	61	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9825	9833		10.1074/jbc.M110764200	http://dx.doi.org/10.1074/jbc.M110764200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11781317	hybrid			2022-12-27	WOS:000174549200032
J	Yang, B; Bankir, L; Gillespie, A; Epstein, CJ; Verkman, AS				Yang, B; Bankir, L; Gillespie, A; Epstein, CJ; Verkman, AS			Urea-selective concentrating defect in transgenic mice lacking urea transporter UT-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY; CLONING; LOCALIZATION; WATER; EXPRESSION; PROTEIN; ERYTHROCYTES; PERMEABILITY; ORGANIZATION; AQUAPORIN-1	Urea transporter UT-B has been proposed to be the major urea transporter in erythrocytes and kidney-descending vasa recta. The mouse UT-B cDNA was isolated and encodes a 384-amino acid urea-transporting glycoprotein expressed in kidney, spleen, brain, ureter, and urinary bladder. The mouse UT-B gene was analyzed, and UT-B knockout mice were generated by targeted gene deletion of exons 3-6. The survival and growth of UT-B knockout mice were not different from wild-type littermates. Urea permeability was 45-fold lower in erythrocytes from knockout mice than from those in wild-type mice. Daily urine output was 1.5-fold greater in UT-B- deficient mice (p < 0.01), and urine osmolality (U-osm) was lower (1532 +/- 71 versus 2056 +/- 83 moswd kgH(2)O, mean +/- S.E., p < 0.001). After 24 h of water deprivation, U-osm (in mosm/kgH(2)O) was 2403 +/- 38 in UT-B null mice and 3438 +/- 98 in wild-type mice (p < 0.001). Plasma urea concentration (P-urea) was 30% higher, and urine urea concentration (U-urea) was 35% lower in knockout mice than in wild-type mice, resulting in a much lower U-urea/P-urea ratio (61 +/- 5 versus 124 +/- 9, p < 0.001). Thus, the capacity to concentrate urea in the urine is more severely impaired than the capacity to concentrate other solutes. Together with data showing a disproportionate reduction in the concentration of urea compared with salt in homogenized renal inner medullas of UT-B null mice, these data define a novel "urea-selective" urinary concentrating defect in UT-B null mice. The UT-B null mice generated for these studies should also be useful in establishing the role of facilitated urea transport in extrarenal organs expressing UT-B.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med & Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Pediat, San Francisco, CA 94143 USA; Inst Fer Moulin, INSERM, U367, F-75005 Paris, France	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Yang, B (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med & Physiol, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	byang@itsa.ucsf.edu	BANKIR, Lise/AAK-2733-2020	BANKIR, Lise/0000-0002-3321-0819	NHLBI NIH HHS [HL51854, HL58198, HL60288] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051854, P50HL060288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bagnasco SM, 2001, AM J PHYSIOL-RENAL, V281, pF400, DOI 10.1152/ajprenal.2001.281.3.F400; BANKIR L, 1985, AM J PHYSIOL, V249, pR643, DOI 10.1152/ajpregu.1985.249.6.R643; Bankir L, 2000, EXP PHYSIOL, V85, p243S, DOI 10.1111/j.1469-445X.2000.tb00029.x; Bankir L, 2000, KIDNEY, V6th, P637; Couriaud C, 1996, BBA-GENE STRUCT EXPR, V1309, P197, DOI 10.1016/S0167-4781(96)00172-8; CRAWFORD JD, 1959, AM J PHYSIOL, V196, P545, DOI 10.1152/ajplegacy.1959.196.3.545; Fenton RA, 2000, AM J PHYSIOL-CELL PH, V279, pC1425, DOI 10.1152/ajpcell.2000.279.5.C1425; FENTON RA, 2002, IN PRESS AM J PHYSL; FROHLICH O, 1991, AM J PHYSIOL, V260, pC778, DOI 10.1152/ajpcell.1991.260.4.C778; Karakashian A, 1999, J AM SOC NEPHROL, V10, P230; KLAHR S, 1967, AM J MED, V43, P84, DOI 10.1016/0002-9343(67)90150-7; KNEPPER MA, 1987, KIDNEY INT, V31, P629, DOI 10.1038/ki.1987.44; KRIZ W, 1981, AM J PHYSIOL, V241, pR3, DOI 10.1152/ajpregu.1981.241.1.R3; LASSITER WE, 1961, AM J PHYSIOL, V200, P1139, DOI 10.1152/ajplegacy.1961.200.6.1139; Lucien N, 1998, J BIOL CHEM, V273, P12973, DOI 10.1074/jbc.273.21.12973; Masilamani S, 2000, KIDNEY, P595; Nakayama Y, 2001, BBA-GENE STRUCT EXPR, V1518, P19, DOI 10.1016/S0167-4781(00)00311-0; Nielsen S, 1996, P NATL ACAD SCI USA, V93, P5495, DOI 10.1073/pnas.93.11.5495; OLIVES B, 1994, J BIOL CHEM, V269, P31649; SANDS JM, 1992, J AM SOC NEPHROL, V2, P1689; Sands JM, 1999, J AM SOC NEPHROL, V10, P635; Sands JM, 1997, AM J PHYSIOL-RENAL, V273, pF321, DOI 10.1152/ajprenal.1997.273.3.F321; Shayakul C, 1997, AM J PHYSIOL-RENAL, V272, pF654, DOI 10.1152/ajprenal.1997.272.5.F654; Shayakul C, 1996, J CLIN INVEST, V98, P2580, DOI 10.1172/JCI119077; Sidoux-Walter F, 1999, J BIOL CHEM, V274, P30228, DOI 10.1074/jbc.274.42.30228; SMITH CP, 1995, J CLIN INVEST, V96, P1556, DOI 10.1172/JCI118194; Terris JM, 2001, AM J PHYSIOL-RENAL, V280, pF325, DOI 10.1152/ajprenal.2001.280.2.F325; Timmer RT, 2001, AM J PHYSIOL-CELL PH, V281, pC1318, DOI 10.1152/ajpcell.2001.281.4.C1318; Tsukaguchi H, 1997, J CLIN INVEST, V99, P1506, DOI 10.1172/JCI119313; VALTIN H, 1977, AM J PHYSIOL, V233, pF491, DOI 10.1152/ajprenal.1977.233.6.F491; Yang BX, 1998, J BIOL CHEM, V273, P9369, DOI 10.1074/jbc.273.16.9369; Yang BX, 2000, J BIOL CHEM, V275, P2686, DOI 10.1074/jbc.275.4.2686; Yang BX, 2001, J BIOL CHEM, V276, P624, DOI 10.1074/jbc.M008664200	33	159	176	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10633	10637		10.1074/jbc.M200207200	http://dx.doi.org/10.1074/jbc.M200207200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11792714	hybrid			2022-12-27	WOS:000174549200134
J	Celver, J; Vishnivetskiy, SA; Chavkin, C; Gurevich, VV				Celver, J; Vishnivetskiy, SA; Chavkin, C; Gurevich, VV			Conservation of the phosphate-sensitive elements in the arrestin family of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VISUAL ARRESTIN; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; COUPLED RECEPTORS; PHOSPHORYLATION-RECOGNITION; BINDING; RHODOPSIN; MECHANISM; SELECTIVITY; ACTIVATION	Arrestins play a key role in the homologous desensitization of G protein-coupled receptors (GPCRs). These cytosolic proteins selectively bind to the agonist-activated and GPCR kinase-phosphorylated forms of the GPCR, precluding its further interaction with the G protein. Certain mutations in visual arrestin yield "constitutively active" proteins that bind with high affinity to the light-activated form of rhodopsin without requiring phosphorylation. The crystal structure of visual arrestin shows that these activating mutations perturb two groups of intramolecular interactions that keep arrestin in its basal (inactive) state. Here we introduced homologous mutations into arrestin2 and arrestin3 and found that the resulting mutants bind to the beta(2)-adrenoreceptor in vitro in a phosphorylation-independent fashion. The same mutants effectively desensitize both the beta(2)-adrenergic and delta-opioid receptors in the absence of receptor phosphorylation in Xenopus oocytes. Moreover, the arrestin mutants also desensitize the truncated delta-opioid receptor from which the C terminus, containing critical phosphorylation sites, has been removed. Conservation of the phosphate-sensitive hot spots in nonvisual arrestins suggests that the overall fold is similar to that of visual arrestin and that the mechanisms whereby receptor-attached phosphates drive arrestin transition into the active binding competent state are conserved throughout the arrestin family of proteins.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	Vanderbilt University; University of Washington; University of Washington Seattle	Gurevich, VV (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, 221 Kirkland Hall, Nashville, TN 37232 USA.	Vsevolod.Gurevich@mcmail.vanderbilt.edu	Gurevich, Vsevolod/A-3236-2008; Vishnivetskiy, Sergey/AAJ-8661-2020; Chavkin, Charles/G-2797-2010	Gurevich, Vsevolod/0000-0002-3950-5351; 	NEI NIH HHS [EY11500] Funding Source: Medline; NIDA NIH HHS [DA07278, R37 DA011672, DA11672] Funding Source: Medline; NIGMS NIH HHS [GM63097] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063097] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007278, R01DA011672, R37DA011672] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		DONOSO LA, 1990, CURR EYE RES, V9, P343, DOI 10.3109/02713689008999622; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 2000, METHOD ENZYMOL, V315, P422; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; Gurevich VV, 1996, METHOD ENZYMOL, V275, P382; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HAN M, 2001, SCIENCE, V8, P869; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Koch WJ, 2000, ANNU REV PHYSIOL, V62, P237, DOI 10.1146/annurev.physiol.62.1.237; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; Mendez A, 2000, NEURON, V28, P153, DOI 10.1016/S0896-6273(00)00093-3; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; Smith WC, 2000, INVEST OPHTH VIS SCI, V41, P2445; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451	33	96	98	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9043	9048		10.1074/jbc.M107400200	http://dx.doi.org/10.1074/jbc.M107400200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11782458	hybrid			2022-12-27	WOS:000174400600042
J	Pirch, T; Quick, M; Nietschke, M; Langkamp, M; Jung, H				Pirch, T; Quick, M; Nietschke, M; Langkamp, M; Jung, H			Sites important for Na+ and substrate binding in the Na+/proline transporter of Escherichia coli, a member of the Na+/solute symporter family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING SEGMENTS; NA+/GLUCOSE COTRANSPORTER; MELIBIOSE PERMEASE; ACIDIC RESIDUES; PROLINE UPTAKE; PROTEIN; RECONSTITUTION; EXPRESSION; TOPOLOGY; PURIFICATION	To elucidate the functional importance of transmembrane domain 11 in the Na+/proline transporter (PutP) of Escherichia coli we analyzed the effect of replacing Ser-54 through Gly-58. Substitution of Asp-55 or Met-56 dramatically reduces the apparent affinity for Na+ and Li+ in a cation-dependent manner. Conversely, Cys in place of Gly-58 significantly reduces only the apparent proline affinity while substitution of Ser-57 results in a dramatic reduction of the apparent proline and cation affinities. Interestingly, upon increasing the proline concentration the apparent Na+ affinity of Ser-57 replacement mutants converges toward the wild-type value, indicating a close cooperativity between cation and substrate site(s). This notion is supported by the fact that Na+-stimulated site-specific fluorescence labeling of a single Cys at position 57 is completely reversed by the addition of proline. Similar results are obtained upon labeling of a Cys at position 54 or 58. Taken together, these results indicate that Asp-55 and Met-56 are located at or close to the ion-binding site while Ser-54, Ser-57, and Gly-58 may be close to the proline translocation pathway. In addition, the data prod at an involvement of the latter residues in ligand-induced conformational dynamics that are crucial for cation-coupled transport.	Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany	University Osnabruck	Jung, H (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, Barbarastr 11, D-49069 Osnabruck, Germany.		Jung, Heinrich/K-3790-2014	Jung, Heinrich/0000-0002-5450-3063				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Diez-Sampedro A, 2001, J BIOL CHEM, V276, P49188, DOI 10.1074/jbc.M108286200; DILA DK, 1986, J BACTERIOL, V168, P590, DOI 10.1128/jb.168.2.590-594.1986; HANADA K, 1988, J BIOL CHEM, V263, P7181; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; Jung H, 1998, BBA-BIOENERGETICS, V1365, P60, DOI 10.1016/S0005-2728(98)00044-9; Jung H, 1998, J BIOL CHEM, V273, P26400, DOI 10.1074/jbc.273.41.26400; Jung H, 1998, BIOCHEMISTRY-US, V37, P11083, DOI 10.1021/bi980684b; Jung H, 2001, BBA-BIOENERGETICS, V1505, P131, DOI 10.1016/S0005-2728(00)00283-8; Jung H, 2001, MICROBIAL TRANSPORT, P47; Meinild AK, 2001, BIOCHEMISTRY-US, V40, P11897, DOI 10.1021/bi011026l; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Panayotova-Heiermann M, 1999, FEBS LETT, V459, P386, DOI 10.1016/S0014-5793(99)01292-2; PanayotovaHeiermann M, 1997, J BIOL CHEM, V272, P20324, DOI 10.1074/jbc.272.33.20324; PanayotovaHeiermann M, 1996, J BIOL CHEM, V271, P10029, DOI 10.1074/jbc.271.17.10029; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POURCHER T, 1993, J BIOL CHEM, V268, P3209; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; Quick M, 1998, BIOCHEMISTRY-US, V37, P13800, DOI 10.1021/bi980562j; Quick M, 1999, BIOCHEMISTRY-US, V38, P13523, DOI 10.1021/bi991256o; Quick M, 1996, EUR J BIOCHEM, V239, P732, DOI 10.1111/j.1432-1033.1996.0732u.x; Quick M, 1997, BIOCHEMISTRY-US, V36, P4631, DOI 10.1021/bi963063w; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; Riedel C, 2001, TRENDS BIOCHEM SCI, V26, P490, DOI 10.1016/S0968-0004(01)01904-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STALMACH ME, 1983, J BACTERIOL, V156, P481, DOI 10.1128/JB.156.2.481-486.1983; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; Wegener C, 2000, BIOCHEMISTRY-US, V39, P4831, DOI 10.1021/bi992442x; Wilson TH, 2001, BBA-BIOENERGETICS, V1505, P121, DOI 10.1016/S0005-2728(00)00282-6; Wright EM, 1998, AM J PHYSIOL-GASTR L, V275, pG879, DOI 10.1152/ajpgi.1998.275.5.G879; Wright EM, 2001, AM J PHYSIOL-RENAL, V280, pF10, DOI 10.1152/ajprenal.2001.280.1.F10; ZANI ML, 1993, J BIOL CHEM, V268, P3216	34	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8790	8796		10.1074/jbc.M111008200	http://dx.doi.org/10.1074/jbc.M111008200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11756453	hybrid			2022-12-27	WOS:000174400600007
J	Garnier, C; Lafitte, D; Tsvetkov, PO; Barbier, P; Leclerc-Devin, J; Millot, JM; Briand, C; Makarov, AA; Catelli, MG; Peyrot, V				Garnier, C; Lafitte, D; Tsvetkov, PO; Barbier, P; Leclerc-Devin, J; Millot, JM; Briand, C; Makarov, AA; Catelli, MG; Peyrot, V			Binding of ATP to heat shock protein 90 - Evidence for an ATP-binding site in the C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE PREDICTION; HSP90 MOLECULAR CHAPERONE; IN-VIVO; CRYSTAL-STRUCTURE; NEURAL NETWORKS; GELDANAMYCIN; DIMERIZATION; INFORMATION; MECHANISM; MAGNESIUM	The presence of a nucleotide binding site on hsp90 was very controversial until x-ray structure of the hsp90 N-terminal domain, showing a nonconventional nucleotide binding site, appeared. A recent study suggested that the hsp90 C-terminal domain also binds ATP (Marcu, M. G., Chadli, A., Bouhouche, L, Catelli, M. G., and Neckers, L. M. (2000) J. Biol. Chem. 275, 3718137186). In this paper, the interactions of ATP with native hsp90 and its recombinant N-terminal (positions 1-221) and C-terminal (positions 446-728) domains were studied by isothermal titration calorimetry, scanning differential calorimetry, and fluorescence spectroscopy. Results clearly demonstrate that hsp90 possesses a second ATP-binding site located on the C-terminal part of the protein. The association constant between this domain of hsp90 and ATP-Mg and a comparison with the binding constant on the full-length protein are reported for the first time. Secondary structure prediction revealed motifs compatible with a Rossmann fold in the C-terminal part of hsp90. It is proposed that this potential Rossmann fold may constitute the C-terminal ATP-binding site. This work also suggests allosteric interaction between N- and C-terminal domains of hsp90.	Fac Pharm Marseille, UMR CNRS 6032, F-13385 Marseille 5, France; ICGM, CNRS, UPR 1524, F-75014 Paris, France; Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia; Fac Pharm, Lab Spectroscopie Biomol, F-51096 Reims, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Universite de Reims Champagne-Ardenne	Peyrot, V (corresponding author), Fac Pharm Marseille, UMR CNRS 6032, 27 Blvd Jean Moulin, F-13385 Marseille 5, France.		Barbier, Pascale/AAE-1781-2019; peyrot, vincent/B-6365-2015; Makarov, Alexander/P-5279-2016	lafitte, daniel/0000-0001-9921-7522; GARNIER, Cyrille/0000-0002-5715-8218				Barbier P, 1995, BIOCHEMISTRY-US, V34, P16821, DOI 10.1021/bi00051a033; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; CALLEBAUT I, 1994, CR ACAD SCI III-VIE, V317, P721; Chadli A, 1999, J BIOL CHEM, V274, P4133, DOI 10.1074/jbc.274.7.4133; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; Garnier C, 1998, BIOCHEM BIOPH RES CO, V249, P197, DOI 10.1006/bbrc.1998.9108; Garnier C, 2001, EUR J BIOCHEM, V268, P2402, DOI 10.1046/j.1432-1327.2001.02121.x; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; HAALAND DM, 1988, ANAL CHEM, V60, P1193, DOI 10.1021/ac00162a020; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; MCCLELLAND JL, 1988, EXPLORATIONS PARALLE, V3, P318; Meng X, 1996, J CELL SCI, V109, P1677; MILLOT JM, 1994, ANAL CHIM ACTA, V295, P233, DOI 10.1016/0003-2670(94)80228-9; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; MINTON AP, 1994, MODERN ANAL ULTRACEN, P119; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; Nemoto T, 1998, BIOCHEM J, V330, P989, DOI 10.1042/bj3300989; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Ponomarev MA, 2000, BIOCHEMISTRY-US, V39, P4527, DOI 10.1021/bi992420a; Privalov P L, 1986, Methods Enzymol, V131, P4; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200; ROMANI A, 1992, ARCH BIOCHEM BIOPHYS, V298, P1, DOI 10.1016/0003-9861(92)90086-C; ROST B, 1995, PROTEINS, V23, P295, DOI 10.1002/prot.340230304; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1994, PROTEINS, V20, P216, DOI 10.1002/prot.340200303; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; Scheibel T, 1999, MOL MICROBIOL, V34, P701, DOI 10.1046/j.1365-2958.1999.01632.x; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Soga S, 1998, J BIOL CHEM, V273, P822, DOI 10.1074/jbc.273.2.822; Stafford WF, 1994, MODERN ANAL ULTRACEN, P119; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Weikl T, 2000, J MOL BIOL, V303, P583, DOI 10.1006/jmbi.2000.4157; YONEZAWA N, 1988, EUR J BIOCHEM, V177, P1, DOI 10.1111/j.1432-1033.1988.tb14337.x; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; [No title captured]	44	130	134	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12208	12214		10.1074/jbc.M111874200	http://dx.doi.org/10.1074/jbc.M111874200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805114	hybrid			2022-12-27	WOS:000174846400079
J	Birbach, A; Gold, P; Binder, BR; Hofer, E; de Martin, R; Schmid, JA				Birbach, A; Gold, P; Binder, BR; Hofer, E; de Martin, R; Schmid, JA			Signaling molecules of the NF-kappa B pathway shuttle constitutively between cytoplasm and nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPORT SIGNAL; IKK-ALPHA; TRANSCRIPTION FACTORS; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; CYCLIN D1; ACTIVATION; KINASE; LOCALIZATION; EXPRESSION	We aimed to investigate the dynamics of the NF-kappaB signaling pathway in living cells using GFP variants of p65-NF-kappaB, IkappaBalpha, tumor necrosis factor-receptor associated factor 2 (TRAF2), the NF-kappaB inducing kinase (NIK) and IkappaB kinases (IKK1 and IKK2). Detailed kinetic analysis of constitutive nucleocytoplasmic shuttling processes revealed that IkappaBalpha enters the nucleus faster than p65. Examination of signaling molecules upstream of NF-kappaB and IkappaBalpha revealed a predominant cytoplasmic localization at steady state. However, after addition of leptomycin B, NIK rapidly accumulated in the nucleus, whereas we could not detect any significant effect on TRAF2 or IKK2. Using various truncation mutants of NIK, we identified a functional nuclear export signal within the COOH-terminal region 795-805, which counteracts the inherent NLS at amino acids 143-149. Prolonged incubation in the presence of LMB also leads to nuclear accumulation of IKK1, which was dependent on a lysine residue at position 44, which is also essential for kinase activity. Investigation of endogenous protein levels by immunofluorescence staining and Western blots verified the results obtained with GFP chimeras. We conclude that NF-kappaB(.)IkappaB complexes and the upstream signaling kinases NIK and IKK1 shuttle between cytoplasm and nucleus of nonactivated cells and that this process leads to a basal transcriptional activity of NF-kappaB.	Univ Vienna, Dept Vasc Biol & Thrombosis Res, A-1235 Vienna, Austria; Competence Ctr Biomol Therapeut, A-1235 Vienna, Austria	University of Vienna	Schmid, JA (corresponding author), Brunnerstr 59, A-1235 Vienna, Austria.		Schmid, Johannes A./C-7659-2009	Schmid, Johannes A./0000-0002-6586-3507				ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83; de Martin R, 1999, MUTAT RES-REV MUTAT, V437, P231, DOI 10.1016/S1383-5742(99)00089-7; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Oitzinger W, 2001, BLOOD, V97, P1611, DOI 10.1182/blood.V97.6.1611; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; Renard P, 2000, J BIOL CHEM, V275, P15193, DOI 10.1074/jbc.275.20.15193; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Schmid JA, 2000, J BIOL CHEM, V275, P17035, DOI 10.1074/jbc.M000291200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yamamoto Y, 2000, MOL CELL BIOL, V20, P3655, DOI 10.1128/MCB.20.10.3655-3666.2000; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yang JM, 2001, CANCER RES, V61, P4901; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697	45	245	258	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10842	10851		10.1074/jbc.M112475200	http://dx.doi.org/10.1074/jbc.M112475200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801607	hybrid			2022-12-27	WOS:000174613100014
J	Krogan, NJ; Dover, J; Khorrami, S; Greenblatt, JF; Schneider, J; Johnston, M; Shilatifard, A				Krogan, NJ; Dover, J; Khorrami, S; Greenblatt, JF; Schneider, J; Johnston, M; Shilatifard, A			COMPASS, a histone H3 (lysine 4) methyltransferase required for telomeric silencing of gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; REPRESS TRANSCRIPTION; DOMAIN PROTEINS; TRITHORAX; CHROMATIN; REGION	The trithorax (Trx) family of proteins is required for maintaining a specific pattern of gene expression in some organisms. Recently we reported the isolation and characterization of COMPASS, a multiprotein complex that includes the Trx-related protein Set1of the yeast Saccharomyces cerevisiae. Here we report that COMPASS catalyzes methylation of the fourth lysine of histone H3 in vitro. Setl and several other components of COMPASS are also required for histone H3 methylation in vivo and for transcriptional silencing of a gene located near a chromosome telomere.	St Louis Univ, Sch Med, Dept Biochem, St Louis, MO 63104 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Univ Toronto, Banting & Best Dept Med Res, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada	Saint Louis University; Washington University (WUSTL); University of Toronto	Shilatifard, A (corresponding author), St Louis Univ, Sch Med, Dept Biochem, 1402 S Grand Blvd, St Louis, MO 63104 USA.		Johnston, Mark/K-3543-2019; Johnston, Mark/R-6156-2019	Johnston, Mark/0000-0002-4932-7229; 	NATIONAL CANCER INSTITUTE [R01CA089455] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA089455] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berger SL, 2001, ONCOGENE, V20, P3007, DOI 10.1038/sj.onc.1204324; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Corda Y, 1999, NAT GENET, V21, P204, DOI 10.1038/5991; de la Barre AE, 2000, EMBO J, V19, P379, DOI 10.1093/emboj/19.3.379; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; Horita DA, 2001, J MOL BIOL, V307, P861, DOI 10.1006/jmbi.2001.4515; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; STASSEN MJ, 1995, MECH DEVELOP, V52, P209, DOI 10.1016/0925-4773(95)00402-M; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Thon G, 2000, GENETICS, V155, P551; THON G, 1994, GENETICS, V138, P29; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Urnov FD, 2001, ONCOGENE, V20, P2991, DOI 10.1038/sj.onc.1204323; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	29	316	327	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10753	10755		10.1074/jbc.C200023200	http://dx.doi.org/10.1074/jbc.C200023200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11805083	hybrid			2022-12-27	WOS:000174613100002
J	Clarkson, MR; Murphy, M; Gupta, S; Lambe, T; Mackenzie, HS; Godson, C; Martin, F; Brady, HR				Clarkson, MR; Murphy, M; Gupta, S; Lambe, T; Mackenzie, HS; Godson, C; Martin, F; Brady, HR			High glucose-altered gene expression in mesangial cells - Actin-regulatory protein gene expression is triggered by oxidative stress and cytoskeletal disassembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; LYSYL OXIDASE; P38 MAPK; TGF-BETA; PROFILIN; KINASE; FIBRONECTIN; GTPASE	High extracellular glucose plays a pivotal role in the pathophysiology of diabetic nephropathy. Here we report 200 genes, identified using suppression-subtractive hybridization, that are differentially expressed when human mesangial cells are propagated in high ambient glucose in vitro. The major functional classes of genes identified included modulators and products of extracellular matrix protein metabolism, regulators of cell growth and turnover, and a cohort of actin cytoskeleton regulatory proteins. Actin cytoskeletal disassembly is a prominent feature of diabetic nephropathy. The induction of actin cytoskeleton regulatory gene expression by high glucose was attenuated by the inhibitor of reactive oxygen species generation, carbonyl cyanide m-chlorophenylhydrazone but not by the protein kinase C inhibitor GF 109203X and was not mimicked by the addition of transforming growth factor beta. Enhanced expression of actin cytoskeleton regulatory genes was also observed following disruption of the mesangial cell actin cytoskeleton by cytochalasin D. In aggregate, these results suggest that the induction of genes encoding actin cytoskeleton regulatory proteins (a) is a prominent component of the mesangial cell transcriptomic response in diabetic nephropathy and (b) is dependent on oxidative stress, is independent of protein kinase C and transforming growth factor-beta, and represents an adaptive response to actin cytoskeleton disassembly.	Univ Coll Dublin, Mater Misericordiae Hosp, Dept Med & Therapeut, Dublin 7, Ireland; Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dept Pharmacol, Dublin 4, Ireland; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; Dublin Mol Med Ctr, Dublin 7, Ireland	Mater Misericordiae University Hospital; University College Dublin; University College Dublin; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Trinity College Dublin; University College Dublin	Brady, HR (corresponding author), Univ Coll Dublin, Mater Misericordiae Hosp, Dept Med & Therapeut, 41 Eccles St, Dublin 7, Ireland.	hrbrady@mater.ie	Lambe, Teresa/E-5733-2016	Lambe, Teresa/0000-0001-7711-897X				AYO SH, 1990, AM J PATHOL, V136, P1339; AYO SH, 1991, AM J PHYSIOL, V261, pF571, DOI 10.1152/ajprenal.1991.261.4.F571; Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; Blanchoin L, 2000, CURR BIOL, V10, P1273, DOI 10.1016/S0960-9822(00)00749-1; BRADY HR, 1992, KIDNEY INT, V42, P480, DOI 10.1038/ki.1992.312; Cortes P, 2000, KIDNEY INT, V58, P2452, DOI 10.1046/j.1523-1755.2000.00428.x; COUNTS DF, 1981, J PHARMACOL EXP THER, V219, P675; DIXON AJ, 1980, J CLIN PATHOL, V33, P1021, DOI 10.1136/jcp.33.11.1021; Essawy M, 1997, NEPHROL DIAL TRANSPL, V12, P43, DOI 10.1093/ndt/12.1.43; Freeman NL, 1996, MOL CELL BIOL, V16, P548; Ha HJ, 2000, KIDNEY INT, V58, pS19, DOI 10.1046/j.1523-1755.2000.07704.x; Ha HJ, 1999, FREE RADICAL BIO MED, V26, P944, DOI 10.1016/S0891-5849(98)00276-7; Hahn A, 2000, J BIOL CHEM, V275, P37429, DOI 10.1074/jbc.M000976200; HANSCH GM, 1995, J CELL PHYSIOL, V163, P451, DOI 10.1002/jcp.1041630304; Hoffman BB, 1998, MINER ELECTROL METAB, V24, P190, DOI 10.1159/000057369; Hu ED, 2001, EXP NEPHROL, V9, P265; KAGAN HM, 1994, PATHOL RES PRACT, V190, P910; Kang SW, 2001, KIDNEY INT, V60, P543, DOI 10.1046/j.1523-1755.2001.060002543.x; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; KREISBERG JI, 1994, KIDNEY INT, V46, P1019, DOI 10.1038/ki.1994.362; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P5910; Lazarus HM, 1995, MATRIX BIOL, V14, P727, DOI 10.1016/S0945-053X(05)80015-0; McLennan SV, 1998, NEPHRON, V79, P293, DOI 10.1159/000045052; McMahon R, 2000, J BIOL CHEM, V275, P9901, DOI 10.1074/jbc.275.14.9901; Morris MC, 2000, J BIOL CHEM, V275, P28849, DOI 10.1074/jbc.M002942200; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; NAKAMURA T, 1994, RENAL PHYSIOL BIOCH, V17, P316; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; PARVING HH, 1996, BRENNER RECTORS KIDN, P1864; Randazzo PA, 2000, P NATL ACAD SCI USA, V97, P4011, DOI 10.1073/pnas.070552297; Roth D, 1999, FEBS LETT, V460, P411, DOI 10.1016/S0014-5793(99)01383-6; SCHOR N, 1981, KIDNEY INT, V20, P442, DOI 10.1038/ki.1981.160; SOHN RH, 1994, BIOESSAYS, V16, P465, DOI 10.1002/bies.950160705; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Stevenson VA, 2000, CURR BIOL, V10, pR695, DOI 10.1016/S0960-9822(00)00712-0; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; Taal MW, 2000, KIDNEY INT, V58, P1664, DOI 10.1046/j.1523-1755.2000.00327.x; Tamura M, 2000, J AM SOC NEPHROL, V11, P423, DOI 10.1681/ASN.V113423; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; *USRDS, 1999, AM J KIDNEY DIS S, V34, pS40; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Wilmer WA, 2001, KIDNEY INT, V60, P858, DOI 10.1046/j.1523-1755.2001.060003858.x; Wolf G, 2000, KIDNEY INT, V58, pS59, DOI 10.1046/j.1523-1755.2000.07710.x; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; ZHOU XP, 1995, LAB INVEST, V73, P372	45	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9707	9712		10.1074/jbc.M109172200	http://dx.doi.org/10.1074/jbc.M109172200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11784718	hybrid			2022-12-27	WOS:000174549200016
J	Kaur, J; Cutler, DF				Kaur, J; Cutler, DF			P-selectin targeting to secretory lysosomes of Rbl-2H3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE MEMBRANE-PROTEIN; WEIBEL-PALADE BODIES; CYTOPLASMIC DOMAIN; REGULATED SECRETION; ENDOTHELIAL-CELLS; PLASMA-MEMBRANE; PC12 CELLS; MAST-CELLS; DI-LEUCINE; MULTIVESICULAR BODIES	The biogenesis of secretory lysosomes, which combine characteristics of both lysosomes and secretory granules, is currently of high interest. In particular, it is not clear whether delivery of membrane proteins to the secretory lysosome requires lysosomal, secretory granule, or some novel targeting determinants. Heterologous expression of P-selectin has established that this membrane protein contains targeting signals for both secretory granules and lysosomes. P-selectin is therefore an ideal probe with which to determine the signals required for targeting to secretory lysosomes. We have exploited subcellular fractionation and immunofluorescence microscopy to monitor targeting of transiently expressed wild-type and mutant horseradish peroxidase (HRP)-P-selectin chimeras to secretory lysosomes of Rb1-2H3 cells. The exposure of the HRP chimeras to intracellular proteolysis was also determined as a third monitor of secretory lysosome targeting. Our data show that HRP-P-selectin accumulates in secretory lysosomes of Rb1-2H3 cells using those cytoplasmic sequences previously found to be sufficient for targeting to conventional lysosomes. This work highlights the similar sorting signals used for targeting of membrane proteins to conventional lysosomes and secretory lysosomes.	UCL, MRC Lab Mol Cell Biol, Cell Biol Unit, London WC1E 6BT, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	MRC Laboratory Molecular Biology; University of London; University College London; University of London; University College London	Cutler, DF (corresponding author), UCL, MRC Lab Mol Cell Biol, Cell Biol Unit, Gower St, London WC1E 6BT, England.	d.cutler@ucl.ac.uk		Cutler, Daniel/0000-0002-4288-7530				Andrews NW, 2000, TRENDS CELL BIOL, V10, P316, DOI 10.1016/S0962-8924(00)01794-3; Arribas M, 2000, TRAFFIC, V1, P783, DOI 10.1034/j.1600-0854.2000.011005.x; Baldassarre M, 2000, J CELL SCI, V113, P741; Baram D, 1999, J EXP MED, V189, P1649, DOI 10.1084/jem.189.10.1649; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; Blagoveshchenskaya AD, 1999, MOL BIOL CELL, V10, P3979, DOI 10.1091/mbc.10.11.3979; Blagoveshchenskaya AD, 2000, MOL BIOL CELL, V11, P1801, DOI 10.1091/mbc.11.5.1801; Blagoveshchenskaya AD, 1998, J BIOL CHEM, V273, P2729, DOI 10.1074/jbc.273.5.2729; Blagoveshchenskaya AD, 1999, J CELL BIOL, V145, P1419, DOI 10.1083/jcb.145.7.1419; Blagoveshchenskaya AD, 2000, METHOD ENZYMOL, V327, P45, DOI 10.1016/S0076-6879(00)27266-2; Blagoveshchenskaya AD, 1998, J BIOL CHEM, V273, P27896, DOI 10.1074/jbc.273.43.27896; BONFANTI R, 1989, BLOOD, V73, P1109; BONIFACINO JS, 1989, J CELL SCI, V92, P701; Bossi G, 1999, NAT MED, V5, P90, DOI 10.1038/4779; Calvo PA, 1999, J BIOL CHEM, V274, P12780, DOI 10.1074/jbc.274.18.12780; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; Detter JC, 2000, P NATL ACAD SCI USA, V97, P4144, DOI 10.1073/pnas.080517697; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; Dragonetti A, 2000, J CELL SCI, V113, P3289; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; Griffiths GM, 1996, TRENDS CELL BIOL, V6, P329, DOI 10.1016/0962-8924(96)20031-5; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; Hartwell DM, 1998, J CELL BIOL, V143, P1129, DOI 10.1083/jcb.143.4.1129; Heijnen HFG, 1998, BLOOD, V91, P2313, DOI 10.1182/blood.V91.7.2313.2313_2313_2325; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Israels SJ, 1996, THROMB HAEMOSTASIS, V75, P623; ISRAELS SJ, 1992, BLOOD, V80, P143; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; MASTERSON WJ, 1992, PROTEIN TARGETING PR, P242; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; Modderman PW, 1998, BIOCHEM J, V336, P153, DOI 10.1042/bj3360153; NISHIBORI M, 1993, J CLIN INVEST, V91, P1775, DOI 10.1172/JCI116388; Norcott JP, 1996, J CELL BIOL, V134, P1229, DOI 10.1083/jcb.134.5.1229; Pastural E, 1997, NAT GENET, V16, P289, DOI 10.1038/ng0797-289; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; SETIADI H, 1995, J BIOL CHEM, V270, P26818, DOI 10.1074/jbc.270.45.26818; Simmen T, 1999, J CELL SCI, V112, P45; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; Stinchcombe JC, 1999, J CELL BIOL, V147, P1, DOI 10.1083/jcb.147.1.1; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Straley KS, 1998, MOL BIOL CELL, V9, P1683, DOI 10.1091/mbc.9.7.1683; VIJAYASARADHI S, 1995, J CELL BIOL, V130, P807, DOI 10.1083/jcb.130.4.807; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Xu K, 1998, J CELL SCI, V111, P2385; Youssefian T, 2000, BLOOD, V95, P4004, DOI 10.1182/blood.V95.12.4004.010k03_4004_4007	46	10	10	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10498	10505		10.1074/jbc.M111293200	http://dx.doi.org/10.1074/jbc.M111293200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11788597	hybrid			2022-12-27	WOS:000174549200118
J	Roger, B; Moisand, A; Amalric, F; Bouvet, P				Roger, B; Moisand, A; Amalric, F; Bouvet, P			Repression of RNA polymerase I transcription by nucleolin is independent of the RNA sequence that is transcribed	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOMA ASCITES-CELLS; RIBOSOMAL-RNA; DNA-BINDING; PROTEINS; LOCALIZATION; PHOSPHORYLATION; TERMINATION; SPACER; IDENTIFICATION; VISUALIZATION	Nucleolin is one of the most abundant non-ribosomal proteins of the nucleolus. Several studies in vitro have shown that nucleolin is involved in several steps of ribosome biogenesis, including the regulation of rDNA transcription, rRNA processing, and ribosome assembly. However, the different steps of ribosome biogenesis are highly coordinated, and therefore it is not clear to what extent nucleolin is involved in each of these steps. It has been proposed that the interaction of nucleolin with the rDNA sequence and with nascent pre-rRNA leads to the blocking of RNA polymerase I (RNA pot I) transcription. To test this model and to get molecular insights into the role of nucleolin in RNA pot I transcription, we studied the function of nucleolin in Xenopus oocytes. We show that injection of a 2-4-fold excess of Xenopus or hamster nucleolin in stage VI Xenopus oocytes reduces the accumulation of 40 S pre-rRNA 3-fold, whereas transcription by RNA polymerase II and III is not affected. Direct analysis of rDNA transcription units by electron microscopy reveals that the number of polymerase complexes/ rDNA unit is drastically reduced in the presence of increased amounts of nucleolin and corresponds to the level of reduction of 40 S pre-rRNA. Transcription from DNA templates containing various combinations of RNA polymerase I or II promoters in fusion with rDNA or CAT sequences was analyzed in the presence of elevated amounts of nucleolin. It was shown that nucleolin leads to transcription repression from a minimal polymerase I promoter, independently of the nature of the RNA sequence that is transcribed. Therefore, we propose that nucleolin affects RNA pot I transcription by acting directly on the transcription machinery or on the rDNA promoter sequences and not, as previously thought, through interaction with the nascent pre-rRNA.	Ecole Normale Super Lyon, CNRS, UMR 5665, Mol & Cellular Biol Lab, F-69364 Lyon, France; CNRS, UMR 5089, Lab Pharmacol & Biol Struct, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Bouvet, P (corresponding author), Ecole Normale Super Lyon, CNRS, UMR 5665, Mol & Cellular Biol Lab, 46 Allee Italie, F-69364 Lyon, France.	pbouvet@ens-lyon.fr	, Bouvet/AAC-8779-2020	Bouvet, Philippe/0000-0003-4524-2233				Abadia-Molina F, 1998, BIOL CELL, V90, P355, DOI 10.1016/S0248-4900(98)80016-6; Allain FHT, 2000, EMBO J, V19, P6870, DOI 10.1093/emboj/19.24.6870; BELL SP, 1989, CELL, V59, P489, DOI 10.1016/0092-8674(89)90032-9; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; Bouvet P, 1998, J BIOL CHEM, V273, P19025, DOI 10.1074/jbc.273.30.19025; BUGLER B, 1982, EUR J BIOCHEM, V128, P475; Busch H, 1997, J TUMOR MARKER ONCOL, V12, P5; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CHOOI WY, 1981, P NATL ACAD SCI-BIOL, V78, P4823, DOI 10.1073/pnas.78.8.4823; COPENHAVER GP, 1994, NUCLEIC ACIDS RES, V22, P2651, DOI 10.1093/nar/22.13.2651; DEWINTER RFJ, 1987, J MOL BIOL, V196, P813, DOI 10.1016/0022-2836(87)90407-4; DEWINTER RFJ, 1986, CELL, V44, P313, DOI 10.1016/0092-8674(86)90765-8; EGYHAZI E, 1988, EXP CELL RES, V178, P264, DOI 10.1016/0014-4827(88)90397-7; ERARD M, 1990, EUR J BIOCHEM, V191, P19, DOI 10.1111/j.1432-1033.1990.tb19088.x; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; EVERS R, 1995, EMBO J, V14, P1248, DOI 10.1002/j.1460-2075.1995.tb07108.x; FIREK S, 1989, MOL CELL BIOL, V9, P3777, DOI 10.1128/MCB.9.9.3777; GALL JG, 1991, METHOD CELL BIOL, V36, P149; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Ginisty H, 1999, J CELL SCI, V112, P761; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; GRUMMT I, 1986, CELL, V45, P837, DOI 10.1016/0092-8674(86)90558-1; GRUMMT I, 1986, CELL, V47, P901, DOI 10.1016/0092-8674(86)90805-6; Hadjiolov A.A., 1985, CELL BIOL MONOGRAPHS, V12; HARLAND R, 1988, DEVELOPMENT, V102, P837; HENDERSON SL, 1989, GENE DEV, V3, P212, DOI 10.1101/gad.3.2.212; Henras A, 1998, EMBO J, V17, P7078, DOI 10.1093/emboj/17.23.7078; HERNANDEZVERDUN D, 1991, J CELL SCI, V99, P465; HU CH, 1994, MOL CELL BIOL, V14, P2871, DOI 10.1128/MCB.14.5.2871; JORDAN G, 1987, NATURE, V329, P489, DOI 10.1038/329489a0; Langst G, 1997, NUCLEIC ACIDS RES, V25, P511, DOI 10.1093/nar/25.3.511; Langst G, 1997, EMBO J, V16, P760, DOI 10.1093/emboj/16.4.760; Langst G, 1998, EMBO J, V17, P3135, DOI 10.1093/emboj/17.11.3135; MAHAJAN PB, 1991, MOL CELL BIOCHEM, V104, P195; Mason SW, 1997, EMBO J, V16, P163, DOI 10.1093/emboj/16.1.163; MCSTAY B, 1986, CELL, V47, P913, DOI 10.1016/0092-8674(86)90806-8; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; MILLER OL, 1969, SCIENCE, V164, P955, DOI 10.1126/science.164.3882.955; MOSS T, 1983, NATURE, V302, P223, DOI 10.1038/302223a0; MOUGEY EB, 1993, GENE DEV, V7, P1609, DOI 10.1101/gad.7.8.1609; Mougey EB, 1996, J BIOL CHEM, V271, P27138, DOI 10.1074/jbc.271.43.27138; OLSON MOJ, 1983, BIOCHEMISTRY-US, V22, P3345, DOI 10.1021/bi00283a007; OLSON MOJ, 1975, J MOL BIOL, V97, P611, DOI 10.1016/S0022-2836(75)80062-3; OLSON MOJ, 1983, BIOCHEMISTRY-US, V22, P3187, DOI 10.1021/bi00282a023; ORRICK LR, 1973, P NATL ACAD SCI USA, V70, P1316, DOI 10.1073/pnas.70.5.1316; Osheim YN, 1998, METHOD CELL BIOL, V53, P471; Osheim YN, 1996, J CELL BIOL, V133, P943, DOI 10.1083/jcb.133.5.943; Pinol-Roma S, 1999, MOL BIOL CELL, V10, P77, DOI 10.1091/mbc.10.1.77; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; SAPP M, 1986, NUCLEIC ACIDS RES, V14, P6803, DOI 10.1093/nar/14.17.6803; Scheer U, 1999, CURR OPIN CELL BIOL, V11, P385, DOI 10.1016/S0955-0674(99)80054-4; SCHEER U, 1990, BIOESSAYS, V12, P14, DOI 10.1002/bies.950120104; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; Schulz M, 2001, BIOCHEM BIOPH RES CO, V280, P476, DOI 10.1006/bbrc.2000.4141; Serin G, 1996, BIOCHIMIE, V78, P530, DOI 10.1016/0300-9084(96)84759-6; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; SIPOS K, 1991, BIOCHEM BIOPH RES CO, V177, P673, DOI 10.1016/0006-291X(91)91841-Y; SMID A, 1992, J MOL BIOL, V227, P635, DOI 10.1016/0022-2836(92)90213-4; SUZUKI N, 1991, BIOCHIM BIOPHYS ACTA, V1092, P367, DOI 10.1016/S0167-4889(97)90014-8; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wool I. G., 1996, TRANSLATIONAL CONTRO, P685; [No title captured]	65	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10209	10219		10.1074/jbc.M106412200	http://dx.doi.org/10.1074/jbc.M106412200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11773064	Green Published, hybrid			2022-12-27	WOS:000174549200081
J	Wang, CY; Yang, F; He, XP; Je, HS; Zhou, JZ; Eckermann, K; Kawamura, D; Feng, L; Shen, L; Lu, B				Wang, CY; Yang, F; He, XP; Je, HS; Zhou, JZ; Eckermann, K; Kawamura, D; Feng, L; Shen, L; Lu, B			Regulation of neuromuscular synapse development by glial cell line-derived neurotrophic factor and neurturin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE-MUSCLE INTERACTIONS; GDNF-FAMILY; DEVELOPING MOTONEURONS; TRANSMITTER RELEASE; QUANTAL SECRETION; FINE-STRUCTURE; MOTOR-NEURONS; RECEPTOR; TRANSMISSION; POTENTIATION	Glial cell line-derived neurotrophic factor (GDNF) is known for its potent effect on neuronal survival, but its role in the development and function of synapses is not well studied. Using Xenopus nerve-muscle co-cultures, we show that GDNF and its family member neurturin (NRTN) facilitate the development of the neuromuscular junction (NMJ). Long-term application of GDNF significantly increased the total length of neurites in the motoncurons. GDNF also caused an increase in the number and the size of synaptic vesicle clustering, as demonstrated by synaptobrevin-GFP fluorescent imaging, and FM dye staining. Electrophysiological experiments revealed two effects of GDNF on synaptic transmission at NMJ. First, GDN-F markedly increased the frequency of spontaneous transmission and decreased the variability of evoked transmission, suggesting an enhancement of transmitter secretion. Second, GDNF elicited a small increase in the quantal size, without affecting the average rise and decay times of synaptic currents. Imaging analysis showed that the size of acetylcholine receptor clusters at synapses increased in muscle cells overexpressing GDNF. Neurturin had very similar effects as GDNF. These results suggest that GDNF and NRTN are new neuromodulators that regulate the development of the neuromuscular synapse through both pre- and postsynaptic mechanisms.	NICHHD, NIH, Unit Synapse Dev & Plast, Washington, DC 20052 USA; George Washington Univ, Grad Program Genet, Washington, DC 20052 USA; NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; Chinese Acad Sci, Inst Neurosci, Shanghai 200031, Peoples R China	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); George Washington University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Chinese Academy of Sciences	Lu, B (corresponding author), NICHHD, NIH, Unit Synapse Dev & Plast, Bldg 49,Rm 6A-80,49 Convent Dr,MSC4480, Washington, DC 20052 USA.	lub@codon.nih.gov	Lu, Bai/A-4018-2012; Je, Shawn/AHC-0995-2022; Yang, Feng/C-9530-2011	Yang, Feng/0000-0003-1275-6641; Je, hyunsoo/0000-0002-2924-5621; Lu, Bai/0000-0001-5418-9759	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000714] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ahmari SE, 2000, NAT NEUROSCI, V3, P445, DOI 10.1038/74814; Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; Bilak MM, 1999, MOL CELL NEUROSCI, V13, P326, DOI 10.1006/mcne.1999.0756; BUCHANAN J, 1989, J NEUROSCI, V9, P1540; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; EVERS J, 1989, J NEUROSCI, V9, P1523; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Garces A, 2000, J NEUROSCI, V20, P4992; Golden JP, 1999, EXP NEUROL, V158, P504, DOI 10.1006/exnr.1999.7127; Gonzalez M, 1999, NEURON, V24, P567, DOI 10.1016/S0896-6273(00)81113-7; He XP, 2000, J CELL BIOL, V149, P783, DOI 10.1083/jcb.149.4.783; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Ho TW, 2000, EXP NEUROL, V161, P664, DOI 10.1006/exnr.1999.7290; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; KELLY AM, 1969, J CELL BIOL, V42, P154, DOI 10.1083/jcb.42.1.154; KIDOKORO Y, 1984, Neuroscience Research, V1, P157, DOI 10.1016/S0168-0102(84)80013-9; KIDOKORO Y, 1980, DEV BIOL, V78, P464, DOI 10.1016/0012-1606(80)90347-4; KIM HG, 1994, P NATL ACAD SCI USA, V91, P12341, DOI 10.1073/pnas.91.25.12341; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; KULLBERG RW, 1977, DEV BIOL, V60, P101, DOI 10.1016/0012-1606(77)90113-0; Leitner ML, 1999, J NEUROSCI, V19, P9322; LESSMANN V, 1994, NEUROREPORT, V6, P21; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Liou JC, 1997, J PHYSIOL-LONDON, V503, P129, DOI 10.1111/j.1469-7793.1997.129bi.x; Liou JC, 1997, J NEUROSCI, V17, P2459; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; LU B, 1993, NATURE, V363, P76, DOI 10.1038/363076a0; Lu B, 1999, J NEUROSCI RES, V58, P76, DOI 10.1002/(SICI)1097-4547(19991001)58:1<76::AID-JNR8>3.0.CO;2-0; LU B, 1992, NEURON, V8, P521, DOI 10.1016/0896-6273(92)90280-Q; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Mikaels A, 2000, EUR J NEUROSCI, V12, P446, DOI 10.1046/j.1460-9568.2000.00924.x; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; NAKAJIMA Y, 1980, DEV BIOL, V77, P52, DOI 10.1016/0012-1606(80)90456-X; Nguyen QT, 1998, SCIENCE, V279, P1725, DOI 10.1126/science.279.5357.1725; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; Oppenheim RW, 2000, J NEUROSCI, V20, P5001; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; PENG HB, 1982, J NEUROSCI, V2, P1760; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Ribchester RR, 1998, J PHYSIOL-LONDON, V512, P635, DOI 10.1111/j.1469-7793.1998.635bd.x; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; Soler RM, 1999, J NEUROSCI, V19, P9160; Stoop R, 1996, J NEUROSCI, V16, P3256; STOOP R, 1995, SCIENCE, V267, P695, DOI 10.1126/science.7839148; TAKAHASHI T, 1987, J NEUROSCI, V7, P473; Takei N, 1997, J NEUROCHEM, V68, P370; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Wang CY, 2001, NEURON, V32, P99, DOI 10.1016/S0896-6273(01)00434-2; WANG T, 1995, J NEUROSCI, V15, P4796; Wang XH, 1998, J NEUROSCI, V18, P4985; Wang XH, 1997, NEURON, V19, P825, DOI 10.1016/S0896-6273(00)80964-2; Widenfalk J, 1997, J NEUROSCI, V17, P8506; Xie KW, 1997, J NEUROSCI, V17, P2947; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; Yang F, 2001, NAT NEUROSCI, V4, P19, DOI 10.1038/82858; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	69	68	71	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10614	10625		10.1074/jbc.M106116200	http://dx.doi.org/10.1074/jbc.M106116200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11790765	hybrid			2022-12-27	WOS:000174549200132
J	Zhou, B; Cron, RQ; Wu, BR; Genin, A; Wang, ZL; Liu, S; Robson, P; Baldwin, HS				Zhou, B; Cron, RQ; Wu, BR; Genin, A; Wang, ZL; Liu, S; Robson, P; Baldwin, HS			Regulation of the murine Nfatc1 gene by NFATc2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; ATP-DEFICIENT MICE; TRANSCRIPTION FACTOR; NF-AT; NUCLEAR FACTOR; FAMILY MEMBERS; CYCLOSPORINE-A; DNA-BINDING; FUNCTIONAL-CHARACTERIZATION; INTERLEUKIN-4 PROMOTER	NFAT proteins play a key role in the inducible expression of cytokine genes in T lymphocytes. NFATc1 and NFATc2 are the predominant NFAT family members in the peripheral immune system. NFATc2 is found abundantly in the cytoplasm of resting T cells, whereas Nfatc1 expression is induced during T cell activation. To investigate Nfatc1 regulation, we characterized the structure of the murine Nfatc1 gene and its W-flanking region. A 290-bp sequence proximal to the transcription start site is highly conserved between mouse and human and possesses both basal and inducible promoter activities. Multiple binding sites for transcription factors were identified within this region, including a consensus NFAT-binding site. This promoter segment was cyclosporin A-sensitive, and mutation of the NFAT site abrogated inducible promoter activity and inhibited formation of an inducible DNA-protein complex containing NFATc2 in primary T cells. Overexpression of NFATc2 increased inducible Nfatc1 promoter activity, whereas this inducibility was attenuated in NFATc2(-/-)splenocytes. This study suggests that pre-existing NFATc2 contributes to the subsequent induction of Nfatc1 during T cell activation.	Childrens Hosp Philadelphia, Div Cardiol, Dept Pediat, Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Rheumatol, Dept Pediat, Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Nucle Acid & Prot Core, Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Baldwin, HS (corresponding author), Childrens Hosp Philadelphia, Div Cardiol, Dept Pediat, Joseph Stokes Jr Res Inst, 3615 Civ Ctr Blvd,ARC 702, Philadelphia, PA 19104 USA.		Robson, Paul/A-3464-2009	Robson, Paul/0000-0002-0191-3958; Cron, Randy/0000-0003-2661-3086	NHLBI NIH HHS [P50HL62177] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL062177] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi S, 2000, J BIOL CHEM, V275, P14708, DOI 10.1074/jbc.275.19.14708; Amasaki Y, 1998, J IMMUNOL, V160, P2324; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Bert AG, 2000, J IMMUNOL, V165, P5646, DOI 10.4049/jimmunol.165.10.5646; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Chuvpilo S, 1999, J IMMUNOL, V162, P7294; Chuvpilo S, 1999, IMMUNITY, V10, P261, DOI 10.1016/S1074-7613(00)80026-6; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Cron RQ, 1997, J IMMUNOL METHODS, V205, P145, DOI 10.1016/S0022-1759(97)00065-3; Cron RQ, 1999, J IMMUNOL, V162, P860; Cron RQ, 2000, CLIN IMMUNOL, V94, P179, DOI 10.1006/clim.1999.4831; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Decker EL, 1998, J BIOL CHEM, V273, P26923, DOI 10.1074/jbc.273.41.26923; Dzialo-Hatton R, 2001, J IMMUNOL, V166, P4534, DOI 10.4049/jimmunol.166.7.4534; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Garcia-Rodriguez C, 2000, EUR J IMMUNOL, V30, P2432, DOI 10.1002/1521-4141(2000)30:8<2432::AID-IMMU2432>3.0.CO;2-F; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; GRABTREE GR, 1999, CELL, V96, P611; Heyer J, 1997, IMMUNOBIOLOGY, V198, P162, DOI 10.1016/S0171-2985(97)80037-X; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; Hodge MR, 1996, SCIENCE, V274, P1903, DOI 10.1126/science.274.5294.1903; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Kiani A, 1997, IMMUNITY, V7, P849, DOI 10.1016/S1074-7613(00)80403-3; KleinHessling S, 1996, P NATL ACAD SCI USA, V93, P15311, DOI 10.1073/pnas.93.26.15311; Lindgren H, 2001, J IMMUNOL, V166, P4578, DOI 10.4049/jimmunol.166.7.4578; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; Pan S, 1997, BIOCHEM BIOPH RES CO, V240, P314, DOI 10.1006/bbrc.1997.7381; Pankratova EV, 1998, FEBS LETT, V426, P81, DOI 10.1016/S0014-5793(98)00316-0; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; PETRAK D, 1994, J IMMUNOL, V153, P2046; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rengarajan J, 2000, IMMUNITY, V12, P293, DOI 10.1016/S1074-7613(00)80182-X; Sareneva T, 1998, IMMUNOLOGY, V93, P350; SCHUBERT LA, 1995, J BIOL CHEM, V270, P29624; Schuh K, 1998, EUR J IMMUNOL, V28, P2456, DOI 10.1002/(SICI)1521-4141(199808)28:08<2456::AID-IMMU2456>3.0.CO;2-9; Serfling E, 2000, BBA-MOL CELL RES, V1498, P1, DOI 10.1016/S0167-4889(00)00082-3; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Sherman MA, 1999, J IMMUNOL, V162, P2820; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; Timmerman LA, 1997, J IMMUNOL, V159, P2735; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; Xiao S, 1999, EUR J IMMUNOL, V29, P3456, DOI 10.1002/(SICI)1521-4141(199911)29:11<3456::AID-IMMU3456>3.3.CO;2-2; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1; Zhou B, 1997, J CLIN INVEST, V100, P3070, DOI 10.1172/JCI119862; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	66	99	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10704	10711		10.1074/jbc.M107068200	http://dx.doi.org/10.1074/jbc.M107068200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11786533	hybrid			2022-12-27	WOS:000174549200145
J	Curtis, KK; Francis, SA; Oluwatosin, Y; Kane, PM				Curtis, KK; Francis, SA; Oluwatosin, Y; Kane, PM			Mutational analysis of the subunit C (Vma5p) of the yeast vacuolar H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; CLATHRIN-COATED VESICLE; SACCHAROMYCES-CEREVISIAE; V-ATPASES; ADENOSINE-TRIPHOSPHATASES; ELECTRON-MICROSCOPY; GENES; MUTANTS; DISSOCIATION; (H+)-ATPASE	Subunit C is a V-1 sector subunit found in all vacuolar H+-ATPases (V-ATPases) that may be part of the peripheral stalk connecting the peripheral V-1 sector with the membrane-bound V. sector of the enzyme (Wilkens, S., Vasilyeva, E., and Forgac, M. (1999) J. Biol. Chem. 274, 31804-31810). To elucidate subunit C function, we performed random and site-directed mutagenesis of the yeast VMA5 gene. Site-directed mutations in the most highly conserved region of Vma5p, residues 305-325, decreased catalytic activity of the V-ATPase by up to 48% without affecting assembly. A truncation mutant (K360stop) identified by random mutagenesis suggested a small region near the C terminus of the protein (amino acids 382-388) might be important for subunit stability. Site-directed mutagenesis revealed that three aromatic amino acids in this region (Tyr-382, Phe-385, and Tyr-388) in addition to four other conserved aromatic amino acids (Phe-260, Tyr-262, Phe-296, Phe-300) are essential for stable assembly of V-1 with V-0, although alanine substitutions at these positions support some activity in vivo. Surprisingly, three mutations (F260A, Y262A, and F385A) greatly decrease the stability of the V-ATPase in vitro but increase its k(cat) for ATP hydrolysis and proton transport by at least 3-fold. The peripheral stalk of V-ATPases must balance the stability essential for productive catalysis with the dynamic instability involved in regulation; these three mutations may perturb that balance.	SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Kane, PM (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.	kanepm@mail.upstate.edu			NIGMS NIH HHS [GM50322, R01 GM050322] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; BELTRAN C, 1992, J BIOL CHEM, V267, P774; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; Charsky CMH, 2000, J BIOL CHEM, V275, P37232, DOI 10.1074/jbc.M006640200; Cross RL, 2000, BBA-BIOENERGETICS, V1458, P270, DOI 10.1016/S0005-2728(00)00079-7; Curtis KK, 2002, J BIOL CHEM, V277, P2716, DOI 10.1074/jbc.M107777200; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Forgac M, 1999, J BIOENERG BIOMEMBR, V31, P57, DOI 10.1023/A:1005496530380; Graham LA, 1999, J BIOENERG BIOMEMBR, V31, P39, DOI 10.1023/A:1005492429471; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kane PM, 1999, J BIOENERG BIOMEMBR, V31, P49, DOI 10.1023/A:1005444513542; KANE PM, 1989, J BIOL CHEM, V264, P19236; Kane PM, 1999, J BIOL CHEM, V274, P17275, DOI 10.1074/jbc.274.24.17275; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacLeod KJ, 1998, J BIOL CHEM, V273, P150, DOI 10.1074/jbc.273.1.150; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Oka T, 1997, J BIOL CHEM, V272, P24387, DOI 10.1074/jbc.272.39.24387; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Schumacher K, 1999, GENE DEV, V13, P3259, DOI 10.1101/gad.13.24.3259; Sherman F., 1982, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; Xu T, 2000, J BIOL CHEM, V275, P22075, DOI 10.1074/jbc.M002983200; Zhang JW, 1998, J BIOL CHEM, V273, P18470, DOI 10.1074/jbc.273.29.18470	45	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8979	8988		10.1074/jbc.M111708200	http://dx.doi.org/10.1074/jbc.M111708200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11777935	hybrid			2022-12-27	WOS:000174400600034
J	Kim, YJ; Kim, KP; Rhee, HJ; Das, S; Rafter, JD; Oh, YS; Cho, W				Kim, YJ; Kim, KP; Rhee, HJ; Das, S; Rafter, JD; Oh, YS; Cho, W			Internalized group V secretory phospholipase A(2) acts on the perinuclear membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELLS; GROUP IIA; ENZYMES; BINDING; ROLES	Mammalian secretory phospholipases A(2) (sPLA(2)) have been implicated in cellular eicosanoid biosynthesis but the mechanism of their cellular action remains unknown. To elucidate the spatiotemporal dynamics of sPLA(2) mobilization and determine the site of its lipolytic action, we performed time-lapse confocal microscopic imaging of fluorescently labeled sPLA(2) acting on human embryonic kidney (HEK) 293 cells the membranes of which are labeled with a fluorogenic phospholipid, N-((6-(2,4-dinitrophenyl)amino) hexanoyl)-1-hexadecanoyl-2-(4,4-difluoro-5,7-dimethyl-4- bora-3a,4a-diaza-s-indacene-3-pentanoyl)-sn-glycero-3- phosphoethanolamine. The Western blotting analysis of HEK293 cells treated with exogenous sPLA(2)s showed that not only the affinity for heparan sulfate proteoglycan but also other factors, such as sPLA(2) hydrolysis products or cytokines, are necessary for the internalization of sPLA(2) into HEK293 cells. Live cell imaging showed that the hydrolysis of fluorogenic phospholipids incorporated into HEK293 cell membranes was synchronized with the spatiotemporal dynamics of sPLA(2) internalization, detectable initially at the plasma membrane and then at the perinuclear region. Also, immunocytostaining showed that human group V sPILA(2) induced the translocation of 5-lipoxygenase to the nuclear envelope at which they were co-localized. Together, these studies provide the first experimental evidence that the internalized sPILA(2) acts on the nuclear envelope to provide arachidonate for other enzymes involved in the eicosanoid biosynthesis.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, W (corresponding author), Univ Illinois, Dept Chem, MC 111,845 W Taylor St, Chicago, IL 60607 USA.			Kim, Kwang Pyo/0000-0003-0095-3787	NIGMS NIH HHS [GM52598] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anthonsen MW, 2001, J BIOL CHEM, V276, P30527, DOI 10.1074/jbc.M008481200; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Bingham CO, 1999, J BIOL CHEM, V274, P31476, DOI 10.1074/jbc.274.44.31476; BRETSCHER MS, 1972, NATURE-NEW BIOL, V236, P11, DOI 10.1038/newbio236011a0; Brock TG, 1997, J BIOL CHEM, V272, P8276, DOI 10.1074/jbc.272.13.8276; Cho W, 2000, BBA-MOL CELL BIOL L, V1488, P48, DOI 10.1016/S1388-1981(00)00109-8; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; Enomoto A, 2000, BIOCHEM BIOPH RES CO, V276, P667, DOI 10.1006/bbrc.2000.3468; Farber SA, 1999, J BIOL CHEM, V274, P19338, DOI 10.1074/jbc.274.27.19338; Farber SA, 2001, SCIENCE, V292, P1385, DOI 10.1126/science.1060418; Han SK, 1998, BIOCHEM J, V331, P353, DOI 10.1042/bj3310353; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hendrickson HS, 1999, ANAL BIOCHEM, V276, P27, DOI 10.1006/abio.1999.4280; Houliston RA, 2001, BIOCHEM BIOPH RES CO, V287, P881, DOI 10.1006/bbrc.2001.5681; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; Munoz NM, 2000, HYBRIDOMA, V19, P171, DOI 10.1089/02724570050031220; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; Sumandea M, 1999, BIOCHEMISTRY-US, V38, P16290, DOI 10.1021/bi9921384; Williams SD, 2000, J LIPID RES, V41, P1585	25	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9358	9365		10.1074/jbc.M110987200	http://dx.doi.org/10.1074/jbc.M110987200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11777916	hybrid			2022-12-27	WOS:000174400600084
J	Price, RR; Morris, DP; Biswas, G; Smith, MP; Schwinn, DA				Price, RR; Morris, DP; Biswas, G; Smith, MP; Schwinn, DA			Acute agonist-mediated desensitization of the human alpha(1a)-adrenergic receptor is primarily independent of carboxyl terminus regulation - Implications for regulation of alpha(1a)AR splice variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; ALPHA(1)-ADRENERGIC RECEPTOR; ALPHA-1-ADRENERGIC RECEPTORS; DEPENDENT PHOSPHORYLATION; PROMOTED DESENSITIZATION; CARDIAC MYOCYTES; HUMAN PROSTATE; IN-VIVO; KINASE; EXPRESSION	Despite important roles in myocardial hypertrophy and benign prostatic hyperplasia, little is known about acute effects of agonist stimulation on alpha(1a)-adrenergic receptor (alpha(1a)AR) signaling and function. Regulatory mechanisms are likely complex since 12 distinct human alpha(1a)AR carboxyl-terminal splice variants have been isolated. After determining the predominance of the alpha(1a-1)AR isoform in human heart and prostate, we stably expressed an epitope-tagged alpha(1a-1)AR cDNA in rat-1 fibroblasts and subsequently examined regulation of signaling, phosphorylation, and internalization of the receptor. Human alpha(1a-1)AR-mediated inositol phosphate signaling is acutely desensitized in response to both agonist and phorbol 12-myristate 13-acetate (PMA) exposure. Concurrent with desensitization, alpha(1a)ARs in (32)Pi- labeled cells are rapidly phosphorylated in response to both NE and PMA stimulation. Despite the ability of PKC to desensitize alpha(1a)ARs when directly activated with PMA inhibitors of PKC have no effect on agonist-mediated desensitization. In contrast, involvement of GRK kinases is suggested by the ability of GRK2 to desensitize alpha(1a)ARs. Internalization of cell surface alpha(1a)ARs also occurs in response to agonist stimulation (but not PKC activation), but is initiated more slowly than receptor desensitization. Significantly, deletion of the alpha(1a)AR carboxyl terminus has no effect on receptor internalization or either agonist-induced or GRK-mediated receptor desensitization. Because mechanisms underlying acute agonist-mediated regulation of human alpha(1a)ARs are primarily independent of the carboxyl terminus, they may be common to all functional alpha(1a)AR isoforms.	Duke Univ, Dept Anesthesiol, Med Ctr, Durham, NC 27710 USA; Duke Univ, Dept Pharmacol & Canc Biol, Med Ctr, Durham, NC 27710 USA; Duke Univ, Dept Surg, Med Ctr, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Schwinn, DA (corresponding author), Duke Univ, Dept Anesthesiol, Med Ctr, Box 3094, Durham, NC 27710 USA.	schwi001@mc.duke.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049103, R37HL049103] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR30] Funding Source: Medline; NHLBI NIH HHS [HL49103] Funding Source: Medline; NIA NIH HHS [AG05128, AG00745] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Autelitano DJ, 1998, J MOL CELL CARDIOL, V30, P1515, DOI 10.1006/jmcc.1998.0717; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Bohm SK, 1997, BIOCHEM J, V322, P1; Chang DJ, 1998, FEBS LETT, V422, P279, DOI 10.1016/S0014-5793(98)00024-6; Coge F, 1999, BIOCHEM J, V343, P231, DOI 10.1042/0264-6021:3430231; Diviani D, 1997, J BIOL CHEM, V272, P28712, DOI 10.1074/jbc.272.45.28712; Diviani D, 1996, J BIOL CHEM, V271, P5049; FORRAY C, 1994, MOL PHARMACOL, V45, P703; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Graham RM, 1996, CIRC RES, V78, P737, DOI 10.1161/01.RES.78.5.737; Habib A, 1997, J BIOL CHEM, V272, P7191, DOI 10.1074/jbc.272.11.7191; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HIPKIN RW, 1995, J BIOL CHEM, V270, P26683, DOI 10.1074/jbc.270.44.26683; HIRASAWA A, 1995, FEBS LETT, V363, P256, DOI 10.1016/0014-5793(95)00330-C; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; MARSHALL I, 1995, BRIT J PHARMACOL, V115, P781, DOI 10.1111/j.1476-5381.1995.tb15001.x; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; Medina LD, 1998, FEBS LETT, V422, P141, DOI 10.1016/S0014-5793(97)01615-3; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Razik MA, 1997, J BIOL CHEM, V272, P28237, DOI 10.1074/jbc.272.45.28237; Rokosh DG, 1996, J BIOL CHEM, V271, P5839, DOI 10.1074/jbc.271.10.5839; Schwinn D A, 1998, Adv Pharmacol, V42, P390; SCHWINN DA, 1995, J PHARMACOL EXP THER, V272, P134; SUGIYA H, 1988, AM J PHYSIOL, V255, pC149, DOI 10.1152/ajpcell.1988.255.2.C149; Suzuki F, 2000, BRIT J PHARMACOL, V129, P1569, DOI 10.1038/sj.bjp.0703242; Szekeres PG, 1998, MOL PHARMACOL, V53, P759, DOI 10.1124/mol.53.4.759; TERZIC A, 1993, PHARMACOL REV, V45, P147; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; TOBIN AB, 1992, MOL PHARMACOL, V42, P1042; Vazquez-Prado J, 2000, J BIOL CHEM, V275, P6553, DOI 10.1074/jbc.275.9.6553; VazquezPrado J, 1997, J BIOL CHEM, V272, P27330, DOI 10.1074/jbc.272.43.27330; VazquezPrado J, 1996, MOL PHARMACOL, V50, P17; Wang JF, 2000, MOL PHARMACOL, V57, P687, DOI 10.1124/mol.57.4.687; Zhu SJ, 1996, EUR J PHARMACOL, V299, P205, DOI 10.1016/0014-2999(95)00838-1	38	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9570	9579		10.1074/jbc.M111762200	http://dx.doi.org/10.1074/jbc.M111762200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11781325	hybrid			2022-12-27	WOS:000174400600110
J	Robinson, DN; Ocon, SS; Rock, RS; Spudich, JA				Robinson, DN; Ocon, SS; Rock, RS; Spudich, JA			Dynacortin is a novel actin bundling protein that localizes to dynamic actin structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICTYOSTELIUM-DISCOIDEUM; ARP2/3 COMPLEX; CLEAVAGE FURROW; CORTICAL TENSION; CELL MOTILITY; RHO-FAMILY; CYTOKINESIS; MYOSIN; CORTEXILLINS; CYTOSKELETON	Dynacortin is a novel protein that was discovered in a genetic suppressor screen of a Dictyostelium discoideum cytokinesis-deficient mutant cell line devoid of the cleavage furrow actin bundling protein, cortexillin I. While dynacortin is highly enriched in the cortex, particularly in cell-surface protrusions, it is excluded from the cleavage furrow cortex during cytokinesis. Here, we describe the biochemical characterization of this new protein. Purified dynacortin is an 80-kDa dimer with a large 5.7-nm Stokes radius. Dynacortin cross-links actin filaments into parallel arrays with a mole ratio of one dimer to 1.3 actin monomers and a 3.1 mum K-d. Using total internal reflection fluorescence microscopy, GFP-dynacortin and the actin bundling protein coronin-GFP are seen to concentrate in highly dynamic cortical structures with assembly and disassembly half-lives of about 15 s. These results indicate that cells have evolved different actin-filament cross-linking proteins with complementary cellular distributions that collaborate to orchestrate complex cell shape changes.	Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA	Stanford University	Spudich, JA (corresponding author), Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA.			Robinson, Douglas/0000-0003-1236-4891	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040509] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40509] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boyne JR, 2000, J CELL SCI, V113, P4533; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; Faix J, 1996, CELL, V86, P631, DOI 10.1016/S0092-8674(00)80136-1; Faix J, 1998, J CELL SCI, V111, P3059; Faix J, 2001, EMBO J, V20, P3705, DOI 10.1093/emboj/20.14.3705; Gerald N, 1998, J CELL BIOL, V141, P483, DOI 10.1083/jcb.141.2.483; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Howard J., 2001, MECH MOTOR PROTEINS; Insall R, 2001, CELL MOTIL CYTOSKEL, V50, P115, DOI 10.1002/cm.10005; Larochelle DA, 1996, J CELL BIOL, V133, P1321, DOI 10.1083/jcb.133.6.1321; Laue T.M., 1992, ANAL ULTRACENTRIFUGA; LOOMIS WF, 1987, METHOD CELL BIOL, V28, P31; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; Matzke R, 2001, NAT CELL BIOL, V3, P607, DOI 10.1038/35078583; Moores SL, 1996, P NATL ACAD SCI USA, V93, P443, DOI 10.1073/pnas.93.1.443; Mullins RD, 2000, METHOD ENZYMOL, V325, P214; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; Rivero F, 1999, MOL BIOL CELL, V10, P1205, DOI 10.1091/mbc.10.4.1205; Robinson DN, 1996, TRENDS CELL BIOL, V6, P474, DOI 10.1016/0962-8924(96)84945-2; Robinson DN, 2000, J CELL BIOL, V150, P823, DOI 10.1083/jcb.150.4.823; Robinson DN, 2001, CURR BIOL, V11, pR737, DOI 10.1016/S0960-9822(01)00434-1; Robinson DN, 2000, TRENDS CELL BIOL, V10, P228, DOI 10.1016/S0962-8924(00)01747-5; Seastone DJ, 1998, MOL BIOL CELL, V9, P2891, DOI 10.1091/mbc.9.10.2891; Shannon KB, 1999, MOL BIOL CELL, V10, P283, DOI 10.1091/mbc.10.2.283; Simson R, 1998, BIOPHYS J, V74, P514, DOI 10.1016/S0006-3495(98)77808-7; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Weber I, 2000, CURR BIOL, V10, P501, DOI 10.1016/S0960-9822(00)00452-8; Weber I, 1999, EMBO J, V18, P586, DOI 10.1093/emboj/18.3.586; Welch MD, 1999, TRENDS CELL BIOL, V9, P423, DOI 10.1016/S0962-8924(99)01651-7	32	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9088	9095		10.1074/jbc.M112144200	http://dx.doi.org/10.1074/jbc.M112144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11782490	hybrid			2022-12-27	WOS:000174400600048
J	Bannerman, DD; Tupper, JC; Erwert, RD; Winn, RK; Harlan, JM				Bannerman, DD; Tupper, JC; Erwert, RD; Winn, RK; Harlan, JM			Divergence of bacterial lipopolysaccharide pro-apoptotic signaling downstream of IRAK-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RECEPTOR-ASSOCIATED KINASE; DERMAL ENDOTHELIAL-CELLS; LUNG INJURY; ACTIVATION; ENDOTOXIN; PATHWAY; MICE; FADD; EXPRESSION	The vascular endothelium is a key target of circulating bacterial lipopolysaccharide (LPS). LPS elicits a wide array of endothelial responses, including the up-regulation of cytokines, adhesion molecules, and tissue factor, many of which are dependent on NF-kappaB activation. In addition, LPS has been demonstrated to induce endothelial apoptosis both in vitro and in vivo. Although the mechanism by which LPS activates NF-kappaB has been well elucidated, the signaling pathway(s) involved in LPS-induced apoptosis remains unknown. Using a variety of dominant negative constructs, we have identified a role for MyD88 and interleukin-1 receptor-associated kinase-1 (IRAK-1) in mediating LPS pro-apoptotic signaling in human endothelial cells. We also demonstrate that LPS-induced endothelial NF-kappaB activation and apoptosis occur independent of one another. Together, these data suggest that the proximal signaling molecules involved in LPS-induced NF-kappaB activation have a requisite involvement in LPS-induced apoptosis and that the pathways leading to NF-kappaB activation and apoptosis diverge downstream of IRAK-1.	Univ Washington, Sch Med, Div Hematol, Dept Surg, Seattle, WA 98104 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98104 USA; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Bannerman, DD (corresponding author), Univ Washington, Sch Med, Div Hematol, Dept Surg, Box 359756,Harborview R&T Bldg,Rm 521,325 9th Ave, Seattle, WA 98104 USA.	dbannerm@u.washington.edu			NHLBI NIH HHS [HL18645, HL03174] Funding Source: Medline; NIGMS NIH HHS [GM42686, GM07037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042686] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Aliprantis AO, 2000, EMBO J, V19, P3325, DOI 10.1093/emboj/19.13.3325; Bannerman DD, 1999, LAB INVEST, V79, P1181; Bannerman DD, 2001, J BIOL CHEM, V276, P14924, DOI 10.1074/jbc.M100819200; Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; COOPERSTOCK MS, 1974, ANTIMICROB AGENTS CH, V6, P422, DOI 10.1128/AAC.6.4.422; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; Daun JM, 2000, J INTERF CYTOK RES, V20, P843, DOI 10.1089/10799900050163217; de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Frey EA, 1998, MICROB PATHOGENESIS, V24, P101, DOI 10.1006/mpat.1997.0178; Fujita M, 1998, INT ARCH ALLERGY IMM, V117, P202, DOI 10.1159/000024011; Hack CE, 2001, CRIT CARE MED, V29, pS21, DOI 10.1097/00003246-200107001-00011; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Heimberg H, 2001, DIABETES, V50, P2219, DOI 10.2337/diabetes.50.10.2219; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; HOYT DG, 1995, AM J PHYSIOL-LUNG C, V269, pL171, DOI 10.1152/ajplung.1995.269.2.L171; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Karahashi H, 2000, J ENDOTOXIN RES, V6, P33, DOI 10.1177/09680519000060010501; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawasaki M, 2000, AM J PATHOL, V157, P597, DOI 10.1016/S0002-9440(10)64570-1; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368; MARTIN MA, 1992, CLIN INFECT DIS, V14, P1213, DOI 10.1093/clinids/14.6.1213; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Neuzil J, 2001, BIOCHEMISTRY-US, V40, P4686, DOI 10.1021/bi002498n; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; RYSECK RP, 1991, ONCOGENE, V6, P533; Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301; Tapping RI, 1997, J BIOL CHEM, V272, P23157, DOI 10.1074/jbc.272.37.23157; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Zen K, 1999, J BIOL CHEM, V274, P28808, DOI 10.1074/jbc.274.40.28808; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001	59	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8048	8053		10.1074/jbc.M111249200	http://dx.doi.org/10.1074/jbc.M111249200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11777917	hybrid			2022-12-27	WOS:000174268000054
J	Horak, J; Regelmann, J; Wolf, DH				Horak, J; Regelmann, J; Wolf, DH			Two distinct proteolytic systems responsible for glucose-induced degradation of fructose-1,6-bisphosphatase and the Gal2p transporter in the yeast Saccharomyces cerevisiae share the same protein components of the glucose signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE PROTEINS; EXTERNAL AMINO-ACIDS; CATABOLITE INACTIVATION; MALTOSE PERMEASE; GALACTOSE TRANSPORTER; COUPLED RECEPTOR; GENE-EXPRESSION; UBIQUITIN; PHOSPHORYLATION; ENCODES	Addition of glucose to Saccharomyces cerevisiae inactivates the galactose transporter Gal2p and fructose-1,6-bisphosphatase (FBPase) by a mechanism called glucose- or catabolite-induced inactivation, which ultimately results in a degradation of both proteins. It is well established, however, that glucose induces internalization of Gal2p into the endocytotic pathway and its subsequent proteolysis in the vacuole, whereas FBPase is targeted to the 26 S proteasome for proteolysis under similar inactivation conditions. Here we report that two distinct proteolytic systems responsible for specific degradation of two conditionally short-lived protein targets, Gal2p and FBPase, utilize most (if not all) protein components of the same glucose sensing (signaling) pathway. Indeed, initiation of Gal2p and FBPase proteolysis appears to require rapid transport of those substrates of the Hxt transporters that are at least partially metabolized by hexokinase Hxk2p. Also, maltose transported via the maltose-specific transporter(s) generates an appropriate signal that culminates in the degradation of both proteins. In addition, Grrlp and Reg1p were found to play a role in transduction of the glucose signal for glucose-induced proteolysis of Gal2p and FBPase. Thus, one signaling pathway initiates two different proteolytic mechanisms of catabolite degradation, proteasomal proteolysis and endocytosis followed by lysosomal proteolysis.	Univ Stuttgart, Inst Biochem, D-70569 Stuttgart, Germany; Acad Sci Czech Republ, Inst Physiol, Dept Membrane Transport, CR-14220 Prague, Czech Republic	University of Stuttgart; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences	Wolf, DH (corresponding author), Univ Stuttgart, Inst Biochem, Pfaffenwaldring 55, D-70569 Stuttgart, Germany.	dieter.wolf@uni-stuttgart.de	Horak, Jaroslav/C-2930-2012					BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; Bernard F, 2001, FEBS LETT, V496, P81, DOI 10.1016/S0014-5793(01)02412-7; BEULLENS M, 1990, CURR MICROBIOL, V21, P39, DOI 10.1007/BF02090098; Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chiang HL, 1996, J BIOL CHEM, V271, P9934, DOI 10.1074/jbc.271.17.9934; Colombo S, 1998, EMBO J, V17, P3326, DOI 10.1093/emboj/17.12.3326; FLICK JS, 1991, MOL CELL BIOL, V11, P5101, DOI 10.1128/MCB.11.10.5101; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Hammerle M, 1998, J BIOL CHEM, V273, P25000, DOI 10.1074/jbc.273.39.25000; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HILT W, 2000, PROTEASOMES WORLD RE, P1; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOLZER H, 1989, RBC-CELL BIOL REV, V21, P305; HOLZER H, 1976, TRENDS BIOCHEM SCI, V1, P178, DOI 10.1016/S0968-0004(76)80018-7; Horak J, 1997, BBA-REV BIOMEMBRANES, V1331, P41, DOI 10.1016/S0304-4157(96)00015-9; Horak J, 1997, J BACTERIOL, V179, P1541, DOI 10.1128/jb.179.5.1541-1549.1997; Horak J, 2001, J BACTERIOL, V183, P3083, DOI 10.1128/JB.183.10.3083-3088.2001; Iraqui I, 1999, MOL CELL BIOL, V19, P989; Jiang H, 1997, MOL BIOL CELL, V8, P1293, DOI 10.1091/mbc.8.7.1293; Jiang H, 2000, J BACTERIOL, V182, P647, DOI 10.1128/JB.182.3.647-654.2000; Jiang H, 2000, MOL GEN GENET, V263, P411, DOI 10.1007/s004380051185; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; Kraakman L, 1999, MOL MICROBIOL, V32, P1002, DOI 10.1046/j.1365-2958.1999.01413.x; Krampe S, 1998, FEBS LETT, V441, P343, DOI 10.1016/S0014-5793(98)01583-X; Kruckeberg AL, 1998, BIOESSAYS, V20, P972, DOI 10.1002/(SICI)1521-1878(199812)20:12<972::AID-BIES2>3.0.CO;2-M; Kruckeberg AL, 1996, ARCH MICROBIOL, V166, P283, DOI 10.1007/s002030050385; Lafuente MJ, 2000, MOL MICROBIOL, V35, P161, DOI 10.1046/j.1365-2958.2000.01688.x; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; Liang H, 1996, MOL BIOL CELL, V7, P1953, DOI 10.1091/mbc.7.12.1953; LUCERO P, 1993, FEBS LETT, V333, P165, DOI 10.1016/0014-5793(93)80397-D; Medintz I, 1996, J BACTERIOL, V178, P2245, DOI 10.1128/jb.178.8.2245-2254.1996; Ozcan S, 1998, EMBO J, V17, P2566, DOI 10.1093/emboj/17.9.2566; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; Ozcan S, 1996, MOL CELL BIOL, V16, P6419; OZCAN S, 1995, MOL CELL BIOL, V15, P1564; Ozcan S, 1996, P NATL ACAD SCI USA, V93, P12428, DOI 10.1073/pnas.93.22.12428; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Randez-Gil F, 1998, MOL CELL BIOL, V18, P2940, DOI 10.1128/MCB.18.5.2940; RIBALLO E, 1995, J BACTERIOL, V177, P5622, DOI 10.1128/jb.177.19.5622-5627.1995; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Schmidt MC, 1999, MOL CELL BIOL, V19, P4561; SCHORK SM, 1995, J BIOL CHEM, V270, P26446, DOI 10.1074/jbc.270.44.26446; SCHORK SM, 1994, FEBS LETT, V349, P270, DOI 10.1016/0014-5793(94)00668-7; Schule T, 2000, EMBO J, V19, P2161, DOI 10.1093/emboj/19.10.2161; Schulte F, 2000, J BACTERIOL, V182, P540, DOI 10.1128/JB.182.2.540-542.2000; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; Thevelein JM, 2000, ENZYME MICROB TECH, V26, P819, DOI 10.1016/S0141-0229(00)00177-0; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Wieczorke R, 1999, FEBS LETT, V464, P123, DOI 10.1016/S0014-5793(99)01698-1; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; Xue Y, 1998, EMBO J, V17, P1996, DOI 10.1093/emboj/17.7.1996	59	42	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8248	8254		10.1074/jbc.M107255200	http://dx.doi.org/10.1074/jbc.M107255200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11773046	hybrid			2022-12-27	WOS:000174268000080
J	Niedziela, T; Lukasiewicz, J; Jachymek, W; Dzieciatkowska, M; Lugowski, C; Kenne, L				Niedziela, T; Lukasiewicz, J; Jachymek, W; Dzieciatkowska, M; Lugowski, C; Kenne, L			Core oligosaccharides of Plesiomonas shigelloides O54 : H2 (strain CNCTC 113/92) - Structural and serological analysis of the lipopolysaccharide core region, the O-antigen biological repeating unit, and the linkage between them	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON GROUP-1 ANTIGEN; SALMONELLA LIPOPOLYSACCHARIDE; POLYACRYLAMIDE GELS; ISOBUTYL ESTERS; AMINO-ACIDS; POLYSACCHARIDE; SEPTICEMIA; AEROMONAS; SHIGELLA-DYSENTERIAE-1; SHIGELLA-FLEXNERI-6	The structure of the core oligosaccharide moiety of the lipopolysaccharide (LPS) of Plesiomonas shigelloides O54 (strain CNCTC 113/92) has been investigated by H-1 and C-13 NMR, fast atom bombardment mass spectrometry (MS)/MS, matrix-assisted laser-desorption/ionization time-of-flight MS, monosaccharide and methylation analysis, and immunological methods. It was concluded that the main core oligosaccharide of this strain is composed of a decasaccharide with the following structure: [GRAPHICS] in which L-alpha-D-Hepp is L-glycero-alpha-D-manno-heptopyranose. The nonasaccharide variant of the core oligosaccharide (similar to10%), devoid Of beta-D-Glcp substituting the alpha-D-GlcpN at C-6, was also identified. The core oligosaccharide substituted at C-4 of the outer core beta-D-Glcp residue with the single 0polysaccharide repeating unit was also isolated yielding a hexadecasaccharide structure. The determination of the monosaccharides involved in the linkage between the O-specific polysaccharide part and the core, as well as the presence of -->3)-D-beta-D-Hepp-(1--> instead of -->3,4)-D-beta-D-Hepp-(1--> in the repeating unit, revealed the structure of the biological repeating unit of the 0-antigen. The core oligosaccharides are not substituted by phosphate residues and represent novel core type of bacterial LPS that is characteristic for the Plesiomonas shigelloides serotype O54. Serological screening of 69 different O-serotypes of P. shigelloides suggests that epitopes similar to the core oligosaccharide of serotype 054 (strain CNCTC 113/92) might also be present in the core region of the serotypes 024 (strain CNCTC 92/89), 037 (strain CNCTC 39/89) and 096 (strain CNCTC 5133) LPS.	Swedish Univ Agr Sci, Dept Chem, SE-75007 Uppsala, Sweden; L Hirsfeld Inst Immunol & Expt Therapy, PL-53114 Wroclaw, Poland	Swedish University of Agricultural Sciences; Polish Academy of Sciences; Hirszfeld Institute of Immunology & Experimental Therapy of the Polish Academy of Sciences	Kenne, L (corresponding author), Swedish Univ Agr Sci, Dept Chem, POB 7015, SE-75007 Uppsala, Sweden.	Lennart.Kenne@kemi.slu.se		Niedziela, Tomasz/0000-0002-9333-3175; Jachymek, Wojciech/0000-0001-8963-3020; Lukasiewicz, Jolanta/0000-0001-8081-7261				ALBERT MJ, 1993, J MED MICROBIOL, V39, P211, DOI 10.1099/00222615-39-3-211; ALDOVA E, 1992, SYST APPL MICROBIOL, V15, P70, DOI 10.1016/S0723-2020(11)80141-4; Aldova E, 2000, FOLIA MICROBIOL, V45, P301, DOI 10.1007/BF02817550; ALDOVA E, 1987, ZBL BAKT-INT J MED M, V265, P253; ALDOVA E, 1992, SYST APPL MICROBIOL, V15, P247, DOI 10.1016/S0723-2020(11)80098-6; BHAT UR, 1991, CARBOHYD RES, V220, P219, DOI 10.1016/0008-6215(91)80020-N; Boratynski J, 1998, GLYCOCONJUGATE J, V15, P131, DOI 10.1023/A:1007067513242; Bravo L, 1998, Cent Eur J Public Health, V6, P67; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P394; CLARK RB, 1991, J INFECTION, V23, P89, DOI 10.1016/0163-4453(91)94217-8; Czaja J, 2000, EUR J BIOCHEM, V267, P1672, DOI 10.1046/j.1432-1327.2000.01161.x; DELFORGE ML, 1995, CLIN INFECT DIS, V21, P692, DOI 10.1093/clinids/21.3.692; Farmer J. J., 1992, The Prokaryotes. A handbook on the biology of bacteria: ecophysiology, isolation, identification, applications. Volume III.., P3012; Fujita Kozo, 1994, Acta Paediatrica Japonica, V36, P450; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; GERWIG GJ, 1979, CARBOHYD RES, V77, P1, DOI 10.1016/S0008-6215(00)83788-X; Goddard T., 2001, SPARKY; GORIN PAJ, 1975, CAN J CHEM, V53, P1212, DOI 10.1139/v75-168; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; JANSSON PE, 1989, CARBOHYD RES, V188, P169, DOI 10.1016/0008-6215(89)84069-8; JENNINGS HJ, 1981, J IMMUNOL, V127, P1011; KNIREL YA, 1993, BIOCHEMISTRY-MOSCOW+, V58, P84; KONDO S, 1992, CARBOHYD RES, V231, P55, DOI 10.1016/0008-6215(92)84007-F; KONDO S, 1991, EUR J BIOCHEM, V200, P689, DOI 10.1111/j.1432-1033.1991.tb16233.x; KORNER RJ, 1992, ZBL BAKT-INT J MED M, V277, P334; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee ACW, 1996, PEDIATR HEMAT ONCOL, V13, P265, DOI 10.3109/08880019609030826; Levy D A, 1998, MMWR CDC Surveill Summ, V47, P1; LINNERBORG M, 1995, EUR J BIOCHEM, V231, P839, DOI 10.1111/j.1432-1033.1995.0839d.x; LUGOWSKI C, 1978, EUR J BIOCHEM, V91, P89, DOI 10.1111/j.1432-1033.1978.tb20941.x; MACKENZIE SL, 1974, J CHROMATOGR, V97, P19, DOI 10.1016/S0021-9673(01)97579-X; MACKENZIE SL, 1977, J CHROMATOGR, V132, P485, DOI 10.1016/S0021-9673(00)82912-X; Niedziela T, 1996, EUR J BIOCHEM, V237, P635, DOI 10.1111/j.1432-1033.1996.0635p.x; Olsthoorn MMA, 1998, J BIOL CHEM, V273, P3817, DOI 10.1074/jbc.273.7.3817; Petersson C, 1997, EUR J BIOCHEM, V244, P580, DOI 10.1111/j.1432-1033.1997.00580.x; RAUTELIN H, 1995, SCAND J INFECT DIS, V27, P495, DOI 10.3109/00365549509047052; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Riley PA, 1996, CLIN INFECT DIS, V23, P206, DOI 10.1093/clinids/23.1.206a; RUIMY R, 1994, INT J SYST BACTERIOL, V44, P416, DOI 10.1099/00207713-44-3-416; SAWARDEKER JS, 1965, ANAL CHEM, V37, P1602, DOI 10.1021/ac60231a048; SHAW DH, 1992, CARBOHYD RES, V231, P83, DOI 10.1016/0008-6215(92)84010-P; SHIMADA T, 1994, CURR MICROBIOL, V28, P351, DOI 10.1007/BF01570200; SHIMADA T, 1978, JPN J MED SCI BIOL, V31, P135, DOI 10.7883/yoken1952.31.135; Susskind M, 1998, J BIOL CHEM, V273, P7006, DOI 10.1074/jbc.273.12.7006; Taylor R. L., 1976, METHODS CARBOHYDRATE, V7, P149; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VOLLER A, 1975, LANCET, V1, P426; Westphal O., 1965, METHODS CARBOHYDRATE, V5, P83, DOI DOI 10.1016/J.WATRES.2010.04.030; Yamada S, 1997, EPIDEMIOL INFECT, V119, P121, DOI 10.1017/S0950268897007942	50	48	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11653	11663		10.1074/jbc.M111885200	http://dx.doi.org/10.1074/jbc.M111885200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11796731	hybrid			2022-12-27	WOS:000174846400007
J	Sukumaran, SK; Prasadarao, NV				Sukumaran, SK; Prasadarao, NV			Regulation of protein kinase C in Escherichia coli K1 invasion of human brain microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; MYRISTOYL-ELECTROSTATIC SWITCH; BACTERIAL-MENINGITIS; MARCKS; ACTIVATION; IDENTIFICATION; CONTRIBUTES; CALMODULIN; EXPERIENCE; SUBSTRATE	Escherichia coli is one of the most important pathogens involved in the development of neonatal meningitis in many parts of the world. Traversal of E. coli across the blood-brain barrier is a crucial event in the pathogenesis of E. coli meningitis. Our previous studies have shown that outer membrane protein A (OmpA) expression is necessary in E. coli for a mechanism involving actin filaments in its passage through the endothelial cells. Focal adhesion kinase (FAK) and phosphatidylinositol 3-kinase (PI3K) have also been activated in host cells during the process of invasion. In an attempt to elucidate the mechanisms leading to actin filament condensation, we have focused our attention on protein kinase C (PKC), an enzyme central to many signaling events, including actin rearrangement. In the current study, specific PKC inhibitors, bisindolmaleimide and a PKC-inhibitory peptide, inhibited E. coli invasion of human brain microvascular endothelial cells (HBMEC) by more than 75% in a dose-dependent manner, indicating a significant role played by this enzyme in the invasion process. Our results further showed that OmpA+ E. coli induces significant activation of PKC in HBMEC as measured by the PepTag nonradioactive assay. In addition, we identified that the PKC isoform activated in E. coli invasion is a member of the conventional family of PKC, PKC-alpha, which requires calcium for activation. Immunocytochemical studies have indicated that the activated PKC-alpha is associated with actin condensation beneath the bacterial entry site. Overexpression of a dominant negative mutant of PKC-alpha in HBMEC abolished the E. coli invasion without significant changes in FAK phosphorylation or PI3K activity patterns. In contrast, in HBMEC overexpressing the mutant forms of either FAK or PI3K, E. coli-induced PKC activation was significantly blocked. Furthermore, our studies showed that activation of PKC-alpha induces the translocation of myristoylated alanine-rich protein kinase C substrate, an actin cross-linking protein and a substrate for PKC-alpha, from the membrane to cytosol. This is the first report of FAK- and PI3K-dependent PKC-alpha activation in bacterial invasion related to cytoskeletal reorganization.	Univ So Calif, Div Infect Dis, Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA; Univ So Calif, Keck Sch Med, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California; University of Southern California	Prasadarao, NV (corresponding author), Univ So Calif, Div Infect Dis, Childrens Hosp Los Angeles, MS 51,4650 Sunset Blvd, Los Angeles, CA 90027 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040567, R01AI040567] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40567] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; Arbuzova A, 1997, J BIOL CHEM, V272, P27167, DOI 10.1074/jbc.272.43.27167; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Bubb MR, 1999, J BIOL CHEM, V274, P36472, DOI 10.1074/jbc.274.51.36472; Crane JK, 1997, INFECT IMMUN, V65, P3277, DOI 10.1128/IAI.65.8.3277-3285.1997; Dehio M, 1998, FEBS LETT, V424, P84, DOI 10.1016/S0014-5793(98)00144-6; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; DwyerNield LD, 1996, AM J PHYSIOL-LUNG C, V270, pL526, DOI 10.1152/ajplung.1996.270.4.L526; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; GLADSTONE IM, 1990, PEDIATR INFECT DIS J, V9, P819, DOI 10.1097/00006454-199011000-00009; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HUANG SH, 1995, INFECT IMMUN, V63, P4470, DOI 10.1128/IAI.63.11.4470-4475.1995; Huang SH, 1999, INFECT IMMUN, V67, P2103, DOI 10.1128/IAI.67.5.2103-2109.1999; Koedel U, 1999, INFECT DIS CLIN N AM, V13, P549, DOI 10.1016/S0891-5520(05)70094-5; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leib SL, 1999, INFECT DIS CLIN N AM, V13, P527, DOI 10.1016/S0891-5520(05)70093-3; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Meyer TF, 1999, CLIN INFECT DIS, V28, P433, DOI 10.1086/515160; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; Prasadarao NV, 1999, INFECT IMMUN, V67, P5775, DOI 10.1128/IAI.67.11.5775-5783.1999; Prasadarao NV, 1999, INFECT IMMUN, V67, P1131, DOI 10.1128/IAI.67.3.1131-1138.1999; Prasadarao NV, 1996, INFECT IMMUN, V64, P146, DOI 10.1128/IAI.64.1.146-153.1996; Reddy MA, 2000, INFECT IMMUN, V68, P6423, DOI 10.1128/IAI.68.11.6423-6430.2000; Reddy MA, 2000, J BIOL CHEM, V275, P36769, DOI 10.1074/jbc.M007382200; Rosenshine I, 1996, EMBO J, V15, P2613, DOI 10.1002/j.1460-2075.1996.tb00621.x; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; Soh JW, 1999, MOL CELL BIOL, V19, P1313; STINS MF, 1994, AM J PATHOL, V145, P1228; UNHANAND M, 1993, J PEDIATR-US, V122, P15, DOI 10.1016/S0022-3476(05)83480-8; Yarmola EG, 2001, J BIOL CHEM, V276, P22351, DOI 10.1074/jbc.M101457200; Zhao Y, 2000, AM J PHYSIOL-CELL PH, V279, pC1611, DOI 10.1152/ajpcell.2000.279.5.C1611	35	47	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12253	12262		10.1074/jbc.M110740200	http://dx.doi.org/10.1074/jbc.M110740200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805101	hybrid			2022-12-27	WOS:000174846400085
J	Garofalo, T; Lenti, L; Longo, A; Misasi, R; Mattei, V; Pontieri, GM; Pavan, A; Sorice, M				Garofalo, T; Lenti, L; Longo, A; Misasi, R; Mattei, V; Pontieri, GM; Pavan, A; Sorice, M			Association of GM3 with Zap-70 induced by T cell activation in plasma membrane microdomains - GM3 as a marker of microdomains in human lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOSIALOGANGLIOSIDE GM3; LIPID RAFTS; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; FUNCTIONAL RAFTS; CD4-LCK COMPLEX; GANGLIOSIDE; CD4; TCR; PROTEIN	Recent evidence demonstrated that T cell activation leads to the redistribution of membrane and intracellular kinase-rich raft microdomains at the site of TCR engagement. In this investigation we demonstrated by high performance thin layer chromatography, gas chromatographic, and mass spectrometric analyses that GM3 is the main ganglioside constituent of these microdomains in human lymphocytes. Then we analyzed GM3 distribution and its interaction with the phosphorylation protein Zap-70. Human T lymphocytes were stimulated with anti-CD3 and anti-CD28. Immunofluorescence microscopy analysis revealed a clustered GM3 distribution over the cell surface and an intracellular localization resembling specific cytoplasmic compartment(s). Scanning confocal microscopy showed that T cell activation induced a significant association between GM3 and Zap-70, as revealed by nearly complete colocalization areas; very few colocalization areas were detected in unstimulated cells. Coimmunoprecipitation experiments revealed that GM3 was immunoprecipitated by anti-Zap-70 only after co-stimulation through CD3 and CD28 as detected by both thin layer chromatography and immunoblotting. Therefore, T cell activation does not promote a redistribution of glycosphingolipid-enriched microdomains but induces Zap-70 translocation in selective membrane domains in which Zap-70 may interact with GM3. These findings suggest that GM3 is a component of a multimolecular signaling complex involved in T cell activation.	Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy; Univ Aquila, Dipartimento Med Sperimentale, I-67100 Laquila, Italy	Sapienza University Rome; University of L'Aquila	Sorice, M (corresponding author), Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Viale Regina Elena 324, I-00161 Rome, Italy.	maurizio.sorice@uniroma1.it	Sorice, Maurizio/Q-5079-2019; Sousa, Maria/HCI-9642-2022; Mattei, Vincenzo/AAQ-3667-2020	Mattei, Vincenzo/0000-0003-4677-088X; Garofalo, Tina/0000-0003-0645-2510; Sorice, Maurizio/0000-0003-3534-1502				Barenholz Y, 1975, Methods Enzymol, V35, P529, DOI 10.1016/0076-6879(75)35180-X; BLUE ML, 1987, J IMMUNOL, V139, P3949; Ebert PJR, 2000, J IMMUNOL, V165, P5435, DOI 10.4049/jimmunol.165.10.5435; ESSELMAN WJ, 1972, METHOD ENZYMOL, V28, P149; Garofalo T, 1998, J BIOL CHEM, V273, P35153, DOI 10.1074/jbc.273.52.35153; GAY D, 1988, P NATL ACAD SCI USA, V85, P5629, DOI 10.1073/pnas.85.15.5629; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; HUBER LA, 1991, EUR J IMMUNOL, V21, P2761, DOI 10.1002/eji.1830211117; Iwabuchi K, 2000, METHOD ENZYMOL, V312, P488; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; KIGUCHI K, 1990, J BIOCHEM-TOKYO, V107, P8, DOI 10.1093/oxfordjournals.jbchem.a123016; KOTANI M, 1992, BIOCHIM BIOPHYS ACTA, V1117, P97, DOI 10.1016/0304-4165(92)90168-T; Leyton L, 1999, MOL IMMUNOL, V36, P755, DOI 10.1016/S0161-5890(99)00086-3; Merritt WD, 1996, CELL IMMUNOL, V173, P131, DOI 10.1006/cimm.1996.0259; Millan J, 2001, EUR J IMMUNOL, V31, P467, DOI 10.1002/1521-4141(200102)31:2<467::AID-IMMU467>3.0.CO;2-1; MISASI R, 1993, CLIN IMMUNOL IMMUNOP, V67, P216, DOI 10.1006/clin.1993.1068; Misasi R, 1998, J NEUROCHEM, V71, P2313; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; Parolini I, 1999, J BIOL CHEM, V274, P14176, DOI 10.1074/jbc.274.20.14176; Parolini I, 1996, BLOOD, V87, P3783, DOI 10.1182/blood.V87.9.3783.bloodjournal8793783; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; PREVITI M, 1992, J CHROMATOGR, V605, P221, DOI 10.1016/0021-9673(92)85240-T; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; Saint-Ruf C, 2000, NATURE, V406, P524, DOI 10.1038/35020093; SCHAUER R, 1978, METHOD ENZYMOL, V50, P83; SEKINE M, 1984, J BIOCHEM-TOKYO, V95, P155, DOI 10.1093/oxfordjournals.jbchem.a134579; SHAROM FJ, 1978, BIOCHIM BIOPHYS ACTA, V507, P280, DOI 10.1016/0005-2736(78)90423-6; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sorice M, 1997, J LIPID RES, V38, P969; SORICE M, 1995, SCAND J IMMUNOL, V41, P148, DOI 10.1111/j.1365-3083.1995.tb03547.x; Sorice M, 2000, GLYCOCONJUGATE J, V17, P247, DOI 10.1023/A:1026501609699; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; Tuosto L, 2001, EUR J IMMUNOL, V31, P345, DOI 10.1002/1521-4141(200102)31:2<345::AID-IMMU345>3.3.CO;2-C; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251; YUASA H, 1990, TISSUE ANTIGENS, V36, P47, DOI 10.1111/j.1399-0039.1990.tb01799.x; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	48	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11233	11238		10.1074/jbc.M109601200	http://dx.doi.org/10.1074/jbc.M109601200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11781312	hybrid			2022-12-27	WOS:000174613100062
J	Hashimoto, M; Hsu, LJ; Rockenstein, E; Takenouchi, T; Mallory, M; Masliah, E				Hashimoto, M; Hsu, LJ; Rockenstein, E; Takenouchi, T; Mallory, M; Masliah, E			alpha-synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; INTERACTING PROTEIN-1; NACP/ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; ALTERED EXPRESSION; MESSENGER-RNA; LEWY BODIES; WILD-TYPE; JNK; GENE	The expression of a-synuclein, a synaptic molecule implicated in the pathogenesis of neurodegenerative disorders such as Parkinson's disease and Lewy body disease is increased upon injury to the nervous system, indicating that it might play a role in regeneration and plasticity; however, the mechanisms are unclear. Because c-Jun N-terminal kinase (JNK), a member of the mitogen-activated protein kinase family, plays an important role in stress response, the main objective of the present study was to better understand the involvement of this pathway in the signaling responses associated with resistance to injury in cells expressing alpha-synuclein. For this purpose, the JNK-signaling pathway was investigated in alpha-synuclein-transfected neuronal cell line glucose transporter (GT) 1-7 under oxidative stress conditions. Although hydrogen peroxide challenge resulted in JNK activation and cell death in cells transfected with vector control or beta-synuclein, alpha-synuclein-transfected cells were resistant to hydrogen peroxide, and JNK was not activated. The inactivation of JNK in the a-synuclein-transfected cells was associated with increased expression and activity of JNK-interacting protein (JIP)-1b/islet-brain (IB)1, the scaffold protein for the JNK pathway. Similarly, cells transfected with JIP1b/IB1 were resistant to hydrogen peroxide associated with inactivation of the JNK pathway. In these cells, expression of endogenous a-synuclein was significantly increased at the protein level. Furthermore, alpha-synuclein was co-localized with JIP-1b/IB1 in the growth cones. Taken together, these results suggest that increased alpha-synuclein expression might protect cells from oxidative stress by inactivation of JNK via increased expression of JIP-1b/IB1. Furthermore, interactions between a-synuclein and JIP-1b/IB1 may play a mutual role in the neuronal response to injury and neurodegeneration.	Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Masliah, E (corresponding author), Univ Calif San Diego, Sch Med, Dept Neurosci, 9500 Gilman Dr, La Jolla, CA 92093 USA.	emasliah@ucsd.edu			NATIONAL INSTITUTE ON AGING [R01AG010689, R37AG018440, R01AG018440, P50AG005131] Funding Source: NIH RePORTER; NIA NIH HHS [AG5131, AG10689, AG18440] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS JD, 1991, FREE RADICAL BIO MED, V10, P161, DOI 10.1016/0891-5849(91)90009-R; Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; BONNY C, 1995, MOL ENDOCRINOL, V9, P1413, DOI 10.1210/me.9.10.1413; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Cohen G, 2000, ANN NY ACAD SCI, V899, P112; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Harding TC, 2001, J BIOL CHEM, V276, P4531, DOI 10.1074/jbc.C000815200; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Hashimoto M, 2000, AM J PATHOL, V156, P734, DOI 10.1016/S0002-9440(10)64777-3; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Hsu L, 2001, J NEUROSCI RES, V64, P193, DOI 10.1002/jnr.1065; Hsu LJ, 1998, J NEUROCHEM, V71, P338; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; Jensen PH, 1999, EUR J NEUROSCI, V11, P3369, DOI 10.1046/j.1460-9568.1999.00754.x; Kanda S, 2000, NEUROSCIENCE, V97, P279, DOI 10.1016/S0306-4522(00)00077-4; Kholodilov NG, 1999, NEUROSCI LETT, V275, P105, DOI 10.1016/S0304-3940(99)00740-5; Kholodilov NG, 1999, J NEUROCHEM, V73, P2586, DOI 10.1046/j.1471-4159.1999.0732586.x; Kim IJ, 1999, J NEUROCHEM, V72, P1335, DOI 10.1046/j.1471-4159.1999.721335.x; Ko LW, 2000, J NEUROCHEM, V75, P2546, DOI 10.1046/j.1471-4159.2000.0752546.x; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Masliah E, 2000, ANN NY ACAD SCI, V924, P68; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Matsuda S, 2001, J NEUROSCI, V21, P6597; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Pellet JB, 2000, EUR J NEUROSCI, V12, P621, DOI 10.1046/j.1460-9568.2000.00945.x; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rockenstein E, 2001, BRAIN RES, V914, P48, DOI 10.1016/S0006-8993(01)02772-X; Saha AR, 2000, EUR J NEUROSCI, V12, P3073, DOI 10.1046/j.1460-9568.2000.00210.x; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Surguchov A, 1999, MOL CELL NEUROSCI, V13, P95, DOI 10.1006/mcne.1999.0735; Tabrizi SJ, 2000, HUM MOL GENET, V9, P2683, DOI 10.1093/hmg/9.18.2683; Takeda A, 1998, AM J PATHOL, V152, P367; Takenouchi T, 2001, MOL CELL NEUROSCI, V17, P141, DOI 10.1006/mcne.2000.0923; Tompkins MM, 1997, BRAIN RES, V775, P24, DOI 10.1016/S0006-8993(97)00874-3; Tompkins MM, 1997, AM J PATHOL, V150, P119; Trojanowski JQ, 2000, ANN NY ACAD SCI, V924, P62; Van Uden E, 2000, J BIOL CHEM, V275, P30525, DOI 10.1074/jbc.M001151200; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wilson CA, 1999, J NEUROPATH EXP NEUR, V58, P787, DOI 10.1097/00005072-199908000-00001; Xia XG, 2001, P NATL ACAD SCI USA, V98, P10433, DOI 10.1073/pnas.181182298; Zhou WB, 2000, BRAIN RES, V866, P33, DOI 10.1016/S0006-8993(00)02215-0	60	165	171	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11465	11472		10.1074/jbc.M111428200	http://dx.doi.org/10.1074/jbc.M111428200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11790792	hybrid			2022-12-27	WOS:000174613100091
J	Huang, CC; Smith, CV; Glickman, MS; Jacobs, WR; Sacchettini, JC				Huang, CC; Smith, CV; Glickman, MS; Jacobs, WR; Sacchettini, JC			Crystal structures of mycolic acid cyclopropane synthases from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-PI INTERACTIONS; ANOMALOUS DIFFRACTION; FATTY-ACIDS; BIOSYNTHESIS; DNA; MECHANISM; METHYLTRANSFERASES; IDENTIFICATION; SEQUENCE; PURIFICATION	Mycolic acids are major components of the cell wall of Mycobacterium tuberculosis. Several studies indicate that functional groups in the acyl chain of mycolic acids are important for pathogenesis and persistence. There are at least three mycolic acid cyclopropane synthases (PcaA, CmaA1, and CmaA2) that are responsible for these site-specific modifications of mycolic acids. To derive information on the specificity and enzyme mechanism of the family of proteins, the crystal structures of CmaA1, CmaA2, and PcaA were solved to 2-, 2-, and 2.65-Angstrom resolution, respectively. All three enzymes have a seven-stranded alpha/beta fold similar to other methyltransferases with the location and interactions with the cofactor S-adenosyl-L-methionine conserved. The structures of the ternary complexes demonstrate the position of the mycolic acid substrate binding site. Close examination of the active site reveals electron density that we believe represents a bicarbonate ion. The structures support the hypothesis that these enzymes catalyze methyl transfer via a carbocation mechanism in which the bicarbonate ion acts as a general base. In addition, comparison of the enzyme structures reveals a possible mechanism for substrate specificity. These structures provide a foundation for rational-drug design, which may lead to the development of new inhibitors effective against persistent bacteria.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Yeshiva Univ Albert Einstein Coll Med, Montefiore Med Ctr, Div Infect Dis, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Montefiore Med Ctr, Dept Microbiol & Immunol, Howard Hughes Med Inst, Bronx, NY 10461 USA	Texas A&M University System; Texas A&M University College Station; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	sacchett@tamu.edu		Glickman, Michael S/0000-0001-7918-5164; Jacobs, William/0000-0003-3321-3080	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI046392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062410] Funding Source: NIH RePORTER; NIAID NIH HHS [AI46392] Funding Source: Medline; NIGMS NIH HHS [GM62410] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang YY, 1999, MOL MICROBIOL, V33, P249, DOI 10.1046/j.1365-2958.1999.01456.x; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Djordjevic S, 1997, STRUCTURE, V5, P545, DOI 10.1016/S0969-2126(97)00210-4; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Dubnau E, 1997, MOL MICROBIOL, V23, P313, DOI 10.1046/j.1365-2958.1997.2301589.x; Dubnau E, 2000, MOL MICROBIOL, V36, P630, DOI 10.1046/j.1365-2958.2000.01882.x; Duncan K, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P297; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Fu ZJ, 1996, BIOCHEMISTRY-US, V35, P11985, DOI 10.1021/bi961068n; GEORGE KM, 1995, J BIOL CHEM, V270, P27292, DOI 10.1074/jbc.270.45.27292; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; Glickman MS, 2001, J BIOL CHEM, V276, P2228, DOI 10.1074/jbc.C000652200; Grogan DW, 1997, MICROBIOL MOL BIOL R, V61, P429, DOI 10.1128/.61.4.429-441.1997; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; Kremer L, 2001, J BIOL CHEM, V276, P27967, DOI 10.1074/jbc.M103687200; Kremer L, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P173; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Long SB, 1998, BIOCHEMISTRY-US, V37, P9612, DOI 10.1021/bi980708e; McKinney JD, 1998, BIOMED RES REP, P51; Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parris KD, 2000, STRUCT FOLD DES, V8, P883, DOI 10.1016/S0969-2126(00)00178-7; Parrish NM, 1998, TRENDS MICROBIOL, V6, P107, DOI 10.1016/S0966-842X(98)01216-5; POGOLOTTI AL, 1988, J BIOL CHEM, V263, P7461; QURESHI N, 1984, J BACTERIOL, V157, P46, DOI 10.1128/JB.157.1.46-52.1984; QURESHI N, 1980, J BIOL CHEM, V255, P182; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; SANTI DV, 1987, BIOCHEMISTRY-US, V26, P8599, DOI 10.1021/bi00400a016; Schluckebier G, 1998, BIOL CHEM, V379, P389; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WANG AY, 1992, BIOCHEMISTRY-US, V31, P11020, DOI 10.1021/bi00160a011; Yuan Y, 1998, MOL MICROBIOL, V29, P1449, DOI 10.1046/j.1365-2958.1998.01026.x; YUAN Y, 1995, P NATL ACAD SCI USA, V92, P6630, DOI 10.1073/pnas.92.14.6630; Yuan Y, 1996, P NATL ACAD SCI USA, V93, P12828, DOI 10.1073/pnas.93.23.12828; Yuan Y, 1997, J BIOL CHEM, V272, P10041; Zhang YM, 2001, J BIOL CHEM, V276, P8231, DOI 10.1074/jbc.M008042200; [No title captured]	54	73	81	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11559	11569		10.1074/jbc.M111698200	http://dx.doi.org/10.1074/jbc.M111698200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11756461	hybrid			2022-12-27	WOS:000174613100103
J	Mattison, K; Kenney, LJ				Mattison, K; Kenney, LJ			Phosphorylation alters the interaction of the response regulator OmpR with its sensor kinase EnvZ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORIN GENE-EXPRESSION; ESCHERICHIA-COLI K-12; TRANSCRIPTIONAL ACTIVATOR; TRANSMEMBRANE RECEPTOR; PHOSPHATASE-ACTIVITIES; BACTERIAL CHEMOTAXIS; MUTATIONAL ANALYSIS; SIGNAL TRANSDUCER; PROTEIN-KINASE; BINDING	OmpR and EnvZ comprise a two-component system that regulates the porin genes ompF and ompC in response to changes in osmolarity. EnvZ is autophosphorylated by intracellular ATP on a histidine residue, and it transfers the phosphoryl group to an aspartic acid residue of OmpR. EnvZ can also dephosphorylate phospho-OmpR (OmpR-P) to control the cellular level of OmpR-P. At low osmolarity, OmpR-P levels are low because of either low EnvZ kinase or high EnvZ phosphatase activities. At high osmolarity, OmpR-P is elevated. It has been proposed that EnvZ phosphatase is the activity that is regulated by osmolarity. OmpR is a two-domain response regulator; phosphorylation of OmpR increases its affinity for DNA, and DNA binding stimulates phosphorylation. The step that is affected by DNA depends upon the phosphodonor employed. In the present work, we have used fluorescence anisotropy and phosphotransfer assays to examine OmpR interactions with EnvZ. Our results indicate that phosphorylation greatly reduces the affinity of OmpR for the kinase, whereas DNA does not affect their interaction. The results presented cast serious doubts on the role of the EnvZ phosphatase in response to signaling in vivo.	Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA	Oregon Health & Science University	Kenney, LJ (corresponding author), Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, L-220,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058746] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58746, R01 GM058746] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOL CHEM, V264, P14090; AIBA H, 1989, J BIOCHEM-TOKYO, V106, P5, DOI 10.1093/oxfordjournals.jbchem.a122817; Ames SK, 1999, P NATL ACAD SCI USA, V96, P11792, DOI 10.1073/pnas.96.21.11792; BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; Blat Y, 1998, J MOL BIOL, V284, P1191, DOI 10.1006/jmbi.1998.2224; Castelli ME, 2000, J BIOL CHEM, V275, P22948, DOI 10.1074/jbc.M909335199; DELGADO J, 1993, MOL MICROBIOL, V10, P1037, DOI 10.1111/j.1365-2958.1993.tb00974.x; Dutta R, 2000, J BIOL CHEM, V275, P38645, DOI 10.1074/jbc.M005872200; Dutta R, 1996, J BIOL CHEM, V271, P1424, DOI 10.1074/jbc.271.3.1424; HALL MN, 1981, J MOL BIOL, V146, P23, DOI 10.1016/0022-2836(81)90364-8; Head CG, 1998, J MOL BIOL, V281, P857, DOI 10.1006/jmbi.1998.1985; Hoch JA, 1995, 2 COMPONENT SIGNAL T; Hsing WH, 1998, J BACTERIOL, V180, P4538, DOI 10.1128/JB.180.17.4538-4546.1998; Huang KJ, 1996, J MOL BIOL, V262, P615, DOI 10.1006/jmbi.1996.0540; IGO MM, 1989, GENE DEV, V3, P598, DOI 10.1101/gad.3.5.598; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; JIN T, 1993, J MOL BIOL, V232, P484, DOI 10.1006/jmbi.1993.1404; Jung K, 2001, J BIOL CHEM, V276, P40896, DOI 10.1074/jbc.M107871200; Kenney LJ, 1997, ARCH BIOCHEM BIOPHYS, V346, P303, DOI 10.1006/abbi.1997.0315; KENNEY LJ, 1995, P NATL ACAD SCI USA, V92, P8866, DOI 10.1073/pnas.92.19.8866; Kim C, 2001, J MOL BIOL, V307, P119, DOI 10.1006/jmbi.2000.4389; LI JY, 1995, BIOCHEMISTRY-US, V34, P14626, DOI 10.1021/bi00045a003; MATSUYAMA SI, 1986, J BACTERIOL, V168, P1309, DOI 10.1128/jb.168.3.1309-1314.1986; Montagne M, 2001, J BACTERIOL, V183, P1787, DOI 10.1128/JB.183.5.1787-1791.2001; Nakano MM, 2001, J BACTERIOL, V183, P1938, DOI 10.1128/JB.183.6.1938-1944.2001; Park H, 1997, J BACTERIOL, V179, P4382, DOI 10.1128/jb.179.13.4382-4390.1997; Pratt L., 1995, 2 COMPONENT SIGNAL T, P105; Qin L, 2001, P NATL ACAD SCI USA, V98, P908, DOI 10.1073/pnas.031383098; RAMPERSAUD A, 1994, J BIOL CHEM, V269, P12559; RUSSO FD, 1991, J MOL BIOL, V222, P567, DOI 10.1016/0022-2836(91)90497-T; Silversmith RE, 1999, TRENDS MICROBIOL, V7, P16, DOI 10.1016/S0966-842X(98)01409-7; SLAUCH JM, 1989, J MOL BIOL, V210, P281, DOI 10.1016/0022-2836(89)90330-6; Tran VK, 2000, J MOL BIOL, V299, P1257, DOI 10.1006/jmbi.2000.3809; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; WANNER BL, 1996, ESCHERICHIA COLI SAL, V1, P1359; Williams SB, 1997, J BACTERIOL, V179, P721, DOI 10.1128/jb.179.3.721-729.1997; WOOTTON JC, 1989, PROTEIN ENG, V2, P535, DOI 10.1093/protein/2.7.535	37	55	57	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11143	11148		10.1074/jbc.M111128200	http://dx.doi.org/10.1074/jbc.M111128200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11799122	hybrid			2022-12-27	WOS:000174613100051
J	Armano, S; Coco, S; Bacci, A; Pravettoni, E; Schenk, U; Verderio, C; Varoqui, H; Erickson, JD; Matteoli, M				Armano, S; Coco, S; Bacci, A; Pravettoni, E; Schenk, U; Verderio, C; Varoqui, H; Erickson, JD; Matteoli, M			Localization and functional relevance of system A neutral amino acid transporters in cultured hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLIAL-CELLS; GLUTAMINASE ACTIVITY; GLUTAMATE; ASTROCYTES; CLEARANCE; SYNAPTOSOMES; TRAFFICKING; TRANSMITTER; METABOLISM; SYNAPSE	Glutamine and alanine are important precursors for the synthesis of glutamate. Provided to neurons by neighboring astrocytes, these amino acids are internalized by classical system A amino acid carriers. In particular, System A transporter (SAT1) is a highly efficient glutamine transporter, whereas SAT2 exhibits broad specificity for neutral amino acids with a preference for alanine. We investigated the localization and the functional relevance of SAT1 and SAT2 in primary cultures of hippocampal neurons. Both carriers have been expressed since early developmental stages and are uniformly distributed throughout all neuronal processes. However, whereas SAT1 is present in axonal growth cones and can be detected at later developmental stages at the sites of synaptic contacts, SAT2 does not appear to be significantly expressed in these compartments. The non-metabolizable amino acid analogue alpha-(methylamino)-isobutyric acid, a competitive inhibitor of system A carriers, significantly reduced miniature excitatory postsynaptic current amplitude in neurons growing on top of astrocytes, being ineffective in pure neuronal cultures. alpha-(Methylamino)-isobutyric acid did not alter neuronal responsitivity to glutamate, thus excluding a postsynaptic effect. These data indicate that system A carriers are expressed with a different subcellular distribution in hippocampal neurons and play a crucial role in controlling the astrocyte-mediated supply of glutamatergic neurons with neurotransmitter precursors.	Dept Med Pharmacol, Consiglio Nazl Ric Cellular, I-20129 Milan, Italy; Dept Med Pharmacol, Mol Pharmacol & B Ceccarelli Ctr, I-20129 Milan, Italy; Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Matteoli, M (corresponding author), Dept Med Pharmacol, Consiglio Nazl Ric Cellular, Via Vanvitelli 32, I-20129 Milan, Italy.	MichelaM@csfic.mi.cnr.it	Coco, Silvia/AAD-6719-2022; Verderio, Claudia/K-4415-2016; Matteoli, Michela/K-4526-2018	Verderio, Claudia/0000-0001-7216-5873; Matteoli, Michela/0000-0002-3569-7843; Bacci, Alberto/0000-0002-3355-5892; COCO, SILVIA/0000-0002-3883-9472				Bacci A, 1999, PHILOS T R SOC B, V354, P403, DOI 10.1098/rstb.1999.0393; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BARTLETT WP, 1984, J NEUROSCI, V4, P1944; Bergles DE, 1999, CURR OPIN NEUROBIOL, V9, P293, DOI 10.1016/S0959-4388(99)80043-9; Bezzi P, 2001, CURR OPIN NEUROBIOL, V11, P387, DOI 10.1016/S0959-4388(00)00223-3; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; Bode BP, 2001, J NUTR, V131, p2475S, DOI 10.1093/jn/131.9.2475S; BOOHER J, 1972, Neurobiology (Copenhagen), V2, P97; BRADFORD HF, 1976, BRAIN RES, V110, P115, DOI 10.1016/0006-8993(76)90212-2; Buckley KM, 2000, J PHYSIOL-LONDON, V525, P11, DOI 10.1111/j.1469-7793.2000.t01-2-00011.x; Calegari F, 1999, J BIOL CHEM, V274, P22539, DOI 10.1074/jbc.274.32.22539; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; Coco S, 1997, EUR J NEUROSCI, V9, P1902, DOI 10.1111/j.1460-9568.1997.tb00757.x; CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025; DEROUICHE A, 1995, J NEUROSCI RES, V42, P131, DOI 10.1002/jnr.490420115; DOTTI CG, 1988, J NEUROSCI, V8, P1454; GUIDOTTI GG, 1978, BIOCHIM BIOPHYS ACTA, V515, P329, DOI 10.1016/0304-4157(78)90009-6; HAMBERGER AC, 1979, BRAIN RES, V168, P513, DOI 10.1016/0006-8993(79)90306-8; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; HERTZ L, 1988, GLUTAMATE GLUTAMINE; JENDELOVA P, 1991, GLIA, V4, P56, DOI 10.1002/glia.440040107; KIHARA M, 1989, J NEUROCHEM, V52, P1127, DOI 10.1111/j.1471-4159.1989.tb01857.x; LAAKE JH, 1995, J NEUROCHEM, V65, P871; MARTINEZHERNANDEZ A, 1977, SCIENCE, V195, P1356, DOI 10.1126/science.14400; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; MURATA Y, 1995, JPN J PHARMACOL, V68, P279, DOI 10.1254/jjp.68.279; NICKLAS WJ, 1983, GLUTAMINE GLUTAMATE, P219; Pfrieger FW, 1996, CURR OPIN NEUROBIOL, V6, P615, DOI 10.1016/S0959-4388(96)80093-6; Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684; Reimer RJ, 2000, P NATL ACAD SCI USA, V97, P7715, DOI 10.1073/pnas.140152797; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; SHANK RP, 1984, J NEUROCHEM, V42, P1153, DOI 10.1111/j.1471-4159.1984.tb12724.x; Sibson NR, 1997, P NATL ACAD SCI USA, V94, P2699, DOI 10.1073/pnas.94.6.2699; Su TZ, 1997, BRAIN RES, V757, P69, DOI 10.1016/S0006-8993(97)00139-X; Sugawara M, 2000, BBA-BIOMEMBRANES, V1509, P7, DOI 10.1016/S0005-2736(00)00349-7; Trudeau LE, 1999, J NEUROPHYSIOL, V81, P2627, DOI 10.1152/jn.1999.81.6.2627; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; Verderio C, 1999, EUR J NEUROSCI, V11, P2793, DOI 10.1046/j.1460-9568.1999.00697.x; WESTERGAARD N, 1995, DEV NEUROSCI-BASEL, V17, P203, DOI 10.1159/000111288; Yao DD, 2000, J BIOL CHEM, V275, P22790, DOI 10.1074/jbc.M002965200; YU ACH, 1983, J NEUROCHEM, V41, P1484, DOI 10.1111/j.1471-4159.1983.tb00849.x; Yudkoff M, 1996, J NEUROCHEM, V66, P2136; Zhou Q, 2000, J PHYSIOL-LONDON, V525, P195, DOI 10.1111/j.1469-7793.2000.t01-1-00195.x	44	57	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10467	10473		10.1074/jbc.M110942200	http://dx.doi.org/10.1074/jbc.M110942200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11788594	hybrid			2022-12-27	WOS:000174549200114
J	Arosio, D; Cui, S; Ortega, C; Chovanec, M; Di Marco, S; Baldini, G; Falaschi, A; Vindigni, A				Arosio, D; Cui, S; Ortega, C; Chovanec, M; Di Marco, S; Baldini, G; Falaschi, A; Vindigni, A			Studies on the mode of Ku interaction with DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; V(D)J RECOMBINATION; HELICASE-II; BINDING; COMPLEXES; REPRESSOR; ENDS	The Ku heterodimer plays a central role in non-homologous end-joining. The binding of recombinant Ku to DNA has been investigated by dynamic light scattering, double-filter binding, fluorescence spectroscopy, and band shift assays. The hydrodynamic radius of Ku in solution is 5.2 nm and does not change when a 25-bp double-strand DNA (dsDNA) fragment (1325) is added, indicating that only one Ku molecule binds to a 25-bp fragment. The dissociation constant (k(d)) for the binding to D25 is 3.8 +/- 0.9 nm. If both ends of the substrate are closed with hairpin loops, Ku is still able to bind with little change in the k(d). The k(d) is not affected by ATP, Mg2+, or ionic strength. However, the addition of bovine serum albumin decreases the kd by 2-fold. DNA substrates of 50 bp can bind two Ku molecules, whereas three molecules are bound to a 75-bp substrate. Data analysis with the Hill equation yields a value of the Hill coefficient (n) close to 1, and the kd values for the binding of Ku to both ends of these substrates are the same. Thus, we demonstrate that there is no cooperative interaction among the Ku heterodimers binding longer substrates.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Univ Sussex, Genome Damage & Stabil Unit, Brighton BN1 9RR, E Sussex, England; P Angeletti SpA, IRBM, I-00040 Pomezia, Rome, Italy; Univ Milan, Dipartimento Fis, I-20126 Milan, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB); University of Sussex; Merck & Company; University of Milan	Vindigni, A (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	vindigni@icgeb.trieste.it	Di Marco, Stefania -/C-3859-2009; Sheng, CUI/M-6405-2013; Chovanec, Miroslav/H-6818-2018; Cui, Sheng/AAQ-1721-2020; arosio, daniele/B-3160-2012	Sheng, CUI/0000-0001-6329-3582; Chovanec, Miroslav/0000-0001-9120-5084; 				Ail JA, 1999, J MOL BIOL, V293, P815, DOI 10.1006/jmbi.1999.3185; Arosio D, 2002, BIOPOLYMERS, V63, P1, DOI 10.1002/bip.1057; AROSIO D, 1995, THESIS U MILAN MILAN; BARKLEY MD, 1981, BIOCHEMISTRY-US, V20, P3842, DOI 10.1021/bi00516a027; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Cantor C.R., 1980, BIOPHYS CHEM; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; DEVRIES DJ, 1989, LIFE SCI, V44, P711, DOI 10.1016/0024-3205(89)90382-2; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Ellison V, 2001, CELL, V106, P655, DOI 10.1016/S0092-8674(01)00498-6; FALZON M, 1993, J BIOL CHEM, V268, P10546; Huffman JL, 2001, J BIOL CHEM, V276, P40537, DOI 10.1074/jbc.M105675200; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; Jones JM, 2001, STRUCTURE, V9, P881, DOI 10.1016/S0969-2126(01)00658-X; KOPPEL DE, 1972, J CHEM PHYS, V57, P4814, DOI 10.1063/1.1678153; KOZMIK Z, 1990, NUCLEIC ACIDS RES, V18, P2198, DOI 10.1093/nar/18.8.2198; LIDE DR, 1996, CRC HDB CHEM PHYSICS; Lieber MR, 1997, CURR OPIN GENET DEV, V7, P99, DOI 10.1016/S0959-437X(97)80116-5; Ma YM, 2001, BIOCHEMISTRY-US, V40, P9638, DOI 10.1021/bi010932v; MIMORI T, 1986, J BIOL CHEM, V261, P375; MISRA VK, 1994, J MOL BIOL, V238, P264, DOI 10.1006/jmbi.1994.1286; Novac O, 2001, MOL BIOL CELL, V12, P3386, DOI 10.1091/mbc.12.11.3386; Ochem AE, 1997, J BIOL CHEM, V272, P29919, DOI 10.1074/jbc.272.47.29919; Riballo E, 2001, J BIOL CHEM, V276, P31124, DOI 10.1074/jbc.M103866200; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; SHARP KA, 1995, CURR OPIN STRUC BIOL, V5, P323, DOI 10.1016/0959-440X(95)80093-X; Singleton BK, 1999, MOL CELL BIOL, V19, P3267; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Watrob H, 2001, BIOCHEMISTRY-US, V40, P683, DOI 10.1021/bi002055j; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; West RB, 1998, MOL CELL BIOL, V18, P5908, DOI 10.1128/MCB.18.10.5908; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Zhao JK, 1999, BIOCHEMISTRY-US, V38, P2152, DOI 10.1021/bi9825246	41	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9741	9748		10.1074/jbc.M111916200	http://dx.doi.org/10.1074/jbc.M111916200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11796732	hybrid			2022-12-27	WOS:000174549200021
J	Barsyte-Lovejoy, D; Galanis, A; Sharrocks, AD				Barsyte-Lovejoy, D; Galanis, A; Sharrocks, AD			Specificity determinants in MAPK signaling to transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOCKING SITES; KINASE; TRANSDUCTION; ACTIVATION; CONTAINS; ELK-1; MKK3; ERK	One critical component in determining the specificity, fidelity, and efficiency of MAPK substrate phosphorylation is the presence of distinct docking domains in the substrate proteins. These docking domains are found in a range of substrates, including the transcription factors myocyte enhancer factor-2A and SAP-1. However, the sequences of these motifs differ, as does their targeting preferences by MAPKs, with SAP-1 being targeted by both the ERK and p38 isoforms, whereas myocyte enhancer factor-2A is targeted only by certain members of the p38 subfamily. Here, we have investigated the specificity determinants within these motifs and generated a model for how specificity is generated. We demonstrate that residues throughout the docking domains play important roles in the recognition process. However residues located at different positions are important for discriminating between ERK and p38 MAPKs. Furthermore, the docking domains can be further subdivided into submotifs, which are differentially required for phosphorylation by ERK or p38 MAPKs. We have used loss- and gain-of-function mutagenesis to identify residues that discriminate between ERK and p38 MAPKs, residues that act to promote suboptimal interactions, and regions that are differentially required depending on the kinase involved. A model is proposed to explain how specificity is generated within these short docking domains.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Newcastle Univ, Sch Med, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Manchester; Newcastle University - UK	Sharrocks, AD (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	a.d.sharrocks@man.ac.uk	Galanis, Alex/ABF-4762-2020	Galanis, Alex/0000-0001-9991-3173				Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Ducret C, 2000, ONCOGENE, V19, P5063, DOI 10.1038/sj.onc.1203892; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Galanis A, 2001, J BIOL CHEM, V276, P965, DOI 10.1074/jbc.M007697200; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; JANKNECHT R, 1995, ONCOGENE, V10, P1209; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; Ornatsky OI, 1999, NUCLEIC ACIDS RES, V27, P2646, DOI 10.1093/nar/27.13.2646; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SETH A, 1992, J BIOL CHEM, V267, P24796; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; West AG, 1997, MOL CELL BIOL, V17, P2876, DOI 10.1128/MCB.17.5.2876; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zhao M, 1999, MOL CELL BIOL, V19, P21	26	67	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9896	9903		10.1074/jbc.M108145200	http://dx.doi.org/10.1074/jbc.M108145200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11786537	hybrid			2022-12-27	WOS:000174549200040
J	Cui, YJ; Wang, WX; Fan, Z				Cui, YJ; Wang, WX; Fan, Z			Cytoplasmic vestibule of the weak inward rectifier Kir6.2 potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNELS; SULFONYLUREA RECEPTOR; N-TERMINUS; C-TERMINUS; INHIBITION; MECHANISM; RECTIFICATION; PORE; DETERMINANTS; RESIDUES	Intracellular application of certain charged methanethiosulfonate (MTS) reagents modified and irreversibly inhibited Kir6.2 channels when cysteine substitutions were introduced at positions Ile-210, Ile-211, or Ser-212 within the putative cytoplasmic region. Inhibition depends on the spatial dimensions of the MTS reagents. Reaction of MTS reagents, having head diameters of 7.6-8.2 Angstrom, with cysteines introduced at position Ser-212 must occur in more than two subunits of the tetrameric Kir6.2 complex to inhibit channel activity. MTS reagents with head diameters less than 6.6 Angstrom modified cysteines without causing channel inhibition. An MTS reagent with a head diameter of similar to10 Angstrom could neither modify nor inhibit the channels. Channel inhibition is interpreted as blockage of the intracellular vestibule by NITS reagents that enter the channel vestibule and react with the cysteine residues at vestibule-lining positions. Data are consistent with the hypothesis that residues Ile-210-Ser-212 line a funnel-shaped vestibule of 20-25 Angstrom in diameter, which remains unchanged during channel gating.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Fan, Z (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.				NHLBI NIH HHS [HL-58133] Funding Source: Medline; NIGMS NIH HHS [GM61943] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058133, R29HL058133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061943] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Babenko AP, 1999, BIOCHEM BIOPH RES CO, V255, P231, DOI 10.1006/bbrc.1999.0172; Baukrowitz T, 1999, EMBO J, V18, P847, DOI 10.1093/emboj/18.4.847; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; Capener CE, 2000, BIOPHYS J, V78, P2929, DOI 10.1016/S0006-3495(00)76833-0; Choe H, 1999, BIOPHYS J, V76, P1988, DOI 10.1016/S0006-3495(99)77357-1; DAVIES NW, 1989, J PHYSIOL-LONDON, V413, P31, DOI 10.1113/jphysiol.1989.sp017640; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; Enkvetchakul D, 2001, BIOPHYS J, V80, P719, DOI 10.1016/S0006-3495(01)76051-1; Fan Z, 1999, J GEN PHYSIOL, V114, P251, DOI 10.1085/jgp.114.2.251; FAN Z, 1990, J PHYSIOL-LONDON, V430, P273, DOI 10.1113/jphysiol.1990.sp018291; Jan LY, 1997, J PHYSIOL-LONDON, V505, P267, DOI 10.1111/j.1469-7793.1997.267bb.x; Kubo Y, 2001, J PHYSIOL-LONDON, V531, P645, DOI 10.1111/j.1469-7793.2001.0645h.x; Lancaster MK, 2000, J BIOL CHEM, V275, P35831, DOI 10.1074/jbc.M006565200; LOPATIN AN, 1995, J GEN PHYSIOL, V106, P923, DOI 10.1085/jgp.106.5.923; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; Loussouarn G, 2000, J BIOL CHEM, V275, P1137, DOI 10.1074/jbc.275.2.1137; Loussouarn G, 2001, P NATL ACAD SCI USA, V98, P4227, DOI 10.1073/pnas.061452698; Lu T, 1999, P NATL ACAD SCI USA, V96, P9926, DOI 10.1073/pnas.96.17.9926; Lu T, 2001, NAT NEUROSCI, V4, P239, DOI 10.1038/85080; Luchian T, 1997, J PHYSIOL-LONDON, V505, P13, DOI 10.1111/j.1469-7793.1997.013bc.x; Minor DL, 1999, CELL, V96, P879, DOI 10.1016/S0092-8674(00)80597-8; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; Reimann F, 1999, J PHYSIOL-LONDON, V518, P325, DOI 10.1111/j.1469-7793.1999.0325p.x; Reimann F, 1999, CURR OPIN CELL BIOL, V11, P503, DOI 10.1016/S0955-0674(99)80073-8; TAGLIALATELA M, 1995, EMBO J, V14, P5532, DOI 10.1002/j.1460-2075.1995.tb00240.x; Trapp S, 1998, J GEN PHYSIOL, V112, P325, DOI 10.1085/jgp.112.3.325; Trapp S, 1998, J GEN PHYSIOL, V112, P333, DOI 10.1085/jgp.112.3.333; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; Yi BA, 2001, NEURON, V29, P657, DOI 10.1016/S0896-6273(01)00241-0	37	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10523	10530		10.1074/jbc.M109118200	http://dx.doi.org/10.1074/jbc.M109118200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11790775	hybrid			2022-12-27	WOS:000174549200121
J	Daines, MO; Hershey, GKK				Daines, MO; Hershey, GKK			A novel mechanism by which interferon-gamma can regulate interleukin (IL)-13 responses - Evidence for intracellular stores of IL-13 receptor alpha-2 and their rapid mobilization by interferon-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELLS; POLYMORPHONUCLEAR CELLS; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; IFN-GAMMA; T-CELLS; EXPRESSION; CLONING; MONOCYTES; ASTHMA	Interleukin (IL)-13 mediates its activities via a complex receptor system. Interleukin-13 receptor alpha-1 chain (IL-13Ralpha1) binds IL-13 with low affinity, but does not signal. However, when IL-13Ralpha1 combines with IL-4 receptor alpha (1L-4Ralpha), a signaling high affinity receptor complex for IL-13 is generated. In contrast, IL-13Ralpha2 alone binds IL-13 with high affinity, but does not signal and has been postulated to be a decoy receptor. Herein, we investigated the cellular localization of IL-13Ra2 and the regulation of its expression by confocal microscopy and flow cytometry in primary and cultured cells. Our results demonstrate that IL-13Ralpha2 is largely an intracellular molecule, which is rapidly mobilized from intracellular stores following treatment with interferon (IFN)-gamma. Up-regulation of IL-13Ralpha2 surface expression in response to IFN-gamma was rapid, did not require protein synthesis, and resulted in diminished IL-13 signaling. These results provide the first evidence that the IL-13Ralpha2 is predominantly an intracellular molecule and demonstrate a novel mechanism by which IFN-gamma can regulate IL-13 responses.	Childrens Hosp, Med Ctr, Div Allergy & Immunol, Dept Pediat, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Hershey, GKK (corresponding author), Childrens Hosp, Med Ctr, Div Allergy & Immunol, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	gurjit.hershey@chmcc.org		Khurana Hershey, Gurjit/0000-0001-6663-977X; Daines, Michael/0000-0003-2464-9034	NICHD NIH HHS [P30HD2887] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Andrews RP, 2001, CLIN IMMUNOL, V100, P298, DOI 10.1006/clim.2001.5082; Andrews RP, 2001, J IMMUNOL, V166, P1716, DOI 10.4049/jimmunol.166.3.1716; Black HR, 1998, AM J RESP CELL MOL, V19, P210, DOI 10.1165/ajrcmb.19.2.3053; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BOSSU P, 1995, AM J PATHOL, V147, P1852; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; COLOTTA F, 1994, J BIOL CHEM, V269, P12403; Dickensheets HL, 1997, J IMMUNOL, V159, P6226; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Graber P, 1998, EUR J IMMUNOL, V28, P4286, DOI 10.1002/(SICI)1521-4141(199812)28:12<4286::AID-IMMU4286>3.0.CO;2-H; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Guo JA, 1997, GENOMICS, V42, P141, DOI 10.1006/geno.1997.4628; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; Li L, 1999, J IMMUNOL, V162, P2477; Li Y, 1998, J IMMUNOL, V161, P7007; Linsley PS, 1996, IMMUNITY, V4, P535, DOI 10.1016/S1074-7613(00)80480-X; Martin MU, 1997, EUR CYTOKINE NETW, V8, P5; MAUDSLEY DJ, 1987, IMMUNOLOGY, V61, P189; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Orchansky PL, 1999, J BIOL CHEM, V274, P20818, DOI 10.1074/jbc.274.30.20818; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RE F, 1993, EUR J IMMUNOL, V23, P570, DOI 10.1002/eji.1830230242; Takeda K, 1996, J IMMUNOL, V157, P3220; Urban JF, 1998, IMMUNITY, V8, P255, DOI 10.1016/S1074-7613(00)80477-X; Webb DC, 2000, J IMMUNOL, V165, P108, DOI 10.4049/jimmunol.165.1.108; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhang JG, 1997, J BIOL CHEM, V272, P9474; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	39	81	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10387	10393		10.1074/jbc.M108109200	http://dx.doi.org/10.1074/jbc.M108109200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11786536	hybrid			2022-12-27	WOS:000174549200104
J	Schneider, M; Nagashima, M; Knappe, S; Zhao, L; Morser, J; Nesheim, M				Schneider, M; Nagashima, M; Knappe, S; Zhao, L; Morser, J; Nesheim, M			Amino acid residues in the P6-P ' 3 region of thrombin-activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA PROCARBOXYPEPTIDASE-B; PROTEIN-C; FACTOR-V; COMPLEX; CARBOXYPEPTIDASE; COAGULATION	Thrombin bound to thrombomodulin activates thrombin-activable fibrinolysis inhibitor (TAFI) and protein C much more efficiently than thrombin alone. Although thrombomodulin has been proposed to alter the thrombin active site, the recently determined structure of the thrombin-thrombomodulin complex does not support this proposal. In this study, the contribution of amino acids near the activation site of TAFI toward thrombomodulin dependence was determined, utilizing four variants of TAFI with specific substitutions in the P6-P'3 region surrounding the Arg-92 cleavage site. Two point mutants had either the Ser-90 or Asp-87 of TAFI replaced with Ala, a third mutant had the thrombim activation site of the fibrinogen Bbeta-chain substituted into positions 91-95 of TAFI, and a fourth mutant had the thrombin activation site of protein C substituted into positions 90-95 of TAFI. Each of these mutants was expressed, purified, and characterized with respect to activation kinetics and functional properties of the enzyme. Even though fibrinogen is poorly cleaved by thrombin-thrombomodulin, the fibrinogen activation site does not significantly alter the thrombomodulin dependence of TAFI activation. The TAFI variant with the protein C activation sequence is only slowly activated by thrombin-thrombomodulin, and not at all by free thrombin. Mutating Asp-87 to Ala increases the catalytic efficiency of activation 3-fold both in the presence and absence of thrombomodulin, whereas mutating Ser-90 to Ala effects only minor kinetic differences compared with wild type TAFI. The thermal stabilities and antifibrinolytic properties of the enzymes were not substantially altered by any of the mutations that allowed for efficient activation of the enzyme. We conclude that residues in the P6-P'3 region of TAFI do not determine the thrombomodulin dependence of activation, which lends support to the argument that the role of thrombomodulin is to optimally orient thrombin and its substrate, rather than to allosterically alter the specificity of the thrombin active site.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; Berlex Biosci, Richmond, CA 94804 USA	Queens University - Canada; Queens University - Canada	Nesheim, M (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	nesheimm@post.queensu.ca						Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Boffa MB, 2000, J BIOL CHEM, V275, P12868, DOI 10.1074/jbc.275.17.12868; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; EATON DL, 1991, J BIOL CHEM, V266, P21833; ESMON CT, 1982, J BIOL CHEM, V257, P7944; ESMON CT, 1991, ANN NY ACAD SCI, V614, P30; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; Hall SW, 1999, J BIOL CHEM, V274, P25510, DOI 10.1074/jbc.274.36.25510; LEBONNIEC BF, 1993, J BIOL CHEM, V268, P19055; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165; Mao SS, 1999, J BIOL CHEM, V274, P35046, DOI 10.1074/jbc.274.49.35046; Mock WL, 1999, BIOORG MED CHEM LETT, V9, P187, DOI 10.1016/S0960-894X(98)00715-X; Neville D M Jr, 1974, Methods Enzymol, V32, P92; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; Walker JB, 1999, J BIOL CHEM, V274, P5201, DOI 10.1074/jbc.274.8.5201; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; WANG W, 1994, J BIOL CHEM, V269, P15937; Wang W, 2000, J BIOL CHEM, V275, P22942, DOI 10.1074/jbc.M001760200; Zhao L, 1998, THROMB HAEMOSTASIS, V80, P949	25	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9944	9951		10.1074/jbc.M111685200	http://dx.doi.org/10.1074/jbc.M111685200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11786552	hybrid			2022-12-27	WOS:000174549200046
J	Van Mullem, V; Wery, M; Werner, M; Vandenhaute, J; Thuriaux, P				Van Mullem, V; Wery, M; Werner, M; Vandenhaute, J; Thuriaux, P			The Rpb9 subunit of RNA polymerase II binds transcription factor TFIIE and interferes with the SAGA and elongator histone acetyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; FACTOR-SII; FACTOR-S; IN-VIVO; GENE; DNA; COMPLEX; PROTEIN; INITIATION; SYSTEM	Rpb9 is a small subunit of yeast RNA polymerase 11 participating in elongation and formed of two conserved zinc domains. rpb9 mutants are viable, with a strong sensitivity to nucleotide-depleting drugs. Deleting the C-terminal domain down to the first 57 amino acids has no detectable growth defect. Thus, the critical part of Rpb9 is limited to a N-terminal half that contacts the lobe of the second largest subunit (Rpb2) and forms a beta-addition motif with the 'Jaw" of the largest subunit (Rpb1). Rpb9 has homology to the TFIIS elongation factor, but mutants inactivated for both proteins are indistinguishable from rpb9 single mutants. In contrast, rpb9 mutants are lethal in cells lacking the histone acetyltransferase activity of the RNA polymerase 11 Elongator and SAGA factors. In a two-hybrid test, Rpb9 physically interacts with Tfa1, the largest subunit of TFIIE. The interacting fragment, comprising amino acids 62-164 of Tfa1, belongs to a conserved zinc motif. Tfa1 is immunoprecipitated by RNA polymerase II. This co-purification is strongly reduced in rpb9-Delta, suggesting that Rpb9 contributes to the recruitment of TFIIE on RNA polymerase II.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France; Fac Univ Notre Dame Paix, Mol Genet Lab, B-5000 Namur, Belgium	CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Namur	Thuriaux, P (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, Batiment 142, F-91191 Gif Sur Yvette, France.		Wery, Maxime/AAR-2426-2020; Werner, Michel/B-7316-2009	Wery, Maxime/0000-0003-3004-471X; Werner, Michel/0000-0002-2965-5858				Awrey DE, 1997, J BIOL CHEM, V272, P14747, DOI 10.1074/jbc.272.23.14747; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Briand JF, 2001, MOL CELL BIOL, V21, P6056, DOI 10.1128/MCB.21.17.6056-6065.2001; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; Chedin S, 1998, GENE DEV, V12, P3857, DOI 10.1101/gad.12.24.3857; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Davie JK, 2000, MOL CELL BIOL, V20, P5960, DOI 10.1128/MCB.20.16.5960-5973.2000; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; Flores A, 1999, P NATL ACAD SCI USA, V96, P7815, DOI 10.1073/pnas.96.14.7815; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Hausner W, 2000, J BIOL CHEM, V275, P12393, DOI 10.1074/jbc.275.17.12393; Hemming SA, 2000, J BIOL CHEM, V275, P35506, DOI 10.1074/jbc.M004721200; Hemming SA, 2000, J BIOL CHEM, V275, P2288, DOI 10.1074/jbc.275.4.2288; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; Imazawa Y, 2001, MOL GEN GENET, V264, P852, DOI 10.1007/s004380000375; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; John S, 2000, GENE DEV, V14, P1196; Kugel JF, 1998, P NATL ACAD SCI USA, V95, P9232, DOI 10.1073/pnas.95.16.9232; Kuldell NH, 1997, MOL CELL BIOL, V17, P5288, DOI 10.1128/MCB.17.9.5288; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; LILJELUND P, 1992, P NATL ACAD SCI USA, V89, P9302, DOI 10.1073/pnas.89.19.9302; LIU ZH, 1993, FEBS LETT, V335, P73, DOI 10.1016/0014-5793(93)80442-W; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MCKUNE K, 1995, MOL CELL BIOL, V15, P6895; Minakhin L, 2001, P NATL ACAD SCI USA, V98, P892, DOI 10.1073/pnas.98.3.892; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NOGI Y, 1993, MOL CELL BIOL, V13, P114, DOI 10.1128/MCB.13.1.114; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Pan GH, 1997, J BIOL CHEM, V272, P24563, DOI 10.1074/jbc.272.39.24563; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; RIVA M, 1986, P NATL ACAD SCI USA, V83, P1554, DOI 10.1073/pnas.83.6.1554; Rozenfeld S, 2001, EMBO REP, V2, P598, DOI 10.1093/embo-reports/kve136; Sakurai H, 1997, J BIOL CHEM, V272, P15936, DOI 10.1074/jbc.272.25.15936; SAWADOGO M, 1980, J BIOL CHEM, V255, P12; SHPAKOVSKI GV, 1995, MOL CELL BIOL, V15, P4702; SIKORSKI RS, 1989, GENETICS, V122, P19; VANMULLEN V, 2002, IN PRESS MOL MICROBI; Wind M, 2000, BIOESSAYS, V22, P327, DOI 10.1002/(SICI)1521-1878(200004)22:4<327::AID-BIES3>3.0.CO;2-4; Wittschieben BO, 2000, EMBO J, V19, P3060, DOI 10.1093/emboj/19.12.3060; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; WOYCHIK NA, 1991, J BIOL CHEM, V266, P19053; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	51	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10220	10225		10.1074/jbc.M107207200	http://dx.doi.org/10.1074/jbc.M107207200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11779853	hybrid			2022-12-27	WOS:000174549200082
J	Johnson, CA; White, DA; Lavender, JS; O'Neill, LP; Turner, BM				Johnson, CA; White, DA; Lavender, JS; O'Neill, LP; Turner, BM			Human class I histone deacetylase complexes show enhanced catalytic activity in the presence of ATP and co-immunoprecipitate with the ATP-dependent chaperone protein Hsp70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-COR; ACETYLATION; TRANSCRIPTION; BINDING; TAILS; H4; IDENTIFICATION; REPRESSION; COMPONENT; CLONING	Antibodies to histone deacetylases (HDACs) have been used to immuno-isolate deacetylase complexes from HeLa cell extracts. Complexes shown to contain HDAC I, HDAC3, HDAC6, and HDAC1+2 as their catalytic subunits have been used in an antibody-based assay that detects deacetylation of whole histories at defined lysines. The class 11 deacetylase HDAC6 was inactive in this assay, but the three class I enzymes deacetylated all histone lysines tested, although with varying efficiency. In comparison to HDAC1, HDAC3 preferentially deacetylated lysines 5 and 12 of H4 and lysine 5 of H2A. H4 tails in purified mononucleosomes were refractory to deacetylation by both HDAC1 and HDAC3, unless ATP was added to the reaction mix. Surprisingly, ATP a so consistently enhanced cleavage of free, non-nucleosomal histones, but not small peptides, by both enzyme complexes. We found no evidence that ATP operates by phosphorylation of components of the HDAC complex but have shown that HDACs 1, 2, and 3 all co-immunoprecipitate with the ATP-dependent chaperone protein Hsp70. Another common ATP-dependent chaperone, Hsp90, was absent from all HDAC complexes tested, whereas Hsp60 associated with HDAC1 only. We suggest that Hsp chaperone proteins enhance the deacetylase activity of HDAC complexes by ATP-dependent manipulation of protein substrates.	Univ Birmingham, Sch Med, Dept Anat, Chromatin & Gene Express Grp, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Turner, BM (corresponding author), Univ Birmingham, Sch Med, Dept Anat, Chromatin & Gene Express Grp, Birmingham B15 2TT, W Midlands, England.	b.m.turner@bham.ac.uk		Johnson, Colin/0000-0002-2979-8234				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Barlow AL, 2001, EXP CELL RES, V265, P90, DOI 10.1006/excr.2001.5162; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Cai R, 2001, BIOCHEM BIOPH RES CO, V283, P445, DOI 10.1006/bbrc.2001.4786; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Dutta S, 2001, MOL CELL, V8, P841, DOI 10.1016/S1097-2765(01)00354-9; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fenton WA, 1997, PROTEIN SCI, V6, P743; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Grant PA, 1999, SEMIN CELL DEV BIOL, V10, P169, DOI 10.1006/scdb.1999.0298; Gregory RI, 2001, MOL CELL BIOL, V21, P5426, DOI 10.1128/MCB.21.16.5426-5436.2001; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Harlow E., 1988, ANTIBODIES LAB MANUA; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kolle D, 1999, BIOCHEMISTRY-US, V38, P6769, DOI 10.1021/bi982702v; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Li W, 1996, BIOCHEM J, V314, P631, DOI 10.1042/bj3140631; Marmorstein R, 2001, NAT REV MOL CELL BIO, V2, P422, DOI 10.1038/35073047; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Morales V, 2000, MOL CELL BIOL, V20, P7230, DOI 10.1128/MCB.20.19.7230-7237.2000; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Ryan J, 1999, J CELL SCI, V112, P2441; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SENDRA R, 1988, PLANT MOL BIOL, V11, P857, DOI 10.1007/BF00019525; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Van den Wyngaert I, 2000, FEBS LETT, V478, P77, DOI 10.1016/S0014-5793(00)01813-5; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wang XY, 2000, J BIOL CHEM, V275, P35013, DOI 10.1074/jbc.M004998200; WHITE DA, 1999, METHODS COMPANION ME, V10, P417; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697	53	101	107	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9590	9597		10.1074/jbc.M107942200	http://dx.doi.org/10.1074/jbc.M107942200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11777905	hybrid			2022-12-27	WOS:000174400600112
J	Krepinsky, J; Ingram, AJ; James, L; Ly, H; Thai, K; Cattran, DC; Miller, JA; Scholey, JW				Krepinsky, J; Ingram, AJ; James, L; Ly, H; Thai, K; Cattran, DC; Miller, JA; Scholey, JW			17 beta-estradiol modulates mechanical strain-induced MAPK activation in mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE; COLLAGEN-SYNTHESIS; EXTRACELLULAR-MATRIX; STRETCH-RELAXATION; RAT; ESTROGEN; PROLIFERATION; HYPERTENSION; PRESSURE	Gender is an important determinant of clinical outcome across a broad spectrum of kidney diseases, but the mechanism(s) responsible for the protective effect of female gender have not been fully elucidated. Remnant kidney glomerular injury is limited in female rats compared with male rats despite similar elevations in glomerular capillary pressure. In vitro, mechanical strain leads to the activation of p44/42 mitogen-activated kinase (p44/42 MAPK) and Jun N-terminal kinase/stress-activated protein kinase (SAPK) in glomerular mesangial cells (MC). Accordingly, we studied the effect of 17beta-estradiol on mechanical strain-induced signal transduction in MC. Exposure of MC to mechanical strain increased p44/42 MAPK activation (3-fold) and SAPK activation (2.5-fold), and kinase activation was inhibited by pretreatment with 17beta-estradiol (10(-8) to 10(-11) m) for 24 h in a dose-dependent manner. Mechanical strain-induced nuclear translocation of p44/42 MAPK and SAPK and nuclear protein binding to AP-1 were also attenuated by 17beta-estradiol. The inhibitory effects of 17beta-estradiol were not reproduced by the cell-impermeable estrogen, BSA/17beta-estradiol, nor did preincubation with 17beta-estradiol lead to actin cytoskeleton disassembly or impaired stress fiber formation. However, 17beta-estradiol did increase base-line levels of the dual specificity phosphatase MKP-1. The inhibitory effects of 17beta-estradiol on p44/42 MAPK activation and SAPK activation, translocation, and AP-1 binding were all abrogated by the estrogen receptor antagonist, ICI-182,780. We conclude that attenuation of mechanical strain-induced MAPK activation by 17beta-estradiol is dependent on intracellular estrogen receptor. The attenuation of stretch-induced kinase activation may be due, at least in part, to an effect of 17beta-estradiol on MKP-1 expression. Together, these findings add insight into the protective effect of gender on renal disease progression.	Univ Toronto, Dept Med, Toronto, ON M5G 2C4, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 1Y2, Canada	University of Toronto; McMaster University	Krepinsky, J (corresponding author), Univ Hlth Network, Toronto Gen Hosp, 13 EN-243,200 Elizabeth St, Toronto, ON MUG 2C4, Canada.			James, Leighton/0000-0002-7613-705X				AKAI Y, 1994, AM J PHYSIOL, V267, pC482, DOI 10.1152/ajpcell.1994.267.2.C482; ANDERSON S, 1985, J CLIN INVEST, V76, P612, DOI 10.1172/JCI112013; Bonacchi A, 2001, J BIOL CHEM, V276, P9945, DOI 10.1074/jbc.M010303200; BRENNER BM, 1985, AM J PHYSIOL, V249, P324; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Goetz RM, 1999, P NATL ACAD SCI USA, V96, P2788, DOI 10.1073/pnas.96.6.2788; Gorodeski GI, 2000, AM J PHYSIOL-CELL PH, V279, pC2028, DOI 10.1152/ajpcell.2000.279.6.C2028; Hamaguchi A, 1998, J AM SOC NEPHROL, V9, P372; Haneda M, 1999, EUR J PHARMACOL, V365, P1, DOI 10.1016/S0014-2999(98)00857-7; HARRIS RC, 1992, LAB INVEST, V66, P548; HARRIS RC, 1994, KIDNEY INT, V45, P17; INGRAM A, 1995, KIDNEY INT, V48, P1857, DOI 10.1038/ki.1995.484; Ingram AJ, 2000, KIDNEY INT, V58, P1431, DOI 10.1046/j.1523-1755.2000.00305.x; Ingram AJ, 2000, AM J PHYSIOL-RENAL, V279, pF243, DOI 10.1152/ajprenal.2000.279.2.F243; Ingram AJ, 2000, J BIOL CHEM, V275, P40301, DOI 10.1074/jbc.M007018200; Ingram AJ, 1999, KIDNEY INT, V55, P476, DOI 10.1046/j.1523-1755.1999.00276.x; Ingram AJ, 2000, KIDNEY INT, V58, P1067, DOI 10.1046/j.1523-1755.2000.00264.x; Ishida T, 1999, DIABETES, V48, P595, DOI 10.2337/diabetes.48.3.595; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kawata Y, 1998, J BIOL CHEM, V273, P16905, DOI 10.1074/jbc.273.27.16905; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kwan G, 1996, KIDNEY INT, V50, P1173, DOI 10.1038/ki.1996.425; LOMBET JR, 1989, J LAB CLIN MED, V114, P66; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; MUNGER K, 1988, AM J PHYSIOL, V254, pF223, DOI 10.1152/ajprenal.1988.254.2.F223; Neugarten J, 1999, AM J PHYSIOL-RENAL, V277, pF875, DOI 10.1152/ajprenal.1999.277.6.F875; Neugarten J, 2000, AM J PHYSIOL-RENAL, V279, pF309, DOI 10.1152/ajprenal.2000.279.2.F309; Nuedling S, 1999, FEBS LETT, V454, P271, DOI 10.1016/S0014-5793(99)00816-9; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; RISER BL, 1992, J CLIN INVEST, V90, P1932, DOI 10.1172/JCI116071; SILBIGER SR, 1995, AM J KIDNEY DIS, V25, P515, DOI 10.1016/0272-6386(95)90119-1; Singer CA, 1999, J NEUROSCI, V19, P2455; Su LF, 2001, J BIOL CHEM, V276, P3231, DOI 10.1074/jbc.M005547200; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; Yasuda T, 1996, CONTRIB NEPHROL, V118, P222; Yasuda T, 1996, J CLIN INVEST, V98, P1991, DOI 10.1172/JCI119003	38	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9387	9394		10.1074/jbc.M106670200	http://dx.doi.org/10.1074/jbc.M106670200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11777903	hybrid			2022-12-27	WOS:000174400600088
J	Liu, GM; Zhang, YG; Bode, AM; Ma, WY; Dong, ZG				Liu, GM; Zhang, YG; Bode, AM; Ma, WY; Dong, ZG			Phosphorylation of 4E-BP1 is mediated by the p38/MSK1 pathway in response to UVB irradiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHAS-I; MAP KINASE; 4E-BINDING PROTEIN-1; MALIGNANT-MELANOMA; MAMMALIAN TARGET; RAT ADIPOCYTES; CELL-GROWTH; RAPAMYCIN; INITIATION	In resting cells, eIF4E-binding protein 1 (4E-BP1) binds to the eukaryotic initiation factor-4E (eIF-4E), preventing formation of a functional eIF-4F complex essential for cap-dependent initiation of translation. Phosphorylation of 4E-BP1 dissociates it from eIF-4E, relieving the translation block. Studies suggested that insulin- or growth factor-induced 4E-BP1 phosphorylation is mediated by phosphatidylinositol 3-kinase (PI3-kinase) and its downstream protein kinase, Akt. In the present study we demonstrated that UVB induced 4EBP1 phosphorylation at multiple sites, Thr-36, Thr-45, Ser-64, and Thr-69, leading to dissociation of 4E-BP1 from eIF-4E. UVB-induced phosphorylation of 4E-BP1 was blocked by p38 kinase inhibitors, PD169316 and SB202190, and MSK1 inhibitor, H89, but not by mitogen-activated protein kinase kinase inhibitors, PD98059 or U0126. The PI3-kinase inhibitor, wortmannin, did not block UVB-induced 4E-BP1 phosphorylation, but blocked both UVB- and insulin-induced activation of PI3-kinase and phosphorylation of Akt. 4E-BP1 phosphorylation was blocked in JB6 Cl 41 cells expressing a dominant negative p38 kinase or dominant negative MSK1, but not in cells expressing dominant negative ERK2, JNK1, or PI3-kinase p85 subunit. Our results suggest that UVB induces phosphorylation of 4E-BP1, leading to the functional dissociation of 4E-BP1 from eIF-4E. The p38/MSK1 pathway, but not PI3-kinase or Akt, is required for mediating the UVB-induced 4E-BP1 phosphorylation.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.			Zhang, Yiguo/0000-0003-3910-2779	NATIONAL CANCER INSTITUTE [R37CA081064, R29CA074916, R01CA077646, R01CA081064] Funding Source: NIH RePORTER; NCI NIH HHS [CA81064, CA74916, CA77646] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bentham G, 1996, INT J EPIDEMIOL, V25, P1132, DOI 10.1093/ije/25.6.1132; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Fadden P, 1997, J BIOL CHEM, V272, P10240; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Heesom KJ, 1998, BIOCHEM J, V336, P39, DOI 10.1042/bj3360039; Heesom KJ, 1999, FEBS LETT, V457, P489, DOI 10.1016/S0014-5793(99)01094-7; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Langford IH, 1998, STAT MED, V17, P41, DOI 10.1002/(SICI)1097-0258(19980115)17:1<41::AID-SIM712>3.0.CO;2-0; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MATSUI MS, 1995, PHOTOCARCINOGENESIS, P21; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Whalen SG, 1996, J BIOL CHEM, V271, P11831, DOI 10.1074/jbc.271.20.11831; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200	34	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8810	8816		10.1074/jbc.M110477200	http://dx.doi.org/10.1074/jbc.M110477200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11777913	hybrid			2022-12-27	WOS:000174400600010
J	Livengood, JA; Scoggin, KES; Van Orden, K; McBryant, SJ; Edayathumangalam, RS; Laybourn, PJ; Nyborg, JK				Livengood, JA; Scoggin, KES; Van Orden, K; McBryant, SJ; Edayathumangalam, RS; Laybourn, PJ; Nyborg, JK			p53 transcriptional activity is mediated through the SRC1-interacting domain of CBP/p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING-PROTEIN; CELL LEUKEMIA-VIRUS; WILD-TYPE P53; HISTONE ACETYLATION; TAX PROTEIN; IN-VITRO; TRANSACTIVATION FUNCTION; NUCLEAR RECEPTORS; COACTIVATOR CBP; TERMINAL DOMAIN	The tumor suppressor p53 recruits the cellular coactivator CBP/p300 to mediate the transcriptional activation of target genes. In this study, we identify a novel p53-interacting region in CBP/p300, which we call CR2, located near the carboxyl terminus. The 95-amino acid CR2 region (amino acids 2055-2150) is located adjacent to the C/H3 domain and corresponds precisely with the minimal steroid receptor coactivator 1 (SRC1)-interacting domain of CBP (also called IBiD). We show that the region of p53 that participates in the C112 interaction resides within the first 107 amino acids of the protein. p53 binds strongly to the CR2 domain of both CBP and the highly homologous coactivator p300. Importantly, an in-frame deletion of CR2 within the full-length p300 protein strongly compromises p300-mediated p53 transcriptional activation from a chromatin template in vitro. The identification of the p53-interacting CR2 domain in CBP/p300 prompted us to ask if the human T-cell leukemia virus (HTLV-1) Tax protein, which also interacts with CR2, competes with p53 for binding to this domain. We show that p53 and Tax exhibit mutually exclusive binding to the CR2 region, possibly contributing to the previously reported Tax repression of p53 function. Together, these studies identify and molecularly characterize a new p53 binding site on CBP/p300 that participates in coactivator-mediated p53 transcription function. The identity of the p53.CR2 interaction indicates that at least three distinct sites on CBP/p300 may participate in mediating p53 transactivation.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Nyborg, JK (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.			Scoggin, Kirsten/0000-0003-1348-641X	NCI NIH HHS [R01 CA055035, R01 CA055035-08, CA-55035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA055035, R01CA055035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bulger M., 1994, METH MOL G, V5, P241; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Dallas PB, 1997, J VIROL, V71, P1726, DOI 10.1128/JVI.71.2.1726-1731.1997; De Guzman RN, 2000, J MOL BIOL, V303, P243, DOI 10.1006/jmbi.2000.4141; DYNAN WS, 1987, GENETIC ENG PRINCIPL, V9, P75; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FUJIINAKATA T, 1992, J BIOL CHEM, V267, P20980; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; Georges SA, 2002, MOL CELL BIOL, V22, P127, DOI 10.1128/MCB.22.1.127-137.2002; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Glass CK, 2000, GENE DEV, V14, P121; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; Ito T, 2000, GENE DEV, V14, P1899; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Jones SN, 1996, GENE, V175, P209, DOI 10.1016/0378-1119(96)00151-5; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Lemasson I, 2001, J BIOL CHEM, V276, P15720, DOI 10.1074/jbc.M100131200; Lenzmeier BA, 1999, J MOL BIOL, V291, P731, DOI 10.1006/jmbi.1999.2969; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Mori N, 1997, BLOOD, V90, P4924, DOI 10.1182/blood.V90.12.4924.4924_4924_4932; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; O'Connor MJ, 1999, J VIROL, V73, P3574; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; Scolnick DM, 1997, CANCER RES, V57, P3693; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Van Orden K, 2000, GENE EXPRESSION, V9, P29; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Xiao G, 1998, ONCOGENE, V16, P1171, DOI 10.1038/sj.onc.1201631; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yie JM, 1999, P NATL ACAD SCI USA, V96, P13108, DOI 10.1073/pnas.96.23.13108; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	63	53	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9054	9061		10.1074/jbc.M108870200	http://dx.doi.org/10.1074/jbc.M108870200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11782467	hybrid			2022-12-27	WOS:000174400600044
J	Seta, K; Nanamori, M; Modrall, JG; Neubig, RR; Sadoshima, J				Seta, K; Nanamori, M; Modrall, JG; Neubig, RR; Sadoshima, J			AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ANGIOTENSIN-II RECEPTOR; VASCULAR SMOOTH-MUSCLE; LIVER EPITHELIAL-CELLS; MAP KINASE ACTIVATION; TYROSINE-KINASE; TYPE-1 RECEPTOR; SIGNAL-TRANSDUCTION; DIRECT STIMULATION; CARDIAC MYOCYTES	Angiotensin II (Ang II) type I receptors (AT1Rs) activate tyrosine kinases, including Src. Whether or not tyrosine kinase activation by AT1R occurs independently of heterotrimeric G protein coupling and, if so, the cellular function of such a mechanism are unknown. To address these questions, we used an AT1aR intracellular second loop mutant, which lacks heterotrimeric G protein coupling (AT1a-i2m). Surprisingly, Ang II-induced Src activation was preserved in AT1a-i2m, which was not attenuated by inhibiting protein kinase C and Ca2+ or by inhibiting Galpha(i) or Galpha(q) in CHO-K1 cells. By contrast, Ang II-induced Src activation was abolished in a C-terminally truncated AT1a-(1-309), where Ang II-induced inositol phosphate response was preserved. Ang II activates ERKs via a Src-Ras-dependent mechanism in AT1a-i2m. ERKs activated by AT1a-i2m phosphorylate their cytoplasmic targets, including p90(RSK), but fail to translocate into the nucleus or to cause cell proliferation. Ang II-induced nuclear translocation of ERKs by wild type AT1aR was inhibited by overexpression of nuclear exportin Crm-1, while that by AT1a-i2m was restored by leptomycin B, an inhibitor of Crm-1. In summary, while Src and ERKs are activated by Ang II even without heterotrimeric G protein coupling, the carboxyl terminus of the AT1 receptor is required for activation of Src. Interestingly, ERKs activated by heterotrimeric G protein-independent mechanisms fail to phosphorylate nuclear targets due to lack of inhibition of Crm-1-induced nuclear export of ERKs. These results suggest that heterotrimeric G protein-dependent and -independent signaling mechanisms play distinct roles in Ang II-mediated cellular responses.	Univ Med & Dent New Jersey, New Jersey Med Sch, Cardiovasc Res Inst, Dept Cell Biol, Newark, NJ 07103 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Texas, SW Med Ctr, Dept Surg, Dallas, TX 75390 USA; Dallas Vet Affairs Med Ctr, Dallas, TX 75390 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Michigan System; University of Michigan; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sadoshima, J (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Cardiovasc Res Inst, Dept Cell Biol, 185 S Orange Ave MSB G 609, Newark, NJ 07103 USA.	Sadoshju@umdnj.edu		Sadoshima, Junichi/0000-0003-3724-4132; Neubig, Richard/0000-0003-0501-0008	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067727, R01HL067724] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67727, HL67724] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; Aoki H, 2000, BIOCHEM J, V347, P275, DOI 10.1042/0264-6021:3470275; Araki T, 1998, EMBO J, V17, P4018, DOI 10.1093/emboj/17.14.4018; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Bernstein KE, 1998, LAB INVEST, V78, P3; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Brzostowski JA, 2001, TRENDS BIOCHEM SCI, V26, P291, DOI 10.1016/S0968-0004(01)01804-7; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Daviet L, 1999, J BIOL CHEM, V274, P17058, DOI 10.1074/jbc.274.24.17058; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DICKENSON JM, 1995, BRIT J PHARMACOL, V116, P2889, DOI 10.1111/j.1476-5381.1995.tb15941.x; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Doan TN, 2001, J BIOL CHEM, V276, P20954, DOI 10.1074/jbc.C100199200; EARP HS, 1995, J BIOL CHEM, V270, P28440; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; Fan GF, 2001, J BIOL CHEM, V276, P13240, DOI 10.1074/jbc.M011578200; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Gales C, 2000, J BIOL CHEM, V275, P17321, DOI 10.1074/jbc.M909801199; Griendling K K, 1994, Adv Pharmacol, V28, P269, DOI 10.1016/S1054-3589(08)60498-6; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Guillemot L, 2000, J BIOL CHEM, V275, P26349, DOI 10.1074/jbc.M001614200; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Hulleman E, 1999, J CELL PHYSIOL, V180, P325, DOI 10.1002/(SICI)1097-4652(199909)180:3<325::AID-JCP3>3.0.CO;2-R; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Marrero MB, 1998, AM J PHYSIOL-CELL PH, V275, pC1216, DOI 10.1152/ajpcell.1998.275.5.C1216; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Modrall JG, 2001, AM J PHYSIOL-CELL PH, V281, pC801, DOI 10.1152/ajpcell.2001.281.3.C801; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; Sadoshima J, 1998, CIRC RES, V82, P1352, DOI 10.1161/01.RES.82.12.1352; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIRAI H, 1995, HYPERTENSION, V25, P726, DOI 10.1161/01.HYP.25.4.726; Thompson JB, 1998, J PHARMACOL EXP THER, V285, P216; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; ULLIAN ME, 1989, J CLIN INVEST, V84, P840, DOI 10.1172/JCI114244; Venema RC, 1998, J BIOL CHEM, V273, P7703, DOI 10.1074/jbc.273.13.7703; Venema RC, 1998, J BIOL CHEM, V273, P30795, DOI 10.1074/jbc.273.46.30795; Wang DM, 2000, J BIOL CHEM, V275, P12223, DOI 10.1074/jbc.275.16.12223; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zou YZ, 1998, CIRC RES, V82, P337, DOI 10.1161/01.RES.82.3.337; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	74	125	129	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9268	9277		10.1074/jbc.M109221200	http://dx.doi.org/10.1074/jbc.M109221200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11777928	hybrid			2022-12-27	WOS:000174400600073
J	von Bulow, R; Schmidt, B; Dierks, T; Schwabauer, N; Schilling, K; Weber, E; Uson, I; von Figura, K				von Bulow, R; Schmidt, B; Dierks, T; Schwabauer, N; Schilling, K; Weber, E; Uson, I; von Figura, K			Defective oligomerization of arylsulfatase A as a cause of its instability in lysosomes and metachromatic leukodystrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SULFATASE DEFICIENCY; MANNOSE 6-PHOSPHATE; CATHEPSIN-B; INHIBITORS; SPECIFICITY; PROTEINASES; EXPRESSION; MUTATIONS; MECHANISM; CYSTEINE	In one of the most common mutations causing metachromatic leukodystrophy, the P426L-allele of arylsulfatase A (ASA), the deficiency of ASA results from its instability in lysosomes. Inhibition of lysosomal cysteine proteinases protects the P426L-ASA and restores the sulfatide catabolism in fibroblasts of the patients. P426L-ASA, but not wild type ASA, was cleaved by purified cathepsin L at threonine 421 yielding 54- and 9-kDa fragments. X-ray crystallography at 2.5-Angstrom resolution showed that cleavage is not due to a difference in the protein fold that would expose the peptide bond following threonine 421 to proteases. Octamerization, which depends on protonation of Glu-424, was impaired for P426L-ASA. The mutation lowers the pH for the octamer/ dimer equilibrium by 0.6 pH units from pH 5.8 to 5.2. A second oligomerization mutant (ASA-A464R) was generated that failed to octamerize even at pH 4.8. A464R-ASA was degraded in lysosomes to catalytically active 54-kDa intermediate. In cathepsin L-deficient fibroblasts, degradation of P426L-ASA and A464R-ASA to the 54-kDa fragment was reduced, while further degradation was blocked. This indicates that defective oligomerization of ASA allows degradation of ASA to a catalytically active 54-kDa intermediate by lysosomal cysteine proteinases, including cathepsin L. Further degradation of the 54-kDa intermediate critically depends on cathepsin L and is modified by the structure of the 9-kDa cleavage product.	Univ Gottingen, Biochem Abt 2, D-37073 Gottingen, Germany; Klinikum Friedrich Schiller Univ, Inst Biochem 1, D-07743 Jena, Germany; Univ Halle Wittenberg, Inst Physiol Chem, D-06097 Halle Saale, Germany; Univ Gottingen, Lehrstuhl Strukt Chem, D-37077 Gottingen, Germany	University of Gottingen; Friedrich Schiller University of Jena; Martin Luther University Halle Wittenberg; University of Gottingen	Schmidt, B (corresponding author), Univ Gottingen, Biochem Abt 2, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.		Dierks, Thomas/A-3596-2012	Dierks, Thomas/0000-0001-6426-1339; Weber, Ekkehard/0000-0002-4014-4303				ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BARTH ML, 1993, HUM GENET, V91, P73; Berger J, 1997, AM J MED GENET, V69, P335, DOI 10.1002/(SICI)1096-8628(19970331)69:3<335::AID-AJMG22>3.3.CO;2-P; BRESCIANI R, 1992, EUR J CELL BIOL, V58, P57; Brinker A, 2000, EUR J BIOCHEM, V267, P5085, DOI 10.1046/j.1432-1327.2000.01570.x; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; Kirschke H, 1995, PROTEIN PROFILE, V2, P1587; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Maubach G, 1997, EUR J BIOCHEM, V250, P745, DOI 10.1111/j.1432-1033.1997.00745.x; MCPHERSON A, 1992, J CRYST GROWTH, V122, P161, DOI 10.1016/0022-0248(92)90239-F; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PENZIEN JM, 1993, AM J HUM GENET, V52, P557; POLTEN A, 1991, NEW ENGL J MED, V324, P18, DOI 10.1056/NEJM199101033240104; Reinheckel T, 2001, BIOL CHEM, V382, P735, DOI 10.1515/BC.2001.089; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; SOMMERLADE HJ, 1994, BIOCHEM J, V297, P123, DOI 10.1042/bj2970123; STEIN C, 1989, J BIOL CHEM, V264, P1252; TOWATARI T, 1979, EUR J BIOCHEM, V102, P279, DOI 10.1111/j.1432-1033.1979.tb06290.x; VOGEL A, 1991, EUR J BIOCHEM, V200, P591, DOI 10.1111/j.1432-1033.1991.tb16222.x; VONFIGURA K, 1986, AM J HUM GENET, V39, P371; VONFIGURA K, 1983, P NATL ACAD SCI-BIOL, V80, P6066; VONFIGURA K, 2001, METABOLIC MOL BASES, P3695; WAHEED A, 1982, EUR J BIOCHEM, V123, P317, DOI 10.1111/j.1432-1033.1982.tb19770.x	29	27	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9455	9461		10.1074/jbc.M111993200	http://dx.doi.org/10.1074/jbc.M111993200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11777924	hybrid			2022-12-27	WOS:000174400600096
J	Dinchuk, JE; Focht, RJ; Kelley, JA; Henderson, NL; Zolotarjova, NI; Wynn, R; Neff, NT; Link, J; Huber, RM; Burn, TC; Rupar, MJ; Cunningham, MR; Selling, BH; Ma, JH; Stern, AA; Hollis, GF; Stein, RB; Friedman, PA				Dinchuk, JE; Focht, RJ; Kelley, JA; Henderson, NL; Zolotarjova, NI; Wynn, R; Neff, NT; Link, J; Huber, RM; Burn, TC; Rupar, MJ; Cunningham, MR; Selling, BH; Ma, JH; Stern, AA; Hollis, GF; Stein, RB; Friedman, PA			Absence of post-translational aspartyl beta-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL SARCOPLASMIC-RETICULUM; K-DEPENDENT PROTEINS; ACTIVE-SITE REGION; HUMAN FACTOR-IX; HYDROXYASPARTIC ACID; CALCIUM-BINDING; RESIDUES; PURIFICATION; NOTCH; CALSEQUESTRIN	The BAH genomic locus encodes three distinct proteins: junctin, humbug, and BAH. All three proteins share common exons, but differ significantly based upon the use of alternative terminal exons. The biological roles of BAH and humbug and their functional relationship to junctin remain unclear. To evaluate the role of BAH in vivo, the catalytic domain of BAH was specifically targeted such that the coding regions of junctin and humbug remained undisturbed. BAH null mice lack measurable BAH protein in several tissues, lack aspartyl beta-hydroxylase activity in liver preparations, and exhibit no hydroxylation of the epidermal growth factor (EGF) domain of clotting Factor X. In addition to reduced fertility in females, BAH null mice display several developmental defects including syndactyly, facial dysmorphology, and a mild defect in hard palate formation. The developmental defects present in BAH null mice are similar to defects observed in knock-outs and hypomorphs of the Notch ligand Serrate-2. In this work, beta-hydroxylation of Asp residues in EGF domains is demonstrated for a soluble form of a Notch ligand, human Jagged-1. These results along with recent reports that another post-translational modification of EGF domains in Notch gene family members (glycosylation by Fringe) alters Notch pathway signaling, lends credence to the suggestion that aspartyl beta-hydroxylation may represent another post-translational modification of EGF domains that can modulate Notch pathway signaling. Previous work has demonstrated increased levels of BAH in certain tumor tissues and a role for BAH in tumorigenesis has been proposed. The role of hydroxylase in tumor formation was tested directly by crossing BAH KO mice with an intestinal tumor model, APCmin mice. Surprisingly, BAH null/APCmin mice show a statistically significant increase in both intestinal polyp size and number when compared with BAH wild-type/APCmin controls. These results suggest that, in contrast to expectations, loss of BAH catalytic activity may promote tumor formation.	Bristol Myers Squibb Co, Pharma Res Labs, Wilmington, DE 19880 USA	Bristol-Myers Squibb	Dinchuk, JE (corresponding author), Bristol Myers Squibb Co, Pharma Res Labs, Wilmington, DE 19880 USA.	joseph.dinchuk@bms.com; ghollis@incyte.com	Huber, Rudolf M./L-2464-2019	Huber, Rudolf M./0000-0001-7041-6368; Burn, Timothy/0000-0001-6648-4333				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; DERIAN CK, 1989, J BIOL CHEM, V264, P6615; Dinchuk JE, 2000, J BIOL CHEM, V275, P39543, DOI 10.1074/jbc.M006753200; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; FERNLUND P, 1983, J BIOL CHEM, V258, P2509; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Goruppi S, 1997, FEBS LETT, V415, P59, DOI 10.1016/S0014-5793(97)01093-4; GRONKE RS, 1989, P NATL ACAD SCI USA, V86, P3609, DOI 10.1073/pnas.86.10.3609; GRONKE RS, 1990, J BIOL CHEM, V265, P8558; HARLOW E, 1968, ANTIBOTIDIES LAB MAN; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Hillman MC, 2001, PROTEIN EXPRES PURIF, V23, P359, DOI 10.1006/prep.2001.1514; Ince N, 2000, CANCER RES, V60, P1261; JIA S, 1994, P NATL ACAD SCI USA, V91, P7227, DOI 10.1073/pnas.91.15.7227; JIA S, 1992, J BIOL CHEM, V267, P14322; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; Kadesch T, 2000, EXP CELL RES, V260, P1, DOI 10.1006/excr.2000.4921; Lavaissiere L, 1996, J CLIN INVEST, V98, P1313, DOI 10.1172/JCI118918; McGinnis K, 1996, BIOCHEMISTRY-US, V35, P3957, DOI 10.1021/bi951520n; McGinnis K, 1998, BBA-PROTEIN STRUCT M, V1387, P454, DOI 10.1016/S0167-4838(98)00130-7; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; MONKOVIC DD, 1992, BIOCHEM BIOPH RES CO, V189, P233, DOI 10.1016/0006-291X(92)91549-6; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Nakamura T, 1999, J BIOL CHEM, V274, P22476, DOI 10.1074/jbc.274.32.22476; NELSON RM, 1991, J BIOL CHEM, V266, P20586; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Sidow A, 1997, NATURE, V389, P722, DOI 10.1038/39587; STENFLO J, 1991, BLOOD, V78, P1637; SUNNERHAGEN MS, 1993, J BIOL CHEM, V268, P23339; Treves S, 2000, J BIOL CHEM, V275, P39555, DOI 10.1074/jbc.M005473200; WANG QP, 1991, J BIOL CHEM, V266, P14004; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	34	81	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12970	12977		10.1074/jbc.M110389200	http://dx.doi.org/10.1074/jbc.M110389200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11773073	hybrid			2022-12-27	WOS:000175036300063
J	Denhez, F; Wilcox-Adelman, SA; Baciu, PC; Saoncella, S; Lee, S; French, B; Neveu, W; Goetinck, PF				Denhez, F; Wilcox-Adelman, SA; Baciu, PC; Saoncella, S; Lee, S; French, B; Neveu, W; Goetinck, PF			Syndesmos, a syndecan-4 cytoplasmic domain interactor, binds to the focal adhesion adaptor proteins paxillin and Hic-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; TYROSINE PHOSPHORYLATION; PDZ PROTEIN; INTEGRINS; ACTIN; TRANSDUCTION; CASK/LIN-2	Syndecan-4 and integrins are the primary transmembrane receptors of focal adhesions in cells adherent to extracellular matrix molecules. Syndesmos is a cytoplasmic protein that interacts specifically with the cytoplasmic domain of syndecan-4, and it co-localizes with syndecan-4 in focal contacts. In the present study we sought possible interactors with syndesmos. We find that syndesmos interacts with the focal adhesion adaptor protein paxillin. The binding of syndesmos to paxillin is direct, and these interactions are triggered by the activation of protein kinase C. Syndesmos also binds the paxillin homolog, Hic-5. The connection of syndecan-4 with paxillin through syndesmos parallels the connection between paxillin and integrins and may thus reflect the cooperative signaling of these two receptors in the assembly of focal adhesions and actin stress fibers.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Goetinck, PF (corresponding author), MGH E, Cutaneous Biol Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.	paul.goetinck@cbrc2.mgh.harvard.edu			NICHD NIH HHS [HD-37490, F32-HD41235] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037490, F32HD041235] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; Baciu PC, 2000, J CELL SCI, V113, P315; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Couchman JR, 1999, J CELL SCI, V112, P3415; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Ethell IM, 2000, J CELL BIOL, V151, P53, DOI 10.1083/jcb.151.1.53; Gao YH, 2000, J CELL PHYSIOL, V184, P373, DOI 10.1002/1097-4652(200009)184:3<373::AID-JCP12>3.0.CO;2-I; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Horowitz A, 1999, BIOCHEMISTRY-US, V38, P15871, DOI 10.1021/bi991363i; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; SALGIA R, 1995, ONCOGENE, V11, P1149; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Turner CE, 2000, J CELL SCI, V113, P4139; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; WOODS A, 1992, J CELL SCI, V101, P277; Zimmermann P, 1999, FASEB J, V13, pS91	32	51	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12270	12274		10.1074/jbc.M110291200	http://dx.doi.org/10.1074/jbc.M110291200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805099	hybrid			2022-12-27	WOS:000174846400087
J	Dermitzaki, E; Tsatsanis, C; Gravanis, A; Margioris, AN				Dermitzaki, E; Tsatsanis, C; Gravanis, A; Margioris, AN			Corticotropin-releasing hormone induces Fas ligand production and apoptosis in PC12 cells via activation of p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOREACTIVE CORTICOTROPIN; FACTOR RECEPTORS; ADRENAL-MEDULLA; SYMPATHETIC NEURONS; RAT CHROMAFFIN; IN-VITRO; DEATH; EXPRESSION; ANTAGONIST; PITUITARY	Recent experimental findings involve corticotropin-releasing hormone (CRH) in the cellular response to noxious stimuli and possibly apoptosis. The aim of the present work was to examine the effect of CRH on apoptosis and the Fas/Fas ligand system in an in vitro model, the PC12 rat pheochromocytoma cell line, which is widely used in the study of apoptosis and at the same time expresses the CRH/CRH receptor system. We have found the following. CRH induced Fas ligand production and apoptosis. These effects were mediated by the CRH type I receptor because its antagonist antalarmin blocked CRH-induced apoptosis and Fas ligand expression. CRH activated p38 mitogen-activated protein kinase, which was found to be essential for CRH-induced apoptosis and Fas ligand production. CRH also promoted a rapid and transient activation of ERK1/2, which, however, was not necessary for either CRH-induced apoptosis or Fas ligand production. Thus, CRH promotes PC12 apoptosis via the CRH type I receptor, which induces Fas ligand production via activation of p38.	Univ Crete, Sch Med, Dept Clin Chem Biochem, GR-71110 Iraklion, Greece; Univ Crete, Sch Med, Dept Pharmacol, GR-71110 Iraklion, Greece	University of Crete; University of Crete	Margioris, AN (corresponding author), Univ Crete, Sch Med, Dept Clin Chem Biochem, GR-71110 Iraklion, Greece.	andym@med.uoc.gr	Tsatsanis, Christos/AAM-9362-2020	Tsatsanis, Christos/0000-0003-1214-4151				AGUILERA G, 1987, ANN NY ACAD SCI, V512, P48, DOI 10.1111/j.1749-6632.1987.tb24950.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bornstein SR, 1998, ENDOCRINOLOGY, V139, P1546, DOI 10.1210/en.139.4.1546; Brar BK, 2000, J BIOL CHEM, V275, P8508, DOI 10.1074/jbc.275.12.8508; BRUHN TO, 1987, ANN NY ACAD SCI, V512, P115, DOI 10.1111/j.1749-6632.1987.tb24954.x; Brunson KL, 2001, P NATL ACAD SCI USA, V98, P8856, DOI 10.1073/pnas.151224898; Chan RS, 1996, BRAIN PATHOL, V6, P481, DOI 10.1111/j.1750-3639.1996.tb00877.x; EDWARDS AV, 1988, J PHYSIOL-LONDON, V400, P89, DOI 10.1113/jphysiol.1988.sp017112; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Grammatopoulos DK, 2000, MOL ENDOCRINOL, V14, P2076, DOI 10.1210/me.14.12.2076; HASHIMOTO K, 1984, PEPTIDES, V5, P707, DOI 10.1016/0196-9781(84)90011-1; HATZOGLOU A, 1992, ANN CLIN BIOCHEM, V29, P659, DOI 10.1177/000456329202900607; Horstmann S, 1998, J NEUROSCI RES, V52, P483, DOI 10.1002/(SICI)1097-4547(19980515)52:4<483::AID-JNR12>3.3.CO;2-Y; Ishikawa Y, 1999, BIOCHEM BIOPH RES CO, V264, P696, DOI 10.1006/bbrc.1999.1542; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Karteris E, 2000, J CLIN ENDOCR METAB, V85, P1989, DOI 10.1210/jc.85.5.1989; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Kolasa K, 2000, NEUROSCIENCE, V101, P541, DOI 10.1016/S0306-4522(00)00406-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LYONS MK, 1991, BRAIN RES, V545, P339, DOI 10.1016/0006-8993(91)91310-W; Maecker H, 1997, BRAIN RES, V744, P166, DOI 10.1016/S0006-8993(96)01207-3; MARKOWSKA A, 1993, CELL TISSUE RES, V272, P439, DOI 10.1007/BF00318550; Maroney AC, 1999, J NEUROCHEM, V73, P1901; MAZZOCCHI G, 1994, MOL CELL NEUROSCI, V5, P345, DOI 10.1006/mcne.1994.1041; MINAMINO N, 1988, PEPTIDES, V9, P37, DOI 10.1016/0196-9781(88)90007-1; Misasi R, 2001, FASEB J, V15, P467, DOI 10.1096/fj.00-0217com; NERI G, 1991, RES EXP MED, V191, P291, DOI 10.1007/BF02576685; NICHOLSON WE, 1987, REGUL PEPTIDES, V18, P173, DOI 10.1016/0167-0115(87)90006-1; Okosi A, 1998, NEUROPEPTIDES, V32, P167, DOI 10.1016/S0143-4179(98)90033-6; Pedersen WA, 2001, NEUROBIOL DIS, V8, P492, DOI 10.1006/nbdi.2001.0395; Perrin MH, 1999, ANN NY ACAD SCI, V885, P312, DOI 10.1111/j.1749-6632.1999.tb08687.x; Powers JF, 1999, CELL TISSUE RES, V295, P21, DOI 10.1007/s004410051209; Ribak CE, 1996, DEV BRAIN RES, V91, P245, DOI 10.1016/0165-3806(95)00183-2; Rossant CJ, 1999, ENDOCRINOLOGY, V140, P1525, DOI 10.1210/en.140.4.1525; Saeger W., 1993, Zentralblatt fuer Pathologie, V139, P157; SASAKI A, 1990, J CLIN ENDOCR METAB, V70, P996, DOI 10.1210/jcem-70-4-996; SUDA T, 1986, ACTA ENDOCRINOL-COP, V111, P546, DOI 10.1530/acta.0.1110546; TSUCHIHASHI T, 1992, JPN J CLIN ONCOL, V22, P232; UDELSMAN R, 1986, NATURE, V319, P147, DOI 10.1038/319147a0; USUI T, 1988, MOL ENDOCRINOL, V2, P871, DOI 10.1210/mend-2-9-871; Venihaki M, 1998, ENDOCRINOLOGY, V139, P713, DOI 10.1210/en.139.2.713; Venihaki M, 1997, ENDOCRINOLOGY, V138, P698, DOI 10.1210/en.138.2.698; Willenberg HS, 2000, MOL PSYCHIATR, V5, P137, DOI 10.1038/sj.mp.4000720; Wong ML, 1999, LIFE SCI, V65, pPL53, DOI 10.1016/S0024-3205(99)00268-4; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yan XX, 1998, HIPPOCAMPUS, V8, P231, DOI 10.1002/(SICI)1098-1063(1998)8:3<231::AID-HIPO6>3.0.CO;2-M	47	84	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12280	12287		10.1074/jbc.M111236200	http://dx.doi.org/10.1074/jbc.M111236200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11790788	hybrid			2022-12-27	WOS:000174846400089
J	Klein, C; Sunahara, RK; Hudson, TY; Heyduk, T; Howlett, AC				Klein, C; Sunahara, RK; Hudson, TY; Heyduk, T; Howlett, AC			Zinc inhibition of cAMP signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL-CYCLASE; CATALYTIC MECHANISM; NEURONAL DEATH; ASCORBIC-ACID; NITRIC-OXIDE; BRAIN; BINDING; NEUROTOXICITY; TRANSPORT; DIVERSITY	Zn2+ is required as either a catalytic or structural component for a large number of enzymes and thus contributes to a variety of important biological processes. We report here that low micromolar concentrations of Zn2+ inhibited hormone- or forskolin-stimulated cAMP production in N18TG2 neuroblastoma cells. Similarly, low concentrations inhibited hormone- and forskolin-stimulated adenylyl cyclase (AC) activity in membrane preparations and did so primarily by altering the V-max of the enzyme. Zn2+ also inhibited recombinant isoforms, indicating that this reflects a direct interaction with the enzyme. The IC50 for Zn2+ inhibition was similar to1-2 muM with a Hill coefficient of 1.33. The dose-response curve for Zn2+ inhibition was identical for AC1, AC5, and AC6 as well as for the C441R mutant of AC5 whose defect appears to be in one of the catalytic metal binding sites. However, AC2 displayed a distinct dose-response curve. These data in combination with the findings that Zn2+ inhibition was not competitive with Mg2+ or Mg2+/ATP suggest that the inhibitory Zn2+ binding site is distinct from the metal binding sites involved in catalysis. The prestimulated enzyme was found to be less susceptible to Zn2+ inhibition, suggesting that the ability of Zn2+ to inhibit AC could be significantly influenced by the coincidence timing of the input signals to the enzyme.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; N Carolina Cent Univ, JL Chambers Res Inst, Neurosci & Drug Abuse Res Program, Durham, NC 27707 USA	Saint Louis University; University of Michigan System; University of Michigan; University of North Carolina; North Carolina Central University	Klein, C (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	kleinc@slu.edu	Sunahara, Roger/AAJ-8667-2020	Howlett, Allyn/0000-0002-2810-0164	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM050514, R01GM034497, R37GM034497, R01GM050514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003690, K05DA000182] Funding Source: NIH RePORTER; NIDA NIH HHS [K05-DA00182, R01 DA003690, DA 03690] Funding Source: Medline; NIGMS NIH HHS [GM34497, GM50514] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSTROM CO, 1974, ANAL BIOCHEM, V58, P459, DOI 10.1016/0003-2697(74)90214-0; Choi DW, 1996, COLD SPRING HARB SYM, V61, P385; Colvin RA, 2000, J NUTR, V130, p1484S, DOI 10.1093/jn/130.5.1484S; Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163; Derbyshire V, 1995, METHOD ENZYMOL, V262, P363; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; GRUNEWALD RA, 1993, BRAIN RES REV, V18, P123, DOI 10.1016/0165-0173(93)90010-W; HOWLETT AC, 1982, MOL PHARMACOL, V21, P664; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; McVey M, 1999, J BIOL CHEM, V274, P18887, DOI 10.1074/jbc.274.27.18887; MONS N, 1995, TRENDS NEUROSCI, V18, P536, DOI 10.1016/0166-2236(95)98375-9; OKE AF, 1987, ANN NY ACAD SCI, V498, P1, DOI 10.1111/j.1749-6632.1987.tb23747.x; Powell SR, 2000, J NUTR, V130, p1447S, DOI 10.1093/jn/130.5.1447S; ROTH BL, 1984, J NEUROCHEM, V42, P1145, DOI 10.1111/j.1471-4159.1984.tb12723.x; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Tao YP, 1998, J PHARMACOL EXP THER, V286, P298; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Tesmer JJG, 1998, CURR OPIN STRUC BIOL, V8, P713, DOI 10.1016/S0959-440X(98)80090-0; Trombley PQ, 2000, BIOCHEMISTRY-MOSCOW+, V65, P807; Truong-Tran AQ, 2000, J NUTR, V130, p1459S, DOI 10.1093/jn/130.5.1459S; TSOU CL, 1988, ADV ENZYMOL RAMB, V61, P381; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; WENSINK J, 1988, J NEUROCHEM, V50, P782, DOI 10.1111/j.1471-4159.1988.tb02982.x; XIE XM, 1991, NATURE, V349, P521, DOI 10.1038/349521a0; ZALEWSKI PD, 1993, BIOCHEM J, V296, P403, DOI 10.1042/bj2960403; Zhang RQ, 2001, BBA-PROTEIN STRUCT M, V1545, P6, DOI 10.1016/S0167-4838(00)00254-5; Zimmermann G, 1998, J BIOL CHEM, V273, P19650, DOI 10.1074/jbc.273.31.19650	34	59	68	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11859	11865		10.1074/jbc.M108808200	http://dx.doi.org/10.1074/jbc.M108808200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805091	hybrid			2022-12-27	WOS:000174846400034
J	Rosenblum, MEK; Schmidt, K; Freas, J; Mastri, M; Fay, PJ				Rosenblum, MEK; Schmidt, K; Freas, J; Mastri, M; Fay, PJ			Cofactor activities of factor VIIIa and A2 subunit following cleavage of A1 subunit at Arg(336)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; INTRINSIC-FACTOR XASE; LENGTH CROSS-LINKING; PORCINE FACTOR-VIII; FACTOR-IXA; CATALYZED PROTEOLYSIS; FACTOR-X; A1/A3-C1-C2 DIMER; INTERACTIVE SITE; INACTIVATION	Factor VIIIa consists of three subunits designated A1, A2, and A3-C1-C2. The isolated A2 subunit possesses limited cofactor activity in stimulating factor IXa-catalyzed activation of factor X. This activity is markedly enhanced by the A1 subunit (inter-subu-nit K-d = 1.8 mum). The C-terminal region of A1 subunit (residues 337-372) is thought to represent an A2-interactive site. This region appears critical to factor VIIIa, because proteolysis at Arg(336) by activated protein C or factor IXa is inactivating. A truncated A1 (A1(336)) showed similar affinity for A2 subunit (Kd = 0.9 muM) and stimulated its cofactor activity to similar to50% that observed for native A1. However, A1336 was unable to reconstitute factor VIIIa activity in the presence of A2 and A3-C1-C2 subunits. Fluorescence anisotropy of fluorescein (Fl)-FFR-factor IXa was differentially altered by factor VIIIa trimers containing either A1 or A1(336). Fluorescence energy transfer demonstrated that, although Fl-A1(336)/A3-C1-C2 bound acrylodan-A2 with similar affinity as the native dimer, an increased inter-fluorophore separation was observed. These results indicate that the C-terminal region of A1 appears necessary to properly orient A2 subunit relative to factor IXa in the cofactor rather than directly stimulate A2 and elucidate the mechanism for cofactor inactivation following cleavage at this site.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Fay, PJ (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, POB 610,601 Elmwood Ave, Rochester, NY 14642 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616, R01HL038199] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30616, HL 38199, HL 07152] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano K, 1998, THROMB HAEMOSTASIS, V79, P557; CASILLAS G, 1971, COAGULATION, V4, P107; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FAY PJ, 1993, J BIOL CHEM, V268, P17861; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; FAY PJ, 1994, J BIOL CHEM, V269, P20522; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; Fay PJ, 2001, J BIOL CHEM, V276, P12434, DOI 10.1074/jbc.M009539200; Fay PJ, 1999, J BIOL CHEM, V274, P15401, DOI 10.1074/jbc.274.22.15401; Koszelak ME, 2000, J BIOL CHEM, V275, P27137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; Lapan KA, 1997, J BIOL CHEM, V272, P2082; Lapan KA, 1998, THROMB HAEMOSTASIS, V80, P418, DOI 10.1055/s-0037-1615223; Lenting PJ, 1998, BLOOD, V92, P3983, DOI 10.1182/blood.V92.11.3983.423k51_3983_3996; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; Lu DS, 1996, BLOOD, V87, P4708, DOI 10.1182/blood.V87.11.4708.bloodjournal87114708; O'Brien LM, 2000, BLOOD, V95, P1714, DOI 10.1182/blood.V95.5.1714.005k40_1714_1720; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; OBrien LM, 1997, BLOOD, V90, P3943, DOI 10.1182/blood.V90.10.3943; OBRIEN LM, 1995, J BIOL CHEM, V270, P27087, DOI 10.1074/jbc.270.45.27087; PERSSON E, 1995, BIOCHEMISTRY-US, V34, P12775, DOI 10.1021/bi00039a038; Regan LM, 1996, J BIOL CHEM, V271, P3982; REGAN LM, 1994, J BIOL CHEM, V269, P9445; Sarafanov AG, 2001, J BIOL CHEM, V276, P11970, DOI 10.1074/jbc.M008046200; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; Wakabayashi H, 2001, BIOCHEMISTRY-US, V40, P10293, DOI 10.1021/bi010353q; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	37	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11664	11669		10.1074/jbc.M200037200	http://dx.doi.org/10.1074/jbc.M200037200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11799130	hybrid			2022-12-27	WOS:000174846400008
J	Vucic, D; Deshayes, K; Ackerly, H; Pisabarro, MT; Kadkhodayan, S; Fairbrother, WJ; Dixit, VM				Vucic, D; Deshayes, K; Ackerly, H; Pisabarro, MT; Kadkhodayan, S; Fairbrother, WJ; Dixit, VM			SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-LAP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; PROMOTES APOPTOSIS; CASPASE ACTIVATION; STRUCTURAL BASIS; NMR STRUCTURE; CYTOCHROME-C; IAP; PROTEIN; GENE; XIAP	Inhibitors of apoptosis (IAPs) physically interact with a variety of pro-apoptotic proteins and inhibit apoptosis induced by diverse stimuli. X-linked IAP (X-IAP) is a prototype UP family member that inhibits several caspases, the effector proteases of apoptosis. The inhibitory activity of X-IAP is regulated by SMAC, a protein that is processed to its active form upon receipt of a death stimulus. Cleaved SMAC binds X-IAP and antagonizes its anti-apoptotic activity. Here we show that melanoma LAP (ML-IAP), a potent anti-cell death protein and caspase inhibitor, physically interacts with SMAC through its BIR (baculovirus IAP repeat) domain. In addition to binding full-length SMAC, MI-IAP BIR associates with SMAC peptides that are derived from the amino terminus of active, processed SMAC. This high affinity interaction is very specific and can be completely abolished by single amino acid mutations either in the amino terminus of active SMAC or in the BIR domain of ML-IAP. In cells expressing ML-IAP and X-IAP, SMAC coexpression or addition of SMAC peptides abrogates the ability of the IAPs to inhibit cell death. These results demonstrate the feasibility of using SMAC peptides as a way to sensitize IAP-expressing cells to pro-apoptotic stimuli such as chemotherapeutic agents.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioanalyt Res & Dev, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Dixit, VM (corresponding author), Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA.	dixit@gene.com	Pisabarro, M. Teresa/D-4270-2012; dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326				Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Deveraux QL, 1999, J CLIN IMMUNOL, V19, P388, DOI 10.1023/A:1020502800208; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; FERHAGEN AM, 2002, J BIOL CHEM, V277, P445; Fesik SW, 2001, SCIENCE, V294, P1477, DOI 10.1126/science.1062236; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Kaiser WJ, 1998, FEBS LETT, V440, P243, DOI 10.1016/S0014-5793(98)01465-3; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; MARTINS IM, 2001, J BIOL CHEM, V276, P439; McCarthy JV, 1998, J BIOL CHEM, V273, P24009, DOI 10.1074/jbc.273.37.24009; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun CH, 2000, J BIOL CHEM, V275, P33777, DOI 10.1074/jbc.M006226200; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uren AG, 1999, P NATL ACAD SCI USA, V96, P10170, DOI 10.1073/pnas.96.18.10170; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012	46	122	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12275	12279		10.1074/jbc.M112045200	http://dx.doi.org/10.1074/jbc.M112045200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11801603	hybrid			2022-12-27	WOS:000174846400088
J	Mansky, KC; Sankar, U; Han, JH; Ostrowski, MC				Mansky, KC; Sankar, U; Han, JH; Ostrowski, MC			Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; MUSCLE DIFFERENTIATION; KINASE; GENE; OSTEOCLAST; MEMBER; FAMILY; MOUSE; INVOLVEMENT; EXPRESSION	Receptor activator of NF-kappaB ligand (RANKL) activates signaling pathways that regulate osteoclast differentiation, function, and survival. The microphthalmia transcription factor (MITF) is required for terminal differentiation of osteoclasts. To determine whether MITF could be a target of RANKL signaling, a phosphospecific MITF antibody directed against conserved residue Ser(307), a potential mitogen-activated protein kinase (MAPK) site, was produced. Using this antibody, we could demonstrate that MITF was rapidly and persistently phosphorylated upon stimulation of primary osteoclasts with RANKL and that phosphorylation of Ser(307) correlated with expression of the target gene tartrate-resistant acid phosphatase. MITF phosphorylation at Ser(307) also correlated with persistent activation of p38 MAPK, and p38 MAPK could utilize MITF Ser(307) as a substrate in vitro. The phosphorylation of MITF and activation of target gene expression in osteoclasts were blocked by p38 MAPK inhibitor SB203580. In transient transfections, a constitutively active Rac1 or MKK6 gene could collaborate with MITF to activate the tartrate-resistant acid phosphatase gene promoter dependent on Ser(307). Dominant negative p38 a and 0 could inhibit the collaboration between upstream signaling components and MITF in the transient assays. These results indicate that MITF is a target for the RANKL signaling pathway in osteoclasts and that phosphorylation of MITF leads to an increase in osteoclast-specific gene expression.	Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Scripps Research Institute	Ostrowski, MC (corresponding author), Ohio State Univ, Dept Mol Genet, 496 W 12th Ave, Columbus, OH 43210 USA.	ostrowski.4@osu.edu	Sankar, Uma/AHE-2383-2022; Han, J/G-4671-2010; Ostrowski, Michael/H-3108-2011	Ostrowski, Michael/0000-0003-2948-6297; Mansky, Kim/0000-0002-2826-5030	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008568, R01AR044719] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-44719, F32-AR08568] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HOLTROP ME, 1981, METAB BONE DIS RELAT, V3, P123, DOI 10.1016/0221-8747(81)90030-8; HSU H, 2000, P NATL ACAD SCI USA, V97, P7829; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kumar S, 1999, BIOCHEM BIOPH RES CO, V263, P825, DOI 10.1006/bbrc.1999.1454; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Luchin A, 2001, J BIOL CHEM, V276, P36703, DOI 10.1074/jbc.M106418200; Luchin A, 2000, J BONE MINER RES, V15, P451, DOI 10.1359/jbmr.2000.15.3.451; Mansky KC, 2002, J LEUKOCYTE BIOL, V71, P295; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; MUNDY GR, 1974, NEW ENGL J MED, V291, P1041, DOI 10.1056/NEJM197411142912001; Obata T, 2000, CRIT CARE MED, V28, pN67, DOI 10.1097/00003246-200004001-00008; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAISZ LG, 1992, DISORDERS BONE MINER, P287; Rehli M, 1999, GENOMICS, V56, P111, DOI 10.1006/geno.1998.5588; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; THESINGH CW, 1985, BONE, V6, P43, DOI 10.1016/8756-3282(85)90406-5; Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097-2765(01)00360-4; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505; Zhao M, 1999, MOL CELL BIOL, V19, P21	45	182	191	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11077	11083		10.1074/jbc.M111696200	http://dx.doi.org/10.1074/jbc.M111696200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11792706	hybrid			2022-12-27	WOS:000174613100043
J	Won, HS; Lee, TW; Park, SH; Lee, BJ				Won, HS; Lee, TW; Park, SH; Lee, BJ			Stoichiometry and structural effect of the cyclic nucleotide binding to cyclic AMP receptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ACTIVATOR PROTEIN; CAP-DNA COMPLEX; INDUCED CONFORMATIONAL-CHANGES; NUCLEAR-MAGNETIC-RESONANCE; ESCHERICHIA-COLI; FOOTPRINTING TECHNIQUE; RNA-POLYMERASE; LAC PROMOTER; CAMP; CRP	Cyclic AMP receptor protein (CRP) is a homodimeric protein, which is activated by cAMP binding to function as a transcriptional regulator of many genes in prokaryotes. Until now, the actual number of cAMP molecules that can be bound by CRP in solution has been ambiguous. In this work, we performed a nuclear magnetic resonance study on CRP to investigate the stoichiometry of cyclic nucleotide binding to CRP. A series of H-1-N-15 heteronuclear single quantum coherence (HSQC) spectra of the protein in the absence and in the presence of cAMP or cGMP were analyzed. The addition of cAMP to CRP induced a biphasic spectral change up to 4 equivalents, whereas the cGMP addition made a monophasic change up to 2 equivalents. Altogether, the results not only established for the first time that CRP possesses two cyclic AMP-binding sites in each monomer, even in a solution without DNA, but also suggest that the syn-cAMP binding sites of the CRP dimer can be formed by an allosteric conformational change of the protein upon the binding of two anti-cAMPs at the N-terminal domain. In addition, a residue-specific inspection of the spectral changes provides some new structural information about the cAMP-induced allosteric activation of CRP.	Seoul Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, Seoul 151742, South Korea	Seoul National University (SNU)	Lee, BJ (corresponding author), Seoul Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, Seoul 151742, South Korea.		Lee, Bong-Jin/AAQ-1609-2020	Lee, Bong-Jin/0000-0001-7896-2961				AIBA H, 1983, CELL, V32, P141, DOI 10.1016/0092-8674(83)90504-4; Baichoo N, 1999, J MOL BIOL, V290, P37, DOI 10.1006/jmbi.1999.2858; Baichoo N, 1999, PROTEIN SCI, V8, P518; Baichoo N, 1997, BIOCHEMISTRY-US, V36, P10830, DOI 10.1021/bi970714v; BLAZY B, 1992, BIOCHIM BIOPHYS ACTA, V1120, P223, DOI 10.1016/0167-4838(92)90274-H; CHENG XD, 1993, BIOCHEMISTRY-US, V32, P8130, DOI 10.1021/bi00083a011; Chu SY, 2001, J BIOL CHEM, V276, P11230, DOI 10.1074/jbc.M010428200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; EBRIGHT RH, 1985, J MOL BIOL, V182, P91, DOI 10.1016/0022-2836(85)90030-0; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; Fried MG, 2001, J BIOL CHEM, V276, P11226, DOI 10.1074/jbc.M009087200; GARNER MM, 1982, BIOCHEMISTRY-US, V21, P6032, DOI 10.1021/bi00267a001; Harman JG, 2001, BBA-PROTEIN STRUCT M, V1547, P1, DOI 10.1016/S0167-4838(01)00187-X; HEYDUK E, 1992, BIOCHEMISTRY-US, V31, P3682, DOI 10.1021/bi00129a017; HEYDUK E, 1992, J BIOL CHEM, V267, P3200; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; HEYDUK T, 1989, BIOCHEMISTRY-US, V28, P6914, DOI 10.1021/bi00443a021; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KUMAR SA, 1980, FEBS LETT, V109, P121, DOI 10.1016/0014-5793(80)81324-X; LEE BJ, 1991, BIOCHEMISTRY-US, V30, P9047, DOI 10.1021/bi00101a020; LEE BJ, 1990, J BIOCHEM-TOKYO, V107, P304, DOI 10.1093/oxfordjournals.jbchem.a123043; Lee TW, 2001, J BIOCHEM-TOKYO, V130, P57, DOI 10.1093/oxfordjournals.jbchem.a002962; Li B, 1998, NUCLEIC ACIDS RES, V26, P2075, DOI 10.1093/nar/26.9.2075; Malecki J, 2000, J BIOL CHEM, V275, P8480, DOI 10.1074/jbc.275.12.8480; Mukhopadhyay J, 1999, FEBS LETT, V453, P215, DOI 10.1016/S0014-5793(99)00719-X; NIU W, 1994, J MOL BIOL, V243, P595, DOI 10.1016/0022-2836(94)90034-5; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; Passner JM, 1997, P NATL ACAD SCI USA, V94, P2843, DOI 10.1073/pnas.94.7.2843; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHANBLATT SH, 1983, P NATL ACAD SCI-BIOL, V80, P1594, DOI 10.1073/pnas.80.6.1594; TAKAHASHI M, 1980, BIOCHEMISTRY-US, V19, P5124, DOI 10.1021/bi00563a029; TSUGITA A, 1982, FEBS LETT, V144, P304, DOI 10.1016/0014-5793(82)80659-5; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Won HS, 2000, BIOCHEMISTRY-US, V39, P13953, DOI 10.1021/bi000012x; Won HS, 2000, J BIOMOL NMR, V16, P79, DOI 10.1023/A:1008398103476; WU CW, 1974, BIOCHEMISTRY-US, V13, P2573, DOI 10.1021/bi00709a016	38	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11450	11455		10.1074/jbc.M112411200	http://dx.doi.org/10.1074/jbc.M112411200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11781328	hybrid			2022-12-27	WOS:000174613100089
J	Hiraoka, M; Abe, A; Shayman, JA				Hiraoka, M; Abe, A; Shayman, JA			Cloning and characterization of a lysosomal phospholipase A(2), 1-O-acylceramide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; PURIFICATION; CERAMIDE	Recently, a novel enzyme, 1-O-acylceramide synthase (ACS), was purified and characterized from bovine brain. This enzyme has both calcium-independent phospholipase A(2) and transacylase activities. The discovery of this enzyme led us to propose a new pathway for ceramide metabolism in which the sn-2-acyl group of either phosphatidylethanolamine or phosphatidylcholine is transferred to the 1-hydroxyl group of ceramide. In this study, the partial amino acid sequences from the purified enzyme revealed that the enzyme contains amino acid sequences identical to those of human lecithin:cholesterol acyltransferase-like lysophospholipase (LLPL). The coding sequences of the mouse, bovine, and human genes were obtained from the respective kidney cDNAs by PCR. The open reading frames of LLPL were cloned into pcDNA3 to generate carboxyl-terminally tagged proteins. The expression of mouse LLPL in COS-7 cells demonstrated that transfected cells had higher transacylase and phospholipase A(2) activities than did non-transfected cells. Immunoprecipitation confirmed that LLPL had ACS activity. There were no significant lecithin:cholesterol acyltransferase and lysophospholipase activities in the mouse LLPL-transfected cells under either acidic or neutral conditions. Amino acid sequences from cDNAs of mouse, human, and bovine LLPLs demonstrated a signal peptide cleavage site, one lipase motif (AXSXG), and several N-linked glycosylation sites in each LLPL molecule. The replacement of serine with alanine in the lipase motif of mouse LLPL resulted in elimination of enzyme activity, indicating that the serine residue is part of the catalytic site. Deglycosylation of mouse, human, and bovine LLPLs yielded core proteins with a molecular mass of 42 kDa without change in enzyme activities. LLPL was post-translationally modified by signal peptide cleavage and N-linked glycosylation, and each mature LLPL had the same size core protein. Subcellular fractionation demonstrated that ACS activity co-localized with N-acetylglucosaminidase. Therefore, LLPL encodes a novel lysosomal enzyme, ACS.	Univ Michigan, Sch Med, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Shayman, JA (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, Div Nephrol, POB 0676,1560 MSRB 2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NIDDK NIH HHS [R01 DK55823] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe A, 1996, J BIOL CHEM, V271, P14383, DOI 10.1074/jbc.271.24.14383; Abe A, 1998, J BIOL CHEM, V273, P8467, DOI 10.1074/jbc.273.14.8467; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Jonas A, 2000, BBA-MOL CELL BIOL L, V1529, P245, DOI 10.1016/S1388-1981(00)00153-0; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kim TS, 1997, J BIOL CHEM, V272, P2542; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; SchmidtDannert C, 1997, METHOD ENZYMOL, V284, P194; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Taniyama Y, 1999, BIOCHEM BIOPH RES CO, V257, P50, DOI 10.1006/bbrc.1999.0411; WALTON DC, 1967, METHOD ENZYMOL, V10, P245	17	84	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10090	10099		10.1074/jbc.M111977200	http://dx.doi.org/10.1074/jbc.M111977200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11790796	hybrid			2022-12-27	WOS:000174549200065
J	Jin, P; Weiger, TM; Wu, YY; Levitan, IB				Jin, P; Weiger, TM; Wu, YY; Levitan, IB			Phosphorylation-dependent functional coupling of hSlo calcium-dependent potassium channel and its h beta 4 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNEL; PROTEIN-KINASE-A; BETA-SUBUNIT; LARGE-CONDUCTANCE; NERVE-TERMINALS; MOLECULAR-BASIS; RAT-BRAIN; INACTIVATION; VOLTAGE; MODULATION	The auxiliary beta4 subunit of the human slowpoke calciumdependent potassium (slo) channel is expressed predominantly in the brain. Co-expression of beta4 subunit with the slo channel a subunit in HEK293 and Chinese hamster ovary cells slows channel activation and deactivation and also shifts the voltage dependence of the channel to more depolarized potentials. We show here that the functional interaction between the hbeta4 subunit and the slo channel is influenced by the phosphorylation state of hbeta4. Treatment of cells with okadaic acid (OA) reduces the effect of hbeta4 on slo channel activation kinetics and voltage dependence but not on slo channel deactivation kinetics. The effect of OA can be blocked by mutating three putative serine/threonine phosphorylation sites in hbeta4 (Thr-11/Ser-17/Ser-210) to alanines, suggesting that OA potentiates phosphorylation of hbeta4 and thereby suppresses its functional coupling to the slo channel. Mutation of Ser-17 alone to a negatively charged residue (S17E) can mimic the effect of OA. Mutating all three phosphorylation sites in hbeta4 to negatively charged residues (T11D/S17E/S210E) not only suppresses the effect of hbeta4 on slo channel activation kinetics and voltage dependence, it also suppresses its effect on slo channel deactivation kinetics. Co-immunoprecipitation/Western blot experiments indicate that all of these hbeta4 mutants, as well as the wild-type hbeta4, bind to the slo channel. Taken together, these data suggest that phosphorylation of the beta4 subunit dynamically regulates the functional coupling between the beta4 subunit and the pore-forming a subunit of the slo channel. In addition, phosphorylation of different residues in hbeta4 differentially influences its effects on slo channel activation kinetics, deactivation kinetics, and voltage dependence.	Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA; Salzburg Univ, Inst Zool, A-5020 Salzburg, Austria	University of Pennsylvania; Salzburg University	Jin, P (corresponding author), Univ Penn, Sch Med, Dept Neurosci, 233 Stemmler Hall,3450 Hamilton Walk, Philadelphia, PA 19104 USA.		Weiger, Thomas M/D-8133-2017	Weiger, Thomas M/0000-0002-5231-930X				ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; Behrens R, 2000, FEBS LETT, V474, P99, DOI 10.1016/S0014-5793(00)01584-2; BIELEFELDT K, 1994, J PHYSIOL-LONDON, V475, P241, DOI 10.1113/jphysiol.1994.sp020065; Brenner R, 2000, J BIOL CHEM, V275, P6453, DOI 10.1074/jbc.275.9.6453; Bunemann M, 1999, J BIOL CHEM, V274, P33851, DOI 10.1074/jbc.274.48.33851; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; Dworetzky SI, 1996, J NEUROSCI, V16, P4543; EGAN TM, 1993, J NEUROPHYSIOL, V69, P1433, DOI 10.1152/jn.1993.69.5.1433; Gerhardstein BL, 1999, BIOCHEMISTRY-US, V38, P10361, DOI 10.1021/bi990896o; GHO M, 1992, J EXP BIOL, V170, P93; Hanner M, 1998, J BIOL CHEM, V273, P16289, DOI 10.1074/jbc.273.26.16289; Klaerke DA, 1996, J MEMBRANE BIOL, V151, P11, DOI 10.1007/s002329900053; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; Kwak YG, 1999, J BIOL CHEM, V274, P13928, DOI 10.1074/jbc.274.20.13928; Levin G, 1996, J BIOL CHEM, V271, P29321, DOI 10.1074/jbc.271.46.29321; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; Martens JR, 1999, TRENDS CARDIOVAS MED, V9, P253, DOI 10.1016/S1050-1738(00)00037-2; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 2000, P NATL ACAD SCI USA, V97, P5562, DOI 10.1073/pnas.100118597; Nimigean CM, 1999, J GEN PHYSIOL, V113, P425, DOI 10.1085/jgp.113.3.425; PALLANCK L, 1994, HUM MOL GENET, V3, P1239, DOI 10.1093/hmg/3.8.1239; Ramanathan K, 1999, SCIENCE, V283, P215, DOI 10.1126/science.283.5399.215; REINHART PH, 1991, J NEUROSCI, V11, P1627; REINHART PH, 1995, J NEUROSCI, V15, P4572; REINHART PH, 1989, NEURON, V2, P1031, DOI 10.1016/0896-6273(89)90227-4; ROBITAILLE R, 1993, J PHYSIOLOGY-PARIS, V87, P15, DOI 10.1016/0928-4257(93)90020-T; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; Tang XD, 2001, J GEN PHYSIOL, V117, P253, DOI 10.1085/jgp.117.3.253; Tian LJ, 2001, J BIOL CHEM, V276, P7717, DOI 10.1074/jbc.C000741200; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Wallner M, 1999, P NATL ACAD SCI USA, V96, P4137, DOI 10.1073/pnas.96.7.4137; Wang J, 1999, J Neurosci, V19, pRC4; Weiger TM, 2000, J NEUROSCI, V20, P3563, DOI 10.1523/JNEUROSCI.20-10-03563.2000; Xia XM, 1999, J NEUROSCI, V19, P5255, DOI 10.1523/jneurosci.19-13-05255.1999; Xia XM, 2000, J NEUROSCI, V20, P4890; Zhou Y, 1999, NEURON, V22, P809, DOI 10.1016/S0896-6273(00)80739-4	39	20	21	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10014	10020		10.1074/jbc.M107682200	http://dx.doi.org/10.1074/jbc.M107682200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11790768	hybrid			2022-12-27	WOS:000174549200055
J	Sriskanda, V; Shuman, S				Sriskanda, V; Shuman, S			Conserved residues in domain Ia are required for the reaction of Escherichia coli DNA ligase with NAD(+)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MUTATIONAL ANALYSIS; NICK; IDENTIFICATION; ADENYLATION; MECHANISM	NAD(+)-dependent DNA ligases are present in all bacteria and are essential for growth. Their unique substrate specificity compared with ATP-dependent human DNA ligases recommends the NAD(+) ligases as targets for the development of new broad-spectrum antibiotics. A plausible strategy for drug discovery is to identify the structural components of bacterial DNA ligase that interact with NAD(+) and then to isolate small molecules that recognize these components and thereby block the binding of NAD(+) to the ligase. The limitation to this strategy is that the structural determinants of NAD(+) specificity are not known. Here we show that reactivity of Escherichia coli DNA ligase (LigA) with NAD(+) requires N-terminal domain la, which is unique to, and conserved among, NAD(+) ligases but absent from ATP-dependent ligases. Deletion of domain la abolished the scaling of 3'-OH/'5-PO4 nicks and the reaction with NAD(+) to form ligase-adenylate but had no effect on phosphodiester formation at a preadenylated nick. Alanine substitutions at conserved residues within domain la either reduced (His-23, Tyr-35) or abolished (Tyr-22, Asp-32, Asp-36) scaling of a 5'-PO4 nick and adenylyl transfer from NAD(+) without affecting ligation of pre-formed DNA-adenylate. We suggest that these five side chains comprise a binding site for the nicotinamide mononucleotide moiety of NAD(+). Structure-activity relationships were clarified by conservative substitutions.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063611] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63611] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		GOTTESMAN MM, 1973, J MOL BIOL, V77, P531, DOI 10.1016/0022-2836(73)90221-0; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Kaczmarek FS, 2001, J BACTERIOL, V183, P3016, DOI 10.1128/JB.183.10.3016-3024.2001; KONRAD EB, 1973, J MOL BIOL, V77, P519, DOI 10.1016/0022-2836(73)90220-9; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; LEHMAN IR, 1974, SCIENCE, V186, P790; Lim JH, 2001, ARCH BIOCHEM BIOPHYS, V388, P253, DOI 10.1006/abbi.2001.2291; Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3079, DOI 10.1093/nar/24.15.3079; Mackey ZB, 1999, J BIOL CHEM, V274, P21679, DOI 10.1074/jbc.274.31.21679; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Odell M, 1999, J BIOL CHEM, V274, P14032, DOI 10.1074/jbc.274.20.14032; PARK UE, 1989, J BACTERIOL, V171, P2173, DOI 10.1128/jb.171.4.2173-2180.1989; Petit MA, 2000, NUCLEIC ACIDS RES, V28, P4642, DOI 10.1093/nar/28.23.4642; Sekiguchi J, 1997, J VIROL, V71, P9679, DOI 10.1128/JVI.71.12.9679-9684.1997; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; Singleton MR, 1999, STRUCTURE, V7, P35, DOI 10.1016/S0969-2126(99)80007-0; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P525, DOI 10.1093/nar/26.2.525; Sriskanda V, 1999, NUCLEIC ACIDS RES, V27, P3953, DOI 10.1093/nar/27.20.3953; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P4618, DOI 10.1093/nar/26.20.4618; Sriskanda V, 2001, NUCLEIC ACIDS RES, V29, P4930, DOI 10.1093/nar/29.24.4930; Sriskanda V, 2001, J BIOL CHEM, V276, P36100, DOI 10.1074/jbc.M105643200; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; Timson DJ, 1999, J MOL BIOL, V285, P73, DOI 10.1006/jmbi.1998.2302; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wilkinson A, 2001, MOL MICROBIOL, V40, P1241, DOI 10.1046/j.1365-2958.2001.02479.x	26	42	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9695	9700		10.1074/jbc.M111164200	http://dx.doi.org/10.1074/jbc.M111164200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11781321	hybrid			2022-12-27	WOS:000174549200014
J	Tafani, M; Karpinich, NO; Hurster, KA; Pastorino, JG; Schneider, T; Russo, MA; Farber, JL				Tafani, M; Karpinich, NO; Hurster, KA; Pastorino, JG; Schneider, T; Russo, MA; Farber, JL			Cytochrome c release upon Fas receptor activation depends on translocation of full-length Bid and the induction of the mitochondrial permeability transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; INDUCED APOPTOSIS; FRAGMENTS PRIOR; CYCLOSPORINE-A; DEATH; BAX; PORE; PROTEIN; POLY(ADP-RIBOSE); CLEAVAGE	In Jurkat cells Bid was cleaved upon activation of the Fas receptor with an anti-Fas antibody. The caspase-8 inhibitor benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp-(OMe)-CH2F (IETD) prevented the cleavage of Bid and the loss of viability. The nuclear enzyme poly(ADP-ribose)polymerase (PARP) was also cleaved upon the activation of caspases, and IETD similarly prevented PARP cleavage. The PARP inhibitor 3-aminobenzamide (3-AB) restored the cell killing in the presence of IETD, an effect that occurred without restoration of the cleavage of Bid or PARP. In the presence of 3-AB and IETD, translocation occurred of full-length Bid to the mitochondria. The induction of the mitochondrial permeability transition (MPT) was documented by the cyclosporin A (CyA) sensitivity of the release of cytochrome c, the release of malate dehydrogenase from the mitochondrial matrix, the loss of the mitochondrial membrane potential, and the pronounced swelling of these organelles, as assessed by electron microscopy. In addition to preventing all evidence of the MPT, CyA prevented the loss of cell viability, without effect on the cleavage of either Bid or PARP. The prevention of PARP cleavage by inhibition of caspase-3 resulted in a 10-fold activation of the enzyme and a resultant depletion of NAD and ATP. The PARP inhibitor 3-AB prevented the loss of NAD and ATP. Depletion of ATP by metabolic inhibitors similarly prevented the cell killing. It is concluded that the cleaving of PARP in Fas-mediated apoptosis allowed expression of an energy-dependent cell death program that included the translocation of full-length Bid to the mitochondria with induction of the MPT.	Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy	Jefferson University; Sapienza University Rome	Farber, JL (corresponding author), Thomas Jefferson Univ, Dept Pathol, Rm 208,Jefferson Alumni Hall, Philadelphia, PA 19107 USA.	john.farber@mail.tju.edu	Tafani, Marco/U-7230-2019; Tafani, Marco/C-3275-2017	Tafani, Marco/0000-0001-7128-810X; Tafani, Marco/0000-0001-7128-810X	NIDDK NIH HHS [DK38305] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038305] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Belaud-Rotureau MA, 2000, APOPTOSIS, V5, P551, DOI 10.1023/A:1009693630664; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNOFSKY C, 1973, ANAL BIOCHEM, V53, P452, DOI 10.1016/0003-2697(73)90094-8; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; BROWN DG, 1993, J BIOL CHEM, V268, P3037; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Feldmann G, 2000, HEPATOLOGY, V31, P674, DOI 10.1002/hep.510310318; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; HAYAISHI O, 1977, ANNU REV BIOCHEM, V46, P95, DOI 10.1146/annurev.bi.46.070177.000523; IGBAVBOA U, 1989, BIOCHEM BIOPH RES CO, V161, P619, DOI 10.1016/0006-291X(89)92644-2; IKEJIMA M, 1987, J BIOL CHEM, V262, P17641; KANE AB, 1985, AM J PHYSIOL, V249, pC256, DOI 10.1152/ajpcell.1985.249.3.C256; Kantrow SP, 1997, BIOCHEM BIOPH RES CO, V232, P669, DOI 10.1006/bbrc.1997.6353; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; O'Connor L, 1999, Results Probl Cell Differ, V23, P173; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; Pawlowski J, 2000, P NATL ACAD SCI USA, V97, P529, DOI 10.1073/pnas.97.2.529; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STUBBERFIELD CR, 1988, BIOCHEM PHARMACOL, V37, P3967, DOI 10.1016/0006-2952(88)90081-0; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2000, GENE DEV, V14, P2060; WIELCKENS K, 1986, ENDOCRINOLOGY, V119, P2383, DOI 10.1210/endo-119-5-2383; YAMAMOTO K, 1992, BIOCHEM PHARMACOL, V43, P1119, DOI 10.1016/0006-2952(92)90620-X; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zingarelli B, 1996, J IMMUNOL, V156, P350	49	101	103	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10073	10082		10.1074/jbc.M111350200	http://dx.doi.org/10.1074/jbc.M111350200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11790791	hybrid			2022-12-27	WOS:000174549200063
J	Schultz, JR; Loven, MA; Melvin, VMS; Edwards, DP; Nardulli, AM				Schultz, JR; Loven, MA; Melvin, VMS; Edwards, DP; Nardulli, AM			Differential modulation of DNA conformation by estrogen receptors alpha and beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RESPONSE ELEMENTS; ER-ALPHA; TRANSCRIPTION ACTIVATION; STRUCTURAL ORGANIZATION; ALLOSTERIC MODULATION; TISSUE DISTRIBUTION; BINDING DOMAIN; HMG DOMAIN; BENDS DNA	The human estrogen receptor (ER) induces transcription of estrogen-responsive genes upon binding to estrogen and the estrogen response element (ERE). To determine whether receptor-induced changes in DNA structure are related to transactivation, we compared the abilities of ERalpha and ERbeta to activate transcription and induce distortion and bending in DNA. ERalpha induced higher levels of transcription than ERbeta in the presence of 17beta-estradiol. In circular permutation experiments ERalpha induced greater distortion in DNA fragments containing the consensus ERE sequence than ERbeta. Phasing analysis indicated that ERalpha induced a bend directed toward the major groove of the DNA helix but that ERbeta failed to induce a directed DNA bend. Likewise, the ERalpha DNA binding domain (DBD) and hinge region induced a bend directed toward the major groove of the DNA helix, but the ERbeta DBD and hinge region failed to bend ERE-containing DNA fragments. Using receptor chimeras we demonstrated that the ERalpha DBD C-terminal extension is required for directed DNA bending. Transient transfection assays revealed that appropriately oriented DNA bending enhances receptor-mediated transactivation. The different abilities of ERalpha and ERbeta to induce change in DNA structure could foster or inhibit the interaction of regulatory proteins with the receptor and other transcription factors and help to explain how estrogen-responsive genes are differentially regulated by these two receptors.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Colorado, Mol Biol Program, Denver, CO 80262 USA; Univ Colorado, Dept Pathol, Denver, CO 80262 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Denver	Nardulli, AM (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.	anardull@life.uiuc.edu	Schroeder, Jennifer R/G-3679-2014	Schroeder, Jennifer R/0000-0002-1975-721X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053884, R56DK053884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007283] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53884] Funding Source: Medline; NIGMS NIH HHS [T32 GM07283] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1993, CURR BIOL, V3, P182, DOI 10.1016/0960-9822(93)90268-S; CHANG TC, 1992, MOL ENDOCRINOL, V6, P346, DOI 10.1210/me.6.3.346; CHODOSH LA, 1989, CURRENT PROTOCOLS MO, V2; Couse JF, 1997, ENDOCRINOLOGY, V138, P4613, DOI 10.1210/en.138.11.4613; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; Dotzlaw H, 1997, J CLIN ENDOCR METAB, V82, P2371, DOI 10.1210/jc.82.7.2371; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; Ghirlando R, 2000, J BIOL CHEM, V275, P28152; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Hess RA, 1997, NATURE, V390, P509, DOI 10.1038/37352; Jones PS, 1999, J BIOL CHEM, V274, P32008, DOI 10.1074/jbc.274.45.32008; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1994, NUCL ACIDS MOL BIOL, V7, P70; Kim J, 1997, MOL CELL BIOL, V17, P3173, DOI 10.1128/MCB.17.6.3173; Kobryn K, 2000, MOL MICROBIOL, V37, P145, DOI 10.1046/j.1365-2958.2000.01981.x; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Landel CC, 1997, J STEROID BIOCHEM, V63, P59, DOI 10.1016/S0960-0760(97)00073-3; Lazennec G, 1997, MOL ENDOCRINOL, V11, P1375, DOI 10.1210/me.11.9.1375; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEIDIG F, 1992, J BIOL CHEM, V267, P913; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Loven MA, 2001, J BIOL CHEM, V276, P45282, DOI 10.1074/jbc.M106211200; Loven MA, 2001, MOL CELL ENDOCRINOL, V181, P151, DOI 10.1016/S0303-7207(01)00491-9; LU XP, 1993, MOL CELL BIOL, V13, P6509, DOI 10.1128/MCB.13.10.6509; MADER S, 1993, NUCLEIC ACIDS RES, V21, P1125, DOI 10.1093/nar/21.5.1125; MAXWELL BL, 1987, MOL ENDOCRINOL, V1, P25, DOI 10.1210/mend-1-1-25; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; MELVIN VMS, 2001, P 83 ANN END SOC M J, P100; MENDELSON ME, 1994, CURR OPIN CARDIOL, V9, P619, DOI 10.1097/00001573-199409000-00018; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; NARDULLI AM, 1995, MOL ENDOCRINOL, V9, P1064, DOI 10.1210/me.9.8.1064; NARDULLI AM, 1993, MOL ENDOCRINOL, V7, P331, DOI 10.1210/me.7.3.331; Nardulli AM, 1996, MOL ENDOCRINOL, V10, P694, DOI 10.1210/me.10.6.694; NARDULLI AM, 1993, RECEPTOR, V3, P247; NARDULLI AM, 1992, MOL CELL BIOL, V12, P2037, DOI 10.1128/MCB.12.5.2037; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; OGAWA Y, 1995, J BIOL CHEM, V270, P9272, DOI 10.1074/jbc.270.16.9272; Onoe Y, 1997, ENDOCRINOLOGY, V138, P4509, DOI 10.1210/en.138.10.4509; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Petz LN, 1997, J STEROID BIOCHEM, V60, P31, DOI 10.1016/S0960-0760(96)00171-9; Potthoff SJ, 1996, MOL ENDOCRINOL, V10, P1095, DOI 10.1210/me.10.9.1095; Prendergast P, 1996, MOL ENDOCRINOL, V10, P393, DOI 10.1210/me.10.4.393; Rasko T, 2000, NUCLEIC ACIDS RES, V28, P3083, DOI 10.1093/nar/28.16.3083; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; REESE JC, 1991, NUCLEIC ACIDS RES, V19, P6595, DOI 10.1093/nar/19.23.6595; SABBAH M, 1992, BIOCHEM BIOPH RES CO, V185, P944, DOI 10.1016/0006-291X(92)91718-6; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHAPIRO DJ, 1993, STEROID HORMONE RECE, P75; SHULEMOVICH K, 1995, NUCLEIC ACIDS RES, V23, P811, DOI 10.1093/nar/23.5.811; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; Subbiah MTR, 1998, P SOC EXP BIOL MED, V217, P23; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; ToranAllerand CD, 1996, J STEROID BIOCHEM, V56, P169, DOI 10.1016/0960-0760(95)00234-0; Tremblay GB, 1998, CANCER RES, V58, P877; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; TURNER RT, 1994, ENDOCR REV, V15, P275, DOI 10.1210/er.15.3.275; Ujvari A, 2000, J MOL BIOL, V295, P1173, DOI 10.1006/jmbi.1999.3418; VANDERVLIET PC, 1993, BIOESSAYS, V15, P25, DOI 10.1002/bies.950150105; VONHIPPEL PH, 1994, SCIENCE, V263, P769, DOI 10.1126/science.8303292; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; Werner MH, 1996, SCIENCE, V271, P778, DOI 10.1126/science.271.5250.778; WHITE R, 1987, MOL ENDOCRINOL, V1, P735, DOI 10.1210/mend-1-10-735; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; Wood JR, 1998, MOL CELL BIOL, V18, P1927, DOI 10.1128/MCB.18.4.1927; Wood JR, 2001, MOL ENDOCRINOL, V15, P1114, DOI 10.1210/me.15.7.1114; Zhao Q, 1998, MOL CELL, V1, P849, DOI 10.1016/S1097-2765(00)80084-2; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	75	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8702	8707		10.1074/jbc.M108491200	http://dx.doi.org/10.1074/jbc.M108491200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11773069	hybrid			2022-12-27	WOS:000174268000136
J	Wilson, R; Freddi, S; Bateman, JF				Wilson, R; Freddi, S; Bateman, JF			Collagen X chains harboring Shmid metaphyseal chondrodysplasia NC1 domain mutations are selectively retained and degraded in stably transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; CARBOXYL-TERMINAL DOMAIN; IN-VITRO; ENDOCHONDRAL OSSIFICATION; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; ALPHA-1(X) NC1; MESSENGER-RNA; PROCOLLAGEN; CARTILAGE	Collagen X is a short chain, homotrimeric collagen expressed specifically by hypertrophic chondrocytes during endochondral bone formation and growth. Although the exact role of collagen X remains unresolved, mutations in the COL10A1 gene disrupt growth plate function and result in Schmid metaphyseal chondrodysplasia (SMCD). With the exception of two mutations that impair signal peptide cleavage during alpha1(X) chain biosynthesis, SMCD mutations are clustered within the carboxyl-terminal NC1 domain. The formation of stable NC1 domain timers is a critical stage in collagen X assembly, suggesting that mutations within this domain may result in subunit mis-folding or reduce trimer stability. When expressed in transiently transfected cells, alpha1(X) chains containing SMCD mutations were unstable and presumed to be degraded intracellularly. More recently, in vitro studies have shown that certain missense mutations may exert a dominant negative effect on alpha1(X) chain assembly by formation of mutant homotrimers and normal-mutant heterotrimers. In contrast, analysis of cartilage tissue from two SMCD patients revealed that the truncated mutant message was fully degraded, resulting in 50% reduction of functional collagen X within the growth plate. Therefore, in the absence of data that conclusively demonstrates the full cellular response to mutant collagen X chains, the molecular mechanisms underlying SMCD remain controversial. To address this, we closely examined the effect of two NC1 domain mutations, one frameshift mutation (1963del10) and one missense mutation (Y598D), using both semi-permeabilized cell and stable cell transfection expression systems. Although able to assemble to a limited extent in both systems, we show that, in intact cells, collagen X chains harboring both SMCD mutations did not evade quality control mechanisms within the secretory pathway and were degraded intracellularly. Furthermore, co-expression of wild-type and mutant chains in stable transfected cells demonstrated that, although wild-type chains were secreted, mutant chains were largely excluded from hetero-trimer formation. Our data indicate, therefore, that the predominant effect of the NC1 mutations Y598D and 1963del10 is a reduction in the amount of functional collagen X within the growth cartilage extracellular matrix.	Royal Childrens Hosp, Murdoch Childrens Royal Inst, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Paediat, Cell & Matrix Biol Res Unit, Parkville, Vic 3052, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne	Bateman, JF (corresponding author), Royal Childrens Hosp, Murdoch Childrens Royal Inst, Flemington Rd, Parkville, Vic 3052, Australia.		Wilson, Richard/H-8429-2012	Wilson, Richard/0000-0003-0152-4394; Bateman, John/0000-0001-8542-0730				Bengtsson E, 2000, J BIOL CHEM, V275, P40695, DOI 10.1074/jbc.M007917200; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; Chan D, 1999, J BIOL CHEM, V274, P13091, DOI 10.1074/jbc.274.19.13091; Chan D, 1998, J CLIN INVEST, V101, P1490, DOI 10.1172/JCI1976; CHESSLER SD, 1992, J BIOL CHEM, V267, P7751; DHARMAVARAM RM, 1994, HUM MOL GENET, V3, P507, DOI 10.1093/hmg/3.3.507; Dublet B, 1999, J BIOL CHEM, V274, P18909, DOI 10.1074/jbc.274.27.18909; GRANT WT, 1987, J BIOL CHEM, V262, P9844; Gregory CA, 2000, J MED GENET, V37, P627, DOI 10.1136/jmg.37.8.627; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Ikegawa S, 1997, HUM MUTAT, V9, P131, DOI 10.1002/(SICI)1098-1004(1997)9:2<131::AID-HUMU5>3.3.CO;2-U; KAO WWY, 1977, J BIOL CHEM, V252, P8391; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; Kwan KM, 1997, J CELL BIOL, V136, P459, DOI 10.1083/jcb.136.2.459; Lamande SR, 1999, SEMIN CELL DEV BIOL, V10, P455, DOI 10.1006/scdb.1999.0317; Marks DS, 1999, J BIOL CHEM, V274, P3632, DOI 10.1074/jbc.274.6.3632; McLaughlin SH, 1998, BIOCHEM J, V331, P793, DOI 10.1042/bj3310793; McLaughlin SH, 1999, J BIOL CHEM, V274, P7570, DOI 10.1074/jbc.274.11.7570; POOLE AR, 1989, J CELL BIOL, V109, P2547, DOI 10.1083/jcb.109.5.2547; REICHENBERGER E, 1992, FEBS LETT, V311, P305, DOI 10.1016/0014-5793(92)81126-7; REICHENBERGER E, 1991, DEV BIOL, V148, P562, DOI 10.1016/0012-1606(91)90274-7; SCHMID TM, 1985, J CELL BIOL, V100, P598, DOI 10.1083/jcb.100.2.598; SCHMID TM, 1989, CONNECT TISSUE RES, V20, P215, DOI 10.3109/03008208909023890; Tasab M, 2000, EMBO J, V19, P2204, DOI 10.1093/emboj/19.10.2204; THOMAS JT, 1991, BIOCHEM J, V280, P617, DOI 10.1042/bj2800617; WALLIS GA, 1994, AM J HUM GENET, V54, P169; Wallis GA, 1996, J MED GENET, V33, P450, DOI 10.1136/jmg.33.6.450; Walmsley AR, 1999, J BIOL CHEM, V274, P14884, DOI 10.1074/jbc.274.21.14884; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637; Wilson RR, 2000, METH MOL B, V139, P1	35	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12516	12524		10.1074/jbc.M112044200	http://dx.doi.org/10.1074/jbc.M112044200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11805116	hybrid			2022-12-27	WOS:000175036300007
J	Brissova, M; Shiota, M; Nicholson, WE; Gannon, M; Knobel, SM; Piston, DW; Wright, CVE; Powers, AC				Brissova, M; Shiota, M; Nicholson, WE; Gannon, M; Knobel, SM; Piston, DW; Wright, CVE; Powers, AC			Reduction in pancreatic transcription factor PDX-1 impairs glucose-stimulated insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-2 DIABETES-MELLITUS; FACTOR-I GENE; HOMEODOMAIN PROTEIN IDX-1; BETA-CELL DYSFUNCTION; GLUCOKINASE GENE; HOMEOBOX FACTOR; B-CELLS; MISSENSE MUTATIONS; INTRACELLULAR CA2+; AMINO-ACIDS	Complete lack of transcription factor PDX-1 leads to pancreatic agenesis, whereas heterozygosity for PDX-1 mutations has been recently noted in some individuals with maturity-onset diabetes of the young (MODY) and in some individuals with type 2 diabetes. To determine how alterations in PDX-1 affect islet function, we examined insulin secretion and islet physiology in mice with one PDX-1 allele inactivated. PDX-1(+/-) mice had a normal fasting blood glucose and pancreatic insulin content but had impaired glucose tolerance and secreted less insulin during glucose tolerance testing. The expression of PDX-1 and glucose transporter 2 in islets from PDX-1(+/-) mice was reduced to 68 and 55%, respectively, whereas glucokinase expression was not significantly altered. NAD(P)H generation in response to glucose was reduced by 30% in PDX-1(+/-) mice. The in situ perfused pancreas of PDX-1(+/-) mice secreted about 45% less insulin when stimulated with 16.7 m(M) glucose. The K-m for insulin release was similar in wild type and PDX-1(+/-) mice. Insulin secretion in response to 20 mm arginine was unchanged; the response to 10 n(M) glucagon. like peptide-1 was slightly increased. However, insulin secretory responses to 10 m(M) 2-ketoisocaproate and 20 m(M) KCI were significantly reduced (by 61 and 66%, respectively). These results indicate that a modest reduction in PDX-1 impairs several events in glucose-stimulated insulin secretion (such as NAD(P)H generation, mitochondrial function, and/or mobilization of intracellular Ca2+) and that PDX-1 is important for normal function of adult pancreatic islets.	Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA; Vanderbilt Univ, Div Endocrinol Diabet & Metab, Dept Med, Med Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University; Vanderbilt University	Powers, AC (corresponding author), Vanderbilt Univ, Div Endocrinol Diabet & Metab, Dept Med, Med Ctr, 715 PRB, Nashville, TN 37232 USA.		Gannon, Maureen A/F-9060-2012		NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, R01DK055233, R01DK053434] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK55233, DK20593, DK42502, DK53434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; ASHCROFT FM, 1987, J PHYSIOL-LONDON, V385, P517, DOI 10.1113/jphysiol.1987.sp016505; BONNEVIENIELSEN V, 1981, DIABETES, V30, P424, DOI 10.2337/diabetes.30.5.424; Carty MD, 1997, J BIOL CHEM, V272, P11986, DOI 10.1074/jbc.272.18.11986; CHARLES S, 1982, BIOCHEM J, V268, P7538; Clocquet AR, 2000, DIABETES, V49, P1856, DOI 10.2337/diabetes.49.11.1856; DAVALLI AM, 1995, DIABETES, V44, P104, DOI 10.2337/diabetes.44.1.104; DEVOS A, 1995, J CLIN INVEST, V96, P2489, DOI 10.1172/JCI118308; Dutta S, 1998, NATURE, V392, P560, DOI 10.1038/33311; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; Gerrish K, 2000, J BIOL CHEM, V275, P3485, DOI 10.1074/jbc.275.5.3485; Gremlich S, 1997, J BIOL CHEM, V272, P30261, DOI 10.1074/jbc.272.48.30261; GUZ Y, 1995, DEVELOPMENT, V121, P11; Habener JF, 1998, P ASSOC AM PHYSICIAN, V110, P12; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; Hansen L, 2000, J CLIN ENDOCR METAB, V85, P1323, DOI 10.1210/jc.85.3.1323; Harmon JS, 1999, DIABETES, V48, P1995, DOI 10.2337/diabetes.48.10.1995; HENQUIN JC, 1981, AM J PHYSIOL, V240, pE245, DOI 10.1152/ajpendo.1981.240.3.E245; HERMANS MP, 1987, DIABETOLOGIA, V30, P659; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; Jonsson J, 1995, INT J DEV BIOL, V39, P789; Kajimoto Y, 1997, J CLIN INVEST, V100, P1840, DOI 10.1172/JCI119712; Kesavan P, 1997, BIOCHEM J, V322, P57, DOI 10.1042/bj3220057; KOMATSU M, 1995, P NATL ACAD SCI USA, V92, P10728, DOI 10.1073/pnas.92.23.10728; LAYCHOCK SG, 1991, ENDOCRINOLOGY, V129, P3043, DOI 10.1210/endo-129-6-3043; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; LENZEN S, 1982, J BIOL CHEM, V257, P6631; LENZEN S, 1985, J BIOL CHEM, V260, P2629; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Macfarlane WM, 1999, J CLIN INVEST, V104, pR33, DOI 10.1172/JCI7449; Offield MF, 1996, DEVELOPMENT, V122, P983; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; OLSON LK, 1995, P NATL ACAD SCI USA, V92, P9127, DOI 10.1073/pnas.92.20.9127; PANTEN U, 1989, BIOCHEM PHARMACOL, V38, P1217, DOI 10.1016/0006-2952(89)90327-4; Patterson GH, 2000, P NATL ACAD SCI USA, V97, P5203, DOI 10.1073/pnas.090098797; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; Piston DW, 1999, J BIOL CHEM, V274, P1000, DOI 10.1074/jbc.274.2.1000; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; ROBERTSON RP, 1994, DIABETES, V43, P1085, DOI 10.2337/diabetes.43.9.1085; SCHMIDT HHHW, 1992, SCIENCE, V255, P721, DOI 10.1126/science.1371193; Smith PA, 1997, J PHYSIOL-LONDON, V499, P625, DOI 10.1113/jphysiol.1997.sp021955; STEFAN Y, 1987, J CLIN INVEST, V80, P175, DOI 10.1172/JCI113045; Stoffers DA, 1998, J CLIN INVEST, V102, P232, DOI 10.1172/JCI2242; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Stoffers DA, 2000, DIABETES, V49, P741, DOI 10.2337/diabetes.49.5.741; Stoffers DA, 1997, TRENDS ENDOCRIN MET, V8, P145, DOI 10.1016/S1043-2760(97)00008-8; Sweet IR, 1997, DIABETOLOGIA, V40, P112, DOI 10.1007/s001250050652; Tanizawa Y, 1999, DIABETOLOGIA, V42, P887, DOI 10.1007/s001250051242; Thorens B, 2000, J BIOL CHEM, V275, P23751, DOI 10.1074/jbc.M002908200; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Watada H, 1996, BIOCHEM BIOPH RES CO, V229, P746, DOI 10.1006/bbrc.1996.1875; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; Weir GC, 1997, ACTA DIABETOL, V34, P177, DOI 10.1007/s005920050071; Yajima H, 1999, DIABETES, V48, P1006, DOI 10.2337/diabetes.48.5.1006; Zangen DH, 1997, DIABETES, V46, P258, DOI 10.2337/diabetes.46.2.258	60	299	306	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11225	11232		10.1074/jbc.M111272200	http://dx.doi.org/10.1074/jbc.M111272200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11781323	hybrid			2022-12-27	WOS:000174613100061
J	Li, XA; Titlow, WB; Jackson, BA; Giltiay, N; Nikolova-Karakashian, M; Uittenbogaard, A; Smart, EJ				Li, XA; Titlow, WB; Jackson, BA; Giltiay, N; Nikolova-Karakashian, M; Uittenbogaard, A; Smart, EJ			High density lipoprotein binding to scavenger receptor, class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENOS ACTIVATION; PLASMALEMMAL CAVEOLAE; SIGNAL-TRANSDUCTION; CELLS; CALCIUM; LOCALIZATION; INCREASES; DOMAINS; LIVER	Recently it has been demonstrated that high density lipoprotein (HDL) binding to scavenger receptors, class B, type I (SR-BI) stimulates endothelial nitric-oxide synthase (eNOS) activity. In the present studies we used a Chinese hamster ovary cell system and a human microvascular endothelial cell line to confirm that HDL stimulates eNOS activity in a SR-BI-dependent manner. Importantly, we have extended these studies to examine the mechanism whereby HDL binding to SR-BI stimulates eNOS. eNOS can be stimulated by an increase in intracellular calcium, by phosphorylation by Akt kinase, or by an increase in intracellular ceramide. Calcium imagining studies and experiments with the calcium chelator, 1,2-bis(o-aminophenoxy)ethane-NN, N',N'-tetraacetic acid tetra (acetoxymethyl) ester demonstrated that HDL binding to SR-BI does not induce an increase in intracellular calcium. Antibodies specific for activated Akt kinase demonstrated that HDL binding to SR-BI does not induce Akt kinase activation. However, HDL binding to SR-BI caused a reversible increase in intracellular ceramide levels from 97 +/- 14 pmol/mg of protein to 501 +/- 21 pmol/mg of protein. In addition, C-2-ceramide stimulated eNOS to the same extent as HDL, whereas C-2-dihydroceramide did not stimulate eNOS. We conclude that EO:)L binding to SR-BI stimulates eNOS by increasing intracellular ceramide levels and is independent of an increase in intracellular calcium or Akt kinase phosphorylation.	Univ Kentucky, Sch Med, Dept Physiol, Lexington, KY 40536 USA	University of Kentucky	Smart, EJ (corresponding author), Univ Kentucky, Sch Med, Dept Physiol, 423 Sanders Brown,800 Limestone St, Lexington, KY 40536 USA.	ejsmart@uky.edu	Giltiay, Natalia/AAH-2130-2019; Giltiay, Natalia V./H-8655-2019	Giltiay, Natalia/0000-0001-7284-514X; 	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015592] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062844, R01HL064056, R29HL058475, R01HL058475] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR15592] Funding Source: Medline; NHLBI NIH HHS [HL64056, HL62844, HL58475] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnal JF, 1999, CELL MOL LIFE SCI, V55, P1078, DOI 10.1007/s000180050358; Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512; DAVDA RK, 1993, HYPERTENSION, V21, P939, DOI 10.1161/01.HYP.21.6.939; Dobrowsky RT, 2000, CELL SIGNAL, V12, P81, DOI 10.1016/S0898-6568(99)00072-8; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Feron O, 1999, CURR OPIN NEPHROL HY, V8, P55, DOI 10.1097/00041552-199901000-00010; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Honda HM, 1999, ATHEROSCLEROSIS, V143, P299, DOI 10.1016/S0021-9150(98)00302-5; Igarashi J, 1999, P NATL ACAD SCI USA, V96, P12583, DOI 10.1073/pnas.96.22.12583; Jorgensen MS, 2000, J NEUROSCI RES, V59, P760, DOI 10.1002/(SICI)1097-4547(20000315)59:6<760::AID-JNR8>3.0.CO;2-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Matveev S, 1999, J LIPID RES, V40, P1647; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; Nofer JR, 2001, J BIOL CHEM, V276, P34480, DOI 10.1074/jbc.M103782200; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; STRACHAN AF, 1988, BIOCHEM J, V250, P203, DOI 10.1042/bj2500203; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278; Urban S, 2000, J BIOL CHEM, V275, P33409, DOI 10.1074/jbc.M004031200; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986	28	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11058	11063		10.1074/jbc.M110985200	http://dx.doi.org/10.1074/jbc.M110985200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11792700	hybrid			2022-12-27	WOS:000174613100040
J	Lorenzo, E; Ruiz-Ruiz, C; Quesada, AJ; Hernandez, G; Rodriguez, A; Lopez-Rivas, A; Redondo, JM				Lorenzo, E; Ruiz-Ruiz, C; Quesada, AJ; Hernandez, G; Rodriguez, A; Lopez-Rivas, A; Redondo, JM			Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-INDUCED APOPTOSIS; NF-KAPPA-B; APO-1/FAS RECEPTOR/LIGAND SYSTEM; BREAST-TUMOR-CELLS; REACTIVE OXYGEN; UP-REGULATION; CYTOCHROME-C; FAS LIGAND; T-CELLS; IN-VIVO	Regulation of the homeostasis of vascular endothelium is critical for the processes of vascular remodeling and angiogenesis under physiological and pathological conditions. Here we show that doxorubicin (Dox), a drug used in antitumor therapy, triggered a marked accumulation of p53 and induced CD95 gene expression and apoptosis in proliferating human umbilical vein endothelial cells (HUVECs). Transfection and site-directed mutagenesis experiments using the CD95 promoter fused to an intronic enhancer indicated the requirement for a p53 site for Dox-induced promoter activation. Furthermore, the p53 inhibitor pifithrin-alpha (PFT-alpha) blocked both promoter inducibility and protein up-regulation of CD95 in response to Dox. Up-regulated CD95 in Dox-treated cells was functional in eliciting apoptosis upon incubation of the cells with an agonistic CD95 antibody. However, Dox-mediated apoptosis was independent of CD95/CD95L interaction. The analysis of apoptosis in the presence of PFT-alpha and benzyloxycarbonyl-Val-Ala-DL-Asp-fluoromethylketone revealed that both p53 and caspase activation are required for Dox-mediated apoptosis of HUVECs. Finally, Dox triggered Bcl-2 down-egulation, cytochrome c release from mitochondria, and the activation of caspases 9 and 3, suggesting the involvement of a mitochondrially operated pathway of apoptosis. These results highlight the role of p53 in the response of primary endothelial cells to genotoxic drugs and may reveal a novel mechanism underlying the antitumoral properties of Dox, related to its ability to induce apoptosis in proliferating endothelial cells.	Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; CNIC, E-18001 Granada, Spain; Inst Parasitol & Biomed, E-18001 Granada, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Centro Nacional de Investigaciones Cardiovasculares (CNIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Redondo, JM (corresponding author), Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Ruiz-Ruiz, Carmen/I-8792-2017; Marquez, Antonio A. Rodriguez/L-2422-2013; Redondo, Juan Miguel/H-6351-2015; Lopez-Rivas, Abelardo/E-5115-2015	Ruiz-Ruiz, Carmen/0000-0002-6243-6227; Marquez, Antonio A. Rodriguez/0000-0003-2455-6583; Redondo, Juan Miguel/0000-0001-5779-9122; Lopez-Rivas, Abelardo/0000-0002-9351-9690				Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Armesilla AL, 1999, MOL CELL BIOL, V19, P2032; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; Bjorkerud S, 1996, AM J PATHOL, V149, P367; BOCHATONPIALLAT ML, 1995, AM J PATHOL, V146, P1059; Cardier JE, 1999, FASEB J, V13, P1950, DOI 10.1096/fasebj.13.14.1950; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Dimmeler S, 2000, CIRC RES, V87, P434; Dimmeler S, 1998, EUR CYTOKINE NETW, V9, P697; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fuchs EJ, 1997, CANCER RES, V57, P2550; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Fulda S, 1997, CANCER RES, V57, P3823; Gamen S, 1997, FEBS LETT, V417, P360, DOI 10.1016/S0014-5793(97)01282-9; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; Gnad R, 2001, EXP CELL RES, V264, P244, DOI 10.1006/excr.2001.5165; HAN DKM, 1995, AM J PATHOL, V147, P267; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Izquierdo M, 1996, J IMMUNOL, V157, P21; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Karsan A, 1996, J Atheroscler Thromb, V3, P75; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Konorev EA, 1999, ARCH BIOCHEM BIOPHYS, V368, P421, DOI 10.1006/abbi.1999.1337; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LLESUY SF, 1990, TOXICOLOGY, V63, P187, DOI 10.1016/0300-483X(90)90042-F; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Maecker HL, 2000, CANCER RES, V60, P4638; Maestre N, 2001, CANCER RES, V61, P2558; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Munoz C, 1996, J IMMUNOL, V157, P3587; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakamura T, 2000, CIRCULATION, V102, P572; OEHM A, 1992, J BIOL CHEM, V267, P10709; OKUDA S, 1986, KIDNEY INT, V29, P502, DOI 10.1038/ki.1986.28; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Petak I, 2000, CANCER RES, V60, P2643; PETRAK D, 1994, J IMMUNOL, V153, P2046; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Raffo AJ, 2000, ONCOGENE, V19, P6216, DOI 10.1038/sj.onc.1203995; RICHARDSON BC, 1994, EUR J IMMUNOL, V24, P2640, DOI 10.1002/eji.1830241111; Ruiz-Ruiz MD, 1999, CELL DEATH DIFFER, V6, P271, DOI 10.1038/sj.cdd.4400490; Sarvazyan N, 1996, AM J PHYSIOL-HEART C, V271, pH2079, DOI 10.1152/ajpheart.1996.271.5.H2079; SASAKI T, 1987, J CLIN INVEST, V80, P1735, DOI 10.1172/JCI113265; Sata M, 1998, J CLIN INVEST, V102, P1682, DOI 10.1172/JCI3531; Sata M, 1998, NAT MED, V4, P415, DOI 10.1038/nm0498-415; Sata M, 2000, ARTERIOSCL THROM VAS, V20, P309, DOI 10.1161/01.ATV.20.2.309; Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307; SINHA BK, 1987, BIOCHEM PHARMACOL, V36, P793, DOI 10.1016/0006-2952(87)90164-X; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; Suhara T, 1998, J IMMUNOL, V160, P4042; Tietze MK, 2000, CANCER GENE THER, V7, P1315, DOI 10.1038/sj.cgt.0241; Villunger A, 1997, CANCER RES, V57, P3331; Winthrop MD, 1997, CANCER, V80, P2529, DOI 10.1002/(SICI)1097-0142(19971215)80:12+<2529::AID-CNCR27>3.0.CO;2-D; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x; Zheng Y, 2001, J IMMUNOL, V166, P4949, DOI 10.4049/jimmunol.166.8.4949	71	126	132	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10883	10892		10.1074/jbc.M107442200	http://dx.doi.org/10.1074/jbc.M107442200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11779855	hybrid			2022-12-27	WOS:000174613100019
J	Charter, NW; Mahal, LK; Koshland, DE; Bertozzi, CR				Charter, NW; Mahal, LK; Koshland, DE; Bertozzi, CR			Differential effects of unnatural sialic acids on the polysialylation of the neural cell adhesion molecule and neuronal behavior	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYSIALIC ACID; HUMAN POLYSIALYLTRANSFERASE; NEURITE OUTGROWTH; OLFACTORY-BULB; EXPRESSION; STX; BIOSYNTHESIS; BRAIN; GLYCOPROTEINS; PRECURSORS	In this study we have examined how unnatural sialic acids can alter polysialic acid expression and influence the adhesive properties of the neural cell adhesion molecule (NCAM). Unnatural sialic acids are generated by metabolic conversion of synthetic N-acyl mannosamines and are typically incorporated into cell-surface glyco-conjugates. However, N-butanoylmannosamine and N-pentanoylmannosamine are effective inhibitors of polysialic acid (PSA) synthesis in stably transfected HeLa cells expressing NCAM and the polysialyltransferase STX. These cells were used as substrates to examine the effect of inhibiting PSA synthesis on the development of neurons derived from the chick dorsal root ganglion. N-butanoylmannosamine blocked polysialylation of NCAM and significantly reduced neurite outgrowth comparable with enzymatic removal of PSA by endoneuraminidases. As a result, neurite outgrowth was similar to that observed for non-polysialylated NCAM. In contrast, previous studies have shown that N-propanoyl sialic acid (SiaProp), generated from N-propanoylmannosamine, is readily accepted by polysialyltransferases and permits the extension of poly(SiaProp) on NCAM. Despite being immunologically distinct, poly(SiaProp) can promote neurite outgrowth similarly to natural polysialic acid. Thus, subtle structural differences in PSA resulting from the incorporation of SiaProp residues do not alter the antiadhesive properties of polysialylated NCAM.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Chem, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Charter, NW (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.	ncharter@uclink4.berkeley.edu	Mahal, Lara/GRY-7287-2022	Mahal, Lara/0000-0003-4791-8524	NIDDK NIH HHS [DK09765] Funding Source: Medline; NIGMS NIH HHS [GM58867-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK009765, R01DK009765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058867, R37GM058867] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; BAUMANN H, 1993, BIOCHEMISTRY-US, V32, P4007, DOI 10.1021/bi00066a022; Becker CG, 1996, J NEUROSCI RES, V45, P143, DOI 10.1002/(SICI)1097-4547(19960715)45:2<143::AID-JNR6>3.0.CO;2-A; Charter NW, 2000, GLYCOBIOLOGY, V10, P1049, DOI 10.1093/glycob/10.10.1049; Collins BE, 1997, J BIOL CHEM, V272, P1248, DOI 10.1074/jbc.272.2.1248; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; FINNE J, 1982, J BIOL CHEM, V257, P1966; Flyer HJL, 1996, CURR OPIN NEUROBIOL, V6, P113, DOI 10.1016/S0959-4388(96)80016-X; FOX GB, 1995, J NEUROCHEM, V65, P2796; Franceschini I, 2001, GLYCOBIOLOGY, V11, P231, DOI 10.1093/glycob/11.3.231; GOON S, 2000, GLYCOCHEMISTRY PRINC, P641; Hildebrandt H, 1998, CANCER RES, V58, P779; Hildebrandt H, 1998, J NEUROCHEM, V71, P2339; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; Jacobs CL, 2000, METHOD ENZYMOL, V327, P260, DOI 10.1016/S0076-6879(00)27282-0; KAYSER H, 1992, J BIOL CHEM, V267, P16934; Keppler OT, 2001, GLYCOBIOLOGY, V11, p11R, DOI 10.1093/glycob/11.2.11R; Keppler OT, 1998, BIOCHEM BIOPH RES CO, V253, P437, DOI 10.1006/bbrc.1998.9650; KEPPLER OT, 1995, J BIOL CHEM, V270, P1308, DOI 10.1074/jbc.270.3.1308; Kojima N, 1996, J BIOL CHEM, V271, P22058, DOI 10.1074/jbc.271.36.22058; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; LEE VMY, 1986, J NEUROSCI, V6, P514; LEE VMY, 1987, J NEUROSCI, V7, P3474; Liu TM, 2000, J BIOL CHEM, V275, P32832, DOI 10.1074/jbc.C000573200; Mahal LK, 1997, SCIENCE, V276, P1125, DOI 10.1126/science.276.5315.1125; Mahal LK, 2001, SCIENCE, V294, P380, DOI 10.1126/science.1062192; MICHALIDES R, 1994, INT J CANCER, P34; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; Parnas D, 1998, BRAIN RES PROTOC, V2, P333, DOI 10.1016/S1385-299X(98)00009-9; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; Rutishauser U, 1998, J CELL BIOCHEM, V70, P304, DOI 10.1002/(SICI)1097-4644(19980901)70:3<304::AID-JCB3>3.0.CO;2-R; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; Schmidt C, 1998, J BIOL CHEM, V273, P19146, DOI 10.1074/jbc.273.30.19146; Tanaka F, 2000, CANCER RES, V60, P3072; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; YANG PF, 1994, J BIOL CHEM, V269, P23039; ZHANG H, 1992, J NEUROSCI, V12, P3107, DOI 10.1523/JNEUROSCI.12-08-03107.1992	41	41	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9255	9261		10.1074/jbc.M111619200	http://dx.doi.org/10.1074/jbc.M111619200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11786551	hybrid			2022-12-27	WOS:000174400600071
J	Scheid, MP; Huber, M; Damen, JE; Hughes, M; Kang, V; Neilsen, P; Prestwich, GD; Krystal, G; Duronio, V				Scheid, MP; Huber, M; Damen, JE; Hughes, M; Kang, V; Neilsen, P; Prestwich, GD; Krystal, G; Duronio, V			Phosphatidylinositol (3,4,5)P-3 is essential but not sufficient for protein kinase B (PKB) activation; phosphatidylinositol (3,4)P-2 is required for PKB phosphorylation at Ser-473 - Studies using cells from SH2-containing inositol-5-phosphatase knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHATASE SHIP; GLYCOGEN-SYNTHASE KINASE-3; PLECKSTRIN HOMOLOGY DOMAIN; FC-GAMMA-RIIB; POLYPHOSPHATE 5-PHOSPHATASE; SIGNAL-TRANSDUCTION; 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN-KINASE-1; PHOSPHOINOSITIDE-3-OH KINASE; INDUCED DEGRANULATION; TARGETED DISRUPTION	Using bone marrow derived mast cells from SH2-containing inositol-5-phosphatase (SHIP) +/+ and -/-mice, we found that the loss of SHIP leads to a dramatic increase in Steel Factor (SF)-stimulated phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P-3), a substantial reduction in PI(3,4)P-2, and no change in PI(4,5)P-2 levels. We also found that SF-induced activation of protein kinase B (PKB) is increased and prolonged in SHIP-/- cells, due in large part to more PKB associating with the plasma membrane in these cells. Pretreatment of SHIP-/- cells with 25 mum LY294002 resulted in complete inhibition of SF-induced PI(3,4)P-2, while still yielding PI(3,4,5)P3 levels similar to those achieved in SHIP+/+ cells. This offered a unique opportunity to study the regulation of PKB by PI(3,4,5)P,, in the absence of PI(3,4)P,. Under these conditions, PKB activity was markedly reduced compared with that in SF-stimulated SHIP+/+ cells, even though more PKB localized to the plasma membrane. Although phosphoinositide-dependent kinase I mediated phosphorylation of PKB at Thr-308 was unaffected by LY294002, phosphorylation at Ser-473 was dramatically reduced. Moreover, intracellular delivery of PI(3,4)P2 to LY294002-pretreated, SF-stimulated SHIP-/- cells increased phosphorylation of PKB at Ser-473 and increased PKB activity. These results are consistent with a model in which SHIP serves as a regulator of both activity and subcellular localization of PKB.	Vancouver Hosp, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6H 3Z6, Canada; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Univ Freiburg, Dept Mol Immunol, D-79108 Freiburg, Germany; Max Planck Inst Immunbiol, D-79108 Freiburg, Germany; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	University of British Columbia; University of British Columbia; British Columbia Cancer Agency; University of Freiburg; Max Planck Society; Utah System of Higher Education; University of Utah	Duronio, V (corresponding author), Vancouver Hosp, Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.		Hughes, Michael/N-6039-2015	Hughes, Michael/0000-0002-7925-6070; Krystal, Gerald/0000-0002-1961-6281	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R42GM057705, R41GM057705] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57705] Funding Source: Medline; NINDS NIH HHS [NS29632] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V81, P3204; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Hsu YR, 1997, J BIOL CHEM, V272, P6406, DOI 10.1074/jbc.272.10.6406; Huber M, 2000, J IMMUNOL, V165, P124, DOI 10.4049/jimmunol.165.1.124; Huber M, 1998, EMBO J, V17, P7311, DOI 10.1093/emboj/17.24.7311; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; Jacob A, 1999, J BIOL CHEM, V274, P13704, DOI 10.1074/jbc.274.19.13704; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kisseleva MV, 2000, J BIOL CHEM, V275, P20110, DOI 10.1074/jbc.M910119199; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, LEUKEMIA, V11, P181, DOI 10.1038/sj.leu.2400559; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Miura K, 1998, BLOOD, V92, P1206, DOI 10.1182/blood.V92.4.1206.416k01_1206_1218; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Ozaki S, 2000, P NATL ACAD SCI USA, V97, P11286, DOI 10.1073/pnas.210197897; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vosseller K, 1997, MOL BIOL CELL, V8, P909, DOI 10.1091/mbc.8.5.909; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	59	139	140	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9027	9035		10.1074/jbc.M106755200	http://dx.doi.org/10.1074/jbc.M106755200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11781306	hybrid			2022-12-27	WOS:000174400600040
J	Wong, CHY; Ko, WH				Wong, CHY; Ko, WH			Stimulation of Cl- secretion via membrane-restricted Ca2+ signaling mediated by P2Y receptors in polarized epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIMIDINE NUCLEOTIDE RECEPTORS; EQUINE CULTURED EPITHELIA; RAT SUBMANDIBULAR-GLAND; OPERATED HTRP3 CHANNELS; ENDOPLASMIC-RETICULUM; ANION SECRETION; ION-TRANSPORT; EXTRACELLULAR ATP; P-2 RECEPTORS; CELLS	Extracellular nucleotides such as ATP have been shown to regulate ion transport processes in a variety of epithelia. This effect is mediated by the activation of plasma membrane P2Y receptors, which leads to Ca2+ signaling cascade. Ion transport processes (e.g. activation of apical calcium-dependent Cl- channels) are then stimulated via an increase in [Ca2+](i). Many polarized epithelia express apical and/or basolateral P2Y receptors. To test whether apical and basolateral stimulation of P2Y receptors elicit polarized Ca2+ signaling and anion secretion, we simultaneously measured the two parameters in polarized epithelia. Although activation of P2Y receptors located at both apical and basolateral membranes evoked an increase in [Ca2+](i), only apical P2Y receptors-coupled Ca2+ release stimulated an increase in anion secretion. Moreover, the calcium influx evoked by apical and basolateral P2Y receptor stimulation is predominately via the basolateral membrane domain. It appears that the apical P2Y receptor-regulated Ca2+ release and activation of apical Cl- channels is compartmentalized in polarized epithelia with basolateral P2Y-stimulated Ca2+ release failing to activate anion secretion. These data suggest that there may be two distinct ATP-releasable Ca2+ pools, each coupled to apical and basolateral membrane receptor but linked to the same calcium influx pathway located at the basolateral membrane.	Chinese Univ Hong Kong, Dept Physiol, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong	Ko, WH (corresponding author), Chinese Univ Hong Kong, Dept Physiol, Shatin, Hong Kong, Peoples R China.		Ko, Hung/R-1802-2018	Ko, Hung/0000-0002-2041-402X				Ahn JS, 2000, AM J PHYSIOL-CELL PH, V279, pC286, DOI 10.1152/ajpcell.2000.279.2.C286; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Bovell DL, 2000, EUR J PHARMACOL, V403, P45, DOI 10.1016/S0014-2999(00)00570-7; Clunes MT, 1998, BRIT J PHARMACOL, V124, P845, DOI 10.1038/sj.bjp.0701942; Gordjani N, 1997, CELL CALCIUM, V22, P121, DOI 10.1016/S0143-4160(97)90112-3; Guo X, 1997, J MEMBRANE BIOL, V155, P239, DOI 10.1007/s002329900176; Guo XW, 1995, AM J PHYSIOL-CELL PH, V269, pC1457, DOI 10.1152/ajpcell.1995.269.6.C1457; Homolya L, 1999, J BIOL CHEM, V274, P26454, DOI 10.1074/jbc.274.37.26454; Homolya L, 2000, J CELL BIOL, V150, P1349, DOI 10.1083/jcb.150.6.1349; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; Ito Y, 2001, TOXICOL APPL PHARM, V176, P101, DOI 10.1006/taap.2001.9261; Kerstan D, 1999, CELL CALCIUM, V26, P253, DOI 10.1054/ceca.1999.0088; Kiselyov K, 1999, TRENDS NEUROSCI, V22, P334, DOI 10.1016/S0166-2236(99)01426-5; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Ko WH, 1998, J PHYSIOL-LONDON, V512, P471, DOI 10.1111/j.1469-7793.1998.471be.x; Ko WH, 1999, J MEMBRANE BIOL, V170, P205, DOI 10.1007/s002329900550; Ko WH, 1997, BRIT J PHARMACOL, V121, P150, DOI 10.1038/sj.bjp.0701093; KO WH, 1994, J EXP BIOL, V190, P239; Ko WH, 1996, J PHYSIOL-LONDON, V497, P19, DOI 10.1113/jphysiol.1996.sp021746; Ko WH, 1996, J PHYSIOL-LONDON, V493, P885, DOI 10.1113/jphysiol.1996.sp021431; LARSEN EH, 1990, J PHYSIOL-LONDON, V424, P109, DOI 10.1113/jphysiol.1990.sp018058; Lee MG, 1998, J PHYSIOL-LONDON, V513, P341, DOI 10.1111/j.1469-7793.1998.341bb.x; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; McAlroy HL, 2000, BRIT J PHARMACOL, V131, P1651, DOI 10.1038/sj.bjp.0703743; Nicholas RA, 1996, MOL PHARMACOL, V50, P224; Paradiso AM, 2001, J GEN PHYSIOL, V117, P53, DOI 10.1085/jgp.117.1.53; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Park MK, 2000, EMBO J, V19, P5729, DOI 10.1093/emboj/19.21.5729; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Petersen OH, 2001, TRENDS NEUROSCI, V24, P271, DOI 10.1016/S0166-2236(00)01787-2; Putney JW, 2000, CELL MOL LIFE SCI, V57, P1272, DOI 10.1007/PL00000765; Ralevic V, 1998, PHARMACOL REV, V50, P413; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; REISIN IL, 1994, J BIOL CHEM, V269, P20584; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; STUTTS MJ, 1994, AM J PHYSIOL-CELL PH, V267, pC1442, DOI 10.1152/ajpcell.1994.267.5.C1442; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Thomas J, 2001, J MEMBRANE BIOL, V183, P115, DOI 10.1007/s00232-001-0059-4; Turner JT, 1997, AM J PHYSIOL-CELL PH, V273, pC1100, DOI 10.1152/ajpcell.1997.273.3.C1100; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Wilson SM, 1998, BRIT J PHARMACOL, V124, P832, DOI 10.1038/sj.bjp.0701888; WILSON SM, 1993, J EXP BIOL, V183, P179; WONG PYD, 1988, BRIT J PHARMACOL, V95, P1315, DOI 10.1111/j.1476-5381.1988.tb11770.x; [No title captured]	48	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9016	9021		10.1074/jbc.M111917200	http://dx.doi.org/10.1074/jbc.M111917200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11779875	hybrid			2022-12-27	WOS:000174400600038
J	Jehn, BM; Dittert, I; Beyer, S; von der Mark, K; Bielke, W				Jehn, BM; Dittert, I; Beyer, S; von der Mark, K; Bielke, W			c-Cbl binding and ubiquitin-dependent lysosomal degradation of membrane-associated Notch1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; LIGAND-INDUCED INTERNALIZATION; FACTOR RECEPTOR; MYOGENIC DIFFERENTIATION; HORMONE RECEPTOR; PLASMA-MEMBRANE; PROTEASOME; PROTEIN; REGULATOR; SIGNAL	Regulation of Notch1 activity is critical for cell fate decisions and differentiation of skeletal myoblasts. We have employed the skeletal myoblast cell line C2C12 to study posttranslational regulation of Notch1 protein levels during myogenesis. Although the major degradation pathway of the activated intracellular Notch1 fragment appears to involve ubiquitination and degradation by the 26 S proteasome, we provide evidence for an alternative catalytic pathway where the endogenous, transmembrane form of Notch1 is targeted to the lysosomal compartment. Immunoprecipitation analysis revealed ubiquitin-dependent accumulation of transmembrane Notch1 protein after treatment with the lysosomal inhibitor chloroquine but not after treatment with various proteasome inhibitors. This finding was supported by the observation that the transmembrane form of Notch1 was tyrosine-phosphorylated and specifically coprecipitated with the ubiquitin ligase c-Cbl. Our data suggest a regulatory mechanism down-regulating Notch1 protein levels already at the cellular surface, possibly with consequences for Notch-dependent signal transduction during terminal differentiation processes.	Univ Erlangen Nurnberg, Dept Expt Med 1, Nikolaus Fiebiger Zentrum, D-91054 Erlangen, Germany; Univ Erlangen Nurnberg, Div Mol Immunol, Dept Internal Med 3, D-91054 Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg	Bielke, W (corresponding author), Univ Erlangen Nurnberg, Dept Expt Med 1, Nikolaus Fiebiger Zentrum, Gluckstr 6, D-91054 Erlangen, Germany.							Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BLAKE TJ, 1991, ONCOGENE, V6, P653; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Cornell M, 1999, GENETICS, V152, P567; Denis G, 1999, CELL DEATH DIFFER, V6, P689, DOI 10.1038/sj.cdd.4400542; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; Gardrat F, 1997, MOL BIOL REP, V24, P77, DOI 10.1023/A:1006877214153; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Kim SS, 1998, FEBS LETT, V433, P47, DOI 10.1016/S0014-5793(98)00883-7; Klapper LN, 2000, CANCER RES, V60, P3384; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Mugita N, 1999, INT J MOL MED, V3, P127; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; Sawasdikosol S, 2000, BBA-REV CANCER, V1471, pM1, DOI 10.1016/S0304-419X(00)00013-5; Schweisguth F, 1999, P NATL ACAD SCI USA, V96, P11382, DOI 10.1073/pnas.96.20.11382; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wilson-Rawls J, 1999, MOL CELL BIOL, V19, P2853	38	110	112	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8033	8040		10.1074/jbc.M108552200	http://dx.doi.org/10.1074/jbc.M108552200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11777909	hybrid			2022-12-27	WOS:000174268000052
J	Moise, L; Piserchio, A; Basus, VJ; Hawrot, E				Moise, L; Piserchio, A; Basus, VJ; Hawrot, E			NMR structural analysis of alpha-bungarotoxin and its complex with the principal alpha-neurotoxin-binding sequence on the alpha 7 subunit of a neuronal nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; 3-DIMENSIONAL SOLUTION STRUCTURE; CORRELATION SPECTROSCOPY; CURAREMIMETIC TOXINS; TORPEDO-CALIFORNICA; CRYSTAL-STRUCTURE; H-1-NMR SPECTRA; EPSILON-SUBUNIT; MATRIX ANALYSIS; GAMMA-SUBUNIT	We report a new, higher resolution NMR structure of alpha-bungarotoxin that defines the structure-determining disulfide core and beta-sheet regions. We further report the NAIR structure of the stoichiometric complex formed between alpha-bungarotoxin and a recombinantly expressed 19-mer peptide ((178)IPGKRTESFYECCKEPYPD(196)) derived from the alpha7 subunit of the chick neuronal nicotinic acetylcholine receptor. A comparison of these two structures reveals binding-induced stabilization of the flexible tip of finger 11 in alpha-bungarotoxin. The conformational rearrangements in the toxin create an extensive binding surface involving both sides of the alpha7 19-mer hairpin-like structure. At the contact zone, Ala(7), Ser(9), and Ile(11) in finger I and Arg(16), Lys(38), Val(39), and Val(40) in finger 11 of alpha-bungarotoxin interface with Phe(186), Tyr(187), Glu(188), and Tyr(194) in the alpha719-mer underscoring the importance of receptor aromatic residues as critical neurotoxin-binding determinants. Superimposing the structure of the complex onto that of the acetylcholine-binding protein (11913), a soluble homologue of the extracellular domain of the alpha7 receptor, places alpha-bungarotoxin at the peripheral surface of the inter-subunit interface occluding the agonist-binding site. The disulfide-rich core of alpha-bungarotoxin is suggested to be tilted in the direction of the membrane surface with finger II extending into the proposed ligand-binding cavity.	Brown Med Sch, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA; Brown Univ, Dept Chem, Providence, RI 02912 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Brown University; Brown University; University of California System; University of California San Francisco	Hawrot, E (corresponding author), Brown Med Sch, Dept Mol Pharmacol Physiol & Biotechnol, Box G-B391, Providence, RI 02912 USA.	Edward_Hawrot@brown.edu	Moise, Lenny/AAE-7448-2019	Moise, Lenny/0000-0002-4410-865X	NCRR NIH HHS [RR-01081, RR08240] Funding Source: Medline; NIGMS NIH HHS [GM32629] Funding Source: Medline; NINDS NIH HHS [NS34348] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034348] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antil S, 1999, J BIOL CHEM, V274, P34851, DOI 10.1074/jbc.274.49.34851; Antil-Delbeke S, 2000, J BIOL CHEM, V275, P29594, DOI 10.1074/jbc.M909746199; Avizonis DZ, 1996, J AM CHEM SOC, V118, P13031, DOI 10.1021/ja962005v; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BASUS VJ, 1988, BIOCHEMISTRY-US, V27, P2763, DOI 10.1021/bi00408a016; BASUS VJ, 1984, J MAGN RESON, V60, P138, DOI 10.1016/0022-2364(84)90039-8; BETZEL C, 1991, J BIOL CHEM, V266, P21530; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BORGIAS BA, 1989, METHOD ENZYMOL, V176, P169; BORGIAS BA, 1990, J MAGN RESON, V87, P475, DOI 10.1016/0022-2364(90)90305-S; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHANDRAS.R, 1969, BIOCHIM BIOPHYS ACTA, V188, P1, DOI 10.1016/0005-2795(69)90039-7; CHIAPPINELLI VA, 1993, NATURAL SYNTHETIC NE, P65; Connolly PJ, 1996, BIOCHEMISTRY-US, V35, P418, DOI 10.1021/bi9520287; COURTURIER S, 1990, NEURON, V5, P847; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; GENTILE LN, 1995, ANN NY ACAD SCI, V757, P222, DOI 10.1111/j.1749-6632.1995.tb17479.x; GODDARD TD, 2001, SPARKY, V3; GRIESINGER C, 1985, J AM CHEM SOC, V107, P6394, DOI 10.1021/ja00308a042; GRIESMANN GE, 1990, J NEUROCHEM, V54, P1541, DOI 10.1111/j.1471-4159.1990.tb01202.x; Gros E., 1967, METHOD ENZYMOL, V11, P238; Grutter T, 2001, TRENDS BIOCHEM SCI, V26, P459, DOI 10.1016/S0968-0004(01)01921-1; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; Guenneugues M, 1997, BIOCHEMISTRY-US, V36, P16097, DOI 10.1021/bi971293k; Harel M, 2001, NEURON, V32, P265, DOI 10.1016/S0896-6273(01)00461-5; HAVEL TF, 1979, BIOPOLYMERS, V18, P73, DOI 10.1002/bip.1979.360180108; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KACHALSKY SG, 1995, P NATL ACAD SCI USA, V92, P10801, DOI 10.1073/pnas.92.23.10801; KAO PN, 1986, J BIOL CHEM, V261, P8085; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Kelley LA, 1996, PROTEIN ENG, V9, P1063, DOI 10.1093/protein/9.11.1063; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; KULIOPULOS A, 1994, J AM CHEM SOC, V116, P4599, DOI 10.1021/ja00090a008; KUNTZ ID, 1989, METHOD ENZYMOL, V177, P159; LEROY E, 1994, J BIOMOL STRUCT DYN, V12, P1; Levandoski MM, 1999, J BIOL CHEM, V274, P26113, DOI 10.1074/jbc.274.37.26113; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; Malany S, 2000, BIOCHEMISTRY-US, V39, P15388, DOI 10.1021/bi001825o; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MCLANE KE, 1991, J BIOL CHEM, V266, P15230; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; MISHINA M, 1985, NATURE, V313, P364, DOI 10.1038/313364a0; MOORE MA, 1995, BBA-BIOMEMBRANES, V1235, P336, DOI 10.1016/0005-2736(95)80022-8; NIRMALA NR, 1989, J MAGN RESON, V82, P659, DOI 10.1016/0022-2364(89)90232-1; Osaka H, 2000, J BIOL CHEM, V275, P5478, DOI 10.1074/jbc.275.8.5478; PEARCE SFA, 1990, P ROY SOC B-BIOL SCI, V241, P207, DOI 10.1098/rspb.1990.0087; Penkett CJ, 1998, BIOCHEMISTRY-US, V37, P17054, DOI 10.1021/bi9814080; Pletneva EV, 2001, J AM CHEM SOC, V123, P6232, DOI 10.1021/ja010401u; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Rosenthal JA, 1999, BIOCHEMISTRY-US, V38, P7847, DOI 10.1021/bi990045g; Sambrook J., 1989, MOL CLONING LAB MANU; Samson AO, 2001, BIOCHEMISTRY-US, V40, P5464, DOI 10.1021/bi0022689; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; Scherf T, 1997, P NATL ACAD SCI USA, V94, P6059, DOI 10.1073/pnas.94.12.6059; Scherf T, 2001, P NATL ACAD SCI USA, V98, P6629, DOI 10.1073/pnas.111164298; Servent D, 1997, J BIOL CHEM, V272, P24279, DOI 10.1074/jbc.272.39.24279; Shen F, 1996, J BIOL CHEM, V271, P4827; Sine SM, 1997, J BIOL CHEM, V272, P23521, DOI 10.1074/jbc.272.38.23521; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; SKLENAR V, 1987, J MAGN RESON, V73, P375, DOI 10.1016/0022-2364(87)90214-9; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SUKUMARAN DK, 1991, J AM CHEM SOC, V113, P706, DOI 10.1021/ja00002a067; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; VANGUNSTEREN WF, 1987, GROMOS MANUAL; VANSCHAIK RC, 1993, J MOL BIOL, V234, P751, DOI 10.1006/jmbi.1993.1624; Venters RA, 1996, J MOL BIOL, V264, P1101, DOI 10.1006/jmbi.1996.0699; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WALKER JW, 1981, BIOCHEMISTRY-US, V20, P2191, DOI 10.1021/bi00511a018; Wang XH, 2000, NAT STRUCT BIOL, V7, P505, DOI 10.1038/75921; WEMMER DE, 1994, METHOD ENZYMOL, V239, P739; WILSON PT, 1985, P NATL ACAD SCI USA, V82, P8790, DOI 10.1073/pnas.82.24.8790; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Xia ZX, 1996, J MOL BIOL, V259, P480, DOI 10.1006/jmbi.1996.0334; Zeng HY, 2001, J BIOL CHEM, V276, P22930, DOI 10.1074/jbc.M102300200; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011	82	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12406	12417		10.1074/jbc.M110320200	http://dx.doi.org/10.1074/jbc.M110320200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11790782	hybrid			2022-12-27	WOS:000174846400106
J	Kwon, M; Caplan, JF; Filipenko, NR; Choi, KS; Fitzpatrick, SL; Zhang, LB; Waisman, DM				Kwon, M; Caplan, JF; Filipenko, NR; Choi, KS; Fitzpatrick, SL; Zhang, LB; Waisman, DM			Identification of annexin II heterotetramer as a plasmin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE-ISOMERASE; PROSTATE CARCINOMA-CELLS; FLUORESCEINTHIOCARBAMYL-INSULIN; ANGIOGENESIS INHIBITOR; NEOPLASTIC-CELLS; BOND REDUCTION; ANGIOSTATIN; GENERATION; TETRAMER; ACTIVATION	Annexin II heterotetramer (AIIt) is a Ca2(+)- and phospholipid-binding protein that consists of two copies of a p36 and p11 subunit. AIIt regulates the production and autoproteolysis of plasmin at the cell surface. In addition to its role as a key cellular protease, plasmin also plays a role in angiogenesis as the precursor for antiangiogenic proteins. Recently we demonstrated that the primary antiangiogenic plasmin fragment, called A(61) (Lys(78)-LyS(468)) was released from cultured cells. In the present study we report for the first time that AIR possesses an intrinsic plasmin reductase activity. AIR stimulated the reduction of the plasmin CyS462-CyS541 bond in a time- and concentration-dependent manner, which resulted in the release of A(61) from plasmin. Mutagenesis of p36 C334S and either p11 C61S or p11 C82S inactivated the plasmin reductase activity of the isolated subunits, suggesting that specific cysteinyl residues participated in the plasmin reductase activity of each subunit. Furthermore, we demonstrated that the loss of AIR from the cell surface of HT1080 cells transduced with a retroviral vector encoding p11 antisense dramatically reduced the cellular production of A(61) from plasminogen. This is the first demonstration that AIIt regulates the cellular production of the antiangiogenic plasminogen fragment, A(61).	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary	Waisman, DM (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Zhang, Libo/0000-0001-7072-4408; Waisman, David/0000-0002-5097-9662	NCI NIH HHS [CA78639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ayala-Sanmartin J, 2000, BIOCHEMISTRY-US, V39, P15179, DOI 10.1021/bi000501x; Cornelius LA, 1998, J IMMUNOL, V161, P6845; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Essex DW, 1999, BRIT J HAEMATOL, V104, P448, DOI 10.1046/j.1365-2141.1999.01197.x; Falcone DJ, 1998, J BIOL CHEM, V273, P31480, DOI 10.1074/jbc.273.47.31480; Filipenko NR, 2001, J BIOL CHEM, V276, P5310, DOI 10.1074/jbc.M009710200; Fitzpatrick SL, 2000, BIOCHEMISTRY-US, V39, P1021, DOI 10.1021/bi991411z; Gately S, 1996, CANCER RES, V56, P4887; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; Ghahary A, 1998, J INVEST DERMATOL, V110, P800; Heidtmann HH, 1999, BRIT J CANCER, V81, P1269, DOI 10.1038/sj.bjc.6692167; Heuck AP, 1997, J BIOCHEM BIOPH METH, V34, P213, DOI 10.1016/S0165-022X(97)00014-6; Heuck AP, 1997, ANAL BIOCHEM, V248, P94, DOI 10.1006/abio.1997.2123; JOHNSSON N, 1990, J BIOL CHEM, V265, P14464; Kang HM, 1999, TRENDS CARDIOVAS MED, V9, P92, DOI 10.1016/S1050-1738(99)00012-2; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; Kassam G, 2001, J BIOL CHEM, V276, P8924, DOI 10.1074/jbc.M009071200; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; Lahav J, 2000, FEBS LETT, V475, P89, DOI 10.1016/S0014-5793(00)01630-6; Langenbach KJ, 1999, J BIOL CHEM, V274, P7032, DOI 10.1074/jbc.274.11.7032; Lay AJ, 2000, NATURE, V408, P869, DOI 10.1038/35048596; Lijnen HR, 1998, BIOCHEMISTRY-US, V37, P4699, DOI 10.1021/bi9731798; Mai JX, 2000, BBA-PROTEIN STRUCT M, V1477, P215, DOI 10.1016/S0167-4838(99)00274-5; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; Morikawa W, 2000, J BIOL CHEM, V275, P38912, DOI 10.1074/jbc.M005402200; O'Neill S, 2000, J BIOL CHEM, V275, P36984, DOI 10.1074/jbc.M003279200; O'Reilly MS, 1999, J BIOL CHEM, V274, P29568, DOI 10.1074/jbc.274.41.29568; OREILLY MS, 1994, COLD SPRING HARB SYM, V59, P471, DOI 10.1101/SQB.1994.059.01.052; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; Soderberg A, 2000, CANCER RES, V60, P2281; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; Stathakis P, 1999, J BIOL CHEM, V274, P8910, DOI 10.1074/jbc.274.13.8910; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; WU HL, 1987, P NATL ACAD SCI USA, V84, P8793, DOI 10.1073/pnas.84.24.8793	36	35	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10903	10911		10.1074/jbc.M111219200	http://dx.doi.org/10.1074/jbc.M111219200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11781322	hybrid			2022-12-27	WOS:000174613100021
J	Mahfoud, R; Garmy, N; Maresca, M; Yahi, N; Puigserver, A; Fantini, J				Mahfoud, R; Garmy, N; Maresca, M; Yahi, N; Puigserver, A; Fantini, J			Identification of a common sphingolipid-binding domain in Alzheimer, prion, and HIV-1 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOMEMBRANES; ENVIRONMENT; MODEL	The V3 loop of the human immunodeficiency virus (HIV)-1 surface envelope glycoprotein gp120 is a sphingolipid-binding domain mediating the attachment of HIV-1 to plasma membrane microdomains (rafts). Sphingolipid-induced conformational changes in gp120 are required for HIV-1 fusion. Galactosylceramide and sphingomyelin have been detected in highly purified preparations of prion rods, suggesting that the prion protein (PrP) may interact with selected sphingolipids. Moreover, a major conformational transition of the Alzheimer beta-amyloid peptide has been observed upon interaction with sphingolipid-containing membranes. Structure similarity searches with the combinatorial extension method revealed the presence of a W-like domain in the human prion protein PrP and in the Alzheimer beta-amyloid peptide. In each case, synthetic peptides derived from the predicted W-like domain were found to interact with monomolecular films of galactosylceramide and sphingomyelin at the air-water interface. The W-like domain of PrP is a disulfide-linked loop (Cys(179)- Cys(214)) that includes the E200K mutation site associated with familial Creutzfeldt-Jakob disease. This mutation abrogated sphingomyelin recognition. The identification of a common sphingolipid-binding motif in gp120, PrP, and P-amyloid peptide underscores the role of lipid rafts in the pathogenesis of HIV-1, Alzheimer, and prion diseases and may provide new therapeutic strategies.	Fac Sci & Tech St Jerome, Inst Mediterraneen Rech Nutr, UMR 1111, Inst Natl Rech Agron, F-13397 Marseille 20, France	INRAE; UDICE-French Research Universities; Aix-Marseille Universite	Fantini, J (corresponding author), Fac Sci & Tech St Jerome, Inst Mediterraneen Rech Nutr, UMR 1111, Inst Natl Rech Agron, F-13397 Marseille 20, France.		Maresca, Marc/AAG-9148-2019	Maresca, Marc/0000-0002-3585-4765; Fantini, Jacques/0000-0001-8653-5521				Brown RE, 1998, J CELL SCI, V111, P1; Fantini J, 2000, METHOD ENZYMOL, V311, P626; Fujita E, 2000, Carbohydr Lett, V4, P53; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; MAGGIO B, 1994, PROG BIOPHYS MOL BIO, V62, P55, DOI 10.1016/0079-6107(94)90006-X; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Naslavsky N, 1999, J BIOL CHEM, V274, P20763, DOI 10.1074/jbc.274.30.20763; NYHOLM PG, 1995, INT J BIOL MACROMOL, V17, P199, DOI 10.1016/0141-8130(95)92686-K; QUINN PJ, 1994, LIPID HDB, P465; Shao XG, 2000, NUCLEIC ACIDS RES, V28, P2643, DOI 10.1093/nar/28.14.2643; Sinha K, 2000, MOL MICROBIOL, V37, P1041, DOI 10.1046/j.1365-2958.2000.02091.x; Sutton JM, 2001, FEBS LETT, V493, P45, DOI 10.1016/S0014-5793(01)02273-6; Zhang YB, 2000, J BIOL CHEM, V275, P33650, DOI 10.1074/jbc.C000483200	16	185	194	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11292	11296		10.1074/jbc.M111679200	http://dx.doi.org/10.1074/jbc.M111679200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11792705	hybrid			2022-12-27	WOS:000174613100069
J	Santos-Ocana, C; Do, TQ; Padilla, S; Navas, P; Clarke, CF				Santos-Ocana, C; Do, TQ; Padilla, S; Navas, P; Clarke, CF			Uptake of exogenous coenzyme Q and transport to mitochondria is required for bc(1) complex stability in yeast coq mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; CYTOCHROME BC(1); UBIQUINONE BIOSYNTHESIS; TISSUE CONCENTRATIONS; ELECTRON-TRANSFER; INNER MEMBRANE; GENE ENCODES; PROTEIN; CLK-1	Coenzyme Q (Q) is an essential component of the mitochondrial respiratory chain in eukaryotic cells but also is present in other cellular membranes where it acts as an antioxidant. Because Q synthesis machinery in Saccharomyces cerevisiae is located in the mitochondria, the intracellular distribution of Q indicates the existence of intracellular Q transport. In this study, the uptake of exogenous Q(6) by yeast and its transport from the plasma membrane to mitochondria was assessed in both wild-type and in Q-Iess coq7 mutants derived from four distinct laboratory yeast strains. Q(6) supplementation of medium containing ethanol, a non-fermentable carbon source, rescued growth in only two of the four coq7 mutant strains. Following culture in medium containing dextrose, the added Q(6) was detected in the plasma membrane of each of four coq7 mutants tested. This detection of Q, in the plasma membrane was corroborated by measuring ascorbate stabilization activity, as catalyzed by NADH-ascorbate free radical reductase, a transmembrane redox activity that provides a functional assay of plasma membrane Q(6). These assays indicate that each of the four coq7 mutant strains assimilate exogenous Q(6) into the plasma membrane. The two coq7 mutant strains rescued by Q(6) supplementation for growth on ethanol contained mitochondrial Q(6) levels similar to wild type. However, the content of Q(6) in mitochondria from the non-rescued strains was only 35 and 8%, respectively, of that present in the corresponding wild-type parental strains. In yeast strains rescued by exogenous Q(6), succinate-cytochrome c reductase activity was partially restored, whereas non-rescued strains contained very low levels of activity. There was a strong correlation between mitochondrial Q(6) content, succinate-cytochrome c reductase activity, and steady state levels of the cytochrome c(1) polypeptide. These studies show that transport of extracellular Q(6) to the mitochondria operates in yeast but is strain-dependent. When Q biosynthesis is disrupted in yeast strains with defects in the intracellular transport of exogenous Q, the be, complex is unstable. These results indicate that delivery of exogenous Q(6) to mitochondria is required fore activity and stability of the bc(1) complex in yeast coq mutants.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Pablo de Olavide, Lab Andaluz Biol, Seville 41013, Spain	University of California System; University of California Los Angeles; Universidad Pablo de Olavide	Clarke, CF (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.	cathy@mbi.ucla.edu	Ocaña, Carlos Santos/E-8115-2011; NAVAS, PLACIDO/R-5943-2019	Ocaña, Carlos Santos/0000-0002-2379-796X; NAVAS, PLACIDO/0000-0002-4115-7966	NIGMS NIH HHS [GM45952] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmadzadeh M, 1996, CELL BIOCHEM FUNCT, V14, P201; Bader MW, 2000, J BIOL CHEM, V275, P26082, DOI 10.1074/jbc.M003850200; Barkovich RJ, 1997, J BIOL CHEM, V272, P9182; Bartoschek S, 2001, J BIOL CHEM, V276, P35231, DOI 10.1074/jbc.C100365200; Bathori G, 1999, J BIOL CHEM, V274, P29607, DOI 10.1074/jbc.274.42.29607; BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; Beal MF, 1996, CURR OPIN NEUROBIOL, V6, P661, DOI 10.1016/S0959-4388(96)80100-0; Belogrudov GI, 2001, ARCH BIOCHEM BIOPHYS, V392, P48, DOI 10.1006/abbi.2001.2448; BOUSQUET I, 1991, EMBO J, V10, P2023, DOI 10.1002/j.1460-2075.1991.tb07732.x; Brasseur G, 1997, EUR J BIOCHEM, V246, P103, DOI 10.1111/j.1432-1033.1997.t01-1-00103.x; BUETTNER GR, 1988, J BIOCHEM BIOPH METH, V16, P27, DOI 10.1016/0165-022X(88)90100-5; CHANG A, 1995, J CELL BIOL, V128, P39, DOI 10.1083/jcb.128.1.39; Dallner G, 2000, FREE RADICAL BIO MED, V29, P285, DOI 10.1016/S0891-5849(00)00307-5; Darrouzet E, 2001, TRENDS BIOCHEM SCI, V26, P445, DOI 10.1016/S0968-0004(01)01897-7; Daum G, 1998, YEAST, V14, P1471, DOI 10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y; Dibrov E, 1997, J BIOL CHEM, V272, P9175; Do TQ, 2001, J BIOL CHEM, V276, P18161, DOI 10.1074/jbc.M100952200; Dutton PL, 2000, COENZYME Q OXIDATION, P65, DOI [10.1201/9781420036701.sec1b, DOI 10.1201/9781420036701.SEC1B]; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Fang M, 1998, BBA-MOL CELL RES, V1404, P85, DOI 10.1016/S0167-4889(98)00049-4; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; Finazzi G, 1997, BIOCHEMISTRY-US, V36, P2867, DOI 10.1021/bi962717y; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; Gille L, 2000, ARCH BIOCHEM BIOPHYS, V375, P347, DOI 10.1006/abbi.1999.1649; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GomezDiaz C, 1997, BIOCHEM BIOPH RES CO, V234, P79, DOI 10.1006/bbrc.1997.6582; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; Hihi AK, 2002, J BIOL CHEM, V277, P2202, DOI 10.1074/jbc.M109034200; HOUSER RM, 1977, J BIOL CHEM, V252, P4017; Hsu AY, 1996, BIOCHEMISTRY-US, V35, P9797, DOI 10.1021/bi9602932; Jiang N, 2001, J BIOL CHEM, V276, P29218, DOI 10.1074/jbc.M103686200; Jonassen T, 2000, J BIOL CHEM, V275, P12381, DOI 10.1074/jbc.275.17.12381; Jonassen T, 1996, ARCH BIOCHEM BIOPHYS, V330, P285, DOI 10.1006/abbi.1996.0255; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; KAGAN VE, 1996, HDB ANTIOXIDANTS, V1, P157; KALEN A, 1987, BIOCHIM BIOPHYS ACTA, V926, P70, DOI 10.1016/0304-4165(87)90183-8; Kuras R, 1997, J BIOL CHEM, V272, P32427, DOI 10.1074/jbc.272.51.32427; LANGSJOEN H, 1994, ARTERIOSCLER THROMB, V15, pS165; Langsjoen PH, 1999, BIOFACTORS, V9, P273, DOI 10.1002/biof.5520090224; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Lonnrot K, 1998, BIOCHEM MOL BIOL INT, V44, P727; MARBOIS BN, 1994, GENE, V138, P213; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Matthews RT, 1998, P NATL ACAD SCI USA, V95, P8892, DOI 10.1073/pnas.95.15.8892; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MOHR D, 1992, BIOCHIM BIOPHYS ACTA, V1126, P247, DOI 10.1016/0005-2760(92)90237-P; MOMOSE K, 1972, J BIOL CHEM, V247, P3930; NAVAS P, 1994, BBA-REV BIOMEMBRANES, V1197, P1, DOI 10.1016/0304-4157(94)90016-7; OECHSNER U, 1992, MOL GEN GENET, V232, P447, DOI 10.1007/BF00266250; PARKS LW, 1995, ANNU REV MICROBIOL, V49, P95, DOI 10.1146/annurev.mi.49.100195.000523; Poon WW, 1999, J BIOL CHEM, V274, P21665, DOI 10.1074/jbc.274.31.21665; Proft M, 1995, EMBO J, V14, P6116, DOI 10.1002/j.1460-2075.1995.tb00302.x; REAHAL S, 1992, DRUG METAB DISPOS, V20, P423; Rotig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9; Santos-Ocana C, 1998, J BIOENERG BIOMEMBR, V30, P465, DOI 10.1023/A:1020542230308; Santos-Ocana C, 1998, J BIOL CHEM, V273, P8099, DOI 10.1074/jbc.273.14.8099; SCHNEIDER JC, 1991, MOL CELL BIOL, V11, P4934, DOI 10.1128/MCB.11.10.4934; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; Shults CW, 1998, NEUROLOGY, V50, P793, DOI 10.1212/WNL.50.3.793; Snyder CH, 1999, J BIOL CHEM, V274, P31209, DOI 10.1074/jbc.274.44.31209; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; SUN IL, 1992, P NATL ACAD SCI USA, V89, P11126, DOI 10.1073/pnas.89.23.11126; TAKAHASHIM, 2001, BIOCHEM BIOPH RES CO, V286, P534; Thomas SR, 1996, ARTERIOSCL THROM VAS, V16, P687, DOI 10.1161/01.ATV.16.5.687; TRUMPOWER BL, 1974, J BIOL CHEM, V249, P3041; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; Vajo Z, 1999, MAMM GENOME, V10, P1000, DOI 10.1007/s003359901147; van Meer G, 1998, TRENDS CELL BIOL, V8, P29, DOI 10.1016/S0962-8924(97)01196-3; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; Walter L, 2000, J BIOL CHEM, V275, P29521, DOI 10.1074/jbc.M004128200; Wang WY, 1997, J GEN APPL MICROBIOL, V43, P217, DOI 10.2323/jgam.43.217; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Wollman FA, 1999, BBA-BIOENERGETICS, V1411, P21, DOI 10.1016/S0005-2728(99)00043-2; ZHANG YY, 1995, J NUTR, V125, P446	78	85	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10973	10981		10.1074/jbc.M112222200	http://dx.doi.org/10.1074/jbc.M112222200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11788608	hybrid, Green Published			2022-12-27	WOS:000174613100029
J	Waghray, A; Keppler, D; Sloane, BF; Schuger, L; Chen, YQ				Waghray, A; Keppler, D; Sloane, BF; Schuger, L; Chen, YQ			Analysis of a truncated form of cathepsin H in human prostate tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITORS STEFIN-A; CYSTEINE PROTEASES; ENZYME; PROGRESSION; CANCER; EXPRESSION; CARCINOMA; TISSUE; GENE	Increased expression of proteases has been correlated with the malignant progression of a variety of tumors. We found a significant increase in cathepsin H expression in high-grade prostatic intraepithelial neoplasia and carcinoma of the prostate. Two forms of cathepsin H, the full-length form (CTSH) and a truncated form with a 12-amino acid deletion in its signal peptide region (CTSHDelta10-21), were identified by cDNA sequence analysis. This deletion occurred not at the genomic level but likely at the RNA processing level. Both forms are expressed in prostate tissues as well as LNCaP, PC-3, and DU-145 prostate cancer cell lines. The deletion within the signal peptide region affected the trafficking of cathepsin H. Fluorescence microscopy, subcellular fractionation, and activity data indicated that the truncated form was perinuclear and secreted and had a reduced lysosomal association as compared with the full-length cathepsin H. Furthermore, the truncated cathepsin H was enzymatically active. Therefore, an increase in overall cathepsin H expression, particularly in the truncated form with a high secretion propensity, may affect cell biological behaviors such as those associated with tumor progression.	Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Dept Pharmacol, Detroit, MI 48201 USA; Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA; Wayne State Univ, Ctr Mol Med & Genet, Detroit, MI 48201 USA	Wayne State University; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University	Chen, YQ (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Med Ctr Blvd, Winston Salem, NC 27157 USA.		Chen, Yong Q/AAI-9864-2021; Sloane, Bonnie F/A-1050-2009; Keppler, Daniel/B-4309-2012	Chen, Yong Q/0000-0003-4747-4708; 	NIEHS NIH HHS [R01ES11124] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011124] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANGLIKER H, 1989, BIOCHEM J, V262, P63, DOI 10.1042/bj2620063; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BERQUIN IM, 1995, GENE, V159, P143, DOI 10.1016/0378-1119(95)00072-E; Budihna M, 1996, BIOL CHEM H-S, V377, P385, DOI 10.1515/bchm3.1996.377.6.385; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; CHEN YQ, 1995, CANCER RES, V55, P4536; Claus V, 1998, J BIOL CHEM, V273, P9842, DOI 10.1074/jbc.273.16.9842; del Re EC, 2000, BRIT J CANCER, V82, P1317; Fernandez PL, 2001, INT J CANCER, V95, P51, DOI 10.1002/1097-0215(20010120)95:1<51::AID-IJC1009>3.0.CO;2-J; Friedrich B, 1999, EUR J CANCER, V35, P138, DOI 10.1016/S0959-8049(98)00273-1; FUCHS R, 1989, NUCLEIC ACIDS RES, V17, P9471, DOI 10.1093/nar/17.22.9471; GABRIJELCIC D, 1992, EUR J CLIN CHEM CLIN, V30, P69; Guncar G, 1998, STRUCTURE, V6, P51; Hulkower KI, 2000, EUR J BIOCHEM, V267, P4165, DOI 10.1046/j.1432-1327.2000.01458.x; JERALA R, 1994, EUR J BIOCHEM, V224, P797, DOI 10.1111/j.1432-1033.1994.00797.x; Keppler D, 1996, ENZYME PROTEIN, V49, P94, DOI 10.1159/000468619; Kos J, 1997, CLIN CANCER RES, V3, P1815; Lenarcic B, 1996, FEBS LETT, V395, P113, DOI 10.1016/0014-5793(96)00984-2; Mai JX, 2000, BBA-PROTEIN STRUCT M, V1477, P215, DOI 10.1016/S0167-4838(99)00274-5; Mehtani S, 1998, J BIOL CHEM, V273, P13236, DOI 10.1074/jbc.273.21.13236; NISHIMURA Y, 1987, BIOCHEM BIOPH RES CO, V146, P159, DOI 10.1016/0006-291X(87)90705-4; Nitatori T, 1996, ADV EXP MED BIOL, V389, P177; Paciucci R, 1996, FEBS LETT, V385, P72, DOI 10.1016/0014-5793(96)00352-3; Sameni M, 2000, NEOPLASIA, V2, P496, DOI 10.1038/sj.neo.7900116; Simpson JC, 2000, EMBO REP, V1, P287, DOI 10.1093/embo-reports/kvd058; Sivaparvathi M, 1996, CANCER LETT, V104, P121, DOI 10.1016/0304-3835(96)04242-5; TAKAHASHI T, 1988, J BIOL CHEM, V263, P10952; TSUSHIMA H, 1991, INT J CANCER, V48, P726, DOI 10.1002/ijc.2910480516; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Waghray A, 2001, CANCER RES, V61, P4283; Yan SQ, 1998, BIOL CHEM, V379, P113	32	55	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11533	11538		10.1074/jbc.M109557200	http://dx.doi.org/10.1074/jbc.M109557200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11796715	hybrid			2022-12-27	WOS:000174613100100
J	Ayene, IS; Stamato, TD; Mauldin, SK; Biaglow, JE; Tuttle, SW; Jenkins, SF; Koch, CJ				Ayene, IS; Stamato, TD; Mauldin, SK; Biaglow, JE; Tuttle, SW; Jenkins, SF; Koch, CJ			Mutation in the glucose-6-phosphate dehydrogenase gene leads to inactivation of Ku DNA end binding during oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; HYDROGEN-PEROXIDE; REDOX REGULATION; PENTOSE CYCLE; CHEMICAL TERATOGENESIS; PHENYLARSINE OXIDE; GLUTATHIONE LEVELS; ACTIVITY INVITRO; DEFICIENT; APOPTOSIS	Glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the oxidative pentose phosphate cycle, regulates the NADPH/NADP(+) ratio in eukaryotic cells. G6PD deficiency is one of the most common mutations in humans and is known to cause health problems for hundreds of millions worldwide. Although it is known that decreased G6PD functionality can result in increased susceptibility to oxidative stress, the molecular targets of this stress are not known. Using a Chinese hamster ovary G6PD-null mutant, we previously demonstrated that exposure to a thiol-specific oxidant, hydroxyethyldisulfide, caused enhanced radiation sensitivity and an inability to repair DNA double strand breaks. We now demonstrate a molecular mechanism for these observations: the direct inhibition of DNA end binding activity of the Ku heterodimer, a DNA repair protein, by oxidation of its cysteine residues. Inhibition of Ku DNA end binding was found to be reversible by treatment of the nuclear extract with dithiothreitol, suggesting that the homeostatic regulation of reduced cysteine residues in Ku is a critical function of G6PD and the oxidative pentose cycle. In summary, we have discovered a new layer of DNA damage repair, that of the functional maintenance of repair proteins themselves. In view of the rapidly escalating number of roles ascribed to Ku, these results may have widespread ramifications.	Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA; Lankeneau Inst Med Res, Wynnewood, PA 19096 USA	University of Pennsylvania; Lankenau Medical Center; Lankenau Institute for Medical Research	Ayene, IS (corresponding author), Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA.				NATIONAL CANCER INSTITUTE [R37CA044982, R01CA049498, R01CA044982, R01CA045277] Funding Source: NIH RePORTER; NCI NIH HHS [CA45277, CA44982, CA49498] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AJMANI AK, 1995, J EXP MED, V181, P2049, DOI 10.1084/jem.181.6.2049; Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; Ayene IS, 2000, INT J RADIAT BIOL, V76, P1523; Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; Baker M A, 1984, Toxicol Pathol, V12, P331; Banki K, 1996, J BIOL CHEM, V271, P32994, DOI 10.1074/jbc.271.51.32994; Biaglow JE, 1998, INT J RADIAT ONCOL, V42, P769, DOI 10.1016/S0360-3016(98)00313-7; Biaglow JE, 2000, BIOCHEM BIOPH RES CO, V273, P846, DOI 10.1006/bbrc.2000.3024; Bjornstedt M, 1997, BIOMED ENVIRON SCI, V10, P271; Bogumil R, 2000, EUR J BIOCHEM, V267, P1407, DOI 10.1046/j.1432-1327.2000.01133.x; Boros LG, 1997, CANCER RES, V57, P4242; Castro L, 2001, NUTRITION, V17, P161, DOI 10.1016/S0899-9007(00)00570-0; Chinenov Y, 1998, J BIOL CHEM, V273, P6203, DOI 10.1074/jbc.273.11.6203; Cocco P, 1998, BLOOD, V91, P706, DOI 10.1182/blood.V91.2.706.706_706_709; DEVE GS, 1997, INDIAN J EXP BIOL, V35, P155; DWORKIN CR, 1986, LIFE SCI, V38, P1451, DOI 10.1016/0024-3205(86)90557-6; EFFERTH T, 1995, J MOL MED-JMM, V73, P47, DOI 10.1007/BF00203619; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; GETTS RC, 1994, J BIOL CHEM, V269, P15981; HELD KD, 1993, RADIAT RES, V134, P383, DOI 10.2307/3578201; Ho HY, 2000, FREE RADICAL BIO MED, V29, P156, DOI 10.1016/S0891-5849(00)00331-2; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Khadir A, 1999, ARCH BIOCHEM BIOPHYS, V370, P163, DOI 10.1006/abbi.1999.1393; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; Martini G, 1996, BIOESSAYS, V18, P631, DOI 10.1002/bies.950180806; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MCBRIDE AA, 1992, P NATL ACAD SCI USA, V89, P7531, DOI 10.1073/pnas.89.16.7531; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P8883, DOI 10.1021/bi00100a023; Morgan WA, 1998, TOXICOL LETT, V94, P209, DOI 10.1016/S0378-4274(98)00024-1; Nicol CJ, 2000, FASEB J, V14, P111, DOI 10.1096/fasebj.14.1.111; NOACK H, 1992, ANAL BIOCHEM, V202, P162, DOI 10.1016/0003-2697(92)90222-S; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; RABENSTEIN DL, 1995, BBA-PROTEIN STRUCT M, V1249, P29, DOI 10.1016/0167-4838(95)00067-5; Raghavachari N, 1996, EXP EYE RES, V63, P433, DOI 10.1006/exer.1996.0133; Ruwende C, 1998, J MOL MED, V76, P581, DOI 10.1007/s001090050253; RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; SEEGER W, 1986, AM REV RESPIR DIS, V133, P1029; Sommer D, 2000, EUR J BIOCHEM, V267, P2312, DOI 10.1046/j.1432-1327.2000.01240.x; Spolarics Z, 1998, J LEUKOCYTE BIOL, V63, P534, DOI 10.1002/jlb.63.5.534; Tian WN, 1998, J BIOL CHEM, V273, P10609, DOI 10.1074/jbc.273.17.10609; Tian WN, 1999, AM J PHYSIOL-CELL PH, V276, pC1121, DOI 10.1152/ajpcell.1999.276.5.C1121; Tuttle S, 2000, RADIAT RES, V153, P781, DOI 10.1667/0033-7587(2000)153[0781:GPDATO]2.0.CO;2; TUTTLE SW, 1992, INT J RADIAT ONCOL, V22, P671, DOI 10.1016/0360-3016(92)90500-H; VARNES ME, 1984, BIOCHEM PHARMACOL, V33, P1671, DOI 10.1016/0006-2952(84)90290-9; VOET D, 1995, BIOCHEMISTRY-US, P617; VULLIAMY T, 1992, TRENDS GENET, V8, P138, DOI 10.1016/0168-9525(92)90372-B; Wells PG, 1997, MUTAT RES-FUND MOL M, V396, P65, DOI 10.1016/S0027-5107(97)00175-9; ZHANG WW, 1993, BIOCHEM J, V293, P769, DOI 10.1042/bj2930769	52	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9929	9935		10.1074/jbc.M111366200	http://dx.doi.org/10.1074/jbc.M111366200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11788599	hybrid			2022-12-27	WOS:000174549200044
J	Lee, TH; Avraham, H; Lee, SH; Avraham, S				Lee, TH; Avraham, H; Lee, SH; Avraham, S			Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIDDLE CEREBRAL-ARTERY; NF-KAPPA-B; FACTOR VEGF; GENE-EXPRESSION; INFLAMMATORY MEDIATORS; SIGNAL-TRANSDUCTION; ISCHEMIC BRAIN; RAT-BRAIN; HYPOXIA; PERMEABILITY	Hypoxia, a strong inducer for vascular endothelial growth factor (VEGF)/vascular permeable factor (VPF) expression, regulates leukocyte infiltration through the up-regulation of adhesion molecules and chemokine release. To determine whether VEGF/VPF is directly involved in chemokine secretion, we analyzed its effects on chemokine expression in human brain microvascular endothelial cells (HBMECs) by using a human cytokine cDNA array kit. Cytokine array analysis revealed a significant increase in expression of monocyte chemoattractant protein-1 and the chemokine receptor CXCR4 in HBMECs, a result similar to that described previously in other endothelial cells. Interestingly, we also observed that VEGF/VPF induced interleukin-8 (IL-8) expression in HBMECs and that IL-8 mRNA was maximal after I h of VEGF/VPF treatment of the cells. Enzyme-linked immunosorbent assay data and immunoprecipitation analysis revealed that although VEGF/VPF induced IL-8 expression at the translational level in HBMECs, basic fibroblast growth factor failed to induce this protein expression within 12 h. VEGF/VPF increased IL-8 production in HBMECs through activation of nuclear factor-KB via calcium and phosphatidylinositol 3-kinase pathways, whereas the ERK pathway was not involved in this process. Supernatants of the VEGF/VPF-treated HBMECs significantly increased neutrophil migration across the HBMEC monolayer compared with those of the untreated control. Furthermore, addition of anti-IL-8 antibody blocked this increased migration, indicating that VEGF/VPF induced the functional expression of IL-8 protein in HBMECs. Taken together, these data demonstrate for the first time that VEGF/VPF induces IL-8 expression in HBMECs and contributes to leukocyte infiltration through the expression of chemokines, such as IL-8, in endothelial cells.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Natl Canc Ctr, Neurooncol Clin, Kyonggi Do 411351, South Korea	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; National Cancer Center - Korea (NCC)	Avraham, S (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.			Avraham, Hava/0000-0002-7545-3640	NATIONAL CANCER INSTITUTE [R01CA076226] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039558] Funding Source: NIH RePORTER; NCI NIH HHS [CA76226] Funding Source: Medline; NHLBI NIH HHS [HL51456] Funding Source: Medline; NINDS NIH HHS [NS39558] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BETZ AL, 1997, VASOGENIC BRAIN EDEM, P156; Bona E, 1999, PEDIATR RES, V45, P500, DOI 10.1203/00006450-199904010-00008; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Fischer S, 1999, AM J PHYSIOL-CELL PH, V276, pC812; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Hayashi T, 1997, STROKE, V28, P2039, DOI 10.1161/01.STR.28.10.2039; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Kovacs Z, 1996, STROKE, V27, P1865, DOI 10.1161/01.STR.27.10.1865; Kurose I, 1997, J CLIN INVEST, V99, P867, DOI 10.1172/JCI119251; Lennmyr F, 1998, J NEUROPATH EXP NEUR, V57, P874, DOI 10.1097/00005072-199809000-00009; Marti HH, 1998, P NATL ACAD SCI USA, V95, P15809, DOI 10.1073/pnas.95.26.15809; Marumo T, 1999, DIABETES, V48, P1131, DOI 10.2337/diabetes.48.5.1131; Mayhan WG, 1999, AM J PHYSIOL-CELL PH, V276, pC1148, DOI 10.1152/ajpcell.1999.276.5.C1148; Munoz C, 1996, BLOOD, V88, P3482, DOI 10.1182/blood.V88.9.3482.bloodjournal8893482; Nelson PJ, 2001, IMMUNITY, V14, P377, DOI 10.1016/S1074-7613(01)00118-2; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; OLESEN SP, 1986, BRAIN RES, V368, P24, DOI 10.1016/0006-8993(86)91038-3; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P654, DOI 10.1097/00005072-199906000-00010; Proescholdt MA, 1999, J NEUROPATH EXP NEUR, V58, P613, DOI 10.1097/00005072-199906000-00006; Qi JF, 1997, BLOOD, V90, P3595, DOI 10.1182/blood.V90.9.3595; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Salcedo R, 1999, AM J PATHOL, V154, P1125, DOI 10.1016/S0002-9440(10)65365-5; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; SWENSSON O, 1991, J INVEST DERMATOL, V96, P682, DOI 10.1111/1523-1747.ep12470606; TANIGUCHI N, 2000, EXPT PROTOCOLS REACT, P40; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369	39	146	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10445	10451		10.1074/jbc.M107348200	http://dx.doi.org/10.1074/jbc.M107348200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11784713	hybrid			2022-12-27	WOS:000174549200111
J	Yagyu, H; Lutz, EP; Kako, Y; Marks, S; Hu, YY; Choi, SY; Bensadoun, A; Goldberg, IJ				Yagyu, H; Lutz, EP; Kako, Y; Marks, S; Hu, YY; Choi, SY; Bensadoun, A; Goldberg, IJ			Very low density lipoprotein (VLDL) receptor-deficient mice have reduced lipoprotein lipase activity - Possible causes of hypertriglyceridemia and reduced body mass with VLDL receptor deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; TISSUE-SPECIFIC EXPRESSION; B TRANSGENIC MICE; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMA-LIPOPROTEINS; KNOCKOUT MICE; LDL RECEPTOR; ATHEROSCLEROSIS; METABOLISM; MECHANISM	Although very low density lipoprotein (VLDL) receptor (VLDLr) knockout mice have been reported to have no lipoprotein abnormalities, they develop less adipose tissue than control mice when fed a high calorie diet. Mice that are deficient in adipose tissue expression of lipoprotein lipase (LpL) also have less fat, but only when crossed with ob/ob mice. We hypothesized that the VLDLr, a protein that will bind and transport LpL, is required for optimal LpL actions in vivo and that hypertriglyceridemia due to VLDLr deficiency is exacerbated by either LpL, deficiency or VLDL overproduction. Fasted VLDLr knockout (VLDLr0) mice were more hypertriglyceridemic than controls (2-fold greater triglyceride levels). The hypertriglyceridemia due to VLDLrO was even more evident when VLDLrO mice were crossed with heterozygous LpL-deficient (LpL1) and human apolipoprotein B (apoB) transgenic mice. This was due to an increase in apoB48-containing VLDL. [H-3]VLDL turnover studies showed that VLDL-triglyceride clearance in VLDLr0/LpL1 mice was impaired by 50% compared with LpL1 mice. VLDLr0/LpL1 mice had less LpL activity in postheparin plasma, heart, and skeletal muscle. Infection of mice with an adenovirus-expressing receptor-associated protein, an inhibitor of the VLDLr, reduced LpL activity in wild type but not VLDLrO mice. Therefore, the VLDLr is required for normal LpL regulation in vivo, and the disruption of VLDLr results in hypertriglyceridemia associated with decreased LpL activity.	Columbia Univ, Dept Med, New York, NY 10032 USA; Palo Alto Med Fdn, Palo Alto, CA 94301 USA; Cornell Univ, Div Nutrit Sci, Ithaca, NY 14853 USA	Columbia University; Palo Alto Medical Foundation Research Institute; Cornell University	Goldberg, IJ (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.				NHLBI NIH HHS [HL56984, HL45095, HL14990] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL045095, P50HL056984, R01HL014990, R01HL045095] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453; GOLDBERG IJ, 1986, J CLIN INVEST, V78, P1523, DOI 10.1172/JCI112744; Goldberg IJ, 1996, J LIPID RES, V37, P693; Goudriaan JR, 2001, ARTERIOSCL THROM VAS, V21, P1488, DOI 10.1161/hq0901.095147; HERZ J, 1991, J BIOL CHEM, V266, P21232; Hocquette JF, 1998, COMP BIOCHEM PHYS B, V121, P201, DOI 10.1016/S0305-0491(98)10090-1; Ikemoto S, 1997, AM J PHYSIOL-ENDOC M, V273, pE37, DOI 10.1152/ajpendo.1997.273.1.E37; Kako Y, 1999, J LIPID RES, V40, P2185; Kosaka S, 2001, CIRCULATION, V103, P1142, DOI 10.1161/01.CIR.103.8.1142; Kwok S, 1997, HORM METAB RES, V29, P524, DOI 10.1055/s-2007-979094; Li ZH, 2000, J LIPID RES, V41, P1912; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; Lutz EP, 2001, J CLIN INVEST, V107, P1183, DOI 10.1172/JCI11774; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; Merkel M, 1998, J CLIN INVEST, V102, P893, DOI 10.1172/JCI2912; Obunike JC, 2001, J BIOL CHEM, V276, P8934, DOI 10.1074/jbc.M008813200; OKA K, 1994, EUR J BIOCHEM, V224, P975, DOI 10.1111/j.1432-1033.1994.00975.x; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; SCHNEEMAN BO, 1993, P NATL ACAD SCI USA, V90, P2069, DOI 10.1073/pnas.90.5.2069; Tacken PJ, 2000, J LIPID RES, V41, P2055; Tacken PJ, 2001, CURR OPIN LIPIDOL, V12, P275, DOI 10.1097/00041433-200106000-00006; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; van Vlijmen BJM, 1999, J BIOL CHEM, V274, P35219, DOI 10.1074/jbc.274.49.35219; Veniant MM, 1998, J CLIN INVEST, V102, P1559, DOI 10.1172/JCI4164; Voyiaziakis E, 1998, J LIPID RES, V39, P313; Weinstock PH, 1995, J CLIN INVEST, V96, P2555, DOI 10.1172/JCI118319; Weinstock PH, 1997, P NATL ACAD SCI USA, V94, P10261, DOI 10.1073/pnas.94.19.10261; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; Xiang SQ, 1999, J LIPID RES, V40, P1655; Yagyu H, 2000, J BIOL CHEM, V275, P21324, DOI 10.1074/jbc.M002541200; Zechner R, 1997, CURR OPIN LIPIDOL, V8, P77, DOI 10.1097/00041433-199704000-00005	36	92	104	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10037	10043		10.1074/jbc.M109966200	http://dx.doi.org/10.1074/jbc.M109966200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11790777	hybrid			2022-12-27	WOS:000174549200058
J	Tompa, P; Mucsi, Z; Orosz, G; Friedrich, P				Tompa, P; Mucsi, Z; Orosz, G; Friedrich, P			Calpastatin subdomains A and C are activators of calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL CONSERVED REGION; CALMODULIN-LIKE DOMAINS; MU-CALPAIN; PROTEINASE-INHIBITOR; ENDOGENOUS INHIBITOR; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; NEUTRAL PROTEASE; PIG CALPASTATIN; CALCIUM	The inhibitory domains of calpastatin contain three highly conserved regions, A, B, and C, of which A and C bind calpain in a strictly Ca2+-dependent manner but have no inhibitory activity whereas region B inhibits calpain on its own. We synthesized the 19-mer oligopeptides corresponding to regions A and C of human calpastatin domain I and tested their effect on human erythrocyte mu-calpain and rat m-calpain. The two peptides significantly activate both calpains: the Ca2+ concentration required for half-maximal activity is lowered from 4.3 to 2.4 mum for mu-calpain and from 250 to 140 mum for m-calpain. The EC50 concentration of the peptides is 7.5 mum for mu-calpain and 25 mum for m-calpain. It is noteworthy that at low Ca2+ concentrations (1-2 mum for mu-calpain and 70-110 mum for m-calpain) both enzymes are activated about 10-fold by the peptides. Based on these findings, it is suggested that calpastatin fragments may have a role in calpain activation in vivo. Furthermore, these activators open new avenues to cell biological studies of calpain function and eventually may alleviate pathological states caused by calpain malfunction.	Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest, Hungary; Eotvos Lorand Univ, Res Grp Peptide Chem, Hungarian Acad Sci, Budapest, Hungary	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University; Hungarian Academy of Sciences	Tompa, P (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, POB 7, H-1518 Budapest, Hungary.	tompa@enzim.hu	Mucsi, Zoltan/J-9404-2019					Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Baier LJ, 2000, J CLIN INVEST, V106, pR69, DOI 10.1172/JCI10665; Baki A, 1996, BIOCHEM J, V318, P897, DOI 10.1042/bj3180897; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Croce K, 1999, J BIOL CHEM, V274, P36321, DOI 10.1074/jbc.274.51.36321; De Tullio R, 2000, FEBS LETT, V475, P17, DOI 10.1016/S0014-5793(00)01613-6; Donkor IO, 2000, CURR MED CHEM, V7, P1171, DOI 10.2174/0929867003374129; ELCE JS, 1995, PROTEIN ENG, V8, P843, DOI 10.1093/protein/8.8.843; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; EMORI Y, 1988, J BIOL CHEM, V263, P2364; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; IMAJOH S, 1985, FEBS LETT, V187, P47, DOI 10.1016/0014-5793(85)81211-4; KAPPRELL HP, 1989, J BIOL CHEM, V264, P17888; Kato M, 2000, J BIOCHEM, V127, P297, DOI 10.1093/oxfordjournals.jbchem.a022607; MA H, 1993, J BIOCHEM, V113, P591, DOI 10.1093/oxfordjournals.jbchem.a124088; MA H, 1994, J BIOL CHEM, V269, P24430; MAKI M, 1987, FEBS LETT, V223, P174, DOI 10.1016/0014-5793(87)80531-8; MAKI M, 1989, J BIOL CHEM, V264, P18866; MAKI M, 1988, J BIOL CHEM, V263, P10254; Mellgren RL, 1997, BIOCHEM BIOPH RES CO, V236, P555, DOI 10.1006/bbrc.1997.7003; MELLGREN RL, 1993, J BIOL CHEM, V268, P653; Melloni E, 1998, BIOCHEM BIOPH RES CO, V249, P583, DOI 10.1006/bbrc.1998.9200; Michetti M, 1996, FEBS LETT, V392, P11, DOI 10.1016/0014-5793(96)00775-2; NISHIMURA T, 1991, J BIOL CHEM, V266, P11842; Ono Y, 1998, J BIOL CHEM, V273, P17073, DOI 10.1074/jbc.273.27.17073; OTSUKA Y, 1987, J BIOL CHEM, V262, P5839; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Suzuki K, 1998, FEBS LETT, V433, P1, DOI 10.1016/S0014-5793(98)00856-4; SUZUKI K, 1981, J BIOCHEM-TOKYO, V90, P1787, DOI 10.1093/oxfordjournals.jbchem.a133656; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; TAKANO E, 1995, FEBS LETT, V362, P93, DOI 10.1016/0014-5793(95)00219-Y; Thompson VF, 2000, METH MOL B, V144, P3; Tompa P, 2001, BIOCHEM BIOPH RES CO, V280, P1333, DOI 10.1006/bbrc.2001.4279; TULLIO RD, 1999, BIOCHEM J, V343, P467; Wang K K, 1997, Adv Pharmacol, V37, P117; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; YANG HQ, 1994, J BIOL CHEM, V269, P18977	44	43	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9022	9026		10.1074/jbc.C100700200	http://dx.doi.org/10.1074/jbc.C100700200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11809743	hybrid			2022-12-27	WOS:000174400600039
J	Giraud, S; Bienvenu, F; Avril, S; Gascan, H; Heery, DM; Coqueret, O				Giraud, S; Bienvenu, F; Avril, S; Gascan, H; Heery, DM; Coqueret, O			Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR-1; ESTROGEN-RECEPTOR; NUCLEAR-RECEPTOR; MEDIATED TRANSACTIVATIONS; BINDING-PROTEIN; GENE-REGULATION; V-SRC; ACTIVATION; CHROMATIN; P300	Signal transducer and activator of transcription 3 (STAT3) transcription factors are cytoplasmic proteins that induce gene activation in response to cytokine receptor stimulation. Following tyrosine phosphorylation, STAT3 proteins dimerize, translocate to the nucleus, and activate specific target genes. This transcriptional activation by STAT3 proteins has been shown to require the recruitment of coactivators such as CREB-binding protein (CBP)/p300. In the present study, we show that steroid receptor coactivator 1, NcoA/SRC1a, originally identified as a nuclear receptor coactivator, also functions as a coactivator of STAT3 proteins. In coimmunoprecipitations, NcoA/SRC1a was found to associate with STAT3 following IL-6 stimulation of HepG2 hepatoma cells. Pull-down experiments indicated that the N-terminal part of NcoA/SRC1a associates with the activation domain of STAT3. Overexpression of NcoA/SRC1a or its SRC1e isoform enhanced transcriptional activation by STAT3 proteins in transient transfection experiments. This ability of NcoA/SRC1a to enhance STAT3 activity is dependent upon the presence of the CBP-interacting domain, activation domain 1. Using chromatin immunoprecipitation assays, we found that STAT3, NcoA/SRC1a, and CBP/p300 are simultaneously recruited to the p21(waf1) promoter following interleukin-6 stimulation. Taken together, these data suggest that CBP/p300 and NcoA/SRC1a may function in a common pathway to regulate STAT3 transcriptional activity.	CHU Angers, INSERM, EMI U 9928, F-49033 Angers, France; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; University of Leicester	Coqueret, O (corresponding author), CHU Angers, INSERM, EMI U 9928, 4 Rue Larrey, F-49033 Angers, France.		Coqueret, Olivier/K-9660-2015; AVRIL, sylvie/K-6024-2015	Coqueret, Olivier/0000-0002-2843-7867; Avril, Sylvie/0000-0003-0574-6752; Heery, David/0000-0002-5035-2392				Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Litterst CM, 2001, J BIOL CHEM, V276, P45713, DOI 10.1074/jbc.M108132200; Liu Z, 1999, P NATL ACAD SCI USA, V96, P9485, DOI 10.1073/pnas.96.17.9485; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; ONATE SA, 1995, SCIENCE, V270, P1354; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; STRUHL K, 1999, GENE DEV, V122, P599; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yoo JY, 2001, J BIOL CHEM, V276, P26421, DOI 10.1074/jbc.M009935200; Zhang XK, 2001, J BIOL CHEM, V276, P33576, DOI 10.1074/jbc.M104978200; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	50	119	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8004	8011		10.1074/jbc.M111486200	http://dx.doi.org/10.1074/jbc.M111486200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11773079	hybrid			2022-12-27	WOS:000174268000049
J	Motz, M; Kober, I; Girardot, C; Loeser, E; Bauer, U; Albers, M; Moeckel, G; Minch, E; Voss, H; Kilger, C; Koegl, M				Motz, M; Kober, I; Girardot, C; Loeser, E; Bauer, U; Albers, M; Moeckel, G; Minch, E; Voss, H; Kilger, C; Koegl, M			Elucidation of an archaeal replication protein network to generate enhanced PCR enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE; SLIDING CLAMPS; SEQUENCE; ORGANIZATION; FIDELITY; DATABASE; LOADER	Thermostable DNA polymerases are an important tool in molecular biology. To exploit the archaeal repertoire of proteins involved in DNA replication for use in PCR, we elucidated the network of proteins implicated in this process in Archaeoglobus fulgidus. To this end, we performed extensive yeast two-hybrid screens using putative archaeal replication factors as starting points. This approach yielded a protein network involving 30 proteins potentially implicated in archaeal DNA replication including several novel factors. Based on these results, we were able to improve PCR reactions catalyzed by archaeal DNA polymerases by supplementing the reaction with predicted polymerase co-factors. In this approach we concentrated on the archaeal proliferating cell nuclear antigen (PCNA) homologue. This protein is known to encircle DNA as a ring in eukaryotes, tethering other proteins to DNA. Indeed, addition of A. fulgidus PCNA resulted in marked stimulation of PCR product generation. The PCNA-binding domain was determined, and a hybrid DNA polymerase was constructed by grafting this domain onto the classical PCR enzyme from Thermus aquaticus, Taq DNA polymerase. Addition of PCNA to PCR reactions catalyzed by the fusion protein greatly stimulated product generation, most likely by tethering the enzyme to DNA. This sliding clamp-induced increase of PCR performance implies a promising novel micromechanical principle for the development of PCR enzymes with enhanced processivity.	LION Biosci Ktiengesell, Exploratory Res, D-69120 Heidelberg, Germany; LION Biosci Ktiengesell, Life Sci Informat, D-69120 Heidelberg, Germany; LION Biosci Ktiengesell, Prot & Assays, D-69120 Heidelberg, Germany		Koegl, M (corresponding author), LION Biosci AG, Prot & Assays, Neuenheimer Feld 515-519, D-69120 Heidelberg, Germany.	manfred.koegl@lionbioscience.com	Girardot, Charles/AAF-2417-2020	Girardot, Charles/0000-0003-4301-3920				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Cann IKO, 1999, J BACTERIOL, V181, P6591, DOI 10.1128/JB.181.21.6591-6599.1999; Cann IKO, 1999, GENETICS, V152, P1249; Cann IKO, 1998, P NATL ACAD SCI USA, V95, P14250, DOI 10.1073/pnas.95.24.14250; Eckert K A, 1991, PCR Methods Appl, V1, P17; Grebe TW, 1999, ADV MICROB PHYSIOL, V41, P139, DOI 10.1016/S0065-2911(08)60167-8; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; Hudson JR, 1997, GENOME RES, V7, P1169, DOI 10.1101/gr.7.12.1169; James P, 1996, GENETICS, V144, P1425; Keck JL, 2000, CHEM BIOL, V7, pR63, DOI 10.1016/S1074-5521(00)00094-6; Kelman Z, 2000, J BIOL CHEM, V275, P7327, DOI 10.1074/jbc.275.10.7327; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; MAKI S, 1988, J BIOL CHEM, V263, P6547; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsurimoto T, 1998, BBA-GENE STRUCT EXPR, V1443, P23, DOI 10.1016/S0167-4781(98)00204-8; Uemori T, 1997, GENES CELLS, V2, P499, DOI 10.1046/j.1365-2443.1997.1380336.x; UEMORI T, 1999, Patent No. 9900506; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Zannis-Hadjopoulos M, 1999, J CELL BIOCHEM, P1	28	43	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16179	16188		10.1074/jbc.M107793200	http://dx.doi.org/10.1074/jbc.M107793200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11805086	hybrid			2022-12-27	WOS:000175510400128
J	Kaneto, H; Sharma, A; Suzuma, K; Laybutt, DR; Xu, G; Bonner-Weir, S; Weir, GC				Kaneto, H; Sharma, A; Suzuma, K; Laybutt, DR; Xu, G; Bonner-Weir, S; Weir, GC			Induction of c-Myc expression suppresses insulin gene transcription by inhibiting NeuroD/BETA2-mediated transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; BINDING PROTEIN BETA; HIGH GLUCOSE; RAT; ELEMENT; JUN; DIFFERENTIATION; SEQUENCES; PROMOTER; PDX-1	Insulin biosynthesis and secretion are critical for pancreatic beta-cell function, but both are impaired under diabetic conditions. We have found that hyperglycemia induces the expression of the basic helix-loop-helix transcription factor c-Myc in islets in several different diabetic models. To examine the possible implication of c-Myc in beta-cell dysfunction, c-Myc was overexpressed in isolated rat islets using adenovirus. Adenovirus-mediated c-Myc overexpression suppressed both insulin gene transcription and glucose-stimulated insulin secretion. Insulin protein content, determined by immunostaining, was markedly decreased in c-Myc-overexpressing cells. In gel-shift assays c-Myc bound to the E-box in the insulin gene promoter region. Furthermore, in betaTC1, MIN6, and HIT-T15 cells and primary rat islets, wild type insulin gene promoter activity was dramatically decreased by c-Myc overexpression, whereas the activity of an E-box mutated insulin promoter was not affected. In HeLa and HepG2 cells c-Myc exerted a suppressive effect on the insulin promoter activity only in the presence of NeuroD/BETA2 but not PDX-1. Both c-Myc and NeuroD can bind the E-box element in the insulin promoter, but unlike NeuroD, the c-Myc transactivation domain lacked the ability to activate insulin gene expression. Additionally p300, a co-activator of NeuroD, did not function as a co-activator of c-Myc. In conclusion, increased expression of c-Myc in beta-cells suppresses the insulin gene transcription by inhibiting NeuroD-mediated transcriptional activation. This mechanism may explain some of the beta-cell dysfunction found in diabetes.	Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.	Kaneto, H (corresponding author), Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, 1 Joslin Pl, Boston, MA 02215 USA.	kaneto@osb.att.ne.jp; gordon.weir@joslin.harvard.edu		Bonner-Weir, Susan/0000-0003-4682-0656	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035449] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 35449] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bonner-Weir S, 2000, P NATL ACAD SCI USA, V97, P7999, DOI 10.1073/pnas.97.14.7999; BONNERWEIR S, 1983, J CLIN INVEST, V71, P1544, DOI 10.1172/JCI110910; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; Dang CV, 1999, MOL CELL BIOL, V19, P1; Dutta S, 1998, NATURE, V392, P560, DOI 10.1038/33311; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; Glick E, 2000, J BIOL CHEM, V275, P2199, DOI 10.1074/jbc.275.3.2199; GUZ Y, 1995, DEVELOPMENT, V121, P11; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HENDERSON E, 1994, MOL CELL BIOL, V14, P655, DOI 10.1128/MCB.14.1.655; Ihara Y, 1999, DIABETES, V48, P927, DOI 10.2337/diabetes.48.4.927; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Jonas JC, 2001, J BIOL CHEM, V276, P35375, DOI 10.1074/jbc.M105020200; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kaneto H, 1997, J BIOL CHEM, V272, P29137, DOI 10.1074/jbc.272.46.29137; Kaneto H, 1999, DIABETES, V48, P2398, DOI 10.2337/diabetes.48.12.2398; Kaneto H, 2002, J BIOL CHEM, V277, P3680, DOI 10.1074/jbc.M109647200; Kaneto H, 2001, J BIOL CHEM, V276, P31099, DOI 10.1074/jbc.M104115200; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; LAYBUTT DR, IN PRESS DIABETES; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Li DWC, 1997, MOL CELL BIOCHEM, V173, P59, DOI 10.1023/A:1006828402225; Lu M, 1997, J BIOL CHEM, V272, P28349, DOI 10.1074/jbc.272.45.28349; Malecki MT, 1999, NAT GENET, V23, P323, DOI 10.1038/15500; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Pelengaris S, 2000, CURR OPIN GENET DEV, V10, P100, DOI 10.1016/S0959-437X(99)00046-5; Peshavaria M, 1997, MOL CELL BIOL, V17, P3987, DOI 10.1128/MCB.17.7.3987; Poitout V, 1996, J CLIN INVEST, V97, P1041, DOI 10.1172/JCI118496; ROBINSON GLWG, 1995, MOL CELL BIOL, V15, P1398; ROBINSON GLWG, 1994, J BIOL CHEM, V269, P2452; Sander M, 1998, P NATL ACAD SCI USA, V95, P11572, DOI 10.1073/pnas.95.20.11572; Seufert J, 1998, J CLIN INVEST, V101, P2528, DOI 10.1172/JCI2401; Sharma A, 1999, MOL CELL BIOL, V19, P704; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; TOKUYAMA Y, 1995, DIABETES, V44, P1447, DOI 10.2337/diabetes.44.12.1447; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Wang HY, 2001, J BIOL CHEM, V276, P25279, DOI 10.1074/jbc.M101233200; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564; Zangen DH, 1997, DIABETES, V46, P258, DOI 10.2337/diabetes.46.2.258	56	51	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12998	13006		10.1074/jbc.M111148200	http://dx.doi.org/10.1074/jbc.M111148200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11799123	hybrid			2022-12-27	WOS:000175036300066
J	Choi, J; Ko, J; Park, E; Lee, JR; Yoon, J; Lim, S; Kim, E				Choi, J; Ko, J; Park, E; Lee, JR; Yoon, J; Lim, S; Kim, E			Phosphorylation of stargazin by protein kinase A regulates its interaction with PSD-95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GLUR1 SUBUNIT; AMPA RECEPTOR; POSTSYNAPTIC DENSITY; MOUSE STARGAZER; GAMMA-SUBUNIT; MUTANT MOUSE; PDZ DOMAIN; RAT-BRAIN; CHANNEL; BINDING	Stargazin is the first transmembrane protein known to associate with AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate) glutamate receptors (AMPARs) and regulate their synaptic targeting by two distinct mechanisms, specifically via delivery of AMPARs to the surface membrane and synaptic targeting of these receptors by binding to PSD-95/SAP-90 and related PDZ proteins. However, it is not known whether and how this stargazin-mediated synaptic targeting of AMPs its regulated. Stargazin interacts with the PDZ domains of PSD-95 through the C-terminal PDZ-binding motif. The stargazin C terminus contains a consensus sequence for phosphorylation by cAMP-dependent protein kinase A (PKA). Phosphorylation site-specific stargazin antibodies reveal that the stargazin C terminus is phosphorylated at the Thr-321 residue in heterologous cells and in vivo. Stargazin phosphorylation is enhanced by the catalytic subunit of PKA. Mutations mimicking stargazin phosphorylation (T321E and T321D) lead to elimination of yeast two-hybrid interactions, in vitro coimmunoprecipitation, and coclustering between stargazin and PSD-95. Phosphorylated stargazin shows a selective loss of coimmunoprecipitation with PSD-95 in heterologous cells and limited enrichment in postsynaptic density fractions of rat brain. These results suggest that phosphorylation of the stargazin C terminus by PKA regulates its interaction with PSD-95 and synaptic targeting of AMPARs.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Kim, E (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Kim, Eunjoon/C-1566-2011					Banke TG, 2000, J NEUROSCI, V20, P89, DOI 10.1523/JNEUROSCI.20-01-00089.2000; Burgess DL, 2001, GENOMICS, V71, P339, DOI 10.1006/geno.2000.6440; Burgess DL, 1999, GENOME RES, V9, P1204, DOI 10.1101/gr.9.12.1204; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Chu PJ, 2001, GENE, V280, P37, DOI 10.1016/S0378-1119(01)00738-7; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Hashimoto K, 1999, J NEUROSCI, V19, P6027, DOI 10.1523/JNEUROSCI.19-14-06027.1999; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; Kang MG, 2001, J BIOL CHEM, V276, P32917, DOI 10.1074/jbc.M100787200; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Klugbauer N, 2000, FEBS LETT, V470, P189, DOI 10.1016/S0014-5793(00)01306-5; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; MAURER RA, 1989, J BIOL CHEM, V264, P6870; Nakagawa T, 2000, SCIENCE, V290, P2270; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; NOEBELS JL, 1990, EPILEPSY RES, V7, P129, DOI 10.1016/0920-1211(90)90098-G; Osten P, 2000, NEURON, V27, P313, DOI 10.1016/S0896-6273(00)00039-8; Puranam RS, 1998, NAT GENET, V19, P313, DOI 10.1038/1194; Qiao XO, 1996, J NEUROSCI, V16, P640; Qiao XX, 1998, J NEUROSCI, V18, P6990; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Tomita S, 2001, J CELL BIOL, V153, pF19, DOI 10.1083/jcb.153.5.F19; Wyszynski M, 1998, NEUROPHARMACOLOGY, V37, P1335, DOI 10.1016/S0028-3908(98)00120-8	34	100	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12359	12363		10.1074/jbc.M200528200	http://dx.doi.org/10.1074/jbc.M200528200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805122	hybrid			2022-12-27	WOS:000174846400099
J	Bernardo, MM; Brown, S; Li, ZH; Fridman, R; Mobashery, S				Bernardo, MM; Brown, S; Li, ZH; Fridman, R; Mobashery, S			Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MATRIX METALLOPROTEINASE-2; TISSUE INHIBITOR; IV COLLAGENASE; ACTIVE-SITE; 1-MATRIX METALLOPROTEINASE; 72-KDA GELATINASE; CATALYTIC DOMAIN; MMP INHIBITORS; ACTIVATION; PROGELATINASE	Gelatinases have been shown to play a key role in angiogenesis and tumor metastasis. Small molecular weight synthetic inhibitors for these enzymes are highly sought for potential use as anti-metastatic agents. Virtually all of the known inhibitors of matrix metalloproteinases (MMPs) are broad spectrum. We report herein the synthesis and kinetic characterization of two compounds, 4-(4-phenoxyphenylsulfonyl)butane-1,2-dithiol (compound 1) and 5-(4-phenoxyphenylsulfonyl)pentane-1,2-dithiol (compound 2), that are potent and selective gelatinase inhibitors. These compounds are slow, tight-binding inhibitors of gelatinases (MMP-2 and MMP-9) with K-i values in the nanomolar range. In contrast, competitive inhibition of the catalytic domain of membrane-type 1 metalloproteinase (MMP-14(cat)) with comparable K-i values (K-i similar to200 n(M)) was observed. Binding to stromelysin (MMP-3) was substantially weaker, with Ki values in the micromolar range (K-i similar to10 mu(M)). No binding to matrilysin (MMP-7) and collagenase 1 (MMP-1) was detected at inhibitor concentrations up to 60 mu(M). We have previously shown that synthetic MMP inhibitors work synergistically with TIMP-2 in the promotion of pro-MMP-2 activation by MT1-MMP in a process that depends on the affinity of the inhibitor toward MT1-MMP. It is shown herein that the dithiols are significantly less efficient (>100-fold) than marimastat, a broad-spectrum MMP inhibitor, in enhancing pro-MMP-2 activation in cells infected to express MT1-MMP, consistent with the lower affinity of the dithiols toward MT1-MMP. Thus, in contrast to broad-spectrum MMP inhibitors, the dithiols are less likely to promote MT1-MMP-dependent pro-MMP-2 activation in the presence of TIMP-2, while maintaining their ability to inhibit active MMP-2 effectively.	Wayne State Univ, Dept Chem, Detroit, MI 48202 USA; Wayne State Univ, Dept Pathol, Detroit, MI 48202 USA; Wayne State Univ, Dept Pharmacol, Detroit, MI 48202 USA; Wayne State Univ, Dept Biochem & Mol Biol, Detroit, MI 48202 USA; Wayne State Univ, Inst Drug Design, Detroit, MI 48202 USA	Wayne State University; Wayne State University; Wayne State University; Wayne State University; Wayne State University	Mobashery, S (corresponding author), Wayne State Univ, Dept Chem, Detroit, MI 48202 USA.	som@chem.wayne.edu			NCI NIH HHS [CA-61986, CA-82298] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061986, R01CA082298] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Babine RE, 1997, CHEM REV, V97, P1359, DOI 10.1021/cr960370z; Bohacek R, 1996, J AM CHEM SOC, V118, P8231, DOI 10.1021/ja950818y; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Brown PD, 1998, BREAST CANCER RES TR, V52, P125, DOI 10.1023/A:1006119319695; Brown S, 2000, J AM CHEM SOC, V122, P6799, DOI 10.1021/ja001461n; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Fink CA, 1995, J MED CHEM, V38, P5023, DOI 10.1021/jm00026a009; Freskos JN, 1999, BIOORG MED CHEM LETT, V9, P943, DOI 10.1016/S0960-894X(99)00116-X; FRIDMAN R, 1993, BIOCHEM J, V289, P411, DOI 10.1042/bj2890411; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; Gaucher JF, 1999, BIOCHEMISTRY-US, V38, P12569, DOI 10.1021/bi991043z; Gervasi DC, 1996, BIOCHEM BIOPH RES CO, V228, P530, DOI 10.1006/bbrc.1996.1694; GOMEZMONTERREY I, 1994, J MED CHEM, V37, P1865, DOI 10.1021/jm00038a016; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; HOLMQUIST B, 1979, P NATL ACAD SCI USA, V76, P6216, DOI 10.1073/pnas.76.12.6216; Kleifeld O, 2001, J BIOL CHEM, V276, P17125, DOI 10.1074/jbc.M011604200; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P85; Kotra LP, 2001, J AM CHEM SOC, V123, P3108, DOI 10.1021/ja001896a; Kruger A, 2001, CANCER RES, V61, P1272; Lichte A, 1996, FEBS LETT, V397, P277, DOI 10.1016/S0014-5793(96)01206-9; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; Moses MA, 1997, STEM CELLS, V15, P180, DOI 10.1002/stem.150180; MULLERSTEFFNER HM, 1992, J BIOL CHEM, V267, P9606; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Nagase H, 1997, BIOL CHEM, V378, P151; Nguyen M, 2001, INT J BIOCHEM CELL B, V33, P960, DOI 10.1016/S1357-2725(01)00007-3; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Olson MW, 2000, J BIOL CHEM, V275, P2661, DOI 10.1074/jbc.275.4.2661; Paulvannan K, 1999, SYNLETT, P1371; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; Price A, 1999, CLIN CANCER RES, V5, P845; Rasmussen HS, 1997, PHARMACOL THERAPEUT, V75, P69, DOI 10.1016/S0163-7258(97)00023-5; Sang QXA, 2000, BIOCHEM BIOPH RES CO, V274, P780, DOI 10.1006/bbrc.2000.3212; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Segel I.H., 1975, ENZYME KINETICS; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shalinsky DR, 1999, CLIN CANCER RES, V5, P1905; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Toth M, 1997, CANCER RES, V57, P3159; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Wu Z, 1996, J AM CHEM SOC, V118, P1785, DOI 10.1021/ja953652+; Yamamoto M, 1998, J MED CHEM, V41, P1209, DOI 10.1021/jm970404a; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	50	69	70	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11201	11207		10.1074/jbc.M111021200	http://dx.doi.org/10.1074/jbc.M111021200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11790786	hybrid			2022-12-27	WOS:000174613100058
J	Dawson, S; Apcher, S; Mee, M; Higashitsuji, H; Baker, R; Uhle, S; Dubiel, W; Fujita, J; Mayer, RJ				Dawson, S; Apcher, S; Mee, M; Higashitsuji, H; Baker, R; Uhle, S; Dubiel, W; Fujita, J; Mayer, RJ			Gankyrin is an ankyrin-repeat oncoprotein that interacts with CDK4 kinase and the S6 ATPase of the 26 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-INDUCED DEGRADATION; NF-KAPPA-B; REGULATORY PARTICLE; ESSENTIAL COFACTOR; C-MYC; SACCHAROMYCES-CEREVISIAE; RETINOBLASTOMA PROTEIN; 20S PROTEASOME; FISSION YEAST; UBIQUITIN	A yeast two-hybrid screen with the human S6 (TBP7, RPT3) ATPase of the 26 S proteasome has identified gankyrin, a liver oncoprotein, as an interacting protein. Gankyrin interacts with both free and regulatory complex-associated S6 ATPase and is not stably associated with the 26 S particle. Deletional mutagenesis shows that the C-terminal 78 amino acids of the S6 ATPase are necessary and sufficient to mediate the interaction with gankyrin. Deletion of an orthologous gene in Saccharomyces cerevisiae suggests that it is dispensable for cell growth and viability. Overexpression and precipitation of tagged gankyrin from cultured cells detects a complex containing co-transfected tagged S6 ATPase (or endogenous S6) and endogenous cyclin D-dependent kinase CDK4. The proteasomal ATPases are part of the AAA (ATPases associated with diverse cellular activities) family, members of which are molecular chaperones; gankyrin complexes may therefore influence CDK4 function during oncogenesis.	Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci,Lab Intracellular Proteolysis, Nottingham NG7 2UH, England; Australian Natl Univ, John Curtin Sch Med Res, Div Mol Med, Ubiquitin Lab, Canberra, ACT 2601, Australia; Kyoto Univ, Fac Med, Dept Clin Mol Biol, Sakyo Ku, Kyoto 606, Japan; Humboldt Univ, Div Mol Biol, Dept Surg, Fac Med Charite, D-10117 Berlin, Germany	University of Nottingham; Australian National University; John Curtin School of Medical Research; Kyoto University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Dawson, S (corresponding author), Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci,Lab Intracellular Proteolysis, Nottingham NG7 2UH, England.	Simon.Dawson@nottingham.ac.uk	Apcher, Sebastien/B-6356-2015; Apcher, Sebastien/P-2590-2018	Dubiel, Wolfgang/0000-0002-3393-0701				BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Boyer SN, 1996, CANCER RES, V56, P4620; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; Chen Y, 1997, J BIOL CHEM, V272, P24081, DOI 10.1074/jbc.272.38.24081; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; Dawson S, 1997, MOL BIOL REP, V24, P39, DOI 10.1023/A:1006800522814; DeMartino GN, 1996, J BIOL CHEM, V271, P3112, DOI 10.1074/jbc.271.6.3112; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; Gaulin JF, 2000, J BIOL CHEM, V275, P16658, DOI 10.1074/jbc.275.22.16658; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gorbea C, 2000, J BIOL CHEM, V275, P875, DOI 10.1074/jbc.275.2.875; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HALL TG, 1987, J BIOL CHEM, V262, P10537; Hastings RA, 1999, J BIOL CHEM, V274, P25691, DOI 10.1074/jbc.274.36.25691; Henke W, 1999, MOL BIOL REP, V26, P29, DOI 10.1023/A:1006991419464; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; ISHIDA N, 1993, FEBS LETT, V324, P345, DOI 10.1016/0014-5793(93)80148-N; Jarrousse AS, 1999, J BIOL CHEM, V274, P5925, DOI 10.1074/jbc.274.9.5925; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Makino Y, 1997, J BIOL CHEM, V272, P23201, DOI 10.1074/jbc.272.37.23201; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Park TJ, 2001, MOL CARCINOGEN, V30, P138, DOI 10.1002/mc.1022; Petit F, 1997, BIOCHEM J, V326, P93, DOI 10.1042/bj3260093; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Richmond C, 1997, J BIOL CHEM, V272, P13403, DOI 10.1074/jbc.272.20.13403; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Saito A, 1997, GENE, V203, P241, DOI 10.1016/S0378-1119(97)00524-6; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schmidtke G, 1997, J MOL BIOL, V268, P95, DOI 10.1006/jmbi.1997.0947; Seeger M, 1996, J MOL BIOL, V263, P423, DOI 10.1006/jmbi.1996.0586; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a	71	104	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10893	10902		10.1074/jbc.M107313200	http://dx.doi.org/10.1074/jbc.M107313200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11779854	hybrid			2022-12-27	WOS:000174613100020
J	Efendiev, R; Bertorello, AM; Zandomeni, R; Cinelli, AR; Pedemonte, CH				Efendiev, R; Bertorello, AM; Zandomeni, R; Cinelli, AR; Pedemonte, CH			Agonist-dependent regulation of renal Na+,K+-ATPase activity is modulated by intracellular sodium concentration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NA+-K+-ATPASE; PROXIMAL TUBULE; ALPHA-SUBUNIT; INTRARENAL DOPAMINE; EPITHELIAL-CELLS; PLASMA-MEMBRANE; PHOSPHORYLATION; RAT; RECRUITMENT	We tested the hypothesis that the level of intracellular sodium modulates the hormonal regulation of the Na+,K+-ATPase activity in proximal tubule cells. By using digital imaging fluorescence microscopy of a sodium-sensitive dye, we determined that the sodium ionophore monensin induced a dose-specific increase of intracellular sodium. A correspondence between the elevation of intracellular sodium and the level of dopamine-induced inhibition of Na+,K+-ATPase activity was determined. At basal intracellular sodium concentration, stimulation of cellular protein kinase C by phorbol 12-myristate 13-acetate (PMA) promoted a significant increase in Na+,K+-ATPase activity; however, this activation was gradually reduced as the concentration of intracellular sodium was increased to become a significant inhibition at concentrations of intracellular sodium higher than 16 mM. Under these conditions, PMA and dopamine share the same signaling pathway to inhibit the Na+,K+-ATPase. The effects of PMA and dopamine on the Na+,K+-ATPase activity and the modulation of these effects by different intracellular sodium concentrations were not modified when extracellular and intracellular calcium were almost eliminated. These results suggest that the level of intracellular sodium modulates whether hormones stimulate, inhibit, or have no effect on the Na+,K+-ATPase activity leading to a tight control of sodium reabsorption.	Univ Houston, Coll Pharm, Houston, TX 77204 USA; SUNY Brooklyn, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA; INTA, Ctr Invest Ciencias Agropecuarias, RA-1712 Buenos Aires, DF, Argentina; Karolinska Inst, Dept Mol Med, S-17176 Stockholm, Sweden	University of Houston System; University of Houston; State University of New York (SUNY) System; Instituto Nacional de Tecnologia Agropecuaria (INTA); Karolinska Institutet	Pedemonte, CH (corresponding author), Univ Houston, Coll Pharm, Bldg SR2,Rm 555,4800 Calhoun Rd, Houston, TX 77204 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053460] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53460] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aperia AC, 2000, ANNU REV PHYSIOL, V62, P621, DOI 10.1146/annurev.physiol.62.1.621; BERTORELLO A, 1988, AM J PHYSIOL, V254, pF795, DOI 10.1152/ajprenal.1988.254.6.F795; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; BERTORELLO AM, 1993, AM J PHYSIOL, V265, pF743, DOI 10.1152/ajprenal.1993.265.6.F743; Brismar H, 1998, P NATL ACAD SCI USA, V95, P5573, DOI 10.1073/pnas.95.10.5573; Chibalin AV, 1998, J BIOL CHEM, V273, P8814, DOI 10.1074/jbc.273.15.8814; CHIBALIN AV, 1992, J BIOL CHEM, V267, P22378; Chibalin AV, 1999, J BIOL CHEM, V274, P1920, DOI 10.1074/jbc.274.4.1920; CINELLI AR, 1995, J NEUROPHYSIOL, V73, P2017, DOI 10.1152/jn.1995.73.5.2017; Efendiev R, 1999, FEBS LETT, V456, P45, DOI 10.1016/S0014-5793(99)00925-4; Efendiev R, 2000, BIOCHEMISTRY-US, V39, P9884, DOI 10.1021/bi0007831; FISONE G, 1994, J BIOL CHEM, V269, P9368; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HABER RS, 1987, AM J PHYSIOL, V253, pF26, DOI 10.1152/ajprenal.1987.253.1.F26; HANSELL P, 1991, KIDNEY INT, V39, P253, DOI 10.1038/ki.1991.30; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; Hussain T, 1998, HYPERTENSION, V32, P187, DOI 10.1161/01.HYP.32.2.187; Li DL, 2000, AM J PHYSIOL-RENAL, V278, pF823, DOI 10.1152/ajprenal.2000.278.5.F823; LOWNDES JM, 1990, BIOCHIM BIOPHYS ACTA, V1052, P143, DOI 10.1016/0167-4889(90)90069-P; MCDONOUGH AA, 1990, SEMIN NEPHROL, V10, P400; MIDDLETON JP, 1993, J BIOL CHEM, V268, P15958; MINTA A, 1989, J BIOL CHEM, V264, P19449; MOORE EDW, 1993, P NATL ACAD SCI USA, V90, P8058, DOI 10.1073/pnas.90.17.8058; Ominato M, 1996, J MEMBRANE BIOL, V152, P235, DOI 10.1007/s002329900101; Pedemonte CH, 1997, MOL PHARMACOL, V52, P88, DOI 10.1124/mol.52.1.88; Pedemonte CH, 1997, J MEMBRANE BIOL, V155, P219, DOI 10.1007/s002329900174; PRESSLEY TA, 1988, J MEMBRANE BIOL, V105, P187, DOI 10.1007/BF01870996; PRESSMAN BC, 1982, ANNU REV PHARMACOL, V22, P465, DOI 10.1146/annurev.pa.22.040182.002341; RuizOpazo N, 1997, HYPERTENSION, V30, P191, DOI 10.1161/01.HYP.30.2.191; SERI I, 1990, AM J PHYSIOL, V258, pF52, DOI 10.1152/ajprenal.1990.258.1.F52; SERI K, 1990, AM J PHYSIOL, V258, pF52; SLOBODYANSKY E, 1995, AM J PHYSIOL-RENAL, V268, pF279, DOI 10.1152/ajprenal.1995.268.2.F279; SOARESDASILVA P, 1992, BRIT J PHARMACOL, V105, P811, DOI 10.1111/j.1476-5381.1992.tb09062.x; SOARESDASILVA P, 1993, BIOCHEM PHARMACOL, V45, P1791, DOI 10.1016/0006-2952(93)90435-Y; TAORMINO JP, 1990, J BIOL CHEM, V265, P4116; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Wang ZQ, 1997, HYPERTENSION, V29, P228, DOI 10.1161/01.HYP.29.1.228	37	49	49	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11489	11496		10.1074/jbc.M108182200	http://dx.doi.org/10.1074/jbc.M108182200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11796710	hybrid			2022-12-27	WOS:000174613100094
J	Mao, HW; Rosenthal, KS				Mao, HW; Rosenthal, KS			An N-terminal arginine-rich cluster and a proline-alanine-threonine repeat region determine the cellular localization of the herpes simplex virus type 1 ICP34.5 protein and its ligand, protein phosphatase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT COMPLEX; GAMMA(1)34.5 PROTEIN; NUCLEOLAR LOCALIZATION; ENDOPLASMIC-RETICULUM; NUCLEAR-LOCALIZATION; PREMATURE SHUTOFF; CARBOXYL-TERMINUS; KINASE PKR; DOMAIN; GENE	The ICP34.5 protein facilitates herpes simplex virus replication by binding and activating protein phosphatase 1 (PP1) by means of a very conserved C-terminal GADD34-like region. Natural variants of the ICP34.5 differing in the number of arginines in an Arg-rich cluster at the N terminus and the number of Pro-Ala-Thr repeats in the central bridge region of the protein were cloned as fusion proteins with a reporter peptide (c-Myc or hrGFP) at the C terminus. The natural variants were obtained from strains differing in passage history, tissue culture behavior, and neuroinvasive disease potential. In transfected cells, these variants localized to different subcellular compartments. The N-terminal Arg-rich cluster acted as a cellular localization signal for discrete regions of the nucleus and cytoplasm, but the ultimate location of ICP34.5 was determined by the number of Pro-Ala-Thr repeats in the central bridge region. PP1 colocalized with the ICP34.5 variant in cells expressing the ICP34.5. The ICP34.5-mediated, herpes simplex virus strain-dependent differences in the modulation of PP1 location and function may be responsible for the strain-associated differences in tissue culture behavior and virulence of the virus.	Northeastern Ohio Univ Coll Med & Pharm, Coll Med, Rootstown, OH 44272 USA	Northeast Ohio Medical University (NEOMED)	Rosenthal, KS (corresponding author), Northeastern Ohio Univ Coll Med & Pharm, Coll Med, 4209 State Route 44 Box 95, Rootstown, OH 44272 USA.	ksr@neoucom.edu	Rosenthal, Ken/L-7810-2019		NINDS NIH HHS [1 R15 NS40324] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R15NS040324] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKERMANN M, 1986, J VIROL, V58, P843, DOI 10.1128/JVI.58.3.843-850.1986; ALLAN V, 1995, J CELL BIOL, V128, P879, DOI 10.1083/jcb.128.5.879; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Andreansky S, 1997, CANCER RES, V57, P1502; Bloecher A, 2000, J CELL BIOL, V149, P125, DOI 10.1083/jcb.149.1.125; BOLOVAN CA, 1994, J VIROL, V68, P48, DOI 10.1128/JVI.68.1.48-55.1994; Bower JR, 1999, J VIROL, V73, P3843, DOI 10.1128/JVI.73.5.3843-3853.1999; BROWN SM, 1994, J GEN VIROL, V75, P3679, DOI 10.1099/0022-1317-75-12-3679; BROWN SM, 1994, J GEN VIROL, V75, P2367, DOI 10.1099/0022-1317-75-9-2367; Brown SM, 1997, J VIROL, V71, P9442, DOI 10.1128/JVI.71.12.9442-9449.1997; Cassady KA, 1998, J VIROL, V72, P7005; Cassady KA, 2002, J VIROL, V76, P942, DOI 10.1128/JVI.76.3.942-949.2002; Cheng GF, 2001, VIROLOGY, V290, P115, DOI 10.1006/viro.2001.1148; Cheng GF, 2001, J VIROL, V75, P3666, DOI 10.1128/JVI.75.8.3666-3674.2001; CHOU J, 1990, SCIENCE, V250, P1262, DOI 10.1126/science.2173860; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CHOU J, 1995, P NATL ACAD SCI USA, V92, P10516, DOI 10.1073/pnas.92.23.10516; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; CHOU J, 1990, J VIROL, V64, P1014, DOI 10.1128/JVI.64.3.1014-1020.1990; CHOU J, 1994, J VIROL, V68, P8304, DOI 10.1128/JVI.68.12.8304-8311.1994; D'Agostino DM, 2000, J VIROL, V74, P11899, DOI 10.1128/JVI.74.24.11899-11910.2000; DIX RD, 1983, INFECT IMMUN, V40, P103, DOI 10.1128/IAI.40.1.103-112.1983; Goatley LC, 1999, J GEN VIROL, V80, P525, DOI 10.1099/0022-1317-80-3-525; Gustafson WC, 1998, BIOCHEM J, V331, P387, DOI 10.1042/bj3310387; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; He B, 1996, J VIROL, V70, P84, DOI 10.1128/JVI.70.1.84-90.1996; He B, 1998, J BIOL CHEM, V273, P20737, DOI 10.1074/jbc.273.33.20737; HOLLAND TC, 1983, J VIROL, V45, P672, DOI 10.1128/JVI.45.2.672-682.1983; Liu QG, 2001, VIROLOGY, V285, P91, DOI 10.1006/viro.2001.0922; Loregian A, 2000, VIROLOGY, V273, P139, DOI 10.1006/viro.2000.0390; MCKAY EM, 1993, J GEN VIROL, V74, P2493, DOI 10.1099/0022-1317-74-11-2493; MCKIE EA, 1994, J GEN VIROL, V75, P733, DOI 10.1099/0022-1317-75-4-733; Mohr I, 1996, EMBO J, V15, P4759, DOI 10.1002/j.1460-2075.1996.tb00853.x; Mohr I, 2001, J VIROL, V75, P5189, DOI 10.1128/JVI.75.11.5189-5196.2001; Mulvey M, 1999, J VIROL, V73, P3375, DOI 10.1128/JVI.73.4.3375-3385.1999; Nam YS, 2001, J VIROL, V75, P2957, DOI 10.1128/JVI.75.6.2957-2971.2001; PERNG GC, 1995, J VIROL, V69, P3033, DOI 10.1128/JVI.69.5.3033-3041.1995; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Raine DA, 1998, FEBS LETT, V436, P343, DOI 10.1016/S0014-5793(98)01163-6; Randazzo BP, 1997, J GEN VIROL, V78, P3333, DOI 10.1099/0022-1317-78-12-3333; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; ROBERTSON LM, 1992, J GEN VIROL, V73, P967, DOI 10.1099/0022-1317-73-4-967; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0; Thebault S, 2000, EUR J CELL BIOL, V79, P834, DOI 10.1078/0171-9335-00111; Tian B, 2001, J BIOL CHEM, V276, P9936, DOI 10.1074/jbc.M007328200; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; WARD PL, 1994, TRENDS GENET, V10, P267, DOI 10.1016/0168-9525(90)90009-U	48	25	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11423	11431		10.1074/jbc.M111553200	http://dx.doi.org/10.1074/jbc.M111553200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11788604	hybrid			2022-12-27	WOS:000174613100086
J	Ben-Zeev, O; Mao, HZ; Doolittle, MH				Ben-Zeev, O; Mao, HZ; Doolittle, MH			RETRACTED: Maturation of lipoprotein lipase in the endoplasmic reticulum - Concurrent formation of functional dimers and inactive aggregates (Retracted article. See vol. 294, pg. 12565, 2019)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							PROTEIN DISULFIDE-ISOMERASE; CULTURED MOUSE ADIPOCYTES; ANTI-CHAPERONE ACTIVITY; QUALITY-CONTROL; INTRACELLULAR-TRANSPORT; TRANSIENT AGGREGATION; SECRETORY PATHWAY; TRICORN PROTEASE; ADIPOSE-CELLS; DEGRADATION	The maturation of lipoprotein lipase (LPL) into a catalytically active enzyme was believed to occur only after its transport from the endoplasmic reticulum (ER) to the Golgi apparatus. To test this hypothesis, LPL located in these two subcellular compartments was separated and compared. Heparin affinity chromatography resolved low affinity, inactive LPL displaying ER characteristics from a high affinity, active fraction exhibiting both ER and Golgi forms. The latter forms were further separated by beta-ricin chromatography and were found to have comparable activities per unit of LPL mass. Thus, LPL must reach a functional conformation in the ER. Active LPL, regardless of its cellular location, exhibited the expected dimer conformation. However, inactive LPL, found only in the ER, was highly aggregated. Kinetic analysis indicated a concurrent formation of LPL dimer and aggregate and indicated that the two forms have dissimilar fates. Whereas the dimer remained stable even when confined to the ER, the aggregate was degraded. Degradation rates were not affected by proteasomal or lysosomal inhibitors but were markedly reduced by ATP depletion. Lowering the redox potential in the ER by dithiothreitol caused the dimer to associate with calnexin, BiP, and protein-disulfide isomerase to form large, inactive complexes; dithiothreitol removal induced complex dissociation with restoration of the functional LPL dimer. In contrast, the LPL aggregate was only poorly associated with ER chaperones, appearing to be trapped in an irreversible, inactive conformation destined for ER degradation.	VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles	Doolittle, MH (corresponding author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 113,Rm 312, Los Angeles, CA 90073 USA.	markdool@ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28481] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AILHAUD G, 1990, CLIN BIOCHEM, V23, P343, DOI 10.1016/0009-9120(90)90034-R; AMRI EZ, 1986, BIOCHIM BIOPHYS ACTA, V875, P334, DOI 10.1016/0005-2760(86)90184-0; Benedetti C, 2000, BIOCHEM BIOPH RES CO, V278, P530, DOI 10.1006/bbrc.2000.3838; BENZEEV O, 1992, J BIOL CHEM, V267, P6219; BENZEEV O, 1998, LIPASE PHOSPHOLIPASE, P257; Bergo M, 1996, BIOCHEM J, V313, P893, DOI 10.1042/bj3130893; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Briquet-Laugier V, 1999, J LIPID RES, V40, P2044; BRIQUETLAUGIER V, 1998, LIPASE PHOSPHOLIPASE, P81; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Busca R, 1996, J BIOL CHEM, V271, P2139, DOI 10.1074/jbc.271.4.2139; Cabral CM, 2000, J BIOL CHEM, V275, P25015, DOI 10.1074/jbc.M910172199; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; COTNER T, 1995, J BIOL CHEM, V270, P2379, DOI 10.1074/jbc.270.5.2379; Doolittle MH, 1998, J LIPID RES, V39, P934; DOOLITTLE MH, 1998, LIPASE PHOSPHOLIPASE, P215; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fayadat L, 2000, J BIOL CHEM, V275, P15948, DOI 10.1074/jbc.M905763199; FERREIRA LR, 1994, J CELL BIOCHEM, V56, P518, DOI 10.1002/jcb.240560412; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; Gillece P, 1999, J CELL BIOL, V147, P1443, DOI 10.1083/jcb.147.7.1443; Goldberg IJ, 1996, J LIPID RES, V37, P693; Guthapfel R, 1996, J BIOL CHEM, V271, P2663, DOI 10.1074/jbc.271.5.2663; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Jannatipour M, 1998, BIOCHEMISTRY-US, V37, P17253, DOI 10.1021/bi981785c; Kamhi-Nesher S, 2001, MOL BIOL CELL, V12, P1711, DOI 10.1091/mbc.12.6.1711; Kellokumpu S, 1997, J BIOL CHEM, V272, P2770, DOI 10.1074/jbc.272.5.2770; KIM PS, 1991, J BIOL CHEM, V266, P12412; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KRAPP A, 1995, J LIPID RES, V36, P2362; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIU GQ, 1993, BIOCHEM J, V292, P277, DOI 10.1042/bj2920277; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; LODISH HF, 1993, J BIOL CHEM, V268, P20598; Lookene A, 1997, J BIOL CHEM, V272, P766, DOI 10.1074/jbc.272.2.766; Lookene A, 1996, BIOCHEMISTRY-US, V35, P12155, DOI 10.1021/bi960008e; Lutz EP, 2001, J CLIN INVEST, V107, P1183, DOI 10.1172/JCI11774; MARKS MS, 1995, J BIOL CHEM, V270, P10475, DOI 10.1074/jbc.270.18.10475; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; Masuno H, 1998, BIOCHEM J, V329, P461, DOI 10.1042/bj3290461; MASUNO H, 1992, J LIPID RES, V33, P1343; MCCRACKEN AA, 2000, GENOME BIOL, V1, P1013; MIZUOCHI T, 1984, J BIOCHEM-TOKYO, V95, P1209, DOI 10.1093/oxfordjournals.jbchem.a134711; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; MULVEY M, 1995, J VIROL, V69, P1621, DOI 10.1128/JVI.69.3.1621-1627.1995; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Negroiu G, 2000, J BIOL CHEM, V275, P32200, DOI 10.1074/jbc.M005186200; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; Park JW, 1996, BIOCHEM J, V317, P125, DOI 10.1042/bj3170125; Park JW, 1997, BBA-LIPID LIPID MET, V1344, P132, DOI 10.1016/S0005-2760(96)00146-4; Primm TP, 1996, J BIOL CHEM, V271, P33664, DOI 10.1074/jbc.271.52.33664; PUIG A, 1994, J BIOL CHEM, V269, P7764; SEMB H, 1989, J BIOL CHEM, V264, P4195; Sideraki V, 2000, BIOCHEMISTRY-US, V39, P1180, DOI 10.1021/bi992246q; SIMSOLO RB, 1992, J LIPID RES, V33, P1777; Tagliavacca L, 2000, BIOCHEMISTRY-US, V39, P1973, DOI 10.1021/bi991896r; Tamura N, 1998, CELL, V95, P637, DOI 10.1016/S0092-8674(00)81634-7; Tamura T, 1996, SCIENCE, V274, P1385, DOI 10.1126/science.274.5291.1385; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; Taubes G, 1996, SCIENCE, V271, P1493, DOI 10.1126/science.271.5255.1493; VANNIER C, 1989, J BIOL CHEM, V264, P13206; VANNIER C, 1985, J BIOL CHEM, V260, P4424; VANNIER C, 1989, J BIOL CHEM, V264, P13199; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	78	61	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10727	10738		10.1074/jbc.M108128200	http://dx.doi.org/10.1074/jbc.M108128200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11796709	hybrid			2022-12-27	WOS:000174549200148
J	Schlesinger, TK; Bonvin, C; Jarpe, MB; Fanger, GR; Cardinaux, JR; Johnson, GL; Widmann, C				Schlesinger, TK; Bonvin, C; Jarpe, MB; Fanger, GR; Cardinaux, JR; Johnson, GL; Widmann, C			Apoptosis stimulated by the 91-kDa caspase cleavage MEKK1 fragment requires translocation to soluble cellular compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; FAS LIGAND EXPRESSION; POLY(ADP-RIBOSE) POLYMERASE; RESPONSE ELEMENT; TERMINAL KINASE; PLASMA-MEMBRANE; RAS PROTEINS; DEATH; CELLS	MEKK1, a 196-kDa mitogen-activated protein kinase (MAPK) kinase kinase, generates anti-apoptotic signaling as a full-length protein but induces apoptosis when cleaved by caspases. Here, we show that caspase-dependent cleavage of MEKK1 relocalizes the protease-generated 91-kDa kinase fragment from a particulate fraction to a soluble cytoplasmic fraction. Relocalization of MEKK1 catalytic activity is necessary for the pro-apoptotic function of MEKK1. The addition of a membrane-targeting signal to the 91-kDa fragment inhibits caspase activation and the induction of apoptosis but does not change the activation of JNK, ERK, NFkappaB, or p300. These results identify the caspase cleavage of MEKK1 as a dynamic regulatory mechanism that alters the subcellular distribution of MEKK1, changing its function to pro-apoptotic signaling, which does not depend on the currently described MEKK1 effectors.	Univ Lausanne, Inst Cellular Biol & Morphol, CH-1005 Lausanne, Switzerland; Univ Lausanne Hosp, Dept Internal Med, Botnar Unit, CH-1005 Lausanne, Switzerland; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA; Univ Lausanne, Inst Physiol, CH-1005 Lausanne, Switzerland; Univ Lausanne, Dept Child & Adolescent Psychiat, CH-1005 Lausanne, Switzerland	University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Lausanne; University of Lausanne	Widmann, C (corresponding author), IBCM, Bugnon 9, CH-1005 Lausanne, Switzerland.		Widmann, Christian/N-9851-2013; Cardinaux, Jean-René/G-5391-2012	Widmann, Christian/0000-0002-6881-0363; Cardinaux, Jean-René/0000-0001-6423-0014	NIDDK NIH HHS [DK37871, DK48845] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048845, R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BONVIN C, 2001, CELL SIGNAL, V13, P1; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; Cook SJ, 2000, BIOCHEM SOC T, V28, P233, DOI 10.1042/bst0280233; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Foo SY, 1999, TRENDS GENET, V15, P229; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Gabai VL, 1998, FEBS LETT, V438, P1, DOI 10.1016/S0014-5793(98)01242-3; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Harvey KJ, 2001, CYTOMETRY, V43, P273, DOI 10.1002/1097-0320(20010401)43:4<273::AID-CYTO1059>3.0.CO;2-3; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; HOWE CL, 1988, P NATL ACAD SCI USA, V85, P7577, DOI 10.1073/pnas.85.20.7577; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; Jiang W, 1998, BIOTECHNIQUES, V24, P349; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LASSIGNALJOHNSO.N, 1996, J BIOL CHEM, V271, P3229; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mandic A, 2001, MOL CELL BIOL, V21, P3684, DOI 10.1128/MCB.21.11.3684-3691.2001; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Salvioli S, 2001, FEBS LETT, V492, P9, DOI 10.1016/S0014-5793(01)02199-8; See RH, 2001, J BIOL CHEM, V276, P16310, DOI 10.1074/jbc.M008113200; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	63	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10283	10291		10.1074/jbc.M106885200	http://dx.doi.org/10.1074/jbc.M106885200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11782455	hybrid			2022-12-27	WOS:000174549200090
J	Serrador, JM; Vicente-Manzanares, M; Calvo, J; Barreiro, O; Montoya, MC; Schwartz-Albiez, R; Furthmayr, H; Lozano, F; Sanchez-Madrid, F				Serrador, JM; Vicente-Manzanares, M; Calvo, J; Barreiro, O; Montoya, MC; Schwartz-Albiez, R; Furthmayr, H; Lozano, F; Sanchez-Madrid, F			A novel serine-rich motif in the intercellular adhesion molecule 3 is critical for its ezrin/radixin/moesin-directed subcellular targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN BINDING; ERM PROTEINS; EXTRACELLULAR-MATRIX; CELL-ADHESION; IN-VIVO; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; CYTOPLASMIC REGION; SIGNALING PATHWAY; T-LYMPHOCYTES; EZRIN	Intercellular adhesion molecule 3 (ICAM-3) is a leukocyte-specific receptor involved in primary immune responses. We have investigated the interaction between ICAM-3 and ezrin/radixin/moesin (ERM) proteins and its role in LFA-1-induced cell-cell interactions and membrane positioning of ICAM-3 in polarized migrating lymphocytes. Protein-protein binding assays demonstrated a phosphatidylinositol 4,5-bisphosphate-induced association between ICAM-3 and the amino-terminal domain of ERM proteins. This interaction was not essential for the binding of ICAM-3 to LFA-1. Dynamic fluorescence videomicroscopy studies of cells demonstrated that moesin and ICAM-3 coordinately redistribute on the plasma membrane during lymphocyte migration. Furthermore, overexpression of the amino-terminal domain of moesin, which lacks the consensus moesin actin-binding site, caused the subcellular mislocalization of ICAM-3. A CD4 chimerical protein containing the cytoplasmic tail of ICAM-3 was targeted to the trailing edge. Point mutation of Ser(487), Ser(489), and Ser(496) to alanine in the juxtamembrane region of ICAM-3 significantly impaired both ERM binding and polarization of ICAM-3. ERM-directed polarization of ICAM-3 was also impaired by phosphorylation-like mutation of Ser(487) and Ser(489), but not of Ser(496). Our results underscore the key role of specific serine residues within the cytoplasmic region of ICAM-3 for its ERM-directed positioning at the trailing edge of motile lymphocytes.	Univ Autonoma Madrid, Hosp Princesa, Serv Immunol, E-28006 Madrid, Spain; Stanford Univ, Dept Pathol, Palo Alto, CA 94304 USA; German Canc Res Ctr, Tumor Immunol Programme, D-69120 Heidelberg, Germany; Hosp Clin Barcelona, Serv Immunol, E-08036 Barcelona, Spain	Autonomous University of Madrid; Hospital de La Princesa; Stanford University; Helmholtz Association; German Cancer Research Center (DKFZ); University of Barcelona; Hospital Clinic de Barcelona	Sanchez-Madrid, F (corresponding author), Univ Autonoma Madrid, Hosp Princesa, Serv Immunol, E-28006 Madrid, Spain.		Montoya, María/N-1558-2014; Sanchez-Madrid, Francisco/M-7889-2016; Bustelo, Xose R./A-9526-2010; Vicente-Manzanares, Miguel/H-1010-2018; Lozano-Soto, Francisco/AAB-7930-2019; Furthmayr, Heinz -/A-6295-2010; Serrador, Juan M/K-2718-2014; LOZANO, FRANCISCO/AAB-7888-2019; Calvo, Javier/AAC-8810-2022	Montoya, María/0000-0001-8878-7028; Sanchez-Madrid, Francisco/0000-0001-5303-0762; Bustelo, Xose R./0000-0001-9398-6072; Vicente-Manzanares, Miguel/0000-0001-5943-3220; Lozano-Soto, Francisco/0000-0003-3714-2304; Serrador, Juan M/0000-0003-4710-3077; LOZANO, FRANCISCO/0000-0003-1119-4368; Calvo, Javier/0000-0002-1732-9449				AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; Amieva MR, 1999, J CELL SCI, V112, P111; Barret C, 2000, J CELL BIOL, V151, P1067, DOI 10.1083/jcb.151.5.1067; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; CAMPANERO MR, 1994, J CELL BIOL, V127, P867, DOI 10.1083/jcb.127.3.867; CAMPANERO MR, 1993, J CELL BIOL, V123, P1007, DOI 10.1083/jcb.123.4.1007; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Defacque H, 2000, EMBO J, V19, P199, DOI 10.1093/emboj/19.2.199; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DELPOZO MA, 1995, J CELL BIOL, V131, P495, DOI 10.1083/jcb.131.2.495; Edwards SD, 2001, BIOCHEMISTRY-US, V40, P7061, DOI 10.1021/bi010419h; Gahmberg CG, 1997, CURR OPIN CELL BIOL, V9, P643, DOI 10.1016/S0955-0674(97)80117-2; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Hayashi K, 1999, J CELL SCI, V112, P1149; Hayflick JS, 1997, J BIOL CHEM, V272, P22207, DOI 10.1074/jbc.272.35.22207; Heiska L, 1998, J BIOL CHEM, V273, P21893, DOI 10.1074/jbc.273.34.21893; Helander TS, 1996, NATURE, V382, P265, DOI 10.1038/382265a0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Huang LQ, 1999, J BIOL CHEM, V274, P12803, DOI 10.1074/jbc.274.18.12803; Keller H, 1998, CELL MOTIL CYTOSKEL, V40, P342, DOI 10.1002/(SICI)1097-0169(1998)40:4<342::AID-CM3>3.3.CO;2-8; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; LOZANO F, 1992, EUR J BIOCHEM, V203, P321, DOI 10.1111/j.1432-1033.1992.tb19862.x; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; MCFARLAND W, 1969, SCIENCE, V163, P818, DOI 10.1126/science.163.3869.818; Montoya MC, 2002, NAT IMMUNOL, V3, P159, DOI 10.1038/ni753; Nakamura F, 1999, MOL BIOL CELL, V10, P2669, DOI 10.1091/mbc.10.8.2669; NUEDA A, 1995, CELL IMMUNOL, V164, P163, DOI 10.1006/cimm.1995.1157; Parlato S, 2000, EMBO J, V19, P5123, DOI 10.1093/emboj/19.19.5123; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yonemura S, 1999, J CELL BIOL, V145, P1497, DOI 10.1083/jcb.145.7.1497	45	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10400	10409		10.1074/jbc.M110694200	http://dx.doi.org/10.1074/jbc.M110694200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11784723	hybrid			2022-12-27	WOS:000174549200106
J	Soubannier, V; Vaillier, J; Paumard, P; Coulary, B; Schaeffer, J; Velours, J				Soubannier, V; Vaillier, J; Paumard, P; Coulary, B; Schaeffer, J; Velours, J			In the absence of the first membrane-spanning segment of subunit 4(b), the yeast ATP synthase is functional but does not dimerize or oligomerize	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; BLUE NATIVE ELECTROPHORESIS; SACCHAROMYCES-CEREVISIAE; F1F0-ATP SYNTHASE; PROTEIN COMPLEXES; STRUCTURAL GENE; IDENTIFICATION; F1-ATPASE; STALK; RECONSTITUTION	The N-terminal portion of the mitochondrial b-subunit is anchored in the inner mitochondrial membrane by two hydrophobic segments. We investigated the role of the first membrane-spanning segment, which is absent in prokaryotic and chloroplastic enzymes. In the absence of the first membrane-spanning segment of the yeast subunit (subunit 4), a strong decrease in the amount of subunit g was found. The mutant ATP synthase did not dimerize or oligomerize, and mutant cells displayed anomalous mitochondrial morphologies with onion-like structures. This phenotype is similar to that of the null mutant in the ATP20 gene that encodes subunit g, a component involved in the dimerization/oligomerization of ATP synthase. Our data indicate that the first membrane-spanning segment of the mitochondrial b-subunit is not essential for the function of the enzyme since its removal did not directly alter the oxidative phosphorylation. It is proposed that the unique membrane-spanning segment of subunit g and the first membrane-spanning segment of subunit 4 interact, as shown by cross-linking experiments. We hypothesize that in eukaryotic cells the b-subunit has evolved to accommodate the interaction with the g-subunit, an associated ATP synthase component only present in the mitochondrial enzyme.	Univ Bordeaux 2, CNRS, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Velours, J (corresponding author), Univ Bordeaux 2, CNRS, Inst Biochim & Genet Cellulaires, 1 Rue Camille St Saens, F-33077 Bordeaux, France.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALLEN RD, 1995, PROTOPLASMA, V189, P1, DOI 10.1007/BF01280286; ALLEN RD, 1989, J CELL BIOL, V108, P2233, DOI 10.1083/jcb.108.6.2233; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arnold I, 1997, FEBS LETT, V411, P195, DOI 10.1016/S0014-5793(97)00691-1; Arnold I, 1999, J BIOL CHEM, V274, P36, DOI 10.1074/jbc.274.1.36; Bateson M, 1999, J BIOL CHEM, V274, P7462, DOI 10.1074/jbc.274.11.7462; Belogrudov GI, 1996, J BIOL CHEM, V271, P20340, DOI 10.1074/jbc.271.34.20340; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Bottcher B, 2000, BBA-BIOENERGETICS, V1458, P404, DOI 10.1016/S0005-2728(00)00090-6; Boyle GM, 1999, EUR J BIOCHEM, V262, P315, DOI 10.1046/j.1432-1327.1999.00345.x; Cherepanov DA, 1999, FEBS LETT, V449, P1, DOI 10.1016/S0014-5793(99)00386-5; Collinson IR, 1996, BIOCHEMISTRY-US, V35, P12640, DOI 10.1021/bi960969t; COLLINSON IR, 1994, J MOL BIOL, V242, P408; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; DECHATEAUBODEAU GA, 1976, BIOCHIMIE PARIS, V58, P601; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; Fillingame RH, 1999, SCIENCE, V286, P1687, DOI 10.1126/science.286.5445.1687; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GrandierVazeille X, 1996, ANAL BIOCHEM, V242, P248, DOI 10.1006/abio.1996.0460; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; Guerin B, 1979, Methods Enzymol, V55, P149; Hausrath AC, 1999, P NATL ACAD SCI USA, V96, P13697, DOI 10.1073/pnas.96.24.13697; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mueller DM, 2000, J BIOENERG BIOMEMBR, V32, P391, DOI 10.1023/A:1005532104617; PAUL MF, 1992, EUR J BIOCHEM, V205, P163, DOI 10.1111/j.1432-1033.1992.tb16764.x; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P325, DOI 10.1023/A:1005594800983; RIGOULET M, 1979, FEBS LETT, V102, P18, DOI 10.1016/0014-5793(79)80919-9; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHWERZMANN K, 1986, ARCH BIOCHEM BIOPHYS, V250, P1, DOI 10.1016/0003-9861(86)90695-8; Soubannier V, 1999, BIOCHEMISTRY-US, V38, P15017, DOI 10.1021/bi9916067; Spannagel C, 1998, BIOCHEMISTRY-US, V37, P615, DOI 10.1021/bi9714971; Spannagel C, 1998, BBA-BIOMEMBRANES, V1414, P260, DOI 10.1016/S0005-2736(98)00174-6; Stephens AN, 2000, EUR J BIOCHEM, V267, P6443, DOI 10.1046/j.1432-1327.2000.01733.x; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; TOKLADIS K, 1996, NATURE, V384, P585; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; Vaillier J, 1999, J BIOL CHEM, V274, P543, DOI 10.1074/jbc.274.1.543; VELOURS J, 1988, EUR J BIOCHEM, V170, P637, DOI 10.1111/j.1432-1033.1988.tb13745.x; Velours J, 2001, J BIOL CHEM, V276, P8602, DOI 10.1074/jbc.M008123200; Velours J, 2000, J BIOENERG BIOMEMBR, V32, P383, DOI 10.1023/A:1005580020547; YOSHIDA M, 1975, J BIOL CHEM, V250, P7910	48	65	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10739	10745		10.1074/jbc.M111882200	http://dx.doi.org/10.1074/jbc.M111882200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11799128	hybrid			2022-12-27	WOS:000174549200149
J	Wheeler, TC; Chin, LS; Li, YK; Roudabush, FL; Li, LA				Wheeler, TC; Chin, LS; Li, YK; Roudabush, FL; Li, LA			Regulation of synaptophysin degradation by mammalian homologues of Seven in Absentia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; LONG-TERM POTENTIATION; MESSENGER-RNA EXPRESSION; DENTATE GYRUS; PC12 CELLS; NEUROMUSCULAR SYNAPSES; TRANSMITTER SECRETION; ALZHEIMERS-DISEASE; MURINE HOMOLOGS	Synaptophysin is an integral membrane protein of synaptic vesicles characterized by four transmembrane domains with both termini facing the cytoplasm. Although synaptophysin has been implicated in neurotransmitter release, and decreased synaptophysin levels have been associated with several neurodegenerative diseases, the molecular mechanism that regulates the degradation of synaptophysin remains unsolved. Using the cytoplasmic C terminus of synaptophysin as bait in a yeast two-hybrid screen, we identified two synaptophysin-binding proteins, Siah-1A and Siah-2, which are rat homologues of Drosophila Seven in Absentia. We demonstrated that Siah-1A and Siah-2 associate with synaptophysin both in vitro and in vivo and defined the binding domains of synaptophysin and Siah that mediate their association. Siah proteins exist in both cytosolic and membrane-associated pools and co-localize with synaptophysin on synaptic vesicles and early endosomes. In addition, Siah proteins interact specifically with the brain-enriched E2 ubiquitin-conjugating enzyme UbcH8 and facilitate the ubiquitination of synaptophysin. Furthermore, overexpression of Siah proteins promotes the degradation of synaptophysin via the ubiquitin-proteasome pathway. Our findings indicate that Siah proteins function as E3 ubiquitin-protein ligases to regulate the ubiquitination and degradation of synaptophysin.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	Emory University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Li, LA (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.			Chin, Lih-Shen/0000-0002-0817-0368	NINDS NIH HHS [NS36320] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036320] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDER J, 1995, J NEUROSCI, V15, P511; ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; ALDER J, 1992, NEURON, V9, P759, DOI 10.1016/0896-6273(92)90038-F; Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; BIXBY JL, 1992, MOL BRAIN RES, V13, P339, DOI 10.1016/0169-328X(92)90217-Y; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; Bogdan S, 2001, MECH DEVELOP, V103, P61, DOI 10.1016/S0925-4773(01)00332-X; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; BUCKLEY KM, 1987, J CELL BIOL, V105, P2447, DOI 10.1083/jcb.105.6.2447; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CHAPMAN A P, 1992, Biochemical Society Transactions, V20, p155S; CHAPMAN AP, 1994, NEUROSCI LETT, V168, P238, DOI 10.1016/0304-3940(94)90459-6; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHILCOTE TJ, 1995, J CELL BIOL, V129, P219, DOI 10.1083/jcb.129.1.219; Chin LS, 2000, J BIOL CHEM, V275, P1191, DOI 10.1074/jbc.275.2.1191; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Daly C, 1997, J NEUROSCI, V17, P2365; Daly C, 2000, P NATL ACAD SCI USA, V97, P6120, DOI 10.1073/pnas.97.11.6120; de Wit H, 1999, MOL BIOL CELL, V10, P4163, DOI 10.1091/mbc.10.12.4163; DELLA NG, 1993, DEVELOPMENT, V117, P1333; DEVOTO SH, 1989, J COMP NEUROL, V290, P154, DOI 10.1002/cne.902900110; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; EASTWOOD SL, 1995, NEUROSCIENCE, V69, P339, DOI 10.1016/0306-4522(95)00324-C; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ESHKIND LG, 1995, CELL TISSUE RES, V282, P423, DOI 10.1007/s004410050493; FEANY MB, 1993, J CELL BIOL, V123, P575, DOI 10.1083/jcb.123.3.575; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; Glantz LA, 1997, ARCH GEN PSYCHIAT, V54, P943; Glantz LA, 2000, BIOL PSYCHIAT, V48, P389, DOI 10.1016/S0006-3223(00)00923-9; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEINONEN O, 1995, NEUROSCIENCE, V64, P375, DOI 10.1016/0306-4522(94)00422-2; Holloway AJ, 1997, GENOMICS, V41, P160, DOI 10.1006/geno.1997.4642; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Ishikawa K, 1999, GENES CELLS, V4, P381, DOI 10.1046/j.1365-2443.1999.00269.x; Janz R, 1999, NEURON, V24, P687, DOI 10.1016/S0896-6273(00)81122-8; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; Kimura M, 1997, CYTOGENET CELL GENET, V78, P107, DOI 10.1159/000134639; KNAUS P, 1990, NEURON, V5, P453, DOI 10.1016/0896-6273(90)90084-S; Kubo S, 2001, J NEUROCHEM, V78, P42, DOI 10.1046/j.1471-4159.2001.00364.x; LAH JJ, 1993, J NEUROCYTOL, V22, P92, DOI 10.1007/BF01181573; LECLERC N, 1989, J COMP NEUROL, V280, P197, DOI 10.1002/cne.902800204; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; LEUBE RE, 1987, EMBO J, V6, P3261, DOI 10.1002/j.1460-2075.1987.tb02644.x; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; LYNCH MA, 1994, NEUROSCIENCE, V60, P1, DOI 10.1016/0306-4522(94)90197-X; MARAZZI G, 1993, DEV DYNAM, V197, P115, DOI 10.1002/aja.1001970205; MASLIAH E, 1994, NEUROSCI LETT, V174, P67, DOI 10.1016/0304-3940(94)90121-X; McMahon HT, 1996, P NATL ACAD SCI USA, V93, P4760, DOI 10.1073/pnas.93.10.4760; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Mullany P, 1997, NEUROPHARMACOLOGY, V36, P973, DOI 10.1016/S0028-3908(97)00073-7; Mullany PM, 1998, NEUROREPORT, V9, P2489, DOI 10.1097/00001756-199808030-00012; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; Neufeld TP, 1998, GENETICS, V148, P277; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schwartz AL, 1999, ANNU REV MED, V50, P57; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Sourisseau T, 2001, J CELL SCI, V114, P1409; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; SUDHOF TC, 1987, NUCLEIC ACIDS RES, V15, P9607, DOI 10.1093/nar/15.22.9607; Sugita S, 1999, J BIOL CHEM, V274, P18893, DOI 10.1074/jbc.274.27.18893; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	81	143	149	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10273	10282		10.1074/jbc.M107857200	http://dx.doi.org/10.1074/jbc.M107857200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11786535	hybrid, Green Published			2022-12-27	WOS:000174549200089
J	Inaba, T; Nagano, Y; Nagasaki, T; Sasaki, Y				Inaba, T; Nagano, Y; Nagasaki, T; Sasaki, Y			Distinct localization of two closely related Ypt3/Rab11 proteins on the trafficking pathway in higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; TRANS-GOLGI NETWORK; DOWN-REGULATED EXPRESSION; PEA PISUM-SATIVUM; ENDOPLASMIC-RETICULUM; VACUOLAR PROTEIN; CULTURED-CELLS; H+-ATPASE; ARABIDOPSIS; MEMBRANE	Ypt/Rab proteins are Ras-related small GTPases that act on the intracellular membrane through the trafficking pathway, and their function depends on their localization. Approximately 25 genes encoding Ypt3/Rab11-related proteins exist in Arabidopsis, but the reason for the presence of many genes in plants remains unclear. Pea Pra2 and Pra3, members of Ypt3/Rab11, are closely related proteins. Because possible orthologs are conserved among dicots, they can be studied to determine their possible localization. Biochemical analysis revealed that these proteins were localized on distinct membranes in pea. Furthermore, using green fluorescent protein-Pra2 and green fluorescent protein-Pra3 fusion proteins, we demonstrated that these proteins are distinctively localized on the trafficking pathway in tobacco Bright Yellow 2 cells. Pra2 was predominantly localized on Golgi stacks and endosomes, which did not support the localization of Pra2 on the endoplasmic reticulum (Kang, J. G., Yun, J., Kim, D. H., Chung, K. S., Fujioka, S., Kim, J. I., Dae, H. W., Yoshida, S., Takatsuto, S., Song, P. S., and Park, C. M. (2001) Cell 105, 625-636). In contrast, Pra3 was likely to be localized on the trans-Golgi network and/or the prevacuolar compartment. We concluded that Pra2 and Pra3 proteins are distinctively localized on the trafficking pathway. This finding suggests that functional diversification takes place in the plant Ypt3/Rab11 family.	Nagoya Univ, Grad Sch Agr Sci, Lab Plant Mol Biol, Nagoya, Aichi 4648601, Japan	Nagoya University	Sasaki, Y (corresponding author), Nagoya Univ, Grad Sch Agr Sci, Lab Plant Mol Biol, Nagoya, Aichi 4648601, Japan.		Nagano, Yukio/H-8734-2019	Nagano, Yukio/0000-0001-5030-676X; Inaba, Takehito/0000-0003-1750-454X				Ahmed SU, 1997, PLANT PHYSIOL, V114, P325, DOI 10.1104/pp.114.1.325; ALI MS, 1985, PLANT CELL PHYSIOL, V26, P1119; Benli M, 1996, EMBO J, V15, P6460, DOI 10.1002/j.1460-2075.1996.tb01037.x; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Borg S, 1997, PLANT J, V11, P237, DOI 10.1046/j.1365-313X.1997.11020237.x; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; Czernic P, 1996, PLANT MOL BIOL, V31, P255, DOI 10.1007/BF00021788; FUJITA M, 1985, PLANT CELL PHYSIOL, V26, P389, DOI 10.1093/oxfordjournals.pcp.a076922; Geldner N, 2001, NATURE, V413, P425, DOI 10.1038/35096571; HOBBS MC, 1991, BIOCHEM J, V277, P653, DOI 10.1042/bj2770653; Inaba T, 1999, PLANT PHYSIOL, V120, P491, DOI 10.1104/pp.120.2.491; Inaba T, 2000, J BIOL CHEM, V275, P19723, DOI 10.1074/jbc.M001337200; Jedd G, 1997, J CELL BIOL, V137, P563, DOI 10.1083/jcb.137.3.563; Kang JG, 2001, CELL, V105, P625, DOI 10.1016/S0092-8674(01)00370-1; Kim DH, 2001, PLANT CELL, V13, P287, DOI 10.1105/tpc.13.2.287; Kitaura Y, 2001, J BIOL CHEM, V276, P14053, DOI 10.1074/jbc.M008649200; LORD JM, 1973, J CELL BIOL, V57, P659, DOI 10.1083/jcb.57.3.659; Matsuda N, 2000, CELL STRUCT FUNCT, V25, P11, DOI 10.1247/csf.25.11; Matsuoka K, 1995, PLANT J, V8, P877, DOI 10.1046/j.1365-313X.1995.8060877.x; MATSUOKA K, 1991, P NATL ACAD SCI USA, V88, P834, DOI 10.1073/pnas.88.3.834; MATSUURAENDO C, 1992, PLANT PHYSIOL, V100, P718, DOI 10.1104/pp.100.2.718; NAGANO Y, 1995, P NATL ACAD SCI USA, V92, P6314, DOI 10.1073/pnas.92.14.6314; NAGANO Y, 1993, PLANT CELL PHYSIOL, V34, P447; Nagano Y, 2001, J BIOL CHEM, V276, P22238, DOI 10.1074/jbc.M102474200; NAGAO T, 1987, PLANT CELL PHYSIOL, V28, P1181; Nebenfuhr A, 1999, PLANT PHYSIOL, V121, P1127, DOI 10.1104/pp.121.4.1127; Pelham HRB, 1998, TRENDS CELL BIOL, V8, P45, DOI 10.1016/S0962-8924(97)01185-9; Ralston L, 2001, ARCH BIOCHEM BIOPHYS, V393, P222, DOI 10.1006/abbi.2001.2483; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; TAIZ L, 1998, PLANT PHYSIOL, P419; Takeuchi M, 2000, PLANT J, V23, P517, DOI 10.1046/j.1365-313x.2000.00823.x; The Arabidopsis Genome Initiative, 2000, NATURE, V408, P796; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Ueda T, 1996, MOL GEN GENET, V250, P533; Ueda T, 2001, EMBO J, V20, P4730, DOI 10.1093/emboj/20.17.4730; Wang XY, 2000, J BIOL CHEM, V275, P29138, DOI 10.1074/jbc.M004410200; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; Yahara N, 2001, MOL BIOL CELL, V12, P221, DOI 10.1091/mbc.12.1.221; YOSHIDA K, 1993, P NATL ACAD SCI USA, V90, P6636, DOI 10.1073/pnas.90.14.6636; Zheng HY, 1999, MOL BIOL CELL, V10, P2251, DOI 10.1091/mbc.10.7.2251	42	48	54	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9183	9188		10.1074/jbc.M111491200	http://dx.doi.org/10.1074/jbc.M111491200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11756458	hybrid			2022-12-27	WOS:000174400600061
J	Meunier, C; Bordereaux, D; Porten, F; Gisselbrecht, S; Chretien, S; Courtois, G				Meunier, C; Bordereaux, D; Porten, F; Gisselbrecht, S; Chretien, S; Courtois, G			Cloning and characterization of a family of proteins associated with Mpl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINOCEREBELLAR ATAXIA TYPE-2; THROMBOPOIETIN RECEPTOR; C-MPL; TYROSINE PHOSPHORYLATION; MEGAKARYOCYTE GROWTH; 3-KINASE ACTIVATION; KINASE PATHWAY; DOMAIN; GENE; DIFFERENTIATION	Thrombopoietin (TPO) controls the formation of megakaryocytes and platelets from hematopoietic stem cells via activation of the c-Mpl receptor and multiple downstream signal transduction pathways. We used two-hybrid screening to identify new proteins that interacted with the cytoplasmic domain of Mpl, and we found a new family of proteins designated A2D (for Ataxin-2 Domain protein). The A2D are 130-kDa proteins that have three regions similar to those of Ataxin-2, the gene product causing familial type 2 spinocerebellar ataxia. A2D has several isoforms with different C-terminal domains, all produced from a single gene by alternative splicing. Northern blotting indicated that the A2D gene is widely expressed in immortalized cell lines and hematopoietic and fetal tissues. A2D proteins were constitutively associated with Mpl in vivo in human hematopoietic UT7 cells. TPO also caused the release of A2D from the activated receptor, and the phosphorylation of A2D on tyrosines residues was dependent on the Mpl C-terminal domain. Finally, A2D bound to the unstimulated erythropoietin receptor, whereas erythropoietin caused dissociation from the erythropoietin receptor, suggesting that A2D proteins are new components of the cytokine signaling system.	ICGM, INSERM, U363, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Courtois, G (corresponding author), ICGM, INSERM, U363, 27 Rue Faubourg St Jacques, F-75014 Paris, France.	courtois@cochin.inserm.fr	Chretien, Stany/M-5166-2018; PORTEU, Françoise/I-8445-2016	PORTEU, Françoise/0000-0002-2403-4163; courtois, genevieve/0000-0001-6370-5575				Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Aguiar J, 1999, BIOCHEM BIOPH RES CO, V254, P315, DOI 10.1006/bbrc.1998.9929; BENIT L, 1994, J VIROL, V68, P5270; Bouscary D, 2001, ONCOGENE, V20, P2197, DOI 10.1038/sj.onc.1204317; Bunting S, 1997, BLOOD, V90, P3423, DOI 10.1182/blood.V90.9.3423; CHERIF D, 1989, HUM GENET, V81, P358, DOI 10.1007/BF00283691; COURTOIS G, 1995, J VIROL, V69, P2794, DOI 10.1128/JVI.69.5.2794-2800.1995; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; Dorsch M, 1999, BLOOD, V94, P2676, DOI 10.1182/blood.V94.8.2676.420k28_2676_2685; Drachman JG, 1999, J BIOL CHEM, V274, P13480, DOI 10.1074/jbc.274.19.13480; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; Fichelson S, 1999, BLOOD, V94, P1601, DOI 10.1182/blood.V94.5.1601.417k19_1601_1613; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Garcia J, 2001, MOL CELL BIOL, V21, P2659, DOI 10.1128/MCB.21.8.2659-2670.2001; Gaur M, 2001, BLOOD, V97, P1653, DOI 10.1182/blood.V97.6.1653; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; Geijsen N, 2001, SCIENCE, V293, P1136, DOI 10.1126/science.1059157; Guillard C, 2001, J BIOL CHEM, V276, P2007, DOI 10.1074/jbc.M003527200; Hinnen A, 1992, Biotechnology, V24, P337; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; KAUSHANSKY K, 1995, THROMB HAEMOSTASIS, V74, P521; Kaushansky K, 1997, STEM CELLS, V15, P97, DOI 10.1002/stem.5530150813; Kimura S, 1998, P NATL ACAD SCI USA, V95, P1195, DOI 10.1073/pnas.95.3.1195; Klockgether T, 1997, NAT MED, V3, P149, DOI 10.1038/nm0297-149; Koyano S, 1999, NEUROSCI LETT, V273, P117, DOI 10.1016/S0304-3940(99)00656-4; Lorenzetti D, 1997, NEUROLOGY, V49, P1009, DOI 10.1212/WNL.49.4.1009; Luoh SM, 2000, MOL CELL BIOL, V20, P507, DOI 10.1128/MCB.20.2.507-515.2000; Matsuda S, 1996, ONCOGENE, V12, P705; METHIA N, 1995, CR ACAD SCI III-VIE, V318, P479; Miyakawa Y, 2000, J BIOL CHEM, V275, P32214, DOI 10.1074/jbc.M005080200; Miyakawa Y, 1997, BLOOD, V89, P2789, DOI 10.1182/blood.V89.8.2789; Miyakawa Y, 2001, J BIOL CHEM, V276, P2494, DOI 10.1074/jbc.M002633200; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Porteu F, 1996, MOL CELL BIOL, V16, P2473; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; Rojnuckarin P, 1999, BLOOD, V94, P1273, DOI 10.1182/blood.V94.4.1273.416k04_1273_1282; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; Sahba S, 1998, GENOMICS, V47, P359, DOI 10.1006/geno.1997.5131; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Sattler M, 1997, J CELL PHYSIOL, V171, P28; Shibata H, 2000, HUM MOL GENET, V9, P1303, DOI 10.1093/hmg/9.9.1303; Solar GP, 1998, BLOOD, V92, P4, DOI 10.1182/blood.V92.1.4.413k38_4_10; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; Wallach D, 1998, CURR OPIN IMMUNOL, V10, P131, DOI 10.1016/S0952-7915(98)80240-9; Wendling F, 1998, EUR CYTOKINE NETW, V9, P221	50	22	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9139	9147		10.1074/jbc.M105970200	http://dx.doi.org/10.1074/jbc.M105970200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11784712	hybrid			2022-12-27	WOS:000174400600055
J	Mazurek, A; Berardini, M; Fishel, R				Mazurek, A; Berardini, M; Fishel, R			Activation of human MutS homologs by 8-oxo-guanine DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION-COUPLED REPAIR; MISMATCH-REPAIR; SACCHAROMYCES-CEREVISIAE; OXIDATIVE DAMAGE; MOLECULAR SWITCH; ESCHERICHIA-COLI; PROTEIN MUTS; OGG1 GENE; CLONING; CELLS	The DNA lesion 8-oxo-guanine (8-oxo-G) is a highly mutagenic product of the interaction between reactive oxygen species and DNA. To maintain genomic integrity, cells have evolved mechanisms capable of removing this frequently arising oxidative lesion. Mismatch repair (MMR) appears to be one pathway associated with the repair of 8-oxo-G lesions (DeWeese, T. L., Shipman, J. M., Larrier, N. A., Buckley, N. M., Kidd, L. R., Groopman, J. D., Cutler, R. G., te Riele, H., and Nelson, W. G. (1998) Proc. Natl. Acad. Sci. U. S. A 95, 11915-11920; Ni, T. T., Marsischky, G. T., and Kolodner, R. D. (1999) Mol. Cell 4, 439-444). Here we report the effect of double-stranded DNA oligonucleotides containing a single 8-oxo-G on the DNA binding affinity, ATPase, and ADP --> ATP exchange activities of hMSH2-hMSH6 and hMSH2-bMSH3. We found that hMSH2-hMSH6 binds the oligonucleotide DNA substrates with the following affinities: S-oxo-G/T > 8-oxo-G/G > 8-oxo-G/A > 8-oxo-G/C approximate to G/C. A similar trend was observed for DNA-stimulated ATPase and ADP --> ATP exchange activities of hMSH2-hMSH6. In contrast, hMSH2-hMSH3 did not appear to bind any of the 8-oxo-G containing DNA substrates nor was there enhanced ATPase or ADP --> ATP exchange activities. These results suggest that only hMSH2-hMSH6 is activated by recognition of 8-oxo-G lesions. Our data are consistent with the notion that post-replication MMR only participates in the repair of mismatched 8-oxo-G lesions.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Genet & Mol Biol Program, Philadelphia, PA 19107 USA	Jefferson University	Fishel, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Genet & Mol Biol Program, BLSB933,233 S 10th St, Philadelphia, PA 19107 USA.				NATIONAL CANCER INSTITUTE [R01CA067007, R01CA056542] Funding Source: NIH RePORTER; NCI NIH HHS [CA56542, CA67007, R01 CA067007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Berardini M, 2000, J BIOL CHEM, V275, P27851; Blackwell LJ, 2001, J BIOL CHEM, V276, P34339, DOI 10.1074/jbc.M104256200; Boldogh I, 2001, NUCLEIC ACIDS RES, V29, P2802, DOI 10.1093/nar/29.13.2802; BROWN TC, 1988, CELL, V54, P705, DOI 10.1016/S0092-8674(88)80015-1; Bruner SD, 1998, CURR BIOL, V8, P393, DOI 10.1016/S0960-9822(98)70158-7; CADET J, 1985, INT J RADIAT BIOL, V47, P127, DOI 10.1080/09553008514550201; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; DeWeese TL, 1998, P NATL ACAD SCI USA, V95, P11915, DOI 10.1073/pnas.95.20.11915; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Earley MC, 1998, P NATL ACAD SCI USA, V95, P15487, DOI 10.1073/pnas.95.26.15487; FANG WH, 1993, J BIOL CHEM, V268, P11838; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Fishel R, 2001, CANCER RES, V61, P7369; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gong JG, 1999, NATURE, V399, P806; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Hazra IK, 1998, NUCLEIC ACIDS RES, V26, P5116, DOI 10.1093/nar/26.22.5116; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; HUNTER WN, 1987, J BIOL CHEM, V262, P9962; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Leadon SA, 1997, CANCER RES, V57, P3784; LEONARD GA, 1990, P NATL ACAD SCI USA, V87, P9573, DOI 10.1073/pnas.87.24.9573; Loft S, 1996, J MOL MED, V74, P297, DOI 10.1007/BF00207507; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Marra G, 2001, P NATL ACAD SCI USA, V98, P7164, DOI 10.1073/pnas.121136498; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Ni TT, 1999, MOL CELL, V4, P439, DOI 10.1016/S1097-2765(00)80346-9; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; Scicchitano David A., 1997, Environmental Health Perspectives, V105, P145, DOI 10.2307/3433403; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; WAGNER JR, 1992, P NATL ACAD SCI USA, V89, P3380, DOI 10.1073/pnas.89.8.3380; WAGNER JR, 1990, METHOD ENZYMOL, V186, P502; Wilson T, 1999, J BIOL CHEM, V274, P21659, DOI 10.1074/jbc.274.31.21659; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; Zhang H, 1999, CANCER RES, V59, P3021	52	129	130	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8260	8266		10.1074/jbc.M111269200	http://dx.doi.org/10.1074/jbc.M111269200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11756455	hybrid			2022-12-27	WOS:000174268000082
J	Patzke, H; Tsai, LH				Patzke, H; Tsai, LH			Calpain-mediated cleavage of the cyclin-dependent kinase-5 activator p39 to p29	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL-SPECIFIC ACTIVATOR; CDK5 ACTIVATOR; NERVOUS-SYSTEM; EXPRESSION; PROTEASE; DEATH; PLASTICITY; PROTEINS; CASPASE	The activity of cyclin-dependent kinase-5 (Cdk5) is tightly regulated by binding of its neuronal activators p35 and p39. Upon neurotoxic insults, p35 is cleaved to p25 by the Ca2+-dependent protease calpain. p25 is ac. cumulated in ischemic brains and in brains of patients with Alzheimer's disease. p25 deregulates Cdk5 activity by causing prolonged activation and mislocalization of Cdk5. It is unknown whether p39, which is expressed throughout the adult rat brain, is cleaved by calpain, and whether this contributes to deregulation of Cdk5. Here, we show that calpain cleaved p39 in vitro, resulting in generation of a C-terminal p29 fragment. In vivo, p29 was generated in ischemic brain concomitant with increased calpain activity. In fresh brain lysates, generation of p29 was Ca2+-dependent, and calpain inhibitors abolished p29 production. The Ca2+ ionophore ionomycin and the excitotoxin glutamate induced production of p29 in cultures of cortical neurons in a calpain-dependent manner. Like p25, p29 was more stable than p39 and caused redistribution of Cdk5 in cortical neurons. Our data suggest that neurotoxic insults lead to calpain-mediated conversion of p39 to p29, which might contribute to deregulation of Cdk5.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Tsai, LH (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Armenise Bldg,Rm 342,200 Longwood Ave, Boston, MA 02115 USA.				NIGMS NIH HHS [GM 53049] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053049] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahlijanian MK, 2000, P NATL ACAD SCI USA, V97, P2910, DOI 10.1073/pnas.040577797; Alvarez A, 1999, FEBS LETT, V459, P421, DOI 10.1016/S0014-5793(99)01279-X; Bibb JA, 2001, NATURE, V410, P376, DOI 10.1038/35066591; Cai XH, 1997, NEUROSCI RES, V28, P355, DOI 10.1016/S0168-0102(97)00063-1; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.0.CO;2-K; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Humbert S, 2000, J CELL SCI, V113, P975; Humbert S, 2000, NEUROREPORT, V11, P2213, DOI 10.1097/00001756-200007140-00030; Ko J, 2001, J NEUROSCI, V21, P6758; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Matus A, 2000, SCIENCE, V290, P754, DOI 10.1126/science.290.5492.754; MOLINARI M, 1995, J BIOL CHEM, V270, P14576, DOI 10.1074/jbc.270.24.14576; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Nguyen MD, 2001, NEURON, V30, P135, DOI 10.1016/S0896-6273(01)00268-9; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Nixon RA, 2000, ANN NY ACAD SCI, V924, P117; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Pariat M, 2000, BIOCHEM J, V345, P129, DOI 10.1042/0264-6021:3450129; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; Sabatini BL, 2001, CURR OPIN NEUROBIOL, V11, P349, DOI 10.1016/S0959-4388(00)00218-X; SASAKI T, 1984, J BIOL CHEM, V259, P2489; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; SIESJO BK, 1978, BRAIN ENERGY METABOL, P454; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; Taniguchi S, 2001, FEBS LETT, V489, P46, DOI 10.1016/S0014-5793(00)02431-5; Tarricone C, 2001, MOL CELL, V8, P657, DOI 10.1016/S1097-2765(01)00343-4; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Van den Haute C, 2001, NEUROBIOL DIS, V8, P32, DOI 10.1006/nbdi.2000.0333; Wang K., 1999, CALPAIN, P179; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Zheng M, 1998, J NEUROBIOL, V35, P141, DOI 10.1002/(SICI)1097-4695(199805)35:2<141::AID-NEU2>3.0.CO;2-4	45	106	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8054	8060		10.1074/jbc.M109645200	http://dx.doi.org/10.1074/jbc.M109645200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11784720	hybrid			2022-12-27	WOS:000174268000055
J	Delehedde, M; Lyon, M; Vidyasagar, R; McDonnell, TJ; Fernig, DG				Delehedde, M; Lyon, M; Vidyasagar, R; McDonnell, TJ; Fernig, DG			Hepatocyte growth factor/scatter factor binds to small heparin-derived oligosaccharides and stimulates the proliferation of human HaCaT keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; FIBROBLAST-GROWTH; SULFATE PROTEOGLYCANS; FACTOR REVEALS; RECEPTOR; HGF/SF; INHIBITOR; CHLORATE; DOMAINS; NK1	Hepatocyte growth factor/scatter factor (HGF/SF) acts via a dual receptor system consisting of the MET tyrosine kinase receptor and heparan sulfate or dermatan sulfate proteoglycans. In optical biosensor binding assays, competition by oligosaccharides for binding of HGF/SF to immobilized heparin showed that disaccharides failed to compete, whereas tetrasaccharides inhibited HGF/SF binding (IC50 8 mug/ml). The inhibitory potency of the oligosaccharides increased as their length increased by successive disaccharide units, to reach a maximum (IC50 1 mug/ml) at degree of polymerization (dp) 10. In binding assays, HGF/SF was found to bind directly to oligosaccharides as small as dp 4, and the binding parameters were similar for oligosaccharides of dp 4-14 (k(alpha) 2.2-45.3 x 10(6) M-1 s(-1), k(d) 0.033-0.039 s(-1), and K-d 9-16 nM). In human keratinocytes, HGF/SF stimulated DNA synthesis, and this was dependent on a sustained phosphorylation of p42/44(MAPK). In chlorate-treated and hence sulfated glycosaminoglycan-deficient HaCaT cells, the stimulation of DNA synthesis by HGF/SF was almost abolished. Heparin-derived oligosaccharides from dp 2 to dp 24 were added together with HGF/SF to chlorate-treated cells to determine the minimum size of oligosaccharides able to restore HGF/SF activity. At restricted concentrations of oligosaccharides (4 ng/ml), HGF/SF required decasaccharides, whereas at higher concentrations (100 ng/ml) even tetrasaccharides were able to partly restore DNA synthesis. The results suggest that HGF/SF binds to a tetrasaccharide and that although this is sufficient to enable the stimulation of DNA synthesis, longer oligosaccharides are more efficient, perhaps by virtue of their ability to bind more easily other molecules.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Univ Manchester, Christie Hosp Natl Hlth Serv Trust, Canc Res Campaign, Dept Med Oncol, Manchester M20 4BX, Lancs, England; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Liverpool; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; University of Texas System; UTMD Anderson Cancer Center	Delehedde, M (corresponding author), Univ Liverpool, Sch Biol Sci, Life Sci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.	dgfernig@liv.ac.uk	Fernig, David G/A-3590-2008	Fernig, David G/0000-0003-4875-4293; Lyon, Malcolm/0000-0001-9575-6879; DELEHEDDE, Maryse/0000-0003-2724-143X	NCI NIH HHS [P01 CA68233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA068233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; Bechard D, 2001, J BIOL CHEM, V276, P48341, DOI 10.1074/jbc.M108395200; BELLUSCI S, 1994, J CELL SCI, V107, P1277; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Boukamp P, 1997, GENE CHROMOSOME CANC, V19, P201, DOI 10.1002/(SICI)1098-2264(199708)19:4<201::AID-GCC1>3.0.CO;2-0; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Boukamp P, 1999, ONCOGENE, V18, P5638, DOI 10.1038/sj.onc.1202934; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Chirgadze DY, 1999, NAT STRUCT BIOL, V6, P72; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; Comoglio PM, 2001, SEMIN CANCER BIOL, V11, P153, DOI 10.1006/scbi.2000.0366; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deakin JA, 1999, J CELL SCI, V112, P1999; Delehedde M, 2000, J BIOL CHEM, V275, P33905, DOI 10.1074/jbc.M005949200; Delehedde M, 2001, J INVEST DERMATOL, V116, P366, DOI 10.1046/j.1523-1747.2001.01260.x; Delehedde M, 2001, J MAMMARY GLAND BIOL, V6, P253, DOI 10.1023/A:1011367423085; Delehedde M, 2001, EUR J BIOCHEM, V268, P4423, DOI 10.1046/j.1432-1327.2001.02363.x; Delehedde M, 1996, EXP CELL RES, V229, P398, DOI 10.1006/excr.1996.0385; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fernig D G, 2001, Methods Mol Biol, V171, P505; Gallagher JT, 2000, PROTEOGLYCANS STRUCT, P27; GREVE H, 1988, J BIOL CHEM, V263, P12886; Hartmann G, 1998, CURR BIOL, V8, P125, DOI 10.1016/S0960-9822(98)70059-4; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; Kinsella L, 1998, GLYCOCONJUGATE J, V15, P419, DOI 10.1023/A:1006986104865; Lietha D, 2001, EMBO J, V20, P5543, DOI 10.1093/emboj/20.20.5543; LYON M, 1994, J BIOL CHEM, V269, P11216; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Lyon M, 2002, J BIOL CHEM, V277, P1040, DOI 10.1074/jbc.M107506200; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; Rahmoune H, 1998, BIOCHEMISTRY-US, V37, P6003, DOI 10.1021/bi972468t; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rosen EM, 1997, CIBA F SYMP, V212, P215; Rubin JS, 2001, J BIOL CHEM, V276, P32977, DOI 10.1074/jbc.M105486200; Sadir R, 1998, J BIOL CHEM, V273, P10919, DOI 10.1074/jbc.273.18.10919; Safaiyan F, 1999, J BIOL CHEM, V274, P36267, DOI 10.1074/jbc.274.51.36267; Sakata H, 1997, J BIOL CHEM, V272, P9457; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; Sergeant N, 2000, J BIOL CHEM, V275, P17094, DOI 10.1074/jbc.M000237200; Stuart KA, 2000, INT J EXP PATHOL, V81, P17, DOI 10.1046/j.1365-2613.2000.00138.x; To CTT, 1998, ONCOL REP, V5, P1013; Trusolino L, 1998, FASEB J, V12, P1267, DOI 10.1096/fasebj.12.13.1267; Zhou HJ, 1999, BIOCHEMISTRY-US, V38, P14793, DOI 10.1021/bi9908641; Zhou HJ, 1998, STRUCTURE, V6, P109, DOI 10.1016/S0969-2126(98)00012-4; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	49	45	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12456	12462		10.1074/jbc.M111345200	http://dx.doi.org/10.1074/jbc.M111345200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11799124	hybrid			2022-12-27	WOS:000174846400112
J	Brin, E; Leis, J				Brin, E; Leis, J			Changes in the mechanism of DNA integration in vitro induced by base substitutions in the HIV-1U5 and U3 terminal sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; FULL-SITE INTEGRATION; RETROVIRUS-LIKE DNA; VIRAL-DNA; CONCERTED INTEGRATION; CATALYTIC DOMAIN; PROTEIN; ENDS; U5; BINDING	We have reconstituted concerted human immunodeficiency virus type 1 (HIV-1) integration with specially designed mini-donor DNA, a supercoiled plasmid acceptor, purified bacterial-derived HIV-1 integrase (IN), and host HMG-I(Y) protein (Hindmarsh, P., Ridky, T., Reeves, R., Andrake, M., Skalka, A. M., and Leis, J. (1999) J. Virol. 73, 2994-3003). Integration in this system is dependent upon the mini donor DNA having IN recognition sequences at both ends and the reaction products have all of the features associated with integration of viral DNA in vivo. Using this system, we explored the relationship between the HIV-1 U3 and U5 IN recognition sequences by analyzing substrates that contain either two U3 or two U5 terminal sequences. Both substrates caused severe defects to integration but with different effects on the mechanism indicating that the U3 and the U5 sequences are both required for concerted DNA integration. We have also used the reconstituted system to compare the mechanism of integration catalyzed by HIV-1 to that of avian sarcoma virus by analyzing the effect of defined mutations introduced into U3 or U5 ends of the respective wild type DNA substrates. Despite sequence differences between avian sarcoma virus and HIV-1 IN and their recognition sequences, the consequences of analogous base pair substitutions at the same relative positions of the respective IN recognition sequences were very similar. This highlights the common mechanism of integration shared by these two different viruses.	Northwestern Univ, Sch Med, Dept Microbiol & Immunol, Chicago, IL 60611 USA	Northwestern University	Leis, J (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol & Immunol, 303 E Chicago Ave, Chicago, IL 60611 USA.	j-leis@northwestern.edu			NCI NIH HHS [CA52047, CA38046] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052047, R01CA038046] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aiyar A, 1996, J VIROL, V70, P3571, DOI 10.1128/JVI.70.6.3571-3580.1996; Brown HEV, 1999, J VIROL, V73, P9011, DOI 10.1128/JVI.73.11.9011-9020.1999; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; Cherepanov P, 1999, NUCLEIC ACIDS RES, V27, P2202, DOI 10.1093/nar/27.10.2202; COBRINIK D, 1991, J VIROL, V65, P3864, DOI 10.1128/JVI.65.7.3864-3872.1991; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; FITZGERALD ML, 1992, J VIROL, V66, P6257, DOI 10.1128/JVI.66.11.6257-6263.1992; FITZGERALD ML, 1991, ANAL BIOCHEM, V196, P19, DOI 10.1016/0003-2697(91)90111-6; GOODARZI G, 1995, J VIROL, V69, P6090, DOI 10.1128/JVI.69.10.6090-6097.1995; Heuer TS, 1998, BIOCHEMISTRY-US, V37, P6667, DOI 10.1021/bi972949c; Heuer TS, 1997, BIOCHEMISTRY-US, V36, P10655, DOI 10.1021/bi970782h; Hindmarsh P, 1999, J VIROL, V73, P2994, DOI 10.1128/JVI.73.4.2994-3003.1999; Hindmarsh P, 1999, MICROBIOL MOL BIOL R, V63, P836, DOI 10.1128/MMBR.63.4.836-843.1999; Hindmarsh P, 2001, J VIROL, V75, P1132, DOI 10.1128/JVI.75.3.1132-1141.2001; JONES KS, 1992, J BIOL CHEM, V267, P16037; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; Katzman M, 1999, ADV VIRUS RES, V52, P371, DOI 10.1016/S0065-3527(08)60307-3; KUKOLJ G, 1995, GENE DEV, V9, P2556, DOI 10.1101/gad.9.20.2556; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; Masuda T, 1998, J VIROL, V72, P8396, DOI 10.1128/JVI.72.10.8396-8402.1998; MURPHY JE, 1992, J VIROL, V66, P5092, DOI 10.1128/JVI.66.8.5092-5095.1992; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; VANGENT DC, 1991, NUCLEIC ACIDS RES, V19, P3821, DOI 10.1093/nar/19.14.3821; VINCENT KA, 1990, NUCLEIC ACIDS RES, V18, P6045, DOI 10.1093/nar/18.20.6045; Vora A, 2001, J VIROL, V75, P3556, DOI 10.1128/JVI.75.8.3556-3567.2001; VORA AC, 1995, J VIROL, V69, P7483, DOI 10.1128/JVI.69.12.7483-7488.1995; Vora AC, 1997, J BIOL CHEM, V272, P23938, DOI 10.1074/jbc.272.38.23938; VORA AC, 1994, NUCLEIC ACIDS RES, V22, P4454, DOI 10.1093/nar/22.21.4454; Wei SQ, 1998, P NATL ACAD SCI USA, V95, P10535, DOI 10.1073/pnas.95.18.10535; Yang ZN, 2000, J MOL BIOL, V296, P535, DOI 10.1006/jmbi.1999.3463; Zhou HB, 2001, J VIROL, V75, P1359, DOI 10.1128/JVI.75.3.1359-1370.2001	36	13	14	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10938	10948		10.1074/jbc.M108116200	http://dx.doi.org/10.1074/jbc.M108116200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11788585	hybrid			2022-12-27	WOS:000174613100025
J	Gewurz, BE; Ploegh, HL; Tortorella, D				Gewurz, BE; Ploegh, HL; Tortorella, D			US2, a human cytomegalovirus-encoded type I membrane protein, contains a non-cleavable amino-terminal signal peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ENDOPLASMIC-RETICULUM; SEQUENCE RECOGNITION; INTERNAL SIGNAL; TRANSPORT; ER; EFFICIENCY; LIMITS; IDENTIFICATION; TRANSLOCON	The human cytomegalovirus US2 gene product targets major histocompatibility class I molecules for degradation in a proteasome-dependent fashion. Degradation requires interaction between the endoplasmic reticulum (ER) lumenal domains of US2 and class I. While ER insertion of US2 is essential for US2 function, US2 lacks a cleavable signal peptide. Radiosequence analysis of glycosylated US2 confirms the presence of the NH2 terminus predicted on the basis of the amino acid sequence, with no evidence for processing by signal peptidase. Despite the absence of cleavage, the US2 NH2-terminal segment constitutes its signal peptide and is sufficient to drive ER translocation of chimeric reporter proteins, again without further cleavage. The putative US2 signal peptide c-region is responsible for the absence of cleavage, despite the presence of a suitable -3,-1 amino acid motif for signal peptidase recognition. In addition, the US2 signal peptide affects the early processing events of the nascent polypeptide, altering the efficiency of ER insertion and subsequent N-linked glycosylation. To our knowledge, US2 is the first example of a membrane protein that does not contain a cleavable signal peptide, yet otherwise behaves like a type I membrane glycoprotein.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Ploegh, HL (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave,Armenise Bldg,Rm 137, Boston, MA 02115 USA.	ploegh@hms.harvard.edu		Tortorella, Domenico/0000-0003-0961-3535	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI033456] Funding Source: NIH RePORTER; NIAID NIH HHS [5R37-AI33456] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Belin D, 1996, EMBO J, V15, P468, DOI 10.1002/j.1460-2075.1996.tb00379.x; Bellovino D, 2001, J BIOL CHEM, V276, P13949, DOI 10.1074/jbc.M006779200; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; FOLZ RJ, 1986, J BIOL CHEM, V261, P4752; FOLZ RJ, 1988, J BIOL CHEM, V263, P2070; Furman MH, 2002, J BIOL CHEM, V277, P3258, DOI 10.1074/jbc.M109765200; Gewurz BE, 2001, P NATL ACAD SCI USA, V98, P6794, DOI 10.1073/pnas.121172898; Hegde RS, 1999, TRENDS CELL BIOL, V9, P132, DOI 10.1016/S0962-8924(99)01504-4; HEGNER M, 1992, J BIOL CHEM, V267, P16928; Heinrich SU, 2000, CELL, V102, P233, DOI 10.1016/S0092-8674(00)00028-3; Huppa JB, 1997, J EXP MED, V186, P393, DOI 10.1084/jem.186.3.393; JAIN RG, 1994, J BIOL CHEM, V269, P16305; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; Keenan RJ, 1998, CELL, V94, P181, DOI 10.1016/S0092-8674(00)81418-X; LINGAPPA VR, 1979, NATURE, V281, P117, DOI 10.1038/281117a0; Lurain NS, 1999, J VIROL, V73, P10040, DOI 10.1128/JVI.73.12.10040-10050.1999; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; Miyakawa K, 1999, J BIOL CHEM, V274, P29352, DOI 10.1074/jbc.274.41.29352; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; NOTHWEHR SF, 1989, J BIOL CHEM, V264, P3979; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; PLOEGH HL, 1995, CURRENT PROTOCOLS PR; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Rehm A, 2001, EMBO J, V20, P1573, DOI 10.1093/emboj/20.7.1573; Revest JM, 2000, J BIOL CHEM, V275, P8083, DOI 10.1074/jbc.275.11.8083; RUSSEL M, 1981, P NATL ACAD SCI-BIOL, V78, P1717, DOI 10.1073/pnas.78.3.1717; Rutkowski DT, 2001, P NATL ACAD SCI USA, V98, P7823, DOI 10.1073/pnas.141125098; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; Soriano S, 1997, BIOCHEM J, V324, P579, DOI 10.1042/bj3240579; TABE L, 1984, J MOL BIOL, V180, P645, DOI 10.1016/0022-2836(84)90031-7; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Tortorella D, 1998, J CELL BIOL, V142, P365, DOI 10.1083/jcb.142.2.365; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; von Heijne G, 1998, NATURE, V396, P111, DOI 10.1038/24036; VONHEIJNE G, 1991, J BIOL CHEM, V266, P15240; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Zheng T, 1999, J BIOL CHEM, V274, P36623, DOI 10.1074/jbc.274.51.36623	45	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11306	11313		10.1074/jbc.M107904200	http://dx.doi.org/10.1074/jbc.M107904200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11790769	hybrid			2022-12-27	WOS:000174613100071
J	Kawata, Y; Suzuki, H; Higaki, Y; Denisenko, O; Schullery, D; Abrass, C; Bomsztyk, K				Kawata, Y; Suzuki, H; Higaki, Y; Denisenko, O; Schullery, D; Abrass, C; Bomsztyk, K			bcn-1 element-dependent activation of the laminin gamma 1 chain gene by the cooperative action of transcription factor E3 (TFE3) and Smad proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; NUCLEAR RIBONUCLEOPROTEIN K; BETA-INDUCED TRANSCRIPTION; LEUCINE-ZIPPER PROTEINS; DNA-BINDING; BASEMENT-MEMBRANES; PROMOTER; EXPRESSION; FUSION; SP1	Laminin is a major component of the extracellular matrix. The laminin gamma1 chain is the least variant component of the laminin heterotrimeric assembly. The laminin gamma1 chain gene (LAMC1) expression is induced by several factors, including transforming growth factor-P (TGF-beta). LAMC1 promoter contains a highly conserved transcriptional element, bcn-1. We screened cDNA libraries with the yeast one-hybrid system to identify transcriptional factors that are recognized by the bcn-1 motif. Using this strategy we isolated the basic helix-loop-helix/leucine zipper (bHLHzip) E-box-binding transcription factor, TFE3. Until now, the E-box was the only element known to recruit the bHLHzip transcription factors. Although the bcn-1 element only remotely resembles the E-box sequence, we show that TFE3 binds and activates the bcn-1 element. TFE3 cooperates with Smad proteins in the activation of the LAMC1 promoter in cells, an effect that is critically dependent not only on the bcn-1 element but also on one of the Smad-binding elements (SBE). The cooperative induction of the LAMC1 promoter and the endogenous LAMC1 gene by TFE3 and Smad3 is augmented by the TGF-beta signaling pathway. Thus, the bcn-1 is a novel TFE3-dependent TGF-beta target element that regulates LAMC1 gene expression.	Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Bomsztyk, K (corresponding author), Univ Washington, Dept Med, Div Nephrol, Box 356521, Seattle, WA 98195 USA.	karolb@u.washington.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045978, R37DK045978] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45978] Funding Source: Medline; NIGMS NIH HHS [GM45134] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSON DR, 1993, KIDNEY INT, V43, P73, DOI 10.1038/ki.1993.13; ABRASS CK, 1995, KIDNEY INT, V47, P25, DOI 10.1038/ki.1995.3; ADLER S, 1986, J CLIN INVEST, V77, P762, DOI 10.1172/JCI112372; ARTANDI SE, 1994, MOL CELL BIOL, V14, P7704, DOI 10.1128/MCB.14.12.7704; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Carter RS, 1997, MOL CELL BIOL, V17, P18, DOI 10.1128/MCB.17.1.18; Choi ME, 2000, KIDNEY INT, V58, pS53, DOI 10.1046/j.1523-1755.2000.07709.x; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; Deutzmann Rainer, 1995, P41; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER DE, 1992, P NATL ACAD SCI USA, V89, P11779, DOI 10.1073/pnas.89.24.11779; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; Hansen K, 1999, PATHOBIOLOGY, V67, P84, DOI 10.1159/000028055; Heimann P, 2001, CANCER RES, V61, P4130; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hill CS, 1996, CELL SIGNAL, V8, P533, DOI 10.1016/S0898-6568(96)00122-2; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KALLUNKI T, 1991, J BIOL CHEM, V266, P221; Kedar V, 1997, MOL BRAIN RES, V47, P87, DOI 10.1016/S0169-328X(97)00062-4; Kedar Vishram, 1996, Indian Journal of Experimental Biology, V34, P939; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Lietard J, 1997, AM J PATHOL, V151, P1663; Luo X, 1996, MOL CELL BIOL, V16, P1367; Marmillot P, 1998, BBA-GENE STRUCT EXPR, V1395, P228, DOI 10.1016/S0167-4781(97)00153-X; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Murray P, 2000, J CELL BIOL, V150, P1215, DOI 10.1083/jcb.150.5.1215; OGAWA K, 1988, J BIOL CHEM, V263, P8384; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; ONeill BC, 1997, AM J PHYSIOL-RENAL, V273, pF411, DOI 10.1152/ajprenal.1997.273.3.F411; Ostrowski J, 2000, J BIOL CHEM, V275, P3619, DOI 10.1074/jbc.275.5.3619; Parks CL, 1996, J BIOL CHEM, V271, P4417; Phillips SL, 1999, DIABETES, V48, P2083, DOI 10.2337/diabetes.48.10.2083; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; RICHARDSON CA, 1995, AM J PHYSIOL-RENAL, V268, pF273, DOI 10.1152/ajprenal.1995.268.2.F273; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shnyreva M, 2000, J BIOL CHEM, V275, P15498, DOI 10.1074/jbc.275.20.15498; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; Suzuki H, 1998, AM J PHYSIOL-RENAL, V275, pF518, DOI 10.1152/ajprenal.1998.275.4.F518; Suzuki H, 1996, J BIOL CHEM, V271, P18981, DOI 10.1074/jbc.271.31.18981; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Tunggal P, 2000, MICROSC RES TECHNIQ, V51, P214, DOI 10.1002/1097-0029(20001101)51:3<214::AID-JEMT2>3.0.CO;2-J; Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097-2765(01)00360-4; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 2000, ONCOGENE, V19, P69, DOI 10.1038/sj.onc.1203255; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505	59	15	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11375	11384		10.1074/jbc.M111284200	http://dx.doi.org/10.1074/jbc.M111284200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801598	hybrid			2022-12-27	WOS:000174613100080
J	Phillips, RS; Ramso, SBV; Blackshear, PJ				Phillips, RS; Ramso, SBV; Blackshear, PJ			Members of the tristetraprolin family of tandem CCCH zinc finger proteins exhibit CRM1-dependent nucleocytoplasmic shuttling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; AU-RICH ELEMENTS; MESSENGER-RNA DEGRADATION; EARLY-RESPONSE GENES; CYTOPLASMIC LOCALIZATION; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; BINDING PROTEIN; HUMAN HOMOLOG; PORE COMPLEX	Members of the tristetraprolin (TTP) family of CCCH tandem zinc finger proteins can bind directly to certain types of AU-rich elements (AREs) in mRNA. Experiments in TTP-deficient mice have shown that TTP is involved in the physiological destabilization of at least two cytokine mRNAs, those encoding tumor necrosis factor a and granulocyte-macrophage colony-stimulating factor. The two other known mammalian members of the TTP family, CMG1 and TIS11D, also contain ARE-binding CCCH tandem zinc finger domains and can also destabilize ARE-containing mRNAs. To investigate the effects of primary sequence on the subcellular localization of these proteins, we constructed green fluorescent protein fusions with TTP, CMG1, and TIS11D; these were predominantly cytoplasmic when expressed in 293 or HeLa cells. Deletion and mutation analyses revealed functional nuclear export signals in the amino terminus of TTP and in the carboxyl termini of CMG1 and TIS11D. This type of leucine-rich nuclear export signal interacts with the nuclear export receptor CRM1; abrogation of CRM1 activity resulted in nuclear accumulation of TTP, CMG1, and TIS11D. These proteins are thus nucleocytoplasmic shuttling proteins and rely on CRM1 for their export from the nucleus. Although TTP, CMG1, and TIS11D lack known nuclear import sequences, mapping experiments revealed that their nuclear accumulation required an intact tandem zinc finger domain but did not require RNA binding ability. These findings suggest possible roles for nuclear import and export in the regulation of cellular TTP, CMG1, and TIS11D activity.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Off Clin Res & Lab Signal Transduct, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University; Duke University	Blackshear, PJ (corresponding author), NIEHS, Lab Signal Transduct, NIH, A2-05,111 Alexander Dr, Res Triangle Pk, NC 27709 USA.		Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090080, Z01ES090080] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allen TD, 2000, J CELL SCI, V113, P1651; Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; Askjaer P, 1999, MOL CELL BIOL, V19, P6276; Begitt A, 2000, P NATL ACAD SCI USA, V97, P10418, DOI 10.1073/pnas.190318397; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Bogerd HP, 1998, J VIROL, V72, P8627, DOI 10.1128/JVI.72.11.8627-8635.1998; BUSTIN SA, 1994, DNA CELL BIOL, V13, P449, DOI 10.1089/dna.1994.13.449; Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Coburn GA, 2001, GENE DEV, V15, P1194, DOI 10.1101/gad.888201; Cullen BR, 2000, MOL CELL BIOL, V20, P4181, DOI 10.1128/MCB.20.12.4181-4187.2000; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Dobner T, 2001, CURR TOP MICROBIOL, V259, P25; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fornerod M, 1997, CELL, V90, P1051; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gaubatz S, 2001, MOL CELL BIOL, V21, P1384, DOI 10.1128/MCB.21.4.1384-1392.2001; GOMPERTS M, 1990, ONCOGENE, V5, P1081; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Hammarskjold ML, 2001, CURR TOP MICROBIOL, V259, P77; Hauber J, 2001, CURR TOP MICROBIOL, V259, P55; HEXIMER SP, 1993, DNA CELL BIOL, V12, P73, DOI 10.1089/dna.1993.12.73; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Kim FJ, 1996, MOL CELL BIOL, V16, P5147; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Lai WS, 2001, J BIOL CHEM, V276, P23144, DOI 10.1074/jbc.M100680200; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; Lai WS, 1998, J BIOL CHEM, V273, P506, DOI 10.1074/jbc.273.1.506; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; Maclean KN, 1998, BRIT J BIOMED SCI, V55, P184; MACLEAN KN, 1995, GENOMICS, V30, P89, DOI 10.1006/geno.1995.0014; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Mohamed AJ, 2000, J BIOL CHEM, V275, P40614, DOI 10.1074/jbc.M006952200; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; NIE XF, 1995, GENE, V152, P285, DOI 10.1016/0378-1119(94)00696-P; Ning ZQ, 1996, EUR J IMMUNOL, V26, P2356, DOI 10.1002/eji.1830261013; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V19, P3454, DOI 10.1093/nar/19.12.3454; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, ONCOGENE, V4, P119; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	73	86	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11606	11613		10.1074/jbc.M111457200	http://dx.doi.org/10.1074/jbc.M111457200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11796723	hybrid			2022-12-27	WOS:000174613100109
J	Yan, CH; Wang, H; Boyd, DD				Yan, CH; Wang, H; Boyd, DD			ATF3 represses 72-kDa type IV collagenase (MMP-2) expression by antagonizing p53-dependent trans-activation of the collagenase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; NF-KAPPA-B; TRANSCRIPTION FACTORS; GENE-EXPRESSION; MATRIX METALLOPROTEINASES; METASTASIS; BINDING; PROTEIN; SP1; PHOSPHORYLATION	The murine homologue of the ATF3 transcription factor increases tumor metastases but, surprisingly, represses 72-kDa type IV metalloproteinase (MMP-2) expression. The current study describes a novel mechanism by which ATF3 regulates transcription. Progressive deletions of the MMP-2 promoter indicated a 38-base pair region (-1659/-1622) necessary for the ATF3-mediated repression. This region lacked CREB/ AP-1 motifs but contained a consensus p53 motif shown previously to regulate MMP-2 expression. The activity of a p53 response element-driven luciferase reporter was reduced in ATF3-expressing HT1080 clones. Although MMP-2 promoter activity was not repressed by ATF3 in p53-deficient Saos-2 cells, p53 re-expression increased MMP-2 promoter activity and restored the sensitivity to ATF3. The activity of a GAL4-driven reporter in HT1080 cells co-expressing the full-length p53 sequence fused to the GAL4 DNA binding domain was diminished by ATF3 p53-ATF3 protein-protein interactions were demonstrated both in vivo and in vitro. Cell cycle analysis, performed as an independent assay of p53 function, revealed that gamma-irradiation-induced slowed G(2)/M cell. cycle progression (attributable to p53) was countered by ATF3. Thus, ATF3 represses MMP-2 expression by decreasing the trans-activation of this gene by p53.	MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Boyd, DD (corresponding author), MD Anderson Canc Ctr, Dept Canc Biol, Box 179,1515 Holcombe Blvd, Houston, TX 77030 USA.	dboyd@mdanderson.org		Yan, Chunhong/0000-0002-3974-7991	NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845, P50DE011906] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58311] Funding Source: Medline; NIDCR NIH HHS [P50 DE11906-01, R01 DE10845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; Agarwal ML, 2001, ONCOGENE, V20, P2527, DOI 10.1038/sj.onc.1204353; Allen-Jennings AE, 2001, J BIOL CHEM, V276, P29507, DOI 10.1074/jbc.M100986200; AMICI C, 1989, INT J CANCER, V43, P171, DOI 10.1002/ijc.2910430131; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Blaydes JP, 2001, J BIOL CHEM, V276, P4699, DOI 10.1074/jbc.M003485200; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; FRISCH SM, 1990, ONCOGENE, V5, P75; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Hai T, 1999, GENE EXPRESSION, V7, P321; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hasan S, 1999, BIOCHEM BIOPH RES CO, V258, P663, DOI 10.1006/bbrc.1999.0661; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Hua J, 1996, CANCER RES, V56, P5279; Ishiguro T, 1996, CANCER RES, V56, P875; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jean D, 2000, MOL CELL BIOCHEM, V212, P19, DOI 10.1023/A:1007128101751; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Kupferman ME, 2000, AM J PATHOL, V157, P1777, DOI 10.1016/S0002-9440(10)64815-8; Levrero M, 2000, J CELL SCI, V113, P1661; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; Moses MA, 1998, CANCER RES, V58, P1395; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Nawa T, 2000, BIOCHEM BIOPH RES CO, V275, P406, DOI 10.1006/bbrc.2000.3332; NEAD MA, 1995, J INVEST DERMATOL, V105, P668, DOI 10.1111/1523-1747.ep12324367; Paulson TG, 1998, MOL CELL BIOL, V18, P3089, DOI 10.1128/MCB.18.5.3089; Peng YC, 2001, MOL CELL BIOL, V21, P5913, DOI 10.1128/MCB.21.17.5913-5924.2001; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Prives C, 1999, J PATHOL, V187, P112; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; RADINSKY R, 1994, ONCOGENE, V9, P1877; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; SUN Y, 1993, FASEB J, V7, P944, DOI 10.1096/fasebj.7.10.8344492; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; WATSON SA, 1995, CANCER RES, V55, P3629; Wiederschain D, 2001, J BIOL CHEM, V276, P27999, DOI 10.1074/jbc.M102400200; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Yan CH, 2001, J BIOL CHEM, V276, P1164, DOI 10.1074/jbc.M008681200; Zimmermann J, 2000, ONCOGENE, V19, P2913, DOI 10.1038/sj.onc.1203606	53	84	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10804	10812		10.1074/jbc.M112069200	http://dx.doi.org/10.1074/jbc.M112069200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11792711	hybrid			2022-12-27	WOS:000174613100010
J	Yoo, JS; Moyer, BD; Bannykh, S; Yoo, HM; Riordan, JR; Balch, WE				Yoo, JS; Moyer, BD; Bannykh, S; Yoo, HM; Riordan, JR; Balch, WE			Non-conventional trafficking of the cystic fibrosis transmembrane conductance regulator through the early secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ATPASE; CFTR CHLORIDE CHANNELS; ENDOPLASMIC-RETICULUM; VESICULAR TRANSPORT; COPII VESICLES; SYNTAXIN 8; TRANSIENT-EXPRESSION; EPITHELIAL-CELLS; CARGO SELECTION; GOLGI TRANSPORT	The mechanism(s) of cystic fibrosis transmembrane conductance regulator (CFTR) trafficking from the endoplasmic reticulum (ER) through the Golgi apparatus, the step impaired in individuals afflicted with the prevalent CFTR-DeltaF508 mutation leading to cystic fibrosis, is largely unknown. Recent morphological observations suggested that CFTR is largely absent from the Golgi in situ (Bannykh, S. I., Bannykh, G. L, Fish, K. N., Moyer, B. D., Riordan, J. R., and Balch, W. E. (2000) Traffic 1, 852-870), raising the possibility of a novel trafficking pathway through the early secretory pathway. We now report that export of CFTR from the ER is regulated by the conventional coat protein complex II (COPII) in all cell types tested. Remarkably, in a cell type-specific manner, processing of CFTR from the core-glycosylated (band B) ER form to the complex-glycosylated (band Q isoform. followed a non-conventional pathway that was insensitive to dominant negative Arf1, Rab1a/Rab2 GTPases, or the SNAP REceptor (SNARE) component syntaxin 5, all of which block the conventional trafficking pathway from the ER to the Golgi. Moreover, CFTR transport through the non-conventional pathway was potently blocked by overexpression of the late endosomal target-SNARE syntaxin 13, suggesting that recycling through a late Golgi/endosomal system was a prerequisite for CFTR maturation. We conclude that CFTR transport in the early secretory pathway can involve a novel pathway between the ER and late Golgi/endosomal compartments that may influence developmental expression of CFTR on the cell surface in polarized epithelial cells.	Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA 92037 USA; Mayo Clin, Mayo Fdn & SC Johnson Med Res Ctr, Scottsdale, AZ 85259 USA	Scripps Research Institute; Mayo Clinic; Mayo Clinic Phoenix	Balch, WE (corresponding author), Scripps Res Inst, Dept Cell & Mol Biol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	webalch@scripps.edu			NIDDK NIH HHS [DK 51870] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051870] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Aridor M, 1999, J BIOL CHEM, V274, P4389, DOI 10.1074/jbc.274.7.4389; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Aridor M, 2000, J BIOL CHEM, V275, P35673, DOI 10.1074/jbc.C000449200; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Bannykh SI, 2000, TRAFFIC, V1, P852, DOI 10.1034/j.1600-0854.2000.011105.x; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bradbury NA, 1999, PHYSL REV S, V79, P175, DOI DOI 10.1152/physrev.1999.79.1.S175; Chang XB, 1999, MOL CELL, V4, P137, DOI 10.1016/S1097-2765(00)80196-3; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CLAYSON ET, 1989, J VIROL, V63, P2278, DOI 10.1128/JVI.63.5.2278-2288.1989; Dascher C, 1996, J BIOL CHEM, V271, P15866, DOI 10.1074/jbc.271.27.15866; DASCHER C, 1994, J BIOL CHEM, V269, P29363; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DASCHER C, 1995, METHOD ENZYMOL, V257, P165; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FUKUDA M, 1984, BIOCHIM BIOPHYS ACTA, V780, P119, DOI 10.1016/0304-419X(84)90002-7; Ghosh S, 1999, MOL BIOL CELL, V10, P455, DOI 10.1091/mbc.10.2.455; Gilbert A, 1998, EXP CELL RES, V242, P144, DOI 10.1006/excr.1998.4101; Girod A, 1999, NAT CELL BIOL, V1, P423, DOI 10.1038/15658; GOTTLIEB C, 1975, J BIOL CHEM, V250, P3303; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; Herman EM, 1999, PLANT CELL, V11, P601, DOI 10.1105/tpc.11.4.601; Hirling H, 2000, EUR J NEUROSCI, V12, P1913, DOI 10.1046/j.1460-9568.2000.00076.x; Howard M, 2000, AM J PHYSIOL-CELL PH, V279, pC375, DOI 10.1152/ajpcell.2000.279.2.C375; Huang LP, 1999, NAT GENET, V23, P329, DOI 10.1038/15507; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Jilling T, 1997, INT REV CYTOL, V172, P193, DOI 10.1016/S0074-7696(08)62361-X; Jourdan N, 1997, J VIROL, V71, P8268, DOI 10.1128/JVI.71.11.8268-8278.1997; KABCENELL AK, 1985, J CELL BIOL, V101, P1270, DOI 10.1083/jcb.101.4.1270; Kartner N, 1998, METHOD ENZYMOL, V292, P629; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOPITO RR, 1999, PHYSIOL REV, V79, P167; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; Ladinsky MS, 1999, J CELL BIOL, V144, P1135, DOI 10.1083/jcb.144.6.1135; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LOFFING J, 1998, AM J PHYSIOL, V275, P913; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Mickle JE, 1998, CLIN CHEST MED, V19, P443, DOI 10.1016/S0272-5231(05)70092-7; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Moyer BD, 2001, TRAFFIC, V2, P268, DOI 10.1034/j.1600-0854.2001.1o007.x; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; Naren AP, 2000, J CLIN INVEST, V105, P377, DOI 10.1172/JCI8631; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; O'Riordan CR, 2000, GLYCOBIOLOGY, V10, P1225, DOI 10.1093/glycob/10.11.1225; Ostedgaard LS, 1999, J CELL SCI, V112, P2091; Pelham HRB, 2000, CELL, V102, P713, DOI 10.1016/S0092-8674(00)00060-X; PETERS KW, 1999, AM J PHYSIOL, V277, P174; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; Prekeris R, 1999, MOL BIOL CELL, V10, P3891, DOI 10.1091/mbc.10.11.3891; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; Riordan JR, 1999, AM J HUM GENET, V64, P1499, DOI 10.1086/302429; RIORDAN JR, 1989, SCIENCE, V245, P1066; Roberg KJ, 1999, J CELL BIOL, V145, P659, DOI 10.1083/jcb.145.4.659; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; Rowe T, 1998, SCIENCE, V279, P696, DOI 10.1126/science.279.5351.696; Scales SJ, 2000, INT REV CYTOL, V195, P67; Shimoni Y, 2000, J CELL BIOL, V151, P973, DOI 10.1083/jcb.151.5.973; Skach WR, 2000, KIDNEY INT, V57, P825, DOI 10.1046/j.1523-1755.2000.00921.x; Stanton BA, 1997, WIEN KLIN WOCHENSCHR, V109, P457; Storrie B, 2000, TRENDS CELL BIOL, V10, P385, DOI 10.1016/S0962-8924(00)01818-3; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Subramaniam VN, 2000, J CELL SCI, V113, P997; Sutterlin C, 1997, J CELL SCI, V110, P2703; TABAS I, 1978, J BIOL CHEM, V253, P7779; Thoreau V, 1999, BIOCHEM BIOPH RES CO, V257, P577, DOI 10.1006/bbrc.1999.0503; Tisdale EJ, 1999, MOL BIOL CELL, V10, P1837, DOI 10.1091/mbc.10.6.1837; Tisdale EJ, 1996, J BIOL CHEM, V271, P29372, DOI 10.1074/jbc.271.46.29372; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Tisdale EJ, 1998, J BIOL CHEM, V273, P17269, DOI 10.1074/jbc.273.27.17269; Toyooka K, 2000, J CELL BIOL, V148, P453, DOI 10.1083/jcb.148.3.453; URBANI L, 1990, J BIOL CHEM, V265, P1919; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; White J, 1999, J CELL BIOL, V147, P743, DOI 10.1083/jcb.147.4.743; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	96	151	153	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11401	11409		10.1074/jbc.M110263200	http://dx.doi.org/10.1074/jbc.M110263200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11799116	hybrid			2022-12-27	WOS:000174613100083
J	Allen, SCH; Barrett, CML; Ray, N; Robinson, C				Allen, SCH; Barrett, CML; Ray, N; Robinson, C			Essential cytoplasmic domains in the Escherichia coli TatC protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-PH PATHWAY; EXPORT PATHWAY; SIGNAL PEPTIDE; SEC; TRANSLOCATION; SYSTEM; TRANSPORT; MEMBRANE; DISTINCT; COMPLEX	The twin-arginine translocation (Tat) system mediates the transport of proteins across the bacterial plasma membrane and chloroplast thylakoid membrane. Operating in parallel with Sec-type systems in these membranes, the Tat system is completely different in both structural and mechanistic terms, and is uniquely able to catalyze the translocation of fully folded proteins across coupled membranes. TatC is an essential, multispanning component that has been proposed to form part of the binding site for substrate precursor proteins. In this study we have tested the importance of conserved residues on the periplasmic and cytoplasmic face of the Escherichia coli protein. We find that many of the mutations on the cytoplasmic face have little or no effect. However, substitution at several positions in the extreme N-terminal cytoplasmic region or the predicted first cytoplasmic loop lead to a significant or complete loss of Tat-dependent export. The mutated strains are unable to grow anaerobically on trimethylamine N-oxide minimal media and are unable to export trimethylamine-N-oxide reductase (TorA). The same mutants are completely unable to export a chimeric protein, comprising the TorA signal peptide linked to green fluorescent protein, indicating that translocation is blocked rather than cofactor insertion into the TorA mature protein. The data point to two essential cytoplasmic domains on the TatC protein that are essential for export.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of Warwick	Robinson, C (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.							Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; Bolhuis A, 2000, FEBS LETT, V472, P88, DOI 10.1016/S0014-5793(00)01428-9; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; Clark SA, 1997, MOL BIOL CELL, V8, P923, DOI 10.1091/mbc.8.5.923; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; Dykxhoorn DM, 1996, GENE, V177, P133, DOI 10.1016/0378-1119(96)00289-2; Hynds PJ, 1998, J BIOL CHEM, V273, P34868, DOI 10.1074/jbc.273.52.34868; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; Mori H, 1998, J BIOL CHEM, V273, P11405, DOI 10.1074/jbc.273.19.11405; Mori H, 2001, FEBS LETT, V501, P65, DOI 10.1016/S0014-5793(01)02626-6; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; Robinson C, 2001, NAT REV MOL CELL BIO, V2, P350, DOI 10.1038/35073038; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Santini CL, 2001, J BIOL CHEM, V276, P8159, DOI 10.1074/jbc.C000833200; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sargent F, 1999, J BIOL CHEM, V274, P36073, DOI 10.1074/jbc.274.51.36073; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Thomas JD, 2001, MOL MICROBIOL, V39, P47, DOI 10.1046/j.1365-2958.2001.02253.x; VOELKER R, 1995, EMBO J, V14, P3905, DOI 10.1002/j.1460-2075.1995.tb00062.x; Walker MB, 1999, J CELL BIOL, V147, P267, DOI 10.1083/jcb.147.2.267; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wexler M, 2000, J BIOL CHEM, V275, P16717, DOI 10.1074/jbc.M000800200; Wexler M, 1998, FEBS LETT, V431, P339, DOI 10.1016/S0014-5793(98)00790-X; Yahr TL, 2001, EMBO J, V20, P2472, DOI 10.1093/emboj/20.10.2472	30	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10362	10366		10.1074/jbc.M109135200	http://dx.doi.org/10.1074/jbc.M109135200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11781311	hybrid			2022-12-27	WOS:000174549200100
J	Fedosov, SN; Berglund, L; Fedosova, NU; Nexo, E; Petersen, TE				Fedosov, SN; Berglund, L; Fedosova, NU; Nexo, E; Petersen, TE			Comparative analysis of cobalamin binding kinetics and ligand protection for intrinsic factor, transcobalamin, and haptocorrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-ATOM ABSTRACTION; CARBON BOND HOMOLYSIS; PICHIA-PASTORIS; AQUOCOBALAMIN; RECOGNITION; VITAMIN-B12; EXPRESSION; PROTEINS; MUTASE; MILK	Changes in the absorbance spectrum of aquo-cobalamin (Cbl.OH2) revealed that its binding to transcobalamin (TC) is followed by slow conformational reorganization of the protein-ligand complex (Fedosov, S. N., Fedosova, N. U., Nexo, E., and Petersen, T. E. (2000) J. Biol. Chem. 275, 11791-11798). Two phases were also observed for TC when interacting with a Cbl-analogue cobinamide (Cbi), but not with other cobalamins. The slow phase had no relation to the ligand recognition, since both Cbl and Cbi bound rapidly and in one step to intrinsic factor (IF) and haptocorrin (HC), namely the proteins with different Cbl specificity. Spectral transformations observed for TC in the slow phase were similar to those upon histidine complexation with Cbl.OH2 and Cbi. In contrast to a closed structure of TC.Cbl.OH2, the analogous IF and HC complexes revealed accessibility of Cbl's upper face to the external reagents. The binders decreased sensitivity of adenosyl-Cbl (Cbl.Ado) to light in the range: free ligand, IF., HC., TC.Cbl.Ado. The spectrum of TC.Cbl.Ado differed from those of IF and HC and mimicked Cbl.Ado participating in catalysis. The above data suggest presence of a histidine-containing cap shielding the Cbl-binding site in TC. The cap coordinates to certain corrinoids and, possibly, produces an incapsulated Ado-radical when Cbl.Ado is bound.	Aarhus Univ, Prot Chem Lab, Dept Mol & Struct Biol, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Biophys, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, AKH, Dept Clin Biochem, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University; Aarhus University	Fedosov, SN (corresponding author), Aarhus Univ, Prot Chem Lab, Dept Mol & Struct Biol, Sci Pk,Gustav Wieds Vej 10, DK-8000 Aarhus C, Denmark.		Fedosov, Sergey N./J-2340-2019	Fedosov, Sergey N./0000-0002-7016-2959; Fedosova, Natalya U./0000-0002-1706-6108; Nexo, Ebba/0000-0001-9406-9081				Allen R H, 1975, Prog Hematol, V9, P57; ANDREWS ER, 1991, FEBS LETT, V281, P90, DOI 10.1016/0014-5793(91)80365-A; Eigen M., 1974, QUANTUM STAT MECH NA, pp 37; Fedosov SN, 1999, J BIOL CHEM, V274, P26015, DOI 10.1074/jbc.274.37.26015; Fedosov SN, 1995, BIOCHEMISTRY-US, V34, P16082, DOI 10.1021/bi00049a023; Fedosov SN, 1996, BBA-PROTEIN STRUCT M, V1292, P113, DOI 10.1016/0167-4838(95)00173-5; Fedosov SN, 2000, J BIOL CHEM, V275, P11791, DOI 10.1074/jbc.275.16.11791; GIMSING P, 1983, COBALAMINS, P7; GORDON M, 1992, BIOCHIM BIOPHYS ACTA, V1132, P276, DOI 10.1016/0167-4781(92)90161-R; GORDON MM, 1991, AM J PHYSIOL, V260, pG736, DOI 10.1152/ajpgi.1991.260.5.G736; GRASBECK R, 1967, SCAND J CLIN LAB I S, V95, P7; KOLHOUSE JF, 1977, J CLIN INVEST, V60, P1381, DOI 10.1172/JCI108899; MARCHAJ A, 1995, J AM CHEM SOC, V117, P11640, DOI 10.1021/ja00152a003; MARQUES HM, 1988, J BIOL CHEM, V263, P12378; Marsh ENG, 1998, BIOCHEMISTRY-US, V37, P11864, DOI 10.1021/bi980512e; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; NEXO E, 1976, BIOCHIM BIOPHYS ACTA, V446, P143, DOI 10.1016/0005-2795(76)90106-9; NEXO E, 1975, SCAND J HAEMATOL, V14, P320; NEXO E, 1998, VITAMIN B12 B12 PROT, P461, DOI DOI 10.1002/9783527612192.CH30; NEXO E, 1982, B12, V2, P47; OUADROS EV, 1993, BLOOD, V81, P1239; Padmakumar R, 1997, BIOCHEMISTRY-US, V36, P3713, DOI 10.1021/bi962503g; Pratt J. M., 1972, INORGANIC CHEM VITAM, VB12; STUPPERICH E, 1991, EUR J BIOCHEM, V199, P299, DOI 10.1111/j.1432-1033.1991.tb16124.x; Wen JP, 2000, BBA-GENE STRUCT EXPR, V1490, P43, DOI 10.1016/S0167-4781(99)00218-3	25	54	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9989	9996		10.1074/jbc.M111399200	http://dx.doi.org/10.1074/jbc.M111399200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11788601	hybrid, Green Published			2022-12-27	WOS:000174549200052
J	Reddy, MA; Thimmalapura, PR; Lanting, L; Nadler, JL; Fatima, S; Natarajan, R				Reddy, MA; Thimmalapura, PR; Lanting, L; Nadler, JL; Fatima, S; Natarajan, R			The oxidized lipid and lipoxygenase product 12(S)-hydroxyeicosatetraenoic acid induces hypertrophy and fibronectin transcription in vascular smooth muscle cells via p38 MAPK and cAMP response element-binding protein activation - Mediation of angiotensin II effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; GROWTH-FACTOR; 12-HYDROXYEICOSATETRAENOIC ACID; ARACHIDONATE 12-LIPOXYGENASE; MESANGIAL CELLS; LEUKOCYTE-TYPE; HIGH GLUCOSE; KINASE-C; EXPRESSION; 12/15-LIPOXYGENASE	Evidence suggests that the arachidonic acid metabolite of 12-lipoxygenase, 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE), not only mediates the effects of angiotensin II (AngII), but also has direct effects on hypertrophy and matrix protein production in vascular smooth muscle cells (VSMCs). This study is aimed at identifying the signaling pathways involved in these events. Treatment of porcine VSMCs with 12(S)-HETE led to the activation of Ras and p38 MAPK. It also stimulated phosphorylation, DNA-binding activity, and transactivation of the transcription factor cAMP response element (CRE)-binding protein. In addition, 12(S)-HETE induced transcription from a fibronectin promoter containing multiple CREs. AngII also induced transactivation of CRE-binding protein and transcription from the fibronectin promoter. A specific p38 MAPK inhibitor (SB202190) as well as a dominant-negative Ras mutant (Ras-N17) blocked both 12(S)-HETE and AngII effects. In addition, inhibitors of lipoxygenase also blocked AngII effects. Both 12(S)-HETE and AngII increased cellular hypertrophy with similar potency, and this was significantly blocked by SB202190. Stable overexpression of murine leukocyte-type 12/15-lipoxygenase in VSMCs increased the levels of cell-associated 12(S)HETE as well as basal activity of both ERK and p38 MAPKs. Furthermore, these 12-lipoxygenase-overexpressing cells displayed significantly greater cellular hypertrophy relative to mock-transfected cells. These results show for the first time that oxidized lipids such as 12(S)-HETE can induce VSMC growth and matrix gene expression and mediate growth factor effects via activation of the Ras-MAPK pathway and key target transcription factors.	City Hope Natl Med Ctr, Beckman Res Inst, Gonda Diabet Ctr, Duarte, CA 91010 USA; Univ Virginia, Sch Med, Dept Endocrinol, Charlottesville, VA 22908 USA; Univ Tennessee, Dept Pharmacol, Memphis, TN 38163 USA	City of Hope; Beckman Research Institute of City of Hope; University of Virginia; University of Tennessee System; University of Tennessee Health Science Center	Natarajan, R (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Gonda Diabet Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA.	rnatarajan@coh.org		Reddy, Marpadga A/0000-0001-9259-7243	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058191] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL55798] Funding Source: Medline; NIDDK NIH HHS [R01DK58191] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonipillai I, 1996, J CLIN ENDOCR METAB, V81, P1940, DOI 10.1210/jc.81.5.1940; Cathcart MK, 2000, FREE RADICAL BIO MED, V28, P1726, DOI 10.1016/S0891-5849(00)00230-6; CHEN XS, 1994, J BIOL CHEM, V269, P13979; Coffey MJ, 2001, P NATL ACAD SCI USA, V98, P8006, DOI 10.1073/pnas.141136098; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; Cyrus T, 2001, CIRCULATION, V103, P2277; DEAN DC, 1989, MOL CELL BIOL, V9, P1498, DOI 10.1128/MCB.9.4.1498; DEAN DC, 1990, J BIOL CHEM, V265, P3522; Fujita H, 1999, ATHEROSCLEROSIS, V147, P69, DOI 10.1016/S0021-9150(99)00165-3; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; Gonzalez-Nunez D, 2001, HYPERTENSION, V37, P334, DOI 10.1161/01.HYP.37.2.334; GU JL, 1994, ENDOCRINOLOGY, V134, P70, DOI 10.1210/en.134.1.70; Gu JL, 2001, CIRCULATION, V103, P1446, DOI 10.1161/01.CIR.103.10.1446; HADA T, 1994, BBA-LIPID LIPID MET, V1211, P221, DOI 10.1016/0005-2760(94)90272-0; HERBERTSSON H, 1992, FEBS LETT, V298, P249, DOI 10.1016/0014-5793(92)80069-S; Kang SW, 2001, KIDNEY INT, V59, P1354, DOI 10.1046/j.1523-1755.2001.0590041354.x; KATOH T, 1994, KIDNEY INT, V46, P341, DOI 10.1038/ki.1994.280; Kuhn H, 1999, FEBS LETT, V449, P7, DOI 10.1016/S0014-5793(99)00396-8; LEGRAND AB, 1991, J BIOL CHEM, V266, P7570; LIU B, 1995, P NATL ACAD SCI USA, V92, P9323, DOI 10.1073/pnas.92.20.9323; Muthalif MM, 1998, P NATL ACAD SCI USA, V95, P12701, DOI 10.1073/pnas.95.21.12701; NADLER JL, 1987, J CLIN INVEST, V80, P1763, DOI 10.1172/JCI113269; Nahman NS, 1996, J LAB CLIN MED, V127, P599; NAKAO J, 1982, ATHEROSCLEROSIS, V44, P339, DOI 10.1016/0021-9150(82)90008-9; Natarajan R, 1999, HYPERTENSION, V33, P378, DOI 10.1161/01.HYP.33.1.378; Natarajan R, 1996, J CELL PHYSIOL, V169, P391, DOI 10.1002/(SICI)1097-4652(199611)169:2<391::AID-JCP19>3.3.CO;2-Q; Natarajan R, 1997, HYPERTENSION, V30, P873, DOI 10.1161/01.HYP.30.4.873; Natarajan R, 1997, AM J PHYSIOL-HEART C, V273, pH2224, DOI 10.1152/ajpheart.1997.273.5.H2224; NATARAJAN R, 1993, P NATL ACAD SCI USA, V90, P4947, DOI 10.1073/pnas.90.11.4947; Natarajan R, 2002, DIABETOLOGIA, V45, P125, DOI 10.1007/s125-002-8253-x; Natarajan R, 2001, ARTERIOSCL THROM VAS, V21, P1408, DOI 10.1161/hq0901.095278; NATARAJAN R, 1994, HYPERTENSION, V23, pI142, DOI 10.1161/01.HYP.23.1_Suppl.I142; Natarajan R, 1999, CARDIOVASC RES, V41, P489, DOI 10.1016/S0008-6363(98)00312-5; NATARAJAN R, 1994, MOL CELL ENDOCRINOL, V101, P59, DOI 10.1016/0303-7207(94)90219-4; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; Patricia MK, 2001, CIRC RES, V88, P659, DOI 10.1161/hh0701.088838; Patricia MK, 1999, ARTERIOSCL THROM VAS, V19, P2615, DOI 10.1161/01.ATV.19.11.2615; RAO GN, 1994, J BIOL CHEM, V269, P32586; ROY P, 1994, BBA-LIPID LIPID MET, V1214, P171, DOI 10.1016/0005-2760(94)90041-8; Sigari F, 1997, ARTERIOSCL THROM VAS, V17, P3639, DOI 10.1161/01.ATV.17.12.3639; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; STERN N, 1993, ENDOCRINOLOGY, V133, P843, DOI 10.1210/en.133.2.843; STERN N, 1989, AM J PHYSIOL, V257, pH434, DOI 10.1152/ajpheart.1989.257.2.H434; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; WATANABE T, 1993, EUR J BIOCHEM, V212, P605, DOI 10.1111/j.1432-1033.1993.tb17699.x; Wen YS, 1996, AM J PHYSIOL-CELL PH, V271, pC1212, DOI 10.1152/ajpcell.1996.271.4.C1212; Wen YS, 2001, CIRC RES, V88, P70, DOI 10.1161/01.RES.88.1.70; Wen YS, 1997, CIRC RES, V81, P651; Yerneni KKV, 1999, DIABETES, V48, P855, DOI 10.2337/diabetes.48.4.855; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142; Zhu MY, 2000, J NEUROPHYSIOL, V84, P2494, DOI 10.1152/jn.2000.84.5.2494	54	104	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9920	9928		10.1074/jbc.M111305200	http://dx.doi.org/10.1074/jbc.M111305200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11786549	hybrid			2022-12-27	WOS:000174549200043
J	Sparrow, CP; Baffic, J; Lam, MH; Lund, EG; Adams, AD; Fu, XA; Hayes, N; Jones, AB; Macnaul, KL; Ondeyka, J; Singh, S; Wang, JH; Zhou, GC; Moller, DE; Wright, SD; Menke, JG				Sparrow, CP; Baffic, J; Lam, MH; Lund, EG; Adams, AD; Fu, XA; Hayes, N; Jones, AB; Macnaul, KL; Ondeyka, J; Singh, S; Wang, JH; Zhou, GC; Moller, DE; Wright, SD; Menke, JG			A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; CASSETTE TRANSPORTER 1; CELLULAR CHOLESTEROL; TANGIER-DISEASE; DENSITY-LIPOPROTEIN; MEDIATED EFFLUX; PHOSPHOLIPID EFFLUX; APOA-I; BINDING; RECEPTOR	The LXR nuclear receptors are intracellular sensors of cholesterol excess and are activated by various oxysterols. LXRs have been shown to regulate multiple genes of lipid metabolism, including ABCA1 (formerly known as ABC1). ABCA1 is a lipid pump that effluxes cholesterol and phospholipid out of cells. ABCA1 deficiency causes extremely low high density lipoprotein (HDL) levels, demonstrating the importance of ABCA1 in the formation of HDL. The present work shows that the acetyl-podocarpic dimer (APD) is a potent, selective agonist for both LXRalpha (NR1H3) and LXRbeta (NR1H2). In transient transactivation assays, APD was similar to1000-fold more potent, and yielded similar to6-fold greater maximal stimulation, than the widely used LXR agonist 22-(R)-hydroxycholesterol. APD induced ABCA1 mRNA levels, and increased efflux of both cholesterol and phospholipid, from multiple cell types. Gas chromatography-mass spectrometry measurements demonstrated that APD stimulated efflux of endogenous cholesterol, eliminating any possible artifacts of cholesterol labeling. For both mRNA induction and stimulation of cholesterol efflux, APD was found to be more effective than was cholesterol loading. Taken together, these data show that APD is a more effective LXR agonist than endogenous oxysterols. LXR agonists may therefore be useful for the prevention and treatment of atherosclerosis, especially in the context of low HDL levels.	Merck Res Labs, Rahway, NJ 07065 USA	Merck & Company	Sparrow, CP (corresponding author), Merck Res Labs, Bldg 80W,126 E Lincoln Ave, Rahway, NJ 07065 USA.	Carl_Sparrow@Merck.com						Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brousseau ME, 2000, J LIPID RES, V41, P433; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Costet P, 2000, J BIOL CHEM, V275, P28240; DeBose-Boyd RA, 2001, P NATL ACAD SCI USA, V98, P1477, DOI 10.1073/pnas.98.4.1477; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Gelissen IC, 1996, J BIOL CHEM, V271, P17852, DOI 10.1074/jbc.271.30.17852; GOWN AM, 1986, AM J PATHOL, V125, P191; Hailman E, 1996, J IMMUNOL, V156, P4384; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; KILSDONK EPC, 1995, J LIPID RES, V36, P505; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Kritharides L, 1998, ARTERIOSCL THROM VAS, V18, P1589, DOI 10.1161/01.ATV.18.10.1589; KRITHARIDES L, 1995, ARTERIOSCL THROM VAS, V15, P276, DOI 10.1161/01.ATV.15.2.276; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Mendez AJ, 1996, J LIPID RES, V37, P2510; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; RANGANATHAN S, 1989, BIOCHEM CELL BIOL, V67, P719, DOI 10.1139/o89-107; Repa JJ, 1999, CURR OPIN BIOTECH, V10, P557, DOI 10.1016/S0958-1669(99)00031-2; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; SERFATYLACROSNIERE C, 1994, ATHEROSCLEROSIS, V107, P85, DOI 10.1016/0021-9150(94)90144-9; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; WALTER M, 1994, BIOCHEM BIOPH RES CO, V205, P850, DOI 10.1006/bbrc.1994.2742; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Westman J, 1998, ARTERIOSCL THROM VAS, V18, P554, DOI 10.1161/01.ATV.18.4.554; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594	41	109	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10021	10027		10.1074/jbc.M108225200	http://dx.doi.org/10.1074/jbc.M108225200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11790770	hybrid			2022-12-27	WOS:000174549200056
J	Traweger, A; Fang, D; Liu, YC; Stelzhammer, W; Krizbai, IA; Fresser, F; Bauer, HC; Bauer, H				Traweger, A; Fang, D; Liu, YC; Stelzhammer, W; Krizbai, IA; Fresser, F; Bauer, HC; Bauer, H			The tight junction-specific protein occludin is a functional target of the E3 ubiquitin-protein ligase itch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEUBIQUITINATING ENZYME; PROTEASOME PATHWAY; BETA-CATENIN; ZO-1; DOMAINS; CELLS; PERMEABILITY; RECOGNITION; DEGRADATION; COMPONENTS	Tight junctions create a highly selective diffusion barrier between epithelial and endothelial cells by preventing the free passage of molecules and ions across the paracellular pathway. Although the regulation of this barrier is still enigmatic, there is evidence that junctional transmembrane proteins are critically involved. Recent evidence confirms the notion that occludin, a four-pass integral plasma-membrane protein, is a functional component of the paracellular barrier. The overall hydrophilicity of occludin predicts two extracellular loops bounded by NH(2)- and COOH-terminal cytoplasmic domains. To date, the binding of the COOH terminus of occludin to intracellular proteins is well documented, but information concerning the function of the cytoplasmic NH(2) terminus is still lacking. Using yeast two-hybrid screening we have identified a novel interaction between occludin and the E3 ubiquitin-protein ligase Itch, a member of the HECT domain-containing ubiquitin-protein ligases. We have found that the NH(2)-terminal portion of occludin binds specifically to a multidomain of Itch, consisting of four WW motifs. This interaction has been confirmed by our results from in vivo and in vitro co-immunoprecipitation experiments. In addition, we provide evidence that Itch is specifically involved in the ubiquitination of occludin in vivo, and that the degradation of occludin is sensitive to proteasome inhibition.	Austrian Acad Sci, Inst Mol Biol, A-5020 Salzburg, Austria; La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA; Inst Biophys, Biol Res Ctr, Szeged, Hungary; Univ Innsbruck, Inst Med Biol & Human Genet, A-6020 Innsbruck, Austria	Austrian Academy of Sciences; La Jolla Institute for Immunology; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; University of Innsbruck	Bauer, HC (corresponding author), Austrian Acad Sci, Inst Mol Biol, Billrothstr 11, A-5020 Salzburg, Austria.	hcbauer@imb.oeaw.ac.at	Fang, Deyu/I-7245-2013; Traweger, Andreas/M-1460-2015	Fang, Deyu/0000-0002-4211-2751; Traweger, Andreas/0000-0002-0220-4766; LIU, YUN-CAI/0000-0002-0996-7109; Krizbai, Istvan/0000-0002-0764-1527				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Abriel H, 2000, FEBS LETT, V466, P377, DOI 10.1016/S0014-5793(00)01098-X; Balda MS, 2000, J CELL BIOCHEM, V78, P85, DOI 10.1002/(SICI)1097-4644(20000701)78:1<85::AID-JCB8>3.3.CO;2-6; Balda MS, 1998, J CELL SCI, V111, P541; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; Citi S, 1998, BBA-MOL CELL RES, V1448, P1, DOI 10.1016/S0167-4889(98)00125-6; Cordenonsi M, 1999, J CELL BIOL, V147, P1569, DOI 10.1083/jcb.147.7.1569; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Dunn R, 2001, MOL BIOL CELL, V12, P421, DOI 10.1091/mbc.12.2.421; Duttweiler HM, 1996, TRENDS GENET, V12, P340, DOI 10.1016/S0168-9525(96)80008-4; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gietz RD, 1997, MOL CELL BIOCHEM, V172, P67, DOI 10.1023/A:1006859319926; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Huber D, 2000, J BIOL CHEM, V275, P5773, DOI 10.1074/jbc.275.8.5773; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; McCarthy KM, 1996, J CELL SCI, V109, P2287; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Musil LS, 2000, J BIOL CHEM, V275, P25207, DOI 10.1074/jbc.275.33.25207; PENN EJ, 1987, J CELL BIOL, V105, P2327, DOI 10.1083/jcb.105.5.2327; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; Taya S, 1999, GENES CELLS, V4, P757, DOI 10.1046/j.1365-2443.1999.00297.x; Taya S, 1998, J CELL BIOL, V142, P1053, DOI 10.1083/jcb.142.4.1053; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tsukamoto T, 1999, J BIOL CHEM, V274, P24579, DOI 10.1074/jbc.274.35.24579; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; VanItallie CM, 1997, J CELL SCI, V110, P1113; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; Zarrinpar A, 2000, NAT STRUCT BIOL, V7, P611, DOI 10.1038/77891	38	159	169	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10201	10208		10.1074/jbc.M111384200	http://dx.doi.org/10.1074/jbc.M111384200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11782481	hybrid			2022-12-27	WOS:000174549200080
J	Hemi, R; Paz, K; Wertheim, N; Karasik, A; Zick, Y; Kanety, H				Hemi, R; Paz, K; Wertheim, N; Karasik, A; Zick, Y; Kanety, H			Transactivation of ErbB2 and ErbB3 by tumor necrosis factor-alpha and anisomycin leads to impaired insulin signaling through serine/threonine phosphorylation of IRS proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; INDUCED TYROSINE PHOSPHORYLATION; RECEPTOR SUBSTRATE-1 IRS-1; 3T3-L1 ADIPOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; CROSS-TALK; TNF-ALPHA; KINASE-B; RESISTANCE; ACTIVATION	The cellular pathways involved in the impairment of insulin signaling by cellular stress, triggered by the inflammatory cytokine tumor necrosis factor-alpha (TNF) or by translational inhibitors like cycloheximide and anisomycin were studied. Similar to TNF, cycloheximide and anisomycin stimulated serine phosphorylation of IRS-1 and IRS-2, reduced their ability to interact with the insulin receptor, inhibited the insulin-induced tyrosine phosphorylation of IRS proteins, and diminished their association with phosphatidylinositol 3-kinase (PI3K). These defects were partially reversed by wortmannin and LY294002, indicating that a PI3K-regulated step is critical for the impairment of insulin signaling by cellular stress. Induction of cellular stress resulted in complex formation between PI3K and ErbB2/ErbB3 and enhanced PI3K activity, implicating ErbB proteins as downstream effectors of stress-induced insulin resistance. Indeed, stimulation of ErbB2/ErbB3 by NDFbeta1, the ErbB3 ligand, inhibited IRS protein tyrosine phosphorylation and recruitment of downstream effectors. Specific inhibitors of the ErbB2 tyrosine kinase abrogated the activation of ErbB2/ErbB3 and in parallel prevented the reduction in IRS protein functions. Taken together, our results suggest a novel mechanism by which cellular stress induces cross-talk between two different signaling pathways. Stress-dependent transactivation of ErbB2/ErbB3 receptors triggers a PI3K cascade that induces serine phosphorylation of IRS proteins culminating in insulin resistance.	Chaim Sheba Med Ctr, Inst Endocrinol, IL-52601 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science	Kanety, H (corresponding author), Chaim Sheba Med Ctr, Inst Endocrinol, IL-52601 Tel Hashomer, Israel.	hkanety@sheba.health.gov.il	Zick, Yehiel/K-1479-2012					Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; BARRY AM, 1995, AM J MED, V98, P75; BONADONNA RC, 1991, DIABETES METAB, V17, P112; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Chen D, 1999, MOL CELL BIOL, V19, P4684; Del Aguila LF, 2000, AM J PHYSIOL-ENDOC M, V279, pE206, DOI 10.1152/ajpendo.2000.279.1.E206; Emkey R, 1997, J BIOL CHEM, V272, P31182, DOI 10.1074/jbc.272.49.31182; Engelman JA, 2000, MOL ENDOCRINOL, V14, P1557, DOI 10.1210/me.14.10.1557; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; Hanna AN, 1999, J BIOL CHEM, V274, P12722, DOI 10.1074/jbc.274.18.12722; Hiraoka E, 2001, AM J PHYSIOL-HEART C, V280, pH1861, DOI 10.1152/ajpheart.2001.280.4.H1861; Hirota K, 2001, J BIOL CHEM, V276, P25953, DOI 10.1074/jbc.M011021200; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Ikezu T, 1997, J BIOL CHEM, V272, P25289, DOI 10.1074/jbc.272.40.25289; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; KANETY H, 1994, P NATL ACAD SCI USA, V91, P1853, DOI 10.1073/pnas.91.5.1853; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Le Roith D, 2001, DIABETES CARE, V24, P588, DOI 10.2337/diacare.24.3.588; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Moller DE, 2000, TRENDS ENDOCRIN MET, V11, P212, DOI 10.1016/S1043-2760(00)00272-1; Murthy S, 2000, J BIOL CHEM, V275, P9222, DOI 10.1074/jbc.275.13.9222; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; OLEFSKY JM, 1993, ADV EXP MED BIOL, V334, P129; OSHEROV N, 1993, J BIOL CHEM, V268, P11134; Ozes ON, 1999, NATURE, V401, P82; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Ricort JM, 1997, J BIOL CHEM, V272, P19814, DOI 10.1074/jbc.272.32.19814; Rudich A, 1998, DIABETES, V47, P1562, DOI 10.2337/diabetes.47.10.1562; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; SHANGRAW RE, 1989, METABOLISM, V38, P983, DOI 10.1016/0026-0495(89)90010-3; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang X, 2001, J BIOL CHEM, V276, P25456, DOI 10.1074/jbc.M102418200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8	57	41	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8961	8969		10.1074/jbc.M109391200	http://dx.doi.org/10.1074/jbc.M109391200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11779863	hybrid			2022-12-27	WOS:000174400600032
J	Okumura, Y; Kamikubo, Y; Curriden, SA; Wang, JY; Kiwada, T; Futaki, S; Kitagawa, K; Loskutoff, DJ				Okumura, Y; Kamikubo, Y; Curriden, SA; Wang, JY; Kiwada, T; Futaki, S; Kitagawa, K; Loskutoff, DJ			Kinetic analysis of the interaction between vitronectin and the urokinase receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; SERUM SPREADING FACTOR; SOMATOMEDIN-B DOMAIN; HEPARIN-BINDING PROPERTIES; S-PROTEIN VITRONECTIN; CELL-ADHESION; HUMAN-PLASMA; COLLAGEN-BINDING; TYPE-1; IDENTIFICATION	Although the urokinase receptor (uPAR) binds to vitronectin (VN) and promotes the adhesion of cells to this matrix protein, the biochemical details of this interaction remain unclear. VN variants were employed in BIAcore experiments to examine the uPAR-VN interaction in detail and to compare it to the interaction of VN with other ligands. Heparin and plasminogen bound to VN fragments containing the heparin-binding domain, indicating that this domain was functionally active in the recombinant peptides. However, no significant binding was detected when uPAR was incubated with this domain, and neither heparin nor plasminogen competed with it for binding to VN. In fact, uPAR only bound to fragments containing the somatomedin B (SMB) domain, and monoclonal antibodies (mAbs) that bind to this domain competed with uPAR for binding to VN. Monoclonal antibody 8E6 also inhibited uPAR binding to VN, and this mAb was shown to recognize sulfated tyrosine residues 56 and 59 in the region adjacent to the SMB domain. Destruction of this site by acid treatment eliminated mAb 8E6 binding but had no effect on uPAR binding. Thus, there appears to be a single binding site for uPAR in VN, and it is located in the SMB domain and is distinct from the epitope recognized by mAb 8E6. Inhibition of uPAR binding to VN by mAb 8E6 probably results from steric hindrance.	Scripps Res Inst, Div Vasc Biol, Dept Cell Biol, La Jolla, CA 92037 USA; Abbott Labs, Abbott Pk, IL 60064 USA; Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan; Niigata Coll Pharm, Niigata 9502081, Japan	Scripps Research Institute; Abbott Laboratories; Kyoto University	Loskutoff, DJ (corresponding author), Scripps Res Inst, Div Vasc Biol, Dept Cell Biol, 10550 N Torrey Pines Rd,VB-3, La Jolla, CA 92037 USA.	loskutof@scripps.edu		Futaki, Shiroh/0000-0002-0124-4002	NHLBI NIH HHS [HL31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES DW, 1985, J BIOL CHEM, V260, P9117; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Ehnebom J, 2000, FIBRINOLYSIS PROTEOL, V14, P47, DOI 10.1054/fipr.2000.0052; GEBB C, 1986, J BIOL CHEM, V261, P6698; Gechtman Z, 1997, BIOCHEM J, V325, P339, DOI 10.1042/bj3250339; GECHTMAN Z, 1993, FEBS LETT, V315, P293, DOI 10.1016/0014-5793(93)81181-X; HAYASHI M, 1985, J BIOCHEM-TOKYO, V98, P1135, DOI 10.1093/oxfordjournals.jbchem.a135363; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; Higazi AAR, 1996, BLOOD, V87, P3545, DOI 10.1182/blood.V87.9.3545.bloodjournal8793545; HILDEBRAND A, 1988, J BIOL CHEM, V263, P2436; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; HUTTNER WB, 1984, METHOD ENZYMOL, V107, P200; ISHIKAWA M, 1992, BIOCHIM BIOPHYS ACTA, V1121, P173, DOI 10.1016/0167-4838(92)90351-D; IZUMI M, 1988, CELL STRUCT FUNCT, V13, P217, DOI 10.1247/csf.13.217; JENNE D, 1989, EUR J BIOCHEM, V185, P391, DOI 10.1111/j.1432-1033.1989.tb15127.x; Kitagawa K, 2001, J ORG CHEM, V66, P1, DOI 10.1021/jo000895y; KOST C, 1992, J BIOL CHEM, V267, P12098; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; MIMURO J, 1993, BIOCHEMISTRY-US, V32, P2314, DOI 10.1021/bi00060a024; Philips M, 2000, FIBRINOLYSIS PROTEOL, V14, P22, DOI 10.1054/fipr.2000.0047; Podor TJ, 2000, J BIOL CHEM, V275, P25402, DOI 10.1074/jbc.M000362200; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1990, BIOCHEM BIOPH RES CO, V168, P966, DOI 10.1016/0006-291X(90)91123-A; Preissner KT, 1998, THROMB RES, V89, P1, DOI 10.1016/S0049-3848(97)00298-3; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; Royle G, 2001, ANAL BIOCHEM, V296, P245, DOI 10.1006/abio.2001.5316; SEIFFERT D, 1995, FEBS LETT, V368, P155, DOI 10.1016/0014-5793(95)00630-R; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; Seiffert D, 1996, J BIOL CHEM, V271, P29644, DOI 10.1074/jbc.271.47.29644; Seiffert D, 1997, J BIOL CHEM, V272, P13705, DOI 10.1074/jbc.272.21.13705; SIGURDARDOTTIR O, 1992, FIBRINOLYSIS, V6, P27, DOI 10.1016/0268-9499(92)90044-I; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; TOMASINI BR, 1989, BIOCHEMISTRY-US, V28, P7617, DOI 10.1021/bi00445a017; TOMASINI BR, 1988, BLOOD, V72, P903; TOMASINIJOHANSSON BR, 1993, MATRIX, V13, P203, DOI 10.1016/S0934-8832(11)80004-1; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; WEI Y, 1994, J BIOL CHEM, V269, P32380; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	48	60	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9395	9404		10.1074/jbc.M111225200	http://dx.doi.org/10.1074/jbc.M111225200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11773078	hybrid			2022-12-27	WOS:000174400600089
J	Fan, WH; Jin, SQ; Tong, T; Zhao, HC; Fan, FY; Antinore, MJ; Rajasekaran, B; Wu, M; Zhan, QM				Fan, WH; Jin, SQ; Tong, T; Zhao, HC; Fan, FY; Antinore, MJ; Rajasekaran, B; Wu, M; Zhan, QM			BRCA1 regulates GADD45 through its interactions with the OCT-1 and CAAT motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE RESPONSE; HISTONE H2B GENE; P53-REGULATED PROTEIN GADD45; CELL-CYCLE CHECKPOINT; TUMOR-SUPPRESSOR; OVARIAN-CANCER; TRANSCRIPTION FACTORS; NF-Y; EXPRESSION; INDUCTION	BRCA1, a breast and ovarian cancer susceptibility gene, has been implicated in gene regulation. Previous studies demonstrate that BRCA1 induces GADD45, a p53-regulated and stress-inducible gene that plays an important role in cellular response to DNA damage. However, the mechanism(s) by which BRCA1 regulates GADD45 remains unclear. In this report, we have shown that BRCA1 activation of the GADD45 promoter is mediated through the OCT-1 and CAAT motifs located at the GADD45 promoter region. Site-directed mutations of both OCT-1 and CAAT motifs abrogate induction of the GADD45 promoter by BRCA1. Both OCT-1 and CAAT motifs are able to confer BRCA1 inducibility in a non-related minimal promoter. Physical associations of BRCA1 protein with transcription factors Oct-1 and NF-YA which directly bind to the OCT-1 and CAAT motifs, are established by biotin-streptavidin pull-down and co-immunoprecipitation assays. Such protein interactions are required for interaction of BRCA1 with the GADD45 promoter because either immunodepletion of Oct-1 and NF-YA proteins or mutations in the OCT-1 and CAAT motifs disrupt BRCA1 binding to the GADD45 promoter. These findings indicate that BRCA1 can up-regulate its targeted genes through protein-protein interactions and provide a novel mechanism by which BRCA1 participates in transcriptional regulation.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Chinese Acad Med Sci, Inst Canc, Natl Lab Mol Oncol, Beijing 100021, Peoples R China	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Medical Sciences - Peking Union Medical College	Zhan, QM (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, BST W-945,200 Lothrop St, Pittsburgh, PA 15213 USA.				NCI NIH HHS [R01 CA 93640-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093640] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen GC, 2001, BIOCHEM BIOPH RES CO, V284, P507, DOI 10.1006/bbrc.2001.5003; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; EASTON DF, 1995, AM J HUM GENET, V56, P265; Eraly SA, 1998, MOL ENDOCRINOL, V12, P469, DOI 10.1210/me.12.4.469; Fadel BM, 1999, J BIOL CHEM, V274, P20376, DOI 10.1074/jbc.274.29.20376; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FORD D, 1995, BRIT J CANCER, V72, P805, DOI 10.1038/bjc.1995.417; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1990, PROG CLIN BIOL RES, V340, P315; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HINKLEY C, 1992, MOL CELL BIOL, V12, P4400, DOI 10.1128/MCB.12.10.4400; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; Larson JS, 1997, CANCER RES, V57, P3351; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Matuoka K, 1999, EXP CELL RES, V253, P365, DOI 10.1006/excr.1999.4605; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shao NS, 1996, ONCOGENE, V13, P1; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; STURM RA, 1988, NUCLEIC ACIDS RES, V16, P8571, DOI 10.1093/nar/16.17.8571; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhao HC, 2000, EXP CELL RES, V258, P92, DOI 10.1006/excr.2000.4906; Zhao HC, 2000, CANCER RES, V60, P6276; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7	61	108	117	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8061	8067		10.1074/jbc.M110225200	http://dx.doi.org/10.1074/jbc.M110225200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11777930	hybrid			2022-12-27	WOS:000174268000056
J	Rang, A; Bruns, M; Heise, T; Will, H				Rang, A; Bruns, M; Heise, T; Will, H			Antiviral activity of interferon-alpha against hepatitis B virus can be studied in non-hepatic cells and is independent of MxA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; REPLICATION; ELEMENT; TRANSCRIPTION; INHIBITION; RESISTANCE; PROTEINS; GENOME; SYSTEM	It is well established that interferon-alpha can induce non-cytotoxic intracellular suppression of hepatitis B virus replication, but the mechanisms involved are unclear. Cell culture studies to characterize these mechanisms are restricted, in part because hepatitis B virus replicates almost exclusively in liver-derived cells. To overcome this limitation we used a cytomegalovirus promoter-controlled hepatitis B virus expression system, which leads to intracellular viral replication even in non-hepatic cell lines. In this experimental system interferon-alpha treatment specifically suppressed viral replication demonstrating that antiviral activities against hepatitis B virus are not restricted to hepatic cells. Furthermore, the interferon-inducible MxA protein was recently reported to play a key role in the antiviral action of interferon-alphaa against hepatitis B virus. Our data demonstrate that interferon-alpha also suppresses hepatitis B virus replication in MxA-deficient HEp2 cells, indicating that MxA is not essential for these activities. Taken together, our data imply that the experimental approach presented can also be adapted to established cell lines which are deficient in parts of the signal transduction pathway or other elements located further downstream, providing important insights into mechanisms specifically suppressing hepatitis B virus.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Rang, A (corresponding author), Bundesinst Gesundheitlichen Verbraucherschutz & V, D-14195 Berlin, Germany.	a.rang@bgvv.de						CASELMANN WH, 1992, J INFECT DIS, V166, P966, DOI 10.1093/infdis/166.5.966; DAVIS MG, 1994, ANTIMICROB AGENTS CH, V38, P2921, DOI 10.1128/AAC.38.12.2921; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Foster GR, 1997, SEMIN LIVER DIS, V17, P287, DOI 10.1055/s-2007-1007205; Frese M, 2001, J GEN VIROL, V82, P723, DOI 10.1099/0022-1317-82-4-723; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; Gordien E, 2001, J VIROL, V75, P2684, DOI 10.1128/JVI.75.6.2684-2691.2001; Haller O, 1998, REV SCI TECH OIE, V17, P220, DOI 10.20506/rst.17.1.1084; Haque SJ, 1998, SEMIN ONCOL, V25, P14; HAYASHI Y, 1989, J VIROL, V63, P2936, DOI 10.1128/JVI.63.7.2936-2940.1989; Hope TJ, 1997, CHEM BIOL, V4, P335, DOI 10.1016/S1074-5521(97)90124-1; HUANG JK, 1993, MOL CELL BIOL, V13, P7476, DOI 10.1128/MCB.13.12.7476; HUANG ZM, 1994, J VIROL, V68, P3193, DOI 10.1128/JVI.68.5.3193-3199.1994; ISAACS A, 1987, J INTERFERON RES, V7, P429, DOI 10.1089/jir.1987.7.429; Landis H, 1998, J VIROL, V72, P1516, DOI 10.1128/JVI.72.2.1516-1522.1998; Nakao K, 1999, J BIOL CHEM, V274, P28075, DOI 10.1074/jbc.274.40.28075; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; Raney AK, 2001, J VIROL, V75, P2900, DOI 10.1128/JVI.75.6.2900-2911.2001; Rang A, 1999, J HEPATOL, V31, P791, DOI 10.1016/S0168-8278(99)80279-7; Rang A, 2001, J BIOL CHEM, V276, P3531, DOI 10.1074/jbc.C000584200; Romero R, 1996, HEPATOLOGY, V23, P17, DOI 10.1053/jhep.1996.v23.pm0008550037; SCHALLER H, 1991, CURR TOP MICROBIOL, V168, P21; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Smith GJ, 1998, NUCLEIC ACIDS RES, V26, P4818, DOI 10.1093/nar/26.21.4818; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; TURKASPA R, 1990, J VIROL, V64, P1821, DOI 10.1128/JVI.64.4.1821-1824.1990; Yen TSB, 1998, SEMIN VIROL, V8, P319	28	32	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7645	7647		10.1074/jbc.C100729200	http://dx.doi.org/10.1074/jbc.C100729200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11781305	hybrid			2022-12-27	WOS:000174268000005
J	Terskikh, AV; Fradkov, AF; Zaraisky, AG; Kajava, AV; Angres, B				Terskikh, AV; Fradkov, AF; Zaraisky, AG; Kajava, AV; Angres, B			Analysis of DsRed mutants - Space around the fluorophore accelerates fluorescence development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; MUTAGENESIS; CORAL	Earlier mutagenesis of the red fluorescent protein drFP583, also called DsRed, resulted in a mutant named Fluorescent Timer (Terskikh, A., Fradkov, A., Ermakova, G., Zaraisky, A., Tan, P., Kajava, A. V., Zhao, X., Lukyanov, S., Matz, M., Kim, S., Weissman, I., and Siebert, P. (2000) Science 290, 1585-1588). Further mutagenesis generated variants with novel and improved fluorescent properties. The mutant called AG4 exhibits only green fluorescence. The mutant, called E5up (V105A), shows complete fluorophore maturation, eventually eliminating residual green fluorescence present in DsRed. Finally, the mutant, called E57 (V105A, I161T, S197A), matures faster than DsRed as demonstrated in vitro with purified protein and in vivo with recombinant protein expressed in Escherichia coli and Xenopus leavis. Comparative analysis of the mutants in the context of the crystal structure of DsRed suggests that mutants with free space around the fluorophore mature faster and more completely.	Stanford Univ, Dept Pathol, Sch Med, Beckman Ctr, Stanford, CA 94305 USA; Russian Acad Sci, Shemiakin & Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; NIH, Ctr Mol Modeling, Ctr Informat Technol, Bethesda, MD 20892 USA; BD Biosci Clontech, Palo Alto, CA 94303 USA	Stanford University; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT)	Terskikh, AV (corresponding author), Stanford Univ, Dept Pathol, Sch Med, Beckman Ctr, 279 Campus Dr, Stanford, CA 94305 USA.	Alexey.Terskikh@Stanford.edu	Zaraisky, Andrey G/Q-2323-2016; Terskikh, Alexey/U-8407-2019; Kajava, Andrey V/E-1107-2014	Zaraisky, Andrey G/0000-0003-4681-8169; Kajava, Andrey V/0000-0002-2342-6886	CENTER FOR INFORMATION TECHNOLOGY [Z01CT000259] Funding Source: NIH RePORTER	CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT))		Baird GS, 2000, P NATL ACAD SCI USA, V97, P11984, DOI 10.1073/pnas.97.22.11984; Bevis BJ, 2002, NAT BIOTECHNOL, V20, P83, DOI 10.1038/nbt0102-83; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Gross LA, 2000, P NATL ACAD SCI USA, V97, P11990, DOI 10.1073/pnas.97.22.11990; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Kimata Y, 1997, Tanpakushitsu Kakusan Koso, V42, P1187; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Patterson G, 2001, J CELL SCI, V114, P837; Terskikh A, 2000, SCIENCE, V290, P1585, DOI 10.1126/science.290.5496.1585; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Verkhusha VV, 2001, J BIOL CHEM, V276, P29621, DOI 10.1074/jbc.C100200200; Wall MA, 2000, NAT STRUCT BIOL, V7, P1133; Wiehler J, 2001, FEBS LETT, V487, P384, DOI 10.1016/S0014-5793(00)02365-6; Yarbrough D, 2001, P NATL ACAD SCI USA, V98, P462, DOI 10.1073/pnas.98.2.462; ZACHARIAS DA, 2000, 11 INT S BIOL CHEM S	18	63	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7633	7636		10.1074/jbc.C100694200	http://dx.doi.org/10.1074/jbc.C100694200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11773062	hybrid			2022-12-27	WOS:000174268000002
J	Xia, P; Wang, LJ; Moretti, PAB; Albanese, N; Chai, FG; Pitson, SM; D'Andrea, RJ; Gamble, JR; Vadas, MA				Xia, P; Wang, LJ; Moretti, PAB; Albanese, N; Chai, FG; Pitson, SM; D'Andrea, RJ; Gamble, JR; Vadas, MA			Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROGRAMMED CELL-DEATH; FACTOR RECEPTOR; ADAPTER PROTEINS; STRUCTURAL BASIS; TERMINAL KINASE; ACTIVATION; TNF; APOPTOSIS; SPHINGOSINE-1-PHOSPHATE	Tumor necrosis factor-alpha (TNF) receptor-associated factor 2 (TRAF2) is one of the major mediators of TNF receptor superfamily transducing TNF signaling to various functional targets, including activation of NF-kappaB, JNK, and antiapoptosis. We investigated how TRAF2 mediates differentially the distinct downstream signals. We now report a novel mechanism of TRAF2-mediated signal transduction revealed by an association of TRAF2 with sphingosine kinase (SphK), a lipid kinase that is responsible for the production of sphingosine 1-phosphate. We identified a TRAF2-binding motif of SphK that mediated the interaction between TRAF2 and SphK resulting in the activation of the enzyme, which in turn is required for TRAF2-mediated activation of NF-kappaB but not JNK In addition, by using a kinase inactive dominant-negative SphK and a mutant SphK that lacks TRAF2-binding motif we show that the interaction of TRAF2 with SphK and subsequent activation of SphK are critical for prevention of apoptosis during TNF stimulation. These findings show a role for SphK in the signal transduction by TRAF2 specifically leading to activation of NF-kappaB and antiapoptosis.	Inst Med & Vet Sci, Hanson Inst, Div Human Immunol, Adelaide, SA 5000, Australia; Univ Adelaide, Adelaide, SA 5000, Australia	Hanson Institute; Institute Medical & Veterinary Science Australia; University of Adelaide	Xia, P (corresponding author), Inst Med & Vet Sci, Hanson Inst, Div Human Immunol, Frome Rd, Adelaide, SA 5000, Australia.		Pitson, Stuart/B-9342-2009; Vadas, Mathew/R-1378-2019; Xia, Pu/G-3090-2010	Pitson, Stuart/0000-0002-9527-2740; Xia, Pu/0000-0003-4705-8878; Gamble, Jennifer/0000-0002-0179-9964				Adam-Klages S, 1998, J LEUKOCYTE BIOL, V63, P678, DOI 10.1002/jlb.63.6.678; Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Pitson SM, 2000, BIOCHEM J, V350, P429, DOI 10.1042/0264-6021:3500429; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; Shatrov VA, 1997, BIOCHEM BIOPH RES CO, V234, P121, DOI 10.1006/bbrc.1997.6598; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Xia P, 1999, J BIOL CHEM, V274, P33143, DOI 10.1074/jbc.274.46.33143; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Ye H, 2000, P NATL ACAD SCI USA, V97, P8961, DOI 10.1073/pnas.160241997; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453	49	242	262	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7996	8003		10.1074/jbc.M111423200	http://dx.doi.org/10.1074/jbc.M111423200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11777919	hybrid			2022-12-27	WOS:000174268000048
J	Clarke, TE; Braun, V; Winkelmann, G; Tari, LW; Vogel, HJ				Clarke, TE; Braun, V; Winkelmann, G; Tari, LW; Vogel, HJ			X-ray crystallographic structures of the Escherichia coli periplasmic protein FhuD bound to hydroxamate-type siderophores and the antibiotic albomycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; OUTER-MEMBRANE; IRON TRANSPORT; SOLUTION CONFORMATION; ACTIVE-TRANSPORT; BINDING; FERRICHROME; SPECIFICITY; RECEPTORS; CHELATORS	Siderophore-binding proteins play an essential role in the uptake of iron in many Gram-positive and Gram-negative bacteria. FhuD is an ATP-binding cassette-type (ABC-type) binding protein involved in the uptake of hydroxamate-type siderophores in Escherichia coli. Structures of FhuD complexed with the antibiotic albomycin, the fungal siderophore coprogen and the drug Desferal have been determined at high resolution by x-ray crystallography. FhuD has an unusual bilobal structure for a periplasmic ligand binding protein, with two mixed beta/alpha domains connected by a long alpha-helix. The binding site for hydroxamate-type ligands is composed of a shallow pocket that lies between these two domains. Recognition of siderophores primarily occurs through interactions between the iron-hydroxamate centers of each siderophore and the side chains of several key residues in the binding pocket. Rearrangements of side chains within the binding pocket accommodate the unique structural features of each siderophore. The backbones of the siderophores are not involved in any direct interactions with the protein, demonstrating how siderophores with considerable chemical and structural diversity can be bound by FhuD. For albomycin, which consists of an antibiotic group attached to a hydroxamate siderophore, electron density for the antibiotic portion was not observed. Therefore, this study provides a basis for the rational design of novel bacteriostatic agents, in the form of siderophore-antibiotic conjugates that can act as "Trojan horses," using the hydroxamate-type siderophore uptake system to actively deliver antibiotics directly into targeted pathogens.	Univ Calgary, Dept Biol Sci, Struct Biol Res Grp, Calgary, AB T2N 1N4, Canada; Univ Tubingen, Dept Microbiol Membranphysiol, D-72076 Tubingen, Germany	University of Calgary; Eberhard Karls University of Tubingen	Tari, LW (corresponding author), Univ Calgary, Dept Biol Sci, Struct Biol Res Grp, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	leslie.tari@syrrx.com; vogel@ucalgary.ca	Clarke, Teresa/ABA-7292-2021	Clarke, Teresa/0000-0001-9718-3226	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR012408] Funding Source: NIH RePORTER; NCRR NIH HHS [1P41 RR12408-01A1] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ATKIN CL, 1968, BIOCHEMISTRY-US, V7, P3734, DOI 10.1021/bi00850a054; Braun V, 1998, MET IONS BIOL SYST, V35, P67; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1111/j.1574-6976.1995.tb00177.x; BRAUN V, 1983, J BACTERIOL, V156, P308, DOI 10.1128/JB.156.1.308-315.1983; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; Clarke TE, 2000, NAT STRUCT BIOL, V7, P287; CLARKE TE, 2002, IN PRESS BIOMETALS; Clarke Teresa E., 2001, Current Topics in Medicinal Chemistry, V1, P7, DOI 10.2174/1568026013395623; CONSTANTINE KL, 1990, BIOPOLYMERS, V30, P239, DOI 10.1002/bip.360300303; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Ferguson AD, 2000, PROTEIN SCI, V9, P956, DOI 10.1110/ps.9.5.956; FOLAJTAR DA, 1982, J AM CHEM SOC, V104, P5775, DOI 10.1021/ja00385a036; HARTMANN A, 1979, EUR J BIOCHEM, V99, P517, DOI 10.1111/j.1432-1033.1979.tb13283.x; HERSHKO C, 1992, MOL ASPECTS MED, V13, P113, DOI 10.1016/0098-2997(92)90013-P; HOSSAIN MB, 1986, ACTA CRYSTALLOGR C, V42, P1305, DOI 10.1107/S0108270186092466; HOSSAIN MB, 1987, J AM CHEM SOC, V109, P4948, DOI 10.1021/ja00250a031; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LLINAS M, 1972, INT J PEPT PROT RES, V4, P157; LLINAS M, 1970, J MOL BIOL, V52, P399, DOI 10.1016/0022-2836(70)90409-2; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; MCLACHLAN DRC, 1991, CAN MED ASSOC J, V145, P793; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PUGSLEY AP, 1987, J GEN MICROBIOL, V133, P3505; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; ROHRBACH MR, 1995, J BACTERIOL, V177, P7186, DOI 10.1128/jb.177.24.7186-7193.1995; ROHRBACH MR, 1995, MOL GEN GENET, V248, P33, DOI 10.1007/BF02456611; Roosenberg JM, 2000, CURR MED CHEM, V7, P159, DOI 10.2174/0929867003375353; ROUSSEL A, 1989, TURBO FRODO SILICON; Schryvers AB, 1999, MOL MICROBIOL, V32, P1117, DOI 10.1046/j.1365-2958.1999.01411.x; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; VANDERHELM D, 1981, ACTA CRYSTALLOGR B, V37, P323, DOI 10.1107/S056774088100294X	36	106	109	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13966	13972		10.1074/jbc.M109385200	http://dx.doi.org/10.1074/jbc.M109385200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11805094	hybrid			2022-12-27	WOS:000175096000081
J	Pontsler, AV; St Hilaire, A; Marathe, GK; Zimmerman, GA; McIntyre, TM				Pontsler, AV; St Hilaire, A; Marathe, GK; Zimmerman, GA; McIntyre, TM			Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PPAR-GAMMA; ATHEROSCLEROTIC LESIONS; GENE-EXPRESSION; FATTY-ACIDS; TRANSCRIPTIONAL REGULATION; MONONUCLEAR PHAGOCYTES; ENDOTHELIAL-CELLS; CARCINOMA-CELLS; HUMAN PLASMA	Low density lipoprotein (LDL) oxidation and monocyte infiltration of the vessel wall underlie atherogenesis. These cells express cyclooxygenase-2, but the way oxidized LDL stimulates cyclooxygenase-2 transcription is unknown. Oxidized LDL, oxidatively fragmented phospholipids isolated from oxidized LDL, a synthetic oxidized alkylphospholipid (azPC) that is a potent peroxisome proliferator activated receptor (PPAR) gamma agonist, or the PPARgamma agonist rosiglitazone all induced cyclooxygenase-2 expression and enhanced prostaglandin E-2 (PGE(2)) secretion in primary human monocytes. The cyclooxygenase-2 inhibitor NS398 blocked PPARgamma-induced PGE(2) secretion. Phospholipase A(1) and A(2) digestion shows that oxidized alkylphospholipids, and not oxidized fatty acids, were the relevant agonists. The upstream PPAR-responsive element (PPRE) of cyclooxygenase-2 was required for induction of a luciferase reporter by oxidized phospholipids, azPC, and rosiglitazone, and a (COX-2 PPRE)(3)-luciferase reporter was responsive to these PPARgamma agonists. Circulating human monocytes do not contain PPARgamma, but PPARgamma was induced rapidly (<4 h) in monocytes upon ligation of surface ICAM-3, but not P-selectin glycoprotein-1 even though both interactions prime cytokine secretion. Cyclooxygenase-2 induction by oxidized phospholipids only occurred in monocytes containing PPARgamma. Thus PPARgamma was induced rapidly in primary monocytes by appropriate outside-in signaling, sensitizing them to previously undetectable agonists in oxidized LDL. Cyclooxygenase-2 and PGE(2) secretion are induced, not inhibited, by selective PPARy agonists that include oxidatively fragmented phospholipids in oxidized LDL.	Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; Univ Utah, Dept Human Mol Biol, Salt Lake City, UT 84112 USA; Univ Utah, Genet Program, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	McIntyre, TM (corresponding author), Univ Utah, Dept Pathol, 4130 EIHG,15 N 2030 E, Salt Lake City, UT 84112 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050153, R37HL044525, R01HL044513, R01HL044525] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 44513, HL 50153, HL 44525] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Babaev VR, 2000, CIRCULATION, V102, P176; Baker CSR, 1999, ARTERIOSCL THROM VAS, V19, P646, DOI 10.1161/01.ATV.19.3.646; Bamba H, 1999, INT J CANCER, V83, P470, DOI 10.1002/(SICI)1097-0215(19991112)83:4<470::AID-IJC6>3.3.CO;2-6; Belton O, 2000, CIRCULATION, V102, P840; BHUYAN BK, 1986, CANCER RES, V46, P1688; Bishop-Bailey D, 2000, BRIT J PHARMACOL, V129, P823, DOI 10.1038/sj.bjp.0703149; Bonazzi A, 2000, J BIOL CHEM, V275, P2837, DOI 10.1074/jbc.275.4.2837; Burleigh ME, 2000, CIRCULATION, V102, P42; Camp HS, 2000, DIABETES, V49, P539, DOI 10.2337/diabetes.49.4.539; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Cipollone F, 2001, CIRCULATION, V104, P921, DOI 10.1161/hc3401.093152; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; Delerive P, 2000, FEBS LETT, V471, P34, DOI 10.1016/S0014-5793(00)01364-8; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DIAGNE A, 1984, BIOCHIM BIOPHYS ACTA, V793, P221, DOI 10.1016/0005-2760(84)90324-2; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49; ELSTAD MR, 1988, J IMMUNOL, V140, P1618; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; Feldhaus MJ, 1998, J IMMUNOL, V161, P6280; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Fyrnys B, 1997, ADV EXP MED BIOL, V407, P93; Ghosh AK, 2000, J PHARMACOL EXP THER, V295, P802; GLAVIND J, 1952, ACTA PATHOL MIC SC, V30, P1; Hayflick JS, 1997, J BIOL CHEM, V272, P22207, DOI 10.1074/jbc.272.35.22207; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; Hong BK, 2000, YONSEI MED J, V41, P82, DOI 10.3349/ymj.2000.41.1.82; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Hull MA, 1999, BRIT J CANCER, V79, P1399, DOI 10.1038/sj.bjc.6690224; Hunter JG, 2001, J BIOL CHEM, V276, P38297; Ikawa H, 2001, EXP CELL RES, V267, P73, DOI 10.1006/excr.2001.5233; Inoue H, 2000, J BIOL CHEM, V275, P28028; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Jira W, 1998, CHEM PHYS LIPIDS, V91, P1, DOI 10.1016/S0009-3084(97)00095-9; Kessel JM, 1998, J IMMUNOL, V160, P5579; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Kitamura Y, 1999, BIOCHEM BIOPH RES CO, V254, P582, DOI 10.1006/bbrc.1998.9981; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Ledwith BJ, 1997, J BIOL CHEM, V272, P3707, DOI 10.1074/jbc.272.6.3707; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Leininger MT, 1999, BIOCHEM BIOPH RES CO, V263, P749, DOI 10.1006/bbrc.1999.1467; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; Mahoney TS, 2001, P NATL ACAD SCI USA, V98, P10284, DOI 10.1073/pnas.181201398; Marathe GK, 2001, J LIPID RES, V42, P1430; Marathe GK, 1999, J BIOL CHEM, V274, P28395, DOI 10.1074/jbc.274.40.28395; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; Maxey KM, 2000, PROSTAG OTH LIPID M, V62, P15, DOI 10.1016/S0090-6980(00)00072-1; McIntyre TM, 1999, J BIOL CHEM, V274, P25189, DOI 10.1074/jbc.274.36.25189; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Mummidi S, 2001, J BIOL CHEM, V276, P33196, DOI 10.1074/jbc.M009807200; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Paik JH, 2000, J BIOL CHEM, V275, P28173; Prescott SM, 2000, J CLIN INVEST, V105, P1511, DOI 10.1172/JCI10241; Reis ED, 2000, P NATL ACAD SCI USA, V97, P12764, DOI 10.1073/pnas.210394497; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Rizza C, 1999, LAB INVEST, V79, P1227; Schlame M, 1996, J LIPID RES, V37, P2608; Schonbeck U, 1999, AM J PATHOL, V155, P1281, DOI 10.1016/S0002-9440(10)65230-3; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Shattuck-Brandt RL, 2000, GASTROENTEROLOGY, V118, P337, DOI 10.1016/S0016-5085(00)70216-2; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Tokumura A, 1996, LIPIDS, V31, P1251, DOI 10.1007/BF02587909; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tsubouchi Y, 2001, BIOCHEM BIOPH RES CO, V283, P750, DOI 10.1006/bbrc.2001.4847; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; YAGI K, 1984, BIOESSAYS, V1, P58, DOI 10.1002/bies.950010205; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZEMBOWICZ A, 1995, J CLIN INVEST, V96, P1688, DOI 10.1172/JCI118211	79	92	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13029	13036		10.1074/jbc.M109546200	http://dx.doi.org/10.1074/jbc.M109546200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11809750	hybrid			2022-12-27	WOS:000175036300069
J	Sun, XM; Bratton, SB; Butterworth, M; MacFarlane, M; Cohen, GM				Sun, XM; Bratton, SB; Butterworth, M; MacFarlane, M; Cohen, GM			Bcl-2 and Bcl-x(L) inhibit CD95-mediated apoptosis by preventing mitochondrial release of Smac/DIABLO and subsequent inactivation of X-linked inhibitor-of-apoptosis protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CD95 TYPE-I; CASPASE ACTIVATION; STRUCTURAL BASIS; CELL-DEATH; SIGNALS APOPTOSIS; NMR STRUCTURE; XIAP; FAS; IAP	Bcl-2 and Bcl-x(L) are reported to inhibit CD95-mediated apoptosis in "type II" but not in "type I" cells. In the present studies, we found that stimulation of CD95 receptors, with either agonistic antibody or CD95 ligand, resulted in the activation of caspase-8, which in turn processed caspase-3 between its large and small subunits. However, in contrast to control cells, those overexpressing either Bcl-2 or Bcl-x(L) displayed a distinctive pattern of caspase-3 processing. Indeed, the resulting p20/p12 caspase-3 was not active and did not undergo normal autocatalytic processing to form p17/p12 caspase-3, because it was bound to and inhibited by endogenous X-linked inhibitor-of-apoptosis protein (XIAP). Importantly, Bcl-2 and Bcl-x(L) inhibited the release of both cytochrome c and Smac from mitochondria. However, since Smac alone was sufficient to promote caspase-3 activity in vitro by inactivating XIAP, we proposed the existence of a death receptor-induced, Smac-dependent and apoptosome-independent pathway. This type II pathway was subsequently reconstituted in vitro using purified recombinant proteins at endogenous concentrations. Thus, mitochondria and associated Bcl-2 and Bcl-x(L) proteins may play a functional role in death receptor-induced apoptosis by modulating the release of Smac. Our data strongly suggest that the relative ratios of XIAP (and other inhibitor-of-apoptosis proteins) to active caspase-3 and Smac may dictate, in part, whether a cell exhibits a type I or type II phenotype.	Univ Leicester, Med Res Council Toxicol Unit, Leicester LE1 9HN, Leics, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Leicester	Cohen, GM (corresponding author), Univ Leicester, Med Res Council Toxicol Unit, Lancaster Rd POB 138 Hodgkin Bldg Lancaster Rd, Leicester LE1 9HN, Leics, England.	gmc2@le.ac.uk	Cohen, Gerald M/A-1687-2008	Bratton, Shawn/0000-0003-2895-5020				Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Bratton SB, 2001, TRENDS PHARMACOL SCI, V22, P306, DOI 10.1016/S0165-6147(00)01718-1; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hartmann BL, 1999, ONCOGENE, V18, P713, DOI 10.1038/sj.onc.1202339; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Huang DCS, 2000, CELL DEATH DIFFER, V7, P754, DOI 10.1038/sj.cdd.4400683; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schmitz I, 1999, CELL DEATH DIFFER, V6, P821, DOI 10.1038/sj.cdd.4400569; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Sun CH, 2000, J BIOL CHEM, V275, P33777, DOI 10.1074/jbc.M006226200; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vu CCQ, 2001, J BIOL CHEM, V276, P37602, DOI 10.1074/jbc.M104810200; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhang XD, 2001, CANCER RES, V61, P7339; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	62	201	204	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11345	11351		10.1074/jbc.M109893200	http://dx.doi.org/10.1074/jbc.M109893200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801595	hybrid			2022-12-27	WOS:000174613100076
J	Yan, C; Naltner, A; Martin, M; Naltner, M; Fangman, JM; Gurel, O				Yan, C; Naltner, A; Martin, M; Naltner, M; Fangman, JM; Gurel, O			Transcriptional stimulation of the surfactant protein B gene by STAT3 in respiratory epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; ACTIVATION; LUNG; EXPRESSION; FAMILY; FETAL; PHOSPHORYLATION; FACTOR-3; PROMOTER; ALPHA	The function of the lung is dependent upon differentiation and proliferation of respiratory epithelial cells and the synthesis/secretion of surfactant lipids and proteins into air space. During the respiratory inflammatory response, cytokines produced by macrophages and epithelial cells in the respiratory system have significant influence on surfactant protein homeostasis. We report here that among family members of Janus family tyrosine kinase (JAK) and signal transducers and activators of transcription (STAT), only JAK 1 and STAT3 stimulated the -500 to +41 promoter activity of the surfactant protein B (SP-B) gene in respiratory epithelial cells. JAK1 and STAT3 were co-localized in alveolar type II epithelial cells where SP-B is synthesized and secreted. Interleukin 6 and interleukin 11, known to activate STAT3 synergistically, stimulated the SP-B promoter activity with retinoic acid, which is at least partially mediated through interactions between STAT3 and retinoid nuclear receptor enhanceosome proteins in pulmonary epithelial cells.	Childrens Hosp, Med Ctr, Div Pulm Biol, Grad Program Mol & Dev Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Yan, C (corresponding author), Childrens Hosp, Med Ctr, Div Pulm Biol, Grad Program Mol & Dev Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Cong.Yan@chmcc.org			NHLBI NIH HHS [HL-61803, HL56387, R01 HL061803] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056387, R01HL061803, P50HL056387] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Bogue CW, 1996, AM J PHYSIOL-LUNG C, V271, pL862, DOI 10.1152/ajplung.1996.271.5.L862; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BRUNO MA, 1995, AM J PHYSIOL-LUNG C, V268, pL381; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; George TN, 1997, PEDIATR RES, V41, P692, DOI 10.1203/00006450-199705000-00015; Holgate ST, 2000, CLIN EXP ALLERGY, V30, P1; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Massaro GD, 1996, AM J PHYSIOL-LUNG C, V270, pL305, DOI 10.1152/ajplung.1996.270.2.L305; Naltner A, 2000, J BIOL CHEM, V275, P56, DOI 10.1074/jbc.275.1.56; Naltner A, 2000, AM J PHYSIOL-LUNG C, V279, pL1066, DOI 10.1152/ajplung.2000.279.6.L1066; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; Stahlman MT, 1996, J HISTOCHEM CYTOCHEM, V44, P673, DOI 10.1177/44.7.8675988; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Takizawa H, 1998, INT J MOL MED, V1, P367; Tokieda K, 1997, AM J PHYSIOL-LUNG C, V273, pL875, DOI 10.1152/ajplung.1997.273.4.L875; Ward NS, 2000, AM J RESP CELL MOL, V22, P535, DOI 10.1165/ajrcmb.22.5.3808; Waxman AB, 1999, CHEST, V116, p8S, DOI 10.1378/chest.116.suppl_1.8S; WHITSETT JA, 1995, PHYSIOL REV, V75, P749, DOI 10.1152/physrev.1995.75.4.749; Yan C, 1997, J BIOL CHEM, V272, P17327, DOI 10.1074/jbc.272.28.17327; YAN C, 1990, J BIOL CHEM, V265, P20188; Yan C, 2001, J BIOL CHEM, V276, P21686, DOI 10.1074/jbc.M011378200; Yan C, 1998, AM J PHYSIOL-LUNG C, V275, pL239, DOI 10.1152/ajplung.1998.275.2.L239; YAN C, 1995, J BIOL CHEM, V270, P24852, DOI 10.1074/jbc.270.42.24852; Zhang P, 2000, IMMUNOL REV, V173, P39, DOI 10.1034/j.1600-065X.2000.917306.x; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	36	52	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10967	10972		10.1074/jbc.M109986200	http://dx.doi.org/10.1074/jbc.M109986200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11788590	hybrid			2022-12-27	WOS:000174613100028
J	Gil, A; Gutierrez, LM; Carrasco-Serrano, C; Alonso, MT; Viniegra, S; Criado, M				Gil, A; Gutierrez, LM; Carrasco-Serrano, C; Alonso, MT; Viniegra, S; Criado, M			Modifications in the C terminus of the synaptosome-associated protein of 25 kDa (SNAP-25) and in the complementary region of synaptobrevin affect the final steps of exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM NEUROTOXIN-A; PERMEABILIZED CHROMAFFIN CELLS; SNARE COMPLEX; KINETIC COMPONENTS; STRUCTURAL-CHANGES; MEMBRANE-FUSION; MECHANISM; INHIBITION; DOCKING; RELEASE	Fusion proteins made Of green fluorescent protein coupled to SNAP-25 or synaptobrevin were overexpressed in bovine chromaffin cells in order to study the role of critical protein domains in exocytosis. Point mutations in the C-terminal domain of SNAP-25 (K201E and L203E) produced a marked inhibition of secretion, whereas single (Q174K, Q53K) and double mutants (Q174K/Q53K) of amino acids from the so-called zero layer only produced a moderate alteration in secretion. The importance of the SNAP-25 C-terminal domain in exocytosis was also confirmed by the similar effect on secretion of mutations in analogous residues of synaptobrevin (A82D, L84E). The effects on the initial rate and magnitude of secretion correlated with the alteration of single vesicle fusion kinetics since the amperometric spikes from cells expressing SNAP-25 L203E and K201E and synaptobrevin A82D and L84E mutants had lower amplitudes and larger half-width values than the ones from controls, suggesting slower neurotransmitter release kinetics than that found in cells expressing the wild-type proteins or zero layer mutants of SNAP-25. We conclude that a small domain of the SNAP-25 C terminus and its counterpart in synaptobrevin play an essential role in the final membrane fusion step of exocytosis.	Univ Miguel Hernandez, CSIC, Dept Biochem & Mol Biol, San Juan 03550, Alicante, Spain; Univ Miguel Hernandez, CSIC, Inst Neurociencias, San Juan 03550, Alicante, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Criado, M (corresponding author), Univ Miguel Hernandez, CSIC, Dept Biochem & Mol Biol, San Juan 03550, Alicante, Spain.		Criado, Manuel/K-5109-2014; Gutierrez, Luis/K-8633-2014; Viniegra, Salvador/K-5063-2014	Criado, Manuel/0000-0002-3953-0346; Gutierrez, Luis/0000-0002-0512-7858; Viniegra, Salvador/0000-0002-3892-8563				ARCHER BT, 1990, J BIOL CHEM, V265, P17267; Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; BARK IC, 1994, GENE, V139, P291, DOI 10.1016/0378-1119(94)90773-0; BENNETT M, 1993, P NATL ACAD SCI USA, P2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Colliver TL, 2000, J NEUROCHEM, V74, P1086; Criado M, 1999, P NATL ACAD SCI USA, V96, P7256, DOI 10.1073/pnas.96.13.7256; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; GELLER AI, 1993, P NATL ACAD SCI USA, V90, P7603, DOI 10.1073/pnas.90.16.7603; Gil A, 1998, EUR J NEUROSCI, V10, P3369, DOI 10.1046/j.1460-9568.1998.00341.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gutierrez LM, 1997, J BIOL CHEM, V272, P2634, DOI 10.1074/jbc.272.5.2634; HERRINGTON J, 1994, PULSE CONTROL V43 IG; Katz L, 1998, EMBO J, V17, P6200, DOI 10.1093/emboj/17.21.6200; LAWRENCE GW, 1994, EUR J BIOCHEM, V222, P325, DOI 10.1111/j.1432-1033.1994.tb18871.x; Lawrence GW, 1997, BIOCHEMISTRY-US, V36, P3061, DOI 10.1021/bi9622478; Lim F, 1996, BIOTECHNIQUES, V20, P460; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Pihel K, 1996, BIOPHYS J, V71, P1633, DOI 10.1016/S0006-3495(96)79368-2; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Rice LM, 1997, FEBS LETT, V415, P49, DOI 10.1016/S0014-5793(97)01091-0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; Schroeder TJ, 1996, BIOPHYS J, V70, P1061, DOI 10.1016/S0006-3495(96)79652-2; Segura F, 2000, J NEUROSCI METH, V103, P151, DOI 10.1016/S0165-0270(00)00309-5; SPAETE RR, 1982, CELL, V30, P285; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wei SH, 2000, EMBO J, V19, P1279, DOI 10.1093/emboj/19.6.1279; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642	37	36	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9904	9910		10.1074/jbc.M110182200	http://dx.doi.org/10.1074/jbc.M110182200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11786540	hybrid			2022-12-27	WOS:000174549200041
J	Jiang, H; Peterson, RS; Wang, WH; Bartnik, E; Knudson, CB; Knudson, W				Jiang, H; Peterson, RS; Wang, WH; Bartnik, E; Knudson, CB; Knudson, W			A requirement for the CD44 cytoplasmic domain for hyaluronan binding, pericellular matrix assembly, and receptor-mediated endocytosis in COS-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTICULAR CHONDROCYTES; ANTISENSE INHIBITION; TRANSMEMBRANE DOMAIN; IDENTIFICATION; INTERNALIZATION; DEGRADATION; EXPRESSION; ACID; PHOSPHORYLATION; KERATINOCYTES	CD44-negative COS-7 cells were transfected with expression constructs for CD44 (H) under bar (the predominant CD44 isoform), CD44 (E) under bar (epithelial isoform), or truncation mutant derivatives lacking the carboxyl-terminal 67 amino acids of the cytoplasmic domain, CD44 (H) under bar Delta67 and CD44 (E) under bar Delta67. The truncation mutant CD44HDelta67 is identical to a naturally occurring alternatively spliced "short tail" CD44 isoform (CD44st), which incorporates exon 19 in place of exon 20. CD44st lacks intracellular signaling motifs as well as protein domains necessary for interaction with cytoskeletal components. Transfection of COS-7 cells with each construct yielded equivalent levels of mRNA expression, whereas no CD44 expression was observed in parental, nontransfected COS-7 cells. Western analysis and immunostaining of COS-7 transfectants confirmed CD44 protein expression of the truncation mutant derivatives. COS-7 cells transfected with CD44H or CD44E gained the capacity to bind fluorescein-conjugated HA (fl-HA) and assemble HA-dependent pericellular matrices in the presence of exogenously added HA and proteoglyean. In addition, the CD44H- and CD44E-transfected cells were able to internalize surface-bound fl-HA. COS-7 cells transfected with the vector alone or with either of the mutant CD44 isoforms, CD44HDelta67 or CD44EDelta67, did not exhibit the capacity to assemble pericellular matrices or to bind and internalize the fl-HA. Cotransfection of CD44Delta67 mutants together with CD44H reduced the size of the HA-dependent pericellular matrices. Transfection of bovine articular chondrocytes with CD44Delta67 also inhibited pericellular matrix assembly. Collectively, these results indicate an obligatory requirement for the CD44 receptor cytoplasmic domain for ligand (HA) binding, formation and retention of the pericellular matrix, as well as CD44-mediated endocytosis of HA. In addition, the results suggest a potential regulatory role for the differentially expressed alternatively spliced short tail CD44 isoform.	Rush Presbyterian St Lukes Med Ctr, Rush Med Coll, Dept Biochem, Chicago, IL 60612 USA; Aventis Pharma Deutschland GmbH, DG Thrombot & Degenerat Joint Dis, D-65926 Frankfurt, Germany	Rush University; Sanofi-Aventis	Knudson, W (corresponding author), Rush Presbyterian St Lukes Med Ctr, Rush Med Coll, Dept Biochem, 1653 W Congress Pkwy, Chicago, IL 60612 USA.	wknudson@rush.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039239, R01AR039507, R01AR043384] Funding Source: NIH RePORTER; NIAMS NIH HHS [P50-AR39239, R01 AR043384, R01 AR039507, R01-AR39507] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aguiar DJ, 1999, EXP CELL RES, V252, P292, DOI 10.1006/excr.1999.4641; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; CHOW G, 1995, J BIOL CHEM, V270, P27734, DOI 10.1074/jbc.270.46.27734; Chow G, 1998, ARTHRITIS RHEUM-US, V41, P1411, DOI 10.1002/1529-0131(199808)41:8<1411::AID-ART10>3.0.CO;2-Z; Clark RA, 1996, J CELL BIOL, V134, P1075, DOI 10.1083/jcb.134.4.1075; CULTY M, 1994, J CELL PHYSIOL, V160, P275, DOI 10.1002/jcp.1041600209; CULTY M, 1992, J CELL BIOL, V116, P1055, DOI 10.1083/jcb.116.4.1055; GOLDSTEIN LA, 1990, IMMUNOGENETICS, V32, P389; HUA Q, 1993, J CELL SCI, V106, P365; Jiang H, 2001, ARTHRITIS RHEUM-US, V44, P2599, DOI 10.1002/1529-0131(200111)44:11<2599::AID-ART440>3.0.CO;2-Y; KALOMIRIS EL, 1988, J CELL BIOL, V106, P319, DOI 10.1083/jcb.106.2.319; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Knudson CB, 1999, BIOCHEM SOC T, V27, P142, DOI 10.1042/bst0270142; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; Knudson CB, 1998, WENN GR INT, V72, P161; Knudson W, 1996, EXP CELL RES, V228, P216, DOI 10.1006/excr.1996.0320; KNUDSON W, 1993, P NATL ACAD SCI USA, V90, P4003, DOI 10.1073/pnas.90.9.4003; KNUDSON W, 1999, GLYCOFORUM, P1; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Lesley J, 2000, EUR J IMMUNOL, V30, P245, DOI 10.1002/1521-4141(200001)30:1<245::AID-IMMU245>3.3.CO;2-O; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; Liu D, 1996, J EXP MED, V183, P1987, DOI 10.1084/jem.183.5.1987; Liu DC, 1997, J IMMUNOL, V159, P2702; Liu DC, 1998, CELL IMMUNOL, V190, P132, DOI 10.1006/cimm.1998.1397; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; Madry H, 2000, GENE THER, V7, P286, DOI 10.1038/sj.gt.3301086; Nishida Y, 1999, J BIOL CHEM, V274, P21893, DOI 10.1074/jbc.274.31.21893; Nishida Y, 2000, ARTHRITIS RHEUM, V43, P1315, DOI 10.1002/1529-0131(200006)43:6<1315::AID-ANR14>3.0.CO;2-#; ORKIN RW, 1982, J BIOL CHEM, V257, P5821; PERSCHL A, 1995, EUR J IMMUNOL, V25, P495, DOI 10.1002/eji.1830250228; PURE E, 1995, J EXP MED, V181, P55, DOI 10.1084/jem.181.1.55; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Tammi R, 2001, J BIOL CHEM, V276, P35111, DOI 10.1074/jbc.M103481200; UFF CR, 1995, EUR J IMMUNOL, V25, P1883, DOI 10.1002/eji.1830250714; Zhou B, 2000, J BIOL CHEM, V275, P37733, DOI 10.1074/jbc.M003030200	37	79	80	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10531	10538		10.1074/jbc.M108654200	http://dx.doi.org/10.1074/jbc.M108654200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11792695	hybrid			2022-12-27	WOS:000174549200122
J	Molinaro, A; De Castro, C; Lanzetta, R; Evidente, A; Parrilli, M; Holst, O				Molinaro, A; De Castro, C; Lanzetta, R; Evidente, A; Parrilli, M; Holst, O			Lipopolysaccharides possessing two L-glycero-D-manno-heptopyranosyl-alpha-(1 -> 5)-3-deoxy-D-manno-oct-2-ulopyranosonic acid moieties in the core region - The structure of the core region of the lipopolysaccharides from Burkholderia caryophylli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENUS-SPECIFIC EPITOPE; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; ACETYL SUBSTITUTION; C-13 ASSIGNMENTS; ROUGH STRAIN; POLYSACCHARIDE; IDENTIFICATION; PERMETHYLATION; BIOSYNTHESIS	The carbohydrate backbone of the core-lipid A region was characterized from the lipopolysaccharides (LPSs) of the plant-pathogenic bacterium Burkholderia caryophylli. For the first time, the presence of two moieties of L-glycero-D-manno-heptopyranosyl-alpha-(1-->5)-3-deoxy-D-manno-oct-2-ulopyranosonic acid was identified in a core region, which is of particular interest with regard to the biosynthesis of this and of LPSs in general. The LPSs of B. caryophylli were degraded by mild hydrazinolysis (de-O-acylation), treatment with 48% aqueous HF at 4 degreesC (cleavage of phosphate groups and destruction of the O-specific polysaccharides), reduction with NaBH4, and de-N-acylation utilizing hot KOH. The major oligosaccharide representing the carbohydrate backbone of the core region and lipid A was isolated by high-performance anion-exchange chromatography. Its analysis employing compositional and methylation analyses, matrix-assisted laser desorption/ionization mass spectrometry, and H-1 and C-13 NMR spectroscopy applying various one-dimensional and two-dimensional experiments identified the following structure. [GRAPHICS] All sugars are pyranoses and alpha-linked, if not stated otherwise. Hep, is L-glycero-D-manno-heptose, Kdo is 3-de-oxy-D-manno-oct-2-ulosonic acid.	Univ Naples Federico II, Dipartimento Chim Organ & Biochim, I-80126 Naples, Italy; Res Ctr Borstel, Div Struct Biochem, Ctr Med & Biosci, D-23845 Borstel, Germany; Univ Naples Federico II, Dipartimento Sci Chimicoagr, I-80055 Portici, Italy	University of Naples Federico II; Forschungszentrum Borstel; University of Naples Federico II	Holst, O (corresponding author), Res Ctr Borstel, Div Struct Biochem, Ctr Med & Biosci, Parkallee 22, D-23845 Borstel, Germany.	oholst@fz-borstel.de	Molinaro, Antonio/J-1866-2012; Evidente, Antonio/N-9357-2013; De Castro, Cristina/I-5899-2012	Evidente, Antonio/0000-0001-9110-1656; De Castro, Cristina/0000-0002-5147-1756; Parrilli, Michelangelo/0000-0001-8858-3623; Molinaro, Antonio/0000-0002-3456-7369; LANZETTA, Rosa/0000-0002-1472-5825				ADINOLFI M, 1995, CARBOHYD RES, V274, P223, DOI 10.1016/0008-6215(95)00127-F; ADINOLFI M, 1995, CARBOHYD RES, V267, P307, DOI 10.1016/0008-6215(94)00302-V; Adinolfi M, 1996, CARBOHYD RES, V284, P119, DOI 10.1016/0008-6215(96)00019-5; Adinolfi M, 1996, CARBOHYD RES, V284, P111, DOI 10.1016/0008-6215(96)00018-3; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BIRNBAUM GI, 1987, J CARBOHYD CHEM, V6, P17, DOI 10.1080/07328308708058858; Brade H, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P229; Burkholder WH, 1941, PHYTOPATHOLOGY, V31, P199; CHRISTIAN R, 1985, TETRAHEDRON LETT, V26, P3951, DOI 10.1016/S0040-4039(00)98695-7; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; De Castro C, 2001, CARBOHYD RES, V335, P205, DOI 10.1016/S0008-6215(01)00220-8; Dow M, 2000, ANNU REV PHYTOPATHOL, V38, P241, DOI 10.1146/annurev.phyto.38.1.241; GOLDMAN RC, 1988, J BIOL CHEM, V263, P5217; Gronow S, 2001, J ENDOTOXIN RES, V7, P3, DOI 10.1179/096805101101532468; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; Heinrichs DE, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P305; HOLST O, 1991, CARBOHYD RES, V215, P323, DOI 10.1016/0008-6215(91)84031-9; HOLST O, 1995, EUR J BIOCHEM, V229, P194, DOI 10.1111/j.1432-1033.1995.tb20455.x; HOLST O, 1989, CARBOHYD RES, V188, P212, DOI 10.1016/0008-6215(89)84073-X; HOLST O, 1993, EUR J BIOCHEM, V214, P703, DOI 10.1111/j.1432-1033.1993.tb17971.x; Holst O, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P115; HOLST O, 1994, EUR J BIOCHEM, V222, P183, DOI 10.1111/j.1432-1033.1994.tb18856.x; HOLST O, 2000, METHODS MOL BIOL BAC, P345; ISSHIKI Y, 1998, 5 C INT END SOC SEP; KACA W, 1988, CARBOHYD RES, V179, P289, DOI 10.1016/0008-6215(88)84125-9; KANNENBERG EL, 1998, RHIZOBIACEAE, P119; KAWAHARA K, 1998, 5 C INT END SOC SANT; MAMAT U, 1998, COMPREHENSIVE NATURA, V3, P179; MOHAN S, 1994, J BACTERIOL, V176, P6944, DOI 10.1128/JB.176.22.6944-6951.1994; Molinaro A, 2000, ANGEW CHEM INT EDIT, V39, P156, DOI 10.1002/(SICI)1521-3773(20000103)39:1<156::AID-ANIE156>3.0.CO;2-B; Moll H, 1997, CARBOHYD RES, V304, P91, DOI 10.1016/S0008-6215(97)00210-3; PALLERONI NJ, 1993, ANTON LEEUW INT J G, V64, P231, DOI 10.1007/BF00873084; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; RADZIEJEWSKALEBRECHT J, 1989, EUR J BIOCHEM, V183, P573, DOI 10.1111/j.1432-1033.1989.tb21086.x; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Rick PD, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P283; RUCKER SP, 1989, MOL PHYS, V68, P509, DOI 10.1080/00268978900102331; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUMMERS MF, 1986, J AM CHEM SOC, V108, P4285, DOI 10.1021/ja00275a008; Susskind M, 1998, J BIOL CHEM, V273, P7006, DOI 10.1074/jbc.273.12.7006; Velasco J, 1998, CARBOHYD RES, V306, P283, DOI 10.1016/S0008-6215(97)10029-5; Vinogradov E, 2000, EUR J BIOCHEM, V267, P262, DOI 10.1046/j.1432-1327.2000.01001.x; VINOGRADOV EV, 1992, EUR J BIOCHEM, V210, P491, DOI 10.1111/j.1432-1033.1992.tb17447.x	43	33	33	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10058	10063		10.1074/jbc.M110283200	http://dx.doi.org/10.1074/jbc.M110283200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11790781	hybrid			2022-12-27	WOS:000174549200061
J	Ryan, SE; Hill, DG; Baenziger, JE				Ryan, SE; Hill, DG; Baenziger, JE			Dissecting the chemistry of nicotinic receptor-ligand interactions with infrared difference spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE BINDING-SITE; TORPEDO-CALIFORNICA; ALPHA-SUBUNIT; DESENSITIZATION; RESIDUES; AGONISTS; LIPIDS	The physical interactions that occur between the nicotinic acetylcholine receptor from Torpedo and the agonists carbamylcholine and tetramethylamine have been studied using both conventional infrared difference spectroscopy and a novel double-ligand difference technique. The latter was developed to isolate vibrational bands from residues in a membrane receptor that interact with individual functional groups on a small molecule ligand. The binding of either agonist leads to an increase in vibrational intensity at frequencies centered near 1663, 1655, 1547, 1430, and 1059 cm(-1) indicating that both induce a conformational change from the resting to the desensitized state. Vibrational shifts near 1580, 1516, 1455, 1334, and between 1300 and 1400 cm(-1) are assigned to structural perturbations of tyrosine and possibly both tryptophan and charged carboxylic acid residues upon the formation of receptor-quaternary amine interactions, with the relatively intense feature near 1516 cm(-1) indicating a key role for tyrosine. Other vibrational bands suggest the involvement of additional side chains in agonist binding. Two side-chain vibrational shifts from 1668 and 1605 cm-1 to 1690 and 1620 cm(-1), respectively, could reflect the formation of a hydrogen bond between the ester carbonyl of carbamylcholine and an arginine residue. The results demonstrate the potential of the double-ligand difference technique for dissecting the chemistry of membrane receptor-ligand interactions and provide new insight into the nature of nicotinic receptor-agonist interactions.	Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Baenziger, JE (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.			Baenziger, John/0000-0002-2888-5328				AYLWIN ML, 1994, MOL PHARMACOL, V46, P1149; Baenziger JE, 1997, BIOCHEMISTRY-US, V36, P3617, DOI 10.1021/bi962845m; Baenziger JE, 2000, J BIOL CHEM, V275, P777, DOI 10.1074/jbc.275.2.777; BAENZIGER JE, 1992, BIOPHYS J, V61, P983, DOI 10.1016/S0006-3495(92)81905-7; BAENZIGER JE, 1993, BIOCHEMISTRY-US, V32, P5448, DOI 10.1021/bi00071a022; BAENZIGER JE, 2002, VIBRATIONAL SPECTROS; Barth A, 2000, PROG BIOPHYS MOL BIO, V74, P141, DOI 10.1016/S0079-6107(00)00021-3; BOYD ND, 1980, BIOCHEMISTRY-US, V19, P5344, DOI 10.1021/bi00564a031; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CHANGEUX JP, 1992, Q REV BIOPHYS, V25, P395, DOI 10.1017/S0033583500004352; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; Fahmy K, 1998, BIOPHYS J, V75, P1306, DOI 10.1016/S0006-3495(98)74049-4; Heberle J, 1996, APPL SPECTROSC, V50, P588, DOI 10.1366/0003702963905907; Kearney PC, 1996, MOL PHARMACOL, V50, P1401; LUYTEN WHML, 1986, J NEUROSCI RES, V16, P51, DOI 10.1002/jnr.490160107; MCCARTHY MP, 1992, J BIOL CHEM, V267, P7655; MICHELSON M, 1973, ACETYLCHOLINE APPROA; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; PETERSON GL, 1989, J NEUROSCI RES, V22, P488, DOI 10.1002/jnr.490220415; Ryan SE, 2001, J BIOL CHEM, V276, P4796, DOI 10.1074/jbc.M007063200; Ryan SE, 1996, J BIOL CHEM, V271, P24590, DOI 10.1074/jbc.271.40.24590; Ryan SE, 1999, MOL PHARMACOL, V55, P348, DOI 10.1124/mol.55.2.348; SINE SM, 1994, J BIOL CHEM, V269, P8808; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088; Zscherp C, 2001, BIOCHEMISTRY-US, V40, P1875, DOI 10.1021/bi002567y	29	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10420	10426		10.1074/jbc.M107412200	http://dx.doi.org/10.1074/jbc.M107412200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11782459	hybrid			2022-12-27	WOS:000174549200108
J	Weyand, M; Schlichting, I; Herde, P; Marabotti, A; Mozzarelli, A				Weyand, M; Schlichting, I; Herde, P; Marabotti, A; Mozzarelli, A			Crystal structure of the beta Ser(178) -> Pro mutant of tryptophan synthase - A "knock-out" allosteric enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(2)BETA(2) COMPLEX REVEALS; INDUCED CONFORMATIONAL-CHANGES; ALPHA-SUBUNIT; SALMONELLA-TYPHIMURIUM; BIENZYME COMPLEX; ESCHERICHIA-COLI; BETA-SUBUNIT; INTERSUBUNIT COMMUNICATION; INDOLE-3-GLYCEROL PHOSPHATE; MACROMOLECULAR STRUCTURES	The catalytic activity of the pyridoxal 5'-phosphate-dependent tryptophan synthase alpha(2)/beta(2) complex is allosterically regulated. The hydrogen bond between the helix betaH6 residue betaSer(178) and the loop alphaL6 residue Gly(181) was shown to be critical in ligand-induced inter-subunit signaling, with the alpha-beta communication being completely lost in the mutant betaSer(178) --> Pro (Marabotti, A., De Biase, D., Tramonti, A., Bettati, S., and Mozzarelli, A (2001) J. Biol Chem. 276,17747-17753). The structural basis of the impaired allosteric regulation was investigated by determining the crystal structures of the mutant betaSer(178) --> Pro in the absence and presence of the a-subunit ligands indole-3-acetylglycine and glycerol 3-phosphate. The mutation causes local and distant conformational changes especially in the beta-subunit. The ligand-free structure exhibits larger differences at the N-terminal part of helix betaH6, whereas the enzyme ligand complexes show differences at the C-terminal side. In contrast to the wild-type enzyme loop alphaL6 remains in an open conformation even in the presence of alpha-ligands. This effects the equilibrium between active and inactive conformations of the alpha-active site, altering k(cat) and K-m, and forms the structural basis for the missing allosteric communication between the alpha- and beta-subunits.	Max Planck Inst Mol Physiol, Phys Biochem Abt, D-44227 Dortmund, Germany; Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; Univ Parma, Natl Inst Phys Matter, I-43100 Parma, Italy	Max Planck Society; University of Parma; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Parma	Schlichting, I (corresponding author), Max Planck Inst Mol Physiol, Phys Biochem Abt, D-44227 Dortmund, Germany.	ilme.schlichting@mpi-dortmund.mpg.de	Schlichting, Ilme/I-1339-2013; Mozzarelli, Andrea/C-3615-2014	Mozzarelli, Andrea/0000-0003-3762-0062; Marabotti, Anna/0000-0002-9510-5205				ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRZOVIC PS, 1993, BIOCHEMISTRY-US, V32, P10404, DOI 10.1021/bi00090a016; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P1180, DOI 10.1021/bi00119a030; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Ferrari D, 2001, BIOCHEMISTRY-US, V40, P7421, DOI 10.1021/bi002892l; Hiraga K, 1997, J BIOL CHEM, V272, P4935, DOI 10.1074/jbc.272.8.4935; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LU ZC, 1993, J BIOL CHEM, V268, P8727; Marabotti A, 2001, J BIOL CHEM, V276, P17747, DOI 10.1074/jbc.M011781200; Marabotti A, 2000, BBA-PROTEIN STRUCT M, V1476, P287, DOI 10.1016/S0167-4838(99)00242-3; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miles E W, 1995, Subcell Biochem, V24, P207; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OGASAHARA K, 1992, J BIOL CHEM, V267, P5222; Pan P, 1996, BIOCHEMISTRY-US, V35, P5002, DOI 10.1021/bi960033k; PERACCHI A, 1995, BIOCHEMISTRY-US, V34, P9459, DOI 10.1021/bi00029a022; Peracchi A, 1996, BIOCHEMISTRY-US, V35, P1872, DOI 10.1021/bi951889c; Rhee S, 1998, J BIOL CHEM, V273, P8553, DOI 10.1074/jbc.273.15.8553; Rhee S, 1998, BIOCHEMISTRY-US, V37, P10653, DOI 10.1021/bi980779d; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; Rowlett R, 1998, BIOCHEMISTRY-US, V37, P2961, DOI 10.1021/bi972286z; RUVINOV SB, 1995, J BIOL CHEM, V270, P17333, DOI 10.1074/jbc.270.29.17333; Sachpatzidis A, 1999, BIOCHEMISTRY-US, V38, P12665, DOI 10.1021/bi9907734; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; SCHOMBURG D, 1988, J MOL GRAPHICS, V6, P161, DOI 10.1016/0263-7855(88)80069-9; WEISCHET WO, 1976, EUR J BIOCHEM, V65, P365, DOI 10.1111/j.1432-1033.1976.tb10350.x; Weyand M, 1999, BIOCHEMISTRY-US, V38, P16469, DOI 10.1021/bi9920533; Weyand M, 2002, J BIOL CHEM, V277, P10647, DOI 10.1074/jbc.M111285200; YANG XJ, 1992, J BIOL CHEM, V267, P7520; YANG XJ, 1993, J BIOL CHEM, V268, P22269	48	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10653	10660		10.1074/jbc.M111031200	http://dx.doi.org/10.1074/jbc.M111031200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11756454	hybrid			2022-12-27	WOS:000174549200138
J	Cao, HM; Courchesne, WE; Mastick, CC				Cao, HM; Courchesne, WE; Mastick, CC			A phosphotyrosine-dependent protein interaction screen reveals a role for phosphorylation of caveolin-1 on tyrosine 14 - Recruitment of C-terminal Src kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-GROWTH; INTEGRIN; FAMILY; MEMBRANE; SITES; CSK; FYN	Caveolin-1 is a substrate for nonreceptor tyrosine kinases including Src, Fyn, and Abl. To investigate the function of caveolin-1 phosphorylation, we modified the Gal4-based yeast two-hybrid system to screen for phosphorylation-dependent protein interactions. A cDNA library was screened using the N terminus of caveolin-1 as bait in a yeast strain expressing the catalytic domain of Abl. We identified two proteins in this screen that interact with caveolin-1 in a phosphorylation-dependent manner: tumor necrosis factor-a receptor-associated factor 2 (TRAF2) and C-terminal Src kinase (Csk). TRAF2 bound to nonphosphorylated caveolin-1, but this association was increased 3-fold by phosphorylation. In contrast, association of Csk with caveolin-1 was completely dependent on phosphorylation of caveolin-1, both for fusion proteins in yeast (>35-fold difference in affinity) and for endogenous proteins in tissue culture cells. Our data suggest that phosphorylation of caveolin-1 leads to Csk translocation into caveolae. This may induce a feedback loop that leads to inactivation of the Src family kinases that are highly enriched in caveolae.	Univ Nevada, Dept Biochem, Reno, NV 89557 USA; Univ Nevada, Dept Microbiol, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno	Mastick, CC (corresponding author), Univ Nevada, Dept Biochem, Mail Stop 330, Reno, NV 89557 USA.		Mastick, Cynthia/G-9841-2017; Cao, Haiming/P-4634-2016	Mastick, Cynthia/0000-0003-4769-5412; 	NIDDK NIH HHS [DK56197] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056197] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Aoki T, 1999, EXP CELL RES, V253, P629, DOI 10.1006/excr.1999.4652; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Feng X, 2001, J BIOL CHEM, V276, P8341, DOI 10.1074/jbc.M007116200; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Ko YG, 1998, J CELL BIOCHEM, V71, P524, DOI 10.1002/(SICI)1097-4644(19981215)71:4<524::AID-JCB7>3.3.CO;2-2; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; Mastick CC, 2001, EXP CELL RES, V266, P142, DOI 10.1006/excr.2001.5205; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; Nomura R, 1999, MOL BIOL CELL, V10, P975, DOI 10.1091/mbc.10.4.975; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Stahlhut M, 2000, EXP CELL RES, V261, P111, DOI 10.1006/excr.2000.4960; Stearman R, 1998, GENE, V212, P197, DOI 10.1016/S0378-1119(98)00179-6; Takeuchi S, 2000, J BIOL CHEM, V275, P29183, DOI 10.1074/jbc.C000326200; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470	28	173	177	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8771	8774		10.1074/jbc.C100661200	http://dx.doi.org/10.1074/jbc.C100661200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11805080	hybrid			2022-12-27	WOS:000174400600005
J	Katschinski, DM; Le, L; Heinrich, D; Wagner, KF; Hofer, T; Schindler, SG; Wenger, RH				Katschinski, DM; Le, L; Heinrich, D; Wagner, KF; Hofer, T; Schindler, SG; Wenger, RH			Heat induction of the unphosphorylated form of hypoxia-inducible factor-1 alpha is dependent on heat shock protein-90 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; HELIX-LOOP-HELIX; UBIQUITIN-PROTEASOME PATHWAY; DIOXIN SIGNAL-TRANSDUCTION; FACTOR 1-ALPHA HIF-1-ALPHA; ARNT TRANSCRIPTION FACTOR; GLUCOCORTICOID RECEPTOR; BINDING-ACTIVITY; FACTOR-I; HSP90	Hypoxia-inducible factor (HIF)-1alpha is the oxygen-sensitive subunit of HIF-1alpha transcriptional master regulator of oxygen homeostasis. Oxygen-dependent prolyl hydroxylation targets HIF-1alpha for ubiquitinylation and proteasomal degradation. Unexpectedly, we found that exposing mice to elevated temperatures resulted in a strong HIF-1alpha induction in kidney, liver, and spleen. To elucidate the molecular mechanisms responsible for this effect, HepG2 hepatoma cells were exposed to different temperatures (34-42 degreesC) under normoxic (20% O-2) or hypoxic (3% O-2) conditions. Heat was sufficient to stabilize mainly a phosphatase-resistant, low molecular weight form of HIF-1alpha (termed HIF-1alpha.). Heat-induced HIF-1alpha. accumulated in the nucleus but neither bound to DNA nor trans-activated reporter or target gene expression, demonstrating the need for post-translational modifications for these functions. The protein banding pattern of heat-induced HIF-1alpha in immunoblot analyses was clearly distinct from the HIF-1alpha pattern after prolyl hydroxylase inhibition (by hypoxia or iron chelation/replacement) or following proteasome, inhibition, suggesting that heat stabilizes HIF-1alpha by a novel mechanism. Inhibition of the ATP-dependent chaperone activity of HSP90 by novobiocin or geldanamycin prevented heat-induced as well as hypoxia-induced HIF-1alpha accumulation, indicating a common role of the HSP90 chaperone activity in HIF-1alpha stabilization by these two environmental parameters.	Med Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany; Med Univ Lubeck, Dept Anaesthesiol, D-23538 Lubeck, Germany; Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland	University of Lubeck; University of Lubeck; University of Zurich	Katschinski, DM (corresponding author), Univ Leipzig, Carl Ludwig Inst Physiol, Liebigstr 27, D-04103 Leipzig, Germany.		Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839				ANDERSON RL, 1991, EXP CELL RES, V197, P100, DOI 10.1016/0014-4827(91)90485-D; ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; CARVER LA, 1994, J BIOL CHEM, V269, P30109; Chen EY, 2001, CANCER RES, V61, P2429; Chilov D, 1999, J CELL SCI, V112, P1203; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Cvoro A, 1998, J STEROID BIOCHEM, V67, P319; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Gradin K, 1999, J BIOL CHEM, V274, P13511, DOI 10.1074/jbc.274.19.13511; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Marcu MG, 2000, JNCI-J NATL CANCER I, V92, P242, DOI 10.1093/jnci/92.3.242; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; METZEN E, 1995, RESP PHYSIOL, V100, P101, DOI 10.1016/0034-5687(94)00125-J; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; NGUYEN VT, 1989, J BIOL CHEM, V264, P10487; NIH, 2010, GUIDE CARE USE LAB A, V8th, DOI [10.1163/1573-3912_islam_DUM_3825, DOI 10.1163/1573-3912_ISLAM_DUM_3825]; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SANCHEZ ER, 1992, J BIOL CHEM, V267, P17; Segnitz B, 1997, J BIOL CHEM, V272, P18694, DOI 10.1074/jbc.272.30.18694; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; SHUE GL, 1994, J BIOL CHEM, V269, P2707; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 2000, J EXP BIOL, V203, P1253; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	48	125	129	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9262	9267		10.1074/jbc.M110377200	http://dx.doi.org/10.1074/jbc.M110377200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11779866	Green Accepted, hybrid			2022-12-27	WOS:000174400600072
J	Lacroix, I; Lipcey, C; Imbert, J; Kahn-Perles, B				Lacroix, I; Lipcey, C; Imbert, J; Kahn-Perles, B			Sp1 transcriptional activity is up-regulated by phosphatase 2A in dividing T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; NF-KAPPA-B; PROMOTER ACTIVITY; BINDING PROTEIN; O-GLYCOSYLATION; SP-FAMILY; FUNCTIONAL INTERACTIONS; CELL-ACTIVATION; WAF1/CIP1 GENE; EXPRESSION	We have followed Sp1 expression in primary human T lymphocytes induced, via CD2 plus CD28 costimulation, to sustained proliferation and subsequent return to quiescence. Binding of Sp1 to wheat germ agglutinin lectin was not modified following activation, indicating that the overall glycosylation of the protein was unchanged. Sp1 underwent, instead, a major dephosphorylation that correlated with cyclin A expression and, thus, with cell cycle progression. A similar change was observed in T cells that re-entered cell cycle following secondary interleukin-2 stimulation, as well as in serum-induced proliferating NIH/3T3 fibroblasts. Phosphatase 2A (PP2A) appears involved because 1) treatment of dividing cells with okadaic acid or cantharidin inhibited Sp1 dephosphorylation and 2) PP2A dephosphorylated Sp1 in vitro and strongly interacted with Sp1 in vivo. Sp1 dephosphorylation is likely to increase its transcriptional activity because PP2A overexpression potentiated Sp1 site-driven chloramphenicol acetyltransferase expression in dividing Kit225 T cells and okadaic acid reversed this effect. This increase might be mediated by a stronger affinity of dephosphorylated Sp1 for DNA, as illustrated by the reduced DNA occupancy by hyperphosphorylated Sp factors from cantharidin- or nocodazole-treated cells. Finally, Sp1 dephosphorylation appears to occur throughout cell cycle except for mitosis, a likely common feature to all cycling cells.	INSERM, U119, Unite Cancerol Expt, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Kahn-Perles, B (corresponding author), INSERM, U119, Unite Cancerol Expt, 27 Blvd Lei Roure, F-13009 Marseille, France.	kahn@marseille.inserm.fr	Kahn-Perlès, Brigitte/M-3513-2016; Imbert, Jean/G-3248-2013; Imbert, Jean/AAG-1165-2020	Kahn-Perlès, Brigitte/0000-0001-5673-5901; Imbert, Jean/0000-0002-0478-9593; Imbert, Jean/0000-0002-0478-9593				Adnane J, 1999, ONCOGENE, V18, P239, DOI 10.1038/sj.onc.1202297; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; BORJA PF, 2001, EMBO J, V20, P5737; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; CERDAN C, 1992, J IMMUNOL, V149, P2255; Chen F, 2000, ANTICANCER RES, V20, P661; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; Cook T, 1999, ANN NY ACAD SCI, V880, P94, DOI 10.1111/j.1749-6632.1999.tb09513.x; COSTELLO R, 1993, EUR J IMMUNOL, V23, P608, DOI 10.1002/eji.1830230304; COSTELLO R, 1993, CELL GROWTH DIFFER, V4, P329; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; Gartel AL, 2000, ONCOGENE, V19, P5182, DOI 10.1038/sj.onc.1203900; Haidweger E, 2001, J MOL BIOL, V306, P201, DOI 10.1006/jmbi.2000.4406; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Harrison SM, 2000, DEV BIOL, V227, P358, DOI 10.1006/dbio.2000.9878; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HONKANEN RE, 1993, FEBS LETT, V330, P283, DOI 10.1016/0014-5793(93)80889-3; HORI T, 1987, BLOOD, V70, P1069; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KahnPerles B, 1997, J BIOL CHEM, V272, P21774, DOI 10.1074/jbc.272.35.21774; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Krehan A, 2000, J BIOL CHEM, V275, P18327, DOI 10.1074/jbc.M909736199; KREK W, 1995, METHOD ENZYMOL, V254, P114; Kumar AP, 1998, BIOCHEM BIOPH RES CO, V252, P517, DOI 10.1006/bbrc.1998.9676; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LEFEBVRE P, 1995, J BIOL CHEM, V270, P10806, DOI 10.1074/jbc.270.18.10806; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LI YM, 1992, P NATL ACAD SCI USA, V89, P11867, DOI 10.1073/pnas.89.24.11867; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Matsuda S, 2000, IMMUNOPHARMACOLOGY, V47, P119, DOI 10.1016/S0162-3109(00)00192-2; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Naar AM, 1998, COLD SPRING HARB SYM, V63, P189, DOI 10.1101/sqb.1998.63.189; Noe V, 1998, ONCOGENE, V16, P1931, DOI 10.1038/sj.onc.1201718; Pagliuca A, 2000, J CELL BIOCHEM, V76, P360, DOI 10.1002/(SICI)1097-4644(20000301)76:3<360::AID-JCB3>3.0.CO;2-1; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PIERRES A, 1988, EUR J IMMUNOL, V18, P685, DOI 10.1002/eji.1830180505; Rameil P, 2000, ONCOGENE, V19, P2086, DOI 10.1038/sj.onc.1203542; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Rohr O, 1997, J BIOL CHEM, V272, P31149, DOI 10.1074/jbc.272.49.31149; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Rotheneder H, 1999, J MOL BIOL, V293, P1005, DOI 10.1006/jmbi.1999.3213; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Schafer D, 1997, FEBS LETT, V417, P325, DOI 10.1016/S0014-5793(97)01314-8; Schoenthal Axel H., 1998, Frontiers in Bioscience, V3, pD1262; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779; Treichel D, 2001, MECH DEVELOP, V101, P175, DOI 10.1016/S0925-4773(00)00544-X; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Whitmire JK, 2000, CURR OPIN IMMUNOL, V12, P448, DOI 10.1016/S0952-7915(00)00119-9; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Zhang SY, 1997, ARCH BIOCHEM BIOPHYS, V338, P227, DOI 10.1006/abbi.1996.9809	69	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9598	9605		10.1074/jbc.M111444200	http://dx.doi.org/10.1074/jbc.M111444200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11779871	hybrid			2022-12-27	WOS:000174400600113
J	Dennes, A; Madsen, P; Nielsen, MS; Petersen, CM; Pohlmann, R				Dennes, A; Madsen, P; Nielsen, MS; Petersen, CM; Pohlmann, R			The yeast vps10p cytoplasmic tail mediates lysosomal sorting in mammalian cells and interacts with human GGAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; TRANS-GOLGI NETWORK; FACTOR-II RECEPTOR; SACCHAROMYCES-CEREVISIAE; VACUOLAR HYDROLASES; PROTEIN; CLATHRIN; BINDING; ENZYMES; SIGNALS	Yeast Vps10p is a receptor for transport of the soluble vacuolar hydrolase carboxypeptidase Y to the lysosome-like vacuole. Its functional equivalents in mammalian cells are the mannose 6-phosphate receptors that mediate sorting to lysosomes of mannose 6-phosphate-containing lysosomal proteins. A chimeric receptor was constructed by substituting the cytoplasmic domain of M, 300,000 mannose 6-phosphate receptor with the Vps10p cytoplasmic tail. Expression of the chimera in cells lacking endogenous mannose 6-phosphate receptors resulted in a subcellular receptor distribution and an efficiency in sorting of lysosomal enzymes similar to that of the wild type M-r 300,000 mannose 6-phosphate receptor. Moreover, the cytoplasmic tail of the Vps10p was found to interact with GGA1 and GGA2, two mammalian members of a recently discovered family of clathrin-binding cytosolic proteins that participate in trans-Golgi network-endosome trafficking in both mammals and yeast. Our findings suggest a conserved machinery for Golgi-endosome/vacuole sorting and may serve as a model for future studies of yeast proteins.	Univ Munster, Inst Physiol Chem & Pathobiochem, Univ Klinikum Munster, D-48149 Munster, Germany; Aarhus Univ, Dept Med Biochem & Cell Biol, DK-8000 Aarhus C, Denmark	University of Munster; Aarhus University	Pohlmann, R (corresponding author), Univ Munster, Inst Physiol Chem & Pathobiochem, Univ Klinikum Munster, Waldeyerstr 15, D-48149 Munster, Germany.		Nielsen, Morten Schallburg/G-9498-2016	Nielsen, Morten Schallburg/0000-0001-9863-9694; Madsen, Peder Sondergaard/0000-0002-8845-4802				ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; CEREGHINO JL, 1995, MOL BIOL CELL, V6, P1089, DOI 10.1091/mbc.6.9.1089; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; CLAIRMONT KB, 1991, J BIOL CHEM, V266, P12131; Conibear E, 1998, BBA-MOL CELL RES, V1404, P211, DOI 10.1016/S0167-4889(98)00058-5; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; Costaguta G, 2001, MOL BIOL CELL, V12, P1885, DOI 10.1091/mbc.12.6.1885; Dell'Angelica EC, 2001, CELL, V106, P395, DOI 10.1016/S0092-8674(01)00470-6; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Deloche O, 2001, MOL BIOL CELL, V12, P475, DOI 10.1091/mbc.12.2.475; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; KLIONSKY DJ, 1990, J BIOL CHEM, V265, P5349; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; KOSTER A, 1994, EUR J BIOCHEM, V224, P685, DOI 10.1111/j.1432-1033.1994.00685.x; LeBorgne R, 1997, J CELL BIOL, V137, P335; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Meyer C, 2000, EMBO J, V19, P2193, DOI 10.1093/emboj/19.10.2193; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Sandholzer U, 2000, J BIOL CHEM, V275, P14132, DOI 10.1074/jbc.275.19.14132; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SEEGER M, 1992, EMBO J, V11, P2811, DOI 10.1002/j.1460-2075.1992.tb05348.x; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Tikkanen R, 2000, TRAFFIC, V1, P631, DOI 10.1034/j.1600-0854.2000.010807.x; VONFIGURA K, 1984, EMBO J, V3, P1281, DOI 10.1002/j.1460-2075.1984.tb01963.x; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; WENDLAND M, 1989, BIOCHEM J, V260, P201, DOI 10.1042/bj2600201; WENK J, 1991, BIOCHEM INT, V23, P723; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	44	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12288	12293		10.1074/jbc.M112295200	http://dx.doi.org/10.1074/jbc.M112295200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11801606	hybrid			2022-12-27	WOS:000174846400090
J	Fernandez, J; Bode, B; Koromilas, A; Diehl, JA; Krukovets, I; Snider, MD; Hatzoglou, M				Fernandez, J; Bode, B; Koromilas, A; Diehl, JA; Krukovets, I; Snider, MD; Hatzoglou, M			Translation mediated by the internal ribosome entry site of the cat-1 mRNA is regulated by glucose availability in a PERK kinase-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE SYNTHETASE GENE; UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM; MAMMALIAN HOMOLOG; INITIATION; ACTIVATION; EXPRESSION; STRESS; PHOSPHORYLATION	The cationic amino acid transporter, Cat-1, is a high affinity transporter of the essential amino acids, arginine and lysine. Expression of the cat-1 gene is known to be regulated by amino acid availability. It is shown here that cat-1 gene expression is also induced by Glc limitation, which causes a 7-fold increase in cat-1 mRNA, a 30-fold induction of Cat-1 protein levels, and a 4-fold stimulation of arginine uptake. Glc limitation is known to induce the unfolded protein response (UPR) by altering protein glycosylation in the endoplasmic reticulum (ER). The studies here demonstrate that synthesis of Cat-1 occurs during the UPR when global protein synthesis is inhibited. The 5'-UTR of the cat-1 mRNA contains an internal ribosomal entry site (IRES) that is activated by amino acid starvation by a mechanism that involves phosphorylation of the translation initiation factor, eukaryotic initiation factor 2alpha, by the GCN2 kinase. It is shown here that translation from the cat-1/IRES is also induced by Glc deprivation in a manner dependent upon phosphorylation of eukaryotic initiation factor 2alpha by the transmembrane ER kinase, PERK. Because PERK is a key constituent of the UPR, it is concluded that induction of cat-1 gene expression is part of the adaptive response of cells to ER stress. These results also demonstrate that regulation of IRES activity in cellular mRNAs is part of the mechanism by which the UPR protects cells from unfolded proteins in the ER.	Case Western Reserve Univ, Dept Nutr, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Sch Med, Cleveland, OH 44106 USA; St Louis Univ, Dept Biol, St Louis, MO 63103 USA; McGill Univ, Jewish Gen Hosp, Dept Microbiol, Montreal, PQ H3T 1E2, Canada; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	Case Western Reserve University; Case Western Reserve University; Saint Louis University; McGill University; University of Nebraska System; University of Nebraska Medical Center	Hatzoglou, M (corresponding author), Case Western Reserve Univ, Dept Nutr, Sch Med, 10900 Euclid Ave, Cleveland, OH 44106 USA.	mxh8@po.cwru.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053307, T32DK007319] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32 DK07319, R01 DK53307-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aulak KS, 1999, J BIOL CHEM, V274, P30424, DOI 10.1074/jbc.274.43.30424; Aulak KS, 1996, J BIOL CHEM, V271, P29799, DOI 10.1074/jbc.271.47.29799; Barbosa-Tessmann IP, 1999, BIOCHEM J, V339, P151, DOI 10.1042/0264-6021:3390151; Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Bruhat A, 2000, MOL CELL BIOL, V20, P7192, DOI 10.1128/MCB.20.19.7192-7204.2000; CHOI SY, 1992, J BIOL CHEM, V267, P286; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Fernandez J, 2002, J BIOL CHEM, V277, P2050, DOI 10.1074/jbc.M109199200; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Hyatt SL, 1997, J BIOL CHEM, V272, P19951, DOI 10.1074/jbc.272.32.19951; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kleijn M, 2000, BIOCHEM J, V347, P399, DOI 10.1042/0264-6021:3470399; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Merrick WC, 2000, COLD SPRING HARBOR M, V39, P89; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Niwa M, 2000, P NATL ACAD SCI USA, V97, P12396, DOI 10.1073/pnas.250476097; Proud CG, 1997, BIOCHEM J, V328, P329; Ron D, 2000, COLD SPRING HARBOR M, V39, P547; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Sonenberg N, 2001, SCIENCE, V293, P818, DOI 10.1126/science.1062937; Sood R, 2000, GENETICS, V154, P787; WINNING RS, 1992, DIFFERENTIATION, V49, P1, DOI 10.1111/j.1432-0436.1992.tb00763.x; Yamaguchi A, 1999, J CELL BIOL, V147, P1195, DOI 10.1083/jcb.147.6.1195; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000	30	73	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11780	11787		10.1074/jbc.M110778200	http://dx.doi.org/10.1074/jbc.M110778200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11781318	hybrid			2022-12-27	WOS:000174846400024
J	Krause, E; Gobel, A; Schulz, I				Krause, E; Gobel, A; Schulz, I			Cell side-specific sensitivities of intracellular Ca2+ stores for inositol 1,4,5-trisphosphate, cyclic ADP-ribose, and nicotinic acid adenine dinucleotide phosphate in permeabilized pancreatic acinar cells from mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; RYANODINE RECEPTORS; EXOCRINE PANCREAS; ZYMOGEN GRANULES; WAVE-PROPAGATION; CALCIUM STORES; RELEASE; TRISPHOSPHATE; OSCILLATIONS; NAADP	In pancreatic acinar cells hormonal stimulation leads to a cytosolic Ca2+ wave that starts in the apical cell pole and subsequently propagates toward the basal cell side. We used permeabilized pancreatic acinar cells from mouse and the mag-fura-2 technique, which allows direct monitoring of changes in [Ca2+] of intracellular stores. We show here that Ca2+ can be released from stores in all cellular regions by inositol 1,4,5-trisphosphate. Stores at the apical cell pole showed a higher affinity to inositol 1,4,5-trisphosphate (EC50 = 89 nM) than those at the basolateral side (EC50 = 256 nM). In contrast, cADP-ribose, a modifier of Ca2+-induced Ca2+ release, and nicotinic acid adenine dinucleotide phosphate (NAADP) were able to release Ca2+ exclusively from intracellular stores located at the basolateral cell side. Our data agree with observations that upon stimulation Ca2+ is released initially at the apical cell side and that this is caused by high affinity inositol 1,4,5-trisphosphate receptors. Moreover, our findings allow the conclusion that in Ca2+ wave propagation from the apical to the basolateral cell side observed in pancreatic acinar cells Ca2+-induced Ca2+ release, modulated by cADP-ribose and/or NAADP, might be involved.	Univ Saarland, Inst Physiol, D-66421 Homburg, Germany	Saarland University	Schulz, I (corresponding author), Univ Saarland, Inst Physiol, Gebaude 58, D-66421 Homburg, Germany.	schulz@med-ph.uni-sb.de		Krause, Elmar/0000-0003-0891-2373				Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; Fitzsimmons TJ, 2000, BIOCHEM J, V351, P265, DOI 10.1042/0264-6021:3510265; Fogarty KE, 2000, J PHYSIOL-LONDON, V526, P515, DOI 10.1111/j.1469-7793.2000.t01-1-00515.x; Galione A, 2000, BIOL CELL, V92, P197, DOI 10.1016/S0248-4900(00)01070-4; Genazzani AA, 1997, TRENDS PHARMACOL SCI, V18, P108, DOI 10.1016/S0165-6147(96)01036-X; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; Gobel A, 2001, CELL CALCIUM, V29, P29, DOI 10.1054/ceca.2000.0154; Gonzalez A, 1999, BIOCHEM BIOPH RES CO, V261, P726, DOI 10.1006/bbrc.1999.1106; Gonzalez A, 1998, AM J PHYSIOL-CELL PH, V275, pC810, DOI 10.1152/ajpcell.1998.275.3.C810; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hofer AM, 1996, CELL CALCIUM, V20, P235, DOI 10.1016/S0143-4160(96)90029-9; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; Krause E, 1996, J BIOL CHEM, V271, P32523, DOI 10.1074/jbc.271.51.32523; Lee HC, 2000, J MEMBRANE BIOL, V173, P1, DOI 10.1007/s002320001001; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; Lee Hon Cheung, 1998, Cell Biochemistry and Biophysics, V28, P1, DOI 10.1007/BF02738306; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; Park MK, 2000, EMBO J, V19, P5729, DOI 10.1093/emboj/19.21.5729; Parys JB, 1996, PFLUG ARCH EUR J PHY, V432, P359, DOI 10.1007/s004240050145; PARYS JB, 1995, CELL CALCIUM, V17, P239, DOI 10.1016/0143-4160(95)90070-5; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Pfeiffer F, 1998, AM J PHYSIOL-CELL PH, V274, pC663; PUTNEY JW, 1990, PHARMACOL THERAPEUT, V48, P427, DOI 10.1016/0163-7258(90)90059-B; Sabnis RW, 1997, BIOTECH HISTOCHEM, V72, P253, DOI 10.3109/10520299709082249; Straub SV, 2000, J GEN PHYSIOL, V116, P547, DOI 10.1085/jgp.116.4.547; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; THORN P, 1993, CELL CALCIUM, V14, P746, DOI 10.1016/0143-4160(93)90100-K; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; Tojyo Y, 1997, CELL CALCIUM, V22, P455, DOI 10.1016/S0143-4160(97)90073-7; vandePut FHMM, 1996, J BIOL CHEM, V271, P4999; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Yule DI, 1997, J BIOL CHEM, V272, P9093	42	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11696	11702		10.1074/jbc.M107794200	http://dx.doi.org/10.1074/jbc.M107794200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11809747	hybrid			2022-12-27	WOS:000174846400013
J	Piwien-Pilipuk, G; Ayala, A; Machado, A; Galigniana, MD				Piwien-Pilipuk, G; Ayala, A; Machado, A; Galigniana, MD			Impairment of mineralocorticoid receptor (MR)-dependent biological response by oxidative stress and aging - Correlation with post-translational modification of MR and decreased ADP-ribosylatable level of elongation factor 2 in kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; REQUIRES INTACT CYTOSKELETON; GLUCOCORTICOID RECEPTOR; FACTOR-II; RAT-KIDNEY; CUMENE HYDROPEROXIDE; LIPID-PEROXIDATION; STEROID-BINDING; KINASE-1 PDK1; INHIBITION	Acute and chronic treatments of mice with the glutathione-depleting agent, L-buthionine-(SR)-sulfoximine (BSO), impaired the mineralocorticoid receptor (MR)dependent biological response by inhibiting aldosterone binding. This steroid-binding inhibition was fully reversed when reducing agents were added to kidney cytosol obtained from mice treated for 5 h, but it was only partially reversed in cytosol obtained from mice treated for 10 days. Although the oligomeric structure of the MR-hsp90 heterocomplex was always unaffected, a decreased amount of MR protein was evidenced after the long term treatment. Such a deleterious effect was correlated with a post-translational modification of MR, as demonstrated by an increased level of receptor carbonylation. In addition, a failure at the elongation/termination step was also observed during the receptor translation process in a reticulocyte lysate system. Thus, a high polyribosomes/monomers ratio and both increased proteolysis and decreased ADP-ribosylatable concentration of elongation factor 2 (EF-2) were shown. Importantly, similar observations were also performed in vivo after depletion of glutathione. Notwithstanding the EF-2 functional disruption, not all renal proteins were equally affected as the MR. Interestingly, both EF-2 and AM expressed in old mice were similarly affected as in L-buthionine-(SR)-sulfoximine-treated young mice. We therefore propose that a dramatic depletion of glutathione in kidney cells mimics the cumulative effect of aging which, at the end, may lead to a renal mineralocorticoid dysfunction.	Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, RA-1428 Buenos Aires, DF, Argentina; Univ Sevilla, Fac Farm, Dept Bioquim Bromatol & Toxicol, E-41012 Seville, Spain	University of Buenos Aires; University of Sevilla	Galigniana, MD (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.		IBIS, ENVEJECIMIENTO/O-9381-2015; Ayala, Antonio/N-7591-2019	Ayala, Antonio/0000-0001-9711-3711; GALIGNIANA, MARIO/0000-0002-9130-8574				ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Ayala A, 1996, J BIOL CHEM, V271, P23105, DOI 10.1074/jbc.271.38.23105; AYUSOPARRILLA MS, 1976, J BIOL CHEM, V251, P7785; Bae GU, 1999, J BIOL CHEM, V274, P32596, DOI 10.1074/jbc.274.46.32596; BAUD L, 1986, AM J PHYSIOL, V251, pF765, DOI 10.1152/ajprenal.1986.251.5.F765; Bhargava A, 2001, ENDOCRINOLOGY, V142, P1587, DOI 10.1210/en.142.4.1587; BURTON G, 1995, MOL PHARMACOL, V47, P535; CALIGNIANA MD, 2000, CURR TOP STEROID RES, V3, P1; CeballosPicot I, 1996, FREE RADICAL BIO MED, V21, P845, DOI 10.1016/0891-5849(96)00233-X; DASGUPTA A, 1992, NEPHRON, V60, P56, DOI 10.1159/000186705; DAVYDOVA EK, 1993, EUR J BIOCHEM, V215, P291, DOI 10.1111/j.1432-1033.1993.tb18034.x; Dean RT, 1997, BIOCHEM J, V324, P1; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; FALVEY AK, 1970, J MOL BIOL, V53, P21, DOI 10.1016/0022-2836(70)90043-4; Galicka A, 2000, BIOCHEM BIOPH RES CO, V269, P553, DOI 10.1006/bbrc.2000.2322; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; Galigniana MD, 1999, J BIOL CHEM, V274, P16222, DOI 10.1074/jbc.274.23.16222; Galigniana MD, 2000, MOL PHARMACOL, V58, P58, DOI 10.1124/mol.58.1.58; Galigniana MD, 1996, LIFE SCI, V59, P511, DOI 10.1016/0024-3205(96)00331-1; Galigniana MD, 1998, BIOCHEM J, V333, P555, DOI 10.1042/bj3330555; Galigniana MD, 1999, BIOCHEM J, V341, P585, DOI 10.1042/0264-6021:3410585; HENSHAW EC, 1973, J BIOL CHEM, V248, P4367; HIMMELFARB J, 1993, J AM SOC NEPHROL, V4, P178; HOERZ W, 1969, P NATL ACAD SCI USA, V63, P1206, DOI 10.1073/pnas.63.4.1206; HOWARD GA, 1970, J BIOL CHEM, V245, P6237; KABAT D, 1969, BIOCHEMISTRY-US, V8, P3743; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; LENZ AG, 1989, ANAL BIOCHEM, V177, P419, DOI 10.1016/0003-2697(89)90077-8; LO YYC, 1996, J BIOL CHEM, V271, P15073; Lupo B, 1998, BIOCHEMISTRY-US, V37, P12153, DOI 10.1021/bi980593e; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; Merker K, 2000, ARCH BIOCHEM BIOPHYS, V375, P50, DOI 10.1006/abbi.1999.1657; NATH KA, 1990, J CLIN INVEST, V86, P1179, DOI 10.1172/JCI114824; Parrado J, 1999, FREE RADICAL BIO MED, V26, P362, DOI 10.1016/S0891-5849(98)00202-0; Pearce D, 2001, TRENDS ENDOCRIN MET, V12, P341, DOI 10.1016/S1043-2760(01)00439-8; Piwien-Pilipuk G, 1998, MOL CELL ENDOCRINOL, V144, P119, DOI 10.1016/S0303-7207(98)00142-7; Piwien-Pilipuk G, 2000, BBA-MOL CELL RES, V1495, P263, DOI 10.1016/S0167-4889(99)00166-4; Prasad N, 2000, BIOCHEMISTRY-US, V39, P6929, DOI 10.1021/bi000387i; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Preville X, 1999, EXP CELL RES, V247, P61, DOI 10.1006/excr.1998.4347; QUIAN MQ, 1996, BIOCHIM BIOPHYS ACTA, V1310, P293; RIIS B, 1989, BIOCHEM BIOPH RES CO, V159, P1141, DOI 10.1016/0006-291X(89)92228-6; ROBERTSON NM, 1993, MOL ENDOCRINOL, V7, P1226, DOI 10.1210/me.7.9.1226; RYAZANOV AG, 1989, FEBS LETT, V251, P187, DOI 10.1016/0014-5793(89)81452-8; SCORNIK OA, 1974, J BIOL CHEM, V249, P3876; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; SMULSON ME, 1970, J BIOL CHEM, V245, P5350; Souque A, 1996, J STEROID BIOCHEM, V57, P315, DOI 10.1016/0960-0760(95)00278-2; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; TAFFE BG, 1987, J BIOL CHEM, V262, P12143; TAMARIT J, 1997, J BIOL CHEM, V271, P3027; Verbeke P, 2001, CELL BIOL INT, V25, P845, DOI 10.1006/cbir.2001.0789; WEISSBACH H, 1976, ANNU REV BIOCHEM, V45, P191, DOI 10.1146/annurev.bi.45.070176.001203; YOSHIOKA T, 1990, KIDNEY INT, V38, P282, DOI 10.1038/ki.1990.197	57	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11896	11903		10.1074/jbc.M109530200	http://dx.doi.org/10.1074/jbc.M109530200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11809749	hybrid			2022-12-27	WOS:000174846400039
J	Riccio, A; Mattei, C; Kelsell, RE; Medhurst, AD; Calver, AR; Randall, AD; Davis, JB; Benham, CD; Pangalos, MN				Riccio, A; Mattei, C; Kelsell, RE; Medhurst, AD; Calver, AR; Randall, AD; Davis, JB; Benham, CD; Pangalos, MN			Cloning and functional expression of human short TRP7, a candidate protein for store-operated Ca2+ influx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; CA2+-PERMEABLE CATION CHANNEL; DROSOPHILA TRP; INTRACELLULAR CALCIUM; MOLECULAR-CLONING; COUPLED RECEPTOR; HTRP3 CHANNELS; HUMAN HOMOLOG; CELLS; DEPLETION	The regulation and control of plasma membrane Ca2+ fluxes is critical for the initiation and maintenance of a variety of signal transduction cascades. Recently, the study of transient receptor potential channels (TRPs) has suggested that these proteins have an important role to play in mediating capacitative calcium entry. In this study, we have isolated a cDNA from human brain that encodes a novel transient receptor potential channel termed human TRP7 (hTRP7). hTRP7 is a member of the short TRP channel family and is 98% homologous to mouse TRP7 (mTRP7). At the mRNA level hTRP7 was widely expressed in tissues of the central nervous system, as well as some peripheral tissues such as pituitary gland and kidney. However, in contrast to mTRP7, which is highly expressed in heart and lung, hTRP7 was undetectable in these tissues. For functional analysis, we heterologously expressed hTRP7 cDNA in an human embryonic kidney cell line. In comparison with untransfected cells depletion of intracellular calcium stores in hTRP7-expressing cells, using either carbachol or thapsigargin, produced a marked increase in the subsequent level of Ca2+ influx. This increased Ca2+ entry was blocked by inhibitors of capacitative calcium entry such as La3+ and Gd3+. Furthermore, transient transfection of an hTRP7 antisense expression construct into cells expressing hTRP7 eliminated the augmented store-operated Ca2+ entry. Our findings suggest that hTRP7 is a store-operated calcium channel, a finding in stark contrast to the mouse orthologue, mTRP7, which is reported to enhance Ca2+ influx independently of store depletion, and suggests that human and mouse TRP7 channels may fulfil different physiological roles.	GlaxoSmithKline, Neurol Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Genet Res, Harlow CM19 5AW, Essex, England	GlaxoSmithKline; GlaxoSmithKline	Pangalos, MN (corresponding author), GSK Neurol Ctr Excellence Drug Discovery, New Frontiers Sci Pk N,3rd Ave,Rm H17-1-133, Harlow CM19 5AW, Essex, England.	Menelas_N_Pangalos@gsk.com	Mattei, Cesar/K-5286-2015	Mattei, Cesar/0000-0002-2214-2611; Randall, Andrew/0000-0001-8852-3671				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARIKAWA K, 1990, J CELL BIOL, V110, P1993, DOI 10.1083/jcb.110.6.1993; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; CANTIELLO HF, 1995, KIDNEY INT, V48, P970, DOI 10.1038/ki.1995.379; Chambers JK, 2000, J BIOL CHEM, V275, P10767, DOI 10.1074/jbc.275.15.10767; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLAPHAM DE, 1995, NATURE, V375, P634, DOI 10.1038/375634a0; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Davies E, 1993, Semin Cell Biol, V4, P139; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Halaszovich CR, 2000, J BIOL CHEM, V275, P37423, DOI 10.1074/jbc.M007010200; HARTENECK C, 1995, FEBS LETT, V358, P297, DOI 10.1016/0014-5793(94)01455-A; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HOFMANN K, 1992, COMPUT APPL BIOSCI, V8, P331; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU YF, 1995, BIOCHEM J, V305, P605, DOI 10.1042/bj3050605; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Livak KJ, 1999, GENET ANAL-BIOMOL E, V14, P143, DOI 10.1016/S1050-3862(98)00019-9; Medhurst AD, 2000, J NEUROSCI METH, V98, P9, DOI 10.1016/S0165-0270(00)00178-3; MILLS JW, 1994, FASEB J, V8, P1161, DOI 10.1096/fasebj.8.14.7958622; Monk PD, 1996, J NEUROCHEM, V67, P2227; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; Putney JW, 2001, NATURE, V410, P648, DOI 10.1038/35070704; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 1997, CELL CALCIUM, V21, P257, DOI 10.1016/S0143-4160(97)90050-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SACHS F, 1991, MOL CELL BIOCHEM, V104, P57; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; WONG F, 1989, NEURON, V3, P81, DOI 10.1016/0896-6273(89)90117-7; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Xu XZS, 2000, NEURON, V26, P647, DOI 10.1016/S0896-6273(00)81201-5; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zhu Y, 2001, MOL PHARMACOL, V59, P434, DOI 10.1124/mol.59.3.434; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	65	95	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12302	12309		10.1074/jbc.M112313200	http://dx.doi.org/10.1074/jbc.M112313200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805119	Green Published, hybrid			2022-12-27	WOS:000174846400092
J	Sears, RC; Nevins, JR				Sears, RC; Nevins, JR			Signaling networks that link cell proliferation and cell fate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							C-MYC; RESTRICTION POINT; CYCLIN D1; P53-DEPENDENT APOPTOSIS; TRANSGENIC MICE; CYTOCHROME-C; DNA-DAMAGE; IN-VIVO; S-PHASE; RAS		Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Genet, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute	Nevins, JR (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Genet, Box 3054, Durham, NC 27710 USA.							Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Beier R, 2000, EMBO J, V19, P5813, DOI 10.1093/emboj/19.21.5813; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Dang CV, 1999, MOL CELL BIOL, V19, P1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; delPeso L, 1997, SCIENCE, V278, P687; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOU QP, 1993, CANCER RES, V53, P1493; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELSON A, 1995, ONCOGENE, V11, P181; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lin WC, 2001, GENE DEV, V15, P1833; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; SBERR CJ, 1996, SCIENCE, V274, P1672; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SEARS R, 2000, GENE DEV, V14, P2105; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	73	272	284	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11617	11620		10.1074/jbc.R100063200	http://dx.doi.org/10.1074/jbc.R100063200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805123	hybrid			2022-12-27	WOS:000174846400001
J	Shimoni, E; Baasov, T; Ravid, U; Shoham, Y				Shimoni, E; Baasov, T; Ravid, U; Shoham, Y			The trans-anethole degradation pathway in an Arthrobacter sp.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-KETOADIPATE PATHWAY; FERULIC ACID; ACINETOBACTER-CALCOACETICUS; MOLECULAR CHARACTERIZATION; PSEUDOMONAS SP; STRAIN HR199; EUGENOL; METABOLISM; PROTOCATECHUATE; CATABOLISM	A bacterial strain (TA13) capable of utilizing t-anethole as the sole carbon source was isolated from soil. The strain was identified as Arthrobacter aurescens based on its 16 S rRNA gene sequence. Key steps of the degradation pathway of t-anethole were identified by the use of t-anethole-blocked mutants and specific inducible enzymatic activities. In addition to t-anethole, strain TA13 is capable of utilizing anisic acid, anisaldehyde, and anisic alcohol as the sole carbon source. t-Anethole-blocked mutants were obtained following mutagenesis and penicillin enrichment. Some of these blocked mutants, accumulated in the presence of t-anethole quantitative amounts of t-anethole-diol, anisic acid, and 4,6-dicarboxy-2-pyrone and traces of anisic alcohol and anisaldehyde. Enzymatic activities induced by t-anethole included: 4-methoxybenzoate O-demethylase, p-hydroxybenzoate 3-hydroxylase, and protocatechuate-4,5-dioxygenase. These findings indicate that t-anethole is metabolized to protocatechuic acid through t-anethole-diol, anisaldehyde, anisic acid, and p-hydroxybenzoic acid. The protocatechuic acid is then cleaved by protocatechuate-4,5-dioxygenase to yield 2-hydroxy-4-carboxy muconate-semialdehyde. Results from inducible uptake ability and enzymatic assays indicate that at least three regulatory units are involved in the t-anethole degradation pathway. These findings provide new routes for environmental friendly production processes of valuable aromatic chemicals via bioconversion of phenylpropenoids.	Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Catalysis Sci & Technol, IL-32000 Haifa, Israel; Agr Res Org, Newe Yaar Res Ctr, IL-90095 Ramat Yishay, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Technion Israel Institute of Technology	Shoham, Y (corresponding author), Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel.		Shoham, Yuval/M-4409-2013; Baasov, Timor/L-5173-2019	Baasov, Timor/0000-0002-1427-2619				Abraham WR, 1988, BIOFLAVOUR 87 ANAL B, P399; ANDREONI V, 1995, APPL MICROBIOL BIOT, V42, P830, DOI 10.1007/BF00191177; Belitz H -D, 1999, FOOD CHEM; BERNHARDT FH, 1977, EUR J BIOCHEM, V72, P107, DOI 10.1111/j.1432-1033.1977.tb11230.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANOVAS JL, 1968, EUR J BIOCHEM, V3, P293, DOI 10.1111/j.1432-1033.1968.tb19529.x; CANOVAS JL, 1967, EUR J BIOCHEM, V1, P289, DOI 10.1111/j.1432-1033.1967.tb00073.x; CRAWFORD RL, 1975, J BACTERIOL, V121, P794, DOI 10.1128/JB.121.3.794-799.1975; DAGLEY S, 1986, BACTERIA; DELNERI D, 1995, BBA-GEN SUBJECTS, V1244, P363, DOI 10.1016/0304-4165(95)00021-3; DOTEN RC, 1987, J BACTERIOL, V169, P3168, DOI 10.1128/jb.169.7.3168-3174.1987; EATON RW, 1982, J BACTERIOL, V151, P48, DOI 10.1128/JB.151.1.48-57.1982; ELSEMORE DA, 1994, J BACTERIOL, V176, P7659, DOI 10.1128/JB.176.24.7659-7666.1994; Fraaije MW, 1997, APPL ENVIRON MICROB, V63, P435, DOI 10.1128/AEM.63.2.435-439.1997; FURUKAWA K, 1982, APPL ENVIRON MICROB, V44, P619, DOI 10.1128/AEM.44.3.619-626.1982; Gasson MJ, 1998, J BIOL CHEM, V273, P4163, DOI 10.1074/jbc.273.7.4163; GERISCHER U, 1993, 93 ANN M AM SOC MICR, P238; GREEN NR, 1978, MUTAT RES, V57, P115, DOI 10.1016/0027-5107(78)90257-9; GURUJEYALAKSHMI G, 1987, CURR MICROBIOL, V16, P69, DOI 10.1007/BF01588174; HAGEDORN C, 1975, CAN J MICROBIOL, V21, P353, DOI 10.1139/m75-050; HAGEDORN SR, 1985, J BACTERIOL, V163, P640, DOI 10.1128/JB.163.2.640-647.1985; Harwood CS, 1996, ANNU REV MICROBIOL, V50, P553, DOI 10.1146/annurev.micro.50.1.553; HAYAISHI O, 1957, J BIOL CHEM, V229, P905; HOSOKAWA K, 1970, J BIOL CHEM, V245, P5304; HOSOKAWA K, 1966, J BIOL CHEM, V241, P2453; JOHNSON BF, 1971, J BACTERIOL, V107, P476, DOI 10.1128/JB.107.2.476-485.1971; Johnson TA, 1999, MICROBIOL RES, V153, P349, DOI 10.1016/S0944-5013(99)80049-4; KARAPINAR M, 1987, INT J FOOD MICROBIOL, V4, P161, DOI 10.1016/0168-1605(87)90023-7; KARAPINAR M, 1990, INT J FOOD MICROBIOL, V10, P193, DOI 10.1016/0168-1605(90)90066-E; Karegoudar TB, 1999, J MICROBIOL, V37, P123; KLAGES U, 1979, FEMS MICROBIOL LETT, V6, P201, DOI 10.1111/j.1574-6968.1979.tb03703.x; KOJIMA Y, 1961, J BIOL CHEM, V236, P2223; Krebs K. G., 1969, THIN LAYER CHROMATOG, P854; LECHNER U, 1988, J BASIC MICROB, V28, P629, DOI 10.1002/jobm.3620280918; MACDONALD DL, 1954, J BIOL CHEM, V210, P809; MARKS TS, 1984, BIOCHEM BIOPH RES CO, V124, P669, DOI 10.1016/0006-291X(84)91607-3; MARUYAMA K, 1979, J BIOCHEM-TOKYO, V86, P1671, DOI 10.1093/oxfordjournals.jbchem.a132687; MARUYAMA K, 1978, J BIOCHEM, V83, P1125, DOI 10.1093/oxfordjournals.jbchem.a132002; *MIDI INC, 1992, MICR ID SYST OP MAN; Mohan RS, 2000, J ORG CHEM, V65, P1407, DOI 10.1021/jo991521b; MULLER R, 1988, BIOL CHEM H-S, V369, P567, DOI 10.1515/bchm3.1988.369.2.567; Nichols NN, 1997, J BACTERIOL, V179, P5056, DOI 10.1128/jb.179.16.5056-5061.1997; ORNSTON LN, 1966, J BIOL CHEM, V241, P3800; ORNSTON LN, 1971, BACTERIOL REV, V35, P87, DOI 10.1128/MMBR.35.2.87-116.1971; Overhage J, 1999, APPL ENVIRON MICROB, V65, P951; Priefert H, 1999, ARCH MICROBIOL, V172, P354, DOI 10.1007/s002030050772; Priefert H, 1997, J BACTERIOL, V179, P2595, DOI 10.1128/JB.179.8.2595-2607.1997; Rabenhorst J, 1996, APPL MICROBIOL BIOT, V46, P470, DOI 10.1007/s002530050846; Rabenhorst J., 1991, Deutsches Patentampt DE, Patent No. [39 20 A1, 3920]; RAHOUTI M, 1989, APPL ENVIRON MICROB, V55, P2391, DOI 10.1128/AEM.55.9.2391-2398.1989; RAVID U, 1983, J NAT PROD, V46, P848, DOI 10.1021/np50030a004; ROSAZZA JPN, 1995, ASM NEWS, V61, P241; STEINBUCHEL A, 1998, Patent No. 0845532; SUTHERLAND JB, 1981, APPL ENVIRON MICROB, V41, P442, DOI 10.1128/AEM.41.2.442-448.1981; SUTHERLAND JB, 1983, CAN J MICROBIOL, V29, P1253, DOI 10.1139/m83-195; SWANSON AB, 1979, MUTAT RES, V60, P143, DOI 10.1016/0027-5107(79)90178-7; TADASA K, 1977, AGR BIOL CHEM TOKYO, V41, P925, DOI 10.1080/00021369.1977.10862621; TADASA K, 1983, AGR BIOL CHEM TOKYO, V47, P2639, DOI 10.1080/00021369.1983.10866004; TRESGUERRES ME, 1970, EUR J BIOCHEM, V14, P445, DOI 10.1111/j.1432-1033.1970.tb00309.x; ZAITSEV GM, 1991, FEMS MICROBIOL LETT, V81, P171	60	31	40	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11866	11872		10.1074/jbc.M109593200	http://dx.doi.org/10.1074/jbc.M109593200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805095	hybrid			2022-12-27	WOS:000174846400035
J	Shin, JS; Yu, MH				Shin, JS; Yu, MH			Kinetic dissection of alpha(1)-antitrypsin inhibition mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; SERPIN-PROTEINASE COMPLEX; REACTIVE CENTER LOOP; PORCINE PANCREATIC ELASTASE; BETA-SHEET-A; ALPHA(1)-PROTEINASE INHIBITOR; ALPHA-1-PROTEINASE INHIBITOR; NATIVE STRAIN; CATHEPSIN-G; INSERTION	Serpins (serine protease inhibitors) inhibit target proteases by forming a stable covalent complex in which the cleaved reactive site loop of the serpin is inserted into beta-sheet A of the serpin with concomitant translocation of the protease to the opposite of the initial binding site. Despite recent determination of the crystal structures of a Michaelis protease-serpin complex as well as a stable covalent complex, details on the kinetic mechanism remain unsolved mainly due to difficulties in measuring kinetic parameters of acylation, protease translo. cation, and deacylation steps. To address the problem, we applied a mathematical model developed on the basis of a suicide inhibition mechanism to the stopped-flow kinetics of fluorescence resonance energy transfer during complex formation between alpha(1)-antitrypsin, a prototype serpin, and proteases. Compared with the hydrolysis of a peptide substrate, acylation of the protease by alpha(1)-antitrypsin is facilitated, whereas deacylation of the acyl intermediate is strongly suppressed during the protease translocation. The results from nucleophile susceptibility of the acyl intermediate suggest strongly that the active site of the protease is already perturbed during translocation.	Korea Inst Sci & Technol, Prot Strain Res Ctr, Natl Creat Res Init, Sungbuk Ku, Seoul 136791, South Korea	Korea Institute of Science & Technology (KIST)	Yu, MH (corresponding author), Korea Inst Sci & Technol, Prot Strain Res Ctr, Natl Creat Res Init, Sungbuk Ku, 39-1 Hawolgok Dong, Seoul 136791, South Korea.	mhyu@kist.re.kr						BEATTY K, 1980, J BIOL CHEM, V255, P3931; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Calugaru SV, 2001, J BIOL CHEM, V276, P32446, DOI 10.1074/jbc.M104731200; Chaillan-Huntington CE, 1998, J BIOL CHEM, V273, P4569, DOI 10.1074/jbc.273.8.4569; CHASE T, 1970, METHOD ENZYMOL, V75, P20; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; Duranton J, 1998, BIOCHEMISTRY-US, V37, P11239, DOI 10.1021/bi980223q; Fa M, 2000, STRUCT FOLD DES, V8, P397, DOI 10.1016/S0969-2126(00)00121-0; FERSHT A, 1984, ENZYME STRUCTURE MEC, P193; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; Gils A, 1997, J BIOL CHEM, V272, P12662, DOI 10.1074/jbc.272.19.12662; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; Hopkins PCR, 1997, J BIOL CHEM, V272, P3905, DOI 10.1074/jbc.272.7.3905; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Im H, 1999, J BIOL CHEM, V274, P11072, DOI 10.1074/jbc.274.16.11072; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; Kurth T, 1997, BIOCHEMISTRY-US, V36, P10098, DOI 10.1021/bi970937l; Kvassman JO, 1998, BIOCHEMISTRY-US, V37, P15491, DOI 10.1021/bi9814787; KWON KS, 1994, J BIOL CHEM, V269, P9627; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; Lee C, 2000, P NATL ACAD SCI USA, V97, P7727, DOI 10.1073/pnas.97.14.7727; Lee KN, 1996, NAT STRUCT BIOL, V3, P497, DOI 10.1038/nsb0696-497; Luo Y, 1999, J BIOL CHEM, V274, P17733, DOI 10.1074/jbc.274.25.17733; MCRAE B, 1980, BIOCHEMISTRY-US, V19, P3973, DOI 10.1021/bi00558a013; Mellet P, 1998, J BIOL CHEM, V273, P9119, DOI 10.1074/jbc.273.15.9119; Mellet P, 2000, J BIOL CHEM, V275, P10788, DOI 10.1074/jbc.275.15.10788; OMalley KM, 1997, J BIOL CHEM, V272, P5354, DOI 10.1074/jbc.272.8.5354; PANNELL R, 1974, BIOCHEMISTRY-US, V13, P5439, DOI 10.1021/bi00723a031; Peterson FC, 2001, BIOCHEMISTRY-US, V40, P6284, DOI 10.1021/bi010100x; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; RENAUD A, 1983, J BIOL CHEM, V258, P8312; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCHELLENBERGER V, 1989, EUR J BIOCHEM, V179, P161, DOI 10.1111/j.1432-1033.1989.tb14534.x; Seo EJ, 2000, J BIOL CHEM, V275, P16904, DOI 10.1074/jbc.M001006200; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Shrikumar A, 1998, J BIOL CHEM, V273, P17459, DOI 10.1074/jbc.273.28.17459; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; THOMPSON RC, 1973, BIOCHEMISTRY-US, V12, P57, DOI 10.1021/bi00725a011; THOMPSON RC, 1970, P NATL ACAD SCI USA, V67, P1734, DOI 10.1073/pnas.67.4.1734; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; Ye S, 2001, NAT STRUCT BIOL, V8, P979, DOI 10.1038/nsb1101-979	46	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11629	11635		10.1074/jbc.M111168200	http://dx.doi.org/10.1074/jbc.M111168200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11786547	hybrid			2022-12-27	WOS:000174846400004
J	Hayashi, H; Szaszi, K; Coady-Osberg, N; Orlowski, J; Kinsella, JL; Grinstein, S				Hayashi, H; Szaszi, K; Coady-Osberg, N; Orlowski, J; Kinsella, JL; Grinstein, S			A slow pH-dependent conformational transition underlies a novel mode of activation of the epithelial Na+/H+ exchanger-3 isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL PROXIMAL TUBULE; HAMSTER OVARY CELLS; DIFFICILE TOXIN-B; PROTEIN-KINASE-C; NA/H EXCHANGER; THYMIC LYMPHOCYTES; MEMBRANE-VESICLES; APICAL MEMBRANE; MODIFIER SITE; NHE3 ACTIVITY	Allosteric control of Na+/H- exchange by intracellular protons ensures rapid and accurate regulation of the intracellular pH. Although this allosteric effect was heretofore thought to occur almost instantaneously, we report here the occurrence of a slower secondary activation of the epithelial Na+/H- exchanger (NHE)-3 isoform. This slow activation mode developed over the course of minutes and was unique to NHE3 and the closely related isoform NHE5, but was not observed in NHE1 or NHE2. Activation of NHE3 was not due to increased density of exchangers at the cell surface, nor was it accompanied by detectable changes in phosphorylation. The association of NHE3 with the cytoskeleton, assessed by its retention in the detergent-insoluble fraction, was similarly unaffected by acidification. In contrast to the slow progressive activation elicited by acidification, deactivation occurred very rapidly upon restoration of the physiological pH. We propose that NHE3 undergoes a slow pH-dependent transition from a less active to a more active state, likely by changing its conformation or state of association.	Hosp Sick Children, Res Inst, Cell Biol Program, Toronto, ON M5G 1X8, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; NIA, Cardiovasc Sci Lab, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Grinstein, S (corresponding author), Hosp Sick Children, Res Inst, Cell Biol Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Hayashi, Hisayoshi/K-5883-2013; Szaszi, Katalin/J-7522-2012	Szaszi, Katalin/0000-0002-2490-8422; Orlowski, John/0000-0001-7371-175X				AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; BROWN CDA, 1984, BIOCHIM BIOPHYS ACTA, V769, P471, DOI 10.1016/0005-2736(84)90332-8; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; GHOSH S, 1988, ANAL BIOCHEM, V169, P227, DOI 10.1016/0003-2697(88)90278-3; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; GRINSTEIN S, 1984, J GEN PHYSIOL, V84, P585, DOI 10.1085/jgp.84.4.585; HELMLEKOLB C, 1993, PFLUG ARCH EUR J PHY, V425, P34, DOI 10.1007/BF00374501; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V416, P615, DOI 10.1007/BF00370605; HORIE S, 1990, P NATL ACAD SCI USA, V87, P4742, DOI 10.1073/pnas.87.12.4742; IGARASHI P, 1992, AM J PHYSIOL, V263, pF83, DOI 10.1152/ajprenal.1992.263.1.F83; Ishibashi H, 1999, P NATL ACAD SCI USA, V96, P9949, DOI 10.1073/pnas.96.17.9949; Janecki AJ, 1998, J BIOL CHEM, V273, P8790, DOI 10.1074/jbc.273.15.8790; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KAPUS A, 1994, J BIOL CHEM, V269, P23544; Kinsella JL, 1998, BIOCHEM CELL BIOL, V76, P743, DOI 10.1139/bcb-76-5-743; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; REILLY RF, 1991, AM J PHYSIOL, V261, pF1088, DOI 10.1152/ajprenal.1991.261.6.F1088; RIEGLER M, 1995, J CLIN INVEST, V95, P2004, DOI 10.1172/JCI117885; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Shugrue CA, 1999, J AM SOC NEPHROL, V10, P1649; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Szabo EZ, 2000, J BIOL CHEM, V275, P6302, DOI 10.1074/jbc.275.9.6302; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; Wiederkehr MR, 1999, AM J PHYSIOL-CELL PH, V276, pC1205, DOI 10.1152/ajpcell.1999.276.5.C1205; YAMAJI Y, 1995, P NATL ACAD SCI USA, V92, P6274, DOI 10.1073/pnas.92.14.6274; Yang XJ, 2000, AM J PHYSIOL-CELL PH, V279, pC410, DOI 10.1152/ajpcell.2000.279.2.C410; Zhao H, 1999, J BIOL CHEM, V274, P3978, DOI 10.1074/jbc.274.7.3978	38	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11090	11096		10.1074/jbc.M111868200	http://dx.doi.org/10.1074/jbc.M111868200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11792708	hybrid			2022-12-27	WOS:000174613100045
J	Holtkotter, O; Nieswandt, B; Smyth, N; Muller, W; Hafner, M; Schulte, V; Krieg, T; Eckes, B				Holtkotter, O; Nieswandt, B; Smyth, N; Muller, W; Hafner, M; Schulte, V; Krieg, T; Eckes, B			Integrin alpha(2)-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GLYCOPROTEIN-VI; CELL-ADHESION; 3-DIMENSIONAL COLLAGEN; INDUCED AGGREGATION; MURINE DEVELOPMENT; THROMBUS FORMATION; GAMMA-CHAIN; EXPRESSION; BINDING; ALPHA(2)BETA(1)	The integrin alpha(2)-subunit was ablated in mice by targeted deletion of the ITGA2 gene. alpha(2)-Deficient animals develop normally, are fertile, and reproduce. Surprisingly, no obvious anatomical or histological differences were observed in mutant mice. Besides its significance in tissue morphogenesis, integrin alpha(2)beta(1), has been reported to play a major role in hemostasis by mediating platelet adhesion and activation on subendothelial collagen. To define its role in hemostasis, alpha(2)-deficient platelets were analyzed for their capacity to adhere to and aggregate in response to fibrillar or soluble collagen type L We show that aggregation of alpha(2)-deficient platelets to fibrillar collagen is delayed but not reduced, whereas aggregation to enzymatically digested soluble collagen is abolished. Furthermore, alpha(2)-deficient platelets normally adhere to fibrillar collagen. However, in the presence of an antibody against GPVI (activating platelet collagen receptor), adhesion of alpha(2)-deficient but not wild type platelets is abrogated. These results demonstrate that integrin alpha(2)beta(1), significantly contributes to platelet adhesion to (fibrillar) collagen, which is further confirmed by the abolished adhesion of alpha(2)-deficient platelets to soluble collagen. Thus, alpha(2)beta(1), plays a supportive rather than an essential role in platelet-collagen interactions. These results are in agreement with the observation that alpha(2)beta(1)-deficient animals suffer no bleeding anomalies.	Univ Cologne, Dept Dermatol, D-50931 Cologne, Germany; Univ Cologne, Inst Biochem 2, D-50931 Cologne, Germany; Univ Cologne, Inst Genet, D-50931 Cologne, Germany; Univ Witten Herdecke, Dept Mol Oncol, Wuppertal, Germany	University of Cologne; University of Cologne; University of Cologne; Witten Herdecke University	Eckes, B (corresponding author), Univ Cologne, Dept Dermatol, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.	beate.eckes@uni-koeln.de	Hafner, Martin/B-9040-2008; Muller, Werner/B-9044-2008	Hafner, Martin/0000-0003-0769-1812; Muller, Werner/0000-0002-1297-9725; Smyth, Neil/0000-0002-3734-2149				Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Bergmeier W, 2000, BLOOD, V95, P886, DOI 10.1182/blood.V95.3.886.003k45_886_893; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; COLLER BS, 1989, BLOOD, V74, P182; De Arcangelis A, 2000, TRENDS GENET, V16, P389, DOI 10.1016/S0168-9525(00)02074-6; de Fougerolles AR, 2000, J CLIN INVEST, V105, P721, DOI 10.1172/JCI7911; Decline F, 2001, J CELL SCI, V114, P811; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Fassler R, 1996, CURR OPIN CELL BIOL, V8, P641, DOI 10.1016/S0955-0674(96)80105-0; Gardner H, 1996, DEV BIOL, V175, P301, DOI 10.1006/dbio.1996.0116; Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Kadler KE, 1996, BIOCHEM J, V316, P1; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KEHREL B, 1988, BLOOD, V71, P1074; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Moog S, 2001, BLOOD, V98, P1038, DOI 10.1182/blood.V98.4.1038; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1994, BIOCHEM J, V299, P791, DOI 10.1042/bj2990791; Nieswandt B, 2000, BLOOD, V96, P2520; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Nieswandt B, 2001, J EXP MED, V193, P459, DOI 10.1084/jem.193.4.459; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; SAELMAN EUM, 1994, BLOOD, V83, P1244; Santoro SA, 1999, BLOOD, V93, P3575, DOI 10.1182/blood.V93.11.3575.411a45_3575_3577; Savage B, 1999, BLOOD, V94, P2704, DOI 10.1182/blood.V94.8.2704.420k41_2704_2715; Schulte V, 2001, J BIOL CHEM, V276, P364, DOI 10.1074/jbc.M007536200; Sheppard D, 2000, MATRIX BIOL, V19, P203, DOI 10.1016/S0945-053X(00)00065-2; Siljander P, 1999, ARTERIOSCL THROM VAS, V19, P3033, DOI 10.1161/01.ATV.19.12.3033; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; Watson S, 2000, PLATELETS, V11, P252; WU JE, 1994, DEV DYNAM, V199, P292, DOI 10.1002/aja.1001990405; Zigrino P, 2001, EUR J CELL BIOL, V80, P68, DOI 10.1078/0171-9335-00134; ZUTTER MM, 1990, AM J PATHOL, V137, P113	50	207	217	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10789	10794		10.1074/jbc.M112307200	http://dx.doi.org/10.1074/jbc.M112307200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11788609	hybrid			2022-12-27	WOS:000174613100008
J	Windhorst, S; Frank, E; Georgieva, DN; Genov, N; Buck, F; Borowski, P; Weber, W				Windhorst, S; Frank, E; Georgieva, DN; Genov, N; Buck, F; Borowski, P; Weber, W			The major extracellular protease of the nosocomial pathogen Stenotrophomonas maltophilia - Characterization of the protein and molecular cloning of the gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; AMINO-ACID; DICHELOBACTER-NODOSUS; 2 SUBTILISINS; XANTHOMONAS; PURIFICATION; SEQUENCE; IDENTIFICATION; PNEUMONIA; INFECTION	Stenotrophoinonas maltophilia is increasingly emerging as a multiresistant pathogen in the hospital environment. In immunosuppressed patients, these bacteria may cause severe infections associated with tissue lesions such as pulmonary hemorrhage. This suggests proteolysis as a possible pathogenic mechanism in these infections. This study describes a protease with broad specificity secreted by S. maltophilia. The gene, termed StmPr1, codes for a 63-kDa precursor that is processed to the mature protein of 47 kDa. The enzyme is an alkaline serine protease that, by sequence homology and enzymic properties, can be further classified as a new member of the family of subtilases. It differs from the classic subtilisins in molecular size, in substrate specificity, and probably in the architecture of the active site. The StmPr1 protease is able to degrade several human proteins from serum and connective tissue. Furthermore, pan-protease inhibitors such as alpha(1)-antitrypsin and alpha(2)-macroglobulin were unable to abolish the activity of the bacterial protease. The data support the interpretation that the extracellular protease of S. maltophilia functions as a pathogenic factor and thus could serve as a target for the development of therapeutic agents.	Univ Hamburg, Klinikum Eppendorf, Inst Med Biochem & Mol Biol, D-20246 Hamburg, Germany; Univ Hamburg, Klinikum Eppendorf, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany	University of Hamburg; University of Hamburg	Weber, W (corresponding author), Univ Hamburg, Klinikum Eppendorf, Inst Med Biochem & Mol Biol, Martinistr 52, D-20246 Hamburg, Germany.	weber@uke.uni-hamburg.de						Babe LM, 1998, BBA-PROTEIN STRUCT M, V1386, P211, DOI 10.1016/S0167-4838(98)00110-1; BOETHLING RS, 1975, J BACTERIOL, V121, P933, DOI 10.1128/JB.121.3.933-941.1975; Denton M, 1998, CLIN MICROBIOL REV, V11, P57, DOI 10.1128/CMR.11.1.57; Elsner HA, 1997, ANN HEMATOL, V74, P155; Georgieva DN, 2001, ARCH BIOCHEM BIOPHYS, V387, P197, DOI 10.1006/abbi.2000.2249; GOA J, 1953, SCAND J CLIN LAB INV, V5, P218, DOI 10.3109/00365515309094189; GRON H, 1992, BIOCHEMISTRY-US, V31, P6011, DOI 10.1021/bi00141a008; GUNTHER N, 1990, J BIOL CHEM, V265, P22082; JANY KD, 1986, FEBS LETT, V199, P139, DOI 10.1016/0014-5793(86)80467-7; JOHANSEN JT, 1968, CR TRAV LAB CARLSB, V36, P365; KOBAYASHI T, 1985, AGR BIOL CHEM TOKYO, V49, P693, DOI 10.1080/00021369.1985.10866798; KORTT AA, 1994, BIOCHEM J, V299, P521, DOI 10.1042/bj2990521; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLEY GG, 1992, EUR J BIOCHEM, V210, P13, DOI 10.1111/j.1432-1033.1992.tb17385.x; LIU YN, 1990, MOL GEN GENET, V220, P433, DOI 10.1007/BF00391750; MARKLAND FS, 1967, J BIOL CHEM, V242, P5198; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; Ohkoshi Y, 1999, INTERNAL MED, V38, P671, DOI 10.2169/internalmedicine.38.671; PALLERONI NJ, 1993, INT J SYST BACTERIOL, V43, P606, DOI 10.1099/00207713-43-3-606; PLANTNER JJ, 1991, ANAL BIOCHEM, V195, P129, DOI 10.1016/0003-2697(91)90307-F; Quinn JP, 1998, CLIN INFECT DIS, V27, pS117, DOI 10.1086/514912; Rao MB, 1998, MICROBIOL MOL BIOL R, V62, P597, DOI 10.1128/MMBR.62.3.597-635.1998; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SWINGS J, 1983, INT J SYST BACTERIOL, V33, P409, DOI 10.1099/00207713-33-2-409; Tamura H, 1998, J GASTROENTEROL, V33, P412, DOI 10.1007/s005350050105; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRAVIS J, 1995, TRENDS MICROBIOL, V3, P405, DOI 10.1016/S0966-842X(00)88988-X; Tsujibo H, 1996, BIOSCI BIOTECH BIOCH, V60, P1284, DOI 10.1271/bbb.60.1284; WEBER W, 1984, J BIOL CHEM, V259, P4631; [No title captured]	32	79	88	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11042	11049		10.1074/jbc.M109525200	http://dx.doi.org/10.1074/jbc.M109525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11796713	hybrid			2022-12-27	WOS:000174613100038
J	Yamagata, H; Yonesu, K; Hirata, A; Aizono, Y				Yamagata, H; Yonesu, K; Hirata, A; Aizono, Y			TGTCACA motif is a novel cis-regulatory enhancer element involved in fruit-specific expression of the cucumisin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-BOX; MELON FRUITS; BINDING-PROTEINS; I-BOX; PROMOTER; ETHYLENE; TOMATO; PLANTS; IDENTIFICATION; TRANSCRIPTION	Cucumisin, a subtilisin-like serine protease, is expressed at high levels in the fruit of melon (Cucumis melo L.) and accumulates in the juice. We investigated roles of the promoter regions and DNA-protein interactions in fruit-specific expression of the cucumisin gene. In transient expression analysis, a chimeric gene construct containing a 1.2-kb cucumisin promoter fused to a P-glucuronidase (GUS) reporter gene was expressed in fruit tissues at high levels, but the promoter activities in leaves and stems were very low. Deletion analysis indicated that a positive regulatory region is located between nucleotides -234 and -214 relative to the transcriptional initiation site. Gain-of-function experiments revealed that this 20-bp sequence conferred fruit specificity and contained a regulatory enhancer. Gel mobility shift experiments demonstrated the presence of fruit nuclear factors that interact with the cucumisin promoter. A typical G-box (GACACGTGTC) present in the 20-bp sequence did not bind fruit protein, but two possible cis-elements, an I-box-like sequence (AGATAT-GATAAAA) and an odd base palindromic TGTCACA motif, were identified in the promoter region between positions -254 and -215. The I-box-like sequence bound more tightly to fruit nuclear protein than the TGTCACA motif. The I-box-like sequence functions as a negative regulatory element, and the TGTCACA motif is a novel enhancer element necessary for fruit-specific expression of the cucumisin gene. Specific nucleotides responsible for the binding of fruit nuclear protein in these two elements were also determined.	Kobe Univ, Fac Agr, Biochem Lab, Nada Ku, Kobe, Hyogo 6578501, Japan	Kobe University	Yamagata, H (corresponding author), Kobe Univ, Fac Agr, Biochem Lab, Nada Ku, Rokkodai Cho 1, Kobe, Hyogo 6578501, Japan.							ANDERSON SL, 1995, P NATL ACAD SCI USA, V92, P1500, DOI 10.1073/pnas.92.5.1500; Ayub R, 1996, NAT BIOTECHNOL, V14, P862, DOI 10.1038/nbt0796-862; Baum K, 1997, PLANT J, V12, P463, DOI 10.1046/j.1365-313X.1997.12020463.x; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; Daniell H, 2001, TRENDS PLANT SCI, V6, P219, DOI 10.1016/S1360-1385(01)01922-7; Fluhr R, 1998, TRENDS PLANT SCI, V3, P141, DOI 10.1016/S1360-1385(98)01226-6; FOSTER R, 1994, FASEB J, V8, P192, DOI 10.1096/fasebj.8.2.8119490; Foster R., 1992, Methods in Arabidopsis research., P378; GALLIE DR, 1987, NUCLEIC ACIDS RES, V15, P8693, DOI 10.1093/nar/15.21.8693; Giovannoni J, 2001, ANNU REV PLANT PHYS, V52, P725, DOI 10.1146/annurev.arplant.52.1.725; GOFF SA, 1991, GENE DEV, V5, P298, DOI 10.1101/gad.5.2.298; GOFF SA, 1990, EMBO J, V9, P2517, DOI 10.1002/j.1460-2075.1990.tb07431.x; GRAY J, 1992, PLANT MOL BIOL, V19, P69, DOI 10.1007/BF00015607; Ishige F, 1999, PLANT J, V18, P443, DOI 10.1046/j.1365-313X.1999.00456.x; JEFFERSON RA, 1987, EMBO J, V6, P3901; LAM E, 1989, PLANT CELL, V1, P1147, DOI 10.1105/tpc.1.12.1147; Lelievre JM, 1997, PHYSIOL PLANTARUM, V101, P727, DOI 10.1111/j.1399-3054.1997.tb01057.x; MANZARA T, 1991, PLANT CELL, V3, P1305, DOI 10.1105/tpc.3.12.1305; MEIER I, 1994, NUCLEIC ACIDS RES, V22, P470, DOI 10.1093/nar/22.3.470; MEIER I, 1995, PLANT PHYSIOL, V107, P1105, DOI 10.1104/pp.107.4.1105; Millar AJ, 1992, PLANT MOL BIOL REP, V10, P324, DOI 10.1007/BF02668909; OCHMAN H, 1988, GENETICS, V120, P621; OHMETAKAGI M, 1995, PLANT CELL, V7, P173, DOI 10.1105/tpc.7.2.173; POTRYKUS I, 1991, ANNU REV PLANT PHYS, V42, P205, DOI 10.1146/annurev.pp.42.060191.001225; ROGERS SO, 1985, PLANT MOL BIOL, V5, P69, DOI 10.1007/BF00020088; Rose A, 1999, PLANT J, V20, P641, DOI 10.1046/j.1365-313X.1999.00638.x; Ruf S, 2001, NAT BIOTECHNOL, V19, P870, DOI 10.1038/nbt0901-870; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; TERZAGHI WB, 1995, ANNU REV PLANT PHYS, V46, P445, DOI 10.1146/annurev.pp.46.060195.002305; WILLIAMS ME, 1992, PLANT CELL, V4, P485, DOI 10.1105/tpc.4.4.485; YAMAGATA H, 1989, AGR BIOL CHEM TOKYO, V53, P1009, DOI 10.1080/00021369.1989.10869404; YAMAGATA H, 1994, J BIOL CHEM, V269, P32725; YAMAMOTO M, 1995, PLANT CELL PHYSIOL, V36, P591	33	47	62	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11582	11590		10.1074/jbc.M109946200	http://dx.doi.org/10.1074/jbc.M109946200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11782472	hybrid			2022-12-27	WOS:000174613100106
J	Alfalah, M; Jacob, R; Naim, HY				Alfalah, M; Jacob, R; Naim, HY			Intestinal dipeptidyl peptidase IV is efficiently sorted to the apical membrane through the concerted action of N- and O-glycans as well as association with lipid microdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL SORTING SIGNAL; GPI-ANCHORED PROTEINS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; INFLUENZA-VIRUS HEMAGGLUTININ; LACTASE-PHLORHIZIN HYDROLASE; BORDER SUCRASE-ISOMALTASE; POLARIZED MDCK CELLS; CANINE KIDNEY-CELLS; EPITHELIAL-CELLS; INTRACELLULAR-TRANSPORT	The apical sorting of human intestinal dipeptidyl peptidase IV (DPPIV) occurs through complex N-linked and O-linked carbohydrates. Inhibition of O-linked glycosylation by benzyl-N-acetyl-alpha-D-galactosaminide affects significantly the sorting behavior of DPPIV in intestinal Caco-2 and HT-29 cells. However, random delivery to the apical and basolateral membranes and hence a more drastic effect on the sorting of DPPIV in both cell types is only observed when, in addition to O-glycans, the processing of N-glycans is affected by swainsonine, an inhibitor of mannosidase II. Together the data indicate that both types of glycosylation are critical components of the apical sorting signal of DPPIV. The sorting mechanism of DPPIV implicates its association with detergent-insoluble membrane microdomains containing cholesterol and sphingolipids, whereas an efficient association largely depends on the presence of a fully complex N- and O-linked glycosylated DPPIV. Interestingly, cholesterol is a more critical component in this context than sphingolipids, because cholesterol depletion by beta-cyclodextrin affects the detergent solubility and the sorting behavior of DPPIV more strongly than fumonisin, an inhibitor of sphingolipid synthesis.	Sch Vet Med Hannover, Dept Physiol Chem, D-30559 Hannover, Germany	University of Veterinary Medicine Hannover, Foundation	Naim, HY (corresponding author), Sch Vet Med Hannover, Dept Physiol Chem, Bunteweg 17, D-30559 Hannover, Germany.		Jacob, Ralf/B-8163-2011; Al Falah, Dr. Marwan/C-6281-2011					Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BYRD JC, 1995, EUR J CANCER, V31A, P1498, DOI 10.1016/0959-8049(95)00248-H; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; DEHOOP M, 1995, J CELL BIOL, V130, P1447, DOI 10.1083/jcb.130.6.1447; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; ELBEIN AD, 1983, J CELL PHYSIOL, V115, P265, DOI 10.1002/jcp.1041150309; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fan H, 1997, EUR J BIOCHEM, V246, P243, DOI 10.1111/j.1432-1033.1997.00243.x; FRANSEN JAM, 1991, J CELL BIOL, V115, P45, DOI 10.1083/jcb.115.1.45; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GONZALEZ A, 1993, J BIOL CHEM, V268, P6662; GRANOVSKY M, 1994, EUR J BIOCHEM, V221, P1039, DOI 10.1111/j.1432-1033.1994.tb18822.x; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; Jacob R, 1999, J BIOL CHEM, V274, P8061, DOI 10.1074/jbc.274.12.8061; Jacob R, 2001, CURR BIOL, V11, P1444, DOI 10.1016/S0960-9822(01)00446-8; Jacob R, 1997, EUR J CELL BIOL, V72, P54; KOJIMA N, 1992, BIOCHEM BIOPH RES CO, V182, P1288, DOI 10.1016/0006-291X(92)91872-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LeGall AH, 1997, J BIOL CHEM, V272, P4559, DOI 10.1074/jbc.272.7.4559; Lin S, 1997, J BIOL CHEM, V272, P26300, DOI 10.1074/jbc.272.42.26300; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; Lipardi C, 2000, MOL BIOL CELL, V11, P531, DOI 10.1091/mbc.11.2.531; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MATTER K, 1989, J BIOL CHEM, V264, P13131; MATTER K, 1991, BIOCHEMISTRY-US, V30, P1916, DOI 10.1021/bi00221a026; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MISUMI Y, 1992, BIOCHIM BIOPHYS ACTA, V1131, P333, DOI 10.1016/0167-4781(92)90036-Y; Moolenaar CEC, 1997, J CELL SCI, V110, P557; Muniz M, 2000, EMBO J, V19, P10, DOI 10.1093/emboj/19.1.10; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 2001, NESTLE NUTR WORKSH S, V46, P195; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; QUINN MT, 1992, J BIOL CHEM, V267, P7303; RAGNO P, 1992, EXP CELL RES, V203, P236, DOI 10.1016/0014-4827(92)90060-L; Ramachandran U, 1997, ARCH BIOCHEM BIOPHYS, V342, P29, DOI 10.1006/abbi.1997.0101; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; ROUSSET M, 1979, CANCER RES, V39, P531; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Slimane TA, 2000, EXP CELL RES, V258, P184; SOOLE KL, 1992, J CELL SCI, V102, P495; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; ULLRICH O, 1991, J BIOL CHEM, V266, P3518; VOGEL LK, 1992, J BIOL CHEM, V267, P2794; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WANG E, 1991, J BIOL CHEM, V266, P14486; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929	62	54	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10683	10690		10.1074/jbc.M109357200	http://dx.doi.org/10.1074/jbc.M109357200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11773049	hybrid			2022-12-27	WOS:000174549200142
J	Huang, X; Zeng, R; Ding, XM; Mao, X; Ding, Y; Rao, ZH; Xie, Y; Jiang, WH; Zhao, GP				Huang, X; Zeng, R; Ding, XM; Mao, X; Ding, Y; Rao, ZH; Xie, Y; Jiang, WH; Zhao, GP			Affinity alkylation of the Trp-b4 residue of the beta-subunit of the glutaryl 7-aminocephalosporanic acid acylase of Pseudomonas sp 130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; PURIFICATION	Glutaryl 7-aminocephalosporanic acid acylase of Pseudomonas sp. 130 (C130) was irreversibly inhibited in a time-dependent manner by two substrate analogs bearing side chains of variable length, namely 7beta-bromoacetyl aminocephalosporanic acid (BA-7-ACA) and 7beta-3-bromopropionyl aminocephalosporanic acid (BP-7-ACA). The inhibition of the enzyme with BA-7-ACA was attributable to reaction with a single amino acid residue within the 6-subunit proven by comparative matrix assisted laser desorption/ionization-time of flight mass spectrometry. Further mass spectrometric analysis demonstrated that the fourth tryptophan residue of the,6-subunit, Trp-B4, was alkylated by BA-7-ACA. By H-1-C-13 HSQC spectroscopy of C130 labeled by BA-2-C-13-7-ACA it was shown that tryptophan residue(s) in the enzyme was alkylated, forming a carbon-carbon bond. Replacing Trp-B4 with other amino acid residues caused increases in K-m, decreases in k(cat), and instability of enzyme activity. None of the mutant enzymes except W-B4Y could be affinity-alkylated, but all were competitively inhibited by BA-7-ACA. Kinetic studies revealed that both BA-7-ACA and BP-7-ACA could specifically alkylate Trp-B4 of C130 as well as Tyr-B4 of the mutant W-B4Y. Because these alkylations were energy-requiring under physiological conditions, it is likely that the affinity labeling reactions were catalyzed by the C130 enzyme itself. The Trp-B4 residue is located in the middle of a characteristic alphabetabetaalpha sandwich structure. Therefore, a large conformational alteration during inhibitor binding and transition state formation is likely and suggests that a major conformational change is induced by substrate binding during the course of catalysis.	Chinese Acad Sci, Lab Microbial Mol Physiol, Inst Plant Physiol & Ecol, Shanghai 200032, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200032, Peoples R China; Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China; Tsing Hua Univ, Sch Life Sci, Beijing 100084, Peoples R China	Chinese Academy of Sciences; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Hong Kong University of Science & Technology; Tsinghua University	Jiang, WH (corresponding author), Chinese Acad Sci, Lab Microbial Mol Physiol, Inst Plant Physiol & Ecol, 345 Lingling Lu, Shanghai 200032, Peoples R China.		Rao, Zihe/HCH-6944-2022	Zhao, Guo-Ping/0000-0002-7621-6620				BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; BRAUNWARTH JB, 1962, J ORG CHEM, V27, P2064, DOI 10.1021/jo01053a037; BREITMAIR E, 1987, CARBON 13 NMR SPECTR, P314; CONDREA E, 1985, CAN J PHYSIOL PHARM, V63, P331, DOI 10.1139/y85-060; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Eckenhoff RG, 1996, J BIOL CHEM, V271, P15521, DOI 10.1074/jbc.271.26.15521; EVANS BLB, 1981, ARCH BIOCHEM BIOPHYS, V206, P362, DOI 10.1016/0003-9861(81)90103-X; HOULIHAN WJ, 1972, INDOLES 1, P90; HUANG YC, 1984, J BIOL CHEM, V259, P2481; ICHIKAWA S, 1981, AGR BIOL CHEM TOKYO, V45, P2231, DOI 10.1080/00021369.1981.10864878; ISOGAI T, 1990, J BIOCHEM-TOKYO, V108, P1063, DOI 10.1093/oxfordjournals.jbchem.a123306; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kim Y, 2001, CHEM BIOL, V8, P1253, DOI 10.1016/S1074-5521(01)00092-8; Kim Y, 2000, STRUCTURE, V8, P1059, DOI 10.1016/S0969-2126(00)00505-0; KOSHLAND DE, 1964, J AM CHEM SOC, V86, P1448, DOI 10.1021/ja01061a045; Lee Y. S., 2000, BIOCHIM BIOPHYS ACTA, V1519, P123; Li Y, 1998, PROTEIN EXPRES PURIF, V12, P233, DOI 10.1006/prep.1997.0823; Li Y, 1999, EUR J BIOCHEM, V262, P713, DOI 10.1046/j.1432-1327.1999.00417.x; LOO JA, 1993, ANAL CHEM, V65, P425, DOI 10.1021/ac00052a020; LOUDON GM, 1970, J BIOL CHEM, V245, P2247; LOUDON GM, 1969, J AM CHEM SOC, V91, P2792, DOI 10.1021/ja01038a068; MATSUDA A, 1985, J BACTERIOL, V163, P1222, DOI 10.1128/JB.163.3.1222-1228.1985; Mortz E, 1996, P NATL ACAD SCI USA, V93, P8264, DOI 10.1073/pnas.93.16.8264; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; PASCHAL JW, 1978, J ORG CHEM, V43, P2013, DOI 10.1021/jo00404a037; Schramm VL, 1998, ANNU REV BIOCHEM, V67, P693, DOI 10.1146/annurev.biochem.67.1.693; Shan SO, 1996, SCIENCE, V272, P97, DOI 10.1126/science.272.5258.97; SHIBUYA Y, 1981, AGR BIOL CHEM TOKYO, V45, P1561, DOI 10.1080/00021369.1981.10864767; YANG Y, 1990, J BIOTECHNOL, V7, P99	29	9	10	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10256	10264		10.1074/jbc.M108683200	http://dx.doi.org/10.1074/jbc.M108683200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11782466	hybrid			2022-12-27	WOS:000174549200087
J	Gorrell, A; Wang, WY; Underbakke, E; Hou, ZL; Honzatko, RB; Fromm, HJ				Gorrell, A; Wang, WY; Underbakke, E; Hou, ZL; Honzatko, RB; Fromm, HJ			Determinants of L-aspartate and IMP recognition in Escherichia coli adenylosuccinate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; CRYSTAL-STRUCTURES; DIRECTED MUTATION; ISOTOPE EXCHANGE; BINDING-SITE; RESIDUES; IDENTIFICATION; MECHANISM; COMPLEXES; CATALYSIS	Adenylosuccinate synthetase governs the first committed step in the de novo synthesis of AMP. Mutations of conserved residues in the synthetase from Escherichia coli reveal significant roles for VaJ(273) and Thr(300) in the recognition Of L-aspartate, even though these residues do not or cannot hydrogen bond with the substrate. The mutation of Thr(300) to alanine increases the K-m for L-aspartate by 30-fold. In contrast, its mutation to valine causes no more than a 4-fold increase in the K-m for L-aspartate, while increasing k(cat) by 3-fold. Mutations of VaJ(273) to alanine, threonine, or asparagine increase the K-m for L-aspartate from 15- to 40-fold, and concomitantly decrease the K-i for dicarboxylate analogues Of L-aspartate by up to 40-fold. The above perturbations are comparable with those resulting from the elimination of a hydrogen bond between the enzyme and substrate: alanine mutations of Thr(128) and Thr(129) increase the K-m for IMP by up to 30-fold and the alanine mutation of Thr(301) abolishes catalysis supported by L-aspartate, but has no effect on catalysis supported by hydroxylamine. Structure-based mechanisms, by which the above residues influence substrate recognition, are presented.	Iowa State Univ Sci & Technol, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Fromm, HJ (corresponding author), Iowa State Univ Sci & Technol, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.			Underbakke, Eric/0000-0003-4269-7339	NINDS NIH HHS [NS10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BASS MB, 1987, ARCH BIOCHEM BIOPHYS, V256, P335, DOI 10.1016/0003-9861(87)90454-1; BASS MB, 1984, J BIOL CHEM, V259, P2330; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1986, J BIOL CHEM, V261, P3637; Choe JY, 1999, BIOCHEMISTRY-US, V38, P6953, DOI 10.1021/bi990159s; COOPER BF, 1986, BIOCHEMISTRY-US, V25, P7323, DOI 10.1021/bi00371a013; FonnePfister R, 1996, P NATL ACAD SCI USA, V93, P9431, DOI 10.1073/pnas.93.18.9431; FROMM HJ, 1958, BIOCHIM BIOPHYS ACTA, V29, P255, DOI 10.1016/0006-3002(58)90182-3; GALE GR, 1968, BIOCHEM PHARMACOL, V17, P2495, DOI 10.1016/0006-2952(68)90144-5; Honzatko RB, 1999, ADV ENZYMOL RAMB, V73, P57, DOI 10.1002/9780470123195.ch3; Honzatko RB, 1999, ARCH BIOCHEM BIOPHYS, V370, P1, DOI 10.1006/abbi.1999.1383; HOU Z, 2002, IN PRESS J BIOL CHEM, V277; Hou ZL, 1999, J BIOL CHEM, V274, P17505, DOI 10.1074/jbc.274.25.17505; Kang C, 1996, J BIOL CHEM, V271, P29722, DOI 10.1074/jbc.271.47.29722; KANG CH, 1995, J BIOL CHEM, V270, P15539, DOI 10.1074/jbc.270.26.15539; Kang CH, 1997, J BIOL CHEM, V272, P11881, DOI 10.1074/jbc.272.18.11881; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1977, ENZFITTER NONLINEAR, P13; LIEBERMAN I, 1956, J BIOL CHEM, V223, P327; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; LUI F, 1990, J BIOL CHEM, V265, P7401; Poland BW, 1996, J MOL BIOL, V264, P1013, DOI 10.1006/jmbi.1996.0693; POLAND BW, 1993, J BIOL CHEM, V268, P25334; Poland BW, 1996, J BIOL CHEM, V271, P15407, DOI 10.1074/jbc.271.26.15407; Poland BW, 1997, J BIOL CHEM, V272, P15200, DOI 10.1074/jbc.272.24.15200; POLAND BW, 1996, BIOCHEMISTRY-US, V35, P12753; PORTER DJT, 1983, ARCH BIOCHEM BIOPHYS, V225, P157, DOI 10.1016/0003-9861(83)90019-X; RUDOLPH FB, 1969, J BIOL CHEM, V244, P3832; SIEGEL WH, 1977, APPL ENVIRON MICROB, V34, P512, DOI 10.1128/AEM.34.5.512-517.1977; SPECTOR T, 1976, BIOCHIM BIOPHYS ACTA, V445, P509, DOI 10.1016/0005-2744(76)90104-2; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wang WY, 1997, J BIOL CHEM, V272, P7078, DOI 10.1074/jbc.272.11.7078; Wang WY, 1997, J BIOL CHEM, V272, P16911, DOI 10.1074/jbc.272.27.16911; Wang WY, 1998, J BIOL CHEM, V273, P16000, DOI 10.1074/jbc.273.26.16000; WANG WY, 1995, J BIOL CHEM, V270, P13160, DOI 10.1074/jbc.270.22.13160	38	7	7	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8817	8821		10.1074/jbc.M111810200	http://dx.doi.org/10.1074/jbc.M111810200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11781326	hybrid			2022-12-27	WOS:000174400600011
J	DeMott, MS; Beyret, E; Wong, D; Bales, BC; Hwang, JT; Greenberg, MM; Demple, B				DeMott, MS; Beyret, E; Wong, D; Bales, BC; Hwang, JT; Greenberg, MM; Demple, B			Covalent trapping of human DNA polymerase beta by the oxidative DNA lesion 2-deoxyribonolactone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; ENDONUCLEASE APE1; STRANDED-DNA; PATHWAY; DAMAGE; 3'-EXO/ENDONUCLEASE; REQUIREMENT; SUBSTRATE; CLEAVAGE; PROTEIN	Oxidized abasic residues in DNA constitute a major class of radiation and oxidative damage. Free radical attack on the nucleotidyl C-1' carbon yields 2-deoxyribonolactone (dL) as a significant lesion. Although dL residues are efficiently incised by the main human abasic endonuclease enzyme Ape1, we show here that subsequent excision by human DNA polymerase beta is impaired at dL compared with unmodified abasic sites. This inhibition is accompanied by accumulation of a protein-DNA cross-link not observed in reactions of polymerase beta with unmodified abasic sites, although a similar form can be trapped by reduction with sodium borohydride. The formation of the stably cross-linked species with dL depends on the polymerase lysine 72 residue, which forms a Schiff base with the C-1 aldehyde during excision of an unmodified abasic site. In the case of a dL residue, attack on the lactone C-1 by lysine 72 proceeds more slowly and evidently produces an amide linkage, which resists further processing. Consequently dL residues may not be readily repaired by "short-patch" base excision repair but instead function as suicide substrates in the formation of protein-DNA crosslinks that may require alternative modes of repair.	Harvard Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA	Harvard University; Harvard T.H. Chan School of Public Health; Colorado State University	Demple, B (corresponding author), Harvard Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA.			BEYRET, ERGIN/0000-0003-1980-532X	NATIONAL CANCER INSTITUTE [T32CA009078, R01CA071993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040000] Funding Source: NIH RePORTER; NCI NIH HHS [CA71993, T32-CA09078] Funding Source: Medline; NIEHS NIH HHS [T32-ES07155] Funding Source: Medline; NIGMS NIH HHS [GM40000, GM54996] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; Chaudhry MA, 1999, BIOCHEM PHARMACOL, V57, P531, DOI 10.1016/S0006-2952(98)00327-X; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; Demple B, 1997, ENVIRON HEALTH PERSP, V105, P931, DOI 10.2307/3433306; Deterding LJ, 2000, J BIOL CHEM, V275, P10463, DOI 10.1074/jbc.275.14.10463; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; Garcia-Diaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200; GREENBERG MM, 1999, COMPREHENSIVE NATURA, V7, P371; Hashimoto M, 2001, J AM CHEM SOC, V123, P3161, DOI 10.1021/ja003354z; Hwang JT, 1999, NUCLEIC ACIDS RES, V27, P3805, DOI 10.1093/nar/27.19.3805; Hwang JT, 1999, J AM CHEM SOC, V121, P4311, DOI 10.1021/ja990152y; Izumi T, 2000, CARCINOGENESIS, V21, P1329, DOI 10.1093/carcin/21.7.1329; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Lindahl T, 2000, MUTAT RES-REV MUTAT, V462, P129, DOI 10.1016/S1383-5742(00)00024-7; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Matsumoto Y, 1998, BIOCHEMISTRY-US, V37, P6456, DOI 10.1021/bi9727545; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Xu YJ, 1998, J BIOL CHEM, V273, P28837, DOI 10.1074/jbc.273.44.28837	26	100	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7637	7640		10.1074/jbc.C100577200	http://dx.doi.org/10.1074/jbc.C100577200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11805079	hybrid			2022-12-27	WOS:000174268000003
J	Wells, L; Gao, Y; Mahoney, JA; Vosseller, K; Chen, C; Rosen, A; Hart, GW				Wells, L; Gao, Y; Mahoney, JA; Vosseller, K; Chen, C; Rosen, A; Hart, GW			Dynamic O-glycosylation of nuclear and cytosolic proteins - Further characterization of the nucleocytoplasmic beta-N-acetylglucosaminidase, O-GlcNAcase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC PROTEINS; ALZHEIMERS-DISEASE; LINKED GLYCOSYLATION; D-GLUCOSAMINIDASE; ACTIVE-SITE; TRANSFERASE; IDENTIFICATION; HYALURONIDASE; CHROMOSOME; ACTIVATION	beta-O-linked N-acetylglucosamine (0-GIcNAc) is an abundant and dynamic post-translational modification implicated in protein regulation that appears to be functionally more similar to phosphorylation than to classical glycosylation. There are nucleocytoplasmic enzymes for the attachment and removal of 0-GIcNAc. Here, we further characterize the recently cloned beta-N-acetylglucosaminidase, O-GlcNAcase. Both recombinant and purified endogenous O-GlcNAcase rapidly release free GlcNAc from O-GlcNAc-modified peptide substrates. The recombinant enzyme functions as a monomer and has kinetic parameters (K-m = 1.1 mm for paranitrophenyl-GleNAc, k(cat) = 1 s(-1)) that are similar to those of lysosomal hexosaminidases. The endogenous O-GlcNAcase appears to be in a complex with other proteins and is predominantly localized to the cytosol. Overexpression of the enzyme in living cells results in decreased O-GlcNAc modification of nucleocytoplasmic proteins. Finally, we show that the enzyme is a substrate for caspase-3 but, suprisingly, the cleavage has no effect on in vitro O-GlcNAcase activity. These studies support the identification of this protein as an O-GlcNAcase and identify important interactions and modifications that may regulate the enzyme and O-GlcNAc cycling.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Hart, GW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St,517 WBSB, Baltimore, MD 21205 USA.	gwhart@jhmi.edu	Wells, Lance/H-3118-2013	Hart, Gerald/0000-0001-7812-4351; Wells, Lance/0000-0003-4956-5363	NCI NIH HHS [CA83261] Funding Source: Medline; NICHD NIH HHS [HD13563] Funding Source: Medline; NIDCR NIH HHS [DE12354] Funding Source: Medline; NIGMS NIH HHS [GM20528] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD013563, R01HD013563] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [F32CA083261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE012354] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE012354] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM020528] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antoine JC, 1999, ARCH NEUROL-CHICAGO, V56, P172, DOI 10.1001/archneur.56.2.172; Arnold CS, 1996, J BIOL CHEM, V271, P28741, DOI 10.1074/jbc.271.46.28741; Bertram L, 2000, SCIENCE, V290, P2302, DOI 10.1126/science.290.5500.2302; BEUTLER E, 1977, ANN HUM GENET, V41, P163, DOI 10.1111/j.1469-1809.1977.tb01911.x; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CHOU CF, 1993, J BIOL CHEM, V268, P4465; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Comtesse N, 2001, BIOCHEM BIOPH RES CO, V283, P634, DOI 10.1006/bbrc.2001.4815; Dong DLY, 1996, J BIOL CHEM, V271, P20845, DOI 10.1074/jbc.271.34.20845; DONG DLY, 1994, J BIOL CHEM, V269, P19321; Elson LA, 1933, BIOCHEM J, V27, P1824, DOI 10.1042/bj0271824; Fernandes MJG, 1997, J BIOL CHEM, V272, P814, DOI 10.1074/jbc.272.2.814; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Griffith LS, 1999, EUR J BIOCHEM, V262, P824, DOI 10.1046/j.1432-1327.1999.00439.x; Grutter MG, 2000, CURR OPIN STRUC BIOL, V10, P649, DOI 10.1016/S0959-440X(00)00146-9; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Haltiwanger RS, 1997, BIOCHEM BIOPH RES CO, V231, P237, DOI 10.1006/bbrc.1997.6110; Hanover JA, 1999, ARCH BIOCHEM BIOPHYS, V362, P38, DOI 10.1006/abbi.1998.1016; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Heckel D, 1998, HUM MOL GENET, V7, P1859, DOI 10.1093/hmg/7.12.1859; Hou YM, 2000, BIOCHEMISTRY-US, V39, P6219, DOI 10.1021/bi992464j; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Lian QY, 2001, EXP NEUROL, V167, P158, DOI 10.1006/exnr.2000.7534; Lubas WA, 2000, J BIOL CHEM, V275, P10983, DOI 10.1074/jbc.275.15.10983; Lubas WA, 1997, J BIOL CHEM, V272, P9316; Lubec G, 1999, J NEURAL TRANSM-SUPP, P161; MAHURAN D, 1985, ISOZYMES-CURR T BIOL, V12, P229; Mukerjee N, 2001, BIOCHEM BIOPH RES CO, V285, P1192, DOI 10.1006/bbrc.2001.5278; Muzzarelli RAA, 1999, EXS, V87, P235; Myers A, 2000, SCIENCE, V290, P2304, DOI 10.1126/science.290.5500.2304; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Nobile C, 1999, GENOMICS, V62, P86, DOI 10.1006/geno.1999.5988; OVERDIJK B, 1981, BIOCHIM BIOPHYS ACTA, V659, P255, DOI 10.1016/0005-2744(81)90052-8; Rex-Mathes M, 2001, BIOCHIMIE, V83, P583, DOI 10.1016/S0300-9084(01)01305-0; Roos MD, 1998, P ASSOC AM PHYSICIAN, V110, P422; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; Rosen A, 1997, J CELL BIOCHEM, V64, P50, DOI 10.1002/(SICI)1097-4644(199701)64:1<50::AID-JCB8>3.0.CO;2-Z; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; Vosseller K, 2001, BIOCHIMIE, V83, P575, DOI 10.1016/S0300-9084(01)01295-0; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; YOSHIDA K, 1994, CLIN CHIM ACTA, V226, P55, DOI 10.1016/0009-8981(94)90102-3	48	199	218	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					1755	1761		10.1074/jbc.M109656200	http://dx.doi.org/10.1074/jbc.M109656200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11788610	hybrid			2022-12-27	WOS:000173421300019
J	Denda, K; Shimomura, T; Kawaguchi, T; Miyazawa, K; Kitamura, N				Denda, K; Shimomura, T; Kawaguchi, T; Miyazawa, K; Kitamura, N			Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE INHIBITOR; MATRIX-DEGRADING PROTEASE; BREAST-CANCER CELLS; PROTEOLYTIC CLEAVAGE; TRYPSIN-INHIBITOR; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; PURIFICATION; EXPRESSION; FORM	Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is a Kunitz-type serine protease inhibitor identified as a strong inhibitor of hepatocyte growth factor (HGF) activator and matriptase. HAI-1 is first produced in a membrane-integrated form with two Kunitz domains in its extracellular region, and subsequent ectodomain shedding releases two major secreted forms, one with a single Kunitz domain and one with two Kunitz domains. To determine the roles of the Kunitz domains in the inhibitory activity of HAI-1 against serine proteases, we constructed various HAI-1 mutant proteins and examined their inhibitory activity against HGF activator and trypsin. The N-terminal Kunitz domain (Kunitz 1) had potent inhibitory activity against both HGF activator and trypsin, whereas the C-terminal Kunitz domain (Kunitz II) had only very weak inhibitory activity against HGF activator, although its potency against trypsin was equivalent to that of Kunitz L These results indicate that Kunitz I is the functional domain of HAI-1 for inhibiting the HGF-converting activity of HGF activator. Furthermore, the presence of two Kunitz domains affected the inhibitory activity of HAI-1 against HGF activator, and it showed a similar, but not additive, level of inhibitory activity against trypsin when compared with that of the individual Kunitz domains. These results suggest that serine protease binding sites of Kunitz I and Kunitz 11 are located close to each other and that proteolytic processing to generate HAI-1 with only one Kunitz domain regulates the activity of HAI-1.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Sci Biol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Mitsubishi Pharma Corp, Res Ctr, Aoba Ku, Yokohama, Kanagawa 2270033, Japan	Tokyo Institute of Technology; Mitsubishi Tanabe Pharma Corporation	Kitamura, N (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Sci Biol, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.		MIYAZAWA, KEIJI/I-9713-2014					Benaud C, 2001, EUR J BIOCHEM, V268, P1439, DOI 10.1046/j.1432-1327.2001.02016.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; Itoh H, 2000, AM J PHYSIOL-GASTR L, V278, pG635, DOI 10.1152/ajpgi.2000.278.4.G635; ITOH H, 1994, J BIOL CHEM, V269, P3818; Kataoka H, 1999, J HISTOCHEM CYTOCHEM, V47, P673, DOI 10.1177/002215549904700509; KATSOKA H, 2000, J BIOL CHEM, V275, P40453; Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558; KIDO H, 1988, J BIOL CHEM, V263, P18104; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1997, J BIOL CHEM, V272, P9147; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MORISHITA H, 1994, THROMB RES, V73, P193, DOI 10.1016/0049-3848(94)90098-1; NAKA D, 1992, J BIOL CHEM, V267, P20114; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; SHI YE, 1993, CANCER RES, V53, P1409; Shimomura T, 1999, J BIOCHEM-TOKYO, V126, P821, DOI 10.1093/oxfordjournals.jbchem.a022522; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Xu YB, 1998, J MOL BIOL, V276, P955, DOI 10.1006/jmbi.1997.1582	26	56	64	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14053	14059		10.1074/jbc.M112263200	http://dx.doi.org/10.1074/jbc.M112263200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11805118	hybrid			2022-12-27	WOS:000175096000092
J	Kirsch, M; de Groot, H				Kirsch, M; de Groot, H			Formation of peroxynitrite from reaction of nitroxyl anion with molecular oxygen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; TYROSINE NITRATION; CARBON-DIOXIDE; SUPEROXIDE-DISMUTASE; OXIDATION REACTIONS; SECONDARY-AMINES; S-NITROSOTHIOLS; DECOMPOSITION; NO; GENERATION	Peroxynitrite (ONOO-/ONOOH) is generally expected to be formed in vivo from the diffusion-controlled reaction between superoxide (O-2(.-)) and nitric oxide ((NO)-N-.). In the present paper we show that under aerobic conditions the nitroxyl anion (NO-), released from Angeli's salt (disodium diazen-1-ium-1,2,2-triolate, -ON=NO2-), generated peroxy-nitrite with a yield of about 65%. Simultaneously, hydroxyl radicals are formed from the nitroxyl anion with a yield of about 3% via a minor, peroxy-nitrite-independent pathway. Further experiments clearly underline that the chemistry of NO- in the presence of oxygen is mainly characterized by peroxynitrite and not by HO. radicals. Quantum-chemical calculations predict that peroxynitrite formation should proceed via intermediary formation of (NO)-N-. and O-2(.-), probably by an electron-transfer mechanism. This prediction is supported by the fact that H2O2 is formed during the decay of NO- in the presence of superoxide dismutase (Cu(II),Zn-SOD). Since the nitroxyl anion may be released endogenously by a variety of biomolecules, substantial amounts of peroxynitrite might be formed in vivo via NO- in addition to the "classical" (NO)-N-. + O-2(.-) pathway.	Univ Klinikum Essen, Inst Physiol Chem, D-45122 Essen, Germany	University of Duisburg Essen	Kirsch, M (corresponding author), Univ Klinikum Essen, Inst Physiol Chem, Hufelandstr 55, D-45122 Essen, Germany.	michael.kirsch@uni-essen.de						ANDRUSSOW L, 1927, ANGEW CHEM, V40, P171; ANGELI A, 1903, GAZZ CHIM ITAL, V33, P245; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; Bartberger MD, 2001, P NATL ACAD SCI USA, V98, P2194, DOI 10.1073/pnas.041481598; Bauernschmitt R, 1996, CHEM PHYS LETT, V256, P454, DOI 10.1016/0009-2614(96)00440-X; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bonini MG, 1999, J BIOL CHEM, V274, P10802, DOI 10.1074/jbc.274.16.10802; CHALLIS BC, 1979, J CHEM SOC PERK T 1, P299, DOI 10.1039/p19790000299; CHALLIS BC, 1989, CANCER SURV, V8, P363; DONALD CE, 1986, INORG CHEM, V25, P2676, DOI 10.1021/ic00236a004; FEHSENFELD FC, 1966, J CHEM PHYS, V45, P1844, DOI 10.1063/1.1727844; Foresman JB, 1996, J PHYS CHEM-US, V100, P16098, DOI 10.1021/jp960488j; FRISCH MJ, 2000, GAUSSIAN 98W REVISIO; FUKUTO JM, 1993, BIOCHEM BIOPH RES CO, V196, P707, DOI 10.1006/bbrc.1993.2307; Gerasimov OV, 1999, INORG CHEM, V38, P4317, DOI 10.1021/ic990384y; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; Goldstein S, 1998, J AM CHEM SOC, V120, P3458, DOI 10.1021/ja9733043; Goldstein S, 1999, CHEM RES TOXICOL, V12, P132, DOI 10.1021/tx9802522; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; GRATZEL M, 1970, BERICH BUNSEN GESELL, V74, P1003; HADDAD IY, 1994, AM J PHYSIOL, V267, pL242, DOI 10.1152/ajplung.1994.267.3.L242; Hodges GR, 1999, J AM CHEM SOC, V121, P10695, DOI 10.1021/ja991077u; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Hughes MN, 1999, BBA-BIOENERGETICS, V1411, P263, DOI 10.1016/S0005-2728(99)00019-5; HUGHES MN, 1968, J CHEM SOC A, P450, DOI 10.1039/j19680000450; IOANNIDIS I, 1993, BIOCHEM J, V296, P341, DOI 10.1042/bj2960341; Jourd'heuil D, 2001, J BIOL CHEM, V276, P28799, DOI 10.1074/jbc.M102341200; Kirsch M, 2000, CHEM RES TOXICOL, V13, P451, DOI 10.1021/tx990138z; Kirsch M, 1999, J BIOL CHEM, V274, P24664, DOI 10.1074/jbc.274.35.24664; Kirsch M, 1998, J BIOL CHEM, V273, P12716, DOI 10.1074/jbc.273.21.12716; Kirsch M, 2000, J BIOL CHEM, V275, P16702, DOI 10.1074/jbc.M909228199; Kirsch M, 2001, FASEB J, V15, P1569, DOI 10.1096/fj.00-0823hyp; Kirsch M, 2001, CHEM-EUR J, V7, P3313, DOI 10.1002/1521-3765(20010803)7:15<3313::AID-CHEM3313>3.0.CO;2-7; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; KLINGENBERG M, 1985, METHOD ENZYMAT AN, V7, P251; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; Kortum G, 1940, Z PHYS CHEM B-CHEM E, V48, P32; KRASNOVSKY AA, 1981, CHEM PHYS LETT, V81, P443, DOI 10.1016/0009-2614(81)85647-3; Lehnig M, 1999, ARCH BIOCHEM BIOPHYS, V368, P303, DOI 10.1006/abbi.1999.1268; Lemercier JN, 1997, ARCH BIOCHEM BIOPHYS, V345, P160, DOI 10.1006/abbi.1997.0240; Liochev SI, 2001, J BIOL CHEM, V276, P35253, DOI 10.1074/jbc.M104237200; Lomonosova EE, 1998, FREE RADICAL BIO MED, V24, P522, DOI 10.1016/S0891-5849(97)00295-5; Lymar SV, 1998, INORG CHEM, V37, P294, DOI 10.1021/ic970946i; Masuda M, 2000, CHEM RES TOXICOL, V13, P301, DOI 10.1021/tx990120o; Mayer B, 1998, J BIOL CHEM, V273, P3264, DOI 10.1074/jbc.273.6.3264; Meli R, 1999, HELV CHIM ACTA, V82, P722, DOI 10.1002/(SICI)1522-2675(19990505)82:5<722::AID-HLCA722>3.3.CO;2-R; MIERTUS S, 1981, CHEM PHYS, V55, P117, DOI 10.1016/0301-0104(81)85090-2; Miles AM, 1996, METHOD ENZYMOL, V268, P105; Miranda KM, 2001, J BIOL CHEM, V276, P1720, DOI 10.1074/jbc.M006174200; Moller C, 1934, PHYS REV, V46, P0618, DOI 10.1103/PhysRev.46.618; MURPHY ME, 1991, P NATL ACAD SCI USA, V88, P10860, DOI 10.1073/pnas.88.23.10860; Ohshima H, 1999, NITRIC OXIDE-BIOL CH, V3, P132, DOI 10.1006/niox.1999.0216; Ohshima H, 1999, FREE RADICAL BIO MED, V26, P1305, DOI 10.1016/S0891-5849(98)00327-X; Pfeiffer S, 2000, J BIOL CHEM, V275, P6346, DOI 10.1074/jbc.275.9.6346; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; Reif A, 2001, FREE RADICAL BIO MED, V30, P803, DOI 10.1016/S0891-5849(01)00477-4; Richeson CE, 1998, J AM CHEM SOC, V120, P7211, DOI 10.1021/ja980871x; ROSS AB, 1998, NDRL NIST SOLUTION K; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; SEDDON WA, 1970, CAN J CHEMISTRY, V48, P393, DOI 10.1139/v70-063; SEDDON WA, 1973, CAN J CHEM, V51, P1123, DOI 10.1139/v73-166; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; Stoyanovsky DA, 1999, J AM CHEM SOC, V121, P5093, DOI 10.1021/ja990318v; TSAI JHM, 1994, J AM CHEM SOC, V116, P4115, DOI 10.1021/ja00088a072; Uppu RM, 1996, ANAL BIOCHEM, V236, P242, DOI 10.1006/abio.1996.0162; Uppu RM, 2000, J AM CHEM SOC, V122, P6911, DOI 10.1021/ja000270h; Uppu RM, 1999, J AM CHEM SOC, V121, P9738, DOI 10.1021/ja9921165; VanUffelen BE, 1998, BIOCHEM J, V330, P719; WHEELER GL, 1969, ANAL CHIM ACTA, V46, P239, DOI 10.1016/S0003-2670(01)95624-7; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; WIBERG N, 1995, HOLLEMANWIBERG LEHRB; Wong PSY, 1998, BIOCHEMISTRY-US, V37, P5362, DOI 10.1021/bi973153g; Xia Y, 1997, P NATL ACAD SCI USA, V94, P12705, DOI 10.1073/pnas.94.23.12705	76	89	90	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13379	13388		10.1074/jbc.M108079200	http://dx.doi.org/10.1074/jbc.M108079200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11799109	hybrid			2022-12-27	WOS:000175096000006
J	Lee, KK; Yonehara, S				Lee, KK; Yonehara, S			Phosphorylation and dimerization regulate nucleocytoplasmic shuttling of mammalian STE20-like kinase (MST)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; P21-ACTIVATED PROTEIN-KINASE; CASPASE-MEDIATED ACTIVATION; GERMINAL CENTER KINASE; AMINO-ACID-SEQUENCE; TRANSCRIPTION FACTOR; MAPKAP KINASE-2; APOPTOSIS; STRESS; IDENTIFICATION	Mammalian STE20-like kinase (MST) is a member of the yeast STE20-related kinase family and proteolytically activated by caspase during apoptosis. However, its other cellular functions are not known, including its activation mechanism, substrate(s), and subcellular localization. In this report, using anti-MST monoclonal antibodies, we clearly show that endogenous MST is localized in cytoplasm in a leptomycin B-dependent manner. Analyses with serial deletions and point mutations show that MST has two functional nuclear export signals and, unexpectedly, another localization motif for nuclear import. When cells are treated with leptomycin, monomeric MST is accumulated more rapidly in the nucleus than dimeric MST, indicating that dimerization contributes to the cytoplasmic retention of MST. Okadaic acid, an inhibitor of phosphatase 2A, induces activation of MST and translocation into the nucleus. Using phosphopeptide-specific antibody, we directly show that okadaic acid induces phosphorylation in the activation loop of MST, and, once phosphorylated, MST is rapidly translocated to the nucleus. However, kinase-deficient MST does not enter the nucleus, indicating that phosphorylation and activation is required for okadaic acid-induced nuclear translocation. In apoptotic cells, the activation of MST does not require phosphorylation in the activation loop and occurs through the release of C-terminal regulatory domain by caspase-dependent cleavage. Kinase-deficient MST functions dominant-negatively and represses okadaic acid-induced morphological change indicating that MST plays a role in okadaic acid-induced cellular shrinkage. Our identification of cytoplasmic and nuclear localization motifs and phosphorylation-dependent translocation of MST suggests that regulation of localization is important to the biological function of MST, including its effects on cellular morphology.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Lee, KK (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.							Aurisicchio L, 1998, J BIOL CHEM, V273, P1477, DOI 10.1074/jbc.273.3.1477; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Chen YR, 1999, ONCOGENE, V18, P7370, DOI 10.1038/sj.onc.1203116; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; FELDHERR CM, 1994, INT REV CYTOL, V151, P183, DOI 10.1016/S0074-7696(08)62633-9; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Watabe M, 2000, J BIOL CHEM, V275, P8766, DOI 10.1074/jbc.275.12.8766; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	42	68	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12351	12358		10.1074/jbc.M108138200	http://dx.doi.org/10.1074/jbc.M108138200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805089	hybrid			2022-12-27	WOS:000174846400098
J	Wu, YJ; Chen, LW; Zheng, PS; Yang, BB				Wu, YJ; Chen, LW; Zheng, PS; Yang, BB			beta(1)-Integrin-mediated glioma cell adhesion and free radical-induced apoptosis are regulated by binding to a C-terminal domain of PG-M/versican	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE MOTIFS; ARG-GLY-ASP; SULFATE PROTEOGLYCAN; G1 DOMAIN; G3 DOMAIN; HYALURONIC-ACID; LECTIN DOMAINS; HUMAN VERSICAN; CORE PROTEIN; TENASCIN-R	Integrins are cell-surface glycoproteins that mediate cell activities, including tissue morphogenesis, development, immune response, and cancer, through interaction with extracellular proteins. Here we report a novel means by which integrin signaling and functions are regulated. In pull-down assays and immunoprecipitation, beta(1)-integrin bound to the C-terminal domain of PG-M/versican, an extracellular chondroitin sulfate proteoglycan. This was confirmed by cell-surface binding assays. Binding was calcium- and manganese-dependent. Upon native gel electrophoresis, beta(1)-integrin comigrated with the C-terminal domain of PG-M/versican. The interaction of beta(1)-integrin with the C-terminal domain of PG-M/versican activated focal adhesion kinase, enhanced integrin expression, and promoted cell adhesion. As a result, cells expressing the C-terminal domain of PG-M/versican were resistant to free radical-induced apoptosis. As the PG-M/versican peptide used in this study does not contain the RGD consensus-binding motif for integrins, the mechanism of the observed binding represents an entirely new function.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Yang, BB (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Res Bldg S110,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							Ang LC, 1999, J NEUROPATH EXP NEUR, V58, P597, DOI 10.1097/00005072-199906000-00004; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; BINETTE F, 1994, J BIOL CHEM, V269, P19116; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; Cao L, 1998, MATRIX BIOL, V17, P379, DOI 10.1016/S0945-053X(98)90090-7; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chen LW, 2002, J BIOL CHEM, V277, P2657, DOI 10.1074/jbc.M101153200; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Condic ML, 1997, NATURE, V389, P852, DOI 10.1038/39878; Day JM, 1999, J BIOL CHEM, V274, P38107, DOI 10.1074/jbc.274.53.38107; Domowicz MS, 2000, J BIOL CHEM, V275, P35098, DOI 10.1074/jbc.275.45.35098; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ITO K, 1995, J BIOL CHEM, V270, P958, DOI 10.1074/jbc.270.2.958; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; Kiani C, 2002, CELL RES, V12, P19, DOI 10.1038/sj.cr.7290106; Kiani C, 2001, BIOCHEM J, V354, P199, DOI 10.1042/0264-6021:3540199; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; LANDOLT RM, 1995, DEVELOPMENT, V121, P2303; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Luo W, 1996, J BIOL CHEM, V271, P16447, DOI 10.1074/jbc.271.28.16447; MARGOLIS RU, 1994, METHOD ENZYMOL, V245, P105; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; NASO MF, 1994, J BIOL CHEM, V269, P32999; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Paulus W, 1996, J NEUROPATH EXP NEUR, V55, P528, DOI 10.1097/00005072-199605000-00005; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; STANLEY P, 1994, EMBO J, V13, P1790, DOI 10.1002/j.1460-2075.1994.tb06447.x; Stigson M, 1997, J BIOL CHEM, V272, P3246, DOI 10.1074/jbc.272.6.3246; Vitale C, 2001, P NATL ACAD SCI USA, V98, P5764, DOI 10.1073/pnas.091097198; Wu YJ, 2001, J BIOL CHEM, V276, P14178, DOI 10.1074/jbc.M100618200; YAMAGATA M, 1986, J BIOL CHEM, V261, P3526; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yang BL, 2000, J BIOL CHEM, V275, P21255, DOI 10.1074/jbc.M001443200; Yang BL, 1999, J CELL BIOCHEM, V72, P210, DOI 10.1002/(SICI)1097-4644(19990201)72:2<210::AID-JCB5>3.0.CO;2-E; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; Zako M, 1997, J BIOL CHEM, V272, P9325, DOI 10.1074/jbc.272.14.9325; Zhang Y, 1999, J CELL BIOCHEM, V73, P445, DOI 10.1002/(SICI)1097-4644(19990615)73:4<445::AID-JCB3>3.0.CO;2-D; Zhang Y, 1998, J BIOL CHEM, V273, P33054, DOI 10.1074/jbc.273.49.33054; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	49	109	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12294	12301		10.1074/jbc.M110748200	http://dx.doi.org/10.1074/jbc.M110748200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805102	hybrid			2022-12-27	WOS:000174846400091
J	Hotze, EM; Heuck, AP; Czajkowsky, DM; Shao, ZF; Johnson, AE; Tweten, RK				Hotze, EM; Heuck, AP; Czajkowsky, DM; Shao, ZF; Johnson, AE; Tweten, RK			Monomer-monomer interactions drive the prepore to pore conversion of a beta-barrel-forming cholesterol-dependent cytolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCAL ALPHA-HEMOLYSIN; ANTHRAX PROTECTIVE ANTIGEN; PERFRINGENS THETA-TOXIN; PERFRINGOLYSIN-O; MEMBRANE INSERTION; LIPID-BILAYERS; MECHANISM; PROTEIN; IDENTIFICATION; MITOCHONDRIAL	Perfringolysin O (PFO), a cholesterol-dependent cytolysin, forms large oligomeric pore complexes comprised of up to 50 PFO molecules. In the present studies a mutant of PFO (PFOY181A) has been identified that traps PFO in a multimeric prepore complex that cannot insert its transmembrane beta-hairpins and therefore cannot form a pore. Remarkably, PFOY181A can be induced to insert its transmembrane beta-hairpins if functional PFO is incorporated into the PFOY181A oligomeric prepore complex. Furthermore, the transition from prepore to pore appears to be an "all or none" process; partial insertion of the transmembrane beta-barrel does not occur. Therefore, cooperative interactions between the monomers of the prepore drive the prepore to pore conversion that results in the formation of the transmembrane beta-barrel.	Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Univ Virginia, Hlth Sci Ctr, Charlottesville, VA 22908 USA; Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; University of Virginia; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Tweten, RK (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA.	Rod-Tweten@ouhsc.edu	Shao, Zhifeng/B-6075-2013; Johnson, Arthur E/G-3457-2012		NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR007720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037657, R37AI037657] Funding Source: NIH RePORTER; NCRR NIH HHS [RRO7720] Funding Source: Medline; NIAID NIH HHS [AI37657, R01 AI037657] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; Czajkowsky DM, 1999, P NATL ACAD SCI USA, V96, P2001, DOI 10.1073/pnas.96.5.2001; Fang Y, 1997, BIOCHEMISTRY-US, V36, P9518, DOI 10.1021/bi970600j; Gabriel K, 2001, TRENDS BIOCHEM SCI, V26, P36, DOI 10.1016/S0968-0004(00)01684-4; HARRIS RW, 1991, INFECT IMMUN, V59, P2499, DOI 10.1128/IAI.59.7.2499-2501.1991; HARRIS RW, 1991, J BIOL CHEM, V266, P6936; Heuck AP, 2000, MOL CELL, V6, P1233, DOI 10.1016/S1097-2765(00)00119-2; Heuck AP, 2001, BIOCHEMISTRY-US, V40, P9065, DOI 10.1021/bi0155394; Hotze EM, 2001, J BIOL CHEM, V276, P8261, DOI 10.1074/jbc.M009865200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; OLOFSSON A, 1993, FEBS LETT, V319, P125, DOI 10.1016/0014-5793(93)80050-5; Palmer M, 1998, EMBO J, V17, P1598, DOI 10.1093/emboj/17.6.1598; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; Shatursky O, 1999, CELL, V99, P293, DOI 10.1016/S0092-8674(00)81660-8; Shepard LA, 2000, BIOCHEMISTRY-US, V39, P10284, DOI 10.1021/bi000436r; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Tweten RK, 2001, CURR TOP MICROBIOL, V257, P15; Valeva A, 1996, EMBO J, V15, P1857, DOI 10.1002/j.1460-2075.1996.tb00536.x; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1	23	104	110	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11597	11605		10.1074/jbc.M111039200	http://dx.doi.org/10.1074/jbc.M111039200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11799121	hybrid			2022-12-27	WOS:000174613100108
J	Leboulle, G; Crippa, M; Decrem, Y; Mejri, N; Brossard, M; Bollen, A; Godfroid, E				Leboulle, G; Crippa, M; Decrem, Y; Mejri, N; Brossard, M; Bollen, A; Godfroid, E			Characterization of a novel salivary immunosuppressive protein from Ixodes ricinus ticks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORRELIA-BURGDORFERI; IN-VITRO; CYTOKINE PRODUCTION; ELASTASE INHIBITOR; INTERFERON-GAMMA; GLAND EXTRACTS; MESSENGER-RNA; C3H/HEJ MICE; BALB/C MICE; IFN-GAMMA	In tick salivary glands, several genes are induced during the feeding process, leading to the expression of new proteins. These proteins are typically secreted in tick saliva and are potentially involved in the modulation of the host immune and hemostatic responses. In a previous study, the construction and the analysis of a subtractive library led to the identification of Ixodes ricinus immunosuppressor (Iris), a novel protein, differentially expressed in I. ricinus salivary glands during the blood meal. In the present study, the data strongly suggest that this protein is secreted by tick salivary glands into the saliva. In addition, Iris is also found to modulate T lymphocyte and macrophage responsiveness by inducing a Th2 type response and by inhibiting the production of pro-inflammatory cytokines. In conclusion, these results suggest that Iris is an immunosuppressor, which might play an important role in the modulation of host immune response.	Free Univ Brussels, B-6041 Gosselies, Belgium; Univ Neuchatel, Inst Zool, CH-2007 Neuchatel, Switzerland	University of Neuchatel	Godfroid, E (corresponding author), Free Univ Brussels, Rue des Prof Jeener & Brachet 12, B-6041 Gosselies, Belgium.	godfroid@sga.ulb.ac.be						ALLEN J R, 1973, International Journal for Parasitology, V3, P195, DOI 10.1016/0020-7519(73)90024-6; Bergman DK, 1998, J MED ENTOMOL, V35, P505, DOI 10.1093/jmedent/35.4.505; Brossard M, 1997, MED VET ENTOMOL, V11, P270, DOI 10.1111/j.1365-2915.1997.tb00406.x; Christe M, 2000, PARASITOL RES, V86, P491, DOI 10.1007/s004360050699; FROHMAN BH, 1995, PCR PRIMER LAB MANUA, P381; Fuchsberger N, 1995, EXP APPL ACAROL, V19, P671, DOI 10.1007/BF00145255; Ganapamo F, 1996, IMMUNOLOGY, V87, P259, DOI 10.1046/j.1365-2567.1996.450512.x; GANAPAMO F, 1995, IMMUNOLOGY, V85, P120; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; JUNG HI, 1995, J BIOL CHEM, V270, P13879, DOI 10.1074/jbc.270.23.13879; Kopecky J, 1998, PARASITE IMMUNOL, V20, P169; LEBOULLE G, 2002, IN PRESS AM J TROP M; Mejri N, 2001, PARASITE IMMUNOL, V23, P61, DOI 10.1046/j.1365-3024.2001.00356.x; RAMACHANDRA RN, 1992, J MED ENTOMOL, V29, P818, DOI 10.1093/jmedent/29.5.818; REMOLDODONNELL E, 1989, J EXP MED, V169, P1071, DOI 10.1084/jem.169.3.1071; SAUER JR, 1995, ANNU REV ENTOMOL, V40, P245, DOI 10.1146/annurev.en.40.010195.001333; URIOSTE S, 1994, J EXP MED, V180, P1077, DOI 10.1084/jem.180.3.1077; Valenzuela JG, 2000, J BIOL CHEM, V275, P18717, DOI 10.1074/jbc.M001486200; WANG H, 1994, PARASITOLOGY, V109, P517, DOI 10.1017/S003118200008077X; WIKEL SK, 1982, ANN TROP MED PARASIT, V76, P627, DOI 10.1080/00034983.1982.11687593; Yang D, 2001, J BIOCHEM-TOKYO, V129, P561, DOI 10.1093/oxfordjournals.jbchem.a002891; Zeidner N, 1996, J INFECT DIS, V173, P187, DOI 10.1093/infdis/173.1.187; Zeidner N, 1997, INFECT IMMUN, V65, P3100, DOI 10.1128/IAI.65.8.3100-3106.1997; Zeidner NS, 2000, PARASITE IMMUNOL, V22, P581, DOI 10.1046/j.1365-3024.2000.00339.x	24	128	135	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10083	10089		10.1074/jbc.M111391200	http://dx.doi.org/10.1074/jbc.M111391200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11792703	hybrid, Green Submitted			2022-12-27	WOS:000174549200064
J	Stout, CE; Costantin, JL; Naus, CCG; Charles, AC				Stout, CE; Costantin, JL; Naus, CCG; Charles, AC			Intercellular calcium signaling in astrocytes via ATP release through connexin hemichannels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C6 GLIOMA-CELLS; GAP JUNCTION; GLIAL-CELLS; SYNAPTIC TRANSMISSION; EXTRACELLULAR CALCIUM; MEMBRANE CONDUCTANCE; VERTEBRATE RETINA; GLUTAMATE; WAVES; MODULATION	Astrocytes are capable of widespread intercellular communication via propagated increases in intracellular Ca2+ concentration. We have used patch clamp, dye flux, ATP assay, and Ca2+ imaging techniques to show that one mechanism for this intercellular Ca2+ signaling in astrocytes is the release of ATP through connexin channels ("hemichannels") in individual cells. Astrocytes showed low Ca2+-activated whole-cell currents consistent with connexin hemichannel currents that were inhibited by the connexin channel inhibitor flufenamic acid (FFA). Astrocytes also showed molecular weight-specific influx and release of dyes, consistent with flux through connexin hemichannels. Transmembrane dye flux evoked by mechanical stimulation was potentiated by low Ca2+ and was inhibited by FFA and Gd3+. Mechanical stimulation also evoked release of ATP that was potentiated by low Ca2+ and inhibited by FFA and Gd3+. Similar whole-cell currents, transmembrane dye flux, and ATP release were observed in C6 glioma cells expressing connexin43 but were not observed in parent C6 cells. The connexin hemichannel activator quinine evoked ATP release and Ca2+ signaling in astrocytes and in C6 cells expressing connexin43. The propagation of intercellular Ca2+ waves in astrocytes was also potentiated by quinine and inhibited by FFA and Gd3+. Release of ATP through connexin hemichannels represents a novel signaling pathway for intercellular communication in astrocytes and other non-excitable cells.	Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; Loma Linda Univ, Sch Med, Loma Linda, CA 92350 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA; Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Loma Linda University; University of California System; University of California Berkeley; Western University (University of Western Ontario)	Charles, AC (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Neurol, 710 Westwood Plaza, Los Angeles, CA 90095 USA.				NINDS NIH HHS [R29 NS32283, R01 NS39961] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032283, R01NS039961] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Araque A, 1998, EUR J NEUROSCI, V10, P2129, DOI 10.1046/j.1460-9568.1998.00221.x; Bruzzone S, 2001, FASEB J, V15, P10; Charles A, 1998, GLIA, V24, P39, DOI 10.1002/(SICI)1098-1136(199809)24:1<39::AID-GLIA5>3.0.CO;2-W; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; CLARK BA, 1994, EUR J NEUROSCI, V6, P1406, DOI 10.1111/j.1460-9568.1994.tb01002.x; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Cotrina ML, 2000, J NEUROSCI, V20, P2835; Dixon DB, 1996, VISION RES, V36, P3925, DOI 10.1016/S0042-6989(96)00129-0; FINKBEINER SM, 1993, GLIA, V9, P83, DOI 10.1002/glia.440090202; Fry T, 2001, MICROSC RES TECHNIQ, V52, P289, DOI 10.1002/1097-0029(20010201)52:3<289::AID-JEMT1014>3.0.CO;2-0; Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19-02-00520.1999; Harks EGA, 2001, J PHARMACOL EXP THER, V298, P1033; Hofer A, 1998, GLIA, V24, P141, DOI 10.1002/(SICI)1098-1136(199809)24:1<141::AID-GLIA13>3.0.CO;2-R; Innocenti B, 2000, J NEUROSCI, V20, P1800; John SA, 1999, J BIOL CHEM, V274, P236, DOI 10.1074/jbc.274.1.236; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; LIU TF, 1995, METHOD FIND EXP CLIN, V17, P23; MALCHOW RP, 1994, J GEN PHYSIOL, V104, P1039, DOI 10.1085/jgp.104.6.1039; NAUS CCG, 1992, CELL MOL NEUROBIOL, V12, P163, DOI 10.1007/BF00713370; Newman EA, 1998, J NEUROSCI, V18, P4022; NOWAK L, 1987, J NEUROSCI, V7, P101; Parpura V, 2000, P NATL ACAD SCI USA, V97, P8629, DOI 10.1073/pnas.97.15.8629; Queiroz G, 1999, NEUROSCIENCE, V91, P1171, DOI 10.1016/S0306-4522(98)00644-7; Toyofuku T, 1998, J BIOL CHEM, V273, P1519, DOI 10.1074/jbc.273.3.1519; Venance L, 1998, J PHYSIOL-LONDON, V510, P429, DOI 10.1111/j.1469-7793.1998.429bk.x; Wang ZQ, 2000, ANAL CHEM, V72, P2001, DOI 10.1021/ac9912146; White TW, 1999, EUR J NEUROSCI, V11, P1883, DOI 10.1046/j.1460-9568.1999.00607.x; Zampighi GA, 1999, J GEN PHYSIOL, V113, P507, DOI 10.1085/jgp.113.4.507; Zanotti S, 1997, J NEUROCHEM, V69, P594; Zhang DQ, 2000, P NATL ACAD SCI USA, V97, P14754, DOI 10.1073/pnas.010325897; Zhang Y, 1998, J PHYSIOL-LONDON, V508, P763, DOI 10.1111/j.1469-7793.1998.763bp.x; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	34	690	704	1	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10482	10488		10.1074/jbc.M109902200	http://dx.doi.org/10.1074/jbc.M109902200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11790776	hybrid			2022-12-27	WOS:000174549200116
J	Kupriyanova, TA; Kandror, V; Kandror, KV				Kupriyanova, TA; Kandror, V; Kandror, KV			Isolation and characterization of the two major intracellular Glut4 storage compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; GLUCOSE-TRANSPORTER GLUT4; 3T3-L1 ADIPOCYTES; TRANSFERRIN RECEPTORS; PLASMA-MEMBRANE; INSULIN; SURFACE; REDISTRIBUTION; TRAFFICKING; VESICLES	In rat adipose cells, intracellular Glut4 resides in two distinct vesicular populations one of which contains cellugyrin whereas another lacks this protein (Kupriyanova, T. A., and Kandror, K. V. (2000) J. Biol. Chem. 275, 36263-36268). Cell surface biotinylated MPR and I-125-labeled transferrin are accumulated in cellugyrin-positive vesicles and to a lesser extent in cellugyrin-negative vesicles. An average cellugyrin-positive vesicle carries not more than one molecule of either Glut4, insulin-responsive aminopeptidase (IRAP), or transferrin receptor (TfR), whereas cellugyrin-negative vesicles contain five to six molecules of Glut4, more than 10 molecules of IRAP, and still one molecule of TfR per vesicle. Cellugyrin-negative vesicles are translocated to the cell surface after insulin stimulation, whereas cellugyrin-positive vesicles maintain intracellular localization both in the absence and in the presence of insulin and, therefore, may be involved in interendosomal protein transport. Both cellugyrin-positive and cellugyrin-negative vesicles are present in extracts of non-homogenized cells and therefore may represent the major form of Glut4 storage in vivo.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Kandror, KV (corresponding author), Boston Univ, Sch Med, Dept Biochem, K121 715 Albany St, Boston, MA 02118 USA.			Kandror, Konstantin/0000-0002-8601-9313	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200, R01DK052057, R01DK056736, R56DK052057] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56736, P30 DK46200, DK52057] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; Bogan JS, 1999, J CELL BIOL, V146, P609, DOI 10.1083/jcb.146.3.609; CORMONT M, 1993, J BIOL CHEM, V268, P19491; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; Foster LJ, 2001, J BIOL CHEM, V276, P44212, DOI 10.1074/jbc.M102964200; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; HERMAN GA, 1994, P NATL ACAD SCI USA, V91, P12750, DOI 10.1073/pnas.91.26.12750; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; Janz R, 1998, J BIOL CHEM, V273, P2851, DOI 10.1074/jbc.273.5.2851; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KANDROR K, 1994, J BIOL CHEM, V269, P138; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Kandror KV, 1998, BIOCHEM J, V331, P829, DOI 10.1042/bj3310829; Kandror KV, 1996, J BIOL CHEM, V271, P21703, DOI 10.1074/jbc.271.36.21703; Kandror KV, 1999, J BIOL CHEM, V274, P25210, DOI 10.1074/jbc.274.36.25210; Kupriyanova TA, 2000, J BIOL CHEM, V275, P36263, DOI 10.1074/jbc.M002797200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lim SN, 2001, MOL BIOL CELL, V12, P981, DOI 10.1091/mbc.12.4.981; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Malide D, 2000, J CELL SCI, V113, P4203; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Millar CA, 2000, TRAFFIC, V1, P141, DOI 10.1034/j.1600-0854.2000.010206.x; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; OKA Y, 1984, P NATL ACAD SCI-BIOL, V81, P4028, DOI 10.1073/pnas.81.13.4028; Ramm G, 2000, MOL BIOL CELL, V11, P4079, DOI 10.1091/mbc.11.12.4079; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; Robinson MS, 1996, CELL, V84, P13, DOI 10.1016/S0092-8674(00)80988-5; Roh C, 2000, AM J PHYSIOL-ENDOC M, V279, pE893, DOI 10.1152/ajpendo.2000.279.4.E893; Roh C, 2001, J BIOL CHEM, V276, P35990, DOI 10.1074/jbc.M102791200; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SATOH S, 1993, J BIOL CHEM, V268, P17820; Simpson F, 2001, TRAFFIC, V2, P2, DOI 10.1034/j.1600-0854.2001.020102.x; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; TANNER LI, 1987, J BIOL CHEM, V262, P8975; Verges M, 1999, P NATL ACAD SCI USA, V96, P10146, DOI 10.1073/pnas.96.18.10146; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; WARDZALA LJ, 1984, J BIOL CHEM, V259, P8378	41	58	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9133	9138		10.1074/jbc.M106999200	http://dx.doi.org/10.1074/jbc.M106999200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11782457	hybrid			2022-12-27	WOS:000174400600054
J	Roelofs, J; Van Haastert, PJM				Roelofs, J; Van Haastert, PJM			Characterization of two unusual guanylyl cyclases from Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE ADENYLYL-CYCLASE; ACTIVATED PROTEIN-KINASE; CATALYTIC DOMAINS; DISCOIDEUM; DISTINCT; CGMP; PARAMECIUM; RESPONSES; TOPOLOGY; ENCODES	Guanylyl cyclase A (GCA) and soluble guanylyl cyclase (sGC) encode GCs in Dictyostelium and have a topology similar to 12-transmembrane and soluble adenylyl cyclase, respectively. We demonstrate that all detectable GC activity is lost in a cell line in which both genes have been inactivated. Cell lines with one gene inactivated were used to characterize the other guanylyl cyclase (i.e. GCA in sgc(-) null cells and sGC in gea(-)null cells). Despite the different topologies, the enzymes have many properties in common. In vivo, extracellular cAMP activates both enzymes via a G-protein-coupled receptor. In vitro, both enzymes are activated by GTPgammaS (K-a = 11 and 8 muM for GCA and sGC, respectively). The addition of GTPgammaS leads to a 1.5-fold increase of V-max and a 3.5-fold increase of the affinity for GTP. Ca2+ inhibits both GCA and sGC with K-i of about 50 and 200 nM, respectively. Other biochemical properties are very different; GCA is expressed mainly during growth and multicellular development, whereas sGC is expressed mainly during cell aggregation. Folic acid and cAMP activate GCA maximally about 2.5-fold, whereas sGC is activated about 8-fold. Osmotic stress strongly stimulates sGC but has no effect on GCA activity. Finally, GCA is exclusively membrane-bound and is active mainly with Mg2+, whereas sGC is predominantly soluble and more active with Mn2+.	Univ Groningen, Dept Biochem, NL-9747 AG Groningen, Netherlands	University of Groningen	Van Haastert, PJM (corresponding author), Univ Groningen, Dept Biochem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	P.J.M.van.Haastert@chem.rug.nl	Roelofs, Jeroen/AAC-5119-2021	Roelofs, Jeroen/0000-0003-0944-2465				Beuve A, 1999, METHODS, V19, P545, DOI 10.1006/meth.1999.0896; BOYMARCOTTE E, 1982, GENE, V20, P433, DOI 10.1016/0378-1119(82)90212-8; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; Carucci DJ, 2000, J BIOL CHEM, V275, P22147, DOI 10.1074/jbc.M001021200; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; de Alda JAGO, 2000, J BACTERIOL, V182, P3839, DOI 10.1128/JB.182.13.3839-3842.2000; Emala CW, 1999, AM J PHYSIOL-LUNG C, V276, pL564, DOI 10.1152/ajplung.1999.276.4.L564; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; FRANKE J, 1977, P NATL ACAD SCI USA, V74, P2157, DOI 10.1073/pnas.74.5.2157; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Hurley JH, 1998, CURR OPIN STRUC BIOL, V8, P770, DOI 10.1016/S0959-440X(98)80097-3; JANSSENS PMW, 1989, J BIOL CHEM, V264, P4329; JANSSENS PMW, 1988, BIOCHEM BIOPH RES CO, V150, P405, DOI 10.1016/0006-291X(88)90535-9; Kasahara M, 2001, J BIOL CHEM, V276, P10564, DOI 10.1074/jbc.M008006200; Kim HJ, 1998, J BIOL CHEM, V273, P30859, DOI 10.1074/jbc.273.47.30859; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Linder JU, 1999, EMBO J, V18, P4222, DOI 10.1093/emboj/18.15.4222; Linder JU, 2000, J BIOL CHEM, V275, P11235, DOI 10.1074/jbc.275.15.11235; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; Meima M, 1999, SEMIN CELL DEV BIOL, V10, P567, DOI 10.1006/scdb.1999.0340; Meima ME, 1999, DEV BIOL, V212, P182, DOI 10.1006/dbio.1999.9352; PADH H, 1984, ARCH BIOCHEM BIOPHYS, V229, P73, DOI 10.1016/0003-9861(84)90131-0; Parent CA, 1996, ANNU REV BIOCHEM, V65, P411; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; Roelofs J, 2001, J BIOL CHEM, V276, P40740, DOI 10.1074/jbc.M105154200; Roelofs J, 2001, EMBO J, V20, P4341, DOI 10.1093/emboj/20.16.4341; Roelofs J, 2001, NATURE, V411, P1013, DOI 10.1038/35082627; Roelofs J, 2001, BIOCHEM J, V354, P697, DOI 10.1042/0264-6021:3540697; SNAARJAGALSKA BE, 1994, METHOD ENZYMOL, V237, P387; Soderbom F, 1999, DEVELOPMENT, V126, P5463; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; SUTOH K, 1993, PLASMID, V30, P150, DOI 10.1006/plas.1993.1042; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; VALKEMA R, 1992, BIOCHEM BIOPH RES CO, V186, P263, DOI 10.1016/S0006-291X(05)80802-2; vanHaastert PJM, 1997, FEBS LETT, V410, P25, DOI 10.1016/S0014-5793(97)00416-X; Wedel BJ, 2001, ANNU REV PHYSIOL, V63, P215, DOI 10.1146/annurev.physiol.63.1.215; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	46	39	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9167	9174		10.1074/jbc.M111437200	http://dx.doi.org/10.1074/jbc.M111437200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11777934	hybrid, Green Published			2022-12-27	WOS:000174400600059
J	Peng, LH; Payne, AH				Peng, LH; Payne, AH			AP-2 gamma and the homeodomain protein distal-less 3 are required for placental-specific expression of the murine 3 beta-hydroxysteroid dehydrogenase VI gene, Hsd3b6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN-CLEAVAGE ENZYME; HUMAN CHORIONIC-GONADOTROPIN; DNA-BINDING PROTEINS; VERTEBRATE DEVELOPMENT; TRANSCRIPTION FACTORS; EARLY-PREGNANCY; FAMILY; ELEMENTS; PROMOTER; P450SCC	The enzyme 3beta-hydroxysteroid dehydrogenase/isomerase (3beta-HSD) is essential for the biosynthesis of all active steroid hormones. It exists as multiple isoforms in humans and rodents, each the product of a distinct gene. Human 3beta-HSD I in placenta is essential for placental progesterone biosynthesis and thus is essential for the maintenance of pregnancy. The murine ortholog, 3beta-HSD VI, is the only isoform expressed in giant trophoblast cells during the first half of mouse pregnancy. This study was designed to identify the cis-acting element(s) and the associated transcription factors required for trophoblast-specific expression of 3beta-HSD VI. Transfection studies in placental and non-placental cells identified a novel 66-bp trophoblast-specific enhancer element located between -2896 and -2831 of the 3beta-HSD VI promoter. DNase protection analysis of the enhancer element identified three trophoblast-specific binding sites, FPI, FPII, and FPIII. Electrophoretic mobility shift assays with oligonucleotides representing the protected sequences, FPI and FPIII, and nuclear extracts isolated from human JEG-3 cells and from mouse trophoblast cells, demonstrated the same binding pattern that was distinct from the binding pattern with mouse Leydig cell nuclear proteins. Further electrophoretic mobility shift assays identified AP-2gamma and the homeodomain protein, lix 3, as the transcription factors that specifically bind to FPI and FPIII, respectively. Site-specific mutations in each of the binding sites eliminated enhancer activity indicating that AP-2gamma and Dlx 3, together with an additional transcription factor(s) that are conserved between humans and mice, are required for trophoblast-specific expression of 3beta-HSD VI.	Stanford Univ, Sch Med, Div Reprod Biol, Dept Gynecol & Obstet, Stanford, CA 94305 USA	Stanford University	Payne, AH (corresponding author), Stanford Univ, Sch Med, Div Reprod Biol, Dept Gynecol & Obstet, 300 Pasteur Dr, Stanford, CA 94305 USA.	anita.payne@stanford.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD031398] Funding Source: NIH RePORTER; NICHD NIH HHS [U54 HD 31398] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abbaszade IG, 1997, ENDOCRINOLOGY, V138, P1392, DOI 10.1210/en.138.4.1392; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arensburg J, 1999, ENDOCRINOLOGY, V140, P5220, DOI 10.1210/en.140.11.5220; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Baker PJ, 1999, EUR J BIOCHEM, V260, P911, DOI 10.1046/j.1432-1327.1999.00245.x; Beanan MJ, 2000, DEV DYNAM, V218, P545, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1026>3.0.CO;2-B; Bendall AJ, 2000, GENE, V247, P17, DOI 10.1016/S0378-1119(00)00081-0; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; Clarke TR, 1996, DNA CELL BIOL, V15, P387, DOI 10.1089/dna.1996.15.387; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; GUERIN SL, 1995, MOL ENDOCRINOL, V9, P1583, DOI 10.1210/me.9.11.1583; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Howard G, 1997, ENDOCRINOLOGY, V138, P4649, DOI 10.1210/en.138.11.4649; Huang NW, 2000, J BIOL CHEM, V275, P2852, DOI 10.1074/jbc.275.4.2852; Jacquemin P, 1998, DEV DYNAM, V212, P423, DOI 10.1002/(SICI)1097-0177(199807)212:3<423::AID-AJA10>3.0.CO;2-1; Knofler M, 2000, ENDOCRINOLOGY, V141, P3737, DOI 10.1210/en.141.10.3737; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LeersSucheta S, 1997, J BIOL CHEM, V272, P7960, DOI 10.1074/jbc.272.12.7960; LiCalsi C, 2000, NUCLEIC ACIDS RES, V28, P1036, DOI 10.1093/nar/28.4.1036; Miller WL, 1998, CLIN PERINATOL, V25, P799, DOI 10.1016/S0095-5108(18)30084-8; Mohibullah N, 1999, NUCLEIC ACIDS RES, V27, P2760, DOI 10.1093/nar/27.13.2760; Morasso MI, 1999, P NATL ACAD SCI USA, V96, P162, DOI 10.1073/pnas.96.1.162; Park CHJ, 1996, MOL CELL ENDOCRINOL, V116, P157, DOI 10.1016/0303-7207(95)03707-1; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; PENG L, 2001, IN PRESS MOL CELL EN; RHEAUME E, 1991, MOL ENDOCRINOL, V5, P1147, DOI 10.1210/mend-5-8-1147; Roberson MS, 2001, J BIOL CHEM, V276, P10016, DOI 10.1074/jbc.M007481200; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Roux K H, 1997, Methods Mol Biol, V67, P39; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shi DQ, 1998, J BIOL CHEM, V273, P27331, DOI 10.1074/jbc.273.42.27331; THE VL, 1989, MOL ENDOCRINOL, V3, P1310, DOI 10.1210/mend-3-8-1310; TREMBLAY Y, 1993, MOL ENDOCRINOL, V7, P355, DOI 10.1210/me.7.3.355; VOUTILAINEN R, 1986, J CLIN ENDOCR METAB, V63, P1145, DOI 10.1210/jcem-63-5-1145; WOOD WM, 1989, J BIOL CHEM, V264, P14840	39	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7945	7954		10.1074/jbc.M106765200	http://dx.doi.org/10.1074/jbc.M106765200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11773066	hybrid			2022-12-27	WOS:000174268000042
J	Mahadeva, R; Dafforn, TR; Carrelll, RW; Lomas, DA				Mahadeva, R; Dafforn, TR; Carrelll, RW; Lomas, DA			6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization - Implications for the prevention of Z alpha(1)-antitrypsin-related cirrhosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SHEET-A; REACTIVE-LOOP; ANGSTROM STRUCTURE; INHIBITORY CONFORMATION; DISEASE; ALPHA-1-ANTITRYPSIN; ANTITHROMBIN; LIVER; DEFICIENCY; INSERTION	Conformational diseases such as amyloidosis, Alzhei- mer's disease, prion diseases, and the serpinopathies are all caused by structural rearrangements within a protein that transform it into a pathological species. These diseases are typified by the Z variant of alpha(1)-antitrypsin (E342K), which causes the retention of protein within hepatocytes as inclusion bodies that are associated with neonatal hepatitis and cirrhosis. The inclusion bodies result from the Z mutation perturbing the conformation of the protein, which facilitates a sequential interaction between the reactive center loop of one molecule and beta-sheet A of a second. Therapies to prevent liver disease must block this reactive loop-beta-sheet polymerization without interfering with other proteins of similar tertiary structure. We have used reactive loop peptides to explore the differences between the pathogenic Z and normal M alpha(1)-antitrypsin. The results show that the reactive loop is likely to be partially inserted into beta-sheet A in Z alpha(1)-antitrypsin. This conformational difference from M alpha(1)-antitrypsin was exploited with a 6-mer reactive loop peptide (FLEAIG) that selectively and stably bound Z alpha(1)-antitrypsin. The importance of this finding is that the peptide prevented the polymerization of Z a,antitrypsin and did not significantly anneal to other proteins (such as antithrombin, alpha(1)-antichymotrypsin, and plasminogen activator inhibitor-1) with a similar tertiary structure. These findings provide a lead compound for the development of small molecule inhibitors that can be used to treat patients with Z alpha(1)-antitrypsin deficiency. Furthermore they demonstrate how a conformational disease process can be selectively inhibited with a small peptide.	Univ Cambridge, Cambridge Inst Med Res, Resp Med Unit, Dept Med, Cambridge CB2 2XY, England; Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England	University of Cambridge; University of Cambridge		rm232@cam.ac.uk	Dafforn, Tim/A-9072-2015	Dafforn, Tim/0000-0003-2257-6679				AULAK KS, 1993, J BIOL CHEM, V268, P18088; BJORK I, 1992, J BIOL CHEM, V267, P1976; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; Burrows JAJ, 2000, P NATL ACAD SCI USA, V97, P1796, DOI 10.1073/pnas.97.4.1796; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Chang WSW, 1996, BIOCHEM J, V314, P647, DOI 10.1042/bj3140647; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; Devlin GL, 2001, AM J RESP CELL MOL, V24, P727, DOI 10.1165/ajrcmb.24.6.4407; Dunstone MA, 2000, PROTEIN SCI, V9, P417; ELDERING E, 1995, J BIOL CHEM, V270, P2579, DOI 10.1074/jbc.270.6.2579; Elliott PR, 2000, PROTEIN SCI, V9, P1274, DOI 10.1110/ps.9.7.1274; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Elliott PR, 1996, NAT STRUCT BIOL, V3, P910, DOI 10.1038/nsb1196-910; ERIKSSON S, 1965, ACTA MED SCAND, VS177, P5; ERIKSSON S, 1986, NEW ENGL J MED, V314, P736, DOI 10.1056/NEJM198603203141202; Fa M, 2000, STRUCT FOLD DES, V8, P397, DOI 10.1016/S0969-2126(00)00121-0; Fitton HL, 1997, BIOL CHEM, V378, P1059; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; Huntington JA, 1999, J MOL BIOL, V293, P449, DOI 10.1006/jmbi.1999.3184; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Kim SJ, 2001, J MOL BIOL, V306, P109, DOI 10.1006/jmbi.2000.4357; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1995, J BIOL CHEM, V270, P5282, DOI 10.1074/jbc.270.10.5282; Mahadeva R, 1999, J CLIN INVEST, V103, P999, DOI 10.1172/JCI4874; PERLMUTTER DH, 1999, SCHIFFS DIS LIVER, P1131; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SHARP HL, 1969, J LAB CLIN MED, V73, P934; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Sivasothy P, 2000, J BIOL CHEM, V275, P33663, DOI 10.1074/jbc.M004054200; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; Xue YF, 1998, STRUCT FOLD DES, V6, P627, DOI 10.1016/S0969-2126(98)00064-1	39	132	137	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					6771	6774		10.1074/jbc.C100722200	http://dx.doi.org/10.1074/jbc.C100722200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11773044	hybrid			2022-12-27	WOS:000174104300004
J	Tang, TTL; Dowbenko, D; Jackson, A; Toney, L; Lewin, DA; Dent, AL; Lasky, LA				Tang, TTL; Dowbenko, D; Jackson, A; Toney, L; Lewin, DA; Dent, AL; Lasky, LA			The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE B; TUMOR-SUPPRESSOR; GENE-EXPRESSION; FAMILY-MEMBER; CELL-DEATH; SURVIVAL; SIGNALS; INSULIN; DIFFERENTIATION; TRANSLOCATION	(T)he activation of the AKT/protein kinase B kinases by mutation of the PTEN lipid phosphatase results in enhanced survival of a diversity of tumors. This resistance to apoptosis is partly accomplished by the inhibition of genetic programs induced by a subfamily of forkhead transcription factors including AFX. Here we describe an AFX-regulated pathway that appears to account for at least part of this apoptotic regulatory system. Cells induced to synthesize an active form of AFX die by activating the apoptotic death pathway. An analysis of genes regulated by AFX demonstrated that BCL-6, a transcriptional repressor, is up-regulated similar to4-7-fold. An examination of the BCL-6 promoter demonstrated that AFX bound to specific target sites that could activate transcription. BCL-X-L, an anti-apoptotic protein, contains potential BCL-6 target sites in its promoter. An analysis of endogenous BCL-X-L levels in AFX-expressing cells revealed enhanced down-regulation of the transcript (similar to1.3-1.7-fold) and protein, and BCL-6 directly binds to and suppresses the BCL-XL promoter. Finally, macrophages isolated from BCL-6-/- mice show enhanced survival in vitro. These results suggest that AFX regulates apoptosis in part by suppressing the levels of anti-apoptotic BCL-XL through the transcriptional repressor BCL-6.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; CuraGen Corp, Dept Collaborat Res, New Haven, CT 06511 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Div Microbiol & Immunol, Indianapolis, IN 46202 USA	Roche Holding; Genentech; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Lasky, LA (corresponding author), Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA.	larsky@earthlink.net	tang, tina/GRX-7859-2022					Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Kojima S, 2001, DEVELOPMENT, V128, P57; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kumagai T, 1999, ONCOGENE, V18, P467, DOI 10.1038/sj.onc.1202306; Leenders H, 2000, EUR J IMMUNOL, V30, P2980, DOI 10.1002/1521-4141(200010)30:10<2980::AID-IMMU2980>3.0.CO;2-9; Leverrier Y, 1999, CELL DEATH DIFFER, V6, P290, DOI 10.1038/sj.cdd.4400492; Li DM, 1997, CANCER RES, V57, P2124; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lossos IS, 2001, BLOOD, V98, P945, DOI 10.1182/blood.V98.4.945; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; OHASHI K, 1995, BIOCHEM BIOPH RES CO, V214, P461, DOI 10.1006/bbrc.1995.2309; Ohneda O, 2000, IMMUNITY, V12, P141, DOI 10.1016/S1074-7613(00)80167-3; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shimkets RA, 1999, NAT BIOTECHNOL, V17, P798, DOI 10.1038/11743; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Staudt L M, 1999, Int Rev Immunol, V18, P381, DOI 10.3109/08830189909088490; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yamamura T, 2001, AM J PHYSIOL-HEART C, V280, pH1191, DOI 10.1152/ajpheart.2001.280.3.H1191; Yamochi T, 1999, ONCOGENE, V18, P487, DOI 10.1038/sj.onc.1202334	47	171	178	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14255	14265		10.1074/jbc.M110901200	http://dx.doi.org/10.1074/jbc.M110901200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11777915	hybrid			2022-12-27	WOS:000175096000117
J	Dauksaite, V; Akusjarvi, G				Dauksaite, V; Akusjarvi, G			Human splicing factor ASF/SF2 encodes for a repressor domain required for its inhibitory activity on pre-mRNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SR PROTEINS; 5-SPLICE-SITE RECOGNITION; PREMESSENGER RNA; COAT PROTEIN; SITE CHOICE; IN-VIVO; BINDING; ENHANCER; FAMILY	The essential splicing factor ASF/SF2 activates or represses splicing depending on where on the pre-mRNA it binds. We have shown previously that ASF/SF2 inhibits adenovirus IIIa pre-mRNA splicing by binding to an intronic repressor element. Here we used MS2-ASF/SF2 fusion proteins to show that the second RNA binding domain (RBD2) is both necessary and sufficient for the splicing repressor function of ASF/SF2. Furthermore, we show that the completely conserved SWQDLKD motif in ASF/SF2-RBD2 is essential for splicing repression. Importantly, this heptapeptide motif is unlikely to be directly involved in RNA binding given its position within the predicted structure of RBD2. The activity of the ASF/SF2-RBD2 domain in splicing was position-dependent. Thus, tethering RBD2 to the IIIa intron resulted in splicing repression, whereas RBD2 binding at the second exon had no effect on IIIa splicing. The splicing repressor activity of RBD2 was not unique to the IIIa pre-mRNA, as binding of RBD2 at an intronic position in the rabbit beta-globin pre-mRNA also resulted in splicing inhibition. Taken together, our results suggest that ASF/SF2 encode distinct domains responsible for its function as a splicing enhancer or splicing repressor protein.	Uppsala Univ, Dept Med Biochem & Microbiol, BMC, S-75123 Uppsala, Sweden	Uppsala University	Akusjarvi, G (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, BMC, Box 582, S-75123 Uppsala, Sweden.	goran.akusjarvi@imbim.uu.se						AKUSJARVI G, 1999, RRD VIROLOGY III, V1, P621; Bai YD, 1999, NUCLEIC ACIDS RES, V27, P1126, DOI 10.1093/nar/27.4.1126; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; Chew SL, 1999, P NATL ACAD SCI USA, V96, P10655, DOI 10.1073/pnas.96.19.10655; Cook CR, 1998, VIROLOGY, V242, P211, DOI 10.1006/viro.1997.8983; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; Gozani O, 1996, GENE DEV, V10, P233, DOI 10.1101/gad.10.2.233; Graveley BR, 1998, EMBO J, V17, P6747, DOI 10.1093/emboj/17.22.6747; Graveley BR, 1998, MOL CELL, V1, P765, DOI 10.1016/S1097-2765(00)80076-3; Graveley BR, 1999, CURR BIOL, V9, pR6, DOI 10.1016/S0960-9822(99)80032-3; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Lutzelberger M, 1999, NUCLEIC ACIDS RES, V27, P2618, DOI 10.1093/nar/27.13.2618; Molin M, 2000, J VIROL, V74, P9002, DOI 10.1128/JVI.74.19.9002-9009.2000; Moore DD, 1995, GLOB MOB SURV; MUHLEMANN O, 1999, METH MOLEC MED, V21, P203; Petersen-Mahrt SK, 1999, EMBO J, V18, P1014, DOI 10.1093/emboj/18.4.1014; ROSCIGNO RF, 1995, RNA, V1, P692; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Shi H, 1997, MOL CELL BIOL, V17, P2649, DOI 10.1128/MCB.17.5.2649; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; TARN WY, 1995, P NATL ACAD SCI USA, V92, P2504, DOI 10.1073/pnas.92.7.2504; UHLENBECK OC, 1983, J BIOMOL STRUCT DYN, V1, P539, DOI 10.1080/07391102.1983.10507460; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; van Oordt WVH, 2000, NUCLEIC ACIDS RES, V28, P4822, DOI 10.1093/nar/28.24.4822; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; WANG Z, 1995, RNA, V1, P21; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; Yue B G, 2000, Nucleic Acids Res, V28, pE14, DOI 10.1093/nar/28.5.e14; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	43	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12579	12586		10.1074/jbc.M107867200	http://dx.doi.org/10.1074/jbc.M107867200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11801589	hybrid			2022-12-27	WOS:000175036300014
J	Irwin, W; Fontaine, E; Agnolucci, L; Penzo, D; Betto, R; Bortolotto, S; Reggiani, C; Salviati, G; Bernardi, P				Irwin, W; Fontaine, E; Agnolucci, L; Penzo, D; Betto, R; Bortolotto, S; Reggiani, C; Salviati, G; Bernardi, P			Bupivacaine myotoxicity is mediated by mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; LOCAL-ANESTHETIC BUPIVACAINE; SKELETAL-MUSCLE MITOCHONDRIA; ASCITES TUMOR-CELLS; CYCLOSPORINE-A; OXIDATIVE-PHOSPHORYLATION; EXTRAOCULAR-MUSCLES; DUCHENNE DYSTROPHY; MEMBRANE; DEATH	We have investigated the effects of the myotoxic local anesthetic bupivacaine on rat skeletal muscle mitochondria and isolated myofibers from flexor digitorum. brevis, extensor digitorum longus, soleus, and from the proximal, striated portion of the esophagus. In isolated mitochondria, bupivacaine caused a concentration-dependent mitochondrial depolarization and pyridine nucleotide oxidation, which were matched by an increased oxygen consumption at bupivacaine concentrations of 1.5 mm or less at pH 7.4, whereas respiration was inhibited at higher concentrations. As a consequence of depolarization, bupivacaine caused the opening of the permeability transition pore (PTP), a cyclosporin A-sensitive inner membrane channel that plays a key role in many forms of cell death. In intact flexor digitorum brevis fibers bupivacaine caused mitochondrial depolarization and pyridine nucleotides oxidation that were matched by increased concentrations of cytosolic free Ca2+, release of cytochrome c, and eventually, hypercontracture. Both mitochondrial depolarization and cytochrome c release were inhibited by cyclosporin A, indicating that PTP opening rather than bupivacaine as such was responsible for these events. Similar responses to bupivacaine were observed in the soleus, which is highly oxidative. In contrast, fibers from the esophagus (which we show to be more fatigable than flexor digitorum brevis fibers) and from the highly glycolytic extensor digitorum longus didn't undergo pyridine nucleotide oxidation upon the addition of bupivacaine and were resistant to bupivacaine toxicity. These results suggest that active oxidative metabolism is a key determinant in bupivacaine toxicity, that bupivacaine myotoxicity is a relevant model of mitochondrial dysfunction involving the PTP and Ca2+ dysregulation, and that it represents a promising system to test new PTP inhibitors that may prove relevant in spontaneous myopathies where mitochondria have long been suspected to play a role.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Dept Anat & Physiol, I-35121 Padua, Italy; CNR, Unit Study Muscle Pathophysiol, I-35121 Padua, Italy; CNR, Unit Study Biomembranes, I-35121 Padua, Italy; Univ Grenoble 1, Lab Bioenerget Fondamentale & Appl, F-38041 Grenoble, France	University of Padua; University of Padua; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Bernardi, P (corresponding author), Dipartimento Sci Biomed Sperimentali, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.	bernardi@bio.unipd.it	Bernardi, Paolo/C-3656-2008; Salviati, Giancarlo/F-4947-2016; Fontaine, Eric/ABA-8853-2020	Bernardi, Paolo/0000-0001-9187-3736; Salviati, Giancarlo/0000-0002-9828-6371; Fontaine, Eric/0000-0002-5204-9477	Telethon [1141] Funding Source: Medline	Telethon(Fondazione Telethon)		Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Bernardi P, 1999, ITAL J NEUROL SCI, V20, P395; BROWN RH, 1995, CURR OPIN NEUROL, V8, P373, DOI 10.1097/00019052-199510000-00009; Burgess DH, 1999, CELL DEATH DIFFER, V6, P256, DOI 10.1038/sj.cdd.4400489; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DABADIE P, 1987, FEBS LETT, V226, P77, DOI 10.1016/0014-5793(87)80554-9; DELACOUSSAYE JE, 1992, ANESTH ANALG, V74, P698; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; ELEDJAM JJ, 1989, ANESTH ANALG, V69, P732; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FITTS RH, 1994, PHYSIOL REV, V74, P49, DOI 10.1152/physrev.1994.74.1.49; FLORIDI A, 1994, ONCOL RES, V6, P593; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; FRANCOOBREGON A, 1994, J PHYSIOL-LONDON, V481, P299, DOI 10.1113/jphysiol.1994.sp020440; GARLID KD, 1983, J BIOL CHEM, V258, P7974; GROUSELLE M, 1990, BIOCHEM J, V271, P269, DOI 10.1042/bj2710269; HALLCRAGGS ECB, 1980, BRIT J EXP PATHOL, V61, P139; HAWORTH RA, 1980, J MEMBRANE BIOL, V54, P231, DOI 10.1007/BF01870239; IMBERTI R, 1993, J PHARMACOL EXP THER, V265, P392; KAMINSKI HJ, 1992, ANN NEUROL, V32, P586, DOI 10.1002/ana.410320418; KARPATI G, 1986, AM J MED GENET, V25, P653, DOI 10.1002/ajmg.1320250407; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu YW, 1997, AM J PHYSIOL-CELL PH, V272, pC1919, DOI 10.1152/ajpcell.1997.272.6.C1919; Madsen K, 1996, ANAL BIOCHEM, V237, P37, DOI 10.1006/abio.1996.0197; MILBURN A, 1976, J NEUROCYTOL, V5, P425, DOI 10.1007/BF01181649; MOKRI B, 1975, NEUROLOGY, V25, P1111, DOI 10.1212/WNL.25.12.1111; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; NONAKA I, 1983, ACTA NEUROPATHOL, V60, P167, DOI 10.1007/BF00691863; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; Porter JD, 2001, NEUROMUSCULAR DISORD, V11, P197, DOI 10.1016/S0960-8966(00)00171-1; Porter JD, 1998, J CELL SCI, V111, P1801; PORTER JD, 1988, INVEST OPHTH VIS SCI, V29, P163; Porter JD, 1996, NEUROLOGY, V46, P30, DOI 10.1212/WNL.46.1.30; Pulselli R, 1996, ONCOL RES, V8, P267; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SCHONFELD P, 1992, FEBS LETT, V304, P273, DOI 10.1016/0014-5793(92)80636-U; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; STEER JH, 1986, J NEUROL SCI, V75, P343, DOI 10.1016/0022-510X(86)90081-X; STEER JH, 1986, J NEUROL SCI, V73, P205, DOI 10.1016/0022-510X(86)90131-0; SUN XC, 1992, J BIOL CHEM, V267, P19147; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; SZTARK F, 1994, ANESTH ANALG, V78, P335, DOI 10.1213/00000539-199402000-00023; TALMADGE RJ, 1993, J APPL PHYSIOL, V75, P2337, DOI 10.1152/jappl.1993.75.5.2337; TERADA H, 1990, J BIOL CHEM, V265, P7837; VANDAM K, 1990, FEBS LETT, V277, P131, DOI 10.1016/0014-5793(90)80826-5; VINOGRADOV A, 1972, ARCH BIOCHEM BIOPHYS, V152, P646, DOI 10.1016/0003-9861(72)90261-5; Westerblad H, 1998, ACTA PHYSIOL SCAND, V162, P253, DOI 10.1046/j.1365-201X.1998.0301f.x; WROGEMANN K, 1976, LANCET, V1, P672	62	139	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12221	12227		10.1074/jbc.M108938200	http://dx.doi.org/10.1074/jbc.M108938200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11790774	hybrid			2022-12-27	WOS:000174846400081
J	Galinier, A; Lavergne, JP; Geourjon, C; Fieulaine, S; Nessler, S; Jault, JM				Galinier, A; Lavergne, JP; Geourjon, C; Fieulaine, S; Nessler, S; Jault, JM			A new family of phosphotransferases with a P-loop motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; GRAM-POSITIVE BACTERIA; PHOSPHOENOLPYRUVATE CARBOXYKINASE; PROTEIN-KINASE; BACILLUS-SUBTILIS; ENERGY-TRANSFER; HPR KINASE; BINDING; ENZYME; NUCLEOTIDE	In most Gram-positive bacteria, catabolite repression is mediated by a bifunctional enzyme, the histidine-containing protein kinase/phosphatase (HprK/P). Based either on its primary sequence or on its recently solved three-dimensional structure, no straightforward homology with other known proteins was found. However, we showed here that HprK/P exhibits a restricted homology with an unrelated phosphotransferase, the phosphoenolpyruvate carboxykinase. This includes notably two consecutive Asp residues from the phosphoenolpyruvate carboxykinase active site, whose equivalent residues were mutated in Bacillus subtilis HprK/P. Characterization of the corresponding mutants emphasizes the crucial role of these Asp residues in the HprK/P functioning. Furthermore, superimposition of HprK/P and phosphoenolpyruvate carboxykinase active sites supports the view that both enzymes bear significant resemblance in their overall mechanism of functioning showing that these two enzymes constitute a new family of phosphotransferases.	CNRS, Inst Biol Struct & Microbiol, UPR 9043, Lab Chim Bacterienne, F-13402 Marseille, France; Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot, F-69367 Lyon, France; CNRS, UPR 9063, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Jault, JM (corresponding author), CNRS, Inst Biol Struct & Microbiol, UPR 9043, Lab Chim Bacterienne, 31 Chemin Joseph Aiguier, F-13402 Marseille, France.		Nessler, Sylvie/R-4296-2016; jault, jean-michel/G-2086-2012	Nessler, Sylvie/0000-0003-4973-9941; jault, jean-michel/0000-0003-1743-2777				Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; DEUTSCHER J, 1995, MOL MICROBIOL, V15, P1049, DOI 10.1111/j.1365-2958.1995.tb02280.x; DORGAN LJ, 1984, J BIOL CHEM, V259, P2816; Fieulaine S, 2001, EMBO J, V20, P3917, DOI 10.1093/emboj/20.15.3917; Galinier A, 1998, P NATL ACAD SCI USA, V95, P1823, DOI 10.1073/pnas.95.4.1823; Galinier A, 1997, P NATL ACAD SCI USA, V94, P8439, DOI 10.1073/pnas.94.16.8439; GALLEY WC, 1976, NATURE, V261, P521, DOI 10.1038/261521a0; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hlavaty JJ, 1997, BIOCHEMISTRY-US, V36, P3389, DOI 10.1021/bi962255o; Hlavaty JJ, 1997, BIOCHEMISTRY-US, V36, P15514, DOI 10.1021/bi970574p; HOU SY, 1995, J BACTERIOL, V177, P1620, DOI 10.1128/jb.177.6.1620-1623.1995; Huynh PL, 2000, J BACTERIOL, V182, P1895, DOI 10.1128/JB.182.7.1895-1902.2000; Izard T, 2000, EMBO J, V19, P2690, DOI 10.1093/emboj/19.11.2690; Jault JM, 2000, J BIOL CHEM, V275, P1773, DOI 10.1074/jbc.275.3.1773; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAMMANN M, 1989, NUCLEIC ACIDS RES, V17, P5404, DOI 10.1093/nar/17.13.5404; Kravanja M, 1999, MOL MICROBIOL, V31, P59, DOI 10.1046/j.1365-2958.1999.01146.x; LAMOLA AA, 1969, ENERGY TRANSFER ORGA, P18; Matte A, 1996, J MOL BIOL, V256, P126, DOI 10.1006/jmbi.1996.0072; Matte A, 1997, J BIOL CHEM, V272, P8105, DOI 10.1074/jbc.272.13.8105; Moreno MS, 2001, MOL MICROBIOL, V39, P1366, DOI 10.1046/j.1365-2958.2001.02328.x; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Reizer J, 1998, MOL MICROBIOL, V27, P1157, DOI 10.1046/j.1365-2958.1998.00747.x; SAIER MH, 1995, TRENDS BIOCHEM SCI, V20, P267, DOI 10.1016/S0968-0004(00)89041-6; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Tari LW, 1997, NAT STRUCT BIOL, V4, P990, DOI 10.1038/nsb1297-990; Tari LW, 1996, NAT STRUCT BIOL, V3, P355, DOI 10.1038/nsb0496-355; Urbatsch IL, 2000, J BIOL CHEM, V275, P25031, DOI 10.1074/jbc.M003962200; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	32	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11362	11367		10.1074/jbc.M109527200	http://dx.doi.org/10.1074/jbc.M109527200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11796714	hybrid			2022-12-27	WOS:000174613100078
J	Haynes, CA; Koder, RL; Miller, AF; Rodgers, DW				Haynes, CA; Koder, RL; Miller, AF; Rodgers, DW			Structures of nitroreductase in three states - Effects of inhibitor binding and reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI NITROREDUCTASE; MAJOR FLAVIN REDUCTASE; CRYSTAL-STRUCTURE; VIBRIO-FISCHERI; BIOLUMINESCENT BACTERIUM; NAD(P)H-FLAVIN OXIDOREDUCTASE; BIOCHEMICAL-CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; STEADY-STATE; NADH OXIDASE	The crystal structure of the nitroreductase enzyme from Enterobacter cloacae has been determined for the oxidized form in separate complexes with benzoate and acetate inhibitors and for the two-electron reduced form. Nitroreductase is a member of a group of enzymes that reduce a broad range of nitroaromatic compounds and has potential uses in chemotherapy and bioremediation. The monomers of the nitroreductase dimer adopt an alpha+beta fold and together bind two flavin mononucleotide prosthetic groups at the dimer interface. In the oxidized enzyme, the flavin ring system adopts a strongly bent (16degrees) conformation, and the bend increases (25degrees) in the reduced form of the enzyme, roughly the conformation predicted for reduced flavin free in solution. Because free oxidized flavin is planar, the induced bend in the oxidized enzyme may favor reduction, and it may also account for the characteristic inability of the enzyme to stabilize the one electron-reduced semiquinone flavin, which is also planar. Both inhibitors bind over the pyrimidine and central rings of the flavin in partially overlapping sites. Comparison of the two inhibitor complexes shows that a portion of helix H6 can flex to accommodate the differently sized inhibitors suggesting a mechanism for accommodating varied substrates.	Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Ctr Struct Biol, Lexington, KY 40536 USA; Univ Kentucky, Dept Chem, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky	Rodgers, DW (corresponding author), Univ Kentucky, Dept Mol & Cellular Biochem, 800 Rose St, Lexington, KY 40536 USA.	rodgers@focus.gws.uky.edu	Koder, Ronald L/A-6089-2008; Miller, Anne-Frances/M-7703-2017	Koder, Ronald/0000-0003-0868-4972				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Breinlinger EC, 1998, J AM CHEM SOC, V120, P8606, DOI 10.1021/ja9809556; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRYANT C, 1991, J BIOL CHEM, V266, P4119; BRYANT C, 1991, J BIOL CHEM, V266, P4126; BRYANT CP, 1990, THESIS U CALIFORNIA; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Cavelier G, 2001, PROTEINS, V43, P420, DOI 10.1002/prot.1055.abs; Chung KT, 1996, ENVIRON MOL MUTAGEN, V27, P67, DOI 10.1002/(SICI)1098-2280(1996)27:1<67::AID-EM9>3.0.CO;2-B; DIXON DA, 1979, BIOCHEMISTRY-US, V18, P5770, DOI 10.1021/bi00593a004; Esteve-Nunez A, 2001, MICROBIOL MOL BIOL R, V65, P335, DOI 10.1128/MMBR.65.3.335-352.2001; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; FRITCHIE CJ, 1975, ACTA CRYSTALLOGR B, V31, P454, DOI 10.1107/S0567740875003019; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HALL LH, 1987, INT J QUANTUM CHEM, V31, P195, DOI 10.1002/qua.560310203; Hasford JJ, 1997, J ORG CHEM, V62, P5244, DOI 10.1021/jo9703865; HECHT HJ, 1995, NAT STRUCT BIOL, V2, P1109, DOI 10.1038/nsb1295-1109; INOUYE S, 1994, FEBS LETT, V347, P163, DOI 10.1016/0014-5793(94)00528-1; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KNOX RJ, 1993, CANCER METAST REV, V12, P195, DOI 10.1007/BF00689810; Kobori T, 2001, J BIOL CHEM, V276, P2816, DOI 10.1074/jbc.M002617200; Koder RL, 1998, BBA-PROTEIN STRUCT M, V1387, P395, DOI 10.1016/S0167-4838(98)00151-4; Koder RL, 1998, PROTEIN EXPRES PURIF, V13, P53, DOI 10.1006/prep.1997.0866; KODER RL, 1999, THESIS J HOPKINS U B; Koike H, 1998, J MOL BIOL, V280, P259, DOI 10.1006/jmbi.1998.1871; KUO MC, 1974, ACTA CRYSTALLOGR B, VB 30, P1766, DOI 10.1107/S0567740874005772; LEI BF, 1994, J BACTERIOL, V176, P3552, DOI 10.1128/JB.176.12.3552-3558.1994; Lennon BW, 1999, PROTEIN SCI, V8, P2366; LI RB, 1995, P NATL ACAD SCI USA, V92, P8846, DOI 10.1073/pnas.92.19.8846; Liochev SI, 1999, P NATL ACAD SCI USA, V96, P3537, DOI 10.1073/pnas.96.7.3537; Lovering AL, 2001, J MOL BIOL, V309, P203, DOI 10.1006/jmbi.2001.4653; Ludwig ML, 1997, BIOCHEMISTRY-US, V36, P1259, DOI 10.1021/bi962180o; MASSEY V, 1969, J BIOL CHEM, V244, P3999; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; MCCALLA DR, 1971, BIOCHEM PHARMACOL, V20, P3532, DOI 10.1016/0006-2952(71)90459-X; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; Meyer M, 1996, J MOL STRUC-THEOCHEM, V364, P139, DOI 10.1016/0166-1280(96)04491-0; MICHAEL NP, 1994, FEMS MICROBIOL LETT, V124, P195, DOI 10.1111/j.1574-6968.1994.tb07284.x; MOONEN CTW, 1984, BIOCHEMISTRY-US, V23, P4868, DOI 10.1021/bi00316a008; MOONEN CTW, 1984, BIOCHEMISTRY-US, V23, P4859, DOI 10.1021/bi00316a007; MULLER F, 1991, CHEM BIOCH FLAVOENZY, V1, P2; MULLER YA, 1994, J MOL BIOL, V237, P315, DOI 10.1006/jmbi.1994.1233; Murthy YVSN, 1996, J BIOL CHEM, V271, P19915, DOI 10.1074/jbc.271.33.19915; Nakai S, 1999, THEOR CHEM ACC, V103, P109, DOI 10.1007/s002140050521; Niculescu-Duvaz I, 1999, ANTI-CANCER DRUG DES, V14, P517; NISHINO SF, 1993, APPL ENVIRON MICROB, V59, P2520, DOI 10.1128/AEM.59.8.2520-2525.1993; NORRESTAM R, 1972, ACTA CRYSTALL B-STRU, VB 28, P440, DOI 10.1107/S0567740872002547; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1988, BIOCHEMISTRY-US, V27, P4465, DOI 10.1021/bi00412a038; PARK HJ, 1993, EUR J BIOCHEM, V211, P909; PARK HJ, 1992, EUR J BIOCHEM, V205, P881, DOI 10.1111/j.1432-1033.1992.tb16853.x; Parkinson GN, 2000, J MED CHEM, V43, P3624, DOI 10.1021/jm000159m; PLATENKAMP RJ, 1987, EUR BIOPHYS J BIOPHY, V14, P393, DOI 10.1007/BF00254862; PORTER DJT, 1978, ACTA CRYSTALLOGR B, V34, P598, DOI 10.1107/S056774087800360X; PROCHASKA KJ, 1991, OXIDATIVE STRESS OXI, P195; Purohit V, 2000, CHEM RES TOXICOL, V13, P673, DOI 10.1021/tx000002x; Rafii F, 1998, ANTIMICROB AGENTS CH, V42, P1121, DOI 10.1128/AAC.42.5.1121; RICKERT DE, 1987, DRUG METAB REV, V18, P23, DOI 10.3109/03602538708998299; Rodgers DW, 1997, METHOD ENZYMOL, V276, P183, DOI 10.1016/S0076-6879(97)76059-2; Rodgers JD, 2001, WATER RES, V35, P2101, DOI 10.1016/S0043-1354(00)00505-4; Sera N, 1996, MUTAT RES-FUND MOL M, V349, P137, DOI 10.1016/0027-5107(95)00173-5; SPAIN JC, 1995, ANNU REV MICROBIOL, V49, P523, DOI 10.1146/annurev.mi.49.100195.002515; STEWART RC, 1985, J BIOL CHEM, V260, P3639; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P13531, DOI 10.1021/bi961400v; TEDESCHI G, 1995, J BIOL CHEM, V270, P1198, DOI 10.1074/jbc.270.3.1198; TOKIWA H, 1986, CRIT REV TOXICOL, V17, P23, DOI 10.3109/10408448609037070; Trickey P, 2000, BIOCHEMISTRY-US, V39, P7678, DOI 10.1021/bi9927181; TRUS BL, 1969, ACTA CRYSTALL B-STRU, VB 25, P1911, DOI 10.1107/S0567740869004900; VAZQUEZ SA, 1992, J CHEM SOC P2, V6, P889; WATANABE M, 1990, NUCLEIC ACIDS RES, V18, P1059, DOI 10.1093/nar/18.4.1059; WOUTERS J, 1994, J CHEM CRYSTALLOGR, V24, P607, DOI 10.1007/BF01671675; ZENNO S, 1994, J BACTERIOL, V176, P3536, DOI 10.1128/JB.176.12.3536-3543.1994; Zenno S, 1996, J BIOCHEM-TOKYO, V120, P736; Zenno S, 1996, J BACTERIOL, V178, P4508, DOI 10.1128/jb.178.15.4508-4514.1996; Zenno SH, 1996, J BACTERIOL, V178, P4731, DOI 10.1128/jb.178.15.4731-4733.1996; Zheng YJ, 1996, J AM CHEM SOC, V118, P9402, DOI 10.1021/ja9608151	81	112	115	2	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11513	11520		10.1074/jbc.M111334200	http://dx.doi.org/10.1074/jbc.M111334200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11805110	hybrid			2022-12-27	WOS:000174613100097
J	Deneke, J; Ziegelin, G; Lurz, R; Lanka, E				Deneke, J; Ziegelin, G; Lurz, R; Lanka, E			Phage N15 telomere resolution - Target requirements for recognition and processing by the protelomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOMIC SEQUENCE; LOOP STRUCTURE; ALPHA-PROTEIN; LINEAR DNA; N-15; CONSTRUCTION; EVOLUTION; CLONING	The Escherichia coli prophage N15 exists as a linear DNA molecule with covalently closed ends. Purified N15 protelomerase TelN is the only protein required to convert circular DNA substrates to the linear form with hairpin termini. Within the center of the telomerase occupancy site tos, the target for TelN is the 56-bp telRL consisting of the central 22-bp palindrome telO and two 14-bp Ranking inverted sequence repetitions. DNase I footprinting of TelN-telRL complexes shows a segment of similar to50 bp protected by TelN. Surface plasmon resonance studies demonstrate that this extended footprint is caused by two TelN molecules bound to telRL. Stable TelN-target DNA complexes are achieved with telRL; however, the additional sequences of tos stabilize the TelN-target complexes. TelO alone is not sufficient for specific stable complex formation. However, processing can occur, i.e. generation of the linear covalently closed DNA. Within the context of telRL, sequences of telO are involved in specific TelN-telRL complex formation, in processing itself, and/or in recognition of the processing site. The sequence of the central (CG)(3) within telO that is part of a 14-bp stretch proposed to have Z-DNA conformation is essential for processing but not for formation of specific TelN-telRL complexes. The concerted action of both TelN molecules at the target site is the basis for telomere resolution. Capturing of reaction intermediates demonstrates that TelN binds covalently to the 3'-phosphoryl of the cleaved strands.	Max Planck Inst Mol Genet, Abt Lehrach, D-14195 Berlin, Germany	Max Planck Society	Lanka, E (corresponding author), Max Planck Inst Mol Genet, Abt Lehrach, Ihnestr 73,Dahlem, D-14195 Berlin, Germany.	lanka@molgen.mpg.de						BALZER D, 1992, NUCLEIC ACIDS RES, V20, P1851, DOI 10.1093/nar/20.8.1851; BAROUDY BM, 1982, CELL, V28, P315, DOI 10.1016/0092-8674(82)90349-X; Bustamante C, 1999, J BIOL CHEM, V274, P16665, DOI 10.1074/jbc.274.24.16665; Casjens S, 1999, CURR OPIN MICROBIOL, V2, P529, DOI 10.1016/S1369-5274(99)00012-0; Chaconas G, 2001, EMBO J, V20, P3229, DOI 10.1093/emboj/20.12.3229; COTMORE SF, 1987, ADV VIRUS RES, V33, P91, DOI 10.1016/S0065-3527(08)60317-6; COVARRUBIAS L, 1982, GENE, V17, P79, DOI 10.1016/0378-1119(82)90103-2; CUMMINGS DJ, 1992, INT REV CYTOL, V141, P1, DOI 10.1016/S0074-7696(08)62062-8; Deneke J, 2000, P NATL ACAD SCI USA, V97, P7721, DOI 10.1073/pnas.97.14.7721; DINOUEL N, 1993, MOL CELL BIOL, V13, P2315, DOI 10.1128/MCB.13.4.2315; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; FISCHER P, 1994, BIOTECHNIQUES, V16, P828; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GAROFF H, 1981, ANAL BIOCHEM, V115, P450, DOI 10.1016/0003-2697(81)90031-2; GONZALEZ A, 1986, NUCLEIC ACIDS RES, V14, P6835, DOI 10.1093/nar/14.17.6835; Goodner B, 2001, SCIENCE, V294, P2323, DOI 10.1126/science.1066803; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P3274, DOI 10.1128/MCB.5.11.3274; HINNEBUSCH J, 1991, J BACTERIOL, V173, P7233, DOI 10.1128/jb.173.22.7233-7239.1991; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; Jumas-Bilak E, 1998, J BACTERIOL, V180, P2749, DOI 10.1128/JB.180.10.2749-2755.1998; Kobryn K, 2001, CURR OPIN MICROBIOL, V4, P558, DOI 10.1016/S1369-5274(00)00251-4; LURZ R, 1987, J BIOL CHEM, V262, P16575; MORIN GB, 1986, CELL, V46, P873, DOI 10.1016/0092-8674(86)90069-3; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; Ravin NV, 2001, J MOL BIOL, V312, P899, DOI 10.1006/jmbi.2001.5019; Ravin V, 2000, J MOL BIOL, V299, P53, DOI 10.1006/jmbi.2000.3731; Rybchin VN, 1999, MOL MICROBIOL, V33, P895, DOI 10.1046/j.1365-2958.1999.01533.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEARS LE, 1992, BIOTECHNIQUES, V13, P626; Speck C, 1999, EMBO J, V18, P6169, DOI 10.1093/emboj/18.21.6169; SPIESS E, 1988, METHOD MICROBIOL, V20, P293, DOI 10.1016/S0580-9517(08)70057-6; STOPPEL RD, 1995, BIOMETALS, V8, P70; SVARCHEVSKY AN, 1986, THESIS LENINGRAD STA; VOSTROV AA, 1992, GENETIKA+, V28, P186; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; ZIEGELIN G, 1989, J BIOL CHEM, V264, P11989; ZIEGELIN G, 1995, J BACTERIOL, V177, P4333, DOI 10.1128/jb.177.15.4333-4341.1995; ZIEGELIN G, 1993, EMBO J, V12, P3703, DOI 10.1002/j.1460-2075.1993.tb06045.x	40	37	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10410	10419		10.1074/jbc.M111769200	http://dx.doi.org/10.1074/jbc.M111769200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11788606	hybrid			2022-12-27	WOS:000174549200107
J	Gow, AJ; Chen, QP; Hess, DT; Day, BJ; Ischiropoulos, H; Stamler, JS				Gow, AJ; Chen, QP; Hess, DT; Day, BJ; Ischiropoulos, H; Stamler, JS			Basal and stimulated protein S-nitrosylation in multiple cell types and tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; CYSTEINE ANTIBODIES; LOCALIZATION; MOLECULE	There is substantial evidence that protein S-nitrosylation provides a significant route through which nitric oxide (NO)-derived bioactivity is conveyed. However, most examples of S-nitrosylation have been characterized on the basis of analysis in vitro, and relatively little progress has been made in assessing the participant forms of nitric-oxide synthase (NOS) or the dynamics of protein S-nitrosylation in situ. Here we utilize antibodies specific for the nitrosothiol (SNO) moiety to provide an immunohistochemical demonstration that protein S-nitrosylation is coupled to the activity of each of the major forms of NOS. In cultured endothelial cells, SNOprotein immunoreactivity increases in response to Ca2+- stimulated endothelial NOS (eNOS) activity, and in aortic rings, endothelium-derived and eNOS-mediated relaxation (EDRF) is coupled to increased protein S-nitrosylation in both endothelial and associated smooth muscle cells. In cultured macrophages, SNO-protein levels increase upon cytokine induction of induced NOS (iNOS), and in PC12 cells, increased protein S-nitrosylation is linked to nerve growth factor induction of neuronal NOS (nNOS). In addition, we describe developmental and pathophysiological. increases in SNOprotein immunoreactivity within human lung. These results, which demonstrate Ca2+, neurohumoral, growth factor, cytokine, and developmental regulation of protein S-nitrosylation that is coupled to NOS expression and activity, provide unique evidence for the proposition that this ubiquitous NO-derived post-translational protein modification serves as a major effector of NO-related bioactivity.	Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute	Ischiropoulos, H (corresponding author), Stokes Res Inst, 3517 Civ Ctr Blvd, Philadelphia, PA 19140 USA.		Gow, Andrew/N-8566-2013; Gow, Andrew/AAR-2309-2020	Gow, Andrew/0000-0003-0876-5158; Gow, Andrew/0000-0003-0876-5158; Stamler, Jonathan/0000-0002-6866-1572				BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Cohen RA, 1999, CIRC RES, V84, P210, DOI 10.1161/01.RES.84.2.210; DVIS KL, 2001, ANN REV PHARM TOXICO, V41, P203; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Ignarro LJ, 1999, BIOSCIENCE REP, V19, P51, DOI 10.1023/A:1020150124721; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; Lorch SA, 2000, PEDIATR RES, V47, P798, DOI 10.1203/00006450-200006000-00020; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Mnaimneh S, 1999, CR ACAD SCI III-VIE, V322, P311, DOI 10.1016/S0764-4469(99)80067-5; Mnaimneh S, 1997, J IMMUNOL, V158, P308; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098	16	239	246	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9637	9640		10.1074/jbc.C100746200	http://dx.doi.org/10.1074/jbc.C100746200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11796706	hybrid			2022-12-27	WOS:000174549200005
J	He, B; Minges, JT; Lee, LW; Wilson, EM				He, B; Minges, JT; Lee, LW; Wilson, EM			The FXXLF motif mediates androgen receptor-specific interactions with coregulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; HUMAN PROSTATE CELLS; NUCLEAR RECEPTOR; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASE; DEPENDENT INTERACTION; MOLECULAR-CLONING; HORMONE RECEPTORS; COACTIVATOR TIF2; PROTEIN	The androgen receptor (AR) activation function 2 region of the ligand binding domain binds the LXXLL motifs of p160 coactivators weakly, engaging instead in an androgen-dependent, interdomain interaction with an FXXLF motif in the AR NH2 terminus. Here we show that FXXLF motifs are present in previously reported AR coactivators ARA70/RFG, AJRA55/Hic-5, and ARA54, which account for their selection in yeast two-hybrid screens. Mammalian two-hybrid assays, ligand dissociation rate studies, and glutathione S-transferase adsorption assays indicate androgen-dependent selective interactions of these FXXLF motifs with the AR ligand binding domain. Mutagenesis of residues within activation function 2 indicates distinct but overlapping binding sites where specificity depends on sequences within and flanking the FXXLF motif. Mutagenesis of the FXXLF motifs eliminated interaction with the ligand binding domain but only modestly reduced AR coactivation in transcription assays. The studies indicate that the FXXLF binding motif is specific for the AR and mediates interactions both within the AR and with coregulatory proteins.	Univ N Carolina, Labs Reprod Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Wilson, EM (corresponding author), Univ N Carolina, Labs Reprod Biol, CB 7500,Rm 374,Med Sci Bldg, Chapel Hill, NC 27599 USA.				NICHD NIH HHS [U54-HD35041, HD16910] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016910, R37HD016910, U54HD035041] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; Chan KK, 1998, GENE, V210, P345, DOI 10.1016/S0378-1119(97)00644-6; Chang CY, 1999, MOL CELL BIOL, V19, P8226; CHAPMAN MS, 2001, 83 END SOC ANN M DEN; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Gregory CW, 2001, CANCER RES, V61, P4315; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hofman K, 2000, MOL CELL ENDOCRINOL, V168, P21, DOI 10.1016/S0303-7207(00)00311-7; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Ito K, 2001, EUR J BIOCHEM, V268, P2725, DOI 10.1046/j.1432-1327.2001.02169.x; Jia YF, 2001, J BIOL CHEM, V276, P39911, DOI 10.1074/jbc.M103510200; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; KLEINERMAN DI, 1996, J UROLOGY, V155, P624; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Needham M, 2000, J STEROID BIOCHEM, V72, P35, DOI 10.1016/S0960-0760(00)00027-3; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Norris JD, 1998, J BIOL CHEM, V273, P6679, DOI 10.1074/jbc.273.12.6679; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Tan J, 1997, MOL ENDOCRINOL, V11, P450, DOI 10.1210/me.11.4.450; Tan JA, 2000, ENDOCRINOLOGY, V141, P3440, DOI 10.1210/en.141.9.3440; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Tsuji SY, 2001, BIOCHEMISTRY-US, V40, P2317, DOI 10.1021/bi002462v; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Yang L, 2000, MOL BIOL CELL, V11, P2007, DOI 10.1091/mbc.11.6.2007; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; ZHOU ZX, 1994, RECENT PROG HORM RES, V49, P249; Zhou ZX, 2002, MOL ENDOCRINOL, V16, P287, DOI 10.1210/me.16.2.287; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208	66	153	157	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10226	10235		10.1074/jbc.M111975200	http://dx.doi.org/10.1074/jbc.M111975200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11779876	hybrid, Green Published			2022-12-27	WOS:000174549200083
J	Luthy, L; Grutter, MG; Mittl, PRE				Luthy, L; Grutter, MG; Mittl, PRE			The crystal structure of Helicobacter pylori cysteine-rich protein B reveals a novel fold for a penicillin-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME SEQUENCE; INFECTION; MOLSCRIPT; ALIGNMENT; CAGA	Colonization of the gastric mucosa with the spiral-shaped Gram-negative proteobacterium Helicobacter pylori is probably the most common chronic infection in humans. The genomes of H. pylori strains J99 and 26695 have been completely sequenced. Functional and three-dimensional structural information is available for less than one third of all open reading frames. We investigated the function and three-dimensional structure of a member from a family of cysteine-rich hypothetical proteins that are unique to H. pylori and Campylobacter jejuni. The structure of H. pylori cysteine-rich protein (Hcp) B possesses a modular architecture consisting of four alpha/alpha-motifs that are cross-linked by disulfide bridges. The Hcp repeat is similar to the tetratricopeptide repeat, which is frequently found in protein/protein interactions. In contrast to the tetratricopeptide repeat, the Hcp repeat is 36 amino acids long. HcpB is capable of binding and hydrolyzing 6-amino penicillinic acid and 7-amino cephalosporanic acid derivatives. The HcpB fold is distinct from the fold of any known penicillin-binding protein, indicating that the Hcp proteins comprise a new family of penicillin-binding proteins. The putative penicillin binding site is located in an amphipathic groove on the concave side of the molecule.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Mittl, PRE (corresponding author), Univ Zurich, Inst Biochem, Winterthurer Str 190, CH-8057 Zurich, Switzerland.	mittl@bioc.unizh.ch	Mittl, Peer/E-5352-2017					Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; BLASER MJ, 1995, CANCER RES, V55, P2111; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Brodersen DE, 2000, ACTA CRYSTALLOGR D, V56, P431, DOI 10.1107/S0907444900000834; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cao P, 1998, INFECT IMMUN, V66, P2984, DOI 10.1128/IAI.66.6.2984-2986.1998; Costa K, 1999, J BACTERIOL, V181, P3710, DOI 10.1128/JB.181.12.3710-3715.1999; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Doig P, 1999, MICROBIOL MOL BIOL R, V63, P675, DOI 10.1128/MMBR.63.3.675-707.1999; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Graham DY, 1998, HELICOBACTER, V3, P145, DOI 10.1046/j.1523-5378.1998.08031.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karita M, 1997, INFECT IMMUN, V65, P4158, DOI 10.1128/IAI.65.10.4158-4164.1997; KELLY JA, 1986, SCIENCE, V231, P1429, DOI 10.1126/science.3082007; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krishnamurthy P, 1999, J BACTERIOL, V181, P5107, DOI 10.1128/JB.181.16.5107-5110.1999; Massova I, 1998, ANTIMICROB AGENTS CH, V42, P1; McGee DJ, 1999, CURR TOP MICROBIOL, V241, P155; Mittl PRE, 2000, J BIOL CHEM, V275, P17693, DOI 10.1074/jbc.M001869200; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Nelson DE, 2001, J BACTERIOL, V183, P3055, DOI 10.1128/JB.183.10.3055-3064.2001; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Powell J, 1992, Eur J Cancer Prev, V1, P265, DOI 10.1097/00008469-199204000-00008; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Simala-Grant JL, 2001, J ANTIMICROB CHEMOTH, V47, P555, DOI 10.1093/jac/47.5.555; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; WARREN JR, 1983, LANCET, V1, P1273	35	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10187	10193		10.1074/jbc.M108993200	http://dx.doi.org/10.1074/jbc.M108993200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11777911	hybrid			2022-12-27	WOS:000174549200078
J	Murphy, GA; Graham, SM; Morita, S; Reks, SE; Rogers-Graham, K; Vojtek, A; Kelley, GG; Der, CJ				Murphy, GA; Graham, SM; Morita, S; Reks, SE; Rogers-Graham, K; Vojtek, A; Kelley, GG; Der, CJ			Involvement of phosphatidylinositol 3-kinase, but not RalGDS, in TC21/R-Ras2-mediated transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS-RELATED PROTEIN; NUCLEOTIDE DISSOCIATION STIMULATOR; RAS/RAL SIGNALING CASCADE; RIE-1 EPITHELIAL-CELLS; R-RAS; KINASE CASCADE; NIH3T3 CELLS; H-RAS; GUANOSINE TRIPHOSPHATASES; FUNCTIONAL-ANALYSIS	Oncogenic Ras and activated forms of the Ras-related protein TC21/R-Ras2 share similar abilities to alter cell proliferation. However, in contrast to Ras, we found previously that TC21 fails to activate the Raf-1 serine/threonine kinase. Thus, TC21 must utilize non-Raf effectors to regulate cell function. In this study, we determined that TC21 interacts strongly with some (RalGDS, RGL, RGL2/Rlf, AF6, and the phosphatidylinositol 3-kinase (PI3K) catalytic subunit p110delta), and weakly with other Ras-GTP-binding proteins. In addition, library screening identified novel TC21-interacting proteins. We also determined that TC21, similar to Ras, mediates activation of phospholipase Cepsilon. We then examined if RalGDS, a RalA guanine nucleotide exchange factor, or PI3K are effectors for TC21-mediated signaling and cell proliferation in murine fibroblasts. We found that overexpression of full-length RalGDS reduced the focus forming activity of activated TC21. Furthermore, expression of activated Ras, but not TC21, enhanced GTP loading on RalA. In fact, TC21 attenuated insulin-stimulated RalA-GTP formation. In contrast, like Ras, expression of activated TC21 resulted in membrane translocation and an increase in the PI3K-dependent phosphorylation of Akt, and inhibition of PI3K activity interfered with TC21 focus formation. Finally, unlike Ras, TC21 did not activate the Rac small GTPase, indicating that Ras may not activate Rac by PI3K. Taken together, these results suggest that PI3K, but not RalGDS, is an important mediator of cell proliferation by TC21.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; SUNY Upstate Med Univ, Dept Med, Syracuse, NY 13210 USA; SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Michigan System; University of Michigan	Murphy, GA (corresponding author), Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.	gmurphy@med.unc.edu		Der, Channing/0000-0002-7751-2747; Repasky, Gretchen/0000-0001-6466-6467	NATIONAL CANCER INSTITUTE [R01CA055008, R01CA042978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056294] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978, CA55008] Funding Source: Medline; NIDDK NIH HHS [DK56294] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; AUBERGER P, 1989, CELL, V58, P631, DOI 10.1016/0092-8674(89)90098-6; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1992, NATURE, V356, P663, DOI 10.1038/356663a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWN WM, 1992, CELL, V68, P7, DOI 10.1016/0092-8674(92)90200-V; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CARBONI JM, 1995, ONCOGENE, V10, P1905; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Clark GJ, 1996, ONCOGENE, V12, P169; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; COX AD, 1994, ONCOGENE, V9, P3281; CUADRADO A, 1993, ONCOGENE, V8, P2443; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Fiordalisi JJ, 2001, METHOD ENZYMOL, V332, P3; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; Goldstein BJ, 1998, MOL CELL BIOCHEM, V182, P91, DOI 10.1023/A:1006812218502; Graham SM, 1996, MOL CELL BIOL, V16, P6132; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; Graham SM, 2001, METHOD ENZYMOL, V333, P203; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HAN LM, 1995, MOL CELL BIOL, V15, P1318; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HUANG Y, 1995, ONCOGENE, V11, P1255; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kigawa T, 1998, FEBS LETT, V441, P413, DOI 10.1016/S0014-5793(98)01596-8; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; LopezBarahona M, 1996, ONCOGENE, V12, P463; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Movilla N, 1999, ONCOGENE, V18, P5860, DOI 10.1038/sj.onc.1202968; Murphy GA, 1997, MOL BIOL CELL, V8, P2591, DOI 10.1091/mbc.8.12.2591; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Okazaki M, 1996, CANCER RES, V56, P2387; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Park SH, 1995, ONCOGENE, V11, P2349; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; Rosario M, 2001, MOL CELL BIOL, V21, P3750, DOI 10.1128/MCB.21.11.3750-3762.2001; Rusyn EV, 2000, ONCOGENE, V19, P4685, DOI 10.1038/sj.onc.1203836; SAEZ R, 1994, ONCOGENE, V9, P2977; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sheng HM, 1999, ONCOGENE, V18, P855, DOI 10.1038/sj.onc.1202397; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; Vetter IR, 1999, FEBS LETT, V451, P175, DOI 10.1016/S0014-5793(99)00555-4; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Voss M, 1999, J BIOL CHEM, V274, P34691, DOI 10.1074/jbc.274.49.34691; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	96	35	40	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9966	9975		10.1074/jbc.M109059200	http://dx.doi.org/10.1074/jbc.M109059200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11788587	hybrid			2022-12-27	WOS:000174549200049
J	Shamay, M; Barak, O; Doitsh, G; Ben-Dor, I; Shaul, Y				Shamay, M; Barak, O; Doitsh, G; Ben-Dor, I; Shaul, Y			Hepatitis B virus pX interacts with HBXAP, a PHD finger protein to coactivate transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HBV-ENCODED COACTIVATOR; LONG TERMINAL REPEAT; X-ASSOCIATED PROTEIN; NF-KAPPA-B; BINDING-PROTEIN; DNA-BINDING; KINASE-C; GENE; LEUKEMIA; ENHANCER	Hepatitis B virus (HBV) gene expression is mainly regulated at the transcription initiation level. The viral X protein (pX) is a transcription coactivator/mediator targeting TFIIB for the recruitment of RNA polymerase II. Here we report a novel pX nuclear target designated HBXAP (hepatitis B virus X-associated protein). HBXAP is a novel cellular nuclear protein containing a PHD (plant homology domain) finger, a domain shared by many proteins that play roles in chromatin remodeling, transcription coactivation, and oncogenesis. pX physically interacts with HBXAP in vitro and in vivo via the HBXAP region containing the PHD finger. At the functional level HBXAP increases HBV transcription in a pX-dependent manner suggesting a role for this interaction in the virus life cycle. Interestingly, HBXAP collaborates with pX in coactivating the transcriptional activator NF-kappaB. Coactivation of NF-kappaB was also observed in tumor necrosis factor alpha-treated cells suggesting that pX-HBXAP functional collaboration localized downstream to the NF-kappaB nuclear import. Collectively our data suggest that pX recruits and potentiates a novel putative transcription coactivator to regulate NF-kappaB. The implication of pX-HBXAP interaction in the development of hepatocellular carcinoma is discussed.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shaul, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.							AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Agami R, 1999, NATURE, V399, P809; Aguiar RCT, 1997, BLOOD, V90, P3130, DOI 10.1182/blood.V90.8.3130; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Barak O, 2001, VIROLOGY, V283, P110, DOI 10.1006/viro.2001.0883; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Cong YS, 1997, J BIOL CHEM, V272, P16482, DOI 10.1074/jbc.272.26.16482; DEMEDINA T, 1994, VIROLOGY, V202, P401, DOI 10.1006/viro.1994.1356; Doitsh G, 1999, ONCOGENE, V18, P7506, DOI 10.1038/sj.onc.1203209; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; FAKTOR O, 1990, ONCOGENE, V5, P867; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; Giles RH, 1997, LEUKEMIA, V11, P2087, DOI 10.1038/sj.leu.2400882; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Haviv I, 1998, GENE DEV, V12, P1217, DOI 10.1101/gad.12.8.1217; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Melegari M, 1998, J VIROL, V72, P1737, DOI 10.1128/JVI.72.3.1737-1743.1998; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Purcell NH, 2001, AM J PHYSIOL-GASTR L, V280, pG669, DOI 10.1152/ajpgi.2001.280.4.G669; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Shamay M, 2001, ONCOGENE, V20, P6811, DOI 10.1038/sj.onc.1204879; SHAMAY M, 2001, IN PRESS GENOMICS; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SZEPETOWSKI P, 1992, ONCOGENE, V7, P2513; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Waris G, 2001, MOL CELL BIOL, V21, P7721, DOI 10.1128/MCB.21.22.7721-7730.2001; Weil R, 1999, MOL CELL BIOL, V19, P6345; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	46	48	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9982	9988		10.1074/jbc.M111354200	http://dx.doi.org/10.1074/jbc.M111354200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11788598	hybrid			2022-12-27	WOS:000174549200051
J	Ahmad, Z; Salim, M; Maines, MD				Ahmad, Z; Salim, M; Maines, MD			Human biliverdin reductase is a leucine zipper-like DNA-binding protein and functions in transcriptional activation of heme oxygenase-1 by oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; NUCLEOTIDE-SEQUENCE; REGULATORY PROTEINS; ESCHERICHIA-COLI; MESSENGER-RNA; HEAT-SHOCK; C-FOS; GENE; JUN; YEAST	Human biliverdin reductase (hBVR) is a serine/threonine kinase that catalyzes reduction of the heme oxygenase (HO) activity product, biliverdin, to bilirubin. A domain of biliverdin reductase (BVR) has primary structural features that resemble leucine zipper proteins. A heptad repeat of five leucines (L-1-L-5), a basic domain, and a conserved alanine characterize the domain. In hBVR, a lysine replaces L-3. The secondary structure model of hBVR predicts an alpha-helix-turn-beta-sheet for this domain. hBVR translated by the rabbit reticulocyte lysate system appears on a nondenaturing gel as a single band with molecular mass of similar to69 kDa. The protein on a denaturing gel separates into two anti-hBVR immunoreactive proteins of similar to39.9 + 34.6 kDa. The dimeric form, but not purified hBVR, binds to a 100-mer DNA fragment corresponding to the mouse HO-1 (hsp32) promoter region encompassing two activator protein (AP-1) sites. The specificity of DNA binding is suggested by the following: (a) hBVR does not bind to the same DNA fragment with one or zero AP-1 sites; (b) a 56-bp random DNA with one AP-1 site does not form a complex with hBVR; (c) in vitro translated HO-1 does not interact with the 100-mer DNA fragment with two AP-1 sites; (d) mutation of Lys(143), Leu(150), or Leu(157) blocks both the formation of the similar to69-kDa specimens and hBVR DNA complex formation; and (e) purified preparations of hBVR or hHO-1 do not bind to DNA with two AP-1 sites. The potential significance of the AP-1 binding is suggested by the finding that the response of HO-1, in COS cells stably transfected with antisense hBVR, with 66% reduced BVR activity, to superoxide anion (O-2(.)) formed by menadione is attenuated, whereas induction by heme is not affected. We propose a role for BVR in the signaling cascade for AP-1 complex activation necessary for HO-1 oxidative stress response.	Univ Rochester, Med Ctr, Dept Biochem Biophys, Sch Med & Dent, Rochester, NY 14642 USA	University of Rochester	Maines, MD (corresponding author), Univ Rochester, Med Ctr, Dept Biochem Biophys, Sch Med & Dent, Box 712 601 Elmwood Ave, Rochester, NY 14642 USA.			Ahmad, Zulfiqar/0000-0001-7306-8151	NIEHS NIH HHS [ES04391, ES04066] Funding Source: Medline; NIGMS NIH HHS [R15 GM085771] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES004391, R01ES004066, R01ES004391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM085771] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad Z, 2001, J BIOL CHEM, V276, P18450, DOI 10.1074/jbc.M100550200; ALAM J, 1994, J BIOL CHEM, V269, P1001; ALAM J, 1992, J BIOL CHEM, V267, P21894; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EWING JF, 1991, P NATL ACAD SCI USA, V88, P5364, DOI 10.1073/pnas.88.12.5364; FAKHRAI H, 1992, J BIOL CHEM, V267, P4023; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GILLETTE JR, 1957, J PHARMACOL EXP THER, V119, P532; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HUANG TJ, 1989, J BIOL CHEM, V264, P7844; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KEYSE SM, 1990, CARCINOGENESIS, V11, P787, DOI 10.1093/carcin/11.5.787; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; Kikuchi A, 2001, NAT STRUCT BIOL, V8, P221, DOI 10.1038/84955; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987; Lee PJ, 2000, AM J PHYSIOL-LUNG C, V279, pL175, DOI 10.1152/ajplung.2000.279.1.L175; Maines M.D., 1992, HEME OXYGENASE CLIN; MAINES MD, 1993, ARCH BIOCHEM BIOPHYS, V300, P320, DOI 10.1006/abbi.1993.1044; Maines MD, 1996, EUR J BIOCHEM, V235, P372, DOI 10.1111/j.1432-1033.1996.00372.x; Maines MD, 2001, J PHARMACOL EXP THER, V296, P1091; MAINES MD, 1986, J BIOL CHEM, V261, P411; MCCORMACK T, 1994, CELL, V79, P1133, DOI 10.1016/0092-8674(94)90004-3; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; Ramirez-Carrozzi VR, 2001, J BIOL CHEM, V276, P21797, DOI 10.1074/jbc.M101494200; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Salim M, 2001, J BIOL CHEM, V276, P10929, DOI 10.1074/jbc.M010753200; Sambrook J., 2002, MOL CLONING LAB MANU; Schluchter WM, 1997, J BIOL CHEM, V272, P13562, DOI 10.1074/jbc.272.21.13562; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x	53	93	98	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9226	9232		10.1074/jbc.M108239200	http://dx.doi.org/10.1074/jbc.M108239200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11773068	hybrid, Green Submitted			2022-12-27	WOS:000174400600067
J	Stein, AJ; Geiger, JH				Stein, AJ; Geiger, JH			The crystal structure and mechanism of 1-L-myo-inositol-1-phosphate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOINOSITOL 1-PHOSPHATE SYNTHASE; MYO-INOSITOL-1-PHOSPHATE SYNTHASE; L-MYO-INOSITOL-1-PHOSPHATE SYNTHASE; BOVINE TESTIS; INOSITOL; BIOSYNTHESIS; GLUCOSE; LITHIUM; BRAIN; YEAST	1-L-myo-Inositol-1-phosphate synthase catalyzes the conversion Of D-glucose 6-phosphate to 1-L-myo-inositol-1-phosphate (MIP), the first and rate-limiting step in the biosynthesis of all inositol-containing compounds. It involves an oxidation, intramolecular aldol cyclization, and reduction. We have determined the first crystal structure of MIP synthase. We present structures of both the NAD-bound enzyme and the enzyme bound to an inhibitor, 2-deoxy-glucitol-6-phosphate. While 58 amino acids are disordered in the unbound form of the enzyme in the vicinity of the active site, the inhibitor nucleates the folding of this domain in a striking example of induced fit, serving to completely encapsulate it within the enzyme. Three helices and a long beta-strand are formed in this process. We postulate a mechanism for the conversion based on the structure of the inhibitor-bound complex.	Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA	Michigan State University	Geiger, JH (corresponding author), Michigan State Univ, Dept Chem, 320 Chem, E Lansing, MI 48824 USA.	geiger@cem.msu.edu		Geiger, James/0000-0002-9443-4488				ABUABIED M, 1994, PLANT PHYSIOL, V106, P1689, DOI 10.1104/pp.106.4.1689; ADHIKARI J, 1983, FEBS LETT, V163, P46, DOI 10.1016/0014-5793(83)81159-4; ADHIKARI J, 1988, INDIAN J BIOCHEM BIO, V25, P408; ARGANOFF BW, 1991, INOSITOL PHOSPHATES, V463, P20; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARNETT JEG, 1968, BIOCHEM J, V108, P125, DOI 10.1042/bj1080125; BELMAKER RG, 1995, DEPRESSION MANIA NEU; Belmaker RH, 1996, ANNU REV MED, V47, P47; Benevides JM, 2000, BIOCHEMISTRY-US, V39, P548, DOI 10.1021/bi990053x; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Chen LJ, 2000, BIOCHEMISTRY-US, V39, P12415, DOI 10.1021/bi001517q; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; EXTON JH, 1986, ADV CYCLIC NUCL PROT, V20, P211; Frey P. A., 1987, PYRIDINE NUCLEOTIDE, P461; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; HASEGAWA R, 1981, P NATL ACAD SCI-BIOL, V78, P4863, DOI 10.1073/pnas.78.8.4863; Ishitani M, 1996, PLANT J, V9, P537, DOI 10.1046/j.1365-313X.1996.09040537.x; JOHNSON MD, 1994, PLANT PHYSIOL, V105, P1023, DOI 10.1104/pp.105.3.1023; JOHNSON MD, 1995, PLANT PHYSIOL, V109, P721; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOSHLAND DE, 1994, ANGEW CHEM INT EDIT, V33, P2375; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOEWUS FA, 1962, BIOCHEM BIOPH RES CO, V7, P204, DOI 10.1016/0006-291X(62)90175-4; LOEWUS MW, 1977, J BIOL CHEM, V252, P7221; LOEWUS MW, 1980, J BIOL CHEM, V255, P1710; LOEWUS MW, 1980, CARBOHYD RES, V82, P333, DOI 10.1016/S0008-6215(00)85707-9; LOEWUS MW, 1973, PLANT SCI LETT, V1, P368; Lohia A, 1999, MOL BIOCHEM PARASIT, V98, P67, DOI 10.1016/S0166-6851(98)00147-9; Majumder AL, 1997, BBA-LIPID LIPID MET, V1348, P245, DOI 10.1016/S0005-2760(97)00122-7; MAUCK LA, 1980, BIOCHEMISTRY-US, V19, P3623, DOI 10.1021/bi00556a031; Migaud ME, 1996, J AM CHEM SOC, V118, P495, DOI 10.1021/ja952570i; MIGAUD ME, 1995, J AM CHEM SOC, V117, P5154, DOI 10.1021/ja00123a019; OTWINOWSKI Z, 1996, METHODS ENZYMOL, V276; Park D, 2000, BBA-GENE STRUCT EXPR, V1494, P277, DOI 10.1016/S0167-4781(00)00085-3; PITTNER F, 1978, H-S Z PHYSIOL CHEM, V359, P1395, DOI 10.1515/bchm2.1978.359.2.1395; PITTNER F, 1976, H-S Z PHYSIOL CHEM, V357, P1667, DOI 10.1515/bchm2.1976.357.2.1667; POTTER BVL, 1995, ANGEW CHEM INT EDIT, V34, P1933, DOI 10.1002/anie.199519331; Scapin G, 1996, BIOCHEMISTRY-US, V35, P13540, DOI 10.1021/bi961628i; Scapin G, 1998, BIOCHEMISTRY-US, V37, P3278, DOI 10.1021/bi9727949; SHERMAN WR, 1969, J BIOL CHEM, V244, P5703; SHERMAN WR, 1981, BIOCHIM BIOPHYS ACTA, V660, P299, DOI 10.1016/0005-2744(81)90174-1; SMART CC, 1993, PLANT J, V4, P279, DOI 10.1046/j.1365-313X.1993.04020279.x; Stein AJ, 2000, ACTA CRYSTALLOGR D, V56, P348, DOI 10.1107/S0907444999016777; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tian F, 1999, J AM CHEM SOC, V121, P5795, DOI 10.1021/ja9900196; Vaden DL, 2001, J BIOL CHEM, V276, P15466, DOI 10.1074/jbc.M004179200; WANG X, 1995, PLANT PHYSIOL, V110, P336; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; WONG YHH, 1982, METHOD ENZYMOL, V90, P309	55	48	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9484	9491		10.1074/jbc.M109371200	http://dx.doi.org/10.1074/jbc.M109371200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11779862	hybrid			2022-12-27	WOS:000174400600100
J	Yang, WM; Tsai, SC; Wen, YD; Fejer, G; Seto, E				Yang, WM; Tsai, SC; Wen, YD; Fejer, G; Seto, E			Functional domains of histone deacetylase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; TRANSCRIPTIONAL REPRESSION; N-COR; CRM1; COMPLEX; YEAST; HDAC3; PROTEINS; CLONING; ACETYLATION	Post-translational modifications of histones, in general, and acetylation/deacetylation, in particular, can dramatically alter gene expression in eukaryotic cells. In humans, four highly homologous class I HDAC enzymes (HDAC1, HDAC2, HDAC3, and HDAC8) have been identified to date. Although HDAC3 shares some structural and functional similarities with other class I HDACs, it exists in multisubunit complexes separate and different from other known HDAC complexes, implying that individual HDACs might function in a distinct manner. In this current study, to understand further the cellular function of HDAC3 and to uncover possible unique roles this protein may have in gene regulation, we performed a detailed analysis of HDAC3 using deletion mutations. Surprisingly, we found that the non-conserved C-terminal region of HDAC3 is required for both deacetylase and transcriptional repression activity. In addition, we discovered that the central portion of the HDAC3 protein possesses a nuclear export signal, whereas the C-terminal part of HDAC3 contributes to the protein's localization in the nucleus. Finally, we found that HDAC3 forms oligomers in vitro and in vivo and that the N-terminal portion of HDAC3 is necessary for this property. These data indicate that HDAC3 comprises separate, non-overlapping domains that contribute to the unique properties and function of this protein.	Univ S Florida, Interdisciplinary Oncol Program, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Seto, E (corresponding author), Univ S Florida, Interdisciplinary Oncol Program, H Lee Moffit Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Fejer, Gyorgy/D-5080-2011	Yang, Wen-Ming/0000-0002-5871-5979	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058486] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58486] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bogerd HP, 1998, J VIROL, V72, P8627, DOI 10.1128/JVI.72.11.8627-8635.1998; Buggy JJ, 2000, BIOCHEM J, V350, P199, DOI 10.1042/0264-6021:3500199; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Dangond F, 1999, Mol Cell Biol Res Commun, V2, P91, DOI 10.1006/mcbr.1999.0156; Dangond F, 1998, BIOCHEM BIOPH RES CO, V242, P648, DOI 10.1006/bbrc.1997.8033; Elfgang C, 1999, P NATL ACAD SCI USA, V96, P6229, DOI 10.1073/pnas.96.11.6229; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guenther MG, 2000, GENE DEV, V14, P1048; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Khochbin S, 2001, FEBS LETT, V494, P141, DOI 10.1016/S0014-5793(01)02327-4; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Mahlknecht U, 1999, CYTOGENET CELL GENET, V86, P237, DOI 10.1159/000015347; Mahlknecht U, 1999, CYTOGENET CELL GENET, V84, P192, DOI 10.1159/000015256; Mahlknecht U, 1999, GENOMICS, V56, P197, DOI 10.1006/geno.1998.5645; Marmorstein R, 2001, CURR OPIN GENET DEV, V11, P155, DOI 10.1016/S0959-437X(00)00173-8; McArthur GA, 1998, COLD SPRING HARB SYM, V63, P423, DOI 10.1101/sqb.1998.63.423; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Nakatani Y, 2001, GENES CELLS, V6, P79, DOI 10.1046/j.1365-2443.2001.00411.x; Neumann G, 2000, EMBO J, V19, P6751, DOI 10.1093/emboj/19.24.6751; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Ossareh-Nazari B, 1999, EXP CELL RES, V252, P236, DOI 10.1006/excr.1999.4599; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Takami Y, 2000, J BIOL CHEM, V275, P16191, DOI 10.1074/jbc.M908066199; Taplick J, 2001, J MOL BIOL, V308, P27, DOI 10.1006/jmbi.2001.4569; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Tsai RYL, 1997, BIOTECHNIQUES, V23, P794, DOI 10.2144/97235bm06; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; Van den Wyngaert I, 2000, FEBS LETT, V478, P77, DOI 10.1016/S0014-5793(00)01813-5; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zheng GX, 1997, J BIOL CHEM, V272, P31855, DOI 10.1074/jbc.272.50.31855; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697	69	178	185	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9447	9454		10.1074/jbc.M105993200	http://dx.doi.org/10.1074/jbc.M105993200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11779848	hybrid			2022-12-27	WOS:000174400600095
J	Berger, AL; Ikuma, M; Hunt, JF; Thomas, PJ; Welsh, MJ				Berger, AL; Ikuma, M; Hunt, JF; Thomas, PJ; Welsh, MJ			Mutations that change the position of the putative gamma-phosphate linker in the nucleotide binding domains of CFTR alter channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS; ATP-BINDING; CRYSTAL-STRUCTURE; MULTIDRUG-RESISTANCE; ESCHERICHIA-COLI; CHLORIDE CHANNEL; ACTIVE-SITE; CL-CHANNELS; HYDROLYSIS; CASSETTE	The cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel is an ATP-binding cassette transporter that contains conserved nucleotide-binding domains (NBDs). In CFTR, the NBDs bind and hydrolyze ATP to open and close the channel. Crystal structures of related NBDs suggest a structural model with an important signaling role for a gamma-phosphate linker peptide that couples bound nucleotide to movement of an a-helical subdomain. We mutated two residues in CFTR that the structural model predicts will uncouple effects of nucleotide binding from movement of the alpha-helical subdomain. These residues are Gln-493 and Gln-1291, which may directly connect the ATP gamma-phosphate to the gamma-phosphate linker, and residues Asn-505 and Asn-1303, which may for hydrogen bonds that stabilize the linker. In NBD1, Q493A reduced the frequency of channel opening, suggesting a role for this residue in coupling ATP binding to channel opening. In contrast, N505C increased the frequency of channel opening, consistent with a role for Asn-505 in stabilizing the inactive state of the NBD. In NBD2, Q1291A decreased the effects of pyrophosphate without altering other functions. Mutations of Asn-1303 decreased the rate of channel opening and closing, suggesting an important role for NBD2 in controlling channel burst duration. These findings are consistent with both the bacterial NBD structural model and gating models for CFTR. Our results extend models of nucleotide-induced structural changes from bacterial NBDs to a functional mammalian ATP-binding cassette transporter.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; Columbia University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Welsh, MJ (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Internal Med, 500 EMRB, Iowa City, IA 52242 USA.	mjwelsh@blue.weeg.uiowa.edu	Thomas, Philip J/F-7115-2012	Welsh, Michael/0000-0002-1646-6206	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL051670, R01HL029851, R37HL029851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29851, HL51670] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aleksandrov AA, 2000, J PHYSIOL-LONDON, V528, P259, DOI 10.1111/j.1469-7793.2000.00259.x; Aleksandrov L, 2001, J BIOL CHEM, V276, P12918, DOI 10.1074/jbc.M100515200; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1992, ADENINE NUCLEOTIDES, P399; CARSON MR, 1995, J BIOL CHEM, V270, P20466, DOI 10.1074/jbc.270.35.20466; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; Carson MR, 1995, BIOPHYS J, V69, P2443, DOI 10.1016/S0006-3495(95)80113-X; CARSON MR, 1994, BIOPHYS J, V67, P1867, DOI 10.1016/S0006-3495(94)80668-X; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Dawson David C., 1999, Physiological Reviews, V79, pS47; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; Harrington MA, 1999, J BIOL CHEM, V274, P27536, DOI 10.1074/jbc.274.39.27536; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Ikuma M, 2000, P NATL ACAD SCI USA, V97, P8675, DOI 10.1073/pnas.140220597; JONES CT, 1992, HUM MOL GENET, V1, P11, DOI 10.1093/hmg/1.1.11; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lapinski PE, 2001, J BIOL CHEM, V276, P7526, DOI 10.1074/jbc.M009448200; Mathews CJ, 1998, J MEMBRANE BIOL, V163, P55, DOI 10.1007/s002329900370; OSBORNE L, 1992, HUM GENET, V89, P653, DOI 10.1007/BF00221957; Ramjeesingh M, 1999, BIOCHEMISTRY-US, V38, P1463, DOI 10.1021/bi982243y; RAMJEESINGH M, 1995, PED PULMONOL S, V12; Reddy MM, 1996, AM J PHYSIOL-CELL PH, V271, pC35, DOI 10.1152/ajpcell.1996.271.1.C35; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; Schultz BD, 1996, J MEMBRANE BIOL, V151, P63, DOI 10.1007/s002329900058; SCHULTZ BD, 1995, J GEN PHYSIOL, V105, P329, DOI 10.1085/jgp.105.3.329; Sheppard DN, 1999, PHYSIOL REV, V79, P23; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P11921, DOI 10.1021/bi001220s; Weinreich F, 1999, J GEN PHYSIOL, V114, P55, DOI 10.1085/jgp.114.1.55; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200; Zeltwanger S, 1999, J GEN PHYSIOL, V113, P541, DOI 10.1085/jgp.113.4.541	43	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2125	2131		10.1074/jbc.M109539200	http://dx.doi.org/10.1074/jbc.M109539200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11788611	hybrid			2022-12-27	WOS:000173421300070
J	Sai, X; Kawamura, Y; Kokame, K; Yamaguchi, H; Shiraishi, H; Suzuki, R; Suzuki, T; Kawaichi, M; Miyata, T; Kitamura, T; De Strooper, B; Yanagisawa, K; Komano, H				Sai, X; Kawamura, Y; Kokame, K; Yamaguchi, H; Shiraishi, H; Suzuki, R; Suzuki, T; Kawaichi, M; Miyata, T; Kitamura, T; De Strooper, B; Yanagisawa, K; Komano, H			Endoplasmic reticulum stress-inducible protein, herp, enhances presenilin-mediated generation of amyloid beta-protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; GAMMA-SECRETASE CLEAVAGE; PRECURSOR PROTEIN; INTRAMEMBRANE CLEAVAGE; COGNITIVE IMPAIRMENT; MISSENSE MUTATIONS; AMINO-ACID; GENE; HOMOCYSTEINE; PARKIN	Presenilin (PS) is essential for the gamma-cleavage required for the generation of the C terminus of amyloid beta-protein (Abeta). However, the mechanism underlying PS-mediated gamma-cleavage remains unclear. We have identified Herp cDNA by our newly developed screening method for the isolation of cDNAs that increase the degree of gamma-cleavage. Herp was originally identified as a homocysteine-responsive protein, and its expression is up-regulated by endoplasmic reticulum stress. Herp is an endoplasmic reticulum-localized membrane protein that has a ubiquitin-like domain. Here, we report that a high expression of Herp in cells increases the level of Abeta generation, although not in PS-deficient cells. We found that Herp interacts with both PSI and PS2. Thus, Herp regulates PS-mediated Abeta generation, possibly through its binding to PS. Immunohistochemical analysis of a normal human brain section with an anti-Herp antibody revealed the exclusive staining of neurons and vascular smooth muscle cells. Moreover, the antibody strongly stained activated microglia in senile plaques in the brain of patients with Alzheimer disease. Taken together, Herp could be involved in Abeta accumulation, including the formation of senile plaques and vascular Abeta deposits.	Natl Inst Longev Sci, Dept Dementia Res, Obu, Aichi 4748522, Japan; Japan Sci & Technol Corp, Kawaguchi, Saitama 3320012, Japan; Natl Cardiovasc Ctr, Res Inst, Osaka 5658565, Japan; Gunma Univ, Sch Hlth Sci, Maebashi, Gumma 3718511, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan; Nara Inst Sci & Technol, Div Gene Funct Anim, Nara 63001, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Cellular Therapy, Tokyo 1088639, Japan; Katholieke Univ Leuven, Neuronal Cell Biol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium	Japan Science & Technology Agency (JST); National Cerebral & Cardiovascular Center - Japan; Gunma University; Hokkaido University; Nara Institute of Science & Technology; University of Tokyo; KU Leuven	Komano, H (corresponding author), Natl Inst Longev Sci, Dept Dementia Res, 36-3 Gengo, Obu, Aichi 4748522, Japan.	hkomano@nils.go.jp	Kitamura, Toshio/AAA-2071-2021; De Strooper, Bart/F-6507-2012; Suzuki, Toshiharu/B-5342-2013; de+Strooper, Bart/Z-1638-2019	De Strooper, Bart/0000-0001-5455-5819; Kokame, Koichi/0000-0002-9654-6299				ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; Gottfries CG, 1998, J NEURAL TRANSM, V105, P773, DOI 10.1007/s007020050094; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; Kokame K, 2001, J BIOL CHEM, V276, P9199, DOI 10.1074/jbc.M010486200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lehmann M, 1999, DEMENT GERIATR COGN, V10, P12, DOI 10.1159/000017092; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Miller JW, 1999, NUTR REV, V57, P126; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Onishi M, 1996, EXP HEMATOL, V24, P324; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Saura CA, 2000, J BIOL CHEM, V275, P17136, DOI 10.1074/jbc.M909624199; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Sudoh S, 2000, EUR J BIOCHEM, V267, P2036, DOI 10.1046/j.1432-1327.2000.01206.x; Sudoh S, 1998, J NEUROCHEM, V71, P1535; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Tomita S, 1998, J BIOL CHEM, V273, P19304, DOI 10.1074/jbc.273.30.19304; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Xu X, 2001, NAT GENET, V27, P23, DOI 10.1038/83717; Yamada M, 2000, NEUROPATHOLOGY, V20, P8, DOI 10.1046/j.1440-1789.2000.00268.x; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	41	118	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12915	12920		10.1074/jbc.M112372200	http://dx.doi.org/10.1074/jbc.M112372200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11799129	hybrid			2022-12-27	WOS:000175036300056
J	Zhou, TJ; Kurnasov, O; Tomchick, DR; Binns, DD; Grishin, NV; Marquez, VE; Osterman, AL; Zhang, H				Zhou, TJ; Kurnasov, O; Tomchick, DR; Binns, DD; Grishin, NV; Marquez, VE; Osterman, AL; Zhang, H			Structure of human nicotinamide/nicotinic acid mononucleotide adenylyltransferase - Basis for the dual substrate specificity and activation of the oncolytic agent tiazofurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMN ADENYLYLTRANSFERASE; HUMAN PLACENTA; NAD; CRYSTALLOGRAPHY; BIOSYNTHESIS; CONSERVATION; CONSEQUENCES; METABOLISM; RESISTANCE; ANALOGS	Nicotinamide/nicotinate mononueleotide (NMN/ NaMN)adenylyltransferase (NMNAT) is an indispensable enzyme in the biosynthesis of NAD(+) and NADP(+). Human NMNAT displays unique dual substrate specificity toward both NMN and NaMN, thus flexible in participating in both de novo and salvage pathways of NAD synthesis. Human NMNAT also catalyzes the rate-limiting step of the metabolic conversion of the anticancer agent tiazofurin to its active form tiazofurin adenine dinucleotide (TAD). The tiazofurin resistance is mainly associated with the low NMNAT activity in the cell. We have solved the crystal structures of human NMNAT in complex with NAD, deamido-NAD, and a non-hydrolyzable TAD analogue beta-CR2-TAD. These complex structures delineate the broad substrate specificity of the enzyme toward both NAIN and NaMN and reveal the structural mechanism for adenylation of tiazofurin nucleotide. The crystal structure of human NMNAT also shows that it forms a barrel-like hexamer with the predicted nuclear localization signal sequence located on the outside surface of the barrel, supporting its functional role of interacting with the nuclear transporting proteins, The results from the analytical ultracentrifugation studies are consistent with the formation of a hexamer in solution under certain conditions.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Integrated Genom Inc, Chicago, IL 60612 USA; NCI, Frederick Canc Res & Dev Ctr, Med Chem Lab, Frederick, MD 21702 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Zhang, H (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA.		Tomchick, Diana/HGV-2018-2022; Marquez, Victor/AAP-3549-2021	Tomchick, Diana/0000-0002-7529-4643	NIGMS NIH HHS [GM 63689-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063689] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDUCCI E, 1992, BIOCHEM BIOPH RES CO, V189, P1275, DOI 10.1016/0006-291X(92)90211-3; Begley TP, 2001, VITAM HORM, V61, P103; BORITZKI TJ, 1985, BIOCHEM PHARMACOL, V34, P1109, DOI 10.1016/0006-2952(85)90617-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burkle A, 2001, CANCER LETT, V163, P1, DOI 10.1016/S0304-3835(00)00694-7; CARNEY DN, 1985, J CLIN INVEST, V75, P175, DOI 10.1172/JCI111671; COONEY DA, 1983, ADV ENZYME REGUL, V21, P271, DOI 10.1016/0065-2571(83)90019-5; D'Angelo I, 2000, STRUCTURE, V8, P993, DOI 10.1016/S0969-2126(00)00190-8; Doherty AJ, 2000, NUCLEIC ACIDS RES, V28, P4051, DOI 10.1093/nar/28.21.4051; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Emanuelli M, 2001, J BIOL CHEM, V276, P406, DOI 10.1074/jbc.M008700200; EMANUELLI M, 1992, ARCH BIOCHEM BIOPHYS, V298, P29, DOI 10.1016/0003-9861(92)90089-F; GOLDSTEIN BM, 1988, J MED CHEM, V31, P1026, DOI 10.1021/jm00400a024; GOLDSTEIN BM, 1983, J AM CHEM SOC, V105, P7416, DOI 10.1021/ja00363a035; Jayaram HN, 1999, CURR MED CHEM, V6, P561; JAYARAM HN, 1993, CANCER RES, V53, P2344; JAYARAM HN, 1985, ADV ENZYME REGUL, V24, P67, DOI 10.1016/0065-2571(85)90070-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; Magni G, 1999, ADV ENZYMOL RAMB, V73, P135, DOI 10.1002/9780470123195.ch5; MARQUEZ VE, 1986, J MED CHEM, V29, P1726, DOI 10.1021/jm00159a027; NYBURG SC, 1985, ACTA CRYSTALLOGR B, V41, P274, DOI 10.1107/S0108768185002129; Olland AM, 2002, J BIOL CHEM, V277, P3698, DOI 10.1074/jbc.M109670200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PENFOUND T, 1996, ESCHERICHIA COLI SAL, V1, P721; Raffaelli N, 1997, J BACTERIOL, V179, P7718, DOI 10.1128/jb.179.24.7718-7723.1997; RUGGIERI S, 1990, BIOCHEMISTRY-US, V29, P2501, DOI 10.1021/bi00462a010; Saridakis V, 2001, J BIOL CHEM, V276, P7225, DOI 10.1074/jbc.M008810200; Schweiger M, 2001, FEBS LETT, V492, P95, DOI 10.1016/S0014-5793(01)02180-9; Wilkinson A, 2001, MOL MICROBIOL, V40, P1241, DOI 10.1046/j.1365-2958.2001.02479.x; Zhang QH, 2000, CHEMOECOLOGY, V10, P69, DOI 10.1007/s000490050010; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	33	75	81	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13148	13154		10.1074/jbc.M111469200	http://dx.doi.org/10.1074/jbc.M111469200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11788603	hybrid			2022-12-27	WOS:000175036300084
J	Fulton, DC; Edwards, A; Pilling, E; Robinson, HL; Fahy, B; Seale, R; Kato, L; Donald, AM; Geigenberger, P; Martin, C; Smith, AM				Fulton, DC; Edwards, A; Pilling, E; Robinson, HL; Fahy, B; Seale, R; Kato, L; Donald, AM; Geigenberger, P; Martin, C; Smith, AM			Role of granule-bound starch synthase in determination of amylopectin structure and starch granule morphology in potato	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE PYROPHOSPHORYLASE ACTIVITIES; SOLANUM-TUBEROSUM L; PISUM-SATIVUM-L; BRANCHING ENZYME; MAIZE ENDOSPERM; CHLAMYDOMONAS-REINHARDTII; ADP-GLUCOSE; FUNCTIONAL-ANALYSIS; PEA EMBRYOS; RICE-STARCH	Reductions in activity of SSIII, the major isoform of starch synthase responsible for amylopectin synthesis in the potato tuber, result in fissuring of the starch granules. To discover the causes of the fissuring, and thus to shed light on factors that influence starch granule morphology in general, SSIII antisense lines were compared with lines with reductions in the major granule-bound isoform of starch synthase (GBSS) and lines with reductions in activity of both SSIII and GBSS (SSIII/GBSS antisense lines). This revealed that fissuring resulted from the activity of GBSS in the SSIII antisense background. Control (untransformed) lines and GBSS and SSIII/GBSS antisense lines had unfissured granules. Starch analyses showed that granules from SSIII antisense tubers had a greater number of long glucan chains than did granules from the other lines, in the form of larger amylose molecules and a unique fraction of very long amylopectin chains. These are likely to result from increased through GBSS in SSIII antisense tubers, in response to the elevated content of ADP-glucose in these tubers. It is proposed that the long glucan chains disrupt organization of the semi-crystalline parts of the matrix, setting up stresses in the matrix that lead to fissuring.	John Innes Ctr Plant Sci Res, Dept Metab Biol, Norwich NR4 7UH, Norfolk, England; John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England; Univ Cambridge, Cavendish Lab, Dept Phys, Cambridge CB3 0HE, England; Max Planck Inst Mol Plant Physiol, D-14476 Golm, Germany	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Cambridge; Max Planck Society	Smith, AM (corresponding author), John Innes Ctr Plant Sci Res, Dept Metab Biol, Colney Lane, Norwich NR4 7UH, Norfolk, England.		Geigenberger, Peter/A-2041-2010	Geigenberger, Peter/0000-0001-9512-349X				Abel GJW, 1996, PLANT J, V10, P981, DOI 10.1046/j.1365-313X.1996.10060981.x; BABA T, 1987, STARCH-STARKE, V39, P52, DOI 10.1002/star.19870390207; Beckles DM, 2001, PLANT PHYSIOL, V125, P818, DOI 10.1104/pp.125.2.818; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BHATTACHARYYA MK, 1990, CELL, V60, P115, DOI 10.1016/0092-8674(90)90721-P; BOYER CD, 1976, CROP SCI, V16, P298, DOI 10.2135/cropsci1976.0011183X001600020038x; BOYER CD, 1976, STARCH STAERKE, V12, P405; Buleon A, 1997, PLANT PHYSIOL, V115, P949, DOI 10.1104/pp.115.3.949; CAMERON RE, 1992, POLYMER, V33, P2628, DOI 10.1016/0032-3861(92)91147-T; Cao HP, 2000, ARCH BIOCHEM BIOPHYS, V373, P135, DOI 10.1006/abbi.1999.1547; Clarke BR, 1999, PLANTA, V209, P324, DOI 10.1007/s004250050639; COLONNA P, 1984, CARBOHYD RES, V126, P233, DOI 10.1016/0008-6215(84)85381-1; Craig J, 1998, PLANT CELL, V10, P413, DOI 10.1105/tpc.10.3.413; CREECH RG, 1965, GENETICS, V52, P1175; DELRUE B, 1992, J BACTERIOL, V174, P3612, DOI 10.1128/JB.174.11.3612-3620.1992; Denyer K, 1996, PLANT PHYSIOL, V112, P779, DOI 10.1104/pp.112.2.779; Denyer K, 1996, PLANT J, V10, P1135, DOI 10.1046/j.1365-313X.1996.10061135.x; DRY I, 1992, PLANT J, V2, P193; EDWARDS A, 1995, PLANT J, V8, P283, DOI 10.1046/j.1365-313X.1995.08020283.x; Edwards A, 1999, PLANT J, V17, P251, DOI 10.1046/j.1365-313X.1999.00371.x; Edwards A, 1999, EUR J BIOCHEM, V266, P724, DOI 10.1046/j.1432-1327.1999.00861.x; Geigenberger P, 1997, PLANTA, V201, P502, DOI 10.1007/s004250050095; HEDLEY CL, 1986, ANN BOT-LONDON, V58, P371, DOI 10.1093/oxfordjournals.aob.a087215; HIZUKURI S, 1989, CARBOHYD RES, V189, P227, DOI 10.1016/0008-6215(89)84099-6; JENKINS JPJ, 1993, STARCH-STARKE, V45, P417; Jenkins PJ, 1995, INT J BIOL MACROMOL, V17, P315, DOI 10.1016/0141-8130(96)81838-1; Kim KN, 1998, PLANT MOL BIOL, V38, P945, DOI 10.1023/A:1006057609995; Kossmann J, 1999, PLANTA, V208, P503, DOI 10.1007/s004250050587; KUIPERS AGJ, 1994, PLANT CELL, V6, P43, DOI 10.1105/tpc.6.1.43; Li Z, 1999, THEOR APPL GENET, V98, P1208, DOI 10.1007/s001220051186; Lloyd JR, 1999, BIOCHEM J, V338, P515, DOI 10.1042/0264-6021:3380515; Lloyd JR, 1999, PLANTA, V209, P230, DOI 10.1007/s004250050627; MADDELEIN ML, 1994, J BIOL CHEM, V269, P25150; Marshall J, 1996, PLANT CELL, V8, P1121, DOI 10.1105/tpc.8.7.1121; MERLO L, 1993, J PLANT PHYSIOL, V142, P392, DOI 10.1016/S0176-1617(11)81243-5; REDDY KR, 1993, CARBOHYD POLYM, V22, P267; Shannon J., 1984, STARCH CHEM TECHNOLO, P25, DOI 10.1016/B978-0-12-746270-7.50009-4; Singletary GW, 1997, PLANT PHYSIOL, V113, P293, DOI 10.1104/pp.113.1.293; SMITH AM, 1988, PLANTA, V175, P270, DOI 10.1007/BF00392437; SMITH AM, 1990, PLANTA, V182, P599, DOI 10.1007/BF02341037; SOWOKINOS JR, 1976, PLANT PHYSIOL, V57, P63, DOI 10.1104/pp.57.1.63; Tatge H, 1999, PLANT CELL ENVIRON, V22, P543, DOI 10.1046/j.1365-3040.1999.00437.x; Tomlinson KL, 1997, PLANT J, V11, P31, DOI 10.1046/j.1365-313X.1997.11010031.x; Umemoto T, 1999, STARCH-STARKE, V51, P58, DOI [10.1002/(SICI)1521-379X(199903)51:2<58::AID-STAR58>3.0.CO;2-J, 10.1002/(SICI)1521-379X(199903)51:2&lt;58::AID-STAR58&gt;3.0.CO;2-J]; van de Wal M, 1998, J BIOL CHEM, V273, P22232, DOI 10.1074/jbc.273.35.22232; VandenKoornhuyse N, 1996, J BIOL CHEM, V271, P16281, DOI 10.1074/jbc.271.27.16281; Visser RGF, 1997, STARCH-STARKE, V49, P438, DOI 10.1002/star.19970491103; WANG YJ, 1993, CEREAL CHEM, V70, P171; YEH JY, 1981, STARKE, V33, P222, DOI 10.1002/star.19810330703	49	61	73	4	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10834	10841		10.1074/jbc.M111579200	http://dx.doi.org/10.1074/jbc.M111579200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801600	hybrid			2022-12-27	WOS:000174613100013
J	Hancock, MK; Haskins, DJ; Sun, GJ; Dahms, NM				Hancock, MK; Haskins, DJ; Sun, GJ; Dahms, NM			Identification of residues essential for carbohydrate recognition by the insulin-like growth factor II/mannose 6-phosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; LYSOSOMAL-ENZYME RECOGNITION; LEUKEMIA INHIBITORY FACTOR; TUMOR SUPPRESSOR GENE; MANNOSE 6-PHOSPHATE; LIGAND-BINDING; MANNOSE-6-PHOSPHATE RECEPTOR; FACTOR-BETA-1 PRECURSOR; MUTATIONAL ANALYSIS; MISSENSE MUTATIONS	Two distinct mannose 6-phosphate (Man-6-P) receptors (MPRs), the cation-dependent MPR (CD-MPR) and the insulin-like growth factor II/MPR (IGF-II/MPR), recognize a diverse population of Man-6-P-containing ligands. The IGF-II/MPR is a type I transmembrane glycoprotein with a large extracytoplasmic region composed of 15 repeating domains that display sequence identity to each other and to the single extracytoplasmic domain of the CD-MPR. A structure-based sequence alignment of the two distinct Man-6-P-binding sites of the IGF-II/MPR with the CD-MPR implicates several residues of IGF-II/ MPR domains 3 and 9 as essential for Man-6-P binding. To test this hypothesis single amino acid substitutions were made in constructs encoding either the N- or the C-terminal Man-6-P-binding sites of the bovine IGF-II/ MPR. The mutant IGF-II/MPRs secreted from COS-1 cells were analyzed by pentamannosyl phosphate-agarose affinity chromatography, identifying four residues (Gln-392, Ser-431, Glu-460, and Tyr-465) in domain 3 and four residues (Gln-1292, His-1329, Glu-1354, and Tyr-1360) in domain 9 as essential for Man-6-P recognition. Binding affinity studies using the lysosomal enzyme, beta-glucuronidase, confirmed these results. Together these analyses provide strong evidence that the two Man-6-P-binding sites of the IGF-II/MPR are structurally similar to each other and to the CD-MPR and utilize a similar carbohydrate recognition mechanism.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Dahms, NM (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042667, R56DK042667, R29DK042667] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42667] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABA T, 1988, CARBOHYD RES, V177, P153, DOI 10.1016/0008-6215(88)85049-3; Blanchard F, 1999, J BIOL CHEM, V274, P24685, DOI 10.1074/jbc.274.35.24685; Blanchard F, 1998, J BIOL CHEM, V273, P20886, DOI 10.1074/jbc.273.33.20886; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BRUNETTI CR, 1994, J BIOL CHEM, V269, P17067; BRUNETTI CR, 1995, J VIROL, V69, P3517, DOI 10.1128/JVI.69.6.3517-3528.1995; Brunetti CR, 1998, J VIROL, V72, P3330, DOI 10.1128/JVI.72.4.3330-3339.1998; Byrd JC, 1999, J BIOL CHEM, V274, P24408, DOI 10.1074/jbc.274.34.24408; Dahms NM, 1996, BIOCHEM SOC T, V24, P136, DOI 10.1042/bst0240136; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; deSouza AT, 1997, FASEB J, V11, P60, DOI 10.1096/fasebj.11.1.9034167; Devi GR, 1999, CANCER RES, V59, P4314; DISTLER JJ, 1991, J BIOL CHEM, V266, P21687; FAUST PL, 1987, J CELL BIOL, V105, P1947, DOI 10.1083/jcb.105.5.1947; FISCHER HD, 1980, J BIOL CHEM, V255, P5069; Godar S, 1999, EUR J IMMUNOL, V29, P1004, DOI 10.1002/(SICI)1521-4141(199903)29:03<1004::AID-IMMU1004>3.0.CO;2-Q; GRIFFITHS GM, 1993, J CELL BIOL, V120, P885, DOI 10.1083/jcb.120.4.885; Hankins GR, 1996, ONCOGENE, V12, P2003; Ikushima H, 2000, P NATL ACAD SCI USA, V97, P8439, DOI 10.1073/pnas.97.15.8439; Jackson D, 1997, ENDOCRINOLOGY, V138, P149, DOI 10.1210/en.138.1.149; Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496-375; Jirtle RL, 1999, EXP CELL RES, V248, P18, DOI 10.1006/excr.1999.4453; Kanamori S, 1998, BIOCHEM BIOPH RES CO, V251, P204, DOI 10.1006/bbrc.1998.9416; Killian JK, 2000, MOL CELL, V5, P707, DOI 10.1016/S1097-2765(00)80249-X; Killian JK, 2001, MAMM GENOME, V12, P513, DOI 10.1007/s003350020026; Kong FM, 2000, ONCOGENE, V19, P1572, DOI 10.1038/sj.onc.1203437; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOVACINA KS, 1989, BIOCHEM BIOPH RES CO, V160, P393, DOI 10.1016/0006-291X(89)91669-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LUDWIG T, 1994, GENE, V142, P311, DOI 10.1016/0378-1119(94)90282-8; MA ZM, 1991, J BIOL CHEM, V266, P10589; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MARKS DL, 1991, AM J PHYSIOL, V261, pG349, DOI 10.1152/ajpgi.1991.261.2.G349; Marron-Terada PG, 2000, BIOCHEMISTRY-US, V39, P2243, DOI 10.1021/bi992226o; Marron-Terada PG, 1998, J BIOL CHEM, V273, P22358, DOI 10.1074/jbc.273.35.22358; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; MunierLehmann H, 1996, BIOCHEM SOC T, V24, P133, DOI 10.1042/bst0240133; Oates AJ, 1998, BREAST CANCER RES TR, V47, P269, DOI 10.1023/A:1005959218524; OKA Y, 1985, J BIOL CHEM, V260, P9435; Olson LJ, 1999, J BIOL CHEM, V274, P29889, DOI 10.1074/jbc.274.42.29889; Olson LJ, 1999, J BIOL CHEM, V274, P36905, DOI 10.1074/jbc.274.52.36905; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; POHLMANN R, 1987, P NATL ACAD SCI USA, V84, P5575, DOI 10.1073/pnas.84.16.5575; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; Roberts DL, 1998, CELL, V93, P639, DOI 10.1016/S0092-8674(00)81192-7; Saris JJ, 2001, AM J PHYSIOL-HEART C, V280, pH1706, DOI 10.1152/ajpheart.2001.280.4.H1706; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMODA H, 1991, CARBOHYD RES, V213, P37, DOI 10.1016/S0008-6215(00)90596-2; TONG PY, 1988, J BIOL CHEM, V263, P2585; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; Topp KS, 1997, EXP EYE RES, V64, P343, DOI 10.1006/exer.1996.0209; van Kesteren CAM, 1997, HYPERTENSION, V30, P1389, DOI 10.1161/01.HYP.30.6.1389; Volpert O, 1996, ENDOCRINOLOGY, V137, P3871, DOI 10.1210/en.137.9.3871; WENDLAND M, 1991, J BIOL CHEM, V266, P7132; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; Yerramalla UL, 2000, COMP BIOCHEM PHYS B, V127, P433, DOI 10.1016/S0305-0491(00)00259-5; ZHOU M, 1995, P NATL ACAD SCI USA, V92, P9762, DOI 10.1073/pnas.92.21.9762	64	48	49	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11255	11264		10.1074/jbc.M109855200	http://dx.doi.org/10.1074/jbc.M109855200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11799115	hybrid			2022-12-27	WOS:000174613100065
J	Kato, K; Horiuchi, S; Takahashi, A; Ueoka, Y; Arima, T; Matsuda, T; Kato, H; Nishida, J; Nakabeppu, Y; Wake, N				Kato, K; Horiuchi, S; Takahashi, A; Ueoka, Y; Arima, T; Matsuda, T; Kato, H; Nishida, J; Nakabeppu, Y; Wake, N			Contribution of estrogen receptor alpha to oncogenic K-Ras-mediated NIH3T3 cell transformation and its implication for escape from senescence by modulating the p53 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; TRANSCRIPTIONAL ACTIVATION; P16(INK4A); MECHANISMS; INHIBITORS; P15(INK4B); LINKS; P16	We previously reported that enhanced transcriptional activation of estrogen receptor alpha (ERalpha) contributed to [(12)Val]K-Ras-mediated NIH3T3 cell transformation. Functional inactivation of ERalpha by a dominant negative mutant of ERalpha (DNER) in the presence of activated K-Ras 4B mutant arrested the cell cycle at G(0)/G(1), subsequently provoking replicative cell senescence, finally abrogating tumorigenic potential. p53-dependent upregulation of p21 was implicated in this cell senescence induction. Alterations in the MDM2 protein in response to DNER accounted for this p21-mediated cell senescence induction. An oncogenic K-Ras 413 mutant significantly increased MDM2 proteins coprecipitated with p53, and suppressed p53 transcriptional activity. In turn, DNER exerted its function to decrease MDM2 proteins coprecipitated with p53, followed by the stimulation of p53 activity in the presence of the oncogenic K-Ras 4B mutant. In addition, overexpression of wild type ERalpha in NIH3T3 cells resulted in the significant increase in the MDM2 protein level and the resultant suppression of p53 transcriptional activity. Finally, we demonstrated that c-Jun expression overcame the suppression and resultant enhancement of p21 protein level in response to DNER. The data imply that the ERalpha-AP1 pathway activated by oncogenic K-Ras 413 mutant contributes to the NIH3T3 cells' transformation by modulating p53 transcriptional activity through MDM2.	Kyushu Univ, Dept Mol Genet, Div Mol & Cell Therapeut, Med Inst Bioregulat, Beppu, Oita 8740838, Japan; Kyushu Univ, Med Inst Bioregulat, Div Neurofunct Genomics, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Kato, K (corresponding author), Kyushu Univ, Dept Mol Genet, Div Mol & Cell Therapeut, Med Inst Bioregulat, Tsurumihara 4546, Beppu, Oita 8740838, Japan.	kkatoh@tsurumi.beppu.kyushu-u.ac.jp	Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BOS JL, 1989, CANCER RES, V49, P4682; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; INCE BA, 1993, J BIOL CHEM, V268, P14026; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kato K, 1997, ONCOGENE, V15, P3037, DOI 10.1038/sj.onc.1201497; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KUMAR R, 1990, ONCOGENE, V5, P1271; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Liu GZ, 2000, CANCER RES, V60, P1810; Lloyd AC, 1998, CURR OPIN GENET DEV, V8, P43, DOI 10.1016/S0959-437X(98)80060-9; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; QUELLE DE, 1995, ONCOGENE, V11, P635; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; TSUJI Y, 1995, MOL CELL BIOL, V15, P5152; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Yu CL, 1997, BIOCHEM BIOPH RES CO, V239, P617, DOI 10.1006/bbrc.1997.7522; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	29	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11217	11224		10.1074/jbc.M107391200	http://dx.doi.org/10.1074/jbc.M107391200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11781307	hybrid			2022-12-27	WOS:000174613100060
J	Kuhn-Nentwig, L; Muller, J; Schaller, J; Walz, A; Dathe, M; Nentwig, W				Kuhn-Nentwig, L; Muller, J; Schaller, J; Walz, A; Dathe, M; Nentwig, W			Cupiennin 1, a new family of highly basic antimicrobial peptides in the venom of the spider Cupiennius salei (Ctenidae)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SECONDARY STRUCTURE; ANTIBIOTICS; PROTEINS; MELITTIN; ANTIBACTERIAL; MEMBRANES; SKIN; MICROORGANISMS; MAGAININ-2	A new family of antimicrobial peptides was isolated from the venom of Cupiennius salei. The peptides were purified to homogeneity, and the sequence of cupiennin la was determined by Edman degradation: GFGALFKFLAKKVAKTVAKQAAKQGAKYVVNKQME-NH2. The amino acid sequences of cupiennin 1b, c, and d were obtained by a combination of sequence analysis and mass spectrometric measurements of comparative tryptic peptide mapping. All peptides consist of 35 amino acid residues and are characterized by a more hydrophobic N-terminal chain region and a C terminus composed preferentially of polar and charged residues. e total charge of all cupiennins calculated under physiological conditions is +8, and their C terminus, formed by a glutamic acid residue, is amidated. Conformational studies of the peptides revealed a high helix forming potential. Antimicrobial assays on bacteria with cupiennin 1a, 1d, and synthesized cupiennins 1a* and 1d* showed minimal inhibitory concentrations for bacteria in the submicromolar range. Their lytic effect on human red blood cells was lower by a factor of 8 to 14 than the highly hemolytic melittin. Cupiennin 1a, 1b, 1d, 1a*, and 1d* showed pronounced insecticidal activity. The immediate biological effects and the structural properties of the isolated cupiennins indicate a membrane-destroying mode of action on prokaryotic as well as eukaryotic cells.	Univ Bern, Inst Zool, CH-3012 Bern, Switzerland; Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland; Univ Bern, Theodor Kocher Inst, CH-3012 Bern, Switzerland; Inst Mol Pharmacol, D-13125 Berlin, Germany	University of Bern; University of Bern; University of Bern	Kuhn-Nentwig, L (corresponding author), Univ Bern, Inst Zool, Baltzerstr 6, CH-3012 Bern, Switzerland.	lucia.kuhn@zos.unibe.ch	Nentwig, Wolfgang/A-6624-2011					ADAMS ME, 1989, J COMP PHYSIOL A, V164, P333, DOI 10.1007/BF00612993; Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; BINDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93; BOEVE JL, 1995, TOXICON, V33, P1347, DOI 10.1016/0041-0101(95)00066-U; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Cavallarin L, 1998, MOL PLANT MICROBE IN, V11, P218, DOI 10.1094/MPMI.1998.11.3.218; CHANG JY, 1991, ANAL BIOCHEM, V197, P52, DOI 10.1016/0003-2697(91)90354-V; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Conde R, 2000, FEBS LETT, V471, P165, DOI 10.1016/S0014-5793(00)01384-3; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; Dathe M, 2000, MEMBRANE STRUCTURE IN DISEASE AND DRUG THERAPY, P1; Dathe M, 1997, FEBS LETT, V403, P208, DOI 10.1016/S0014-5793(97)00055-0; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; Diaz-Achirica P, 1998, BIOCHEM J, V330, P453, DOI 10.1042/bj3300453; Dimarcq JL, 1998, BIOPOLYMERS, V47, P465, DOI 10.1002/(SICI)1097-0282(1998)47:6<465::AID-BIP5>3.0.CO;2-#; EhretSabatier L, 1996, J BIOL CHEM, V271, P29537, DOI 10.1074/jbc.271.47.29537; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; Escoubas P, 1995, TOXICON, V33, P1549, DOI 10.1016/0041-0101(95)00107-7; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Ghosh JK, 1997, J BIOL CHEM, V272, P31609, DOI 10.1074/jbc.272.50.31609; Haeberli S, 2000, TOXICON, V38, P373, DOI 10.1016/S0041-0101(99)00167-1; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; Helmerhorst EJ, 1999, FEBS LETT, V449, P105, DOI 10.1016/S0014-5793(99)00411-1; Hetru Charles, 1998, P40; Kragol G, 2001, BIOCHEMISTRY-US, V40, P3016, DOI 10.1021/bi002656a; Krishnakumari V, 1997, J PEPT RES, V50, P88; Kuhn-Nentwig L, 1998, NATURWISSENSCHAFTEN, V85, P136, DOI 10.1007/s001140050471; Kuhn-Nentwig L, 2000, ARCH INSECT BIOCHEM, V44, P101, DOI 10.1002/1520-6327(200007)44:3&lt;101::AID-ARCH1&gt;3.0.CO;2-S; KUHNNENTWIG L, 1994, TOXICON, V32, P287, DOI 10.1016/0041-0101(94)90082-5; LEHRMAN SR, 1990, BIOCHEMISTRY-US, V29, P5590, DOI 10.1021/bi00475a025; Malli H, 1999, J EXP BIOL, V202, P2083; Malli H, 1998, TOXICON, V36, P1959, DOI 10.1016/S0041-0101(98)00120-2; Matsuzaki K, 1999, FEBS LETT, V449, P221, DOI 10.1016/S0014-5793(99)00443-3; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; Oh D, 2000, BIOCHEMISTRY-US, V39, P11855, DOI 10.1021/bi000453g; Oren Z, 1997, BIOCHEMISTRY-US, V36, P1826, DOI 10.1021/bi962507l; Otvos L, 2000, BIOCHEMISTRY-US, V39, P14150, DOI 10.1021/bi0012843; Park CB, 1998, BIOCHEM BIOPH RES CO, V244, P253, DOI 10.1006/bbrc.1998.8159; PARK JM, 1994, BIOCHEM BIOPH RES CO, V205, P948, DOI 10.1006/bbrc.1994.2757; Pearson WR, 1997, GENOMICS, V46, P24, DOI 10.1006/geno.1997.4995; Rozek T, 2000, EUR J BIOCHEM, V267, P5330, DOI 10.1046/j.1432-1327.2000.01536.x; Schroder JM, 1999, BIOCHEM PHARMACOL, V57, P121, DOI 10.1016/S0006-2952(98)00226-3; Shin SY, 1998, BIOCHEM MOL BIOL INT, V44, P1119; Silva PI, 2000, J BIOL CHEM, V275, P33464, DOI 10.1074/jbc.M001491200; Simmaco M, 1998, BIOPOLYMERS, V47, P435, DOI 10.1002/(SICI)1097-0282(1998)47:6<435::AID-BIP3>3.3.CO;2-#; Torres-Larios A, 2000, EUR J BIOCHEM, V267, P5023, DOI 10.1046/j.1432-1327.2000.01556.x; VIITALA J, 1985, TRENDS BIOCHEM SCI, V10, P392, DOI 10.1016/0968-0004(85)90067-2; Vorland LH, 1999, SCAND J INFECT DIS, V31, P467; Wachinger M, 1998, J GEN VIROL, V79, P731, DOI 10.1099/0022-1317-79-4-731; Wu MH, 1999, J BIOL CHEM, V274, P29, DOI 10.1074/jbc.274.1.29; XU K, 1989, Acta Zoologica Sinica, V35, P300; Yans LZ, 1998, J BIOL CHEM, V273, P2059, DOI 10.1074/jbc.273.4.2059; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	55	82	92	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11208	11216		10.1074/jbc.M111099200	http://dx.doi.org/10.1074/jbc.M111099200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11792701	hybrid			2022-12-27	WOS:000174613100059
J	Wang, FS; Wang, CJ; Sheen-Chen, SM; Kuo, YR; Chen, RF; Yang, KD				Wang, FS; Wang, CJ; Sheen-Chen, SM; Kuo, YR; Chen, RF; Yang, KD			Superoxide mediates shock wave induction of ERK-dependent osteogenic transcription factor (CBFA1) and mesenchymal cell differentiation toward osteoprogenitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASES; MARROW STROMAL CELLS; NITRIC-OXIDE; TRANSFORMING GROWTH-FACTOR-BETA-1; HYDROGEN-PEROXIDE; PROSTAGLANDIN E-2; CARDIAC MYOCYTES; REACTIVE OXYGEN; SHEAR STRESS; PDGF-BB	Extracorporeal shock wave (ESW) is an alternative non-invasive method for the promotion of bone growth and tendon repair. In an animal model, we have reported that ESW promoted bone marrow osteoprogenitor growth through transforming growth factor-beta1 induction. We have further explored the mechanism for the ESW promotion of osteogenesis. Results showed that an optimal ESW treatment at 0.16 mJ/mm(2) for 500 impulses rapidly induced a higher O-2(-) and ONOO- production associated with a decrease of nitric oxide level in 1 h, and induced a higher transforming growth factor-beta1 production in 24 h, and a higher colony-forming units-osteoprogenitor formation in 12 days. The colony-forming units-osteoprogenitor colonies revealed positive staining of bone alkaline phosphatase and turned into bone nodules in 21 days. Early scavenging of O-2(-) but not Ca2+, H2O2 or prostaglandin E-2 suppressed osteoprogenitor cell growth and maturation. Scavenging of O-2(-) by superoxide dismutase raised the nitric oxide level back to the basal level and suppressed ESW-promoted osteoprogenitor cell growth, whereas inhibition of ONOO- by urate or NO by N-nitro-L-arginine methyl ester did not affect ESW promotion of osteogenesis, indicating that O-2(-) acted as an early signal for ESW-induced cell growth. Further studies demonstrated that ESW induced ERK activation, and blockage of O-2(-) production or inhibition of tyrosine kinase, but not protein kinase A and C inhibitors, suppressed ESW-induced ERK activation. In support that O-2(-) mediated the ESW-induced ERK activation and osteogenic differentiation, we further demonstrated that scavenging of O-2(-) by superoxide dismutase and inhibition of ERK activation by PD98059 decreased specific osteogenic transcription factor, core binding factor A1 activation, and decreased osteocalcin expression. Taken together, we showed that ESW-induced O-2(-) production followed by tyrosine kinase-mediated ERK activation and core binding factor A1 activation resulted in osteogenic cell growth and maturation. Thus, an appropriate modulation of redox reaction by ESW may have some positive effect on the bone regeneration.	Chang Gung Mem Hosp, Dept Med Res, Kaohsiung 833, Taiwan; Chang Gung Mem Hosp, Dept Orthoped Surg, Kaohsiung 833, Taiwan; Chang Gung Mem Hosp, Dept Gen Surg, Kaohsiung 833, Taiwan; Chang Gung Mem Hosp, Dept Trauma, Kaohsiung 833, Taiwan	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital	Yang, KD (corresponding author), Off Vice Superintendents, 123 Ta Pei Rd, Kaohsiung 833, Taiwan.	yangkd@adm.cgmh.org.tw	Chen, Rong-Fu/AAI-8593-2021	Chen, Rong-Fu/0000-0001-7529-5390				Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Andrades JA, 1999, EXP CELL RES, V250, P485, DOI 10.1006/excr.1999.4528; Aubin JE, 1999, J CELL BIOCHEM, V72, P396, DOI 10.1002/(SICI)1097-4644(19990301)72:3<396::AID-JCB9>3.3.CO;2-Y; Bellocq A, 1999, AM J RESP CELL MOL, V21, P128, DOI 10.1165/ajrcmb.21.1.3379; BELLOWS CG, 1987, ENDOCRINOLOGY, V121, P1985, DOI 10.1210/endo-121-6-1985; Beutler S, 1999, UNFALLCHIRURG, V102, P839, DOI 10.1007/s001130050492; Biri H, 1998, NEPHRON, V79, P181, DOI 10.1159/000045022; Cassiede P, 1996, J BONE MINER RES, V11, P1264; Chae HJ, 2000, IMMUNOPHARM IMMUNOT, V22, P317, DOI 10.3109/08923970009016423; Chaudhary LR, 1997, BIOCHEM BIOPH RES CO, V238, P134, DOI 10.1006/bbrc.1997.7256; Chiu JJ, 1999, CIRC RES, V85, P238, DOI 10.1161/01.RES.85.3.238; CHUA CC, 2000, BIOCHIM BIOPHYS ACTA, V1496, P69; Delius M, 1998, ULTRASOUND MED BIOL, V24, P1055, DOI 10.1016/S0301-5629(98)00070-2; Delius M, 1999, CANCER RES, V59, P5227; Deora AA, 2000, BIOCHEMISTRY-US, V39, P9901, DOI 10.1021/bi992954b; Durot I, 2000, FREE RADICAL BIO MED, V29, P846, DOI 10.1016/S0891-5849(00)00382-8; ENDL E, 1995, ULTRASOUND MED BIOL, V21, P569, DOI 10.1016/0301-5629(94)00133-X; GAMBIHLER S, 1990, ULTRASOUND MED BIOL, V16, P587, DOI 10.1016/0301-5629(90)90024-7; Grossman N, 1998, LASER SURG MED, V22, P212, DOI 10.1002/(SICI)1096-9101(1998)22:4<212::AID-LSM5>3.0.CO;2-S; HIKIJI H, 2000, AM J PHYSIOL, V278, pR1031; Hishikawa K, 1997, CIRC RES, V81, P797; Huber P, 1999, PHYS MED BIOL, V44, P1427, DOI 10.1088/0031-9155/44/6/301; Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645; Jan CR, 1998, NEPHRON, V78, P187, DOI 10.1159/000044909; Jope RS, 2000, ARCH BIOCHEM BIOPHYS, V376, P365, DOI 10.1006/abbi.2000.1728; KAZUO I, 1999, J TRAUMA, V47, P946; Kobayashi H, 2000, BIOCHEM BIOPH RES CO, V273, P630, DOI 10.1006/bbrc.2000.2981; Kokubu T, 1999, BIOCHEM BIOPH RES CO, V256, P284, DOI 10.1006/bbrc.1999.0318; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Lauer U, 1997, GENE THER, V4, P710, DOI 10.1038/sj.gt.3300462; LENNON DP, 1995, EXP CELL RES, V219, P211, DOI 10.1006/excr.1995.1221; Li PF, 1999, FEBS LETT, V448, P206, DOI 10.1016/S0014-5793(99)00370-1; Li PF, 1997, CIRCULATION, V96, P3602; LIGEMAN JE, 1996, NEPHRON, V16, P487; Liu P, 1999, CALCIFIED TISSUE INT, V65, P173, DOI 10.1007/s002239900678; LONG MW, 1997, J CLIN INVEST, V95, P3; Lopez-Ongil S, 2000, J BIOL CHEM, V275, P26423, DOI 10.1074/jbc.M000767200; Luo XP, 1999, FREE RADICAL BIO MED, V26, P1357, DOI 10.1016/S0891-5849(98)00334-7; Mikuni-Takagaki Y, 1999, J BONE MINER METAB, V17, P57, DOI 10.1007/s007740050065; Nieto N, 1999, HEPATOLOGY, V30, P987, DOI 10.1002/hep.510300433; ODonnell VB, 1996, BIOCHEM J, V318, P805, DOI 10.1042/bj3180805; Oyama J, 1998, J CLIN INVEST, V101, P2207, DOI 10.1172/JCI986; Reiff DA, 2001, J TRAUMA, V50, P433, DOI 10.1097/00005373-200103000-00006; Sarica K, 1996, UROL INT, V57, P221, DOI 10.1159/000282918; Satomura K, 2000, J CELL BIOCHEM, V78, P391; Sauer H, 1999, J CELL BIOCHEM, V75, P710, DOI 10.1002/(SICI)1097-4644(19991215)75:4<710::AID-JCB16>3.0.CO;2-Z; Schulz K, 1999, NITRIC OXIDE-BIOL CH, V3, P225, DOI 10.1006/niox.1999.0226; Siwik DA, 1999, CIRC RES, V85, P147, DOI 10.1161/01.RES.85.2.147; Smalt R, 1997, AM J PHYSIOL-ENDOC M, V273, pE751, DOI 10.1152/ajpendo.1997.273.4.E751; Souren JEM, 1996, BIOCHEM BIOPH RES CO, V227, P816, DOI 10.1006/bbrc.1996.1590; Sun JS, 1997, CELL MOL LIFE SCI, V53, P967, DOI 10.1007/s000180050118; Thamilselvan S, 2000, J UROLOGY, V164, P224, DOI 10.1016/S0022-5347(05)67499-X; von Eiff C, 2000, J MED MICROBIOL, V49, P709, DOI 10.1099/0022-1317-49-8-709; Vozenin-Brotons MC, 2001, FREE RADICAL BIO MED, V30, P30, DOI 10.1016/S0891-5849(00)00431-7; Wang CJ, 2001, CLIN ORTHOP RELAT R, P112; Wang CJ, 2001, CLIN ORTHOP RELAT R, P95; Wang FS, 2001, BIOCHEM BIOPH RES CO, V287, P648, DOI 10.1006/bbrc.2001.5654; WANG FS, 2002, IN PRESS J BONE JT S; Warren MC, 2000, FREE RADICAL BIO MED, V29, P537, DOI 10.1016/S0891-5849(00)00353-1; Xiao ZS, 1999, J CELL BIOCHEM, V74, P596, DOI 10.1002/(SICI)1097-4644(19990915)74:4<596::AID-JCB9>3.0.CO;2-F; Yang KD, 1998, ACTA HAEMATOL-BASEL, V99, P191, DOI 10.1159/000040838; Yang KD, 2000, PEDIATR RES, V48, P829, DOI 10.1203/00006450-200012000-00021; Yoo JU, 1998, J BONE JOINT SURG AM, V80A, P1745, DOI 10.2106/00004623-199812000-00004; Zaman G, 1997, J BONE MINER RES, V12, P769, DOI 10.1359/jbmr.1997.12.5.769; Zhong P, 1999, J ACOUST SOC AM, V105, P1997, DOI 10.1121/1.426733	65	142	158	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10931	10937		10.1074/jbc.M104587200	http://dx.doi.org/10.1074/jbc.M104587200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11784711	hybrid			2022-12-27	WOS:000174613100024
J	Chen, XY; Bonne, S; Hatzfeld, M; van Roy, F; Green, KJ				Chen, XY; Bonne, S; Hatzfeld, M; van Roy, F; Green, KJ			Protein binding and functional characterization of plakophilin 2 - Evidence for its diverse roles in desmosomes and beta-catenin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; INTERMEDIATE FILAMENTS; TRANSCRIPTIONAL ACTIVATION; STRATIFIED EPITHELIA; NUCLEAR-LOCALIZATION; MULTIGENE FAMILY; EMBRYONIC HEART; PLAQUE PROTEIN; P120 CATENIN; PLAKOGLOBIN	Plakophilins are a subfamily of p120-related arm-repeat proteins that can be found in both desmosomes and the nucleus. Among the three known plakophilin members, plakophilin I has been linked to a genetic skin disorder and shown to play important roles in desmosome assembly and organization. However, little is known about the binding partners and functions of the most widely expressed member, plakophilin 2. To better understand the cellular functions of plakophilin 2, we have examined its protein interactions with other junctional molecules using co-immunoprecipitation and yeast two-hybrid assays. Here we show that plakophilin 2 can interact directly with several desmosomal components, including desmoplakin, plakoglobin, desmoglein I and 2, and desmocollin la and 2a. The head domain of plakophilin 2 is critical for most of these interactions and is sufficient to direct plakophilin 2 to cell borders. In addition, plakophilin 2 is less efficient than plakophilin I in localizing to the nucleus and enhancing the recruitment of excess desmoplakin to cell borders in transiently transfected COS cells. Furthermore, plakophilin 2 is able to associate with beta-catenin through its head domain, and the expression of plakophilin 2 in SW480 cells up-regulates the endogenous beta-catenin/T cell factor-signaling activity. This up-regulation by plakophilin 2 is abolished by ectopic expression of E-cadherin, suggesting that these proteins compete for the same pool of signaling active beta-catenin. Our results demonstrate that plakophilin 2 interacts with a broader repertoire of desmosomal components than plakophilin 1 and provide new insight into the possible roles of plakophilin 2 in regulating the signaling activity of beta-catenin.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Dermatol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; State Univ Ghent VIB, Dept Biol Mol, Mol Cell Biol Unit, B-9000 Ghent, Belgium; Univ Halle, Mol Biol Grp Med Fac, D-06097 Halle An Der Saale, Germany	Northwestern University; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Flanders Institute for Biotechnology (VIB); Ghent University; Martin Luther University Halle Wittenberg	Green, KJ (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	kgreen@northwestern.edu	van Roy, Frans M/C-6123-2009	van Roy, Frans M/0000-0003-4358-1039	NIAMS NIH HHS [AR41836, R01 AR43380] Funding Source: Medline; NIDCR NIH HHS [P01 DE12328] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043380, R01AR041836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; ANGST BD, 1990, J CELL SCI, V97, P247; Bierkamp C, 1996, DEV BIOL, V180, P780, DOI 10.1006/dbio.1996.0346; Bonne S, 1999, J CELL SCI, V112, P2265; Bornslaeger EA, 2001, J CELL SCI, V114, P727; Bornslaeger EA, 1996, J CELL BIOL, V134, P985, DOI 10.1083/jcb.134.4.985; BUXTON RS, 1993, J CELL BIOL, V121, P481, DOI 10.1083/jcb.121.3.481; Charpentier E, 2000, J CELL BIOL, V149, P503, DOI 10.1083/jcb.149.2.503; Chitaev NA, 1996, J CELL BIOL, V133, P359, DOI 10.1083/jcb.133.2.359; Cowin P, 1996, CURR OPIN CELL BIOL, V8, P56, DOI 10.1016/S0955-0674(96)80049-4; Dierick H, 1999, CURR TOP DEV BIOL, V43, P153, DOI 10.1016/S0070-2153(08)60381-6; Garrod D, 1996, CURR OPIN CELL BIOL, V8, P670, DOI 10.1016/S0955-0674(96)80108-6; Gaudry CA, 2001, J BIOL CHEM, V276, P24871, DOI 10.1074/jbc.M102731200; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; Guger KA, 2000, DEV BIOL, V223, P441, DOI 10.1006/dbio.2000.9770; Hakimelahi S, 2000, J BIOL CHEM, V275, P10905, DOI 10.1074/jbc.275.15.10905; HATZFELD M, 1994, J CELL SCI, V107, P2259; Hatzfeld M, 2000, J CELL BIOL, V149, P209, DOI 10.1083/jcb.149.1.209; Hofmann I, 2000, J CELL SCI, V113, P2471; Ishii K, 2001, J INVEST DERMATOL, V117, P26, DOI 10.1046/j.0022-202x.2001.01400.x; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; KOCH PJ, 1994, CURR OPIN CELL BIOL, V6, P682, DOI 10.1016/0955-0674(94)90094-9; Kolligs FT, 2000, GENE DEV, V14, P1319; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kowalczyk AP, 1999, J BIOL CHEM, V274, P18145, DOI 10.1074/jbc.274.26.18145; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; Kowalczyk AP, 1998, J CELL SCI, V111, P3045; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; McGrath JA, 1997, NAT GENET, V17, P240, DOI 10.1038/ng1097-240; McKoy G, 2000, LANCET, V355, P2119, DOI 10.1016/S0140-6736(00)02379-5; Mertens C, 2001, P NATL ACAD SCI USA, V98, P7795, DOI 10.1073/pnas.141219498; Mertens C, 1996, J CELL BIOL, V135, P1009, DOI 10.1083/jcb.135.4.1009; Moll I, 1997, J INVEST DERMATOL, V108, P139, DOI 10.1111/1523-1747.ep12332388; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; Nelson RW, 1999, J CELL BIOL, V147, P367, DOI 10.1083/jcb.147.2.367; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Norvell SM, 1998, J CELL SCI, V111, P1305; Orsulic S, 1999, J CELL SCI, V112, P1237; Palka HL, 1997, J CELL SCI, V110, P2359; Ruiz P, 1996, J CELL BIOL, V135, P215, DOI 10.1083/jcb.135.1.215; Schmidt A, 1999, DIFFERENTIATION, V64, P291, DOI 10.1046/j.1432-0436.1999.6450291.x; Schmidt A, 1997, CELL TISSUE RES, V290, P481, DOI 10.1007/s004410050956; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Smith EA, 1998, J CELL BIOL, V141, P1229, DOI 10.1083/jcb.141.5.1229; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; Wahl JK, 1996, J CELL SCI, V109, P1143; WHITE FH, 1984, J CELL SCI, V66, P411; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Witcher LL, 1996, J BIOL CHEM, V271, P10904, DOI 10.1074/jbc.271.18.10904; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474; Zhurinsky J, 2000, J CELL SCI, V113, P3127	56	168	169	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10512	10522		10.1074/jbc.M108765200	http://dx.doi.org/10.1074/jbc.M108765200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11790773	hybrid			2022-12-27	WOS:000174549200120
J	Gromer, S; Gross, JH				Gromer, S; Gross, JH			Methylseleninate is a substrate rather than an inhibitor of mammalian thioredoxin reductase - Implications for the antitumor effects of selenium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-REDUCTASE; PLASMODIUM-FALCIPARUM; HUMAN PLACENTA; IN-VIVO; SELENOCYSTEINE; MECHANISM; SYSTEM; LIVER; NADPH; ACID	Biochemical and clinical evidence indicates that monomethylated selenium compounds are crucial for the tumor preventive effects of the trace element selenium and that methylselenol (CH3SeH) is a key metabolite. As suggested by Ganther (Ganther, H. E. (1999) Carcinogenesis 20, 1657-1666), methylselenol and its precursor methylseleninate might exert their effects by inhibition of the selenoenzyme thioredoxin reductase via the irreversible formation of a diselenide bridge. Here we report that methylseleninate does not act as an inhibitor of mammalian thioredoxin reductase but is in fact an excellent substrate (K-m of 18 muM, k(cat) of 23 s(-1)), which is reduced by the enzyme according to the equation 2 NADPH + 2 H+ + CH3SeO2H --> 2NADP(+) 2 H2O + CH3SeH. The selenium-containing product of this reaction was identified by mass spectrometry. Nascent methylselenol was found to efficiently reduce both H2O2 and glutathione disulfide. The implications of these findings for the antitumor activity of selenium are discussed. Methylseleninate was a poor substrate not only for human glutathione reductase but also for the non-selenium thioredoxin reductases enzymes from Drosophila melanogaster and Plasmodium falciparum. This suggests that the catalytic selenocysteine residue of mammalian thioredoxin reductase is essential for methylseleninate reduction.	Heidelberg Univ, Biochem Ctr, D-69120 Heidelberg, Germany; Heidelberg Univ, Inst Organ Chem, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Gromer, S (corresponding author), Biochemiezentrum Heidelberg, Neuenheimer Feld 328,5 OG, D-69120 Heidelberg, Germany.	Stephan.Gromer@gmx.de		Gross, Jurgen/0000-0003-0748-2535				Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, METHOD ENZYMOL, V300, P226; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; Arteel GE, 1999, CHEM RES TOXICOL, V12, P264, DOI 10.1021/tx980223r; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Besse D, 1997, ANGEW CHEM INT EDIT, V36, P883, DOI 10.1002/anie.199708831; Bhamre S, 2000, MOL CELL BIOCHEM, V211, P9, DOI 10.1023/A:1007121506445; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; Bjornstedt M, 1996, BIOCHEMISTRY-US, V35, P8511, DOI 10.1021/bi9528762; BUCHELER US, 1990, GENE, V96, P271, DOI 10.1016/0378-1119(90)90263-Q; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580; DIPLOCK AT, 1973, BIOCHEM J, V134, P283, DOI 10.1042/bj1340283; Fujiwara N, 1999, BIOCHEM J, V340, P439, DOI 10.1042/0264-6021:3400439; GANTHER HE, 1984, ANAL BIOCHEM, V138, P396, DOI 10.1016/0003-2697(84)90828-5; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; Ganther HE, 2001, J NUTR, V131, P301, DOI 10.1093/jn/131.2.301; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Gromer S, 1997, FEBS LETT, V412, P318, DOI 10.1016/S0014-5793(97)00816-8; Gromer S, 1999, REDOX REP, V4, P221, DOI 10.1179/135100099101534936; Gromer S, 1998, BIOCHEM J, V332, P591, DOI 10.1042/bj3320591; Gromer S, 2002, METHOD ENZYMOL, V347, P382; GROMER S, 1998, THESIS R KARLS U HEI, P112; Hill KE, 1997, ANAL BIOCHEM, V253, P123, DOI 10.1006/abio.1997.2373; Ip C, 2000, CANCER RES, V60, P2882; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Kanzok SM, 2000, J BIOL CHEM, V275, P40180, DOI 10.1074/jbc.M007633200; Kohrle J, 2000, BIOL CHEM, V381, P849, DOI 10.1515/BC.2000.107; LANE HW, 1983, CANCER RES, V43, P1558; MEDINA D, 1984, CANCER LETT, V24, P227, DOI 10.1016/0304-3835(84)90141-1; Medina D, 1986, Adv Exp Med Biol, V206, P465; MULLER S, 1994, BIOCHEMISTRY-US, V33, P3404, DOI 10.1021/bi00177a034; Muller S, 1996, MOL BIOCHEM PARASIT, V80, P215, DOI 10.1016/0166-6851(96)02694-1; *NAT AC SCI I MED, 2000, DIET REF INT VIT C V, V1, P284; OBLONG JE, 1993, BIOCHEMISTRY-US, V32, P7271, DOI 10.1021/bi00079a025; POWIS G, 1994, ONCOL RES, V6, P539; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Schrauzer GN, 2000, CELL MOL LIFE SCI, V57, P1864, DOI 10.1007/PL00000668; Schrauzer GN, 2000, J NUTR, V130, P1653, DOI 10.1093/jn/130.7.1653; Sinha R, 2001, BIOCHEM PHARMACOL, V61, P311, DOI 10.1016/S0006-2952(00)00545-1; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Tamura T, 1995, BIOFACTORS, V5, P99; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	44	62	64	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9701	9706		10.1074/jbc.M109234200	http://dx.doi.org/10.1074/jbc.M109234200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11782468	hybrid			2022-12-27	WOS:000174549200015
J	Hu, HM; Arcinas, M; Boxer, LM				Hu, HM; Arcinas, M; Boxer, LM			A myc-associated zinc finger protein-related factor binding site is required for the deregulation of c-myc expression by the immunoglobulin heavy chain gene enhancers in Burkitt's lymphoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; KAPPA-B; PROMOTER SHIFT; TRANSCRIPTION; ACTIVATION; ELEMENTS; CELLS; TRANSLOCATION; ALLELE; INVIVO	The deregulation of expression of the c-myc gene in Burkitt's lymphoma results from the translocation that links one c-myc allele to one of the immunoglobulin genes. This physical linkage promotes interactions between c-myc and immunoglobulin gene regulatory elements that affect c-myc transcription initiation and elongation. We have located a region in the c-myc promoter that is required for the complete activation by the immunoglobulin heavy chain gene enhancer. This regulatory element contains a core sequence, GGGAGG, similar to the GA box recognized by the transcription factor Myc-associated zinc finger protein (MAZ). UV cross-link analysis indicated that the mass of this protein did not correspond to that of MAZ, suggesting that a protein related to but distinct from MAZ bound to this site. Mutation of this regulatory element resulted in a loss of promoter activity induced by the immunoglobulin heavy chain gene enhancer. This site was also required for the c-myc promoter shift from P2 to P1. In vivo foot-printing revealed that this site was occupied on the translocated c-myc allele but not on the untranslocated allele. Taken together, these findings suggest that this regulatory element is required for the full activation of c-myc promoter activity by the immunoglobulin heavy chain gene enhancer.	Stanford Univ, Sch Med, Ctr Clin Sci Res 1155, Dept Med, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care System, Ctr Mol Biol Med, Palo Alto, CA USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Boxer, LM (corresponding author), Stanford Univ, Sch Med, Ctr Clin Sci Res 1155, Dept Med, Stanford, CA 94305 USA.				NATIONAL CANCER INSTITUTE [R01CA069322] Funding Source: NIH RePORTER; NCI NIH HHS [CA69322] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; Geltinger C, 1996, GENE EXPRESSION, V6, P113; Gerbitz A, 1999, ONCOGENE, V18, P1745, DOI 10.1038/sj.onc.1202468; JI L, 1995, J BIOL CHEM, V270, P13392, DOI 10.1074/jbc.270.22.13392; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; Kanda K, 2000, J BIOL CHEM, V275, P32338, DOI 10.1074/jbc.M004148200; KESSLER DJ, 1992, ONCOGENE, V7, P2447; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; MAJELLO B, 1995, ONCOGENE, V10, P1841; MOBERG KH, 1992, ONCOGENE, V7, P411; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; PYRE JJ, 1992, BIOCHEMISTRY-US, V31, P4102; Song J, 1998, J BIOL CHEM, V273, P20603, DOI 10.1074/jbc.273.32.20603; STROBL LJ, 1993, ONCOGENE, V8, P1437; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; TAUB R, 1984, CELL, V37, P511, DOI 10.1016/0092-8674(84)90381-7; Wittekindt NE, 2000, NUCLEIC ACIDS RES, V28, P800, DOI 10.1093/nar/28.3.800	21	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9819	9824		10.1074/jbc.M111426200	http://dx.doi.org/10.1074/jbc.M111426200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11777933	hybrid			2022-12-27	WOS:000174549200031
J	Kennett, SB; Moorefield, KS; Horowitz, JM				Kennett, SB; Moorefield, KS; Horowitz, JM			Sp3 represses gene expression via the titration of promoter-specific transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; TRANSACTIVATION DOMAIN; RETINOBLASTOMA PROTEIN; FUNCTIONAL-ANALYSIS; NEGATIVE REGULATION; SIGNALING PATHWAY; WAF1/CIP1 GENE; GC ELEMENT; RB PROTEIN; ACTIVATION	We have determined previously that Sp3 encodes three distinct gene products as follows: a full-length protein (Sp3) that is an activator of transcription and two isoforms (M1 and M2) derived via internal translational initiation that function as transcriptional repressors. To identify amino acids and functions required for transcriptional repression, we employed PCR-directed mutagenesis to create a panel of mutated M2 proteins. Biochemical and functional analyses of these mutated proteins indicate that functions encoded by the M2 carboxyl terminus, such as DNA binding activity and the capacity to form multimeric complexes, are not required or sufficient for transcriptional repression. Instead, a 93-amino acid portion of the trans-activation domain was shown to be the minimal portion of M2 required to block Sp-dependent gene expression. Transcriptional analysis of three Sp-dependent promoters showed that mutations sustained by many M2 proteins result in promoter-specific effects. Regions of M2 required for physical interactions with five TATA box-associated factors (TAF(II)s) were mapped, and mutations that disrupt the interaction of M2 with two of these proteins, TAF(II)70 and TAF(II)40, were identified. We conclude that Sp3-mediated transcriptional repression is due, at least in part, to competition for promoter-specific transcription factors.	N Carolina State Univ, Coll Vet Med, Dept Anat Physiol Sci & Radiol, Raleigh, NC 27606 USA	University of North Carolina; North Carolina State University	Horowitz, JM (corresponding author), N Carolina State Univ, Coll Vet Med, Dept Anat Physiol Sci & Radiol, 4700 Hillsborough St, Raleigh, NC 27606 USA.				NCI NIH HHS [CA53248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Chang YC, 2001, MOL CELL BIOL, V21, P1121, DOI 10.1128/MCB.21.4.1121-1131.2001; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CORNWELL MM, 1993, J BIOL CHEM, V268, P15347; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Lin MC, 1997, J CLIN INVEST, V99, P737, DOI 10.1172/JCI119219; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MILTENBERGER RJ, 1993, J BIOL CHEM, V268, P15674; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Pena P, 1999, MOL ENDOCRINOL, V13, P1402, DOI 10.1210/me.13.8.1402; PERSENGIEV SP, 1995, P NATL ACAD SCI USA, V92, P9107, DOI 10.1073/pnas.92.20.9107; PHILLIPSEN S, 1991, NUCLEIC ACIDS RES, V27, P2991; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Rojo-Niersbach E, 1999, J BIOL CHEM, V274, P33778, DOI 10.1074/jbc.274.47.33778; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Sohm F, 1999, ONCOGENE, V18, P2762, DOI 10.1038/sj.onc.1202634; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1992, CELL GROWTH DIFFER, V3, P597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; Yan GZ, 1997, J NEUROSCI, V17, P6122; Zaccolo M, 1996, J MOL BIOL, V255, P589, DOI 10.1006/jmbi.1996.0049	46	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9780	9789		10.1074/jbc.M108661200	http://dx.doi.org/10.1074/jbc.M108661200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11773047	hybrid			2022-12-27	WOS:000174549200026
J	Simpson, MA; Wilson, CM; Furcht, LT; Spicer, AP; Oegema, TR; McCarthy, JB				Simpson, MA; Wilson, CM; Furcht, LT; Spicer, AP; Oegema, TR; McCarthy, JB			Manipulation of hyaluronan synthase expression in prostate adenocarcinoma cells alters pericellular matrix retention and adhesion to bone marrow endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC PROGENITORS; ACID; RECEPTOR; SURFACE; MIGRATION; CD44; GLYCOSAMINOGLYCANS; PREREQUISITE; PROMOTES; GROWTH	Prostate cancer metastasis to bone marrow involves initial adhesion of tumor cells to the bone marrow endothelium, followed by transmigration and proliferation within the marrow. Rapid, specific adhesion of highly metastatic prostate adenocarcinoma cells (PC3M-LN4) to bone marrow endothelial cell (BMEC) lines requires a pericellular hyaluronan (HA) matrix and correlates with dramatically up-regulated RA synthase (HAS) expression. Non-metastatic prostate tumor cells (LNCaP) do not assemble a HA matrix, adhere poorly to BMECs, and express normal levels of HAS. Preferential bone metastasis of prostate carcinoma cells may therefore be facilitated by tumor cell HA biosynthesis. In this report, HAS gene expression was manipulated to investigate the direct impact of prostate tumor cell HA production on adhesion to BMECs. PC3M-LN4 cells stably transfected with antisense HAS2 and HAS3 failed to form pericellular matrices. Adhesion of these transfectants to BMECs was significantly diminished, comparable to the low level exhibited by LNCaP cells. Upon transfection with full-length HAS2 or HAS3, the non-adherent LNCaP cells retained pericellular HA and adhered to BMECs. The results of this study are consistent with a model in which HA matrix formation, BMEC adhesion, and metastatic potential are mediated by HAS expression.	Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Orthoped Surg, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA; Texas A&M Univ, Inst Biosci & Technol, College Stn, TX 77843 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Texas A&M University System; Texas A&M University College Station	McCarthy, JB (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, POB 609 UMHC,420 Delaware St S E, Minneapolis, MN 55455 USA.	mccar001@tc.umn.edu			NATIONAL CANCER INSTITUTE [R37CA021463, F32CA084619, R01CA021463] Funding Source: NIH RePORTER; NCI NIH HHS [CA21463, 1F32-CA84619-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; DEKLERK DP, 1983, PROSTATE, V4, P73, DOI 10.1002/pros.2990040107; DEKLERK DP, 1984, J UROLOGY, V131, P1008, DOI 10.1016/S0022-5347(17)50750-8; DELPECH B, 1990, INT J CANCER, V46, P388, DOI 10.1002/ijc.2910460309; Evanko SP, 1999, ARTERIOSCL THROM VAS, V19, P1004, DOI 10.1161/01.ATV.19.4.1004; Gakunga P, 1997, DEVELOPMENT, V124, P3987; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 1999, CANCER RES, V59, P2499; Jacobson A, 2000, BIOCHEM J, V348, P29, DOI 10.1042/0264-6021:3480029; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; KNUDSON CB, 1985, DEV BIOL, V112, P308, DOI 10.1016/0012-1606(85)90401-4; KOOCHEKPOUR S, 1995, INT J CANCER, V63, P450, DOI 10.1002/ijc.2910630325; Kosaki R, 1999, CANCER RES, V59, P1141; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Li Y, 2001, BRIT J CANCER, V85, P600, DOI 10.1054/bjoc.2001.1922; Liu NF, 2001, CANCER RES, V61, P5207; Lokeshwar VB, 1997, CANCER RES, V57, P773; Lokeshwar VB, 2001, J BIOL CHEM, V276, P11922, DOI 10.1074/jbc.M008432200; Lokeshwar VB, 2000, J BIOL CHEM, V275, P27641; MANLEY G, 1987, J CLIN PATHOL, V40, P626, DOI 10.1136/jcp.40.6.626; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; Nandi A, 2000, J BIOL CHEM, V275, P14939, DOI 10.1074/jbc.275.20.14939; Okada T, 1999, CLIN EXP METASTAS, V17, P623, DOI 10.1023/A:1006715504719; PAPAYANNOPOULOU T, 1995, P NATL ACAD SCI USA, V92, P9647, DOI 10.1073/pnas.92.21.9647; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; REED RK, 1988, ACTA PHYSIOL SCAND, V134, P405, DOI 10.1111/j.1748-1716.1988.tb08508.x; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; Savani RC, 2001, J BIOL CHEM, V276, P36770, DOI 10.1074/jbc.M102273200; Schweitzer KM, 1997, LAB INVEST, V76, P25; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Simpson MA, 2001, J BIOL CHEM, V276, P17949, DOI 10.1074/jbc.M010064200; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Yung S, 2000, KIDNEY INT, V58, P1953, DOI 10.1111/j.1523-1755.2000.00367.x; ZHANG LR, 1995, CANCER RES, V55, P428; Zhang W, 2000, BIOCHEM J, V349, P91, DOI 10.1042/0264-6021:3490091	39	96	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10050	10057		10.1074/jbc.M110069200	http://dx.doi.org/10.1074/jbc.M110069200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11790779	hybrid			2022-12-27	WOS:000174549200060
J	Arneric, M; Traven, A; Staresincic, L; Sopta, M				Arneric, M; Traven, A; Staresincic, L; Sopta, M			The retinoblastoma family of proteins directly represses transcription in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; GENE-PRODUCT; HISTONE DEACETYLASE; BINDING-PROTEIN; ACTIVATION DOMAIN; RB INTERACTS; E2F; COMPLEX; YEAST; PHOSPHORYLATION	The retinoblastoma family of proteins are key cell cycle regulatory molecules important for the differentiation of various mammalian cell types. The retinoblastoma protein regulates transcription of a variety of genes either by blocking the activation domain of various activators or by active repression via recruitment to appropriate promoters. We show here that the retinoblastoma family of proteins functions as direct transcriptional repressors in a heterologous yeast system when fused to the DNA binding domain of Gal4. Mapping experiments indicate that either the A or the B domain of the pocket region is sufficient for repression in vivo. As is the case in mammalian cells, a phosphorylation site mutant of the retinoblastoma protein is a stronger transcriptional repressor than the wild type protein. We show that transcriptional repression by pRb is dependent on CLN3 in vivo. Furthermore, the yeast histone deacetylase components, RPD3 and SIN3, are required for transcriptional repression.	Rudjer Boskovic Inst, Dept Mol Genet, Zagreb, Croatia	Rudjer Boskovic Institute	Sopta, M (corresponding author), Rudjer Boskovic Inst, Dept Mol Genet, Bijenicka 54, Zagreb, Croatia.		Traven, Ana/H-8174-2017	Traven, Ana/0000-0001-6252-3104				ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; Cross FR, 1997, YEAST, V13, P647, DOI 10.1002/(SICI)1097-0061(19970615)13:7<647::AID-YEA115>3.0.CO;2-#; de Jager SM, 1999, PLANT MOL BIOL, V41, P295, DOI 10.1023/A:1006398232003; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P946, DOI 10.1093/nar/22.6.946; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAMEL PA, 1992, ONCOGENE, V7, P693; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; Kennedy BK, 2001, P NATL ACAD SCI USA, V98, P8720, DOI 10.1073/pnas.151240898; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Pearson A, 1997, ONCOGENE, V15, P2643, DOI 10.1038/sj.onc.1201451; Ross JF, 2001, GENE DEV, V15, P392, DOI 10.1101/gad.858501; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Shao ZH, 1997, ONCOGENE, V15, P385, DOI 10.1038/sj.onc.1201204; Siegert JL, 1999, MOL CELL BIOL, V19, P846; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0	48	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8797	8801		10.1074/jbc.M111900200	http://dx.doi.org/10.1074/jbc.M111900200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11773081	hybrid			2022-12-27	WOS:000174400600008
J	Lai, WS; Kennington, EA; Blackshear, PJ				Lai, WS; Kennington, EA; Blackshear, PJ			Interactions of CCCH zinc finger proteins with mRNA - Non-binding tristetraprolin mutants exert an inhibitory effect on degradation of Au-rich element-containing mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; TNF-ALPHA; DEADENYLATION; GENE; FAMILY; TIS11; DESTABILIZATION; EXPRESSION; HOMOLOG; CELLS	Tristetraprolin (TTP), the prototype of a small family of CCCH tandem zinc finger (TZF) domain proteins, is a physiological stimulator of instability of the mRNAs encoding tumor necrosis factor-a and granulocyte/macrophage colony-stimulating factor in certain cell types. TTP stimulates mRNA turnover after binding to class II AU-rich elements (AREs) within the X-untranslated regions of both mRNAs. In turn, this binding is dependent upon the key CCCH residues in the TZF domain. To evaluate other primary sequence requirements for ARE binding in this novel mRNA-binding domain, we mutated many of the conserved residues within the TZF domain of human TTP and evaluated the effects of these mutations on RNA binding in a cell-free system and TTP-induced mRNA instability in cell transfection experiments. These mutations revealed a number of conserved amino acids that were required for binding and begin to define the primary protein sequence requirements for this novel mRNA-binding motif. Unexpectedly, all of the point mutations that prevented TTP binding to RNA also caused an increase in steady-state levels of ARE-containing mRNAs in cell transfection experiments. Actinomycin D experiments suggested that this effect was due to inhibition of mRNA turnover. Although expression of the mutant form of TTP could also inhibit the destruction of tumor necrosis factor-a mRNA by wild-type TTP, the primary mechanism did not involve heterodimerization with wild-type TTP because the 293 cells used in these studies express no detectable endogenous TTP. These data suggest that TTP may act, at least in part, by physically interacting with an enzyme activity or protein complex and functionally stimulating its ability to deadenylate class II ARE-containing mRNAs.	NIEHS, NIH, Off Clin Res, Res Triangle Pk, NC 27709 USA; NIEHS, NIH, Lab Signal Transduct, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University	Blackshear, PJ (corresponding author), NIEHS, NIH, Off Clin Res, POB 12233,A2-05,111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	black009@niehs.nih.gov	Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090080, ZIAES090080] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carballo E, 2001, BLOOD, V98, P2389, DOI 10.1182/blood.V98.8.2389; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; De J, 1999, GENE, V228, P133, DOI 10.1016/S0378-1119(98)00617-9; GOMPERTS M, 1990, ONCOGENE, V5, P1081; Kronnie GT, 1999, DEV GENES EVOL, V209, P443, DOI 10.1007/s004270050276; Lai WS, 2001, J BIOL CHEM, V276, P23144, DOI 10.1074/jbc.M100680200; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; LAI WS, 1995, J BIOL CHEM, V270, P25266, DOI 10.1074/jbc.270.42.25266; Lai WS, 1998, J BIOL CHEM, V273, P506, DOI 10.1074/jbc.273.1.506; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; MA QF, 1995, ONCOGENE, V10, P487; MA QF, 1994, ONCOGENE, V9, P3329; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; NIE XF, 1995, GENE, V152, P285, DOI 10.1016/0378-1119(94)00696-P; Seydoux G, 1996, NATURE, V382, P713, DOI 10.1038/382713a0; Stevens CJM, 1998, INT J DEV BIOL, V42, P181; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V19, P3454, DOI 10.1093/nar/19.12.3454; Thompson MJ, 1996, GENE, V174, P225, DOI 10.1016/0378-1119(96)00084-4; VARNUM BC, 1989, ONCOGENE, V4, P119; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611	26	122	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9606	9613		10.1074/jbc.M110395200	http://dx.doi.org/10.1074/jbc.M110395200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11782475	hybrid			2022-12-27	WOS:000174400600114
J	Nishida, M; Schey, KL; Takagahara, S; Kontani, K; Katada, T; Urano, Y; Nagano, T; Nagao, T; Kurose, H				Nishida, M; Schey, KL; Takagahara, S; Kontani, K; Katada, T; Urano, Y; Nagano, T; Nagao, T; Kurose, H			Activation mechanism of G(i) and G(o) by reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; ALPHA-SUBUNITS; O-2 SENSOR; PROTEIN; OXIDASE; OXIDATION; MODEL; H2O2	Reactive oxygen species are proposed to work as intracellular mediators. One of their target proteins is the a subunit of heterotrimeric GTP-binding proteins (Galpha(i) and Galpha(o)), leading to activation. H2O2 is one of the reactive oxygen species and activates purified Galpha(i2). However, the activation requires the presence of Fe2+ suggesting that H2O2 is converted to more reactive species such as .OH. The analysis with mass spectrometry shows that seven cysteine residues (Cys(66), Cys(112), Cys(140), cys(255), Cys(287), Cys(326), and Cys(352)) of Galpha(i2) are modified by the treatment with .OH. Among these cysteine residues, Cys(66), Cys(112), Cys(140), Cys(255), and Cys(352) are not involved in .OH-induced activation of Galpha(i2). Although the modification of Cys(287) but not Cys(326) is required for subunit dissociation, the modification of both Cys(287) and Cys(326) is necessary for the activation of Galpha(i2) as determined by pertussis toxin-catalyzed ADP-ribosylation, conformation-dependent change of trypsin digestion pattern or guanosine 5'-3-O-(thio)triphosphate binding. Wild type Gai2 but not Cys(287)- or Cys(326)-substituted mutants are activated by UV light, singlet oxygen, superoxide anion, and nitric oxide, indicating that these oxidative stresses activate Gai2 by the mechanism similar to .OH-induced activation. Because Cys(287) exists only in G(i) family, this study explains the selective activation of G(i)/G(o) by oxidative stresses.	Univ Tokyo, Pharmacol Lab, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Natl Inst Physiol Sci, Ctr Integrat Biosci, Div Mol & Cellular Physiol, Okazaki, Aichi 4448585, Japan; Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29403 USA	University of Tokyo; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Okazaki Institute for Integrative Bioscience (OIIB); Medical University of South Carolina	Kurose, H (corresponding author), Univ Tokyo, Pharmacol Lab, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-2 Hongo, Tokyo 1130033, Japan.	kurose@mol.f.u-tokyo.ac.jp	Urano, Yasuteru/H-1380-2012	Nishida, Motohiro/0000-0002-2587-5458				Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; AUBRY JM, 1989, J ORG CHEM, V54, P726, DOI 10.1021/jo00264a046; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; CIOBRA MA, 1997, P NATL ACAD SCI USA, V94, P9932; Cuzzocrea S, 2001, PHARMACOL REV, V53, P135; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Fu XW, 2000, P NATL ACAD SCI USA, V97, P4374, DOI 10.1073/pnas.97.8.4374; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hoshi T, 2001, J PHYSIOL-LONDON, V531, P1, DOI 10.1111/j.1469-7793.2001.0001j.x; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; JONES DT, 1987, J BIOL CHEM, V262, P14241; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; LIRI T, 1994, NATURE, V371, P164; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; Marin EP, 2001, J BIOL CHEM, V276, P27400, DOI 10.1074/jbc.C100198200; McIntire WE, 1998, J BIOL CHEM, V273, P33135, DOI 10.1074/jbc.273.50.33135; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; Posner BA, 1998, J BIOL CHEM, V273, P21752, DOI 10.1074/jbc.273.34.21752; Shiina T, 2000, J BIOL CHEM, V275, P29082, DOI 10.1074/jbc.M909757199; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488	36	47	48	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9036	9042		10.1074/jbc.M107392200	http://dx.doi.org/10.1074/jbc.M107392200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11781308	hybrid			2022-12-27	WOS:000174400600041
J	Ratineau, C; Petry, MW; Mutoh, H; Leiter, AB				Ratineau, C; Petry, MW; Mutoh, H; Leiter, AB			Cyclin D1 represses the basic helix-loop-helix transcription factor, BETA2/NeuroD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; CELL-CYCLE; GENE-EXPRESSION; TERMINAL DIFFERENTIATION; ENTEROENDOCRINE CELLS; KINASE-ACTIVITY; PROTEIN; P300; ACTIVATION; INHIBITION	Expression of the hormone secretin in enteroendocrine cells is restricted to the nondividing villus compartment of the intestine, implying that terminal differentiation is linked to cell cycle arrest and that differentiation is repressed in actively proliferating cells. We have shown previously that the basic helix-loop-helix protein, BETA2/NeuroD, induces cell cycle withdrawal in addition to increasing secretin gene expression. A number of transcription factors important for differentiation are repressed by D cyclins. Repression by D cyclins appears to be independent of its effects on the cell cycle. We show that cyclin D1 represses BETA2/NeuroD-dependent transcription of the secretin gene. Examination of cyclin box mutants shows that repression is unrelated to Cdk4 activation. Although cyclin D1 and BETA2 associate in vivo, they do not directly interact. Cyclin D1 may be recruited to BETA2 by binding to the C-terminal domain of the p300 coactivator, downstream from the BETA2-binding site. In the small intestine, cyclin D1 expression occurs only in the actively proliferating crypts of Lieberkuhn but not in villi. Thus repression by cyclin D I may serve to prevent secretin gene transcription from occurring in relatively immature epithelial progenitor cells.	Tufts Univ, Div Gastroenterol, New England Med Ctr, Sch Med,GRASP Digest Dis Ctr, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Leiter, AB (corresponding author), Tufts Univ, Div Gastroenterol, New England Med Ctr, Sch Med,GRASP Digest Dis Ctr, 218,750 Washington St, Boston, MA 02111 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052870, P30DK034928, R01DK043673] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30-DK34928, DK52870, DK43673] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adnane J, 1999, ONCOGENE, V18, P239, DOI 10.1038/sj.onc.1202297; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; INOKUCHI H, 1985, GASTROENTEROLOGY, V89, P1014, DOI 10.1016/0016-5085(85)90202-1; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; KATO J, 1993, GENE DEV, V7, P331; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Mutoh H, 1997, P NATL ACAD SCI USA, V94, P3560, DOI 10.1073/pnas.94.8.3560; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; SERFAS MS, 1993, AM J PHYSIOL, V265, pG506, DOI 10.1152/ajpgi.1993.265.3.G506; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	32	66	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8847	8853		10.1074/jbc.M110747200	http://dx.doi.org/10.1074/jbc.M110747200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11788592	hybrid			2022-12-27	WOS:000174400600016
J	Robert, F; Blanchette, M; Maes, O; Chabot, B; Coulombe, B				Robert, F; Blanchette, M; Maes, O; Chabot, B; Coulombe, B			A human RNA polymerase II-containing complex associated with factors necessary for spliceosome assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; C-TERMINAL DOMAIN; SPLICING FACTORS; NUCLEAR MATRIX; MAMMALIAN NUCLEI; LARGEST SUBUNIT; SITE SELECTION; TRANSCRIPTION; PROTEINS; PHOSPHORYLATION	Transcription and splicing are coordinated processes in mammalian cells. We have used affinity chromatography with immobilized transcription elongation factor SII to purify a protein complex that contains core RNA polymerase II (RNA Pol II), the general transcription initiation factors, and several splicing factors, including the U1, U2, and U4 small nuclear RNPs, the U2AF(65), and serine/arginine-rich proteins. The splicing factors and the transcription machinery co-purify through a gel filtration column and co-immunoprecipitate in experiments using an anti-U2AF(65) antibody, indicating that they are part of a unique complex. Although the RNA Pol II-containing complex does not possess splicing activity, it can complement small nuclear RN-P-inactivated extracts and can promote the formation of a pre-spliceosome complex. Because interactions between components of the splicing and transcription machineries occur in the context of a complex containing a hypophosphorylated RNA Pol II capable of initiating transcription, our results suggest that the coupling between transcription and splicing begins before transcription initiation.	Inst Rech Clin Montreal, Lab Gene Transcript, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, Sherbrooke, PQ J1H 5N4, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; University of Sherbrooke	Coulombe, B (corresponding author), Inst Rech Clin Montreal, Lab Gene Transcript, 110 Ave Pins Quest, Montreal, PQ H2W 1R7, Canada.		Robert, Francois/D-2316-2012; Chabot, Benoit/A-8943-2008	Chabot, Benoit/0000-0003-0994-0042	Canadian Institutes of Health Research [14309-2] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		BAUREN G, 1994, CELL, V76, P183, DOI 10.1016/0092-8674(94)90182-1; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; CHABOT B, 1995, NUCLEIC ACIDS RES, V23, P3206, DOI 10.1093/nar/23.16.3206; Chabot B., 1994, RNA PROCESSING PRACT, VI, P1; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; Coulombe Benoit, 1992, Gene Expression, V2, P99; Coulombre B, 1999, MICROBIOL MOL BIOL R, V63, P457, DOI 10.1128/MMBR.63.2.457-478.1999; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Douziech M, 1999, J BIOL CHEM, V274, P19868, DOI 10.1074/jbc.274.28.19868; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; FU XD, 1995, RNA, V1, P663; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; Kadener S, 2001, EMBO J, V20, P5759, DOI 10.1093/emboj/20.20.5759; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Lewis JD, 2000, SCIENCE, V288, P1385, DOI 10.1126/science.288.5470.1385; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Moore M., 1993, RNA WORLD, P303; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Pan GH, 1997, J BIOL CHEM, V272, P24563, DOI 10.1074/jbc.272.39.24563; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; Roberts GC, 1998, NUCLEIC ACIDS RES, V26, P5568, DOI 10.1093/nar/26.24.5568; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; Vincent M, 1996, NUCLEIC ACIDS RES, V24, P4649, DOI 10.1093/nar/24.23.4649; Yoshida T, 1999, FEBS LETT, V457, P251, DOI 10.1016/S0014-5793(99)01048-0; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZHANG GH, 1994, NATURE, V372, P809	44	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9302	9306		10.1074/jbc.M110516200	http://dx.doi.org/10.1074/jbc.M110516200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11773074	hybrid, Green Accepted			2022-12-27	WOS:000174400600077
J	Furman, C; Short, SM; Subramanian, RR; Zetter, BR; Roberts, TM				Furman, C; Short, SM; Subramanian, RR; Zetter, BR; Roberts, TM			DEF-1/ASAP1 is a GTPase-activating protein (GAP) for ARF1 that enhances cell motility through a GAP-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 FIBROBLASTS; ACTIN STRESS FIBERS; FOCAL ADHESIONS; BINDING-PROTEIN; ADP-RIBOSYLATION; PAXILLIN RECRUITMENT; MEMBRANE; RHO; TRANSPORT; CYTOSKELETON	DEF-1/ASAP1 is an ADP-ribosylation factor GTPase-activating protein (ARF GAP) that localizes to focal adhesions and is involved in cytoskeletal regulation. In this paper, we use a cell-based ARF GAP assay to demonstrate that DEF-1 functions as a GAP for ARF1 and not ARF6 in vivo. This degree of substrate preference was unique to DEF-1, as other ARF GAP proteins, ACAP1, ACAP2, and ARFGAP1, were able to function on both ARF1 and ARF6. Since transient overexpression of DEF-1 has been shown to interfere with focal adhesion formation and platelet-derived growth factor-induced membrane ruffling, we investigated whether NIH 3T3 cells stably expressing DEF-1 have altered cell motility. Here we report that ectopic DEF-1 enhances cell migration toward PDGF as well as IGF-1. This chemotactic effect appears to result from a general increase in cell motility, as DEF-1-expressing cells also exhibit enhanced levels of basal and chemokinetic motility. The increase in cell motility is dependent on DEF-1 GAP activity, since a DEF-1 mutant lacking the GAP domain failed to stimulate motility. This suggests that DEF-1 alters cell motility through the deactivation of ARF1. In contrast, the inhibition of cell spreading by DEF-1 was not dependent on GAP activity, indicating that spreading and motility are altered by DEF-1 through different pathways.	Harvard Univ, Sch Med, Dept Canc Biol, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Surg Res, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Roberts, TM (corresponding author), Harvard Univ, Sch Med, Dept Canc Biol, Dana Farber Canc Inst, Boston, MA 02115 USA.			Subramanian, Romesh/0000-0001-5586-9895				Andreev J, 1999, MOL CELL BIOL, V19, P2338; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; IRIT H, 1998, J BIOL CHEM, V273, P24786; Jackson TR, 2000, J CELL BIOL, V151, P627, DOI 10.1083/jcb.151.3.627; KAHN RA, 1986, J BIOL CHEM, V261, P7906; King FJ, 1999, MOL CELL BIOL, V19, P2330; Kondo A, 2000, MOL BIOL CELL, V11, P1315, DOI 10.1091/mbc.11.4.1315; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Mandiyan V, 1999, EMBO J, V18, P6890, DOI 10.1093/emboj/18.24.6890; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Randazzo P. A., 2000, SCI STKE; Randazzo PA, 2000, P NATL ACAD SCI USA, V97, P4011, DOI 10.1073/pnas.070552297; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	37	69	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7962	7969		10.1074/jbc.M109149200	http://dx.doi.org/10.1074/jbc.M109149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11773070	hybrid			2022-12-27	WOS:000174268000044
J	Bassermann, F; Jahn, T; Miething, C; Seipel, P; Bai, RY; Coutinho, S; Tybulewicz, VL; Peschel, C; Duyster, J				Bassermann, F; Jahn, T; Miething, C; Seipel, P; Bai, RY; Coutinho, S; Tybulewicz, VL; Peschel, C; Duyster, J			Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; GTP EXCHANGE FACTOR; DNA-BINDING ACTIVITY; T-CELL RECEPTOR; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; PHILADELPHIA-CHROMOSOME; HEMATOPOIETIC-CELLS; ADAPTER PROTEIN; SIGNALING PATHWAYS	Vav is a guanine nucleotide exchange factor for the Rho/Rac family predominantly expressed in hematopoietic cells and implicated in cell proliferation and cytoskeletal organization. The oncogenic tyrosine kinase Bcr-Abl has been shown to activate Rac-1, which is important for Bcr-Abl induced leukemogenesis. Previous studies by Matsuguchi et al. (Matsuguchi, T., Inhorn, R. C., Carlesso, N., Xu, G., Druker, B., and Griffin, J. D. (1995) EMBO J. 14, 257-265) describe enhanced phosphorylation of Vav in Bcr-Abl-expressing Mo7e cells yet fail to demonstrate association of the two proteins. Here, we report the identification of a direct complex between Vav and Bcr-Abl in yeast, in vitro and in vivo. Furthermore, we show tyrosine phosphorylation of Vav by Bcr-Abl. Mutational analysis revealed that the SH2 domain and the C-terminal SH3 domain as well as a tetraproline motif directly adjacent to the N-terminal SH3 domain of Vav are important for establishing this phosphotyrosine dependent interaction. Activation of Rac-1 by Bcr-Abl was abrogated by co-expression of the Vav C terminus encoding the SH3-SH2-SH3 domains as a dominant-negative construct. Bcr-Abl transduced primary bone marrow from Vav knock-out mice showed reduced proliferation in a culture cell transformation assay compared with wild-type bone marrow. These results suggest, that Bcr-Abl utilizes Vav as a guanine nucleotide exchange factor to activate Rac-1 in a process that involves a folding mechanism of the Vav C terminus. Given the importance of Rac-1 activation for Bcr-Abl-mediated leukemogenesis, this mechanism may be crucial for the molecular pathogenesis of chronic myeloid leukemia and of importance for other signal transduction pathways leading to the activation of Rac-1.	Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, D-81675 Munich, Germany; Natl Inst Med Res, London NW7 1AA, England	Technical University of Munich; University of Munich; MRC National Institute for Medical Research	Duyster, J (corresponding author), Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, Trogerstr 32, D-81675 Munich, Germany.	justus.duyster@lrz.tum.de	Miething, Cornelius/F-9498-2014	Miething, Cornelius/0000-0003-4699-3805; Tybulewicz, Victor/0000-0003-2439-0798				ADAMS JM, 1992, ONCOGENE, V7, P611; Afar DEH, 1997, IMMUNITY, V6, P773, DOI 10.1016/S1074-7613(00)80452-5; ALAI M, 1992, J BIOL CHEM, V267, P18021; Bai RY, 1998, ONCOGENE, V17, P941, DOI 10.1038/sj.onc.1202024; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Coutinho S, 2000, BLOOD, V96, P618; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Germani A, 1999, MOL CELL BIOL, V19, P3798; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jahn T, 2001, J BIOL CHEM, V276, P43419, DOI 10.1074/jbc.M107030200; KATZAV S, 1995, ONCOGENE, V11, P1079; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; ODA T, 1994, J BIOL CHEM, V269, P22925; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sattler M, 1996, ONCOGENE, V12, P839; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Shuai K, 1996, ONCOGENE, V13, P247; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12437	12445		10.1074/jbc.M112397200	http://dx.doi.org/10.1074/jbc.M112397200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11790798	hybrid			2022-12-27	WOS:000174846400110
J	Grinberg, M; Sarig, R; Zaltsman, Y; Frumkin, D; Grammatikakis, N; Reuveny, E; Gross, A				Grinberg, M; Sarig, R; Zaltsman, Y; Frumkin, D; Grammatikakis, N; Reuveny, E; Gross, A			tBID homooligomerizes in the mitochondrial membrane to induce apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CHANNEL ACTIVITY; DEATH; BAX; BCL-2; PROTEIN; BH3	Activation of the tumor necrosis factor R1/Fas receptor results in the cleavage of cytosolic BID to truncated tBID. tBID translocates to the mitochondria to induce the oligomerization of BAX or BAK, resulting in the release of cytochrome c (Cyt c). Here we demonstrate that in tumor necrosis factor alpha-activated FL5.12 cells, tBID becomes part of a 45-kDa cross-linkable mitochondrial complex that does not include BAX or BAK. Using fluorescence resonance energy transfer analysis and co-immunoprecipitation, we demonstrate that tBID-tBID interactions occur in the mitochondria of living cells. Cross-linking experiments using a tBID-GST chimera indicated that tBID forms homotrimers in the mitochondrial membrane. To test the functional consequence of tBID oligomerization, we expressed a chimeric FKBP-tBID molecule. Enforced dimerization of FKBP-tBID by the bivalent ligand FK1012 resulted in Cyt c, release, caspase activation, and apoptosis. Surprisingly, enforced dimerization of tBID did not result in the dimerization of either BAX or BAK. Moreover, a tBID BH3 mutant (G94E), which does not interact with or induce the dimerization of either BAX or BAK, formed the 45kDa complex and induced both Cyt c release and apoptosis. Thus, tBID oligomerization may represent an alternative mechanism for inducing mitochondrial dysfunction and apoptosis.	Weizmann Inst Sci, Dept Biol Regulat, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Queens Univ, Dept Microbiol & Immunol, Kingston, ON K7L 3N6, Canada	Weizmann Institute of Science; Weizmann Institute of Science; Queens University - Canada	Gross, A (corresponding author), Weizmann Inst Sci, Dept Biol Regulat, IL-76100 Rehovot, Israel.	atan.gross@weizmann.ac.il	Gross, Atan/ABC-2640-2020					Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	24	133	136	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12237	12245		10.1074/jbc.M104893200	http://dx.doi.org/10.1074/jbc.M104893200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805084	hybrid			2022-12-27	WOS:000174846400083
J	Xie, Y; Chen, CM; Stevenson, MA; Auron, PE; Calderwood, SK				Xie, Y; Chen, CM; Stevenson, MA; Auron, PE; Calderwood, SK			Heat shock factor 1 represses transcription of IL-1 beta gene through physical interaction with the nuclear factor of interleukin 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; PROINTERLEUKIN 1-BETA GENE; TISSUE-SPECIFIC EXPRESSION; COLONY-STIMULATING FACTOR; C/EBP-RELATED PROTEINS; DNA-BINDING ABILITY; HUMAN-MONOCYTES; ANTIINFLAMMATORY DRUGS; CYTOKINE PRODUCTION	Heat shock factor (HSF) 1 is the major heat shock transcription factor that regulates stress-inducible synthesis of heat shock proteins and is also essential in protection against endotoxic shock. Following our previous study, which demonstrated the transcriptional repression of the IL-1beta gene by HSF1 (Cahill, C. M., Waterman, W. R., Xie, Y., Auron, P. E., and Calderwood, S. K. (1996) J. Biol. Chem. 271, 24874-24879), we have examined the mechanisms of transcriptional repression. Our studies show that HSF1 represses the lipopolyliposaccharide-induced transcription of the IL-1beta promoter through direct interaction with the nuclear factor of interleukin 6 (NF-IL6, also known as CCAAT enhancer binding protein (C/EBP(beta), an essential regulator in IL-1beta transcription. We show for the first time that HSF1 binds directly to NF-IL6 in vivo and antagonizes its activity. The HSF1/NF-IL6 interaction involves a sequence of HSF1 containing the trimerization and regulatory domains and the bZip region of NF-IL6. HSF1 has little effect on IL-1beta promoter activity stimulated by the essential monocytic transcription factor Spi.1 but is strongly inhibitory to transcriptional activation by NF-IL6 and to the synergistic activation by NF-IL6 and Spi.1. Because of its ability to bind to specific C/EBP elements in the promoters of multiple genes and its ability to interact with other transcription factors, NF-IL6 is involved in transcriptional regulation of a wide range of genes. Interaction between HSF1 and NF-IL6 could thus be an important mechanism in HSF1 regulation of general gene transcription during endotoxin stress.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiat Oncol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med,Mol & Cell Biol Lab, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Calderwood, SK (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	stuart_calderwood@dfci.harvard.edu			NCI NIH HHS [CA31303, CA47407, CA50642, CA68544] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050642, R01CA047407, P01CA031303, R01CA068544] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; AURON PE, 1994, EUR CYTOKINE NETW, V5, P573; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Brown IR, 1996, J NEUROSCI RES, V44, P52, DOI 10.1002/(SICI)1097-4547(19960401)44:1<52::AID-JNR7>3.0.CO;2-H; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; DINARELLO CA, 1986, CANCER RES, V46, P6236; Farkas T, 1998, MOL CELL BIOL, V18, P906, DOI 10.1128/MCB.18.2.906; FENTON MJ, 1988, J IMMUNOL, V140, P2267; FENTON MJ, 1987, J IMMUNOL, V138, P3972; FINCATO G, 1991, BLOOD, V77, P579; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; Gewert K, 1999, CELL SIGNAL, V11, P665, DOI 10.1016/S0898-6568(99)00014-5; He HY, 2000, CELL STRESS CHAPERON, V5, P406, DOI 10.1379/1466-1268(2000)005<0406:HAHSFC>2.0.CO;2; Housby JN, 1999, CYTOKINE, V11, P347, DOI 10.1006/cyto.1998.0437; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; KAPPEL M, 1991, IMMUNOLOGY, V73, P304; Kluger MJ, 1996, INFECT DIS CLIN N AM, V10, P1, DOI 10.1016/S0891-5520(05)70282-8; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; McKnight SL, 1992, TRANSCRIPTIONAL REGU, P771; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Mink S, 1996, MOL CELL BIOL, V16, P1316; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; NATSUKA S, 1992, BLOOD, V79, P460; PAHL HL, 1993, J BIOL CHEM, V268, P5014; POLLA BS, 1987, AM J PHYSIOL, V252, pC640, DOI 10.1152/ajpcell.1987.252.6.C640; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SARIBAN E, 1988, J CLIN INVEST, V81, P1506, DOI 10.1172/JCI113482; SCHMIDT JA, 1988, J IMMUNOL, V141, P2027; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Singh IS, 2000, J BIOL CHEM, V275, P9841, DOI 10.1074/jbc.275.13.9841; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soncin F, 1996, BIOCHEM BIOPH RES CO, V229, P479, DOI 10.1006/bbrc.1996.1829; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Stevenson MA, 1999, J IMMUNOL, V163, P5608; Swolin-Eide D, 1998, J ENDOCRINOL, V156, P107, DOI 10.1677/joe.0.1560107; Tang D, 2001, BIOCHEM BIOPH RES CO, V280, P280, DOI 10.1006/bbrc.2000.4118; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Teshima S, 1996, BIOCHEM J, V315, P497, DOI 10.1042/bj3150497; THOMASSIN H, 1992, NUCLEIC ACIDS RES, V20, P3091, DOI 10.1093/nar/20.12.3091; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; VELASCO S, 1991, J CLIN INVEST, V87, P1674, DOI 10.1172/JCI115184; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200; Yiangou M, 1998, BBA-GENE STRUCT EXPR, V1396, P191, DOI 10.1016/S0167-4781(97)00188-7; YOST HJ, 1986, CELL, V45, P185, DOI 10.1016/0092-8674(86)90382-X; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; [No title captured]	71	128	142	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11802	11810		10.1074/jbc.M109296200	http://dx.doi.org/10.1074/jbc.M109296200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11801594	hybrid			2022-12-27	WOS:000174846400027
J	Faber, KN; Haan, GJ; Baerends, RJS; Kram, AM; Veenhuis, M				Faber, KN; Haan, GJ; Baerends, RJS; Kram, AM; Veenhuis, M			Normal peroxisome development from vesicles induced by truncated Hansenula polymorpha Pex3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROXYACETONE SYNTHASE; SELECTIVE INACTIVATION; ENDOPLASMIC-RETICULUM; DEFICIENT MUTANTS; TARGETING SIGNAL; PICHIA-PASTORIS; ALCOHOL OXIDASE; N-TERMINUS; BIOGENESIS; MEMBRANE	We show that the synthesis of the N-terminal 50 amino acids of Pex3p (Pex3p(1-50)) in Hansenula polymorpha pex3 cells is associated with the formation of vesicular membrane structures. Biochemical and ultrastructural findings suggest that the nuclear membrane is the donor membrane compartment of these vesicles. These structures also contain Pex14p and can develop into functional peroxisomes after subsequent reintroduction of the full-length Pex3p protein. We discuss the significance of this finding in relation to peroxisome reintroduction, e.g. in case peroxisomes are lost due to failure in inheritance.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, GBB, NL-9750 AA Haren, Netherlands	University of Groningen	Veenhuis, M (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, GBB, Postbus 14, NL-9750 AA Haren, Netherlands.							Baerends RJS, 2000, J BIOL CHEM, V275, P9986, DOI 10.1074/jbc.275.14.9986; Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; BENDAYAN M, 1982, J HISTOCHEM CYTOCHEM, V30, P81, DOI 10.1177/30.1.6172469; BRAVERMAN N, 1995, HUM MOL GENET, V4, P1791, DOI 10.1093/hmg/4.suppl_1.1791; DOUMA AC, 1985, ARCH MICROBIOL, V143, P237, DOI 10.1007/BF00411242; DOUMA AC, 1987, ARCH MICROBIOL, V147, P42, DOI 10.1007/BF00492903; Elgersma Y, 1998, J CELL BIOL, V140, P807, DOI 10.1083/jcb.140.4.807; Erdmann R, 1997, TRENDS CELL BIOL, V7, P400, DOI 10.1016/S0962-8924(97)01126-4; Faber KN, 1998, MOL CELL BIOL, V18, P936, DOI 10.1128/MCB.18.2.936; FABER KN, 1995, FEBS LETT, V357, P115, DOI 10.1016/0014-5793(94)01317-T; FABER KN, 1994, CURR GENET, V25, P305, DOI 10.1007/BF00351482; FABER KN, 1994, P NATL ACAD SCI USA, V91, P12985, DOI 10.1073/pnas.91.26.12985; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; GLEESON MA, 1988, YEAST, V4, P293, DOI 10.1002/yea.320040407; Gotte K, 1998, MOL CELL BIOL, V18, P616; Hettema EH, 1999, BBA-MOL CELL RES, V1451, P17, DOI 10.1016/S0167-4889(99)00087-7; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; Kiel JAKW, 1995, FEBS LETT, V377, P434, DOI 10.1016/0014-5793(95)01385-7; Kunau WH, 1998, CURR OPIN MICROBIOL, V1, P232, DOI 10.1016/S1369-5274(98)80016-7; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Mullen RT, 1999, PLANT CELL, V11, P2167, DOI 10.1105/tpc.11.11.2167; Salomons FA, 2000, J BIOL CHEM, V275, P12603, DOI 10.1074/jbc.275.17.12603; Sambrook J., 2002, MOL CLONING LAB MANU; South ST, 2000, J CELL BIOL, V149, P1345, DOI 10.1083/jcb.149.7.1345; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Titorenko VI, 2000, J CELL BIOL, V148, P29, DOI 10.1083/jcb.148.1.29; Titorenko VI, 1998, TRENDS BIOCHEM SCI, V23, P231, DOI 10.1016/S0968-0004(98)01226-2; Titorenko VI, 2001, TRENDS CELL BIOL, V11, P22, DOI 10.1016/S0962-8924(00)01865-1; van der Klei IJ, 1998, EMBO J, V17, P3608, DOI 10.1093/emboj/17.13.3608; VANDERKLEI IJ, 1991, YEAST, V7, P813, DOI 10.1002/yea.320070806; VANDIJKEN JP, 1976, ARCH MICROBIOL, V111, P137; Veenhuis M, 1996, FEBS LETT, V383, P114, DOI 10.1016/0014-5793(96)00220-7; VEENHUIS M, 1983, ARCH MICROBIOL, V134, P193, DOI 10.1007/BF00407757; VEENHUIS M, 1992, CELL BIOCHEM FUNCT, V10, P175, DOI 10.1002/cbf.290100307; Wanders RJA, 1999, NEUROCHEM RES, V24, P565, DOI 10.1023/A:1022592014988; WATERHAM HR, 1993, EMBO J, V12, P4785, DOI 10.1002/j.1460-2075.1993.tb06167.x; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973	44	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11026	11033		10.1074/jbc.M112347200	http://dx.doi.org/10.1074/jbc.M112347200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11790797	Green Published, hybrid			2022-12-27	WOS:000174613100036
J	Geijtenbeek, TBH; van Duijnhoven, GCF; van Vliet, SJ; Krieger, E; Vriend, G; Figdor, CG; van Kooyk, Y				Geijtenbeek, TBH; van Duijnhoven, GCF; van Vliet, SJ; Krieger, E; Vriend, G; Figdor, CG; van Kooyk, Y			Identification of different binding sites in the dendritic cell-specific receptor DC-SIGN for intercellular adhesion molecule 3 and HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HAMSTER OVARY CELLS; ENVELOPE GLYCOPROTEIN; T-CELLS; PROTEIN; GP120; REPLICATION; RECOGNITION; INFECTION; LECTIN	The novel dendritic cell (DC)-specific human immunodeficiency virus type 1 (HIV-1) receptor DC-SIGN plays a key role in the dissemination of HIV-1 by DC. DC-SIGN is thought to capture HIV-1 at mucosal sites of entry, facilitating transport to lymphoid tissues, where DC-SIGN efficiently transmits HIV-1 to T cells. DC-SIGN is also important in the initiation of immune responses by regulating DC-T cell interactions through intercellular adhesion molecule 3 (ICAM-3). We have characterized the mechanism of ligand binding by DC-SIGN and identified the crucial amino acids involved in this process. Strikingly, the HIV-1 gp120 binding site in DC-SIGN is different from that of ICAM-3, consistent with the observation that glycosylation of gp120, in contrast to ICAM-3, is not crucial to the interaction with DC-SIGN. A specific mutation in DC-SIGN abrogated ICAM-3 binding, whereas the HIV-1 gp120 interaction was unaffected. This DC-SIGN mutant captured HIV-1 and infected T cells in trans as efficiently as wild-type DC-SIGN, demonstrating that ICAM-3 binding is not necessary for HIV-1 transmission. This study provides a basis for the design of drugs that inhibit or alter interactions of DC-SIGN with gp120 but not with ICAM-3 or vice versa and that have a therapeutic value in immunological diseases and/or HIV-1 infections.	Vrije Univ Amsterdam, Ctr Med, Dept Mol Cell Biol, NL-1081 BT Amsterdam, Netherlands; Univ Nijmegen, Med Ctr, Dept Tumor Immunol, NL-6525 GA Nijmegen, Netherlands; Univ Nijmegen, Med Ctr, Ctr Mol & Biomol Informat, NL-6525 GA Nijmegen, Netherlands	Vrije Universiteit Amsterdam; Radboud University Nijmegen; Radboud University Nijmegen	Geijtenbeek, TBH (corresponding author), Vrije Univ Amsterdam, Ctr Med, Dept Mol Cell Biol, Vd Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.		Figdor, Carl G/A-4232-2010; Geijtenbeek, Teunis/C-2229-2009; Van Vliet, Sandra/AAO-9534-2020; Vriend, G./H-8112-2014; Vriend, Gert/D-6730-2011	Figdor, Carl G/0000-0002-2366-9212; van Vliet, Sandra/0000-0003-1811-2687; Van Kooyk, Yvette/0000-0001-5997-3665				Astoul CH, 2000, BIOCHEM BIOPH RES CO, V274, P455, DOI 10.1006/bbrc.2000.3166; Baribaud FD, 2001, J VIROL, V75, P10281, DOI 10.1128/JVI.75.21.10281-10289.2001; Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671; BERNSTEIN HB, 1994, J VIROL, V68, P463, DOI 10.1128/JVI.68.1.463-468.1994; Cameron P, 1996, J LEUKOCYTE BIOL, V59, P158, DOI 10.1002/jlb.59.2.158; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; Caminschi I, 2001, MOL IMMUNOL, V38, P365, DOI 10.1016/S0161-5890(01)00067-0; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Funatsu O, 2001, EUR J BIOCHEM, V268, P1020, DOI 10.1046/j.1432-1327.2001.01960.x; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Goldstein H, 2000, J INFECT DIS, V181, P921, DOI 10.1086/315351; Granelli-Piperno A, 1999, CURR BIOL, V9, P21, DOI 10.1016/S0960-9822(99)80043-8; HAIGWOOD NL, 1990, AIDS RES HUM RETROV, V6, P855, DOI 10.1089/aid.1990.6.855; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; LOBST ST, 1994, J BIOL CHEM, V269, P15505; Meier M, 2000, J MOL BIOL, V300, P857, DOI 10.1006/jmbi.2000.3853; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; MIZUOCHI T, 1988, BIOCHEM J, V254, P599, DOI 10.1042/bj2540599; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Park CG, 2001, INT IMMUNOL, V13, P1283, DOI 10.1093/intimm/13.10.1283; Pohlmann S, 2001, J VIROL, V75, P4664, DOI 10.1128/JVI.75.10.4664-4672.2001; Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398; Saifuddin M, 2000, J GEN VIROL, V81, P949, DOI 10.1099/0022-1317-81-4-949; Soilleux EJ, 2000, J IMMUNOL, V165, P2937, DOI 10.4049/jimmunol.165.6.2937; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; VRIEND G, 1993, J COMPUT AID MOL DES, V7, P367, DOI 10.1007/BF02337558; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEISSMAN D, 1995, P NATL ACAD SCI USA, V92, P826, DOI 10.1073/pnas.92.3.826	34	146	161	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11314	11320		10.1074/jbc.M111532200	http://dx.doi.org/10.1074/jbc.M111532200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11799126	Green Published, hybrid			2022-12-27	WOS:000174613100072
J	Novac, O; Alvarez, D; Pearson, CE; Price, GB; Zannis-Hadjopoulos, M				Novac, O; Alvarez, D; Pearson, CE; Price, GB; Zannis-Hadjopoulos, M			The human cruciform-binding protein, CBP, is involved in DNA replication and associates in vivo with mammalian replication origins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SIGNALING PATHWAYS; FORMALDEHYDE CROSS-LINKING; ENRICHED ORS FRAGMENTS; MONKEY DNA; NUCLEAR MATRIX; AUTONOMOUS REPLICATION; DELETION ANALYSIS; INVERTED REPEATS; RAF-1 KINASE; CELL-CYCLE	We previously identified and purified from human (HeLa) cells a 66-kDa cruciform-binding protein, CBP,,with binding specificity for cruciform DNA regardless of its sequence. DNA cruciforms have been implicated in the regulation of initiation of DNA replication. CBP is a member of the 14-3-3 family of proteins, which are conserved regulatory molecules expressed in all eukaryotes. Here, the in vivo association of CBP/14-3-3 with mammalian origins of DNA replication was analyzed by studying its association with the monkey replication origins ors8 and ors12, as assayed by a chromatin immunoprecipitation assay and quantitative PCR analysis. The association of the 14-3-3beta, -epsilon, -gamma, and -xi isoforms with these origins was found to be similar to9-fold higher, compared with other portions of the genome, in logarithmically growing cells. In addition, the association of these isoforms with ors8 and ors12 was also analyzed as a function of the cell cycle. Higher binding of 14-3-3beta, -epsilon, -gamma, and -delta isoforms with ors8 and ors12 was found at the G(1)/S border, by comparison with other stages of the cell cycle. The CBP/14-3-3 cruciform. binding activity was also found to be maximal at the G(1)/S boundary. The involvement of 14-3-3 in mammalian DNA replication was analyzed by studying the effect of anti14-3-3beta, -epsilon, -gamma, and -xi antibodies in the in vitro replication of p186, a plasmid containing the minimal replication origin of ors8. Anti-14-3-3epsilon, -gamma, and -xi antibodies alone or in combination inhibited p186 replication by similar to50-80%, while anti-14-3-3beta antibodies had a lesser effect (similar to25-50%). All of the antibodies tested were also able to interfere with CBP binding to cruciform DNA. The results indicate that CBP/14-3-3 is an origin-binding protein, acting at the initiation step of DNA replication by binding to cruciform-containing molecules, and dissociates after origin firing.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Toronto, Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada	McGill University; McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Zannis-Hadjopoulos, M (corresponding author), McGill Univ, McGill Canc Ctr, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	mzannis@med.mcgill.ca		Pearson, Christopher/0000-0001-9545-4205				Abarca D, 1999, FEBS LETT, V462, P377, DOI 10.1016/S0014-5793(99)01560-4; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P23, DOI 10.1002/jcb.240520105; DAYN A, 1992, NUCLEIC ACIDS RES, V20, P5991, DOI 10.1093/nar/20.22.5991; DIJKWEL PA, 1992, MOL CELL BIOL, V12, P3715, DOI 10.1128/MCB.12.9.3715; DOTT PJ, 1976, BIOCHEMISTRY-US, V15, P4120, DOI 10.1021/bi00663a032; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; FRAPPIER L, 1987, P NATL ACAD SCI USA, V84, P6668, DOI 10.1073/pnas.84.19.6668; FRIED M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P143, DOI 10.1016/0167-4781(91)90095-4; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; Gohring F, 1997, BIOCHEMISTRY-US, V36, P8276, DOI 10.1021/bi970480f; HAND R, 1978, CELL, V15, P317, DOI 10.1016/0092-8674(78)90001-6; Hecht A, 1999, METHOD ENZYMOL, V304, P399; Homesley L, 2000, GENE DEV, V14, P913; JACKSON V, 1978, CELL, V15, P945, DOI 10.1016/0092-8674(78)90278-7; Jackson V, 1999, METHODS, V17, P125, DOI 10.1006/meth.1998.0724; KAUFMANN G, 1985, MOL CELL BIOL, V5, P721, DOI 10.1128/MCB.5.4.721; Kriesel JD, 1997, J NEUROVIROL, V3, P441, DOI 10.3109/13550289709031190; LANDRY S, 1991, BIOCHIM BIOPHYS ACTA, V1088, P234, DOI 10.1016/0167-4781(91)90059-U; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Lipps G, 2001, NUCLEIC ACIDS RES, V29, P904, DOI 10.1093/nar/29.4.904; Lobachev KS, 1998, GENETICS, V148, P1507; MAH DCW, 1993, J CELL SCI, V105, P807; Matsunaga S, 2000, IMMUNOL LETT, V75, P47, DOI 10.1016/S0165-2478(00)00273-X; MCMURRAY CT, 1991, P NATL ACAD SCI USA, V88, P666, DOI 10.1073/pnas.88.2.666; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Nickerson JA, 1997, P NATL ACAD SCI USA, V94, P4446, DOI 10.1073/pnas.94.9.4446; NOIROT P, 1990, P NATL ACAD SCI USA, V87, P8560, DOI 10.1073/pnas.87.21.8560; Novac O, 2001, MOL BIOL CELL, V12, P3386, DOI 10.1091/mbc.12.11.3386; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PANAYOTATOS N, 1987, J BIOL CHEM, V262, P11364; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; Pearson CE, 1996, J CELL BIOCHEM, V63, P1; PEARSON CE, 1991, BIOCHIM BIOPHYS ACTA, V1090, P156, DOI 10.1016/0167-4781(91)90096-5; PEARSON CE, 1995, EMBO J, V14, P1571, DOI 10.1002/j.1460-2075.1995.tb07143.x; PEARSON CE, 1994, BIOCHEMISTRY-US, V33, P14185, DOI 10.1021/bi00251a030; Pelletier R, 1999, J CELL BIOCHEM, V74, P562, DOI 10.1002/(SICI)1097-4644(19990915)74:4<562::AID-JCB6>3.3.CO;2-U; Pelletier R, 1997, J CELL BIOCHEM, V66, P87; Pfitzner T, 2000, LEUKEMIA, V14, P754, DOI 10.1038/sj.leu.2401706; RAO BS, 1990, GENE, V87, P233; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Ritzi M, 1998, J BIOL CHEM, V273, P24543, DOI 10.1074/jbc.273.38.24543; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; Rosenquist M, 2000, J MOL EVOL, V51, P446, DOI 10.1007/s002390010107; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SOLOMON MJ, 1985, P NATL ACAD SCI USA, V82, P6470, DOI 10.1073/pnas.82.19.6470; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; SPIRO C, 1993, P NATL ACAD SCI USA, V90, P4606, DOI 10.1073/pnas.90.10.4606; STEPHENS RE, 1977, J BIOL CHEM, V252, P166; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Todd A, 1998, BIOCHEMISTRY-US, V37, P14317, DOI 10.1021/bi980768k; TODD A, 1995, J CELL BIOCHEM, V57, P280, DOI 10.1002/jcb.240570212; Treuner K, 1998, J BIOL CHEM, V273, P31744, DOI 10.1074/jbc.273.48.31744; Viswanathan M, 2000, J MOL BIOL, V302, P553, DOI 10.1006/jmbi.2000.4088; Wadkins RM, 2000, CURR MED CHEM, V7, P1; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; WARD GK, 1991, EXP CELL RES, V195, P92, DOI 10.1016/0014-4827(91)90503-M; WARD GK, 1990, EXP CELL RES, V188, P235, DOI 10.1016/0014-4827(90)90165-7; Williamson DH, 2001, J MOL BIOL, V306, P159, DOI 10.1006/jmbi.2000.4385; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zannis-Hadjopoulos M, 1998, CRIT REV EUKAR GENE, V8, P81, DOI 10.1615/CritRevEukarGeneExpr.v8.i1.40; Zannis-Hadjopoulos M, 1999, J CELL BIOCHEM, P1; ZANNISHADJOPOUL.M, 1992, DNA REPLICATION REGU, P107; ZANNISHADJOPOULOS M, 1984, J MOL BIOL, V179, P577, DOI 10.1016/0022-2836(84)90156-6; ZANNISHADJOPOULOS M, 1988, EMBO J, V7, P1837, DOI 10.1002/j.1460-2075.1988.tb03016.x; ZANNNISHADJOPOULOS M, 1985, MOL CELL BIOL, V5, P1621, DOI 10.1128/MCB.5.7.1621; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717; ZHENG GX, 1991, J MOL BIOL, V221, P107, DOI 10.1016/0022-2836(91)80208-C	75	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11174	11183		10.1074/jbc.M107902200	http://dx.doi.org/10.1074/jbc.M107902200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11805087	hybrid			2022-12-27	WOS:000174613100055
J	Barsotti, C; Tozzi, MG; Ipata, PL				Barsotti, C; Tozzi, MG; Ipata, PL			Purine and pyrimidine salvage in whole rat brain - Utilization of ATP-derived ribose-1-phosphate and 5-phosphoribosyl-1-pyrophosphate generated in experiments with dialyzed cell-free extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT FOREBRAIN ISCHEMIA; ENERGY-STATE; RIBOSE 1-PHOSPHATE; FOCAL ISCHEMIA; URACIL SALVAGE; 5'-NUCLEOTIDASE; METABOLISM; INHIBITION; PHOSPHORIBOSYLPYROPHOSPHATE; 5-FLUOROURACIL	The object of this work stems from our previous studies on the mechanisms responsible of ribose-1-phosphate- and 5-phosphoribosyl-1-pyrophosphate-mediated nucleobase salvage and 5-fluorouracil activation in rat brain (Mascia, L., Cappiello M., Cherri, S., and Ipata, P. L. (2000) Biochim. Biophys. Acta 1474, 70-74; Mascia, L., Cotrufo, T., Cappiello, M., and Ipata, P. L. (1999) Biochim. Biophys. Acta 1472, 93-98). Here we show that when ATP at "physiological concentration" is added to dialyzed extracts of rat brain in the presence of natural nucleobases or 5-fluorouracil, adenine-, hypoxanthine-, guanine-, uracil-, and 5-fluorouracil-ribonucleotides are synthesized. The molecular mechanism of this peculiar nueleotide synthesis relies on the capacity of rat brain to salvage purine and pyrimidine bases by deriving ribose-1-phosphate and 5-phosphoribosyl-1-pyrophosphate from ATP even in the absence of added pentose or pentose phosphates. The levels of the two sugar phosphates formed are compatible with those of synthesized nucleotides. We propose that the ATP-mediated 5-phosphoribosyl-1-pyrophosphate synthesis occurs through the action of purine nucleoside phosphorylase, phosphopentomutase, and 5-phosphoribosyl-1-pyrophosphate synthetase. Furthering our previous observations on the effect of ATP in the 5-phosphoribosyl-1-pyrophosphate-mediated 5-fluorouracil activation in rat liver (Mascia, L., and Ipata, P. L. (2001) Biochem. Pharmacol. 62, 213-218), we now show that the ratio [5-phosphoribosyl-1-pyrophosphate]/[ATP] plays a major role in modulating adenine salvage in rat brain. On the basis of our in vitro results, we suggest that massive ATP degradation, as it occurs in brain during ischemia, might lead to an increase of the intracellular 5-phosphoribosyl-1-pyrophosphate and ribose-1-phosphate pools, to be utilized for nucleotide resynthesis during reperfusion.	Univ Pisa, Dept Physiol & Biochem, I-56126 Pisa, Italy; Univ Sassari, Dept Drug Sci, I-07100 Sassari, Italy	University of Pisa; University of Sassari	Ipata, PL (corresponding author), Univ Pisa, Dept Physiol & Biochem, Via Santa Maria 55, I-56126 Pisa, Italy.		Tozzi, Maria Grazia/A-6018-2016	Tozzi, Maria Grazia/0000-0002-1075-7096				ALLSOP J, 1984, ADV EXP MED BIOL, V165, P21; Barsotti C, 2002, BIOCHEM PHARMACOL, V63, P117, DOI 10.1016/S0006-2952(01)00845-0; BECKER MA, 1986, BIOCHIM BIOPHYS ACTA, V882, P168, DOI 10.1016/0304-4165(86)90151-0; BETZ RE, 1985, CANC LETT, V28, P263; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPPIELLO M, 1998, BIOCHIM BIOPHYS ACTA, V1421, P273; CRUMRINE RC, 1991, J CEREBR BLOOD F MET, V11, P272, DOI 10.1038/jcbfm.1991.59; FLAKS JG, 1963, METHOD ENZYMOL, V6, P144; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; Giorgelli F, 1997, BBA-GEN SUBJECTS, V1335, P16, DOI 10.1016/S0304-4165(96)00117-1; GOTTO AM, 1969, CANCER RES, V29, P807; GREM JL, 1996, CANC CHEMOTHERAPY BI, P149; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; HISANAGA K, 1986, J NEUROCHEM, V47, P1344, DOI 10.1111/j.1471-4159.1986.tb00763.x; IPATA PL, 1981, ANAL BIOCHEM, V112, P151, DOI 10.1016/0003-2697(81)90272-4; Jurkowitz MS, 1998, J NEUROCHEM, V71, P535; KING MT, 1990, ANAL BIOCHEM, V187, P179, DOI 10.1016/0003-2697(90)90438-F; KLEIHUES P, 1974, J NEUROCHEM, V23, P417, DOI 10.1111/j.1471-4159.1974.tb04374.x; LJUNGGREN B, 1974, BRAIN RES, V73, P291, DOI 10.1016/0006-8993(74)91050-6; MALLOL J, 1988, NEUROCHEM INT, V12, P61, DOI 10.1016/0197-0186(88)90149-0; MARKLEY HG, 1973, BIOCHIM BIOPHYS ACTA, V309, P23, DOI 10.1016/0005-2744(73)90313-6; Marques AFP, 1998, J NEUROCHEM, V71, P1241; Mascia L, 2000, BBA-GEN SUBJECTS, V1524, P45, DOI 10.1016/S0304-4165(00)00139-2; Mascia L, 1999, BBA-GEN SUBJECTS, V1472, P93, DOI 10.1016/S0304-4165(99)00108-7; Mascia L, 2001, BIOCHEM PHARMACOL, V62, P213, DOI 10.1016/S0006-2952(01)00650-5; MASCIA L, 2000, BIOCHIM BIOPHYS ACTA, V1474, P3585; NORDSTROM CH, 1978, J NEUROCHEM, V30, P479, DOI 10.1111/j.1471-4159.1978.tb06553.x; Orford MR, 1996, J NEUROCHEM, V67, P795; Paschen W, 2000, J NEUROCHEM, V75, P1675, DOI 10.1046/j.1471-4159.2000.0751675.x; PESI R, 1994, ARCH BIOCHEM BIOPHYS, V312, P75, DOI 10.1006/abbi.1994.1282; PETERS GJ, 1987, EUR J CANCER CLIN ON, V23, P1869, DOI 10.1016/0277-5379(87)90053-8; Phillis JW, 1996, J NEUROCHEM, V67, P1525; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; PULSINELLI WA, 1983, J NEUROCHEM, V40, P1500, DOI 10.1111/j.1471-4159.1983.tb13599.x; SCHWARTZ PM, 1985, BIOCHEM PHARMACOL, V34, P3585, DOI 10.1016/0006-2952(85)90737-3; SIMS NR, 1987, J NEUROCHEM, V49, P1367, DOI 10.1111/j.1471-4159.1987.tb01001.x; Sonoda T, 1998, BBA-PROTEIN STRUCT M, V1387, P32, DOI 10.1016/S0167-4838(98)00106-X; STONE TW, 1991, PURINES BASIC CLIN A, P8; TEZUKA M, 1986, J PHARMACOBIO-DYNAM, V9, P962; Torrecilla A, 2001, J NEUROCHEM, V76, P1291, DOI 10.1046/j.1471-4159.2001.00084.x; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361	41	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9865	9869		10.1074/jbc.M111418200	http://dx.doi.org/10.1074/jbc.M111418200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11782482	Green Published, hybrid			2022-12-27	WOS:000174549200036
J	Kissil, JL; Johnson, KC; Eckman, MS; Jacks, T				Kissil, JL; Johnson, KC; Eckman, MS; Jacks, T			Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; RAS TRANSFORMATION; ERM PROTEINS; NEUROFIBROMATOSIS TYPE-2; PLASMA-MEMBRANE; CELL-ADHESION; RHO-GTPASES; RAC1; ACTIVATION; INVASION	The Nf2 tumor suppressor gene product merlin is related to the membrane-cytoskeleton linker proteins of the band 4.1 superfamily, including ezrin, radixin, and moesin (ERMs). Merlin is regulated by phosphorylation in a Rac/cdc42-dependent fashion. We report that the phosphorylation of merlin at serine 518 is induced by the p21-activated kinase PAK2. This is demonstrated by biochemical fractionation, use of active and dominant-negative mutants of PAK2, and immunodepletion. By using wild-type and mutated forms of merlin and phospho-directed antibodies, we show that phosphorylation of merlin at serine 518 leads to dramatic protein relocalization.	MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Canc Res Ctr, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Jacks, T (corresponding author), MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA.							Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; del Peso L, 1997, ONCOGENE, V15, P3047; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Giovannini M, 2000, GENE DEV, V14, P1617; Gusella JF, 1999, BBA-REV CANCER, V1423, pM29, DOI 10.1016/S0304-419X(99)00005-0; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 1998, CELL GROWTH DIFFER, V9, P287; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	31	174	181	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10394	10399		10.1074/jbc.M200083200	http://dx.doi.org/10.1074/jbc.M200083200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11782491	Green Published, hybrid			2022-12-27	WOS:000174549200105
J	Minor, KH; Peterson, CB				Minor, KH; Peterson, CB			Plasminogen activator inhibitor type 1 promotes the self-association of vitronectin into complexes exhibiting altered incorporation into the extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; MULTIMERIC VITRONECTIN; RGD PEPTIDES; S-PROTEIN; BINDING; INTEGRINS; PLASMA; PAI-1; FORM; COLOCALIZATION	Serine proteinase inhibitors, including plasminogen activator inhibitor type 1 (PAI-1) and antithrombin, are key regulators of hemostatic processes such as thrombosis and wound healing. Much evidence suggests that PAI-1 can influence such processes, as well as pathological events like tumor metastasis, through its ability to directly regulate binding of blood platelets and cells to extracellular substrata. One way that PAI-1 influences these processes may be mediated through its binding to the plasma protein vitronectin. Binding to PAI-1 results in the incorporation of vitronectin into a higher order complex with a potential for multivalent interactions (Podor, T. J., Shaughnessy, S. G., Blackburn, M. N., and Peterson, C. B. (2000) J. Biol. Chem. 275,25402-25410). In this study, evidence is provided to support this concept from studies on the effects of PAI-1-induced multimerization on the interactions of vitronectin with matrix components and cell surface receptors. By monitoring complex formation and stability over time using size-exclusion high performance liquid chromatography, a correlation is made between PAI-1-induced multimerization and enhanced cell/matrix binding properties of vitronectin. This evidence indicates that PAI-1 alters the adhesive functions of vitronectin by converting the protein via the higher order complex to a self-associated, multivalent species that is functionally distinct from the abundant monomeric form found in the circulation.	Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville	Peterson, CB (corresponding author), Univ Tennessee, Dept Biochem & Cellular & Mol Biol, M407 Walters Life Sci Bldg, Knoxville, TN 37996 USA.				NHLBI NIH HHS [HL50676] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050676, R29HL050676] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BITTORF SV, 1993, J BIOL CHEM, V268, P24838; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; Germer M, 1998, EUR J BIOCHEM, V253, P669, DOI 10.1046/j.1432-1327.1998.2530669.x; Gibson A, 1997, J BIOL CHEM, V272, P5112, DOI 10.1074/jbc.272.8.5112; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; Gladson CL, 2000, NEUROSCI LETT, V283, P157, DOI 10.1016/S0304-3940(00)00876-4; Harbeck N, 2000, INT J BIOL MARKER, V15, P79, DOI 10.1177/172460080001500115; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; Ho CH, 1999, GYNECOL ONCOL, V75, P397, DOI 10.1006/gyno.1999.5610; Inuzuka S, 1997, SCAND J GASTROENTERO, V32, P1052, DOI 10.3109/00365529709011224; Kwaan HC, 2000, BRIT J CANCER, V82, P1702; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATALLO ZS, 1986, THROMB RES, V43, P507, DOI 10.1016/0049-3848(86)90071-X; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; PANETTI TS, 1995, J BIOL CHEM, V270, P18593, DOI 10.1074/jbc.270.31.18593; PANETTI TS, 1993, J BIOL CHEM, V268, P11988; Pedersen AN, 2000, CANCER RES, V60, P6927; Podor TJ, 2000, J BIOL CHEM, V275, P25402, DOI 10.1074/jbc.M000362200; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1989, BLUT, V59, P419, DOI 10.1007/BF00349063; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P189; Schvartz I, 1999, INT J BIOCHEM CELL B, V31, P539, DOI 10.1016/S1357-2725(99)00005-9; Seiffert D, 1996, J BIOL CHEM, V271, P29644, DOI 10.1074/jbc.271.47.29644; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stoop AA, 2000, ARTERIOSCL THROM VAS, V20, P1143, DOI 10.1161/01.ATV.20.4.1143; Tecimer C, 2001, GYNECOL ONCOL, V80, P48, DOI 10.1006/gyno.2000.6015; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; Wilkins-Port CE, 1998, BBA-MOL CELL RES, V1404, P353, DOI 10.1016/S0167-4889(98)00076-7; ZANETTI A, 1994, BLOOD, V84, P1116, DOI 10.1182/blood.V84.4.1116.bloodjournal8441116; Zheng Q, 2000, J CANCER RES CLIN, V126, P641, DOI 10.1007/s004320000146; Zhuang P, 1997, J BIOL CHEM, V272, P6858, DOI 10.1074/jbc.272.11.6858	34	47	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10337	10345		10.1074/jbc.M109564200	http://dx.doi.org/10.1074/jbc.M109564200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11796716	hybrid			2022-12-27	WOS:000174549200097
J	Tanaka, M; Ueda, A; Kanamori, H; Ideguchi, H; Yang, J; Kitajima, S; Ishigatsubo, Y				Tanaka, M; Ueda, A; Kanamori, H; Ideguchi, H; Yang, J; Kitajima, S; Ishigatsubo, Y			Cell-cycle-dependent regulation of human aurora a transcription is mediated by periodic repression of E4TF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS EMBRYOS; BINDING PROTEIN ALPHA/BETA; HUMAN COLORECTAL CANCERS; CHROMOSOME SEGREGATION; GENE PROMOTER; CENTROSOME AMPLIFICATION; BUDDING YEAST; KINASE FAMILY; MESSENGER-RNA; ETS FAMILY	Human aurora A is a serine-threonine kinase that controls various mitotic events. The transcription of aurora A mRNA varies throughout the cell cycle and peaks during G(2)/M. To clarify the transcriptional mechanism, we first cloned the 1.8-kb 5'-flanking region of aurora A including the first exon. Transient expression of aurora A promoter-luciferase constructs containing a series of 5'-truncated sequences or site-directed mutations identified a 7-bp sequence (CTTCCGG) from -85 to -79 as a positive regulatory element. Electromobility shift assays identified the binding of positive regulatory proteins to the CTTCCGG element. Anti-E4TF1-60 antibody generated a supershifted complex. Furthermore, coexpression of E4TF1-60 and E4TF1-53 markedly increased aurora A promoter activity. Synchronized cells transfected with the aurora A promoter-luciferase constructs revealed that the promoter activity of aurora A increased in the S phase and peaked at G2/M. In addition, we identified a tandem repressor element, CDE/CHR, just downstream of the CTTCCGG element, and mutation within this element led to a loss of cell cycle regulation. We conclude that the transcription of aurora A is positively regulated by E4TF1, a ubiquitously expressed ETS family protein, and that the CDE/CHR element was essential for the G(2)/M-specific transcription of aurora A.	Yokohama City Univ, Sch Med, Dept Internal Med 1, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Bacteriol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Tokyo 1138510, Japan	Yokohama City University; Yokohama City University; Tokyo Medical & Dental University (TMDU)	Ishigatsubo, Y (corresponding author), Yokohama City Univ, Sch Med, Dept Internal Med 1, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.							Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Atlas E, 2000, ONCOGENE, V19, P1933, DOI 10.1038/sj.onc.1203516; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; CHAN CSM, 1993, GENETICS, V135, P677; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; Dohna CLZ, 2000, FEBS LETT, V484, P77, DOI 10.1016/S0014-5793(00)02133-5; Fajas L, 2000, FEBS LETT, V471, P29, DOI 10.1016/S0014-5793(00)01363-6; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Fontijn RD, 2001, MOL CELL BIOL, V21, P2944, DOI 10.1128/MCB.21.8.2944-2955.2001; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Hoare S, 1999, ENDOCRINOLOGY, V140, P2268, DOI 10.1210/en.140.5.2268; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; HWANG A, 1995, J BIOL CHEM, V270, P28419; Kamura T, 1997, J BIOL CHEM, V272, P11361; Khurana TS, 1999, MOL BIOL CELL, V10, P2075, DOI 10.1091/mbc.10.6.2075; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; Marx J, 2001, SCIENCE, V292, P426, DOI 10.1126/science.292.5516.426; MAUXION F, 1989, MOL CELL BIOL, V9, P3548, DOI 10.1128/MCB.9.8.3548; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Miyazaki M, 1999, CANCER RES, V59, P5283; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Reich A, 1999, DNA CELL BIOL, V18, P593, DOI 10.1089/104454999315141; Roghi C, 1998, J CELL SCI, V111, P557; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; Sambrook J., 2002, MOL CLONING LAB MANU; SAVOYSKY E, 1994, ONCOGENE, V9, P1839; Sawa C, 1996, NUCLEIC ACIDS RES, V24, P4954, DOI 10.1093/nar/24.24.4954; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; Schweppe RE, 2001, NUCLEIC ACIDS RES, V29, P1251, DOI 10.1093/nar/29.5.1251; Scrittori L, 2001, J BIOL CHEM, V276, P30002, DOI 10.1074/jbc.M102701200; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHANNON MF, 1990, MOL CELL BIOL, V10, P2950, DOI 10.1128/MCB.10.6.2950; Sowa Y, 1997, CANCER RES, V57, P3145; Tanaka T, 1999, CANCER RES, V59, P2041; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; Vassias I, 1998, J BIOL CHEM, V273, P8287, DOI 10.1074/jbc.273.14.8287; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; Wang XJ, 1998, ONCOGENE, V17, P35, DOI 10.1038/sj.onc.1201890; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATANABE H, 1990, EMBO J, V9, P841, DOI 10.1002/j.1460-2075.1990.tb08181.x; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; Woollard A, 1999, MECH DEVELOP, V82, P95, DOI 10.1016/S0925-4773(99)00020-9; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	67	94	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10719	10726		10.1074/jbc.M108252200	http://dx.doi.org/10.1074/jbc.M108252200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11790771	hybrid			2022-12-27	WOS:000174549200147
J	Gunther, MR; Peters, JA; Sivaneri, MK				Gunther, MR; Peters, JA; Sivaneri, MK			Histidinyl radical formation in the self-peroxidation reaction of bovine copper-zinc superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; INTRACYTOPLASMIC HYALINE INCLUSIONS; DIFFERENTIAL SCANNING CALORIMETRY; DENSITY-FUNCTIONAL CALCULATIONS; TRANSGENIC MOUSE MODEL; EPR CONTINUOUS-FLOW; HYDROGEN-PEROXIDE; CU,ZN-SUPEROXIDE DISMUTASE; OXIDATIVE DAMAGE; SPIN-TRAP	In the absence of suitable oxidizable substrates, the peroxidase reaction of copper-zinc superoxide dismutase (SOD) oxidizes SOD itself, ultimately resulting in its inactivation. A SOD-centered free radical adduct of 2-methyl-2-nitrosopropane (MNP) was detected upon incubation of SOD with the spin trap and a hydroperoxide (either H2O2 or peracetic acid). Proteolysis by Pronase converted the anisotropic electron paramagnetic resonance (EPR) spectrum of MNP/SOD to a nearly isotropic spectrum with resolved hyperfine couplings to several atoms with non-zero nuclear spin. Authentic histidinyl radical (from histidine + HO.) formed a MNP adduct with a very similar EPR spectrum to that of the Pronase-treated MNP/(SOD)-S-., suggesting that the latter was centered on a histidine residue. An additional hyperfine coupling was detected when histidine specifically C-13-labeled at C-2 of the imidazole ring was used, providing evidence for trapping at that atom. All of the experimental spectra were convincingly simulated assuming hyperfine couplings to 2 nearly equivalent nitrogen atoms and 2 different protons, also consistent with trapping at C-2 of the imidazole ring. Free histidinyl radical consumed oxygen, implying peroxyl radical formation. MNP-inhibitable oxygen consumption was also observed when cuprous SOD but not cupric SOD was added to a H2O2 solution. Formation of 2-oxohistidine, the stable product of the SOD-hydroperoxide reaction, required oxygen and was inhibited by MNP. These results support formation of a transient SOD-peroxyl radical.	W Virginia Univ, Dept Biochem & Mol Pharmacol, Morgantown, WV 26506 USA	West Virginia University	Gunther, MR (corresponding author), W Virginia Univ, Dept Biochem & Mol Pharmacol, POB 9142, Morgantown, WV 26506 USA.							Ahmed MS, 2000, J NEUROL SCI, V176, P88, DOI 10.1016/S0022-510X(00)00317-8; Andrus PK, 1998, J NEUROCHEM, V71, P2041; BANSAL KM, 1975, J PHYS CHEM-US, V79, P1775, DOI 10.1021/j100584a006; BATEMAN RC, 1987, BIOCHEMISTRY-US, V26, P4237, DOI 10.1021/bi00388a009; BORDERS CL, 1985, ARCH BIOCHEM BIOPHYS, V241, P472, DOI 10.1016/0003-9861(85)90572-7; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Crow JP, 1997, J NEUROCHEM, V69, P1936; D'Orazio M, 2000, BIOCHEM BIOPH RES CO, V272, P81, DOI 10.1006/bbrc.2000.2730; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Deterding LJ, 1998, J BIOL CHEM, V273, P12863, DOI 10.1074/jbc.273.21.12863; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Ferrante RJ, 1997, ANN NEUROL, V42, P326, DOI 10.1002/ana.410420309; Goto JJ, 2000, J BIOL CHEM, V275, P1007, DOI 10.1074/jbc.275.2.1007; GUNTHER MR, 1995, ARCH BIOCHEM BIOPHYS, V316, P515, DOI 10.1006/abbi.1995.1068; Hawkins CL, 2001, BBA-BIOENERGETICS, V1504, P196, DOI 10.1016/S0005-2728(00)00252-8; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; Kato S, 1996, J NEUROPATH EXP NEUR, V55, P1089, DOI 10.1097/00005072-199655100-00009; Lassmann G, 2000, J PHYS CHEM A, V104, P9144, DOI 10.1021/jp001437w; Lassmann G, 1999, J PHYS CHEM A, V103, P1283, DOI 10.1021/jp9843454; LEPOCK JR, 1985, ARCH BIOCHEM BIOPHYS, V241, P243, DOI 10.1016/0003-9861(85)90380-7; Liochev SI, 1998, ARCH BIOCHEM BIOPHYS, V352, P237, DOI 10.1006/abbi.1998.0616; Lyons TJ, 1996, P NATL ACAD SCI USA, V93, P12240, DOI 10.1073/pnas.93.22.12240; MAKINO K, 1981, RADIAT RES, V86, P294, DOI 10.2307/3575507; RAO PS, 1975, J PHYS CHEM-US, V79, P1260, DOI 10.1021/j100580a006; Reinholz MM, 1999, EXP NEUROL, V159, P204, DOI 10.1006/exnr.1999.7142; ROE JA, 1988, BIOCHEMISTRY-US, V27, P950, DOI 10.1021/bi00403a017; SAMUNI A, 1973, J PHYS CHEM-US, V77, P1629, DOI 10.1021/j100632a007; Sankarapandi S, 1999, J BIOL CHEM, V274, P1226, DOI 10.1074/jbc.274.3.1226; Shibata N, 1996, J NEUROPATH EXP NEUR, V55, P481, DOI 10.1097/00005072-199604000-00011; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P6675, DOI 10.1073/pnas.95.12.6675; Trotti D, 1999, NAT NEUROSCI, V2, P427, DOI 10.1038/8091; TschirretGuth RA, 1996, ARCH BIOCHEM BIOPHYS, V335, P93, DOI 10.1006/abbi.1996.0485; UCHIDA K, 1994, J BIOL CHEM, V269, P2405; UCHIDA K, 1986, BIOCHEM BIOPH RES CO, V138, P659, DOI 10.1016/S0006-291X(86)80547-2; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; WILKS A, 1992, J BIOL CHEM, V267, P8827; Yim HS, 1997, J BIOL CHEM, V272, P8861	40	34	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9160	9166		10.1074/jbc.M107342200	http://dx.doi.org/10.1074/jbc.M107342200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11777904	hybrid, Green Published			2022-12-27	WOS:000174400600058
J	Maurady, A; Zdanov, A; de Moissac, D; Beaudry, D; Sygusch, J				Maurady, A; Zdanov, A; de Moissac, D; Beaudry, D; Sygusch, J			A conserved glutamate residue exhibits multifunctional catalytic roles in D-fructose-1,6-bisphosphate aldolases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT MUSCLE ALDOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE; ELECTRON-DENSITY MAPS; CRYSTAL-STRUCTURE; FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE; ACTIVE-SITE; ACETOACETATE DECARBOXYLASE; TERMINAL REGION; REFINEMENT; RESOLUTION	The aldolase catalytic cycle consists of a number of proton transfers that interconvert covalent enzyme intermediates. Glu-1137 is a conserved amino acid that is located in the mammalian fructose-1,6-bisphosphate aldolase active site. Its central location, within hydrogen bonding distance of three other conserved active site residues: Lys-146, Glu-189, and Schiff base-forming Lys-229, makes it an ideal candidate for mediating proton transfers. Point mutations, Glu-187 --> Gln, Ala, which would inhibit proton transfers significantly, compromise activity. Trapping of enzymatic intermediates in Glu-187 mutants defines a proton transfer role for Glu-187 in substrate cleavage and Schiff base formation. Structural data show that loss of Glu-187 negative charge results in hydrogen bond formation between Lys-146 and Lys-229 consistent with a basic pK(a) for Lys229 in native enzyme and supporting nucleophilic activation of Lys-229 by Glu-187 during Schiff base formation. The crystal structures also substantiate Glu-187 and Glu-189 as present in ionized form in native enzyme, compatible with their role of catalyzing proton exchange with solvent as indicated from solvent isotope effects. The proton exchange mechanism ensures Glu-187 basicity throughout the catalytic cycle requisite for mediating proton transfer and electrostatic stabilization of ketamine intermediates. Glutamate general base catalysis is a recurrent evolutionary feature of Schiff base-forming aldolases.	Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada; NCI, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21702 USA; Univ Sherbrooke, Dept Biochem, Fleurimont, PQ J1H 5N4, Canada	Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Sherbrooke	Sygusch, J (corresponding author), Univ Montreal, Dept Biochem, CP 6128,Stn Ctr Ville, Montreal, PQ H3C 3J7, Canada.		Maurady, Amal/AAO-8911-2020	maurady, amal/0000-0001-9298-717X; Sygusch, Jurgen/0000-0002-6629-2128				Allard J, 2001, P NATL ACAD SCI USA, V98, P3679, DOI 10.1073/pnas.071380898; ANAI M, 1973, ARCH BIOCHEM BIOPHYS, V156, P712, DOI 10.1016/0003-9861(73)90324-X; AVIGAD G, 1972, ARCH BIOCHEM BIOPHYS, V153, P337, DOI 10.1016/0003-9861(72)90454-7; Berenblum I, 1938, BIOCHEM J, V32, P295, DOI 10.1042/bj0320295; BERTHIAUME L, 1993, J BIOL CHEM, V268, P10826; Blom N, 1997, NAT STRUCT BIOL, V4, P36, DOI 10.1038/nsb0197-36; Blom N, 1998, ACTA CRYSTALLOGR D, V54, P461, DOI 10.1107/S0907444997006549; Blonski C, 1997, BIOCHEM J, V323, P71, DOI 10.1042/bj3230071; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Choi KH, 1999, BIOCHEMISTRY-US, V38, P12655, DOI 10.1021/bi9828371; Chudzik DM, 2000, J MOL BIOL, V300, P697, DOI 10.1006/jmbi.2000.3910; COOK PF, 1991, ENZYME MECH ISOTOPE, P85; COOK PF, 1991, ENZYME MECH ISOTOPE, P81; CREIGHTON TE, 1983, PROTEINS STRUCTURES, P150; Dalby A, 1999, PROTEIN SCI, V8, P291; DIAMOND R, 1992, PROTEIN SCI, V1, P1279, DOI 10.1002/pro.5560011006; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; GAMBLIN SJ, 1991, J MOL BIOL, V219, P573, DOI 10.1016/0022-2836(91)90650-U; GRAZI E, 1975, BIOCHEM J, V151, P167, DOI 10.1042/bj1510167; GRAZI E, 1962, BIOCHEM BIOPH RES CO, V9, P38, DOI 10.1016/0006-291X(62)90083-9; GRAZI E, 1978, BIOCHEM J, V175, P361, DOI 10.1042/bj1750361; HARTMAN FC, 1976, J BIOL CHEM, V251, P3057; HEALY MJ, 1973, BIOCHEMISTRY-US, V12, P35, DOI 10.1021/bi00725a006; HESTER G, 1991, FEBS LETT, V292, P237, DOI 10.1016/0014-5793(91)80875-4; Highbarger LA, 1996, BIOCHEMISTRY-US, V35, P41, DOI 10.1021/bi9518306; HOWARD AJ, 1990, XGEN USER GUIDE VERS; IYENGAR R, 1981, BIOCHEMISTRY-US, V20, P1223, DOI 10.1021/bi00508a026; Jia J, 1996, STRUCTURE, V4, P715, DOI 10.1016/S0969-2126(96)00077-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELLEY PM, 1986, PLANT PHYSIOL, V82, P1076, DOI 10.1104/pp.82.4.1076; Kim H, 1998, BIOCHEMISTRY-US, V37, P4388, DOI 10.1021/bi972233h; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; KREEVOY MM, 1980, J AM CHEM SOC, V102, P3315, DOI 10.1021/ja00530a002; KUO DJ, 1985, BIOCHEMISTRY-US, V24, P3947, DOI 10.1021/bi00336a022; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MODEL P, 1968, BIOCHEMISTRY-US, V7, P1339, DOI 10.1021/bi00844a014; MORRIS AJ, 1994, BIOCHEMISTRY-US, V33, P12291, DOI 10.1021/bi00206a036; MORRIS AJ, 1993, J BIOL CHEM, V268, P1095; Morris AJ, 1996, PROTEIN ENG, V9, P61, DOI 10.1093/protein/9.1.61; PINE SH, 1987, ORGANIC CHEM, P100; POLLACK RM, 1977, J AM CHEM SOC, V99, P8232, DOI 10.1021/ja00467a018; RACKER E, 1952, J BIOL CHEM, V196, P347; RAY BD, 1983, J AM CHEM SOC, V105, P3731, DOI 10.1021/ja00349a075; ROSE IA, 1965, J BIOL CHEM, V240, P1758; ROSE IA, 1985, BIOCHEMISTRY-US, V24, P3952, DOI 10.1021/bi00336a023; ROSE IA, 1987, J BIOL CHEM, V262, P692; RUTTER WJ, 1964, FED PROC, V23, P1248; SCHMIDT DE, 1971, BIOCHEMISTRY-US, V10, P1249; SYGUSCH J, 1987, P NATL ACAD SCI USA, V84, P7846, DOI 10.1073/pnas.84.22.7846; Sygusch J, 1996, J CRYST GROWTH, V162, P167, DOI 10.1016/0022-0248(95)00956-6; WARREN S, 1966, BIOCHEMISTRY-US, V5, P817, DOI 10.1021/bi00867a002	53	41	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9474	9483		10.1074/jbc.M107600200	http://dx.doi.org/10.1074/jbc.M107600200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11779856	hybrid			2022-12-27	WOS:000174400600099
J	Green, DM; Marfatia, KA; Crafton, EB; Zhang, X; Cheng, XD; Corbett, AH				Green, DM; Marfatia, KA; Crafton, EB; Zhang, X; Cheng, XD; Corbett, AH			Nab2p is required for poly(A) RNA export in Saccharomyces cerevisiae and is regulated by arginine methylation via Hmt1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTATIONS; MESSENGER-RNA; BINDING-PROTEINS; NUCLEAR TRANSPORT; RECOGNITION MOTIF; SPLICING FACTORS; HNRNP PROTEINS; BUDDING YEAST; GENE ENCODES; IN-VITRO	From transcription to translation, mRNA is complexed with heterogeneous nuclear ribonucleoproteins (hnRN-P proteins) that mediate mRNA processing, export from the nucleus, and delivery into the cytoplasm. Although the mechanism is unknown, export of mature mRNA from the nucleus is a critical regulatory step in gene expression. Analyses of hnRNP proteins have shown that many of these proteins are required for this essential cellular process. In this study, we characterize the Saccharomyces cerevisiae Nab2 protein, which was first identified as a poly(A) RNA-binding protein (Anderson, J. T., Wilson, S. M., Datar, K. V., and Swanson, M. S. (1993) Mol. Cell. Biol. 13, 2730-2741). Our work indicates that poly(A) RNA export from the nucleus is dependent upon a functional Nab2 protein; correspondingly, export of Nab2p from the nucleus is dependent upon ongoing RNA polymerase 11 transcription. Furthermore, we show that Nab2p is modified within its RGG domain by the type I protein-arginine methyltransferase, Hmt1p. Our experiments demonstrate that arginine methylation is required for the export of Nab2p from the nucleus and therefore establish an in vivo effect of this modification. Overall, these experiments provide evidence that Nab2p is an hnRNP protein that is required for poly(A) RNA export and whose export from the nucleus is regulated by Hmt1p.	Emory Univ, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Corbett, AH (corresponding author), Emory Univ, Dept Biochem, 1510 Clifton Rd,NE, Atlanta, GA 30322 USA.		Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895	NIGMS NIH HHS [T32 GM008490, R01 GM058728] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008490, R01GM058728] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 1997, METHODS YEAST GENETI; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Akker SA, 2001, J MOL ENDOCRINOL, V27, P123, DOI 10.1677/jme.0.0270123; Amrani N, 1997, MOL CELL BIOL, V17, P3694, DOI 10.1128/MCB.17.7.3694; ANDERSON JT, 1993, MOL CELL BIOL, V13, P2730, DOI 10.1128/MCB.13.5.2730; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOSSIE MA, 1992, MOL BIOL CELL, V3, P875, DOI 10.1091/mbc.3.8.875; Brachmann CB, 1998, YEAST, V14, P115; COBIANCHI F, 1993, NUCLEIC ACIDS RES, V21, P949, DOI 10.1093/nar/21.4.949; Corbett AH, 1996, J BIOL CHEM, V271, P18477, DOI 10.1074/jbc.271.31.18477; Cramer P, 2001, FEBS LETT, V498, P179, DOI 10.1016/S0014-5793(01)02485-1; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Duncan K, 2000, CURR BIOL, V10, P687, DOI 10.1016/S0960-9822(00)00527-3; Forsburg SL, 2001, NAT REV GENET, V2, P659, DOI 10.1038/35088500; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Henry M, 1996, GENETICS, V142, P103; Henry MF, 1996, MOL CELL BIOL, V16, P3668; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; Jones AL, 2000, P NATL ACAD SCI USA, V97, P3224, DOI 10.1073/pnas.050432997; KAHANA JA, 1995, P NATL ACAD SCI USA, V92, P9707, DOI 10.1073/pnas.92.21.9707; Kahana JA, 1998, MOL BIOL CELL, V9, P1741, DOI 10.1091/mbc.9.7.1741; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Kessler MM, 1997, GENE DEV, V11, P2545, DOI 10.1101/gad.11.19.2545; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Lee DCY, 1999, J BIOL CHEM, V274, P29031, DOI 10.1074/jbc.274.41.29031; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; LIU Q, 1995, MOL CELL BIOL, V15, P2800; Liu Y, 1999, P NATL ACAD SCI USA, V96, P6739, DOI 10.1073/pnas.96.12.6739; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Michelitsch MD, 2000, P NATL ACAD SCI USA, V97, P11910, DOI 10.1073/pnas.97.22.11910; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; PINOLROMA S, 1993, MOL CELL BIOL, V13, P5762, DOI 10.1128/MCB.13.9.5762; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; Ruiz-Echevarria MJ, 2000, CELL, V101, P741, DOI 10.1016/S0092-8674(00)80886-7; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLENSTEDT G, 1993, J CELL BIOL, V123, P785, DOI 10.1083/jcb.123.4.785; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Shatkin AJ, 2000, NAT STRUCT BIOL, V7, P838, DOI 10.1038/79583; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Siebel CW, 1999, P NATL ACAD SCI USA, V96, P5440, DOI 10.1073/pnas.96.10.5440; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGLETON DR, 1995, J CELL SCI, V108, P265; SOULARD M, 1993, NUCLEIC ACIDS RES, V21, P4210, DOI 10.1093/nar/21.18.4210; Strasser K, 1999, FEBS LETT, V452, P77, DOI 10.1016/S0014-5793(99)00537-2; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Strawn LA, 2001, J BIOL CHEM, V276, P6445, DOI 10.1074/jbc.M008311200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Wong DH, 1997, MOL CELL BIOL, V17, P3755, DOI 10.1128/MCB.17.7.3755; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754; Zenklusen D, 2001, MOL CELL BIOL, V21, P4219, DOI 10.1128/MCB.21.13.4219-4232.2001; Zenklusen D, 2001, FEBS LETT, V498, P150, DOI 10.1016/S0014-5793(01)02482-6; Zhang X, 2000, EMBO J, V19, P3509, DOI 10.1093/emboj/19.14.3509; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	71	148	151	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7752	7760		10.1074/jbc.M110053200	http://dx.doi.org/10.1074/jbc.M110053200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11779864	hybrid			2022-12-27	WOS:000174268000018
J	Cain, SA; Monk, PN				Cain, SA; Monk, PN			The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN C3A RECEPTOR; ANAPHYLATOXIN C5A; CELLS; LIGAND; PHOSPHORYLATION; EXPRESSION; ACTIVATION; TERMINUS; MUTATION; AGONIST	The substantial variations in the responses of cells to the anaphylatoxin C5a and its desarginated form, C5adR(74), suggest that more than one type of cell surface receptor for these ligands might exist. However, only a single receptor for C5a and C5adR(74), CD88, has been characterized to date. Here we report that the orphan receptor C5L2/gpr77, which shares 35% amino acid identity with CD88, binds C5a with high affinity but has a 10-fold higher affinity for C5adR(74) than CD88. C5L2 also has a moderate affinity for anaphylatoxin C3a, but cross-competition studies suggest that C3a binds to a distinct site from C5a. C4a was able to displace C3a, suggesting that C5L2, like the C3a receptor, may have a low binding affinity for this anaphylatoxin. Unlike CD88 and C3a receptor, C5L2 transfected into RBL-2H3 cells does not support degranulation or increases in intracellular [Ca2+] and is not rapidly internalized in response to ligand binding. However, ligation of C5L2 by anaphylatoxin did potentiate the degranulation response to cross-linkage of the high affinity IgE receptor by a pertussis toxin-sensitive mechanism. These results suggest that C5L2 is an anaphylatoxin-binding protein with unique ligand binding and signaling properties.	Univ Sheffield, Sch Med, Dept Neurol, Sheffield S10 2RX, S Yorkshire, England	University of Sheffield	Monk, PN (corresponding author), Univ Sheffield, Sch Med, Dept Neurol, E Floor,Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	p.monk@shef.ac.uk	Monk, Peter/C-6155-2008; Cain, Stuart A/G-2836-2017	Monk, Peter/0000-0003-4637-3059; Cain, Stuart/0000-0001-8417-1058				Ahamed J, 2001, J IMMUNOL, V167, P3559, DOI 10.4049/jimmunol.167.7.3559; ALI H, 1994, J BIOL CHEM, V269, P24557; ALI H, 1993, J BIOL CHEM, V268, P24247; Bhatia M, 2001, AM J PHYSIOL-GASTR L, V280, pG974, DOI 10.1152/ajpgi.2001.280.5.G974; Bock D, 1997, EUR J IMMUNOL, V27, P1522, DOI 10.1002/eji.1830270631; BOKISCH VA, 1970, J CLIN INVEST, V49, P2427, DOI 10.1172/JCI106462; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; Cain SA, 2000, J IMMUNOL METHODS, V245, P139, DOI 10.1016/S0022-1759(00)00282-9; Cain SA, 2001, BIOCHEM PHARMACOL, V61, P1571, DOI 10.1016/S0006-2952(01)00608-6; Cain SA, 2001, BIOCHEMISTRY-US, V40, P14047, DOI 10.1021/bi011055w; Chao TH, 1999, J BIOL CHEM, V274, P9721, DOI 10.1074/jbc.274.14.9721; Crass T, 1999, BIOCHEMISTRY-US, V38, P9712, DOI 10.1021/bi990139q; Eglite S, 2000, J IMMUNOL, V165, P2183, DOI 10.4049/jimmunol.165.4.2183; GALLIN JI, 1992, INFLAMMATION BASIC P, P63; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Geva A, 2000, J BIOL CHEM, V275, P35393, DOI 10.1074/jbc.M005602200; Lee DK, 2001, MOL BRAIN RES, V86, P13, DOI 10.1016/S0169-328X(00)00242-4; Lienenklaus S, 1998, J IMMUNOL, V161, P2089; Mastellos D, 2001, J IMMUNOL, V166, P2479, DOI 10.4049/jimmunol.166.4.2479; MERY L, 1993, EUR J HAEMATOL, V51, P282; MONK PN, 1994, EUR J IMMUNOL, V24, P2922, DOI 10.1002/eji.1830241152; MONK PN, 1993, RECEPTOR, V3, P77; MONK PN, 1995, J BIOL CHEM, V270, P16625, DOI 10.1074/jbc.270.28.16625; Mukherjee P, 2000, J NEUROIMMUNOL, V105, P124, DOI 10.1016/S0165-5728(99)00261-1; Murphy PM, 2000, PHARMACOL REV, V52, P145; O'Barr SA, 2001, J IMMUNOL, V166, P4154, DOI 10.4049/jimmunol.166.6.4154; Ohno M, 2000, MOL IMMUNOL, V37, P407, DOI 10.1016/S0161-5890(00)00067-5; Paczkowski NJ, 1999, BRIT J PHARMACOL, V128, P1461, DOI 10.1038/sj.bjp.0702938; Prossnitz ER, 1999, BIOCHEMISTRY-US, V38, P2240, DOI 10.1021/bi982274t; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Zwirner J, 1999, MOL IMMUNOL, V36, P877, DOI 10.1016/S0161-5890(99)00109-1	31	197	213	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					7165	7169		10.1074/jbc.C100714200	http://dx.doi.org/10.1074/jbc.C100714200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11773063	hybrid			2022-12-27	WOS:000174104300054
J	Ginjala, V; Holmgren, C; Ulleras, E; Kanduri, C; Pant, V; Lobanenkov, V; Franklin, G; Ohlsson, R				Ginjala, V; Holmgren, C; Ulleras, E; Kanduri, C; Pant, V; Lobanenkov, V; Franklin, G; Ohlsson, R			Multiple cis elements within the Igf2/H19 insulator domain organize a distance-dependent silencer - A cautionary note	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPRINTED EXPRESSION; HISTONE ACETYLATION; CHROMATIN STRUCTURE; H19/IGF2 LOCUS; MOUSE H19; METHYLATION; CTCF; GENE	The 5'-flank of the H19 gene harbors a differentially methylated imprinting control region that represses the maternally derived Igf2 and paternally derived H19 alleles. Here we show that the H19 imprinting control region (ICR) is a potent silencer when positioned in a promoter-proximal position. The silencing effect is not alleviated by trichostatin A treatment, suggesting that it does not involve histone deacetylase functions. When the H19 ICR is separated from the promoter by more than 1.2 +/- 0.3 kb, however, trichostatin A stimulates promoter activity 10-fold. Deletion analyses revealed that the silencing feature extended throughout the ICR segment. Finally, chromatin immunopurification analyses revealed that the H19 ICR prevented trichostatin A-dependent reacetylation of histones in the promoter region in a proximal but not in a distal position. We argue that these features are likely to be side effects of the H19 ICR, rather than explaining the mechanism of silencing of the paternal H19 allele. We issue a cautionary note, therefore, that the interpretation of insulator/ silencer data could be erroneous should the distance issue not be taken into consideration.	Uppsala Univ, Dept Dev & Genet Evolut Biol Ctr, S-75236 Uppsala, Sweden; NIAID, Lab Immunopathol, NIH, Bethesda, MD 20892 USA	Uppsala University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Ohlsson, R (corresponding author), Uppsala Univ, Dept Dev & Genet Evolut Biol Ctr, Norbyvagen 18A, S-75236 Uppsala, Sweden.	Rolf.Ohlsson@ebc.uu.se	Ginjala, Vasudeva/E-5869-2019; Lobanenkov, Victor/ABD-5710-2021; Lobanenkov, Victor V./AGQ-8903-2022	Kanduri, Chandrasekhar/0000-0001-6271-9078; Lobanenkov, Victor/0000-0001-6665-3635; Pant, Vinod/0000-0002-3286-1804	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000860, Z01AI000859, Z01AI000860] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Holmgren C, 2001, CURR BIOL, V11, P1128, DOI 10.1016/S0960-9822(01)00314-1; Kaffer CR, 2000, GENE DEV, V14, P1908; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Kanduri C, 2000, CURR BIOL, V10, P449, DOI 10.1016/S0960-9822(00)00442-5; KANDURI M, 2001, IN PRESS MOL CELL BI; Lutz M, 2000, NUCLEIC ACIDS RES, V28, P1707, DOI 10.1093/nar/28.8.1707; Lyko F, 1997, NAT GENET, V16, P171, DOI 10.1038/ng0697-171; Olek A, 1997, NAT GENET, V17, P275, DOI 10.1038/ng1197-275; Svensson K, 1998, DEVELOPMENT, V125, P61; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Ulleras E, 2001, EXP CELL RES, V270, P188, DOI 10.1006/excr.2001.5338; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	16	5	5	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					5707	5710		10.1074/jbc.C100552200	http://dx.doi.org/10.1074/jbc.C100552200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11777900	hybrid			2022-12-27	WOS:000173989200003
J	Koch, HG; Moser, M; Schimz, KL; Muller, M				Koch, HG; Moser, M; Schimz, KL; Muller, M			The integration of YidC into the cytoplasmic membrane of Escherichia coli requires the signal recognition particle, SecA and SecYEG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANE; PLASMA-MEMBRANE; INDEPENDENT TRANSLOCATION; PROTEIN TRANSLOCATION; TARGETING PATHWAYS; INSERTION; SRP; RIBOSOME; BACTERIA; TOPOLOGY	The integration of the polytopic membrane protein YidC into the inner membrane of Escherichia coli was analyzed employing an in vitro system. Upon integration of in vitro synthesized YidC, a 42-kDa. membrane protected fragment was detected, which could be immunoprecipitated with polyclonal anti-YidC antibodies. The occurrence of this fragment is in agreement with the predicted topology of YidC and probably encompasses the first two transmembrane domains and the connecting 320-amino acid-long periplasmic loop. The integration of YidC was strictly dependent on the signal recognition particle and SecA. YidC could not be integrated in the absence of SecY, SecE, or SecG, suggesting that YidC, in contrast to its mitochondrial orthologue Oxalp, cannot engage a SecYEG-independent protein-conducting channel.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Forschungszentrum Julich, Inst Biotechnol, D-52425 Julich, Germany	University of Freiburg; Helmholtz Association; Research Center Julich	Koch, HG (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	Hans-Georg.Koch@biochemie.uni-freiburg.de						Akiyama Y, 1996, J BIOL CHEM, V271, P31196, DOI 10.1074/jbc.271.49.31196; BABA T, 1990, J BACTERIOL, V172, P7005, DOI 10.1128/jb.172.12.7005-7010.1990; Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Behrmann M, 1998, J BIOL CHEM, V273, P13898, DOI 10.1074/jbc.273.22.13898; DALBEY RE, 1995, TRENDS CELL BIOL, V5, P380, DOI 10.1016/S0962-8924(00)89079-0; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; Koch HG, 2000, J CELL BIOL, V150, P689, DOI 10.1083/jcb.150.3.689; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; Luirink J, 2001, FEBS LETT, V501, P1, DOI 10.1016/S0014-5793(01)02616-3; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; Matsumoto G, 1997, EMBO J, V16, P6384, DOI 10.1093/emboj/16.21.6384; Muller M, 2001, PROG NUCLEIC ACID RE, V66, P107; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; Neumann-Haefelin C, 2000, EMBO J, V19, P6419, DOI 10.1093/emboj/19.23.6419; Newitt JA, 1998, J BIOL CHEM, V273, P12451, DOI 10.1074/jbc.273.20.12451; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; Saaf A, 1998, J BIOL CHEM, V273, P30415, DOI 10.1074/jbc.273.46.30415; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Scotti PA, 1999, J BIOL CHEM, V274, P29883, DOI 10.1074/jbc.274.42.29883; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; van der Laan M, 2001, EMBO REP, V2, P519, DOI 10.1093/embo-reports/kve106; WHITLEY P, 1994, EMBO J, V13, P4653, DOI 10.1002/j.1460-2075.1994.tb06788.x; YAMADA H, 1989, J BIOL CHEM, V264, P18577	33	36	36	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					5715	5718		10.1074/jbc.C100683200	http://dx.doi.org/10.1074/jbc.C100683200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11777926	hybrid			2022-12-27	WOS:000173989200005
J	Lamb, DC; Nienhaus, K; Arcovito, A; Draghi, F; Miele, AE; Brunori, M; Nienhaus, GU				Lamb, DC; Nienhaus, K; Arcovito, A; Draghi, F; Miele, AE; Brunori, M; Nienhaus, GU			Structural dynamics of myoglobin - Ligand migration among protein cavities studied by Fourier transform infrared/temperature derivative spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; CARBONMONOXY-MYOGLOBIN; HEME-PROTEINS; CRYSTAL-STRUCTURE; BINDING SITE; POCKET; MUTANT; TEMPERATURES; INTERMEDIATE; TRANSITIONS	Fourier transform infrared (FTIR) spectroscopy in the CO stretch bands combined with temperature derivative spectroscopy (TDS) was used to characterize intermediate states obtained by photolysis of two sperm whale mutant myoglobins, YQR (L29(B10)Y, H64(E7)Q, T67(E10)R) and YQRF (with an additional 1107(G8)F replacement). Both mutants assume two different bound-state conformations, A(0) and A(3), which can be distinguished by their different CO bands near 1965 an 19 cm(-1). They most likely originate from different conformations of the Gln-64 side chain. Within each A substate, a number of photoproduct states have been characterized on the basis of the temperature dependence of recombination in TDS experiments. Different locations and orientations of the ligand within the protein can be distinguished by the infrared spectra of the photolyzed CO. Recombination from the primary docking site, B, near the heme dominates below 50 K. Above 60 K, ligand rebinding occurs predominantly from a secondary docking site, C', in which the CO is trapped in the Xe4 cavity on the distal side, as shown by crystallography of photolyzed YQR and L29W myoglobin CO. Another kinetic state (C'') has been identified from which rebinding occurs around 130 K. Moreover, a population appearing above the solvent glass transition at similar to180 K (D state) is assigned to rebinding from the Xe1 cavity, as suggested by the photoproduct structure of the L29W sperm whale myoglobin mutant. For both the YQR and YQRF mutants, rebinding from the B sites near the heme differs for the two A substates, supporting the view that the return of the ligand from the C', C'', and D states is not governed by the recombination barrier at the heme iron but rather by migration to the active site. Comparison of YQR and YQRF shows that access to the Xe4 site (C') is severely restricted by introduction of the bulky Phe side chain at position 107.	Univ Ulm, Dept Biophys, D-89069 Ulm, Germany; Univ Roma La Sapienza, CNR, Ctr Biol Mol, I-00185 Rome, Italy; Univ Illinois, Dept Phys, Urbana, IL 61801 USA	Ulm University; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; University of Illinois System; University of Illinois Urbana-Champaign	Nienhaus, GU (corresponding author), Univ Ulm, Dept Biophys, D-89069 Ulm, Germany.		Nienhaus, Gerd Ulrich/G-8698-2012; Arcovito, Alessandro/I-5552-2012; Lamb, Don C/G-9501-2014; Miele, Adriana E./F-4083-2011	Nienhaus, Gerd Ulrich/0000-0002-5027-3192; Arcovito, Alessandro/0000-0002-8384-4844; Lamb, Don C/0000-0002-0232-1903; Miele, Adriana E./0000-0002-4637-2606; Brunori, Maurizio/0000-0002-7795-1635				AHMED AM, 1991, CHEM PHYS, V158, P329, DOI 10.1016/0301-0104(91)87076-8; ALBEN JO, 1982, P NATL ACAD SCI-BIOL, V79, P3744, DOI 10.1073/pnas.79.12.3744; ANSARI A, 1994, BIOCHEMISTRY-US, V33, P5128, DOI 10.1021/bi00183a017; ANSARI A, 1987, BIOPHYS CHEM, V26, P337, DOI 10.1016/0301-4622(87)80034-0; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BERENDZEN J, 1990, P NATL ACAD SCI USA, V87, P1, DOI 10.1073/pnas.87.1.1; BRAUNSTEIN DP, 1993, BIOPHYS J, V65, P2447, DOI 10.1016/S0006-3495(93)81310-9; Brunori M, 1999, BIOPHYS J, V76, P1259, DOI 10.1016/S0006-3495(99)77289-9; Brunori M, 2001, EMBO REP, V2, P674, DOI 10.1093/embo-reports/kve159; Brunori M, 2000, P NATL ACAD SCI USA, V97, P2058, DOI 10.1073/pnas.040459697; Chu K, 2000, NATURE, V403, P921, DOI 10.1038/35002641; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; Draghi F, 2002, J BIOL CHEM, V277, P7509, DOI 10.1074/jbc.M109206200; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; GIBSON QH, 1957, NATURE, V180, P1416, DOI 10.1038/1801416b0; GIBSON QH, 1989, J BIOL CHEM, V264, P20155; Hartmann H, 1996, P NATL ACAD SCI USA, V93, P7013, DOI 10.1073/pnas.93.14.7013; Johnson JB, 1996, BIOPHYS J, V71, P1563, DOI 10.1016/S0006-3495(96)79359-1; KENDREW JC, 1960, NATURE, V185, P422, DOI 10.1038/185422a0; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; Lim MH, 1997, NAT STRUCT BIOL, V4, P209, DOI 10.1038/nsb0397-209; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; MOURANT JR, 1993, BIOPHYS J, V65, P1496, DOI 10.1016/S0006-3495(93)81218-9; Muller JD, 1999, BIOPHYS J, V77, P1036, DOI 10.1016/S0006-3495(99)76954-7; Nienhaus G. U., 1996, ENCY APPL PHYSICS, V15, P163; NIENHAUS GU, 1994, BIOCHEMISTRY-US, V33, P13413, DOI 10.1021/bi00249a030; Nienhaus GU, 1998, BIOCHEMISTRY-US, V37, P6819, DOI 10.1021/bi972843h; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; Ostermann A, 2000, NATURE, V404, P205, DOI 10.1038/35004622; PERUTZ MF, 1966, J MOL BIOL, V21, P199, DOI 10.1016/0022-2836(66)90088-X; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; POST F, 1993, BIOPHYS J, V64, P1833, DOI 10.1016/S0006-3495(93)81554-6; POWERS L, 1987, BIOCHEMISTRY-US, V26, P4785, DOI 10.1021/bi00389a028; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; Schlichting I, 2000, CURR OPIN STRUC BIOL, V10, P744, DOI 10.1016/S0959-440X(00)00158-5; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; SHIMADA H, 1982, J BIOL CHEM, V257, P1893; Srajer V, 2001, BIOCHEMISTRY-US, V40, P13802, DOI 10.1021/bi010715u; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; TRAVAGLINI ALLOCATELLI C, 1994, FEBS LETT, V352, P63, DOI 10.1016/0014-5793(94)00918-X; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6; YOUNG RD, 1991, CHEM PHYS, V158, P315, DOI 10.1016/0301-0104(91)87075-7; ZHAO XF, 1995, J BIOL CHEM, V270, P20763, DOI 10.1074/jbc.270.35.20763	49	77	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11636	11644		10.1074/jbc.M109892200	http://dx.doi.org/10.1074/jbc.M109892200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11792698	hybrid			2022-12-27	WOS:000174846400005
J	Post, PL; Tyska, MJ; O'Connell, CB; Johung, K; Hayward, A; Mooseker, MS				Post, PL; Tyska, MJ; O'Connell, CB; Johung, K; Hayward, A; Mooseker, MS			Myosin-IXb is a single-headed and processive motor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; UNCONVENTIONAL MYOSINS; LIGHT-CHAIN; ACTIN; MOVEMENT; KINESIN; BRAIN; RHO; EXPRESSION; MOLECULES	Class IX myosins are unique among the many classes of known actin-based motors in that the tail region of these myosins contains a GTPase-activating protein domain for the small GTP-binding protein, Rho. Previous studies on human myosin-M indicate that this myosin is mechanochemically active and exhibits actin-binding properties similar to the processive motor, myosin-Va. Motility analysis of antibody-tethered myosin-IXb performed using the sliding actin filament assay indicates that this myosin does exhibit properties characteristic of a processive motor. Like myosin-Va, the velocity of myosin-IXb remains constant (38.2 +/- 1.2 nm/s) even at single motor/filament densities. At low motor densities, filaments can be seen passing through and pivoting about single points on the motility surface. Analysis of filament landing rates as a function of motor density also indicates that a single motor is sufficient for filament movement. However, in contrast to myosin-Va, which uses coordinated motion of its two heads to move processively along the filament, hydrodynamic and chemical cross-linking studies indicate that under the conditions tested, myosin-IXb is a single-headed motor consisting of a single heavy chain and associated light chains.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Dept Pathol, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Mooseker, MS (corresponding author), Yale Univ, MCD Biol, KBT 352, POB 208103, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK055389, F32DK010113, R37DK025387, R01DK025387] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-10113, DK-25387, DK 55389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bahler M, 2000, BBA-MOL CELL RES, V1496, P52, DOI 10.1016/S0167-4889(00)00008-2; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; Chieregatti E, 1998, J CELL SCI, V111, P3597; Coluccio LM, 1997, AM J PHYSIOL-CELL PH, V273, pC347, DOI 10.1152/ajpcell.1997.273.2.C347; Espindola FS, 2000, CELL MOTIL CYTOSKEL, V47, P269, DOI 10.1002/1097-0169(200012)47:4<269::AID-CM2>3.3.CO;2-7; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Kalhammer G, 1997, FEBS LETT, V414, P599, DOI 10.1016/S0014-5793(97)01076-4; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Muller RT, 1997, MOL BIOL CELL, V8, P2039, DOI 10.1091/mbc.8.10.2039; Nascimento AAC, 1996, J BIOL CHEM, V271, P17561, DOI 10.1074/jbc.271.29.17561; Okada Y, 2000, P NATL ACAD SCI USA, V97, P640, DOI 10.1073/pnas.97.2.640; Post PL, 1998, J CELL SCI, V111, P941; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Reck-Peterson SL, 2001, J CELL BIOL, V153, P1121, DOI 10.1083/jcb.153.5.1121; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Sakakibara H, 1999, NATURE, V400, P586, DOI 10.1038/23066; Sirotkin V, 2000, MOL REPROD DEV, V57, P111, DOI 10.1002/1098-2795(200010)57:2<111::AID-MRD2>3.0.CO;2-T; Stevens RC, 1998, J CELL BIOL, V142, P711, DOI 10.1083/jcb.142.3.711; Tanford C., 1961, PHYSICAL CHEM MACROM, P317; Tauhata SBF, 2001, J BIOL CHEM, V276, P39812, DOI 10.1074/jbc.M102583200; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Wirth JA, 1996, J CELL SCI, V109, P653	28	70	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11679	11683		10.1074/jbc.M111173200	http://dx.doi.org/10.1074/jbc.M111173200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11801597	hybrid			2022-12-27	WOS:000174846400010
J	Tung, CS; Walsh, DA; Trewhella, J				Tung, CS; Walsh, DA; Trewhella, J			A structural model of the catalytic subunit-regulatory subunit dimeric complex of the cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR PEPTIDE; SKELETAL-MUSCLE; NUCLEIC-ACIDS; FORCE-FIELD; BINDING; HOLOENZYME; ACTIVATION; DISSOCIATION; RECOGNITION; CLONING	Previous neutron scattering studies elaborated the topographical relationship of the regulatory (R-IIalpha) and catalytic (C-alpha) subunits of the cAMP-dependent protein kinase. We present here the results of a set of computations that lead to an atomic model of the cAMP-dependent protein kinase heterodimer, Delta(1-91)R(IIalpha)-C-alpha. The first step in the modeling utilized the crystal structures for the porcine C-alpha and bovine Delta(1-90)R(Ialpha) or rat Delta(1-111)R(IIbeta), to homology-model structures of the species and isoforms that had been used in the neutron scattering experiments (bovine C-alpha subunit and murine Delta(1-91)R(IIalpha) subunit, respectively). A docking procedure, constrained by the dimensions and positions of the ellipsoids in the neutron-derived R-C model as well as mutagenesis data, was used to develop "best fit" models for the heterodimer. Simulated annealing, molecular dynamics, and energy minimization were then used to refine the side chain packing at the heterodimer interface. For comparison, the calculations were done using the homology models derived from both the R-Ialpha and R-IIbeta crystal structures. Both resultant models had many similarities. Each predicted similar interfaces. The R-Ialpha-based model has 25% more hydrogen bonds than that based on R-IIbeta, with seven of these potential bonds in common. The distribution of hydrophobic, polar, and charged residues at the interface was similar for both models, with a distribution more characteristic of the exposed surface residues than those in the protein interior. The calculated interface area in each is relatively small (<2000 Angstrom(2)). The R-Ialpha-based model, however, has a significantly better fit with the scattering data and is therefore the one of distinctly higher probability. With its small interface area that has a high proportion of charged and polar residues, the complex appears poised for dissociation, and each subunit existing as a stable entity. This result is consistent with the known physiological events required for cAMP-dependent activation of the kinase.	Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA; Los Alamos Natl Lab, Theoret Biol & Biophys Grp, Los Alamos, NM 87545 USA; Univ Calif Davis, Sch Vet Med, Dept Med & Epidemiol, Davis, CA 95616 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; University of California System; University of California Davis	Trewhella, J (corresponding author), Los Alamos Natl Lab, Biosci Div, Mail Stop M888, Los Alamos, NM 87545 USA.			Trewhella, Jill/0000-0002-8555-6766	PHS HHS [13616] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BUILDER SE, 1980, J BIOL CHEM, V255, P3514; CHAU V, 1980, BIOCHEMISTRY-US, V19, P924, DOI 10.1021/bi00546a016; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; Diller TC, 2001, STRUCTURE, V9, P73, DOI 10.1016/S0969-2126(00)00556-6; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; Gibson RM, 1997, J BIOL CHEM, V272, P16343, DOI 10.1074/jbc.272.26.16343; Gibson RM, 1997, PROTEIN SCI, V6, P1825, DOI 10.1002/pro.5560060903; GOLDSTEIN H, 1950, CLASSICAL MECH, P149; Huang LJS, 1998, J BIOL CHEM, V273, P26739, DOI 10.1074/jbc.273.41.26739; Hubbard SJ., 1993, COMPUTER PROGRAM; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JOHNSON DA, 1993, BIOCHEMISTRY-US, V32, P6402, DOI 10.1021/bi00076a013; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LALLI E, 1994, J BIOL CHEM, V269, P17359; OLAH GA, 1993, BIOCHEMISTRY-US, V32, P3649, DOI 10.1021/bi00065a018; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; Sahara S, 1996, FEBS LETT, V384, P138, DOI 10.1016/0014-5793(96)00302-X; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; Street AG, 1999, P NATL ACAD SCI USA, V96, P9074, DOI 10.1073/pnas.96.16.9074; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TSUZUKI J, 1978, BIOCHEMISTRY-US, V17, P2961, DOI 10.1021/bi00608a004; Tung CS, 1999, J BIOMOL STRUCT DYN, V17, P347, DOI 10.1080/07391102.1999.10508366; Tung CS, 1997, BIOPHYS J, V72, P876, DOI 10.1016/S0006-3495(97)78722-8; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WIEMANN S, 1992, BIOCHIM BIOPHYS ACTA, V1171, P93, DOI 10.1016/0167-4781(92)90144-O; YANG SM, 1995, BIOCHEMISTRY-US, V34, P6267, DOI 10.1021/bi00019a002; Zhao JK, 1998, J BIOL CHEM, V273, P30448, DOI 10.1074/jbc.273.46.30448	39	25	26	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12423	12431		10.1074/jbc.M110298200	http://dx.doi.org/10.1074/jbc.M110298200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11799117	hybrid			2022-12-27	WOS:000174846400108
J	Nikki, M; Merilainen, J; Lehto, VP				Nikki, M; Merilainen, J; Lehto, VP			FAP52 regulates actin organization via binding to filamin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; PROTEIN ABP-280; ALPHA-ACTININ; CYTOPLASMIC DOMAINS; FOCAL ADHESIONS; IDENTIFICATION; PURIFICATION; COMPLEX; REGION; FAMILY	FAP52, a focal adhesion-associated phosphoprotein, is a member of a FAP52/PACSIN/syndapin family of proteins. They share a multidomain structure and are implicated in actin-based and endocytotic functions. We show, by using both native and recombinant proteins, that FAP52 selectively binds to the actin cross-linking protein filamin (ABP-280). This was based on an affinity purification followed by a sequence determination by mass spectrometry, co-immunoprecipitation, overlay binding, and surface plasmon resonance analysis. Binding studies with deletion mutants showed that the sites of the interaction map to the highly a-helical N-terminal part of FAP52 and to the C-terminal region of filamin, which also contains binding sites to some transmembrane signaling proteins. In immunofluorescence and immunoelectron microscopy of cultured fibroblasts, a different overall subcellular distribution was seen for filamin and FAP52 except for a stress fiber-focal adhesion junction where they showed a notable overlap. Overexpression of the full-length and mutant forms of FAP52 led to an extensive reorganization of actin and filamin in cultured fibroblasts. Thus, the results show that FAP52 interacts with filamin, and we propose that this interaction is important in linking and coordinating the events between focal adhesions and the actin cytoskeleton.	Univ Oulu, Dept Pathol, FIN-90014 Oulu, Finland; Thermo Labsyst OY, Lab Technol Div, FIN-00811 Helsinki, Finland; Univ Helsinki, Dept Pathol, FIN-00290 Helsinki, Finland	University of Oulu; University of Helsinki	Lehto, VP (corresponding author), Univ Oulu, Dept Pathol, POB 5000 Aspistie 5, FIN-90014 Oulu, Finland.							ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Awata H, 2001, J BIOL CHEM, V276, P34871, DOI 10.1074/jbc.M100775200; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; HEGGENESS MH, 1977, P NATL ACAD SCI USA, V74, P3883, DOI 10.1073/pnas.74.9.3883; Hjalm G, 2001, J BIOL CHEM, V276, P34880, DOI 10.1074/jbc.M100784200; LANGANGER G, 1984, J CELL BIOL, V99, P1324, DOI 10.1083/jcb.99.4.1324; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Li M, 2000, MOL PHARMACOL, V57, P446, DOI 10.1124/mol.57.3.446; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Merilainen J, 1997, J BIOL CHEM, V272, P23278, DOI 10.1074/jbc.272.37.23278; Meyer SC, 1997, J BIOL CHEM, V272, P2914, DOI 10.1074/jbc.272.5.2914; MITTAL B, 1987, CELL MOTIL CYTOSKEL, V8, P345, DOI 10.1002/cm.970080407; Modregger J, 2000, J CELL SCI, V113, P4511; NUNNALLY MH, 1980, J CELL BIOL, V87, P219, DOI 10.1083/jcb.87.1.219; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Ritter B, 1999, FEBS LETT, V454, P356, DOI 10.1016/S0014-5793(99)00830-3; Sambrook J., 1989, MOL CLONING, pA1; SCHLOSS JA, 1979, P NATL ACAD SCI USA, V76, P4484, DOI 10.1073/pnas.76.9.4484; SHARMA CP, 1995, J IMMUNOL, V154, P3461; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Takafuta T, 1998, J BIOL CHEM, V273, P17531, DOI 10.1074/jbc.273.28.17531; WEIHING RR, 1985, CAN J BIOCHEM CELL B, V63, P397, DOI 10.1139/o85-059; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; Zhang WJ, 1998, J NEUROSCI, V18, P914	36	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11432	11440		10.1074/jbc.M111753200	http://dx.doi.org/10.1074/jbc.M111753200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11790794	hybrid			2022-12-27	WOS:000174613100087
J	Segade, F; Trask, BC; Broekelmann, TJ; Pierce, RA; Mecham, RP				Segade, F; Trask, BC; Broekelmann, TJ; Pierce, RA; Mecham, RP			Identification of a matrix-binding domain in MAGP1 and MAGP2 and intracellular localization of alternative splice forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROFIBRIL-ASSOCIATED GLYCOPROTEIN; FIBRILLIN-CONTAINING MICROFIBRILS; GENE; ELASTIN; EXPRESSION; COMPONENT; PROTEINS; ANTIGEN; CLONING; BOVINE	MAGP1 is a small molecular mass protein associated with microfibrils in the extracellular matrix (EM. To identify the molecular basis of its interaction with other microfibrillar proteins, deletion constructs of MAGP1 were expressed in a mammalian cell system that served as a model for microfibril assembly. This study identified a 54-amino acid sequence in the carboxyl-terminal region of the protein that defines a matrix-binding domain that is sufficient to target MAGP1 to the ECM. Site-directed mutagenesis demonstrated that binding activity is dependent on the presence of 7 cysteine residues in this sequence. MAGP2 contains a sequence similar to the matrix-binding domain of MAGP1, but could not associate with the ECM because of a single amino acid change. Two naturally occurring MAGP1 splice variants, MAGP1B (human-specific) and MAGP1D (found in mice), localized intracellularly when expressed as chimeric proteins with green fluorescent protein in rat lung fibroblasts. This suggests a second action site for MAGP1.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Barnes Jewish Hosp, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Barnes Jewish Hosp, Div Pulm & Crit Care Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	Mecham, RP (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Campus Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.	bmecham@cellbiology.wustl.edu			NHLBI NIH HHS [HL61006, HL53325, HL62295] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062295, R37HL053325, R01HL053325, P50HL061006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASHIR MM, 1994, BIOCHEMISTRY-US, V33, P593, DOI 10.1021/bi00168a026; Brekken RA, 2000, MATRIX BIOL, V19, P569, DOI 10.1016/S0945-053X(00)00105-0; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; BrownAugsburger P, 1996, BIOCHEM J, V318, P149, DOI 10.1042/bj3180149; CHEN YP, 1993, J BIOL CHEM, V268, P27381; DAVIS EC, 1994, J CELL SCI, V107, P727; FARACO J, 1995, GENOMICS, V25, P630, DOI 10.1016/0888-7543(95)80004-6; Finnis ML, 1997, J BIOL CHEM, V272, P22817, DOI 10.1074/jbc.272.36.22817; Frankfater C, 2000, MAMM GENOME, V11, P191, DOI 10.1007/s003350010036; GIBSON MA, 1986, J BIOL CHEM, V261, P1429; Gibson MA, 1998, J HISTOCHEM CYTOCHEM, V46, P871, DOI 10.1177/002215549804600802; Gibson MA, 1999, J BIOL CHEM, V274, P13060, DOI 10.1074/jbc.274.19.13060; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; Gooden MD, 1999, J CELL BIOCHEM, V74, P152, DOI 10.1002/(SICI)1097-4644(19990801)74:2<152::AID-JCB2>3.0.CO;2-4; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Hastings KEM, 1996, J MOL EVOL, V42, P631, DOI 10.1007/BF02338796; Hatzinikolas G, 1998, J BIOL CHEM, V273, P29309, DOI 10.1074/jbc.273.45.29309; Henderson M, 1996, J HISTOCHEM CYTOCHEM, V44, P1389, DOI 10.1177/44.12.8985131; Kimura M., 1983, NEUTRAL THEORY MOL E; KUMARATILAKE JS, 1989, EUR J CELL BIOL, V50, P117; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; PATTANAKITSAKUL SN, 1992, J BIOL CHEM, V267, P7814; Patthy L, 1999, GENE, V238, P103, DOI 10.1016/S0378-1119(99)00228-0; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Robb BW, 1999, MOL BIOL CELL, V10, P3595, DOI 10.1091/mbc.10.11.3595; Robinson PN, 2000, J MED GENET, V37, P9, DOI 10.1136/jmg.37.1.9; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Segade F, 2000, MATRIX BIOL, V19, P671, DOI 10.1016/S0945-053X(00)00115-3; Trask BC, 2000, MOL BIOL CELL, V11, P1499, DOI 10.1091/mbc.11.5.1499; Trask BC, 2001, BIOCHEMISTRY-US, V40, P4372, DOI 10.1021/bi002738z; TRASK BC, 1999, THESIS WASHINGTON U; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	35	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11050	11057		10.1074/jbc.M110347200	http://dx.doi.org/10.1074/jbc.M110347200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11796718	Green Published, hybrid			2022-12-27	WOS:000174613100039
J	Murate, T; Suzuki, M; Hattori, M; Takagi, A; Kojima, T; Tanizawa, T; Asano, H; Hotta, T; Saito, H; Yoshida, S; Tamiya-Koizumi, K				Murate, T; Suzuki, M; Hattori, M; Takagi, A; Kojima, T; Tanizawa, T; Asano, H; Hotta, T; Saito, H; Yoshida, S; Tamiya-Koizumi, K			Up-regulation of acid sphingomyelinase during retinoic acid-induced myeloid differentiation of NB4, a human acute promyelocytic leukemia cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PML-RAR-ALPHA; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; DNA-BINDING; IN-VITRO; CERAMIDE; RECEPTORS; GENE; AP-2; VITAMIN-D3	All-trans-retinoic acid (ATRA) induces myeloid differentiation of a human promyelocytic leukemia cell line, NB4, but does not affect its subclone NB4/RA harboring a point-mutated ligand-binding domain (AF2) in retinoic acid receptor alpha (RARalpha) gene. We found that ATRA induced the 4-fold elevation of acid sphingomyelinase (ASMase) activity 24 h after treatment in NB4 cells, but not in NB4/RA cells. ATRA did not affect neutral sphingomyelinase activity in either NB4 or NB4/RA. Upon treatment with ATRA, ceramide, the product of an ASMase reaction, accumulated in NB4 cells. Northern blot analysis showed a marked elevation of the ASMase mRNA 8 h after ATRA treatment, reaching a plateau at 24 h. Regulation of ASMase gene expression was studied by a promoter analysis using luciferase reporter assay. The 5'-upstream flanking region of human ASMase gene (-519/+300) conjugated with the luciferase gene was introduced into COS-7 cells. Luciferase activity in transformed cells markedly increased in response to ATRA stimulation when the wild type RARalpha or the PML/RARalpha hybrid protein was co-expressed. Deletion experiments revealed that a short sequence at the 5'-end (-519/-485) was indispensable for the ATRA response. Within this short region, two retinoic acid-responsive element-like motifs (TGCCCG and TCTCCT) and one AP2-like motif (CCCTTCCC) were identified. Deletion and base-substitution experiments showed that all three motifs are required for the full expression induced by ATRA. Electrophoresis mobility shift assays with the nuclear extract of ATRA-treated NB4 cells showed that proteins were bound specifically to the probe being mediated by all three motifs in the promoter sequence.	Nagoya Univ, Sch Hlth Sci, Higashi Ku, Nagoya, Aichi 4618673, Japan; Nagoya Univ, Grad Sch, Res Inst Dis Mech & Control, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch, Dept Internal Med 1, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Fac Med, Nagoya, Aichi 4668550, Japan; Tokai Univ, Sch Med, Dept Internal Med 4, Isehara, Kanagawa 2591100, Japan	Nagoya University; Nagoya University; Nagoya University; Nagoya University; Tokai University	Murate, T (corresponding author), Nagoya Univ, Sch Hlth Sci, Higashi Ku, Daiko Minami 1-1-20, Nagoya, Aichi 4618673, Japan.		Kojima, Tetsuhito/I-6271-2014; Suzuki, Motoshi/I-7246-2014	Kojima, Tetsuhito/0000-0002-1905-1065; Suzuki, Motoshi/0000-0003-0682-5006				Bertolaso L, 1998, BRIT J HAEMATOL, V100, P541, DOI 10.1046/j.1365-2141.1998.00596.x; CHAMBON P, 1993, GENE, V135, P223, DOI 10.1016/0378-1119(93)90069-F; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Fenaux P, 1997, NEW ENGL J MED, V337, P1076, DOI 10.1056/NEJM199710093371509; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; Herget T, 2000, J BIOL CHEM, V275, P30344, DOI 10.1074/jbc.M000714200; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; Kitamura K, 1997, LEUKEMIA, V11, P1950, DOI 10.1038/sj.leu.2400837; Kizaki M, 1996, BLOOD, V88, P1824; KOIZUMI K, 1980, CANCER RES, V40, P909; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Langmann T, 1999, J LIPID RES, V40, P870; LANOTTE M, 1991, BLOOD, V77, P1080; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Levade T, 1999, CHEM PHYS LIPIDS, V102, P167, DOI 10.1016/S0009-3084(99)00085-7; Liebisch G, 1999, J LIPID RES, V40, P1539; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; Naltner A, 2000, J BIOL CHEM, V275, P56, DOI 10.1074/jbc.275.1.56; NEWRZELLA D, 1992, BIOL CHEM H-S, V373, P1233, DOI 10.1515/bchm3.1992.373.2.1233; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Panariello L, 1996, J BIOL CHEM, V271, P25524, DOI 10.1074/jbc.271.41.25524; Prinetti A, 1997, FEBS LETT, V414, P475, DOI 10.1016/S0014-5793(97)00981-2; Riboni L, 1997, PROG LIPID RES, V36, P153, DOI 10.1016/S0163-7827(97)00008-8; RIBONI L, 1995, J BIOL CHEM, V270, P26868, DOI 10.1074/jbc.270.45.26868; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; Shao WL, 2000, BLOOD, V96, P2233; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Stoffel W, 1999, CHEM PHYS LIPIDS, V102, P107, DOI 10.1016/S0009-3084(99)00079-1; Tennyson CN, 1996, NUCLEIC ACIDS RES, V24, P3059, DOI 10.1093/nar/24.15.3059; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Veiga MP, 1999, BIOPHYS J, V76, P342, DOI 10.1016/S0006-3495(99)77201-2; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Yan C, 1998, AM J PHYSIOL-LUNG C, V275, pL239, DOI 10.1152/ajplung.1998.275.2.L239; Zumbansen M, 1997, J BIOL CHEM, V272, P10904	40	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9936	9943		10.1074/jbc.M111594200	http://dx.doi.org/10.1074/jbc.M111594200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11788605	hybrid			2022-12-27	WOS:000174549200045
J	Daly, C; Ziff, EB				Daly, C; Ziff, EB			Ca2+-dependent formation of a dynamin-synaptophysin complex - Potential role in synaptic vesicle endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN; GTPASE ACTIVITY; IDENTIFICATION; MECHANISM; BINDING; BRAIN	Synaptophysin is a synaptic vesicle (SV) protein of unknown function. Here we show that a repeated sequence in the cytoplasmic tail of synaptophysin mediates the formation of a protein complex containing the GTPase dynamin. The formation of this complex requires a high Ca2+ concentration, suggesting that it occurs preferentially at the sites of SV exocytosis. Coimmunoprecipitation of a dynamin-synaptophysin complex from brain extracts is promoted by dissociation of vesicle-associated membrane protein 2 from synaptophysin. This finding suggests that dynamin only associates with synaptophysin in vivo after vesicle-associated membrane protein 2 (VAMP2) enters the SNARE complex. GTP binding releases dynamin from synaptophysin, possibly serving to regulate dynamin selfassembly during endocytosis. Our results suggest that synaptophysin plays a role in SV recycling by recruiting dynamin to the vesicle membrane.	NYU, Med Ctr, Howard Hughes Med Inst, New York, NY 10016 USA; NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA	Howard Hughes Medical Institute; New York University; New York University	Ziff, EB (corresponding author), NYU, Med Ctr, Howard Hughes Med Inst, 550 1St Ave,MSB 397, New York, NY 10016 USA.			Ziff, Edward/0000-0001-7389-8649; Daly, Christopher/0000-0003-3800-8174	NATIONAL INSTITUTE ON AGING [R01AG013620] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG13620] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bacci A, 2001, J NEUROSCI, V21, P6588, DOI 10.1523/JNEUROSCI.21-17-06588.2001; BIXBY JL, 1992, MOL BRAIN RES, V13, P339, DOI 10.1016/0169-328X(92)90217-Y; CALAKOS N, 1994, J BIOL CHEM, V269, P24534; Cousin MA, 2000, J NEUROSCI, V20, P949, DOI 10.1523/JNEUROSCI.20-03-00949.2000; Daly C, 1997, J NEUROSCI, V17, P2365; Daly C, 2000, P NATL ACAD SCI USA, V97, P6120, DOI 10.1073/pnas.97.11.6120; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ESHKIND LG, 1995, CELL TISSUE RES, V282, P423, DOI 10.1007/s004410050493; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; Janz R, 1999, NEURON, V24, P687, DOI 10.1016/S0896-6273(00)81122-8; KNAUS P, 1990, NEURON, V5, P453, DOI 10.1016/0896-6273(90)90084-S; LEUBE RE, 1994, J CELL BIOL, V127, P1589, DOI 10.1083/jcb.127.6.1589; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; Liu JP, 1996, J NEUROCHEM, V66, P2074; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; McMahon HT, 1996, P NATL ACAD SCI USA, V93, P4760, DOI 10.1073/pnas.93.10.4760; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Sheng ZH, 1998, J BIOENERG BIOMEMBR, V30, P335, DOI 10.1023/A:1021985521748; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Spiwoks-Becker I, 2001, NEUROSCIENCE, V107, P127, DOI 10.1016/S0306-4522(01)00345-1; Stenius K, 1995, J CELL BIOL, V131, P1801, DOI 10.1083/jcb.131.6.1801; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; SUDHOF TC, 1987, NUCLEIC ACIDS RES, V15, P9607, DOI 10.1093/nar/15.22.9607; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366	31	66	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9010	9015		10.1074/jbc.M110815200	http://dx.doi.org/10.1074/jbc.M110815200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11779869	hybrid			2022-12-27	WOS:000174400600037
J	Worby, CA; Simonson-Leff, N; Clemens, JC; Huddler, D; Muda, M; Dixon, JE				Worby, CA; Simonson-Leff, N; Clemens, JC; Huddler, D; Muda, M; Dixon, JE			Drosophila Ack targets its substrate, the sorting nexin DSH3PX1, to a protein complex involved in axonal guidance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; PATHWAY; BINDING; CLONING; DOMAIN	Dock, the Drosophila orthologue of Nck, is an adaptor protein that is known to function in axonal guidance paradigms in the fly including proper development of neuronal connections in photoreceptor cells and axonal tracking in Bolwig's organ. To develop a better understanding of axonal guidance at the molecular level, we purified proteins in a complex with the SH2 domain of Dock from fly Schneider 2 cells. A protein designated p145 was identified and shown to be a tyrosine kinase with sequence similarity to mammalian Cdc-42-associated tyrosine kinases. We demonstrate that Drosophia Ack (DAck) can be co-immunoprecipitated with Dock and DSH3PX1 from fly cell extracts. The domains responsible for the in vitro interaction between Drosophila Ack and Dock were identified, and direct protein-protein interactions between complex members were established. We conclude that DSH3PX1 is a substrate for DAck in vivo and in vitro and define one of the major in vitro sites of DSH3PX1 phosphorylation to be Tyr-56. Tyr-56 is located within the SH3 domain of DSH3PX1, placing it in an important position for regulating the binding of proline-rich targets. We demonstrate that Tyr-56 phosphorylation by DAck diminishes the DSH3PX1 SH3 domain interaction with the Wiskott-Aldrich Syndrome protein while enabling DSH3PX1 to associate with Dock. Furthermore, when Tyr-56 is mutated to aspartate or glutamate, the binding to Wiskott-Aldrich Syndrome protein is abrogated. These results suggest that the phosphorylation of DSH3PX1 by DAck targets this sorting nexin to a protein complex that includes Dock, an adaptor protein important for axonal guidance.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Dixon, JE (corresponding author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.				PHS HHS [18024] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hopper NA, 2000, MOL CELL, V6, P65, DOI 10.1016/S1097-2765(00)00008-3; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; Linseman DA, 2001, J BIOL CHEM, V276, P5622, DOI 10.1074/jbc.M006812200; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Morrogh LM, 1999, EUR J IMMUNOL, V29, P2269; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Strous GJ, 1999, J CELL SCI, V112, P1417; Teo M, 2001, J BIOL CHEM, V276, P18392, DOI 10.1074/jbc.M008795200; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; WORBY C, 1997, CELLS LAB MANUAL, V1, P1; Worby CA, 2001, J BIOL CHEM, V276, P41782, DOI 10.1074/jbc.M107080200; WORBY CA, 2001, SCI STKE; Wu Y, 1998, J BIOL CHEM, V273, P5765, DOI 10.1074/jbc.273.10.5765; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Yang WN, 1999, J BIOL CHEM, V274, P8524, DOI 10.1074/jbc.274.13.8524; Yang WN, 2001, J BIOL CHEM, V276, P43987, DOI 10.1074/jbc.M104819200; Yang WN, 2001, J BIOL CHEM, V276, P17468, DOI 10.1074/jbc.M010893200; Zhang YQ, 1999, GENE, V233, P171, DOI 10.1016/S0378-1119(99)00142-0	26	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9422	9428		10.1074/jbc.M110172200	http://dx.doi.org/10.1074/jbc.M110172200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11773052	hybrid			2022-12-27	WOS:000174400600092
J	Mahboubi, K; Pober, JS				Mahboubi, K; Pober, JS			Activation of signal transducer and activator of transcription 1 (STAT1) is not sufficient for the induction of STAT1-dependent genes in endothelial cells - Comparison of interferon-gamma and oncostatin M	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA CLASS-I; LEUKEMIA-INHIBITORY FACTOR; CYTOKINE RECEPTOR GP130; TUMOR-NECROSIS-FACTOR; SERINE PHOSPHORYLATION; IFN-GAMMA; TYROSINE PHOSPHORYLATION; TARGETED DISRUPTION; MHC EXPRESSION; PROTEIN	We compared human endothelial cell (EC) responses to interferon-gamma (IFNgamma) and oncostatin M (OnM), cytokines that utilize Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling. Both cytokines cause phosphorylation of Tyr residue 701 and Ser residue 727 of STAT1, as shown by immunoblotting. Both activate DNA binding of STAT1 homodimers, shown by electrophoretic mobility shift assay. However, only IFNgamma increases expression of three STAT1-dependent gene products examined, namely transporter associated with antigen processing-1 (TAP1), interferon regulatory factor-1 URF1), and class I major histocompatibility complex (MHC) protein, as demonstrated by immunoblotting. Only IFNgamma increases TAP1 transcription assessed by reporter gene assay. OnM pretreatment or co-treatment does not inhibit IFNgamma responses. Interestingly, IFNgamma activation of STAT1 is considerably more long-lived than that produced by OnM. To determine whether duration is functionally significant, we transduced EC with a chimeric receptor containing extracellular domains of platelet-derived growth factor receptor beta and intracellular regions of gp130, the signaling subunit of the OnM receptor, mutated to prevent binding of the tyrosine phosphatase SHP-2. Addition of platelet-derived growth factor to such transduced cells produces STAT1 activation that is comparable in magnitude and duration to that caused by IFNgamma, but still fails to induce TAP1, IRF1, or class I MHC molecules. OnM also activates STATI. but not transcription of STAT1-dependent genes in HepG2 cells. Transient transfection of HepG2 cells with a STAT-defective mouse IFNgamma receptor failed to complement the OnM STAT signal. We conclude that STAT1 activation is necessary but not sufficient for induction of transcription of IFNgamma-responsive genes. However, signals provided by IFNgamma other than STAT1 activation cannot be provided in trans to complement the response to OnM.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdepartmental Program Vasc Biol & Transplanta, New Haven, CT 06510 USA	Yale University	Pober, JS (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdepartmental Program Vasc Biol & Transplanta, Rm 454,295 Congress Ave, New Haven, CT 06510 USA.	jordan.pober@yale.edu			NHLBI NIH HHS [R37-HL36003, F32-HL10275] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010275, R37HL036003] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMARAL MC, 1993, J CLIN INVEST, V92, P848, DOI 10.1172/JCI116659; Anhuf D, 2000, J IMMUNOL, V165, P2535, DOI 10.4049/jimmunol.165.5.2535; Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; BROWN TJ, 1991, J IMMUNOL, V147, P2175; CAI J, 1994, AM J PATHOL, V145, P74; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; EPPERSON DE, 1992, J IMMUNOL, V149, P3297; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; GOES N, 1995, J IMMUNOL, V155, P4559; Goes N, 1996, TRANSPLANTATION, V62, P1889, DOI 10.1097/00007890-199612270-00036; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Hobart M, 1997, J IMMUNOL, V158, P4260; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; JOLY E, 1991, SCIENCE, V253, P1283, DOI 10.1126/science.1891717; Karmann K, 1996, J EXP MED, V184, P173, DOI 10.1084/jem.184.1.173; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; Ma WL, 1997, J BIOL CHEM, V272, P16585, DOI 10.1074/jbc.272.26.16585; Mahboubi K, 2001, LAB INVEST, V81, P327, DOI 10.1038/labinvest.3780241; Mahboubi K, 2000, J IMMUNOL, V164, P3837, DOI 10.4049/jimmunol.164.7.3837; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Min W, 1996, J IMMUNOL, V156, P3174; Min W, 1998, CIRC RES, V83, P815, DOI 10.1161/01.RES.83.8.815; Modur V, 1997, J CLIN INVEST, V100, P158, DOI 10.1172/JCI119508; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Qiu BS, 1996, DIGEST DIS SCI, V41, P1625, DOI 10.1007/BF02087911; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Ramana CV, 2000, ONCOGENE, V19, P2619, DOI 10.1038/sj.onc.1203525; Saijonmaa O, 1998, AM J PHYSIOL-HEART C, V275, pH662, DOI 10.1152/ajpheart.1998.275.2.H662; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; SCHIEVEN GL, 1992, J IMMUNOL, V149, P1676; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stephens JM, 1998, J BIOL CHEM, V273, P31408, DOI 10.1074/jbc.273.47.31408; Strobl B, 2001, EMBO J, V20, P5431, DOI 10.1093/emboj/20.19.5431; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221; Terstegen L, 2000, J BIOL CHEM, V275, P18810, DOI 10.1074/jbc.M904148199; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; Trepicchio WL, 1996, J IMMUNOL, V157, P3627; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wallace PM, 1999, J IMMUNOL, V162, P5547; Yao LB, 1996, J EXP MED, V184, P81, DOI 10.1084/jem.184.1.81; Zheng L, 2000, J IMMUNOL, V164, P4665, DOI 10.4049/jimmunol.164.9.4665; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	57	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8012	8021		10.1074/jbc.M107542200	http://dx.doi.org/10.1074/jbc.M107542200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11777927	hybrid			2022-12-27	WOS:000174268000050
J	Brandt, SM; Mariani, R; Holland, AU; Hope, TJ; Landau, NR				Brandt, SM; Mariani, R; Holland, AU; Hope, TJ; Landau, NR			Association of chemokine-mediated block to HIV entry with coreceptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ADRENERGIC-RECEPTOR KINASE; PROTEIN-COUPLED RECEPTORS; SMALL-MOLECULE INHIBITOR; BETA(2)-ADRENERGIC RECEPTOR; CELL-LINES; SYNERGISTIC REGULATION; PRIMARY MACROPHAGES; DOWN-MODULATION; CCR5 ANTAGONIST	Chemokines inhibit entry of HIV into CD4(+) T cells more effectively than into macrophages or transfected adherent cells. Here, we tested whether chemokine receptor internalization could account for cell type differences in the effectiveness of chemokines. Infection of CEM T cells expressing stably transduced wild-type CCR5 was much more readily inhibited by chemokine than were transduced HOS cells. This response correlated with the efficiency of CCR5 internalization. A mutated CCR5, termed M7-CCR5, in which the Ser/Thr phosphorylation sites in the cytoplasmic tail were changed to Ala, did not internalize in response to MIP-1alpha. M7-CCR5 was expressed at slightly higher levels than wild-type on stably transduced cell lines and was somewhat more potent as an HIV-1 coreceptor. The mutated receptor mobilized intracellular Ca2+ in response to chemokine to a level 4-fold higher than did the wild type CCR5. Unexpectedly, the receptor was desensitized as efficiently as wild type, suggesting that desensitization does not require cytoplasmic tail phosphorylation. Entry of R5 HIV-1 reporter virus into cells stably expressing M7-CCR5 was largely resistant to blocking by MIP-1alpha. As much as 80% of entry inhibition was attributed to receptor internalization. Aminooxypentane (AOP)-MIP-1alpha was able to induce a low level of M7-CCR5 internalization in HOS and to weakly inhibit HIV-1 entry. Introduction of dominant negative dynamin into HOS cells reduced the ability of chemokine to inhibit infection. The inefficiency of internalization of chemokine receptors in some cell types could allow virus to replicate in vivo in the presence of endogenous chemokine. Last, M7-CCR5 is a useful tool for discriminating coreceptor internalization from binding site masking in the evaluation of small molecule inhibitors of HIV-1 entry.	Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, La Jolla, CA 92037 USA; Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA	Salk Institute; University of California System; University of California San Diego; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Landau, NR (corresponding author), Salk Inst Biol Studies, Infect Dis Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA7214] Funding Source: Medline; NIAID NIH HHS [AI43252, AI36214, AI42397] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214, R01AI043252, R01AI042397] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Amzazi S, 1998, VIROLOGY, V252, P96, DOI 10.1006/viro.1998.9452; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; BERGER EA, 1997, AIDS, V11, P3; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; DENG D, 1996, NATURE, V381, P661; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Doranz BJ, 1997, IMMUNOL RES, V16, P15, DOI 10.1007/BF02786321; Dragic T, 2000, P NATL ACAD SCI USA, V97, P5639, DOI 10.1073/pnas.090576697; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EMI N, 1991, J VIROL, V65, P1202, DOI 10.1128/JVI.65.3.1202-1207.1991; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; Hesselgesser J, 1998, J IMMUNOL, V160, P877; Heveker N, 1998, CURR BIOL, V8, P369, DOI 10.1016/S0960-9822(98)70155-1; Hoffman T L, 1998, AIDS, V12 Suppl A, pS17; KONG GH, 1994, J BIOL CHEM, V269, P13084; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; Sabbe R, 2001, J VIROL, V75, P661, DOI 10.1128/JVI.75.2.661-671.2001; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; Schlador ML, 1997, J BIOL CHEM, V272, P18882, DOI 10.1074/jbc.272.30.18882; Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0; Schols D, 1997, ANTIVIR RES, V35, P147, DOI 10.1016/S0166-3542(97)00025-9; Shiraishi M, 2000, J MED CHEM, V43, P2049, DOI 10.1021/jm9906264; Signoret N, 2000, J CELL BIOL, V151, P1281, DOI 10.1083/jcb.151.6.1281; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Ugolini S, 1997, J IMMUNOL, V159, P3000; Vila-Coro AJ, 1999, J IMMUNOL, V163, P3037; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Ylisastigui L, 2000, VIROLOGY, V278, P412, DOI 10.1006/viro.2000.0670	60	81	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17291	17299		10.1074/jbc.M108232200	http://dx.doi.org/10.1074/jbc.M108232200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11782464	hybrid			2022-12-27	WOS:000175564500124
J	Gagelin, C; Constantin, B; Deprette, C; Ludosky, MA; Recouvreur, M; Cartaud, J; Cognard, C; Raymond, G; Kordeli, E				Gagelin, C; Constantin, B; Deprette, C; Ludosky, MA; Recouvreur, M; Cartaud, J; Cognard, C; Raymond, G; Kordeli, E			Identification of Ank(G107), a muscle-specific ankyrin-G isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATIVELY SPLICED FORMS; MAMMALIAN SKELETAL-MUSCLE; ANION-EXCHANGER; ERYTHROCYTE ANKYRIN; SARCOPLASMIC-RETICULUM; REGULATORY DOMAIN; BINDING PROTEINS; REPEAT DOMAIN; BETA-SPECTRIN; MEMBRANE	We previously showed that alternatively spliced ankyrins-G, the Ank3 gene products, are expressed in skeletal muscle and localize to the postsynaptic folds and to the sarcoplasmic reticulum. Here we report the molecular cloning, tissue expression, and subcellular targeting of Ank(G107), a novel ankyrin-G from rat skeletal muscle. Ank(G107) lacks the entire AN-K repeat domain and contains a 76-residue sequence near the COOH terminus. This sequence shares homology with COOH-terminal sequences of ankyrins-R and ankyrins-B, including the muscle-specific skAnk1. Despite widespread tissue expression of Ank3, the 76-residue sequence is predominantly detected in transcripts of skeletal muscle and heart, including both major 8- and 5.6-kb mRNAs of skeletal muscle. In 15-day-old rat skeletal muscle, antibodies against the 76-residue sequence localized to the sarcolemma and to the postsynaptic membrane and cross-reacted with three endogenous ankyrins-G, including one 130-kDa polypeptide that comigrated with in vitro translated Ank(G107). In adult muscle, these polypeptides appeared significantly decreased, and immunofluorescence labeling was no more detectable. Green fluorescent protein-tagged Ank(G107) transfected in primary cultures of rat myotubes was targeted to the plasma membrane. Deletion of the 76-residue insert resulted in additional cytoplasmic labeling suggestive of a reduced stability of Ank(G107) at the membrane. Recruitment of the COOH-terminal domain to the membrane was much less efficient but still possible only in the presence of the 76-residue insert. We conclude that the 76-residue sequence contributes to the localization and is essential to the stabilization of Ank(G107) at the membrane. These results suggest that tissue-dependent and developmentally regulated alternative processing of ankyrins generates isoforms with distinct sequences, potentially involved in specific protein-protein interactions during differentiation of the sarcolemma and, in particular, of the postsynaptic membrane.	Univ Paris 06, Inst Jacques Monod, Dept Biol Cellulaire, UMR 7529,CNRS, F-75251 Paris 5, France; Univ Paris 07, Inst Jacques Monod, Dept Biol Cellulaire, UMR 7529,CNRS, F-75251 Paris, France; Univ Poitiers, CNRS, UMR 6558, F-86022 Poitiers, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers	Kordeli, E (corresponding author), Univ Paris 06, Inst Jacques Monod, Dept Biol Cellulaire, UMR 7529,CNRS, 2 Pl Jussieu, F-75251 Paris 5, France.		Constantin, Bruno/AAH-6463-2021; COGNARD, Christian/P-5305-2016	Kordeli, Ekaterini/0000-0002-5115-2202; Constantin, Bruno/0000-0003-1668-581X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Birkenmeier CS, 1998, GENOMICS, V50, P79, DOI 10.1006/geno.1998.5305; BIRKENMEIER CS, 1993, J BIOL CHEM, V268, P9533; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Chauhan VS, 2000, CIRC RES, V86, P441, DOI 10.1161/01.RES.86.4.441; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; COGNARD C, 1993, DEVELOPMENT, V117, P1153; DAVIS JQ, 1990, J BIOL CHEM, V265, P17252; DAVIS JQ, 1993, J CELL BIOL, V121, P121, DOI 10.1083/jcb.121.1.121; DAVIS LH, 1992, J BIOL CHEM, V267, P18966; De Matteis MA, 2000, J CELL SCI, V113, P2331; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; FLUCHER BE, 1990, NEURON, V5, P339, DOI 10.1016/0896-6273(90)90170-K; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; Gallagher PG, 1997, J BIOL CHEM, V272, P19220, DOI 10.1074/jbc.272.31.19220; Gallagher PG, 1998, J BIOL CHEM, V273, P1339, DOI 10.1074/jbc.273.3.1339; HALL TG, 1987, J BIOL CHEM, V262, P10537; Hoock TC, 1997, J CELL BIOL, V136, P1059, DOI 10.1083/jcb.136.5.1059; Kordeli E, 1998, J CELL SCI, V111, P2197; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; Lambert S, 1997, J NEUROSCI, V17, P7025; Lambert S, 1996, CURR TOP MEMBR, V43, P129; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; MOON RT, 1985, J CELL BIOL, V100, P152, DOI 10.1083/jcb.100.1.152; MORGANS CW, 1993, J CELL SCI, V105, P1137; NELSON WJ, 1984, P NATL ACAD SCI-BIOL, V81, P3292, DOI 10.1073/pnas.81.11.3292; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; PORTER GA, 1992, J CELL BIOL, V117, P997, DOI 10.1083/jcb.117.5.997; Sambrook J., 2002, MOL CLONING LAB MANU; SRINIVASAN Y, 1992, J BIOL CHEM, V267, P7483; Thevananther S, 1998, J BIOL CHEM, V273, P23952, DOI 10.1074/jbc.273.37.23952; Tuvia S, 1999, J CELL BIOL, V147, P995, DOI 10.1083/jcb.147.5.995; WHITE RA, 1992, MAMM GENOME, V3, P281, DOI 10.1007/BF00292156; Wood SJ, 1998, J CELL BIOL, V140, P675, DOI 10.1083/jcb.140.3.675; Zhang X, 1998, J CELL BIOL, V142, P1571, DOI 10.1083/jcb.142.6.1571; Zhang X, 1996, J BIOL CHEM, V271, P31391, DOI 10.1074/jbc.271.49.31391; Zhou DX, 1997, J CELL BIOL, V136, P621, DOI 10.1083/jcb.136.3.621	40	25	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12978	12987		10.1074/jbc.M111299200	http://dx.doi.org/10.1074/jbc.M111299200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11796721	Green Published, hybrid			2022-12-27	WOS:000175036300064
J	Speranza, G; Mueller, B; Orlandi, M; Morelli, CF; Manitto, P; Schink, B				Speranza, G; Mueller, B; Orlandi, M; Morelli, CF; Manitto, P; Schink, B			Mechanism of anaerobic ether cleavage - Conversion of 2-phenoxyethanol to phenol and acetaldehyde by Acetobacterium sp.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYETHYLENE-GLYCOL; DIOL DEHYDRATASE; FERMENTATIVE DEGRADATION; PELOBACTER-VENETIANUS; PURE CULTURES; RADICALS; BACTERIA; ACETATE; ENZYME; ACIDS	2-Phenoxyethanol is converted into phenol and acetate by a strictly anaerobic Gram-positive bacterium, Acetobacterium strain LuPhet1. Acetate results from oxidation of acetaldehyde that is the early product of the biodegradation process (Frings, J., and Schink, B. (1994) Arch. Microbiol. 162, 199-204). Feeding experiments with resting cell suspensions and 2-phenoxyethanol bearing two deuterium atoms at either carbon of the glycolic moiety as substrate demonstrated that the carbonyl group of the acetate derives from the alcoholic function and the methyl group derives from the adjacent carbon. A concomitant migration of a deuterium atom from C-1 to C-2 was observed. These findings were confirmed by NMR analysis of the acetate obtained by fermentation of 2-phenoxy-[2-C-13,1-H-2(2)]ethanol, 2-phenoxy-[1-C-13,1-H-2(2)]ethanol, and 2-phenoxy-[1,2-C-13(2),1-H-2(2)] ethanol. During the course of the biotransformation process, the molecular integrity of the glycolic unit was completely retained, no loss of the migrating deuterium occurred by exchange with the medium, and the 1,2-deuterium shift was intramolecular. A diol dehydratase-like mechanism could explain the enzymatic cleavage of the ether bond of 2-phenoxyethanol, provided that an intramolecular H/OC6H5 exchange is assumed, giving rise to the hemiacetal precursor of acetaldehyde. However, an alternative mechanism is proposed that is supported by the well recognized propensity of alpha-hydroxyradical and of its conjugate base (ketyl anion) to eliminate a beta-positioned leaving group.	Univ Milan, Dipartimento Chim Organ & Ind, I-20133 Milan, Italy; CNR, Ctr Studio Sostanze Organ Nat, I-20133 Milan, Italy; Univ Konstanz, Fak Biol, D-78457 Constance, Germany	University of Milan; Consiglio Nazionale delle Ricerche (CNR); University of Konstanz	Speranza, G (corresponding author), Univ Milan, Dipartimento Chim Organ & Ind, Via Venezian 21, I-20133 Milan, Italy.	giovanna.speranza@unimi.it	Morelli, Carlo F./R-2869-2016; Speranza, Giovanna/Q-6280-2016	Morelli, Carlo F./0000-0001-6314-6902; Speranza, Giovanna/0000-0003-4544-1515				Arigoni D., 1979, VITAMIN B12, P389; Buckel W, 1996, FEBS LETT, V389, P20, DOI 10.1016/0014-5793(96)00530-3; Buckel W, 1998, FEMS MICROBIOL REV, V22, P523, DOI 10.1016/S0168-6445(98)00038-2; CIOMMER B, 1983, J ORGANOMET CHEM, V244, P319, DOI 10.1016/0022-328X(83)80040-0; Cox D P, 1978, Adv Appl Microbiol, V23, P173, DOI 10.1016/S0065-2164(08)70068-6; DUPUIS J, 1984, ANGEW CHEM INT EDIT, V23, P896, DOI 10.1002/anie.198408961; DWYER DF, 1983, APPL ENVIRON MICROB, V46, P185, DOI 10.1128/AEM.46.1.185-190.1983; EGGER KW, 1973, HELV CHIM ACTA, V56, P1516, DOI 10.1002/hlca.19730560509; FINKE RG, 1984, COORDIN CHEM REV, V54, P1, DOI 10.1016/0010-8545(84)85016-X; FINKE RG, 1983, J AM CHEM SOC, V105, P7592, DOI 10.1021/ja00364a022; FINKE RG, 1990, MOLECULAR MECHANISMS IN BIOORGANIC PROCESSES, P244; FREY PA, 1990, CHEM REV, V90, P1343, DOI 10.1021/cr00105a014; Frey PA, 2000, ARCH BIOCHEM BIOPHYS, V382, P6, DOI 10.1006/abbi.2000.2010; FRINGS J, 1992, APPL ENVIRON MICROB, V58, P2164, DOI 10.1128/AEM.58.7.2164-2167.1992; FRINGS J, 1994, ARCH MICROBIOL, V162, P199, DOI 10.1007/s002030050125; Golding B. T., 1997, COMPREHENSIVE BIOL C, P239; Gottlieb HE, 1997, J ORG CHEM, V62, P7512, DOI 10.1021/jo971176v; GRANT MA, 1983, BIOTECHNOL BIOENG, V25, P627, DOI 10.1002/bit.260250229; GRAY GA, 1969, J MAGN RESON, V1, P41; HAMMERSCHMIDT F, 1988, LIEBIGS ANN CHEM, P537; Hansen P. E., 1984, ANNU REP NMR SPECTRO, V15, P105, DOI [10.1016/S0066-4103(08)60208-2, DOI 10.1016/S0066-4103(08)60208-2]; HOMMELTOFT SI, 1985, J AM CHEM SOC, V107, P2548, DOI 10.1021/ja00294a056; KALINOSWSKI HO, 1988, CARBON 13 NMR SPECTR, P47; KAWAI F, 1987, CRC CR REV BIOTECHN, V6, P273, DOI 10.3109/07388558709089384; MATTA MS, 1987, J AM CHEM SOC, V109, P4916, DOI 10.1021/ja00250a026; MCMILLEN DF, 1982, ANNU REV PHYS CHEM, V33, P493, DOI 10.1146/annurev.pc.33.100182.002425; OBRADORS N, 1991, APPL ENVIRON MICROB, V57, P2383, DOI 10.1128/AEM.57.8.2383-2388.1991; OGAWA T, 1994, J CHEM SOC PERK T 1, P3473, DOI 10.1039/p19940003473; PEARCE BA, 1980, J GEN MICROBIOL, V118, P21; RAGSDALE SW, 1985, J BIOL CHEM, V260, P3970; RETEY J, 1982, STEREOSPECIFICITY OR, P185; SCHINK B, 1983, APPL ENVIRON MICROB, V45, P1905, DOI 10.1128/AEM.45.6.1905-1913.1983; Schramm E, 1991, Biodegradation, V2, P71, DOI 10.1007/BF00114597; Smith DM, 2001, J AM CHEM SOC, V123, P1664, DOI 10.1021/ja001454z; Solladie G, 1998, TETRAHEDRON-ASYMMETR, V9, P3081, DOI 10.1016/S0957-4166(98)00301-2; STRASS A, 1986, APPL MICROBIOL BIOT, V25, P37; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; TAKEUCHI Y, 1992, MAGN RESON CHEM, V30, P58, DOI 10.1002/mrc.1260300111; THELU J, 1980, FEMS MICROBIOL LETT, V8, P187, DOI 10.1016/0378-1097(80)90046-4; TORAYA T, 1994, MET IONS BIOL SYST, V30, P217; Toraya T, 2000, CELL MOL LIFE SCI, V57, P106, DOI 10.1007/s000180050502; VEDERAS JC, 1987, NAT PROD REP, V4, P277, DOI 10.1039/np9870400277; WAGENER S, 1988, APPL ENVIRON MICROB, V54, P561, DOI 10.1128/AEM.54.2.561-565.1988; White GF, 1996, MICROBIOL REV, V60, P216, DOI 10.1128/MMBR.60.1.216-232.1996; WIDDEL F, 1981, ARCH MICROBIOL, V129, P395, DOI 10.1007/BF00406470	45	14	14	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11684	11690		10.1074/jbc.M111059200	http://dx.doi.org/10.1074/jbc.M111059200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805106	hybrid, Green Published			2022-12-27	WOS:000174846400011
J	Cierniewska-Cieslak, A; Cierniewski, CS; Blecka, K; Papierak, M; Michalec, L; Zhang, L; Haas, TA; Plow, EF				Cierniewska-Cieslak, A; Cierniewski, CS; Blecka, K; Papierak, M; Michalec, L; Zhang, L; Haas, TA; Plow, EF			Identification and characterization of two cation binding sites in the integrin beta(3) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; DEPENDENT ADHESION SITE; MEDIATED CELL-ADHESION; FIBRINOGEN GAMMA-CHAIN; LIGAND-BINDING; I-DOMAIN; DIVALENT-CATION; A-DOMAIN; CRYSTAL-STRUCTURE; CROSS-LINKING	The midsegment of the beta(3) subunit has been implicated in the ligand and cation binding functions of the 93 integrins. This region may contain a metal ion-dependent adhesion site (MIDAS) and fold into an I domain-like structure. Two recombinant fragments, beta(3)-(95-373) and beta(3)-(95-301), were expressed and found to bind fibrinogen. Whereas 0.1 mM Ca2+ supported ligand binding to both recombinant fragments, 1.0 m-m Ca2+ suppressed binding to the longer but not the shorter fragment. These properties suggest that beta(3)-(95-373) contains both the ligand-competent (LC) and inhibitory (I) cation binding sites, and beta(3)-(95-301) lacks the I site. In equilibrium dialysis experiments, beta(3)-(95-373) contained two divalent cation binding sites, one reactive with either Mg2+ or Ca2+ and one Ca2+-specific, whereas beta(3)-(95-301) lacked the Ca2+-specific site. Mutant forms of 133495373) suggested that the LC site is a MIDAS motif involving Asp(119), Ser(121), Ser(123), Asp(217), and/or Glu(220) as coordination sites, and the I site was dependent upon residues within beta(3)-(301-323). In a molecular model of beta(3)-(95-373), a second Ca2+ could be docked onto a flexible loop in close proximity to the MIDAS. These results indicate that the ligand competent and Ca2+ specific inhibitory cation binding sites are distinct and reside in beta(3)-(95-373).	Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Mol Cardiol, Cleveland, OH 44195 USA; Amer Red Cross, Jerome H Holland Lab, Rockville, MD 20855 USA; Polish Acad Sci, Ctr Microbiol & Virol, PL-91205 Lodz, Poland; Med Univ Lodz, Dept Biophys, PL-91205 Lodz, Poland	Cleveland Clinic Foundation; Cleveland Clinic Foundation; American Red Cross; Polish Academy of Sciences; Medical University Lodz	Plow, EF (corresponding author), Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, 9500 Euclid Ave,Mail Code NB50, Cleveland, OH 44195 USA.	plowe@ccf.org	Krol, Aleksandra/S-9277-2016	Krol, Aleksandra/0000-0003-0033-1099	NHLBI NIH HHS [HL54924, R01 HL061589, P01 HL054710] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061589, P01HL054710, R01HL054924] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alemany M, 1996, BLOOD, V87, P592, DOI 10.1182/blood.V87.2.592.bloodjournal872592; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BAJT ML, 1994, J BIOL CHEM, V269, P20913; Basani RB, 1997, BLOOD, V90, P3082, DOI 10.1182/blood.V90.8.3082; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BRASS LF, 1984, J CLIN INVEST, V73, P626, DOI 10.1172/JCI111252; BURNS GF, 1986, CELL, V45, P269, DOI 10.1016/0092-8674(86)90391-0; Byzova TV, 1998, THROMB HAEMOSTASIS, V80, P726; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CIERNIEWSKI CS, 1994, BIOCHEMISTRY-US, V33, P12238, DOI 10.1021/bi00206a029; Cierniewski CS, 1999, J BIOL CHEM, V274, P16923, DOI 10.1074/jbc.274.24.16923; CIERNIEWSKI CS, 1987, J BIOL CHEM, V262, P13896; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FARRELL DH, 1994, J BIOL CHEM, V269, P226; GAILIT J, 1988, J BIOL CHEM, V263, P12927; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; GULINO D, 1992, J BIOL CHEM, V267, P1001; Haas TA, 1996, J BIOL CHEM, V271, P6017, DOI 10.1074/jbc.271.11.6017; Haas TA, 1997, PROTEIN ENG, V10, P1395, DOI 10.1093/protein/10.12.1395; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; Hu DD, 1999, J BIOL CHEM, V274, P4633, DOI 10.1074/jbc.274.8.4633; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KLOCZEWIAK M, 1982, BIOCHEM BIOPH RES CO, V107, P181, DOI 10.1016/0006-291X(82)91686-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1987, J BIOL CHEM, V262, P947; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Leitinger B, 1999, BIOCHEM SOC T, V27, P826, DOI 10.1042/bst0270826; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; Loftus JC, 1996, J BIOL CHEM, V271, P2033, DOI 10.1074/jbc.271.4.2033; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; PLOW EF, 1987, BIOCHEM PHARMACOL, V36, P4035, DOI 10.1016/0006-2952(87)90558-2; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RANDI AM, 1994, J BIOL CHEM, V269, P12395; RIVAS GA, 1991, BIOCHEM J, V276, P35, DOI 10.1042/bj2760035; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH JW, 1994, J BIOL CHEM, V269, P960; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong YM, 2001, J BIOL CHEM, V276, P19340, DOI 10.1074/jbc.M008903200; Zar J.H., 1999, ZAR KUHR 5 2019, V4th	70	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11126	11134		10.1074/jbc.M112388200	http://dx.doi.org/10.1074/jbc.M112388200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11796735	hybrid			2022-12-27	WOS:000174613100049
J	Engel, MFM; van Mierlo, CPM; Visser, AJWG				Engel, MFM; van Mierlo, CPM; Visser, AJWG			Kinetic and structural characterization of adsorption-induced unfolding of bovine alpha-lactalbumin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE INTERMEDIATE; BETA-LACTOGLOBULIN; CRYSTAL-STRUCTURES; PROTEIN; STATE; FLUORESCENCE; SURFACES; BINDING; SPECTROSCOPY; FLEXIBILITY	Conformational changes of bovine alpha-lactalbumin induced by adsorption on a hydrophobic interface are studied by fluorescence and circular dichroism spectroscopy. Adsorption of bovine alpha-lactalbumin on hydrophobic polystyrene nanospheres induces a non-native state of the protein, which is characterized by preserved secondary structure, lost tertiary structure, and release of calcium. This partially denatured state therefore resembles a molten globule state, which is an intermediate in the folding of bovine a-lactalbumin. Stopped-flow fluorescence spectroscopy reveals two kinetic phases during adsorption with rate constants k(1) similar to 50 s(-1) and k(2) similar to 8 s(-1). The rate of partial unfolding is remarkably fast and even faster than unfolding induced by the addition of 5.4.M guanidinium hydrochloride to native a-lactalbumin. The large unfolding rates exclude the possibility that unfolding of bovine alpha-lactalbumin to the intermediate state occurs before adsorption takes place. Stopped-flow fluorescence anisotropy experiments show that adsorption of bovine alpha-lactalbumin on polystyrene nanospheres occurs within the dead time (15 ms) of the experiment. This shows that the kinetic processes as determined by stopped-flow fluorescence spectroscopy are not affected by diffusion or association processes but are solely caused by unfolding of bovine alpha-lactalbumin induced by adsorption on the polystyrene surface. A scheme is presented that incorporates the results obtained and describes the adsorption of bovine a-lactalbumin.	Univ Wageningen & Res Ctr, Biochem Lab, NL-6703 HA Wageningen, Netherlands; Univ Wageningen & Res Ctr, Netherlands Org Appl Sci Res, Ctr Prot Technol, NL-6700 EV Wageningen, Netherlands; Univ Wageningen & Res Ctr, Microspect Ctr, NL-6700 ET Wageningen, Netherlands; Free Univ Amsterdam, Fac Earth & Life Sci, Dept Biol Struct, NL-1081 HV Amsterdam, Netherlands	Wageningen University & Research; Netherlands Organization Applied Science Research; Wageningen University & Research; Wageningen University & Research; Vrije Universiteit Amsterdam	Engel, MFM (corresponding author), Univ Wageningen & Res Ctr, Biochem Lab, Dreijenlaan 3, NL-6703 HA Wageningen, Netherlands.		vanMierlo, Carlo p/B-4491-2016; Engel, Maarten F. M./B-4954-2008	vanMierlo, Carlo p/0000-0002-5358-8392; Engel, Maarten F. M./0000-0002-1774-7042				ANDRADE JD, 1986, ADV POLYM SCI, V79, P1; Arai M, 1996, FOLD DES, V1, P275, DOI 10.1016/S1359-0278(96)00041-7; ATKINS JR, 1999, PRINCIPLES FLUORESCE; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; BASZKIN A, 2000, PHYSICAL CHEM BIOL I; Cabilio NR, 2000, LANGMUIR, V16, P8480, DOI 10.1021/la0003948; Canet D, 2001, BIOPHYS J, V80, P1996, DOI 10.1016/S0006-3495(01)76169-3; Chrysina ED, 2000, J BIOL CHEM, V275, P37021, DOI 10.1074/jbc.M004752200; Greene LH, 1999, PROTEIN ENG, V12, P581, DOI 10.1093/protein/12.7.581; HANSSENS I, 1980, BIOCHIM BIOPHYS ACTA, V602, P539, DOI 10.1016/0005-2736(80)90333-8; HAYNES CA, 1994, J COLLOID INTERF SCI, V164, P394, DOI 10.1006/jcis.1994.1182; HAYNES CA, 1995, J COLLOID INTERF SCI, V169, P313, DOI 10.1006/jcis.1995.1039; Karlsson M, 2000, LANGMUIR, V16, P8470, DOI 10.1021/la0002738; Kim S, 1999, J MOL BIOL, V294, P551, DOI 10.1006/jmbi.1999.3250; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P874, DOI 10.1021/bi00325a010; KUWAJIMA K, 1989, J MOL BIOL, V206, P547, DOI 10.1016/0022-2836(89)90500-7; Kuwajima K, 1996, FASEB J, V10, P102, DOI 10.1096/fasebj.10.1.8566530; LINDAHL L, 1984, ANAL BIOCHEM, V140, P394, DOI 10.1016/0003-2697(84)90184-2; Maste MCL, 1996, J COLLOID INTERF SCI, V180, P632, DOI 10.1006/jcis.1996.0348; Noppe W, 1999, BIOSEPARATION, V8, P153, DOI 10.1023/A:1008098009623; NORDE W, 1992, COLLOID SURFACE, V64, P87, DOI 10.1016/0166-6622(92)80164-W; NORDE W, 1992, COLLOID SURFACE, V66, P73, DOI 10.1016/0166-6622(92)80122-I; OROSZLAN P, 1990, J CHROMATOGR, V500, P481, DOI 10.1016/S0021-9673(00)96087-4; OSTROVSKY AV, 1988, BIOPHYS CHEM, V30, P105, DOI 10.1016/0301-4622(88)85008-7; Permyakov EA, 2000, FEBS LETT, V473, P269, DOI 10.1016/S0014-5793(00)01546-5; Pike ACW, 1996, STRUCTURE, V4, P691, DOI 10.1016/S0969-2126(96)00075-5; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Sanghera N, 2000, PROTEIN SCI, V9, P1194, DOI 10.1110/ps.9.6.1194; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SURREY T, 1995, J BIOL CHEM, V270, P28199; SUTTIPRASIT P, 1992, J COLLOID INTERF SCI, V154, P316, DOI 10.1016/0021-9797(92)90146-D; Troullier A, 2000, NAT STRUCT BIOL, V7, P78, DOI 10.1038/71286; VANDERHEEREN G, 1994, J BIOL CHEM, V269, P7090; WAHLGREN MC, 1993, J COLLOID INTERF SCI, V158, P46, DOI 10.1006/jcis.1993.1227; [No title captured]	36	92	97	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10922	10930		10.1074/jbc.M106005200	http://dx.doi.org/10.1074/jbc.M106005200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11782453	hybrid, Green Published			2022-12-27	WOS:000174613100023
J	Fiordalis, JJ; Holly, SP; Johnson, RL; Parise, LV; Cox, AD				Fiordalis, JJ; Holly, SP; Johnson, RL; Parise, LV; Cox, AD			A distinct class of dominant negative Ras mutants - Cytosolic GTP-bound Ras effector domain mutants that inhibit Ras signaling and transformation and enhance cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; INTEGRIN ACTIVATION; PHOSPHATIDYLINOSITOL 3-KINASE; TERMINAL DOMAIN; AKT; BINDING; RAF-1; PHOSPHORYLATION; DIFFERENTIATION; PROLIFERATION	Cytosolic GTP-bound Ras has been shown to act as a dominant negative (DN) inhibitor of Ras by sequestering Raf in non-productive cytosolic complexes. Nevertheless, this distinct class of DN mutants has been neither well characterized nor extensively used to analyze Ras signaling. In contrast, DN Ras17N, which functions by blocking Ras guanine nucleotide exchange factors, has been well characterized and is widely used. Cytosolic GTP-bound Ras mutants could be used to inhibit particular Ras effectors by introducing additional mutations (T35S, E37G or Y40C) that permit them to associate selectively with and inhibit Raf, RalGDS, or phos. phoinositide 3-kinase, respectively. When the wild-type Ras effector binding region is used, cytosolic Ras should associate with all Ras effectors, even those that are not yet identified, making these DN Ras mutants effective inhibitors of multiple Ras functions. We generated cytosolic GTP-bound H-, N-, and K-Ras, and we assessed their ability to inhibit Ras-induced phenotypes. In fibroblasts, cytosolic H-, N-, and K-Ras inhibited Ras-induced Elk-1 activation and focus formation, induced a flattened cell morphology, and increased adhesion to fibronectin through modulation of a beta(1)-subunit-containing integrin, thereby demonstrating that DN activity is not limited to a subset of Ras isoforms. We also generated cytosolic GTP-bound Ras effector domain mutants (EDMs), each of which reduced the ability of cytosolic GTP-bound Ras proteins to inhibit Elk-1 activation and to induce cell flattening, implicating multiple pathways in these phenotypes. In contrast, Ras-induced focus formation, platelet-derived growth factor (PDGF)-, or Ras-induced phospho-Akt levels and cell adhesion to fibronectin were affected by T35S and Y40C EDMs, whereas PDGF- or Ras-induced phospho-Erk levels were affected only by the T35S EDM, implying that a more limited set of Ras-mediated pathways participate in these phenotypes. These data constitute the first extensive characterization of this functionally distinct class of DN Ras inhibitor proteins.	Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Cox, AD (corresponding author), Univ N Carolina, Dept Radiat Oncol, CB 7512, Chapel Hill, NC 27599 USA.	cox@radonc.unc.edu		Cox, Adrienne D./0000-0002-4901-2454	NCI NIH HHS [CA67771, CA76092] Funding Source: Medline; NHLBI NIH HHS [HL06350, HL45100] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076092, U19CA067771] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COX AD, 1995, METHOD ENZYMOL, V255, P195; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Fiordalisi JJ, 2001, METHOD ENZYMOL, V332, P3; Foos G, 2001, METHOD ENZYMOL, V333, P61; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Guan KL, 2000, J BIOL CHEM, V275, P27354; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kinashi T, 2000, J BIOL CHEM, V275, P22590, DOI 10.1074/jbc.M000633200; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Miyake M, 1996, FEBS LETT, V378, P15, DOI 10.1016/0014-5793(95)01416-0; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; POULLET P, 1995, METHOD ENZYMOL, V255, P488; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; SCHLAEPFER DD, 1994, NATURE, V372, P786; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647; Vale T, 2001, CANCER RES, V61, P602; Verheijen MHG, 1999, ONCOGENE, V18, P4435, DOI 10.1038/sj.onc.1202834; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Xue LZ, 2000, J BIOL CHEM, V275, P8817, DOI 10.1074/jbc.275.12.8817; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	58	33	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10813	10823		10.1074/jbc.M107684200	http://dx.doi.org/10.1074/jbc.M107684200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11799108	hybrid			2022-12-27	WOS:000174613100011
J	Gao, G; Westling, J; Thompson, VP; Howell, TD; Gottschall, PE; Sandy, JD				Gao, G; Westling, J; Thompson, VP; Howell, TD; Gottschall, PE; Sandy, JD			Activation of the proteolytic activity of ADAMTS4 (Aggrecanase-1) by C-terminal truncation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROCYTE-MEDIATED CATABOLISM; EXTRACELLULAR-MATRIX; RETINOIC ACID; CARTILAGE; PROTEIN; CLEAVAGE; FAMILY; METALLOPROTEINASE; PROTEOGLYCANS; INTERLEUKIN-1	Proteolysis of the hyalectans (aggrecan, versican, brevican) in vivo appears to result from the activity of ADAMTS4 (aggrecanase-1, herein referred to as an hyalectanase). To examine the mode of activation of AMTS4, a human chondrosarcoma cell line, JJ012, has been stably transfected with the full-length c-DNA for human ADMTS4. The cells synthesized a high molecular weight form of the enzyme (p100), which in serumfree culture was processed to three truncated forms, p75, p60, and p50. Treatment of the p100 form with recombinant furin indicated that the p75 form is generated by the removal of the prodomain by a furin-like activity. Analysis with domain-specific antisera showed that the p60 and p50 forms are generated by C-terminal truncation of the p75 form. The appearance of the p60 and p50 forms in culture medium was prevented by inclusion of a furin inhibitor, inhibitors of glycosylphosphatidylinositol synthesis, glucosamine, a hydroxamate-based matrix metalloproteinase (MMP) inhibitor, and TIMP-1, but not by AEBSF (4-(2-aminoethyl)benzenesulfonyl fluoride) or E64. Only medium samples containing the p60/p50 forms exhibited aggrecanase activity, and isolation of the p75, p60, and p50 forms by preparative SDS-PAGE showed that only p60 and p50 were active in aggrecanase and versicanase assays. Pig synovium and human cartilages also contained ADMTS4 in the p75, p60, and p50 forms. We suggest that in vivo production of proteolytically active ADMTS4 requires not only removal of the prodomain by a furin-like activity but also MMP-mediated removal of a portion of the C-terminal spacer domain.	Univ S Florida, Shriners Hosp Children, Ctr Res Skeletal Dev & Paediat Orthopaed, Tampa, FL 33612 USA; Univ S Florida, Dept Pharmacol & Therapeut, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Sandy, JD (corresponding author), Univ S Florida, Shriners Hosp Children, Ctr Res Skeletal Dev & Paediat Orthopaed, 12502 N Pine Dr, Tampa, FL 33612 USA.							Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Arner EC, 1999, J BIOL CHEM, V274, P6594, DOI 10.1074/jbc.274.10.6594; Cal S, 2001, J BIOL CHEM, V276, P17932, DOI 10.1074/jbc.M100534200; Chen JM, 2000, BIOCHEM J, V352, P327, DOI 10.1042/0264-6021:3520327; DENAULT JB, 1995, FEBS LETT, V362, P276, DOI 10.1016/0014-5793(95)00249-9; Flannery CR, 1999, BIOCHEM BIOPH RES CO, V260, P318, DOI 10.1006/bbrc.1999.0909; HARDINGHAM TE, 1976, BIOCHEM J, V157, P127, DOI 10.1042/bj1570127; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Kramerova IA, 2000, DEVELOPMENT, V127, P5475; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Lemons ML, 2001, J NEUROSCI, V21, P4772, DOI 10.1523/JNEUROSCI.21-13-04772.2001; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Sandy JD, 1999, ARCH BIOCHEM BIOPHYS, V367, P258, DOI 10.1006/abbi.1999.1234; Sandy JD, 1998, BIOCHEM J, V335, P59, DOI 10.1042/bj3350059; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; Sandy JD, 2001, BIOCHEM J, V358, P615, DOI 10.1042/0264-6021:3580615; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Scully SP, 2000, CLIN ORTHOP RELAT R, P291; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Yamaguchi Y, 2000, CELL MOL LIFE SCI, V57, P276, DOI 10.1007/PL00000690; YOCUM SA, 1995, ARCH BIOCHEM BIOPHYS, V316, P827, DOI 10.1006/abbi.1995.1111	26	152	159	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11034	11041		10.1074/jbc.M107443200	http://dx.doi.org/10.1074/jbc.M107443200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11796708	hybrid			2022-12-27	WOS:000174613100037
J	DeMarco, SJ; Chicka, MC; Strehler, EE				DeMarco, SJ; Chicka, MC; Strehler, EE			Plasma membrane Ca2+ ATPase isoform 2b interacts preferentially with Na+/H+ exchanger regulatory factor 2 in apical plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; PDZ DOMAINS; BETA(2)-ADRENERGIC RECEPTOR; SIGNALING MOLECULES; CALCIUM; PROTEIN; CELLS; PUMP; FAMILY; EZRIN	Spatial and temporal regulation of Ca2+ signaling require the assembly of multiprotein complexes linking molecules involved in Ca2+ influx, sensing, buffering, and extrusion. Recent evidence indicates that plasma membrane Ca2+ ATPases (PMCAs) participate in the control of local Ca2+ fluxes, but the mechanism of multiprotein complex formation of specific PMCAs is poorly understood. Using the PMCA2b COOH-terminal tail as bait in a yeast two-hybrid screen, we identified the PSD-95, Dig, ZO-1 (PDZ) domain-containing Na+/H+ exchanger regulatory factor-2 (NHERF2) as an interacting partner. Protein pull-down and coimmunoprecipitation experiments using recombinant PMCA2b and PMCA4b as well as NHERF1 and NHERF2 showed that the interaction of PMCA2b with NHERF2 was specific and selective. PMCA4b did not interact with either of the NHERFs, and PMCA2b selectively preferred NHERF2 over NHERF1. Green fluorescent protein-tagged PMCA2b was expressed at the apical membrane in Madin-Darby canine kidney epithelial cells, where it colocalized with apically targeted NHERF2. Our study identifies NHERF2 as the first specific PDZ partner for PMCA2b not shared with PMCA4b, and demonstrates that PMCA splice forms differing only minimally in their COOH-terminal residues interact with unique PDZ proteins. NHERFs have been implicated in the targeting, retention and regulation of membrane proteins including the beta(2)-adrenergic receptor, cystic fibrosis transmembrane conductance regulator, and Trp4 Ca2+ channel, and NHERF2 is now shown to also interact with PMCA2b. This interaction may allow the functional assembly of PMCA2b in a multiprotein Ca2+ signaling complex, facilitating integrated cross-talk between local Ca2+ influx and efflux.	Mayo Clin, Mayo Grad Sch, Program Mol Neurosci, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Strehler, EE (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	strehler.emanuel@mayo.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058710] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58710] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Blackstone C, 1999, CELL CALCIUM, V26, P181, DOI 10.1054/ceca.1999.0071; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Brini M, 2000, CELL MOL LIFE SCI, V57, P354, DOI 10.1007/PL00000698; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; Carafoli E, 2000, CURR OPIN CHEM BIOL, V4, P152, DOI 10.1016/S1367-5931(99)00069-1; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; Dumont RA, 2001, J NEUROSCI, V21, P5066, DOI 10.1523/JNEUROSCI.21-14-05066.2001; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Fuh G, 2000, J BIOL CHEM, V275, P21486, DOI 10.1074/jbc.275.28.21486; Garcia Michael L., 1999, Frontiers in Bioscience, V4, pd869, DOI 10.2741/Garcia; Gisler SM, 2001, J BIOL CHEM, V276, P9206, DOI 10.1074/jbc.M008745200; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Johnston J.R., 1994, MOL GENETICS YEAST P; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; KOSKKOSICKA D, 1988, J BIOL CHEM, V263, P18184; Krizaj D, 1998, NEURON, V21, P249, DOI 10.1016/S0896-6273(00)80531-0; Kumar Rajiv, 1995, P253; MONTEITH GR, 1995, CELL CALCIUM, V18, P459, DOI 10.1016/0143-4160(95)90009-8; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Penniston JT, 1998, J MEMBRANE BIOL, V165, P101, DOI 10.1007/s002329900424; PENNISTON JT, 1998, ADV MOL CEL A&B, V23, P249; Penniston JT, 1983, CALCIUM CELL FUNCTIO, P99; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Ponting CP, 1997, PROTEIN SCI, V6, P464; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Reinhardt TA, 2000, AM J PHYSIOL-CELL PH, V279, pC1595, DOI 10.1152/ajpcell.2000.279.5.C1595; Rogers MS, 2001, J BIOL CHEM, V276, P12182, DOI 10.1074/jbc.M010056200; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stauffer TP, 1997, BRAIN RES, V748, P21, DOI 10.1016/S0006-8993(96)01282-6; Street VA, 1998, NAT GENET, V19, P390, DOI 10.1038/1284; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; Tsunoda S, 1999, CELL CALCIUM, V26, P165, DOI 10.1054/ceca.1999.0070; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Yamoah EN, 1998, J NEUROSCI, V18, P610; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Zhou SY, 1999, PROG BIOPHYS MOL BIO, V71, P359, DOI 10.1016/S0079-6107(98)00045-5	56	82	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10506	10511		10.1074/jbc.M111616200	http://dx.doi.org/10.1074/jbc.M111616200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11786550	hybrid			2022-12-27	WOS:000174549200119
J	Holm, PS; Bergmann, S; Jurchott, K; Lage, H; Brand, K; Ladhoff, A; Mantwill, K; Curiel, DT; Dobbelstein, M; Dietel, M; Gansbacher, B; Royer, HD				Holm, PS; Bergmann, S; Jurchott, K; Lage, H; Brand, K; Ladhoff, A; Mantwill, K; Curiel, DT; Dobbelstein, M; Dietel, M; Gansbacher, B; Royer, HD			YB-1 relocates to the nucleus in adenovirus-infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; Y-BOX PROTEINS; EARLY REGION-4; MESSENGER-RNA; TRANSCRIPTION FACTOR; P53 STATUS; 55-KILODALTON PROTEIN; LYTIC INFECTION; TUMOR-ANTIGEN; E1B PROTEINS	The adenovirus early proteins E1A and E1B-55kDa are key regulators of viral DNA replication, and it was thought that targeting of p53 by E1B-55kDa is essential for this process. Here we have identified a previously unrecognized function of E1B for adenovirus replication. We found that E1B-55kDa is involved in targeting the transcription factor YB-1 to the nuclei of adenovirus type 5-infected cells where it is associated with viral inclusion bodies believed to be sites of viral transcription and replication. We show that YB-1 facilitates E2 gene expression through the E2 late promoter thus controlling E2 gene activity at later stages of infection. The role of YB-1 for adenovirus replication was demonstrated with an El-minus adenovirus vector containing a YB-1 transgene. In infected cells, AdYB-1 efficiently replicated and produced infectious progeny particles. Thus, adenovirus E1B-55kDa protein and the host cell factor YB-1 act jointly to facilitate adenovirus replication in the late phase of infection.	Tech Univ Munich, Klinikum Rechts Isar, Inst Expt Onkol & Therapie, D-81675 Munich, Germany; Humboldt Univ Klinikum, Charite, Inst Pathol, D-10117 Berlin, Germany; Max Delbruck Zentrum Mol Med, D-13125 Berlin, Germany; Univ Marburg, Inst Virol, D-35037 Marburg, Germany; Univ Dusseldorf, Inst Transplantat Diagnost & Zelltherapeut, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Inst Human Genet & Anthropol, D-40225 Dusseldorf, Germany; Univ Alabama Birmingham, Wallace Tumor Inst, Gene Therapy Program, Birmingham, AL 35294 USA	Technical University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Philipps University Marburg; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; University of Alabama System; University of Alabama Birmingham	Holm, PS (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Inst Expt Onkol & Therapie, Ismaningerstr 22, D-81675 Munich, Germany.	per.s.holm@lrz.tum.de	Royer, Hans-dieter/AAH-6293-2019	Dobbelstein, Matthias/0000-0001-5052-3967; Jurchott, Karsten/0000-0003-1589-0037				Ansari SA, 1999, J GEN VIROL, V80, P2629, DOI 10.1099/0022-1317-80-10-2629; BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; BELTZ GA, 1979, J MOL BIOL, V131, P353, DOI 10.1016/0022-2836(79)90081-0; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BHAT G, 1987, EMBO J, V6, P2045, DOI 10.1002/j.1460-2075.1987.tb02469.x; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; Chansky HA, 2001, CANCER RES, V61, P3586; Chen CY, 2000, GENE DEV, V14, P1236; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEJONG RN, 1999, GENE, V5, P1; Del Valle L, 2000, ANN NEUROL, V48, P932, DOI 10.1002/1531-8249(200012)48:6<932::AID-ANA15>3.0.CO;2-E; Evdokimova VM, 1999, INT J BIOCHEM CELL B, V31, P139, DOI 10.1016/S1357-2725(98)00137-X; FABER M, 1990, J BIOL CHEM, V265, P22243; Fessler SP, 1998, J VIROL, V72, P4049, DOI 10.1128/JVI.72.5.4049-4056.1998; Ganly I, 2001, GENE THER, V8, P369, DOI 10.1038/sj.gt.3301402; GODING CR, 1987, NUCLEIC ACIDS RES, V15, P7761, DOI 10.1093/nar/15.19.7761; Goodrum FD, 1999, J VIROL, V73, P7474, DOI 10.1128/JVI.73.9.7474-7488.1999; Goodrum FD, 1997, J VIROL, V71, P548, DOI 10.1128/JVI.71.1.548-561.1997; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; Grinstein E, 1996, J BIOL CHEM, V271, P9215, DOI 10.1074/jbc.271.16.9215; GUILFOYLE RA, 1985, EMBO J, V4, P707, DOI 10.1002/j.1460-2075.1985.tb03687.x; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; HEMSTROM C, 1991, J VIROL, V65, P1440; Imperiale M J, 1995, Curr Top Microbiol Immunol, V199 ( Pt 2), P139; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; Lage H, 1999, INT J CANCER, V80, P744, DOI 10.1002/(SICI)1097-0215(19990301)80:5<744::AID-IJC19>3.0.CO;2-5; Lasham A, 2000, GENE, V252, P1, DOI 10.1016/S0378-1119(00)00220-1; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MANOHAR CF, 1990, J VIROL, V64, P2457, DOI 10.1128/JVI.64.6.2457-2466.1990; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Medghalchi S, 1997, VIROLOGY, V236, P8, DOI 10.1006/viro.1997.8737; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; PUVIONDUTILLEUL F, 1984, EUR J CELL BIOL, V34, P313; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; REICH NC, 1983, VIROLOGY, V128, P480, DOI 10.1016/0042-6822(83)90274-X; REICHEL R, 1989, J VIROL, V63, P3643, DOI 10.1128/JVI.63.9.3643-3650.1989; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; Rubenwolf S, 1997, J VIROL, V71, P1115, DOI 10.1128/JVI.71.2.1115-1123.1997; Safak M, 1999, J VIROL, V73, P10146, DOI 10.1128/JVI.73.12.10146-10157.1999; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; Shibao K, 1999, INT J CANCER, V83, P732; Stein U, 2001, J BIOL CHEM, V276, P28562, DOI 10.1074/jbc.M100311200; SWAMINATHAN S, 1995, CURR TOP MICROBIOL, V199, P177; Swamynathan SK, 1998, FASEB J, V12, P515, DOI 10.1096/fasebj.12.7.515; Turnell AS, 1999, J VIROL, V73, P2074, DOI 10.1128/JVI.73.3.2074-2083.1999; Van der Vliet P C, 1995, Curr Top Microbiol Immunol, V199 ( Pt 2), P1; VANDENHEUVEL SJL, 1993, J VIROL, V67, P5226, DOI 10.1128/JVI.67.9.5226-5234.1993; WEINBERG DH, 1986, J VIROL, V57, P833, DOI 10.1128/JVI.57.3.833-838.1986; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	70	75	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10427	10434		10.1074/jbc.M106955200	http://dx.doi.org/10.1074/jbc.M106955200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11788582	hybrid			2022-12-27	WOS:000174549200109
J	Konrad, G; Schlecker, T; Faulhammer, F; Mayinger, P				Konrad, G; Schlecker, T; Faulhammer, F; Mayinger, P			Retention of the yeast Sac1p phosphatase in the endoplasmic reticulum causes distinct changes in cellular phosphoinositide levels and stimulates microsomal ATP transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 4-KINASE; PROTEIN TRANSLOCATION; MUTANTS; METABOLISM; INOSITOL; DEFECTS; GOLGI; IDENTIFICATION; INHIBITION	The yeast phosphoinositide phosphatase Sac1p localizes to endoplasmic reticulum (ER) and Golgi membranes and has compartment-specific functions in these organelles. In this study we analyzed in detail the topology of Sac1p. Our data show that Sac1p is a type 11 transmembrane protein with a large N-terminal cytosolic domain, which is anchored in the membrane by the two potential transmembrane helices near the C terminus. Based on this topology, we created a mutation that caused retention of Sac1p in the ER and as a consequence showed specific alterations in cellular phosphoinositide levels. Our results suggest that Sac1p controls a pool of phosphatidylinositol 3-phosphate and phosphatidylinositol 4-phosphate in the ER. Retention of Sac1p in the ER also stimulates ATP transport into the ER lumen but causes the same Golgi-specific defects that are seen in a sac1 null mutant. Taken together this study provides evidence that Sac1p is an important 4-phosphatase in the ER controlling different aspects of ER-based protein processing and secretion.	Heidelberg Univ, Zentrum Mol Biol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Mayinger, P (corresponding author), Heidelberg Univ, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	mayingerp@sun0.urz.uni-heidelberg.de						Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; Damelin M, 2000, MOL CELL, V5, P133, DOI 10.1016/S1097-2765(00)80409-8; Daniele N, 1999, J BIOL CHEM, V274, P3597, DOI 10.1074/jbc.274.6.3597; Foti M, 2001, MOL BIOL CELL, V12, P2396, DOI 10.1091/mbc.12.8.2396; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARLOW E, 1998, ANTIBODIES LAB MANUA, P72; Hughes WE, 2000, BIOCHEM J, V350, P337, DOI 10.1042/0264-6021:3500337; Hughes WE, 2000, J BIOL CHEM, V275, P801, DOI 10.1074/jbc.275.2.801; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Kochendorfer KU, 1999, EMBO J, V18, P1506, DOI 10.1093/emboj/18.6.1506; Maehama T, 2000, ANAL BIOCHEM, V279, P248, DOI 10.1006/abio.2000.4497; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; MAYINGER P, 1993, EMBO J, V12, P659, DOI 10.1002/j.1460-2075.1993.tb05699.x; MAYINGER P, 1995, J CELL BIOL, V131, P1377, DOI 10.1083/jcb.131.6.1377; Nemoto Y, 2000, J BIOL CHEM, V275, P34293, DOI 10.1074/jbc.M003923200; Ooms LM, 2000, MOL CELL BIOL, V20, P9376, DOI 10.1128/MCB.20.24.9376-9390.2000; Phung TL, 1997, J BIOL CHEM, V272, P30693, DOI 10.1074/jbc.272.49.30693; Prinz WA, 2000, J CELL BIOL, V150, P461, DOI 10.1083/jcb.150.3.461; Rivas MP, 1999, MOL BIOL CELL, V10, P2235, DOI 10.1091/mbc.10.7.2235; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schorr M, 2001, CURR BIOL, V11, P1421, DOI 10.1016/S0960-9822(01)00449-3; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SIKORSKI RS, 1989, GENETICS, V122, P19; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Srinivasan S, 1997, EUR J CELL BIOL, V74, P350; Stolz LE, 1998, GENETICS, V148, P1715; Trotter PJ, 1998, J BIOL CHEM, V273, P13189, DOI 10.1074/jbc.273.21.13189; Vincent MJ, 1998, J BIOL CHEM, V273, P950, DOI 10.1074/jbc.273.2.950; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; WIRADJAJA F, 2000, J BIOL CHEM, V134, P2; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236	35	44	46	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10547	10554		10.1074/jbc.M200090200	http://dx.doi.org/10.1074/jbc.M200090200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11792713	hybrid			2022-12-27	WOS:000174549200124
J	Li, B; Yen, TSB				Li, B; Yen, TSB			Characterization of the nuclear export signal of polypyrimidine tract-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSCRIPTIONAL REGULATORY ELEMENT; IMMUNODEFICIENCY-VIRUS TYPE-1; IMPORTIN-ALPHA; LEPTOMYCIN-B; HNRNP-I; TRANSPORT FACTOR; MESSENGER-RNA; PORE COMPLEX; REV; LOCALIZATION	The polypyrimidine tract-binding protein (PTB) is a nuclear protein that regulates alternative splicing. In addition, it plays a role in the cytoplasm during infection by some viruses and functions as a positive effector of hepatitis B virus RNA export. Thus, it presumably contains a nuclear export signal (NES). Using a heterokaryon export assay in transfected cultured cells, we have shown that the N-terminal 25 amino acid residues of PTB function as an autonomous NES, with residues 11-16 being important for its activity. Unlike the heteronuclear ribonucleoprotein A1 NES, this NES is separable from the nuclear localization signal, which spans the entire N-terminal 60 residues of PTB. The PTB NES cannot be shown to bind to CAS or Crm1, cellular receptors known to export proteins from the nucleus, and it functions in the presence of leptomycin B, a specific inhibitor of Crm1-dependent export. PTB deleted of its NES unlike wild type PTB, does not stimulate the export of hepatitis B virus RNA. Therefore, the PTB NES is a functionally important domain of this multifunctional protein that utilizes an unknown export receptor.	Vet Adm Med Ctr, Pathol Serv 113B, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Yen, TSB (corresponding author), Vet Adm Med Ctr, Pathol Serv 113B, 4150 Clement St, San Francisco, CA 94121 USA.				NCI NIH HHS [R01CA55578] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055578] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Bogerd HP, 1999, J BIOL CHEM, V274, P9771, DOI 10.1074/jbc.274.14.9771; BRINKMANN U, 1995, P NATL ACAD SCI USA, V92, P10427, DOI 10.1073/pnas.92.22.10427; Cote CA, 1999, MOL CELL, V4, P431, DOI 10.1016/S1097-2765(00)80345-7; Donnelly M, 2001, J VIROL, V75, P2566, DOI 10.1128/JVI.75.6.2566-2574.2001; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Gosert R, 2000, MOL CELL BIOL, V20, P1583, DOI 10.1128/MCB.20.5.1583-1595.2000; Herold A, 1998, J CELL BIOL, V143, P309, DOI 10.1083/jcb.143.2.309; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hood JK, 1998, J BIOL CHEM, V273, P35142, DOI 10.1074/jbc.273.52.35142; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; Huang ZM, 1996, VIROLOGY, V217, P573, DOI 10.1006/viro.1996.0152; HUANG ZM, 1994, J VIROL, V68, P3193, DOI 10.1128/JVI.68.5.3193-3199.1994; HUANG ZM, 1995, MOL CELL BIOL, V15, P3864; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kunzler M, 1998, FEBS LETT, V433, P185, DOI 10.1016/S0014-5793(98)00892-8; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Michael WM, 1995, COLD SPRING HARB SYM, V60, P663, DOI 10.1101/SQB.1995.060.01.071; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; NISHI K, 1994, J BIOL CHEM, V269, P6320; Paraskeva E, 1999, J CELL BIOL, V145, P255, DOI 10.1083/jcb.145.2.255; Perez I, 1997, BIOCHEMISTRY-US, V36, P11881, DOI 10.1021/bi9711745; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Romanelli MG, 1997, EXP CELL RES, V235, P300, DOI 10.1006/excr.1997.3677; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; Soros V, 2001, VIROLOGY, V280, P199, DOI 10.1006/viro.2000.0752; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; VALCARCEL J, 1997, CURR BIOL, V7, P705; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Zang WQ, 1999, VIROLOGY, V259, P299, DOI 10.1006/viro.1999.9777; Zang WQ, 2001, J VIROL, V75, P10779, DOI 10.1128/JVI.75.22.10779-10786.2001; Zolotukhin AS, 1997, J BIOL CHEM, V272, P11356, DOI 10.1074/jbc.272.17.11356	48	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10306	10314		10.1074/jbc.M109686200	http://dx.doi.org/10.1074/jbc.M109686200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11781313	hybrid			2022-12-27	WOS:000174549200093
J	Laporte, SA; Miller, WE; Kim, KM; Caron, MG				Laporte, SA; Miller, WE; Kim, KM; Caron, MG			beta-arrestin/AP-2 interaction in G protein-coupled receptor internalization - Identification of a beta-arrestin binding site in beta(2)-adaptin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; CLATHRIN ADAPTER; MEDIATED ENDOCYTOSIS; APPENDAGE DOMAIN; SORTING SIGNALS; AP-2; RECOGNITION; COMPLEXES; DYNAMIN; RESENSITIZATION	beta-Arrestins, proteins involved in the turn-off of G protein-coupled receptor (GPCR) activation, bind to the beta(2)-adaptin subunit of the clathrin adaptor AP-2. The interaction of beta(2)-adaptin with beta-arrestin involves critical arginine residues in the C-terminal domain of P-arrestin and plays an important role in initiating clathrin-mediated endocytosis of the beta(2)-adrenergic receptor (beta(2)AR) (Laporte, S. A., Oakley, R. H., Holt, J. A., Barak, L. S., and Caron, M. G. (2000) J. Biol. Chem. 275, 2312023126). However, the beta-arrestin-binding site in beta(2)-adaptin has not been identified, and little is known about the role of beta-arrestin/AP-2 interaction in the endocytosis of other GPCRs. Using in vitro binding assays, we have identified two glutamate residues (Glu-849 and Glu-902) in beta(2)-adaptin that are important in beta-arrestin binding. These residues are located in the platform subdomain of the C terminus of beta(2)-adaptin, where accessory/adapter endocytic proteins for other classes of receptors interact, distinct from the main site where clathrin interacts. The functional significance of the beta-arrestin/AP-2/clathrin complex in the endocytosis of GPCRs such as the beta(2)AR and vasopressin type II receptor was evaluated using mutant constructs of the beta(2)-adaptin C terminus containing either the clathrin and the beta-arrestin binding domains or the beta-arrestin-binding domain alone. When expressed in human embryonic kidney 293 cells, both constructs acted as dominant negatives inhibiting the agonist-induced internalization of the beta(2)AR and the vasopressin type II receptor. In addition, although the beta(2)-adaptin construct containing both the clathrin and,beta-arrestin binding domains was able to block the endocytosis of transferrin receptors, a beta(2)-adaptin construct capable of associating with beta-arrestin but lacking its high affinity clathrin interaction did not interfere with transferrin receptor endocytosis. These results suggest that the interaction of beta-arrestin with beta(2)-adaptin represents a selective endocytic trigger for several members of the GPCR family.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Howard Hughes Med Inst Labs, Durham, NC 27710 USA; Duke Univ, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Dept Med, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University	Caron, MG (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3287, Durham, NC 27710 USA.		Laporte, Stephane/ABC-4228-2021; Laporte, Stephane A/F-3282-2012	Laporte, Stephane/0000-0002-0633-543X; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 19576] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anborgh PH, 2000, MOL ENDOCRINOL, V14, P2040, DOI 10.1210/me.14.12.2040; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; McCoy AJ, 1997, J MOL BIOL, V268, P570, DOI 10.1006/jmbi.1997.0987; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	33	116	122	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9247	9254		10.1074/jbc.M108490200	http://dx.doi.org/10.1074/jbc.M108490200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11777907	hybrid			2022-12-27	WOS:000174400600070
J	Nolan, T; Bower, TM; Brown, AE; Crisanti, A; Catteruccia, F				Nolan, T; Bower, TM; Brown, AE; Crisanti, A; Catteruccia, F			piggyBac-mediated germline transformation of the malaria mosquito Anopheles stephensi using the red fluorescent protein dsRED as a selectable marker	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TRANSFER; TRANSPOSABLE ELEMENT; DROSOPHILA-MELANOGASTER; LINE TRANSFORMATION; PRECISE EXCISION; MINOS; VECTOR	It is estimated that every year malaria infects similar to300 million people and accounts for the death of 2 million individuals. The Plasmodium parasites that cause malaria in humans are transmitted exclusively by mosquito species belonging to the Anopheles genus. The recent development of a gene transfer technology for Anopheles stephensi mosquitoes, using the Minos transposable element marked with the enhanced green fluorescent protein EGFP (Catteruccia, F., Nolan, T., Loukeris, T. G., Blass, C., Savakis, C., Kafatos, F. C., and Crisanti, A. (2000) Nature 405, 959-962), provides now a powerful tool to investigate the role of mosquito molecules involved in the interaction with the malaria parasite. Such technology, when further developed with additional markers and transposable elements, will be invaluable for analyzing the biology of the vector and for developing malaria-resistant mosquitoes to be used as a tool to control malaria transmission in the field. We report here the germline transformation of A. stephensi mosquitoes using a piggyBac-based transposon to drive integration of the gene encoding for the red fluorescent protein dsRED. A. stephensi embryos were injected with transformation vector pPBRED containing the dsRED marker cloned within the arms of piggyBac. Microscopic analysis of G, larvae revealed the presence of seven fluorescent phenotypes whose different molecular origins were confirmed by Southern blotting analysis. Sequencing of the insertion sites in two lines demonstrated that integrations had occurred at TTAA nucleotides in accordance with piggyBac-mediated transpositions.	Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, London SW7 2AZ, England	Imperial College London	Catteruccia, F (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, Sir Alexander Fleming Bldg,Imperial Coll Rd, London SW7 2AZ, England.	f.catteruccia@ic.ac.uk	Nolan, Tony/I-4925-2012	Nolan, Tony/0000-0002-2982-8333; Brown, Anthony/0000-0002-1271-310X; Catteruccia, Flaminia/0000-0003-3295-6683; Crisanti, Andrea/0000-0002-2406-4426				Allen ML, 2001, J MED ENTOMOL, V38, P701, DOI 10.1603/0022-2585-38.5.701; Arca B, 2000, GENETICA, V108, P263, DOI 10.1023/A:1004185024017; Catteruccia F, 2000, NATURE, V405, P959, DOI 10.1038/35016096; Finley KR, 2001, BIOTECHNIQUES, V31, P66, DOI 10.2144/01311st02; FRANZ G, 1994, P NATL ACAD SCI USA, V91, P4746, DOI 10.1073/pnas.91.11.4746; Fraser MJ, 1996, INSECT MOL BIOL, V5, P141, DOI 10.1111/j.1365-2583.1996.tb00048.x; Grossman GL, 2001, INSECT MOL BIOL, V10, P597, DOI 10.1046/j.0962-1075.2001.00299.x; Handler AM, 1999, INSECT MOL BIOL, V8, P449, DOI 10.1046/j.1365-2583.1999.00139.x; Handler AM, 2001, BIOTECHNIQUES, V31, P820; Handler AM, 2000, INSECT MOL BIOL, V9, P605, DOI 10.1046/j.1365-2583.2000.00227.x; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; Klinakis AG, 2000, INSECT MOL BIOL, V9, P269, DOI 10.1046/j.1365-2583.2000.00183.x; LOUKERIS TG, 1995, SCIENCE, V270, P2002, DOI 10.1126/science.270.5244.2002; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Pinkerton AC, 2000, INSECT MOL BIOL, V9, P1, DOI 10.1046/j.1365-2583.2000.00133.x; Rodrigues F, 2001, J BACTERIOL, V183, P3791, DOI 10.1128/JB.183.12.3791-3794.2001; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sarkar A, 1997, GENETICA, V99, P15, DOI 10.1023/A:1018349803656; Thibault ST, 1999, INSECT MOL BIOL, V8, P119, DOI 10.1046/j.1365-2583.1999.810119.x; Warren WD, 1996, GENETICA, V98, P249, DOI 10.1007/BF00057589; Zhang GH, 1996, BIOCHEM BIOPH RES CO, V227, P707, DOI 10.1006/bbrc.1996.1573	23	63	70	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8759	8762		10.1074/jbc.C100766200	http://dx.doi.org/10.1074/jbc.C100766200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11805082	hybrid			2022-12-27	WOS:000174400600002
J	Xiao, H; Yin, TG; Wang, XY; Uchida, T; Chung, J; White, MF; Yang, YC				Xiao, H; Yin, TG; Wang, XY; Uchida, T; Chung, J; White, MF; Yang, YC			Specificity of interleukin-2 receptor gamma chain superfamily cytokines is mediated by insulin receptor substrate-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; TYROSINE PHOSPHORYLATION; ALPHA-CHAIN; BETA-CHAIN; NPEY MOTIF; PH DOMAIN; ACTIVATION; SHC; IDENTIFICATION; PROTEIN	Interleukins 9 (IL-9) and 4 are cytokines within the IL-2 receptor gamma chain (IL-2Rgamma) superfamily that possess similar and unique biological functions. The signaling mechanisms, which may determine cytokine specificity and redundancy, are not well understood. IRS proteins are tyrosine-phosphorylated following IL-9 and IL-4 stimulation, a process in part mediated by JAR tyrosine kinases (Yin, T. G., Keller, S. R., Quelle, F. W., Witthuhn, B. A., Tsang, M. L., Lienhard, G. E., Ihle, J. N., and Yang, Y. C. (1995) J. BioL Chem 270, 20497-20502). In the present study, we used 32D cells stably transfected with insulin receptor (32D(IR)), which do not express any IRS proteins, as a model system to study the requirement of different structural domains of IRS proteins in IL-9- and IL-4-mediated functions. Overexpression of IRS-1 and IRS-2, but not IRS-4, induced proliferation of 32D(IR) cells in response to IL-9. The pleckstrin homology (PH) domain of IRS proteins is required for IRS-mediated proliferation stimulated by IL-9. The phosphotyrosine binding and She and IRS-1 NPXY binding domains are interchangeable for IRS to transduce the proliferative effect of IL-4. Therefore, the PH domain plays different roles in coupling IRS proteins to activated IL-9 and IL-4 receptors. The role of IRS proteins in determining cytokine specificity was corroborated by their ability to interact with different downstream signaling molecules. Although phosphatidylinositol 3'-kinase (PI3K) and Grb-2 interact with tyrosine-phosphorylated IRS proteins, Shp-2 only binds to IRS proteins following IL-4, but not IL-9, stimulation. Although PI3K activity is necessary for the IRS-1/2-mediated proliferative effect of IL-9 and IL-4, Akt activation is only required for cell proliferation induced by IL-4, but not IL-9. These data suggest that IRS-dependent signaling pathways work by recruiting different signaling molecules to determine specificity of IL-2Rgamma superfamily cytokines.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Canc, Cleveland, OH 44106 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Joslin Diabet Ctr, Boston, MA 02115 USA; Eli Lilly Inc, Indianapolis, IN 46285 USA; Pharmacia & Upjohn Inc, Kalamazoo, MI 49007 USA	Case Western Reserve University; Case Western Reserve University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute; Eli Lilly; Pfizer	Yang, YC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 2109 Adelbert Rd,W353, Cleveland, OH 44106 USA.	yxy36@po.cwru.edu			NATIONAL CANCER INSTITUTE [R01CA074833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050570] Funding Source: NIH RePORTER; NCI NIH HHS [CA74833] Funding Source: Medline; NHLBI NIH HHS [HL48819] Funding Source: Medline; NIDDK NIH HHS [DK50570] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; Burks DJ, 2000, NATURE, V407, P377, DOI 10.1038/35030105; Burks DJ, 1998, J BIOL CHEM, V273, P31061, DOI 10.1074/jbc.273.47.31061; Chen XH, 1997, J BIOL CHEM, V272, P6556, DOI 10.1074/jbc.272.10.6556; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; Craparo A, 1997, J BIOL CHEM, V272, P11663; Demoulin JB, 2000, FEBS LETT, V482, P200, DOI 10.1016/S0014-5793(00)02059-7; Demoulin JB, 1999, J BIOL CHEM, V274, P25855, DOI 10.1074/jbc.274.36.25855; Demoulin JB, 1998, CYTOKINES CELL MOL T, V4, P243; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Farhang-Fallah J, 2000, J BIOL CHEM, V275, P40492, DOI 10.1074/jbc.C000611200; Farooq A, 1999, J BIOL CHEM, V274, P6114, DOI 10.1074/jbc.274.10.6114; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Han DC, 2001, ONCOGENE, V20, P346, DOI 10.1038/sj.onc.1204068; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; HOUSSIAU FA, 1993, J IMMUNOL, V150, P2634; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; Kimura MT, 2001, J BIOL CHEM, V276, P17291, DOI 10.1074/jbc.M005453200; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; RENAULD JC, 1994, ONCOGENE, V9, P1327; RENAULD JC, 1995, BLOOD, V85, P1300, DOI 10.1182/blood.V85.5.1300.bloodjournal8551300; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Saito K, 2001, J BIOL CHEM, V276, P16201, DOI 10.1074/jbc.M100873200; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Sliva D, 2000, BIOCHEM J, V345, P741, DOI 10.1042/0264-6021:3450741; Stomski F. C., 1999, Blood, V94, P1933; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; Wang XY, 1999, EXP HEMATOL, V27, P139, DOI 10.1016/S0301-472X(98)00002-2; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; YIN TG, 1994, J BIOL CHEM, V269, P26614; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388; Zhu YX, 1997, J BIOL CHEM, V272, P21334, DOI 10.1074/jbc.272.34.21334	52	25	25	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8091	8098		10.1074/jbc.M106650200	http://dx.doi.org/10.1074/jbc.M106650200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11788580	hybrid			2022-12-27	WOS:000174268000060
J	Menguy, T; Corre, F; Juul, B; Bouneau, L; Lafitte, D; Derrick, PJ; Sharma, PS; Falson, P; Levine, BA; Moller, JV; le Maire, M				Menguy, T; Corre, F; Juul, B; Bouneau, L; Lafitte, D; Derrick, PJ; Sharma, PS; Falson, P; Levine, BA; Moller, JV; le Maire, M			Involvement of the cytoplasmic loop L6-7 in the entry mechanism for transport of Ca2+ through the sarcoplasmic reticulum Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CALCIUM-PUMP; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; TRANSMEMBRANE SEGMENT-6; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEINS; CHARGED RESIDUES; CATION OCCLUSION; BINDING	We previously found that mutants of conserved aspartate residues of sarcoplasmic reticulum Ca2+-ATPase in the cytosolic loop, connecting transmembrane segments M6 and M7 (L6-7 loop), exhibit a strongly reduced sensitivity toward Ca2+ activation of the transport process. In this study, yeast membranes, expressing wild type and mutant Ca2+-ATPases, were reacted with Cr(.)ATP and tested for their ability to occlude 45 Ca2+ by HPLC analysis, after cation resin and Cl,E, treatment. We found that the D813A/D818A mutant that displays markedly low calcium affinity was capable of occluding Ca2+ to the same extent as wild type ATPase. Using NMR and mass spectrometry we have analyzed the conformational properties of the synthetic L6-7 loop and demonstrated the formation of specific 1:1 cation complexes of the peptide with calcium and lanthanum. All three aspartate Asp(813)/Asp(815)/Asp(818) were required to coordinate the trivalent lanthanide ion. Overall these observations suggest a dual function of the loop: in addition to mediating contact between the intramembranous Ca2+-binding sites and the cytosolic phosphorylation site (Zhang, Z., Lewis, D., Sumbilla, C., Inesi G., and Toyoshima, C. (2001) J. Biol. Chem. 276, 15232-15239), the L6-7 loop, in a preceding step, participates in the formation of an entrance port, before subsequent high affinity binding of Ca2+ inside the membrane.	Ctr Etud Saclay, SBFM, DBJC, CEA, F-91191 Gif Sur Yvette, France; Univ Paris 11, Ctr Etud Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; Univ Paris 11, Ctr Etud Saclay, LRA17V, F-91191 Gif Sur Yvette, France; Aarhus Univ, Danish Biomembrane Res Ctr, Dept Biophys, DK-8000 Aarhus C, Denmark; Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England; Univ Warwick, Inst Mass Spectrometry, Coventry CV4 7AL, W Midlands, England; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Aarhus University; University of Warwick; University of Warwick; University of Birmingham	le Maire, M (corresponding author), Ctr Etud Saclay, SBFM, DBJC, CEA, Bat 528, F-91191 Gif Sur Yvette, France.	lemairem@dsvidf.cea.fr		lafitte, daniel/0000-0001-9921-7522; Falson, Pierre/0000-0002-9760-4577				Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; Andersen JP, 1998, TRENDS CARDIOVAS MED, V8, P41, DOI 10.1016/S1050-1738(97)00121-7; Asahi M, 2001, P NATL ACAD SCI USA, V98, P10061, DOI 10.1073/pnas.181348298; Beaulieu H, 1999, BIOCHEM J, V340, P813, DOI 10.1042/0264-6021:3400813; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CENTENO F, 1994, FEBS LETT, V354, P117, DOI 10.1016/0014-5793(94)01104-4; CHAMPEIL P, 1980, P NATL ACAD SCI-BIOL, V77, P2405, DOI 10.1073/pnas.77.5.2405; CHAVANIEU A, 1994, EUR J BIOCHEM, V224, P115, DOI 10.1111/j.1432-1033.1994.tb20002.x; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; Dwek RA., 1973, NUCL MAGNETIC RESONA; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; GARIEPY J, 1983, BIOCHEMISTRY-US, V22, P1765, DOI 10.1021/bi00277a004; GARRIGOS M, 1991, ANAL BIOCHEM, V194, P82, DOI 10.1016/0003-2697(91)90154-L; Groves JD, 1996, P NATL ACAD SCI USA, V93, P12245, DOI 10.1073/pnas.93.22.12245; Hamilton TG, 1999, MOL CELL BIOL, V19, P5298; Hill TJ, 2000, BIOCHEMISTRY-US, V39, P7284, DOI 10.1021/bi000139m; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1980, J BIOL CHEM, V255, P3025; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; Lavanant H, 1998, ANAL BIOCHEM, V255, P74, DOI 10.1006/abio.1997.2441; Lee AG, 2001, BIOCHEM J, V356, P665, DOI 10.1042/0264-6021:3560665; LEE L, 1979, FEBS LETT, V98, P169, DOI 10.1016/0014-5793(79)80176-3; LENOIR G, 2002, IN PRESS BIOCH BIOPH; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MCINTOSH DB, 1991, P NATL ACAD SCI USA, V88, P6437, DOI 10.1073/pnas.88.15.6437; Menguy T, 1998, J BIOL CHEM, V273, P20134, DOI 10.1074/jbc.273.32.20134; Menzel R, 1997, YEAST, V13, P1211, DOI 10.1002/(SICI)1097-0061(199710)13:13<1211::AID-YEA168>3.0.CO;2-8; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Moller JV, 1997, J BIOL CHEM, V272, P29015, DOI 10.1074/jbc.272.46.29015; OR E, 1993, J BIOL CHEM, V268, P16929; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; Poch E, 1998, AM J PHYSIOL-CELL PH, V275, pC1449, DOI 10.1152/ajpcell.1998.275.6.C1449; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; SERPERSU EH, 1982, EUR J BIOCHEM, V122, P347, DOI 10.1111/j.1432-1033.1982.tb05887.x; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; Shainskaya A, 2000, J BIOL CHEM, V275, P2019, DOI 10.1074/jbc.275.3.2019; SILLEN LG, 1964, SPECIAL PUBLICATION, V17, P426; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soulie S, 1996, ANAL BIOCHEM, V236, P363, DOI 10.1006/abio.1996.0183; Soulie S, 1999, BIOCHEMISTRY-US, V38, P5813, DOI 10.1021/bi983039d; Soulie S, 1998, EUR J BIOCHEM, V257, P216, DOI 10.1046/j.1432-1327.1998.2570216.x; Strock C, 1998, J BIOL CHEM, V273, P15104, DOI 10.1074/jbc.273.24.15104; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; TAKISAWA H, 1981, NATURE, V290, P271, DOI 10.1038/290271a0; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VILSEN B, 1992, J BIOL CHEM, V267, P3539; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1992, FEBS LETT, V306, P247, DOI 10.1016/0014-5793(92)81010-J; VILSEN B, 1986, BIOCHIM BIOPHYS ACTA, V855, P429, DOI 10.1016/0005-2736(86)90089-1; VILSEN B, 1995, ACTA PHYSIOL SCAND, V154, P1; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; Zhang ZS, 2000, BIOCHEMISTRY-US, V39, P8758, DOI 10.1021/bi000185m; Zhang ZS, 2001, J BIOL CHEM, V276, P15232, DOI 10.1074/jbc.M010813200	62	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13016	13028		10.1074/jbc.M108899200	http://dx.doi.org/10.1074/jbc.M108899200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11801592	hybrid			2022-12-27	WOS:000175036300068
J	Montes, LR; Ruiz-Arguello, MB; Goni, FM; Alonso, A				Montes, LR; Ruiz-Arguello, MB; Goni, FM; Alonso, A			Membrane restructuring via ceramide results in enhanced solute efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; PHASE-TRANSITION; LIPOSOMES; FUSION; VESICLES; MITOCHONDRIA; CHOLESTEROL; RELEASE; BILAYER; CHAIN	The capacity of ceramides to modify the permeability barrier of cell membranes has been explored. Membrane efflux induced either by in situ generated ceramides (through enzymatic cleavage of sphingomyelin) or by addition of ceramides to preformed membranes has been studied. Large unilamellar vesicles composed of different phospholipids and cholesterol, and containing entrapped fluorescent molecules, have been used as a system to assay ceramide-dependent efflux. Small proportions of ceramide (10 mol % of total lipid) that may exist under physiological conditions of ceramide-dependent signaling have been used in most experiments. When long chain (egg-derived) ceramides are used, both externally added or enzymatically produced ceramides induce release of vesicle contents. However, the same proportion of ceramides generated by sphingomyelinase induce faster and more extensive efflux than when added in organic solution to the preformed vesicles. Under our conditions 10 mol % of N-acetylsphingosine (C-2-ceramide) did not induce any efflux. On the other hand, sphingomyelinase treatment of bilayers containing 50 mol % sphingomyelin gave rise to release of fluorescein-derivatised dextrans of molecular mass approximate to20 kDa, i.e. larger than cytochrome c. These results have been discussed in the light of our own previous data (Ruiz-Arguello, M. B., Basanez, G., Goni, F. M., and Alonso, A. (1996) J. Biol. Chem. 271, 26616-26621) and of the observations by Siskind and Colombini (Siskind, L. J., and Colombini, M. (2000) J. Biol. Chem. 275, 38640 38644). Our spectroscopic observations appear to be in good agreement with the electrophysiological studies of the latter authors. Furthermore, some experiments in this paper have been designed to explore the mechanism of ceramide-induced efflux. Two properties of ceramide, namely its capacity to induce negative monolayer curvature and its tendency to segregate into ceramide-rich domains, appear to be important in the membrane restructuring process.	Univ Basque Country, Ctr Mixto, CSIC, Unidad Biofis, E-48080 Bilbao, Spain; Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country	Alonso, A (corresponding author), Univ Basque Country, Ctr Mixto, CSIC, Unidad Biofis, Aptdo 644, E-48080 Bilbao, Spain.	gbpaliza@lg.ehu.es	Alonso, Alicia/E-5310-2012; Goni, Felix M/M-5425-2015	Alonso, Alicia/0000-0002-2730-7470; Goni, Felix M/0000-0001-6270-9216; Montes, Lidia Ruth/0000-0002-4766-8417				Bai JN, 1997, BIOCHEMISTRY-US, V36, P8840, DOI 10.1021/bi970145r; Basanez G, 2001, J BIOL CHEM, V276, P31083, DOI 10.1074/jbc.M103879200; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Carrer DC, 1999, J LIPID RES, V40, P1978; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Di Paola M, 2000, BIOCHEMISTRY-US, V39, P6660, DOI 10.1021/bi9924415; ELLENS H, 1986, BIOCHEMISTRY-US, V25, P4141, DOI 10.1021/bi00362a023; EPAND RM, 1985, BIOCHEMISTRY-US, V24, P7092, DOI 10.1021/bi00346a011; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Goni FM, 2000, BIOSCIENCE REP, V20, P443, DOI 10.1023/A:1010450702670; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HANNUN YA, 1996, SCIENCE, V274, P1955; HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693, DOI 10.1515/znc-1973-11-1209; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; Holopainen JM, 2000, BIOPHYS J, V78, P830, DOI 10.1016/S0006-3495(00)76640-9; Holopainen JM, 1997, CHEM PHYS LIPIDS, V88, P1, DOI 10.1016/S0009-3084(97)00040-6; Holopainen JM, 2001, BIOPHYS J, V80, P765, DOI 10.1016/S0006-3495(01)76056-0; Huang HW, 1996, BIOCHEM BIOPH RES CO, V220, P834, DOI 10.1006/bbrc.1996.0490; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; LITTLE C, 1975, BIOCHIM BIOPHYS ACTA, V391, P326, DOI 10.1016/0005-2744(75)90256-9; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; NIEVA JL, 1989, BIOCHEMISTRY-US, V28, P7364, DOI 10.1021/bi00444a032; OSTOLAZA H, 1993, BIOCHIM BIOPHYS ACTA, V1147, P81, DOI 10.1016/0005-2736(93)90318-T; PAPAHADJOPOULOS D, 1973, BIOCHIM BIOPHYS ACTA, V311, P330, DOI 10.1016/0005-2736(73)90314-3; Patra SK, 1999, J LIPOSOME RES, V9, P247, DOI 10.3109/08982109909024788; REQUERO MA, 1995, BIOCHEMISTRY-US, V34, P10400, DOI 10.1021/bi00033a011; Ruiz-Arguello MB, 1998, J BIOL CHEM, V273, P22977, DOI 10.1074/jbc.273.36.22977; RuizArguello MB, 1996, J BIOL CHEM, V271, P26616, DOI 10.1074/jbc.271.43.26616; RUIZARGUELLO MB, 2001, IN PRESS CHEM PHYS L; SCHWARZ G, 1990, BIOPHYS J, V58, P577, DOI 10.1016/S0006-3495(90)82401-2; SHAH J, 1995, J LIPID RES, V36, P1936; Simon CG, 1998, BIOCHEMISTRY-US, V37, P2059, DOI 10.1021/bi9710636; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Siskind LJ, 2000, J BIOL CHEM, V275, P38640, DOI 10.1074/jbc.C000587200; Veiga MP, 1999, BIOPHYS J, V76, P342, DOI 10.1016/S0006-3495(99)77201-2; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; XU A, 2001, J BIOL CHEM, V276, P33450	38	118	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11788	11794		10.1074/jbc.M111568200	http://dx.doi.org/10.1074/jbc.M111568200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11796726	hybrid			2022-12-27	WOS:000174846400025
J	Furukawa, K; Yokoyama, K; Sato, T; Wiels, J; Hirayama, Y; Ohta, M; Furukawa, K				Furukawa, K; Yokoyama, K; Sato, T; Wiels, J; Hirayama, Y; Ohta, M; Furukawa, K			Expression of the Gb3/CD77 synthase gene in megakaryoblastic leukemia cells - Implication in the sensitivity to verotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOMA-ASSOCIATED ANTIGEN; HEMOLYTIC-UREMIC SYNDROME; TUBULAR EPITHELIAL-CELLS; CENTER B-CELLS; BURKITT-LYMPHOMA; HUMAN-PLATELETS; SHIGA TOXIN; MONOCLONAL-ANTIBODIES; GLYCOLIPID ANTIGEN; PROTEIN-SYNTHESIS	Expression levels of Gb3/CD77 synthase together with Gb3/CD77 antigen were analyzed using human hematopoietic tumor cell lines and normal cells. Among about 40 kinds of cells, Burkitt lymphoma cells showed the highest gene expression concomitant with the expression levels of Gb3/CD77. Unexpectedly, megakaryoblastic leukemia lines also expressed fairly high levels of mRNA of Gb3/CD77 synthase and its product. A megakaryoblastic leukemia line, MEG-01 was sensitive to verotoxins from Escherichia coli O157 and apoptosis was induced via the caspase pathway. We also demonstrated that the cell surface Gb3/CD77 expression was reduced on differentiated MEG-01 although the mRNA level of the alpha1,4Gal-T gene increased. In this case, the localization of Gb3/CD77 was changed from the cell surface to the cytoplasm as stained with a granular pattern, co-localizing with platelet GPIIb-IIIa, indicating that some of them were platelet precursors. Small particles outside of cells also showed similar staining patterns. These results agreed with the previous report that platelets produced in mature megakaryoblasts abundantly contained Gb3/CD77 antigen. Here, we propose the possibility that verotoxins bind immature megakaryoblasts and induce their apoptosis, leading to the arrest of platelet generation in the bone marrow. This may be one of the causes of thrombocytopenia in patients with hemolytic uremic syndrome.	Nagoya Univ, Sch Med, Dept Biochem 2, Nagoya, Aichi 4660065, Japan; Nagoya Univ, Sch Med, Dept Microbiol, Nagoya, Aichi 4660065, Japan; Chiba Univ, Sch Med, Dept Pediat, Chiba 2608670, Japan; Inst Gustave Roussy, CNRS, UMR 1598, F-94805 Villejuif, France	Nagoya University; Nagoya University; Chiba University; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp	Wiels, Joëlle/AGL-2319-2022	Wiels, Joëlle/0000-0002-3313-2937				BAZAR LS, 1992, EXP HEMATOL, V20, P80; CHONG BH, 1994, BLOOD, V83, P1535; Cooling LLW, 1998, INFECT IMMUN, V66, P4355; COOLING LLW, 1995, J INFECT DIS, V172, P1198, DOI 10.1093/infdis/172.5.1198; ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x; FISHMAN PH, 1976, SCIENCE, V194, P906, DOI 10.1126/science.185697; FONG JSC, 1982, BLOOD, V60, P564; FURUKAWA K, 1993, P NATL ACAD SCI USA, V90, P1972, DOI 10.1073/pnas.90.5.1972; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HAKOMORI SI, 1971, J BIOL CHEM, V246, P2271; HAYASHI K, 1986, ACTA HAEMATOL-BASEL, V75, P141, DOI 10.1159/000206107; JACEWICZ M, 1986, J EXP MED, V163, P1391, DOI 10.1084/jem.163.6.1391; Kaneko K, 2001, NEPHRON, V87, P182, DOI 10.1159/000045909; Karpman D, 2001, BLOOD, V97, P3100, DOI 10.1182/blood.V97.10.3100; Kiyokawa N, 1998, J INFECT DIS, V178, P178, DOI 10.1086/515592; Kiyokawa N, 2001, J CELL BIOCHEM, V81, P128, DOI 10.1002/1097-4644(20010401)81:1<128::AID-JCB1029>3.0.CO;2-G; KLEIN G, 1983, INT J CANCER, V31, P535, DOI 10.1002/ijc.2910310503; Kodama T, 1999, MED MICROBIOL IMMUN, V188, P73, DOI 10.1007/s004300050107; KOERNER TAW, 1989, BLOOD, V74, P274; Kojima Y, 2000, J BIOL CHEM, V275, P15152, DOI 10.1074/jbc.M909620199; KOSTER F, 1978, NEW ENGL J MED, V298, P927, DOI 10.1056/NEJM197804272981702; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; MANGENEY M, 1993, CANCER RES, V53, P5314; MANGENEY M, 1991, EUR J IMMUNOL, V21, P1131, DOI 10.1002/eji.1830210507; MARCUS DM, 1981, SEMIN HEMATOL, V18, P63; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MURRAY LJ, 1985, INT J CANCER, V36, P561, DOI 10.1002/ijc.2910360508; NEILD GH, 1996, OXFORD TXB MED, P3196; NUDELMAN E, 1983, SCIENCE, V220, P509, DOI 10.1126/science.6836295; OBRIEN AD, 1983, LANCET, V1, P702; PHILLIPS DR, 1988, BLOOD, V71, P831; Pijpers AHJM, 2001, J AM SOC NEPHROL, V12, P767, DOI 10.1681/ASN.V124767; Taga S, 1997, BLOOD, V90, P2757, DOI 10.1182/blood.V90.7.2757.2757_2757_2767; TAO RVP, 1973, J LIPID RES, V14, P16; te Loo DMWM, 2000, BLOOD, V95, P3396, DOI 10.1182/blood.V95.11.3396.011k19_3396_3402; Thorpe CM, 1999, ACTA HAEMATOL-BASEL, V102, P51, DOI 10.1159/000040968; Viisoreanu D, 2000, THROMB RES, V98, P403, DOI 10.1016/S0049-3848(00)00191-2; WIELS J, 1981, P NATL ACAD SCI-BIOL, V78, P6485, DOI 10.1073/pnas.78.10.6485; WIELS J, 1984, J BIOL CHEM, V259, P4783; Williams JM, 1997, TOXICOL LETT, V91, P121, DOI 10.1016/S0378-4274(97)03879-4; YAMAKAWA T, 1965, JPN J EXP MED, V35, P201; YAMASHIRO S, 1993, CANCER RES, V53, P5395; YAMASHIRO S, 1994, ONCOGENE, V9, P2461; ZOJA C, 1992, J LAB CLIN MED, V120, P229	45	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11247	11254		10.1074/jbc.M109519200	http://dx.doi.org/10.1074/jbc.M109519200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11782470	hybrid			2022-12-27	WOS:000174613100064
J	Hellberg, CB; Burden-Gulley, SM; Pietz, GE; Brady-Kalnay, SM				Hellberg, CB; Burden-Gulley, SM; Pietz, GE; Brady-Kalnay, SM			Expression of the receptor protein-tyrosine phosphatase, PTP mu, restores E-cadherin-dependent adhesion in human prostate carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; HOMOPHILIC BINDING; CYTOPLASMIC DOMAIN; BETA-SUBUNIT; CATENINS; RACK1; HOMOLOG; CLONING	Normal prostate expresses the receptor protein-tyrosine phosphatase, PTPmu, whereas LNCaP prostate carcinoma cells do not. PTPmu has been shown previously to interact with the E-cadherin complex. LNCaP cells express normal levels of E-cadherin and catenins but do not mediate either PTPmu- or E-cadherin-dependent adhesion. Re-expression of PTPmu restored cell adhesion to PTPmu and to E-cadherin. A mutant form of PTPmu that is catalytically inactive was re-expressed, and it also restored adhesion to PTPmu and to E-cadherin. Expression of PTPmu-extra (which lacks most of the cytoplasmic domain) induced adhesion to PTPmu but not to E-cadherin, demonstrating a requirement for the presence of the intracellular domains of PTPmu to restore E-cadherin-mediated adhesion. We previously observed a direct interaction between the intracellular domain of PTPmu and RACK1, a receptor for activated protein kinase C (PKC). We demonstrate that RACK1 binds to both the catalytically active and inactive mutant form of PTPmu. In addition, we determined that RACK1 binds to the PKCS isoform in LNCaP cells. We tested whether PKC could be playing a role in the ability of PTPmu to restore E-cadherin-dependent adhesion. Activation of PKC reversed the adhesion of PTPmuWT-expressing cells to E-cadherin, whereas treatment of parental LNCaP cells with a PKCdelta-specific inhibitor induced adhesion to E-cadherin. Together, these studies suggest that PTPmu regulates the PKC pathway to restore E-cadherin-dependent adhesion via its interaction with RACK1.	Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA	Case Western Reserve University	Brady-Kalnay, SM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	smb4@po.cwru.edu		Burden-Gulley, Susan/0000-0001-7419-9073				Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; BRACKENBURY R, 1977, J BIOL CHEM, V252, P6835; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1994, J BIOL CHEM, V269, P28472; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; BRADYKALNAY SM, 2001, CELL ADHESION FRONTI, V39, P217; Burden-Gulley SM, 1999, J CELL BIOL, V144, P1323, DOI 10.1083/jcb.144.6.1323; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; GEBBINK MFBG, 1993, BIOCHEMISTRY-US, V32, P13516, DOI 10.1021/bi00212a017; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hiscox S, 1998, INT J ONCOL, V13, P1077; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LEWIS JE, 1994, J CELL SCI, V107, P3615; Llosas MD, 1996, BIOCHEM J, V315, P1049; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Rodriguez MM, 1999, BIOCHEMISTRY-US, V38, P13787, DOI 10.1021/bi991055k; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SKOUDY A, 1995, FEBS LETT, V374, P415, DOI 10.1016/0014-5793(95)01167-D; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; TONKS NK, 1992, COLD SPRING HARB SYM, V57, P87, DOI 10.1101/SQB.1992.057.01.012; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	32	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11165	11173		10.1074/jbc.M112157200	http://dx.doi.org/10.1074/jbc.M112157200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801604	hybrid			2022-12-27	WOS:000174613100054
J	Nakajima, K; Sonoda, H; Mizoguchi, T; Aoki, J; Arai, H; Nagahama, M; Tagaya, M; Tani, K				Nakajima, K; Sonoda, H; Mizoguchi, T; Aoki, J; Arai, H; Nagahama, M; Tagaya, M; Tani, K			A novel phospholipase A(1) with sequence homology to a mammalian Sec23p-interacting protein, p125	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDYLSERINE-SPECIFIC LYSOPHOSPHOLIPASE; GOLGI MATRIX PROTEIN; PHOSPHATIDIC-ACID; ENDOPLASMIC-RETICULUM; COATED VESICLES; CELLS; ACTIVATION; APPARATUS; RELEASE; LIPIDS	p125, a mammalian Sec23p-interacting protein, exhibits sequence homology with bovine testis phosphatidic acid-preferring phospholipase A(1). In this study, we identified and characterized a new homologue of p125, KIAA0725p. KIAA0725p exhibited remarkable sequence similarity with p125 throughout the entire sequence determined but lacked an N-terminal proline-rich, Sec23p-interacting region. In vitro binding analysis showed that KIAA0725p does not bind to Sec23p. KIAA0725p possessed phospholipase A(1) activity preferentially for phosphatidic acid. We examined the effects of overexpression of KIAA0725p on the morphology of organelles. Overexpression of KIAA0725p, like that of p125, caused dispersion of the endoplasmic reticulum-Golgi intermediate compartment and Golgi apparatus. Different from the case of p125, overexpression of KIAA0725p resulted in dispersion of tethering proteins located in the Golgli region and caused aggregation of the endoplasmic reticulum. Our results indicate that KIAA0725p is a new member of the phosphatidic acid-preferring phospholipase A(1) protein family and suggest that the cellular function of KIAA0725p is different from that of p125.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	Tokyo University of Pharmacy & Life Sciences; University of Tokyo	Tani, K (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan.			Aoki, Junken/0000-0001-9435-1896; Sonoda, Hirofumi/0000-0003-3353-1783				ARAI H, 1985, J BIOCHEM-TOKYO, V97, P1525, DOI 10.1093/oxfordjournals.jbchem.a135209; Auger R, 1999, J BIOL CHEM, V274, P28652, DOI 10.1074/jbc.274.40.28652; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Chernomordik L, 1996, CHEM PHYS LIPIDS, V81, P203, DOI 10.1016/0009-3084(96)02583-2; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; DEREWENDA ZS, 1991, BIOCHEM CELL BIOL, V69, P842, DOI 10.1139/o91-125; DOLE VP, 1960, J BIOL CHEM, V235, P2595; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GROENER JEM, 1981, BIOCHIM BIOPHYS ACTA, V665, P306, DOI 10.1016/0005-2760(81)90015-1; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; Han MH, 2001, J BIOL CHEM, V276, P27698, DOI 10.1074/jbc.M101983200; HIDE WA, 1992, J LIPID RES, V33, P167; Higgs HN, 1998, J BIOL CHEM, V273, P5468, DOI 10.1074/jbc.273.10.5468; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P53, DOI 10.1093/oxfordjournals.jbchem.a121907; JONES GA, 1993, J BIOL CHEM, V268, P20845; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Manifava M, 2001, J BIOL CHEM, V276, P8987, DOI 10.1074/jbc.M010308200; Mizoguchi T, 2000, BIOCHEM BIOPH RES CO, V279, P144, DOI 10.1006/bbrc.2000.3846; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Nagai Y, 1999, J BIOL CHEM, V274, P11053, DOI 10.1074/jbc.274.16.11053; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Nemoz G, 1997, MOL PHARMACOL, V51, P242, DOI 10.1124/mol.51.2.242; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Siddhanta A, 2000, J BIOL CHEM, V275, P12023, DOI 10.1074/jbc.275.16.12023; Tagaya M, 1996, J BIOL CHEM, V271, P466, DOI 10.1074/jbc.271.1.466; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tani K, 1999, J BIOL CHEM, V274, P20505, DOI 10.1074/jbc.274.29.20505; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; Uchiyama S, 1999, J BIOCHEM-TOKYO, V125, P1001, DOI 10.1093/oxfordjournals.jbchem.a022378; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Zimmerberg J, 1999, ADV DRUG DELIVER REV, V38, P197, DOI 10.1016/S0169-409X(99)00029-0	41	77	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11329	11335		10.1074/jbc.M111092200	http://dx.doi.org/10.1074/jbc.M111092200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11788596	hybrid			2022-12-27	WOS:000174613100074
J	Shirota, Y; Luo, H; Qin, WP; Kaneko, S; Yamashita, T; Kobayashi, K; Murakami, S				Shirota, Y; Luo, H; Qin, WP; Kaneko, S; Yamashita, T; Kobayashi, K; Murakami, S			Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-B-HEPATITIS; X-PROTEIN; NON-A; HEPATOCELLULAR-CARCINOMA; NONSTRUCTURAL PROTEINS; JAPANESE PATIENTS; TERMINAL REGION; P-PROTEIN; IN-VITRO; GENOME	Hepatitis C virus (HCV) NS5B is RNA-dependent RNA polymerase (RdRP), the essential catalytic enzyme for HCV replication. Recently, NS5A has been reported to be important for the establishment of HCV replication in vitro by the adaptive mutations, although its role in viral replication remains uncertain. Here we report that purified bacterial recombinant NS5A and NS5B directly interact with each other in vitro, detected by glutathione S-transferase (GST) pull-down assay. Furthermore, complex formation of these proteins transiently coexpressed in mammalian cells was detected by coprecipitation. Using terminally and internally truncated NS5A, two discontinuous regions of NS5A (amino acids 105-162 and 277-334) outside of the adaptive mutations were identified to be independently essential for the binding both in vivo and in vitro (Yamashita, T., Kaneko, S., Shirota, Y., Qin, W., Nomura, T., Kobayashi, K., and Mliyrakami, S. (1998) J. Biol. Chem. 273, 15479-15486). We previously examined the effect of His-NS5A on RdRP activity of the soluble recombinant NS5Bt in vitro (see Yamashita et al. above). Wild NS5A weakly stimulated at first (when less than 0.1 molar ratio to NS5B) and then inhibited the NS5Bt RdRP activity in a dose-dependent manner. The internal deletion mutants defective in NS5B binding exhibited no inhibitory effect, indicating that the NS5B binding is necessary for the inhibition. Taken together, our results support the idea that NS5A modulates HCV replication as a component of replication complex.	Kanazawa Univ, Canc Res Inst, Dept Mol Oncol, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Canc Res Inst, Dept Internal Med 1, Kanazawa, Ishikawa 9200934, Japan; Sichuan Univ, W China Hosp, Inst Infect Dis, Chengdu, Sichuan, Peoples R China	Kanazawa University; Kanazawa University; Sichuan University	Murakami, S (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Oncol, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.			Shirota, Yukihiro/0000-0001-6561-4626				ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; Asabe SI, 1997, J VIROL, V71, P790, DOI 10.1128/JVI.71.1.790-796.1997; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; BOUFFARD P, 1995, VIROLOGY, V209, P52, DOI 10.1006/viro.1995.1229; Canter DM, 1996, VIROLOGY, V219, P376, DOI 10.1006/viro.1996.0263; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Dorjsuren D, 1998, MOL CELL BIOL, V18, P7546, DOI 10.1128/MCB.18.12.7546; Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203; FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; HONDA M, 1993, ARCH VIROL, V128, P163, DOI 10.1007/BF01309797; Ishido S, 1998, BIOCHEM BIOPH RES CO, V244, P35, DOI 10.1006/bbrc.1998.8202; JEFFERS LJ, 1992, HEPATOLOGY, V15, P187, DOI 10.1002/hep.1840150204; KANEKO T, 1994, BIOCHEM BIOPH RES CO, V205, P320, DOI 10.1006/bbrc.1994.2667; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Lin C, 1997, J VIROL, V71, P6465, DOI 10.1128/JVI.71.9.6465-6471.1997; Lin Y, 1998, J BIOL CHEM, V273, P27097, DOI 10.1074/jbc.273.42.27097; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; MURAKAMI S, 1994, VIROLOGY, V199, P243, DOI 10.1006/viro.1994.1119; Qin WP, 2002, J BIOL CHEM, V277, P2132, DOI 10.1074/jbc.M106880200; Qin WP, 2001, HEPATOLOGY, V33, P728, DOI 10.1053/jhep.2001.22765; Reed KE, 1997, J VIROL, V71, P7187, DOI 10.1128/JVI.71.10.7187-7197.1997; REED KE, 1995, J VIROL, V69, P4127, DOI 10.1128/JVI.69.7.4127-4136.1995; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SMALLWOOD S, 1994, VIROLOGY, V202, P154, DOI 10.1006/viro.1994.1331; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; TANAKA T, 1995, BIOCHEM BIOPH RES CO, V215, P744, DOI 10.1006/bbrc.1995.2526; Tanaka T, 1996, J VIROL, V70, P3307, DOI 10.1128/JVI.70.5.3307-3312.1996; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479	42	181	189	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11149	11155		10.1074/jbc.M111392200	http://dx.doi.org/10.1074/jbc.M111392200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801599	hybrid, Green Submitted			2022-12-27	WOS:000174613100052
J	Somerville, RA; Oberthur, RC; Havekost, U; MacDonald, F; Taylor, DM; Dickinson, AG				Somerville, RA; Oberthur, RC; Havekost, U; MacDonald, F; Taylor, DM; Dickinson, AG			Characterization of thermodynamic diversity between transmissible spongiform encephalopathy agent strains and its theoretical implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT PRION PROTEIN; PASSAGED SCRAPIE AGENT; CREUTZFELDT-JAKOB; HIGH-TEMPERATURES; INFECTIVITY; PRP; MICE; BSE; STABILITY; DENATURATION	Some transmissible spongiform encephalopathy (TSE) (or "prion") strains, notably those derived from bovine spongiform encephalopathy, are highly resistant to total inactivation by heat. When three TSE strains derived from sheep with scrapie were heated, little inactivation took place at low temperatures, but at higher temperatures, considerable inactivation occurred. The temperature at which substantial inactivation first occurred varied according to TSE strain, and it was calculated to be 70 degreesC for the 22C strain, 84 degreesC for ME7, and 97 degreesC for 22A by fitting the data to a model based on competition between a destructive and a protective reaction. However, PrPSc from mice infected with a range of TSE strains retained similar resistance to proteinase K digestion after heating to below or above these temperatures, showing that the properties of PrPSc responsible for proteinase resistance do not correlate with those conferring thermostability on the TSE agent. The simplest explanation of these data is that the causal agent contains a macromolecular component that is structurally independent of the host, that it varies covalently between TSE strains, and that it is protected by other macromolecular components. The model is in accord with the virino hypothesis, which proposes a host-independent information al molecule protected by the host protein PrP.	Inst Anim Hlth, Neuropathogenesis Unit, Edinburgh EH9 3JF, Midlothian, Scotland; Lab Dr Oberthur GmbH, D-49844 Bawinkel, Germany	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; University of Edinburgh	Somerville, RA (corresponding author), Inst Anim Hlth, Neuropathogenesis Unit, W Mains Rd, Edinburgh EH9 3JF, Midlothian, Scotland.							BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; BRUCE ME, 1987, J GEN VIROL, V68, P79, DOI 10.1099/0022-1317-68-1-79; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BRUCE ME, 1991, J GEN VIROL, V72, P595, DOI 10.1099/0022-1317-72-3-595; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Cambillau C, 2000, J BIOL CHEM, V275, P32383, DOI 10.1074/jbc.C000497200; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; Caughey B, 1997, J VIROL, V71, P4107, DOI 10.1128/JVI.71.5.4107-4110.1997; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chesebro B, 1998, SCIENCE, V279, P42, DOI 10.1126/science.279.5347.42; Daniel RM, 1996, BIOCHEM J, V317, P1, DOI 10.1042/bj3170001; Daniel RM, 2000, CELL MOL LIFE SCI, V57, P250, DOI 10.1007/PL00000688; DICKINSO.AG, 1969, NATURE, V222, P892, DOI 10.1038/222892a0; Dickinson A G, 1976, Front Biol, V44, P209; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; DICKINSON AG, 1978, NEW ENGL J MED, V299, P1413, DOI 10.1056/NEJM197812212992512; Dickinson AG., 1979, SLOW TRANSMISSIBLE D, P13; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; Dougherty R., 1964, TECHNIQUES EXPT VIRO, P169; Fang XW, 2001, P NATL ACAD SCI USA, V98, P4355, DOI 10.1073/pnas.071050698; Farquhar CF, 1998, NATURE, V391, P345, DOI 10.1038/34818; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; Hill AF, 1999, J GEN VIROL, V80, P11, DOI 10.1099/0022-1317-80-1-11; HUNTER GD, 1964, J GEN MICROBIOL, V37, P251, DOI 10.1099/00221287-37-2-251; KIMBERLIN RH, 1983, J NEUROL SCI, V59, P355, DOI 10.1016/0022-510X(83)90021-7; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; MANSON JC, 1994, NEURODEGENERATION, V3, P331; MANUELIDIS L, 1987, EMBO J, V6, P341, DOI 10.1002/j.1460-2075.1987.tb04760.x; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MCKINLEY MP, 1981, SCIENCE, V214, P1259, DOI 10.1126/science.6795721; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Moore RC, 1998, NAT GENET, V18, P118, DOI 10.1038/ng0298-118; OBERTHUR RC, 2001, PRIONEN PRIONKRANKHE, P387; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Poltorak OM, 1998, BIOCHEMISTRY-MOSCOW+, V63, P303; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1980, BIOCHEMISTRY-US, V19, P4883, DOI 10.1021/bi00562a028; PRUSINER SB, 1981, P NATL ACAD SCI-BIOL, V78, P4606, DOI 10.1073/pnas.78.7.4606; Riesner D, 1996, J VIROL, V70, P1714, DOI 10.1128/JVI.70.3.1714-1722.1996; Rohwer R G, 1991, Curr Top Microbiol Immunol, V172, P195; ROHWER RG, 1984, SCIENCE, V223, P600, DOI 10.1126/science.6420887; Rothschild LJ, 2001, NATURE, V409, P1092, DOI 10.1038/35059215; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Schreuder BEC, 1998, VET REC, V142, P474, DOI 10.1136/vr.142.18.474; Schroeder SJ, 2000, BIOCHEMISTRY-US, V39, P9257, DOI 10.1021/bi000229r; Shaked GM, 1999, J BIOL CHEM, V274, P17981, DOI 10.1074/jbc.274.25.17981; Shaked GM, 2001, J BIOL CHEM, V276, P14324, DOI 10.1074/jbc.M007815200; Somerville RA, 1996, ARCH VIROL, V141, P275, DOI 10.1007/BF01718399; Taylor DM, 1998, VET MICROBIOL, V64, P33, DOI 10.1016/S0378-1135(98)00257-0; Taylor DM, 1996, J GEN VIROL, V77, P3161, DOI 10.1099/0022-1317-77-12-3161; TAYLOR DM, 1999, CHARACTERISATION DIA, P108; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Wille H, 1996, J MOL BIOL, V259, P608, DOI 10.1006/jmbi.1996.0343; Winterwerp v The Netherlands, 1979, BAILLI ECHR 1979 2 E	54	73	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11084	11089		10.1074/jbc.M111766200	http://dx.doi.org/10.1074/jbc.M111766200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11792707	hybrid			2022-12-27	WOS:000174613100044
J	Yeh, RH; Yan, XW; Cammer, M; Bresnick, AR; Lawrence, DS				Yeh, RH; Yan, XW; Cammer, M; Bresnick, AR; Lawrence, DS			Real time visualization of protein kinase activity in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY LIGHT-CHAIN; CAGED PEPTIDES; SUBSTRATE-SPECIFICITY; SIGNALING PATHWAYS; MOLECULAR TARGETS; MYOSIN-II; C-ALPHA; PHOSPHORYLATION; ACTIVATION; INHIBITORS	A library of fluorescently labeled protein kinase C (PKC) peptide substrates was prepared to identify a phosphorylation-induced reporter of protein kinase activity. The lead PKC substrate displays a 2.5-fold change in fluorescence intensity upon phosphorylation. PKC activity is readily sampled in cell lysates containing the activated PKCs. Immunodepletion of conventional PKCs from the cell lysate eliminates the fluorescence response, suggesting that this peptide substrate is selectively phosphorylated by PKCalpha, beta, and gamma. Finally, living cells microinjected with the peptide substrate exhibit a 2-fold increase in fluorescence intensity upon exposure to a PKC activator. These results suggest that peptide-based protein kinase biosensors may be useful in monitoring the temporal and spatial dynamics of PKC activity in living cells.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Bresnick, AR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Cammer, Michael/0000-0003-4930-1739				Agarwal R, 2000, BIOCHEM PHARMACOL, V60, P1051, DOI 10.1016/S0006-2952(00)00385-3; BOWMAN BF, 1992, J BIOL CHEM, V267, P5346; Collas P, 1999, J CELL SCI, V112, P977; Curley K, 1999, PHARMACOL THERAPEUT, V82, P347, DOI 10.1016/S0163-7258(98)00055-2; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; Goekjian PG, 1999, CURR MED CHEM, V6, P877; GOSS VL, 1994, J BIOL CHEM, V269, P19074; GSCHWENDT M, 1991, TRENDS BIOCHEM SCI, V16, P167, DOI 10.1016/0968-0004(91)90064-3; Kislauskis EH, 1997, J CELL BIOL, V136, P1263, DOI 10.1083/jcb.136.6.1263; KWON YG, 1994, J BIOL CHEM, V269, P16725; Lawrence DS, 1998, PHARMACOL THERAPEUT, V77, P81, DOI 10.1016/S0163-7258(97)00052-1; LEE TR, 1994, BIOCHEMISTRY-US, V33, P4245, DOI 10.1021/bi00180a019; LEE TR, 1995, J BIOL CHEM, V270, P5375, DOI 10.1074/jbc.270.10.5375; LEE TR, 1993, J AM CHEM SOC, V115, P9888, DOI 10.1021/ja00075a003; Lingameneni R, 2000, FEBS LETT, V473, P265, DOI 10.1016/S0014-5793(00)01532-5; Marriott G, 1999, TRENDS PLANT SCI, V4, P330, DOI 10.1016/S1360-1385(99)01452-1; MCILROY BK, 1991, ANAL BIOCHEM, V195, P148, DOI 10.1016/0003-2697(91)90310-P; Nagai Y, 2000, NAT BIOTECHNOL, V18, P313, DOI 10.1038/73767; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; Pan P, 1997, FEBS LETT, V405, P81, DOI 10.1016/S0014-5793(97)00165-8; Passalacqua M, 1999, FEBS LETT, V453, P249, DOI 10.1016/S0014-5793(99)00729-2; Pirrung MC, 2000, BIOCONJUGATE CHEM, V11, P679, DOI 10.1021/bc000001g; Popoli M, 2001, PHARMACOL THERAPEUT, V89, P149, DOI 10.1016/S0163-7258(00)00108-X; POST PL, 1994, J BIOL CHEM, V269, P12880; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Senderowicz AM, 2001, LEUKEMIA, V15, P1, DOI 10.1038/sj.leu.2401994; Takai Y, 1996, J CELL BIOL, V133, P141, DOI 10.1083/jcb.133.1.141; Tatsu Y, 1999, BIOORG MED CHEM LETT, V9, P1093, DOI 10.1016/S0960-894X(99)00140-7; Varlamova O, 2001, J MUSCLE RES CELL M, V22, P243, DOI 10.1023/A:1012289905754; Walker JW, 1998, P NATL ACAD SCI USA, V95, P1568, DOI 10.1073/pnas.95.4.1568; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Wood JS, 1998, J AM CHEM SOC, V120, P7145, DOI 10.1021/ja980960+; YAN X, 1996, J AM CHEM SOC, V117, P11684; Yan XW, 2000, BIOCHEM J, V349, P709, DOI 10.1042/bj3490709	35	65	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11527	11532		10.1074/jbc.M111300200	http://dx.doi.org/10.1074/jbc.M111300200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11790790	hybrid			2022-12-27	WOS:000174613100099
J	Crosby, D; Poole, AW				Crosby, D; Poole, AW			Interaction of Bruton's tyrosine kinase and protein kinase C theta in platelets - Cross-talk between tyrosine and serine/threonine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; RECEPTOR-GAMMA-CHAIN; VONWILLEBRAND-FACTOR BINDING; SRC FAMILY KINASES; IB-V-IX; GLYCOPROTEIN-IB; STIMULATED PLATELETS; COLLAGEN RECEPTOR; SHEAR-STRESS; BTK FUNCTION	The nonreceptor Bruton's tyrosine kinase (Btk) has been previously shown to associate physically and functionally with members of the protein kinase C (PKC) family of serine/threonine kinases in a variety of cell types. Here we show evidence for a novel interaction between Btk and PKCtheta in platelets activated through the adhesion receptors GP Ib-V-IX and GP VI. Alboaggregin A, a snake venom component capable of activating both receptors in combination, leads to tyrosine phosphorylation of Btk downstream of Src family kinases. Inhibition of Btk by the selective antagonist LFM-A13 causes a reduction in calcium entry, although secretion of 5-hydroxytryptamine is potentiated. Btk is also phosphorylated on threonine residues in a PKC-dependent manner and associates with PKCtheta upon platelet activation by either alboaggregin A or activation of GP Ib-V-IX alone by von Willebrand factor/ristocetin. PKCtheta in turn becomes tyrosine-phosphorylated in a manner dependent upon Src family and Btk kinase activity. Inhibition of Btk activity by LFM-A13 leads to enhancement of PKCtheta activity, whereas nonselective inhibition of PKC activity by bisindolylmaleimide I leads to reduction in Btk activity. We propose a reciprocal feedback interaction between Btk and PKCtheta in platelets, in which PKCtheta positively modulates activity of Btk, which in turn feeds back negatively upon PKCtheta.	Sch Med Sci Bristol, Dept Pharmacol, Bristol BS8 1TD, Avon, England	University of Bristol	Poole, AW (corresponding author), Sch Med Sci Bristol, Dept Pharmacol, Univ Walk, Bristol BS8 1TD, Avon, England.			Poole, Alastair/0000-0002-0868-297X				Afar DEH, 1996, MOL CELL BIOL, V16, P3465; Andrews RK, 1997, INT J BIOCHEM CELL B, V29, P91, DOI 10.1016/S1357-2725(96)00122-7; Asazuma N, 2001, BLOOD, V97, P3989, DOI 10.1182/blood.V97.12.3989; Borowski P, 1998, BIOCHEM J, V331, P649, DOI 10.1042/bj3310649; Cabodi S, 2000, MOL CELL, V6, P1121, DOI 10.1016/S1097-2765(00)00110-6; CHOW TW, 1992, BLOOD, V80, P113; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; Dormann D, 2001, BLOOD, V97, P929, DOI 10.1182/blood.V97.4.929; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Falati S, 1999, BLOOD, V94, P1648, DOI 10.1182/blood.V94.5.1648.417k31_1648_1656; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Genevier HC, 1997, CLIN EXP IMMUNOL, V110, P386, DOI 10.1046/j.1365-2249.1997.4581478.x; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; Johannes FJ, 1999, FEBS LETT, V461, P68, DOI 10.1016/S0014-5793(99)01424-6; Kawakami Y, 2000, P NATL ACAD SCI USA, V97, P7423, DOI 10.1073/pnas.120175097; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; KROLL MH, 1993, J BIOL CHEM, V268, P3520; Laffargue M, 1999, FEBS LETT, V443, P66, DOI 10.1016/S0014-5793(98)01680-9; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; Oda A, 2000, BLOOD, V95, P1663; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Pasquet JM, 2000, EMBO J, V19, P2793, DOI 10.1093/emboj/19.12.2793; PENG ML, 1992, THROMB HAEMOSTASIS, V67, P702; PENG ML, 1991, BIOCHEMISTRY-US, V30, P11529, DOI 10.1021/bi00113a007; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; POOLE AW, 1995, BRIT J PHARMACOL, V115, P101, DOI 10.1111/j.1476-5381.1995.tb16326.x; Quek LS, 1998, CURR BIOL, V8, P1137, DOI 10.1016/S0960-9822(98)70471-3; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; Saito K, 2001, J BIOL CHEM, V276, P16201, DOI 10.1074/jbc.M100873200; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Satterthwaite AB, 1998, SEMIN IMMUNOL, V10, P309, DOI 10.1006/smim.1998.0123; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Wahl MI, 1997, P NATL ACAD SCI USA, V94, P11526, DOI 10.1073/pnas.94.21.11526; Wu Y, 2001, BLOOD, V97, P3836, DOI 10.1182/blood.V97.12.3836; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847	42	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9958	9965		10.1074/jbc.M108965200	http://dx.doi.org/10.1074/jbc.M108965200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11788586	hybrid			2022-12-27	WOS:000174549200048
J	Tobin, KAR; Ulven, SM; Schuster, GU; Steineger, HH; Andresen, SM; Gustafsson, JA; Nebb, HI				Tobin, KAR; Ulven, SM; Schuster, GU; Steineger, HH; Andresen, SM; Gustafsson, JA; Nebb, HI			Liver X receptors as insulin-mediating factors in fatty acid and cholesterol biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL REGULATORY-ELEMENT; NUCLEAR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; BINDING PROTEIN-1C; GENE-EXPRESSION; LXR-ALPHA; TRANSCRIPTIONAL ACTIVITY; GLUCOSE-TRANSPORT; SYNTHASE PROMOTER; RESPONSE PATHWAY	The nuclear receptor liver X receptor (LXR) a, an important regulator of cholesterol and bile acid metabolism, was analyzed after insulin stimulation in liver in vitro and in vivo. A time- and dose-dependent increase in LXRalpha steady-state mRNA level was seen after insulin stimulation of primary rat hepatocytes in culture. A maximal induction of 10-fold was obtained when hepatocytes were exposed to 400 nm insulin for 24 h. Cycloheximide, a potent inhibitor of protein synthesis, prevented induction of LXRalpha mRNA expression by insulin, indicating that the induction is dependent on de novo synthesis of proteins. Stabilization studies using actinomycin D indicated that insulin stimulation increased the half-life of LXRalpha transcripts in cultured primary hepatocytes. Complementary studies where rats and mice were injected with insulin induced LXRa mRNA levels and confirmed our in vitro studies. Furthermore, deletion of both the LXRalpha and LXRbeta genes (double knockout) in mice markedly suppressed insulin-mediated induction of an entire class of enzymes involved in both fatty acid and cholesterol metabolism. The discovery of insulin regulation of LXR in hepatic tissue as well as gene targeting studies in mice provide strong evidence that LXRs plays a central role not only in cholesterol homeostasis, but also in fatty acid metabolism. Further ore, LXRs appear to be important insulin-mediating factors in regulation of lipogenesis.	Univ Oslo, Inst Nutr Res, Inst Basic Med Sci, N-0316 Oslo, Norway; Univ Oslo, Inst Med Biochem, Inst Basic Med Sci, N-0316 Oslo, Norway; Karolinska Inst, Novum, Dept Med Nutr, Ctr Biotechnol, S-14157 Huddinge, Sweden	University of Oslo; University of Oslo; Karolinska Institutet	Nebb, HI (corresponding author), Univ Oslo, Inst Nutr Res, Inst Basic Med Sci, Box 1046 Blindern, N-0316 Oslo, Norway.	h.i.nebb@basalmed.uio.no	Ulven, Stine Marie/ABD-7140-2020					Alberti S, 2000, GENE, V243, P93, DOI 10.1016/S0378-1119(99)00555-7; Alberti S, 2001, J CLIN INVEST, V107, P565, DOI 10.1172/JCI9794; APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; Auwerx J, 1999, CELL, V97, P161; Azzout-Marniche D, 2000, BIOCHEM J, V350, P389, DOI 10.1042/0264-6021:3500389; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Juge-Aubry CE, 1999, J BIOL CHEM, V274, P10505, DOI 10.1074/jbc.274.15.10505; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Latasa MJ, 2000, P NATL ACAD SCI USA, V97, P10619, DOI 10.1073/pnas.180306597; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; O'Brien RM, 2001, BIOCHEM SOC T, V29, P552, DOI 10.1042/BST0290552; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OKADA T, 1994, J BIOL CHEM, V269, P3568; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Repa JJ, 1999, CURR OPIN BIOTECH, V10, P557, DOI 10.1016/S0958-1669(99)00031-2; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; Shalev A, 1996, ENDOCRINOLOGY, V137, P4499, DOI 10.1210/en.137.10.4499; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; SHINAR DM, 1994, GENE, V147, P273, DOI 10.1016/0378-1119(94)90080-9; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; SORENSEN HN, 1992, EUR J BIOCHEM, V208, P705, DOI 10.1111/j.1432-1033.1992.tb17238.x; SORENSEN HN, 1993, BIOCHIM BIOPHYS ACTA, V1171, P263, DOI 10.1016/0167-4781(93)90064-K; STEINEGER HH, 1994, EUR J BIOCHEM, V225, P967, DOI 10.1111/j.1432-1033.1994.0967b.x; Steineger HH, 1998, J LIPID RES, V39, P744; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; Tobin KAR, 2000, MOL ENDOCRINOL, V14, P741, DOI 10.1210/me.14.5.741; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Willy PJ, 1997, GENE DEV, V11, P289, DOI 10.1101/gad.11.3.289; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001	47	151	159	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10691	10697		10.1074/jbc.M109771200	http://dx.doi.org/10.1074/jbc.M109771200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11781314	hybrid			2022-12-27	WOS:000174549200143
J	Fulgosi, H; Soll, J				Fulgosi, H; Soll, J			The chloroplast protein import receptors Toc34 and Toc159 are phosphorylated by distinct protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ENVELOPE MEMBRANES; PRECURSOR PROTEINS; PEA-CHLOROPLASTS; ACTIVATION; PLANTS; GTP; POLYPEPTIDE; COMPONENT; MACHINERY	The molecular composition of chloroplast outer and inner envelope translocons is fairly well established, but little is known about mechanisms and elements involved in import regulation. After synthesis in the cytosol, chloroplast targeted precursor proteins are recognized by outer envelope receptors Toc34 and Toc159. Phosphorylation plays an important role in regulation of Toc34 activity and preprotein binding. Using kinase renaturation assays, we have identified an ATP-dependent 98-kDa outer envelope kinase which is able to selectively phosphorylate Toc34 at a specific site. A 70-kDa outer envelope polypeptide phosphorylating Toc159 was identified by the same strategy. Antiserum against the 98-kDa kinase inhibits phosphorylation of Toc34, whereas labeling of Toc159 remains unaffected. Both kinases do not autophosphorylate in vitro and are unable to utilize myelin basic protein as substrate. We propose that distinct kinases are involved in regulation of chloroplast import via desensitization of preprotein receptors.	Univ Kiel, Inst Bot, D-24118 Kiel, Germany; Univ Munich, Inst Bot, D-80638 Munich, Germany	University of Kiel; University of Munich	Fulgosi, H (corresponding author), Rudjer Boskovic Inst, Dept Mol Genet, Bijenicka 54, HR-10000 Zagreb, Croatia.	fulgosi@rudjer.irb.hr						Baginsky S, 1997, PLANT MOL BIOL, V34, P181, DOI 10.1023/A:1005802909902; Bolter B, 1998, FEBS LETT, V441, P59, DOI 10.1016/S0014-5793(98)01525-7; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; CELENZA JL, 1986, METHOD ENZYMOL, V200, P421; Chang C, 1998, PLANT PHYSIOL, V117, P723, DOI 10.1104/pp.117.3.723; Chen KH, 2000, PLANT PHYSIOL, V122, P813, DOI 10.1104/pp.122.3.813; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; Keegstra K, 1999, CURR OPIN PLANT BIOL, V2, P471, DOI 10.1016/S1369-5266(99)00021-7; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; Kehlenbach RH, 2000, J BIOL CHEM, V275, P17848, DOI 10.1074/jbc.M001455200; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Khwaja A, 1999, BLOOD, V94, P291, DOI 10.1182/blood.V94.1.291.413k10_291_301; Kovtun Y, 1998, NATURE, V395, P716, DOI 10.1038/27240; Martin W, 1998, PLANT PHYSIOL, V118, P9, DOI 10.1104/pp.118.1.9; May T, 2000, PLANT CELL, V12, P53, DOI 10.1105/tpc.12.1.53; SCHALLER GE, 1993, FEBS LETT, V333, P306, DOI 10.1016/0014-5793(93)80676-L; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; Sohrt K, 2000, J CELL BIOL, V148, P1213, DOI 10.1083/jcb.148.6.1213; SOKOLENKO A, 1995, FEBS LETT, V371, P176, DOI 10.1016/0014-5793(95)00892-D; SOLL J, 1985, PLANTA, V166, P394, DOI 10.1007/BF00401178; SOLL J, 1988, PLANTA, V176, P488, DOI 10.1007/BF00397655; SOLL J, 1988, PLANT PHYSIOL, V87, P898, DOI 10.1104/pp.87.4.898; Sveshnikova N, 2000, BIOL CHEM, V381, P687, DOI 10.1515/BC.2000.089; Sveshnikova N, 2000, P NATL ACAD SCI USA, V97, P4973, DOI 10.1073/pnas.080491597; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Torii KU, 2000, CURR OPIN PLANT BIOL, V3, P361, DOI 10.1016/S1369-5266(00)00097-2; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Vener AV, 1998, CURR OPIN PLANT BIOL, V1, P217, DOI 10.1016/S1369-5266(98)80107-6; WAEGEMANN K, 1992, PLANTA, V187, P89, DOI 10.1007/BF00201628; Waegemann K, 1996, J BIOL CHEM, V271, P6545, DOI 10.1074/jbc.271.11.6545; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200	33	33	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8934	8940		10.1074/jbc.M110679200	http://dx.doi.org/10.1074/jbc.M110679200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11773075	hybrid			2022-12-27	WOS:000174400600028
J	Munson, M; Hughson, FM				Munson, M; Hughson, FM			Conformational regulation of SNARE assembly and disassembly in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; SACCHAROMYCES-CEREVISIAE; SHUTTLE VECTORS; ALPHA-SNAP; YEAST; COMPLEX; EXOCYTOSIS; PROTEINS; DOMAIN; SSO1P	SNAP receptor (SNARE) proteins function in intracellular trafficking by forming complexes that bridge vesicle and target membranes prior to fusion. Biochemical studies indicate that the entry of certain SNARE proteins into complexes is inhibited by intramolecular interactions that generate a closed conformation. For example, an essential N-terminal regulatory domain of the yeast plasma membrane SNARE Ssolp sequesters the C-terminal SNARE motif and prevents it from binding to its assembly partners Sec9p and Sncp. Here, we introduce mutations into Ssolp that cause it to remain constitutively open. These open mutants can functionally substitute for wild-type Ssolp protein in vivo, demonstrating that inhibition of SNARE assembly is not the essential function of the N-terminal regulatory domain. Furthermore, the open mutants suppress sec9-4, a mutation that causes a severe defect in SNARE assembly. Elevated levels of SNARE complexes are observed in cells expressing the open mutants. In the presence of sufficient Sec9p, these complexes accumulate to levels that cause severe growth defects. Similarly, overexpression of the open mutants in yeast carrying mutations in the SNARE disassembly machinery impairs growth. Our findings indicate that elevated levels of SNARE complexes can be toxic and that these levels are normally controlled by the SNARE disassembly machinery, by the limited availability of Sec9p, and by the closed conformation of Ssolp.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Hughson, FM (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Munson, Mary/A-9777-2009	Munson, Mary/0000-0003-2297-8053	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038046] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19015] Funding Source: Medline; NINDS NIH HHS [NS38046] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Grote E, 2000, J CELL BIOL, V151, P439, DOI 10.1083/jcb.151.2.439; Grote E, 2000, MOL BIOL CELL, V11, P4051, DOI 10.1091/mbc.11.12.4051; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P293; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P310; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KRAULIS P, 1991, J APPL CRYSTALLOGR, V24, P924; Labbe S, 1999, METHOD ENZYMOL, V306, P145; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; Lerman JC, 2000, BIOCHEMISTRY-US, V39, P8470, DOI 10.1021/bi0003994; Lewis MJ, 2000, MOL BIOL CELL, V11, P23, DOI 10.1091/mbc.11.1.23; May AP, 2001, J BIOL CHEM, V276, P21991, DOI 10.1074/jbc.R100013200; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Miller RK, 2000, MOL BIOL CELL, V11, P2949, DOI 10.1091/mbc.11.9.2949; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Munson M, 2000, NAT STRUCT BIOL, V7, P894; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; Rice LM, 1997, FEBS LETT, V415, P49, DOI 10.1016/S0014-5793(97)01091-0; Rossi G, 1997, J BIOL CHEM, V272, P16610, DOI 10.1074/jbc.272.26.16610; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tochio H, 2001, SCIENCE, V293, P698, DOI 10.1126/science.1062950; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Waters MG, 2000, TRAFFIC, V1, P588, DOI 10.1034/j.1600-0854.2000.010802.x; Weber T, 2000, J CELL BIOL, V149, P1063, DOI 10.1083/jcb.149.5.1063; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247	41	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9375	9381		10.1074/jbc.M111729200	http://dx.doi.org/10.1074/jbc.M111729200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11777922	hybrid			2022-12-27	WOS:000174400600086
J	Shinotsuka, C; Yoshida, Y; Kawamoto, K; Takatsu, H; Nakayama, K				Shinotsuka, C; Yoshida, Y; Kawamoto, K; Takatsu, H; Nakayama, K			Overexpression of an ADP-ribosylation factor-guanine nucleotide exchange factor, BIG2, uncouples brefeldin A-induced adaptor protein-1 coat dissociation and membrane tubulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI MEMBRANES; TRANS-GOLGI; ENDOPLASMIC-RETICULUM; LYSOPHOSPHATIDIC ACID; ORGANELLE STRUCTURE; SYNAPTIC VESICLE; PLASMA-MEMBRANE; BINDING; DOMAIN; ARF	BIG2 is a guanine nucleotide exchange factor (GEF) for the ADP-ribosylation factor (ARF) family of small GTPases, which regulate membrane association of COPI and adaptor protein (AP)-1 coat protein complexes. A fungal metabolite, brefeldin A (BFA), inhibits ARF-GEFs and leads to redistribution of coat proteins from membranes to the cytoplasm and membrane tubulation of the Golgi complex and the trans-Golgi network (TGN). To investigate the function of BIG2, we examined the effects of BIG2-overexpression on the BFA-induced redistribution of ARF, coat proteins, and organelle markers. The BIG2 overexpression blocked BFA-induced redistribution from membranes of APF1 and the AP-1 complex but not that of the COPI complex. These observations indicate that BIG2 is implicated in membrane association of AP-1, but not that of COPI, through activating ARF. Furthermore, not only BIG2 but also ARF1 and AP-1 were found as queues of spherical swellings along the BFA-induced membrane tubules emanating from the TGN. These observations indicate that BFA-induced AP-1 dissociation from TGN membranes and tubulation of TGN membranes are not coupled events and suggest that a BFA target other than ARF-GEFs exists in the cell.	Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan; Univ Tsukuba, Ctr Gene Res, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba; University of Tsukuba	Nakayama, K (corresponding author), Univ Tsukuba, Inst Biol Sci, 1-1-1 Tennohdai, Tsukuba, Ibaraki 3058572, Japan.		Nakayama, Kazuhisa/ABF-2924-2020	Nakayama, Kazuhisa/0000-0001-7701-7183				Al-Awar O, 2000, MOL CELL BIOL, V20, P5998, DOI 10.1128/MCB.20.16.5998-6007.2000; Blum R, 2000, J CELL SCI, V113, P3151; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; CHEVIER P, 1999, CURR OPIN CELL BIOL, V11, P466; Claude A, 1999, J CELL BIOL, V146, P71, DOI 10.1083/jcb.146.1.71; CLUETT EB, 1993, J CELL BIOL, V120, P15, DOI 10.1083/jcb.120.1.15; COOPER MS, 1990, CELL, V61, P135, DOI 10.1016/0092-8674(90)90221-Y; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; DINTZIS SM, 1990, EMBO J, V9, P77, DOI 10.1002/j.1460-2075.1990.tb08082.x; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Hosaka M, 1996, J BIOCHEM-TOKYO, V120, P813; HOSAKA M, 1994, BIOMED RES-TOKYO, V15, P383, DOI 10.2220/biomedres.15.383; Huang FT, 2001, TRAFFIC, V2, P345, DOI 10.1034/j.1600-0854.2001.25020506.x; Jackson C L, 2000, Subcell Biochem, V34, P233; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Klumperman J, 1998, J CELL SCI, V111, P3411; Lippincott-Schwartz J, 1998, HISTOCHEM CELL BIOL, V109, P449, DOI 10.1007/s004180050247; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Mansour SJ, 1999, P NATL ACAD SCI USA, V96, P7968, DOI 10.1073/pnas.96.14.7968; Mironov A, 1997, J CELL BIOL, V139, P1109, DOI 10.1083/jcb.139.5.1109; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Nakata T, 1998, J CELL BIOL, V140, P659, DOI 10.1083/jcb.140.3.659; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Polishchuk RS, 2000, J CELL BIOL, V148, P45, DOI 10.1083/jcb.148.1.45; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Roth MG, 1999, TRENDS CELL BIOL, V9, P174, DOI 10.1016/S0962-8924(99)01535-4; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Scales SJ, 1999, NATURE, V401, P123, DOI 10.1038/43582; Scheel J, 1997, J CELL BIOL, V137, P319, DOI 10.1083/jcb.137.2.319; SCHMID SL, 1995, FASEB J, V9, P1445, DOI 10.1096/fasebj.9.14.7589986; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; Shima DT, 1999, CURR BIOL, V9, P821, DOI 10.1016/S0960-9822(99)80365-0; Spanfo S, 1999, J BIOL CHEM, V274, P17705, DOI 10.1074/jbc.274.25.17705; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Takatsu H, 2000, BIOCHEM BIOPH RES CO, V271, P719, DOI 10.1006/bbrc.2000.2700; Takatsu H, 1998, J BIOL CHEM, V273, P24693, DOI 10.1074/jbc.273.38.24693; TEAL SB, 1994, J BIOL CHEM, V269, P3135; Togawa A, 1999, J BIOL CHEM, V274, P12308, DOI 10.1074/jbc.274.18.12308; TORII S, 1995, J BIOL CHEM, V270, P11574, DOI 10.1074/jbc.270.19.11574; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; WOOD SA, 1992, J CELL BIOL, V119, P273, DOI 10.1083/jcb.119.2.273; Yamaji R, 2000, P NATL ACAD SCI USA, V97, P2567, DOI 10.1073/pnas.97.6.2567; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	51	89	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9468	9473		10.1074/jbc.M112427200	http://dx.doi.org/10.1074/jbc.M112427200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11777925	hybrid			2022-12-27	WOS:000174400600098
J	Yang, ZY; Whelan, J; Babb, R; Bowen, BR				Yang, ZY; Whelan, J; Babb, R; Bowen, BR			An mRNA splice variant of the AFX gene with altered transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; INSULIN-RESPONSE SEQUENCE; FORKHEAD TRANSCRIPTION; ACUTE LEUKEMIAS; FAMILY-MEMBER; FACTOR FKHR; B-MYB; EXPRESSION; GROWTH	Several studies indicate that FKHR and AFX, mammalian homologues of the Caenorhabditis elegans forkhead transcription factor DAF-16, function in the insulin signaling pathway. Here we describe the discovery of a novel AFX isoform, which we designated AFXzeta, in which the first 16 amino acids of the forkhead domain are not present. PCR analysis showed that this isoform. is most abundant in the liver, kidney, and pancreas. In HepG2 cells, overexpressed AFXzeta induced reporter gene activity through the insulin-responsive sequences of the phosphoenolpyruvate carboxykinase (PEPCK), IGFBP-1, and G6Pase promoters. AFXzeta-mediated stimulation was repressed by insulin treatment, by bisperoxovanadate treatment, and by overexpression of constitutively active protein kinase B (PKB). Insulin treatment and PKB overexpression resulted in phosphorylation of AFXzeta. Furthermore, 5-aminoimidazole-4-carboxamide-1-beta-d-ri-bofuranoside (AICAR), an AMP-activated protein kinase activator, repressed AFXzeta-dependent reporter activation. Taken together, these findings suggest that AFX is a downstream target of both the phosphatidylinositol 3-kinase/PKB insulin signaling pathway and an AMP-activated protein kinase-dependent pathway.	Novartis Inst Biomed Res, Summit, NJ 07901 USA	Novartis	Bowen, BR (corresponding author), Novartis Inst Biomed Res, 556 Morris Ave, Summit, NJ 07901 USA.	ben.bowen@pharma.novartis.com	Whelan, James/F-6402-2011	Whelan, James/0000-0001-5754-025X				Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Ayala JE, 1999, DIABETES, V48, P1885, DOI 10.2337/diabetes.48.9.1885; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; Foretz M, 1998, J BIOL CHEM, V273, P14767, DOI 10.1074/jbc.273.24.14767; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Gao G, 1996, J BIOL CHEM, V271, P8675, DOI 10.1074/jbc.271.15.8675; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GOSWAMI R, 1994, ENDOCRINOLOGY, V134, P736, DOI 10.1210/en.134.2.736; GOTTLIEB S, 1994, GENETICS, V137, P107; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Leclerc I, 1998, FEBS LETT, V431, P180, DOI 10.1016/S0014-5793(98)00745-5; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lochhead PA, 2000, DIABETES, V49, P896, DOI 10.2337/diabetes.49.6.896; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MITCHELL J, 1994, MOL ENDOCRINOL, V8, P585, DOI 10.1210/me.8.5.585; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Nakae J, 2001, BIOCHEMISTRY-US, V40, P11768, DOI 10.1021/bi015532m; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; ORLOWSKI CC, 1991, MOL ENDOCRINOL, V5, P1180, DOI 10.1210/mend-5-8-1180; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; Peters U, 1997, HUM GENET, V100, P569, DOI 10.1007/s004390050553; POWELL DR, 1991, J BIOL CHEM, V266, P18868; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; Salamov AA, 1998, BIOINFORMATICS, V14, P384, DOI 10.1093/bioinformatics/14.5.384; SASAKI K, 1984, J BIOL CHEM, V259, P5242; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; Weigelt J, 2001, BIOCHEMISTRY-US, V40, P5861, DOI 10.1021/bi001663w; Wijkander J, 1997, J BIOL CHEM, V272, P21520, DOI 10.1074/jbc.272.34.21520; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1	59	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8068	8075		10.1074/jbc.M106091200	http://dx.doi.org/10.1074/jbc.M106091200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11779849	hybrid			2022-12-27	WOS:000174268000057
J	Pathania, R; Navani, NK; Rajomohan, G; Dikshit, KL				Pathania, R; Navani, NK; Rajomohan, G; Dikshit, KL			Mycobacterium tuberculosis hemoglobin HbO associates with membranes and stimulates cellular respiration of recombinant Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRUNCATED HEMOGLOBINS; LIGAND-BINDING; VITREOSCILLA; PROTEIN; TRANSFORMATION; GROWTH	The truncated hemoglobins HbN and HbO of Mycobacterium tuberculosis H37Rv share little sequence similarity and display structural differences in their EF-loop regions, suggesting distinct function(s) for these hemoglobins. HbO of M. tuberculosis was expressed in Escherichia coli and Mycobacterium smegmatis as a 14.5-kDa homodimeric heme protein exhibiting nearly 50-fold (P-50 similar to0.51) lower oxygen affinity than HbN. 40-50% of HbO remained associated with the cell membranes and significantly enhanced its respiration in comparison with the membrane fractions of control cells or cells overproducing HbN. Oxygen uptake of HbO-associated membranes was decreased by washing and restored by adding HbO. Additionally, membrane vesicles prepared from terminal oxidase-deficient (cyo(-), cyd(-)) mutants of E. coli did not exhibit significant enhancement in oxygen uptake in the presence of HbO, suggesting its interaction(s) with the electron transport chain. Expression of HbO in Mycobacterium bovis bacillus Calmette-Guerin, an experimental model of H. tuberculosis, was observed (0.2-0.5% of total cellular proteins) throughout its aerobic growth. These results provided evidence for the involvement of HbO with the component of aerobic electron transport chain, suggesting that its function may be related to the facilitation of oxygen transfer during aerobic metabolism of H. tuberculosis. Membrane association properties of HbO may thus play a crucial role in sequestering oxygen and facilitating its availability to internalized M. tuberculosis (an obligate aerobe) under the hypoxic conditions of its intracellular habitat.	Inst Microbial Technol, Chandigarh 160036, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Dikshit, KL (corresponding author), Inst Microbial Technol, Sector 39 A, Chandigarh 160036, India.	kanak@imtech.res.in		Govindan, Rajamohan/0000-0002-0208-3546; Pathania, Ranjana/0000-0002-7965-8176				ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BOERMAN SJ, 1982, J GEN APPL MICROBIOL, V28, P35, DOI 10.2323/jgam.28.35; Bolognesi M, 1997, PROG BIOPHYS MOL BIO, V68, P29, DOI 10.1016/S0079-6107(97)00017-5; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; Das TK, 2000, BIOCHEMISTRY-US, V39, P14330, DOI 10.1021/bi001681d; DIKSHIT KL, 1988, GENE, V70, P377, DOI 10.1016/0378-1119(88)90209-0; DIKSHIT RP, 1992, ARCH BIOCHEM BIOPHYS, V293, P241, DOI 10.1016/0003-9861(92)90391-9; Dixit BL, 1998, EUR J BIOCHEM, V254, P202, DOI 10.1046/j.1432-1327.1998.2540202.x; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; FUNG LWM, 1981, BIOCHEMISTRY-US, V20, P7162, DOI 10.1021/bi00528a017; GARBE TR, 1994, MICROBIOL-SGM, V140, P133, DOI 10.1099/13500872-140-1-133; Giardina B, 1981, Methods Enzymol, V76, P417; GREEN GN, 1983, J BACTERIOL, V154, P1269, DOI 10.1128/JB.154.3.1269-1275.1983; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; Hill DR, 1996, J BACTERIOL, V178, P6587, DOI 10.1128/jb.178.22.6587-6598.1996; Imboden P, 1998, GENE, V213, P107, DOI 10.1016/S0378-1119(98)00192-9; IWAASA H, 1990, J BIOL CHEM, V265, P8603; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; LESK AM, 1980, J MOL BIOL, V136, P225, DOI 10.1016/0022-2836(80)90373-3; LIU CY, 1974, J BIOL CHEM, V249, P4261; Milani M, 2001, EMBO J, V20, P3902, DOI 10.1093/emboj/20.15.3902; PARK MK, 1992, CLIN INFECT DIS, V14, P720, DOI 10.1093/clinids/14.3.720; Pesce A, 2000, EMBO J, V19, P2424, DOI 10.1093/emboj/19.11.2424; POTTS M, 1992, SCIENCE, V256, P1690, DOI 10.1126/science.256.5064.1690; Ramandeep, 2001, J BIOL CHEM, V276, P24781, DOI 10.1074/jbc.M009808200; RIGGS AF, 1991, AM ZOOL, V31, P535; Riistama S, 1996, BBA-BIOENERGETICS, V1275, P1, DOI 10.1016/0005-2728(96)00040-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thorsteinsson MV, 1999, BIOCHEMISTRY-US, V38, P2117, DOI 10.1021/bi9819172; Watts RA, 2001, P NATL ACAD SCI USA, V98, P10119, DOI 10.1073/pnas.191349198; WAYNE LG, 1982, INFECT IMMUN, V37, P1042, DOI 10.1128/IAI.37.3.1042-1049.1982; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200; Yeh SR, 2000, J BIOL CHEM, V275, P1679, DOI 10.1074/jbc.275.3.1679	38	62	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15293	15302		10.1074/jbc.M111478200	http://dx.doi.org/10.1074/jbc.M111478200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11796724	hybrid			2022-12-27	WOS:000175510400012
J	Motoki, A; Usui, M; Shimazu, T; Hirano, M; Katoh, S				Motoki, A; Usui, M; Shimazu, T; Hirano, M; Katoh, S			A domain of the manganese-stabilizing protein from Synechococcus elongatus involved in functional binding to photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							33-KDA EXTRINSIC PROTEIN; OXYGEN-EVOLUTION SYSTEM; 33 KDA PROTEIN; SECONDARY STRUCTURE; THERMOPHILIC CYANOBACTERIUM; RECONSTITUTION EXPERIMENTS; DIRECTED MUTAGENESIS; CYANIDIUM-CALDARIUM; CIRCULAR-DICHROISM; EVOLVING COMPLEX	Site-directed mutagenesis was performed to investigate whether the two protease-sensitive sequences Phe(156)-Gly(163) and Arg(184)-Ser(191). of the manganese-stabilizing protein (MSP) from a thermophilic cyanobacterium, Synechococcus elongatus (Motoki, A., Shimazu, T., Hirano, M., and Katoh, S. (1998) Biochim. Biophys. Acta 1365, 492-502), are involved in functional interaction with photosystem II (PSII). The ability of MSP to bind to its functional site on the PSII complex and to reactivate oxygen evolution was dramatically reduced by the substitution of Axg(152), Asp(158), Lys(160), or Axg(162) with uncharged residues, by insertion of a single residue between Phe(156) and Leu(157), or by deletion of Leu(157). Substitution of each of the four charged residues with an identically charged residue showed that the charges at Asp(158), and possibly Lys(160), are important for the electrostatic interaction with PSII The reactivating ability was also strongly affected by the alteration of Phe(156) to Leu. Replacement of Lys(188), the only strictly conserved charged residue in the Arg(184)-Ser(191) sequence, by Gln had only a marginal effect on the function of MSP. High affinity binding of MSP to PSII was also affected significantly by mutation at Axg(152), which is located in a region (Val(148)-Arg(152)) strictly conserved among the 14 sequences so far reported. These results imply that the Val(148)-Gly(163) sequence, which is well conserved among MSPs from cyanobacteria to higher plants, is a domain of MSP for functional interaction with PSII.	Toray Res Ctr Ltd, Dept Biol Sci, Kamakura, Kanagawa 2488555, Japan; Toho Univ, Fac Sci, Dept Biol, Funabashi, Chiba 2748510, Japan	Toray Research Center, Inc.; Toho University	Motoki, A (corresponding author), Toray Res Ctr Ltd, Dept Biol Sci, Kamakura, Kanagawa 2488555, Japan.							BRICKER TM, 1988, FEBS LETT, V231, P111, DOI 10.1016/0014-5793(88)80713-0; Bricker TM, 1998, PHOTOSYNTH RES, V56, P157, DOI 10.1023/A:1006068615220; BURNAP RL, 1994, BIOCHEMISTRY-US, V33, P13712, DOI 10.1021/bi00250a023; EATONRYE JJ, 1989, BIOCHIM BIOPHYS ACTA, V977, P219, DOI 10.1016/S0005-2728(89)80075-1; ENAMI I, 1991, BIOCHIM BIOPHYS ACTA, V1060, P224, DOI 10.1016/S0005-2728(09)91010-6; ENAMI I, 1987, FEBS LETT, V226, P161, DOI 10.1016/0014-5793(87)80571-9; Enami I, 1998, BIOCHEMISTRY-US, V37, P2787, DOI 10.1021/bi9724624; ENAMI I, 1994, BBA-BIOENERGETICS, V1186, P52, DOI 10.1016/0005-2728(94)90134-1; Enami I, 2000, PLANT CELL PHYSIOL, V41, P1354, DOI 10.1093/pcp/pcd069; ENAMI I, 1994, BBA-BIOENERGETICS, V1185, P75, DOI 10.1016/0005-2728(94)90195-3; ENAMI I, 1992, PLANT CELL PHYSIOL, V33, P291, DOI 10.1093/oxfordjournals.pcp.a078253; Enami I, 1995, BBA-BIOENERGETICS, V1232, P208, DOI 10.1016/0005-2728(95)00122-0; Frankel LK, 1999, BIOCHEMISTRY-US, V38, P14271, DOI 10.1021/bi991366v; FRANKEL LK, 1995, BIOCHEMISTRY-US, V34, P7492, DOI 10.1021/bi00022a024; ICHIMURA T, 1992, PLANT CELL PHYSIOL, V33, P299, DOI 10.1093/oxfordjournals.pcp.a078254; ISOGAI Y, 1987, PLANT CELL PHYSIOL, V28, P1493; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KUWABARA T, 1985, BIOCHIM BIOPHYS ACTA, V806, P283, DOI 10.1016/0005-2728(85)90107-0; Lydakis-Simantiris N, 1999, BIOCHEMISTRY-US, V38, P404, DOI 10.1021/bi981847z; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MEI R, 1989, BIOCHEMISTRY-US, V28, P5560, DOI 10.1021/bi00439a033; Miura T, 1997, J BIOL CHEM, V272, P3788, DOI 10.1074/jbc.272.6.3788; MIYAO M, 1984, FEBS LETT, V170, P350, DOI 10.1016/0014-5793(84)81342-3; Motoki A, 1998, BBA-BIOENERGETICS, V1365, P492, DOI 10.1016/S0005-2728(98)00102-9; MOTOKI A, 1995, PHOTOSYNTHESIS LIGHT, V2, P487; MURATA N, 1985, TRENDS BIOCHEM SCI, V10, P122, DOI 10.1016/0968-0004(85)90272-5; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; ODOM WR, 1992, BIOCHEMISTRY-US, V31, P5616, DOI 10.1021/bi00139a027; ONO T, 1986, BIOCHIM BIOPHYS ACTA, V850, P380, DOI 10.1016/0005-2728(86)90194-5; ONO T, 1984, FEBS LETT, V166, P381, DOI 10.1016/0014-5793(84)80117-9; Qian M, 1997, BIOCHEMISTRY-US, V36, P15244, DOI 10.1021/bi9713198; QUEIROLA CB, 1992, THESIS LOUISIANA STA; SAYERS JR, 1992, BIOTECHNIQUES, V13, P592; Seidler A, 1996, EUR J BIOCHEM, V242, P485, DOI 10.1111/j.1432-1033.1996.0485r.x; Seidler A, 1996, PLANT MOL BIOL, V31, P183, DOI 10.1007/BF00020619; Seidler A, 1996, BBA-BIOENERGETICS, V1277, P35, DOI 10.1016/S0005-2728(96)00102-8; SEIDLER A, 1995, PHOTOSYNTHESIS LIGHT, V2, P259; SEIDLER A, 1992, RES PHOTOSYNTHESIS, V2, P409; SHEN JR, 1992, FEBS LETT, V301, P145, DOI 10.1016/0014-5793(92)81235-E; SHEN JR, 1993, BIOCHEMISTRY-US, V32, P1825, DOI 10.1021/bi00058a017; Shutova T, 1997, BIOCHEMISTRY-US, V36, P6350, DOI 10.1021/bi963115h; Sonoyama M, 1996, BBA-PROTEIN STRUCT M, V1297, P167, DOI 10.1016/S0167-4838(96)00099-4; STRICKLAND EH, 1976, CRC HDB BIOCH MOL BI, V3, P141; TANAKA S, 1988, PHOTOSYNTH RES, V17, P255, DOI 10.1007/BF00035452; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; XU Q, 1994, BBA-BIOENERGETICS, V1188, P427, DOI 10.1016/0005-2728(94)90065-5	46	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14747	14756		10.1074/jbc.M100766200	http://dx.doi.org/10.1074/jbc.M100766200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11809745	hybrid			2022-12-27	WOS:000175203000052
J	Shi, HK; Asher, C; Chigaev, A; Yung, Y; Reuveny, E; Seger, R; Garty, H				Shi, HK; Asher, C; Chigaev, A; Yung, Y; Reuveny, E; Seger, R; Garty, H			Interactions of beta and gamma ENaC with Nedd4 can be facilitated by an ERK-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; ACTIVATED PROTEIN-KINASE; SODIUM-CHANNEL; WW DOMAINS; SURFACE EXPRESSION; COLLECTING DUCT; LIDDLE SYNDROME; ALPHA-SUBUNIT; TGF-BETA; ALDOSTERONE	Phosphorylation of the epithelial Na+ channel (ENaC) has been suggested to play a role in its regulation. Here we demonstrate that phosphorylating the carboxyl termini of the beta and gamma subunits facilitates their interactions with the ubiquitin ligase Nedd4 and inhibits channel activity. Three protein kinases, which phosphorylate the carboxyl termini of beta and gammaENaC, have been identified by an in vitro assay. One of these phosphorylates betaThr-613 and gammaThr-623, well-conserved C-tail threonines in the immediate vicinity of the PY motifs. Phosphorylation of gammaThr-623 has also been demonstrated in vivo in channels expressed in Xenopus oocytes, and mutating betaThr-613 and gammaThr-623 into alanine increased the channel activity by 3.5-fold. Effects of the above phosphorylations on interactions between ENaC and Nedd4 have been studied using surface plasmon resonance. Peptides having phospho-threonine at positions beta613 or gamma623 bind the WW domains of Nedd4 two to three times better than the non-phosphorylated analogues, due to higher association rate constants. Using a number of different approaches it was demonstrated that the protein kinase acting on betaThr-613 and gammaThr-623 is the extracellular regulated kinase (ERK). It is suggested that an ERK-mediated phosphorylation of betaThr-613 and gammaThr-623 down-regulates the channel by facilitating its interaction with Nedd4.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Garty, H (corresponding author), Weizmann Inst Sci, Dept Biol Chem, POB 26, IL-76100 Rehovot, Israel.		Chigaev, Alexandre/A-3103-2010	Chigaev, Alexandre/0000-0002-7726-638X				AHN NG, 1990, J BIOL CHEM, V265, P11487; Al-Baldawi NF, 2000, AM J PHYSIOL-CELL PH, V279, pC429, DOI 10.1152/ajpcell.2000.279.2.C429; Asher C, 2001, BIOCHEM BIOPH RES CO, V286, P1228, DOI 10.1006/bbrc.2001.5508; Blazer-Yost BL, 1999, AM J PHYSIOL-CELL PH, V277, pC531, DOI 10.1152/ajpcell.1999.277.3.C531; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Chigaev A, 2001, AM J PHYSIOL-RENAL, V280, pF1030, DOI 10.1152/ajprenal.2001.280.6.F1030; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Farr TJ, 2000, BIOCHEM J, V345, P503, DOI 10.1042/0264-6021:3450503; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Horisberger JD, 1998, CURR OPIN CELL BIOL, V10, P443, DOI 10.1016/S0955-0674(98)80056-2; Husted RF, 2000, AM J PHYSIOL-RENAL, V278, pF425, DOI 10.1152/ajprenal.2000.278.3.F425; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Ji HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1182; Kalmes A, 1999, FEBS LETT, V444, P71, DOI 10.1016/S0014-5793(99)00034-4; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Lin HH, 1999, J BIOL CHEM, V274, P21544, DOI 10.1074/jbc.274.31.21544; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Mastroberardino L, 1998, MOL BIOL CELL, V9, P3417, DOI 10.1091/mbc.9.12.3417; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; PALMER LG, 2000, KIDNEY PHYSL PATHOPH, P251; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Record RD, 1998, AM J PHYSIOL-ENDOC M, V274, pE611, DOI 10.1152/ajpendo.1998.274.4.E611; RUBINFELD H, 1998, CURRENT PROTOCOLS CE; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SEGER R, 1995, J BIOL CHEM, V270, P28325; Shigaev A, 2000, AM J PHYSIOL-RENAL, V278, pF613, DOI 10.1152/ajprenal.2000.278.4.F613; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Spindler B, 1997, PFLUG ARCH EUR J PHY, V434, P323, DOI 10.1007/s004240050403; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Taylor CT, 2000, P NATL ACAD SCI USA, V97, P12091, DOI 10.1073/pnas.220211797; Tian W, 2000, AM J PHYSIOL-RENAL, V279, pF593, DOI 10.1152/ajprenal.2000.279.4.F593; Zentner MD, 1998, J BIOL CHEM, V273, P30770, DOI 10.1074/jbc.273.46.30770	40	104	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13539	13547		10.1074/jbc.M111717200	http://dx.doi.org/10.1074/jbc.M111717200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11805112	hybrid			2022-12-27	WOS:000175096000027
J	Anderson, ED; Molloy, SS; Jean, F; Fei, H; Shimamura, S; Thomas, G				Anderson, ED; Molloy, SS; Jean, F; Fei, H; Shimamura, S; Thomas, G			The ordered and compartment-specific autoproteolytic removal of the furin intramolecular chaperone is required for enzyme activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LYTIC PROTEASE; GOLGI NETWORK LOCALIZATION; PRO-REGION; ENDOPLASMIC-RETICULUM; FOLDING REACTION; SUBTILISIN BPN'; CELL-SURFACE; INTRACELLULAR TRAFFICKING; PROHORMONE CONVERTASES; PROPROTEIN CONVERTASE	The propeptide of furin has multiple roles in guiding the activation of the endoprotease in vivo. The 83-residue N-terminal propeptide is autoproteolytically excised in the endoplasmic reticulum (ER) at the consensus furin site, -Arg(104)-Thr-Lys-Arg(107) down arrow - but remains bound to furin as a potent autoinhibitor. Furin lacking the propeptide is ER-retained and proteolytically inactive. Co-expression with the propeptide, however, restores trans-Golgi network (TGN) localization and enzyme activity, indicating that the furin propeptide is an intramolecular chaperone. Blocking this step results in localization to the ER-Golgi intermediate compartment (ERGIC)/cis-Golgi network (CGN), suggesting the ER and ERGIC/CGN recognize distinct furin folding intermediates. Following transport to the acidified TGN/endosomal compartments, furin cleaves the bound propeptide at a second, internal P1/P6 Arg site (-Arg-Gly-Val(72) -Thr-Lys-Arg(75) down arrow -) resulting in propeptide dissociation and enzyme activation. Cleavage at Arg(75), however, is not required for proper furin trafficking. Kinetic analyses of peptide substrates indicate that the sequential pH-modulated propeptide cleavages result from the differential recognition of these sites by furin. Altering this preference by converting the internal site to a canonical P1/P4 Arg motif (Val(72) --> Arg)caused ER retention and blocked activation of furin, demonstrating that the structure of the furin propeptide mediates folding of the enzyme and directs its pH-regulated, compartment-specific activation in vivo.	Vollum Inst, Portland, OR 97201 USA		Thomas, G (corresponding author), Vollum Inst, Portland, OR 97201 USA.				NIDDK NIH HHS [DK 37274, R01 DK037274] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037274] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson DE, 1999, BIOCHEMISTRY-US, V38, P4728, DOI 10.1021/bi982165e; Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Baker D, 1998, NAT STRUCT BIOL, V5, P1021, DOI 10.1038/4130; BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BAKER D, 1994, BIOCHEMISTRY-US, V33, P7505, DOI 10.1021/bi00190a002; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; Bhattacharjya S, 2001, PROTEIN SCI, V10, P934, DOI 10.1110/ps.41301; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CHIRON MF, 1994, J BIOL CHEM, V269, P18167; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; DAYHUFF TJ, 1992, BIOTECHNIQUES, V13, P500; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; EDER J, 1993, J MOL BIOL, V233, P293, DOI 10.1006/jmbi.1993.1507; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; Fullekrug J, 1997, FEBS LETT, V404, P75, DOI 10.1016/S0014-5793(97)00097-5; GALLAGHER T, 1995, STRUCTURE, V3, P907, DOI 10.1016/S0969-2126(01)00225-8; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; JEAN F, 1995, BIOCHEM J, V307, P689, DOI 10.1042/bj3070689; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; Krysan DJ, 1999, J BIOL CHEM, V274, P23229, DOI 10.1074/jbc.274.33.23229; LEDUC R, 1992, J BIOL CHEM, V267, P14304; Lesage G, 2000, MOL BIOL CELL, V11, P1947, DOI 10.1091/mbc.11.6.1947; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; MOLLOYSS, 1999, TRENDS CELL BIOL, P28; Muller L, 2000, J BIOL CHEM, V275, P39213, DOI 10.1074/jbc.M003547200; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Peters RJ, 1998, BIOCHEMISTRY-US, V37, P12058, DOI 10.1021/bi980883v; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; Sauter NK, 1998, NAT STRUCT BIOL, V5, P945, DOI 10.1038/2919; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Shinde U, 1999, J BIOL CHEM, V274, P15615, DOI 10.1074/jbc.274.22.15615; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SIEZEN RJ, 1995, INTRAMOLECULAR CHAPE, P233; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; Sohl JL, 1998, NATURE, V395, P817, DOI 10.1038/27470; Sohl JL, 1997, BIOCHEMISTRY-US, V36, P3894, DOI 10.1021/bi962341o; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; STRAUSBERG S, 1993, BIOCHEMISTRY-US, V32, P8112, DOI 10.1021/bi00083a009; VANSLYKE JK, 1995, PEPTIDASES NEUROPEPT, V23, P45; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Wolins N, 1997, J CELL BIOL, V139, P1735, DOI 10.1083/jcb.139.7.1735; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509	58	100	102	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12879	12890		10.1074/jbc.M108740200	http://dx.doi.org/10.1074/jbc.M108740200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11799113	Green Accepted, hybrid			2022-12-27	WOS:000175036300052
J	Chauhan, BK; Reed, NA; Zhang, WJ; Duncan, MK; Kilimann, MW; Cvekl, A				Chauhan, BK; Reed, NA; Zhang, WJ; Duncan, MK; Kilimann, MW; Cvekl, A			Identification of genes downstream of Pax6 in the mouse lens using cDNA microarrays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SUBDOMAINS; PAIRED DOMAIN; DROSOPHILA DACHSHUND; CRYSTAL-STRUCTURE; IN-VIVO; EXPRESSION; EYE; PROTEIN; FAMILY; REGION	Pax6 is a transcription factor that regulates the development of the visual, olfactory, and central nervous systems, pituitary, and pancreas. Pax6 is required for in. duction, growth, and maintenance of the lens; however, few direct Pax6 target genes are known. This study was designed to identify batteries of differentially expressed genes in three related systems: 8-week old Pax6 heterozygous lenses, 8-week old Pax6 heterozygous eyes, and transgenic lenses overexpressing PAX6(5a), using high throughput cDNA microarrays containing about 9700 genes. Initially, we obtained almost 400 differentially expressed genes in lenses from mice heterozygous for a Pax6 deletion, suggesting that Pax6 haploinsufficiency causes global changes in the lens transcriptome. Comparisons between the three sets of analyses revealed that paralemmin, molybdopterin synthase sulfurylase, Tel6 oncogene (ETV6), a cleavage-specific factor (Cpsf1) and tangerin A were abnormally expressed in all three experimental models. Semiquantitative reverse transcription (RT)-PCR analysis confirmed that all five of these genes were differentially expressed in Pax-6 heterozygous and Pax6(5a) transgenic lenses. Western blotting and immunohistochemistry demonstrated that paralemmin is found at high levels in the adult lens and confirmed its down-regulation in the Pax6(5a)-transgenic lenses. Collectively, our data provide insights into the genetic programs regulated by Pax6 in the lens.	Yeshiva Univ Albert Einstein Coll Med, Dept Ophthalmol & Visual Sci, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA; Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Delaware; Ruhr University Bochum	Cvekl, A (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Ophthalmol & Visual Sci, 1300 Morris Pk Ave,909 Ullmann, Bronx, NY 10461 USA.		Cvekl, Ales/B-2427-2013	Chauhan, Bharesh/0000-0002-6429-9190; Duncan, Melinda/0000-0003-1570-322X	NATIONAL EYE INSTITUTE [R01EY012221, R01EY012200] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY012221, EY12200, EY12221] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Altmann CR, 1997, DEV BIOL, V185, P119, DOI 10.1006/dbio.1997.8573; Ashery-Padan R, 2000, GENE DEV, V14, P2701, DOI 10.1101/gad.184000; Ayres JA, 2001, GENOMICS, V77, P18, DOI 10.1006/geno.2001.6618; BEEMER FA, 1980, METAB PEDIATR SYST O, V4, P49; Bishop KM, 2000, SCIENCE, V288, P344, DOI 10.1126/science.288.5464.344; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; Carugo KD, 1997, NAT STRUCT BIOL, V4, P175, DOI 10.1038/nsb0397-175; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Collinson JM, 2001, P NATL ACAD SCI USA, V98, P9688, DOI 10.1073/pnas.161144098; Cvekl A, 1999, INVEST OPHTH VIS SCI, V40, P1343; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; Davis RJ, 1999, DEV GENES EVOL, V209, P526, DOI 10.1007/s004270050285; Deissler H, 1997, J BIOL CHEM, V272, P16761, DOI 10.1074/jbc.272.27.16761; Duggan D, 1999, ACM T PROGR LANG SYS, V21, P11, DOI 10.1145/314602.314604; Duncan MK, 2000, INVEST OPHTH VIS SCI, V41, P464; Duncan MK, 2000, J CELL SCI, V113, P3173; Duncan MK, 1998, MOL CELL BIOL, V18, P5579, DOI 10.1128/MCB.18.9.5579; DUNCAN MK, 1995, GENE, V162, P189, DOI 10.1016/0378-1119(95)00363-B; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; Gerstein M, 2000, CURR OPIN STRUC BIOL, V10, P574, DOI 10.1016/S0959-440X(00)00134-2; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GLASER T, 1995, MOL GENETICS OCULAR, P55; Gudas JM, 1999, MOL CELL BIOL, V19, P612; Heyman I, 1999, PSYCHIATR GENET, V9, P85, DOI 10.1097/00041444-199906000-00006; HOGAN BLM, 1986, J EMBRYOL EXP MORPH, V97, P95; Jean D, 1998, MECH DEVELOP, V76, P3, DOI 10.1016/S0925-4773(98)00117-8; JOHNSON JL, 1980, P NATL ACAD SCI-BIOL, V77, P3715, DOI 10.1073/pnas.77.6.3715; Jun S, 1996, DEVELOPMENT, V122, P2639; Kondoh H, 1999, CURR OPIN GENET DEV, V9, P301, DOI 10.1016/S0959-437X(99)80045-8; Kozmik Z, 1997, EMBO J, V16, P6793, DOI 10.1093/emboj/16.22.6793; Kozmik Z, 1999, DEV GENES EVOL, V209, P537, DOI 10.1007/s004270050286; Kutzleb C, 1998, J CELL BIOL, V143, P795, DOI 10.1083/jcb.143.3.795; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Liu L, 1999, CURR EYE RES, V19, P389, DOI 10.1076/ceyr.19.5.389.5289; Livesey FJ, 2000, CURR BIOL, V10, P301, DOI 10.1016/S0960-9822(00)00379-1; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Mansouri A, 1999, TRENDS ENDOCRIN MET, V10, P164, DOI 10.1016/S1043-2760(98)00133-7; Marquardt T, 2001, CELL, V105, P43, DOI 10.1016/S0092-8674(01)00295-1; Mastick GS, 1997, DEVELOPMENT, V124, P1985; McAvoy JW, 2001, INVEST OPHTH VIS SCI, V42, pS457; Meech R, 1999, P NATL ACAD SCI USA, V96, P2420, DOI 10.1073/pnas.96.5.2420; MENDEL RR, 2001, MET IONS BIOL SYST, V39, P1; Mikkola I, 2001, J BIOL CHEM, V276, P4109, DOI 10.1074/jbc.M008882200; NELSON LB, 1984, SURV OPHTHALMOL, V28, P621, DOI 10.1016/0039-6257(84)90184-X; Niimi T, 1999, DEVELOPMENT, V126, P2253; Osumi N, 1997, DEVELOPMENT, V124, P2961; Papatsenko D, 2001, MECH DEVELOP, V101, P143, DOI 10.1016/S0925-4773(00)00581-5; Planque N, 2001, J BIOL CHEM, V276, P29330, DOI 10.1074/jbc.M101812200; Planque N, 2001, J BIOL CHEM, V276, P35751, DOI 10.1074/jbc.M104523200; Reed NA, 2001, J IMMUNOL METHODS, V253, P243, DOI 10.1016/S0022-1759(01)00374-X; Rieger DK, 2001, GENOMICS, V72, P61, DOI 10.1006/geno.2000.6464; Sakai M, 2001, NUCLEIC ACIDS RES, V29, P1228, DOI 10.1093/nar/29.5.1228; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; Schwarz M, 2000, DEVELOPMENT, V127, P4325; Semina EV, 1997, HUM MOL GENET, V6, P2109, DOI 10.1093/hmg/6.12.2109; Semina EV, 1998, NAT GENET, V19, P167, DOI 10.1038/527; Shiraishi A, 1998, INVEST OPHTH VIS SCI, V39, P2554; Sisodiya SM, 2001, NAT GENET, V28, P214, DOI 10.1038/90042; Sivak JM, 2000, DEV BIOL, V222, P41, DOI 10.1006/dbio.2000.9694; Stears RL, 2000, PHYSIOL GENOMICS, V3, P93, DOI 10.1152/physiolgenomics.2000.3.2.93; Stober G, 1999, BIOL PSYCHIAT, V45, P1585, DOI 10.1016/S0006-3223(99)00024-4; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; van Raamsdonk CD, 2000, DEVELOPMENT, V127, P5439; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Xu HE, 1999, GENE DEV, V13, P1263, DOI 10.1101/gad.13.10.1263; Xu PX, 1997, DEVELOPMENT, V124, P219; Yamaguchi Y, 1997, GENES CELLS, V2, P255, DOI 10.1046/j.1365-2443.1997.1170315.x; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zhang WY, 2001, MOL VIS, V7, P1	72	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11539	11548		10.1074/jbc.M110531200	http://dx.doi.org/10.1074/jbc.M110531200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11790784	hybrid			2022-12-27	WOS:000174613100101
J	Lin, S; Shi, Q; Nix, FB; Styblo, M; Beck, MA; Herbin-Davis, KM; Hall, LL; Simeonsson, JB; Thomas, DJ				Lin, S; Shi, Q; Nix, FB; Styblo, M; Beck, MA; Herbin-Davis, KM; Hall, LL; Simeonsson, JB; Thomas, DJ			A novel S-adenosyl-L-methionine : arsenic(III) methyltransferase from rat liver cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOMETHYLARSONOUS ACID MMA(III); THIOETHER S-METHYLTRANSFERASE; IN-VITRO METHYLATION; ARSENIC COMPOUNDS; ENZYMATIC METHYLATION; RABBIT LIVER; HUMAN URINE; MAMMALIAN SYSTEMS; HUMAN HEPATOCYTES; SKIN-CANCER	S-Adenosyl-L-methionine (AdoMet):arsenic (III) methyltransferase, purified from liver cytosol of adult male Fischer 344 rats, catalyzes transfer of a methyl group from AdoMet to trivalent arsenicals producing methylated and dimethylated arsenicals. The kinetics of production of methylated arsenicals in reaction mixtures containing enzyme, AdoMet, dithiothreitol, glutathione (GSH), and arsenite are consistent with a scheme in which monomethylated arsenical produced from arsenite is the substrate for a second methylation reaction that yields dimethylated arsenical. The mRNA for this protein predicts a 369-amino acid residue protein (molecular mass 41056) that contains common methyltransferase sequence motifs. Its sequence is similar to Cyt19, a putative methyltransferase, expressed in human and mouse tissues. Reverse transcription-polymerase chain reaction detects S-adenosyl-L-methionine:arsenic(III) methyltransferase m-RNA in rat tissues and in HepG2 cells, a human cell line that methylates arsenite and methylarsonous acid. S-Adenosyl-L-methionine:arsenic(III) methyltransferase mRNA is not detected in UROtsa cells, an immortalized human urothelial cell line that does not methylate arsenite. Because methylation of arsenic is a critical feature of its metabolism, characterization of this enzyme will improve our understanding of this metalloid's metabolism and its actions as a toxin and a carcinogen.	US EPA, Off Res & Dev, Natl Hlth & Environm Effects Res Lab, Div Expt Toxicol,Pharmacokinet Branch, Res Triangle Pk, NC 27711 USA; Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Curriculum Toxicol, Chapel Hill, NC 27599 USA	United States Environmental Protection Agency; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Thomas, DJ (corresponding author), US EPA, Off Res & Dev, Natl Hlth & Environm Effects Res Lab, Div Expt Toxicol,Pharmacokinet Branch, MD74, Res Triangle Pk, NC 27711 USA.	thomas.david@epa.gov			NIDDK NIH HHS [DK56350] Funding Source: Medline; NIEHS NIH HHS [ES09941] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009941] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aposhian HV, 2000, CHEM RES TOXICOL, V13, P693, DOI 10.1021/tx000114o; Aposhian HV, 1997, ANNU REV PHARMACOL, V37, P397, DOI 10.1146/annurev.pharmtox.37.1.397; Aposhian HV, 2000, TOXICOL APPL PHARM, V165, P74, DOI 10.1006/taap.2000.8922; BUCHET JP, 1988, BIOCHEM PHARMACOL, V37, P3149, DOI 10.1016/0006-2952(88)90313-9; Chouchane S, 2001, CHEM RES TOXICOL, V14, P517, DOI 10.1021/tx000123x; CRECELIUS EA, 1977, ENVIRON HEALTH PERSP, V19, P147, DOI 10.2307/3428467; CULLEN WR, 1984, J INORG BIOCHEM, V21, P179, DOI 10.1016/0162-0134(84)83002-0; Del Razo LM, 2001, TOXICOL APPL PHARM, V174, P282, DOI 10.1006/taap.2001.9226; DELNOMDEDIEU M, 1994, CHEM-BIOL INTERACT, V90, P139, DOI 10.1016/0009-2797(94)90099-X; DelRazo LM, 1997, ARCH TOXICOL, V71, P211; Hall LL, 1997, TOXICOL APPL PHARM, V147, P101, DOI 10.1006/taap.1997.8269; Hamahata A, 1996, BIOCHEM J, V317, P141, DOI 10.1042/bj3170141; Healy SM, 1998, TOXICOL APPL PHARM, V148, P65, DOI 10.1006/taap.1997.8306; Hirata M., 1989, APPL ORGANOMET CHEM, V3, P335, DOI [10.1002/aoc.590030406, DOI 10.1002/AOC.590030406]; HSIEH HS, 1977, BIOCHIM BIOPHYS ACTA, V497, P205; Hsueh YM, 1997, CANCER EPIDEM BIOMAR, V6, P589; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; Kitchin KT, 1999, TERATOGEN CARCIN MUT, V19, P385, DOI 10.1002/(SICI)1520-6866(1999)19:6<385::AID-TCM3>3.3.CO;2-M; Le XC, 2000, ANAL CHEM, V72, P5172, DOI 10.1021/ac000527u; Le XC, 2000, ENVIRON HEALTH PERSP, V108, P1015, DOI 10.2307/3434951; Lin S, 1999, CHEM RES TOXICOL, V12, P924, DOI 10.1021/tx9900775; Lin S, 2001, CHEM RES TOXICOL, V14, P305, DOI 10.1021/tx0001878; Mandal BK, 2001, CHEM RES TOXICOL, V14, P371, DOI 10.1021/tx000246h; Mass MJ, 2001, CHEM RES TOXICOL, V14, P355, DOI 10.1021/tx000251l; MOZIER NM, 1988, J BIOL CHEM, V263, P4527; National Research Council, 1999, ARS DRINK WAT; Petrick JS, 2000, TOXICOL APPL PHARM, V163, P203, DOI 10.1006/taap.1999.8872; Petrick JS, 2001, CHEM RES TOXICOL, V14, P651, DOI 10.1021/tx000264z; Petzoldt JL, 1995, UROL RES, V23, P377, DOI 10.1007/BF00698738; Radabaugh TR, 2000, CHEM RES TOXICOL, V13, P26, DOI 10.1021/tx990115k; REAY PF, 1977, ANAL BIOCHEM, V78, P557, DOI 10.1016/0003-2697(77)90117-8; Reeve AM, 1998, J BIOL CHEM, V273, P30695, DOI 10.1074/jbc.273.46.30695; SCOTT N, 1993, CHEM RES TOXICOL, V6, P102, DOI 10.1021/tx00031a016; SMITH TJ, 1977, ENVIRON HEALTH PERSP, V19, P89, DOI 10.2307/3428456; Styblo M, 1999, CHEM RES TOXICOL, V12, P560, DOI 10.1021/tx990050l; Styblo M, 1996, J CHROMATOGR B, V677, P161, DOI 10.1016/0378-4347(95)00490-4; Styblo M, 1995, TOXICOL APPL PHARM, V135, P172, DOI 10.1006/taap.1995.1220; Styblo M, 1997, CHEM RES TOXICOL, V10, P27, DOI 10.1021/tx960139g; STYBLO M, 1995, J CHROMATOGR B, V668, P21, DOI 10.1016/0378-4347(95)00053-L; Styblo M, 1996, CHEM-BIOL INTERACT, V99, P147, DOI 10.1016/0009-2797(95)03666-0; Styblo M, 2000, ARCH TOXICOL, V74, P289, DOI 10.1007/s002040000134; Thomas DJ, 2001, ARSENIC EXPOSURE AND HEALTH EFFECTS IV, P353; Thomas DJ, 2001, TOXICOL APPL PHARM, V176, P127, DOI 10.1006/taap.2001.9258; Turpeinen R, 1999, SCI TOTAL ENVIRON, V236, P173, DOI 10.1016/S0048-9697(99)00269-7; Vahter M, 2000, TOXICOL LETT, V112, P209, DOI 10.1016/S0378-4274(99)00271-4; WARNER DR, 1995, BBA-PROTEIN STRUCT M, V1246, P160, DOI 10.1016/0167-4838(94)00186-K; Weinshilboum R, 2001, DRUG METAB DISPOS, V29, P601; WU GH, 1992, J GEN MICROBIOL, V138, P2101, DOI 10.1099/00221287-138-10-2101; YAMAUCHI H, 1979, Industrial Health, V17, P79; Yamauchi Hiroshi, 1994, V27, P35; Yu RC, 2000, CANCER EPIDEM BIOMAR, V9, P1259; ZAKHARYAN R, 1995, CHEM RES TOXICOL, V8, P1029, DOI 10.1021/tx00050a006; Zakharyan RA, 1999, TOXICOL APPL PHARM, V158, P9, DOI 10.1006/taap.1999.8687; Zakharyan RA, 1996, TOXICOL APPL PHARM, V140, P77, DOI 10.1006/taap.1996.0199; Zakharyan RA, 1999, CHEM RES TOXICOL, V12, P1278, DOI 10.1021/tx9901231; Zakharyan RA, 2001, CHEM RES TOXICOL, V14, P1051, DOI 10.1021/tx010052h; Zhang XR, 1996, J ANAL ATOM SPECTROM, V11, P1075, DOI 10.1039/ja9961101075	57	285	295	3	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10795	10803		10.1074/jbc.M110246200	http://dx.doi.org/10.1074/jbc.M110246200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11790780	Green Submitted, hybrid, Green Published			2022-12-27	WOS:000174613100009
J	Watanabe, K; Nair, P; Labeit, D; Kellermayer, MSZ; Greaser, M; Labeit, S; Granzier, H				Watanabe, K; Nair, P; Labeit, D; Kellermayer, MSZ; Greaser, M; Labeit, S; Granzier, H			Molecular mechanics of cardiac titin's PEVK and N2B spring elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; ENTROPIC ELASTICITY; STIFFNESS DIVERSITY; PASSIVE TENSION; CONTOUR-LENGTH; LASER TWEEZERS; MUSCLE; PROTEIN; EXTENSIBILITY; IMMUNOGLOBULIN	Titin is a giant elastic protein that is responsible for the majority of passive force generated by the myocardium. Titin's force is derived from its extensible I-band region, which, in the cardiac isoform, comprises three main extensible elements: tandem Ig segments, the PEVK domain, and the N2B unique sequence (N2B-Us). Using atomic force microscopy, we characterized the single molecule force-extension curves of the PEVK and N2B-Us spring elements, which together are responsible for physiological levels of passive force in moderately to highly stretched myocardium. Stretch-release force-extension curves of both the PEVK domain and N2B-Us displayed little hysteresis: the stretch and release data nearly overlapped. The force-extension curves closely followed worm-like chain behavior. Histograms of persistence length (measure of chain bending rigidity) indicated that the single molecule persistence lengths are similar to1.4 and similar to0.65 nm for the PEVK domain and N2B-Us, respectively. Using these mechanical characteristics and those determined earlier for the tandem Ig segment (assuming folded Ig domains), we modeled the cardiac titin extensible region in the sarcomere and calculated the extension of the various spring elements and the forces generated by titin, both as a function of sarcomere length. In the physiological sarcomere length range, predicted values and those obtained experimentally were indistinguishable.	Washington State Univ, Dept Vet & Comparat Anat Pharmacol & Physiol, Pullman, WA 99164 USA; Univ Hosp Mannheim, Dept Anesthesiol & Intens Operat Med, D-68135 Mannheim, Germany; Univ Pecs, Sch Med, Dept Biophys, H-7624 Pecs, Hungary; Univ Wisconsin, Muscle Biol Lab, Madison, WI 53706 USA	Washington State University; Ruprecht Karls University Heidelberg; University of Pecs; University of Wisconsin System; University of Wisconsin Madison	Granzier, H (corresponding author), Washington State Univ, Dept Vet & Comparat Anat Pharmacol & Physiol, Pullman, WA 99164 USA.	granzier@wsunix.wsu.edu		Kellermayer, Miklos/0000-0002-5553-6553	NHLBI NIH HHS [HL62466, HL61497, HL62881] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061497, R01HL062881, R01HL062466] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bang ML, 2001, CIRC RES, V89, P1065, DOI 10.1161/hh2301.100981; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; Carrion-Vazquez M, 2000, PROG BIOPHYS MOL BIO, V74, P63, DOI 10.1016/S0079-6107(00)00017-1; Cazorla O, 2000, CIRC RES, V86, P59, DOI 10.1161/01.RES.86.1.59; Cazorla O, 2001, CIRC RES, V88, P1028, DOI 10.1161/hh1001.090876; Daughdrill GW, 1997, NAT STRUCT BIOL, V4, P285, DOI 10.1038/nsb0497-285; Freiburg A, 2000, CIRC RES, V86, P1114; GRANZIER H, 2002, IN PRESS J PHYSL LON; GRANZIER HL, 1995, BIOPHYS J, V68, P1027, DOI 10.1016/S0006-3495(95)80278-X; Gutierrez-Cruz G, 2001, J BIOL CHEM, V276, P7442, DOI 10.1074/jbc.M008851200; Helmes M, 1999, CIRC RES, V84, P1339, DOI 10.1161/01.RES.84.11.1339; Improta S, 1996, STRUCTURE, V4, P323, DOI 10.1016/S0969-2126(96)00036-6; Irving TC, 2000, AM J PHYSIOL-HEART C, V279, pH2568, DOI 10.1152/ajpheart.2000.279.5.H2568; Kellermayer MSZ, 1997, SCIENCE, V276, P1112, DOI 10.1126/science.276.5315.1112; Kellermayer MSZ, 2000, ADV EXP MED BIOL, V481, P111; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; Li HB, 2000, P NATL ACAD SCI USA, V97, P6527, DOI 10.1073/pnas.120048697; Li HB, 2000, NAT STRUCT BIOL, V7, P1117; Li HB, 2001, P NATL ACAD SCI USA, V98, P10682, DOI 10.1073/pnas.191189098; Linke WA, 1999, J CELL BIOL, V146, P631, DOI 10.1083/jcb.146.3.631; Linke WA, 1996, J MOL BIOL, V261, P62, DOI 10.1006/jmbi.1996.0441; Liversage AD, 2001, J MOL BIOL, V305, P401, DOI 10.1006/jmbi.2000.4279; Ma K, 2001, BIOCHEMISTRY-US, V40, P3427, DOI 10.1021/bi0022792; Millman BM, 1998, PHYSIOL REV, V78, P359, DOI 10.1152/physrev.1998.78.2.359; Minajeva A, 2001, BIOPHYS J, V80, P1442, DOI 10.1016/S0006-3495(01)76116-4; Namba K, 2001, GENES CELLS, V6, P1, DOI 10.1046/j.1365-2443.2001.00384.x; Oberhauser AF, 2001, P NATL ACAD SCI USA, V98, P468, DOI 10.1073/pnas.021321798; Pascual J, 1997, J MOL BIOL, V273, P740, DOI 10.1006/jmbi.1997.1344; Plaxco KW, 1997, NATURE, V386, P657, DOI 10.1038/386657a0; RABANAL F, 1993, BIOPOLYMERS, V33, P1019, DOI 10.1002/bip.360330704; Rief M, 1998, BIOPHYS J, V75, P3008, DOI 10.1016/S0006-3495(98)77741-0; Rief M, 1999, J MOL BIOL, V286, P553, DOI 10.1006/jmbi.1998.2466; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; Trombitas K, 1999, BIOPHYS J, V77, P3189, DOI 10.1016/S0006-3495(99)77149-3; Trombitas K, 2000, BIOPHYS J, V79, P3226, DOI 10.1016/S0006-3495(00)76555-6; Trombitas K, 1998, J CELL BIOL, V140, P853, DOI 10.1083/jcb.140.4.853; TROMBITAS K, 1995, CIRC RES, V77, P856, DOI 10.1161/01.RES.77.4.856; Tskhovrebova L, 2001, J MOL BIOL, V310, P755, DOI 10.1006/jmbi.2001.4700; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Wu YM, 2000, J MOL CELL CARDIOL, V32, P2151, DOI 10.1006/jmcc.2000.1281; Yamasaki R, 2001, BIOPHYS J, V81, P2297, DOI 10.1016/S0006-3495(01)75876-6	42	107	109	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11549	11558		10.1074/jbc.M200356200	http://dx.doi.org/10.1074/jbc.M200356200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11799131	hybrid			2022-12-27	WOS:000174613100102
J	Gable, K; Han, G; Monaghan, E; Bacikova, D; Natarajan, M; Williams, R; Dunn, TM				Gable, K; Han, G; Monaghan, E; Bacikova, D; Natarajan, M; Williams, R; Dunn, TM			Mutations in the yeast LCB1 and LCB2 genes, including those corresponding to the hereditary sensory neuropathy type I mutations, dominantly inactivate serine palmitoyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDOXAL-PHOSPHATE COFACTOR; COA-CONDENSING ENZYME; SACCHAROMYCES-CEREVISIAE; 8-AMINO-7-OXONONANOATE SYNTHASE; SPHINGOLIPID SYNTHESIS; AMINOLEVULINATE SYNTHASE; CLONING; PROTEIN; BIOSYNTHESIS; SUPPRESSORS	It was recently demonstrated that mutations in the human SPTLC1 gene, encoding the Lcb1p subunit of serine palmitoyltransferase (SPT), cause hereditary sensory neuropathy type 1 (1, 2). As a member of the subfamily of pyridoxal 5'-phosphate enzymes known as the alpha-oxoamine synthases, serine palmitoyltransferase catalyzes the committed step of sphingolipid synthesis. The residues that are mutated to cause hereditary sensory neuropathy type I reside in a highly conserved region of Lcb1p that is predicted to be a catalytic domain of Lcb1p on the basis of alignments with other members of the a-oxoamine synthase family. We found that the corresponding mutations in the LCB1 gene of Saccharomyces cerevisiae reduce serine palmitoyltransferase activity. These mutations are dominant and decrease serine palmitoyltransferase activity by 50% when the wild-type and mutant LCB1 alleles are coexpressed. We also show that serine palmitoyltransferase is an Lcb1p-Lcb2p heterodimer and that the mutated Lcb1p proteins retain their ability to interact with Lcb2p. Modeling studies suggest that serine palmitoyltransferase is likely to have a single active site that lies at the Lcb1p-Lcb2p interface and that the mutations in Lcb1p reside near the lysine in Lcb2p that is expected to form the Schiff's base with the pyridoxal 5'-phosphate cofactor. Furthermore, mutations in this lysine and in a histidine residue that is also predicted to be important for pyridoxal 5'-phosphate binding to Lcb2p also dominantly inactivate SPT similar to the hereditary sensory neuropathy type 1-like mutations in Lcb1p.	Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20184 USA; Uniformed Serv Univ Hlth Sci, Dept Biomed Informat, Bethesda, MD 20184 USA	Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA	Dunn, TM (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, 4301 Jones Bridge Rd, Bethesda, MD 20184 USA.			Natarajan, Mukil/0000-0001-8908-7306	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051891] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51891] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexeev D, 1998, J MOL BIOL, V284, P401, DOI 10.1006/jmbi.1998.2086; Auer-Grumbach M, 2000, NEUROLOGY, V54, P45, DOI 10.1212/WNL.54.1.45; Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688; Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; Bejaoui K, 2001, NAT GENET, V27, P261, DOI 10.1038/85817; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; BUEDE R, 1993, J BACTERIOL, V175, P919, DOI 10.1128/JB.175.3.919-919.1993; Dawkins JL, 2001, NAT GENET, V27, P309, DOI 10.1038/85879; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Dunn TM, 2000, METHOD ENZYMOL, V312, P317; Edgar AJ, 2000, EUR J BIOCHEM, V267, P1805, DOI 10.1046/j.1432-1327.2000.01175.x; FERREIRA GC, 1995, PROTEIN SCI, V4, P1001; Gable K, 2000, J BIOL CHEM, V275, P7597, DOI 10.1074/jbc.275.11.7597; Gong J, 1996, BIOCHEMISTRY-US, V35, P14109, DOI 10.1021/bi961296h; Grilley MM, 1998, J BIOL CHEM, V273, P11062, DOI 10.1074/jbc.273.18.11062; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; Hanada K, 2000, J BIOL CHEM, V275, P8409, DOI 10.1074/jbc.275.12.8409; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Ikushiro H, 2001, J BIOL CHEM, V276, P18249, DOI 10.1074/jbc.M101550200; Kolter T, 1998, BRAIN PATHOL, V8, P79; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; Nicholson GA, 1996, NAT GENET, V13, P101, DOI 10.1038/ng0596-101; Riley RT, 2001, ENVIRON HEALTH PERSP, V109, P301, DOI 10.2307/3435022; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sherman F., 1986, METHODS YEAST GENETI; Webster SP, 1998, BIOCHEM SOC T, V26, pS268, DOI 10.1042/bst026s268; Webster SP, 2000, BIOCHEMISTRY-US, V39, P516, DOI 10.1021/bi991620j; WELLS GB, 1983, J BIOL CHEM, V258, P200; ZHAO C, 1994, J BIOL CHEM, V269, P21480	35	85	94	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10194	10200		10.1074/jbc.M107873200	http://dx.doi.org/10.1074/jbc.M107873200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11781309	hybrid, Green Submitted			2022-12-27	WOS:000174549200079
J	Hanwell, D; Ishikawa, T; Saleki, R; Rotin, D				Hanwell, D; Ishikawa, T; Saleki, R; Rotin, D			Trafficking and cell surface stability of the epithelial Na+ channel expressed in epithelial Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIDDLES-SYNDROME MUTATIONS; AE1 ANION-EXCHANGERS; SODIUM-CHANNEL; MDCK CELLS; XENOPUS-OOCYTES; MEMBRANE TOPOLOGY; APICAL MEMBRANE; ANNEXIN XIIIB; BREFELDIN-A; C2 DOMAIN	The apically located epithelial Na+ channel (alphabetagamma-ENaC) plays a key role in the regulation of salt and fluid transport in the kidney and other epithelia, yet its mode of trafficking to the plasma membrane and its cell surface stability in mammalian cells are poorly understood. Because the expression of ENaC in native tissues/cells is very low, we generated epithelial Madin-Darby canine kidney (MDCK) cells stably expressing alphabetagamma-ENaC, where each subunit is tagged differentially at the intracellular C terminus and the beta-subunit is also Myc-tagged at the ectodomain (alpha(HA)beta(Myc),(T7)gamma(FLAG)). ENaC expression in these cells was verified by immunoblotting with antibodies to the tags, and patch clamp analysis has confirmed that the tagged channel is functional. Moreover, using electron microscopy, we demonstrated apical, but not basal, membrane localization of ENaC in these cells. The glycosylation pattern of the intracellular pool of ENaC revealed peptide N-glycosidase F and endoglycosidase H sensitivity. Surprisingly, the cell surface pool of ENaC, analyzed by surface biotinylation, was also core glycosylated and lacked detectable endoglycosidase H-resistant channels. Extraction of the channel from cells in Triton X-100 demonstrated that both intracellular and cell surface pools of ENaC are largely soluble. Moreover, floatation assays to analyze the presence of ENaC in lipid rafts showed that both intracellular and cell surface pools of this channel are not associated with rafts. We have shown previously that the total cellular pool of ENaC is turned over rapidly (t(1/2) similar to 1-2 h). Using cycloheximide treatment and surface biotinylation we now demonstrate that the cell surface pool of ENaC has a similarly short half-life (t(1/2) similar to 1 h), unlike the long half-life reported recently for the Xenopus A6 cells. Collectively, these results help elucidate key aspects of ENaC trafficking and turnover rates in mammalian kidney epithelial cells.	Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Rotin, D (corresponding author), Hosp Sick Children, Cell Biol Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	drotin@sickkids.ca						Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Adair-Kirk TL, 1999, J CELL BIOL, V147, P1237, DOI 10.1083/jcb.147.6.1237; Adams CM, 1997, J BIOL CHEM, V272, P27295, DOI 10.1074/jbc.272.43.27295; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BULLER AL, 1990, J MEMBRANE BIOL, V115, P179, DOI 10.1007/BF01869456; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Coscoy S, 1998, J BIOL CHEM, V273, P8317, DOI 10.1074/jbc.273.14.8317; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Ghosh S, 1999, MOL BIOL CELL, V10, P455, DOI 10.1091/mbc.10.2.455; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; HARDER T, 1994, BBA-MOL CELL RES, V1223, P375, DOI 10.1016/0167-4889(94)90098-1; HIRT RP, 1992, GENE, V111, P199, DOI 10.1016/0378-1119(92)90687-K; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kleyman TR, 2001, AM J PHYSIOL-RENAL, V281, pF213, DOI 10.1152/ajprenal.2001.281.2.F213; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; Lafont F, 1998, J CELL BIOL, V142, P1413, DOI 10.1083/jcb.142.6.1413; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Loffing J, 2000, AM J PHYSIOL-RENAL, V279, pF252, DOI 10.1152/ajprenal.2000.279.2.F252; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; May A, 1997, J AM SOC NEPHROL, V8, P1813; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Plant PJ, 2000, J CELL BIOL, V149, P1473, DOI 10.1083/jcb.149.7.1473; Prince LS, 1998, BIOCHEM J, V336, P705, DOI 10.1042/bj3360705; Prince LS, 1999, AM J PHYSIOL-CELL PH, V276, pC1346, DOI 10.1152/ajpcell.1999.276.6.C1346; Qi JJ, 1999, J BIOL CHEM, V274, P30345, DOI 10.1074/jbc.274.43.30345; RENARD S, 1994, J BIOL CHEM, V269, P12981; Rotin D, 2001, AM J PHYSIOL-RENAL, V281, pF391, DOI 10.1152/ajprenal.2001.281.3.F391; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; Saxena S, 1999, J BIOL CHEM, V274, P20812, DOI 10.1074/jbc.274.30.20812; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Valentijn JA, 1998, J BIOL CHEM, V273, P30344, DOI 10.1074/jbc.273.46.30344; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	52	109	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9772	9779		10.1074/jbc.M110904200	http://dx.doi.org/10.1074/jbc.M110904200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11773057	hybrid			2022-12-27	WOS:000174549200025
J	Reddy, VS; Ali, GS; Reddy, ASN				Reddy, VS; Ali, GS; Reddy, ASN			Genes encoding calmodulin-binding proteins in the Arabidopsis genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PROGRAMMED CELL-DEATH; KINESIN-LIKE PROTEIN; HEAT-SHOCK-PROTEIN; GLUTAMATE-DECARBOXYLASE; PLASMA-MEMBRANE; MOLECULAR-CLONING; PLANT CALMODULIN; FUNCTIONAL-CHARACTERIZATION; REGULATED CA2+-ATPASE; KINASE CASCADE	Analysis of the recently completed Arabidopsis genome sequence indicates that similar to31% of the predicted genes could not be assigned to functional categories, as they do not show any sequence similarity with proteins of known function from other organisms. CalmoduIin (CaM), a ubiquitous and multifunctional Ca2+ sensor, interacts with a wide variety of cellular proteins and modulates their activity/function in regulating diverse cellular processes. However, the primary amino acid sequence of the CaM-binding domain in different CaM-binding proteins (CBPs) is not conserved. One way to identify most of the CBPs in the Arabidopsis genome is by protein-protein interaction-based screening of expression libraries with CaM. Here, using a mixture of radiolabeled CaM isoforms from Arabidopsis, we screened several expression libraries prepared from flower meristem, seedlings, or tissues treated with hormones, an elicitor, or a pathogen. Sequence analysis of 77 positive clones that interact with CaM in a Ca2+-dependent manner revealed 20 CBPs, including 14 previously unknown CBPs. In addition, by searching the Arabidopsis genome sequence with the newly identified and known plant or animal CBPs, we identified a total of 27 CBPs. Among these, 16 CBPs are represented by families with 2-20 members in each family. Gene expression analysis revealed that CBPs and CBP paralogs are expressed differentially. Our data suggest that Arabidopsis has a large number of CBPs including several plant-specific ones. Although CaM is highly conserved between plants and animals, only a few CBPs are common to both plants and animals. Analysis of Arabidopsis CBPs revealed the presence of a variety of interesting domains. Our analyses identified several hypothetical proteins in the Arabidopsis genome as CaM targets, suggesting their involvement in Ca2+-mediated signaling networks.	Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; Colorado State Univ, Cell & Mol Biol Program, Ft Collins, CO 80523 USA	Colorado State University; Colorado State University	Reddy, ASN (corresponding author), Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA.	reddy@lamar.colostate.edu		Reddy, Anireddy/0000-0002-4038-4091				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ALLEN GJ, 1995, PLANT CELL, V7, P1473; Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; ANDREEVA AV, 1999, PHYSIOL PLANTARUM, V106, P209; Arabidopsis Genome Initiative, 2000, Nature (London), V408, P796, DOI 10.1038/35048692; Arazi T, 2000, PLANT MOL BIOL, V42, P591, DOI 10.1023/A:1006345302589; Arazi T, 1999, PLANT J, V20, P171, DOI 10.1046/j.1365-313x.1999.00588.x; Arendt CW, 1997, J BIOL CHEM, V272, P13117, DOI 10.1074/jbc.272.20.13117; BAHLER M, 1994, J CELL BIOL, V126, P375, DOI 10.1083/jcb.126.2.375; BAUM G, 1993, J BIOL CHEM, V268, P19610; Baum G, 1996, EMBO J, V15, P2988, DOI 10.1002/j.1460-2075.1996.tb00662.x; BENASUTTI M, 1992, P NATL ACAD SCI USA, V89, P10974; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Bibikova TN, 1997, PLANTA, V203, P495, DOI 10.1007/s004250050219; Bonza MC, 2000, PLANT PHYSIOL, V123, P1495, DOI 10.1104/pp.123.4.1495; Borevitz JO, 2000, PLANT CELL, V12, P2383, DOI 10.1105/tpc.12.12.2383; Broillet MC, 1999, ANN NY ACAD SCI, V868, P730, DOI 10.1111/j.1749-6632.1999.tb11352.x; Buaboocha T, 2001, PLANTA, V212, P774, DOI 10.1007/s004250000440; BUELT MK, 1994, J BIOL CHEM, V269, P29367; Carninci P, 2000, GENOME RES, V10, P1617, DOI 10.1101/gr.145100; Castets F, 2000, J BIOL CHEM, V275, P19970, DOI 10.1074/jbc.M909782199; Castets F, 1996, J CELL BIOL, V134, P1051, DOI 10.1083/jcb.134.4.1051; CIMLER BM, 1987, J BIOL CHEM, V262, P12158; Clough SJ, 2000, P NATL ACAD SCI USA, V97, P9323, DOI 10.1073/pnas.150005697; DACOSTA E, 1994, PLANT MOL BIOL, V25, P921; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Fromm H, 1992, PLANT MOL BIOL REP, V10, P199, DOI 10.1007/BF02668347; Geisler M, 2000, BBA-BIOMEMBRANES, V1465, P52, DOI 10.1016/S0005-2736(00)00131-0; Gong M, 1998, PLANT PHYSIOL, V116, P429, DOI 10.1104/pp.116.1.429; Groover A, 1999, PLANT PHYSIOL, V119, P375, DOI 10.1104/pp.119.2.375; Haldrup A, 1999, PLANT J, V17, P689, DOI 10.1046/j.1365-313X.1999.00419.x; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Harper JF, 1998, J BIOL CHEM, V273, P1099, DOI 10.1074/jbc.273.2.1099; Hepler PK, 1997, TRENDS PLANT SCI, V2, P79, DOI 10.1016/S1360-1385(97)88385-9; Hong BM, 1999, PLANT PHYSIOL, V119, P1165, DOI 10.1104/pp.119.4.1165; Hsieh HL, 1996, PLANT MOL BIOL, V30, P135, DOI 10.1007/BF00017808; HUANG LQ, 1993, P NATL ACAD SCI USA, V90, P10066, DOI 10.1073/pnas.90.21.10066; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Hwang I, 2000, P NATL ACAD SCI USA, V97, P6224, DOI 10.1073/pnas.97.11.6224; Jakobek JL, 1999, MOL PLANT MICROBE IN, V12, P712, DOI 10.1094/MPMI.1999.12.8.712; Jenkins CM, 2001, J BIOL CHEM, V276, P7129, DOI 10.1074/jbc.M010439200; Jung KM, 2000, PLANT PHYSIOL, V123, P1057, DOI 10.1104/pp.123.3.1057; KAUR KJ, 1994, J BIOL CHEM, V269, P23045; KEETON TP, 1995, BIOCHEM J, V306, P779, DOI 10.1042/bj3060779; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kitani T, 1997, J BIOCHEM-TOKYO, V122, P243; KITANI T, 1994, J BIOCHEM-TOKYO, V115, P637, DOI 10.1093/oxfordjournals.jbchem.a124387; Knight H, 2000, INT REV CYTOL, V195, P269; KOCHHAR S, 1986, BIOCHIM BIOPHYS ACTA, V880, P220, DOI 10.1016/0304-4165(86)90083-8; Kohler C, 1999, PLANT J, V18, P97, DOI 10.1046/j.1365-313X.1999.00422.x; Kohler C, 2000, FEBS LETT, V471, P133, DOI 10.1016/S0014-5793(00)01383-1; KORFHAGE U, 1994, PLANT CELL, V6, P695, DOI 10.1105/tpc.6.5.695; Kutuzov MA, 2001, BIOCHEM BIOPH RES CO, V289, P634, DOI 10.1006/bbrc.2001.6020; Lee CHJ, 1996, J NEUROSCI, V16, P6784; Leng Q, 1999, PLANT PHYSIOL, V121, P753, DOI 10.1104/pp.121.3.753; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; Liao BR, 1995, METHOD CELL BIOL, V49, P487, DOI 10.1016/S0091-679X(08)61475-2; Liu YG, 2000, ONCOGENE, V19, P1579, DOI 10.1038/sj.onc.1203442; Liu ZH, 1998, PLANT MOL BIOL, V38, P889, DOI 10.1023/A:1006019001200; LU YT, 1994, PLANT PHYSIOL BIOCH, V32, P413; LU YT, 1995, PLANT PHYSIOL, V108, P1197, DOI 10.1104/pp.108.3.1197; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; MAEKAWA S, 1993, J BIOL CHEM, V268, P13703; Maser P, 2001, PLANT PHYSIOL, V126, P1646, DOI 10.1104/pp.126.4.1646; MIAO ZH, 1994, PLANT MOL BIOL, V25, P1, DOI 10.1007/BF00024193; MICHAELI T, 1993, J BIOL CHEM, V268, P12925; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; Narasimhulu SB, 1998, PLANT CELL, V10, P957, DOI 10.1105/tpc.10.6.957; Neff MM, 1999, P NATL ACAD SCI USA, V96, P15316, DOI 10.1073/pnas.96.26.15316; Neuteboom LW, 1999, PLANT MOL BIOL, V39, P273, DOI 10.1023/A:1006104205959; Oppenheimer DG, 1997, P NATL ACAD SCI USA, V94, P6261, DOI 10.1073/pnas.94.12.6261; PATIL S, 1995, P NATL ACAD SCI USA, V92, P4897, DOI 10.1073/pnas.92.11.4897; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; POTIER MC, 1995, GENOMICS, V29, P562, DOI 10.1006/geno.1995.9965; Reddy ASN, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-7-research0024; Reddy ASN, 2000, BIOCHEM BIOPH RES CO, V279, P762, DOI 10.1006/bbrc.2000.4032; Reddy ASN, 1996, J BIOL CHEM, V271, P7052, DOI 10.1074/jbc.271.12.7052; Reddy ASN, 2001, PLANT SCI, V160, P381, DOI 10.1016/S0168-9452(00)00386-1; Reddy ASN, 2000, TRENDS PLANT SCI, V5, P503, DOI 10.1016/S1360-1385(00)01792-1; REDDY ASN, 1993, PLANT SCI, V94, P109, DOI 10.1016/0168-9452(93)90012-O; REDDY ASN, 2001, HDB PLANT CROP PHYSL, P697; Reddy VS, 1999, J BIOL CHEM, V274, P31727, DOI 10.1074/jbc.274.44.31727; Reddy VS, 1999, BIOINFORMATICS, V15, P1055; Redpath NT, 1996, J BIOL CHEM, V271, P17547, DOI 10.1074/jbc.271.29.17547; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rogers GC, 1999, J MOL BIOL, V294, P1, DOI 10.1006/jmbi.1999.3249; Safadi F, 2000, J BIOL CHEM, V275, P35457, DOI 10.1074/jbc.M002720200; Sanders D, 1999, PLANT CELL, V11, P691, DOI 10.1105/tpc.11.4.691; SCHLEMMER SR, 1995, J BIOL CHEM, V270, P11040, DOI 10.1074/jbc.270.19.11040; Schuurink RC, 1998, P NATL ACAD SCI USA, V95, P1944, DOI 10.1073/pnas.95.4.1944; SHIEH BH, 1995, NEURON, V14, P201, DOI 10.1016/0896-6273(95)90255-4; SMITH DK, 1992, J BACTERIOL, V174, P5820, DOI 10.1128/jb.174.18.5820-5826.1992; Snedden WA, 2000, PLANT J, V24, P317, DOI 10.1046/j.1365-313x.2000.00877.x; Snedden WA, 1996, J BIOL CHEM, V271, P4148; Snedden WA, 2001, NEW PHYTOL, V151, P35, DOI 10.1046/j.1469-8137.2001.00154.x; Snyder SH, 1998, BRAIN RES REV, V26, P167, DOI 10.1016/S0165-0173(97)00032-5; Song H, 1997, P NATL ACAD SCI USA, V94, P322, DOI 10.1073/pnas.94.1.322; SONNEMANN J, 1991, J BIOL CHEM, V266, P23091; Steinebrunner I, 2000, PLANT PHYSIOL BIOCH, V38, P913, DOI 10.1016/S0981-9428(00)01209-2; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; Subbaiah CC, 2000, J BIOL CHEM, V275, P21678, DOI 10.1074/jbc.M001484200; Sun XT, 2000, PLANT CELL PHYSIOL, V41, P804, DOI 10.1093/pcp/41.6.804; Sunkar R, 2000, PLANT J, V24, P533, DOI 10.1046/j.1365-313x.2000.00901.x; Szymanski DB, 1996, PLANT CELL, V8, P1069, DOI 10.1105/tpc.8.6.1069; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Trewavas AJ, 1998, CURR OPIN PLANT BIOL, V1, P428, DOI 10.1016/S1369-5266(98)80268-9; TRUSCOTT KN, 1994, EUR J BIOCHEM, V222, P277, DOI 10.1111/j.1432-1033.1994.tb18866.x; Veena, 1999, PLANT J, V17, P385, DOI 10.1046/j.1365-313X.1999.00390.x; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vucich VA, 1996, MOL GEN GENET, V252, P510, DOI 10.1007/BF02172397; Wang W, 1996, PLANT MOL BIOL, V31, P683, DOI 10.1007/BF00042240; WATILLON B, 1995, PLANT PHYSIOL, V108, P847, DOI 10.1104/pp.108.2.847; Wendler WMF, 1997, J BIOL CHEM, V272, P8482, DOI 10.1074/jbc.272.13.8482; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; Xu HX, 1998, PLANT CELL, V10, P585, DOI 10.1105/tpc.10.4.585; Xu XZS, 1998, J BIOL CHEM, V273, P31297, DOI 10.1074/jbc.273.47.31297; Xu Y, 2000, PLANT PHYSIOL, V122, P1323, DOI 10.1104/pp.122.4.1323; Yang TB, 2000, J BIOL CHEM, V275, P3137, DOI 10.1074/jbc.275.5.3137; Yang TB, 2000, BIOCHEM BIOPH RES CO, V275, P601, DOI 10.1006/bbrc.2000.3335; Zegzouti H, 1999, PLANT J, V18, P589, DOI 10.1046/j.1365-313x.1999.00483.x; Zhao YD, 2001, SCIENCE, V291, P306, DOI 10.1126/science.291.5502.306; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697; Zik M, 1998, PLANT MOL BIOL, V37, P967, DOI 10.1023/A:1006047623263; [No title captured]	127	160	209	4	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9840	9852		10.1074/jbc.M111626200	http://dx.doi.org/10.1074/jbc.M111626200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11782485	hybrid			2022-12-27	WOS:000174549200034
J	Shields, JM; Rogers-Graham, K; Der, CJ				Shields, JM; Rogers-Graham, K; Der, CJ			Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; CYCLIN D1; EPITHELIAL-CELLS; CARCINOMA-CELLS; FAMILY PROTEINS; RETINOIC ACID; MESSENGER-RNA; HUMAN CANCER; SM22 ALPHA	Activated Ras but not Raf can transform RIE-1 and other epithelial cells, indicating the critical importance of Raf-independent effector function in Ras transformation of epithelial cells. To elucidate the nature of these Raf-independent activities, we utilized representational difference analysis to identify genes aberrantly expressed by Ras through Raf-independent mechanisms in RIE-1 cells. We identified a total of 22 genes, both known and novel, whose expression was either activated (10) or abolished (12) by Ras but not Raf. The genes up-regulated encode proteins involved in protein or DNA synthesis, regulation of protease activity, or ligand binding, whereas those genes down-regulated encode actin cytoskeletal-, extracellular matrix-, and gap junction-associated proteins, and transmembrane receptor- or cytokine-like proteins. These results suggest that a key function of Raf-independent signaling involves deregulation of gene expression. We further characterized transgelin as a gene whose expression was abolished by Ras. Transgelin was identified previously as a protein whose expression was lost in virally transformed cell lines. We show that this loss is regulated at the level of gene expression and that both Raf-dependent and Raf-independent pathways are required to cause Ras down-regulation of transgelin in RIE-1 cells, whereas Raf alone is sufficient to cause its loss in NIH 3T3 fibroblasts. We also found that Ras-dependent and Ras-independent mechanisms can cause the down-regulation of transgelin in human breast and colon carcinoma cells lines and patient-derived tumor samples. We conclude that loss of transgelin gene expression may be an important early event in tumor progression and a diagnostic marker for breast and colon cancer development.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Shields, JM (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, CB 7295, Chapel Hill, NC 27599 USA.	shieldsj@med.unc.edu		Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA063071] Funding Source: NIH RePORTER; NCI NIH HHS [CA63071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; Alaiya AA, 1997, INT J CANCER, V73, P678, DOI 10.1002/(SICI)1097-0215(19971127)73:5<678::AID-IJC11>3.0.CO;2-2; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BOS JL, 1989, CANCER RES, V49, P4682; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; GABBIANI G, 1976, AM J PATHOL, V83, P457; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Glozak MA, 1998, EXP CELL RES, V242, P165, DOI 10.1006/excr.1998.4075; Glozak MA, 1996, DEV BIOL, V179, P458, DOI 10.1006/dbio.1996.0275; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Janssen RAJ, 1997, MOL BIOL CELL, V8, P897, DOI 10.1091/mbc.8.5.897; Janssen RAJ, 1998, J BIOL CHEM, V273, P32182, DOI 10.1074/jbc.273.48.32182; Jernvall J, 1998, DEVELOPMENT, V125, P161; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; Khoo NKS, 1998, INT J CANCER, V77, P440; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Lawson D, 1997, CELL MOTIL CYTOSKEL, V38, P250, DOI 10.1002/(SICI)1097-0169(1997)38:3<250::AID-CM3>3.0.CO;2-9; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MURPHY GA, 2002, IN PRESS ONCOGENE DI; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Ozes ON, 1999, NATURE, V401, P82; Plattner R, 1996, P NATL ACAD SCI USA, V93, P6665, DOI 10.1073/pnas.93.13.6665; Plattner R, 1999, ONCOGENE, V18, P1807, DOI 10.1038/sj.onc.1202482; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; PRINJHA RK, 1994, CELL MOTIL CYTOSKEL, V28, P243, DOI 10.1002/cm.970280307; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Rae RS, 1998, MOL CARCINOGEN, V22, P120, DOI 10.1002/(SICI)1098-2744(199806)22:2<120::AID-MC7>3.0.CO;2-Q; RAO JS, 1990, CANCER RES, V50, P5039; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Sehgal A, 1998, J SURG ONCOL, V69, P99, DOI 10.1002/(SICI)1096-9098(199810)69:2<99::AID-JSO10>3.0.CO;2-M; SHAPLAND C, 1993, J CELL BIOL, V121, P1065, DOI 10.1083/jcb.121.5.1065; SHAPLAND C, 1988, J CELL BIOL, V107, P153, DOI 10.1083/jcb.107.1.153; Shibuta K, 1997, INT J CANCER, V73, P656, DOI 10.1002/(SICI)1097-0215(19971127)73:5<656::AID-IJC8>3.0.CO;2-W; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shields JM, 2001, METHOD ENZYMOL, V332, P221; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Singal R, 2000, ANTICANCER RES, V20, P59; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; Song QB, 1998, DEV BIOL, V196, P119, DOI 10.1006/dbio.1998.8847; SOULE HD, 1990, CANCER RES, V50, P6075; STREULI CH, 1995, J CELL BIOL, V129, P591, DOI 10.1083/jcb.129.3.591; VAN AL, 1997, GENE DEV, V11, P2295; Wang FL, 1996, CANCER RES, V56, P3634; WASYLYK C, 1994, ONCOGENE, V9, P3665; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; WICK M, 1992, ONCOGENE, V7, P859; Wiley HS, 1998, J CELL BIOL, V143, P1317, DOI 10.1083/jcb.143.5.1317; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Yamamura H, 1997, J BIOCHEM, V122, P157; Yip-Schneider MT, 1999, INT J ONCOL, V15, P271; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 2000, GENE DEV, V14, P163; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zimmermann AG, 1997, J BIOL CHEM, V272, P22913, DOI 10.1074/jbc.272.36.22913; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	71	114	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9790	9799		10.1074/jbc.M110086200	http://dx.doi.org/10.1074/jbc.M110086200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11773051	hybrid, Green Published			2022-12-27	WOS:000174549200027
J	Blot, N; Berrier, C; Hugouvieux-Cotte-Pattat, N; Ghazi, A; Condemine, G				Blot, N; Berrier, C; Hugouvieux-Cotte-Pattat, N; Ghazi, A; Condemine, G			The oligogalacturonate-specific porin KdgM of Erwinia chrysanthemi belongs to a new porin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PROTEIN-A; ESCHERICHIA-COLI; OUTER-MEMBRANE; PECTATE LYASES; FUNCTIONAL-CHARACTERIZATION; SALMONELLA-TYPHIMURIUM; PECTINOLYSIS GENES; OMPA PROTEIN; CHANNELS; METABOLISM	The phytopathogenic Gram-negative bacteria Erwinia chrysanthemi secretes pectinases, which are able to degrade the pectic polymers of plant cell walls, and uses the degradation products as a carbon source for growth. We characterized a major outer membrane protein, KdgM, whose synthesis is strongly induced in the presence of pectic derivatives. The corresponding gene was characterized. Analysis of transcriptional fusions showed that the kdgM expression is controlled by the general repressor of pectinolytic genes, KdgR, by the repressor of hexuronate catabolism genes, ExuR, by the pectinase gene repressor, PecS, and by catabolite repression via the cyclic AMP receptor protein (CRP) transcriptional activator. A kdgM mutant is unable to grow on oligogalacturonides longer than trimers, and its virulence is affected. Electrophysiological experiments with planar lipid bilayers showed that KdgM behaves like a voltage-dependent porin that is slightly selective for anions and that exhibits fast block in the presence of trigalacturonate. In contrast to most porins, KdgM seems to be monomeric. KdgM has no homology with currently known porins, but proteins similar to KdgM are present in several bacteria. Therefore, these proteins might constitute a new family of porin channels.	Composante INSA, CNRS, UMR 5122, Unite Microbiol & Genet, F-69621 Villeurbanne, France; Univ Paris Sud, CNRS, Grp Canaux Ion, UMR 8619, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Institut National des Sciences Appliquees de Lyon - INSA Lyon; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Condemine, G (corresponding author), Composante INSA, CNRS, UMR 5122, Unite Microbiol & Genet, Batiment Louis Pasteur,11 Ave Jean Capelle, F-69621 Villeurbanne, France.	condemin@insa-lyon.fr		COTTE-PATTAT, Nicole/0000-0002-4322-160X; Condemine, Guy/0000-0002-3256-3815				ANDRO T, 1984, J BACTERIOL, V160, P1199, DOI 10.1128/JB.160.3.1199-1203.1984; Arora A, 2000, J BIOL CHEM, V275, P1594, DOI 10.1074/jbc.275.3.1594; BARDONNET N, 1992, FEMS MICROBIOL LETT, V93, P243, DOI 10.1111/j.1574-6968.1992.tb05105.x; BARRAS F, 1994, ANNU REV PHYTOPATHOL, V32, P201, DOI 10.1146/annurev.py.32.090194.001221; BENZ R, 1986, J BACTERIOL, V165, P978, DOI 10.1128/jb.165.3.978-986.1986; BENZ R, 1984, EUR J BIOCHEM, V140, P319, DOI 10.1111/j.1432-1033.1984.tb08104.x; Berrier C, 1997, J MEMBRANE BIOL, V156, P105, DOI 10.1007/s002329900193; Bezrukov SM, 2000, FEBS LETT, V476, P224, DOI 10.1016/S0014-5793(00)01753-1; Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; COLLMER A, 1981, P NATL ACAD SCI-BIOL, V78, P3920, DOI 10.1073/pnas.78.6.3920; CONDEMINE G, 1991, MOL MICROBIOL, V5, P2191, DOI 10.1111/j.1365-2958.1991.tb02149.x; CONDEMINE G, 1992, MOL MICROBIOL, V6, P3199, DOI 10.1111/j.1365-2958.1992.tb01775.x; CONDEMINE G, 1986, J BACTERIOL, V165, P937, DOI 10.1128/jb.165.3.937-941.1986; CONDEMINE G, 1987, FEMS MICROBIOL LETT, V42, P39, DOI 10.1016/0378-1097(87)90495-2; Conlan S, 2000, BIOCHEMISTRY-US, V39, P11845, DOI 10.1021/bi001065h; DARGENT B, 1986, EMBO J, V5, P773, DOI 10.1002/j.1460-2075.1986.tb04280.x; DARGENT B, 1987, FEBS LETT, V220, P136, DOI 10.1016/0014-5793(87)80891-8; Fajardo DA, 1998, J BACTERIOL, V180, P4452, DOI 10.1128/JB.180.17.4452-4459.1998; Hauben L, 1998, SYST APPL MICROBIOL, V21, P384, DOI 10.1016/S0723-2020(98)80048-9; HINTON JCD, 1989, MOL MICROBIOL, V3, P1785, DOI 10.1111/j.1365-2958.1989.tb00164.x; Hugouvieux-Cotte-Pattat N, 2001, MOL MICROBIOL, V41, P1125, DOI 10.1046/j.1365-2958.2001.02565.x; Hugouvieux-Cotte-Pattat N, 2001, MOL MICROBIOL, V41, P1113, DOI 10.1046/j.1365-2958.2001.02564.x; HUGOUVIEUXCOTTEPATTAT N, 1985, J BACTERIOL, V162, P248, DOI 10.1128/JB.162.1.248-255.1985; HugouvieuxCottePattat N, 1996, ANNU REV MICROBIOL, V50, P213, DOI 10.1146/annurev.micro.50.1.213; HUGOUVIEUXCOTTEPATTAT N, 1987, J BACTERIOL, V169, P1223, DOI 10.1128/jb.169.3.1223-1231.1987; JI JW, 1987, J GEN MICROBIOL, V133, P793; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANULIS S, 1988, J BACTERIOL, V170, P1825, DOI 10.1128/jb.170.4.1825-1830.1988; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Miller J. H., 1972, EXPT MOL GENETICS, P431; Moczydlowski E., 1986, ION CHANNEL RECONSTI, P75; NASSER W, 1994, J MOL BIOL, V236, P427, DOI 10.1006/jmbi.1994.1155; Nasser W, 1998, MOL MICROBIOL, V29, P1391, DOI 10.1046/j.1365-2958.1998.01022.x; NASSER W, 1992, MOL MICROBIOL, V6, P257, DOI 10.1111/j.1365-2958.1992.tb02007.x; Nasser W, 1999, MOL MICROBIOL, V34, P641, DOI 10.1046/j.1365-2958.1999.01609.x; Nasser W, 1997, MOL MICROBIOL, V26, P1071, DOI 10.1046/j.1365-2958.1997.6472020.x; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; POSSOT O, 1994, MOL MICROBIOL, V12, P287, DOI 10.1111/j.1365-2958.1994.tb01017.x; Praillet T, 1996, MOL MICROBIOL, V20, P391, DOI 10.1111/j.1365-2958.1996.tb02626.x; PREISS J, 1962, J BIOL CHEM, V237, P309; PRESTON JF, 1992, J BACTERIOL, V174, P2039, DOI 10.1128/jb.174.6.2039-2042.1992; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RESIBOIS A, 1984, VIROLOGY, V137, P102, DOI 10.1016/0042-6822(84)90013-8; Reverchon S, 1997, J BACTERIOL, V179, P3500, DOI 10.1128/jb.179.11.3500-3508.1997; REVERCHON S, 1991, MOL MICROBIOL, V5, P2203, DOI 10.1111/j.1365-2958.1991.tb02150.x; REVERCHON S, 1994, MOL MICROBIOL, V11, P1127, DOI 10.1111/j.1365-2958.1994.tb00389.x; ROEDER DL, 1985, J BACTERIOL, V164, P51, DOI 10.1128/JB.164.1.51-56.1985; Roy C, 1999, J BACTERIOL, V181, P3705, DOI 10.1128/JB.181.12.3705-3709.1999; SAINT N, 1993, BIOCHIM BIOPHYS ACTA, V1145, P119, DOI 10.1016/0005-2736(93)90388-G; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SanFrancisco MJD, 1996, MOL PLANT MICROBE IN, V9, P144, DOI 10.1094/MPMI-9-0144; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHINDLER H, 1981, P NATL ACAD SCI-BIOL, V78, P2302, DOI 10.1073/pnas.78.4.2302; Shevchik VE, 1999, J BACTERIOL, V181, P3912, DOI 10.1128/JB.181.13.3912-3919.1999; Shevchik VE, 1999, J BACTERIOL, V181, P1652, DOI 10.1128/JB.181.5.1652-1663.1999; STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F; SUGAWARA E, 1994, J BIOL CHEM, V269, P17981; SUGAWARA E, 1992, J BIOL CHEM, V267, P2507; Surgey N, 1996, J BACTERIOL, V178, P1593, DOI 10.1128/jb.178.6.1593-1599.1996; Tardy F, 1997, J BACTERIOL, V179, P2503, DOI 10.1128/jb.179.8.2503-2511.1997; TATE CG, 1992, J BIOL CHEM, V267, P6923; YELLEN G, 1984, J GEN PHYSIOL, V84, P157, DOI 10.1085/jgp.84.2.157	66	51	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7936	7944		10.1074/jbc.M109193200	http://dx.doi.org/10.1074/jbc.M109193200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11773048	hybrid, Green Published			2022-12-27	WOS:000174268000041
J	Sterner, DE; Wang, X; Bloom, MH; Simon, GM; Berger, SL				Sterner, DE; Wang, X; Bloom, MH; Simon, GM; Berger, SL			The SANT domain of Ada2 is required for normal acetylation of histones by the yeast SAGA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN5 TRANSCRIPTIONAL COACTIVATOR; TATA-BINDING PROTEIN; FUNCTION IN-VIVO; SACCHAROMYCES-CEREVISIAE; ACETYLTRANSFERASE COMPLEXES; NUCLEOSOME ACETYLATION; CHROMATIN STRUCTURE; ACTIVATION; DNA; BROMODOMAIN	Transcription is regulated through chromatin remodeling and histone modification, mediated by large protein complexes. Histone and nucleosome interaction has been shown to be mediated by specific chromatin domains called bromodomains and chromodomains. Here we provide evidence for a similar function of two additional domains within the yeast SAGA complex, containing the histone acetyltransferase Gcn5. We have analyzed deletion and substitution mutations within Gcn5 and Ada2, an interacting protein within SAGA, and have identified substrate recognition functions within the SANT domain of Ada2 and regions of the histone acetyltransferase domain of Gcn5 that are distinct from catalytic function itself. These results suggest that histone and nucleosomal substrate recognition by SAGA involves multiple conserved domains and proteins, beyond those that have been previously identified.	Wistar Inst, Philadelphia, PA 19104 USA	The Wistar Institute	Berger, SL (corresponding author), Wistar Inst, 3601 Spruce St, Philadelphia, PA 19104 USA.			Berger, Shelley/0000-0001-5398-4400	NIGMS NIH HHS [GM19211-02, R01 GM55360-02] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Belotserkovskaya R, 2000, MOL CELL BIOL, V20, P634, DOI 10.1128/MCB.20.2.634-647.2000; Berger SL, 2001, SCIENCE, V292, P64; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Candau R, 1996, J BIOL CHEM, V271, P5237; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Gregory PD, 1998, MOL CELL, V1, P495, DOI 10.1016/S1097-2765(00)80050-7; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Horiuchi J, 1997, MOL CELL BIOL, V17, P3220, DOI 10.1128/MCB.17.6.3220; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; Ikeda K, 1999, MOL CELL BIOL, V19, P855; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Manning ET, 2001, MOL CELL BIOL, V21, P3876, DOI 10.1128/MCB.21.12.3876-3887.2001; Marcus GA, 1996, MOL CELL BIOL, V16, P3197; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Marmorstein R, 2001, J MOL BIOL, V311, P433, DOI 10.1006/jmbi.2001.4859; Marmorstein R, 2001, GENE, V272, P1, DOI 10.1016/S0378-1119(01)00519-4; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P11, DOI 10.1016/0968-0004(96)80878-4; Roberts SM, 1996, MOL CELL BIOL, V16, P3206; Roberts SM, 1997, GENETICS, V147, P451; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Rose MD., 1990, METHODS YEAST GENETI; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; SIKORSKI RS, 1989, GENETICS, V122, P19; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Winston, 1992, TRANSCRIPTIONAL REGU, P1271; WOLFFE A, 1992, CHROMATIN STRUCTURE; Wong MW, 1998, MOL CELL BIOL, V18, P368, DOI 10.1128/MCB.18.1.368; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454	64	92	94	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8178	8186		10.1074/jbc.M108601200	http://dx.doi.org/10.1074/jbc.M108601200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11777910	hybrid			2022-12-27	WOS:000174268000071
J	Touz, MC; Nores, MJ; Slavin, I; Carmona, C; Conrad, JT; Mowatt, MR; Nash, TE; Coronel, CE; Lujan, HD				Touz, MC; Nores, MJ; Slavin, I; Carmona, C; Conrad, JT; Mowatt, MR; Nash, TE; Coronel, CE; Lujan, HD			The activity of a developmentally regulated cysteine proteinase is required for cyst wall formation in the primitive eukaryote Giardia lamblia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-C; BREFELDIN-A; EXPRESSION; DIFFERENTIATION; CARBOHYDRATE; EXCYSTATION; CELL; IDENTIFICATION; LOCALIZATION; PURIFICATION	Giardia is an intestinal parasite that belongs to the earliest diverging branch of the eukaryotic lineage of descent. Giardia undergoes adaptation for survival outside the host's intestine by differentiating into infective cysts. Encystation involves the synthesis and transport of cyst wall constituents to the plasma membrane for release and extracellular organization. Nevertheless, little is known about the molecular events related to cyst wall biogenesis in Giardia. Among the components of the cyst wall there are two proteins that we have previously identified and characterized: CWP1 (26 kDa) and CWP2 (39 kDa). Expression of these proteins is coordinately induced, and both concentrated within encystation-specific secretory vesicles before their extracellular polymerization. Although highly similar to each other at the amino terminus, CWP2 includes a COOH-terminal 121-amino acid extension. Here, we show that this extension, rich in basic residues, is cleaved from CWP2 before cyst wall formation by an intracellular cysteine proteinase activity, which is induced during encystation like CWPs. Specific inhibitors prevent release of cyst wall materials, abolishing cyst wall formation. We also report the purification, cloning, and characterization of the encystation-specific cysteine proteinase responsible for the proteolytic processing of CWP2, which is homologue to lysosomal cathepsin C. Encystation-specific cysteine proteinase ESCP possesses unique characteristics compared with cathepsins from higher eukaryotes, such as a transmembrane domain and a short cytoplasmic tail. These features make this enzyme the most divergent cathepsin C identified to date and provide new insights regarding cyst wall formation in Giardia.	Univ Nacl Cordoba, Fac Ciencias Med, Catedra Bioquim & Biol Mol, RA-5000 Cordoba, Argentina; Fac Ciencias, Unidad BIol Parasitaria, Montevideo 11600, Uruguay; NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA	National University of Cordoba; Universidad de la Republica, Uruguay; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lujan, HD (corresponding author), Univ Nacl Cordoba, Fac Ciencias Med, Catedra Bioquim & Biol Mol, Pabellon Argentina 2de Piso,Ciudad Univ, RA-5000 Cordoba, Argentina.	hlujan@biomed.uncor.edu		TOUZ, MARIA/0000-0002-6769-6896	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000161, Z01AI000161] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adam RD, 2000, INT J PARASITOL, V30, P475, DOI 10.1016/S0020-7519(99)00191-5; ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOUCHER SEM, 1990, INFECT IMMUN, V58, P3516, DOI 10.1128/IAI.58.11.3516-3522.1990; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; CHAR S, 1992, J PROTOZOOL, V39, P642, DOI 10.1111/j.1550-7408.1992.tb04865.x; DIAMOND LS, 1978, T R SOC TROP MED HYG, V27, P487; DUKSIN D, 1982, J BIOL CHEM, V257, P3105; Elmendorf HG, 2001, MOL BIOCHEM PARASIT, V113, P157, DOI 10.1016/S0166-6851(01)00211-0; Erlandsen SL, 1996, J EUKARYOT MICROBIOL, V43, P416, DOI 10.1111/j.1550-7408.1996.tb05053.x; FAUBERT G, 1991, EXP PARASITOL, V72, P345, DOI 10.1016/0014-4894(91)90080-G; FEELY DE, 1991, J PARASITOL, V77, P441, DOI 10.2307/3283133; FRIEND DS, 1966, J CELL BIOL, V29, P317, DOI 10.1083/jcb.29.2.317; GILLIN FD, 1987, SCIENCE, V235, P1040, DOI 10.1126/science.3547646; Gillin FD, 1996, ANNU REV MICROBIOL, V50, P679, DOI 10.1146/annurev.micro.50.1.679; HARE D, 1995, EXP PARASITOL, V68, P168; HELD AB, 2000, MOL BIOL CELL, V11, P1789; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Huete-Perez JA, 1999, J BIOL CHEM, V274, P16249, DOI 10.1074/jbc.274.23.16249; JAMSA E, 1994, YEAST, V10, P355, DOI 10.1002/yea.320100308; JARROLL EL, 1989, MOL BIOCHEM PARASIT, V32, P121, DOI 10.1016/0166-6851(89)90063-7; Jarroll EL, 2001, J EUKARYOT MICROBIOL, V48, P22, DOI 10.1111/j.1550-7408.2001.tb00412.x; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Knodler LA, 1999, J BIOL CHEM, V274, P29805, DOI 10.1074/jbc.274.42.29805; KURIBAYASHI M, 1993, J BIOCHEM-TOKYO, V113, P441, DOI 10.1093/oxfordjournals.jbchem.a124064; LABRIOLA C, 1995, FEMS MICROBIOL LETT, V129, P143, DOI 10.1016/0378-1097(95)00148-X; Lanfredi-Rangel A, 1998, J STRUCT BIOL, V123, P225, DOI 10.1006/jsbi.1998.4035; LEE JC, 1980, BIOCHEMISTRY-US, V19, P6209, DOI 10.1021/bi00567a041; LINDMARK DG, 1988, EXP PARASITOL, V65, P141, DOI 10.1016/0014-4894(88)90116-6; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; Lujan HD, 1996, P NATL ACAD SCI USA, V93, P7628, DOI 10.1073/pnas.93.15.7628; LUJAN HD, 1995, J BIOL CHEM, V270, P4612, DOI 10.1074/jbc.270.9.4612; Lujan HD, 1997, MICROBIOL MOL BIOL R, V61, P294; Lujan HD, 1998, PARASITOL TODAY, V14, P446, DOI 10.1016/S0169-4758(98)01333-7; MACECHKO PT, 1992, MOL BIOCHEM PARASIT, V56, P301, DOI 10.1016/0166-6851(92)90179-N; MANNING P, 1992, J PROTOZOOL, V39, P290, DOI 10.1111/j.1550-7408.1992.tb01317.x; MASON RW, 1993, ADV CELL MOL BIOL M, V1, P81; McArthur AG, 2000, FEMS MICROBIOL LETT, V189, P271, DOI 10.1111/j.1574-6968.2000.tb09242.x; MCCAFFERY JM, 1994, EXP PARASITOL, V79, P220, DOI 10.1006/expr.1994.1086; MCCAFFERY JM, 1990, EXP PARSITOL, V79, P220; McKerrow JH, 1999, INT J PARASITOL, V29, P833, DOI 10.1016/S0020-7519(99)00044-2; MCKERROW JH, 1993, ANNU REV MICROBIOL, V47, P821, DOI 10.1146/annurev.mi.47.100193.004133; Mottram JC, 1998, CURR OPIN MICROBIOL, V1, P455, DOI 10.1016/S1369-5274(98)80065-9; MOWATT MR, 1995, MOL MICROBIOL, V15, P955, DOI 10.1111/j.1365-2958.1995.tb02364.x; MOWATT MR, 1991, MOL BIOCHEM PARASIT, V49, P215, DOI 10.1016/0166-6851(91)90065-E; MUNO D, 1993, ARCH BIOCHEM BIOPHYS, V306, P103, DOI 10.1006/abbi.1993.1486; Muren E, 2001, YEAST, V18, P163, DOI 10.1002/1097-0061(20010130)18:2<163::AID-YEA659>3.0.CO;2-#; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PALMER EG, 1989, MOL BIOCHEM PARASIT, V33, P27; PARENTI DM, 1989, J INFECT DIS, V160, P1076, DOI 10.1093/infdis/160.6.1076; REINER DS, 1990, EUR J CELL BIOL, V53, P142; SAMBROOK J, 1989, MOL CLONING LAB MANU, P298; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Shitara Y, 1998, J CONTROL RELEASE, V55, P35, DOI 10.1016/S0168-3659(98)00025-X; Singer SM, 1998, MOL BIOCHEM PARASIT, V92, P59, DOI 10.1016/S0166-6851(97)00225-9; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; STEINER DF, 1992, J BIOL CHEM, V267, P23435; Svard SG, 1999, MOL BIOCHEM PARASIT, V98, P253, DOI 10.1016/S0166-6851(98)00174-1; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; THOMPSON RCA, 1993, ADV PARASIT, V32, P71, DOI 10.1016/S0065-308X(08)60207-9; Turk B, 1997, BIOL CHEM, V378, P141; UMEZAWA H, 1976, J ANTIBIOT, V29, P97, DOI 10.7164/antibiotics.29.97; Ward W, 1997, CELL, V89, P437, DOI 10.1016/S0092-8674(00)80224-X; WERRIES E, 1991, J PROTOZOOL, V38, P378, DOI 10.1111/j.1550-7408.1991.tb01374.x; WILLIAMS AG, 1995, INT J PARASITOL, V25, P771, DOI 10.1016/0020-7519(94)00201-X; Wolters PJ, 1998, J BIOL CHEM, V273, P15514, DOI 10.1074/jbc.273.25.15514; Wolters PJ, 2000, AM J RESP CELL MOL, V22, P183, DOI 10.1165/ajrcmb.22.2.3767; YEE J, 1995, P NATL ACAD SCI USA, V92, P5615, DOI 10.1073/pnas.92.12.5615; Yu DC, 1998, MOL BIOCHEM PARASIT, V96, P151, DOI 10.1016/S0166-6851(98)00126-1	72	89	90	1	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8474	8481		10.1074/jbc.M110250200	http://dx.doi.org/10.1074/jbc.M110250200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11773053	Green Published, hybrid			2022-12-27	WOS:000174268000108
J	Horvath, A; Nebohacova, M; Lukes, J; Maslov, DA				Horvath, A; Nebohacova, M; Lukes, J; Maslov, DA			Unusual polypeptide synthesis in the kinetoplast-mitochondria from Leishmania tarentolae - Identification of individual de novo translation products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; TRYPANOSOMATID PHYTOMONAS SERPENS; PROTEIN-SYNTHESIS; CRITHIDIA-FASCICULATA; SECONDARY STRUCTURE; RIBOSOMAL-RNAS; MESSENGER-RNA; BRUCEI; DNA; COMPLEXES	The de novo synthesis of cytochrome c oxidase subunits 1, 11 (COI and COII), and apocytochrome b (Cyb) was investigated in kinetoplast-mitochondria of Leishmania. The organelles were isolated after breaking whole cells with nitrogen cavitation. Individual COI, COII, and Cyb polypeptides were identified by fractionation of the kinetoplast membranes, labeled with [S-35]methionine and cysteine, using two-dimensional (9 versus 14% and 20 versus 11%) denaturing gel electrophoresis. The reaction did not require exogenous energy sources or amino acids. On the contrary, the presence of amino acids other than methionine somewhat inhibited the labeling reaction probably by competing with the uptake of labeled amino acids. The synthesis reaction was insensitive to 100 mug/ml chloramphenicol, gentamycin, paromomycin, lincomycin, hygromycin, and tetracycline, as well as cycloheximide. The process showed a linear increase in the amount of synthesized polypeptides during the first 2 h of incubation, followed by a slower accumulation of products for up to 4 It. The de novo synthesized polypeptides were stable for several additional hours. Their assembly into respiratory complexes, investigated using two-dimensional Blue Native/N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine- SDS gels, began early during the incubation and continued throughout the course of the synthesis. This work represents the first unequivocal identification of the polypeptide synthesis in kinetoplasts.	Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside	Maslov, DA (corresponding author), Univ Calif Riverside, Dept Biol, 3401 Watkins Dr, Riverside, CA 92521 USA.		Lukes, Julius/H-6760-2012; Horvath, Anton/V-1097-2018; Nebohacova, Martina/I-3937-2014; Horvath, Anton/I-3626-2014	Lukes, Julius/0000-0002-0578-6618; Horvath, Anton/0000-0003-0785-4204; 	NIAID NIH HHS [AI 40634] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040634] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allemann N, 2000, MOL BIOCHEM PARASIT, V111, P87, DOI 10.1016/S0166-6851(00)00303-0; Aphasizhev R, 2001, J BIOL CHEM, V276, P21280, DOI 10.1074/jbc.M100297200; Beattie D S, 1979, Methods Enzymol, V56, P17; BEATTIE DS, 1987, MITOCHONDRIA PRACTIC, P283; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; Breek CKD, 1997, BIOL CHEM, V378, P837, DOI 10.1515/bchm.1997.378.8.837; Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8; DELACRUZ VF, 1985, NUCLEIC ACIDS RES, V13, P2337, DOI 10.1093/nar/13.7.2337; DELACRUZ VF, 1985, P NATL ACAD SCI USA, V82, P1401, DOI 10.1073/pnas.82.5.1401; DIXON H, 1974, J PROTOZOOL, V21, P450; EPERON IC, 1983, NUCLEIC ACIDS RES, V11, P105, DOI 10.1093/nar/11.1.105; Estevez AM, 1999, GENE, V240, P247, DOI 10.1016/S0378-1119(99)00437-0; Hauser R, 1996, J CELL SCI, V109, P517; HILL RC, 1975, ARCH BIOCHEM BIOPHYS, V170, P392, DOI 10.1016/0003-9861(75)90134-4; Horvath A, 2000, J BIOL CHEM, V275, P17160, DOI 10.1074/jbc.M907246199; Horvath A, 2000, SCIENCE, V287, P1639, DOI 10.1126/science.287.5458.1639; Horvath A, 2000, EXP PARASITOL, V96, P160, DOI 10.1006/expr.2000.4564; KLEISEN CM, 1975, BIOCHIM BIOPHYS ACTA, V390, P78, DOI 10.1016/0005-2787(75)90010-6; Kroon A M, 1979, Methods Enzymol, V56, P29; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUBKUPERSZTEJN R, 1974, BIOCHIM BIOPHYS ACTA, V340, P314, DOI 10.1016/0005-2787(74)90276-7; LEAVER CJ, 1983, METHOD ENZYMOL, V97, P476; MARRES CAM, 1977, BIOCHIM BIOPHYS ACTA, V462, P531, DOI 10.1016/0005-2728(77)90099-8; Maslov DA, 1999, MOL BIOCHEM PARASIT, V99, P207, DOI 10.1016/S0166-6851(99)00028-6; MCLEAN JR, 1958, J BIOL CHEM, V233, P657; McManus MT, 2001, RNA, V7, P167, DOI 10.1017/S1355838201002072; Muller UF, 2001, EMBO J, V20, P1394, DOI 10.1093/emboj/20.6.1394; Nabholz CE, 1999, PARASITOL RES, V85, P779, DOI 10.1007/s004360050631; Nawathean P, 2000, CURR GENET, V38, P95, DOI 10.1007/s002940000135; Poyton R O, 1996, Methods Enzymol, V264, P36, DOI 10.1016/S0076-6879(96)64006-3; PRIEST JW, 1994, J BIOENERG BIOMEMBR, V26, P179, DOI 10.1007/BF00763067; Rusche LN, 2001, MOL CELL BIOL, V21, P979, DOI 10.1128/MCB.21.4.979-989.2001; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHATZ G, 1974, ANNU REV BIOCHEM, V43, P51, DOI 10.1146/annurev.bi.43.070174.000411; Schnaufer A, 2001, SCIENCE, V291, P2159, DOI 10.1126/science.1058655; Shu HH, 1998, PARASITOLOGY, V116, P157, DOI 10.1017/S0031182097002023; Simpson L, 1998, NUCLEIC ACIDS RES, V26, P170, DOI 10.1093/nar/26.1.170; SPITHILL TW, 1981, MOL BIOCHEM PARASIT, V2, P235, DOI 10.1016/0166-6851(81)90103-1; STUART K, 2000, RNA EDITING FRONTIER, P1; Tittawella I, 1998, FEBS LETT, V423, P351, DOI 10.1016/S0014-5793(98)00132-X; ZAITSEVA GN, 1977, MOL CELL BIOCHEM, V14, P47, DOI 10.1007/BF01734164	44	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					7222	7230		10.1074/jbc.M109715200	http://dx.doi.org/10.1074/jbc.M109715200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11773050	hybrid			2022-12-27	WOS:000174104300062
J	Barr, RK; Kendrick, TS; Bogoyevitch, MA				Barr, RK; Kendrick, TS; Bogoyevitch, MA			Identification of the critical features of a small peptide inhibitor of JNK activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE CASCADES; SIGNAL-TRANSDUCTION; ACTIVATION DOMAIN; SCAFFOLD PROTEINS; INDUCED APOPTOSIS; IN-VITRO; BINDING; PATHWAY; CELLS; PHOSPHORYLATION	The c-Jun N-terminal kinases (JNKs) are a subfamily of the mitogen-activated protein kinases (NLAPKs). Although progress in evaluating the functions of other MAPKs has been facilitated by the characterization of specific inhibitors, no JNK-directed inhibitor is commercially available. We have identified a 21-amino acid peptide inhibitor of activated JNKs, based on amino acids 143-163 of the JNK-binding domain (JBD) of the JNK scaffolding protein, JNK-interacting protein-1 (JIP-1). This peptide, I-JIP (Inhibitor of JNK-based on JIP-1), inhibited JNK activity in vitro toward recombinant c-Jun, Elk, and ATF2 up to 90%. A truncated I-JIP (TI-JIP), the C-terminal 11 amino acids of I-JIP, directly interacted with recombinant JNKs but not its substrates as shown by surface plasmon resonance analysis. Scanning alanine replacement within truncated I-JIP identified 4 residues (Arg-156, Pro-157, Leu-160, or Leu-162) as independently critical for inhibition. JBD peptide sequences from JIP-2 and JIP-3 shared these critical residues and accordingly were effective JNK inhibitors. In contrast, peptides based on the JBDs of ATF2 and c-Jun inhibited JNK activity by <40%, which agreed with their lack of homology to the critical Arg-156 and Pro-157. These studies thus define a small peptide inhibitor sequence of JNKs based on the JIP proteins.	Univ Western Australia, Cell Signaling Lab, Dept Biochem, Crawley, WA 6009, Australia; Western Australian Inst Med Res, Perth, WA 6000, Australia	University of Western Australia; University of Western Australia	Bogoyevitch, MA (corresponding author), Univ Western Australia, Cell Signaling Lab, Dept Biochem, 35 Stirling Hwy, Crawley, WA 6009, Australia.			Bogoyevitch, Marie/0000-0001-9745-3716; Barr, Renae/0000-0003-1601-7299				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Borasio GD, 1998, NEUROREPORT, V9, P1435, DOI 10.1097/00001756-199805110-00034; Chen PF, 2000, J BIOL CHEM, V275, P20382, DOI 10.1074/jbc.M001149200; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Eilers A, 2001, J NEUROCHEM, V76, P1439, DOI 10.1046/j.1471-4159.2001.00150.x; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Harding TC, 2001, J BIOL CHEM, V276, P4531, DOI 10.1074/jbc.C000815200; He HP, 1999, CELL DEATH DIFFER, V6, P987, DOI 10.1038/sj.cdd.4400572; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kumagae Y, 1999, MOL BRAIN RES, V67, P10, DOI 10.1016/S0169-328X(99)00013-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Ligterink W, 2000, RES PRO CEL, V27, P11; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Maroney AC, 1999, J NEUROCHEM, V73, P1901; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; Monaco R, 1999, J PROTEIN CHEM, V18, P859, DOI 10.1023/A:1020679229110; Ng DCH, 2001, J BIOL CHEM, V276, P29490, DOI 10.1074/jbc.M100699200; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Quinn JG, 2001, ANAL BIOCHEM, V290, P36, DOI 10.1006/abio.2000.4919; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; TANG SH, 1998, EMBO J, V17, P1740; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Vincenti MP, 2001, J CLIN INVEST, V108, P181; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zhou MM, 1995, J BIOL CHEM, V270, P31119, DOI 10.1074/jbc.270.52.31119	45	193	213	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10987	10997		10.1074/jbc.M107565200	http://dx.doi.org/10.1074/jbc.M107565200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11790767	hybrid			2022-12-27	WOS:000174613100031
J	Dennissen, MABA; Jenniskens, GJ; Pieffers, M; Versteeg, EMM; Petitou, M; Veerkamp, JH; van Kuppevelt, TH				Dennissen, MABA; Jenniskens, GJ; Pieffers, M; Versteeg, EMM; Petitou, M; Veerkamp, JH; van Kuppevelt, TH			Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; MOLECULAR DESIGN; PROTEOGLYCANS; BINDING; HETEROGENEITY; ANTITHROMBIN; EXPRESSION; RECEPTORS; MEMBRANE; VIRUS	Heparan sulfates (HS) are long, linear polysaccharides with a high degree of variability. They bind to a vast number of proteins such as growth factors and cytokines, and these interactions are likely to be mediated by specific HS domains. To investigate the structural diversity and topological distribution of HS domains in tissues, we selected a panel of 10 unique anti-HS antibodies using phage display technology. All 10 antibodies recognize a specific HS epitope as demonstrated by enzyme-linked immunosorbent assay using defined synthetic HS oligosaccharides, modified HS/ heparin molecules, and HS isolated from a variety of organs. The chemical groups involved in the epitopes could be indicated and the position of sulfate groups is of major importance. All HS epitopes have a defined tissue distribution as shown by immunohistochemistry using rat organs. Taken together, the data show that in vivo, a large number of defined HS epitopes exist that do not occur randomly but are tightly, topologically regulated.	Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Med Ctr, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Sanofi Rech, Cardiovasc Thrombosis Dept, F-31036 Toulouse, France	Radboud University Nijmegen; Sanofi-Aventis; Sanofi France	van Kuppevelt, TH (corresponding author), Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Med Ctr, Dept Biochem, POB 9101,194, NL-6500 HB Nijmegen, Netherlands.		van Kuppevelt, A.H.M.S.M./L-4463-2015	Versteeg, Elly/0000-0001-7047-5173				ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866; Conrad H. E., 1998, HEPARIN BINDING PROT; COUCHMAN JR, 1984, NATURE, V307, P650, DOI 10.1038/307650a0; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P4494, DOI 10.1073/pnas.77.8.4494; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jenniskens GJ, 2000, J NEUROSCI, V20, P4099; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Leteux C, 2001, J BIOL CHEM, V276, P12539, DOI 10.1074/jbc.M010291200; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LYON M, 1994, J BIOL CHEM, V269, P11208; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Petitou M, 1999, NATURE, V398, P417, DOI 10.1038/18877; Raats CJI, 2000, KIDNEY INT, V57, P385, DOI 10.1046/j.1523-1755.2000.00858.x; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Safaiyan F, 2000, BIOCHEMISTRY-US, V39, P10823, DOI 10.1021/bi000411s; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; SORRELL JM, 1990, J HISTOCHEM CYTOCHEM, V38, P393, DOI 10.1177/38.3.1689338; TOMLINSON IM, 1992, J MOL BIOL, V227, P776, DOI 10.1016/0022-2836(92)90223-7; Turnbull JE, 1999, P NATL ACAD SCI USA, V96, P2698, DOI 10.1073/pnas.96.6.2698; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; VANPUTTEN JPM, 1995, EMBO J, V14, P2144, DOI 10.1002/j.1460-2075.1995.tb07208.x; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537	34	143	146	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10982	10986		10.1074/jbc.M104852200	http://dx.doi.org/10.1074/jbc.M104852200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11790764	Green Published, hybrid			2022-12-27	WOS:000174613100030
J	Haigis, MC; Kurten, EL; Abel, RL; Raines, RT				Haigis, MC; Kurten, EL; Abel, RL; Raines, RT			KFERQ sequence in ribonuclease A-mediated cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC ACTIVITY; P-30 PROTEIN; CONFORMATIONAL STABILITY; MOLECULAR DETERMINANTS; AMPHIBIAN RIBONUCLEASE; WILD-TYPE; INHIBITOR; BINDING; ANGIOGENIN; ENZYME	Onconase(R) (ONC) is an amphibian ribonuelease that is in clinical trials as a cancer chemotherapeutic agent. ONC is a homolog of ribonuclease A (RNase A). RNase A can be made toxic to cancer cells by replacing Gly(88) with an arginine residue, thereby enabling the enzyme to evade the endogenous cytosolic ribonuclease inhibitor protein (RI). Unlike ONC, RNase A contains a KFERQ sequence (residues 7-11), which signals for lysosomal degradation. Here, substitution of Arg(10) of the KFERQ sequence has no effect on either the cytotoxicity of G88R RNase A or its affinity for RI In contrast, K7A/G88R RNase A is nearly 10-fold more cytotoxic than G88R RNase A and has more than 10-fold less affinity for RI. Up-regulation of the KFERQ-mediated lysosomal degradation pathway has no effect on the cytotoxicity of these ribonucleases. Thus, KFERQ-mediated degradation does not limit the cytotoxicity of RNase A variants. Moreover, only two amino acid substitutions (K7A and G88R) are shown to endow RNase A with cytotoxic activity that is nearly equal to that of ONC.	Univ Wisconsin, Dept Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Raines, RT (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53705 USA.		Raines, Ronald T./A-5009-2013	Raines, Ronald T./0000-0001-7164-1719	NATIONAL CANCER INSTITUTE [R01CA073808] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008293] Funding Source: NIH RePORTER; NCI NIH HHS [CA73808] Funding Source: Medline; NIGMS NIH HHS [T32 GM08293] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarraberes FA, 1997, J CELL BIOL, V137, P825, DOI 10.1083/jcb.137.4.825; ARDELT W, 1991, J BIOL CHEM, V266, P245; BLACKBURN P, 1977, J BIOL CHEM, V252, P5904; BOIX E, 1994, J BIOL CHEM, V269, P2529; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; Bretscher LE, 2000, J BIOL CHEM, V275, P9893, DOI 10.1074/jbc.275.14.9893; Cuervo AM, 1998, J MOL MED-JMM, V76, P6, DOI 10.1007/s109-1998-8099-y; DARZYNKIEWICZ Z, 1988, CELL TISSUE KINET, V21, P169, DOI 10.1111/j.1365-2184.1988.tb00855.x; DELCARDAYRE SB, 1995, ANAL BIOCHEM, V225, P176, DOI 10.1006/abio.1995.1132; DELCARDAYRE SB, 1995, PROTEIN ENG, V8, P261, DOI 10.1093/protein/8.3.261; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DICE JF, 1988, J PROTEIN CHEM, V7, P115, DOI 10.1007/BF01025241; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; DICE JF, 1986, J BIOL CHEM, V261, P6853; DUNN BM, 1975, J MOL BIOL, V95, P497, DOI 10.1016/0022-2836(75)90313-7; Eberhardt ES, 1996, PROTEIN SCI, V5, P1697, DOI 10.1002/pro.5560050823; Fisher BM, 1998, BIOCHEMISTRY-US, V37, P12121, DOI 10.1021/bi980743l; Irie M, 1998, CELL MOL LIFE SCI, V54, P775, DOI 10.1007/s000180050206; Kelemen BR, 1999, NUCLEIC ACIDS RES, V27, P3696, DOI 10.1093/nar/27.18.3696; KIM JS, 1995, BIOCHEM J, V308, P547, DOI 10.1042/bj3080547; Klink TA, 2001, PROTEIN EXPRES PURIF, V22, P174, DOI 10.1006/prep.2001.1422; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Kothandaraman S, 1998, VIROLOGY, V251, P264, DOI 10.1006/viro.1998.9434; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; LEE FS, 1989, BIOCHEMISTRY-US, V28, P3556, DOI 10.1021/bi00434a061; Leland PA, 1998, P NATL ACAD SCI USA, V95, P10407, DOI 10.1073/pnas.95.18.10407; Leland PA, 2001, CHEM BIOL, V8, P405, DOI 10.1016/S1074-5521(01)00030-8; Leland PA, 2000, FEBS LETT, V477, P203, DOI 10.1016/S0014-5793(00)01804-4; Matousek J, 2001, COMP BIOCHEM PHYS C, V129, P175, DOI 10.1016/S1532-0456(01)90202-9; MCELLIGOTT MA, 1985, J BIOL CHEM, V260, P1986; MESSMORE JM, 1995, J AM CHEM SOC, V117, P8057, DOI 10.1021/ja00136a001; MIKULSKI SM, 1995, INT J ONCOL, V6, P889; MIKULSKI SM, 1993, INT J ONCOL, V3, P57; Mikulski SM, 1998, INT J ONCOL, V13, P633; MOSIMANN SC, 1994, J MOL BIOL, V236, P1141, DOI 10.1016/0022-2836(94)90017-5; NEUMANN U, 1994, PROTEIN SCI, V3, P248; NOGUES MV, 1995, BBA-PROTEIN STRUCT M, V1253, P16, DOI 10.1016/0167-4838(95)00138-K; Quirk DJ, 1998, BIOCHEMISTRY-US, V37, P17958, DOI 10.1021/bi981688j; Rybak SM, 1999, EXP CELL RES, V253, P325, DOI 10.1006/excr.1999.4718; SAXENA SK, 1991, J BIOL CHEM, V266, P21208; Schein CH, 1997, NAT BIOTECHNOL, V15, P529, DOI 10.1038/nbt0697-529; SCOFFONE E, 1967, J AM CHEM SOC, V89, P5450, DOI 10.1021/ja00997a028; SELA M, 1957, BIOCHIM BIOPHYS ACTA, V26, P502, DOI 10.1016/0006-3002(57)90096-3; Shapiro R, 2000, J MOL BIOL, V302, P497, DOI 10.1006/jmbi.2000.4075; Vasandani VM, 1996, CANCER RES, V56, P4180; VICENTINI AM, 1990, BIOCHEMISTRY-US, V29, P8827, DOI 10.1021/bi00489a046; WU YN, 1995, J BIOL CHEM, V270, P17476, DOI 10.1074/jbc.270.29.17476; WU YN, 1993, J BIOL CHEM, V268, P10686; Youle R. J., 1997, RIBONUCLEASES STRUCT, P491	51	34	39	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11576	11581		10.1074/jbc.M112227200	http://dx.doi.org/10.1074/jbc.M112227200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801605	hybrid			2022-12-27	WOS:000174613100105
J	Missirlis, F; Ulschmid, JK; Hirosawa-Takamori, M; Gronke, S; Schafer, U; Becker, K; Phillips, JP; Jackle, H				Missirlis, F; Ulschmid, JK; Hirosawa-Takamori, M; Gronke, S; Schafer, U; Becker, K; Phillips, JP; Jackle, H			Mitochondrial and cytoplasmic thioredoxin reductase variants encoded by a single Drosophila gene are both essential for viability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; MELANOGASTER; SELENOCYSTEINE; EXPRESSION; TRANSFORMATION; ORGANIZATION; SELENOENZYME; PURIFICATION; DISRUPTION; SEQUENCE	Defense against oxidative stress in mammals includes the regeneration of the major thiol reductants glutathione and thioredoxin by glutathione reductase and thioredoxin reductase (TrxR), respectively. In contrast, Drosophila, and possibly insects in general, lacks glutathione reductase and must rely solely on the TrxR system. The mammalian TrxRs described so far are selenoproteins that utilize NADPH to reduce protein as well as nonprotein substrates in mitochondria and cytoplasm of cells. We show that a single Drosophila gene, Trxr-1, encodes non-selenocysteine-containing cytoplasmic and mitochondrial TrxR isoforms that differ with respect to their N termini. We generated transcript-specific mutants and used in vivo approaches to explore the biological functions of the two enzyme variants by introducing the corresponding transgenes into different Trxr-1 mutants. The results show that, although the two TrxR isoforms have similar biochemical properties, their biological functions are not interchangeable.	Max Planck Inst Biophys Chem, Abt Mol Entwicklungsbiol, D-37077 Gottingen, Germany; Univ Giessen, Interdisziplinaires Forschungszentrum, D-35392 Giessen, Germany; Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada	Max Planck Society; Justus Liebig University Giessen; University of Guelph	Jackle, H (corresponding author), Max Planck Inst Biophys Chem, Abt Mol Entwicklungsbiol, Fassberg, D-37077 Gottingen, Germany.		Missirlis, Fanis/C-1137-2011	Missirlis, Fanis/0000-0003-0467-8444; Gronke, Sebastian/0000-0002-1539-5346				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; Candas M, 1997, ARCH BIOCHEM BIOPHYS, V339, P323, DOI 10.1006/abbi.1996.9872; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Forjanic JP, 1997, DEV BIOL, V186, P139, DOI 10.1006/dbio.1997.8590; Gasdaska JR, 1999, J BIOL CHEM, V274, P25379, DOI 10.1074/jbc.274.36.25379; Gonzalez-Gaitan M, 2000, EMBO REP, V1, P366, DOI 10.1093/embo-reports/kvd064; GRISWOLD CM, 1993, GENETICS, V134, P781; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Gromer S, 1998, BIOCHEM J, V332, P591, DOI 10.1042/bj3320591; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Kanzok SM, 2000, J BIOL CHEM, V275, P40180, DOI 10.1074/jbc.M007633200; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Missirlis F, 2001, CURR BIOL, V11, P1272, DOI 10.1016/S0960-9822(01)00393-1; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Peter A, 2002, EMBO REP, V3, P34, DOI 10.1093/embo-reports/kvf012; PHILLIPS JP, 1989, P NATL ACAD SCI USA, V86, P2761, DOI 10.1073/pnas.86.8.2761; REICHHART JM, 1998, DROS INFO SERV, V81, P201; RIVERAPOMAR R, 1995, NATURE, V376, P253, DOI 10.1038/376253a0; ROBERTSON HM, 1988, GENETICS, V118, P461; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; SALZ HK, 1994, GENETICS, V136, P1075; Sambrook J., 2002, MOL CLONING LAB MANU; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Sun QA, 2001, J BIOL CHEM, V276, P3106, DOI 10.1074/jbc.M004750200; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Toba G, 2000, GENE, V253, P179, DOI 10.1016/S0378-1119(00)00246-8; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200; [No title captured]	38	62	65	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11521	11526		10.1074/jbc.M111692200	http://dx.doi.org/10.1074/jbc.M111692200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11796729	hybrid, Green Published			2022-12-27	WOS:000174613100098
J	Mitsuda, T; Furukawa, K; Fukumoto, S; Miyazaki, H; Urano, T; Furukawa, K				Mitsuda, T; Furukawa, K; Fukumoto, S; Miyazaki, H; Urano, T; Furukawa, K			Overexpression of ganglioside GM1 results in the dispersion of platelet-derived growth factor receptor from glycolipid-enriched microdomains and in the suppression of cell growth signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOMA B16 CELLS; SWISS 3T3 CELLS; TYROSINE PHOSPHORYLATION; PDGF RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; MEDIATED MODULATION; EXPRESSION CLONING; HUMAN-FIBROBLASTS; PROTEIN-KINASE; LIPID RAFTS	To investigate the molecular mechanisms of gangliosides for the regulation of cell proliferation, Swiss 3T3 cells were transfected with GM2/GD2 synthase and GM1 synthase cDNAs, resulting in the establishment of GM1-expressing (GM1(+)) lines. Compared with the vector control (GM1(-)) cell lines, GM1(+) cells exhibited reduced cell proliferation by stimulation with platelet-derived growth factor (PDGF). In accordance with the reduced cell growth, GM1(+) cells showed earlier decreases in the phosphorylation levels of PDGF receptor and less activation of MAP kinases than GM1(-) cells. To analyze the effects of GM1 expression on the PDGF/PDGF receptor (PDGFR) signals, the glycolipid-enriched microdomain (GEM) was isolated and the following results were obtained. (i) PDGFR predominantly distributed in the non-GEM fraction in GM1(+) cells, while it was present in both GEM and non-GEM fractions in GM1- cells. (ii) Activation of PDGFR as detected by anti-phosphotyrosine antibody occurred almost in parallel with existing amounts of PDGFR in each fraction. (iii) GM1 binds with PDGFR in GEM fractions. These findings suggested that GM1 regulates signals via PDGF/PDGFR by controlling the distribution of PDGFR in- and outside of GEM, and also interacting with PDGFR in the GEM fraction as a functional constituent of the microdomain.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan	Nagoya University	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp		Fukumoto, Satoshi/0000-0002-5046-6891; Urano, Takeshi/0000-0003-3383-3554				ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; BLACKBURN CC, 1986, J BIOL CHEM, V261, P2873; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; DeMali KA, 1997, J BIOL CHEM, V272, P9011; Farooqui T, 1999, ANTICANCER RES, V19, P5007; FRA AM, 1994, J BIOL CHEM, V269, P30745; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Hakomori SI, 1998, ANN NY ACAD SCI, V845, P1, DOI 10.1111/j.1749-6632.1998.tb09657.x; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HYNDS DL, 1995, J NEUROCHEM, V65, P2251; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; Katagiri YU, 1999, J BIOL CHEM, V274, P35278, DOI 10.1074/jbc.274.49.35278; KIM HRC, 1995, P NATL ACAD SCI USA, V92, P9500, DOI 10.1073/pnas.92.21.9500; KING CA, 1975, J INFECT DIS, V131, P643, DOI 10.1093/infdis/131.6.643; KLEINMAN HK, 1979, P NATL ACAD SCI USA, V76, P3367, DOI 10.1073/pnas.76.7.3367; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; MAHADEVAN D, 1995, J BIOL CHEM, V270, P27595, DOI 10.1074/jbc.270.46.27595; MARKWELL MAK, 1981, P NATL ACAD SCI-BIOL, V78, P5406, DOI 10.1073/pnas.78.9.5406; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; VANBROCKLYN J, 1993, J NEUROCHEM, V61, P371; VANIER MT, 1971, J NEUROCHEM, V18, P581, DOI 10.1111/j.1471-4159.1971.tb11988.x; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; WU GS, 1990, J NEUROCHEM, V55, P484, DOI 10.1111/j.1471-4159.1990.tb04161.x; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251; YATES AJ, 1993, EXP CELL RES, V204, P38, DOI 10.1006/excr.1993.1006; YATES AJ, 1995, J NEURO-ONCOL, V24, P65, DOI 10.1007/BF01052661; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	54	98	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11239	11246		10.1074/jbc.M107756200	http://dx.doi.org/10.1074/jbc.M107756200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11782461	hybrid			2022-12-27	WOS:000174613100063
J	Radtke, S; Hermanns, HM; Haan, C; Schmitz-Van de Leur, H; Gascan, H; Heinrich, PC; Behrmann, I				Radtke, S; Hermanns, HM; Haan, C; Schmitz-Van de Leur, H; Gascan, H; Heinrich, PC; Behrmann, I			Novel role of Janus kinase 1 in the regulation of oncostatin M receptor surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM RETENTION; LEUKEMIA INHIBITORY FACTOR; T-CELL RECEPTOR; SIGNAL-TRANSDUCTION PATHWAY; PRE-GOLGI DEGRADATION; DI-LEUCINE MOTIF; ERYTHROPOIETIN RECEPTOR; INTERFERON-ALPHA/BETA; SUBUNIT; CYTOKINE	The oncostatin M receptor (OSMR) is part of a heterodimeric receptor complex that mediates signal transduction of the pleiotropic cytokine OSM via a signaling pathway involving Janus kinases (Jaks) and transcription factors of the signal transducers and activators of transcription (STAT) family. Upon heterologous expression of the OSMR in several cell lines, we observed that its surface expression was significantly enhanced by coexpression of the Janus kinases Jak1, Jak2, and Tyk2 but not Jak3. Chimeric receptors consisting of the extracellular region of the interleukin-5 receptor beta chain and the transmembrane and intracellular part of the OSMR were similarly up-regulated on the plasma membrane when Jak1 was coexpressed. The overall expression level of these constructs did not change significantly, but Jak1 coexpression increased the amount of endoglycosidase H-resistant, fully processed OSMR chimeras. Using mutated receptor and Jak1 constructs, we were able to demonstrate that association of Jak1 with the membrane proximal region of the receptor, but not its kinase activity, is necessary for this effect. Moreover, deletion of the OSMR box1/2 region also resulted in an improved surface expression indicating that this region may contain a signal preventing efficient receptor surface expression in the absence of associated Jaks. Finally we demonstrate that in Jak1-deficient cells, the endogenous OSMR is significantly down-regulated, an effect that can be reversed by transient expression of Jak1 in these cells.	Univ Klinikum, Rhein Westfal TH Aachen, Inst Biochem, D-52074 Aachen, Germany; CHU Angers, INSERM E 9928, F-49033 Angers, France	RWTH Aachen University; RWTH Aachen University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers	Behrmann, I (corresponding author), Univ Klinikum, Rhein Westfal TH Aachen, Inst Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.			Behrmann, Iris/0000-0003-3688-3645				Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Bonifacino J S, 1988, Princess Takamatsu Symp, V19, P87; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; Cohen J, 1997, BIOCHEM J, V327, P391, DOI 10.1042/bj3270391; Dietrich J, 1998, J BIOL CHEM, V273, P26281, DOI 10.1074/jbc.273.41.26281; Dietrich J, 1999, EUR J IMMUNOL, V29, P1719, DOI 10.1002/(SICI)1521-4141(199905)29:05<1719::AID-IMMU1719>3.3.CO;2-D; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Dondi E, 2001, J BIOL CHEM, V276, P47004, DOI 10.1074/jbc.M104316200; Elson GCA, 2000, NAT NEUROSCI, V3, P867, DOI 10.1038/78765; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357-4310(99)01540-3; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Haan C, 2001, J BIOL CHEM, V276, P37451, DOI 10.1074/jbc.M106135200; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hermanns HM, 1999, J IMMUNOL, V163, P6651; Hermanns HM, 2000, J BIOL CHEM, V275, P40742, DOI 10.1074/jbc.M005408200; HILTON DJ, 1995, P NATL ACAD SCI USA, V92, P190, DOI 10.1073/pnas.92.1.190; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; Kuropatwinski KK, 1997, J BIOL CHEM, V272, P15135, DOI 10.1074/jbc.272.24.15135; Lee SJ, 1998, EXP MOL MED, V30, P159, DOI 10.1038/emm.1998.23; LETOURNEUR F, 1995, J CELL BIOL, V129, P971, DOI 10.1083/jcb.129.4.971; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Levin I, 1998, FEBS LETT, V427, P164, DOI 10.1016/S0014-5793(98)00414-1; Levy JB, 1996, ENDOCRINOLOGY, V137, P1159, DOI 10.1210/en.137.4.1159; MALLABIABARRENA A, 1995, EMBO J, V14, P2257, DOI 10.1002/j.1460-2075.1995.tb07220.x; MALLABIABARRENA A, 1992, NATURE, V357, P593, DOI 10.1038/357593a0; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; PAABO S, 1987, CELL, V50, P311, DOI 10.1016/0092-8674(87)90226-1; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; Senaldi G, 1999, P NATL ACAD SCI USA, V96, P11458, DOI 10.1073/pnas.96.20.11458; Shimoda K, 2000, IMMUNITY, V13, P561, DOI 10.1016/S1074-7613(00)00055-8; Supino-Rosin L, 1999, EUR J BIOCHEM, V263, P410, DOI 10.1046/j.1432-1327.1999.00516.x; Wang YP, 2000, J BIOL CHEM, V275, P25273, DOI 10.1074/jbc.M002296200; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973; WILEMAN T, 1993, J CELL BIOL, V122, P67, DOI 10.1083/jcb.122.1.67; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	50	64	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11297	11305		10.1074/jbc.M100822200	http://dx.doi.org/10.1074/jbc.M100822200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11786531	hybrid			2022-12-27	WOS:000174613100070
J	Raffai, RL; Weisgraber, KH				Raffai, RL; Weisgraber, KH			Hypomorphic apolipoprotein E mice - A new model of conditional gene repair to examine apolipoprotein E-mediated metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-DEFICIENT MICE; REMNANT LIPOPROTEIN METABOLISM; HEPARAN-SULFATE PROTEOGLYCANS; BONE-MARROW TRANSPLANTATION; CHYLOMICRON REMNANTS; SEVERE HYPERCHOLESTEROLEMIA; CHOLESTEROL TRANSPORT; SIGNAL-TRANSDUCTION; HEPATIC-UPTAKE; APOPROTEIN-E	In creating an allelic variant of mouse Apoe designed to resemble human apolipoprotein E4 (apoE4), we generated hypomorphic apoE (hypoE) mice that express only similar to5% of normal apoE mRNA levels in all tissues. Insertion of a neo cassette flanked by loxP sites in the third intron of Apoe reduced expression of the Arg-61 allelic variant in hypoE mice and resulted in plasma apoE levels that were similar to2-5% of normal. Unlike other mouse models with low levels of circulating apoE, hypoE mice had a nearly normal lipoprotein cholesterol profile when fed a chow diet. Further reduction of apoE expression in hypoE/Apoe(-/-) heterozygous mice led to an increase in remnant lipoprotein-associated cholesterol levels, demonstrating that hypoE mice express close to the threshold level of Arg-61 apoE required for a normal lipoprotein profile. Unlike wild type mice, hypoE mice were susceptible to diet-induced hypercholesterolemial which was fully reversed within 3 weeks after resumption of a chow diet. In Mx1-Cre transgenic hypoE mice, plasma apoE levels returned to normal within 10 days after gene repair and removal of the neo cassette following induction of Cre recombinase. HypoE mice provide the opportunity for conditional gene repair by crossing with inducible or lineage/cell type-specific Cre transgenic mice, generating new models to dissect the roles of apoE in atherosclerosis regression, immunoregulation, and neurodegeneration.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weisgraber, KH (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.				NHLBI NIH HHS [HL47660] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allan CM, 1997, J BIOL CHEM, V272, P29113, DOI 10.1074/jbc.272.46.29113; AVILA EM, 1982, J BIOL CHEM, V257, P5900; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BOISVERT WA, 1995, J CLIN INVEST, V96, P1118, DOI 10.1172/JCI118098; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Cooper AD, 1997, J LIPID RES, V38, P2173; Desurmont C, 2000, ARTERIOSCL THROM VAS, V20, P435, DOI 10.1161/01.ATV.20.2.435; Grehan S, 2001, J INVEST DERMATOL, V116, P77, DOI 10.1046/j.1523-1747.2001.00213.x; Grehan S, 2001, J NEUROSCI, V21, P812, DOI 10.1523/JNEUROSCI.21-03-00812.2001; Hasty AH, 1999, J LIPID RES, V40, P1529; Huang YD, 1999, ARTERIOSCL THROM VAS, V19, P2952, DOI 10.1161/01.ATV.19.12.2952; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; HUI DY, 1980, J BIOL CHEM, V255, P1775; Ishigami M, 1998, J BIOL CHEM, V273, P20156, DOI 10.1074/jbc.273.32.20156; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JI ZS, 1994, J BIOL CHEM, V269, P2764; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Kuipers F, 1997, J CLIN INVEST, V100, P2915, DOI 10.1172/JCI119841; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Maugeais C, 2000, J LIPID RES, V41, P1673; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Mohn AR, 1999, CELL, V98, P427, DOI 10.1016/S0092-8674(00)81972-8; Nagy A, 2000, GENESIS, V26, P99, DOI 10.1002/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.0.CO;2-B; Nagy A, 1998, CURR BIOL, V8, P661, DOI 10.1016/S0960-9822(98)70254-4; PEPE MG, 1986, J IMMUNOL, V136, P3716; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Raffai RL, 2001, P NATL ACAD SCI USA, V98, P11587, DOI 10.1073/pnas.201279298; REYLAND ME, 1991, J BIOL CHEM, V266, P21099; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Shih SJ, 2000, J BIOL CHEM, V275, P31567, DOI 10.1074/jbc.M005468200; SHIMANO H, 1994, J CLIN INVEST, V93, P2215, DOI 10.1172/JCI117218; Tangirala RK, 2001, J BIOL CHEM, V276, P261, DOI 10.1074/jbc.M003324200; Thorngate FE, 2000, ARTERIOSCL THROM VAS, V20, P1939, DOI 10.1161/01.ATV.20.8.1939; Tsukamoto K, 1999, ARTERIOSCL THROM VAS, V19, P2162, DOI 10.1161/01.ATV.19.9.2162; Veniant MM, 1998, J CLIN INVEST, V102, P1559, DOI 10.1172/JCI4164; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294	44	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11064	11068		10.1074/jbc.M111222200	http://dx.doi.org/10.1074/jbc.M111222200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11792702	hybrid			2022-12-27	WOS:000174613100041
J	Benaud, C; Oberst, M; Hobson, JP; Spiegel, S; Dickson, RB; Lin, CY				Benaud, C; Oberst, M; Hobson, JP; Spiegel, S; Dickson, RB; Lin, CY			Sphingosine 1-phosphate, present in serum-derived lipoproteins, activates matriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR EDG-1; MEMBRANE SERINE-PROTEASE; SIGNALING PATHWAYS; SPHINGOSINE-1-PHOSPHATE; CELLS; CANCER; KINASE; SPHINGOSYLPHOSPHORYLCHOLINE; IDENTIFICATION; LOCALIZATION	We describe here a novel biological function of sphingosine 1-phosphate (S1P): the activation of a serine protease, matriptase. Matriptase is a type II integral membrane serine protease, expressed on the surface of a variety of epithelial cells; it may play an important role in tissue remodeling. We have previously reported that the activation of matriptase is regulated by serum. We have now identified the bioactive component from serum. First, the activity was observed to co-purify with lipoproteins by conventional liquid chromatography and immunoaffinity chromatography. The ability of lipoproteins to induce the activation of matriptase was further confirmed with commercial preparations of low density lipoprotein (LDL) and very low density lipoprotein (VLDL). Next, we observed that the bioactive component of LDL is associated with the phospholipid components of LDL. Fractionation of lipid components of LDL by thin layer chromatography (TLC) revealed that the bioactive component of LDL comigrates with SIP. Nanomolar concentrations of commercially obtained SIP were then observed to induce the rapid activation of matriptase on the surfaces of nontransformed human mammary epithelial cells. Other structurally related sphingolipids, including dihydro-S1P, ceramide I-phosphates, and sphingosine phosphocholine as well as lysophosphatidic acid, can also induce the activation of matriptase, but at significantly higher concentrations than SIP. Furthermore, S1P-dependent matriptase activation is dependent on Ca2+ but not via G(i) protein-coupled receptors. Our results demonstrate that bioactive phospholipids can function as nonprotein activators of a cell surface protease, suggesting a possible mechanistic link between SIP and normal and possibly pathologic tissue remodeling.	Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Lin, CY (corresponding author), Georgetown Univ, Med Ctr, Lombardi Canc Ctr, 3970 Reservoir Rd NW, Washington, DC 20007 USA.		Benaud, Christelle/M-1178-2018		NATIONAL CANCER INSTITUTE [P30CA051008, R21CA080897, P50CA058185] Funding Source: NIH RePORTER; NCI NIH HHS [1P50CA58185, R21CA80897, 2P30-CA-51008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Benaud C, 1998, BREAST CANCER RES TR, V50, P97, DOI 10.1023/A:1006061115909; Benaud C, 2001, EUR J BIOCHEM, V268, P1439, DOI 10.1046/j.1432-1327.2001.02016.x; BORSOS T, 1981, MOL IMMUNOL, V18, P863, DOI 10.1016/0161-5890(81)90008-0; Edsall LC, 1999, ANAL BIOCHEM, V272, P80, DOI 10.1006/abio.1999.4157; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; HUANG RRC, 1990, MOL PHARMACOL, V37, P304; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Kim MG, 1999, IMMUNOGENETICS, V49, P420, DOI 10.1007/s002510050515; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lin CY, 1997, J BIOL CHEM, V272, P9147; MATTIE M, 1994, J BIOL CHEM, V269, P3181; Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3; Okamoto H, 1999, BIOCHEM BIOPH RES CO, V260, P203, DOI 10.1006/bbrc.1999.0886; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pyne S, 2000, PHARMACOL THERAPEUT, V88, P115, DOI 10.1016/S0163-7258(00)00084-X; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; SCHUMAKER VN, 1987, ANNU REV IMMUNOL, V5, P21, DOI 10.1146/annurev.iy.05.040187.000321; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Tamama K, 2001, BIOCHEM J, V353, P139, DOI 10.1042/bj3530139; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Yamazaki Y, 2000, BIOCHEM BIOPH RES CO, V268, P583, DOI 10.1006/bbrc.2000.2162; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	40	75	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10539	10546		10.1074/jbc.M109064200	http://dx.doi.org/10.1074/jbc.M109064200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11792696	hybrid			2022-12-27	WOS:000174549200123
J	Christie, GR; Hajduch, E; Hundal, HS; Proud, CG; Taylor, PM				Christie, GR; Hajduch, E; Hundal, HS; Proud, CG; Taylor, PM			Intracellular sensing of amino acids in Xenopus laevis oocytes stimulates p70 S6 kinase in a target of rapamycin-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE TRANSLATION FACTORS; PROTEIN-SYNTHESIS; TRANSFER-RNA; TRANSPORT; ACTIVATION; P70(S6K); INSULIN; CELLS; INITIATION; SITES	Amino acids exert modulatory effects on proteins involved in control of mRNA translation in animal cells through the target of rapamycin (TOR) signaling pathway. Here we use oocytes of Xenopus laevis to investigate mechanisms by which amino acids are "sensed" in animal cells. Small (similar to48%) but physiologically relevant increases in intracellular but not extracellular total amino acid concentration (or Leu or Trp but not Ala, Glu, or Gln alone) resulted in increased phosphorylation of p70(S6K) and its substrate ribosomal protein S6. This response was inhibited by rapamycin, demonstrating that the effects require the TOR pathway. Alcohols of active amino acids substituted for amino acids with lower efficiency. Oocytes were refractory to changes in external amino acid concentration unless surface permeability of the cell to amino acids was increased by overexpression of the System L amino acid transporter. Amino acid-induced, rapamycin-sensitive activation of p70(S6K) was conferred when System L-expressing oocytes were incubated in extracellular amino acids, supporting intracellular localization of the putative amino acid sensor. In contrast to lower eukaryotes such as yeast, which possess an extracellular amino acid sensor, our findings provide the first direct evidence for an intracellular location for the putative amino acid sensor in animal cells that signals increased amino acid availability to TOR/p70(S6K).	Univ Dundee, Sch Life Sci, Inst Med Sci,Div Mol Physiol, MRC,Nutrient Sensing & Signaling Grp, Dundee DD1 5EH, Scotland	University of Dundee	Proud, CG (corresponding author), Univ Dundee, Sch Life Sci, Inst Med Sci,Div Mol Physiol, MRC,Nutrient Sensing & Signaling Grp, Wellcome Trust Bioctr Complex,Dow St, Dundee DD1 5EH, Scotland.		Hajduch, Eric/B-7332-2008; Taylor, Peter M/A-4667-2010; Hundal, Hari/A-8990-2008	Hajduch, Eric/0000-0002-0125-7751; Hundal, Hari/0000-0002-7621-4932; Proud, Christopher/0000-0003-0704-6442				Armstrong JL, 2001, J BIOL CHEM, V276, P952, DOI 10.1074/jbc.M004812200; Campbell LE, 1999, BIOCHEM J, V344, P433, DOI 10.1042/0264-6021:3440433; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; Christie GR, 2001, CURR OPIN CLIN NUTR, V4, P425, DOI 10.1097/00075197-200109000-00014; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Ferenci T, 1999, CURR OPIN MICROBIOL, V2, P208, DOI 10.1016/S1369-5274(99)80036-8; Forsberg H, 2001, MOL CELL BIOL, V21, P814, DOI 10.1128/MCB.21.3.814-826.2001; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; Hyde R, 2001, BIOCHEM J, V355, P563, DOI 10.1042/bj3550563; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Kleijn M, 2000, BIOCHEM J, V347, P399, DOI 10.1042/0264-6021:3470399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; MIOTTO G, 1994, J BIOL CHEM, V269, P25348; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Peter GJ, 1996, BIOCHEM J, V318, P915, DOI 10.1042/bj3180915; Peter GJ, 1999, BIOCHEM J, V343, P169, DOI 10.1042/0264-6021:3430169; Qiu H, 2001, EMBO J, V20, P1425, DOI 10.1093/emboj/20.6.1425; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Ritchie JWA, 1999, J ENDOCRINOL, V163, pR5, DOI 10.1677/joe.0.163R005; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Schwab MS, 1999, MOL CELL BIOL, V19, P2485; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE715, DOI 10.1152/ajpendo.2000.279.4.E715; Shigemitsu K, 1999, FEBS LETT, V447, P303, DOI 10.1016/S0014-5793(99)00304-X; Taylor P, 1999, BIOMEMBRANE TRANSPOR, P295, DOI [DOI 10.1016/B978-012714510-5/50011-8, 10.1016/B978-012714510-5/50011-8]; Taylor PM, 1996, J EXP BIOL, V199, P923; van Sluijters DA, 2000, BIOCHEM J, V351, P545, DOI 10.1042/0264-6021:3510545; VAUGHAN MH, 1973, J BIOL CHEM, V248, P7087; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; WEK SA, 1995, MOL CELL BIOL, V15, P4497; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621	36	102	106	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9952	9957		10.1074/jbc.M107694200	http://dx.doi.org/10.1074/jbc.M107694200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11788584	hybrid			2022-12-27	WOS:000174549200047
J	Kleerekoper, Q; Hecht, JT; Putkey, JA				Kleerekoper, Q; Hecht, JT; Putkey, JA			Disease-causing mutations in cartilage oligomeric matrix protein cause an unstructured Ca2+ binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING; ENDOPLASMIC-RETICULUM; COMP; PSEUDOACHONDROPLASIA; ASSIGNMENT; SITES; LOOP; 1ST; BIP; APO	Chondrocytes from pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia (EDM1) patients display an enlarged rough endoplasmic reticulum that accumulates extracellular matrix proteins, including cartilage oligomeric matrix protein (COMP). Mutations that cause PSACH and EDM1 are restricted to a 27-kDa Ca2+ binding domain (type 3 repeat). This domain has 13 Ca2+-binding loops with a consensus sequence that conforms to Ca2+-binding loops found in EF hands. Most disease-causing mutations are found in the 11-kDa C-terminal region of this domain. We expressed recombinant native and mutant forms of the type 3 repeat domain (T3) and its 11-kDa C-terminal region (T3-Cterm). T3 and T3-Cterm bind similar to13 and 8 mol of Ca2+/mol of protein, respectively. CD, one-dimensional proton, and two-dimensional H-1-N-15 HSQC spectra of Ca2+-bound T3-Cterm indicate a distinct conformation that has little helical secondary structure, despite the presence of 13 EF hand Ca2+-binding loops. This conformation is also formed within the context of the intact T3. 19 cross-peaks found between 9.0 and 11.4 ppm are consistent with the presence of strong hydrogen bonding patterns' such as those in beta-sheets. Removal of Ca2+ leads to an apparent loss of structure as evidenced by decreased dispersion and loss of all down field resonances. Deletion of Asp-470 (a mutation found in 22% of all PSACH and EDM1. patients) decreased the Ca2+-binding capacity of both T3 and T3-Cterm. by about 3 mol of Ca2+/mol of protein. Two-dimensional H-1-N-15 HSQC spectra of mutated T3-Cterm showed little evidence of defined structure in the presence or absence of Ca2+. The data demonstrate that Ca2+ is required to nucleate folding and to maintain defined structure. Mutation results in a partial loss of Ca2+-binding capacity and prevents Ca2+-dependent folding. Persistence of an unstructured state of the mutated Ca2+ binding domain in COMP is the structural basis for retention of COMP in the rough endoplasmic reticulum of differentiated PSACH and EDM1 chondrocytes.	Univ Texas, Houston Med Sch, Struct Biol Res Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, Houston Med Sch, Struct Biol Res Ctr, Dept Pediat, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Putkey, JA (corresponding author), Univ Texas, Houston Med Sch, Struct Biol Res Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	John.Putkey@uth.tmc.edu			NHLBI NIH HHS [R01HL45724] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045724] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aitio H, 2001, PROTEIN SCI, V10, P74, DOI 10.1110/ps.31201; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; Bieri S, 1998, BIOCHEMISTRY-US, V37, P10994, DOI 10.1021/bi980452c; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; Chen H, 2000, J BIOL CHEM, V275, P26538, DOI 10.1074/jbc.M909780199; COOPER RR, 1973, J BONE JOINT SURG AM, VA 55, P475, DOI 10.2106/00004623-197355030-00003; Creemers JWM, 2000, J BIOL CHEM, V275, P38842, DOI 10.1074/jbc.M006758200; Delot E, 1998, J BIOL CHEM, V273, P26692, DOI 10.1074/jbc.273.41.26692; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; Dyson HJ, 1998, NAT STRUCT BIOL, V5, P499, DOI 10.1038/739; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Hecht JT, 1998, MATRIX BIOL, V17, P269, DOI 10.1016/S0945-053X(98)90080-4; HECHT JT, 1993, GENOMICS, V18, P661, DOI 10.1016/S0888-7543(05)80370-2; Hecht JT, 1998, MATRIX BIOL, V17, P625, DOI 10.1016/S0945-053X(98)90113-5; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; Hecht JT, 2001, MATRIX BIOL, V20, P251, DOI 10.1016/S0945-053X(01)00136-6; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; Hou J, 2000, CELL CALCIUM, V27, P309, DOI 10.1054/ceca.2000.0125; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; KRUDY GA, 1992, BIOCHEMISTRY-US, V31, P1595, DOI 10.1021/bi00121a003; Kuznetsov G, 1997, J BIOL CHEM, V272, P3057, DOI 10.1074/jbc.272.5.3057; LI MX, 1995, BIOCHEMISTRY-US, V34, P8330, DOI 10.1021/bi00026a014; LIN X, 1994, BIOCHEMISTRY-US, V33, P14434, DOI 10.1021/bi00252a009; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; MAYNARD JA, 1972, LAB INVEST, V26, P40; McKeand J, 1996, AM J MED GENET, V63, P406; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; PARDI A, 1983, EUR J BIOCHEM, V137, P445, DOI 10.1111/j.1432-1033.1983.tb07848.x; Prabakaran D, 1996, EUR J CELL BIOL, V70, P134; Precheur B, 1996, FEBS LETT, V395, P89, DOI 10.1016/0014-5793(96)01007-1; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; SAGE EH, 1991, J BIOL CHEM, V266, P14831; Shen ZX, 1995, MATRIX BIOL, V14, P773, DOI 10.1016/S0945-053X(05)80020-4; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Springer TA, 2000, CELL, V102, P275, DOI 10.1016/S0092-8674(00)00033-7; STANESCU V, 1984, J BONE JOINT SURG AM, V66A, P817, DOI 10.2106/00004623-198466060-00002; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; VYAS NK, 1987, NATURE, V327, P635, DOI 10.1038/327635a0; Wang QY, 2001, J VIROL, V75, P2051, DOI 10.1128/JVI.75.5.2051-2058.2001; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Zaia J, 1997, J BIOL CHEM, V272, P14120, DOI 10.1074/jbc.272.22.14120	44	36	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10581	10589		10.1074/jbc.M109944200	http://dx.doi.org/10.1074/jbc.M109944200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11782471	hybrid			2022-12-27	WOS:000174549200128
J	Nicot, C; Relat, J; Woldegiorgis, G; Haro, D; Marrero, PF				Nicot, C; Relat, J; Woldegiorgis, G; Haro, D; Marrero, PF			Pig liver carnitine palmitoyltransferase - Chimera studies show that both the N- and C-terminal regions of the enzyme are important for the unusual high malonyl-CoA sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE POLYPEPTIDE; CATALYTIC ACTIVITY; PICHIA-PASTORIS; I ISOFORMS; EXPRESSION; RESIDUES; CDNA; IDENTIFICATION; MEMBRANE; PROTEINS	Pig and rat liver carnitine palmitoyltransferase I (L-CPTI) share common K-m values for palmitoyl-CoA and carnitine. However, they differ widely in their sensitivity to malonyl-CoA inhibition. Thus, pig L-CPTI has an IC50 for malonyl-CoA of 141 nM, while that of rat L-CPTI is 2 mum. Using chimeras between rat L-CPTI and pig L-CPTI, we show that the entire C-terminal region behaves as a single domain, which dictates the overall malonyl-CoA sensitivity of this enzyme. The degree of malonyl-CoA sensitivity is determined by the structure adopted by this domain. Using deletion mutation analysis, we show that malonyl-CoA sensitivity also depends on the interaction of this single domain with the first 18 N-terminal amino acid residues. We conclude that pig and rat L-CPTI have different malonyl-CoA sensitivity, because the first IS N-terminal amino acid residues interact differently with the C-terminal domain. This is the first study that describes how interactions between the C- and N-terminal regions can determine the malonyl-CoA sensitivity of L-CPTI enzymes using active C-terminal chimeras.	Univ Barcelona, Sch Pharm, Fac Farm, Dept Biochem & Mol Biol, Barcelona 08028, Spain; Oregon Hlth Sci Univ, Oregon Grad Inst, Sch Sci & Engn, Dept Biochem & Mol Biol, Beaverton, OR 97006 USA	University of Barcelona; Oregon Health & Science University	Marrero, PF (corresponding author), Univ Barcelona, Sch Pharm, Fac Farm, Dept Biochem & Mol Biol, Av Diagonal 643, Barcelona 08028, Spain.		Haro, Diego/I-4623-2015; relat, joana/I-5473-2015; Marrero, Pedro F/I-1919-2015	Haro, Diego/0000-0001-9147-0486; relat, joana/0000-0001-8974-1785; 	NHLBI NIH HHS [HL52571] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052571] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN NF, 1994, J BIOL CHEM, V269, P26438; Cohen I, 1998, J BIOL CHEM, V273, P29896, DOI 10.1074/jbc.273.45.29896; Dai J, 2000, J BIOL CHEM, V275, P22020, DOI 10.1074/jbc.M002118200; deVries Y, 1997, BIOCHEMISTRY-US, V36, P5285, DOI 10.1021/bi962875p; Esser V, 1996, J BIOL CHEM, V271, P6972, DOI 10.1074/jbc.271.12.6972; ESSER V, 1993, J BIOL CHEM, V268, P5817; Fraser F, 1997, BIOCHEM J, V323, P711, DOI 10.1042/bj3230711; Jackson VN, 2000, J BIOL CHEM, V275, P38410, DOI 10.1074/jbc.M007722200; Jackson VN, 2000, J BIOL CHEM, V275, P19560, DOI 10.1074/jbc.M002177200; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Nicot C, 2001, BIOCHEMISTRY-US, V40, P2260, DOI 10.1021/bi0024106; Shi JY, 2000, BIOCHEMISTRY-US, V39, P712, DOI 10.1021/bi9918700; Shi JY, 1999, J BIOL CHEM, V274, P9421, DOI 10.1074/jbc.274.14.9421; Shi JY, 1998, BIOCHEMISTRY-US, V37, P11033, DOI 10.1021/bi9803426; Swanson ST, 1998, BIOCHEM J, V335, P513, DOI 10.1042/bj3350513; Waterham HR, 1997, GENE, V186, P37, DOI 10.1016/S0378-1119(96)00675-0; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505; Zhu HF, 1997, BIOCHEM BIOPH RES CO, V239, P498, DOI 10.1006/bbrc.1997.7494; Zhu HF, 1997, ARCH BIOCHEM BIOPHYS, V347, P53, DOI 10.1006/abbi.1997.0314	19	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10044	10049		10.1074/jbc.M109976200	http://dx.doi.org/10.1074/jbc.M109976200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11790778	hybrid, Green Published			2022-12-27	WOS:000174549200059
J	Weyand, M; Schlichting, I; Marabotti, A; Mozzarelli, A				Weyand, M; Schlichting, I; Marabotti, A; Mozzarelli, A			Crystal structures of a new class of allosteric effectors complexed to tryptophan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; ALPHA(2)BETA(2) COMPLEX; ESCHERICHIA-COLI; FLEXIBLE LOOP; BETA-SUBUNIT; ALPHA-2-BETA-2 COMPLEX; CATALYTIC RESIDUE; ACTIVE-SITES; L-SERINE; COMMUNICATION	Tryptophan synthase is a bifunctional alpha(2)/beta(2) complex catalyzing the last two steps of L-tryptophan biosynthesis. The natural substrates of the alpha-subunit indole-3-glycerolphosphate and glyceraldehyde-3-phosphate, and the substrate analogs indole-3-propanolphosphate and DL-alpha-glycerol-3-phosphate are allosteric effectors of the beta-subunit activity. It has been shown recently, that the indole-3-acetyl amino acids indole-3-acetylglycine and indole-3-acetyl-L-aspartic acid are both alpha-subunit inhibitors and beta-subunit allosteric effectors, whereas indole-3-acetyl-L-valine is only an alpha-subunit inhibitor (Marabotti, A., Cozzini, P., and Mozzarelli, A. (2000) Biochim. Biophys. Acta 1476, 287-299). The crystal structures of tryptophan synthase complexed with indole-3-acetylglycine and indole-3-acetyl-L-aspartic acid show that both ligands bind to the active site such that the carboxylate moiety is positioned similarly as the phosphate group of the natural substrates. As a consequence, the residues of the alpha-active site that interact with the ligands are the same as observed in the indole 3-glycerolphosphate-enzyme complex. Ligand binding leads to closure of loop alphaL6 of the alpha-subunit, a key structural element of intersubunit communication. This is in keeping with the allosteric role played by these compounds. The structure of the enzyme complex with indole-3-acetyl-L-valine is quite different. Due to the hydrophobic lateral chain, this molecule adopts a new orientation in the alpha-active site. In this case, closure of loop alphaL6 is no longer observed, in agreement with its functioning only as an inhibitor of the a-subunit reaction.	Max Planck Inst Mol Physiol, Phys Biochem Abt, D-44227 Dortmund, Germany; Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; Univ Parma, Natl Inst Phys Matter, I-43100 Parma, Italy	Max Planck Society; University of Parma; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Parma	Schlichting, I (corresponding author), Max Planck Inst Mol Physiol, Phys Biochem Abt, D-44227 Dortmund, Germany.	ilme.schlichting@mpi-dortmund.mpg.de	Schlichting, Ilme/I-1339-2013; Mozzarelli, Andrea/C-3615-2014	Mozzarelli, Andrea/0000-0003-3762-0062; Marabotti, Anna/0000-0002-9510-5205				Anderson KS, 1999, METHOD ENZYMOL, V308, P111; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Finn J, 1999, BIOORG MED CHEM LETT, V9, P2297, DOI 10.1016/S0960-894X(99)00340-6; Frey M, 1997, SCIENCE, V277, P696, DOI 10.1126/science.277.5326.696; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LAST RL, 1988, SCIENCE, V240, P305, DOI 10.1126/science.240.4850.305; Marabotti A, 2001, J BIOL CHEM, V276, P17747, DOI 10.1074/jbc.M011781200; Marabotti A, 2000, BBA-PROTEIN STRUCT M, V1476, P287, DOI 10.1016/S0167-4838(99)00242-3; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miles E W, 1995, Subcell Biochem, V24, P207; MILES EW, 1988, J BIOL CHEM, V263, P8611; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1991, J BIOL CHEM, V266, P10715; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAGATA S, 1989, J BIOL CHEM, V264, P6288; Pan P, 1997, TRENDS BIOCHEM SCI, V22, P22, DOI 10.1016/S0968-0004(96)10066-9; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; Rhee S, 1998, J BIOL CHEM, V273, P8553, DOI 10.1074/jbc.273.15.8553; Rhee S, 1998, BIOCHEMISTRY-US, V37, P10653, DOI 10.1021/bi980779d; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; RUVINOV SB, 1992, FEBS LETT, V299, P197, DOI 10.1016/0014-5793(92)80246-D; Sachpatzidis A, 1999, BIOCHEMISTRY-US, V38, P12665, DOI 10.1021/bi9907734; SARKER KD, 1995, PROTEINS, V21, P130, DOI 10.1002/prot.340210207; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; SCHOMBURG D, 1988, J MOL GRAPHICS, V6, P161, DOI 10.1016/0263-7855(88)80069-9; WEISCHET WO, 1976, EUR J BIOCHEM, V65, P375, DOI 10.1111/j.1432-1033.1976.tb10351.x; Weyand M, 1999, BIOCHEMISTRY-US, V38, P16469, DOI 10.1021/bi9920533; Weyand M, 2002, J BIOL CHEM, V277, P10653, DOI 10.1074/jbc.M111031200; YANG XJ, 1992, J BIOL CHEM, V267, P7520; YUTANI K, 1987, J BIOL CHEM, V262, P13429	43	41	41	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10647	10652		10.1074/jbc.M111285200	http://dx.doi.org/10.1074/jbc.M111285200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11756456	hybrid			2022-12-27	WOS:000174549200137
J	Agarwalla, S; Kealey, JT; Santi, DV; Stroud, RM				Agarwalla, S; Kealey, JT; Santi, DV; Stroud, RM			Characterization of the 23 S ribosomal RNA m(5)U1939 methyltransferase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M(5)C967 METHYLTRANSFERASE; AMINO-ACID; T-ARM; SEQUENCE; IDENTIFICATION; PSEUDOURIDINE; PROTEINS; INVITRO; CLONING; GENE	An Escherichia coli open reading frame, ygcA, was identified as a putative 23 S ribosomal RNA 5-methyluridine methyltransferase (Gustafsson, C., Reid, R., Greene, P. J., and Santi, D. V. (1996) Nucleic Acids Res. 24, 3756-3762). We have cloned, expressed, and purified the 50-kDa protein encoded by ygcA. The purified enzyme catalyzed the AdoMet-dependent methylation of 23 S rRNA but did not act upon 16 S rRNA or tRNA. A high performance liquid chromatography-based nucleoside analysis identified the reaction product as 5-methyluridine. The enzyme specifically methylated U1939 as determined by a nuclease protection assay and by methylation assays using site-specific mutants of 23 S rRNA. A 40-nucleotide 23 S rRNA fragment (nucleotide 1930-1969) also served as an efficient substrate for the enzyme. The apparent K-m values for the 40-mer RNA oligonucleotide and AdoMet were 3 and 26 gm, respectively, and the apparent k(cat) was 0.06 s(-1). The enzyme contains two equivalents of iron/monomer and has a sequence motif similar to a motif found in iron-sulfur proteins. We propose to name this gene rumA and accordingly name the protein product as RumA for RNA uridine methyltransferase.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Stroud, RM (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.		Stroud, Rhonda/GQZ-0151-2022	Stroud, Rhonda/0000-0001-5242-8015	NIGMS NIH HHS [GM51232] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051232] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Becker HF, 1997, J MOL BIOL, V274, P505, DOI 10.1006/jmbi.1997.1417; Bjork GR, 1999, FEBS LETT, V452, P47, DOI 10.1016/S0014-5793(99)00528-1; BJORK GR, 1996, ESCHERICHIA COLI SAL, V1, P861; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Caldas T, 2000, J BIOL CHEM, V275, P16414, DOI 10.1074/jbc.M001854200; Chatterji D, 2001, CURR OPIN MICROBIOL, V4, P160, DOI 10.1016/S1369-5274(00)00182-X; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; FAUMAN EB, 1999, S ADENOSYLMETHIONINE, P1, DOI DOI 10.1142/9789812813077_0001; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GREENBERG R, 1980, J BIOL CHEM, V255, P8296; GU XG, 1991, BIOCHEMISTRY-US, V30, P2999, DOI 10.1021/bi00226a003; GU XG, 1994, BIOCHEMISTRY-US, V33, P2255, DOI 10.1021/bi00174a036; Gu XR, 1999, BIOCHEMISTRY-US, V38, P4053, DOI 10.1021/bi982364y; Gu XR, 1998, BIOCHEMISTRY-US, V37, P339, DOI 10.1021/bi971590p; Gu XR, 1996, BIOCHEMISTRY-US, V35, P11652, DOI 10.1021/bi9612125; Gustafsson C, 1998, J BACTERIOL, V180, P359, DOI 10.1128/JB.180.2.359-365.1998; Gustafsson C, 1996, NUCLEIC ACIDS RES, V24, P3756, DOI 10.1093/nar/24.19.3756; Gutgsell NS, 2001, RNA, V7, P990, DOI 10.1017/S1355838201000243; Hansen LH, 2001, J MOL BIOL, V310, P1001, DOI 10.1006/jmbi.2001.4836; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Huang LX, 1998, BIOCHEMISTRY-US, V37, P15951, DOI 10.1021/bi981002n; KEALEY JT, 1998, BIOCH PARIS, V76, P1133; KOONIN EV, 1995, P NATL ACAD SCI USA, V92, P11921, DOI 10.1073/pnas.92.25.11921; KRZYZOSIAK W, 1987, BIOCHEMISTRY-US, V26, P2353, DOI 10.1021/bi00382a042; Lovgren JM, 2001, J BACTERIOL, V183, P6957, DOI 10.1128/JB.183.23.6957-6960.2001; Ofengand J, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P175; PERSSON BC, 1992, P NATL ACAD SCI USA, V89, P3995, DOI 10.1073/pnas.89.9.3995; Raychaudhuri S, 1998, RNA, V4, P1407, DOI 10.1017/S1355838298981146; Reid R, 1999, NUCLEIC ACIDS RES, V27, P3138, DOI 10.1093/nar/27.15.3138; Rozenski J, 1999, NUCLEIC ACIDS RES, V27, P196, DOI 10.1093/nar/27.1.196; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; Tscherne JS, 1999, J BIOL CHEM, V274, P924, DOI 10.1074/jbc.274.2.924; Tscherne JS, 1999, BIOCHEMISTRY-US, V38, P1884, DOI 10.1021/bi981880l; VANBUUL CPJJ, 1985, GENE, V38, P65, DOI 10.1016/0378-1119(85)90204-5; WEITZMANN CJ, 1990, NUCLEIC ACIDS RES, V18, P3515, DOI 10.1093/nar/18.12.3515; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	40	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8835	8840		10.1074/jbc.M111825200	http://dx.doi.org/10.1074/jbc.M111825200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11779873	hybrid			2022-12-27	WOS:000174400600014
J	Tohgo, AK; Pierce, KL; Choy, EW; Lefkowitz, RJ; Luttrell, LM				Tohgo, AK; Pierce, KL; Choy, EW; Lefkowitz, RJ; Luttrell, LM			beta-arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SIGNAL-REGULATED KINASES; GROWTH-FACTOR RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; EGF RECEPTOR; CLATHRIN ADAPTER; ACTIVATION; TRANSACTIVATION; ENDOCYTOSIS; CELLS	beta-Arrestins are cytosolic proteins that mediate homologous desensitization of G protein-coupled receptors (GPCRs) by binding to agonist-occupied receptors and by uncoupling them from heterotrimeric G proteins. The recent finding that beta-arrestins bind to some mitogen-activated protein (MAP) kinases has suggested that they might also function as scaffolds for GPCR-stimulated MAP kinase activation. To define the role of beta-arrestins in the regulation of ERK MAP kinases, we examined the effect of beta-arrestin overexpression on ERK1/2 activation and nuclear signaling in COS-7 cells expressing angiotensin II type 1a receptors (AT1aRs). Expression of either beta-arrestin1 or beta-arrestin2 reduced angiotensin-stimulated phosphatidylinositol hydrolysis but paradoxically increased angiotensin-stimulated ERK1/2 phosphorylation. The increase in ERK1/2 phosphorylation in beta-arrestin-expressing cells correlated with activation of a beta-arrestin-bound pool of ERK2. The beta-arrestin-dependent increase in ERK1/2 phosphorylation was accompanied by a significant reduction in ERK1/2-mediated, Elk1-driven transcription of a luciferase reporter. Analysis of the cellular distribution of phospho-ERK1/2 by confocal immunofluorescence microscopy and cellular fractionation revealed that overexpression of beta-arrestin resulted in a significant increase in the cytosolic pool of phospho-ERK1/2 and a corresponding decrease in the nuclear pool of phospho-ERK1/2 following angiotensin stimulation. beta-Arrestin overexpression resulted in formation of a cytoplasmic pool of beta-arrestin-bound phospho-ERK, decreased nuclear translocation of phospho-ERK1/2, and inhibition of Elk1-driven luciferase transcription even when ERK1/2 was activated by overexpression of cRaf-1 in the absence of AT1aR stimulation. These data demonstrate that beta-arrestins facilitate GPCR-mediated ERK activation but inhibit ERK-dependent transcription by binding to phospho-ERK1/2, leading to its retention in the cytosol.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Durham Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27705 USA	Duke University; Duke University; Howard Hughes Medical Institute; Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center	Luttrell, LM (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949				Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; de Gasparo M, 2000, PHARMACOL REV, V52, P415; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Elorza A, 2000, MOL PHARMACOL, V57, P778, DOI 10.1124/mol.57.4.778; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533	34	312	318	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9429	9436		10.1074/jbc.M106457200	http://dx.doi.org/10.1074/jbc.M106457200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11777902	hybrid			2022-12-27	WOS:000174400600093
J	Zhang, DY; Yu, WF; Geisbrecht, BV; Gould, SJ; Sprecher, H; Schulz, H				Zhang, DY; Yu, WF; Geisbrecht, BV; Gould, SJ; Sprecher, H; Schulz, H			Functional characterization of Delta(3),Delta(2)-enoyl-CoA isomerases from rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTASE-DEPENDENT PATHWAY; UNSATURATED FATTY-ACIDS; BETA-OXIDATION; COENZYME-A; DELTA-3,DELTA-2-ENOYL-COA ISOMERASE; 3-HYDROXYACYL-COA DEHYDROGENASE; MOLECULAR-CLONING; ESCHERICHIA-COLI; SENSITIVE METHOD; COA HYDRATASE	The degradation of unsaturated fatty acids by beta-oxidation involves Delta(3),Delta(2) -enoyl-CoA isomerases (enoyl-CoA isomerases) that catalyze 3-cis --> 2-trans and 3-trans --> 2-trans isomerizations of enoyl-CoAs and the 2,5 --> 3,5 isomerization of dienoyl-CoAs. An analysis of rat liver enoyl-CoA isomerases revealed the presence of a monofunctional enoyl-CoA isomerase (ECI) in addition to mitochondrial enoyl-CoA isomerase (MECI) in mitochondria, whereas peroxisomes contain ECI and multifunctional enzyme 1 (MFE1). Thus ECI, which previously had been described as peroxisomal enoyl-CoA isomerase, was found to be present in both peroxisomes and mitochondria. This enzyme seems to be identical with mitochondrial long-chain enoyl-CoA isomerase (Kilponen, J.M., Palosaari, P.M., and Hiltunen, J.K. 1990. Biochem. J. 269, 223-226). All three hepatic enoyl-CoA isomerases have broad chain length specificities but are distinguishable by their preferences for one of the three isomerization reactions. MECI is most active in catalyzing the 3-cis --> 2-trans isomerization; ECI has a preference for the 3-trans --> 2-trans isomerization, and MFE1 is the optimal isomerase for the 2,5 --> 3,5 isomerization. A functional characterization based on substrate specificities and total enoyl-CoA isomerase activities in rat liver leads to the conclusion that the 3-cis 2-trans and 2,5 - 3,5 isomerizations in mitochondria are catalyzed overwhelmingly by MEC1, whereas ECI contributes significantly to the 3-trans - 2-trans isomerization. In peroxisomes, ECI is predicted to be the dominant enzyme for the 3-cis - 2-trans and 3-trans 2-trans isomerizations of long-chain intermediates, whereas MFE1 is the key enzyme in the 2,5 --> 3,5 isomerization.	CUNY City Coll, Dept Chem, New York, NY 10031 USA; CUNY City Coll, Grad Sch, New York, NY 10031 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	City University of New York (CUNY) System; City College of New York (CUNY); City University of New York (CUNY) System; City College of New York (CUNY); Johns Hopkins University; University System of Ohio; Ohio State University	Schulz, H (corresponding author), CUNY City Coll, Dept Chem, Convent Ave 138th St, New York, NY 10031 USA.	hoschu@sci.ccny.cuny.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030847] Funding Source: NIH RePORTER; NCRR NIH HHS [RR03060] Funding Source: Medline; NHLBI NIH HHS [HL30847] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; Binstock J F, 1981, Methods Enzymol, V71 Pt C, P403; Bjerrum OJ, 1986, **NON-TRADITIONAL**, V86th, P315; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; Boxer SE, 1931, J CHEM SOC, P740, DOI 10.1039/jr9310000740; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Engel CK, 1996, EMBO J, V15, P5135, DOI 10.1002/j.1460-2075.1996.tb00897.x; Fong J C, 1981, Methods Enzymol, V71 Pt C, P390; Geisbrecht BV, 1999, J BIOL CHEM, V274, P21797, DOI 10.1074/jbc.274.31.21797; HE XY, 1995, BIOCHEM BIOPH RES CO, V215, P15, DOI 10.1006/bbrc.1995.2428; He XY, 1998, BBA-LIPID LIPID MET, V1392, P119, DOI 10.1016/S0005-2760(98)00031-9; Kiema TR, 1999, BIOCHEMISTRY-US, V38, P2991, DOI 10.1021/bi981646v; KILPONEN JM, 1990, BIOCHEM J, V269, P223, DOI 10.1042/bj2690223; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MULLERNEWEN G, 1991, BIOL CHEM H-S, V372, P613, DOI 10.1515/bchm3.1991.372.2.613; Mursula AM, 2001, J MOL BIOL, V309, P845, DOI 10.1006/jmbi.2001.4671; NEDERGAARD J, 1979, METHOD ENZYMOL, V69, P390; OCHOA S, 1955, METHOD ENZYMOL, V1, P735, DOI 10.1016/0076-6879(55)01128-2; OSUMI T, 1979, BIOCHEM BIOPH RES CO, V89, P580, DOI 10.1016/0006-291X(79)90669-7; OSUMI T, 1985, J BIOL CHEM, V260, P8905; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; Schulz H, 1981, Methods Enzymol, V71 Pt C, P398; Shoukry K, 1998, J BIOL CHEM, V273, P6892, DOI 10.1074/jbc.273.12.6892; STEINMAN H, 1965, METHOD ENZYMOL, V35, P136; Stoffel W., 1979, METHOD ENZYMOL, V14, P99; VanVeldhoven PP, 1996, ANAL BIOCHEM, V237, P17, DOI 10.1006/abio.1996.0194; WEEKS G, 1968, J BIOL CHEM, V243, P1180; WHITE H, 1976, J BIOL CHEM, V251, P1688; YANG SY, 1986, J BIOL CHEM, V261, P5390; Zhang DY, 2001, J BIOL CHEM, V276, P13622, DOI 10.1074/jbc.M011315200	34	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9127	9132		10.1074/jbc.M112228200	http://dx.doi.org/10.1074/jbc.M112228200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11781327	hybrid			2022-12-27	WOS:000174400600053
J	Ma, HP; Saxena, S; Warnock, DG				Ma, HP; Saxena, S; Warnock, DG			Anionic phospholipids regulate native and expressed epithelial sodium channel (ENaC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNELS; POTASSIUM CHANNELS; PIP2; ALDOSTERONE; SENSITIVITY; MECHANISMS; TRANSPORT; SUBUNITS; CLONING; CELLS	Using patch clamp techniques, we found that the epithelial sodium channel (ENaC) activity in the apical membrane of A6 distal nephron cells showed a sudden rundown beginning at 4 min after forming the inside-out configuration. This sudden rundown was prevented by addition of anionic phospholipids such as phosphatidylinositol 4,5-bisphosphate (PIP2), phosphatidylinositol 3,4,5-trisphosphate (PIP3), and phosphatidylserine (PS) to the "cytoplasmic" bath. Conversely, chelation of endogenous PIP2 with anti-PIP2 antibody, hydrolysis of PIP2 with either exogenous phospholipase C (PLC) or activation of endogenous PLC by extracellular ATP, or application of the positively charged molecule, poly-L-lysine, accelerated channel rundown. However, neutral phosphatidylcholine had no effect on ENaC activity. By two-electrode voltage clamp recordings, we demonstrated that PIP2 and PIP3 significantly increased amiloride-sensitive current in Xenopus oocytes injected with cRNAs of rat alpha-, beta-, and gamma-ENaC. However, PIP2 and PIP3 did not affect surface expression of ENaC, indicating that PIP2 and PIP3 regulate ENaC at the level of the inner plasma membrane through a mechanism that is independent of ENaC trafficking. These data suggest that anionic phospholipids may mediate the regulation of ENaC by PLC- or phosphoinositide 3-kinase-coupled receptors.	Univ Alabama, Dept Med, Div Nephrol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Ma, HP (corresponding author), Univ Alabama, Dept Med, Div Nephrol, 1530 3rd Ave S,Sparks Bldg 865, Birmingham, AL 35294 USA.							Ashcroft FM, 1998, SCIENCE, V282, P1059, DOI 10.1126/science.282.5391.1059; Barylko B, 2001, J BIOL CHEM, V276, P7705, DOI 10.1074/jbc.C000861200; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Blazer-Yost BL, 1999, AM J PHYSIOL-CELL PH, V277, pC531, DOI 10.1152/ajpcell.1999.277.3.C531; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chalfant ML, 1999, J BIOL CHEM, V274, P32889, DOI 10.1074/jbc.274.46.32889; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Hilgemann DW, 1997, ANNU REV PHYSIOL, V59, P193, DOI 10.1146/annurev.physiol.59.1.193; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Koster JC, 1999, J GEN PHYSIOL, V114, P203, DOI 10.1085/jgp.114.2.203; Lehrmann H, 2002, J AM SOC NEPHROL, V13, P10, DOI 10.1681/ASN.V13110; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Ma HP, 1996, AM J PHYSIOL-RENAL, V270, pF798, DOI 10.1152/ajprenal.1996.270.5.F798; Ma HP, 2002, AM J PHYSIOL-RENAL, V282, pF501, DOI 10.1152/ajprenal.00147.2001; Paunescu TG, 2000, AM J PHYSIOL-CELL PH, V279, pC236, DOI 10.1152/ajpcell.2000.279.1.C236; Pearce D, 2000, KIDNEY INT, V57, P1283, DOI 10.1046/j.1523-1755.2000.00963.x; Record RD, 1998, AM J PHYSIOL-ENDOC M, V274, pE611, DOI 10.1152/ajpendo.1998.274.4.E611; Saxena S, 1999, J BIOL CHEM, V274, P20812, DOI 10.1074/jbc.274.30.20812; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Tucker JK, 1998, AM J PHYSIOL-CELL PH, V274, pC1081, DOI 10.1152/ajpcell.1998.274.4.C1081; Verrey F, 2000, KIDNEY INT, V57, P1277, DOI 10.1046/j.1523-1755.2000.00962.x; Waldegger S, 1997, P NATL ACAD SCI USA, V94, P4440, DOI 10.1073/pnas.94.9.4440; Yue G, 2000, FASEB J, V14, pA340; Zambon AC, 2000, AM J PHYSIOL-RENAL, V279, pF1045, DOI 10.1152/ajprenal.2000.279.6.F1045	27	135	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7641	7644		10.1074/jbc.C100737200	http://dx.doi.org/10.1074/jbc.C100737200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11809744	hybrid			2022-12-27	WOS:000174268000004
J	Nancy, V; Callebaut, I; El Marjou, A; de Gunzburg, J				Nancy, V; Callebaut, I; El Marjou, A; de Gunzburg, J			The delta subunit of retinal rod cGMP phosphodiesterase regulates the membrane association of Ras and Rap GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; CAAX MOTIF; H-RAS; PROTEIN; BINDING; IDENTIFICATION; LOCALIZATION; PALMITOYLATION	Post-translational modifications of GTPases from the Ras superfamily enable them to associate with membrane compartments where they exert their biological activities. However, no protein acting like Rho and Rab dissociation inhibitor (GDI) that regulate the membrane association of Rho and Rab GTPases has been described for Ras and closely related proteins. We report here that the delta subunit of retinal rod phosphodiesterase (PDEdelta) is able to interact with prenylated Ras and Rap proteins, and to solubilize them from membranes, independently of their nucleotide-bound (GDP or GTP) state. We show that PDEdelta exhibits striking structural similarities with RhoGDI, namely conservation of the Ig-like fold and presence of a series of hydrophobic residues which could act as in RhoGDI to sequester the prenyl group of its target proteins, thereby providing structural support for the biochemical activity of PDEdelta. We observe that the overexpression of PDEdelta interferes with Ras trafficking and propose that it may play a role in the process that delivers prenylated proteins from endomembranes, once they have undergone proteolysis and carboxymethylation, to the structures that ensure trafficking to their respective resident compartments.	Inst Curie, INSERM, U528, Sect Rech, F-75005 Paris, France; Univ Paris 06, Lab Mineral Cristallog, CNRS, UMR 7590, F-75005 Paris, France; Univ Paris 07, Lab Mineral Cristallog, CNRS, UMR 7590, F-75005 Paris, France; Inst Curie, Sect Rech, CNRS, UMR 144, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	de Gunzburg, J (corresponding author), Inst Curie, INSERM, U528, Sect Rech, F-75005 Paris, France.							ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; BERANGER F, 1991, ONCOGENE, V6, P1835; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Cook TA, 2000, BIOCHEMISTRY-US, V39, P13516, DOI 10.1021/bi001070l; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; Ershova G, 1997, CYTOGENET CELL GENET, V79, P139, DOI 10.1159/000134701; Figueroa C, 2001, J BIOL CHEM, V276, P28219, DOI 10.1074/jbc.M101763200; Florio SK, 1996, J BIOL CHEM, V271, P24036, DOI 10.1074/jbc.271.39.24036; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; Higashide T, 1996, J BIOL CHEM, V271, P1797, DOI 10.1074/jbc.271.3.1797; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; ISOMURA M, 1991, ONCOGENE, V6, P119; Linari M, 1999, P NATL ACAD SCI USA, V96, P1315, DOI 10.1073/pnas.96.4.1315; Linari M, 1999, FEBS LETT, V458, P55, DOI 10.1016/S0014-5793(99)01117-5; MADURO M, 1995, GENETICS, V141, P977; Marzesco AM, 1998, J BIOL CHEM, V273, P22340, DOI 10.1074/jbc.273.35.22340; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; Nancy V, 1999, J BIOL CHEM, V274, P8737, DOI 10.1074/jbc.274.13.8737; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; Wu SK, 1996, TRENDS BIOCHEM SCI, V21, P472, DOI 10.1016/S0968-0004(96)10062-1; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	37	96	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15076	15084		10.1074/jbc.M109983200	http://dx.doi.org/10.1074/jbc.M109983200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11786539	hybrid			2022-12-27	WOS:000175203000092
J	Haemmerle, G; Zimmermann, R; Strauss, JG; Kratky, D; Riederer, M; Knipping, G; Zechner, R				Haemmerle, G; Zimmermann, R; Strauss, JG; Kratky, D; Riederer, M; Knipping, G; Zechner, R			Hormone-sensitive lipase deficiency in mice changes the plasma lipid profile by affecting the tissue-specific expression pattern of lipoprotein lipase in adipose tissue and muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; BINDING CASSETTE TRANSPORTER-1; TANGIER-DISEASE; TRANSGENIC MICE; SKELETAL-MUSCLE; MESSENGER-RNA; TRIGLYCERIDE; METABOLISM; ADIPOCYTES	Hormone-sensitive lipase (HSL) is believed to play an important role in the mobilization of fatty acids from triglycerides (TG), diglycerides, and cholesteryl esters in various tissues. Because HSL-mediated lipolysis of TG in adipose tissue (AT) directly feeds non-esterified fatty acids (NEFA) into the vascular system, the enzyme is expected to affect many metabolic processes including the metabolism of plasma lipids and lipoproteins. In the present study we examined these metabolic changes in induced mutant mouse lines that lack HSL expression (HSL-ko mice). During fasting, when HSL is normally strongly induced in AT, HSL-ko animals exhibited markedly decreased plasma concentrations of NEFA (-40%) and TG (-63%), whereas total cholesterol and HDL cholesterol levels were increased (+34%). Except for the increased HDL cholesterol concentrations, these differences were not observed in fed animals, in which HSL activity is generally low. Decreased plasma TG levels in fasted HSL-ko mice were mainly caused by decreased hepatic very low density lipid lipoprotein (VLDL) synthesis as a result of decreased NEFA transport from the periphery to the liver. Reduced NEFA transport was also indicated by a depletion of hepatic TG stores (-99%) and strongly decreased ketone body concentrations in plasma (-80%). Decreased plasma NEFA and TG levels in fasted HSL-ko mice were associated with increased fractional catabolic rates of VLDL-TG and an induction of the tissue-specific lipoprotein lipase (LPL) activity in cardiac muscle, skeletal muscle, and white AT. In brown AT, LPL activity was decreased. Both increased VLDL fractional catabolic rates and increased LPL activity in muscle were unable to provide the heart with sufficient NEFA, which led to decreased tissue TG levels in cardiac muscle. Our results demonstrate that HSL deficiency markedly affects the metabolism of TG-rich lipoproteins by the coordinate down-regulation of VLDL synthesis and up-regulation of LPL in muscle and white adipose tissue. These changes result in an "anti-atherogenic" lipoprotein profile.	Graz Univ, Inst Mol Biol Biochem & Microbiol, A-8010 Graz, Austria; Graz Univ, Inst Med Biochem & Mol Biol, A-8010 Graz, Austria	University of Graz; University of Graz	Zechner, R (corresponding author), Graz Univ, Inst Mol Biol Biochem & Microbiol, Heinrichstr 31A, A-8010 Graz, Austria.		Riederer, Markus/B-5540-2008; Kratky, Dagmar/ABF-5699-2021	Riederer, Markus/0000-0001-7081-1456; Zimmermann, Robert/0000-0002-7354-870X; Zechner, Rudolf/0000-0001-5483-1182; Haemmerle, Guenter/0000-0001-9900-5896; Bogner-Strauss, Juliane/0000-0003-2459-0124; Kratky, Dagmar/0000-0003-1357-7573				AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; Barrans A, 1996, BBA-LIPID LIPID MET, V1300, P73, DOI 10.1016/0005-2760(95)00236-7; BELFRAGE P, 1977, FEBS LETT, V75, P259, DOI 10.1016/0014-5793(77)80099-9; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Bulow J, 1999, J LIPID RES, V40, P2034; Clay MA, 2000, J BIOL CHEM, V275, P9019, DOI 10.1074/jbc.275.12.9019; CONTRERAS JA, 1994, ISRAEL J MED SCI, V30, P778; ELKS ML, 1985, ENDOCRINOLOGY, V116, P2119, DOI 10.1210/endo-116-5-2119; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; Ewart HS, 1999, BIOCHEM J, V340, P485, DOI 10.1042/0264-6021:3400485; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRAYN KN, 1995, ADV ENZYME REGUL, V35, P163, DOI 10.1016/0065-2571(94)00011-Q; FRAYN KN, 1995, P NUTR SOC, V54, P177, DOI 10.1079/PNS19950047; Frayn KN, 1994, AM J PHYSIOL-ENDOC M, V266, P308; GAW A, 1992, LIPOPROTEIN ANAL PRA, P139; Gibbons GF, 2000, BBA-MOL CELL BIOL L, V1483, P37, DOI 10.1016/S1388-1981(99)00182-1; GOLDBERG DI, 1985, J BIOL CHEM, V260, P5879; GOLDBERG I, 1996, CURR OPIN LIPIDOL, V7, P184; Gordon DA, 1997, CURR OPIN LIPIDOL, V8, P131, DOI 10.1097/00041433-199706000-00002; Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; KHOO JC, 1993, J LIPID RES, V34, P1969; Kratky D, 2001, BIOCHEM J, V355, P647, DOI 10.1042/bj3550647; Kuipers F, 1997, J CLIN INVEST, V100, P2915, DOI 10.1172/JCI119841; Langfort J, 1998, ADV EXP MED BIOL, V441, P219; Levak-Frank S, 1999, P NATL ACAD SCI USA, V96, P3165, DOI 10.1073/pnas.96.6.3165; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; Lewis GF, 1997, CURR OPIN LIPIDOL, V8, P146, DOI 10.1097/00041433-199706000-00004; MATHEWS CH, PHYS MED BIOL, V2, P36; McKnight GS, 1998, RECENT PROG HORM RES, V53, P139; Mulder H, 1999, DIABETES, V48, P228, DOI 10.2337/diabetes.48.1.228; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; OSCAI LB, 1981, J APPL PHYSIOL, V50, P250, DOI 10.1152/jappl.1981.50.2.250; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Raclot T, 1998, BIOCHEM BIOPH RES CO, V245, P510, DOI 10.1006/bbrc.1998.8469; Roduit R, 2001, DIABETES, V50, P1970, DOI 10.2337/diabetes.50.9.1970; ROMEIS B, 1989, MIKROSKOPISCHE TECHN, P378; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SADDIK M, 1991, J BIOL CHEM, V266, P8162; Santamarina-Fojo S, 2000, CURR OPIN LIPIDOL, V11, P267, DOI 10.1097/00041433-200006000-00007; SHEPHERD RE, 1981, J APPL PHYSIOL, V50, P143, DOI 10.1152/jappl.1981.50.1.143; Speake BK, 1998, PROG LIPID RES, V37, P1, DOI 10.1016/S0163-7827(97)00012-X; Syu LJ, 1999, MOL CELL, V4, P109, DOI 10.1016/S1097-2765(00)80192-6; SZTALRYD C, 1994, AM J PHYSIOL, V266, P179; Wang SP, 2001, OBES RES, V9, P119, DOI 10.1038/oby.2001.15; Wei SH, 1997, J BIOL CHEM, V272, P14159, DOI 10.1074/jbc.272.22.14159; Weinstock PH, 1995, J CLIN INVEST, V96, P2555, DOI 10.1172/JCI118319; Winzell MS, 2001, DIABETES, V50, P2225, DOI 10.2337/diabetes.50.10.2225; YEAMAN SJ, 1990, BIOCHIM BIOPHYS ACTA, V1052, P128, DOI 10.1016/0167-4889(90)90067-N; Yip RGC, 1999, ENDOCRINOLOGY, V140, P1219, DOI 10.1210/en.140.3.1219	53	120	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12946	12952		10.1074/jbc.M108640200	http://dx.doi.org/10.1074/jbc.M108640200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11809748	hybrid			2022-12-27	WOS:000175036300060
J	Gillotte-Taylor, K; Nickel, M; Johnson, WJ; Francone, OL; Holvoet, P; Lund-Katz, S; Rothblatt, GH; Phillips, MC				Gillotte-Taylor, K; Nickel, M; Johnson, WJ; Francone, OL; Holvoet, P; Lund-Katz, S; Rothblatt, GH; Phillips, MC			Effects of enrichment of fibroblasts with unesterified cholesterol on the efflux of cellular lipids to apolipoprotein A-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; PLASMA-MEMBRANE MICROSOLUBILIZATION; MESSENGER-RNA LEVELS; PHOSPHOLIPID EFFLUX; UP-REGULATION; CELLS; HDL; TRANSPORT; RECEPTOR; DISEASE	This study elucidates the factors underlying the enhancement in efflux of human fibroblast unesterified cholesterol and phospholipid (PL) by lipid-free apolipoprotein (apo) A-I that is induced by cholesterol enrichment of the cells. Doubling the unesterified cholesterol content of the plasma membrane by incubation for 24 h with low density lipoprotein and lipid/cholesterol dispersions increases the pools of PL and cholesterol available for removal by apoA-I from about 0.8-5%; the initial rates of mass release of cholesterol and PL are both increased about 6-fold. Expression of the ATP binding cassette transporter A1 (ABCA1) is critical for this increased efflux of lipids, and cholesterol loading of the fibroblasts over 24 h increases ABCA1 mRNA about 12-fold. The presence of more ABCA1 and cholesterol in the plasma membrane results in a 2-fold increase in the level of specific binding of apoA-I to the cells with no change in binding affinity. Characterization of the species released from either control or cholesterol-enriched cells indicates that the plasma membrane domains from which lipids are removed are cholesterol-enriched with respect to the average plasma membrane composition. Cholesterol enrichment of fibroblasts also affects PL synthesis, and this leads to enhanced release of phosphatidylcholine (PC) relative to sphingomyelin (SM); the ratios of PC to SM solubilized from control and cholesterol-enriched fibroblasts are similar to2/1 and 5/1, respectively. Biosynthesis of PC is critical for this preferential release of PC and the enhanced cholesterol efflux because inhibition of PC synthesis by choline depletion reduces cholesterol efflux from cholesterol-enriched cells. Overall, it is clear that enrichment of fibroblasts with unesterified cholesterol enhances efflux of cholesterol and PL to apoA-I because of three effects, 1) increased PC biosynthesis, 2) increased PC transport via ABCA1, and 3) increased cholesterol in the plas membrane.	Univ Penn, Sch Med, Abramson Res Ctr, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Med Coll Penn & Hahnemann Univ, Dept Biochem, Philadelphia, PA 19129 USA; Pfizer Inc, Div Cent Res, Groton, CT 06340 USA; Katholieke Univ Leuven, Ctr Expt Surg & Anesthesiol, B-3000 Louvain, Belgium	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Drexel University; Pfizer; KU Leuven	Phillips, MC (corresponding author), Univ Penn, Sch Med, Abramson Res Ctr, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.	phillipsmi@email.chop.edu	HOLVOET, PAUL/T-8434-2017	HOLVOET, PAUL/0000-0001-9201-0772; Phillips, Michael/0000-0002-7147-8007	NHLBI NIH HHS [HL22633, HL07443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; Arakawa R, 2000, J LIPID RES, V41, P1952; Barter PJ, 1996, ATHEROSCLEROSIS, V121, P1, DOI 10.1016/0021-9150(95)05675-0; Barter PJ, 1996, CURR OPIN LIPIDOL, V7, P82, DOI 10.1097/00041433-199604000-00006; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BELLINI F, 1984, BIOCHIM BIOPHYS ACTA, V777, P209, DOI 10.1016/0005-2736(84)90422-X; BIELICKI JK, 1992, J LIPID RES, V33, P1699; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Christian AE, 1997, J LIPID RES, V38, P2264; DAVIDSON WS, 1994, J BIOL CHEM, V269, P22975; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Gillotte KL, 1998, J LIPID RES, V39, P1918; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; Gillotte KL, 1996, J BIOL CHEM, V271, P23792, DOI 10.1074/jbc.271.39.23792; Ito J, 2000, J LIPID RES, V41, P894; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; JOHNSON WJ, 1988, J BIOL CHEM, V263, P14099; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; Kellner-Weibel G, 1998, ARTERIOSCL THROM VAS, V18, P423, DOI 10.1161/01.ATV.18.3.423; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Leppimaki P, 2000, EUR J BIOCHEM, V267, P6385, DOI 10.1046/j.1432-1327.2000.01726.x; Leppimaki P, 1998, BIOCHEM J, V335, P285, DOI 10.1042/bj3350285; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Mendez AJ, 1997, J LIPID RES, V38, P1807; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 1996, J LIPID RES, V37, P2473; Oram JF, 2001, J LIPID RES, V42, P1173; Phillips MC, 1998, ATHEROSCLEROSIS, V137, pS13, DOI 10.1016/S0021-9150(97)00312-2; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; Remaley AT, 1998, J LIPID RES, V39, P1231; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rothblat GH, 1999, J LIPID RES, V40, P781; Saito H, 1997, J LIPID RES, V38, P287; Sakr SW, 1999, BBA-MOL CELL BIOL L, V1438, P85, DOI 10.1016/S1388-1981(99)00041-4; Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006; SCOTT RE, 1979, J CELL SCI, V35, P229; SCOTT RE, 1979, J CELL SCI, V35, P245; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Van Bambeke F, 2000, BIOCHEM PHARMACOL, V60, P457, DOI 10.1016/S0006-2952(00)00291-4; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Yokoyama S, 1998, BBA-LIPID LIPID MET, V1392, P1, DOI 10.1016/S0005-2760(98)00032-0; Zhang WW, 1998, J LIPID RES, V39, P1601	55	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11811	11820		10.1074/jbc.M108268200	http://dx.doi.org/10.1074/jbc.M108268200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805090	hybrid			2022-12-27	WOS:000174846400028
J	Kuno, K; Baba, C; Asaka, A; Matsushima, C; Matsushima, K; Hosono, R				Kuno, K; Baba, C; Asaka, A; Matsushima, C; Matsushima, K; Hosono, R			The Caenorhabditis elegans ADAMTS family gene adt-1 is necessary for morphogenesis of the male copulatory organs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL SENSE-ORGANS; C-ELEGANS; METALLOPROTEASE-DISINTEGRIN; PATTERN-FORMATION; MALE TAIL; THROMBOSPONDIN-1 REPEATS; EXTRACELLULAR-MATRIX; RAY MORPHOGENESIS; GROWTH-FACTOR; N-PROTEINASE	Remodeling of the extracellular matrix (EM is pivotal for various biological processes, including organ morphology and development. The Caenorhabditis elegans male tail has male-specific copulatory organs, the rays and the fan. Ray morphogenesis, which involves a rapid remodeling of the ECM, is an important model of morphogenesis, although its mechanism is poorly understood. ADAMTS (a disintegrin-like and metalloproteinase with thrombospondin type I motifs) is a novel metalloproteinase family that is thought to be an important regulator for ECM remodeling during development and pathological states. We report here that a new C. elegans ADAMTS family gene, adt-1, plays an important regulatory role in ray morphogenesis. Inactivation of the adt-1 gene resulted in morphological changes in the rays as well as the appearance of abnormal protuberances around the rays. In addition, mating ability was remarkably impaired in adt-1 deletion mutant males. Furthermore, we found that the green fluorescent protein reporter driven by the adt-1 promoter was specifically expressed throughout the rays in the male tail. We hypothesize that ADT-1 controls the ray extension process via remodeling of the ECM in the cuticle.	Kanazawa Univ, Canc Res Inst, Dept Basic & Clin Oncol, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Fac Med, Dept Phys Informat, Kanazawa, Ishikawa 9200942, Japan; Univ Tokyo, Sch Med, Dept Mol Prevent Med, Bunkyo Ku, Tokyo 113, Japan	Kanazawa University; Kanazawa University; Kanazawa University; University of Tokyo	Kuno, K (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Basic & Clin Oncol, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	kkuno@kenroku.kanazawa-u.ac.jp	KUNO, Kouji/D-8439-2015					Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; BAIRD SE, 1990, GENETICS, V126, P335; BAIRD SE, 1991, DEVELOPMENT, V113, P515; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blelloch R, 1999, NATURE, V399, P586, DOI 10.1038/21196; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; BRENNER S, 1974, GENETICS, V77, P71; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cal S, 2001, J BIOL CHEM, V276, P17932, DOI 10.1074/jbc.M100534200; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; COSTA M, 1988, CELL, V55, P747, DOI 10.1016/0092-8674(88)90131-6; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FITCH DHA, 1995, DEV BIOL, V170, P564, DOI 10.1006/dbio.1995.1237; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HERMAN MA, 1995, CELL, V83, P101, DOI 10.1016/0092-8674(95)90238-4; HITE LA, 1994, ARCH BIOCHEM BIOPHYS, V308, P182, DOI 10.1006/abbi.1994.1026; HODGKIN J, 1979, GENETICS, V91, P67; HODGKIN J, 1983, GENETICS, V103, P43; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; KRAMER JM, 1997, C ELEGANS, V2, P471; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; Kuno K, 1997, GENOMICS, V46, P466, DOI 10.1006/geno.1997.5064; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Li SW, 2001, BIOCHEM J, V355, P271, DOI 10.1042/0264-6021:3550271; LIU KS, 1995, NEURON, V14, P79, DOI 10.1016/0896-6273(95)90242-2; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Morita K, 1999, DEVELOPMENT, V126, P1337; Nishiwaki K, 2000, SCIENCE, V288, P2205, DOI 10.1126/science.288.5474.2205; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Podbilewicz B, 1996, MOL BIOL CELL, V7, P1877, DOI 10.1091/mbc.7.12.1877; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Robker RL, 2000, P NATL ACAD SCI USA, V97, P4689, DOI 10.1073/pnas.080073497; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Salser SJ, 1996, DEVELOPMENT, V122, P1651; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; Tang BL, 1999, FEBS LETT, V445, P223, DOI 10.1016/S0014-5793(99)00119-2; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; WARING DA, 1990, CELL, V60, P123, DOI 10.1016/0092-8674(90)90722-Q; Wen CH, 1997, DEVELOPMENT, V124, P4759; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Woollard A, 2000, GENE DEV, V14, P596; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yamamoto S, 1999, IMMUNOL TODAY, V20, P278, DOI 10.1016/S0167-5699(99)01464-4; Yu RYL, 2000, EMBO J, V19, P3542, DOI 10.1093/emboj/19.14.3542; ZHANG YH, 1995, NATURE, V377, P55, DOI 10.1038/377055a0; ZHAO C, 1995, NATURE, V373, P74, DOI 10.1038/373074a0; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	58	13	16	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12228	12236		10.1074/jbc.M200144200	http://dx.doi.org/10.1074/jbc.M200144200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11796737	hybrid			2022-12-27	WOS:000174846400082
J	Maruoka, T; Nagasoe, Y; Inoue, S; Mori, Y; Goto, J; Ikeda, M; Iida, H				Maruoka, T; Nagasoe, Y; Inoue, S; Mori, Y; Goto, J; Ikeda, M; Iida, H			Essential hydrophilic carboxyl-terminal regions including cysteine residues of the yeast stretch-activated calcium-permeable channel Mid1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSELECTIVE CATION CHANNEL; PHEROMONE RESPONSE PATHWAY; SACCHAROMYCES-CEREVISIAE; ION CHANNELS; MECHANOSENSITIVE CHANNELS; CA2+ SIGNAL; GENE; PROTEIN; MEMBRANE; SUBUNIT	The yeast Saccharomyces cerevisiae MID1 gene en. codes a stretch-activated Ca2+-permeable nonselective cation channel composed of 548 amino acid residues. A physiological role of the Mid1 channel is known to maintain the viability of yeast cells exposed to mating pheromone, but its structural basis remains to be clarified. To solve this problem, we identified the mutation sites of mid1 mutant alleles generated by in vivo ethyl methanesulfonate mutagenesis and found that two mid1 alleles have nonsense mutations at the codon for Trp(441), generating a truncated Mid1 protein lacking two-thirds of the intracellular carboxyl-terminal region from Asn(389) to Thr(548). In vitro random mutagenesis with hydroxylamine also showed that the carboxyl-terminal region is essential. To identify the functional portion of the carboxyl-terminal region in detail, we performed a progressive carboxyl-terminal truncation followed by functional analyses and found that the truncated protein produced from the mid1 allele bearing the amber mutation at the codon for Phe(522) (F522Am) complemented the mating pheromone-induced death phenotype of the mid1 mutant and increased its Ca2+ uptake activity to a wild-type level, whereas N521Am did not. This result indicates that the carboxyl-terminal domain spanning from Asn(389) to Asn(521) is required for Mid1 function. Interestingly, this domain is cysteine-rich, and alanine-scanning mutagenesis revealed that seven out of 10 cysteine residues are unexchangeable. These results clearly indicate that the carboxyl-terminal domain including the cysteine residues is important for Mid1 function.	Tokyo Gakugei Univ, Dept Biol, Koganei, Tokyo 1848501, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Tokyo Gakugei University; Japan Science & Technology Agency (JST)	Iida, H (corresponding author), Tokyo Gakugei Univ, Dept Biol, 4-1-1 Nukui Kita Machi, Koganei, Tokyo 1848501, Japan.	iida@u-gakugei.ac.jp	Iida, Hidetoshi/AAO-5506-2020	Goto, June/0000-0002-4000-9750				Adams A., 1996, METHODS YEAST GENETI; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Blanchard H, 1997, NAT STRUCT BIOL, V4, P532, DOI 10.1038/nsb0797-532; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Carlson BX, 2000, MOL PHARMACOL, V57, P474, DOI 10.1124/mol.57.3.474; Carnero E, 2000, MOL GEN GENET, V264, P173, DOI 10.1007/s004380000318; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; Fischer M, 1997, FEBS LETT, V419, P259, DOI 10.1016/S0014-5793(97)01466-X; FRENCH AS, 1992, ANNU REV PHYSIOL, V54, P135, DOI 10.1146/annurev.physiol.54.1.135; GarciaAnoveros J, 1997, ANNU REV NEUROSCI, V20, P567, DOI 10.1146/annurev.neuro.20.1.567; Ghazi A, 1998, BIOCHIMIE, V80, P357; HOLM C, 1986, GENE, V42, P169, DOI 10.1016/0378-1119(86)90293-3; Hong K, 2000, J NEUROSCI, V20, P2575; IIDA H, 1990, J BIOL CHEM, V265, P13391; IIDA H, 1985, NATURE, V315, P688, DOI 10.1038/315688a0; IIDA H, 1994, MOL CELL BIOL, V14, P8259, DOI 10.1128/MCB.14.12.8259; James P, 1996, GENETICS, V144, P1425; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; Kanzaki M, 1999, SCIENCE, V285, P882, DOI 10.1126/science.285.5429.882; Kanzaki M, 2000, SCIENCE, V288, P1347, DOI 10.1126/science.288.5470.1347; KUBE E, 1992, J BIOL CHEM, V267, P14175; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lin GD, 1997, NAT STRUCT BIOL, V4, P539, DOI 10.1038/nsb0797-539; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Moser NJ, 1996, MOL CELL BIOL, V16, P4824; Nakajima-Shimada J, 2000, CELL STRUCT FUNCT, V25, P125, DOI 10.1247/csf.25.125; Paidhungat M, 1997, MOL CELL BIOL, V17, P6339, DOI 10.1128/MCB.17.11.6339; Pierce J. S., 1970, Journal of the Institute of Brewing, V76, P442; Rose A H, 1975, Methods Cell Biol, V12, P1; ROSE MD, 1991, METHOD ENZYMOL, V194, P195; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SACKIN H, 1995, ANNU REV PHYSIOL, V57, P333, DOI 10.1146/annurev.ph.57.030195.002001; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; Tasaka Y, 2000, BIOCHEM BIOPH RES CO, V269, P265, DOI 10.1006/bbrc.2000.2278; Walker RG, 2000, SCIENCE, V287, P2229, DOI 10.1126/science.287.5461.2229; Withee JL, 1997, MOL BIOL CELL, V8, P263, DOI 10.1091/mbc.8.2.263; YAO XQ, 1995, P NATL ACAD SCI USA, V92, P11711, DOI 10.1073/pnas.92.25.11711; Yao YQ, 1996, J BIOL CHEM, V271, P32881, DOI 10.1074/jbc.271.51.32881	46	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11645	11652		10.1074/jbc.M111603200	http://dx.doi.org/10.1074/jbc.M111603200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11796727	hybrid			2022-12-27	WOS:000174846400006
J	Yi, JZ; Cheng, H; Andrake, MD; Dunbrack, RL; Roder, H; Skalka, AM				Yi, JZ; Cheng, H; Andrake, MD; Dunbrack, RL; Roder, H; Skalka, AM			Mapping the epitope of an inhibitory monoclonal antibody to the C-terminal DNA-binding domain of HIV-1 integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 INTEGRASE; ACTIVE-SITE; DIVALENT-CATIONS; CATALYTIC DOMAIN; IN-VITRO; PROTEIN; CORE; ZINC; MULTIMERIZATION; IDENTIFICATION	Integrase (IN) catalyzes the insertion of retroviral DNA into chromosomal DNA of a host cell and is one of three virus-encoded enzymes that are required for replication. A library of monoclonal antibodies against human immunodeficiency virus type 1 (HIV-1) IN was raised and characterized in our laboratory. Among them, monoclonal antibody (mAb) 33 and mAb32 compete for binding to the C-terminal domain of the HIV-1 IN protein. Here, we show that mAb33 is a strong inhibitor of IN catalytic activity, whereas mAb32 is only weakly inhibitory. Furthermore, as the Fab fragment of mAb32 had no effect on IN activity, inhibition by this mAb may result solely from its bivalency. In contrast, Fab33 did inhibit IN catalytic activity, although bivalent binding by mAb33 may enhance the inhibition. Interaction with Fab33 also prevented DNA binding to the isolated C-terminal domain of IN. Results from size-exclusion chromatography, gel electrophoresis, and matrixassisted laser desorption ionization time-of-flight mass spectrometric analyses revealed that multiple Fab33-IN C-terminal domain complexes exist in solution. Studies using heteronuclear NAIR showed a steep decrease in H-1-N-15 cross-peak intensity for 8 residues in the isolated C-terminal domain upon binding of Fab33, indicating that these residues become immobilized in the complex. Among them, Ala(239) and Ile(251) are buried in the interior of the domain, whereas the remaining residues Phe(213), Arg(224), Tyr(226), Lys(244), Ile(267), and Ile(268)) form a contiguous, solvent-accessible patch on the surface of the protein likely including the epitope of Fab33. Molecular modeling of Fab33 followed by computer-assisted docking with the IN C-terminal domain suggested a structure for the antibody-antigen complex that is consistent with our experimental data and suggested a potential target for anti-AIDS drug design.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Roder, H (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		Roder, Heinrich/B-3455-2009; Dunbrack, Roland/ABG-7141-2020	Roder, Heinrich/0000-0003-1860-2491; Dunbrack, Roland/0000-0001-7674-6667	NATIONAL CANCER INSTITUTE [R01CA071515, P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040385] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927, CA71515] Funding Source: Medline; NIAID NIH HHS [AI40385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633; Asante-Appiah E, 1998, J BIOL CHEM, V273, P35078, DOI 10.1074/jbc.273.52.35078; AsanteAppiah E, 1997, J BIOL CHEM, V272, P16196, DOI 10.1074/jbc.272.26.16196; BIZUBBENDER D, 1994, AIDS RES HUM RETROV, V10, P1105, DOI 10.1089/aid.1994.10.1105; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Bujacz G, 1997, J BIOL CHEM, V272, P18161, DOI 10.1074/jbc.272.29.18161; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567; CHEETHAM JC, 1991, P NATL ACAD SCI USA, V88, P7968, DOI 10.1073/pnas.88.18.7968; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Eijkelenboom APAM, 1997, CURR BIOL, V7, P739, DOI 10.1016/S0960-9822(06)00332-0; Eijkelenboom APAM, 1999, PROTEINS, V36, P556, DOI 10.1002/(SICI)1097-0134(19990901)36:4<556::AID-PROT18>3.0.CO;2-6; EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; Gao K, 2001, EMBO J, V20, P3565, DOI 10.1093/emboj/20.13.3565; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; Heuer TS, 1998, BIOCHEMISTRY-US, V37, P6667, DOI 10.1021/bi972949c; Hindmarsh P, 1999, MICROBIOL MOL BIOL R, V63, P836, DOI 10.1128/MMBR.63.4.836-843.1999; Huang XL, 1998, J MOL BIOL, V281, P61, DOI 10.1006/jmbi.1998.1930; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee SP, 1996, BIOCHEMISTRY-US, V35, P3837, DOI 10.1021/bi952056p; Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o; LevyMintz P, 1996, J VIROL, V70, P8821, DOI 10.1128/JVI.70.12.8821-8832.1996; LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; PURASLUTZKE RA, 1998, J VIROL, V72, P4841; PURASLUTZKE RA, 1994, NUCLEIC ACIDS RES, V22, P4125; Ritchie DW, 2000, PROTEINS, V39, P178, DOI 10.1002/(SICI)1097-0134(20000501)39:2<178::AID-PROT8>3.3.CO;2-Y; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; Visintin M, 1999, P NATL ACAD SCI USA, V96, P11723, DOI 10.1073/pnas.96.21.11723; WOERNER AM, 1992, AIDS RES HUM RETROV, V8, P297, DOI 10.1089/aid.1992.8.297; Yi JZ, 1999, BIOCHEMISTRY-US, V38, P8458, DOI 10.1021/bi982870n; Yi JZ, 2000, BIOPOLYMERS, V55, P308; Yi JZ, 2000, J BIOL CHEM, V275, P38739, DOI 10.1074/jbc.M005499200; Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659	39	23	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12164	12174		10.1074/jbc.M105072200	http://dx.doi.org/10.1074/jbc.M105072200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805085	hybrid			2022-12-27	WOS:000174846400074
J	Morillas, M; Gomez-Puertas, P; Rubi, B; Clotet, J; Arino, J; Valencia, A; Hegardt, FG; Serra, D; Asins, G				Morillas, M; Gomez-Puertas, P; Rubi, B; Clotet, J; Arino, J; Valencia, A; Hegardt, FG; Serra, D; Asins, G			Structural model of a malonyl-CoA-binding site of carnitine octanoyltransferase and carnitine palmitoyltransferase I - Mutational analysis of a malonyl-CoA affinity domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; RAT-LIVER MITOCHONDRIA; 2 HISTIDINE-RESIDUES; PALMITOYL-COA; ACYLTRANSFERASE ACTIVITIES; INSULIN-SECRETION; CHIMERIC PROTEINS; SWISS-MODEL; ACETYL-COA; INHIBITION	Carnitine octanoyltransferase (COT) and carnitine palmitoyltransferase (CPT) I, which facilitate the trans. port of medium- and long-chain fatty acids through the peroxisomal and mitochondrial membranes, are physiologically inhibited by malonyl-CoA. Using an "in silico" macromolecular docking approach, we built a model in which malonyl-CoA could be attached near the catalytic core. This disrupts the positioning of the acyl-CoA substrate in the channel in the model reported for both proteins (Morillas, M., Gomez-Puertas, P., Roca, R., Serra, D., Asins, G., Valencia, A., and Hegardt, F. G. (2001) J. Biol. Chem. 276, 45001-45008). The putative malonyl-CoA domain contained His(340), implicated together with His(131) in COT malonyl-CoA sensitivity (Morillas, M., Clotet, J., Rubi, B., Serra, D., Asins, G., Arino, J., and Hegardt F. G. (2000) FEBS Lett. 466, 183186). When we mutated COT His 131 the IC50 increased, and malonyl-CoA competed with the substrate decanoyl-CoA. Mutation of COT Ala(332), present in the domain 8 amino acids away from His(340), decreased the malonyl-CoA sensitivity of COT. The homologous histidine and alanine residues of L-CPT 1, His(277), His(483), and Ala(478) were also mutated, which decreased malonyl-CoA sensitivity. Natural mutation of Pro(479), which is also located in the malonyl-CoA predicted site, to Leu in a patient with human L-CPT I hereditary deficiency, modified malonyl-CoA sensitivity. We conclude that this malonyl-CoA domain is present in both COT and L-CPT I proteins and might be the site at which malonyl-CoA interacts with the substrate acyl-CoA. Other malonyl-CoA non-inhibitable members of the family, CPT II and carnitine acetyltransferase, do not contain this domain.	Univ Barcelona, Sch Pharm, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; CSIC, Prot Design Grp, Natl Biotechnol Ctr, E-28049 Madrid, Spain; Univ Int Catalunya, Dept Biochem & Mol Biol, Sant Cugat 08190, Spain; Univ Autonoma Barcelona, Sch Vet Med, Dept Biochem & Mol Biol, E-08193 Barcelona, Spain	University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Internacional de Catalunya (UIC); Autonomous University of Barcelona	Hegardt, FG (corresponding author), Univ Barcelona, Sch Pharm, Dept Biochem & Mol Biol, Diagonal 643, E-08028 Barcelona, Spain.		Valencia, Alfonso/I-3127-2015; Arino, Joaquin/D-3756-2011; Gomez-Puertas, Paulino/G-8821-2014; Serra, Dolors/L-3657-2014; Morillas, Montserrat/G-6080-2015	Valencia, Alfonso/0000-0002-8937-6789; Arino, Joaquin/0000-0002-6774-2987; Gomez-Puertas, Paulino/0000-0003-3131-729X; Serra, Dolors/0000-0002-4936-4206; Arino Carmona, Joaquin/0000-0002-0390-4270; Morillas, Montserrat/0000-0001-7068-3167				ABHAIRD NN, 1992, BIOCHEM J, V286, P637, DOI 10.1042/bj2860637; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Anderson RC, 1998, CURR PHARM DESIGN, V4, P1; BIRD MI, 1985, BIOCHEM J, V226, P323, DOI 10.1042/bj2260323; BIRD MI, 1984, BIOCHEM J, V222, P639, DOI 10.1042/bj2220639; Bitar MS, 2001, HORM METAB RES, V33, P577, DOI 10.1055/s-2001-17903; BREMER J, 1985, BIOCHIM BIOPHYS ACTA, V833, P9, DOI 10.1016/0005-2760(85)90247-4; Brown NF, 2001, J LIPID RES, V42, P1134; CASARI G, 1995, NAT STRUCT BIOL, V2, P171, DOI 10.1038/nsb0295-171; COOK GA, 1984, J BIOL CHEM, V259, P2030; COOK GA, 1994, J BIOL CHEM, V269, P8803; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; CORR PB, 1995, HERZ, V20, P156; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530, DOI 10.1093/nar/23.21.4530; DERRICK JP, 1989, BIOCHEM J, V262, P801, DOI 10.1042/bj2620801; Fraser F, 2001, J BIOL CHEM, V276, P20182, DOI 10.1074/jbc.M101078200; Giannessi F, 2001, J MED CHEM, V44, P2383, DOI 10.1021/jm010889+; GRANTHAM BD, 1986, BIOCHEM J, V233, P589, DOI 10.1042/bj2330589; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hamdan M, 2001, PHARMACOL RES, V44, P99, DOI 10.1006/phrs.2001.0829; Holm L, 1996, NUCLEIC ACIDS RES, V24, P206, DOI 10.1093/nar/24.1.206; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Jackson VN, 2000, J BIOL CHEM, V275, P38410, DOI 10.1074/jbc.M007722200; Jackson VN, 2000, J BIOL CHEM, V275, P19560, DOI 10.1074/jbc.M002177200; Jackson VN, 2001, BIOCHEMISTRY-US, V40, P14629, DOI 10.1021/bi011632g; JONES DT, 1995, PROTEINS, V23, P387, DOI 10.1002/prot.340230312; Jones DT, 1999, PROTEINS, P104; KASHFI K, 1994, BBA-LIPID LIPID MET, V1212, P245, DOI 10.1016/0005-2760(94)90259-3; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MILLS SE, 1984, BIOCHEM J, V219, P601, DOI 10.1042/bj2190601; Morillas M, 2000, BIOCHEM J, V351, P495, DOI 10.1042/0264-6021:3510495; Morillas M, 2000, FEBS LETT, V466, P183, DOI 10.1016/S0014-5793(99)01788-3; Morillas M, 2001, J BIOL CHEM, V276, P45001, DOI 10.1074/jbc.M106920200; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; Pazos F., 1997, BIOCOMPUTING EMERGEN, P132; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Ritchie DW, 2000, PROTEINS, V39, P178, DOI 10.1002/(SICI)1097-0134(20000501)39:2<178::AID-PROT8>3.3.CO;2-Y; Rost B, 1996, METHOD ENZYMOL, V266, P525; SADDIK M, 1993, J BIOL CHEM, V268, P25836; SAGGERSON ED, 1982, BIOCHEM J, V202, P397, DOI 10.1042/bj2020397; SAGGERSON ED, 1981, FEBS LETT, V132, P166, DOI 10.1016/0014-5793(81)81152-0; Shi JY, 2000, BIOCHEMISTRY-US, V39, P712, DOI 10.1021/bi9918700; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Shi JY, 1999, J BIOL CHEM, V274, P9421, DOI 10.1074/jbc.274.14.9421; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; STEPHENS TW, 1983, BIOCHEM J, V212, P521, DOI 10.1042/bj2120521; Swanson ST, 1998, BIOCHEM J, V335, P513, DOI 10.1042/bj3350513; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; ZAMMIT VA, 1984, BIOCHEM J, V222, P335, DOI 10.1042/bj2220335; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505; ZIERZ S, 1987, BIOCHEM J, V245, P205, DOI 10.1042/bj2450205	64	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11473	11480		10.1074/jbc.M111628200	http://dx.doi.org/10.1074/jbc.M111628200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11790793	hybrid			2022-12-27	WOS:000174613100092
J	Bourret, RB; Stock, AM				Bourret, RB; Stock, AM			Molecular information processing: Lessons from bacterial chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PHOSPHORYLATION-DEPENDENT BINDING; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; FLAGELLAR SWITCH; PROTEIN; RECEPTOR; CHEW; MECHANISM; LOCALIZATION; PHOSPHATASE		Howard Hughes Med Inst, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of North Carolina; University of North Carolina Chapel Hill	Stock, AM (corresponding author), Howard Hughes Med Inst, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA.	stock@cabm.rutgers.edu	Bourret, Robert/X-3606-2019	Bourret, Robert/0000-0002-6666-9220; Stock, Ann/0000-0002-0446-8079	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047958, R37GM047958] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50860, GM47958, R01 GM050860] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aizawa S-I, 2002, BACILLUS SUBTILIS IT, P437; ALLEY MRK, 1992, GENE DEV, V6, P825, DOI 10.1101/gad.6.5.825; Alon U, 1999, NATURE, V397, P168, DOI 10.1038/16483; BLAT Y, 1994, BIOCHEMISTRY-US, V33, P902, DOI 10.1021/bi00170a008; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; Bren A, 2000, J BACTERIOL, V182, P6865, DOI 10.1128/JB.182.24.6865-6873.2000; Cluzel P, 2000, SCIENCE, V287, P1652, DOI 10.1126/science.287.5458.1652; Duke TAJ, 1999, P NATL ACAD SCI USA, V96, P10104, DOI 10.1073/pnas.96.18.10104; Duke TAJ, 2001, J MOL BIOL, V308, P541, DOI 10.1006/jmbi.2001.4610; Falke JJ, 2001, TRENDS BIOCHEM SCI, V26, P257, DOI 10.1016/S0968-0004(00)01770-9; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; Georgellis D, 1998, J BIOL CHEM, V273, P32864, DOI 10.1074/jbc.273.49.32864; Gestwicki JE, 2000, J BACTERIOL, V182, P6499, DOI 10.1128/JB.182.22.6499-6502.2000; GOULBOURNE EA, 1983, J BACTERIOL, V153, P916, DOI 10.1128/JB.153.2.916-920.1983; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; Kim C, 2001, J MOL BIOL, V307, P119, DOI 10.1006/jmbi.2000.4389; Kirby JR, 2000, MOL MICROBIOL, V35, P44, DOI 10.1046/j.1365-2958.2000.01676.x; Kirby JR, 2001, MOL MICROBIOL, V42, P573, DOI 10.1046/j.1365-2958.2001.02581.x; Li GY, 2000, CELL, V100, P357, DOI 10.1016/S0092-8674(00)80671-6; Li JY, 1997, BIOCHEMISTRY-US, V36, P11851, DOI 10.1021/bi971510h; LI JY, 1995, BIOCHEMISTRY-US, V34, P14626, DOI 10.1021/bi00045a003; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; LUPAS A, 1989, J BIOL CHEM, V264, P17337; Lux R, 1999, MOL BIOL CELL, V10, P1133, DOI 10.1091/mbc.10.4.1133; Maki N, 2000, J BACTERIOL, V182, P4337, DOI 10.1128/JB.182.15.4337-4342.2000; Perego M, 1998, TRENDS MICROBIOL, V6, P366, DOI 10.1016/S0966-842X(98)01350-X; Robinson VL, 2000, NAT STRUCT BIOL, V7, P626, DOI 10.1038/77915; Rosario MML, 1996, MOL MICROBIOL, V21, P511, DOI 10.1111/j.1365-2958.1996.tb02560.x; ROSARIO MML, 1994, J BACTERIOL, V176, P2736, DOI 10.1128/JB.176.9.2736-2739.1994; Schuster M, 2001, P NATL ACAD SCI USA, V98, P6003, DOI 10.1073/pnas.101571298; Sourjik V, 1998, BIOCHEMISTRY-US, V37, P2327, DOI 10.1021/bi972330a; Sourjik V, 2000, MOL MICROBIOL, V37, P740, DOI 10.1046/j.1365-2958.2000.02044.x; SPUDICH JL, 1976, NATURE, V262, P467, DOI 10.1038/262467a0; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Thomas DR, 1999, P NATL ACAD SCI USA, V96, P10134, DOI 10.1073/pnas.96.18.10134; TSANG N, 1973, SCIENCE, V181, P60, DOI 10.1126/science.181.4094.60; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; Wu JG, 1996, BIOCHEMISTRY-US, V35, P4984, DOI 10.1021/bi9530189; Yi TM, 2000, P NATL ACAD SCI USA, V97, P4649, DOI 10.1073/pnas.97.9.4649; Zhang WS, 1996, P NATL ACAD SCI USA, V93, P4649, DOI 10.1073/pnas.93.10.4649	44	178	183	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9625	9628		10.1074/jbc.R100066200	http://dx.doi.org/10.1074/jbc.R100066200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11779877	hybrid, Green Published			2022-12-27	WOS:000174549200002
J	Doronin, S; Wang, HY; Malbon, CC				Doronin, S; Wang, HY; Malbon, CC			Insulin stimulates phosphorylation of the beta 2-adrenergic receptor by the insulin receptor, creating a potent feedback inhibitor of its tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PROTEIN-LINKED RECEPTORS; CROSS-TALK; IN-VIVO; EXPRESSION; SUBSTRATE	Insulin counterregulates catecholamine action at several levels, primarily in liver, fat, and adipose tissue. Herein we observe that expression of increased levels of beta(2)-adrenergic receptor increasingly inhibits insulin-stimulated phosphorylation of its primary downstream substrates (IRS-1,2). In Chinese hamster ovary cells, the insulin receptor phosphorylates dominantly Tyr(364) in the C-terminal cytoplasmic domain of the beta-receptor. A Y364A mutant form of the beta(2)-adrenergic, in contrast, loses it ability to inhibit insulin-stimulated phosphorylation of IRS-1,2. Upon phosphorylation, the C-terminal cytoplasmic domain of the beta(2)-adrenergic receptor demonstrates a potent inhibitory feedback action that can block both insulin-stimuIated autophosphorylation of the insulin receptor and phosphorylation of IRS-1,2 in NIH mouse 3T3-L1 adipocyte membranes. Studies in vitro with purified insulin receptor and the C-terminal cytoplasmic domain of the beta(2)-adrenergic receptor demonstrate that the tyrosine-phosphorylated beta-receptor domain is a potent counterregulatory inhibitor of the insulin receptor tyrosine kinase.	SUNY Stony Brook, Hlth Sci Ctr, Dept Pharmacol, Diabet & Metab Dis Res Program, Stony Brook, NY 11794 USA; SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol, Diabet & Metab Dis Res Program, Stony Brook, NY 11794 USA; SUNY Stony Brook, Hlth Sci Ctr, Dept Biophys, Diabet & Metab Dis Res Program, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Malbon, CC (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Pharmacol, Diabet & Metab Dis Res Program, Stony Brook, NY 11794 USA.		malbon, craig/ABF-3604-2020		PHS HHS [T32] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baltensperger K, 1996, J BIOL CHEM, V271, P1061, DOI 10.1074/jbc.271.2.1061; Doronin S, 2000, PROTEIN EXPRES PURIF, V20, P451, DOI 10.1006/prep.2000.1322; GUEST SJ, 1990, J BIOL CHEM, V265, P5370; HADCOCK JR, 1992, J BIOL CHEM, V267, P26017; Karoor V, 1998, Adv Pharmacol, V42, P425; KAROOR V, 1995, J BIOL CHEM, V270, P25305, DOI 10.1074/jbc.270.43.25305; Karoor V, 1996, J BIOL CHEM, V271, P29347, DOI 10.1074/jbc.271.46.29347; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wang HY, 2000, J BIOL CHEM, V275, P36086, DOI 10.1074/jbc.M004404200; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; WHITE MF, 1994, J BIOL CHEM, V269, P1	12	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10698	10703		10.1074/jbc.M109432200	http://dx.doi.org/10.1074/jbc.M109432200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11782469	hybrid			2022-12-27	WOS:000174549200144
J	Eaton, P; Byers, HL; Leeds, N; Ward, MA; Shattock, MJ				Eaton, P; Byers, HL; Leeds, N; Ward, MA; Shattock, MJ			Detection, quantitation, purification, and identification of cardiac proteins S-thiolated during ischemia and reperfusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ PUMP CURRENT; CREATINE-KINASE; RAT-HEART; OXIDATIVE STRESS; OXIDANT STRESS; GLUTATHIOLATION; INHIBITION; SUBUNIT; RELEASE; PLAYER	We have developed methods that allow detection, quantitation, purification, and identification of cardiac proteins S-thiolated during ischemia and reperfusion. Cysteine was biotinylated and loaded into isolated rat hearts. During oxidative stress, biotin-cysteine forms a disulfide bond with reactive protein cysteines, and these can be detected by probing Western blots with streptavidin-horseradish peroxidase. S-Thiolated proteins were purified using streptavidin-agarose. Thus, we demonstrated that reperfusion and diamide treatment increased S-thiolation of a number of cardiac proteins by 3- and 10-fold, respectively. Dithiothreitol treatment of homogenates fully abolished the signals detected. Fractionation studies indicated that the modified proteins are located within the cytosol, membrane, and myofilament/cytoskeletal compartments of the cardiac cells. This shows that biotin-cysteine gains rapid and efficient intracellular access and acts as a probe for reactive protein cysteines in all cellular locations. Using Western blotting of affinity-purified proteins we identified actin, glyceraldehyde-3-phosphate dehydrogenase, HSP27, protein-tyrosine phosphatase 1B, protein kinase Calpha, and the small G-protein ras as substrates for S-thiolation during reperfusion of the ischemic rat heart. MALDI-TOF mass fingerprint analysis of tryptic peptides independently confirmed actin and glyceraldehyde-3-phosphate dehydrogenase S-thiolation during reperfusion. This approach has also shown that triosephosphate isomerase, aconitate hydratase, M-protein, nucleoside diphosphate kinase B, and myoglobin are S-thiolated during post-ischemic reperfusion.	Kings Coll London, St Thomas Hosp, Rayne Inst, Ctr Cardiovasc Biol & Med, London SE1 7EH, England; Kings Coll London, Inst Psychiat, S Wing Lab, Proteome Sci Plc, London SE5 8AF, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London	Eaton, P (corresponding author), Kings Coll London, St Thomas Hosp, Rayne Inst, Ctr Cardiovasc Biol & Med, London SE1 7EH, England.	philip.eaton@kcl.ac.uk	; Eaton, Philip/I-5444-2015	Ward, Malcolm/0000-0003-2164-6938; Eaton, Philip/0000-0003-0748-2367; Shattock, Michael/0000-0001-6242-7585				Bonini MG, 2001, J BIOL CHEM, V276, P9749, DOI 10.1074/jbc.M008456200; Brooks G, 1996, CIRC RES, V79, P627; Ceconi C, 2000, CARDIOVASC RES, V47, P586, DOI 10.1016/S0008-6363(00)00104-8; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; Cheung PY, 1998, ARCH BIOCHEM BIOPHYS, V350, P104, DOI 10.1006/abbi.1997.0496; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Cohen MV, 2001, CIRC RES, V89, P273, DOI 10.1161/hh1501.094266; COLLISON MW, 1987, BIOCHIM BIOPHYS ACTA, V928, P121, DOI 10.1016/0167-4889(87)90112-1; DUDICH IV, 1995, BBA-PROTEIN STRUCT M, V1253, P163, DOI 10.1016/0167-4838(95)00135-X; Eaton P, 1998, CIRCULATION, V98, P805; Eaton P, 1997, CIRCULATION, V96, P3380; Eaton P, 2001, CIRCULATION, V104, P61; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; GARLICK PB, 1987, CIRC RES, V61, P757, DOI 10.1161/01.RES.61.5.757; GILBERT HF, 2001, ADV ENZYMOL RELAT AR, V63, P69; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; Guertl B, 2000, INT J EXP PATHOL, V81, P349, DOI 10.1046/j.1365-2613.2000.00186.x; HADDOCK PS, 1995, AM J PHYSIOL-HEART C, V269, pH297, DOI 10.1152/ajpheart.1995.269.1.H297; Hallk HM, 1998, CIRCULATION, V98, P220; HEARSE DJ, 1991, CARDIOVASC DRUG THER, V5, P853, DOI 10.1007/BF00053547; Ji YB, 1999, ARCH BIOCHEM BIOPHYS, V362, P67, DOI 10.1006/abbi.1998.1013; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Li JF, 2001, J BIOL CHEM, V276, P3098, DOI 10.1074/jbc.M008260200; Li QY, 2001, J NEUROCHEM, V78, P746, DOI 10.1046/j.1471-4159.2001.00457.x; Liu W, 1999, J CELL SCI, V112, P2409; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; Mallis RJ, 2001, BIOCHEM J, V355, P145, DOI 10.1042/bj3550145; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; MILLER RM, 1990, ARCH BIOCHEM BIOPHYS, V276, P355, DOI 10.1016/0003-9861(90)90732-E; Mohr S, 1996, J BIOL CHEM, V271, P4209; Pullar JM, 1999, AM J PHYSIOL-HEART C, V277, pH1505, DOI 10.1152/ajpheart.1999.277.4.H1505; Pullar JM, 2001, J BIOL CHEM, V276, P22120, DOI 10.1074/jbc.M102088200; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; Reddy S, 1998, FREE RADICAL BIO MED, V25, pS78; SHATTOCK MJ, 1993, CIRC RES, V72, P91, DOI 10.1161/01.RES.72.1.91; Souza JM, 1998, ARCH BIOCHEM BIOPHYS, V360, P187, DOI 10.1006/abbi.1998.0932; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; TAEGTMEYER H, 1997, AM J CARDIOL, pA3; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; Wang HM, 2001, BIOCHEMISTRY-US, V40, P3316, DOI 10.1021/bi002786j; Ward NE, 1998, J BIOL CHEM, V273, P12558, DOI 10.1074/jbc.273.20.12558; Yue Y, 2001, AM J PHYSIOL-HEART C, V281, pH590, DOI 10.1152/ajpheart.2001.281.2.H590; Zavialov A, 1998, INT J BIOL MACROMOL, V22, P163, DOI 10.1016/S0141-8130(98)00014-2; Zucchi R, 1998, CIRC RES, V83, P908	46	151	156	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9806	9811		10.1074/jbc.M111454200	http://dx.doi.org/10.1074/jbc.M111454200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11777920	hybrid			2022-12-27	WOS:000174549200029
J	Hasler, U; Mordasini, D; Bens, M; Bianchi, M; Cluzeaud, F; Rousselot, M; Vandewalle, A; Feraille, E; Martin, PY				Hasler, U; Mordasini, D; Bens, M; Bianchi, M; Cluzeaud, F; Rousselot, M; Vandewalle, A; Feraille, E; Martin, PY			Long term regulation of aquaporin-2 expression in vasopressin-responsive renal collecting duct principal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER CHANNEL EXPRESSION; EPITHELIAL SODIUM-CHANNEL; ADENYLATE CYCLASE; HEART-FAILURE; UP-REGULATION; DEGRADATION; UBIQUITIN; RECEPTOR; LOCALIZATION; ENAC	Fine regulation of water reabsorption by the antidiuretic hormone [8-arginine]vasopressin (AVP) occurs in principal cells of the collecting duct and is largely dependent on regulation of the aquaporin-2 (AQP2) water channel. AVP-inducible long term AQP2 expression was investigated in immortalized mouse cortical collecting duct principal cells. Combined RNase protection assay, Western blot, and immunofluorescence analyses revealed that physiological concentrations of AVP added to the basal side, but not to the apical side, of cells grown on filters induced both AQP2 mRNA and apical protein expression. The stimulatory effect of AVP on AQP2 expression followed a V-2 receptor-dependent pathway because [deamino-8-D-arginine]vasopressin (dDAVP), a specific V2 receptor agonist, produced the same effect as AVP, whereas the V2 antagonist SR121463B antagonized action of both AVP and dDAVP. Moreover, forskolin and cyclic 8-bromo-AMP fully reproduced the effects of AVP on AQP2 expression. Analysis of protein degradation pathways showed that inhibition of proteasomal activity prevented synthesis of AVP-inducible AQP2 mRNA and protein. Once synthesized, AQP2 protein was quickly degraded, a process that involves both the proteasomal and lysosomal pathways. This is the first study that delineates induction and degradation mechanisms of AQP2 endogenously expressed by a renal collecting duct principal cell line.	Univ Paris 07, INSERM, U478, Inst Federat Rech 02, F-75870 Paris 18, France; Fondat Rech Med, Div Nephrol, CH-1211 Geneva 4, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Geneva	Vandewalle, A (corresponding author), Univ Paris 07, INSERM, U478, Inst Federat Rech 02, BP416, F-75870 Paris 18, France.	vandewal@bichat.inserm.fr		Feraille, Eric/0000-0003-1656-8365				Bens M, 1999, J AM SOC NEPHROL, V10, P923; Chabardes D, 1996, J BIOL CHEM, V271, P19264, DOI 10.1074/jbc.271.32.19264; Chou CL, 1999, J CLIN INVEST, V103, P491, DOI 10.1172/JCI5704; DEEN PMT, 1995, J CLIN INVEST, V95, P2291, DOI 10.1172/JCI117920; DIGIOVANNI SR, 1994, P NATL ACAD SCI USA, V91, P8984, DOI 10.1073/pnas.91.19.8984; Ecelbarger CA, 2000, AM J PHYSIOL-RENAL, V279, pF46, DOI 10.1152/ajprenal.2000.279.1.F46; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fujita N, 1995, AM J PHYSIOL-RENAL, V269, pF926, DOI 10.1152/ajprenal.1995.269.6.F926; FUJIWARA TM, 1995, ANNU REV MED, V46, P331; Furuno M, 1996, AM J PHYSIOL-RENAL, V271, pF854, DOI 10.1152/ajprenal.1996.271.4.F854; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; Gonin S, 2001, MOL BIOL CELL, V12, P255, DOI 10.1091/mbc.12.2.255; Hager H, 2001, AM J PHYSIOL-RENAL, V280, pF1093, DOI 10.1152/ajprenal.2001.280.6.F1093; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hozawa S, 1996, AM J PHYSIOL-CELL PH, V270, pC1695, DOI 10.1152/ajpcell.1996.270.6.C1695; IMBERT M, 1975, PFLUG ARCH EUR J PHY, V357, P173, DOI 10.1007/BF00585973; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Katsura T, 1996, AM J PHYSIOL-RENAL, V270, pF548, DOI 10.1152/ajprenal.1996.270.3.F548; Kishore BK, 1996, J CLIN INVEST, V97, P2763, DOI 10.1172/JCI118731; Knepper MA, 1997, AM J PHYSIOL-RENAL, V272, pF3, DOI 10.1152/ajprenal.1997.272.1.F3; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Leitch V, 2001, P NATL ACAD SCI USA, V98, P2894, DOI 10.1073/pnas.041616498; Loffing J, 2000, AM J PHYSIOL-RENAL, V278, pF530, DOI 10.1152/ajprenal.2000.278.4.F530; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200; Maric K, 1998, AM J PHYSIOL-RENAL, V275, pF796, DOI 10.1152/ajprenal.1998.275.5.F796; Maunsbach AB, 1997, J AM SOC NEPHROL, V8, P1; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; Mullins C, 2001, BIOESSAYS, V23, P333, DOI 10.1002/bies.1048; Nielsen S, 1997, P NATL ACAD SCI USA, V94, P5450, DOI 10.1073/pnas.94.10.5450; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; NONOGUCHI H, 1995, J CLIN INVEST, V96, P1768, DOI 10.1172/JCI118222; Ohara M, 1998, J CLIN INVEST, V101, P1076, DOI 10.1172/JCI649; Pfister MF, 1998, P NATL ACAD SCI USA, V95, P1909, DOI 10.1073/pnas.95.4.1909; Promeneur D, 2000, AM J PHYSIOL-RENAL, V279, pF370, DOI 10.1152/ajprenal.2000.279.2.F370; Robert-Nicoud M, 2001, P NATL ACAD SCI USA, V98, P2712, DOI 10.1073/pnas.051603198; Saito T, 2001, KIDNEY INT, V60, P1266, DOI 10.1046/j.1523-1755.2001.00965.x; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; SerradeilLeGal C, 1996, J CLIN INVEST, V98, P2729, DOI 10.1172/JCI119098; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Summa V, 2001, J BIOL CHEM, V276, P47087, DOI 10.1074/jbc.M107165200; Terris J, 1995, AM J PHYSIOL-RENAL, V269, pF775, DOI 10.1152/ajprenal.1995.269.6.F775; Terris J, 1996, AM J PHYSIOL-RENAL, V271, pF414, DOI 10.1152/ajprenal.1996.271.2.F414; Valenti G, 1996, J BIOL CHEM, V271, P24365, DOI 10.1074/jbc.271.40.24365; Vandewalle A, 1999, CURR OPIN NEPHROL HY, V8, P581, DOI 10.1097/00041552-199909000-00009; Vuagniaux G, 2000, J AM SOC NEPHROL, V11, P828, DOI 10.1681/ASN.V115828; Xu DL, 1997, J CLIN INVEST, V99, P1500, DOI 10.1172/JCI119312; Yasui M, 1997, AM J PHYSIOL-RENAL, V272, pF443, DOI 10.1152/ajprenal.1997.272.4.F443	53	144	151	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10379	10386		10.1074/jbc.M111880200	http://dx.doi.org/10.1074/jbc.M111880200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11782489	hybrid			2022-12-27	WOS:000174549200103
J	Miljan, EA; Meuillet, EJ; Mania-Farnell, B; George, D; Yamamoto, H; Simon, HG; Bremer, EG				Miljan, EA; Meuillet, EJ; Mania-Farnell, B; George, D; Yamamoto, H; Simon, HG; Bremer, EG			Interaction of the extracellular domain of the epidermal growth factor receptor with gangliosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA CELL-LINE; MEDIATED MODULATION; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; PDGF RECEPTOR; BINDING; DIMERIZATION; GM3; PROTEIN	Ganglioside GM3 inhibits epidermal growth factor (EGF)-dependent cell proliferation in a variety of cell lines. Both in vitro and in vivo, this glycosphingolipid inhibits the kinase activity of the EGF receptor (EGFR). Furthermore, membrane preparations containing EGFR can bind to GM3-coated surfaces. These data suggest that GM3 may interact directly with the EGFR. In this study, the interaction of gangliosides with the extracellular domain (ECD) of the EGFR was investigated. The purified human recombinant ECD from insect cells bound directly to ganglioside GM3. The ganglioside interaction site appears to be distinct from the EGF-binding site. In agreement with previous reports on the effects of specific gangliosides on EGFR kinase activity, the ECD preferentially interacted with GM3. The order of relative binding of other gangliosides investigated was as follows: GM3 much greater than GM2, GD3, GM4 > GM1, GD1a, GD1b, GT1b, GD2, GQ1b > lactosylceramide. These data suggest that NeuAc-lactose is essential for binding and that any sugar substitution reduces binding. In agreement with the specificity of soluble ECD binding to gangliosides, GM3 specifically inhibited EGFR autophosphorylation. Identification of a ganglioside interaction site on the ECD of the EGFR is consistent with the hypothesis that endogenous GM3 may function as a direct modulator of EGFR activity.	Northwestern Univ, Sch Med, Pediat Brain Tumor Res Program, Dept Neurol Surg, Chicago, IL 60614 USA; Northwestern Univ, Sch Med, Dept Pediat, Chicago, IL 60614 USA; Childrens Mem Inst Educat & Res, Chicago, IL 60614 USA; Northwestern Univ, Sch Med, Robert Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Purdue Univ Calumet, Dept Biol, Hammond, IN 46321 USA; Chicago Inst Neurosurg & Neurores, Chicago, IL 60614 USA	Northwestern University; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Purdue University System; Purdue University	Bremer, EG (corresponding author), Childrens Mem Med Ctr, CMIER Neurobiol, Pediat Brain Tumor Res Program, 2300 Children Pl M-C 226, Chicago, IL 60614 USA.	egbremer@northwestern.edu	Miljan, Erik/AAH-7424-2020		NINDS NIH HHS [NS34333] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bremer E G, 1984, Adv Exp Med Biol, V174, P381; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BREMER EG, 1994, CURR TOP MEMBR, V40, P387, DOI 10.1016/S0070-2161(08)60989-2; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; Domagala T, 2000, GROWTH FACTORS, V18, P11, DOI 10.3109/08977190009003231; Duchemin AM, 1998, ANN NY ACAD SCI, V845, P406, DOI 10.1111/j.1749-6632.1998.tb09696.x; Elleman TC, 2001, BIOCHEMISTRY-US, V40, P8930, DOI 10.1021/bi010037b; Farooqui T, 1999, ANTICANCER RES, V19, P5007; Farooqui T, 1998, ANN NY ACAD SCI, V845, P407, DOI 10.1111/j.1749-6632.1998.tb09697.x; Ferguson KM, 2000, EMBO J, V19, P4632, DOI 10.1093/emboj/19.17.4632; GRIMAUX M, 1989, TUMOR BIOL, V10, P215, DOI 10.1159/000217618; HANAI N, 1988, J BIOL CHEM, V263, P10915; HSU CYJ, 1990, CELL GROWTH DIFFER, V1, P191; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; Hynds DL, 1997, J NEUROSCI RES, V47, P617, DOI 10.1002/(SICI)1097-4547(19970315)47:6<617::AID-JNR7>3.0.CO;2-G; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; Li RX, 2000, J BIOL CHEM, V275, P34213, DOI 10.1074/jbc.M906368199; Li RX, 2001, J BIOL CHEM, V276, P42782, DOI 10.1074/jbc.M101481200; Meuillet EJ, 2000, EXP CELL RES, V256, P74, DOI 10.1006/excr.1999.4509; Meuillet EJ, 1999, CANCER RES, V59, P234; MITSUDA T, 2002, J BIOL CHEM, V10, P1074; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; Odaka M, 1997, J BIOCHEM-TOKYO, V122, P116; Pestana ES, 1999, ONCOGENE, V18, P4069, DOI 10.1038/sj.onc.1202794; Pestana ES, 1997, BRIT J CANCER, V75, P213, DOI 10.1038/bjc.1997.36; Slevin M, 1999, INT J CANCER, V82, P412, DOI 10.1002/(SICI)1097-0215(19990730)82:3<412::AID-IJC15>3.0.CO;2-J; SONG WX, 1991, J BIOL CHEM, V266, P10174; SONNINO S, 1994, CHEM PHYS LIPIDS, V71, P21, DOI 10.1016/0009-3084(94)02304-2; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang XQ, 2001, J INVEST DERMATOL, V116, P69, DOI 10.1046/j.1523-1747.2001.00222.x; Wang XQ, 2001, GLYCOBIOLOGY, V11, P515, DOI 10.1093/glycob/11.7.515; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; Yates AJ, 1998, ANN NY ACAD SCI, V845, P57, DOI 10.1111/j.1749-6632.1998.tb09662.x; YATES AJ, 1995, J NEURO-ONCOL, V24, P65, DOI 10.1007/BF01052661; YEDNAK MA, 1994, MOL CHEM NEUROPATHOL, V21, P369, DOI 10.1007/BF02815362; Zurita AR, 2001, BIOCHEM J, V355, P465, DOI 10.1042/0264-6021:3550465	42	142	146	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10108	10113		10.1074/jbc.M111669200	http://dx.doi.org/10.1074/jbc.M111669200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11796728	hybrid			2022-12-27	WOS:000174549200067
J	Milland, J; Russell, SM; Dodson, HC; McKenzie, IFC; Sandrin, MS				Milland, J; Russell, SM; Dodson, HC; McKenzie, IFC; Sandrin, MS			The cytoplasmic tail of alpha 1,3-galactosyltransferase inhibits Golgi localization of the full-length enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING DOMAIN; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAINS; RETENTION SIGNAL; KIN RECOGNITION; PLASMA-MEMBRANE; CDNA-CLONES; PROTEINS; GLYCOSYLTRANSFERASES; SUFFICIENT	It is currently under debate whether the mechanism of Golgi retention of different glycosyltransferases is determined by sequences in the transmembrane, luminal, or cytoplasmic domains or a combination of these domains. We have shown that the cytoplasmic domains of alpha1,3-galactosyltransferase (GT) and alpha1,2-fucosyl-transferase (FT) are involved in Golgi localization. Here we show that the cytoplasmic tails of GT and FT are sufficient to confer specific Golgi localization. Further, we show that the expression of only the cytoplasmic tail of GT can lead to displacement or inhibition of binding of the whole transferase and that cells expressing the cytoplasmic tail of GT were not able to express fall-length GT or its product, Galalpha1,3Gal. Thus, the presence of the cytoplasmic tail prevented the localization and function of full-length GT, suggesting a possible specific Golgi binding site for GT. The effect was not altered by the inclusion of the transmembrane domain. Although the transmembrane domain may act as an anchor, these data show that, for GT, only the cytoplasmic tail is involved in specific localization to the Golgi.	Austin & Repatriat Med Ctr, Austin Res Inst, John Connell Lab Glycobiol, Heidelberg, Vic 3084, Australia; Peter MacCallum Canc Inst, Melbourne, Vic 3002, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Peter Maccallum Cancer Center	Sandrin, MS (corresponding author), Austin & Repatriat Med Ctr, Austin Res Inst, John Connell Lab Glycobiol, Studley Rd, Heidelberg, Vic 3084, Australia.	m.sandrin@ari.unimelb.edu.au	Russell, Sarah M/B-9341-2009	Russell, Sarah M/0000-0001-5826-9641; Milland, Julie/0000-0003-1368-220X				Andersson AM, 1998, J VIROL, V72, P9585, DOI 10.1128/JVI.72.12.9585-9596.1998; Andersson AM, 1997, J VIROL, V71, P4717, DOI 10.1128/JVI.71.6.4717-4727.1997; Belden WJ, 2001, J BIOL CHEM, V276, P43040, DOI 10.1074/jbc.M108113200; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; Cohney S, 1996, IMMUNOGENETICS, V44, P76, DOI 10.1007/BF02602660; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; DAHDAL RY, 1993, J BIOL CHEM, V268, P26310; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Gleeson PA, 1998, HISTOCHEM CELL BIOL, V109, P517, DOI 10.1007/s004180050252; GLEESON PA, 1994, GLYCOCONJUGATE J, V11, P381, DOI 10.1007/BF00731273; Glick BS, 1997, FEBS LETT, V414, P177, DOI 10.1016/S0014-5793(97)00984-8; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; Gommel DU, 2001, EMBO J, V20, P6751, DOI 10.1093/emboj/20.23.6751; Gonatas JO, 1998, J CELL SCI, V111, P249; Grabenhorst E, 1999, J BIOL CHEM, V274, P36107, DOI 10.1074/jbc.274.51.36107; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LEWIS MJ, 1992, J MOL BIOL, V226, P913, DOI 10.1016/0022-2836(92)91039-R; LINSTEDT AD, 1995, P NATL ACAD SCI USA, V92, P5102, DOI 10.1073/pnas.92.11.5102; LOCKER JK, 1994, J BIOL CHEM, V269, P28263; LUSSIER M, 1995, J CELL BIOL, V131, P913, DOI 10.1083/jcb.131.4.913; MATSUOKA Y, 1994, J BIOL CHEM, V269, P22565; Milland J, 2001, J BIOL CHEM, V276, P12012, DOI 10.1074/jbc.M010018200; Misumi Y, 2001, J BIOL CHEM, V276, P6867, DOI 10.1074/jbc.M010121200; MUNRO S, 1995, BIOCHEM SOC T, V23, P527, DOI 10.1042/bst0230527; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; Nilsson T, 1996, J CELL SCI, V109, P1975; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; Opat AS, 2001, BIOCHIMIE, V83, P763, DOI 10.1016/S0300-9084(01)01312-8; Osman N, 1996, J BIOL CHEM, V271, P33105, DOI 10.1074/jbc.271.51.33105; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; Sandrin Mauro S., 1994, Xenotransplantation, V1, P81, DOI 10.1111/j.1399-3089.1994.tb00053.x; SANDRIN MS, 1992, J IMMUNOL, V149, P1636; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; VAUGHAN HA, 1991, IMMUNOGENETICS, V33, P113; Yang W, 1996, EUR J CELL BIOL, V71, P53; Yang W, 1997, CELL BIOL INT, V21, P223, DOI 10.1006/cbir.1997.0138	45	35	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10374	10378		10.1074/jbc.M111799200	http://dx.doi.org/10.1074/jbc.M111799200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11777923	hybrid			2022-12-27	WOS:000174549200102
J	Nguyen, VP; Saleh, AZM; Arch, AE; Yan, H; Piazza, F; Kim, J; Krolewski, JJ				Nguyen, VP; Saleh, AZM; Arch, AE; Yan, H; Piazza, F; Kim, J; Krolewski, JJ			Stat2 binding to the interferon-alpha receptor 2 subunit is not required for interferon-alpha signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED-GENE FACTOR-3; PROTEIN-TYROSINE KINASE; I INTERFERON; INTRACELLULAR DOMAIN; TRANSCRIPTION FACTOR; REGULATORY REGION; BETA RECEPTOR; U5A CELLS; PHOSPHORYLATION; ACTIVATION	The interferon-alpha (IFNalpha) receptor consists of two subunits, the IFNalpha receptor 1 (IFNaR1) and 2 (IFNaR2) chains. Following ligand binding, IFNaR1 is phosphorylated on tyrosine 466, and this site recruits Stat2 via its SH2 domain. In contrast, IFNaR2 binds Stat2 constitutively. In this study we have characterized the Stat2-IFNaR2 interaction and examined its role in IFNalpha signaling. Stat2 binds the major IFNaR2 protein but not a variant containing a shorter cytoplasmic domain. The interaction does not require a STAT SH2 domain. Both tyrosine-phosphorylated and non-phosphorylated Stat2 bind IFNaR2 in vitro; however, relatively little phosphorylated Stat2 associates with IFNaR2 in vivo. In vitro binding assays defined IFNaR2 residues 418-444 as the minimal interaction domain and site-specific mutation of conserved acidic residues within this domain disrupted in vitro and in vivo binding. An IFNaR2 construct carrying these mutations was either (i) overexpressed in 293T cells or (ii) used to complement IFNaR2-deficient U5A cells. Unexpectedly, the activity of an IFNalpha-dependent reporter gene was not reduced but, instead, was enhanced up to 2-fold. This suggests that this particular IFNaR2-Stat2 interaction is not required for IFNa signaling, but might act to negatively inhibit signaling. Finally, a doubly truncated recombinant fragment of Stat2, spanning residues 136-702, associated with IFNaR2 in vitro, indicating that the interaction with IFNaR2 is direct and occurs in a central region of Stat2 marked by a hydrophobic core.	Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA 92697 USA; Johns Hopkins Univ, Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; Johns Hopkins University; Johns Hopkins Medicine; Columbia University	Krolewski, JJ (corresponding author), Univ Calif Irvine, Coll Med, Dept Pathol, Med Sci D450, Irvine, CA 92697 USA.	jkrolews@uci.edu			NCI NIH HHS [CA56862, CA09054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056862] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; Croze E, 1996, J BIOL CHEM, V271, P33165, DOI 10.1074/jbc.271.52.33165; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; Gibbs VC, 1996, J BIOL CHEM, V271, P28710, DOI 10.1074/jbc.271.45.28710; GRIECO F, 1992, BIOTECHNIQUES, V13, P856; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; Improta T, 1997, CYTOKINE, V9, P383, DOI 10.1006/cyto.1996.0180; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Kotenko SV, 1999, P NATL ACAD SCI USA, V96, P5007, DOI 10.1073/pnas.96.9.5007; Krishnan K, 1997, EUR J BIOCHEM, V247, P298, DOI 10.1111/j.1432-1033.1997.00298.x; Krishnan K, 1998, J BIOL CHEM, V273, P19495, DOI 10.1074/jbc.273.31.19495; Krishnan K, 1996, ONCOGENE, V13, P125; Lackmann M, 1998, GROWTH FACTORS, V16, P39, DOI 10.3109/08977199809017490; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Nadeau OW, 1999, J BIOL CHEM, V274, P4045, DOI 10.1074/jbc.274.7.4045; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Pfeffer LM, 1997, J BIOL CHEM, V272, P11002; Platanias LC, 1998, J BIOL CHEM, V273, P5577, DOI 10.1074/jbc.273.10.5577; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; Russell-Harde D, 2000, J BIOL CHEM, V275, P23981, DOI 10.1074/jbc.M002518200; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yan H, 1996, MOL CELL BIOL, V16, P2074; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	47	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9713	9721		10.1074/jbc.m111161200	http://dx.doi.org/10.1074/jbc.m111161200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11786546	hybrid			2022-12-27	WOS:000174549200017
J	Olson, LJ; Zhang, J; Dahms, NM; Kim, JJP				Olson, LJ; Zhang, J; Dahms, NM; Kim, JJP			Twists and turns of the cation-dependent mannose 6-phosphate receptor - Ligand-bound versus ligand-free receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; CRYSTAL-STRUCTURE; LECTIN; BINDING; RECOGNITION; CARBOHYDRATE; COMPLEX; PROTEIN; ENZYME; ASSOCIATION	Mannose 6-phosphate receptors (MPRs) participate in the biogenesis of lysosomes in higher eukaryotes by transporting soluble acid hydrolases from the trans. Golgi network to late endosomal compartments. The receptors release their ligands into the acidic environment of the late endosome and then return to the trans-Golgi network to repeat the process. However, the mechanism that facilitates ligand binding and dissociation upon changes in pH is not known. We report the crystal structure of the extracytoplasmic domain of the homodimeric cation-dependent MPR in a ligand-free form at pH 6.5. A comparison of the ligand-bound and ligand-free structures reveals a significant change in quaternary structure as well as a reorganization of the binding pocket, with the most prominent change being the relocation of a loop (residues Glu(134)-Cys(141)). The movements involved in the bound-to-free transition of the cation-dependent MPR are reminiscent of those of the oxy-to-deoxy hemoglobin transition. These results allow us to propose a mechanism by which the receptor regulates its ligand binding upon changes in pH; the pK(alpha) of Glu(133) appears to be responsible for ligand release in the acidic environment of the late endosomal compartment, and the pK(alpha) values of the sugar phosphate and His(105) are accountable for its inability to bind ligand at the cell surface where the pH is about 7.4.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Kim, JJP (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	jjkim@mcw.edu			NIDDK NIH HHS [DK42667] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042667, R56DK042667, R29DK042667] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; Bourne Y, 1999, STRUCTURE, V7, P1473, DOI 10.1016/S0969-2126(00)88338-0; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DISTLER JJ, 1987, ANAL BIOCHEM, V166, P65, DOI 10.1016/0003-2697(87)90546-X; Elgavish S, 1998, J MOL BIOL, V277, P917, DOI 10.1006/jmbi.1998.1664; Jain D, 2000, BIOCHEM BIOPH RES CO, V272, P843, DOI 10.1006/bbrc.2000.2871; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leonidas DD, 1998, BIOCHEMISTRY-US, V37, P13930, DOI 10.1021/bi981056x; LI M, 1990, ARCH BIOCHEM BIOPHYS, V283, P150, DOI 10.1016/0003-9861(90)90625-9; Loris R, 2000, J MOL BIOL, V301, P987, DOI 10.1006/jmbi.2000.4016; Manoj N, 1999, ACTA CRYSTALLOGR D, V55, P794, DOI 10.1107/S090744499900044X; Marron-Terada PG, 1998, BIOCHEMISTRY-US, V37, P17223, DOI 10.1021/bi981883y; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MunierLehmann H, 1996, J BIOL CHEM, V271, P15166, DOI 10.1074/jbc.271.25.15166; Nandy A, 1996, BIOCHEMISTRY-US, V35, P12402, DOI 10.1021/bi960785e; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Olson LJ, 1999, J BIOL CHEM, V274, P29889, DOI 10.1074/jbc.274.42.29889; Olson LJ, 1999, J BIOL CHEM, V274, P36905, DOI 10.1074/jbc.274.52.36905; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; Ravishankar R, 2001, PROTEINS, V43, P260, DOI 10.1002/prot.1037; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; RINI JM, 1993, J BIOL CHEM, V268, P10126; Roberts DL, 1998, CELL, V93, P639, DOI 10.1016/S0092-8674(00)81192-7; ROUSSEL A, 1994, BIOGRAPHICS, V4; Sandholzer U, 2000, J BIOL CHEM, V275, P14132, DOI 10.1074/jbc.275.19.14132; Saul FA, 2000, STRUCTURE, V8, P593, DOI 10.1016/S0969-2126(00)00142-8; Shirai T, 1999, STRUCTURE, V7, P1223, DOI 10.1016/S0969-2126(00)80056-8; TONG PY, 1989, J BIOL CHEM, V264, P7970; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; WESTCOTT KR, 1987, J BIOL CHEM, V262, P6101; Wood SD, 1999, ACTA CRYSTALLOGR D, V55, P1264, DOI 10.1107/S0907444999005326; WRIGHT CS, 1993, J MOL BIOL, V232, P620, DOI 10.1006/jmbi.1993.1415; ZHANG Y, 1993, BIOCHEM J, V295, P841, DOI 10.1042/bj2950841	45	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10156	10161		10.1074/jbc.M112230200	http://dx.doi.org/10.1074/jbc.M112230200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11786557	hybrid			2022-12-27	WOS:000174549200074
J	Reeves, CD; Chung, LM; Liu, YQ; Xue, Q; Carney, JR; Revill, WP; Katz, L				Reeves, CD; Chung, LM; Liu, YQ; Xue, Q; Carney, JR; Revill, WP; Katz, L			A new substrate specificity for acyl transferase domains of the ascomycin polyketide synthase in Streptomyces hygroscopicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; CARRIER PROTEIN TRANSACYLASE; BIOSYNTHETIC GENE-CLUSTER; HUMAN LIVER-MICROSOMES; IMMUNOSUPPRESSANT FK506; SORANGIUM-CELLULOSUM; ESCHERICHIA-COLI; EXTENDER UNITS; METABOLISM; CYTOCHROME-P450	Ascomycin (FK520) is a structurally complex macrolide with immunosuppressant activity produced by Streptomyces hygroscopicus. The biosynthetic origin of C12-C15 and the two methoxy groups at C13 and C15 has been unclear. It was previously shown that acetate is not incorporated into C12-C15 of the macrolactone ring. Here, the acyl transferase (AT) of domain 8 in the ascomycin polyketide synthase was replaced with heterologous ATs by double homologous recombination. When AT8 was replaced with methylmalonyl-CoA-specific AT domains, the strains produced 13-methyl-13-desmethoxyascomycin, whereas when AT8 was replaced with a malonyl-specific domain, the strains produced 13-desmethoxyascomycin. These data show that ascomycin AT8 does not use malonyl- or methylmalonyl-CoA as a substrate in its native context. Therefore, AT8 must be specific for a substrate bearing oxygen on the a carbon. Feeding experiments showed that [C-13]glycerol is incorporated into C12-C15 of ascomycin, indicating that both modules 7 and 8 of the polyketide synthase use an extender unit that can be derived from glycerol. When AT6 of the 6-deoxyerythronolide B synthase gene was replaced with ascomycin AT8 and the engineered gene was expressed in Streptomyces lividans, the strain produced 6-deoxyerythronolide B and 2-demethyl-6-deoxyerythronolide B. Therefore, although neither malonyl-CoA nor methylmalonyl-CoA is a substrate for ascomycin AT8 in its native context, both are substrates in the foreign context of the 6-deoxyerythronolide B synthase. Thus, we have demonstrated a new specificity for an AT domain in the ascomycin polyketide synthase and present evidence that specificity can be affected by context.	Kosan Biosci Inc, Hayward, CA 94545 USA	Bristol-Myers Squibb; Kosan Biosciences, Inc.	Reeves, CD (corresponding author), Kosan Biosci Inc, 3832 Bay Ctr Pl, Hayward, CA 94545 USA.			Carney, John/0000-0002-0461-8890	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI046206] Funding Source: NIH RePORTER; NIAID NIH HHS [1R43AI46206-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Byrne K. M., 1993, DEV IND MICROBIOL, V32, P29; HABER A, 1977, J AM CHEM SOC, V99, P3541, DOI 10.1021/ja00452a079; HAYDOCK SF, 1995, FEBS LETT, V374, P246, DOI 10.1016/0014-5793(95)01119-Y; Hill AM, 1998, CHEM COMMUN, P2361, DOI 10.1039/a806112b; IWASAKI K, 1993, RES COMMUN CHEM PATH, V82, P209; IWASAKI K, 1995, DRUG METAB DISPOS, V23, P28; Julien B, 2000, GENE, V249, P153, DOI 10.1016/S0378-1119(00)00149-9; Kakavas SJ, 1997, J BACTERIOL, V179, P7515, DOI 10.1128/jb.179.23.7515-7522.1997; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; Katz L, 1997, CHEM REV, V97, P2557, DOI 10.1021/cr960025+; Khosla C, 1999, ANNU REV BIOCHEM, V68, P219, DOI 10.1146/annurev.biochem.68.1.219; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; Kuhstoss S, 1996, GENE, V183, P231, DOI 10.1016/S0378-1119(96)00565-3; Lampen A, 1995, DRUG METAB DISPOS, V23, P1315; Lau J, 1999, BIOCHEMISTRY-US, V38, P1643, DOI 10.1021/bi9820311; Liu HB, 1999, J BACTERIOL, V181, P6806, DOI 10.1128/JB.181.21.6806-6813.1999; MARSDEN AFA, 1994, SCIENCE, V263, P378, DOI 10.1126/science.8278811; McDaniel R, 1999, P NATL ACAD SCI USA, V96, P1846, DOI 10.1073/pnas.96.5.1846; Motamedi H, 1996, J BACTERIOL, V178, P5243, DOI 10.1128/jb.178.17.5243-5248.1996; Motamedi H, 1998, EUR J BIOCHEM, V256, P528, DOI 10.1046/j.1432-1327.1998.2560528.x; Motamedi H, 1997, EUR J BIOCHEM, V244, P74, DOI 10.1111/j.1432-1033.1997.00074.x; NIELSEN JB, 1991, BIOCHEMISTRY-US, V30, P5789, DOI 10.1021/bi00237a023; Oliynyk M, 1996, CHEM BIOL, V3, P833, DOI 10.1016/S1074-5521(96)90069-1; Ono M, 1998, J ANTIBIOT, V51, P1019, DOI 10.7164/antibiotics.51.1019; Rangan VS, 1997, PROTEIN ENG, V10, P561, DOI 10.1093/protein/10.5.561; Rangan VS, 1997, J BIOL CHEM, V272, P11975, DOI 10.1074/jbc.272.18.11975; Reeves CD, 2001, BIOCHEMISTRY-US, V40, P15464, DOI 10.1021/bi015864r; SCHUPP T, 1995, J BACTERIOL, V177, P3673, DOI 10.1128/jb.177.13.3673-3679.1995; SERRE L, 1995, J BIOL CHEM, V270, P12961, DOI 10.1074/jbc.270.22.12961; SEWING KF, 1994, TRANSPLANT P, V26, P3267; Shafiee A, 1997, J ANTIBIOT, V50, P418, DOI 10.7164/antibiotics.50.418; SHIRAGA T, 1994, BIOCHEM PHARMACOL, V47, P727, DOI 10.1016/0006-2952(94)90136-8; Tang L, 2000, SCIENCE, V287, P640, DOI 10.1126/science.287.5453.640; Wu K, 2000, GENE, V251, P81, DOI 10.1016/S0378-1119(00)00171-2	34	33	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9155	9159		10.1074/jbc.M111915200	http://dx.doi.org/10.1074/jbc.M111915200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11786554	hybrid			2022-12-27	WOS:000174400600057
J	Tuominen, EKJ; Wallace, CJA; Kinnunen, PKJ				Tuominen, EKJ; Wallace, CJA; Kinnunen, PKJ			Phospholipid-cytochrome c interaction - Evidence for the extended lipid anchorage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGE; ALPHA-LACTALBUMIN; EMISSION-SPECTRA; BINDING-SITES; FATTY-ACIDS; PHOSPHATIDYLCHOLINE; MITOCHONDRIA; ASSOCIATION; PROTEINS; STATE	Binding of cytochrome c (cyt c) to fatty acids and acidic phospholipid membranes produces pronounced and essentially identical changes in the spectral properties of cyt c, revealing conformational changes in the protein. The exact mechanism of the interaction of fatty acids and acidic phospholipids with cyt c is unknown. Binding of cyt c to liposomes with high contents (mole fraction X > 0.7) of acidic phospholipids caused spectral changes identical to those due to binding of oleic acid. Fluorescence spectroscopy of a cyt c analog containing a Zn2+ substituted heme moiety and brominated lipid derivatives (9,10)-dibromostearate and 1-palmitoyl-2(9,10)-dibromo-sn-glycero-3-phospho-rac-glyceroI demonstrated a direct contact between the fluorescent [Zn2+-heme] group and the brominated acyl chain. These data constitute direct evidence for interaction between an acyl chain of a membrane phospholipid and the inside of the protein containing the heme moiety and provide direct evidence for the so-called extended-lipid anchorage of cyt c to phospholipid membranes. In this mechanism, one of the phospholipid acyl chains protrudes out of the membrane and intercalates into a hydrophobic channel in cyt c while the other chain remains in the bilayer.	Univ Helsinki, Inst Biomed, Helsinki Biophys & Biomembrane Grp, Dept Biochem, FIN-00014 Helsinki, Finland; Dalhousie Univ, Dept Biochem, Halifax, NS B3H 4H7, Canada	Finland National Institute for Health & Welfare; University of Helsinki; Dalhousie University	Kinnunen, PKJ (corresponding author), Univ Helsinki, Inst Biomed, Helsinki Biophys & Biomembrane Grp, Dept Biochem, POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	Paavo.Kinnunen@Helsinki.Fi						ANNI H, 1995, BIOCHEMISTRY-US, V34, P5744, DOI 10.1021/bi00017a006; BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; CARWTHERN KM, 1996, PROTEIN SCI, V4, P1394; DAWIDOWICZ EA, 1976, BIOCHIM BIOPHYS ACTA, V455, P621, DOI 10.1016/0005-2736(76)90036-5; DICKERSON RE, 1971, J BIOL CHEM, V246, P1511; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; Gennis R.B, 1989, BIOMEMBRANES MOL STR, P23; HAMADA D, 1994, P NATL ACAD SCI USA, V91, P10325, DOI 10.1073/pnas.91.22.10325; HARDESTY BA, 1963, ARCH BIOCHEM BIOPHYS, V100, P1, DOI 10.1016/0003-9861(63)90025-0; HAUSER H, 1980, BIOCHEMISTRY-US, V19, P366, DOI 10.1021/bi00543a018; HAUSER H, 1988, BIOCHEMISTRY-US, V27, P9166, DOI 10.1021/bi00426a014; Jemmerson R, 1999, BIOCHEMISTRY-US, V38, P3599, DOI 10.1021/bi9809268; KAHANA E, 1992, BIOCHEM J, V282, P75, DOI 10.1042/bj2820075; Kinnunen PKJ, 1996, CHEM PHYS LIPIDS, V81, P151, DOI 10.1016/0009-3084(96)02579-0; KINNUNEN PKJ, 1994, CHEM PHYS LIPIDS, V73, P181, DOI 10.1016/0009-3084(94)90181-3; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MARGOLIASH E, 1959, BIOCHEM J, V71, P570, DOI 10.1042/bj0710570; MEERS P, 1994, BIOCHEMISTRY-US, V33, P5829, DOI 10.1021/bi00185a022; MOORE GR, 1990, CYTOCHROMES EVOLUTIO; Nantes IL, 2001, J BIOL CHEM, V276, P153, DOI 10.1074/jbc.M006338200; PACHENCE JM, 1991, BIOPHYS J, V59, P894, DOI 10.1016/S0006-3495(91)82302-5; QUINN PJ, 1969, BIOCHEM J, V115, P65, DOI 10.1042/bj1150065; QUINN PJ, 1969, BIOCHEM J, V113, P791, DOI 10.1042/bj1130791; RYTOMAA M, 1995, J BIOL CHEM, V270, P3197, DOI 10.1074/jbc.270.7.3197; RYTOMAA M, 1992, J BIOL CHEM, V267, P22243; RYTOMAA M, 1994, J BIOL CHEM, V269, P1770; SCHLAME M, 1990, BIOCHEM J, V265, P79, DOI 10.1042/bj2650079; SPECK SH, 1983, FEBS LETT, V164, P379, DOI 10.1016/0014-5793(83)80321-4; Stewart JM, 2000, BIOCHEM CELL BIOL, V78, P675, DOI 10.1139/bcb-78-6-675; Subramanian M, 1998, BIOCHEMISTRY-US, V37, P1394, DOI 10.1021/bi9716581; Svensson M, 2000, P NATL ACAD SCI USA, V97, P4221, DOI 10.1073/pnas.97.8.4221; Tuominen EKJ, 2001, J BIOL CHEM, V276, P19356, DOI 10.1074/jbc.M100853200; VANDERKOOI JM, 1975, EUR J BIOCHEM, V60, P199, DOI 10.1111/j.1432-1033.1975.tb20992.x; VANDERKOOI JM, 1976, EUR J BIOCHEM, V64, P381, DOI 10.1111/j.1432-1033.1976.tb10312.x; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	39	260	277	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8822	8826		10.1074/jbc.M200056200	http://dx.doi.org/10.1074/jbc.M200056200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11781329	hybrid			2022-12-27	WOS:000174400600012
J	Robey, RB; Ma, JF; Santos, AVP; Noboa, OA; Coy, PE; Bryson, JM				Robey, RB; Ma, JF; Santos, AVP; Noboa, OA; Coy, PE; Bryson, JM			Regulation of mesangial cell hexokinase activity and expression by heparin-binding epidermal growth factor-like growth factor - Epidermal growth factors and phorbol esters increase glucose metabolism via a common mechanism involving classic mitogen-activated protein kinase pathway activation and induction of hexokinase II expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENTOSE-PHOSPHATE PATHWAY; GLUCURONATE-XYLULOSE PATHWAY; FACTOR MESSENGER-RNA; RAT-KIDNEY; INTRAMITOCHONDRIAL COMPARTMENTS; OXIDATIVE-PHOSPHORYLATION; EPITHELIAL-CELLS; TYROSINE KINASE; FACTOR-ALPHA; GENE	Heparin-binding epidermal growth factor-like growth factor (HB-EGF) expression and hexokinase (HK) activity are increased in various pathologic renal conditions. Although the mitogenic properties of HB-EGF have been well characterized, its effects on glucose (Glc) metabolism have not. We therefore examined the possibility that HB-EGF might regulate HK activity and expression in glomerular mesangial cells, which constitute the principal renal cell type affected by a variety of pathologic conditions. Protein kinase C (PKC)-dependent classic mitogen-activated protein kinase (MAPK) pathway activation has been associated with increased HK activity in this cell type, so we also examined dependence upon these signaling intermediates. HB-EGF (greater than or equal to10 nM) increased total HK activity over 50% within 12-24 h, an effect mimicked by other EGF receptor agonists, but not by IGF-1 or elevated Glc. EGF receptor and classic MAPK pathway antagonists prevented this increase, as did general inhibitors of gene transcription and protein synthesis. Both HB-EGF and phorbol esters activated the classic MAPK pathway, albeit via PKC-independent and PKC-dependent mechanisms, respectively. Both stimuli were associated with increased HK activity, selectively increased HKII isoform expression, and increased Glc metabolism via both the glycolytic-tricarboxylic acid cycle route and the pentose phosphate pathway. HB-EGF thus constitutes a novel regulator of mesangial cell HK activity and Glc metabolism. HKII is the principal regulated isoform in these cells, as it is in insulin-sensitive peripheral tissues, such as muscle. However, the uniform requirement for classic MAPK pathway activation distinguishes HKIII regulation in mesangial cells from that observed in muscle. These findings suggest a novel mechanism whereby growth factors may couple metabolism to glomerular injury.	Univ Illinois, Coll Med, Dept Med, Nephrol Sect, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA; Vet Affairs Chicago Hlth Care Syst, W Side Div, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Robey, RB (corresponding author), Univ Illinois, Coll Med M C 793, Dept Med, Nephrol Sect, 820 S Wood St,Rm 419W, Chicago, IL 60612 USA.		Noboa, Oscar/Q-8150-2019; Robey, R. Brooks/J-7099-2013	Noboa, Oscar/0000-0002-0975-9924; Robey, R. Brooks/0000-0001-5059-3965				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Allen CB, 1998, AM J PHYSIOL-LUNG C, V274, pL320, DOI 10.1152/ajplung.1998.274.3.L320; ANDERSON JW, 1973, AM J PHYSIOL, V224, P930, DOI 10.1152/ajplegacy.1973.224.4.930; AYO SH, 1991, AM J PHYSIOL, V261, pF571, DOI 10.1152/ajprenal.1991.261.4.F571; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BELTRANDELRIO H, 1991, ARCH BIOCHEM BIOPHYS, V286, P183, DOI 10.1016/0003-9861(91)90026-F; BELTRANDELRIO H, 1992, ARCH BIOCHEM BIOPHYS, V296, P667, DOI 10.1016/0003-9861(92)90625-7; BELTRANDELRIO H, 1992, ARCH BIOCHEM BIOPHYS, V299, P116, DOI 10.1016/0003-9861(92)90252-R; Bos M, 1997, CLIN CANCER RES, V3, P2099; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAITHWAITE SS, 1995, DIABETES, V44, P43, DOI 10.2337/diabetes.44.1.43; BREYER MD, 1990, AM J PHYSIOL, V259, pF553, DOI 10.1152/ajprenal.1990.259.4.F553; Bryson JM, 2002, J BIOL CHEM, V277, P11392, DOI 10.1074/jbc.M110927200; CZECH MP, 1973, J BIOL CHEM, V248, P3636; DUBACH UC, 1960, J CLIN INVEST, V39, P1364, DOI 10.1172/JCI104155; Dunbar AJ, 1999, BIOCHEM J, V344, P713, DOI 10.1042/0264-6021:3440713; Feng LL, 2000, J CLIN INVEST, V105, P341, DOI 10.1172/JCI2869; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Harris R C, 1997, Adv Ren Replace Ther, V4, P43; HARRIS RC, 1988, J CLIN INVEST, V82, P1028, DOI 10.1172/JCI113659; HEILIG CW, 1995, J CLIN INVEST, V96, P1802, DOI 10.1172/JCI118226; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; Horikawa M, 1999, FEBS LETT, V459, P100, DOI 10.1016/S0014-5793(99)01213-2; LAWRENCE GM, 1984, HISTOCHEM J, V16, P697, DOI 10.1007/BF01095276; LEE YJ, 1995, BIOCHEM BIOPH RES CO, V207, P216, DOI 10.1006/bbrc.1995.1175; LEEHEY DJ, 1995, DIABETES, V44, P929, DOI 10.2337/diabetes.44.8.929; MACKAY K, 1988, KIDNEY INT, V33, P677, DOI 10.1038/ki.1988.53; MANDARINO LJ, 1995, AM J PHYSIOL-ENDOC M, V269, pE701; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; Osawa H, 1996, J BIOL CHEM, V271, P16690, DOI 10.1074/jbc.271.28.16690; Paizis K, 1999, KIDNEY INT, V55, P2310, DOI 10.1046/j.1523-1755.1999.00469.x; Paizis K, 1998, KIDNEY INT, V53, P1162, DOI 10.1046/j.1523-1755.1998.00846.x; Pillai SB, 1999, J SURG RES, V87, P225, DOI 10.1006/jsre.1999.5764; Polihronis M, 1996, EXP NEPHROL, V4, P271; PRELLER A, 1992, ARCH BIOCHEM BIOPHYS, V294, P482, DOI 10.1016/0003-9861(92)90715-9; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; Riddle SR, 2000, AM J PHYSIOL-LUNG C, V278, pL407, DOI 10.1152/ajplung.2000.278.2.L407; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Robey RB, 1999, AM J PHYSIOL-RENAL, V277, pF742, DOI 10.1152/ajprenal.1999.277.5.F742; Robey RB, 2000, KIDNEY INT, V57, P2308, DOI 10.1046/j.1523-1755.2000.00091.x; ROBEY RB, 1999, J AM SOC NEPHROL, V10, P689; Sakurai H, 1997, AM J PHYSIOL-RENAL, V273, pF463, DOI 10.1152/ajprenal.1997.273.3.F463; Sebastian S, 2000, BIOCHEM BIOPH RES CO, V270, P886, DOI 10.1006/bbrc.2000.2527; SOCHOR M, 1979, BIOCHEM BIOPH RES CO, V86, P32, DOI 10.1016/0006-291X(79)90378-4; SOCHOR M, 1984, BIOCHEM BIOPH RES CO, V121, P8, DOI 10.1016/0006-291X(84)90680-6; SOCHOR M, 1988, HORM METAB RES, V20, P676, DOI 10.1055/s-2007-1010915; SOCHOR M, 1985, MOL PHYSIOL, V7, P51; SOCHOR M, 1979, ARCH BIOCHEM BIOPHYS, V198, P632, DOI 10.1016/0003-9861(79)90541-1; SPIRO RG, 1976, DIABETOLOGIA, V12, P1, DOI 10.1007/BF01221959; STEER KA, 1982, FEBS LETT, V150, P494, DOI 10.1016/0014-5793(82)80797-7; STEER KA, 1985, DIABETES, V34, P485, DOI 10.2337/diabetes.34.5.485; Takemura T, 1997, J BIOL CHEM, V272, P31036, DOI 10.1074/jbc.272.49.31036; Takemura T, 1999, J PATHOL, V189, P431; TAN MS, 1994, KIDNEY INT, V46, P690, DOI 10.1038/ki.1994.322; TANAKA K, 1976, J CLIN INVEST, V58, P164, DOI 10.1172/JCI108446; Taniguchi N, 1996, DIABETES, V45, pS81, DOI 10.2337/diab.45.3.S81; Tian W, 2000, AM J PHYSIOL-RENAL, V279, pF593, DOI 10.1152/ajprenal.2000.279.4.F593; Tian WN, 1999, AM J PHYSIOL-CELL PH, V276, pC1121, DOI 10.1152/ajpcell.1999.276.5.C1121; VAUGHAN TJ, 1992, BIOCHEM J, V287, P681, DOI 10.1042/bj2870681; Wang YZ, 1996, EXP CELL RES, V225, P382, DOI 10.1006/excr.1996.0189; Wilson JE, 1998, DIABETES, V47, P1544, DOI 10.2337/diabetes.47.10.1544; Xian CJ, 1999, HISTOCHEM CELL BIOL, V111, P467, DOI 10.1007/s004180050383	64	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14370	14378		10.1074/jbc.M111722200	http://dx.doi.org/10.1074/jbc.M111722200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11782486	hybrid			2022-12-27	WOS:000175203000006
J	Kumari, K; Tlapak-Simmons, VL; Baggenstoss, BA; Weigel, PH				Kumari, K; Tlapak-Simmons, VL; Baggenstoss, BA; Weigel, PH			The streptococcal hyaluronan synthases are inhibited by sulfhydryl-modifying reagents, but conserved cysteine residues are not essential for enzyme function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; ESCHERICHIA-COLI; LACTOSE PERMEASE; CHEMICAL MODIFICATION; SCANNING MUTAGENESIS; ACID; IDENTIFICATION; EXPRESSION; MEMBRANE; SITE	Hyaluronan (HA) synthase (HAS) is a membrane-bound enzyme that utilizes UDP-glucuronic acid (GlcUA) and UDP-GIcNAc to synthesize HA. The HAS from Streptococcus pyogenes (spHAS, 419 amino acids) contains six Cys residues, whereas the enzyme from Streptococcus equisimilis (seHAS, 417 amino acids) contains four Cys residues. These Cys residues of seHAS are highly conserved in all Class I HAS family members. Here we investigated the structural and functional roles of these conserved cysteines in seHAS by using site-directed mutagenesis and sensitivity to sulfhydryl modifying reagents. Both seHAS and spHAS were inhibited by sulfhydryl reagents such as N-ethylmaleimide (NEM) and iodoacetamide in a dose-dependent and time-dependent manner. These inhibition curves were biphasic, indicating the presence of sensitive and insensitive components. After treatment of seHAS with NEM, the V-max value was decreased similar to50%,, and the K. values changed only slightly. All the Cys-to-Ala mutants of seHAS were partially active. The least active single (C226A), double (C226A,C262A), or triple (C226A,C262A,C367A) Cys mutants retained 24, 3.2, and 1.4% activity, respectively, compared with wild-type enzyme. Surprisingly, the V-max value of the seHAS(cys-null) mutant was similar to17% of wild-type, although the K-m values for both substrates were increased 3-6-fold. Cys residues, therefore, are not involved in a critical interaction necessary for either substrate binding or catalysis. However, the distribution of HA products was shifted to a smaller size in similar to25% of the seHAS Cys mutants, particularly the triple mutants. Mass spectroscopic analysis of wild-type and Cys-null seHAS as well as the labeling of all double Cys-to-Ala mutants with [C-14]NEM demonstrated that seHAS contains no disulfide bonds. We conclude that the four Cys residues in seHAS are not directly involved in catalysis, but that one or more of these Cys residues are located in or near substrate binding or glycosyltransferase active sites, so that their modification hinders the functions of HAS.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.	paul-weigel@ouhsc.edu			NIGMS NIH HHS [GM35978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATANGELO G, 2000, NEW FRONTIERS MED SC; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; CHAKRABORTI PK, 1992, J BIOL CHEM, V267, P11366; DeAngelis PL, 1999, CELL MOL LIFE SCI, V56, P670, DOI 10.1007/s000180050461; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; DeAngelis PL, 1997, SCIENCE, V278, P1800, DOI 10.1126/science.278.5344.1800; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; FENDERSON BA, 1993, DIFFERENTIATION, V54, P85; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Heldermon C, 2001, J BIOL CHEM, V276, P2037, DOI 10.1074/jbc.M002276200; Hill AV, 1913, BIOCHEM J, V7, P471, DOI 10.1042/bj0070471; Horton MR, 2000, AM J PHYSIOL-LUNG C, V279, pL707, DOI 10.1152/ajplung.2000.279.4.L707; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; ITO K, 1977, CELL, V11, P551, DOI 10.1016/0092-8674(77)90073-3; JUNG K, 1994, BIOCHEMISTRY-US, V33, P3980, DOI 10.1021/bi00179a026; Kass EH, 1944, J EXP MED, V79, P319, DOI 10.1084/jem.79.3.319; KATO H, 1988, J BIOL CHEM, V263, P11646; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Kumari K, 1997, J BIOL CHEM, V272, P32539, DOI 10.1074/jbc.272.51.32539; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; MCDONALD J, 1998, SCI HYALURONAN TODAY, pCH7; Michaelis L, 1913, BIOCHEM Z, V49, P333; Ohno S, 2001, BBA-GENE STRUCT EXPR, V1520, P71, DOI 10.1016/S0167-4781(01)00256-1; Petrov VV, 1997, J BIOL CHEM, V272, P1688, DOI 10.1074/jbc.272.3.1688; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; PREHM P, 1984, BIOCHEM J, V220, P597, DOI 10.1042/bj2200597; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; SUGAHARA K, 1979, J BIOL CHEM, V254, P6252; Tamura N, 2001, J BIOL CHEM, V276, P20330, DOI 10.1074/jbc.M007993200; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4246, DOI 10.1074/jbc.274.7.4246; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4239, DOI 10.1074/jbc.274.7.4239; Toole BP, 1997, J INTERN MED, V242, P35, DOI 10.1046/j.1365-2796.1997.00171.x; Usui T, 1999, INVEST OPHTH VIS SCI, V40, P563; Voss J, 1997, BIOCHEMISTRY-US, V36, P15055, DOI 10.1021/bi971726j; Wang QD, 1999, BIOCHEMISTRY-US, V38, P16777, DOI 10.1021/bi991853a; Ward PN, 2001, INFECT IMMUN, V69, P392, DOI 10.1128/IAI.69.1.392-399.2001; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WEIGEL PH, 1998, SCI HYALURONAN TODAY, pCH7; WESSELS MR, 1994, INFECT IMMUN, V62, P433, DOI 10.1128/IAI.62.2.433-441.1994; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Wolfgang CL, 1997, J BIOL CHEM, V272, P746, DOI 10.1074/jbc.272.2.746; WU JH, 1994, BIOCHEMISTRY-US, V33, P12166, DOI 10.1021/bi00206a020; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497	50	16	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13943	13951		10.1074/jbc.M110638200	http://dx.doi.org/10.1074/jbc.M110638200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11799120	hybrid			2022-12-27	WOS:000175096000078
J	Kroncke, KD; Klotz, LO; Suschek, CV; Sies, H				Kroncke, KD; Klotz, LO; Suschek, CV; Sies, H			Comparing nitrosative versus oxidative stress toward zinc ringer-dependent transcription. Unique role for NO.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; DNA-BINDING EFFICIENCY; SINGLET OXYGEN; ESTROGEN-RECEPTOR; MOLECULAR TARGETS; REGULATORY ROLE; KINETICS; PEROXYNITRITE; DECOMPOSITION; GLUTATHIONE	During inflammatory reactions, cells are under nitrosative and/or oxidative stress. The zinc finger transcription factors vitamin D receptor (VDR) and retinoid X receptor (RXR) were used as a model system to characterize effects of NO. and/or reactive oxygen species on zinc finger-dependent gene expression. Nitric oxide (NO.) as well as H2O2, singlet oxygen (O-1(2)), peroxyl radicals (ROO.), and peroxynitrite (ONOO-), respectively, were shown to inhibit VDR/RXR-DNA complex formation in vitro in a dose-dependent manner. While NO-induced inhibition of VDR/RXR-DNA complex formation could be restored nearly completely by subsequent treatment with dithiothreitol, inhibition by H2O2 proved to be only partially reversible, and inhibition by O-1(2), ROO. or ONOO- was found to be irreversible. In cells transiently transfected with VDR and RXR, subtoxic concentrations of NO. or hydroperoxides and intracellular generation of superoxide anion radicals inhibited VDR/RXR-dependent reporter gene activity in a dose-dependent manner. Interestingly, cells can repair the zinc fingers of VDR and RXR after nitrosative stress but not after oxidative stress. The results indicate that, among the reactive species investigated, only NO. may act sufficiently gentle to be considered as a regulator and not only as an inhibitor of gene expression via zinc finger transcription factors.	Univ Dusseldorf, Dept Med, Res Grp Immunobiol, Biomed Res Ctr, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Dept Med, Inst Physiol Chem 1, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Kroncke, KD (corresponding author), Univ Dusseldorf, Dept Med, Res Grp Immunobiol, Biomed Res Ctr, Bldg 23-12,Moorenstr 5, D-40225 Dusseldorf, Germany.	kroencke@uni-duesseldorf.de	Klotz, Lars Oliver/AAC-5051-2019; Sies, Helmut/B-7266-2008; Sies, Helmut/ABE-7355-2020	Klotz, Lars Oliver/0000-0002-1261-8911; Sies, Helmut/0000-0002-1000-3198; 				AMMENDOLA R, 1994, EUR J BIOCHEM, V225, P483, DOI 10.1111/j.1432-1033.1994.t01-1-00483.x; AUBRY JM, 1985, J AM CHEM SOC, V107, P5844, DOI 10.1021/ja00307a002; Beck KF, 1999, J EXP BIOL, V202, P645; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; Berendji D, 1997, FEBS LETT, V405, P37, DOI 10.1016/S0014-5793(97)00150-6; Berendji D, 1999, MOL MED, V5, P721, DOI 10.1007/BF03402096; Berendji-Grun D, 2001, MOL MED, V7, P748, DOI 10.1007/BF03401964; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broillet MC, 1999, CELL MOL LIFE SCI, V55, P1036, DOI 10.1007/s000180050354; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Casadevall M, 1998, J INORG BIOCHEM, V71, P147, DOI 10.1016/S0162-0134(98)10046-6; CORNELL NW, 1972, ANAL BIOCHEM, V47, P203, DOI 10.1016/0003-2697(72)90293-X; CROW JP, 1995, BIOCHEMISTRY-US, V34, P3544, DOI 10.1021/bi00011a008; DI MASCIO P, 1989, J AM CHEM SOC, V111, P2909, DOI 10.1021/ja00190a027; ESPOSITO F, 1995, BBA-GENE STRUCT EXPR, V1260, P308, DOI 10.1016/0167-4781(94)00209-L; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; HUGHES MN, 1968, J CHEM SOC A, P450, DOI 10.1039/j19680000450; HUTCHISON KA, 1991, J BIOL CHEM, V266, P10505; Kahlen JP, 1996, BIOCHEM BIOPH RES CO, V218, P882, DOI 10.1006/bbrc.1996.0157; Kim PKM, 2001, INT IMMUNOPHARMACOL, V1, P1421, DOI 10.1016/S1567-5769(01)00088-1; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; Knapp LT, 2000, J BIOL CHEM, V275, P24136, DOI 10.1074/jbc.M002043200; KNOEPFEL L, 1994, BIOCHEM BIOPH RES CO, V201, P871, DOI 10.1006/bbrc.1994.1782; Kroncke KD, 2000, ANTIOXID REDOX SIGN, V2, P585, DOI 10.1089/15230860050192341; Kroncke KD, 2000, FASEB J, V14, P166; Kroncke KD, 1998, CLIN EXP IMMUNOL, V113, P147; Kroncke KD, 2001, ANTIOXID REDOX SIGN, V3, P565, DOI 10.1089/15230860152542934; Kroncke KD, 2001, FASEB J, V15, P2503, DOI 10.1096/fj.01-0240hyp; Kroncke KD, 2001, NITRIC OXIDE-BIOL CH, V5, P289, DOI 10.1006/niox.2001.0354; KRONCKE KD, 1994, BIOCHEM BIOPH RES CO, V200, P1105, DOI 10.1006/bbrc.1994.1564; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Liang XS, 1998, MOL CELL ENDOCRINOL, V146, P151, DOI 10.1016/S0303-7207(98)00161-0; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; Nieuwint A W, 1985, Free Radic Res Commun, V1, P1, DOI 10.3109/10715768509056532; NIKI E, 1990, METHOD ENZYMOL, V186, P100; O'Donnell VB, 2001, CIRC RES, V88, P12, DOI 10.1161/01.RES.88.1.12; OHSHIMA H, 1990, FOOD CHEM TOXICOL, V28, P647, DOI 10.1016/0278-6915(90)90173-K; Pfeilschifter J, 2001, PFLUG ARCH EUR J PHY, V442, P479, DOI 10.1007/s004240100586; Pierlot C, 1996, J PHOTOCH PHOTOBIO B, V36, P31, DOI 10.1016/S1011-1344(96)07324-1; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Schindler H, 2001, INT IMMUNOPHARMACOL, V1, P1443, DOI 10.1016/S1567-5769(01)00089-3; SIES H, 1992, MUTAT RES, V275, P367, DOI 10.1016/0921-8734(92)90039-R; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P6992; Uppu RM, 1996, ANAL BIOCHEM, V236, P242, DOI 10.1006/abio.1996.0162; Webster KA, 2001, ANTIOXID REDOX SIGN, V3, P535, DOI 10.1089/15230860152542916; Whittal RM, 2000, BIOCHEMISTRY-US, V39, P8406, DOI 10.1021/bi000282f; Wilcox DE, 2001, ANTIOXID REDOX SIGN, V3, P549, DOI 10.1089/15230860152542925; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; Xu Y, 1998, J AM CHEM SOC, V120, P7375, DOI 10.1021/ja974051g; Zamora R, 2000, MOL MED, V6, P347, DOI 10.1007/BF03401781; Zangger K, 2001, FASEB J, V15, P1303, DOI 10.1096/fj.00-0641fje	57	54	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13294	13301		10.1074/jbc.M111216200	http://dx.doi.org/10.1074/jbc.M111216200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11796720	hybrid			2022-12-27	WOS:000175036300100
J	Lindsay, AJ; Hendrick, AG; Cantalupo, G; Senic-Matuglia, F; Goud, B; Bucci, C; McCaffrey, MW				Lindsay, AJ; Hendrick, AG; Cantalupo, G; Senic-Matuglia, F; Goud, B; Bucci, C; McCaffrey, MW			Rab coupling protein (RCP), a novel Rab4 and Rab11 effector protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; ENDOCYTIC PATHWAY; MEMBRANE-FUSION; EARLY ENDOSOMES; IDENTIFICATION; RABAPTIN-5; DOMAINS; SYSTEM	Rab4 and Rab11 are small GTPases belonging to the Ras superfamily. They both function as regulators along the receptor recycling pathway. We have identified a novel 80-kDa protein that interacts specifically with the GTP-bound conformation of Rab4, and subsequent work has shown that it also interacts strongly with Rab11. We name this protein Rab coupling protein (RCP). RCP is predominantly membrane-bound and is expressed in all cell lines and tissues tested. It colocalizes with early endosomal markers including Rab4 and Rab11 as well as with the transferrin receptor. Overexpression of the carboxyl-terminal region of RCP, which contains the Rab4- and Rab11-interacting domain, results in a dramatic tubulation of the transferrin compartment. Furthermore, expression of this mutant causes a significant reduction in endosomal recycling without affecting Iigand uptake or degradation in quantitative assays. RCP is a homologue of Rip11 and therefore belongs to the recently described Rab11-FIP family.	Univ Coll Cork, Cell & Mol Biol Lab, Dept Biochem, Cork, Ireland; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, I-80131 Naples, Italy; Univ Naples Federico II, Ctr Endocrinol & Oncol Sperimentale G Salvatore, I-80131 Naples, Italy; Univ Lecce, Dipartimento Biol, I-73100 Lecce, Italy; Inst Curie, Lab Mecan Mol Transport Intracellulaire, CNRS, UMR 144, F-75248 Paris 05, France	University College Cork; University of Naples Federico II; University of Naples Federico II; University of Salento; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	McCaffrey, MW (corresponding author), Univ Coll Cork, Cell & Mol Biol Lab, Dept Biochem, Prospect Row, Cork, Ireland.		Senic-Matuglia, Francesca/AAQ-3815-2020; Bucci, Cecilia/F-6699-2012; Lindsay, Andrew J/P-9778-2017; Goud, Bruno/GWC-4807-2022	Bucci, Cecilia/0000-0002-6232-6183; Lindsay, Andrew J/0000-0001-9693-7022; Hendrick, Alan/0000-0002-8604-0462				Bielli A, 2001, BIOCHEM BIOPH RES CO, V281, P1141, DOI 10.1006/bbrc.2001.4468; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Cormont M, 2001, P NATL ACAD SCI USA, V98, P1637, DOI 10.1073/pnas.031586998; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Li L, 2001, J BIOL CHEM, V276, P5265, DOI 10.1074/jbc.M003883200; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Mammoto A, 1999, J BIOL CHEM, V274, P25517, DOI 10.1074/jbc.274.36.25517; Matern H, 2000, EMBO J, V19, P4485, DOI 10.1093/emboj/19.17.4485; McCaffrey MW, 2001, FEBS LETT, V495, P21, DOI 10.1016/S0014-5793(01)02359-6; McLauchlan H, 1998, CURR BIOL, V8, P34, DOI 10.1016/S0960-9822(98)70018-1; MERESSE S, 1995, J CELL SCI, V108, P3349; Nagelkerken B, 2000, BIOCHEM J, V346, P593, DOI 10.1042/0264-6021:3460593; Prekeris R, 2001, J BIOL CHEM, V276, P38966, DOI 10.1074/jbc.M106133200; Prekeris R, 2000, MOL CELL, V6, P1437, DOI 10.1016/S1097-2765(00)00140-4; Rodman JS, 2000, J CELL SCI, V113, P183; Sanger F, 1992, Biotechnology, V24, P104; Schmid SL, 1998, NATURE, V392, P135, DOI 10.1038/32309; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Trischler M, 1999, J CELL SCI, V112, P4773; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; URBE S, 1993, FEBS LETT, V334, P175, DOI 10.1016/0014-5793(93)81707-7; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; Verges M, 1999, P NATL ACAD SCI USA, V96, P10146, DOI 10.1073/pnas.96.18.10146; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; Vitelli R, 1997, J BIOL CHEM, V272, P4391, DOI 10.1074/jbc.272.7.4391; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang DR, 1999, J CLIN INVEST, V104, P1265, DOI 10.1172/JCI8003; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; Zeng JB, 1999, P NATL ACAD SCI USA, V96, P2840, DOI 10.1073/pnas.96.6.2840	44	132	155	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12190	12199		10.1074/jbc.M108665200	http://dx.doi.org/10.1074/jbc.M108665200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11786538	hybrid			2022-12-27	WOS:000174846400077
J	Mushtaq, A; Payton, M; Sim, E				Mushtaq, A; Payton, M; Sim, E			The COOH terminus of arylamine N-acetyltransferase from Salmonella typhimurium controls enzymic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYARYLAMINE O-ACETYLTRANSFERASE; METABOLIC-ACTIVATION; AUTOMATED DOCKING; ESCHERICHIA-COLI; EXPRESSION; PURIFICATION; PROTEINS; NAT1; IDENTIFICATION; ACETYLATION	Arylamine N-acetyltransferases (NATs) are a homologous family of enzymes, which acetylate arylamines, arylhydroxylamines, and arylhydrazines by acetyl transfer from acetyl-coenzyme A (Ac-CoA) and are found in many organisms. NAT was first identified as the enzyme responsible for the inactivation of the anti-tubercular drug isoniazid in humans. The three-dimensional structure of NAT from Salmonella typhimurium has been resolved and shown to have three distinct domains and an active site catalytic triad composed of "Cys(69)-His(107)-Asp(122)," which is typical of hydrolytic enzymes such as the cysteine proteases. The crystal unit cell consists of a dimer of tetramers, with the C terminus of individual monomers juxtaposed. To investigate the function of the first two domains of full-length NAT from S. typhimurium and to investigate the role of the C terminus of NAT, truncation mutants were made with either the C-terminal undecapeptide or the entire third domain (85 amino acids) missing. Unlike the full-length NAT protein (281 amino acids), the truncation mutants of NAT from S. typhimurium are toxic when overexpressed intracellularly in Escherichia coli. Full-length NAT hydrolyses Ac-CoA but only in the presence of an arylamine substrate. Both truncation mutants, however, hydrolyze Ac-CoA even in the absence of arylamine substrate, illustrating that the C-terminal undecapeptide controls hydrolysis of Ac-CoA by NAT from S. typhimurium.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Oxford	Mushtaq, A (corresponding author), Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England.	adeel.mushtaq@pharm.ox.ac.uk						BJORCK A, 1967, BIT, V7, P1, DOI DOI 10.1007/BF01934122; Chang FC, 1998, CURR MICROBIOL, V36, P125, DOI 10.1007/PL00006755; Chung JG, 1997, TOXICOL LETT, V91, P63, DOI 10.1016/S0378-4274(97)03870-8; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; Dang LN, 1999, TOXICOL APPL PHARM, V159, P77, DOI 10.1006/taap.1999.8727; DAVIS NG, 1985, J MOL BIOL, V181, P111, DOI 10.1016/0022-2836(85)90329-8; Delomenie C, 2001, J BACTERIOL, V183, P3417, DOI 10.1128/JB.183.11.3417-3427.2001; Floss HG, 1999, CURR OPIN CHEM BIOL, V3, P592, DOI 10.1016/S1367-5931(99)00014-9; GRAF L, 1988, INT J PEPT PROT RES, V32, P512; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HEIN DW, 1994, ARCH TOXICOL, V68, P129, DOI 10.1007/s002040050045; HEIN DW, 1992, TOXICOL LETT, V64-5, P123, DOI 10.1016/0378-4274(92)90181-I; HUTCHINGS A, 1983, J CHROMATOGR, V277, P385, DOI 10.1016/S0378-4347(00)84863-X; HUTCHINGS B. L., 1941, JOUR BIOL CHEM, V141, P521; JENCKS WP, 1972, J BIOL CHEM, V247, P3756; Josephy PD, 1998, CHEM RES TOXICOL, V11, P70, DOI 10.1021/tx970171q; King CM, 1997, MUTAT RES-FUND MOL M, V376, P123, DOI 10.1016/S0027-5107(97)00034-1; Laskowski RA, 1997, TRENDS BIOCHEM SCI, V22, P488, DOI 10.1016/S0968-0004(97)01140-7; Lawson CL, 1974, SOLVING LEAST SQUARE; Mierendorf RC, 1998, METH MOLEC MED, V13, P257, DOI 10.1385/0-89603-485-2:257; MIEYAL JJ, 1974, J BIOL CHEM, V249, P2633; MINCHIN RF, 1995, BIOCHEM J, V307, P1; Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Pagano M, 1999, ANAL CHIM ACTA, V383, P119, DOI 10.1016/S0003-2670(98)00493-0; Pan SH, 2000, BIOTECHNIQUES, V29, P1234, DOI 10.2144/00296st03; Payton M, 1999, J BACTERIOL, V181, P1343, DOI 10.1128/JB.181.4.1343-1347.1999; Payton M, 2001, MICROBIOL-SGM, V147, P1137, DOI 10.1099/00221287-147-5-1137; PRUSS BM, 1994, MOL MICROBIOL, V12, P973; RIDDLE B, 1971, J BIOL CHEM, V246, P3250; SANDY J, 2002, IN PRESS J MOL BIOL; SIM RB, 1981, BIOCHEM J, V193, P129, DOI 10.1042/bj1930129; Sinclair J, 1997, BIOCHEM PHARMACOL, V53, P11, DOI 10.1016/S0006-2952(96)00592-8; Sinclair JC, 2000, NAT STRUCT BIOL, V7, P560; Sinclair JC, 1998, PROTEIN EXPRES PURIF, V12, P371, DOI 10.1006/prep.1997.0856; TAKAMURA Y, 1988, J GEN MICROBIOL, V134, P2249; THORNE CJR, 1978, TECHNIQUES PROTEIN B, V104, P1; Turk D, 1998, BIOL CHEM, V379, P137, DOI 10.1515/bchm.1998.379.2.137; UEYAMA M, 1974, NUCLEIC ACIDS RES, V1, P823, DOI 10.1093/nar/1.6.823; Upton A, 2000, BBA-GEN SUBJECTS, V1524, P143, DOI 10.1016/S0304-4165(00)00149-5; Upton A, 2001, TRENDS PHARMACOL SCI, V22, P140, DOI 10.1016/S0165-6147(00)01639-4; VASQUEZ JR, 1989, J CELL BIOCHEM, V39, P265, DOI 10.1002/jcb.240390306; WALKER J, 1998, Patent No. 09802559; WARD A, 1995, BIOCHEM PHARMACOL, V49, P1759, DOI 10.1016/0006-2952(95)00087-G; WATANABE M, 1987, BIOCHEM BIOPH RES CO, V147, P974, DOI 10.1016/S0006-291X(87)80165-1; WATANABE M, 1992, J BIOL CHEM, V267, P8429; WATANABE T, 1989, NUMERICAL CALCULATIO; Yu TW, 1999, P NATL ACAD SCI USA, V96, P9051, DOI 10.1073/pnas.96.16.9051; ZINDER ND, 1986, Patent No. 416922; 2000, TRIPOS SYBYL VERSION	50	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12175	12181		10.1074/jbc.M104365200	http://dx.doi.org/10.1074/jbc.M104365200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11799105	hybrid			2022-12-27	WOS:000174846400075
J	McCain, DF; Catrina, IE; Hengge, AC; Zhang, ZY				McCain, DF; Catrina, IE; Hengge, AC; Zhang, ZY			The catalytic mechanism of Cdc25A phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; LOW-MOLECULAR-WEIGHT; TRANSITION-STATE STRUCTURES; SUBSTRATE-TRAPPING MUTANTS; LEAVING GROUP DEPENDENCE; P-NITROPHENYL PHOSPHATE; CRYSTAL-STRUCTURE; CELL-CYCLE; BOVINE HEART; KINASE PHOSPHATASE-3	Cdc25 phosphatases are dual specificity phosphatases that dephosphorylate and activate cyclin-dependent kinases (CDKs), thereby effecting the progression from one phase of the cell cycle to the next. Despite its central role in the cell cycle, relatively little is known about the catalytic mechanism of Cdc25. In order to provide insights into the catalytic mechanism of Cdc25, we have performed a detailed mechanistic analysis of the catalytic domain of human Cdc25A. Our kinetic isotope effect results, Bronsted analysis, and pH dependence studies employing a range of aryl phosphates clearly indicate a dissociative transition state for the Cdc25A reaction that does not involve a general acid for the hydrolysis of substrates with low leaving group p, values (5.45-8.05). Interestingly, our Bronsted analyis and pH dependence studies reveal that Cdc25A employs a different mechanism for the hydrolysis of substrates with high leaving group pK(alpha), values (8.68-9.99) that appears to require the protonation of glutamic acid 431. Mutation of glutamic acid 431 into glutamine leads to a dramatic drop in the hydrolysis rate for the high leaving group pK(alpha) substrates and the disappearance of the basic limb of the pH rate profile for the substrate with a leaving group pK(alpha) of 8.05, indicating that glutamic acid 431 is essential for the efficient hydrolysis of substrates with high leaving group pK(alpha). We suggest that hydrolysis of the high leaving group pK(alpha) substrates proceeds through an unfavored but more catalytically active form of Cdc25A, and we propose several models illustrating this. Since the activity of Cdc25A toward small molecule substrates is several orders of magnitude lower than toward the physiological substrate, cyclin-CDK, we suggest that the cyclin-CDK is able to preferentially induce this more catalytically active form of Cdc25A for efficient phosphothreonine and phosphotyrosine dephosphorylation.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Utah System of Higher Education; Utah State University	Zhang, ZY (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	zyzhang@aecom.yu.edu	Hengge, Alvan C/C-8667-2011	Hengge, Alvan C/0000-0002-5696-2087; Catrina, Irina/0000-0001-5976-4548	NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047297, R01GM047297] Funding Source: NIH RePORTER; NCI NIH HHS [CA69202] Funding Source: Medline; NIGMS NIH HHS [R01 GM047297, GM47297] Funding Source: Medline; OHS HRSA HHS [ST32GM07260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OHS HRSA HHS		BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BIGELEISEN J, 1958, ADV CHEM PHYS, V1, P15; BLACK MJ, 1983, ANAL BIOCHEM, V135, P233, DOI 10.1016/0003-2697(83)90756-X; Broggini M, 2000, ANTICANCER RES, V20, P4835; CALDWELL SR, 1991, BIOCHEMISTRY-US, V30, P7444, DOI 10.1021/bi00244a011; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Chen L, 1996, BIOCHEMISTRY-US, V35, P9349, DOI 10.1021/bi960700+; Chen W, 2000, BIOCHEMISTRY-US, V39, P10781, DOI 10.1021/bi000909u; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; CIRRI P, 1993, EUR J BIOCHEM, V214, P647, DOI 10.1111/j.1432-1033.1993.tb17965.x; Cleland WW, 1995, FASEB J, V9, P1585, DOI 10.1096/fasebj.9.15.8529838; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Eckstein JW, 1996, PROTEIN SCI, V5, P5; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Fjeld CC, 2000, J BIOL CHEM, V275, P6749, DOI 10.1074/jbc.275.10.6749; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Gottlin EB, 1996, J BIOL CHEM, V271, P27445, DOI 10.1074/jbc.271.44.27445; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HALL AD, 1986, BIOCHEMISTRY-US, V25, P4784, DOI 10.1021/bi00365a010; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; Hengge AC, 1996, BIOCHEMISTRY-US, V35, P7084, DOI 10.1021/bi960255i; HENGGE AC, 1994, J AM CHEM SOC, V116, P5045, DOI 10.1021/ja00091a003; Hengge AC, 1997, BIOCHEMISTRY-US, V36, P7928, DOI 10.1021/bi970364c; Hernandez S, 2000, INT J CANCER, V89, P148, DOI 10.1002/(SICI)1097-0215(20000320)89:2<148::AID-IJC8>3.0.CO;2-R; Hernandez S, 2001, LAB INVEST, V81, P465, DOI 10.1038/labinvest.3780254; Hoff RH, 1999, J AM CHEM SOC, V121, P9514, DOI 10.1021/ja992361o; HOFFMANN I, 1994, J CELL SCI, P75; Hofmann K, 1998, J MOL BIOL, V282, P195, DOI 10.1006/jmbi.1998.1998; Iversen LF, 2000, J BIOL CHEM, V275, P10300, DOI 10.1074/jbc.275.14.10300; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; KIRBY AJ, 1967, J AM CHEM SOC, V89, P415, DOI 10.1021/ja00978a044; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Northrop D. B., 1977, ISOTOPE EFFECTS ENZY, P122; OLEARY MH, 1979, J AM CHEM SOC, V101, P3300, DOI 10.1021/ja00506a027; Peng HR, 2001, J MED CHEM, V44, P834, DOI 10.1021/jm0004401; Reynolds RA, 1999, J MOL BIOL, V293, P559, DOI 10.1006/jmbi.1999.3168; Rigas JD, 2001, BIOCHEMISTRY-US, V40, P4398, DOI 10.1021/bi002951v; Sarmiento M, 2000, BIOCHEMISTRY-US, V39, P8171, DOI 10.1021/bi000319w; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; TADDEI N, 1994, FEBS LETT, V350, P328, DOI 10.1016/0014-5793(94)00805-1; Takahashi M, 2000, BIOORG MED CHEM LETT, V10, P2571, DOI 10.1016/S0960-894X(00)00527-8; Tamura K, 1999, ONCOGENE, V18, P6989, DOI 10.1038/sj.onc.1203179; Wang SS, 2000, BIOCHEMISTRY-US, V39, P1903, DOI 10.1021/bi991348d; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; Wu FYH, 1999, EUR J CANCER, V35, P1388, DOI 10.1016/S0959-8049(99)00156-2; Wu L, 1996, BIOCHEMISTRY-US, V35, P5426, DOI 10.1021/bi952885a; Xu X, 1996, J BIOL CHEM, V271, P5118; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; Zhang YL, 2000, J BIOL CHEM, V275, P34205, DOI 10.1074/jbc.M004490200; Zhang YL, 1999, BIOCHEMISTRY-US, V38, P12111, DOI 10.1021/bi990836i; ZHANG ZT, 1994, J BIOL CHEM, V269, P25947; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16389, DOI 10.1021/bi00050a020; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1991, BIOCHEMISTRY-US, V30, P8954, DOI 10.1021/bi00101a006; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16088, DOI 10.1021/bi00049a024; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1; ZHANG ZY, 1995, J BIOL CHEM, V270, P11199, DOI 10.1074/jbc.270.19.11199; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007; Zhao Y, 1996, BIOCHEMISTRY-US, V35, P11797, DOI 10.1021/bi960471r; Zhao Y, 1998, J BIOL CHEM, V273, P5484, DOI 10.1074/jbc.273.10.5484; Zhao Y, 2001, J BIOL CHEM, V276, P32382, DOI 10.1074/jbc.M103369200; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200; Zhou B, 1999, J BIOL CHEM, V274, P35526, DOI 10.1074/jbc.274.50.35526	79	43	43	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11190	11200		10.1074/jbc.M109636200	http://dx.doi.org/10.1074/jbc.M109636200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11805096	hybrid			2022-12-27	WOS:000174613100057
J	Murphy, FR; Issa, R; Zhou, XY; Ratnarajah, S; Nagase, H; Arthur, MJP; Benyon, C; Iredale, JP				Murphy, FR; Issa, R; Zhou, XY; Ratnarajah, S; Nagase, H; Arthur, MJP; Benyon, C; Iredale, JP			Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition - Implications for reversibility of liver fibrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; RNA EXPRESSION; IN-VITRO; PROLIFERATION; LIPOCYTES; RESOLUTION; MECHANISM; TIMP-1; DEATH; INVASION	The activated hepatic stellate cell (HSC) is central to liver fibrosis as the major source of collagens I and III and the tissue inhibitors of metalloproteinase-I (TIMP1). During spontaneous recovery from liver fibrosis, there is a decrease of TIMP expression, an increase in collagenase activity, and increased apoptosis of HSC, highlighting a potential role for TIMP-1 in HSC survival. In this report, we use tissue culture and in vivo models to demonstrate that TIMP-1 directly inhibits HSC apoptosis. TIMP-1 demonstrated a consistent, significant, and dose-dependent antiapoptotic effect for HSC activated in tissue culture and stimulated to undergo apoptosis by serum deprivation, cycloheximide exposure, and nerve growth factor stimulation. A nonfunctional mutated TIMP-1 (T2G mutant) in which all other domains are conserved did not inhibit apoptosis, indicating that inhibition of apoptosis was mediated through MMP inhibition. Synthetic MMP inhibitors also inhibited HSC apoptosis. Studies of experimental liver cirrhosis demonstrated that persistent expression of TIMIP-1 mRNA determined by PCR correlated with persistence of activated HSC quantified by a smooth muscle actin staining, while in fibrosis, loss of activated HSC correlated with a reduction in TIMP-1 mRNA. We conclude that TIMP-1 inhibits apoptosis of activated HSC via MMP inhibition.	Univ Southampton, Liver Grp, Div Infect Inflammat & Repair, Southampton SO16 6YD, Hants, England; Univ London Imperial Coll Sci Technol & Med, Kennedy Inst, London SW7 2AZ, England	University of Southampton; Imperial College London; University of Oxford	Murphy, FR (corresponding author), Univ Southampton, Liver Grp, Div Infect Inflammat & Repair, Level D,S Block,Tremona Rd, Southampton SO16 6YD, Hants, England.	frm105@hotmail.com		Iredale, John/0000-0003-2174-5127				Alcolado R, 1997, CLIN SCI, V92, P103, DOI 10.1042/cs0920103; ARTHUR MJP, 1989, J CLIN INVEST, V84, P1076, DOI 10.1172/JCI114270; BACHEM MG, 1992, J CLIN INVEST, V89, P19, DOI 10.1172/JCI115561; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; BAKER AJ, 1994, J CLIN INVEST, V94, P2105, DOI 10.1172/JCI117565; Barasch J, 1999, J CLIN INVEST, V103, P1299, DOI 10.1172/JCI4586; Benyon RC, 1996, GASTROENTEROLOGY, V110, P821, DOI 10.1053/gast.1996.v110.pm8608892; BOULTON RA, 1995, CLIN SCI, V88, P119, DOI 10.1042/cs0880119; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; Gong WR, 1998, HEPATOLOGY, V28, P492, DOI 10.1002/hep.510280229; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HERBST H, 1991, VIRCHOWS ARCH B, V60, P295, DOI 10.1007/BF02899560; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Iredale JP, 1996, HEPATOLOGY, V24, P176, DOI 10.1002/hep.510240129; IREDALE JP, 1995, CLIN SCI, V89, P75, DOI 10.1042/cs0890075; Issa R, 2001, GUT, V48, P548, DOI 10.1136/gut.48.4.548; Kikuchi K, 1997, J INVEST DERMATOL, V108, P281, DOI 10.1111/1523-1747.ep12286457; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Li GY, 1999, CANCER RES, V59, P6267; Lim MS, 1999, ANN NY ACAD SCI, V878, P522, DOI 10.1111/j.1749-6632.1999.tb07715.x; Madge LA, 1999, J BIOL CHEM, V274, P13643, DOI 10.1074/jbc.274.19.13643; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; Meng Q, 1999, J BIOL CHEM, V274, P10184, DOI 10.1074/jbc.274.15.10184; MILANI S, 1992, HEPATOLOGY, V16, pA186; Ree AH, 1997, CLIN CANCER RES, V3, P1623; Saile B, 1999, HEPATOLOGY, V30, P196, DOI 10.1002/hep.510300144; Saile B, 1997, AM J PATHOL, V151, P1265; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Stahelin BJ, 1998, J CLIN PATHOL-MOL PA, V51, P204; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; Trim N, 2000, AM J PATHOL, V156, P1235, DOI 10.1016/S0002-9440(10)64994-2; Trim N, 2000, HEPATOLOGY, V32, p183A; Valente P, 1998, INT J CANCER, V75, P246, DOI 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B; VYAS SK, 1995, CELLS OF THE HEPATIC SINUSOID, VOL 5, P396; WINWOOD PJ, 1995, HEPATOLOGY, V22, P304; Wright MC, 2001, GASTROENTEROLOGY, V121, P685, DOI 10.1053/gast.2001.27188; Yoshiji H, 2000, HEPATOLOGY, V32, P1248, DOI 10.1053/jhep.2000.20521	42	350	397	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11069	11076		10.1074/jbc.M111490200	http://dx.doi.org/10.1074/jbc.M111490200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11796725	hybrid			2022-12-27	WOS:000174613100042
J	Schneider, D; Skrzypczak, S; Anemuller, S; Schmidt, CL; Seidler, A; Rogner, M				Schneider, D; Skrzypczak, S; Anemuller, S; Schmidt, CL; Seidler, A; Rogner, M			Heterogeneous Rieske proteins in the cytochrome b(6)f complex of Synechocystis PCC6803?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; PHOTOSYSTEM-I; EXPRESSION	The completely sequenced genome of the cyanobacterium Synechocystis PCC6803 contains three open reading frames, petC1, petC2, and petC3, encoding putative Rieske iron-sulfur proteins. After heterologous overexpression, all three gene products have been characterized and shown to be Rieske proteins as typified by sequence analysis and EPR spectroscopy. Two of the overproduced proteins contained already incorporated iron-sulfur clusters, whereas the third one formed unstable aggregates, in which the FeS cluster had to be reconstituted after refolding of the denatured protein. Although EPR spectroscopy showed typical FeS signals for all Rieske proteins, an unusual low midpoint potential was revealed for PetC3 by EPR redox titration. Detailed characterization of Synechocystis membranes indicated that all three Rieske proteins are expressed under physiological conditions. Both for PetC1 and PetC3 the association with the thylakoid membrane was shown, and both could be identified, although in different amounts, in the isolated cytochrome b(6)f complex. The considerably lower redox potential determined for PetC3 indicates heterogeneous cytochrome b(6)f complexes in Synechocystis and suggests still to be established alternative electron transport routes.	Ruhr Univ Bochum, Fak Biol, Lehrstuhl Biochem Pflanzen, D-44780 Bochum, Germany; Med Univ Lubeck, Inst Biochem, D-23562 Lubeck, Germany	Ruhr University Bochum; University of Lubeck	Rogner, M (corresponding author), Ruhr Univ Bochum, Fak Biol, Lehrstuhl Biochem Pflanzen, D-44780 Bochum, Germany.	Matthias.Roegner@ruhr-uni-bochum.de						ANEMULLER S, 1994, EUR J BIOCHEM, V210, P133; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; Crofts AR, 1998, CURR OPIN STRUC BIOL, V8, P501, DOI 10.1016/S0959-440X(98)80129-2; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; GRISSHAMMER R, 1995, Q REV BIOPHYS, V28, P315, DOI 10.1017/S0033583500003504; HAUSKA G, 1997, CYTOCHROME B6FLBC1 B, P389; Henninger T, 1999, J BIOENERG BIOMEMBR, V31, P119, DOI 10.1023/A:1005447710894; Holton B, 1996, BIOCHEMISTRY-US, V35, P15485, DOI 10.1021/bi961367c; IWATA S, 1996, STRUCTURE, V277, P60; Johnson TW, 2000, J BIOL CHEM, V275, P8523, DOI 10.1074/jbc.275.12.8523; Kallas T, 1994, MOL BIOL CYANOBACTER, V1, P259, DOI DOI 10.1007/978-94-011-0227-8_9; Kaneko T, 1997, PLANT CELL PHYSIOL, V38, P1171, DOI 10.1093/oxfordjournals.pcp.a029103; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; Karnauchov I, 1997, FEBS LETT, V408, P206, DOI 10.1016/S0014-5793(97)00427-4; Kramer DM, 1997, BIOCHEMISTRY-US, V36, P4203, DOI 10.1021/bi962241i; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TX, 2000, BIOCHIM BIOPHYS ACTA, V1504, P235; LIEBL U, 1992, J BIOL CHEM, V267, P14068; MAYES ER, 1991, PLANT MOL BIOL, V17, P189; RICH PR, 1980, BIOCHIM BIOPHYS ACTA, V591, P153, DOI 10.1016/0005-2728(80)90229-7; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; ROGNER M, 1990, J BIOL CHEM, V265, P6189; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmidt CL, 1997, BIOCHEM BIOPH RES CO, V234, P283, DOI 10.1006/bbrc.1997.6599; Schneider D, 2000, INDIAN J BIOCHEM BIO, V37, P441; SCHOEPFER R, 1993, GENE, V124, P83, DOI 10.1016/0378-1119(93)90764-T; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876	27	33	33	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10949	10954		10.1074/jbc.M104076200	http://dx.doi.org/10.1074/jbc.M104076200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11788579	hybrid			2022-12-27	WOS:000174613100026
J	Chang, NS				Chang, NS			The non-ankyrin C terminus of I kappa B alpha physically interacts with p53 in vivo and dissociates in response to apoptotic stress, hypoxia, DNA damage, and transforming growth factor-beta 1-mediated growth suppression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR CYTOTOXICITY; TGF-BETA; NUCLEAR TRANSLOCATION; CELL-PROLIFERATION; L929 FIBROBLASTS; EPITHELIAL-CELLS; MATRIX PROTEINS; MESSENGER-RNA; ACTIVATION; DEGRADATION	Transforming growth factor beta (TGF-beta1) suppresses the growth of mink lung Mv1Lu epithelial cells, whereas testicular hyaluronidase abolishes the growth inhibition. Exposure of Mv1Lu cells to TGF-betal rapidly resulted in down-regulation of cytosolic IkappaBalpha and hyaluronidase prevented this effect, suggesting a possible role of IkappaBalpha in the growth regulation. Ectopic expression of wildtype and dominant negative IkappaBalpha prevented TGF-beta1-mediated growth suppression. Nonetheless, the blocking effect of IkappaBalpha is not related to regulation of NF-kappaB function by its N-terminal ankyrin-repeat region (amino acids 1-243). Removal of the PEST (proline-glutamic acid-serine-threonine) domain-containing C terminus (amino acids 244-314) abolished the IkappaBalpha function, and the C terminus alone blocked the TGF-beta1 growth-inhibitory effect. Co-immunoprecipitation by anti-p53 antibody using Mv1Lu and other types of cells, as well as rat liver and spleen, revealed that a portion of cytosolic IkappaBalpha physically interacted with p53. In contrast, Mdm2, an inhibitor of p53, was barely detectable in the immunoprecipitates. The cytosolic p53-IkappaBalpha complex rapidly dissociated in response to apoptotic stress, etoposide-and UV-mediated DNA damage, hypoxia, and TGF-beta1-mediated growth suppression. Also, a rapid increase in the formation of the nuclear p53-IkappaBalpha complex was observed during exposure to etoposide and UV. In contrast, TGF-beta1-mediated promotion of fibroblast growth failed to mediate p,53-IkappaBalpha dissociation. Mapping by yeast two-hybrid showed that the non-ankyrin C terminus of IkappaBalpha physically interacted with the proline-rich region and a phosphorylation site, serine 46, in p53. Deletion of serine 46 or alteration of serine 46 to glycine abolished the p53-IkappaBalpha interaction. Alteration to threonine retained the binding interaction, suggesting that serine 46 phosphorylation is involved in the p53-IkappaBalpha complex formation. Functionally, enhancement of p53 apoptosis was observed when p53 and IkappaBalpha were transiently co-expressed in cells. Together, the IkappaBalpha-p53 complex plays an important role in responses involving growth regulation, apoptosis, and hypoxic stress.	Guthrie Med Ctr, Lab Mol Immunol, Guthrie Res Inst, Sayre, PA 18840 USA		Chang, NS (corresponding author), Guthrie Med Ctr, Lab Mol Immunol, Guthrie Res Inst, Sayre, PA 18840 USA.	nschang@inet.guthrie.org						Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200; Ashcroft GS, 2000, CYTOKINE GROWTH F R, V11, P125, DOI 10.1016/S1359-6101(99)00036-2; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Berger M, 2001, J BIOL CHEM, V276, P3785, DOI 10.1074/jbc.M008879200; Bitzer M, 2000, GENE DEV, V14, P187; BLAYDES JP, 1995, ONCOGENE, V10, P307; Canty TG, 1999, CIRCULATION, V100, P361; Chang NS, 1997, AM J PHYSIOL-CELL PH, V273, pC1987, DOI 10.1152/ajpcell.1997.273.6.C1987; Chang NS, 1998, INT J MOL MED, V2, P653; Chang NS, 2000, BIOCHEM BIOPH RES CO, V267, P194, DOI 10.1006/bbrc.1999.1909; CHANG NS, 1995, J BIOL CHEM, V270, P7765, DOI 10.1074/jbc.270.13.7765; Chang NS, 1998, BIOCHEM BIOPH RES CO, V253, P743, DOI 10.1006/bbrc.1998.9846; Chang NS, 2002, INT J MOL MED, V9, P19; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Doerre S, 1999, J IMMUNOL, V163, P269; Finlay GA, 2000, J BIOL CHEM, V275, P27650; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Lallemand F, 2001, ONCOGENE, V20, P879, DOI 10.1038/sj.onc.1204167; Landesman Y, 1997, CELL SIGNAL, V9, P291, DOI 10.1016/S0898-6568(97)89890-7; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Liu ZQ, 1996, FEBS LETT, V385, P109, DOI 10.1016/0014-5793(96)00360-2; Nagarajan RP, 2000, BIOCHEM J, V348, P591, DOI 10.1042/0264-6021:3480591; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Rorke EA, 2000, EXP CELL RES, V259, P149, DOI 10.1006/excr.2000.4953; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Sovak MA, 1999, CELL GROWTH DIFFER, V10, P537; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; Toda H, 2000, ANTICANCER RES, V20, P165; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; Weil R, 1999, MOL CELL BIOL, V19, P6345; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	39	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					10323	10331		10.1074/jbc.M106607200	http://dx.doi.org/10.1074/jbc.M106607200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11799106	hybrid			2022-12-27	WOS:000174549200095
J	Malakhov, MP; Malakhova, OA; Kim, KI; Ritchie, KJ; Zhang, DE				Malakhov, MP; Malakhova, OA; Kim, KI; Ritchie, KJ; Zhang, DE			UBP43 (USP18) specifically removes ISG15 from conjugated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-SPECIFIC PROTEASE; INDUCED 15-KDA PROTEIN; DEUBIQUITINATING ENZYMES; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; INTERFERON-ALPHA; CLONING; HOMOLOG; FAMILY; BETA	UBP43 shows significant homology to well characterized ubiquitin-specific proteases and previously was shown to hydrolyze ubiquitin-beta-galactosidase fusions in Escherichia coli. In our assays, the activity of UBP43 toward Ub fusions was undetectable in vitro directing us to investigate the possibility of Ub-like proteins such as SUMO, Nedd8, and ISG15 as probable substrates. We consequently demonstrate that UBP43 can efficiently cleave only ISG15 fusions including native ISG15 conjugates linked via isopeptide bonds. In addition to commonly used methods we introduce a new experimental design featuring ISG15-UBP43 fusion self-processing. Deletion of the UBP43 gene in mouse leads to a massive increase of ISG15 conjugates in tissues indicating that UBP43 is a major ISG15-specific protease. UBP43 is the first bona fide ISG15-specific protease reported. Both ISG15 and UBP43 genes are known to be strongly induced by interferon, genotoxic stress, and viral infection. We postulate that UBP43 is necessary to maintain a critical cellular balance of ISG15-conjugated proteins in both healthy and stressed organisms.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Zhang, DE (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM-L51,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dzhang@scripps.edu	KIM, KEUN IL/D-2959-2011	Ritchie, Kenneth/0000-0002-8504-6918	NATIONAL CANCER INSTITUTE [R01CA079849] Funding Source: NIH RePORTER; NCI NIH HHS [CA79849] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER RT, 1994, J BIOL CHEM, V269, P25381; Baker RT, 1999, GENOMICS, V59, P264, DOI 10.1006/geno.1999.5879; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BLOMSTROM DC, 1986, J BIOL CHEM, V261, P8811; Callis J, 2000, CURR OPIN PLANT BIOL, V3, P381, DOI 10.1016/S1369-5266(00)00100-X; Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; DCunha J, 1996, P NATL ACAD SCI USA, V93, P211, DOI 10.1073/pnas.93.1.211; DCunha J, 1996, J IMMUNOL, V157, P4100; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; FARRELL PJ, 1979, NATURE, V279, P523, DOI 10.1038/279523a0; Gilchrist CA, 2000, BBA-PROTEIN STRUCT M, V1481, P297, DOI 10.1016/S0167-4838(00)00134-5; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Kang DC, 2001, GENE, V267, P233, DOI 10.1016/S0378-1119(01)00384-5; Kawakami T, 1999, J BIOCHEM, V126, P612, DOI 10.1093/oxfordjournals.jbchem.a022493; KNIGHT E, 1991, J IMMUNOL, V146, P2280; KNIGHT E, 1988, J BIOL CHEM, V263, P4520; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Layfield R, 1999, ANAL BIOCHEM, V274, P40, DOI 10.1006/abio.1999.4234; Li J, 2001, J BIOL CHEM, V276, P18579, DOI 10.1074/jbc.M100846200; Li XL, 2000, J BIOL CHEM, V275, P8880, DOI 10.1074/jbc.275.12.8880; Lin HJ, 2001, J BIOL CHEM, V276, P20357, DOI 10.1074/jbc.M008761200; Liu LQ, 1999, MOL CELL BIOL, V19, P3029; LOEB KR, 1992, J BIOL CHEM, V267, P7806; LOEB KR, 1994, MOL CELL BIOL, V14, P8408, DOI 10.1128/MCB.14.12.8408; McLaughlin PMJ, 2000, INT J CANCER, V85, P871, DOI 10.1002/(SICI)1097-0215(20000315)85:6<871::AID-IJC22>3.0.CO;2-O; MEMET S, 1991, J INTERFERON RES, V11, P131, DOI 10.1089/jir.1991.11.131; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Potter JL, 1999, J BIOL CHEM, V274, P25061, DOI 10.1074/jbc.274.35.25061; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schwer H, 2000, GENOMICS, V65, P44, DOI 10.1006/geno.2000.6148; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Wilkinson KD, 1998, UBIQUITIN BIOL CELL, P99; WOO SK, 1995, J BIOL CHEM, V270, P18766, DOI 10.1074/jbc.270.32.18766; Yan N, 2000, PLANT PHYSIOL, V124, P1828, DOI 10.1104/pp.124.4.1828; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; Zhang XX, 1999, VIROLOGY, V262, P152, DOI 10.1006/viro.1999.9914	44	364	379	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9976	9981		10.1074/jbc.M109078200	http://dx.doi.org/10.1074/jbc.M109078200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11788588	hybrid			2022-12-27	WOS:000174549200050
J	Nieto, N; Friedman, SL; Cederbaum, AI				Nieto, N; Friedman, SL; Cederbaum, AI			Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; MESSENGER-RNA; HEPG2 CELLS; LIVER; EXPRESSION; ALPHA-1(I); ETHANOL; IRON; FIBROGENESIS; CYP2E1	To evaluate possible fibrogenic effects of CYP2E1-dependent generation of reactive oxygen species, a model was developed using co-cultures of HepG2 cells, which do (E47 cells) or do not (C34 cells) express cytochrome P450 2E1 (CYP2E1) with stellate cells. There was an increase in intra- and extracellular H2O2, lipid peroxidation, and collagen type I protein in stellate cells co-cultured with E47 cells compared with stellate cells alone or co-cultured with C34 cells. The increase in collagen was prevented by antioxidants and a CYP2E1 inhibitor. CYP3A4 did not mimic the stimulatory effects found with CYP2E1. Collagen mRNA levels remained unchanged, and pulse-chase analysis indicated similar half-lives of collagen I protein between both co-cultures. However, collagen protein synthesis was increased in E47 co-culture. Hepatocytes from pyrazole-treated rats (with high levels of CYP2E1) induced collagen protein in primary stellate cells, and antioxidants and CYP2E1 inhibitors blocked this effect. These results suggest that increased translation of collagen mRNA by CYP2E1-derived reactive oxygen species is responsible for the increase in collagen protein produced by the E47 co-culture. These co-culture models may be useful for understanding the impact of CYP2E1-derived ROS on stellate cell function and activation.	CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med & Liver Dis, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Cederbaum, AI (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, Box 1603,1 Gustave L Levy Pl, New York, NY 10029 USA.	arthur.cederbaum@mssm.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA006610, R01AA006610, R01AA003312, R56AA003312] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA03312, AA06610] Funding Source: Medline; NIDDK NIH HHS [DK37340] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245; Baroni GS, 1998, HEPATOLOGY, V27, P720; BEDOSSA P, 1994, HEPATOLOGY, V19, P1262, DOI 10.1016/0270-9139(94)90876-1; CASTILLO T, 1992, HEPATOLOGY, V16, P992, DOI 10.1002/hep.1840160423; Chen Q, 1998, MOL PHARMACOL, V53, P638, DOI 10.1124/mol.53.4.638; DECROMBRUGGHE B, 1987, METHOD ENZYMOL, V144, P61; Deiana L, 1999, FREE RADICAL RES, V31, P237, DOI 10.1080/10715769900300801; Farinati F, 1996, HEPATOLOGY, V23, P1468; Fontana L, 1997, BBA-MOL BASIS DIS, V1362, P135, DOI 10.1016/S0925-4439(97)00056-2; FRAGA CG, 1987, FREE RADICAL BIO MED, V3, P119, DOI 10.1016/S0891-5849(87)80006-0; FRENCH SW, 1993, ALCOHOL ALCOHOLISM, V28, P97; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; GUALDI R, 1994, GASTROENTEROLOGY, V107, P1118, DOI 10.1016/0016-5085(94)90237-2; GUTA T, 1996, J CELL BIOCHEM, V61, P194; HOUGLUM K, 1990, J CLIN INVEST, V86, P1991, DOI 10.1172/JCI114934; KAMIMURA S, 1992, HEPATOLOGY, V16, P448, DOI 10.1002/hep.1840160225; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; KIRK TZ, 1987, J BIOL CHEM, V262, P5540; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; Mari M, 2001, HEPATOLOGY, V33, P652, DOI 10.1053/jhep.2001.22521; Montosi G., 1996, Journal of Hepatology, V25, P74; MORIMOTO M, 1995, J NUTR, V125, P2953; MYERS JC, 1983, J BIOL CHEM, V258, P128; NEBLOCK DS, 1986, BIOCHEMISTRY-US, V25, P6208, DOI 10.1021/bi00368a056; NIEMELA O, 1995, HEPATOLOGY, V22, P1208, DOI 10.1016/0270-9139(95)90630-4; Nieto N, 1999, HEPATOLOGY, V30, P987, DOI 10.1002/hep.510300433; Nieto N, 2001, HEPATOLOGY, V33, P597, DOI 10.1053/jhep.2001.22520; Nieto N, 2000, J BIOL CHEM, V275, P20136, DOI 10.1074/jbc.M001422200; PIETRANGELO A, 1994, HEPATOLOGY, V19, P714, DOI 10.1002/hep.1840190325; REINKE LA, 1985, DRUG METAB DISPOS, V13, P548; ROSSI P, 1987, NUCLEIC ACIDS RES, V15, P8935, DOI 10.1093/nar/15.21.8935; Stefanovic A, 2000, NUCLEIC ACIDS RES, V28, P641, DOI 10.1093/nar/28.2.641; Stefanovic B, 1999, MOL CELL BIOL, V19, P4334; TSUKAMOTO H, 1990, SEMIN LIVER DIS, V10, P56, DOI 10.1055/s-2008-1040457; VEIS A, 1989, J BIOL CHEM, V264, P3884; Vogel S, 2000, J LIPID RES, V41, P882; Wu DF, 2001, MOL PHARMACOL, V59, P795, DOI 10.1124/mol.59.4.795; WU DF, 1993, J PHARMACOL EXP THER, V264, P1468	38	140	147	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9853	9864		10.1074/jbc.M110506200	http://dx.doi.org/10.1074/jbc.M110506200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11782477	hybrid			2022-12-27	WOS:000174549200035
J	Rossig, L; Badorff, C; Holzmann, Y; Zeiher, AM; Dimmeler, S				Rossig, L; Badorff, C; Holzmann, Y; Zeiher, AM; Dimmeler, S			Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21(Cip1) degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATOR; CELL-SURVIVAL; PHOSPHORYLATION; PROTEIN; P21(WAF1/CIP1); LITHIUM; PATHWAY; P21; P53; UBIQUITINATION	Signaling via the phosphoinositide 3-kinase (PI3K)/ AHT pathway is crucial for the regulation of endothelial cell (EC) proliferation and survival, which involves the AKT-dependent phosphorylation of the DNA repair protein P21(CiP1) at Thr-145. Because p21(Cip1) is a short-lived protein with a high proteasomal degradation rate, we investigated the regulation of p21(Cip1) protein levels by PI3K/AKT-dependent signaling. The PI3K inhibitors Ly294002 and wortmannin reduced p21(Cip1) protein abundance in human umbilical vein EC. However, mutation of the ART site Thr-145 into aspartate (T145D) did not increase its protein half-life. We therefore investigated whether a kinase downstream of AKT regulates p21(Cip1) protein levels. In various cell types, AKT phosphorylates and inhibits glycogen synthase kinase-3 (GSK-3). Upon serum stimulation of EC, GSK-3beta was phosphorylated at Ser-9. Site-directed mutagenesis revealed that GSK-3 in vitro phosphorylated p21(Cip1) specifically at Thr-57 within the Cdk binding domain. Overexpression of GSK-3beta decreased p21(Cip1) protein levels in EC, whereas the specific inhibition of GSK-3 with lithium chloride interfered with P21(Cip1) degradation and increased p21(Cip1) protein about 10-fold in EC and cardiac myocytes (30 mm, p < 0.001). These data indicate that GSK-3 triggers p21(Cip1) degradation. In contrast, stimulation of AKT increases p21(Cip1) via inhibitory phosphorylation of GSK-3.	Univ Frankfurt, Dept Internal Med 4, Div Mol Cardiol, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Dimmeler, S (corresponding author), Univ Frankfurt, Dept Internal Med 4, Div Mol Cardiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.			Dimmeler, Stefanie/0000-0002-1045-2436				Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; Chen RW, 1999, J BIOL CHEM, V274, P6039, DOI 10.1074/jbc.274.10.6039; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukuchi K, 2000, BBA-MOL CELL RES, V1496, P207, DOI 10.1016/S0167-4889(00)00018-5; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Lawlor MA, 2000, J CELL BIOL, V151, P1131, DOI 10.1083/jcb.151.6.1131; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Mao CD, 2001, J BIOL CHEM, V276, P26180, DOI 10.1074/jbc.M101188200; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Scott MT, 2000, J BIOL CHEM, V275, P11529, DOI 10.1074/jbc.275.15.11529; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Stivala LA, 2001, ONCOGENE, V20, P563, DOI 10.1038/sj.onc.1204132; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Weiss RH, 2000, J BIOL CHEM, V275, P10285, DOI 10.1074/jbc.275.14.10285; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	29	179	185	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9684	9689		10.1074/jbc.M106157200	http://dx.doi.org/10.1074/jbc.M106157200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11779850	hybrid			2022-12-27	WOS:000174549200012
J	Wang, SX; Shiva, S; Poczatek, MH; Darley-Usmar, V; Murphy-Ullrich, JE				Wang, SX; Shiva, S; Poczatek, MH; Darley-Usmar, V; Murphy-Ullrich, JE			Nitric oxide and cGMP-dependent protein kinase regulation of glucose-mediated thrombospondin 1-dependent transforming growth factor-beta activation in mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; GENE-EXPRESSION; MESSENGER-RNA; DIABETIC-RATS; GMP; TGF-BETA-1; SYNTHASE; STIMULATION	Excessive transforming growth factor-beta (TGF-beta) activity in hyperglycemia contributes to the development of diabetic nephropathy. Glucose stimulation of TGF-beta activity and matrix synthesis are dependent on autocrine thrombospondin 1 (TSP1) to convert latent TGF-beta to its biologically active form. The mechanisms by which glucose regulates TSPI are not known. High glucose inhibits nitric oxide (NO) bioavailability and decreased NO increases TGF-beta activity and extracellular matrix accumulation. Yet, the impact of NO signaling on TSP1 activation of TGF-beta is unknown. We tested the role of NO signaling in the regulation of TSP1 expression and TSP1-dependent TGF-beta activity in rat mesangial cells exposed to high glucose. On exposure to 30 mm glucose, NO accumulation in the conditioned media and intracellular cGMP levels were significantly decreased. The addition of an NO donor prevented the glucose-dependent increase in TSPI mRNA, protein, and TGF-beta bioactivity. The effects of the NO donor were blocked by ODQ (a soluble guanylate cyclase inhibitor) or Rp-8-pCPT-cGMPS (an inhibitor of cGMP-dependent protein kinase). These effects of high glucose were also reversed by the nitric-oxide synthase cofactor tetrahyrobiopterin (BH4). These results show that high glucose mediates increases in TSP1 expression and TSPI-dependent TGF-beta bioactivity through down-modulation of NO-cGMP-dependent protein kinase signaling.	Univ Alabama Birmingham, Cell Adhes & Matrix Res Ctr, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Murphy-Ullrich, JE (corresponding author), Univ Alabama Birmingham, Cell Adhes & Matrix Res Ctr, Dept Pathol, Div Mol & Cellular Pathol, Volker Hall,G038 1670,Univ Blvd, Birmingham, AL 35294 USA.	murphy@path.uab.edu		Darley-Usmar, Victor/0000-0001-8921-7086	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054624] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50061] Funding Source: Medline; NIDDK NIH HHS [DK54624, R01 DK081555] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Batuman O, 2001, Heart Dis, V3, P80; BAYRAKTAR M, 1994, J INT MED RES, V22, P90, DOI 10.1177/030006059402200204; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; Brodsky SV, 2001, AM J PHYSIOL-RENAL, V280, pF480, DOI 10.1152/ajprenal.2001.280.3.F480; Chakravarthy U, 1998, DIABETES, V47, P945, DOI 10.2337/diabetes.47.6.945; CHOI KC, 1997, KIDNEY INT S60, V52, P23; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; CORNWELL TL, 1994, J VASC RES, V31, P330, DOI 10.1159/000159061; CRAVEN PA, 1994, J CLIN INVEST, V93, P311, DOI 10.1172/JCI116961; Craven PA, 1997, DIABETES, V46, P671, DOI 10.2337/diabetes.46.4.671; CRAVEN PA, 1997, KIDNEY INT S60, V52, P46; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Dey NB, 1998, CIRC RES, V82, P139; Ding YX, 2000, AM J PHYSIOL-ENDOC M, V279, pE11, DOI 10.1152/ajpendo.2000.279.1.E11; Francis S H, 1988, Second Messengers Phosphoproteins, V12, P301; Furusu A, 1998, KIDNEY INT, V53, P1760, DOI 10.1046/j.1523-1755.1998.00907.x; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; Holmes DIR, 1997, BIOCHEM BIOPH RES CO, V238, P179, DOI 10.1006/bbrc.1997.7265; Honing MLH, 1998, DIABETES METAB REV, V14, P241, DOI 10.1002/(SICI)1099-0895(1998090)14:3<241::AID-DMR216>3.0.CO;2-R; Iglesias-de la Cruz MC, 2001, KIDNEY INT, V59, P87, DOI 10.1046/j.1523-1755.2001.00469.x; Ishii N, 2001, J AM SOC NEPHROL, V12, P1630, DOI 10.1681/ASN.V1281630; Iwano M, 1996, KIDNEY INT, V49, P1120, DOI 10.1038/ki.1996.162; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; KRAKLING BM, 1999, J CELL SCI, V112, P1599; LAHERTY CD, 1989, J BIOL CHEM, V264, P11222; LINCOLN T, 2000, ADV ORGAN BIOL, V8, P401; Lincoln T., 1996, BIOCH SMOOTH MUSCLE, P257; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; Malek AM, 1999, NEUROSURGERY, V45, P334, DOI 10.1097/00006123-199908000-00028; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; PFEILSCHIFTER J, 1995, KIDNEY INT, V48, pS50; Phelan MW, 1998, J LAB CLIN MED, V132, P519, DOI 10.1016/S0022-2143(98)90131-7; Poczatek MH, 2000, AM J PATHOL, V157, P1353, DOI 10.1016/S0002-9440(10)64649-4; PRABHAKAR S, 2001, AM J PHYSIOL-RENAL, V271, P179; Ribeiro SMF, 1999, J BIOL CHEM, V274, P13586, DOI 10.1074/jbc.274.19.13586; RIFKIN DB, 1993, THROMB HAEMOSTASIS, V70, P177; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26783; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SHARMA K, 1995, DIABETES, V44, P1139, DOI 10.2337/diabetes.44.10.1139; Shindo H, 1996, J CLIN INVEST, V97, P736, DOI 10.1172/JCI118472; Tada H, 1998, NEPHRON, V79, P38, DOI 10.1159/000044989; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; Tamura N, 1996, HYPERTENSION, V27, P552, DOI 10.1161/01.HYP.27.3.552; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Trachtman H, 1997, J AM SOC NEPHROL, V8, P1276; Vasquez-Vivar J, 2000, FEBS LETT, V481, P305, DOI 10.1016/S0014-5793(00)02001-9; VESELY DL, 1979, TRANSPLANTATION, V27, P403; WOLF G, 1992, KIDNEY INT, V42, P647, DOI 10.1038/ki.1992.330; Yevdokimova N, 2001, J AM SOC NEPHROL, V12, P703, DOI 10.1681/ASN.V124703; ZIYADEH FN, 1993, AM J KIDNEY DIS, V22, P736, DOI 10.1016/S0272-6386(12)80440-9; ZIYADEH FN, 1994, J CLIN INVEST, V93, P536, DOI 10.1172/JCI117004; ZIYADEH FN, 1991, KIDNEY INT, V39, P464, DOI 10.1038/ki.1991.57; Zochodne DW, 2000, J NEUROPATH EXP NEUR, V59, P798, DOI 10.1093/jnen/59.9.798	57	71	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9880	9888		10.1074/jbc.M108360200	http://dx.doi.org/10.1074/jbc.M108360200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11784717	hybrid			2022-12-27	WOS:000174549200038
J	Conroy, AT; Sharma, M; Holtz, AE; Wu, CB; Sun, ZJ; Weigel, RJ				Conroy, AT; Sharma, M; Holtz, AE; Wu, CB; Sun, ZJ; Weigel, RJ			A novel zinc finger transcription factor with two isoforms that are differentially repressed by estrogen receptor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST CANCER; REGULATED GENES; ER-BETA; EXPRESSION; IDENTIFICATION; PROTEIN; SUPERFAMILY; SEQUENCE; CDNA; ACTIVATION	Estrogen receptor-alpha (ERalpha) can induce the expression of genes in response to estrogen by binding to estrogen response elements in the promoters of target genes. There is growing evidence that ERalpha can alter patterns of gene expression in response to ligand by regulating the activity of other factors through a direct protein-protein interaction. To identify other factors that are regulated by ERalpha, a yeast two-hybrid screen was performed that identified a novel Cys(2)His(2) zinc finger protein named ZER6. The ZER6 protein contains a Kruppel-associated box domain and Six Cys(2)His(2) zinc fingers. Transcripts from the ZER6 gene can have alternate 5' exons and encode either a p71 or p52 isoform. The p52-ZER6 protein interacts strongly with ERalpha in the presence of 17beta-estradiol, whereas the p71-ZER6 isoform has a HUB-1 amino-terminal domain that inhibits the interaction with ERalpha. A consensus ZER6 binding element was defined using PCR-assisted binding site selection. In COS-1 cells, both the p52 and p71 isoforms can activate transcription through the ZER6 binding element; however, in the presence of ERalpha, transactivation by the p52 isoform is specifically repressed. Overexpression of the p52 isoform was able to abrogate activation by p71-ZER6. Expression of ZER6 was largely restricted to the mammary gland with a lower level of expression in the kidney. We conclude that ZER6 is a novel zinc! finger transcription factor in which regulation of transcription in hormone-responsive cells can be controlled by the relative level of expression of two distinct isoforms.	Stanford Univ, Sch Med, Dept Surg, MSLS, Stanford, CA 94305 USA; Clontech Labs, Palo Alto, CA 94303 USA	Stanford University	Weigel, RJ (corresponding author), Stanford Univ, Sch Med, Dept Surg, MSLS, Rm P214,1201 Welch Rd, Stanford, CA 94305 USA.			Weigel, Ronald/0000-0002-9249-0793	NCI NIH HHS [R01 CA070297, R01 CA087767-03, R01 CA77350, R01 CA087767, R01 CA087767-04, R01 CA070297-11A2, R01 CA070297-12] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087767, R01CA077350, R01CA070297] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; Carmeci C, 1997, GENOMICS, V45, P607, DOI 10.1006/geno.1997.4972; CAVAILLES V, 1991, BIOCHEM BIOPH RES CO, V174, P816, DOI 10.1016/0006-291X(91)91491-T; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; DESJARLAIS JR, 1994, P NATL ACAD SCI USA, V91, P11099, DOI 10.1073/pnas.91.23.11099; Ghosh MG, 2000, CANCER RES, V60, P6367; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; Imanishi M, 2001, EUR J PHARM SCI, V13, P91, DOI 10.1016/S0928-0987(00)00212-8; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Klug A, 1999, J MOL BIOL, V293, P215, DOI 10.1006/jmbi.1999.3007; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Nagaoka M, 2000, J INORG BIOCHEM, V82, P57, DOI 10.1016/S0162-0134(00)00154-9; Okumura K, 1997, NUCLEIC ACIDS RES, V25, P5025, DOI 10.1093/nar/25.24.5025; ONATE SA, 1995, SCIENCE, V270, P1354; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Roy RN, 2000, MOL CELL ENDOCRINOL, V165, P173, DOI 10.1016/S0303-7207(00)00248-3; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Thompson DA, 1997, J STEROID BIOCHEM, V62, P143, DOI 10.1016/S0960-0760(97)00029-0; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183	31	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9326	9334		10.1074/jbc.M107702200	http://dx.doi.org/10.1074/jbc.M107702200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11779858	hybrid			2022-12-27	WOS:000174400600080
J	Cunnick, JM; Meng, SS; Ren, Y; Desponts, C; Wang, HG; Djeu, JY; Wu, J				Cunnick, JM; Meng, SS; Ren, Y; Desponts, C; Wang, HG; Djeu, JY; Wu, J			Regulation of the mitogen-activated protein kinase signaling pathway by SHP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; TYROSINE-PHOSPHATASE; DOCKING PROTEIN; FACTOR RECEPTOR; LYSOPHOSPHATIDIC ACID; ADAPTER PROTEIN; GAB1; BINDING; REQUIREMENT; IDENTIFICATION	Gab1-SHP2 association is required for Erk mitogen-activated protein kinase activation by several growth factors. Gab1-SHP2 interaction activates SHP2. However, an activated SHP2 still needs to associate with Gab1 to mediate Erk activation. It was unclear whether SHP2 is required to dephosphorylate a negative phosphorylation site on Gab1 or whether SHP2 needs the Gab1 pleckstrin homology (PH) domain to target it to the plasma membrane. We found that expression of a fusion protein consisting of the Gab1 PH domain and an active SHP2 (Gab1PH-SHP2DeltaN) induced constitutive Mek1 and Erk2 activation. Linking the active SHP2DeltaN to the PDK1 PH domain or the FRS2beta myristoylation sequence also induced Mek1 activation. Mek1 activation by Gab1PH-SHP2DeltaN was inhibited by an Src inhibitor and by Csk. Significantly, Gab1PH-SHP2DeltaN induced Src activation. Gab1PH-SHP2DeltaN expression activated Ras, and the Gab1PH-SHP2DeltaN-induced Mek1 activation was blocked by RasN17. These findings suggest It at Gab1PH-SHP2DeltaN activated a signaling step upstream of Src and Ras. The SHP2 tyrosine phosphatase activity is essential for the function of the fusion protein. Together, these data show that the Gab1 sequence, besides the PH domain and SHP2 binding sites, is dispensable for Erk activation, suggesting that the primary role of Gab1 association with an activated SHP2 is to target it to the membrane.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, MRC E3, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Inst Biomol Sci, Tampa, FL 33612 USA; Univ S Florida, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Wu, J (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, MRC E3, 12902 Magnolia Dr, Tampa, FL 33612 USA.	wu@moffitt.usf.edu	Wu, Jie/R-2404-2019; Cunnick, Jess/F-1715-2018; Wang, Hong-Gang/A-3018-2015	Wu, Jie/0000-0002-2864-1606; Wang, Hong-Gang/0000-0003-0551-0571	NCI NIH HHS [CA77467, R01 CA077467, R29 CA077467] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA077467, R01CA077467, R29CA077467] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atkinson P H, 1973, Methods Cell Biol, V7, P157; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Wei S, 2000, J IMMUNOL, V165, P3811, DOI 10.4049/jimmunol.165.7.3811; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; XIAO S, 1994, J BIOL CHEM, V269, P21244; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664	31	137	141	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9498	9504		10.1074/jbc.M110547200	http://dx.doi.org/10.1074/jbc.M110547200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11779868	hybrid			2022-12-27	WOS:000174400600102
J	Dong, K; Ren, HM; Allison, WS				Dong, K; Ren, HM; Allison, WS			The fluorescence spectrum of the introduced tryptophans in the alpha(3)(beta 3F155W)(3)gamma subcomplex of the F-1-ATPase from the thermophilic Bacillus PS3 cannot be used to distinguish between the number of nucleoside di- and triphosphates bound to catalytic sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; BINDING CHANGE MECHANISM; 2 BETA-SUBUNITS; ATP HYDROLYSIS; NUCLEOTIDE-BINDING; MITOCHONDRIAL F1-ATPASE; GAMMA-SUBUNIT; WILD-TYPE; ALPHA(3)BETA(3)GAMMA SUBCOMPLEX; OXIDATIVE-PHOSPHORYLATION	It has been reported that shifts in the fluorescence emission spectrum of the introduced tryptophans in the betaF155W mutant of Escherichia coli F, (bovine heart mitochondria F, residue number) can quantitatively distinguish between the number of catalytic sites occupied with ADP and ATP during steady-state ATP hydrolysis (Weber, J., Bowman, C., and Senior, A. E. (1996) J. Biol. ChenL 271, 18711-18718). In contrast, addition of MgADP, Mg-5'-adenylyl beta,y-imidophosphate (MgAMP-PNP), and MgATP in 1:1 ratios to the alpha(3)(betaF155W)(3)gamma subcomplex of thermophilic Bacillus PS3 F-1 (TF1) induced nearly identical blue shifts in the fluorescence emission maximum that was accompanied by quenching. Addition of 2 mm MgADP induced a slightly greater blue shift and a slight increase in intensity over those observed with 1:1 MgADP. However, addition of 2 mm MgAMP-PNP or MgATP induced a much greater blue shift and substantially enhanced fluorescence intensity over those observed in the presence of stoichiometric MgADP or MgAMP-PNP. It is clear from these results that the fluorescence spectrum of the introduced tryptophans in the betaF155W mutant of TF1 does not respond in regular increments at any wavelength as catalytic sites are filled with nucleotides. The fluorescence spectrum observed after entrapping MgADP-fluoroaluminate complexes in two catalytic sites of the betaF155W subcomplex indicates that the fluorescence emission spectrum of the enzyme is maximally perturbed when nucleotides are bound to two catalytic sites. This finding is consistent with accumulating evidence suggesting that only two 13 subunits in the alpha(3)beta(3)gamma subcomplex of TF1 can simultaneously exist in the completely closed conformation.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Allison, WS (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NIGMS NIH HHS [GM 16974] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Allison WS, 2000, J BIOENERG BIOMEMBR, V32, P531, DOI 10.1023/A:1005677310791; Allison WS, 1998, ACCOUNTS CHEM RES, V31, P819, DOI 10.1021/ar960257v; BOEKEMA EJ, 1986, BIOCHIM BIOPHYS ACTA, V851, P353, DOI 10.1016/0005-2728(86)90071-X; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Dou C, 1998, BIOCHEMISTRY-US, V37, P16757, DOI 10.1021/bi981717q; Dou C, 1997, BIOCHEMISTRY-US, V36, P3719, DOI 10.1021/bi962353+; DU ZY, 1989, BIOCHEMISTRY-US, V28, P873, DOI 10.1021/bi00428a070; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; Jault JM, 1996, J BIOL CHEM, V271, P28818, DOI 10.1074/jbc.271.46.28818; JAULT JM, 1993, J BIOL CHEM, V268, P1558; KALASHNIKOVA TY, 1988, EUR J BIOCHEM, V177, P213, DOI 10.1111/j.1432-1033.1988.tb14364.x; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; MINKOV IB, 1980, BIOCHEM INT, V1, P478; MUELLER DM, 1989, J BIOL CHEM, V264, P16552; MURATALIEV MB, 1992, BIOCHEMISTRY-US, V31, P12885, DOI 10.1021/bi00166a025; Nadanaciva S, 2000, BIOCHEMISTRY-US, V39, P9583, DOI 10.1021/bi000941o; Nanda V, 2000, PROTEINS, V40, P112, DOI 10.1002/(SICI)1097-0134(20000701)40:1<112::AID-PROT130>3.0.CO;2-C; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; PENEFSKY HS, 1974, J BIOL CHEM, V249, P3579; Ren H, 1999, J BIOL CHEM, V274, P31366, DOI 10.1074/jbc.274.44.31366; Ren HM, 2000, J BIOL CHEM, V275, P10057, DOI 10.1074/jbc.275.14.10057; Ren HM, 2000, BBA-BIOENERGETICS, V1458, P221, DOI 10.1016/S0005-2728(00)00075-X; Senior AE, 2000, J EXP BIOL, V203, P35; Tsunoda SP, 1999, J BIOL CHEM, V274, P5701, DOI 10.1074/jbc.274.9.5701; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; Vinogradov AD, 2000, J EXP BIOL, V203, P41; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Weber J, 2000, BBA-BIOENERGETICS, V1458, P300, DOI 10.1016/S0005-2728(00)00082-7; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 1999, J BIOL CHEM, V274, P19124, DOI 10.1074/jbc.274.27.19124; Weber J, 1996, J BIOL CHEM, V271, P18711, DOI 10.1074/jbc.271.31.18711; Weber J, 1998, J BIOL CHEM, V273, P33210, DOI 10.1074/jbc.273.50.33210; WILKEMOUNTS S, 1994, ARCH BIOCHEM BIOPHYS, V309, P363, DOI 10.1006/abbi.1994.1125; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	42	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9540	9547		10.1074/jbc.M106911200	http://dx.doi.org/10.1074/jbc.M106911200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11779852	hybrid			2022-12-27	WOS:000174400600107
J	Jiang, P; Kumar, A; Parrillo, JE; Dempsey, LA; Platt, JL; Prinz, RA; Xu, XL				Jiang, P; Kumar, A; Parrillo, JE; Dempsey, LA; Platt, JL; Prinz, RA; Xu, XL			Cloning and characterization of the human heparanase-1 (HPR1) gene promoter - Role of GA-binding protein and Sp1 in regulating HPR1 basal promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2(I) COLLAGEN GENE; TRANSCRIPTION FACTORS; MAMMALIAN HEPARANASE; SP-FAMILY; SULFATE ENDOGLYCOSIDASE; NEUTROPHIL ELASTASE; CANCER METASTASIS; TISSUE INHIBITOR; TUMOR-METASTASIS; HUMAN-MELANOMA	Heparanase-1 (UPR1) is an endoglycosidase that specifically degrades the heparan sulfate chains of proteoglycan, a component of blood vessel walls and the extracellular matrix. Recent studies demonstrated that HPR1 expression is increased in a variety of malignancies and may play a critical role in tumor metastases. The HPR1 gene and its genomic structure have been recently cloned and characterized. To understand the mechanisms of HPR1 gene expression and regulation, we first mapped the transcription start site of the HPR1 gene and found that HPR1 m-RNA was transcribed from the nucleotide position 101 bp upstream of the ATG codon. A 3.5-kb promoter region of the HPR1 gene was cloned. Sequence analysis revealed that the TATA-less, GC-rich promoter of the HPR1 gene belongs to the family of housekeeping genes. This 3.5-kb promoter region exhibited strong promoter activity in two thyroid tumor cell lines. Truncation analysis of the HPR1 promoter identified a minimal 0.3-kb region that had strong basal promoter activity. Truncation and mutational analysis of the HPR1 promoter revealed three Sp1 sites and four Ets-relevant elements (ERE) significantly contributing to basal HPR1 promoter activity. Binding to the Sp1 sites by Sp1 and to the ERE sites by GA-binding protein (GABP) was confirmed by electrophoretic mobility shift assay and competition and supershift electrophoretic mobility shift assays. Cotransfection. of Sp- and GABP-deficient Drosophila SL-2 cells with the HPR1 promoter-driven luciferase construct plus the expression vector encoding the Sp1, Sp3, or GABP gene induced luciferase gene expression. Mutation or truncation of the Sp1 or ERE sites reduced luciferase expression in both SL-2 cells and thyroid tumor cell lines. Coexpression of GABPalpha/beta and Sp1 or Sp3 further increased luciferase reporter gene expression. Our results collectively suggest that Sp1 cooperates with GABP to regulate HPR1 promoter activity.	Rush Presbyterian St Lukes Med Ctr, Dept Gen Surg, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Med, Div Cardiovasc Dis & Crit Care, Chicago, IL 60612 USA; Mayo Clin & Mayo Fdn, Dept Surg, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pediat, Rochester, MN 55905 USA	Rush University; Rush University; Mayo Clinic; Mayo Clinic; Mayo Clinic	Xu, XL (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Gen Surg, 1653 W Congress Pkwy, Chicago, IL 60612 USA.			Platt, Jeffrey/0000-0002-4915-0419	NCI NIH HHS [CA76407] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA076407] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baker E, 1999, CHROMOSOME RES, V7, P319, DOI 10.1023/A:1009235132576; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; Braun H, 1998, J BIOL CHEM, V273, P9821, DOI 10.1074/jbc.273.16.9821; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Conn KJ, 1996, J BIOL CHEM, V271, P28853, DOI 10.1074/jbc.271.46.28853; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dempsey LA, 2000, GLYCOBIOLOGY, V10, P467, DOI 10.1093/glycob/10.5.467; Dong J, 2000, GENE, V253, P171, DOI 10.1016/S0378-1119(00)00251-1; Eccles SA, 1999, NAT MED, V5, P735, DOI 10.1038/10455; Fidler IJ, 1996, J NATL CANCER I, V88, P1700, DOI 10.1093/jnci/88.23.1700; Fidler IJ, 1999, CANCER CHEMOTH PHARM, V43, pS3, DOI 10.1007/s002800051091; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Li XR, 1999, J BIOL CHEM, V274, P35203, DOI 10.1074/jbc.274.49.35203; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MATZNER Y, 1992, J LEUKOCYTE BIOL, V51, P519, DOI 10.1002/jlb.51.6.519; MATZNER Y, 1985, J CLIN INVEST, V76, P1306, DOI 10.1172/JCI112104; McKenzie E, 2000, BIOCHEM BIOPH RES CO, V276, P1170, DOI 10.1006/bbrc.2000.3586; NAKAJIMA M, 1986, CANCER LETT, V31, P277, DOI 10.1016/0304-3835(86)90148-5; NAKAJIMA M, 1983, SCIENCE, V220, P611, DOI 10.1126/science.6220468; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; NAKAJIMA M, 1986, ANAL BIOCHEM, V157, P162, DOI 10.1016/0003-2697(86)90209-5; NAPARSTEK Y, 1984, NATURE, V310, P241, DOI 10.1038/310241a0; Nuchprayoon I, 1999, J BIOL CHEM, V274, P1085, DOI 10.1074/jbc.274.2.1085; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; OGAWA K, 1988, J BIOL CHEM, V263, P8384; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SEWELL RF, 1989, BIOCHEM J, V264, P777, DOI 10.1042/bj2640777; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; VILLENA JA, 1994, J BIOL CHEM, V269, P32649; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Yu M, 1997, J BIOL CHEM, V272, P29060, DOI 10.1074/jbc.272.46.29060	46	78	83	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8989	8998		10.1074/jbc.M105682200	http://dx.doi.org/10.1074/jbc.M105682200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11779847	hybrid			2022-12-27	WOS:000174400600035
J	Uyama, T; Kitagawa, H; Tamura, J; Sugahara, K				Uyama, T; Kitagawa, H; Tamura, J; Sugahara, K			Molecular cloning and expression of human chondroitin N-acetylgalactosaminyltransferase - The key enzyme for chain initiation and elongation of chondroitin/dermatan sulfate on the protein linkage region tetrasaccharide shared by heparin/heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSORS EXT1; HEPARAN-SULFATE; CAENORHABDITIS-ELEGANS; BIOSYNTHESIS; GLYCOSAMINOGLYCANS; GALNAC; PROTEOGLYCANS; ENCODES	Based on sequence homology with the recently cloned human chondroitin synthase, we identified a novel beta1,4-N-acetylgalactosaminyltransferase, which consisted of 532 amino acids with a type 11 transmembrane protein topology. The amino acid sequence displayed 27% identity to that of human chondroitin synthase. The expression of a soluble form of the protein in COS-1 cells produced an active enzyme, which transferred beta1,4-N-acetylgalactosamine (GalNAc) from UDP-[H-3]GalNAc not only to a polymer chondroitin representing growing chondroitin chains (beta-GalNAc transferase II activity) but also to GIcUAbeta1-3Galbeta1-O-C2H4NH-benzyloxycarbonyl, a synthetic substrate for beta-GalNAc transferase I that transfers the first GalNAc to the core tetrasaccharide in the protein linkage region of chondroitin sulfate. Hence, the enzyme is involved in the biosynthetic initiation and elongation of chondroitin sulfate and is the key enzyme responsible for the selective chain assembly of chondroitin/dermatan sulfate on the linkage region tetrasaccharide common to various proteoglycans containing chondroitin/dermatan sulfate or heparin/heparan sulfate chains. The coding region of this enzyme was divided into seven discrete exons and localized to chromosome 8. Northern blot analysis revealed that the chondroitin GalNAc transferase gene exhibited a ubiquitous but markedly differential expression in human tissues and that the expression pattern was similar to that of chondroitin synthase. Thus, more than two distinct enzymes forming the novel gene family are required for chain initiation and elongation in chondroitin/dermatan sulfate as in the biosynthesis of heparin/heparan sulfate.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Tottori Univ, Fac Educ & Reg Sci, Dept Environm Sci, Tottori 6808551, Japan	Kobe Pharmaceutical University; Tottori University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp	Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P905, DOI 10.1093/glycob/7.7.905; KITAGAWA H, 1995, J BIOL CHEM, V270, P22190, DOI 10.1074/jbc.270.38.22190; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; KITAGAWA H, 1995, J BIOCHEM-TOKYO, V117, P1083, DOI 10.1093/oxfordjournals.jbchem.a124810; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Kitagawa H, 2001, J BIOL CHEM, V276, P4834, DOI 10.1074/jbc.C000835200; Kitagawa H, 1999, GLYCOBIOLOGY, V9, P697, DOI 10.1093/glycob/9.7.697; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lidholt K, 1997, GLYCOCONJUGATE J, V14, P737, DOI 10.1023/A:1018525602197; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nadanaka S, 1998, J BIOL CHEM, V273, P33728, DOI 10.1074/jbc.273.50.33728; Nadanaka S, 1999, BIOCHEM J, V340, P353, DOI 10.1042/0264-6021:3400353; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Tamura J, 1996, LIEBIGS ANN, P1239; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Yamada S, 1999, FEBS LETT, V459, P327, DOI 10.1016/S0014-5793(99)01286-7	36	103	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8841	8846		10.1074/jbc.M111434200	http://dx.doi.org/10.1074/jbc.M111434200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11788602	hybrid			2022-12-27	WOS:000174400600015
J	Wilkens, M; Krishnaswamy, S				Wilkens, M; Krishnaswamy, S			The contribution of factor Xa to exosite-dependent substrate recognition by prothrombinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TICK ANTICOAGULANT PEPTIDE; AMINO-ACID-SEQUENCE; CLOTTING FACTOR-V; BOVINE FACTOR XA; ACTIVE-SITE; MACROMOLECULAR SUBSTRATE; BLOOD-COAGULATION; ENZYME COMPLEXES; STUART FACTOR; HEAVY-CHAIN	Kinetic studies support the concept that protein substrate recognition by the prothrombinase complex of coagulation is achieved by interactions at extended macromolecular recognition sites (exosites), distinct from the active site of factor Xa within the complex. We have used this formal kinetic model and a monoclonal antibody directed against Xa (alphaBFX-2b) to investigate the contributions of surfaces on the proteinase to exosite-mediated protein substrate recognition by prothrombinase. alphaBFX-2b bound reversibly to a fluorescent derivative of factor Xa (K-d = 17.1 +/- 5.6 nm) but had no effect on active site function of factor Xa or factor Xa saturably assembled into prothrombinase. In contrast, alphaBFX-2b was a slow, tight binding inhibitor of the cleavage of either prethrombin 2 or meizothrombin des-fragment 1 by prothrombinase (K-i(*) = 0.55 +/- 0.05 nm). Thus, alphaBFX-2b binding to factor Xa within prothrombinase selectively leads to the inhibition of protein substrate cleavage without interfering with active site function. Inhibition kinetics could adequately be accounted for by a kinetic model in which prethrombin 2 and alphaBFX-2b bind in a mutually exclusive way to prothrombinase. These are properties expected of an exosite-directed inhibitor. The site(s) on factor Xa responsible for antibody binding were evaluated by identification of immunoreactive fragments following chemical digestion of human and bovine Xa and were further confirmed with a series of recombinantly expressed fragments. These approaches suggest that residues 82-91 and 102-116 in the proteinase domain contribute to alphaBFX-2b binding. The data establish this antibody as a prototypic exosite-directed inhibitor of prothrombinase and suggest that the occlusion of a surface on factor Xa, spatially removed from the active site, is sufficient to block exosite-dependent recognition of the protein substrate by prothrombinase.	Childrens Hosp Philadelphia, Joseph Stokes Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania	Krishnaswamy, S (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Res Inst, 310 Abramson,3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047465, R01HL062523] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-62523, HL-47465] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; Baugh RJ, 1998, J BIOL CHEM, V273, P4378, DOI 10.1074/jbc.273.8.4378; Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; Betz A, 1997, BIOCHEMISTRY-US, V36, P181, DOI 10.1021/bi962060g; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bevington P. R., 1992, DATA REDUCTION ERROR, P141; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Boskovic DS, 2000, J BIOL CHEM, V275, P38561, DOI 10.1074/jbc.M006637200; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; CHASE T, 1970, METHOD ENZYMOL, V19, P20; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; CHURCH WR, 1988, BLOOD, V72, P1911; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; Dharmawardana KR, 1999, J BIOL CHEM, V274, P18635, DOI 10.1074/jbc.274.26.18635; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; Dickinson CD, 1998, J MOL BIOL, V277, P959, DOI 10.1006/jmbi.1998.1639; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; Esmon CT, 1998, NAT STRUCT BIOL, V5, P933, DOI 10.1038/2906; ESMON CT, 1973, BIOCHIM BIOPHYS ACTA, V310, P289, DOI 10.1016/0005-2795(73)90034-2; ESMON CT, 1974, J BIOL CHEM, V249, P7791; EVANS SA, 1982, J BIOL CHEM, V257, P3014; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; Gomori G, 1942, J LAB CLIN MED, V27, P955; Greenspan NS, 1999, NAT BIOTECHNOL, V17, P936, DOI 10.1038/13590; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; JACKSON CM, 1968, BIOCHEMISTRY-US, V7, P4492, DOI 10.1021/bi00852a046; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; Joseph JS, 1999, BLOOD, V94, P621, DOI 10.1182/blood.V94.2.621.414k25_621_631; KALAFATIS M, 1994, BBA-MOL BASIS DIS, V1227, P113, DOI 10.1016/0925-4439(94)90086-8; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; KRISHNASWAMY S, 1994, BIOCHEMISTRY-US, V33, P7897, DOI 10.1021/bi00191a017; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; MESSIER TL, 1991, GENE, V99, P291, DOI 10.1016/0378-1119(91)90141-W; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; Sabharwal AK, 1997, J BIOL CHEM, V272, P22037, DOI 10.1074/jbc.272.35.22037; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TITANI K, 1975, P NATL ACAD SCI USA, V72, P3082, DOI 10.1073/pnas.72.8.3082; WALKER RK, 1993, J BIOL CHEM, V268, P13920; WALKER RK, 1994, J BIOL CHEM, V269, P27441; Wei AZ, 1998, J MOL BIOL, V283, P147, DOI 10.1006/jmbi.1998.2069	60	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9366	9374		10.1074/jbc.M110848200	http://dx.doi.org/10.1074/jbc.M110848200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11782479	hybrid			2022-12-27	WOS:000174400600085
J	Cermak, L; Simova, S; Pintzas, A; Horejsi, V; Andera, L				Cermak, L; Simova, S; Pintzas, A; Horejsi, V; Andera, L			Molecular mechanisms involved in CD43-mediated apoptosis of TF-1 cells - Roles of transcription, Daxx expression, and adhesion molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC PROGENITOR CELLS; ANTIBODY RECOGNIZING CD43; WISKOTT-ALDRICH SYNDROME; T-LYMPHOBLASTOID-CELLS; CROSS-LINKING; STEM-CELLS; LEUKOSIALIN CD43; LINE HMC-1; ACTIVATION; LYMPHOCYTES	CD43 (leukosialin, sialophorin), an abundant leukocyte surface sialoglycoprotein, regulates leukocyte adhesion and transmits activating signals in T cells and dendritic cells. Immobilized anti-CD43 monoclonal antibody (mAb) MEM-59 has been previously shown to induce apoptosis of hematopoietic progenitors. In this study we show that it also triggers apoptosis of the myeloid progenitor-derived cell line TF-1. The kinetics of the MEM-59-induced apoptosis were unusually slow, with the first apoptotic cells appearing 36-48 h after their contact with the immobilized antibody; in 5 days, 90% of the cells were dead. CD43-mediated apoptosis was enhanced by coimmobilized anti-CD45 mAb and partly suppressed by coimmobilized anti-CD50 (ICAM-3) or anti-CD99 mAb. The MEM-59-triggered apoptosis of TF-1 cells was also inhibited by the overexpression of an apoptotic regulator, Daxx. CD43-mediated apoptosis was preceded by the repression of the DNA binding activity of the transcription factor AP-1. DNA array screening revealed that the expression of several genes encoding apoptosis-regulating proteins, including 14-3-3 proteins and the granulocyte macrophage colony-stimulating factor (GM-CSF) receptor beta-subunit, was repressed in TF-1 cells bound to immobilized MEM-59. The down-regulation of 14-3-3 proteins and GM-CSF receptor beta was accompanied by translocation of the proapoptotic protein Bad to the mitochondria. These results suggest that engagement of CD43 may, presumably through the repressing transcription, initiate a Bad-dependent apoptotic pathway.	Acad Sci Czech Republ, Inst Genet Mol, CZ-14220 Prague 4, Czech Republic; Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, GR-11635 Athens, Greece	Czech Academy of Sciences; National Hellenic Research Foundation	Andera, L (corresponding author), Acad Sci Czech Republ, Inst Genet Mol, Videoska 1083, CZ-14220 Prague 4, Czech Republic.		Andera, Ladislav/ABA-3403-2020; Horejsi, Vaclav/G-3113-2014; Simova, Sarka/F-8625-2014; Cermak, Lukas/N-2254-2016; Andera, Ladislav/A-4536-2011	Horejsi, Vaclav/0000-0003-4925-0142; Cermak, Lukas/0000-0002-8777-3692; 				Aguado E, 1999, J LEUKOCYTE BIOL, V66, P923, DOI 10.1002/jlb.66.6.923; ALVARADO M, 1995, EUR J IMMUNOL, V25, P1051, DOI 10.1002/eji.1830250429; Anzai N, 1999, BLOOD, V93, P3317, DOI 10.1182/blood.V93.10.3317.410k12_3317_3326; Babina M, 1998, BIOCHEM BIOPH RES CO, V243, P163, DOI 10.1006/bbrc.1998.8083; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; Bazil V, 1996, BLOOD, V87, P1272, DOI 10.1182/blood.V87.4.1272.bloodjournal8741272; BAZIL V, 1995, BLOOD, V86, P502, DOI 10.1182/blood.V86.2.502.bloodjournal862502; Bazil V, 1997, STEM CELLS, V15, P13, DOI 10.1002/stem.5530150804; Brown TJ, 1996, J BIOL CHEM, V271, P27686, DOI 10.1074/jbc.271.44.27686; CHAOUCHI N, 1995, J IMMUNOL, V154, P3096; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; Corinti S, 1999, J IMMUNOL, V162, P6331; CYSTER J, 1990, EUR J IMMUNOL, V20, P875, DOI 10.1002/eji.1830200424; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; ELLIES LG, 1994, GLYCOBIOLOGY, V4, P885, DOI 10.1093/glycob/4.6.885; Ellies LG, 1996, BLOOD, V88, P1725, DOI 10.1182/blood.V88.5.1725.bloodjournal8851725; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; Hahn JH, 1997, J IMMUNOL, V159, P2250; Hamad M, 1996, DEV COMP IMMUNOL, V20, P77, DOI 10.1016/0145-305X(95)00037-T; HIRAYAMA F, 1994, INT J HEMATOL, V60, P191; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; JONES AT, 1994, J IMMUNOL, V153, P3426; Kabelitz D, 1995, Curr Top Microbiol Immunol, V200, P1; KITAMURA T, 1989, BLOOD, V73, P375; Klampfer L, 1999, CYTOKINE, V11, P849, DOI 10.1006/cyto.1999.0514; Ko YG, 2001, J BIOL CHEM, V276, P39103, DOI 10.1074/jbc.M105928200; LEFEBVRE JC, 1994, J EXP MED, V180, P1609, DOI 10.1084/jem.180.5.1609; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Lopez-Briones S, 1998, CELL ADHES COMMUN, V6, P465, DOI 10.3109/15419069809010795; MartinezCaceres E, 1996, TISSUE ANTIGENS, V48, P626, DOI 10.1111/j.1399-0039.1996.tb02685.x; Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200; Michaelson JS, 2000, APOPTOSIS, V5, P217, DOI 10.1023/A:1009696227420; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Miura Y, 2001, BIOCHEM BIOPH RES CO, V288, P80, DOI 10.1006/bbrc.2001.5729; MOORE T, 1994, J IMMUNOL, V153, P4978; Nieto M, 1999, BLOOD, V94, P2767, DOI 10.1182/blood.V94.8.2767.420k26_2767_2777; Ostberg JR, 1998, IMMUNOL TODAY, V19, P546, DOI 10.1016/S0167-5699(98)01343-7; Pace KE, 1999, J IMMUNOL, V163, P3801; Pace KE, 2000, J IMMUNOL, V165, P2331, DOI 10.4049/jimmunol.165.5.2331; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; Pedraza-Alva G, 1998, J BIOL CHEM, V273, P14218, DOI 10.1074/jbc.273.23.14218; Pedraza-Alva G, 2001, J BIOL CHEM, V276, P729, DOI 10.1074/jbc.M008494200; PedrazaAlva G, 1996, J BIOL CHEM, V271, P27564, DOI 10.1074/jbc.271.44.27564; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Pettersen RD, 2001, J IMMUNOL, V166, P4931, DOI 10.4049/jimmunol.166.8.4931; Rice J.E., 1997, SUBCELLULAR FRACTION, V1st, P107; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; Rosenstein Y, 1999, IMMUNOL RES, V20, P89, DOI 10.1007/BF02786465; SANCHEZMATEOS P, 1995, BLOOD, V86, P2228, DOI 10.1182/blood.V86.6.2228.bloodjournal8662228; Santana MA, 2000, J BIOL CHEM, V275, P31460, DOI 10.1074/jbc.M005231200; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Serrador JM, 1998, BLOOD, V91, P4632, DOI 10.1182/blood.V91.12.4632.412k17_4632_4644; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; Sohn HW, 1998, AM J PATHOL, V153, P1937, DOI 10.1016/S0002-9440(10)65707-0; Stockl J, 1996, J EXP MED, V184, P1769, DOI 10.1084/jem.184.5.1769; Tada J, 1999, BLOOD, V93, P3723, DOI 10.1182/blood.V93.11.3723.411k02_3723_3735; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; van den Berg TK, 2001, J IMMUNOL, V166, P3637, DOI 10.4049/jimmunol.166.6.3637; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; WEBER S, 1994, IMMUNOLOGY, V82, P638; Woodle ES, 1997, J IMMUNOL, V158, P2156; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885	64	27	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7955	7961		10.1074/jbc.M108048200	http://dx.doi.org/10.1074/jbc.M108048200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11773067	hybrid			2022-12-27	WOS:000174268000043
J	Lehti, K; Lohi, J; Juntunen, MM; Pei, DQ; Keski-Oja, J				Lehti, K; Lohi, J; Juntunen, MM; Pei, DQ; Keski-Oja, J			Oligomerization through hemopexin and cytoplasmic domains regulates the activity and turnover of membrane type 1 matrix metalloproteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; GELATINASE-A; TISSUE INHIBITOR; ACTIVATION; MT1-MMP; PROGELATINASE; COMPLEX; PROTEOLYSIS; INVASION; CLEAVAGE	The formation of multimeric complexes by membrane-type 1 matrix metalloproteinase (MT1-AMP) may facilitate its autocatalytic inactivation or proMMP-2 acti. vation on the cell surface. To characterize these processes, we expressed various glutathione S-trans. ferase/MT1-MMP fusion proteins in human HT-1080 fibrosarcoma cells and SV40-transformed lung fibroblasts and analyzed their effects on MT1-MMP activity and potential homophilic interactions. We report here that MT1-MMP is expressed on the cell surface as oli. gomeric 200-240-kDa complexes containing both the active 60-kDa and autocatalytically processed 43-kDa species. Overexpression of a glutathione S-transferase/ MT1-MMP fusion protein containing the transmembrane and cytoplasmic domains of MT1-MMP inhibited the phorbol 12-myristate 13-acetate-induced autocatalytic cleavage of endogenous MT1-MMP to the 43-kDa species, but not proMMP-2 activation. On the other hand, a similar fusion protein with the hemopexin, transmembrane, and cytoplasmic domains inhibited proMMP-2 activation in a dominant-negative fashion. These results suggest that both the autocatalytic cleavage of MT1-MMP and proMMP-2 activation may be regulated by oligomerization through the cytoplasmic and hemopexin domains. Indeed, either domain, when attached to the cell membrane by a transmembrane domain, formed stable homophilic complexes. Copurification of MT1-MMP with these fusion proteins correlated with their cell-surface co-localization. Thus, MT1-MMP oligomerization through the hemopexin, transmembrane, and cytoplasmic domains controls its catalytic activity.	Univ Helsinki, Biomedicum, Cell Biol Lab, Haartman Inst,Dept Virol, FIN-00014 Helsinki, Finland; Univ Helsinki, Biomedicum, Cell Biol Lab, Haartman Inst,Dept Pathol, FIN-00014 Helsinki, Finland; Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Helsinki; University of Helsinki; University of Minnesota System; University of Minnesota Twin Cities	Keski-Oja, J (corresponding author), Univ Helsinki, Biomedicum, Cell Biol Lab, Haartman Inst,Dept Virol, POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	Jorma.Keski-Oja@Helsinki.Fi		Lehti, Kaisa/0000-0001-9110-8719	NCI NIH HHS [CA 76308] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076308, R29CA076308] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apte SS, 1997, J BIOL CHEM, V272, P25511, DOI 10.1074/jbc.272.41.25511; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Imai K, 1996, CANCER RES, V56, P2707; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kazes I, 2000, BLOOD, V96, P3064, DOI 10.1182/blood.V96.9.3064.h8003064_3064_3069; Kinoh H, 1996, J CELL SCI, V109, P953; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; Lohi J, 2000, GENE, V242, P75, DOI 10.1016/S0378-1119(99)00549-1; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Overall CM, 2000, J BIOL CHEM, V275, P39497, DOI 10.1074/jbc.M005932200; Pei DQ, 2000, J BIOL CHEM, V275, P33988, DOI 10.1074/jbc.M006493200; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Stanton H, 1998, J CELL SCI, V111, P2789; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Valtanen H, 2000, PROTEIN EXPRES PURIF, V19, P66, DOI 10.1006/prep.2000.1216; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	42	113	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8440	8448		10.1074/jbc.M109128200	http://dx.doi.org/10.1074/jbc.M109128200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11779859	hybrid			2022-12-27	WOS:000174268000104
